Torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
ventricular	POS	I-NP
tachycardia	POS	I-NP
during	POS	O
low	POS	O
dose	POS	O
intermittent	POS	O
dobutamine	POS	O
treatment	POS	O
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
dilated	POS	B-NP
cardiomyopathy	POS	I-NP
and	POS	O
congestive	POS	B-NP
heart	POS	I-NP
failure	POS	I-NP
.	POS	O
The	POS	O
authors	POS	O
describe	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
56	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
chronic	POS	O
,	POS	O
severe	POS	O
heart	POS	B-NP
failure	POS	I-NP
secondary	POS	O
to	POS	O
dilated	POS	B-NP
cardiomyopathy	POS	I-NP
and	POS	O
absence	POS	O
of	POS	O
significant	POS	O
ventricular	POS	B-NP
arrhythmias	POS	I-NP
who	POS	O
developed	POS	O
QT	POS	B-NP
prolongation	POS	I-NP
and	POS	O
torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
ventricular	POS	I-NP
tachycardia	POS	I-NP
during	POS	O
one	POS	O
cycle	POS	O
of	POS	O
intermittent	POS	O
low	POS	O
dose	POS	O
(	POS	O
2	POS	O
.	POS	O
5	POS	O
mcg	POS	O
/	POS	O
kg	POS	O
per	POS	O
min	POS	O
)	POS	O
dobutamine	POS	O
.	POS	O
This	POS	O
report	POS	O
of	POS	O
torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
ventricular	POS	I-NP
tachycardia	POS	I-NP
during	POS	O
intermittent	POS	O
dobutamine	POS	O
supports	POS	O
the	POS	O
hypothesis	POS	O
that	POS	O
unpredictable	POS	O
fatal	POS	O
arrhythmias	POS	B-NP
may	POS	O
occur	POS	O
even	POS	O
with	POS	O
low	POS	O
doses	POS	O
and	POS	O
in	POS	O
patients	POS	O
with	POS	O
no	POS	O
history	POS	O
of	POS	O
significant	POS	O
rhythm	POS	B-NP
disturbances	POS	I-NP
.	POS	O
The	POS	O
mechanisms	POS	O
of	POS	O
proarrhythmic	POS	O
effects	POS	O
of	POS	O
Dubutamine	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Positive	POS	O
skin	POS	O
tests	POS	O
in	POS	O
late	POS	O
reactions	POS	O
to	POS	O
radiographic	POS	O
contrast	POS	O
media	POS	O
.	POS	O
In	POS	O
the	POS	O
last	POS	O
few	POS	O
years	POS	O
delayed	POS	O
reactions	POS	O
several	POS	O
hours	POS	O
after	POS	O
the	POS	O
injection	POS	O
of	POS	O
radiographic	POS	O
and	POS	O
contrast	POS	O
materials	POS	O
(	POS	O
PRC	POS	O
)	POS	O
have	POS	O
been	POS	O
described	POS	O
with	POS	O
increasing	POS	O
frequency	POS	O
.	POS	O
The	POS	O
authors	POS	O
report	POS	O
two	POS	O
observations	POS	O
on	POS	O
patients	POS	O
with	POS	O
delayed	POS	O
reactions	POS	O
in	POS	O
whom	POS	O
intradermoreactions	POS	O
(	POS	O
IDR	POS	O
)	POS	O
and	POS	O
patch	POS	O
tests	POS	O
to	POS	O
a	POS	O
series	POS	O
of	POS	O
ionic	POS	O
and	POS	O
non	POS	O
ionic	POS	O
PRC	POS	O
were	POS	O
studied	POS	O
.	POS	O
After	POS	O
angiography	POS	O
by	POS	O
the	POS	O
venous	POS	O
route	POS	O
in	POS	O
patient	POS	O
n	POS	O
degree	POS	O
1	POS	O
a	POS	O
biphasic	POS	O
reaction	POS	O
with	POS	O
an	POS	O
immediate	POS	O
reaction	POS	O
(	POS	O
dyspnea	POS	B-NP
,	POS	O
loss	POS	B-NP
of	POS	I-NP
consciousness	POS	I-NP
)	POS	O
and	POS	O
delayed	POS	O
macro	POS	O
-	POS	O
papular	POS	B-NP
rash	POS	I-NP
appeared	POS	O
,	POS	O
whilst	POS	O
patient	POS	O
n	POS	O
degree	POS	O
2	POS	O
developed	POS	O
a	POS	O
generalised	POS	B-NP
sensation	POS	I-NP
of	POS	I-NP
heat	POS	I-NP
,	POS	O
persistent	POS	O
pain	POS	B-NP
at	POS	O
the	POS	O
site	POS	O
of	POS	O
injection	POS	O
immediately	POS	O
and	POS	O
a	POS	O
generalised	POS	O
macro	POS	O
-	POS	O
papular	POS	B-NP
reaction	POS	I-NP
after	POS	O
24	POS	O
hours	POS	O
.	POS	O
The	POS	O
skin	POS	O
tests	POS	O
revealed	POS	O
positive	POS	O
delayed	POS	O
reactions	POS	O
of	POS	O
24	POS	O
hours	POS	O
and	POS	O
48	POS	O
hours	POS	O
by	POS	O
IDR	POS	O
and	POS	O
patch	POS	O
tests	POS	O
to	POS	O
only	POS	O
some	POS	O
PRC	POS	O
with	POS	O
common	POS	O
chains	POS	O
in	POS	O
their	POS	O
structures	POS	O
.	POS	O
The	POS	O
positive	POS	O
skin	POS	O
tests	POS	O
are	POS	O
in	POS	O
favour	POS	O
of	POS	O
immunological	POS	O
reactions	POS	O
and	POS	O
may	POS	O
help	POS	O
in	POS	O
diagnosis	POS	O
of	POS	O
allergy	POS	B-NP
in	POS	O
the	POS	O
patients	POS	O
.	POS	O
Risk	POS	O
of	POS	O
transient	POS	O
hyperammonemic	POS	B-NP
encephalopathy	POS	I-NP
in	POS	O
cancer	POS	B-NP
patients	POS	O
who	POS	O
received	POS	O
continuous	POS	O
infusion	POS	O
of	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
with	POS	O
the	POS	O
complication	POS	O
of	POS	O
dehydration	POS	B-NP
and	POS	O
infection	POS	O
.	POS	O
From	POS	O
1986	POS	O
to	POS	O
1998	POS	O
,	POS	O
29	POS	O
cancer	POS	B-NP
patients	POS	O
who	POS	O
had	POS	O
32	POS	O
episodes	POS	O
of	POS	O
transient	POS	O
hyperammonemic	POS	B-NP
encephalopathy	POS	I-NP
related	POS	O
to	POS	O
continuous	POS	O
infusion	POS	O
of	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
(	POS	O
5	POS	O
-	POS	O
FU	POS	O
)	POS	O
were	POS	O
identified	POS	O
.	POS	O
None	POS	O
of	POS	O
the	POS	O
patients	POS	O
had	POS	O
decompensated	POS	B-NP
liver	POS	I-NP
disease	POS	I-NP
.	POS	O
Onset	POS	O
of	POS	O
hyperammonemic	POS	B-NP
encephalopathy	POS	I-NP
varied	POS	O
from	POS	O
0	POS	O
.	POS	O
5	POS	O
to	POS	O
5	POS	O
days	POS	O
(	POS	O
mean	POS	O
:	POS	O
2	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
3	POS	O
days	POS	O
)	POS	O
after	POS	O
the	POS	O
initiation	POS	O
of	POS	O
chemotherapy	POS	O
.	POS	O
Plasma	POS	O
ammonium	POS	O
level	POS	O
ranged	POS	O
from	POS	O
248	POS	O
to	POS	O
2387	POS	O
microg	POS	O
%	POS	O
(	POS	O
mean	POS	O
:	POS	O
626	POS	O
+	POS	O
/	POS	O
-	POS	O
431	POS	O
microg	POS	O
%	POS	O
)	POS	O
.	POS	O
Among	POS	O
the	POS	O
32	POS	O
episodes	POS	O
,	POS	O
26	POS	O
(	POS	O
81	POS	O
%	POS	O
)	POS	O
had	POS	O
various	POS	O
degrees	POS	O
of	POS	O
azotemia	POS	B-NP
,	POS	O
18	POS	O
(	POS	O
56	POS	O
%	POS	O
)	POS	O
occurred	POS	O
during	POS	O
bacterial	POS	B-NP
infections	POS	I-NP
and	POS	O
14	POS	O
(	POS	O
44	POS	O
%	POS	O
)	POS	O
without	POS	O
infection	POS	O
occurred	POS	O
during	POS	O
periods	POS	O
of	POS	O
dehydration	POS	B-NP
.	POS	O
Higher	POS	O
plasma	POS	O
ammonium	POS	O
levels	POS	O
and	POS	O
more	POS	O
rapid	POS	O
onset	POS	O
of	POS	O
hyperammonemia	POS	B-NP
were	POS	O
seen	POS	O
in	POS	O
18	POS	O
patients	POS	O
with	POS	O
bacterial	POS	B-NP
infections	POS	I-NP
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
003	POS	O
and	POS	O
0	POS	O
.	POS	O
0006	POS	O
,	POS	O
respectively	POS	O
)	POS	O
and	POS	O
in	POS	O
nine	POS	O
patients	POS	O
receiving	POS	O
high	POS	O
daily	POS	O
doses	POS	O
(	POS	O
2600	POS	O
or	POS	O
1800	POS	O
mg	POS	O
/	POS	O
m2	POS	O
)	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
0001	POS	O
and	POS	O
<	POS	O
0	POS	O
.	POS	O
0001	POS	O
,	POS	O
respectively	POS	O
)	POS	O
.	POS	O
In	POS	O
25	POS	O
out	POS	O
of	POS	O
32	POS	O
episodes	POS	O
(	POS	O
78	POS	O
%	POS	O
)	POS	O
,	POS	O
plasma	POS	O
ammonium	POS	O
levels	POS	O
and	POS	O
mental	POS	O
status	POS	O
returned	POS	O
to	POS	O
normal	POS	O
within	POS	O
2	POS	O
days	POS	O
after	POS	O
adequate	POS	O
management	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
hyperammonemic	POS	B-NP
encephalopathy	POS	I-NP
can	POS	O
occur	POS	O
in	POS	O
patients	POS	O
receiving	POS	O
continuous	POS	O
infusion	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
.	POS	O
Azotemia	POS	B-NP
,	POS	O
body	POS	B-NP
fluid	POS	I-NP
insufficiency	POS	I-NP
and	POS	O
bacterial	POS	B-NP
infections	POS	I-NP
were	POS	O
frequently	POS	O
found	POS	O
in	POS	O
these	POS	O
patients	POS	O
.	POS	O
It	POS	O
is	POS	O
therefore	POS	O
important	POS	O
to	POS	O
recognize	POS	O
this	POS	O
condition	POS	O
in	POS	O
patients	POS	O
receiving	POS	O
continuous	POS	O
infusion	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
quinine	POS	O
and	POS	O
4	POS	O
-	POS	O
aminopyridine	POS	O
on	POS	O
conditioned	POS	O
place	POS	O
preference	POS	O
and	POS	O
changes	POS	O
in	POS	O
motor	POS	O
activity	POS	O
induced	POS	O
by	POS	O
morphine	POS	O
in	POS	O
rats	POS	O
.	POS	O
1	POS	O
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
two	POS	O
unselective	POS	O
potassium	POS	O
(	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
)	POS	O
channel	POS	O
blockers	POS	O
,	POS	O
quinine	POS	O
(	POS	O
12	POS	O
.	POS	O
5	POS	O
,	POS	O
25	POS	O
and	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
4	POS	O
-	POS	O
aminopyridine	POS	O
(	POS	O
1	POS	O
and	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
on	POS	O
conditioned	POS	O
place	POS	O
preference	POS	O
and	POS	O
biphasic	POS	O
changes	POS	O
in	POS	O
motor	POS	O
activity	POS	O
induced	POS	O
by	POS	O
morphine	POS	O
(	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
were	POS	O
tested	POS	O
in	POS	O
Wistar	POS	O
rats	POS	O
.	POS	O
Quinine	POS	O
is	POS	O
known	POS	O
to	POS	O
block	POS	O
voltage	POS	O
-	POS	O
,	POS	O
calcium	POS	O
-	POS	O
and	POS	O
ATP	POS	O
-	POS	O
sensitive	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
channels	POS	O
while	POS	O
4	POS	O
-	POS	O
aminopyridine	POS	O
is	POS	O
known	POS	O
to	POS	O
block	POS	O
voltage	POS	O
-	POS	O
sensitive	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
channels	POS	O
.	POS	O
2	POS	O
.	POS	O
In	POS	O
the	POS	O
counterbalanced	POS	O
method	POS	O
,	POS	O
quinine	POS	O
attenuated	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
place	POS	O
preference	POS	O
,	POS	O
whereas	POS	O
4	POS	O
-	POS	O
aminopyridine	POS	O
was	POS	O
ineffective	POS	O
.	POS	O
In	POS	O
the	POS	O
motor	POS	O
activity	POS	O
test	POS	O
measured	POS	O
with	POS	O
an	POS	O
Animex	POS	O
-	POS	O
activity	POS	O
meter	POS	O
neither	POS	O
of	POS	O
the	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
channel	POS	O
blockers	POS	O
affected	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
hypoactivity	POS	O
,	POS	O
but	POS	O
both	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
channel	POS	O
blockers	POS	O
prevented	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
secondary	POS	O
hyperactivity	POS	B-NP
.	POS	O
3	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
the	POS	O
involvement	POS	O
of	POS	O
quinine	POS	O
-	POS	O
sensitive	POS	O
but	POS	O
not	POS	O
4	POS	O
-	POS	O
aminopyridine	POS	O
-	POS	O
sensitive	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
channels	POS	O
in	POS	O
morphine	POS	O
reward	POS	O
.	POS	O
It	POS	O
is	POS	O
also	POS	O
suggested	POS	O
that	POS	O
the	POS	O
blockade	POS	O
of	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
channels	POS	O
sensitive	POS	O
to	POS	O
these	POS	O
blockers	POS	O
is	POS	O
not	POS	O
sufficient	POS	O
to	POS	O
prevent	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
hypoactivity	POS	O
whereas	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
seems	POS	O
to	POS	O
be	POS	O
connected	POS	O
to	POS	O
both	POS	O
quinine	POS	O
-	POS	O
and	POS	O
4	POS	O
-	POS	O
aminopyridine	POS	O
-	POS	O
sensitive	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
channels	POS	O
.	POS	O
Nociceptin	POS	O
/	POS	O
orphanin	POS	O
FQ	POS	O
and	POS	O
nocistatin	POS	O
on	POS	O
learning	POS	O
and	POS	O
memory	POS	B-NP
impairment	POS	I-NP
induced	POS	O
by	POS	O
scopolamine	POS	O
in	POS	O
mice	POS	O
.	POS	O
1	POS	O
.	POS	O
Nociceptin	POS	O
,	POS	O
also	POS	O
known	POS	O
as	POS	O
orphanin	POS	O
FQ	POS	O
,	POS	O
is	POS	O
an	POS	O
endogenous	POS	O
ligand	POS	O
for	POS	O
the	POS	O
orphan	POS	O
opioid	POS	O
receptor	POS	O
-	POS	O
like	POS	O
receptor	POS	O
1	POS	O
(	POS	O
ORL1	POS	O
)	POS	O
and	POS	O
involves	POS	O
in	POS	O
various	POS	O
functions	POS	O
in	POS	O
the	POS	O
central	POS	O
nervous	POS	O
system	POS	O
(	POS	O
CNS	POS	O
)	POS	O
.	POS	O
On	POS	O
the	POS	O
other	POS	O
hand	POS	O
,	POS	O
nocistatin	POS	O
is	POS	O
recently	POS	O
isolated	POS	O
from	POS	O
the	POS	O
same	POS	O
precursor	POS	O
as	POS	O
nociceptin	POS	O
and	POS	O
blocks	POS	O
nociceptin	POS	O
-	POS	O
induced	POS	O
allodynia	POS	B-NP
and	POS	O
hyperalgesia	POS	B-NP
.	POS	O
2	POS	O
.	POS	O
Although	POS	O
ORL1	POS	O
receptors	POS	O
which	POS	O
display	POS	O
a	POS	O
high	POS	O
degree	POS	O
of	POS	O
sequence	POS	O
homology	POS	O
with	POS	O
classical	POS	O
opioid	POS	O
receptors	POS	O
are	POS	O
abundant	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
,	POS	O
little	POS	O
is	POS	O
known	POS	O
regarding	POS	O
their	POS	O
role	POS	O
in	POS	O
learning	POS	O
and	POS	O
memory	POS	O
.	POS	O
3	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
was	POS	O
designed	POS	O
to	POS	O
investigate	POS	O
whether	POS	O
nociceptin	POS	O
/	POS	O
orphanin	POS	O
FQ	POS	O
and	POS	O
nocistatin	POS	O
could	POS	O
modulate	POS	O
impairment	POS	O
of	POS	O
learning	POS	O
and	POS	O
memory	POS	O
induced	POS	O
by	POS	O
scopolamine	POS	O
,	POS	O
a	POS	O
muscarinic	POS	O
cholinergic	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
using	POS	O
spontaneous	POS	O
alternation	POS	O
of	POS	O
Y	POS	O
-	POS	O
maze	POS	O
and	POS	O
step	POS	O
-	POS	O
down	POS	O
type	POS	O
passive	POS	O
avoidance	POS	O
tasks	POS	O
in	POS	O
mice	POS	O
.	POS	O
4	POS	O
.	POS	O
While	POS	O
nocistatin	POS	O
(	POS	O
0	POS	O
.	POS	O
5	POS	O
-	POS	O
5	POS	O
.	POS	O
0	POS	O
nmol	POS	O
mouse	POS	O
-	POS	O
1	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
administered	POS	O
30	POS	O
min	POS	O
before	POS	O
spontaneous	POS	O
alternation	POS	O
performance	POS	O
or	POS	O
the	POS	O
training	POS	O
session	POS	O
of	POS	O
the	POS	O
passive	POS	O
avoidance	POS	O
task	POS	O
,	POS	O
had	POS	O
no	POS	O
effect	POS	O
on	POS	O
spontaneous	POS	O
alternation	POS	O
or	POS	O
passive	POS	O
avoidance	POS	O
behaviours	POS	O
,	POS	O
a	POS	O
lower	POS	O
per	POS	O
cent	POS	O
alternation	POS	O
and	POS	O
shorter	POS	O
median	POS	O
step	POS	O
-	POS	O
down	POS	O
latency	POS	O
in	POS	O
the	POS	O
retention	POS	O
test	POS	O
were	POS	O
obtained	POS	O
in	POS	O
nociceptin	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
and	POS	O
/	POS	O
or	POS	O
5	POS	O
.	POS	O
0	POS	O
nmol	POS	O
mouse	POS	O
-	POS	O
1	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
-	POS	O
treated	POS	O
normal	POS	O
mice	POS	O
.	POS	O
5	POS	O
.	POS	O
Administration	POS	O
of	POS	O
nocistatin	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
and	POS	O
/	POS	O
or	POS	O
5	POS	O
.	POS	O
0	POS	O
nmol	POS	O
mouse	POS	O
-	POS	O
1	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
30	POS	O
min	POS	O
before	POS	O
spontaneous	POS	O
alternation	POS	O
performance	POS	O
or	POS	O
the	POS	O
training	POS	O
session	POS	O
of	POS	O
the	POS	O
passive	POS	O
avoidance	POS	O
task	POS	O
,	POS	O
attenuated	POS	O
the	POS	O
scopolamine	POS	O
-	POS	O
induced	POS	O
impairment	POS	O
of	POS	O
spontaneous	POS	O
alternation	POS	O
and	POS	O
passive	POS	O
avoidance	POS	O
behaviours	POS	O
.	POS	O
6	POS	O
.	POS	O
These	POS	O
results	POS	O
indicated	POS	O
that	POS	O
nocistatin	POS	O
,	POS	O
a	POS	O
new	POS	O
biologically	POS	O
active	POS	O
peptide	POS	O
,	POS	O
ameliorates	POS	O
impairments	POS	O
of	POS	O
spontaneous	POS	O
alternation	POS	O
and	POS	O
passive	POS	O
avoidance	POS	O
induced	POS	O
by	POS	O
scopolamine	POS	O
,	POS	O
and	POS	O
suggested	POS	O
that	POS	O
these	POS	O
peptides	POS	O
play	POS	O
opposite	POS	O
roles	POS	O
in	POS	O
learning	POS	O
and	POS	O
memory	POS	O
.	POS	O
Meloxicam	POS	O
-	POS	O
induced	POS	O
liver	POS	B-NP
toxicity	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
female	POS	O
patient	POS	O
with	POS	O
rheumatoid	POS	B-NP
arthritis	POS	I-NP
who	POS	O
developed	POS	O
acute	POS	B-NP
cytolytic	POS	I-NP
hepatitis	POS	I-NP
due	POS	O
to	POS	O
meloxicam	POS	O
.	POS	O
Recently	POS	O
introduced	POS	O
in	POS	O
Belgium	POS	O
,	POS	O
meloxicam	POS	O
is	POS	O
the	POS	O
first	POS	O
nonsteroidal	POS	O
antiinflammatory	POS	O
drug	POS	O
with	POS	O
selective	POS	O
action	POS	O
on	POS	O
the	POS	O
inducible	POS	O
form	POS	O
of	POS	O
cyclooxygenase	POS	O
2	POS	O
.	POS	O
The	POS	O
acute	POS	O
cytolytic	POS	B-NP
hepatitis	POS	I-NP
occurred	POS	O
rapidly	POS	O
after	POS	O
meloxicam	POS	O
administration	POS	O
and	POS	O
was	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
antinuclear	POS	O
antibodies	POS	O
suggesting	POS	O
a	POS	O
hypersensitivity	POS	B-NP
mechanism	POS	O
.	POS	O
This	POS	O
first	POS	O
case	POS	O
of	POS	O
meloxicam	POS	O
related	POS	O
liver	POS	B-NP
toxicity	POS	I-NP
demonstrates	POS	O
the	POS	O
potential	POS	O
of	POS	O
this	POS	O
drug	POS	O
to	POS	O
induce	POS	O
hepatic	POS	B-NP
damage	POS	I-NP
.	POS	O
Induction	POS	O
of	POS	O
apoptosis	POS	O
by	POS	O
remoxipride	POS	O
metabolites	POS	O
in	POS	O
HL60	POS	O
and	POS	O
CD34	POS	O
+	POS	O
/	POS	O
CD19	POS	O
-	POS	O
human	POS	O
bone	POS	O
marrow	POS	O
progenitor	POS	O
cells	POS	O
:	POS	O
potential	POS	O
relevance	POS	O
to	POS	O
remoxipride	POS	O
-	POS	O
induced	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
.	POS	O
The	POS	O
antipsychotic	POS	O
agent	POS	O
,	POS	O
remoxipride	POS	O
[	POS	O
(	POS	O
S	POS	O
)	POS	O
-	POS	O
(	POS	O
-	POS	O
)	POS	O
-	POS	O
3	POS	O
-	POS	O
bromo	POS	O
-	POS	O
N	POS	O
-	POS	O
[	POS	O
(	POS	O
1	POS	O
-	POS	O
ethyl	POS	O
-	POS	O
2	POS	O
-	POS	O
pyrrolidinyl	POS	O
)	POS	O
methyl	POS	O
]	POS	O
-	POS	O
2	POS	O
,	POS	O
6	POS	O
-	POS	O
dimethoxybenz	POS	O
amide	POS	O
]	POS	O
has	POS	O
been	POS	O
associated	POS	O
with	POS	O
acquired	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
.	POS	O
We	POS	O
have	POS	O
examined	POS	O
the	POS	O
ability	POS	O
of	POS	O
remoxipride	POS	O
,	POS	O
three	POS	O
pyrrolidine	POS	O
ring	POS	O
metabolites	POS	O
and	POS	O
five	POS	O
aromatic	POS	O
ring	POS	O
metabolites	POS	O
of	POS	O
the	POS	O
parent	POS	O
compound	POS	O
to	POS	O
induce	POS	O
apoptosis	POS	O
in	POS	O
HL60	POS	O
cells	POS	O
and	POS	O
human	POS	O
bone	POS	O
marrow	POS	O
progenitor	POS	O
(	POS	O
HBMP	POS	O
)	POS	O
cells	POS	O
.	POS	O
Cells	POS	O
were	POS	O
treated	POS	O
for	POS	O
0	POS	O
-	POS	O
24	POS	O
h	POS	O
with	POS	O
each	POS	O
compound	POS	O
(	POS	O
0	POS	O
-	POS	O
200	POS	O
microM	POS	O
)	POS	O
.	POS	O
Apoptosis	POS	O
was	POS	O
assessed	POS	O
by	POS	O
fluorescence	POS	O
microscopy	POS	O
in	POS	O
Hoechst	POS	O
33342	POS	O
-	POS	O
and	POS	O
propidium	POS	O
iodide	POS	O
stained	POS	O
cell	POS	O
samples	POS	O
.	POS	O
Results	POS	O
were	POS	O
confirmed	POS	O
by	POS	O
determination	POS	O
of	POS	O
internucleosomal	POS	O
DNA	POS	O
fragmentation	POS	O
using	POS	O
gel	POS	O
electrophoresis	POS	O
for	POS	O
HL60	POS	O
cell	POS	O
samples	POS	O
and	POS	O
terminal	POS	O
deoxynucleotidyl	POS	O
transferase	POS	O
assay	POS	O
in	POS	O
HBMP	POS	O
cells	POS	O
.	POS	O
The	POS	O
catechol	POS	O
and	POS	O
hydroquinone	POS	O
metabolites	POS	O
,	POS	O
NCQ436	POS	O
and	POS	O
NCQ344	POS	O
,	POS	O
induced	POS	O
apoptosis	POS	O
in	POS	O
HL60	POS	O
and	POS	O
HBMP	POS	O
cells	POS	O
in	POS	O
a	POS	O
time	POS	O
-	POS	O
and	POS	O
concentration	POS	O
dependent	POS	O
manner	POS	O
,	POS	O
while	POS	O
the	POS	O
phenols	POS	O
,	POS	O
NCR181	POS	O
,	POS	O
FLA873	POS	O
,	POS	O
and	POS	O
FLA797	POS	O
,	POS	O
and	POS	O
the	POS	O
derivatives	POS	O
formed	POS	O
by	POS	O
oxidation	POS	O
of	POS	O
the	POS	O
pyrrolidine	POS	O
ring	POS	O
,	POS	O
FLA838	POS	O
,	POS	O
NCM001	POS	O
,	POS	O
and	POS	O
NCL118	POS	O
,	POS	O
had	POS	O
no	POS	O
effect	POS	O
.	POS	O
No	POS	O
necrosis	POS	B-NP
was	POS	O
observed	POS	O
in	POS	O
cells	POS	O
treated	POS	O
with	POS	O
NCQ436	POS	O
but	POS	O
NCQ344	POS	O
had	POS	O
a	POS	O
biphasic	POS	O
effect	POS	O
in	POS	O
both	POS	O
cell	POS	O
types	POS	O
,	POS	O
inducing	POS	O
apoptosis	POS	O
at	POS	O
lower	POS	O
concentrations	POS	O
and	POS	O
necrosis	POS	B-NP
at	POS	O
higher	POS	O
concentrations	POS	O
.	POS	O
These	POS	O
data	POS	O
show	POS	O
that	POS	O
the	POS	O
catechol	POS	O
and	POS	O
hydroquinone	POS	O
metabolites	POS	O
of	POS	O
remoxipride	POS	O
have	POS	O
direct	POS	O
toxic	POS	O
effects	POS	O
in	POS	O
HL60	POS	O
and	POS	O
HBMP	POS	O
cells	POS	O
,	POS	O
leading	POS	O
to	POS	O
apoptosis	POS	O
,	POS	O
while	POS	O
the	POS	O
phenol	POS	O
metabolites	POS	O
were	POS	O
inactive	POS	O
.	POS	O
Similarly	POS	O
,	POS	O
benzene	POS	O
-	POS	O
derived	POS	O
catechol	POS	O
and	POS	O
hydroquinone	POS	O
,	POS	O
but	POS	O
not	POS	O
phenol	POS	O
,	POS	O
induce	POS	O
apoptosis	POS	O
in	POS	O
HBMP	POS	O
cells	POS	O
[	POS	O
Moran	POS	O
et	POS	O
al	POS	O
.	POS	O
,	POS	O
Mol	POS	O
.	POS	O
Pharmacol	POS	O
.	POS	O
,	POS	O
50	POS	O
(	POS	O
1996	POS	O
)	POS	O
610	POS	O
-	POS	O
615	POS	O
]	POS	O
.	POS	O
We	POS	O
propose	POS	O
that	POS	O
remoxipride	POS	O
and	POS	O
benzene	POS	O
may	POS	O
induce	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
via	POS	O
production	POS	O
of	POS	O
similar	POS	O
reactive	POS	O
metabolites	POS	O
and	POS	O
that	POS	O
the	POS	O
ability	POS	O
of	POS	O
NCQ436	POS	O
and	POS	O
NCQ344	POS	O
to	POS	O
induce	POS	O
apoptosis	POS	O
in	POS	O
HBMP	POS	O
cells	POS	O
may	POS	O
contribute	POS	O
to	POS	O
the	POS	O
mechanism	POS	O
underlying	POS	O
acquired	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
that	POS	O
has	POS	O
been	POS	O
associated	POS	O
with	POS	O
remoxipride	POS	O
.	POS	O
Synthesis	POS	O
and	POS	O
preliminary	POS	O
pharmacological	POS	O
investigations	POS	O
of	POS	O
1	POS	O
-	POS	O
(	POS	O
1	POS	O
,	POS	O
2	POS	O
-	POS	O
dihydro	POS	O
-	POS	O
2	POS	O
-	POS	O
acenaphthylenyl	POS	O
)	POS	O
piperazine	POS	O
derivatives	POS	O
as	POS	O
potential	POS	O
atypical	POS	O
antipsychotic	POS	O
agents	POS	O
in	POS	O
mice	POS	O
.	POS	O
In	POS	O
research	POS	O
towards	POS	O
the	POS	O
development	POS	O
of	POS	O
new	POS	O
atypical	POS	O
antipsychotic	POS	O
agents	POS	O
,	POS	O
one	POS	O
strategy	POS	O
is	POS	O
that	POS	O
the	POS	O
dopaminergic	POS	O
system	POS	O
can	POS	O
be	POS	O
modulated	POS	O
through	POS	O
manipulation	POS	O
of	POS	O
the	POS	O
serotonergic	POS	O
system	POS	O
.	POS	O
The	POS	O
synthesis	POS	O
and	POS	O
preliminary	POS	O
pharmacological	POS	O
evaluation	POS	O
of	POS	O
a	POS	O
series	POS	O
of	POS	O
potential	POS	O
atypical	POS	O
antipsychotic	POS	O
agents	POS	O
based	POS	O
on	POS	O
the	POS	O
structure	POS	O
of	POS	O
1	POS	O
-	POS	O
(	POS	O
1	POS	O
,	POS	O
2	POS	O
-	POS	O
dihydro	POS	O
-	POS	O
2	POS	O
-	POS	O
acenaphthylenyl	POS	O
)	POS	O
piperazine	POS	O
(	POS	O
7	POS	O
)	POS	O
is	POS	O
described	POS	O
.	POS	O
Compound	POS	O
7e	POS	O
,	POS	O
5	POS	O
-	POS	O
{	POS	O
2	POS	O
-	POS	O
[	POS	O
4	POS	O
-	POS	O
(	POS	O
1	POS	O
,	POS	O
2	POS	O
-	POS	O
dihydro	POS	O
-	POS	O
2	POS	O
-	POS	O
acenaphthylenyl	POS	O
)	POS	O
piperazinyl	POS	O
]	POS	O
ethyl	POS	O
}	POS	O
-	POS	O
2	POS	O
,	POS	O
3	POS	O
-	POS	O
dihy	POS	O
dro	POS	O
-	POS	O
1H	POS	O
-	POS	O
indol	POS	O
-	POS	O
2	POS	O
-	POS	O
one	POS	O
,	POS	O
from	POS	O
this	POS	O
series	POS	O
showed	POS	O
significant	POS	O
affinities	POS	O
at	POS	O
the	POS	O
5	POS	O
-	POS	O
HT1A	POS	O
and	POS	O
5	POS	O
-	POS	O
HT2A	POS	O
receptors	POS	O
and	POS	O
moderate	POS	O
affinity	POS	O
at	POS	O
the	POS	O
D2	POS	O
receptor	POS	O
.	POS	O
7e	POS	O
exhibits	POS	O
a	POS	O
high	POS	O
reversal	POS	O
of	POS	O
catalepsy	POS	B-NP
induced	POS	O
by	POS	O
haloperidol	POS	O
indicating	POS	O
its	POS	O
atypical	POS	O
antipsychotic	POS	O
nature	POS	O
.	POS	O
Sub	POS	O
-	POS	O
chronic	POS	O
inhibition	POS	O
of	POS	O
nitric	POS	O
-	POS	O
oxide	POS	O
synthesis	POS	O
modifies	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
and	POS	O
the	POS	O
number	POS	O
of	POS	O
NADPH	POS	O
-	POS	O
diaphorase	POS	O
neurons	POS	O
in	POS	O
mice	POS	O
.	POS	O
RATIONALE	POS	O
:	POS	O
NG	POS	O
-	POS	O
nitro	POS	O
-	POS	O
L	POS	O
-	POS	O
arginine	POS	O
(	POS	O
L	POS	O
-	POS	O
NOARG	POS	O
)	POS	O
,	POS	O
an	POS	O
inhibitor	POS	O
of	POS	O
nitric	POS	O
-	POS	O
oxide	POS	O
synthase	POS	O
(	POS	O
NOS	POS	O
)	POS	O
,	POS	O
induces	POS	O
catalepsy	POS	B-NP
in	POS	O
mice	POS	O
.	POS	O
This	POS	O
effect	POS	O
undergoes	POS	O
rapid	POS	O
tolerance	POS	O
,	POS	O
showing	POS	O
a	POS	O
significant	POS	O
decrease	POS	O
after	POS	O
2	POS	O
days	POS	O
of	POS	O
sub	POS	O
-	POS	O
chronic	POS	O
L	POS	O
-	POS	O
NOARG	POS	O
treatment	POS	O
.	POS	O
Nitric	POS	O
oxide	POS	O
(	POS	O
NO	POS	O
)	POS	O
has	POS	O
been	POS	O
shown	POS	O
to	POS	O
influence	POS	O
dopaminergic	POS	O
neurotransmission	POS	O
in	POS	O
the	POS	O
striatum	POS	O
.	POS	O
Neuroleptic	POS	B-NP
drugs	POS	O
such	POS	O
as	POS	O
haloperidol	POS	O
,	POS	O
which	POS	O
block	POS	O
dopamine	POS	O
receptors	POS	O
,	POS	O
also	POS	O
cause	POS	O
catalepsy	POS	B-NP
in	POS	O
rodents	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
To	POS	O
investigate	POS	O
the	POS	O
effects	POS	O
of	POS	O
subchronic	POS	O
L	POS	O
-	POS	O
NOARG	POS	O
treatment	POS	O
in	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
and	POS	O
the	POS	O
number	POS	O
of	POS	O
NOS	POS	O
neurons	POS	O
in	POS	O
areas	POS	O
related	POS	O
to	POS	O
motor	POS	O
control	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Male	POS	O
albino	POS	O
Swiss	POS	O
mice	POS	O
were	POS	O
treated	POS	O
sub	POS	O
-	POS	O
chronically	POS	O
(	POS	O
twice	POS	O
a	POS	O
day	POS	O
for	POS	O
4	POS	O
days	POS	O
)	POS	O
with	POS	O
L	POS	O
-	POS	O
NOARG	POS	O
(	POS	O
40	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
or	POS	O
haloperidol	POS	O
(	POS	O
1	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
.	POS	O
Catalepsy	POS	B-NP
was	POS	O
evaluated	POS	O
at	POS	O
the	POS	O
beginning	POS	O
and	POS	O
the	POS	O
end	POS	O
of	POS	O
the	POS	O
treatments	POS	O
.	POS	O
Reduced	POS	O
nicotinamide	POS	O
adenine	POS	O
dinucleotide	POS	O
phosphate	POS	O
-	POS	O
diaphorase	POS	O
(	POS	O
NADPH	POS	O
-	POS	O
d	POS	O
)	POS	O
histochemistry	POS	O
was	POS	O
also	POS	O
employed	POS	O
to	POS	O
visualize	POS	O
NOS	POS	O
as	POS	O
an	POS	O
index	POS	O
of	POS	O
enzyme	POS	O
expression	POS	O
in	POS	O
mice	POS	O
brain	POS	O
regions	POS	O
related	POS	O
to	POS	O
motor	POS	O
control	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
L	POS	O
-	POS	O
NOARG	POS	O
sub	POS	O
-	POS	O
chronic	POS	O
administration	POS	O
produced	POS	O
tolerance	POS	O
of	POS	O
L	POS	O
-	POS	O
NOARG	POS	O
and	POS	O
of	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
.	POS	O
It	POS	O
also	POS	O
induced	POS	O
an	POS	O
increase	POS	O
in	POS	O
the	POS	O
number	POS	O
of	POS	O
NADPH	POS	O
-	POS	O
d	POS	O
-	POS	O
positive	POS	O
cells	POS	O
in	POS	O
the	POS	O
dorsal	POS	O
part	POS	O
of	POS	O
the	POS	O
caudate	POS	O
and	POS	O
accumbens	POS	O
nuclei	POS	O
compared	POS	O
with	POS	O
haloperidol	POS	O
and	POS	O
in	POS	O
the	POS	O
pedunculopontine	POS	O
tegmental	POS	O
nucleus	POS	O
compared	POS	O
with	POS	O
saline	POS	O
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
there	POS	O
was	POS	O
a	POS	O
decrease	POS	O
in	POS	O
NADPH	POS	O
-	POS	O
d	POS	O
neuron	POS	O
number	POS	O
in	POS	O
the	POS	O
substantia	POS	O
nigra	POS	O
,	POS	O
pars	POS	O
compacta	POS	O
in	POS	O
both	POS	O
haloperidol	POS	O
-	POS	O
treated	POS	O
and	POS	O
L	POS	O
-	POS	O
NOARG	POS	O
-	POS	O
treated	POS	O
animals	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
results	POS	O
give	POS	O
further	POS	O
support	POS	O
to	POS	O
the	POS	O
hypothesis	POS	O
that	POS	O
NO	POS	O
plays	POS	O
a	POS	O
role	POS	O
in	POS	O
motor	POS	O
behavior	POS	O
control	POS	O
and	POS	O
suggest	POS	O
that	POS	O
it	POS	O
may	POS	O
take	POS	O
part	POS	O
in	POS	O
the	POS	O
synaptic	POS	O
changes	POS	O
produced	POS	O
by	POS	O
antipsychotic	POS	O
treatment	POS	O
.	POS	O
Prolonged	POS	O
left	POS	O
ventricular	POS	B-NP
dysfunction	POS	I-NP
occurs	POS	O
in	POS	O
patients	POS	O
with	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
after	POS	O
both	POS	O
dobutamine	POS	O
and	POS	O
exercise	POS	O
induced	POS	O
myocardial	POS	B-NP
ischaemia	POS	I-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
determine	POS	O
whether	POS	O
pharmacological	POS	O
stress	POS	O
leads	POS	O
to	POS	O
prolonged	POS	O
but	POS	O
reversible	POS	O
left	POS	O
ventricular	POS	B-NP
dysfunction	POS	I-NP
in	POS	O
patients	POS	O
with	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
,	POS	O
similar	POS	O
to	POS	O
that	POS	O
seen	POS	O
after	POS	O
exercise	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
A	POS	O
randomised	POS	O
crossover	POS	O
study	POS	O
of	POS	O
recovery	POS	O
time	POS	O
of	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
left	POS	O
ventricular	POS	O
function	POS	O
after	POS	O
exercise	POS	O
and	POS	O
dobutamine	POS	O
induced	POS	O
ischaemia	POS	B-NP
.	POS	O
SUBJECTS	POS	O
:	POS	O
10	POS	O
patients	POS	O
with	POS	O
stable	POS	O
angina	POS	B-NP
,	POS	O
angiographically	POS	B-NP
proven	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
,	POS	O
and	POS	O
normal	POS	B-NP
left	POS	I-NP
ventricular	POS	I-NP
function	POS	I-NP
.	POS	O
INTERVENTIONS	POS	O
:	POS	O
Treadmill	POS	O
exercise	POS	O
and	POS	O
dobutamine	POS	O
stress	POS	O
were	POS	O
performed	POS	O
on	POS	O
different	POS	O
days	POS	O
.	POS	O
Quantitative	POS	O
assessment	POS	O
of	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
left	POS	O
ventricular	POS	O
function	POS	O
was	POS	O
performed	POS	O
using	POS	O
transthoracic	POS	O
echocardiography	POS	O
at	POS	O
baseline	POS	O
and	POS	O
at	POS	O
regular	POS	O
intervals	POS	O
after	POS	O
each	POS	O
test	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Both	POS	O
forms	POS	O
of	POS	O
stress	POS	O
led	POS	O
to	POS	O
prolonged	POS	O
but	POS	O
reversible	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
There	POS	O
was	POS	O
no	POS	O
difference	POS	O
in	POS	O
the	POS	O
maximum	POS	O
double	POS	O
product	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
53	POS	O
)	POS	O
or	POS	O
ST	POS	B-NP
depression	POS	I-NP
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
63	POS	O
)	POS	O
with	POS	O
either	POS	O
form	POS	O
of	POS	O
stress	POS	O
.	POS	O
After	POS	O
exercise	POS	O
,	POS	O
ejection	POS	O
fraction	POS	O
was	POS	O
reduced	POS	O
at	POS	O
15	POS	O
and	POS	O
30	POS	O
minutes	POS	O
compared	POS	O
with	POS	O
baseline	POS	O
(	POS	O
mean	POS	O
(	POS	O
SEM	POS	O
)	POS	O
,	POS	O
-	POS	O
5	POS	O
.	POS	O
6	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
)	POS	O
%	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
;	POS	O
and	POS	O
-	POS	O
6	POS	O
.	POS	O
1	POS	O
(	POS	O
2	POS	O
.	POS	O
2	POS	O
)	POS	O
%	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
and	POS	O
at	POS	O
30	POS	O
and	POS	O
45	POS	O
minutes	POS	O
after	POS	O
dobutamine	POS	O
(	POS	O
-	POS	O
10	POS	O
.	POS	O
8	POS	O
(	POS	O
1	POS	O
.	POS	O
8	POS	O
)	POS	O
%	POS	O
and	POS	O
-	POS	O
5	POS	O
.	POS	O
5	POS	O
(	POS	O
1	POS	O
.	POS	O
8	POS	O
)	POS	O
%	POS	O
,	POS	O
both	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Regional	POS	O
analysis	POS	O
showed	POS	O
a	POS	O
reduction	POS	O
in	POS	O
the	POS	O
worst	POS	O
affected	POS	O
segment	POS	O
15	POS	O
and	POS	O
30	POS	O
minutes	POS	O
after	POS	O
exercise	POS	O
(	POS	O
-	POS	O
27	POS	O
.	POS	O
9	POS	O
(	POS	O
7	POS	O
.	POS	O
2	POS	O
)	POS	O
%	POS	O
and	POS	O
-	POS	O
28	POS	O
.	POS	O
6	POS	O
(	POS	O
5	POS	O
.	POS	O
7	POS	O
)	POS	O
%	POS	O
,	POS	O
both	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
and	POS	O
at	POS	O
30	POS	O
minutes	POS	O
after	POS	O
dobutamine	POS	O
(	POS	O
-	POS	O
32	POS	O
(	POS	O
5	POS	O
.	POS	O
3	POS	O
)	POS	O
%	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
The	POS	O
isovolumic	POS	O
relaxation	POS	O
period	POS	O
was	POS	O
prolonged	POS	O
45	POS	O
minutes	POS	O
after	POS	O
each	POS	O
form	POS	O
of	POS	O
stress	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
In	POS	O
patients	POS	O
with	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
,	POS	O
dobutamine	POS	O
induced	POS	O
ischaemia	POS	B-NP
results	POS	O
in	POS	O
prolonged	POS	O
reversible	POS	O
left	POS	O
ventricular	POS	B-NP
dysfunction	POS	I-NP
,	POS	O
presumed	POS	O
to	POS	O
be	POS	O
myocardial	POS	B-NP
stunning	POS	I-NP
,	POS	O
similar	POS	O
to	POS	O
that	POS	O
seen	POS	O
after	POS	O
exercise	POS	O
.	POS	O
Dobutamine	POS	O
induced	POS	O
ischaemia	POS	B-NP
could	POS	O
therefore	POS	O
be	POS	O
used	POS	O
to	POS	O
study	POS	O
the	POS	O
pathophysiology	POS	O
of	POS	O
this	POS	O
phenomenon	POS	O
further	POS	O
in	POS	O
patients	POS	O
with	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
.	POS	O
Anorexigens	POS	O
and	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
in	POS	O
the	POS	O
United	POS	O
States	POS	O
:	POS	O
results	POS	O
from	POS	O
the	POS	O
surveillance	POS	O
of	POS	O
North	POS	O
American	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
The	POS	O
use	POS	O
of	POS	O
appetite	POS	O
suppressants	POS	O
in	POS	O
Europe	POS	O
has	POS	O
been	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
primary	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
(	POS	O
PPH	POS	B-NP
)	POS	O
.	POS	O
Recently	POS	O
,	POS	O
fenfluramine	POS	O
appetite	POS	O
suppressants	POS	O
became	POS	O
widely	POS	O
used	POS	O
in	POS	O
the	POS	O
United	POS	O
States	POS	O
but	POS	O
were	POS	O
withdrawn	POS	O
in	POS	O
September	POS	O
1997	POS	O
because	POS	O
of	POS	O
concerns	POS	O
over	POS	O
adverse	POS	O
effects	POS	O
.	POS	O
MATERIALS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
conducted	POS	O
a	POS	O
prospective	POS	O
surveillance	POS	O
study	POS	O
on	POS	O
patients	POS	O
diagnosed	POS	O
with	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
at	POS	O
12	POS	O
large	POS	O
referral	POS	O
centers	POS	O
in	POS	O
North	POS	O
America	POS	O
.	POS	O
Data	POS	O
collected	POS	O
on	POS	O
patients	POS	O
seen	POS	O
from	POS	O
September	POS	O
1	POS	O
,	POS	O
1996	POS	O
,	POS	O
to	POS	O
December	POS	O
31	POS	O
,	POS	O
1997	POS	O
,	POS	O
included	POS	O
the	POS	O
cause	POS	O
of	POS	O
the	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
and	POS	O
its	POS	O
severity	POS	O
.	POS	O
Patients	POS	O
with	POS	O
no	POS	O
identifiable	POS	O
cause	POS	O
of	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
were	POS	O
classed	POS	O
as	POS	O
PPH	POS	B-NP
.	POS	O
A	POS	O
history	POS	O
of	POS	O
drug	POS	O
exposure	POS	O
also	POS	O
was	POS	O
taken	POS	O
with	POS	O
special	POS	O
attention	POS	O
on	POS	O
the	POS	O
use	POS	O
of	POS	O
antidepressants	POS	O
,	POS	O
anorexigens	POS	O
,	POS	O
and	POS	O
amphetamines	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Five	POS	O
hundred	POS	O
seventy	POS	O
-	POS	O
nine	POS	O
patients	POS	O
were	POS	O
studied	POS	O
,	POS	O
205	POS	O
with	POS	O
PPH	POS	B-NP
and	POS	O
374	POS	O
with	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
from	POS	O
other	POS	O
causes	POS	O
(	POS	O
secondary	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
[	POS	O
SPH	POS	O
]	POS	O
)	POS	O
.	POS	O
The	POS	O
use	POS	O
of	POS	O
anorexigens	POS	O
was	POS	O
common	POS	O
in	POS	O
both	POS	O
groups	POS	O
.	POS	O
However	POS	O
,	POS	O
of	POS	O
the	POS	O
medications	POS	O
surveyed	POS	O
,	POS	O
only	POS	O
the	POS	O
fenfluramines	POS	O
had	POS	O
a	POS	O
significant	POS	O
preferential	POS	O
association	POS	O
with	POS	O
PPH	POS	B-NP
as	POS	O
compared	POS	O
with	POS	O
SPH	POS	B-NP
(	POS	O
adjusted	POS	O
odds	POS	O
ratio	POS	O
for	POS	O
use	POS	O
>	POS	O
6	POS	O
months	POS	O
,	POS	O
7	POS	O
.	POS	O
5	POS	O
;	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
,	POS	O
1	POS	O
.	POS	O
7	POS	O
to	POS	O
32	POS	O
.	POS	O
4	POS	O
)	POS	O
.	POS	O
The	POS	O
association	POS	O
was	POS	O
stronger	POS	O
with	POS	O
longer	POS	O
duration	POS	O
of	POS	O
use	POS	O
when	POS	O
compared	POS	O
to	POS	O
shorter	POS	O
duration	POS	O
of	POS	O
use	POS	O
and	POS	O
was	POS	O
more	POS	O
pronounced	POS	O
in	POS	O
recent	POS	O
users	POS	O
than	POS	O
in	POS	O
remote	POS	O
users	POS	O
.	POS	O
An	POS	O
unexpectedly	POS	O
high	POS	O
(	POS	O
11	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
number	POS	O
of	POS	O
patients	POS	O
with	POS	O
SPH	POS	B-NP
had	POS	O
used	POS	O
anorexigens	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
magnitude	POS	O
of	POS	O
the	POS	O
association	POS	O
with	POS	O
PPH	POS	B-NP
,	POS	O
the	POS	O
increase	POS	O
of	POS	O
association	POS	O
with	POS	O
increasing	POS	O
duration	POS	O
of	POS	O
use	POS	O
,	POS	O
and	POS	O
the	POS	O
specificity	POS	O
for	POS	O
fenfluramines	POS	O
are	POS	O
consistent	POS	O
with	POS	O
previous	POS	O
studies	POS	O
indicating	POS	O
that	POS	O
fenfluramines	POS	O
are	POS	O
causally	POS	O
related	POS	O
to	POS	O
PPH	POS	B-NP
.	POS	O
The	POS	O
high	POS	O
prevalence	POS	O
of	POS	O
anorexigen	POS	O
use	POS	O
in	POS	O
patients	POS	O
with	POS	O
SPH	POS	B-NP
also	POS	O
raises	POS	O
the	POS	O
possibility	POS	O
that	POS	O
these	POS	O
drugs	POS	O
precipitate	POS	O
pulmonary	POS	B-NP
hypertension	POS	I-NP
in	POS	O
patients	POS	O
with	POS	O
underlying	POS	O
conditions	POS	O
associated	POS	O
with	POS	O
SPH	POS	B-NP
.	POS	O
Clinical	POS	O
aspects	POS	O
of	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
and	POS	O
thrombosis	POS	B-NP
and	POS	O
other	POS	O
side	POS	O
effects	POS	O
of	POS	O
heparin	POS	O
therapy	POS	O
.	POS	O
Heparin	POS	O
,	POS	O
first	POS	O
used	POS	O
to	POS	O
prevent	POS	O
the	POS	O
clotting	POS	O
of	POS	O
blood	POS	O
in	POS	O
vitro	POS	O
,	POS	O
has	POS	O
been	POS	O
clinically	POS	O
used	POS	O
to	POS	O
treat	POS	O
thrombosis	POS	B-NP
for	POS	O
more	POS	O
than	POS	O
50	POS	O
years	POS	O
.	POS	O
Although	POS	O
several	POS	O
new	POS	O
anticoagulant	POS	O
drugs	POS	O
are	POS	O
in	POS	O
development	POS	O
,	POS	O
heparin	POS	O
remains	POS	O
the	POS	O
anticoagulant	POS	O
of	POS	O
choice	POS	O
to	POS	O
treat	POS	O
acute	POS	O
thrombotic	POS	B-NP
episodes	POS	O
.	POS	O
The	POS	O
clinical	POS	O
effects	POS	O
of	POS	O
heparin	POS	O
are	POS	O
meritorious	POS	O
,	POS	O
but	POS	O
side	POS	O
effects	POS	O
do	POS	O
exist	POS	O
.	POS	O
Bleeding	POS	O
is	POS	O
the	POS	O
primary	POS	O
untoward	POS	O
effect	POS	O
of	POS	O
heparin	POS	O
.	POS	O
Major	POS	O
bleeding	POS	B-NP
is	POS	O
of	POS	O
primary	POS	O
concern	POS	O
in	POS	O
patients	POS	O
receiving	POS	O
heparin	POS	O
therapy	POS	O
.	POS	O
However	POS	O
,	POS	O
additional	POS	O
important	POS	O
untoward	POS	O
effects	POS	O
of	POS	O
heparin	POS	O
therapy	POS	O
include	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
,	POS	O
heparin	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
osteoporosis	POS	I-NP
,	POS	O
eosinophilia	POS	B-NP
,	POS	O
skin	POS	B-NP
reactions	POS	I-NP
,	POS	O
allergic	POS	B-NP
reactions	POS	I-NP
other	POS	O
than	POS	O
thrombocytopenia	POS	B-NP
,	POS	O
alopecia	POS	B-NP
,	POS	O
transaminasemia	POS	B-NP
,	POS	O
hyperkalemia	POS	B-NP
,	POS	O
hypoaldosteronism	POS	B-NP
,	POS	O
and	POS	O
priapism	POS	B-NP
.	POS	O
These	POS	O
side	POS	O
effects	POS	O
are	POS	O
relatively	POS	O
rare	POS	O
in	POS	O
a	POS	O
given	POS	O
individual	POS	O
,	POS	O
but	POS	O
given	POS	O
the	POS	O
extremely	POS	O
widespread	POS	O
use	POS	O
of	POS	O
heparin	POS	O
,	POS	O
some	POS	O
are	POS	O
quite	POS	O
common	POS	O
,	POS	O
particularly	POS	O
HITT	POS	B-NP
and	POS	O
osteoporosis	POS	B-NP
.	POS	O
Although	POS	O
reasonable	POS	O
incidences	POS	O
of	POS	O
many	POS	O
of	POS	O
these	POS	O
side	POS	O
effects	POS	O
can	POS	O
be	POS	O
"	POS	O
softly	POS	O
"	POS	O
deduced	POS	O
from	POS	O
current	POS	O
reports	POS	O
dealing	POS	O
with	POS	O
unfractionated	POS	O
heparin	POS	O
,	POS	O
at	POS	O
present	POS	O
the	POS	O
incidences	POS	O
of	POS	O
these	POS	O
side	POS	O
effects	POS	O
with	POS	O
newer	POS	O
low	POS	O
molecular	POS	O
weight	POS	O
heparins	POS	O
appear	POS	O
to	POS	O
be	POS	O
much	POS	O
less	POS	O
common	POS	O
.	POS	O
However	POS	O
,	POS	O
only	POS	O
longer	POS	O
experience	POS	O
will	POS	O
more	POS	O
clearly	POS	O
define	POS	O
the	POS	O
incidence	POS	O
of	POS	O
each	POS	O
side	POS	O
effect	POS	O
with	POS	O
low	POS	O
molecular	POS	O
weight	POS	O
preparations	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
bilateral	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
in	POS	O
a	POS	O
patient	POS	O
on	POS	O
tacrolimus	POS	O
(	POS	O
FK506	POS	O
)	POS	O
therapy	POS	O
after	POS	O
liver	POS	O
transplantation	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
bilateral	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
in	POS	O
a	POS	O
patient	POS	O
receiving	POS	O
tacrolimus	POS	O
(	POS	O
FK	POS	O
506	POS	O
,	POS	O
Prograf	POS	O
;	POS	O
Fujisawa	POS	O
USA	POS	O
,	POS	O
Inc	POS	O
,	POS	O
Deerfield	POS	O
,	POS	O
Illinois	POS	O
)	POS	O
for	POS	O
immunosuppression	POS	O
after	POS	O
orthotropic	POS	O
liver	POS	O
transplantation	POS	O
.	POS	O
METHOD	POS	O
:	POS	O
Case	POS	O
report	POS	O
.	POS	O
In	POS	O
a	POS	O
58	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
receiving	POS	O
tacrolimus	POS	O
after	POS	O
orthotropic	POS	O
liver	POS	O
transplantation	POS	O
,	POS	O
serial	POS	O
neuro	POS	O
-	POS	O
ophthalmologic	POS	O
examinations	POS	O
and	POS	O
laboratory	POS	O
studies	POS	O
were	POS	O
performed	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
patient	POS	O
had	POS	O
episodic	POS	B-NP
deterioration	POS	I-NP
of	POS	I-NP
vision	POS	I-NP
in	POS	I-NP
both	POS	I-NP
eyes	POS	I-NP
,	POS	O
with	POS	O
clinical	POS	O
features	POS	O
resembling	POS	O
ischemic	POS	B-NP
optic	POS	I-NP
neuropathies	POS	I-NP
.	POS	O
Deterioration	POS	B-NP
of	POS	I-NP
vision	POS	I-NP
occurred	POS	O
despite	POS	O
discontinuation	POS	O
of	POS	O
the	POS	O
tacrolimus	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Tacrolimus	POS	O
and	POS	O
other	POS	O
immunosuppressive	POS	O
agents	POS	O
may	POS	O
be	POS	O
associated	POS	O
with	POS	O
optic	POS	B-NP
nerve	POS	I-NP
toxicity	POS	I-NP
.	POS	O
Hypercalcemia	POS	B-NP
,	POS	O
arrhythmia	POS	B-NP
,	POS	O
and	POS	O
mood	POS	O
stabilizers	POS	O
.	POS	O
Recent	POS	O
findings	POS	O
in	POS	O
a	POS	O
bipolar	POS	B-NP
patient	POS	O
receiving	POS	O
maintenance	POS	O
lithium	POS	O
therapy	POS	O
who	POS	O
developed	POS	O
hypercalcemia	POS	B-NP
and	POS	O
severe	POS	O
bradyarrhythmia	POS	B-NP
prompted	POS	O
the	POS	O
authors	POS	O
to	POS	O
conduct	POS	O
a	POS	O
retrospective	POS	O
study	POS	O
of	POS	O
bipolar	POS	B-NP
patients	POS	O
with	POS	O
lithium	POS	O
-	POS	O
associated	POS	O
hypercalcemia	POS	B-NP
.	POS	O
A	POS	O
printout	POS	O
of	POS	O
all	POS	O
cases	POS	O
of	POS	O
hypercalcemia	POS	B-NP
that	POS	O
presented	POS	O
during	POS	O
a	POS	O
1	POS	O
-	POS	O
year	POS	O
period	POS	O
was	POS	O
generated	POS	O
.	POS	O
After	POS	O
eliminating	POS	O
spurious	POS	O
hypercalcemias	POS	B-NP
or	POS	O
those	POS	O
associated	POS	O
with	POS	O
intravenous	POS	O
fluids	POS	O
,	POS	O
the	POS	O
authors	POS	O
identified	POS	O
18	POS	O
non	POS	O
-	POS	O
lithium	POS	O
-	POS	O
treated	POS	O
patients	POS	O
with	POS	O
hypercalcemias	POS	B-NP
related	POS	O
to	POS	O
malignancies	POS	B-NP
and	POS	O
other	POS	O
medical	POS	O
conditions	POS	O
(	POS	O
group	POS	O
A	POS	O
)	POS	O
and	POS	O
12	POS	O
patients	POS	O
with	POS	O
lithium	POS	O
-	POS	O
associated	POS	O
hypercalcemia	POS	B-NP
(	POS	O
group	POS	O
B	POS	O
)	POS	O
.	POS	O
Patients	POS	O
in	POS	O
group	POS	O
B	POS	O
were	POS	O
not	POS	O
comparable	POS	O
to	POS	O
those	POS	O
in	POS	O
group	POS	O
A	POS	O
,	POS	O
as	POS	O
the	POS	O
latter	POS	O
were	POS	O
medically	POS	O
compromised	POS	O
and	POS	O
were	POS	O
receiving	POS	O
multiple	POS	O
pharmacotherapies	POS	O
.	POS	O
Thus	POS	O
,	POS	O
two	POS	O
control	POS	O
groups	POS	O
were	POS	O
generated	POS	O
:	POS	O
group	POS	O
C1	POS	O
,	POS	O
which	POS	O
included	POS	O
age	POS	O
-	POS	O
and	POS	O
sex	POS	O
-	POS	O
comparable	POS	O
lithium	POS	O
-	POS	O
treated	POS	O
bipolar	POS	O
normocalcemic	POS	O
patients	POS	O
,	POS	O
and	POS	O
group	POS	O
C2	POS	O
,	POS	O
which	POS	O
included	POS	O
bipolar	POS	B-NP
normocalcemic	POS	I-NP
patients	POS	O
treated	POS	O
with	POS	O
anticonvulsant	POS	O
mood	POS	O
stabilizers	POS	O
.	POS	O
The	POS	O
electrocardiographic	POS	O
(	POS	O
ECG	POS	O
)	POS	O
findings	POS	O
for	POS	O
patients	POS	O
in	POS	O
group	POS	O
B	POS	O
were	POS	O
compared	POS	O
with	POS	O
those	POS	O
of	POS	O
patients	POS	O
in	POS	O
groups	POS	O
C1	POS	O
and	POS	O
C2	POS	O
.	POS	O
It	POS	O
was	POS	O
found	POS	O
that	POS	O
these	POS	O
groups	POS	O
did	POS	O
not	POS	O
differ	POS	O
in	POS	O
their	POS	O
overall	POS	O
frequency	POS	O
of	POS	O
ECG	POS	B-NP
abnormalities	POS	I-NP
;	POS	O
however	POS	O
,	POS	O
there	POS	O
were	POS	O
significant	POS	O
differences	POS	O
in	POS	O
the	POS	O
frequency	POS	O
of	POS	O
conduction	POS	B-NP
defects	POS	I-NP
.	POS	O
Patients	POS	O
with	POS	O
hypercalcemia	POS	B-NP
resulting	POS	O
from	POS	O
medical	POS	O
diseases	POS	O
and	POS	O
bipolar	POS	B-NP
patients	POS	O
with	POS	O
lithium	POS	O
-	POS	O
associated	POS	O
hypercalcemia	POS	B-NP
had	POS	O
significantly	POS	O
higher	POS	O
frequencies	POS	O
of	POS	O
conduction	POS	B-NP
defects	POS	I-NP
.	POS	O
Patients	POS	O
in	POS	O
group	POS	O
A	POS	O
had	POS	O
significant	POS	O
mortality	POS	O
at	POS	O
2	POS	O
-	POS	O
year	POS	O
follow	POS	O
-	POS	O
up	POS	O
(	POS	O
28	POS	O
%	POS	O
)	POS	O
,	POS	O
in	POS	O
contrast	POS	O
to	POS	O
zero	POS	O
mortality	POS	O
in	POS	O
the	POS	O
other	POS	O
three	POS	O
groups	POS	O
.	POS	O
The	POS	O
clinical	POS	O
implications	POS	O
of	POS	O
these	POS	O
findings	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Attenuation	POS	O
of	POS	O
nephrotoxicity	POS	B-NP
by	POS	O
a	POS	O
novel	POS	O
lipid	POS	O
nanosphere	POS	O
(	POS	O
NS	POS	O
-	POS	O
718	POS	O
)	POS	O
incorporating	POS	O
amphotericin	POS	O
B	POS	O
.	POS	O
NS	POS	O
-	POS	O
718	POS	O
,	POS	O
a	POS	O
lipid	POS	O
nanosphere	POS	O
incorporating	POS	O
amphotericin	POS	O
B	POS	O
,	POS	O
is	POS	O
effective	POS	O
against	POS	O
pathogenic	POS	O
fungi	POS	O
and	POS	O
has	POS	O
low	POS	B-NP
toxicity	POS	I-NP
.	POS	O
We	POS	O
compared	POS	O
the	POS	O
toxicity	POS	B-NP
of	POS	O
NS	POS	O
-	POS	O
718	POS	O
with	POS	O
that	POS	O
of	POS	O
Fungizone	POS	O
(	POS	O
amphotericin	POS	O
B	POS	O
-	POS	O
sodium	POS	O
deoxycholate	POS	O
;	POS	O
D	POS	O
-	POS	O
AmB	POS	O
)	POS	O
in	POS	O
vitro	POS	O
using	POS	O
renal	POS	O
cell	POS	O
cultures	POS	O
and	POS	O
in	POS	O
vivo	POS	O
by	POS	O
biochemical	POS	O
analysis	POS	O
,	POS	O
histopathological	POS	O
study	POS	O
of	POS	O
the	POS	O
kidney	POS	O
and	POS	O
pharmacokinetic	POS	O
study	POS	O
of	POS	O
amphotericin	POS	O
B	POS	O
following	POS	O
intravenous	POS	O
infusion	POS	O
of	POS	O
the	POS	O
formulation	POS	O
in	POS	O
rats	POS	O
.	POS	O
Incubation	POS	O
with	POS	O
NS	POS	O
-	POS	O
718	POS	O
resulted	POS	O
in	POS	O
significantly	POS	O
less	POS	O
damage	POS	O
of	POS	O
cultured	POS	O
human	POS	O
renal	POS	O
proximal	POS	O
tubular	POS	O
epithelial	POS	O
cells	POS	O
compared	POS	O
with	POS	O
D	POS	O
-	POS	O
AmB	POS	O
.	POS	O
Serum	POS	O
blood	POS	O
urea	POS	O
and	POS	O
creatinine	POS	O
concentrations	POS	O
increased	POS	O
significantly	POS	O
in	POS	O
rats	POS	O
given	POS	O
an	POS	O
iv	POS	O
infusion	POS	O
of	POS	O
D	POS	O
-	POS	O
AmB	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
but	POS	O
not	POS	O
in	POS	O
those	POS	O
given	POS	O
the	POS	O
same	POS	O
dose	POS	O
of	POS	O
NS	POS	O
-	POS	O
718	POS	O
.	POS	O
Histopathological	POS	O
examination	POS	O
of	POS	O
the	POS	O
kidney	POS	O
showed	POS	O
tubular	POS	O
necrosis	POS	B-NP
in	POS	O
D	POS	O
-	POS	O
AmB	POS	O
-	POS	O
treated	POS	O
rats	POS	O
but	POS	O
no	POS	O
change	POS	O
in	POS	O
NS	POS	O
-	POS	O
718	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
Amphotericin	POS	O
B	POS	O
concentrations	POS	O
in	POS	O
the	POS	O
kidney	POS	O
in	POS	O
NS	POS	O
-	POS	O
718	POS	O
-	POS	O
treated	POS	O
rats	POS	O
were	POS	O
higher	POS	O
than	POS	O
those	POS	O
in	POS	O
D	POS	O
-	POS	O
AmB	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
Our	POS	O
in	POS	O
vitro	POS	O
and	POS	O
in	POS	O
vivo	POS	O
results	POS	O
suggest	POS	O
that	POS	O
incorporation	POS	O
of	POS	O
amphotericin	POS	O
B	POS	O
into	POS	O
lipid	POS	O
nanospheres	POS	O
of	POS	O
NS	POS	O
-	POS	O
718	POS	O
attenuates	POS	O
the	POS	O
nephrotoxicity	POS	B-NP
of	POS	O
amphotericin	POS	O
B	POS	O
.	POS	O
Patterns	POS	O
of	POS	O
sulfadiazine	POS	O
acute	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
Sulfadiazine	POS	O
acute	POS	O
nephrotoxicity	POS	B-NP
is	POS	O
reviving	POS	O
specially	POS	O
because	POS	O
of	POS	O
its	POS	O
use	POS	O
in	POS	O
toxoplasmosis	POS	B-NP
in	POS	O
HIV	POS	B-NP
-	POS	I-NP
positive	POS	I-NP
patients	POS	O
.	POS	O
We	POS	O
report	POS	O
4	POS	O
cases	POS	O
,	POS	O
one	POS	O
of	POS	O
them	POS	O
in	POS	O
a	POS	O
previously	POS	O
healthy	POS	O
person	POS	O
.	POS	O
Under	POS	O
treatment	POS	O
with	POS	O
sulfadiazine	POS	O
they	POS	O
developed	POS	O
oliguria	POS	B-NP
,	POS	O
abdominal	POS	B-NP
pain	POS	I-NP
,	POS	O
renal	POS	B-NP
failure	POS	I-NP
and	POS	O
showed	POS	O
multiple	POS	B-NP
radiolucent	POS	I-NP
renal	POS	I-NP
calculi	POS	I-NP
in	POS	O
echography	POS	O
.	POS	O
All	POS	O
patients	POS	O
recovered	POS	O
their	POS	O
previous	POS	O
normal	POS	O
renal	POS	O
function	POS	O
after	POS	O
adequate	POS	O
hydration	POS	O
and	POS	O
alcalinization	POS	O
.	POS	O
A	POS	O
nephrostomy	POS	O
tube	POS	O
had	POS	O
to	POS	O
be	POS	O
placed	POS	O
in	POS	O
one	POS	O
of	POS	O
the	POS	O
patients	POS	O
for	POS	O
ureteral	POS	B-NP
lithiasis	POS	I-NP
in	POS	O
a	POS	O
single	POS	O
functional	POS	O
kidney	POS	O
.	POS	O
None	POS	O
of	POS	O
them	POS	O
needed	POS	O
dialysis	POS	O
or	POS	O
a	POS	O
renal	POS	O
biopsy	POS	O
because	POS	O
of	POS	O
a	POS	O
typical	POS	O
benign	POS	O
course	POS	O
.	POS	O
Treatment	POS	O
with	POS	O
sulfadiazine	POS	O
requires	POS	O
exquisite	POS	O
control	POS	O
of	POS	O
renal	POS	O
function	POS	O
,	POS	O
an	POS	O
increase	POS	O
in	POS	O
water	POS	O
ingestion	POS	O
and	POS	O
possibly	POS	O
the	POS	O
alcalinization	POS	O
of	POS	O
the	POS	O
urine	POS	O
.	POS	O
We	POS	O
communicate	POS	O
a	POS	O
case	POS	O
in	POS	O
a	POS	O
previously	POS	O
healthy	POS	O
person	POS	O
,	POS	O
a	POS	O
fact	POS	O
not	POS	O
found	POS	O
in	POS	O
the	POS	O
recent	POS	O
literature	POS	O
.	POS	O
Probably	POS	O
many	POS	O
more	POS	O
cases	POS	O
are	POS	O
not	POS	O
detected	POS	O
.	POS	O
We	POS	O
think	POS	O
that	POS	O
a	POS	O
prospective	POS	O
study	POS	O
would	POS	O
be	POS	O
useful	POS	O
.	POS	O
Downbeat	POS	B-NP
nystagmus	POS	I-NP
associated	POS	O
with	POS	O
intravenous	POS	O
patient	POS	O
-	POS	O
controlled	POS	O
administration	POS	O
of	POS	O
morphine	POS	O
.	POS	O
IMPLICATIONS	POS	O
:	POS	O
This	POS	O
case	POS	O
documents	POS	O
a	POS	O
patient	POS	O
who	POS	O
developed	POS	O
dizziness	POS	B-NP
with	POS	O
downbeating	POS	B-NP
nystagmus	POS	I-NP
while	POS	O
receiving	POS	O
a	POS	O
relatively	POS	O
large	POS	O
dose	POS	O
of	POS	O
IV	POS	O
patient	POS	O
-	POS	O
controlled	POS	O
analgesia	POS	O
morphine	POS	O
.	POS	O
Although	POS	O
there	POS	O
have	POS	O
been	POS	O
case	POS	O
reports	POS	O
of	POS	O
epidural	POS	O
morphine	POS	O
with	POS	O
these	POS	O
symptoms	POS	O
and	POS	O
signs	POS	O
,	POS	O
this	POS	O
has	POS	O
not	POS	O
been	POS	O
previously	POS	O
documented	POS	O
with	POS	O
IV	POS	O
or	POS	O
patient	POS	O
-	POS	O
controlled	POS	O
analgesia	POS	O
morphine	POS	O
.	POS	O
Hemodynamic	POS	O
and	POS	O
antiadrenergic	POS	O
effects	POS	O
of	POS	O
dronedarone	POS	O
and	POS	O
amiodarone	POS	O
in	POS	O
animals	POS	O
with	POS	O
a	POS	O
healed	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
The	POS	O
hemodynamic	POS	O
and	POS	O
antiadrenergic	POS	O
effects	POS	O
of	POS	O
dronedarone	POS	O
,	POS	O
a	POS	O
noniodinated	POS	O
compound	POS	O
structurally	POS	O
related	POS	O
to	POS	O
amiodarone	POS	O
,	POS	O
were	POS	O
compared	POS	O
with	POS	O
those	POS	O
of	POS	O
amiodarone	POS	O
after	POS	O
prolonged	POS	O
oral	POS	O
administration	POS	O
,	POS	O
both	POS	O
at	POS	O
rest	POS	O
and	POS	O
during	POS	O
sympathetic	POS	O
stimulation	POS	O
in	POS	O
conscious	POS	O
dogs	POS	O
with	POS	O
a	POS	O
healed	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
All	POS	O
dogs	POS	O
(	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
randomly	POS	O
received	POS	O
orally	POS	O
dronedarone	POS	O
(	POS	O
10	POS	O
and	POS	O
30	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
amiodarone	POS	O
(	POS	O
10	POS	O
and	POS	O
30	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
and	POS	O
placebo	POS	O
twice	POS	O
daily	POS	O
for	POS	O
7	POS	O
days	POS	O
,	POS	O
with	POS	O
a	POS	O
3	POS	O
-	POS	O
week	POS	O
washout	POS	O
between	POS	O
consecutive	POS	O
treatments	POS	O
.	POS	O
Heart	POS	O
rate	POS	O
(	POS	O
HR	POS	O
)	POS	O
,	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
(	POS	O
MBP	POS	O
)	POS	O
,	POS	O
positive	POS	O
rate	POS	O
of	POS	O
increase	POS	O
of	POS	O
left	POS	O
ventricular	POS	O
pressure	POS	O
(	POS	O
+	POS	O
LVdP	POS	O
/	POS	O
dt	POS	O
)	POS	O
,	POS	O
echocardiographically	POS	O
assessed	POS	O
left	POS	O
ventricular	POS	O
ejection	POS	O
fraction	POS	O
(	POS	O
LVEF	POS	O
)	POS	O
,	POS	O
and	POS	O
fractional	POS	O
shortening	POS	O
(	POS	O
FS	POS	O
)	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
chronotropic	POS	O
response	POS	O
to	POS	O
isoproterenol	POS	O
and	POS	O
exercise	POS	O
-	POS	O
induced	POS	O
sympathetic	POS	O
stimulation	POS	O
were	POS	O
evaluated	POS	O
under	POS	O
baseline	POS	O
and	POS	O
posttreatment	POS	O
conditions	POS	O
.	POS	O
Resting	POS	O
values	POS	O
of	POS	O
LVEF	POS	O
,	POS	O
FS	POS	O
,	POS	O
+	POS	O
LVdP	POS	O
/	POS	O
dt	POS	O
,	POS	O
and	POS	O
MBP	POS	O
remained	POS	O
unchanged	POS	O
whatever	POS	O
the	POS	O
drug	POS	O
and	POS	O
the	POS	O
dosing	POS	O
regimen	POS	O
,	POS	O
whereas	POS	O
resting	POS	O
HR	POS	O
was	POS	O
significantly	POS	O
and	POS	O
dose	POS	O
-	POS	O
dependently	POS	O
lowered	POS	O
after	POS	O
dronedarone	POS	O
and	POS	O
to	POS	O
a	POS	O
lesser	POS	O
extent	POS	O
after	POS	O
amiodarone	POS	O
.	POS	O
Both	POS	O
dronedarone	POS	O
and	POS	O
amiodarone	POS	O
significantly	POS	O
reduced	POS	O
the	POS	O
exercise	POS	O
-	POS	O
induced	POS	O
tachycardia	POS	B-NP
and	POS	O
,	POS	O
at	POS	O
the	POS	O
highest	POS	O
dose	POS	O
,	POS	O
decreased	POS	O
the	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
tachycardia	POS	B-NP
.	POS	O
Thus	POS	O
,	POS	O
dronedarone	POS	O
and	POS	O
amiodarone	POS	O
displayed	POS	O
a	POS	O
similar	POS	O
level	POS	O
of	POS	O
antiadrenergic	POS	O
effect	POS	O
and	POS	O
did	POS	O
not	POS	O
impair	POS	O
the	POS	O
resting	POS	O
left	POS	O
ventricular	POS	O
function	POS	O
.	POS	O
Consequently	POS	O
,	POS	O
dronedarone	POS	O
might	POS	O
be	POS	O
particularly	POS	O
suitable	POS	O
for	POS	O
the	POS	O
treatment	POS	O
and	POS	O
prevention	POS	O
of	POS	O
various	POS	O
clinical	POS	O
arrhythmias	POS	B-NP
,	POS	O
without	POS	O
compromising	POS	O
the	POS	O
left	POS	O
ventricular	POS	O
function	POS	O
.	POS	O
Phase	POS	O
2	POS	O
trial	POS	O
of	POS	O
liposomal	POS	O
doxorubicin	POS	O
(	POS	O
40	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
)	POS	O
in	POS	O
platinum	POS	O
/	POS	O
paclitaxel	POS	O
-	POS	O
refractory	POS	O
ovarian	POS	O
and	POS	O
fallopian	POS	B-NP
tube	POS	I-NP
cancers	POS	I-NP
and	POS	O
primary	POS	O
carcinoma	POS	B-NP
of	POS	O
the	POS	O
peritoneum	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Several	POS	O
studies	POS	O
have	POS	O
demonstrated	POS	O
liposomal	POS	O
doxorubicin	POS	O
(	POS	O
Doxil	POS	O
)	POS	O
to	POS	O
be	POS	O
an	POS	O
active	POS	O
antineoplastic	POS	O
agent	POS	O
in	POS	O
platinum	POS	O
-	POS	O
resistant	POS	O
ovarian	POS	B-NP
cancer	POS	I-NP
,	POS	O
with	POS	O
dose	POS	O
limiting	POS	O
toxicity	POS	B-NP
of	POS	O
the	POS	O
standard	POS	O
dosing	POS	O
regimen	POS	O
(	POS	O
50	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
q	POS	O
4	POS	O
weeks	POS	O
)	POS	O
being	POS	O
severe	POS	O
erythrodysesthesia	POS	B-NP
(	POS	O
"	POS	B-NP
hand	POS	I-NP
-	POS	I-NP
foot	POS	I-NP
syndrome	POS	I-NP
"	POS	O
)	POS	O
and	POS	O
stomatitis	POS	B-NP
.	POS	O
We	POS	O
wished	POS	O
to	POS	O
develop	POS	O
a	POS	O
more	POS	O
tolerable	POS	O
liposomal	POS	O
doxorubicin	POS	O
treatment	POS	O
regimen	POS	O
and	POS	O
document	POS	O
its	POS	O
level	POS	O
of	POS	O
activity	POS	O
in	POS	O
a	POS	O
well	POS	O
-	POS	O
defined	POS	O
patient	POS	O
population	POS	O
with	POS	O
platinum	POS	O
/	POS	O
paclitaxel	POS	O
-	POS	O
refractory	POS	O
disease	POS	O
.	POS	O
METHODS	POS	O
AND	POS	O
MATERIALS	POS	O
:	POS	O
Patients	POS	O
with	POS	O
ovarian	POS	B-NP
or	POS	I-NP
fallopian	POS	I-NP
tube	POS	I-NP
cancers	POS	I-NP
or	POS	O
primary	POS	B-NP
peritoneal	POS	I-NP
carcinoma	POS	I-NP
with	POS	O
platinum	POS	O
/	POS	O
paclitaxel	POS	O
-	POS	O
refractory	POS	O
disease	POS	O
(	POS	O
stable	POS	O
or	POS	O
progressive	POS	O
disease	POS	O
following	POS	O
treatment	POS	O
with	POS	O
these	POS	O
agents	POS	O
or	POS	O
previous	POS	O
objective	POS	O
response	POS	O
<	POS	O
3	POS	O
months	POS	O
in	POS	O
duration	POS	O
)	POS	O
were	POS	O
treated	POS	O
with	POS	O
liposomal	POS	O
doxorubicin	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
40	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
q	POS	O
4	POS	O
weeks	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
49	POS	O
patients	POS	O
(	POS	O
median	POS	O
age	POS	O
:	POS	O
60	POS	O
;	POS	O
range	POS	O
41	POS	O
-	POS	O
81	POS	O
)	POS	O
entered	POS	O
this	POS	O
phase	POS	O
2	POS	O
trial	POS	O
.	POS	O
The	POS	O
median	POS	O
number	POS	O
of	POS	O
prior	POS	O
regimens	POS	O
was	POS	O
2	POS	O
(	POS	O
range	POS	O
:	POS	O
1	POS	O
-	POS	O
6	POS	O
)	POS	O
.	POS	O
Six	POS	O
(	POS	O
12	POS	O
%	POS	O
)	POS	O
and	POS	O
4	POS	O
(	POS	O
8	POS	O
%	POS	O
)	POS	O
patients	POS	O
experienced	POS	O
grade	POS	B-NP
2	POS	I-NP
hand	POS	I-NP
-	POS	I-NP
foot	POS	I-NP
syndrome	POS	I-NP
and	POS	O
stomatitis	POS	B-NP
,	POS	O
respectively	POS	O
(	POS	O
no	POS	O
episodes	POS	O
of	POS	O
grade	POS	O
3	POS	O
)	POS	O
.	POS	O
One	POS	O
patient	POS	O
developed	POS	O
grade	POS	O
3	POS	O
diarrhea	POS	B-NP
requiring	POS	O
hospitalization	POS	O
for	POS	O
hydration	POS	O
.	POS	O
Six	POS	O
(	POS	O
12	POS	O
%	POS	O
)	POS	O
individuals	POS	O
required	POS	O
dose	POS	O
reductions	POS	O
.	POS	O
The	POS	O
median	POS	O
number	POS	O
of	POS	O
courses	POS	O
of	POS	O
liposomal	POS	O
doxorubicin	POS	O
administered	POS	O
on	POS	O
this	POS	O
protocol	POS	O
was	POS	O
2	POS	O
(	POS	O
range	POS	O
:	POS	O
1	POS	O
-	POS	O
12	POS	O
)	POS	O
.	POS	O
Four	POS	O
of	POS	O
44	POS	O
patients	POS	O
(	POS	O
9	POS	O
%	POS	O
)	POS	O
evaluable	POS	O
for	POS	O
response	POS	O
exhibited	POS	O
objective	POS	O
and	POS	O
subjective	POS	O
evidence	POS	O
of	POS	O
an	POS	O
antineoplastic	POS	O
effect	POS	O
of	POS	O
therapy	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
This	POS	O
modified	POS	O
liposomal	POS	O
doxorubicin	POS	O
regimen	POS	O
results	POS	O
in	POS	O
less	POS	O
toxicity	POS	B-NP
(	POS	O
stomatitis	POS	B-NP
,	POS	O
hand	POS	B-NP
-	POS	I-NP
foot	POS	I-NP
syndrome	POS	I-NP
)	POS	O
than	POS	O
the	POS	O
standard	POS	O
FDA	POS	O
-	POS	O
approved	POS	O
dose	POS	O
schedule	POS	O
.	POS	O
Definite	POS	O
,	POS	O
although	POS	O
limited	POS	O
,	POS	O
antineoplastic	POS	O
activity	POS	O
is	POS	O
observed	POS	O
in	POS	O
patients	POS	O
with	POS	O
well	POS	O
-	POS	O
defined	POS	O
platinum	POS	O
-	POS	O
and	POS	O
paclitaxel	POS	O
-	POS	O
refractory	POS	O
ovarian	POS	B-NP
cancer	POS	I-NP
.	POS	O
Efficacy	POS	O
of	POS	O
olanzapine	POS	O
in	POS	O
acute	POS	B-NP
bipolar	POS	I-NP
mania	POS	I-NP
:	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
study	POS	O
.	POS	O
The	POS	O
Olanzipine	POS	O
HGGW	POS	O
Study	POS	O
Group	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
We	POS	O
compared	POS	O
the	POS	O
efficacy	POS	O
and	POS	O
safety	POS	O
of	POS	O
olanzapine	POS	O
vs	POS	O
placebo	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
acute	POS	B-NP
bipolar	POS	I-NP
mania	POS	I-NP
.	POS	O
METHODS	POS	O
:	POS	O
Four	POS	O
-	POS	O
week	POS	O
,	POS	O
randomized	POS	O
,	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
parallel	POS	O
study	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
115	POS	O
patients	POS	O
with	POS	O
a	POS	O
DSM	POS	O
-	POS	O
IV	POS	O
diagnosis	POS	O
of	POS	O
bipolar	POS	B-NP
disorder	POS	I-NP
,	POS	O
manic	POS	B-NP
or	POS	O
mixed	POS	O
,	POS	O
were	POS	O
randomized	POS	O
to	POS	O
olanzapine	POS	O
,	POS	O
5	POS	O
to	POS	O
20	POS	O
mg	POS	O
/	POS	O
d	POS	O
(	POS	O
n	POS	O
=	POS	O
55	POS	O
)	POS	O
,	POS	O
or	POS	O
placebo	POS	O
(	POS	O
n	POS	O
=	POS	O
60	POS	O
)	POS	O
.	POS	O
The	POS	O
primary	POS	O
efficacy	POS	O
measure	POS	O
was	POS	O
the	POS	O
Young	POS	O
-	POS	O
Mania	POS	O
Rating	POS	O
Scale	POS	O
(	POS	O
Y	POS	O
-	POS	O
MRS	POS	O
)	POS	O
total	POS	O
score	POS	O
.	POS	O
Response	POS	O
and	POS	O
euthymia	POS	B-NP
were	POS	O
defined	POS	O
,	POS	O
a	POS	O
priori	POS	O
,	POS	O
as	POS	O
at	POS	O
least	POS	O
a	POS	O
50	POS	O
%	POS	O
improvement	POS	O
from	POS	O
baseline	POS	O
to	POS	O
end	POS	O
point	POS	O
and	POS	O
as	POS	O
a	POS	O
score	POS	O
of	POS	O
no	POS	O
less	POS	O
than	POS	O
12	POS	O
at	POS	O
end	POS	O
point	POS	O
in	POS	O
the	POS	O
Y	POS	O
-	POS	O
MRS	POS	O
total	POS	O
score	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Safety	POS	O
was	POS	O
assessed	POS	O
using	POS	O
adverse	POS	O
events	POS	O
,	POS	O
Extrapyramidal	POS	B-NP
Symptom	POS	I-NP
(	POS	O
EPS	POS	B-NP
)	POS	O
rating	POS	O
scales	POS	O
,	POS	O
laboratory	POS	O
values	POS	O
,	POS	O
electrocardiograms	POS	O
,	POS	O
vital	POS	O
signs	POS	O
,	POS	O
and	POS	O
weight	POS	O
change	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Olanzapine	POS	O
-	POS	O
treated	POS	O
patients	POS	O
demonstrated	POS	O
a	POS	O
statistically	POS	O
significant	POS	O
greater	POS	O
mean	POS	O
(	POS	O
+	POS	O
/	POS	O
-	POS	O
SD	POS	O
)	POS	O
improvement	POS	O
in	POS	O
Y	POS	O
-	POS	O
MRS	POS	O
total	POS	O
score	POS	O
than	POS	O
placebo	POS	O
-	POS	O
treated	POS	O
patients	POS	O
(	POS	O
-	POS	O
14	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
12	POS	O
.	POS	O
5	POS	O
and	POS	O
-	POS	O
8	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
12	POS	O
.	POS	O
7	POS	O
,	POS	O
respectively	POS	O
;	POS	O
P	POS	O
<	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
which	POS	O
was	POS	O
evident	POS	O
at	POS	O
the	POS	O
first	POS	O
postbaseline	POS	O
observation	POS	O
1	POS	O
week	POS	O
after	POS	O
randomization	POS	O
and	POS	O
was	POS	O
maintained	POS	O
throughout	POS	O
the	POS	O
study	POS	O
(	POS	O
last	POS	O
observation	POS	O
carried	POS	O
forward	POS	O
)	POS	O
.	POS	O
Olanzapine	POS	O
-	POS	O
treated	POS	O
patients	POS	O
demonstrated	POS	O
a	POS	O
higher	POS	O
rate	POS	O
of	POS	O
response	POS	O
(	POS	O
65	POS	O
%	POS	O
vs	POS	O
43	POS	O
%	POS	O
,	POS	O
respectively	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
02	POS	O
)	POS	O
and	POS	O
euthymia	POS	B-NP
(	POS	O
61	POS	O
%	POS	O
vs	POS	O
36	POS	O
%	POS	O
,	POS	O
respectively	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
01	POS	O
)	POS	O
than	POS	O
placebo	POS	O
-	POS	O
treated	POS	O
patients	POS	O
.	POS	O
There	POS	O
were	POS	O
no	POS	O
statistically	POS	O
significant	POS	O
differences	POS	O
in	POS	O
EPSs	POS	O
between	POS	O
groups	POS	O
.	POS	O
However	POS	O
,	POS	O
olanzapine	POS	O
-	POS	O
treated	POS	O
patients	POS	O
had	POS	O
a	POS	O
statistically	POS	O
significant	POS	O
greater	POS	O
mean	POS	O
(	POS	O
+	POS	O
/	POS	O
-	POS	O
SD	POS	O
)	POS	O
weight	POS	O
gain	POS	O
than	POS	O
placebo	POS	O
-	POS	O
treated	POS	O
patients	POS	O
(	POS	O
2	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
.	POS	O
8	POS	O
vs	POS	O
0	POS	O
.	POS	O
45	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
.	POS	O
3	POS	O
kg	POS	O
,	POS	O
respectively	POS	O
)	POS	O
and	POS	O
also	POS	O
experienced	POS	O
more	POS	O
treatment	POS	O
-	POS	O
emergent	POS	O
somnolence	POS	B-NP
(	POS	O
21	POS	O
patients	POS	O
[	POS	O
38	POS	O
.	POS	O
2	POS	O
%	POS	O
]	POS	O
vs	POS	O
5	POS	O
[	POS	O
8	POS	O
.	POS	O
3	POS	O
%	POS	O
]	POS	O
,	POS	O
respectively	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Olanzapine	POS	O
demonstrated	POS	O
greater	POS	O
efficacy	POS	O
than	POS	O
placebo	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
acute	POS	O
bipolar	POS	B-NP
mania	POS	I-NP
and	POS	O
was	POS	O
generally	POS	O
well	POS	O
tolerated	POS	O
.	POS	O
The	POS	O
effect	POS	O
of	POS	O
pupil	POS	O
dilation	POS	O
with	POS	O
tropicamide	POS	O
on	POS	O
vision	POS	O
and	POS	O
driving	POS	O
simulator	POS	O
performance	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
assess	POS	O
the	POS	O
effect	POS	O
of	POS	O
pupil	POS	O
dilation	POS	O
on	POS	O
vision	POS	O
and	POS	O
driving	POS	O
ability	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
series	POS	O
of	POS	O
tests	POS	O
on	POS	O
various	POS	O
parameters	POS	O
of	POS	O
visual	POS	O
function	POS	O
and	POS	O
driving	POS	O
simulator	POS	O
performance	POS	O
were	POS	O
performed	POS	O
on	POS	O
12	POS	O
healthy	POS	O
drivers	POS	O
,	POS	O
before	POS	O
and	POS	O
after	POS	O
pupil	POS	O
dilation	POS	O
using	POS	O
guttae	POS	O
tropicamide	POS	O
1	POS	O
%	POS	O
.	POS	O
A	POS	O
driving	POS	O
simulator	POS	O
(	POS	O
Transport	POS	O
Research	POS	O
Laboratory	POS	O
)	POS	O
was	POS	O
used	POS	O
to	POS	O
measure	POS	O
reaction	POS	O
time	POS	O
(	POS	O
RT	POS	O
)	POS	O
,	POS	O
speed	POS	O
maintenance	POS	O
and	POS	O
steering	POS	O
accuracy	POS	O
.	POS	O
Tests	POS	O
of	POS	O
basic	POS	O
visual	POS	O
function	POS	O
included	POS	O
high	POS	O
-	POS	O
and	POS	O
low	POS	O
-	POS	O
contrast	POS	O
visual	POS	O
acuity	POS	O
(	POS	O
HCVA	POS	O
and	POS	O
LCVA	POS	O
)	POS	O
,	POS	O
Pelli	POS	O
-	POS	O
Robson	POS	O
contrast	POS	O
threshold	POS	O
(	POS	O
CT	POS	O
)	POS	O
and	POS	O
Goldmann	POS	O
perimetry	POS	O
(	POS	O
FIELDS	POS	O
)	POS	O
.	POS	O
Useful	POS	O
Field	POS	O
of	POS	O
View	POS	O
(	POS	O
UFOV	POS	O
-	POS	O
-	POS	O
a	POS	O
test	POS	O
of	POS	O
visual	POS	O
attention	POS	O
)	POS	O
was	POS	O
also	POS	O
undertaken	POS	O
.	POS	O
The	POS	O
mean	POS	O
differences	POS	O
in	POS	O
the	POS	O
pre	POS	O
-	POS	O
and	POS	O
post	POS	O
-	POS	O
dilatation	POS	O
measurements	POS	O
were	POS	O
tested	POS	O
for	POS	O
statistical	POS	O
significance	POS	O
at	POS	O
the	POS	O
95	POS	O
%	POS	O
level	POS	O
using	POS	O
one	POS	O
-	POS	O
tail	POS	O
paired	POS	O
t	POS	O
-	POS	O
tests	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Pupillary	POS	O
dilation	POS	O
resulted	POS	O
in	POS	O
a	POS	O
statistically	POS	O
significant	POS	O
deterioration	POS	O
in	POS	O
CT	POS	O
and	POS	O
HCVA	POS	O
only	POS	O
.	POS	O
Five	POS	O
of	POS	O
12	POS	O
drivers	POS	O
also	POS	O
exhibited	POS	O
deterioration	POS	O
in	POS	O
LCVA	POS	O
,	POS	O
CT	POS	O
and	POS	O
RT	POS	O
.	POS	O
Little	POS	O
evidence	POS	O
emerged	POS	O
for	POS	O
deterioration	POS	O
in	POS	O
FIELDS	POS	O
and	POS	O
UFOV	POS	O
.	POS	O
Also	POS	O
,	POS	O
7	POS	O
of	POS	O
12	POS	O
drivers	POS	O
appeared	POS	O
to	POS	O
adjust	POS	O
their	POS	O
driving	POS	O
behaviour	POS	O
by	POS	O
reducing	POS	O
their	POS	O
speed	POS	O
on	POS	O
the	POS	O
driving	POS	O
simulator	POS	O
,	POS	O
leading	POS	O
to	POS	O
improved	POS	O
steering	POS	O
accuracy	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Pupillary	POS	O
dilation	POS	O
may	POS	O
lead	POS	O
to	POS	O
a	POS	O
decrease	POS	O
in	POS	O
vision	POS	O
and	POS	O
daylight	POS	O
driving	POS	O
performance	POS	O
in	POS	O
young	POS	O
people	POS	O
.	POS	O
A	POS	O
larger	POS	O
study	POS	O
,	POS	O
including	POS	O
a	POS	O
broader	POS	O
spectrum	POS	O
of	POS	O
subjects	POS	O
,	POS	O
is	POS	O
warranted	POS	O
before	POS	O
guidelines	POS	O
can	POS	O
be	POS	O
recommended	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
isotretinoin	POS	O
embryopathy	POS	B-NP
with	POS	O
bilateral	POS	B-NP
anotia	POS	I-NP
and	POS	O
Taussig	POS	B-NP
-	POS	I-NP
Bing	POS	I-NP
malformation	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
a	POS	O
newborn	POS	O
infant	POS	O
with	POS	O
multiple	POS	B-NP
congenital	POS	I-NP
anomalies	POS	I-NP
(	POS	O
anotia	POS	B-NP
and	POS	O
Taussig	POS	B-NP
-	POS	I-NP
Bing	POS	I-NP
malformation	POS	I-NP
)	POS	O
due	POS	O
to	POS	O
exposure	POS	O
to	POS	O
isotretinoin	POS	O
within	POS	O
the	POS	O
first	POS	O
trimester	POS	O
.	POS	O
In	POS	O
this	POS	O
paper	POS	O
we	POS	O
aim	POS	O
to	POS	O
draw	POS	O
to	POS	O
the	POS	O
fact	POS	O
that	POS	O
caution	POS	O
is	POS	O
needed	POS	O
when	POS	O
prescribing	POS	O
vitamin	POS	O
A	POS	O
-	POS	O
containing	POS	O
drugs	POS	O
to	POS	O
women	POS	O
of	POS	O
childbearing	POS	O
years	POS	O
.	POS	O
Effect	POS	O
of	POS	O
methoxamine	POS	O
on	POS	O
maximum	POS	O
urethral	POS	O
pressure	POS	O
in	POS	O
women	POS	O
with	POS	O
genuine	POS	O
stress	POS	B-NP
incontinence	POS	I-NP
:	POS	O
a	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
,	POS	O
double	POS	O
-	POS	O
blind	POS	O
crossover	POS	O
study	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
study	POS	O
was	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
potential	POS	O
role	POS	O
for	POS	O
a	POS	O
selective	POS	O
alpha1	POS	O
-	POS	O
adrenoceptor	POS	O
agonist	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
urinary	POS	B-NP
stress	POS	I-NP
incontinence	POS	I-NP
.	POS	O
A	POS	O
randomised	POS	O
,	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
,	POS	O
crossover	POS	O
study	POS	O
design	POS	O
was	POS	O
employed	POS	O
.	POS	O
Half	POS	O
log	POS	O
incremental	POS	O
doses	POS	O
of	POS	O
intravenous	POS	O
methoxamine	POS	O
or	POS	O
placebo	POS	O
(	POS	O
saline	POS	O
)	POS	O
were	POS	O
administered	POS	O
to	POS	O
a	POS	O
group	POS	O
of	POS	O
women	POS	O
with	POS	O
genuine	POS	O
stress	POS	B-NP
incontinence	POS	I-NP
while	POS	O
measuring	POS	O
maximum	POS	O
urethral	POS	O
pressure	POS	O
(	POS	O
MUP	POS	O
)	POS	O
,	POS	O
blood	POS	O
pressure	POS	O
,	POS	O
heart	POS	O
rate	POS	O
,	POS	O
and	POS	O
symptomatic	POS	O
side	POS	O
effects	POS	O
.	POS	O
Methoxamine	POS	O
evoked	POS	O
non	POS	O
-	POS	O
significant	POS	O
increases	POS	O
in	POS	O
MUP	POS	O
and	POS	O
diastolic	POS	O
blood	POS	O
pressure	POS	O
but	POS	O
caused	POS	O
a	POS	O
significant	POS	O
rise	POS	O
in	POS	O
systolic	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
significant	POS	O
fall	POS	O
in	POS	O
heart	POS	O
rate	POS	O
at	POS	O
maximum	POS	O
dosage	POS	O
.	POS	O
Systemic	POS	O
side	POS	O
effects	POS	O
including	POS	O
piloerection	POS	B-NP
,	POS	O
headache	POS	B-NP
,	POS	O
and	POS	O
cold	POS	B-NP
extremities	POS	I-NP
were	POS	O
experienced	POS	O
in	POS	O
all	POS	O
subjects	POS	O
.	POS	O
The	POS	O
results	POS	O
indicate	POS	O
that	POS	O
the	POS	O
clinical	POS	O
usefulness	POS	O
of	POS	O
direct	POS	O
,	POS	O
peripherally	POS	O
acting	POS	O
sub	POS	O
-	POS	O
type	POS	O
-	POS	O
selective	POS	O
alpha1	POS	O
-	POS	O
adrenoceptor	POS	O
agonists	POS	O
in	POS	O
the	POS	O
medical	POS	O
treatment	POS	O
of	POS	O
stress	POS	B-NP
incontinence	POS	I-NP
may	POS	O
be	POS	O
limited	POS	O
by	POS	O
associated	POS	O
piloerection	POS	O
and	POS	O
cardiovascular	POS	B-NP
side	POS	I-NP
effects	POS	I-NP
.	POS	O
Hyperglycemic	POS	B-NP
effect	POS	O
of	POS	O
amino	POS	O
compounds	POS	O
structurally	POS	O
related	POS	O
to	POS	O
caproate	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
chronic	POS	O
feeding	POS	O
of	POS	O
small	POS	O
amounts	POS	O
(	POS	O
0	POS	O
.	POS	O
3	POS	O
-	POS	O
3	POS	O
%	POS	O
of	POS	O
diet	POS	O
weight	POS	O
)	POS	O
of	POS	O
certain	POS	O
amino	POS	O
derivatives	POS	O
of	POS	O
caproate	POS	O
resulted	POS	O
in	POS	O
hyperglycemia	POS	B-NP
,	POS	O
an	POS	O
elevated	POS	O
glucose	POS	O
tolerance	POS	O
curve	POS	O
and	POS	O
,	POS	O
occasionally	POS	O
,	POS	O
glucosuria	POS	B-NP
.	POS	O
Effective	POS	O
compounds	POS	O
included	POS	O
norleucine	POS	O
,	POS	O
norvaline	POS	O
,	POS	O
glutamate	POS	O
,	POS	O
epsilon	POS	O
-	POS	O
aminocaproate	POS	O
,	POS	O
methionine	POS	O
,	POS	O
and	POS	O
leucine	POS	O
.	POS	O
Toleration	POS	O
of	POS	O
high	POS	O
doses	POS	O
of	POS	O
angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
inhibitors	POS	O
in	POS	O
patients	POS	O
with	POS	O
chronic	POS	O
heart	POS	B-NP
failure	POS	I-NP
:	POS	O
results	POS	O
from	POS	O
the	POS	O
ATLAS	POS	O
trial	POS	O
.	POS	O
The	POS	O
Assessment	POS	O
of	POS	O
Treatment	POS	O
with	POS	O
Lisinopril	POS	O
and	POS	O
Survival	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Treatment	POS	O
with	POS	O
angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
(	POS	O
ACE	POS	O
)	POS	O
inhibitors	POS	O
reduces	POS	O
mortality	POS	O
and	POS	O
morbidity	POS	O
in	POS	O
patients	POS	O
with	POS	O
chronic	POS	B-NP
heart	POS	I-NP
failure	POS	I-NP
(	POS	O
CHF	POS	B-NP
)	POS	O
,	POS	O
but	POS	O
most	POS	O
affected	POS	O
patients	POS	O
are	POS	O
not	POS	O
receiving	POS	O
these	POS	O
agents	POS	O
or	POS	O
are	POS	O
being	POS	O
treated	POS	O
with	POS	O
doses	POS	O
lower	POS	O
than	POS	O
those	POS	O
found	POS	O
to	POS	O
be	POS	O
efficacious	POS	O
in	POS	O
trials	POS	O
,	POS	O
primarily	POS	O
because	POS	O
of	POS	O
concerns	POS	O
about	POS	O
the	POS	O
safety	POS	O
and	POS	O
tolerability	POS	O
of	POS	O
these	POS	O
agents	POS	O
,	POS	O
especially	POS	O
at	POS	O
the	POS	O
recommended	POS	O
doses	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
examines	POS	O
the	POS	O
safety	POS	O
and	POS	O
tolerability	POS	O
of	POS	O
high	POS	O
-	POS	O
compared	POS	O
with	POS	O
low	POS	O
-	POS	O
dose	POS	O
lisinopril	POS	O
in	POS	O
CHF	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
The	POS	O
Assessment	POS	O
of	POS	O
Lisinopril	POS	O
and	POS	O
Survival	POS	O
study	POS	O
was	POS	O
a	POS	O
multicenter	POS	O
,	POS	O
randomized	POS	O
,	POS	O
double	POS	O
-	POS	O
blind	POS	O
trial	POS	O
in	POS	O
which	POS	O
patients	POS	O
with	POS	O
or	POS	O
without	POS	O
previous	POS	O
ACE	POS	O
inhibitor	POS	O
treatment	POS	O
were	POS	O
stabilized	POS	O
receiving	POS	O
medium	POS	O
-	POS	O
dose	POS	O
lisinopril	POS	O
(	POS	O
12	POS	O
.	POS	O
5	POS	O
or	POS	O
15	POS	O
.	POS	O
0	POS	O
mg	POS	O
once	POS	O
daily	POS	O
[	POS	O
OD	POS	O
]	POS	O
)	POS	O
for	POS	O
2	POS	O
to	POS	O
4	POS	O
weeks	POS	O
and	POS	O
then	POS	O
randomized	POS	O
to	POS	O
high	POS	O
-	POS	O
(	POS	O
35	POS	O
.	POS	O
0	POS	O
or	POS	O
32	POS	O
.	POS	O
5	POS	O
mg	POS	O
OD	POS	O
)	POS	O
or	POS	O
low	POS	O
-	POS	O
dose	POS	O
(	POS	O
5	POS	O
.	POS	O
0	POS	O
or	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
OD	POS	O
)	POS	O
groups	POS	O
.	POS	O
Patients	POS	O
with	POS	O
New	POS	O
York	POS	O
Heart	POS	O
Association	POS	O
classes	POS	O
II	POS	O
to	POS	O
IV	POS	O
CHF	POS	B-NP
and	POS	O
left	POS	O
ventricular	POS	O
ejection	POS	O
fractions	POS	O
of	POS	O
no	POS	O
greater	POS	O
than	POS	O
0	POS	O
.	POS	O
30	POS	O
(	POS	O
n	POS	O
=	POS	O
3164	POS	O
)	POS	O
were	POS	O
randomized	POS	O
and	POS	O
followed	POS	O
up	POS	O
for	POS	O
a	POS	O
median	POS	O
of	POS	O
46	POS	O
months	POS	O
.	POS	O
We	POS	O
examined	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
adverse	POS	O
events	POS	O
and	POS	O
the	POS	O
need	POS	O
for	POS	O
discontinuation	POS	O
and	POS	O
dose	POS	O
reduction	POS	O
during	POS	O
treatment	POS	O
,	POS	O
with	POS	O
a	POS	O
focus	POS	O
on	POS	O
hypotension	POS	B-NP
and	POS	O
renal	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
RESULTS	POS	O
:	POS	O
Of	POS	O
405	POS	O
patients	POS	O
not	POS	O
previously	POS	O
receiving	POS	O
an	POS	O
ACE	POS	O
inhibitor	POS	O
,	POS	O
doses	POS	O
in	POS	O
only	POS	O
4	POS	O
.	POS	O
2	POS	O
%	POS	O
could	POS	O
not	POS	O
be	POS	O
titrated	POS	O
to	POS	O
the	POS	O
medium	POS	O
doses	POS	O
required	POS	O
for	POS	O
randomization	POS	O
because	POS	O
of	POS	O
symptoms	POS	O
possibly	POS	O
related	POS	O
to	POS	O
hypotension	POS	B-NP
(	POS	O
2	POS	O
.	POS	O
0	POS	O
%	POS	O
)	POS	O
or	POS	O
because	POS	O
of	POS	O
renal	POS	B-NP
dysfunction	POS	I-NP
or	POS	O
hyperkalemia	POS	B-NP
(	POS	O
2	POS	O
.	POS	O
3	POS	O
%	POS	O
)	POS	O
.	POS	O
Doses	POS	O
in	POS	O
more	POS	O
than	POS	O
90	POS	O
%	POS	O
of	POS	O
randomized	POS	O
patients	POS	O
in	POS	O
the	POS	O
high	POS	O
-	POS	O
and	POS	O
low	POS	O
-	POS	O
dose	POS	O
groups	POS	O
were	POS	O
titrated	POS	O
to	POS	O
their	POS	O
assigned	POS	O
target	POS	O
,	POS	O
and	POS	O
the	POS	O
mean	POS	O
doses	POS	O
of	POS	O
blinded	POS	O
medication	POS	O
in	POS	O
both	POS	O
groups	POS	O
remained	POS	O
similar	POS	O
throughout	POS	O
the	POS	O
study	POS	O
.	POS	O
Withdrawals	POS	B-NP
occurred	POS	O
in	POS	O
27	POS	O
.	POS	O
1	POS	O
%	POS	O
of	POS	O
the	POS	O
high	POS	O
-	POS	O
and	POS	O
30	POS	O
.	POS	O
7	POS	O
%	POS	O
of	POS	O
the	POS	O
low	POS	O
-	POS	O
dose	POS	O
groups	POS	O
.	POS	O
Subgroups	POS	O
presumed	POS	O
to	POS	O
be	POS	O
at	POS	O
higher	POS	O
risk	POS	O
for	POS	O
ACE	POS	O
inhibitor	POS	O
intolerance	POS	O
(	POS	O
blood	POS	O
pressure	POS	O
,	POS	O
<	POS	O
120	POS	O
mm	POS	O
Hg	POS	O
;	POS	O
creatinine	POS	O
,	POS	O
>	POS	O
or	POS	O
=	POS	O
132	POS	O
.	POS	O
6	POS	O
micromol	POS	O
/	POS	O
L	POS	O
[	POS	O
>	POS	O
or	POS	O
=	POS	O
1	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
dL	POS	O
]	POS	O
;	POS	O
age	POS	O
,	POS	O
>	POS	O
or	POS	O
=	POS	O
70	POS	O
years	POS	O
;	POS	O
and	POS	O
patients	POS	O
with	POS	O
diabetes	POS	B-NP
)	POS	O
generally	POS	O
tolerated	POS	O
the	POS	O
high	POS	O
-	POS	O
dose	POS	O
strategy	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
These	POS	O
findings	POS	O
demonstrate	POS	O
that	POS	O
ACE	POS	O
inhibitor	POS	O
therapy	POS	O
in	POS	O
most	POS	O
patients	POS	O
with	POS	O
CHF	POS	B-NP
can	POS	O
be	POS	O
successfully	POS	O
titrated	POS	O
to	POS	O
and	POS	O
maintained	POS	O
at	POS	O
high	POS	O
doses	POS	O
,	POS	O
and	POS	O
that	POS	O
more	POS	O
aggressive	POS	O
use	POS	O
of	POS	O
these	POS	O
agents	POS	O
is	POS	O
warranted	POS	O
.	POS	O
Cocaine	POS	O
,	POS	O
ethanol	POS	O
,	POS	O
and	POS	O
cocaethylene	POS	O
cardiotoxity	POS	O
in	POS	O
an	POS	O
animal	POS	O
model	POS	O
of	POS	O
cocaine	POS	O
and	POS	O
ethanol	POS	O
abuse	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
Simultaneous	POS	O
abuse	POS	O
of	POS	O
cocaine	POS	O
and	POS	O
ethanol	POS	O
affects	POS	O
12	POS	O
million	POS	O
Americans	POS	O
annually	POS	O
.	POS	O
In	POS	O
combination	POS	O
,	POS	O
these	POS	O
substances	POS	O
are	POS	O
substantially	POS	O
more	POS	O
toxic	POS	O
than	POS	O
either	POS	O
drug	POS	O
alone	POS	O
.	POS	O
Their	POS	O
combined	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
may	POS	O
be	POS	O
due	POS	O
to	POS	O
independent	POS	O
effects	POS	O
of	POS	O
each	POS	O
drug	POS	O
;	POS	O
however	POS	O
,	POS	O
they	POS	O
may	POS	O
also	POS	O
be	POS	O
due	POS	O
to	POS	O
cocaethylene	POS	O
(	POS	O
CE	POS	O
)	POS	O
,	POS	O
a	POS	O
cocaine	POS	O
metabolite	POS	O
formed	POS	O
only	POS	O
in	POS	O
the	POS	O
presence	POS	O
of	POS	O
ethanol	POS	O
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
delineate	POS	O
the	POS	O
role	POS	O
of	POS	O
CE	POS	O
in	POS	O
the	POS	O
combined	POS	O
cardiotoxicity	POS	B-NP
of	POS	O
cocaine	POS	O
and	POS	O
ethanol	POS	O
in	POS	O
a	POS	O
model	POS	O
simulating	POS	O
their	POS	O
abuse	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Twenty	POS	O
-	POS	O
three	POS	O
dogs	POS	O
were	POS	O
randomized	POS	O
to	POS	O
receive	POS	O
either	POS	O
1	POS	O
)	POS	O
three	POS	O
intravenous	POS	O
(	POS	O
IV	POS	O
)	POS	O
boluses	POS	O
of	POS	O
cocaine	POS	O
7	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
with	POS	O
ethanol	POS	O
(	POS	O
1	POS	O
g	POS	O
/	POS	O
kg	POS	O
)	POS	O
as	POS	O
an	POS	O
IV	POS	O
infusion	POS	O
(	POS	O
C	POS	O
+	POS	O
E	POS	O
,	POS	O
n	POS	O
=	POS	O
8	POS	O
)	POS	O
,	POS	O
2	POS	O
)	POS	O
three	POS	O
cocaine	POS	O
boluses	POS	O
only	POS	O
(	POS	O
C	POS	O
,	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
,	POS	O
3	POS	O
)	POS	O
ethanol	POS	O
infusion	POS	O
only	POS	O
(	POS	O
E	POS	O
,	POS	O
n	POS	O
=	POS	O
5	POS	O
)	POS	O
,	POS	O
or	POS	O
4	POS	O
)	POS	O
placebo	POS	O
boluses	POS	O
and	POS	O
infusion	POS	O
(	POS	O
n	POS	O
=	POS	O
4	POS	O
)	POS	O
.	POS	O
Hemodynamic	POS	O
measurements	POS	O
,	POS	O
electrocardiograms	POS	O
,	POS	O
and	POS	O
serum	POS	O
drug	POS	O
concentrations	POS	O
were	POS	O
obtained	POS	O
at	POS	O
baseline	POS	O
,	POS	O
and	POS	O
then	POS	O
at	POS	O
fixed	POS	O
time	POS	O
intervals	POS	O
after	POS	O
each	POS	O
drug	POS	O
was	POS	O
administered	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Two	POS	O
of	POS	O
eight	POS	O
dogs	POS	O
in	POS	O
the	POS	O
C	POS	O
+	POS	O
E	POS	O
group	POS	O
experienced	POS	O
cardiovascular	POS	B-NP
collapse	POS	I-NP
.	POS	O
The	POS	O
most	POS	O
dramatic	POS	O
hemodynamic	POS	O
changes	POS	O
occurred	POS	O
after	POS	O
each	POS	O
cocaine	POS	O
bolus	POS	O
in	POS	O
the	POS	O
C	POS	O
+	POS	O
E	POS	O
and	POS	O
C	POS	O
only	POS	O
groups	POS	O
;	POS	O
however	POS	O
,	POS	O
persistent	POS	O
hemodynamic	POS	O
changes	POS	O
occurred	POS	O
in	POS	O
the	POS	O
C	POS	O
+	POS	O
E	POS	O
group	POS	O
.	POS	O
Peak	POS	O
CE	POS	O
levels	POS	O
were	POS	O
associated	POS	O
with	POS	O
a	POS	O
45	POS	O
%	POS	O
(	POS	O
SD	POS	O
+	POS	O
/	POS	O
-	POS	O
22	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
22	POS	O
%	POS	O
to	POS	O
69	POS	O
%	POS	O
)	POS	O
decrease	POS	O
in	POS	O
cardiac	POS	O
output	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
,	POS	O
a	POS	O
56	POS	O
%	POS	O
(	POS	O
SD	POS	O
+	POS	O
/	POS	O
-	POS	O
23	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
32	POS	O
%	POS	O
to	POS	O
80	POS	O
%	POS	O
)	POS	O
decrease	POS	O
in	POS	O
dP	POS	O
/	POS	O
dt	POS	O
(	POS	O
max	POS	O
)	POS	O
(	POS	O
p	POS	O
<	POS	O
.	POS	O
006	POS	O
)	POS	O
,	POS	O
and	POS	O
a	POS	O
23	POS	O
%	POS	O
(	POS	O
SD	POS	O
+	POS	O
/	POS	O
-	POS	O
15	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
7	POS	O
%	POS	O
to	POS	O
49	POS	O
%	POS	O
)	POS	O
decrease	POS	O
in	POS	O
SVO	POS	O
(	POS	O
2	POS	O
)	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
025	POS	O
)	POS	O
.	POS	O
Ventricular	POS	B-NP
arrhythmias	POS	I-NP
were	POS	O
primarily	POS	O
observed	POS	O
in	POS	O
the	POS	O
C	POS	O
+	POS	O
E	POS	O
group	POS	O
,	POS	O
in	POS	O
which	POS	O
four	POS	O
of	POS	O
eight	POS	O
dogs	POS	O
experienced	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Cocaine	POS	O
and	POS	O
ethanol	POS	O
in	POS	O
combination	POS	O
were	POS	O
more	POS	O
toxic	POS	O
than	POS	O
either	POS	O
substance	POS	O
alone	POS	O
.	POS	O
Co	POS	O
-	POS	O
administration	POS	O
resulted	POS	O
in	POS	O
prolonged	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
and	POS	O
was	POS	O
dysrhythmogenic	POS	O
.	POS	O
Peak	POS	O
serum	POS	O
cocaethylene	POS	O
concentrations	POS	O
were	POS	O
associated	POS	O
with	POS	O
prolonged	POS	O
myocardial	POS	B-NP
depression	POS	I-NP
.	POS	O
Worsening	POS	O
of	POS	O
Parkinsonism	POS	B-NP
after	POS	O
the	POS	O
use	POS	O
of	POS	O
veralipride	POS	O
for	POS	O
treatment	POS	O
of	POS	O
menopause	POS	O
:	POS	O
case	POS	O
report	POS	O
.	POS	O
We	POS	O
describe	POS	O
a	POS	O
female	POS	O
patient	POS	O
with	POS	O
stable	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
who	POS	O
has	POS	O
shown	POS	O
a	POS	O
marked	POS	O
worsening	POS	O
of	POS	O
her	POS	O
motor	POS	O
functions	POS	O
following	POS	O
therapy	POS	O
of	POS	O
menopause	POS	O
related	POS	O
symptoms	POS	O
with	POS	O
veralipride	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
the	POS	O
improvement	POS	O
of	POS	O
her	POS	O
symptoms	POS	O
back	POS	O
to	POS	O
baseline	POS	O
after	POS	O
discontinuation	POS	O
of	POS	O
the	POS	O
drug	POS	O
.	POS	O
We	POS	O
emphasize	POS	O
the	POS	O
anti	POS	O
-	POS	O
dopaminergic	POS	O
effect	POS	O
of	POS	O
veralipride	POS	O
.	POS	O
Viracept	POS	O
and	POS	O
irregular	POS	O
heartbeat	POS	O
warning	POS	O
.	POS	O
A	POS	O
group	POS	O
of	POS	O
doctors	POS	O
in	POS	O
Boston	POS	O
warn	POS	O
that	POS	O
the	POS	O
protease	POS	O
inhibitor	POS	O
Viracept	POS	O
may	POS	O
cause	POS	O
an	POS	O
irregular	POS	O
heart	POS	O
beat	POS	O
,	POS	O
known	POS	O
as	POS	O
bradycardia	POS	B-NP
,	POS	O
in	POS	O
people	POS	O
with	POS	O
HIV	POS	B-NP
.	POS	O
Bradycardia	POS	B-NP
occurred	POS	O
in	POS	O
a	POS	O
45	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
patient	POS	O
who	POS	O
was	POS	O
Viracept	POS	O
in	POS	O
combination	POS	O
with	POS	O
other	POS	O
anti	POS	O
-	POS	O
HIV	POS	O
drugs	POS	O
.	POS	O
The	POS	O
symptoms	POS	O
ceased	POS	O
after	POS	O
switching	POS	O
to	POS	O
another	POS	O
drug	POS	O
combination	POS	O
.	POS	O
Frequency	POS	O
of	POS	O
appearance	POS	O
of	POS	O
myeloperoxidase	POS	O
-	POS	O
antineutrophil	POS	O
cytoplasmic	POS	O
antibody	POS	O
(	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
)	POS	O
in	POS	O
Graves	POS	B-NP
'	POS	I-NP
disease	POS	I-NP
patients	POS	O
treated	POS	O
with	POS	O
propylthiouracil	POS	O
and	POS	O
the	POS	O
relationship	POS	O
between	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
and	POS	O
clinical	POS	O
manifestations	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
Myeloperoxidase	POS	O
antineutrophil	POS	O
cytoplasmic	POS	O
antibody	POS	O
(	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
)	POS	O
-	POS	O
positive	POS	O
vasculitis	POS	B-NP
has	POS	O
been	POS	O
reported	POS	O
in	POS	O
patients	POS	O
with	POS	O
Graves	POS	B-NP
'	POS	I-NP
disease	POS	I-NP
who	POS	O
were	POS	O
treated	POS	O
with	POS	O
propylthiouracil	POS	O
(	POS	O
PTU	POS	O
)	POS	O
.	POS	O
The	POS	O
appearance	POS	O
of	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
in	POS	O
these	POS	O
cases	POS	O
was	POS	O
suspected	POS	O
of	POS	O
being	POS	O
related	POS	O
to	POS	O
PTU	POS	B-NP
because	POS	O
the	POS	O
titres	POS	O
of	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
decreased	POS	O
when	POS	O
PTU	POS	B-NP
was	POS	O
stopped	POS	O
.	POS	O
Nevertheless	POS	O
,	POS	O
there	POS	O
have	POS	O
been	POS	O
no	POS	O
studies	POS	O
on	POS	O
the	POS	O
temporal	POS	O
relationship	POS	O
between	POS	O
the	POS	O
appearance	POS	O
of	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
and	POS	O
vasculitis	POS	B-NP
during	POS	O
PTU	POS	O
therapy	POS	O
,	POS	O
or	POS	O
on	POS	O
the	POS	O
incidence	POS	O
of	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
in	POS	O
untreated	POS	O
Graves	POS	B-NP
'	POS	I-NP
disease	POS	I-NP
patients	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
we	POS	O
sought	POS	O
to	POS	O
address	POS	O
these	POS	O
parameters	POS	O
in	POS	O
patients	POS	O
with	POS	O
Graves	POS	B-NP
'	POS	I-NP
disease	POS	I-NP
.	POS	O
PATIENTS	POS	O
:	POS	O
We	POS	O
investigated	POS	O
102	POS	O
untreated	POS	O
patients	POS	O
with	POS	O
hyperthyroidism	POS	B-NP
due	POS	O
to	POS	O
Graves	POS	B-NP
'	POS	I-NP
disease	POS	I-NP
for	POS	O
the	POS	O
presence	POS	O
of	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
,	POS	O
and	POS	O
for	POS	O
the	POS	O
development	POS	O
vasculitis	POS	B-NP
after	POS	O
starting	POS	O
PTU	POS	O
therapy	POS	O
.	POS	O
Twenty	POS	O
-	POS	O
nine	POS	O
of	POS	O
them	POS	O
were	POS	O
later	POS	O
excluded	POS	O
because	POS	O
of	POS	O
adverse	POS	O
effects	POS	O
of	POS	O
PTU	POS	B-NP
or	POS	O
because	POS	O
the	POS	O
observation	POS	O
period	POS	O
was	POS	O
less	POS	O
than	POS	O
3	POS	O
months	POS	O
.	POS	O
The	POS	O
remaining	POS	O
73	POS	O
patients	POS	O
(	POS	O
55	POS	O
women	POS	O
and	POS	O
18	POS	O
men	POS	O
)	POS	O
,	POS	O
all	POS	O
of	POS	O
whom	POS	O
were	POS	O
examined	POS	O
for	POS	O
more	POS	O
than	POS	O
3	POS	O
months	POS	O
,	POS	O
were	POS	O
adopted	POS	O
as	POS	O
the	POS	O
subjects	POS	O
of	POS	O
the	POS	O
investigation	POS	O
.	POS	O
The	POS	O
median	POS	O
observation	POS	O
period	POS	O
was	POS	O
23	POS	O
.	POS	O
6	POS	O
months	POS	O
(	POS	O
range	POS	O
:	POS	O
3	POS	O
-	POS	O
37	POS	O
months	POS	O
)	POS	O
.	POS	O
MEASUREMENTS	POS	O
:	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
was	POS	O
measured	POS	O
at	POS	O
intervals	POS	O
of	POS	O
2	POS	O
-	POS	O
6	POS	O
months	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Before	POS	O
treatment	POS	O
,	POS	O
the	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
titres	POS	O
of	POS	O
all	POS	O
102	POS	O
untreated	POS	O
Graves	POS	B-NP
'	POS	I-NP
disease	POS	I-NP
patients	POS	O
were	POS	O
within	POS	O
the	POS	O
reference	POS	O
range	POS	O
(	POS	O
below	POS	O
10	POS	O
U	POS	O
/	POS	O
ml	POS	O
)	POS	O
.	POS	O
Three	POS	O
(	POS	O
4	POS	O
.	POS	O
1	POS	O
%	POS	O
)	POS	O
of	POS	O
the	POS	O
73	POS	O
patients	POS	O
were	POS	O
positive	POS	O
for	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
at	POS	O
13	POS	O
,	POS	O
16	POS	O
and	POS	O
17	POS	O
months	POS	O
,	POS	O
respectively	POS	O
,	POS	O
after	POS	O
the	POS	O
start	POS	O
of	POS	O
PTU	POS	O
therapy	POS	O
.	POS	O
In	POS	O
two	POS	O
of	POS	O
them	POS	O
,	POS	O
the	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
titres	POS	O
transiently	POS	O
increased	POS	O
to	POS	O
12	POS	O
.	POS	O
8	POS	O
and	POS	O
15	POS	O
.	POS	O
0	POS	O
U	POS	O
/	POS	O
ml	POS	O
,	POS	O
respectively	POS	O
,	POS	O
despite	POS	O
continued	POS	O
PTU	POS	O
therapy	POS	O
,	POS	O
but	POS	O
no	POS	O
vasculitic	POS	B-NP
disorders	POS	I-NP
developed	POS	O
.	POS	O
In	POS	O
the	POS	O
third	POS	O
patient	POS	O
,	POS	O
the	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
titre	POS	O
increased	POS	O
to	POS	O
204	POS	O
U	POS	O
/	POS	O
ml	POS	O
and	POS	O
she	POS	O
developed	POS	O
a	POS	O
higher	POS	O
fever	POS	B-NP
,	POS	O
oral	POS	B-NP
ulcers	POS	I-NP
and	POS	O
polyarthralgia	POS	B-NP
,	POS	O
but	POS	O
the	POS	O
symptoms	POS	O
resolved	POS	O
2	POS	O
weeks	POS	O
after	POS	O
stopping	POS	O
PTU	POS	O
therapy	POS	O
,	POS	O
and	POS	O
the	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
titre	POS	O
decreased	POS	O
to	POS	O
20	POS	O
.	POS	O
7	POS	O
U	POS	O
/	POS	O
ml	POS	O
by	POS	O
4	POS	O
months	POS	O
after	POS	O
discontinuing	POS	O
PTU	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
PTU	POS	O
therapy	POS	O
may	POS	O
be	POS	O
related	POS	O
to	POS	O
the	POS	O
appearance	POS	O
of	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	B-NP
,	POS	O
but	POS	O
MPO	POS	O
-	POS	O
ANCA	POS	O
does	POS	O
not	POS	O
appear	POS	O
to	POS	O
be	POS	O
closely	POS	O
related	POS	O
to	POS	O
vasculitis	POS	B-NP
.	POS	O
Prevalence	POS	O
of	POS	O
heart	POS	B-NP
disease	POS	I-NP
in	POS	O
asymptomatic	POS	O
chronic	POS	O
cocaine	POS	O
users	POS	O
.	POS	O
To	POS	O
determine	POS	O
the	POS	O
prevalence	POS	O
of	POS	O
heart	POS	B-NP
disease	POS	I-NP
in	POS	O
outpatient	POS	O
young	POS	O
asymptomatic	POS	O
chronic	POS	O
cocaine	POS	O
users	POS	O
,	POS	O
35	POS	O
cocaine	POS	O
users	POS	O
and	POS	O
32	POS	O
age	POS	O
-	POS	O
matched	POS	O
controls	POS	O
underwent	POS	O
resting	POS	O
and	POS	O
exercise	POS	O
electrocardiography	POS	O
(	POS	O
ECG	POS	O
)	POS	O
and	POS	O
Doppler	POS	O
echocardiography	POS	O
.	POS	O
Findings	POS	O
consistent	POS	O
with	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
were	POS	O
detected	POS	O
in	POS	O
12	POS	O
(	POS	O
34	POS	O
%	POS	O
)	POS	O
patients	POS	O
and	POS	O
3	POS	O
(	POS	O
9	POS	O
%	POS	O
)	POS	O
controls	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Decreased	POS	O
left	POS	O
ventricular	POS	O
systolic	POS	O
function	POS	O
was	POS	O
demonstrated	POS	O
in	POS	O
5	POS	O
(	POS	O
14	POS	O
%	POS	O
)	POS	O
patients	POS	O
,	POS	O
but	POS	O
in	POS	O
none	POS	O
of	POS	O
the	POS	O
controls	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
055	POS	O
)	POS	O
.	POS	O
Finally	POS	O
,	POS	O
resting	POS	O
and	POS	O
peak	POS	O
exercise	POS	O
abnormal	POS	O
left	POS	O
ventricular	POS	O
filling	POS	O
was	POS	O
detected	POS	O
in	POS	O
38	POS	O
and	POS	O
35	POS	O
%	POS	O
of	POS	O
patients	POS	O
as	POS	O
compared	POS	O
to	POS	O
19	POS	O
and	POS	O
9	POS	O
%	POS	O
of	POS	O
controls	POS	O
,	POS	O
respectively	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
11	POS	O
and	POS	O
0	POS	O
.	POS	O
02	POS	O
,	POS	O
respectively	POS	O
)	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
coronary	POS	O
artery	POS	O
or	POS	O
myocardial	POS	B-NP
disease	POS	I-NP
is	POS	O
common	POS	O
(	POS	O
38	POS	O
%	POS	O
)	POS	O
in	POS	O
young	POS	O
asymptomatic	POS	O
chronic	POS	O
cocaine	POS	O
users	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
screening	POS	O
ECG	POS	O
and	POS	O
echocardiography	POS	O
may	POS	O
be	POS	O
warranted	POS	O
in	POS	O
these	POS	O
patients	POS	O
.	POS	O
Cardioprotective	POS	O
effects	POS	O
of	POS	O
Picrorrhiza	POS	O
kurroa	POS	O
against	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
myocardial	POS	O
stress	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
cardioprotective	POS	O
effect	POS	O
of	POS	O
the	POS	O
ethanol	POS	O
extract	POS	O
of	POS	O
Picrorrhiza	POS	O
kurroa	POS	O
rhizomes	POS	O
and	POS	O
roots	POS	O
(	POS	O
PK	POS	O
)	POS	O
on	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
in	POS	O
rats	POS	O
with	POS	O
respect	POS	O
to	POS	O
lipid	POS	O
metabolism	POS	O
in	POS	O
serum	POS	O
and	POS	O
heart	POS	O
tissue	POS	O
has	POS	O
been	POS	O
investigated	POS	O
.	POS	O
Oral	POS	O
pre	POS	O
-	POS	O
treatment	POS	O
with	POS	O
PK	POS	O
(	POS	O
80	POS	O
mg	POS	O
kg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
day	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
for	POS	O
15	POS	O
days	POS	O
)	POS	O
significantly	POS	O
prevented	POS	O
the	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
and	POS	O
maintained	POS	O
the	POS	O
rats	POS	O
at	POS	O
near	POS	O
normal	POS	O
status	POS	O
.	POS	O
Phase	POS	O
2	POS	O
early	POS	O
afterdepolarization	POS	B-NP
as	POS	O
a	POS	O
trigger	POS	O
of	POS	O
polymorphic	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
in	POS	O
acquired	POS	B-NP
long	POS	I-NP
-	POS	I-NP
QT	POS	I-NP
syndrome	POS	I-NP
:	POS	O
direct	POS	O
evidence	POS	O
from	POS	O
intracellular	POS	O
recordings	POS	O
in	POS	O
the	POS	O
intact	POS	O
left	POS	O
ventricular	POS	O
wall	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
This	POS	O
study	POS	O
examined	POS	O
the	POS	O
role	POS	O
of	POS	O
phase	POS	O
2	POS	O
early	POS	O
afterdepolarization	POS	B-NP
(	POS	O
EAD	POS	B-NP
)	POS	O
in	POS	O
producing	POS	O
a	POS	O
trigger	POS	O
to	POS	O
initiate	POS	O
torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
(	POS	O
TdP	POS	B-NP
)	POS	O
with	POS	O
QT	POS	B-NP
prolongation	POS	I-NP
induced	POS	O
by	POS	O
dl	POS	O
-	POS	O
sotalol	POS	O
and	POS	O
azimilide	POS	O
.	POS	O
The	POS	O
contribution	POS	O
of	POS	O
transmural	POS	O
dispersion	POS	O
of	POS	O
repolarization	POS	O
(	POS	O
TDR	POS	O
)	POS	O
to	POS	O
transmural	POS	O
propagation	POS	O
of	POS	O
EAD	POS	B-NP
and	POS	O
the	POS	O
maintenance	POS	O
of	POS	O
TdP	POS	B-NP
was	POS	O
also	POS	O
evaluated	POS	O
.	POS	O
METHODS	POS	O
AND	POS	O
RESULTS	POS	O
:	POS	O
Transmembrane	POS	O
action	POS	O
potentials	POS	O
from	POS	O
epicardium	POS	O
,	POS	O
midmyocardium	POS	O
,	POS	O
and	POS	O
endocardium	POS	O
were	POS	O
recorded	POS	O
simultaneously	POS	O
,	POS	O
together	POS	O
with	POS	O
a	POS	O
transmural	POS	O
ECG	POS	O
,	POS	O
in	POS	O
arterially	POS	O
perfused	POS	O
canine	POS	O
and	POS	O
rabbit	POS	O
left	POS	O
ventricular	POS	O
preparations	POS	O
.	POS	O
dl	POS	O
-	POS	O
Sotalol	POS	O
preferentially	POS	O
prolonged	POS	O
action	POS	O
potential	POS	O
duration	POS	O
(	POS	O
APD	POS	O
)	POS	O
in	POS	O
M	POS	O
cells	POS	O
dose	POS	O
-	POS	O
dependently	POS	O
(	POS	O
1	POS	O
to	POS	O
100	POS	O
micromol	POS	O
/	POS	O
L	POS	O
)	POS	O
,	POS	O
leading	POS	O
to	POS	O
QT	POS	O
prolongation	POS	O
and	POS	O
an	POS	O
increase	POS	O
in	POS	O
TDR	POS	O
.	POS	O
Azimilide	POS	O
,	POS	O
however	POS	O
,	POS	O
significantly	POS	O
prolonged	POS	O
APD	POS	O
and	POS	O
QT	POS	O
interval	POS	O
at	POS	O
concentrations	POS	O
from	POS	O
0	POS	O
.	POS	O
1	POS	O
to	POS	O
10	POS	O
micromol	POS	O
/	POS	O
L	POS	O
but	POS	O
shortened	POS	O
them	POS	O
at	POS	O
30	POS	O
micromol	POS	O
/	POS	O
L	POS	O
.	POS	O
Unlike	POS	O
dl	POS	O
-	POS	O
sotalol	POS	O
,	POS	O
azimilide	POS	O
(	POS	O
>	POS	O
3	POS	O
micromol	POS	O
/	POS	O
L	POS	O
)	POS	O
increased	POS	O
epicardial	POS	O
APD	POS	O
markedly	POS	O
,	POS	O
causing	POS	O
a	POS	O
diminished	POS	O
TDR	POS	O
.	POS	O
Although	POS	O
both	POS	O
dl	POS	O
-	POS	O
sotalol	POS	O
and	POS	O
azimilide	POS	O
rarely	POS	O
induced	POS	O
EADs	POS	B-NP
in	POS	O
canine	POS	O
left	POS	O
ventricles	POS	O
,	POS	O
they	POS	O
produced	POS	O
frequent	POS	O
EADs	POS	B-NP
in	POS	O
rabbits	POS	O
,	POS	O
in	POS	O
which	POS	O
more	POS	O
pronounced	POS	O
QT	POS	B-NP
prolongation	POS	I-NP
was	POS	O
seen	POS	O
.	POS	O
An	POS	O
increase	POS	O
in	POS	O
TDR	POS	O
by	POS	O
dl	POS	O
-	POS	O
sotalol	POS	O
facilitated	POS	O
transmural	POS	O
propagation	POS	O
of	POS	O
EADs	POS	B-NP
that	POS	O
initiated	POS	O
multiple	POS	O
episodes	POS	O
of	POS	O
spontaneous	POS	O
TdP	POS	B-NP
in	POS	O
3	POS	O
of	POS	O
6	POS	O
rabbit	POS	O
left	POS	O
ventricles	POS	O
.	POS	O
Of	POS	O
note	POS	O
,	POS	O
although	POS	O
azimilide	POS	O
(	POS	O
3	POS	O
to	POS	O
10	POS	O
micromol	POS	O
/	POS	O
L	POS	O
)	POS	O
increased	POS	O
APD	POS	O
more	POS	O
than	POS	O
dl	POS	O
-	POS	O
sotalol	POS	O
,	POS	O
its	POS	O
EADs	POS	B-NP
often	POS	O
failed	POS	O
to	POS	O
propagate	POS	O
transmurally	POS	O
,	POS	O
probably	POS	O
because	POS	O
of	POS	O
a	POS	O
diminished	POS	O
TDR	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
This	POS	O
study	POS	O
provides	POS	O
the	POS	O
first	POS	O
direct	POS	O
evidence	POS	O
from	POS	O
intracellular	POS	O
action	POS	O
potential	POS	O
recordings	POS	O
that	POS	O
phase	POS	O
2	POS	O
EAD	POS	B-NP
can	POS	O
be	POS	O
generated	POS	O
from	POS	O
intact	POS	O
ventricular	POS	O
wall	POS	O
and	POS	O
produce	POS	O
a	POS	O
trigger	POS	O
to	POS	O
initiate	POS	O
the	POS	O
onset	POS	O
of	POS	O
TdP	POS	B-NP
under	POS	O
QT	POS	O
prolongation	POS	O
.	POS	O
A	POS	O
pilot	POS	O
study	POS	O
to	POS	O
assess	POS	O
the	POS	O
safety	POS	O
of	POS	O
dobutamine	POS	O
stress	POS	O
echocardiography	POS	O
in	POS	O
the	POS	O
emergency	POS	O
department	POS	O
evaluation	POS	O
of	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
.	POS	O
STUDY	POS	O
OBJECTIVE	POS	O
:	POS	O
Chest	POS	B-NP
pain	POS	I-NP
in	POS	O
the	POS	O
setting	POS	O
of	POS	O
cocaine	POS	O
use	POS	O
poses	POS	O
a	POS	O
diagnostic	POS	O
dilemma	POS	O
.	POS	O
Dobutamine	POS	O
stress	POS	O
echocardiography	POS	O
(	POS	O
DSE	POS	O
)	POS	O
is	POS	O
a	POS	O
widely	POS	O
available	POS	O
and	POS	O
sensitive	POS	O
test	POS	O
for	POS	O
evaluating	POS	O
cardiac	POS	B-NP
ischemia	POS	I-NP
.	POS	O
Because	POS	O
of	POS	O
the	POS	O
theoretical	POS	O
concern	POS	O
regarding	POS	O
administration	POS	O
of	POS	O
dobutamine	POS	O
in	POS	O
the	POS	O
setting	POS	O
of	POS	O
cocaine	POS	O
use	POS	O
,	POS	O
we	POS	O
conducted	POS	O
a	POS	O
pilot	POS	O
study	POS	O
to	POS	O
assess	POS	O
the	POS	O
safety	POS	O
of	POS	O
DSE	POS	O
in	POS	O
emergency	POS	O
department	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
.	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
prospective	POS	O
case	POS	O
series	POS	O
was	POS	O
conducted	POS	O
in	POS	O
the	POS	O
intensive	POS	O
diagnostic	POS	O
and	POS	O
treatment	POS	O
unit	POS	O
in	POS	O
the	POS	O
ED	POS	O
of	POS	O
an	POS	O
urban	POS	O
tertiary	POS	O
-	POS	O
care	POS	O
teaching	POS	O
hospital	POS	O
.	POS	O
Patients	POS	O
were	POS	O
eligible	POS	O
for	POS	O
DSE	POS	B-NP
if	POS	O
they	POS	O
had	POS	O
used	POS	O
cocaine	POS	O
within	POS	O
24	POS	O
hours	POS	O
preceding	POS	O
the	POS	O
onset	POS	O
of	POS	O
chest	POS	B-NP
pain	POS	I-NP
and	POS	O
had	POS	O
a	POS	O
normal	POS	O
ECG	POS	O
and	POS	O
tropinin	POS	O
I	POS	O
level	POS	O
.	POS	O
Patients	POS	O
exhibiting	POS	O
signs	POS	O
of	POS	O
continuing	POS	O
cocaine	POS	B-NP
toxicity	POS	I-NP
were	POS	O
excluded	POS	O
from	POS	O
the	POS	O
study	POS	O
.	POS	O
All	POS	O
patients	POS	O
were	POS	O
admitted	POS	O
to	POS	O
the	POS	O
hospital	POS	O
for	POS	O
serial	POS	O
testing	POS	O
after	POS	O
the	POS	O
DSE	POS	O
testing	POS	O
in	POS	O
the	POS	O
intensive	POS	O
diagnostic	POS	O
and	POS	O
treatment	POS	O
unit	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Twenty	POS	O
-	POS	O
four	POS	O
patients	POS	O
were	POS	O
enrolled	POS	O
.	POS	O
Two	POS	O
patients	POS	O
had	POS	O
inadequate	POS	O
resting	POS	O
images	POS	O
,	POS	O
one	POS	O
DSE	POS	O
was	POS	O
terminated	POS	O
because	POS	O
of	POS	O
inferior	POS	B-NP
hypokinesis	POS	I-NP
,	POS	O
another	POS	O
DSE	POS	O
was	POS	O
terminated	POS	O
because	POS	O
of	POS	O
a	POS	O
rate	POS	O
-	POS	O
related	POS	O
atrial	POS	B-NP
conduction	POS	I-NP
deficit	POS	I-NP
,	POS	O
and	POS	O
1	POS	O
patient	POS	O
did	POS	O
not	POS	O
reach	POS	O
the	POS	O
target	POS	O
heart	POS	O
rate	POS	O
.	POS	O
Thus	POS	O
,	POS	O
19	POS	O
patients	POS	O
completed	POS	O
a	POS	O
DSE	POS	O
and	POS	O
reached	POS	O
their	POS	O
target	POS	O
heart	POS	O
rates	POS	O
.	POS	O
None	POS	O
of	POS	O
the	POS	O
patients	POS	O
experienced	POS	O
signs	POS	O
of	POS	O
exaggerated	POS	O
adrenergic	POS	O
response	POS	O
,	POS	O
which	POS	O
was	POS	O
defined	POS	O
as	POS	O
a	POS	O
systolic	POS	O
blood	POS	O
pressure	POS	O
of	POS	O
greater	POS	O
than	POS	O
200	POS	O
mm	POS	O
Hg	POS	O
or	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
tachydysrhythmias	POS	B-NP
(	POS	O
excluding	POS	O
sinus	POS	B-NP
tachycardia	POS	I-NP
)	POS	O
.	POS	O
Further	POS	O
suggesting	POS	O
lack	POS	O
of	POS	O
exaggerated	POS	O
adrenergic	POS	O
response	POS	O
,	POS	O
13	POS	O
(	POS	O
65	POS	O
%	POS	O
)	POS	O
of	POS	O
20	POS	O
patients	POS	O
required	POS	O
supplemental	POS	O
atropine	POS	O
to	POS	O
reach	POS	O
their	POS	O
target	POS	O
heart	POS	O
rates	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
No	POS	O
exaggerated	POS	O
adrenergic	POS	O
response	POS	O
was	POS	O
detected	POS	O
when	POS	O
dobutamine	POS	O
was	POS	O
administered	POS	O
to	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
related	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
.	POS	O
Prenatal	POS	O
cocaine	POS	O
exposure	POS	O
and	POS	O
cranial	POS	O
sonographic	POS	O
findings	POS	O
in	POS	O
preterm	POS	B-NP
infants	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
Prenatal	POS	O
cocaine	POS	O
exposure	POS	O
has	POS	O
been	POS	O
linked	POS	O
with	POS	O
subependymal	POS	B-NP
hemorrhage	POS	I-NP
and	POS	O
the	POS	O
formation	POS	O
of	POS	O
cysts	POS	B-NP
that	POS	O
are	POS	O
detectable	POS	O
on	POS	O
cranial	POS	O
sonography	POS	O
in	POS	O
neonates	POS	O
born	POS	O
at	POS	O
term	POS	O
.	POS	O
We	POS	O
sought	POS	O
to	POS	O
determine	POS	O
if	POS	O
prenatal	POS	O
cocaine	POS	O
exposure	POS	O
increases	POS	O
the	POS	O
incidence	POS	O
of	POS	O
subependymal	POS	B-NP
cysts	POS	I-NP
in	POS	O
preterm	POS	B-NP
infants	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
retrospectively	POS	O
reviewed	POS	O
the	POS	O
medical	POS	O
records	POS	O
and	POS	O
cranial	POS	O
sonograms	POS	O
obtained	POS	O
during	POS	O
a	POS	O
1	POS	O
-	POS	O
year	POS	O
period	POS	O
on	POS	O
122	POS	O
premature	POS	O
(	POS	O
<	POS	O
36	POS	O
weeks	POS	O
of	POS	O
gestation	POS	O
)	POS	O
infants	POS	O
.	POS	O
Infants	POS	O
were	POS	O
categorized	POS	O
into	POS	O
1	POS	O
of	POS	O
2	POS	O
groups	POS	O
:	POS	O
those	POS	O
exposed	POS	O
to	POS	O
cocaine	POS	O
and	POS	O
those	POS	O
not	POS	O
exposed	POS	O
to	POS	O
cocaine	POS	O
.	POS	O
Infants	POS	O
were	POS	O
assigned	POS	O
to	POS	O
the	POS	O
cocaine	POS	O
-	POS	O
exposed	POS	O
group	POS	O
if	POS	O
there	POS	O
was	POS	O
a	POS	O
maternal	POS	O
history	POS	O
of	POS	O
cocaine	POS	B-NP
abuse	POS	I-NP
during	POS	O
pregnancy	POS	O
or	POS	O
if	POS	O
maternal	POS	O
or	POS	O
neonatal	POS	O
urine	POS	O
toxicology	POS	O
results	POS	O
were	POS	O
positive	POS	O
at	POS	O
the	POS	O
time	POS	O
of	POS	O
delivery	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Five	POS	O
of	POS	O
the	POS	O
122	POS	O
infants	POS	O
were	POS	O
excluded	POS	O
from	POS	O
the	POS	O
study	POS	O
because	POS	O
of	POS	O
insufficient	POS	O
medical	POS	O
and	POS	O
drug	POS	O
histories	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
subependymal	POS	B-NP
cysts	POS	I-NP
in	POS	O
the	POS	O
117	POS	O
remaining	POS	O
infants	POS	O
was	POS	O
14	POS	O
%	POS	O
(	POS	O
16	POS	O
of	POS	O
117	POS	O
)	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
subependymal	POS	B-NP
cysts	POS	I-NP
in	POS	O
infants	POS	O
exposed	POS	O
to	POS	O
cocaine	POS	O
prenatally	POS	O
was	POS	O
44	POS	O
%	POS	O
(	POS	O
8	POS	O
of	POS	O
18	POS	O
)	POS	O
compared	POS	O
with	POS	O
8	POS	O
%	POS	O
(	POS	O
8	POS	O
of	POS	O
99	POS	O
)	POS	O
in	POS	O
the	POS	O
unexposed	POS	O
group	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
We	POS	O
found	POS	O
an	POS	O
increased	POS	O
incidence	POS	O
of	POS	O
subependymal	POS	B-NP
cyst	POS	I-NP
formation	POS	O
in	POS	O
preterm	POS	B-NP
infants	POS	O
who	POS	O
were	POS	O
exposed	POS	O
to	POS	O
cocaine	POS	O
prenatally	POS	O
.	POS	O
This	POS	O
result	POS	O
is	POS	O
consistent	POS	O
with	POS	O
results	POS	O
of	POS	O
similar	POS	O
studies	POS	O
in	POS	O
term	POS	O
infants	POS	O
.	POS	O
Thalidomide	POS	B-NP
neuropathy	POS	I-NP
in	POS	O
patients	POS	O
treated	POS	O
for	POS	O
metastatic	POS	B-NP
prostate	POS	I-NP
cancer	POS	I-NP
.	POS	O
We	POS	O
prospectively	POS	O
evaluated	POS	O
thalidomide	POS	O
-	POS	O
induced	POS	O
neuropathy	POS	B-NP
using	POS	O
electrodiagnostic	POS	O
studies	POS	O
.	POS	O
Sixty	POS	O
-	POS	O
seven	POS	O
men	POS	O
with	POS	O
metastatic	POS	B-NP
androgen	POS	I-NP
-	POS	I-NP
independent	POS	I-NP
prostate	POS	I-NP
cancer	POS	I-NP
in	POS	O
an	POS	O
open	POS	O
-	POS	O
label	POS	O
trial	POS	O
of	POS	O
oral	POS	O
thalidomide	POS	O
underwent	POS	O
neurologic	POS	O
examinations	POS	O
and	POS	O
nerve	POS	O
conduction	POS	O
studies	POS	O
(	POS	O
NCS	POS	O
)	POS	O
prior	POS	O
to	POS	O
and	POS	O
at	POS	O
3	POS	O
-	POS	O
month	POS	O
intervals	POS	O
during	POS	O
treatment	POS	O
.	POS	O
NCS	POS	O
included	POS	O
recording	POS	O
of	POS	O
sensory	POS	O
nerve	POS	O
action	POS	O
potentials	POS	O
(	POS	O
SNAPs	POS	O
)	POS	O
from	POS	O
median	POS	O
,	POS	O
radial	POS	O
,	POS	O
ulnar	POS	O
,	POS	O
and	POS	O
sural	POS	O
nerves	POS	O
.	POS	O
SNAP	POS	O
amplitudes	POS	O
for	POS	O
each	POS	O
nerve	POS	O
were	POS	O
expressed	POS	O
as	POS	O
the	POS	O
percentage	POS	O
of	POS	O
its	POS	O
baseline	POS	O
,	POS	O
and	POS	O
the	POS	O
mean	POS	O
of	POS	O
the	POS	O
four	POS	O
was	POS	O
termed	POS	O
the	POS	O
SNAP	POS	O
index	POS	O
.	POS	O
A	POS	O
40	POS	O
%	POS	O
decline	POS	O
in	POS	O
the	POS	O
SNAP	POS	O
index	POS	O
was	POS	O
considered	POS	O
clinically	POS	O
significant	POS	O
.	POS	O
Thalidomide	POS	B-NP
was	POS	O
discontinued	POS	O
in	POS	O
55	POS	O
patients	POS	O
for	POS	O
lack	POS	O
of	POS	O
therapeutic	POS	O
response	POS	O
.	POS	O
Of	POS	O
67	POS	O
patients	POS	O
initially	POS	O
enrolled	POS	O
,	POS	O
24	POS	O
remained	POS	O
on	POS	O
thalidomide	POS	O
for	POS	O
3	POS	O
months	POS	O
,	POS	O
8	POS	O
remained	POS	O
at	POS	O
6	POS	O
months	POS	O
,	POS	O
and	POS	O
3	POS	O
remained	POS	O
at	POS	O
9	POS	O
months	POS	O
.	POS	O
Six	POS	O
patients	POS	O
developed	POS	O
neuropathy	POS	B-NP
.	POS	O
Clinical	POS	O
symptoms	POS	O
and	POS	O
a	POS	O
decline	POS	O
in	POS	O
the	POS	O
SNAP	POS	O
index	POS	O
occurred	POS	O
concurrently	POS	O
.	POS	O
Older	POS	O
age	POS	O
and	POS	O
cumulative	POS	O
dose	POS	O
were	POS	O
possible	POS	O
contributing	POS	O
factors	POS	O
.	POS	O
Neuropathy	POS	B-NP
may	POS	O
thus	POS	O
be	POS	O
a	POS	O
common	POS	O
complication	POS	O
of	POS	O
thalidomide	POS	O
in	POS	O
older	POS	O
patients	POS	O
.	POS	O
The	POS	O
SNAP	POS	O
index	POS	O
can	POS	O
be	POS	O
used	POS	O
to	POS	O
monitor	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
,	POS	O
but	POS	O
not	POS	O
for	POS	O
early	POS	O
detection	POS	O
.	POS	O
Overexpression	POS	O
of	POS	O
copper	POS	O
/	POS	O
zinc	POS	O
-	POS	O
superoxide	POS	O
dismutase	POS	O
protects	POS	O
from	POS	O
kanamycin	POS	O
-	POS	O
induced	POS	O
hearing	POS	B-NP
loss	POS	I-NP
.	POS	O
The	POS	O
participation	POS	O
of	POS	O
reactive	POS	O
oxygen	POS	O
species	POS	O
in	POS	O
aminoglycoside	POS	O
-	POS	O
induced	POS	O
ototoxicity	POS	B-NP
has	POS	O
been	POS	O
deduced	POS	O
from	POS	O
observations	POS	O
that	POS	O
aminoglycoside	POS	O
-	POS	O
iron	POS	O
complexes	POS	O
catalyze	POS	O
the	POS	O
formation	POS	O
of	POS	O
superoxide	POS	O
radicals	POS	O
in	POS	O
vitro	POS	O
and	POS	O
that	POS	O
antioxidants	POS	O
attenuate	POS	O
ototoxicity	POS	B-NP
in	POS	O
vivo	POS	O
.	POS	O
We	POS	O
therefore	POS	O
hypothesized	POS	O
that	POS	O
overexpression	POS	O
of	POS	O
Cu	POS	O
/	POS	O
Zn	POS	O
-	POS	O
superoxide	POS	O
dismutase	POS	O
(	POS	O
h	POS	O
-	POS	O
SOD1	POS	O
)	POS	O
should	POS	O
protect	POS	O
transgenic	POS	O
mice	POS	O
from	POS	O
ototoxicity	POS	B-NP
.	POS	O
Immunocytochemistry	POS	O
confirmed	POS	O
expression	POS	O
of	POS	O
h	POS	O
-	POS	O
SOD1	POS	O
in	POS	O
inner	POS	O
ear	POS	O
tissues	POS	O
of	POS	O
transgenic	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
-	POS	O
TgN	POS	O
[	POS	O
SOD1	POS	O
]	POS	O
3Cje	POS	O
mice	POS	O
.	POS	O
Transgenic	POS	O
and	POS	O
nontransgenic	POS	O
littermates	POS	O
received	POS	O
kanamycin	POS	O
(	POS	O
400	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
weight	POS	O
/	POS	O
day	POS	O
)	POS	O
for	POS	O
10	POS	O
days	POS	O
beginning	POS	O
on	POS	O
day	POS	O
10	POS	O
after	POS	O
birth	POS	O
.	POS	O
Auditory	POS	O
thresholds	POS	O
were	POS	O
tested	POS	O
by	POS	O
evoked	POS	O
auditory	POS	O
brain	POS	O
stem	POS	O
responses	POS	O
at	POS	O
1	POS	O
month	POS	O
after	POS	O
birth	POS	O
.	POS	O
In	POS	O
nontransgenic	POS	O
animals	POS	O
,	POS	O
the	POS	O
threshold	POS	O
in	POS	O
the	POS	O
kanamycin	POS	O
-	POS	O
treated	POS	O
group	POS	O
was	POS	O
45	POS	O
-	POS	O
50	POS	O
dB	POS	O
higher	POS	O
than	POS	O
in	POS	O
saline	POS	O
-	POS	O
injected	POS	O
controls	POS	O
.	POS	O
In	POS	O
the	POS	O
transgenic	POS	O
group	POS	O
,	POS	O
kanamycin	POS	O
increased	POS	O
the	POS	O
threshold	POS	O
by	POS	O
only	POS	O
15	POS	O
dB	POS	O
over	POS	O
the	POS	O
respective	POS	O
controls	POS	O
.	POS	O
The	POS	O
effects	POS	O
were	POS	O
similar	POS	O
at	POS	O
12	POS	O
and	POS	O
24	POS	O
kHz	POS	O
.	POS	O
The	POS	O
protection	POS	O
by	POS	O
overexpression	POS	O
of	POS	O
superoxide	POS	O
dismutase	POS	O
supports	POS	O
the	POS	O
hypothesis	POS	O
that	POS	O
oxidant	POS	O
stress	POS	O
plays	POS	O
a	POS	O
significant	POS	O
role	POS	O
in	POS	O
aminoglycoside	POS	O
-	POS	O
induced	POS	O
ototoxicity	POS	B-NP
.	POS	O
The	POS	O
results	POS	O
also	POS	O
suggest	POS	O
transgenic	POS	O
animals	POS	O
as	POS	O
suitable	POS	O
models	POS	O
to	POS	O
investigate	POS	O
the	POS	O
underlying	POS	O
mechanisms	POS	O
and	POS	O
possible	POS	O
strategies	POS	O
for	POS	O
prevention	POS	O
.	POS	O
Fatty	POS	O
liver	POS	O
induced	POS	O
by	POS	O
tetracycline	POS	O
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
Dose	POS	O
-	POS	O
response	POS	O
relationships	POS	O
and	POS	O
effect	POS	O
of	POS	O
sex	POS	O
.	POS	O
Dose	POS	O
-	POS	O
response	POS	O
relationships	POS	O
,	POS	O
biochemical	POS	O
mechanisms	POS	O
,	POS	O
and	POS	O
sex	POS	O
differences	POS	O
in	POS	O
the	POS	O
experimental	POS	O
fatty	POS	O
liver	POS	O
induced	POS	O
by	POS	O
tetracycline	POS	O
were	POS	O
studied	POS	O
in	POS	O
the	POS	O
intact	POS	O
rat	POS	O
and	POS	O
with	POS	O
the	POS	O
isolated	POS	O
perfused	POS	O
rat	POS	O
liver	POS	O
in	POS	O
vitro	POS	O
.	POS	O
In	POS	O
the	POS	O
intact	POS	O
male	POS	O
and	POS	O
female	POS	O
rat	POS	O
,	POS	O
no	POS	O
direct	POS	O
relationship	POS	O
was	POS	O
observed	POS	O
between	POS	O
dose	POS	O
of	POS	O
tetracycline	POS	O
and	POS	O
hepatic	POS	O
accumulation	POS	O
of	POS	O
triglyceride	POS	O
.	POS	O
With	POS	O
provision	POS	O
of	POS	O
adequate	POS	O
oleic	POS	O
acid	POS	O
as	POS	O
a	POS	O
substrate	POS	O
for	POS	O
the	POS	O
isolated	POS	O
perfused	POS	O
liver	POS	O
,	POS	O
a	POS	O
direct	POS	O
relationship	POS	O
was	POS	O
observed	POS	O
between	POS	O
dose	POS	O
of	POS	O
tetracycline	POS	O
and	POS	O
both	POS	O
accumulation	POS	O
of	POS	O
triglyceride	POS	O
in	POS	O
the	POS	O
liver	POS	O
and	POS	O
depression	POS	B-NP
of	POS	O
output	POS	O
of	POS	O
triglyceride	POS	O
by	POS	O
livers	POS	O
from	POS	O
male	POS	O
and	POS	O
female	POS	O
rats	POS	O
.	POS	O
Marked	POS	O
differences	POS	O
were	POS	O
observed	POS	O
between	POS	O
female	POS	O
and	POS	O
male	POS	O
rats	POS	O
with	POS	O
regard	POS	O
to	POS	O
base	POS	O
line	POS	O
(	POS	O
control	POS	O
)	POS	O
hepatic	POS	O
concentration	POS	O
of	POS	O
triglyceride	POS	O
and	POS	O
output	POS	O
of	POS	O
triglyceride	POS	O
.	POS	O
Accumulation	POS	O
of	POS	O
hepatic	POS	O
triglyceride	POS	O
,	POS	O
as	POS	O
a	POS	O
per	POS	O
cent	POS	O
of	POS	O
control	POS	O
values	POS	O
,	POS	O
in	POS	O
response	POS	O
to	POS	O
graded	POS	O
doses	POS	O
of	POS	O
tetracycline	POS	O
,	POS	O
did	POS	O
not	POS	O
differ	POS	O
significantly	POS	O
between	POS	O
male	POS	O
,	POS	O
female	POS	O
and	POS	O
pregnant	POS	O
rat	POS	O
livers	POS	O
.	POS	O
However	POS	O
,	POS	O
livers	POS	O
from	POS	O
female	POS	O
,	POS	O
and	POS	O
especially	POS	O
pregnant	POS	O
female	POS	O
rats	POS	O
,	POS	O
were	POS	O
strikingly	POS	O
resistant	POS	O
to	POS	O
the	POS	O
effects	POS	O
of	POS	O
tetracycline	POS	O
on	POS	O
depression	POS	B-NP
of	POS	O
output	POS	O
of	POS	O
triglyceride	POS	O
under	POS	O
these	POS	O
experimental	POS	O
conditions	POS	O
.	POS	O
These	POS	O
differences	POS	O
between	POS	O
the	POS	O
sexes	POS	O
could	POS	O
not	POS	O
be	POS	O
related	POS	O
to	POS	O
altered	POS	O
disposition	POS	O
of	POS	O
tetracycline	POS	O
or	POS	O
altered	POS	O
uptake	POS	O
of	POS	O
oleic	POS	O
acid	POS	O
.	POS	O
Depressed	POS	O
hepatic	POS	O
secretion	POS	O
of	POS	O
triglyceride	POS	O
accounted	POS	O
only	POS	O
for	POS	O
30	POS	O
to	POS	O
50	POS	O
%	POS	O
of	POS	O
accumulated	POS	O
hepatic	POS	O
triglyceride	POS	O
,	POS	O
indicating	POS	O
that	POS	O
additional	POS	O
mechanisms	POS	O
must	POS	O
be	POS	O
involved	POS	O
in	POS	O
the	POS	O
production	POS	O
of	POS	O
the	POS	O
triglyceride	POS	O
-	POS	O
rich	POS	O
fatty	POS	O
liver	POS	O
in	POS	O
response	POS	O
to	POS	O
tetracycline	POS	O
.	POS	O
Prednisone	POS	O
induces	POS	O
anxiety	POS	B-NP
and	POS	O
glial	POS	O
cerebral	POS	O
changes	POS	O
in	POS	O
rats	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
assess	POS	O
whether	POS	O
prednisone	POS	O
(	POS	O
PDN	POS	O
)	POS	O
produces	POS	O
anxiety	POS	B-NP
and	POS	O
/	POS	O
or	POS	O
cerebral	POS	O
glial	POS	O
changes	POS	O
in	POS	O
rats	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Male	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
studied	POS	O
and	POS	O
3	POS	O
groups	POS	O
were	POS	O
formed	POS	O
(	POS	O
8	POS	O
rats	POS	O
per	POS	O
group	POS	O
)	POS	O
.	POS	O
The	POS	O
moderate	POS	O
-	POS	O
dose	POS	O
group	POS	O
received	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
PDN	POS	O
released	POS	O
from	POS	O
a	POS	O
subcutaneous	POS	O
implant	POS	O
.	POS	O
In	POS	O
the	POS	O
high	POS	O
-	POS	O
dose	POS	O
group	POS	O
,	POS	O
implants	POS	O
containing	POS	O
PDN	POS	O
equivalent	POS	O
to	POS	O
60	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
were	POS	O
applied	POS	O
.	POS	O
In	POS	O
the	POS	O
control	POS	O
group	POS	O
implants	POS	O
contained	POS	O
no	POS	O
PDN	POS	O
.	POS	O
Anxiety	POS	O
was	POS	O
assessed	POS	O
using	POS	O
an	POS	O
open	POS	O
field	POS	O
and	POS	O
elevated	POS	O
plus	POS	O
-	POS	O
maze	POS	O
devices	POS	O
.	POS	O
The	POS	O
number	POS	O
of	POS	O
cells	POS	O
and	POS	O
cytoplasmic	POS	O
transformation	POS	O
of	POS	O
astrocytes	POS	O
and	POS	O
microglia	POS	O
cells	POS	O
were	POS	O
assessed	POS	O
by	POS	O
immunohistochemical	POS	O
analyses	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Anxiety	POS	B-NP
was	POS	O
documented	POS	O
in	POS	O
both	POS	O
groups	POS	O
of	POS	O
PDN	POS	O
treated	POS	O
rats	POS	O
compared	POS	O
with	POS	O
controls	POS	O
.	POS	O
The	POS	O
magnitude	POS	O
of	POS	O
transformation	POS	O
of	POS	O
the	POS	O
microglia	POS	O
assessed	POS	O
by	POS	O
the	POS	O
number	POS	O
of	POS	O
intersections	POS	O
was	POS	O
significantly	POS	O
higher	POS	O
in	POS	O
the	POS	O
PDN	POS	O
groups	POS	O
than	POS	O
in	POS	O
controls	POS	O
in	POS	O
the	POS	O
prefrontal	POS	O
cortex	POS	O
(	POS	O
moderate	POS	O
-	POS	O
dose	POS	O
,	POS	O
24	POS	O
.	POS	O
1	POS	O
;	POS	O
high	POS	O
-	POS	O
dose	POS	O
,	POS	O
23	POS	O
.	POS	O
6	POS	O
;	POS	O
controls	POS	O
18	POS	O
.	POS	O
7	POS	O
;	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
and	POS	O
striatum	POS	O
(	POS	O
moderate	POS	O
-	POS	O
dose	POS	O
25	POS	O
.	POS	O
6	POS	O
;	POS	O
high	POS	O
-	POS	O
dose	POS	O
26	POS	O
.	POS	O
3	POS	O
;	POS	O
controls	POS	O
18	POS	O
.	POS	O
9	POS	O
;	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
but	POS	O
not	POS	O
in	POS	O
hippocampus	POS	O
.	POS	O
The	POS	O
number	POS	O
of	POS	O
stained	POS	O
microglia	POS	O
cells	POS	O
was	POS	O
significantly	POS	O
higher	POS	O
in	POS	O
the	POS	O
PDN	POS	O
treated	POS	O
groups	POS	O
in	POS	O
the	POS	O
prefrontal	POS	O
cortex	POS	O
than	POS	O
in	POS	O
controls	POS	O
(	POS	O
moderate	POS	O
-	POS	O
dose	POS	O
,	POS	O
29	POS	O
.	POS	O
1	POS	O
;	POS	O
high	POS	O
-	POS	O
dose	POS	O
,	POS	O
28	POS	O
.	POS	O
4	POS	O
;	POS	O
control	POS	O
,	POS	O
17	POS	O
.	POS	O
7	POS	O
cells	POS	O
per	POS	O
field	POS	O
;	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Stained	POS	O
microglia	POS	O
cells	POS	O
were	POS	O
significantly	POS	O
more	POS	O
numerous	POS	O
striatum	POS	O
and	POS	O
hippocampus	POS	O
in	POS	O
the	POS	O
high	POS	O
-	POS	O
dose	POS	O
group	POS	O
compared	POS	O
to	POS	O
controls	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Subacute	POS	O
exposure	POS	O
to	POS	O
PDN	POS	O
induced	POS	O
anxiety	POS	B-NP
and	POS	O
reactivity	POS	O
of	POS	O
microglia	POS	O
.	POS	O
The	POS	O
relevance	POS	O
of	POS	O
these	POS	O
features	POS	O
for	POS	O
patients	POS	O
using	POS	O
PDN	POS	B-NP
remains	POS	O
to	POS	O
be	POS	O
elucidated	POS	O
.	POS	O
Phase	POS	O
II	POS	O
study	POS	O
of	POS	O
carboplatin	POS	O
and	POS	O
liposomal	POS	O
doxorubicin	POS	O
in	POS	O
patients	POS	O
with	POS	O
recurrent	POS	O
squamous	POS	B-NP
cell	POS	I-NP
carcinoma	POS	I-NP
of	POS	I-NP
the	POS	I-NP
cervix	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
The	POS	O
activity	POS	O
of	POS	O
the	POS	O
combination	POS	O
of	POS	O
carboplatin	POS	O
and	POS	O
liposomal	POS	O
doxorubicin	POS	O
was	POS	O
tested	POS	O
in	POS	O
a	POS	O
Phase	POS	O
II	POS	O
study	POS	O
of	POS	O
patients	POS	O
with	POS	O
recurrent	POS	O
cervical	POS	B-NP
carcinoma	POS	I-NP
.	POS	O
METHODS	POS	O
:	POS	O
The	POS	O
combination	POS	O
of	POS	O
carboplatin	POS	O
(	POS	O
area	POS	O
under	POS	O
the	POS	O
concentration	POS	O
curve	POS	O
[	POS	O
AUC	POS	O
]	POS	O
,	POS	O
5	POS	O
)	POS	O
and	POS	O
liposomal	POS	O
doxorubicin	POS	O
(	POS	O
Doxil	POS	O
;	POS	O
starting	POS	O
dose	POS	O
,	POS	O
40	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
)	POS	O
was	POS	O
administered	POS	O
intravenously	POS	O
every	POS	O
28	POS	O
days	POS	O
to	POS	O
37	POS	O
patients	POS	O
with	POS	O
recurrent	POS	O
squamous	POS	B-NP
cell	POS	I-NP
cervical	POS	I-NP
carcinoma	POS	I-NP
to	POS	O
determine	POS	O
antitumor	POS	O
activity	POS	O
and	POS	O
toxicity	POS	B-NP
profile	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Twenty	POS	O
-	POS	O
nine	POS	O
patients	POS	O
were	POS	O
assessable	POS	O
for	POS	O
response	POS	O
,	POS	O
and	POS	O
35	POS	O
patients	POS	O
were	POS	O
assessable	POS	O
for	POS	O
toxicity	POS	B-NP
.	POS	O
The	POS	O
overall	POS	O
response	POS	O
rate	POS	O
was	POS	O
38	POS	O
%	POS	O
,	POS	O
the	POS	O
median	POS	O
time	POS	O
to	POS	O
response	POS	O
was	POS	O
10	POS	O
weeks	POS	O
,	POS	O
the	POS	O
median	POS	O
duration	POS	O
of	POS	O
response	POS	O
was	POS	O
26	POS	O
weeks	POS	O
,	POS	O
and	POS	O
the	POS	O
median	POS	O
survival	POS	O
was	POS	O
37	POS	O
weeks	POS	O
.	POS	O
The	POS	O
main	POS	O
toxic	POS	O
effect	POS	O
was	POS	O
myelosuppression	POS	B-NP
,	POS	O
with	POS	O
Grade	POS	O
3	POS	O
and	POS	O
4	POS	O
neutropenia	POS	B-NP
in	POS	O
16	POS	O
patients	POS	O
,	POS	O
anemia	POS	B-NP
in	POS	O
12	POS	O
patients	POS	O
,	POS	O
thrombocytopenia	POS	B-NP
in	POS	O
11	POS	O
patients	POS	O
,	POS	O
and	POS	O
neutropenic	POS	B-NP
fever	POS	I-NP
in	POS	O
3	POS	O
patients	POS	O
.	POS	O
Four	POS	O
patients	POS	O
had	POS	O
five	POS	O
infusion	POS	O
-	POS	O
related	POS	O
reactions	POS	O
during	POS	O
the	POS	O
infusion	POS	O
of	POS	O
liposomal	POS	O
doxorubicin	POS	O
,	POS	O
leading	POS	O
to	POS	O
treatment	POS	O
discontinuation	POS	O
in	POS	O
three	POS	O
patients	POS	O
.	POS	O
Grade	POS	O
>	POS	O
or	POS	O
=	POS	O
2	POS	O
nonhematologic	POS	O
toxicity	POS	B-NP
included	POS	O
nausea	POS	B-NP
in	POS	O
17	POS	O
patients	POS	O
,	POS	O
emesis	POS	B-NP
in	POS	O
14	POS	O
patients	POS	O
,	POS	O
fatigue	POS	B-NP
in	POS	O
9	POS	O
patients	POS	O
,	POS	O
mucositis	POS	B-NP
and	POS	O
/	POS	O
or	POS	O
stomatitis	POS	B-NP
in	POS	O
8	POS	O
patients	POS	O
,	POS	O
constipation	POS	B-NP
in	POS	O
6	POS	O
patients	POS	O
,	POS	O
weight	POS	B-NP
loss	POS	I-NP
in	POS	O
5	POS	O
patients	POS	O
,	POS	O
hand	POS	B-NP
-	POS	I-NP
foot	POS	I-NP
syndrome	POS	I-NP
in	POS	O
2	POS	O
patients	POS	O
,	POS	O
and	POS	O
skin	POS	B-NP
reactions	POS	I-NP
in	POS	O
3	POS	O
patients	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
combination	POS	O
of	POS	O
carboplatin	POS	O
and	POS	O
liposomal	POS	O
doxorubicin	POS	O
has	POS	O
modest	POS	O
activity	POS	O
in	POS	O
patients	POS	O
with	POS	O
recurrent	POS	O
cervical	POS	B-NP
carcinoma	POS	I-NP
.	POS	O
Antimicrobial	POS	O
-	POS	O
induced	POS	O
mania	POS	B-NP
(	POS	O
antibiomania	POS	B-NP
)	POS	O
:	POS	O
a	POS	O
review	POS	O
of	POS	O
spontaneous	POS	O
reports	POS	O
.	POS	O
The	POS	O
authors	POS	O
reviewed	POS	O
reported	POS	O
cases	POS	O
of	POS	O
antibiotic	POS	O
-	POS	O
induced	POS	O
manic	POS	B-NP
episodes	POS	O
by	POS	O
means	POS	O
of	POS	O
a	POS	O
MEDLINE	POS	O
and	POS	O
PsychLit	POS	O
search	POS	O
for	POS	O
reports	POS	O
of	POS	O
antibiotic	POS	O
-	POS	O
induced	POS	O
mania	POS	B-NP
.	POS	O
Unpublished	POS	O
reports	POS	O
were	POS	O
requested	POS	O
from	POS	O
the	POS	O
World	POS	O
Health	POS	O
Organization	POS	O
(	POS	O
WHO	POS	O
)	POS	O
and	POS	O
the	POS	O
Food	POS	O
and	POS	O
Drug	POS	O
Administration	POS	O
(	POS	O
FDA	POS	O
)	POS	O
.	POS	O
Twenty	POS	O
-	POS	O
one	POS	O
reports	POS	O
of	POS	O
antimicrobial	POS	O
-	POS	O
induced	POS	O
mania	POS	B-NP
were	POS	O
found	POS	O
in	POS	O
the	POS	O
literature	POS	O
.	POS	O
There	POS	O
were	POS	O
6	POS	O
cases	POS	O
implicating	POS	O
clarithromycin	POS	O
,	POS	O
13	POS	O
implicating	POS	O
isoniazid	POS	O
,	POS	O
and	POS	O
1	POS	O
case	POS	O
each	POS	O
implicating	POS	O
erythromycin	POS	O
and	POS	O
amoxicillin	POS	O
.	POS	O
The	POS	O
WHO	POS	O
reported	POS	O
82	POS	O
cases	POS	O
.	POS	O
Of	POS	O
these	POS	O
,	POS	O
clarithromycin	POS	O
was	POS	O
implicated	POS	O
in	POS	O
23	POS	O
(	POS	O
27	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
cases	POS	O
,	POS	O
ciprofloxacin	POS	O
in	POS	O
12	POS	O
(	POS	O
14	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
cases	POS	O
,	POS	O
and	POS	O
ofloxacin	POS	O
in	POS	O
10	POS	O
(	POS	O
12	POS	O
%	POS	O
)	POS	O
cases	POS	O
.	POS	O
Cotrimoxazole	POS	O
,	POS	O
metronidazole	POS	O
,	POS	O
and	POS	O
erythromycin	POS	O
were	POS	O
involved	POS	O
in	POS	O
15	POS	O
reported	POS	O
manic	POS	B-NP
episodes	POS	O
.	POS	O
Cases	POS	O
reported	POS	O
by	POS	O
the	POS	O
FDA	POS	O
showed	POS	O
clarithromycin	POS	O
and	POS	O
ciprofloxacin	POS	O
to	POS	O
be	POS	O
the	POS	O
most	POS	O
frequently	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
mania	POS	B-NP
.	POS	O
Statistical	POS	O
analysis	POS	O
of	POS	O
the	POS	O
data	POS	O
would	POS	O
not	POS	O
have	POS	O
demonstrated	POS	O
a	POS	O
significant	POS	O
statistical	POS	O
correlative	POS	O
risk	POS	O
and	POS	O
was	POS	O
therefore	POS	O
not	POS	O
undertaken	POS	O
.	POS	O
Patients	POS	O
have	POS	O
an	POS	O
increased	POS	O
risk	POS	O
of	POS	O
developing	POS	O
mania	POS	B-NP
while	POS	O
being	POS	O
treated	POS	O
with	POS	O
antimicrobials	POS	O
.	POS	O
Although	POS	O
this	POS	O
is	POS	O
not	POS	O
a	POS	O
statistically	POS	O
significant	POS	O
risk	POS	O
,	POS	O
physicians	POS	O
must	POS	O
be	POS	O
aware	POS	O
of	POS	O
the	POS	O
effect	POS	O
and	POS	O
reversibility	POS	O
.	POS	O
Further	POS	O
research	POS	O
clearly	POS	O
is	POS	O
required	POS	O
to	POS	O
determine	POS	O
the	POS	O
incidence	POS	O
of	POS	O
antimicrobial	POS	O
-	POS	O
induced	POS	O
mania	POS	B-NP
,	POS	O
the	POS	O
relative	POS	O
risk	POS	O
factors	POS	O
of	POS	O
developing	POS	O
an	POS	O
antimicrobial	POS	O
-	POS	O
induced	POS	O
manic	POS	B-NP
episode	POS	O
among	POS	O
various	POS	O
demographic	POS	O
populations	POS	O
,	POS	O
and	POS	O
the	POS	O
incidence	POS	O
of	POS	O
patients	POS	O
who	POS	O
continue	POS	O
to	POS	O
have	POS	O
persistent	POS	O
affective	POS	B-NP
disorders	POS	I-NP
once	POS	O
the	POS	O
initial	POS	O
episode	POS	O
,	POS	O
which	POS	O
occurs	POS	O
while	POS	O
the	POS	O
patient	POS	O
is	POS	O
taking	POS	O
antibiotics	POS	O
,	POS	O
subsides	POS	O
.	POS	O
The	POS	O
authors	POS	O
elected	POS	O
to	POS	O
name	POS	O
this	POS	O
syndrome	POS	O
"	POS	O
antibiomania	POS	B-NP
.	POS	O
"	POS	O
Levodopa	POS	O
-	POS	O
induced	POS	O
ocular	POS	B-NP
dyskinesias	POS	I-NP
in	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
Levodopa	POS	O
-	POS	O
induced	POS	O
ocular	POS	B-NP
dyskinesias	POS	I-NP
are	POS	O
very	POS	O
uncommon	POS	O
.	POS	O
Usually	POS	O
they	POS	O
occur	POS	O
simultaneously	POS	O
with	POS	O
limb	POS	O
peak	POS	O
-	POS	O
dose	POS	O
choreatic	POS	B-NP
dyskinesias	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
on	POS	O
a	POS	O
patient	POS	O
with	POS	O
leftward	POS	O
and	POS	O
upward	POS	O
deviations	POS	O
of	POS	O
gaze	POS	O
during	POS	O
the	POS	O
peak	POS	O
effect	POS	O
of	POS	O
levodopa	POS	O
,	POS	O
and	POS	O
hypothesize	POS	O
that	POS	O
a	POS	O
severe	POS	O
dopaminergic	POS	O
denervation	POS	O
in	POS	O
the	POS	O
caudate	POS	O
nucleus	POS	O
is	POS	O
needed	POS	O
for	POS	O
the	POS	O
appearance	POS	O
of	POS	O
these	POS	O
levodopa	POS	O
-	POS	O
induce	POS	O
ocular	POS	O
dyskinesias	POS	B-NP
.	POS	O
A	POS	O
comparison	POS	O
of	POS	O
glyceryl	POS	O
trinitrate	POS	O
with	POS	O
diclofenac	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
primary	POS	O
dysmenorrhea	POS	B-NP
:	POS	O
an	POS	O
open	POS	O
,	POS	O
randomized	POS	O
,	POS	O
cross	POS	O
-	POS	O
over	POS	O
trial	POS	O
.	POS	O
Primary	POS	B-NP
dysmenorrhea	POS	I-NP
is	POS	O
a	POS	O
syndrome	POS	O
characterized	POS	O
by	POS	O
painful	POS	B-NP
uterine	POS	I-NP
contractility	POS	I-NP
caused	POS	O
by	POS	O
a	POS	O
hypersecretion	POS	O
of	POS	O
endometrial	POS	O
prostaglandins	POS	O
;	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
are	POS	O
the	POS	O
first	POS	O
choice	POS	O
for	POS	O
its	POS	O
treatment	POS	O
.	POS	O
However	POS	O
,	POS	O
in	POS	O
vivo	POS	O
and	POS	O
in	POS	O
vitro	POS	O
studies	POS	O
have	POS	O
demonstrated	POS	O
that	POS	O
myometrial	POS	O
cells	POS	O
are	POS	O
also	POS	O
targets	POS	O
of	POS	O
the	POS	O
relaxant	POS	O
effects	POS	O
of	POS	O
nitric	POS	O
oxide	POS	O
(	POS	O
NO	POS	O
)	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
the	POS	O
efficacy	POS	O
of	POS	O
glyceryl	POS	O
trinitrate	POS	O
(	POS	O
GTN	POS	O
)	POS	O
,	POS	O
an	POS	O
NO	POS	O
donor	POS	O
,	POS	O
in	POS	O
the	POS	O
resolution	POS	O
of	POS	O
primary	POS	O
dysmenorrhea	POS	B-NP
in	POS	O
comparison	POS	O
with	POS	O
diclofenac	POS	O
(	POS	O
DCF	POS	O
)	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
24	POS	O
patients	POS	O
with	POS	O
the	POS	O
diagnosis	POS	O
of	POS	O
severe	POS	O
primary	POS	O
dysmenorrhea	POS	B-NP
were	POS	O
studied	POS	O
during	POS	O
two	POS	O
consecutive	POS	O
menstrual	POS	O
cycles	POS	O
.	POS	O
In	POS	O
an	POS	O
open	POS	O
,	POS	O
cross	POS	O
-	POS	O
over	POS	O
,	POS	O
controlled	POS	O
design	POS	O
,	POS	O
patients	POS	O
were	POS	O
randomized	POS	O
to	POS	O
receive	POS	O
either	POS	O
DCF	POS	O
per	POS	O
os	POS	O
or	POS	O
GTN	POS	O
patches	POS	O
the	POS	O
first	POS	O
days	POS	O
of	POS	O
menses	POS	O
,	POS	O
when	POS	O
menstrual	POS	B-NP
cramps	POS	I-NP
became	POS	O
unendurable	POS	O
.	POS	O
In	POS	O
the	POS	O
subsequent	POS	O
cycle	POS	O
the	POS	O
other	POS	O
treatment	POS	O
was	POS	O
used	POS	O
.	POS	O
Patients	POS	O
received	POS	O
up	POS	O
to	POS	O
3	POS	O
doses	POS	O
/	POS	O
day	POS	O
of	POS	O
50	POS	O
mg	POS	O
DCF	POS	O
or	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
24	POS	O
h	POS	O
transdermal	POS	O
GTN	POS	O
for	POS	O
the	POS	O
first	POS	O
3	POS	O
days	POS	O
of	POS	O
the	POS	O
cycle	POS	O
,	POS	O
according	POS	O
to	POS	O
their	POS	O
needs	POS	O
.	POS	O
The	POS	O
participants	POS	O
recorded	POS	O
menstrual	POS	O
symptoms	POS	O
and	POS	O
possible	POS	O
side	POS	O
-	POS	O
effects	POS	O
at	POS	O
different	POS	O
times	POS	O
(	POS	O
0	POS	O
,	POS	O
30	POS	O
,	POS	O
60	POS	O
,	POS	O
120	POS	O
minutes	POS	O
)	POS	O
after	POS	O
the	POS	O
first	POS	O
dose	POS	O
of	POS	O
medication	POS	O
on	POS	O
the	POS	O
first	POS	O
day	POS	O
of	POS	O
the	POS	O
cycle	POS	O
,	POS	O
with	POS	O
both	POS	O
drugs	POS	O
.	POS	O
The	POS	O
difference	POS	O
in	POS	O
pain	POS	B-NP
intensity	POS	O
score	POS	O
(	POS	O
DPI	POS	O
)	POS	O
was	POS	O
the	POS	O
main	POS	O
outcome	POS	O
variable	POS	O
.	POS	O
Both	POS	O
treatments	POS	O
significantly	POS	O
reduced	POS	O
DPI	POS	O
by	POS	O
the	POS	O
30th	POS	O
minute	POS	O
(	POS	O
GTN	POS	O
,	POS	O
-	POS	O
12	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
17	POS	O
.	POS	O
9	POS	O
;	POS	O
DCF	POS	O
,	POS	O
-	POS	O
18	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
16	POS	O
.	POS	O
6	POS	O
)	POS	O
.	POS	O
However	POS	O
,	POS	O
DCF	POS	O
continued	POS	O
to	POS	O
be	POS	O
effective	POS	O
in	POS	O
reducing	POS	O
pelvic	POS	B-NP
pain	POS	I-NP
for	POS	O
two	POS	O
hours	POS	O
,	POS	O
whereas	POS	O
GTN	POS	O
scores	POS	O
remained	POS	O
more	POS	O
or	POS	O
less	POS	O
stable	POS	O
after	POS	O
30	POS	O
min	POS	O
and	POS	O
significantly	POS	O
higher	POS	O
than	POS	O
those	POS	O
for	POS	O
DFC	POS	B-NP
(	POS	O
after	POS	O
one	POS	O
hour	POS	O
:	POS	O
GTN	POS	O
,	POS	O
-	POS	O
12	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
17	POS	O
.	POS	O
9	POS	O
;	POS	O
DFC	POS	O
,	POS	O
-	POS	O
18	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
16	POS	O
.	POS	O
6	POS	O
and	POS	O
after	POS	O
two	POS	O
hours	POS	O
:	POS	O
GTN	POS	O
,	POS	O
-	POS	O
23	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
20	POS	O
.	POS	O
5	POS	O
;	POS	O
DFC	POS	O
,	POS	O
-	POS	O
59	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
17	POS	O
.	POS	O
9	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
0001	POS	O
)	POS	O
.	POS	O
Low	POS	B-NP
back	POS	I-NP
pain	POS	I-NP
was	POS	O
also	POS	O
relieved	POS	O
by	POS	O
both	POS	O
drugs	POS	O
.	POS	O
Headache	POS	B-NP
was	POS	O
significantly	POS	O
increased	POS	O
by	POS	O
GTN	POS	O
but	POS	O
not	POS	O
by	POS	O
DCF	POS	O
.	POS	O
Eight	POS	O
patients	POS	O
stopped	POS	O
using	POS	O
GTN	POS	O
because	POS	O
headache	POS	B-NP
-	POS	O
-	POS	O
attributed	POS	O
to	POS	O
its	POS	O
use	POS	O
-	POS	O
-	POS	O
became	POS	O
intolerable	POS	O
.	POS	O
These	POS	O
findings	POS	O
indicate	POS	O
that	POS	O
GTN	POS	O
has	POS	O
a	POS	O
reduced	POS	O
efficacy	POS	O
and	POS	O
tolerability	POS	O
by	POS	O
comparison	POS	O
with	POS	O
DCF	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
primary	POS	O
dysmenorrhea	POS	B-NP
.	POS	O
Temocapril	POS	O
,	POS	O
a	POS	O
long	POS	O
-	POS	O
acting	POS	O
non	POS	O
-	POS	O
SH	POS	O
group	POS	O
angiotensin	POS	O
converting	POS	O
enzyme	POS	O
inhibitor	POS	O
,	POS	O
modulates	POS	O
glomerular	POS	B-NP
injury	POS	I-NP
in	POS	O
chronic	POS	O
puromycin	POS	O
aminonucleoside	POS	O
nephrosis	POS	B-NP
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
whether	POS	O
chronic	POS	O
administration	POS	O
of	POS	O
temocapril	POS	O
,	POS	O
a	POS	O
long	POS	O
-	POS	O
acting	POS	O
non	POS	O
-	POS	O
SH	POS	O
group	POS	O
angiotensin	POS	O
converting	POS	O
enzyme	POS	O
(	POS	O
ACE	POS	O
)	POS	O
inhibitor	POS	O
,	POS	O
reduced	POS	O
proteinuria	POS	B-NP
,	POS	O
inhibited	POS	O
glomerular	POS	B-NP
hypertrophy	POS	I-NP
and	POS	O
prevented	POS	O
glomerulosclerosis	POS	B-NP
in	POS	O
chronic	POS	O
puromycin	POS	O
aminonucleoside	POS	O
(	POS	O
PAN	POS	O
)	POS	O
-	POS	O
induced	POS	O
nephrotic	POS	B-NP
rats	POS	O
.	POS	O
Nephrosis	POS	B-NP
was	POS	O
induced	POS	O
by	POS	O
injection	POS	O
of	POS	O
PAN	POS	O
(	POS	O
15mg	POS	O
/	POS	O
100g	POS	O
body	POS	O
weight	POS	O
)	POS	O
in	POS	O
male	POS	O
Sprague	POS	O
-	POS	O
Dawley	POS	O
(	POS	O
SD	POS	O
)	POS	O
rats	POS	O
.	POS	O
Four	POS	O
groups	POS	O
were	POS	O
used	POS	O
,	POS	O
i	POS	O
)	POS	O
the	POS	O
PAN	POS	O
group	POS	O
(	POS	O
14	POS	O
)	POS	O
,	POS	O
ii	POS	O
)	POS	O
PAN	POS	O
/	POS	O
temocapril	POS	O
(	POS	O
13	POS	O
)	POS	O
,	POS	O
iii	POS	O
)	POS	O
temocapril	POS	O
(	POS	O
14	POS	O
)	POS	O
and	POS	O
iv	POS	O
)	POS	O
untreated	POS	O
controls	POS	O
(	POS	O
15	POS	O
)	POS	O
.	POS	O
Temocapril	POS	O
(	POS	O
8	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
)	POS	O
was	POS	O
administered	POS	O
to	POS	O
the	POS	O
rats	POS	O
which	POS	O
were	POS	O
killed	POS	O
at	POS	O
weeks	POS	O
4	POS	O
,	POS	O
14	POS	O
or	POS	O
20	POS	O
.	POS	O
At	POS	O
each	POS	O
time	POS	O
point	POS	O
,	POS	O
systolic	POS	O
blood	POS	O
pressure	POS	O
(	POS	O
BP	POS	O
)	POS	O
,	POS	O
urinary	POS	O
protein	POS	O
excretion	POS	O
and	POS	O
renal	POS	O
histopathological	POS	O
findings	POS	O
were	POS	O
evaluated	POS	O
,	POS	O
and	POS	O
morphometric	POS	O
image	POS	O
analysis	POS	O
was	POS	O
done	POS	O
.	POS	O
Systolic	POS	O
BP	POS	O
in	POS	O
the	POS	O
PAN	POS	O
group	POS	O
was	POS	O
significantly	POS	O
high	POS	O
at	POS	O
4	POS	O
,	POS	O
14	POS	O
and	POS	O
20	POS	O
weeks	POS	O
,	POS	O
but	POS	O
was	POS	O
normal	POS	O
in	POS	O
the	POS	O
PAN	POS	O
/	POS	O
temocapril	POS	O
group	POS	O
.	POS	O
Urinary	POS	O
protein	POS	O
excretion	POS	O
in	POS	O
the	POS	O
PAN	POS	O
group	POS	O
increased	POS	O
significantly	POS	O
,	POS	O
peaking	POS	O
at	POS	O
8	POS	O
days	POS	O
,	POS	O
then	POS	O
decreased	POS	O
at	POS	O
4	POS	O
weeks	POS	O
,	POS	O
but	POS	O
rose	POS	O
again	POS	O
significantly	POS	O
at	POS	O
14	POS	O
and	POS	O
20	POS	O
weeks	POS	O
.	POS	O
Temocapril	POS	O
did	POS	O
not	POS	O
attenuate	POS	O
proteinuria	POS	B-NP
at	POS	O
8	POS	O
days	POS	O
,	POS	O
but	POS	O
it	POS	O
did	POS	O
markedly	POS	O
lower	POS	O
it	POS	O
from	POS	O
weeks	POS	O
4	POS	O
to	POS	O
20	POS	O
.	POS	O
The	POS	O
glomerulosclerosis	POS	B-NP
index	POS	O
(	POS	O
GSI	POS	O
)	POS	O
was	POS	O
6	POS	O
.	POS	O
21	POS	O
%	POS	O
at	POS	O
4	POS	O
weeks	POS	O
and	POS	O
respectively	POS	O
25	POS	O
.	POS	O
35	POS	O
%	POS	O
and	POS	O
30	POS	O
.	POS	O
49	POS	O
%	POS	O
at	POS	O
14	POS	O
and	POS	O
20	POS	O
weeks	POS	O
in	POS	O
the	POS	O
PAN	POS	O
group	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
significant	POS	O
correlation	POS	O
between	POS	O
urinary	POS	O
protein	POS	O
excretion	POS	O
and	POS	O
GSI	POS	O
(	POS	O
r	POS	O
=	POS	O
0	POS	O
.	POS	O
808	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
0001	POS	O
)	POS	O
.	POS	O
The	POS	O
ratio	POS	O
of	POS	O
glomerular	POS	O
tuft	POS	O
area	POS	O
to	POS	O
the	POS	O
area	POS	O
of	POS	O
Bowman	POS	O
'	POS	O
s	POS	O
capsules	POS	O
(	POS	O
GT	POS	O
/	POS	O
BC	POS	O
)	POS	O
in	POS	O
the	POS	O
PAN	POS	O
group	POS	O
was	POS	O
significantly	POS	O
increased	POS	O
,	POS	O
but	POS	O
it	POS	O
was	POS	O
significantly	POS	O
lower	POS	O
in	POS	O
the	POS	O
PAN	POS	O
/	POS	O
temocapril	POS	O
group	POS	O
.	POS	O
It	POS	O
appears	POS	O
that	POS	O
temocapril	POS	O
was	POS	O
effective	POS	O
in	POS	O
retarding	POS	O
renal	POS	O
progression	POS	O
and	POS	O
protected	POS	O
renal	POS	O
function	POS	O
in	POS	O
PAN	POS	O
neprotic	POS	O
rats	POS	O
.	POS	O
Pulmonary	POS	B-NP
hypertension	POS	I-NP
after	POS	O
ibuprofen	POS	O
prophylaxis	POS	B-NP
in	POS	O
very	POS	O
preterm	POS	B-NP
infants	POS	O
.	POS	O
We	POS	O
report	POS	O
three	POS	O
cases	POS	O
of	POS	O
severe	POS	O
hypoxaemia	POS	B-NP
after	POS	O
ibuprofen	POS	O
administration	POS	O
during	POS	O
a	POS	O
randomised	POS	O
controlled	POS	O
trial	POS	O
of	POS	O
prophylactic	POS	O
treatment	POS	O
of	POS	O
patent	POS	O
ductus	POS	B-NP
arteriosus	POS	I-NP
with	POS	O
ibuprofen	POS	O
in	POS	O
premature	POS	O
infants	POS	O
born	POS	O
at	POS	O
less	POS	O
than	POS	O
28	POS	O
weeks	POS	O
of	POS	O
gestation	POS	O
.	POS	O
Echocardiography	POS	O
showed	POS	O
severely	POS	O
decreased	POS	O
pulmonary	POS	O
blood	POS	O
flow	POS	O
.	POS	O
Hypoxaemia	POS	B-NP
resolved	POS	O
quickly	POS	O
on	POS	O
inhaled	POS	O
nitric	POS	O
oxide	POS	O
therapy	POS	O
.	POS	O
We	POS	O
suggest	POS	O
that	POS	O
investigators	POS	O
involved	POS	O
in	POS	O
similar	POS	O
trials	POS	O
pay	POS	O
close	POS	O
attention	POS	O
to	POS	O
pulmonary	POS	O
pressure	POS	O
if	POS	O
hypoxaemia	POS	B-NP
occurs	POS	O
after	POS	O
prophylactic	POS	O
administration	POS	O
of	POS	O
ibuprofen	POS	O
.	POS	O
Hyponatremia	POS	B-NP
and	POS	O
syndrome	POS	O
of	POS	O
inappropriate	POS	O
anti	POS	O
-	POS	O
diuretic	POS	O
hormone	POS	O
reported	POS	O
with	POS	O
the	POS	O
use	POS	O
of	POS	O
Vincristine	POS	O
:	POS	O
an	POS	O
over	POS	O
-	POS	O
representation	POS	O
of	POS	O
Asians	POS	O
?	POS	O
PURPOSE	POS	O
:	POS	O
This	POS	O
retrospective	POS	O
study	POS	O
used	POS	O
a	POS	O
pharmaceutical	POS	O
company	POS	O
'	POS	O
s	POS	O
global	POS	O
safety	POS	O
database	POS	O
to	POS	O
determine	POS	O
the	POS	O
reporting	POS	O
rate	POS	O
of	POS	O
hyponatremia	POS	B-NP
and	POS	O
/	POS	O
or	POS	O
syndrome	POS	O
of	POS	O
inappropriate	POS	O
secretion	POS	O
of	POS	O
anti	POS	O
-	POS	O
diuretic	POS	O
hormone	POS	O
(	POS	O
SIADH	POS	B-NP
)	POS	O
among	POS	O
vincristine	POS	O
-	POS	O
treated	POS	O
patients	POS	O
and	POS	O
to	POS	O
explore	POS	O
the	POS	O
possibility	POS	O
of	POS	O
at	POS	O
-	POS	O
risk	POS	O
population	POS	O
subgroups	POS	O
.	POS	O
METHOD	POS	O
:	POS	O
We	POS	O
searched	POS	O
the	POS	O
Eli	POS	O
Lilly	POS	O
and	POS	O
Company	POS	O
'	POS	O
s	POS	O
computerized	POS	O
adverse	POS	O
event	POS	O
database	POS	O
for	POS	O
all	POS	O
reported	POS	O
cases	POS	O
of	POS	O
hyponatremia	POS	B-NP
and	POS	O
/	POS	O
or	POS	O
SIADH	POS	B-NP
as	POS	O
of	POS	O
1	POS	O
November	POS	O
1999	POS	O
that	POS	O
had	POS	O
been	POS	O
reported	POS	O
during	POS	O
the	POS	O
use	POS	O
of	POS	O
vincristine	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
76	POS	O
cases	POS	O
of	POS	O
hyponatremia	POS	B-NP
and	POS	O
/	POS	O
or	POS	O
SIADH	POS	B-NP
associated	POS	O
with	POS	O
vincristine	POS	O
use	POS	O
were	POS	O
identified	POS	O
.	POS	O
The	POS	O
overall	POS	O
reporting	POS	O
rate	POS	O
was	POS	O
estimated	POS	O
to	POS	O
be	POS	O
1	POS	O
.	POS	O
3	POS	O
/	POS	O
100	POS	O
,	POS	O
000	POS	O
treated	POS	O
patients	POS	O
.	POS	O
The	POS	O
average	POS	O
age	POS	O
of	POS	O
patients	POS	O
was	POS	O
35	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
28	POS	O
.	POS	O
3	POS	O
years	POS	O
,	POS	O
and	POS	O
62	POS	O
%	POS	O
were	POS	O
males	POS	O
.	POS	O
Approximately	POS	O
75	POS	O
%	POS	O
of	POS	O
the	POS	O
patients	POS	O
were	POS	O
receiving	POS	O
treatment	POS	O
for	POS	O
leukemia	POS	B-NP
or	POS	O
lymphoma	POS	B-NP
.	POS	O
Among	POS	O
the	POS	O
39	POS	O
reports	POS	O
that	POS	O
included	POS	O
information	POS	O
on	POS	O
race	POS	O
,	POS	O
the	POS	O
racial	POS	O
distribution	POS	O
was	POS	O
:	POS	O
1	POS	O
Black	POS	O
,	POS	O
3	POS	O
Caucasian	POS	O
,	POS	O
and	POS	O
35	POS	O
Asian	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Our	POS	O
data	POS	O
suggest	POS	O
that	POS	O
Asian	POS	O
patients	POS	O
may	POS	O
be	POS	O
at	POS	O
increased	POS	O
risk	POS	O
of	POS	O
hyponatremia	POS	B-NP
and	POS	O
/	POS	O
or	POS	O
SIADH	POS	B-NP
associated	POS	O
with	POS	O
vincristine	POS	O
use	POS	O
.	POS	O
Although	POS	O
the	POS	O
overall	POS	O
reported	POS	O
rate	POS	O
of	POS	O
SIADH	POS	B-NP
associated	POS	O
with	POS	O
vincristine	POS	O
is	POS	O
very	POS	O
low	POS	O
,	POS	O
physicians	POS	O
caring	POS	O
for	POS	O
Asian	POS	O
oncology	POS	O
patients	POS	O
should	POS	O
be	POS	O
aware	POS	O
of	POS	O
this	POS	O
potential	POS	O
serious	POS	O
but	POS	O
reversible	POS	O
adverse	POS	O
event	POS	O
.	POS	O
Delayed	POS	B-NP
toxicity	POS	I-NP
of	POS	O
cyclophosphamide	POS	O
on	POS	O
the	POS	O
bladder	POS	O
of	POS	O
DBA	POS	O
/	POS	O
2	POS	O
and	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
female	POS	O
mouse	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
describes	POS	O
the	POS	O
delayed	POS	O
development	POS	O
of	POS	O
a	POS	O
severe	POS	O
bladder	POS	B-NP
pathology	POS	I-NP
in	POS	O
a	POS	O
susceptible	POS	O
strain	POS	O
of	POS	O
mice	POS	O
(	POS	O
DBA	POS	O
/	POS	O
2	POS	O
)	POS	O
but	POS	O
not	POS	O
in	POS	O
a	POS	O
resistant	POS	O
strain	POS	O
(	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
)	POS	O
when	POS	O
both	POS	O
were	POS	O
treated	POS	O
with	POS	O
a	POS	O
single	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
dose	POS	O
of	POS	O
cyclophosphamide	POS	O
(	POS	O
CY	POS	O
)	POS	O
.	POS	O
Inbred	POS	O
DBA	POS	O
/	POS	O
2	POS	O
and	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
female	POS	O
mice	POS	O
were	POS	O
injected	POS	O
with	POS	O
CY	POS	O
,	POS	O
and	POS	O
the	POS	O
effect	POS	O
of	POS	O
the	POS	O
drug	POS	O
on	POS	O
the	POS	O
bladder	POS	O
was	POS	O
assessed	POS	O
during	POS	O
100	POS	O
days	POS	O
by	POS	O
light	POS	O
microscopy	POS	O
using	POS	O
different	POS	O
staining	POS	O
procedures	POS	O
,	POS	O
and	POS	O
after	POS	O
30	POS	O
days	POS	O
by	POS	O
conventional	POS	O
electron	POS	O
microscopy	POS	O
.	POS	O
Early	POS	O
CY	POS	O
toxicity	POS	B-NP
caused	POS	O
a	POS	O
typical	POS	O
haemorrhagic	POS	B-NP
cystitis	POS	I-NP
in	POS	O
both	POS	O
strains	POS	O
that	POS	O
was	POS	O
completely	POS	O
repaired	POS	O
in	POS	O
about	POS	O
7	POS	O
-	POS	O
10	POS	O
days	POS	O
.	POS	O
After	POS	O
30	POS	O
days	POS	O
of	POS	O
CY	POS	O
injection	POS	O
ulcerous	POS	B-NP
and	POS	O
non	POS	O
-	POS	O
ulcerous	POS	O
forms	POS	O
of	POS	O
chronic	POS	B-NP
cystitis	POS	I-NP
appeared	POS	O
in	POS	O
86	POS	O
%	POS	O
of	POS	O
DBA	POS	O
/	POS	O
2	POS	O
mice	POS	O
but	POS	O
only	POS	O
in	POS	O
4	POS	O
%	POS	O
of	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
mice	POS	O
.	POS	O
Delayed	POS	O
cystitis	POS	B-NP
was	POS	O
characterized	POS	O
by	POS	O
infiltration	POS	O
and	POS	O
transepithelial	POS	O
passage	POS	O
into	POS	O
the	POS	O
lumen	POS	O
of	POS	O
inflammatory	POS	O
cells	POS	O
and	POS	O
by	POS	O
frequent	POS	O
exfoliation	POS	O
of	POS	O
the	POS	O
urothelium	POS	O
.	POS	O
Mast	POS	O
cells	POS	O
appeared	POS	O
in	POS	O
the	POS	O
connective	POS	O
and	POS	O
muscular	POS	O
layers	POS	O
of	POS	O
the	POS	O
bladder	POS	O
at	POS	O
a	POS	O
much	POS	O
higher	POS	O
number	POS	O
in	POS	O
DBA	POS	O
/	POS	O
2	POS	O
mice	POS	O
than	POS	O
in	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
mice	POS	O
or	POS	O
untreated	POS	O
controls	POS	O
.	POS	O
Electron	POS	O
microscopy	POS	O
disclosed	POS	O
the	POS	O
absence	POS	O
of	POS	O
the	POS	O
typical	POS	O
discoidal	POS	O
vesicles	POS	O
normally	POS	O
present	POS	O
in	POS	O
the	POS	O
cytoplasm	POS	O
of	POS	O
surface	POS	O
cells	POS	O
.	POS	O
Instead	POS	O
,	POS	O
numerous	POS	O
abnormal	POS	O
vesicles	POS	O
containing	POS	O
one	POS	O
or	POS	O
several	POS	O
dark	POS	O
granules	POS	O
were	POS	O
observed	POS	O
in	POS	O
the	POS	O
cytoplasm	POS	O
of	POS	O
cells	POS	O
from	POS	O
all	POS	O
the	POS	O
epithelial	POS	O
layers	POS	O
.	POS	O
Delayed	POS	O
cystitis	POS	B-NP
still	POS	O
persisted	POS	O
in	POS	O
DBA	POS	O
/	POS	O
2	POS	O
mice	POS	O
100	POS	O
days	POS	O
after	POS	O
treatment	POS	O
.	POS	O
These	POS	O
results	POS	O
indicate	POS	O
that	POS	O
delayed	POS	O
toxicity	POS	B-NP
of	POS	O
CY	POS	O
in	POS	O
female	POS	O
DBA	POS	O
/	POS	O
2	POS	O
mice	POS	O
causes	POS	O
a	POS	O
bladder	POS	O
pathology	POS	O
that	POS	O
is	POS	O
not	POS	O
observed	POS	O
in	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
mice	POS	O
.	POS	O
This	POS	O
pathology	POS	O
resembles	POS	O
interstitial	POS	B-NP
cystitis	POS	I-NP
in	POS	O
humans	POS	O
and	POS	O
could	POS	O
perhaps	POS	O
be	POS	O
used	POS	O
as	POS	O
an	POS	O
animal	POS	O
model	POS	O
for	POS	O
studies	POS	O
on	POS	O
the	POS	O
disease	POS	O
.	POS	O
High	POS	O
-	POS	O
dose	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
/	POS	O
folinic	POS	O
acid	POS	O
in	POS	O
combination	POS	O
with	POS	O
three	POS	O
-	POS	O
weekly	POS	O
mitomycin	POS	O
C	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
advanced	POS	O
gastric	POS	B-NP
cancer	POS	I-NP
.	POS	O
A	POS	O
phase	POS	O
II	POS	O
study	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
The	POS	O
24	POS	O
-	POS	O
hour	POS	O
continuous	POS	O
infusion	POS	O
of	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
(	POS	O
5	POS	O
-	POS	O
FU	POS	O
)	POS	O
and	POS	O
folinic	POS	O
acid	POS	O
(	POS	O
FA	POS	O
)	POS	O
as	POS	O
part	POS	O
of	POS	O
several	POS	O
new	POS	O
multidrug	POS	O
chemotherapy	POS	O
regimens	POS	O
in	POS	O
advanced	POS	O
gastric	POS	B-NP
cancer	POS	I-NP
(	POS	O
AGC	POS	O
)	POS	O
has	POS	O
shown	POS	O
to	POS	O
be	POS	O
effective	POS	O
,	POS	O
with	POS	O
low	POS	B-NP
toxicity	POS	I-NP
.	POS	O
In	POS	O
a	POS	O
previous	POS	O
phase	POS	O
II	POS	O
study	POS	O
with	POS	O
3	POS	O
-	POS	O
weekly	POS	O
bolus	POS	O
5	POS	O
-	POS	O
FU	POS	O
,	POS	O
FA	POS	O
and	POS	O
mitomycin	POS	O
C	POS	O
(	POS	O
MMC	POS	O
)	POS	O
we	POS	O
found	POS	O
a	POS	O
low	POS	O
toxicity	POS	B-NP
rate	POS	O
and	POS	O
response	POS	O
rates	POS	O
comparable	POS	O
to	POS	O
those	POS	O
of	POS	O
regimens	POS	O
such	POS	O
as	POS	O
ELF	POS	O
,	POS	O
FAM	POS	O
or	POS	O
FAMTX	POS	O
,	POS	O
and	POS	O
a	POS	O
promising	POS	O
median	POS	O
overall	POS	O
survival	POS	O
.	POS	O
In	POS	O
order	POS	O
to	POS	O
improve	POS	O
this	POS	O
MMC	POS	O
-	POS	O
dependent	POS	O
schedule	POS	O
we	POS	O
initiated	POS	O
a	POS	O
phase	POS	O
II	POS	O
study	POS	O
with	POS	O
high	POS	O
-	POS	O
dose	POS	O
5	POS	O
-	POS	O
FU	POS	O
/	POS	O
FA	POS	O
and	POS	O
3	POS	O
-	POS	O
weekly	POS	O
bolus	POS	O
MMC	POS	O
.	POS	O
PATIENTS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
From	POS	O
February	POS	O
,	POS	O
1998	POS	O
to	POS	O
September	POS	O
,	POS	O
2000	POS	O
we	POS	O
recruited	POS	O
33	POS	O
patients	POS	O
with	POS	O
AGC	POS	O
to	POS	O
receive	POS	O
weekly	POS	O
24	POS	O
-	POS	O
hour	POS	O
5	POS	O
-	POS	O
FU	POS	O
2	POS	O
,	POS	O
600	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
preceded	POS	O
by	POS	O
2	POS	O
-	POS	O
hour	POS	O
FA	POS	O
500	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
for	POS	O
6	POS	O
weeks	POS	O
,	POS	O
followed	POS	O
by	POS	O
a	POS	O
2	POS	O
-	POS	O
week	POS	O
rest	POS	O
period	POS	O
.	POS	O
Bolus	POS	O
MMC	POS	O
10	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
was	POS	O
added	POS	O
in	POS	O
3	POS	O
-	POS	O
weekly	POS	O
intervals	POS	O
.	POS	O
Treatment	POS	O
given	POS	O
on	POS	O
an	POS	O
outpatient	POS	O
basis	POS	O
,	POS	O
using	POS	O
portable	POS	O
pump	POS	O
systems	POS	O
,	POS	O
was	POS	O
repeated	POS	O
on	POS	O
day	POS	O
57	POS	O
.	POS	O
Patients	POS	O
'	POS	O
characteristics	POS	O
were	POS	O
:	POS	O
male	POS	O
/	POS	O
female	POS	O
ratio	POS	O
20	POS	O
/	POS	O
13	POS	O
;	POS	O
median	POS	O
age	POS	O
57	POS	O
(	POS	O
27	POS	O
-	POS	O
75	POS	O
)	POS	O
years	POS	O
;	POS	O
median	POS	O
WHO	POS	O
status	POS	O
1	POS	O
(	POS	O
0	POS	O
-	POS	O
2	POS	O
)	POS	O
.	POS	O
18	POS	O
patients	POS	O
had	POS	O
a	POS	O
primary	POS	O
AGC	POS	O
,	POS	O
and	POS	O
15	POS	O
showed	POS	O
a	POS	O
relapsed	POS	O
AGC	POS	O
.	POS	O
Median	POS	O
follow	POS	O
-	POS	O
up	POS	O
was	POS	O
11	POS	O
.	POS	O
8	POS	O
months	POS	O
(	POS	O
range	POS	O
of	POS	O
those	POS	O
surviving	POS	O
:	POS	O
2	POS	O
.	POS	O
7	POS	O
-	POS	O
11	POS	O
.	POS	O
8	POS	O
months	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
32	POS	O
patients	POS	O
were	POS	O
evaluable	POS	O
for	POS	O
response	POS	O
-	POS	O
complete	POS	O
remission	POS	O
9	POS	O
.	POS	O
1	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
3	POS	O
)	POS	O
,	POS	O
partial	POS	O
remission	POS	O
45	POS	O
.	POS	O
5	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
15	POS	O
)	POS	O
,	POS	O
no	POS	O
change	POS	O
27	POS	O
.	POS	O
3	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
9	POS	O
)	POS	O
,	POS	O
progressive	POS	O
disease	POS	O
15	POS	O
.	POS	O
1	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
5	POS	O
)	POS	O
.	POS	O
Median	POS	O
overall	POS	O
survival	POS	O
time	POS	O
was	POS	O
10	POS	O
.	POS	O
2	POS	O
months	POS	O
[	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
(	POS	O
CI	POS	O
)	POS	O
:	POS	O
8	POS	O
.	POS	O
7	POS	O
-	POS	O
11	POS	O
.	POS	O
6	POS	O
]	POS	O
,	POS	O
and	POS	O
median	POS	O
progression	POS	O
-	POS	O
free	POS	O
survival	POS	O
time	POS	O
was	POS	O
7	POS	O
.	POS	O
6	POS	O
months	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
4	POS	O
.	POS	O
4	POS	O
-	POS	O
10	POS	O
.	POS	O
9	POS	O
)	POS	O
.	POS	O
The	POS	O
worst	POS	O
toxicities	POS	B-NP
(	POS	O
%	POS	O
)	POS	O
observed	POS	O
were	POS	O
(	POS	O
CTC	POS	O
-	POS	O
NCI	POS	O
1	POS	O
/	POS	O
2	POS	O
/	POS	O
3	POS	O
)	POS	O
:	POS	O
leukopenia	POS	B-NP
45	POS	O
.	POS	O
5	POS	O
/	POS	O
18	POS	O
.	POS	O
2	POS	O
/	POS	O
6	POS	O
.	POS	O
1	POS	O
,	POS	O
thrombocytopenia	POS	B-NP
33	POS	O
.	POS	O
3	POS	O
/	POS	O
9	POS	O
.	POS	O
1	POS	O
/	POS	O
6	POS	O
.	POS	O
1	POS	O
,	POS	O
vomitus	POS	O
24	POS	O
.	POS	O
2	POS	O
/	POS	O
9	POS	O
.	POS	O
1	POS	O
/	POS	O
0	POS	O
,	POS	O
diarrhea	POS	B-NP
36	POS	O
.	POS	O
4	POS	O
/	POS	O
6	POS	O
.	POS	O
1	POS	O
/	POS	O
3	POS	O
.	POS	O
0	POS	O
,	POS	O
stomatitis	POS	B-NP
18	POS	O
.	POS	O
2	POS	O
/	POS	O
9	POS	O
.	POS	O
1	POS	O
/	POS	O
0	POS	O
,	POS	O
hand	POS	O
-	POS	O
foot	POS	B-NP
syndrome	POS	I-NP
12	POS	O
.	POS	O
1	POS	O
/	POS	O
0	POS	O
/	POS	O
0	POS	O
.	POS	O
Two	POS	O
patients	POS	O
developed	POS	O
hemolytic	POS	B-NP
-	POS	I-NP
uremic	POS	I-NP
syndrome	POS	I-NP
(	POS	O
HUS	POS	B-NP
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
High	POS	O
-	POS	O
dose	POS	O
5	POS	O
-	POS	O
FU	POS	O
/	POS	O
FA	POS	O
/	POS	O
MMC	POS	O
is	POS	O
an	POS	O
effective	POS	O
and	POS	O
well	POS	O
-	POS	O
tolerated	POS	O
outpatient	POS	O
regimen	POS	O
for	POS	O
AGC	POS	O
(	POS	O
objective	POS	O
response	POS	O
rate	POS	O
54	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
.	POS	O
It	POS	O
may	POS	O
serve	POS	O
as	POS	O
an	POS	O
alternative	POS	O
to	POS	O
cisplatin	POS	O
-	POS	O
containing	POS	O
regimens	POS	O
;	POS	O
however	POS	O
,	POS	O
it	POS	O
has	POS	O
to	POS	O
be	POS	O
considered	POS	O
that	POS	O
possibly	POS	O
HUS	POS	B-NP
may	POS	O
occur	POS	O
.	POS	O
Persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
is	POS	O
associated	POS	O
with	POS	O
impaired	POS	B-NP
renal	POS	I-NP
function	POS	I-NP
in	POS	I-NP
human	POS	I-NP
immunodeficiency	POS	I-NP
virus	POS	I-NP
type	POS	I-NP
1	POS	I-NP
-	POS	I-NP
infected	POS	I-NP
children	POS	O
treated	POS	O
with	POS	O
indinavir	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Prolonged	POS	O
administration	POS	O
of	POS	O
indinavir	POS	O
is	POS	O
associated	POS	O
with	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
a	POS	O
variety	POS	O
of	POS	O
renal	POS	B-NP
complications	POS	I-NP
in	POS	O
adults	POS	O
.	POS	O
These	POS	O
well	POS	O
-	POS	O
documented	POS	O
side	POS	O
effects	POS	O
have	POS	O
restricted	POS	O
the	POS	O
use	POS	O
of	POS	O
this	POS	O
potent	POS	O
protease	POS	O
inhibitor	POS	O
in	POS	O
children	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
A	POS	O
prospective	POS	O
study	POS	O
to	POS	O
monitor	POS	O
indinavir	POS	O
-	POS	O
related	POS	O
nephrotoxicity	POS	B-NP
in	POS	O
a	POS	O
cohort	POS	O
of	POS	O
30	POS	O
human	POS	O
immunodeficiency	POS	B-NP
virus	POS	I-NP
type	POS	I-NP
1	POS	I-NP
-	POS	I-NP
infected	POS	I-NP
children	POS	O
treated	POS	O
with	POS	O
indinavir	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Urinary	POS	O
pH	POS	O
,	POS	O
albumin	POS	O
,	POS	O
creatinine	POS	O
,	POS	O
the	POS	O
presence	POS	O
of	POS	O
erythrocytes	POS	O
,	POS	O
leukocytes	POS	O
,	POS	O
bacteria	POS	O
and	POS	O
crystals	POS	O
,	POS	O
and	POS	O
culture	POS	O
were	POS	O
analyzed	POS	O
every	POS	O
3	POS	O
months	POS	O
for	POS	O
96	POS	O
weeks	POS	O
.	POS	O
Serum	POS	O
creatinine	POS	O
levels	POS	O
were	POS	O
routinely	POS	O
determined	POS	O
at	POS	O
the	POS	O
same	POS	O
time	POS	O
points	POS	O
.	POS	O
Steady	POS	O
-	POS	O
state	POS	O
pharmacokinetics	POS	O
of	POS	O
indinavir	POS	O
were	POS	O
done	POS	O
at	POS	O
week	POS	O
4	POS	O
after	POS	O
the	POS	O
initiation	POS	O
of	POS	O
indinavir	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
cumulative	POS	O
incidence	POS	O
of	POS	O
persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
(	POS	O
>	POS	O
or	POS	O
=	POS	O
75	POS	O
cells	POS	O
/	POS	O
micro	POS	O
L	POS	O
in	POS	O
at	POS	O
least	POS	O
2	POS	O
consecutive	POS	O
visits	POS	O
)	POS	O
after	POS	O
96	POS	O
weeks	POS	O
was	POS	O
53	POS	O
%	POS	O
.	POS	O
Persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
was	POS	O
frequently	POS	O
associated	POS	O
with	POS	O
a	POS	O
mild	POS	O
increase	POS	O
in	POS	O
the	POS	O
urine	POS	O
albumin	POS	O
/	POS	O
creatinine	POS	O
ratio	POS	O
and	POS	O
by	POS	O
microscopic	POS	O
hematuria	POS	B-NP
.	POS	O
The	POS	O
cumulative	POS	O
incidence	POS	O
of	POS	O
serum	POS	O
creatinine	POS	O
levels	POS	O
>	POS	O
50	POS	O
%	POS	O
above	POS	O
normal	POS	B-NP
was	POS	O
33	POS	O
%	POS	O
after	POS	O
96	POS	O
weeks	POS	O
.	POS	O
Children	POS	O
with	POS	O
persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
more	POS	O
frequently	POS	O
had	POS	O
serum	POS	O
creatinine	POS	O
levels	POS	O
of	POS	O
50	POS	O
%	POS	O
above	POS	O
normal	POS	B-NP
than	POS	O
those	POS	O
children	POS	O
without	POS	O
persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
.	POS	O
In	POS	O
children	POS	O
younger	POS	O
than	POS	O
5	POS	O
.	POS	O
6	POS	O
years	POS	O
,	POS	O
persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
was	POS	O
significantly	POS	O
more	POS	O
frequent	POS	O
than	POS	O
in	POS	O
older	POS	O
children	POS	O
.	POS	O
A	POS	O
higher	POS	O
cumulative	POS	O
incidence	POS	O
of	POS	O
persistent	POS	O
leukocyturia	POS	B-NP
was	POS	O
found	POS	O
in	POS	O
children	POS	O
with	POS	O
an	POS	O
area	POS	O
under	POS	O
the	POS	O
curve	POS	O
>	POS	O
19	POS	O
mg	POS	O
/	POS	O
L	POS	O
x	POS	O
h	POS	O
or	POS	O
a	POS	O
peak	POS	O
serum	POS	O
level	POS	O
of	POS	O
indinavir	POS	O
>	POS	O
12	POS	O
mg	POS	O
/	POS	O
L	POS	O
.	POS	O
In	POS	O
4	POS	O
children	POS	O
,	POS	O
indinavir	POS	O
was	POS	O
discontinued	POS	O
because	POS	O
of	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
Subsequently	POS	O
,	POS	O
the	POS	O
serum	POS	O
creatinine	POS	O
levels	POS	O
decreased	POS	O
,	POS	O
the	POS	O
urine	POS	O
albumin	POS	O
/	POS	O
creatinine	POS	O
ratios	POS	O
returned	POS	O
to	POS	O
zero	POS	O
,	POS	O
and	POS	O
the	POS	O
leukocyturia	POS	B-NP
disappeared	POS	O
within	POS	O
3	POS	O
months	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Children	POS	O
treated	POS	O
with	POS	O
indinavir	POS	O
have	POS	O
a	POS	O
high	POS	O
cumulative	POS	O
incidence	POS	O
of	POS	O
persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
.	POS	O
Children	POS	O
with	POS	O
persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
more	POS	O
frequently	POS	O
had	POS	O
an	POS	O
increase	POS	O
in	POS	O
serum	POS	O
creatinine	POS	O
levels	POS	O
of	POS	O
>	POS	O
50	POS	O
%	POS	O
above	POS	O
normal	POS	B-NP
.	POS	O
Younger	POS	O
children	POS	O
have	POS	O
an	POS	O
additional	POS	O
risk	POS	O
for	POS	O
renal	POS	B-NP
complications	POS	I-NP
.	POS	O
The	POS	O
impairment	POS	B-NP
of	POS	I-NP
the	POS	I-NP
renal	POS	I-NP
function	POS	I-NP
in	POS	O
these	POS	O
children	POS	O
occurred	POS	O
in	POS	O
the	POS	O
absence	POS	O
of	POS	O
clinical	POS	O
symptoms	POS	O
of	POS	O
nephrolithiasis	POS	B-NP
.	POS	O
Indinavir	POS	O
-	POS	O
associated	POS	O
nephrotoxicity	POS	B-NP
must	POS	O
be	POS	O
monitored	POS	O
closely	POS	O
,	POS	O
especially	POS	O
in	POS	O
children	POS	O
with	POS	O
risk	POS	O
factors	POS	O
such	POS	O
as	POS	O
persistent	POS	O
sterile	POS	O
leukocyturia	POS	B-NP
,	POS	O
age	POS	O
<	POS	O
5	POS	O
.	POS	O
6	POS	O
years	POS	O
,	POS	O
an	POS	O
area	POS	O
under	POS	O
the	POS	O
curve	POS	O
of	POS	O
indinavir	POS	O
>	POS	O
19	POS	O
mg	POS	O
/	POS	O
L	POS	O
x	POS	O
h	POS	O
,	POS	O
and	POS	O
a	POS	O
C	POS	O
(	POS	O
max	POS	O
)	POS	O
>	POS	O
12	POS	O
mg	POS	O
/	POS	O
L	POS	O
.	POS	O
Utility	POS	O
of	POS	O
troponin	POS	O
I	POS	O
in	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
.	POS	O
Baseline	POS	B-NP
electrocardiogram	POS	I-NP
abnormalities	POS	I-NP
and	POS	O
market	POS	O
elevations	POS	O
not	POS	O
associated	POS	O
with	POS	O
myocardial	POS	B-NP
necrosis	POS	I-NP
make	POS	O
accurate	POS	O
diagnosis	POS	O
of	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
(	POS	O
MI	POS	B-NP
)	POS	O
difficult	POS	O
in	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
.	POS	O
Troponin	POS	O
sampling	POS	O
may	POS	O
offer	POS	O
greater	POS	O
diagnostic	POS	O
utility	POS	O
in	POS	O
these	POS	O
patients	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
assess	POS	O
outcomes	POS	O
based	POS	O
on	POS	O
troponin	POS	O
positivity	POS	O
in	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
chest	POS	I-NP
pain	POS	I-NP
admitted	POS	O
for	POS	O
exclusion	POS	O
of	POS	O
MI	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Outcomes	POS	O
were	POS	O
examined	POS	O
in	POS	O
patients	POS	O
admitted	POS	O
for	POS	O
possible	POS	O
MI	POS	B-NP
after	POS	O
cocaine	POS	O
use	POS	O
.	POS	O
All	POS	O
patients	POS	O
underwent	POS	O
a	POS	O
rapid	POS	O
rule	POS	O
-	POS	O
in	POS	O
protocol	POS	O
that	POS	O
included	POS	O
serial	POS	O
sampling	POS	O
of	POS	O
creatine	POS	O
kinase	POS	O
(	POS	O
CK	POS	O
)	POS	O
,	POS	O
CK	POS	O
-	POS	O
MB	POS	O
,	POS	O
and	POS	O
cardiac	POS	B-NP
troponin	POS	I-NP
I	POS	I-NP
(	POS	O
cTnI	POS	O
)	POS	O
over	POS	O
eight	POS	O
hours	POS	O
.	POS	O
Outcomes	POS	O
included	POS	O
CK	POS	O
-	POS	O
MB	POS	B-NP
MI	POS	I-NP
(	POS	O
CK	POS	O
-	POS	O
MB	POS	O
>	POS	O
or	POS	O
=	POS	O
8	POS	O
ng	POS	O
/	POS	O
mL	POS	O
with	POS	O
a	POS	O
relative	POS	O
index	POS	O
[	POS	O
(	POS	O
CK	POS	O
-	POS	O
MB	POS	O
x	POS	O
100	POS	O
)	POS	O
/	POS	O
total	POS	O
CK	POS	O
]	POS	O
>	POS	O
or	POS	O
=	POS	O
4	POS	O
,	POS	O
cardiac	POS	B-NP
death	POS	I-NP
,	POS	O
and	POS	O
significant	POS	O
coronary	POS	B-NP
disease	POS	I-NP
(	POS	O
>	POS	O
or	POS	O
=	POS	O
50	POS	O
%	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Of	POS	O
the	POS	O
246	POS	O
admitted	POS	O
patients	POS	O
,	POS	O
34	POS	O
(	POS	O
14	POS	O
%	POS	O
)	POS	O
met	POS	O
CK	POS	O
-	POS	O
MB	POS	O
criteria	POS	O
for	POS	O
MI	POS	B-NP
and	POS	O
38	POS	O
(	POS	O
16	POS	O
%	POS	O
)	POS	O
had	POS	O
cTnI	POS	O
elevations	POS	O
.	POS	O
Angiography	POS	O
was	POS	O
performed	POS	O
in	POS	O
29	POS	O
of	POS	O
38	POS	O
patients	POS	O
who	POS	O
were	POS	O
cTnI	POS	O
-	POS	O
positive	POS	O
,	POS	O
with	POS	O
significant	POS	O
disease	POS	O
present	POS	O
in	POS	O
25	POS	O
(	POS	O
86	POS	O
%	POS	O
)	POS	O
.	POS	O
Three	POS	O
of	POS	O
the	POS	O
four	POS	O
patients	POS	O
without	POS	O
significant	POS	O
disease	POS	O
who	POS	O
had	POS	O
cTnI	POS	O
elevations	POS	O
met	POS	O
CK	POS	O
-	POS	O
MB	POS	O
criteria	POS	O
for	POS	O
MI	POS	B-NP
,	POS	O
and	POS	O
the	POS	O
other	POS	O
had	POS	O
a	POS	O
peak	POS	O
CK	POS	O
-	POS	O
MB	POS	O
level	POS	O
of	POS	O
13	POS	O
ng	POS	O
/	POS	O
mL	POS	O
.	POS	O
Sensitivities	POS	O
,	POS	O
specificities	POS	O
,	POS	O
and	POS	O
positive	POS	O
and	POS	O
negative	POS	O
likelihood	POS	O
ratios	POS	O
for	POS	O
predicting	POS	O
cardiac	POS	B-NP
death	POS	I-NP
or	POS	O
significant	POS	O
disease	POS	O
were	POS	O
high	POS	O
for	POS	O
both	POS	O
CK	POS	O
-	POS	O
MB	POS	B-NP
MI	POS	I-NP
and	POS	O
cTnI	POS	O
and	POS	O
were	POS	O
not	POS	O
significantly	POS	O
different	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Most	POS	O
patients	POS	O
with	POS	O
cTnI	POS	O
elevations	POS	O
meet	POS	O
CK	POS	O
-	POS	O
MB	POS	O
criteria	POS	O
for	POS	O
MI	POS	B-NP
,	POS	O
as	POS	O
well	POS	O
as	POS	O
have	POS	O
a	POS	O
high	POS	O
incidence	POS	O
of	POS	O
underlying	POS	O
significant	POS	O
disease	POS	O
.	POS	O
Troponin	POS	O
appears	POS	O
to	POS	O
have	POS	O
an	POS	O
equivalent	POS	O
diagnostic	POS	O
accuracy	POS	O
compared	POS	O
with	POS	O
CK	POS	O
-	POS	O
MB	POS	O
for	POS	O
diagnosing	POS	O
necrosis	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
and	POS	O
suspected	POS	O
MI	POS	B-NP
.	POS	O
Acute	POS	B-NP
interstitial	POS	I-NP
nephritis	POS	I-NP
due	POS	O
to	POS	O
nicergoline	POS	O
(	POS	O
Sermion	POS	O
)	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
acute	POS	O
interstitial	POS	B-NP
nephritis	POS	I-NP
(	POS	O
AIN	POS	B-NP
)	POS	O
due	POS	O
to	POS	O
nicergoline	POS	O
(	POS	O
Sermion	POS	O
)	POS	O
.	POS	O
A	POS	O
50	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
patient	POS	O
admitted	POS	O
to	POS	O
our	POS	O
hospital	POS	O
for	POS	O
fever	POS	B-NP
and	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
.	POS	O
Before	POS	O
admission	POS	O
,	POS	O
he	POS	O
had	POS	O
been	POS	O
taking	POS	O
nicergoline	POS	O
and	POS	O
bendazac	POS	O
lysine	POS	O
due	POS	O
to	POS	O
retinal	POS	B-NP
vein	POS	I-NP
occlusion	POS	I-NP
at	POS	O
ophthalmologic	POS	O
department	POS	O
.	POS	O
Thereafter	POS	O
,	POS	O
he	POS	O
experienced	POS	O
intermittent	POS	B-NP
fever	POS	I-NP
and	POS	O
skin	POS	B-NP
rash	POS	I-NP
.	POS	O
On	POS	O
admission	POS	O
,	POS	O
clinical	POS	O
symptoms	POS	O
(	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
arthralgia	POS	B-NP
and	POS	O
fever	POS	B-NP
)	POS	O
and	POS	O
laboratory	POS	O
findings	POS	O
(	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
eosinophilia	POS	B-NP
and	POS	O
renal	POS	B-NP
failure	POS	I-NP
)	POS	O
suggested	POS	O
AIN	POS	B-NP
,	POS	O
and	POS	O
which	POS	O
was	POS	O
confirmed	POS	O
by	POS	O
pathologic	POS	O
findings	POS	O
on	POS	O
renal	POS	O
biopsy	POS	O
.	POS	O
A	POS	O
lymphocyte	POS	O
transformation	POS	O
test	POS	O
demonstrated	POS	O
a	POS	O
positive	POS	O
result	POS	O
against	POS	O
nicergoline	POS	O
.	POS	O
Treatment	POS	O
was	POS	O
consisted	POS	O
of	POS	O
withdrawal	POS	O
of	POS	O
nicergoline	POS	O
and	POS	O
intravenous	POS	O
methylprednisolone	POS	O
,	POS	O
and	POS	O
his	POS	O
renal	POS	O
function	POS	O
was	POS	O
completely	POS	O
recovered	POS	O
.	POS	O
To	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
this	POS	O
is	POS	O
the	POS	O
first	POS	O
report	POS	O
of	POS	O
nicergoline	POS	O
-	POS	O
associated	POS	O
AIN	POS	B-NP
.	POS	O
Neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
complicated	POS	O
by	POS	O
massive	POS	O
intestinal	POS	B-NP
bleeding	POS	I-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
chronic	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
.	POS	O
A	POS	O
patient	POS	O
with	POS	O
chronic	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
(	POS	O
CRF	POS	B-NP
)	POS	O
developed	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
(	POS	O
NMS	POS	B-NP
)	POS	O
after	POS	O
administration	POS	O
of	POS	O
risperidone	POS	O
and	POS	O
levomepromazine	POS	O
.	POS	O
In	POS	O
addition	POS	O
to	POS	O
the	POS	O
typical	POS	O
symptoms	POS	O
of	POS	O
NMS	POS	B-NP
,	POS	O
massive	POS	O
intestinal	POS	B-NP
bleeding	POS	I-NP
was	POS	O
observed	POS	O
during	POS	O
the	POS	O
episode	POS	O
.	POS	O
This	POS	O
report	POS	O
suggests	POS	O
that	POS	O
NMS	POS	B-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
CRF	POS	B-NP
may	POS	O
be	POS	O
complicated	POS	O
by	POS	O
intestinal	POS	B-NP
bleeding	POS	I-NP
and	POS	O
needs	POS	O
special	POS	O
caution	POS	O
for	POS	O
this	POS	O
complication	POS	O
.	POS	O
Blood	POS	O
brain	POS	O
barrier	POS	O
in	POS	O
right	POS	O
-	POS	O
and	POS	O
left	POS	O
-	POS	O
pawed	POS	O
female	POS	O
rats	POS	O
assessed	POS	O
by	POS	O
a	POS	O
new	POS	O
staining	POS	O
method	POS	O
.	POS	O
The	POS	O
asymmetrical	POS	O
breakdown	POS	O
of	POS	O
the	POS	O
blood	POS	O
-	POS	O
brain	POS	O
barrier	POS	O
(	POS	O
BBB	POS	O
)	POS	O
was	POS	O
studied	POS	O
in	POS	O
female	POS	O
rats	POS	O
.	POS	O
Paw	POS	O
preference	POS	O
was	POS	O
assessed	POS	O
by	POS	O
a	POS	O
food	POS	O
reaching	POS	O
test	POS	O
.	POS	O
Adrenaline	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
was	POS	O
used	POS	O
to	POS	O
destroy	POS	O
the	POS	O
BBB	POS	O
,	POS	O
which	POS	O
was	POS	O
evaluated	POS	O
using	POS	O
triphenyltetrazolium	POS	O
(	POS	O
TTC	POS	O
)	POS	O
staining	POS	O
of	POS	O
the	POS	O
brain	POS	O
slices	POS	O
just	POS	O
after	POS	O
giving	POS	O
adrenaline	POS	O
for	POS	O
30	POS	O
s	POS	O
.	POS	O
In	POS	O
normal	POS	O
rats	POS	O
,	POS	O
the	POS	O
whole	POS	O
brain	POS	O
sections	POS	O
exhibited	POS	O
complete	POS	O
staining	POS	O
with	POS	O
TTC	POS	O
.	POS	O
After	POS	O
adrenaline	POS	O
infusion	POS	O
for	POS	O
30	POS	O
s	POS	O
,	POS	O
there	POS	O
were	POS	O
large	POS	O
unstained	POS	O
areas	POS	O
in	POS	O
the	POS	O
left	POS	O
brain	POS	O
in	POS	O
right	POS	O
-	POS	O
pawed	POS	O
animals	POS	O
,	POS	O
and	POS	O
vice	POS	O
versa	POS	O
in	POS	O
left	POS	O
-	POS	O
pawed	POS	O
animals	POS	O
.	POS	O
Similar	POS	O
results	POS	O
were	POS	O
obtained	POS	O
in	POS	O
seizure	POS	B-NP
-	POS	O
induced	POS	O
breakdown	POS	O
of	POS	O
BBB	POS	O
.	POS	O
These	POS	O
results	POS	O
were	POS	O
explained	POS	O
by	POS	O
an	POS	O
asymmetric	POS	O
cerebral	POS	O
blood	POS	O
flow	POS	O
depending	POS	O
upon	POS	O
the	POS	O
paw	POS	O
preference	POS	O
in	POS	O
rats	POS	O
.	POS	O
It	POS	O
was	POS	O
suggested	POS	O
that	POS	O
this	POS	O
new	POS	O
method	POS	O
and	POS	O
the	POS	O
results	POS	O
are	POS	O
consistent	POS	O
with	POS	O
contralateral	POS	O
motor	POS	O
control	POS	O
that	POS	O
may	POS	O
be	POS	O
important	POS	O
in	POS	O
determining	POS	O
the	POS	O
dominant	POS	O
cerebral	POS	O
hemisphere	POS	O
in	POS	O
animals	POS	O
.	POS	O
Carvedilol	POS	O
protects	POS	O
against	POS	O
doxorubicin	POS	O
-	POS	O
induced	POS	O
mitochondrial	POS	B-NP
cardiomyopathy	POS	I-NP
.	POS	O
Several	POS	O
cytopathic	POS	B-NP
mechanisms	POS	O
have	POS	O
been	POS	O
suggested	POS	O
to	POS	O
mediate	POS	O
the	POS	O
dose	POS	O
-	POS	O
limiting	POS	O
cumulative	POS	O
and	POS	O
irreversible	POS	O
cardiomyopathy	POS	B-NP
caused	POS	O
by	POS	O
doxorubicin	POS	O
.	POS	O
Recent	POS	O
evidence	POS	O
indicates	POS	O
that	POS	O
oxidative	POS	O
stress	POS	O
and	POS	O
mitochondrial	POS	B-NP
dysfunction	POS	I-NP
are	POS	O
key	POS	O
factors	POS	O
in	POS	O
the	POS	O
pathogenic	POS	O
process	POS	O
.	POS	O
The	POS	O
objective	POS	O
of	POS	O
this	POS	O
investigation	POS	O
was	POS	O
to	POS	O
test	POS	O
the	POS	O
hypothesis	POS	O
that	POS	O
carvedilol	POS	O
,	POS	O
a	POS	O
nonselective	POS	O
beta	POS	O
-	POS	O
adrenergic	POS	O
receptor	POS	O
antagonist	POS	O
with	POS	O
potent	POS	O
antioxidant	POS	O
properties	POS	O
,	POS	O
protects	POS	O
against	POS	O
the	POS	O
cardiac	POS	O
and	POS	O
hepatic	POS	O
mitochondrial	POS	O
bioenergetic	POS	O
dysfunction	POS	O
associated	POS	O
with	POS	O
subchronic	POS	O
doxorubicin	POS	O
toxicity	POS	B-NP
.	POS	O
Heart	POS	O
and	POS	O
liver	POS	O
mitochondria	POS	O
were	POS	O
isolated	POS	O
from	POS	O
rats	POS	O
treated	POS	O
for	POS	O
7	POS	O
weeks	POS	O
with	POS	O
doxorubicin	POS	O
(	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
sc	POS	O
/	POS	O
week	POS	O
)	POS	O
,	POS	O
carvedilol	POS	O
(	POS	O
1	POS	O
mg	POS	O
/	POS	O
kg	POS	O
ip	POS	O
/	POS	O
week	POS	O
)	POS	O
,	POS	O
or	POS	O
the	POS	O
combination	POS	O
of	POS	O
the	POS	O
two	POS	O
drugs	POS	O
.	POS	O
Heart	POS	O
mitochondria	POS	O
isolated	POS	O
from	POS	O
doxorubicin	POS	O
-	POS	O
treated	POS	O
rats	POS	O
exhibited	POS	O
depressed	POS	O
rates	POS	O
for	POS	O
state	POS	O
3	POS	O
respiration	POS	O
(	POS	O
336	POS	O
+	POS	O
/	POS	O
-	POS	O
26	POS	O
versus	POS	O
425	POS	O
+	POS	O
/	POS	O
-	POS	O
53	POS	O
natom	POS	O
O	POS	O
/	POS	O
min	POS	O
/	POS	O
mg	POS	O
protein	POS	O
)	POS	O
and	POS	O
a	POS	O
lower	POS	O
respiratory	POS	O
control	POS	O
ratio	POS	O
(	POS	O
RCR	POS	O
)	POS	O
(	POS	O
4	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
6	POS	O
versus	POS	O
5	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
4	POS	O
)	POS	O
compared	POS	O
with	POS	O
cardiac	POS	O
mitochondria	POS	O
isolated	POS	O
from	POS	O
saline	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
Mitochondrial	POS	O
calcium	POS	O
-	POS	O
loading	POS	O
capacity	POS	O
and	POS	O
the	POS	O
activity	POS	O
of	POS	O
NADH	POS	O
-	POS	O
dehydrogenase	POS	O
were	POS	O
also	POS	O
suppressed	POS	O
in	POS	O
cardiac	POS	O
mitochondria	POS	O
from	POS	O
doxorubicin	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
Doxorubicin	POS	O
treatment	POS	O
also	POS	O
caused	POS	O
a	POS	O
decrease	POS	O
in	POS	O
RCR	POS	O
for	POS	O
liver	POS	O
mitochondria	POS	O
(	POS	O
3	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
9	POS	O
versus	POS	O
5	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
for	POS	O
control	POS	O
rats	POS	O
)	POS	O
and	POS	O
inhibition	POS	O
of	POS	O
hepatic	POS	O
cytochrome	POS	O
oxidase	POS	O
activity	POS	O
.	POS	O
Coadministration	POS	O
of	POS	O
carvedilol	POS	O
decreased	POS	O
the	POS	O
extent	POS	O
of	POS	O
cellular	POS	O
vacuolization	POS	O
in	POS	O
cardiac	POS	O
myocytes	POS	O
and	POS	O
prevented	POS	O
the	POS	O
inhibitory	POS	O
effect	POS	O
of	POS	O
doxorubicin	POS	O
on	POS	O
mitochondrial	POS	O
respiration	POS	O
in	POS	O
both	POS	O
heart	POS	O
and	POS	O
liver	POS	O
.	POS	O
Carvedilol	POS	O
also	POS	O
prevented	POS	O
the	POS	O
decrease	POS	O
in	POS	O
mitochondrial	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
loading	POS	O
capacity	POS	O
and	POS	O
the	POS	O
inhibition	POS	O
of	POS	O
the	POS	O
respiratory	POS	O
complexes	POS	O
of	POS	O
heart	POS	O
mitochondria	POS	O
caused	POS	O
by	POS	O
doxorubicin	POS	O
.	POS	O
Carvedilol	POS	O
by	POS	O
itself	POS	O
did	POS	O
not	POS	O
affect	POS	O
any	POS	O
of	POS	O
the	POS	O
parameters	POS	O
measured	POS	O
for	POS	O
heart	POS	O
or	POS	O
liver	POS	O
mitochondria	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
this	POS	O
protection	POS	O
by	POS	O
carvedilol	POS	O
against	POS	O
both	POS	O
the	POS	O
structural	POS	O
and	POS	O
functional	POS	O
cardiac	POS	O
tissue	POS	O
damage	POS	O
may	POS	O
afford	POS	O
significant	POS	O
clinical	POS	O
advantage	POS	O
in	POS	O
minimizing	POS	O
the	POS	O
dose	POS	O
-	POS	O
limiting	POS	O
mitochondrial	POS	B-NP
dysfunction	POS	I-NP
and	POS	O
cardiomyopathy	POS	B-NP
that	POS	O
accompanies	POS	O
long	POS	O
-	POS	O
term	POS	O
doxorubicin	POS	O
therapy	POS	O
in	POS	O
cancer	POS	B-NP
patients	POS	O
.	POS	O
Cocaine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
is	POS	O
more	POS	O
influenced	POS	O
by	POS	O
adenosine	POS	O
receptor	POS	O
agonists	POS	O
than	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
.	POS	O
The	POS	O
influence	POS	O
of	POS	O
adenosine	POS	O
receptor	POS	O
agonists	POS	O
and	POS	O
antagonists	POS	O
on	POS	O
cocaine	POS	O
-	POS	O
and	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
was	POS	O
examined	POS	O
in	POS	O
mice	POS	O
.	POS	O
All	POS	O
adenosine	POS	O
receptor	POS	O
agonists	POS	O
significantly	POS	O
decreased	POS	O
the	POS	O
locomotor	POS	O
activity	POS	O
in	POS	O
mice	POS	O
,	POS	O
and	POS	O
the	POS	O
effects	POS	O
were	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
.	POS	O
It	POS	O
seems	POS	O
that	POS	O
adenosine	POS	O
A1	POS	O
and	POS	O
A2	POS	O
receptors	POS	O
might	POS	O
be	POS	O
involved	POS	O
in	POS	O
this	POS	O
reaction	POS	O
.	POS	O
Moreover	POS	O
,	POS	O
all	POS	O
adenosine	POS	O
receptor	POS	O
agonists	POS	O
:	POS	O
2	POS	O
-	POS	O
p	POS	O
-	POS	O
(	POS	O
2	POS	O
-	POS	O
carboxyethyl	POS	O
)	POS	O
phenethylamino	POS	O
-	POS	O
5	POS	O
'	POS	O
-	POS	O
N	POS	O
-	POS	O
ethylcarboxamidoadenosine	POS	O
(	POS	O
CGS	POS	O
21680	POS	O
)	POS	O
,	POS	O
A2A	POS	O
receptor	POS	O
agonist	POS	O
,	POS	O
N6	POS	O
-	POS	O
cyclopentyladenosine	POS	O
(	POS	O
CPA	POS	O
)	POS	O
,	POS	O
A1	POS	O
receptor	POS	O
agonist	POS	O
,	POS	O
and	POS	O
5	POS	O
'	POS	O
-	POS	O
N	POS	O
-	POS	O
ethylcarboxamidoadenosine	POS	O
(	POS	O
NECA	POS	O
)	POS	O
,	POS	O
A2	POS	O
/	POS	O
A1	POS	O
receptor	POS	O
agonist	POS	O
significantly	POS	O
and	POS	O
dose	POS	O
-	POS	O
dependently	POS	O
decreased	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
locomotor	POS	O
activity	POS	O
.	POS	O
CPA	POS	O
reduced	POS	O
cocaine	POS	O
action	POS	O
at	POS	O
the	POS	O
doses	POS	O
which	POS	O
,	POS	O
given	POS	O
alone	POS	O
,	POS	O
did	POS	O
not	POS	O
influence	POS	O
motility	POS	O
,	POS	O
while	POS	O
CGS	POS	O
21680	POS	O
and	POS	O
NECA	POS	O
decreased	POS	O
the	POS	O
action	POS	O
of	POS	O
cocaine	POS	O
at	POS	O
the	POS	O
doses	POS	O
which	POS	O
,	POS	O
given	POS	O
alone	POS	O
,	POS	O
decreased	POS	O
locomotor	POS	O
activity	POS	O
in	POS	O
animals	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
the	POS	O
involvement	POS	O
of	POS	O
both	POS	O
adenosine	POS	O
receptors	POS	O
in	POS	O
the	POS	O
action	POS	O
of	POS	O
cocaine	POS	O
although	POS	O
agonists	POS	O
of	POS	O
A1	POS	O
receptors	POS	O
seem	POS	O
to	POS	O
have	POS	O
stronger	POS	O
influence	POS	O
on	POS	O
it	POS	O
.	POS	O
The	POS	O
selective	POS	O
blockade	POS	O
of	POS	O
A2	POS	O
adenosine	POS	O
receptor	POS	O
by	POS	O
DMPX	POS	O
(	POS	O
3	POS	O
,	POS	O
7	POS	O
-	POS	O
dimethyl	POS	O
-	POS	O
1	POS	O
-	POS	O
propargylxanthine	POS	O
)	POS	O
significantly	POS	O
enhanced	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
locomotor	POS	O
activity	POS	O
of	POS	O
animals	POS	O
.	POS	O
Caffeine	POS	O
had	POS	O
similar	POS	O
action	POS	O
but	POS	O
the	POS	O
effect	POS	O
was	POS	O
not	POS	O
significant	POS	O
.	POS	O
CPT	POS	O
(	POS	O
8	POS	O
-	POS	O
cyclopentyltheophylline	POS	O
)	POS	O
-	POS	O
-	POS	O
A1	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
did	POS	O
not	POS	O
show	POS	O
any	POS	O
influence	POS	O
in	POS	O
this	POS	O
test	POS	O
.	POS	O
Similarly	POS	O
,	POS	O
all	POS	O
adenosine	POS	O
receptor	POS	O
agonists	POS	O
decreased	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
,	POS	O
but	POS	O
at	POS	O
the	POS	O
higher	POS	O
doses	POS	O
than	POS	O
those	POS	O
which	POS	O
were	POS	O
active	POS	O
in	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
.	POS	O
The	POS	O
selective	POS	O
blockade	POS	O
of	POS	O
A2	POS	O
adenosine	POS	O
receptors	POS	O
(	POS	O
DMPX	POS	O
)	POS	O
and	POS	O
non	POS	O
-	POS	O
selective	POS	O
blockade	POS	O
of	POS	O
adenosine	POS	O
receptors	POS	O
(	POS	O
caffeine	POS	O
)	POS	O
significantly	POS	O
increased	POS	O
the	POS	O
action	POS	O
of	POS	O
amphetamine	POS	O
in	POS	O
the	POS	O
locomotor	POS	O
activity	POS	O
test	POS	O
.	POS	O
Our	POS	O
results	POS	O
have	POS	O
shown	POS	O
that	POS	O
all	POS	O
adenosine	POS	O
receptor	POS	O
agonists	POS	O
(	POS	O
A1	POS	O
and	POS	O
A2	POS	O
)	POS	O
reduce	POS	O
cocaine	POS	O
-	POS	O
and	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
locomotor	POS	O
activity	POS	O
and	POS	O
indicate	POS	O
that	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
is	POS	O
more	POS	O
influenced	POS	O
by	POS	O
adenosine	POS	O
receptor	POS	O
agonists	POS	O
(	POS	O
particularly	POS	O
A1	POS	O
receptors	POS	O
)	POS	O
than	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
hyperactivity	POS	B-NP
.	POS	O
Amiodarone	POS	O
and	POS	O
the	POS	O
risk	POS	O
of	POS	O
bradyarrhythmia	POS	B-NP
requiring	POS	O
permanent	POS	O
pacemaker	POS	O
in	POS	O
elderly	POS	O
patients	POS	O
with	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
and	POS	O
prior	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
OBJECTIVES	POS	O
:	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
whether	POS	O
the	POS	O
use	POS	O
of	POS	O
amiodarone	POS	O
in	POS	O
patients	POS	O
with	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
(	POS	O
AF	POS	B-NP
)	POS	O
increases	POS	O
the	POS	O
risk	POS	O
of	POS	O
bradyarrhythmia	POS	B-NP
requiring	POS	O
a	POS	O
permanent	POS	O
pacemaker	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Reports	POS	O
of	POS	O
severe	POS	O
bradyarrhythmia	POS	B-NP
during	POS	O
amiodarone	POS	O
therapy	POS	O
are	POS	O
infrequent	POS	O
and	POS	O
limited	POS	O
to	POS	O
studies	POS	O
assessing	POS	O
the	POS	O
therapy	POS	O
'	POS	O
s	POS	O
use	POS	O
in	POS	O
the	POS	O
management	POS	O
of	POS	O
patients	POS	O
with	POS	O
ventricular	POS	B-NP
arrhythmias	POS	I-NP
.	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
study	POS	O
cohort	POS	O
of	POS	O
8	POS	O
,	POS	O
770	POS	O
patients	POS	O
age	POS	O
>	POS	O
or	POS	O
=	POS	O
65	POS	O
years	POS	O
with	POS	O
a	POS	O
new	POS	O
diagnosis	POS	O
of	POS	O
AF	POS	B-NP
was	POS	O
identified	POS	O
from	POS	O
a	POS	O
provincewide	POS	O
database	POS	O
of	POS	O
Quebec	POS	O
residents	POS	O
with	POS	O
a	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
(	POS	O
MI	POS	B-NP
)	POS	O
between	POS	O
1991	POS	O
and	POS	O
1999	POS	O
.	POS	O
Using	POS	O
a	POS	O
nested	POS	O
case	POS	O
-	POS	O
control	POS	O
design	POS	O
,	POS	O
477	POS	O
cases	POS	O
of	POS	O
bradyarrhythmia	POS	B-NP
requiring	POS	O
a	POS	O
permanent	POS	O
pacemaker	POS	O
were	POS	O
matched	POS	O
(	POS	O
1	POS	O
:	POS	O
4	POS	O
)	POS	O
to	POS	O
1	POS	O
,	POS	O
908	POS	O
controls	POS	O
.	POS	O
Multivariable	POS	O
logistic	POS	O
regression	POS	O
was	POS	O
used	POS	O
to	POS	O
estimate	POS	O
the	POS	O
odds	POS	O
ratio	POS	O
(	POS	O
OR	POS	O
)	POS	O
of	POS	O
pacemaker	POS	O
insertion	POS	O
associated	POS	O
with	POS	O
amiodarone	POS	O
use	POS	O
,	POS	O
controlling	POS	O
for	POS	O
baseline	POS	O
risk	POS	O
factors	POS	O
and	POS	O
exposure	POS	O
to	POS	O
sotalol	POS	O
,	POS	O
Class	POS	O
I	POS	O
antiarrhythmic	POS	O
agents	POS	O
,	POS	O
beta	POS	O
-	POS	O
blockers	POS	O
,	POS	O
calcium	POS	O
channel	POS	O
blockers	POS	O
,	POS	O
and	POS	O
digoxin	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
amiodarone	POS	O
use	POS	O
was	POS	O
associated	POS	O
with	POS	O
an	POS	O
increased	POS	O
risk	POS	O
of	POS	O
pacemaker	POS	O
insertion	POS	O
(	POS	O
OR	POS	O
:	POS	O
2	POS	O
.	POS	O
14	POS	O
,	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
[	POS	O
CI	POS	O
]	POS	O
:	POS	O
1	POS	O
.	POS	O
30	POS	O
to	POS	O
3	POS	O
.	POS	O
54	POS	O
)	POS	O
.	POS	O
This	POS	O
effect	POS	O
was	POS	O
modified	POS	O
by	POS	O
gender	POS	O
,	POS	O
with	POS	O
a	POS	O
greater	POS	O
risk	POS	O
in	POS	O
women	POS	O
versus	POS	O
men	POS	O
(	POS	O
OR	POS	O
:	POS	O
3	POS	O
.	POS	O
86	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
1	POS	O
.	POS	O
70	POS	O
to	POS	O
8	POS	O
.	POS	O
75	POS	O
vs	POS	O
.	POS	O
OR	POS	O
:	POS	O
1	POS	O
.	POS	O
52	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
0	POS	O
.	POS	O
80	POS	O
to	POS	O
2	POS	O
.	POS	O
89	POS	O
)	POS	O
.	POS	O
Digoxin	POS	O
was	POS	O
the	POS	O
only	POS	O
other	POS	O
medication	POS	O
associated	POS	O
with	POS	O
an	POS	O
increased	POS	O
risk	POS	O
of	POS	O
pacemaker	POS	O
insertion	POS	O
(	POS	O
OR	POS	O
:	POS	O
1	POS	O
.	POS	O
78	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
1	POS	O
.	POS	O
37	POS	O
to	POS	O
2	POS	O
.	POS	O
31	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
This	POS	O
study	POS	O
suggests	POS	O
that	POS	O
the	POS	O
use	POS	O
of	POS	O
amiodarone	POS	O
in	POS	O
elderly	POS	O
patients	POS	O
with	POS	O
AF	POS	B-NP
and	POS	O
a	POS	O
previous	POS	O
MI	POS	B-NP
increases	POS	O
the	POS	O
risk	POS	O
of	POS	O
bradyarrhythmia	POS	B-NP
requiring	POS	O
a	POS	O
permanent	POS	O
pacemaker	POS	O
.	POS	O
The	POS	O
finding	POS	O
of	POS	O
an	POS	O
augmented	POS	O
risk	POS	O
of	POS	O
pacemaker	POS	O
insertion	POS	O
in	POS	O
elderly	POS	O
women	POS	O
receiving	POS	O
amiodarone	POS	O
requires	POS	O
further	POS	O
investigation	POS	O
.	POS	O
Indomethacin	POS	O
-	POS	O
induced	POS	O
morphologic	POS	O
changes	POS	O
in	POS	O
the	POS	O
rat	POS	O
urinary	POS	O
bladder	POS	O
epithelium	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
To	POS	O
evaluate	POS	O
the	POS	O
morphologic	POS	O
changes	POS	O
in	POS	O
rat	POS	O
urothelium	POS	O
induced	POS	O
by	POS	O
indomethacin	POS	O
.	POS	O
Nonsteroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drug	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
is	POS	O
a	POS	O
poorly	POS	O
recognized	POS	O
and	POS	O
under	POS	O
-	POS	O
reported	POS	O
condition	POS	O
.	POS	O
In	POS	O
addition	POS	O
to	POS	O
tiaprofenic	POS	O
acid	POS	O
,	POS	O
indomethacin	POS	O
has	POS	O
been	POS	O
reported	POS	O
to	POS	O
be	POS	O
associated	POS	O
with	POS	O
this	POS	O
condition	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Three	POS	O
groups	POS	O
were	POS	O
established	POS	O
:	POS	O
a	POS	O
control	POS	O
group	POS	O
(	POS	O
n	POS	O
=	POS	O
10	POS	O
)	POS	O
,	POS	O
a	POS	O
high	POS	O
-	POS	O
dose	POS	O
group	POS	O
(	POS	O
n	POS	O
=	POS	O
10	POS	O
)	POS	O
,	POS	O
treated	POS	O
with	POS	O
one	POS	O
intraperitoneal	POS	O
injection	POS	O
of	POS	O
indomethacin	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
and	POS	O
a	POS	O
therapeutic	POS	O
dose	POS	O
group	POS	O
(	POS	O
n	POS	O
=	POS	O
10	POS	O
)	POS	O
in	POS	O
which	POS	O
oral	POS	O
indomethacin	POS	O
was	POS	O
administered	POS	O
3	POS	O
.	POS	O
25	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
weight	POS	O
daily	POS	O
for	POS	O
3	POS	O
weeks	POS	O
.	POS	O
The	POS	O
animals	POS	O
were	POS	O
then	POS	O
killed	POS	O
and	POS	O
the	POS	O
bladders	POS	O
removed	POS	O
for	POS	O
light	POS	O
and	POS	O
electron	POS	O
microscopic	POS	O
studies	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
light	POS	O
microscopic	POS	O
findings	POS	O
showed	POS	O
some	POS	O
focal	POS	O
epithelial	POS	O
degeneration	POS	O
that	POS	O
was	POS	O
more	POS	O
prominent	POS	O
in	POS	O
the	POS	O
high	POS	O
-	POS	O
dose	POS	O
group	POS	O
.	POS	O
When	POS	O
compared	POS	O
with	POS	O
the	POS	O
control	POS	O
group	POS	O
,	POS	O
both	POS	O
indomethacin	POS	O
groups	POS	O
revealed	POS	O
statistically	POS	O
increased	POS	O
numbers	POS	O
of	POS	O
mast	POS	O
cells	POS	O
in	POS	O
the	POS	O
mucosa	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
0001	POS	O
)	POS	O
and	POS	O
penetration	POS	O
of	POS	O
lanthanum	POS	O
nitrate	POS	O
through	POS	O
intercellular	POS	O
areas	POS	O
of	POS	O
the	POS	O
epithelium	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
the	POS	O
difference	POS	O
in	POS	O
mast	POS	O
cell	POS	O
counts	POS	O
between	POS	O
the	POS	O
high	POS	O
and	POS	O
therapeutic	POS	O
dose	POS	O
groups	POS	O
was	POS	O
also	POS	O
statistically	POS	O
significant	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
0001	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Indomethacin	POS	O
resulted	POS	O
in	POS	O
histopathologic	POS	O
findings	POS	O
typical	POS	O
of	POS	O
interstitial	POS	B-NP
cystitis	POS	I-NP
,	POS	O
such	POS	O
as	POS	O
leaky	POS	B-NP
bladder	POS	I-NP
epithelium	POS	I-NP
and	POS	O
mucosal	POS	B-NP
mastocytosis	POS	I-NP
.	POS	O
The	POS	O
true	POS	O
incidence	POS	O
of	POS	O
nonsteroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drug	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
in	POS	O
humans	POS	O
must	POS	O
be	POS	O
clarified	POS	O
by	POS	O
prospective	POS	O
clinical	POS	O
trials	POS	O
.	POS	O
An	POS	O
open	POS	O
-	POS	O
label	POS	O
phase	POS	O
II	POS	O
study	POS	O
of	POS	O
low	POS	O
-	POS	O
dose	POS	O
thalidomide	POS	O
in	POS	O
androgen	POS	O
-	POS	O
independent	POS	O
prostate	POS	B-NP
cancer	POS	I-NP
.	POS	O
The	POS	O
antiangiogenic	POS	O
effects	POS	O
of	POS	O
thalidomide	POS	O
have	POS	O
been	POS	O
assessed	POS	O
in	POS	O
clinical	POS	O
trials	POS	O
in	POS	O
patients	POS	O
with	POS	O
various	POS	O
solid	POS	O
and	POS	O
haematological	POS	O
malignancies	POS	O
.	POS	O
Thalidomide	POS	O
blocks	POS	O
the	POS	O
activity	POS	O
of	POS	O
angiogenic	POS	O
agents	POS	O
including	POS	O
bFGF	POS	O
,	POS	O
VEGF	POS	O
and	POS	O
IL	POS	O
-	POS	O
6	POS	O
.	POS	O
We	POS	O
undertook	POS	O
an	POS	O
open	POS	O
-	POS	O
label	POS	O
study	POS	O
using	POS	O
thalidomide	POS	O
100	POS	O
mg	POS	O
once	POS	O
daily	POS	O
for	POS	O
up	POS	O
to	POS	O
6	POS	O
months	POS	O
in	POS	O
20	POS	O
men	POS	O
with	POS	O
androgen	POS	O
-	POS	O
independent	POS	O
prostate	POS	B-NP
cancer	POS	I-NP
.	POS	O
The	POS	O
mean	POS	O
time	POS	O
of	POS	O
study	POS	O
was	POS	O
109	POS	O
days	POS	O
(	POS	O
median	POS	O
107	POS	O
,	POS	O
range	POS	O
4	POS	O
-	POS	O
184	POS	O
days	POS	O
)	POS	O
.	POS	O
Patients	POS	O
underwent	POS	O
regular	POS	O
measurement	POS	O
of	POS	O
prostate	POS	O
-	POS	O
specific	POS	O
antigen	POS	O
(	POS	O
PSA	POS	O
)	POS	O
,	POS	O
urea	POS	O
and	POS	O
electrolytes	POS	O
,	POS	O
serum	POS	O
bFGF	POS	O
and	POS	O
VEGF	POS	O
.	POS	O
Three	POS	O
men	POS	O
(	POS	O
15	POS	O
%	POS	O
)	POS	O
showed	POS	O
a	POS	O
decline	POS	O
in	POS	O
serum	POS	O
PSA	POS	O
of	POS	O
at	POS	O
least	POS	O
50	POS	O
%	POS	O
,	POS	O
sustained	POS	O
throughout	POS	O
treatment	POS	O
.	POS	O
Of	POS	O
16	POS	O
men	POS	O
treated	POS	O
for	POS	O
at	POS	O
least	POS	O
2	POS	O
months	POS	O
,	POS	O
six	POS	O
(	POS	O
37	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
showed	POS	O
a	POS	O
fall	POS	O
in	POS	O
absolute	POS	O
PSA	POS	O
by	POS	O
a	POS	O
median	POS	O
of	POS	O
48	POS	O
%	POS	O
.	POS	O
Increasing	POS	O
levels	POS	O
of	POS	O
serum	POS	O
bFGF	POS	O
and	POS	O
VEGF	POS	O
were	POS	O
associated	POS	O
with	POS	O
progressive	POS	O
disease	POS	O
;	POS	O
five	POS	O
of	POS	O
six	POS	O
men	POS	O
who	POS	O
demonstrated	POS	O
a	POS	O
fall	POS	O
in	POS	O
PSA	POS	O
also	POS	O
showed	POS	O
a	POS	O
decline	POS	O
in	POS	O
bFGF	POS	O
and	POS	O
VEGF	POS	O
levels	POS	O
,	POS	O
and	POS	O
three	POS	O
of	POS	O
four	POS	O
men	POS	O
with	POS	O
a	POS	O
rising	POS	O
PSA	POS	O
showed	POS	O
an	POS	O
increase	POS	O
in	POS	O
both	POS	O
growth	POS	O
factors	POS	O
.	POS	O
Adverse	POS	O
effects	POS	O
included	POS	O
constipation	POS	B-NP
,	POS	O
morning	POS	B-NP
drowsiness	POS	I-NP
,	POS	O
dizziness	POS	B-NP
and	POS	O
rash	POS	B-NP
,	POS	O
and	POS	O
resulted	POS	O
in	POS	O
withdrawal	POS	O
from	POS	O
the	POS	O
study	POS	O
by	POS	O
three	POS	O
men	POS	O
.	POS	O
Evidence	POS	O
of	POS	O
peripheral	POS	B-NP
sensory	POS	I-NP
neuropathy	POS	I-NP
was	POS	O
found	POS	O
in	POS	O
nine	POS	O
of	POS	O
13	POS	O
men	POS	O
before	POS	O
treatment	POS	O
.	POS	O
In	POS	O
the	POS	O
seven	POS	O
men	POS	O
who	POS	O
completed	POS	O
six	POS	O
months	POS	O
on	POS	O
thalidomide	POS	O
,	POS	O
subclinical	POS	O
evidence	POS	O
of	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
was	POS	O
found	POS	O
in	POS	O
four	POS	O
before	POS	O
treatment	POS	O
,	POS	O
but	POS	O
in	POS	O
all	POS	O
seven	POS	O
at	POS	O
repeat	POS	O
testing	POS	O
.	POS	O
The	POS	O
findings	POS	O
indicate	POS	O
that	POS	O
thalidomide	POS	O
may	POS	O
be	POS	O
an	POS	O
option	POS	O
for	POS	O
patients	POS	O
who	POS	O
have	POS	O
failed	POS	O
other	POS	O
forms	POS	O
of	POS	O
therapy	POS	O
,	POS	O
provided	POS	O
close	POS	O
follow	POS	O
-	POS	O
up	POS	O
is	POS	O
maintained	POS	O
for	POS	O
development	POS	O
of	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
.	POS	O
Central	POS	B-NP
nervous	POS	I-NP
system	POS	I-NP
toxicity	POS	I-NP
following	POS	O
the	POS	O
administration	POS	O
of	POS	O
levobupivacaine	POS	O
for	POS	O
lumbar	POS	B-NP
plexus	POS	I-NP
block	POS	I-NP
:	POS	O
A	POS	O
report	POS	O
of	POS	O
two	POS	O
cases	POS	O
.	POS	O
BACKGROUND	POS	O
AND	POS	O
OBJECTIVES	POS	O
:	POS	O
Central	POS	O
nervous	POS	O
system	POS	O
and	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
following	POS	O
the	POS	O
administration	POS	O
of	POS	O
local	POS	O
anesthetics	POS	O
is	POS	O
a	POS	O
recognized	POS	O
complication	POS	O
of	POS	O
regional	POS	O
anesthesia	POS	O
.	POS	O
Levobupivacaine	POS	O
,	POS	O
the	POS	O
pure	POS	O
S	POS	O
(	POS	O
-	POS	O
)	POS	O
enantiomer	POS	O
of	POS	O
bupivacaine	POS	O
,	POS	O
was	POS	O
developed	POS	O
to	POS	O
improve	POS	O
the	POS	O
cardiac	POS	O
safety	POS	O
profile	POS	O
of	POS	O
bupivacaine	POS	O
.	POS	O
We	POS	O
describe	POS	O
2	POS	O
cases	POS	O
of	POS	O
grand	POS	O
mal	POS	O
seizures	POS	B-NP
following	POS	O
accidental	POS	O
intravascular	POS	O
injection	POS	O
of	POS	O
levobupivacaine	POS	O
.	POS	O
CASE	POS	O
REPORT	POS	O
:	POS	O
Two	POS	O
patients	POS	O
presenting	POS	O
for	POS	O
elective	POS	O
orthopedic	POS	O
surgery	POS	O
of	POS	O
the	POS	O
lower	POS	O
limb	POS	O
underwent	POS	O
blockade	POS	O
of	POS	O
the	POS	O
lumbar	POS	O
plexus	POS	O
via	POS	O
the	POS	O
posterior	POS	O
approach	POS	O
.	POS	O
Immediately	POS	O
after	POS	O
the	POS	O
administration	POS	O
of	POS	O
levobupivacaine	POS	O
0	POS	O
.	POS	O
5	POS	O
%	POS	O
with	POS	O
epinephrine	POS	O
2	POS	O
.	POS	O
5	POS	O
microgram	POS	O
/	POS	O
mL	POS	O
,	POS	O
the	POS	O
patients	POS	O
developed	POS	O
grand	POS	O
mal	POS	O
seizures	POS	B-NP
,	POS	O
despite	POS	O
negative	POS	O
aspiration	POS	O
for	POS	O
blood	POS	O
and	POS	O
no	POS	O
clinical	POS	O
signs	POS	O
of	POS	O
intravenous	POS	O
epinephrine	POS	O
administration	POS	O
.	POS	O
The	POS	O
seizures	POS	B-NP
were	POS	O
successfully	POS	O
treated	POS	O
with	POS	O
sodium	POS	O
thiopental	POS	O
in	POS	O
addition	POS	O
to	POS	O
succinylcholine	POS	O
in	POS	O
1	POS	O
patient	POS	O
.	POS	O
Neither	POS	O
patient	POS	O
developed	POS	O
signs	POS	O
of	POS	O
cardiovascular	POS	B-NP
toxicity	POS	I-NP
.	POS	O
Both	POS	O
patients	POS	O
were	POS	O
treated	POS	O
preoperatively	POS	O
with	POS	O
beta	POS	O
-	POS	O
adrenergic	POS	O
antagonist	POS	O
medications	POS	O
,	POS	O
which	POS	O
may	POS	O
have	POS	O
masked	POS	O
the	POS	O
cardiovascular	POS	O
signs	POS	O
of	POS	O
the	POS	O
unintentional	POS	O
intravascular	POS	O
administration	POS	O
of	POS	O
levobupivacaine	POS	O
with	POS	O
epinephrine	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Although	POS	O
levobupivacaine	POS	O
may	POS	O
have	POS	O
a	POS	O
safer	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
profile	POS	O
than	POS	O
racemic	POS	O
bupivacaine	POS	O
,	POS	O
if	POS	O
adequate	POS	O
amounts	POS	O
of	POS	O
levobupivacaine	POS	O
reach	POS	O
the	POS	O
circulation	POS	O
,	POS	O
it	POS	O
will	POS	O
result	POS	O
in	POS	O
convulsions	POS	B-NP
.	POS	O
Plasma	POS	O
concentrations	POS	O
sufficient	POS	O
to	POS	O
result	POS	O
in	POS	O
central	POS	B-NP
nervous	POS	I-NP
system	POS	I-NP
toxicity	POS	I-NP
did	POS	O
not	POS	O
produce	POS	O
manifestations	POS	O
of	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
in	POS	O
these	POS	O
2	POS	O
patients	POS	O
.	POS	O
Amiodarone	POS	O
-	POS	O
induced	POS	O
torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
during	POS	O
bladder	POS	O
irrigation	POS	O
:	POS	O
an	POS	O
unusual	POS	O
presentation	POS	O
-	POS	O
-	POS	O
a	POS	O
case	POS	O
report	POS	O
.	POS	O
The	POS	O
authors	POS	O
present	POS	O
a	POS	O
case	POS	O
of	POS	O
early	POS	O
(	POS	O
within	POS	O
4	POS	O
days	POS	O
)	POS	O
development	POS	O
of	POS	O
torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
(	POS	O
TdP	POS	B-NP
)	POS	O
associated	POS	O
with	POS	O
oral	POS	O
amiodarone	POS	O
therapy	POS	O
.	POS	O
Consistent	POS	O
with	POS	O
other	POS	O
reports	POS	O
this	POS	O
case	POS	O
of	POS	O
TdP	POS	B-NP
occurred	POS	O
in	POS	O
the	POS	O
context	POS	O
of	POS	O
multiple	POS	O
exacerbating	POS	O
factors	POS	O
including	POS	O
hypokalemia	POS	B-NP
and	POS	O
digoxin	POS	O
excess	POS	O
.	POS	O
Transient	POS	O
prolongation	POS	O
of	POS	O
the	POS	O
QT	POS	O
during	POS	O
bladder	POS	O
irrigation	POS	O
prompted	POS	O
the	POS	O
episode	POS	O
of	POS	O
TdP	POS	B-NP
.	POS	O
It	POS	O
is	POS	O
well	POS	O
known	POS	O
that	POS	O
bradycardia	POS	B-NP
exacerbates	POS	O
acquired	POS	O
TdP	POS	B-NP
.	POS	O
The	POS	O
authors	POS	O
speculate	POS	O
that	POS	O
the	POS	O
increased	POS	O
vagal	POS	O
tone	POS	O
during	POS	O
bladder	POS	O
irrigation	POS	O
,	POS	O
a	POS	O
vagal	POS	O
maneuver	POS	O
,	POS	O
in	POS	O
the	POS	O
context	POS	O
of	POS	O
amiodarone	POS	O
therapy	POS	O
resulted	POS	O
in	POS	O
amiodarone	POS	O
-	POS	O
induced	POS	O
proarrhythmia	POS	B-NP
.	POS	O
In	POS	O
the	POS	O
absence	POS	O
of	POS	O
amiodarone	POS	O
therapy	POS	O
,	POS	O
a	POS	O
second	POS	O
bladder	POS	O
irrigation	POS	O
did	POS	O
not	POS	O
induce	POS	O
TdP	POS	B-NP
despite	POS	O
hypokalemia	POS	B-NP
and	POS	O
hypomagnesemia	POS	B-NP
.	POS	O
Anaesthetic	POS	B-NP
complications	POS	I-NP
associated	POS	O
with	POS	O
myotonia	POS	B-NP
congenita	POS	I-NP
:	POS	O
case	POS	O
study	POS	O
and	POS	O
comparison	POS	O
with	POS	O
other	POS	O
myotonic	POS	B-NP
disorders	POS	I-NP
.	POS	O
Myotonia	POS	B-NP
congenita	POS	I-NP
(	POS	O
MC	POS	B-NP
)	POS	O
is	POS	O
caused	POS	O
by	POS	O
a	POS	O
defect	POS	O
in	POS	O
the	POS	O
skeletal	POS	O
muscle	POS	O
chloride	POS	O
channel	POS	O
function	POS	O
,	POS	O
which	POS	O
may	POS	O
cause	POS	O
sustained	POS	O
membrane	POS	O
depolarisation	POS	O
.	POS	O
We	POS	O
describe	POS	O
a	POS	O
previously	POS	O
healthy	POS	O
32	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
who	POS	O
developed	POS	O
a	POS	O
life	POS	O
-	POS	O
threatening	POS	O
muscle	POS	B-NP
spasm	POS	I-NP
and	POS	O
secondary	POS	O
ventilation	POS	O
difficulties	POS	O
following	POS	O
a	POS	O
preoperative	POS	O
injection	POS	O
of	POS	O
suxamethonium	POS	O
.	POS	O
The	POS	O
muscle	POS	B-NP
spasms	POS	I-NP
disappeared	POS	O
spontaneously	POS	O
and	POS	O
the	POS	O
surgery	POS	O
proceeded	POS	O
without	POS	O
further	POS	O
problems	POS	O
.	POS	O
When	POS	O
subsequently	POS	O
questioned	POS	O
,	POS	O
she	POS	O
reported	POS	O
minor	POS	O
symptoms	POS	O
suggesting	POS	O
a	POS	O
myotonic	POS	B-NP
condition	POS	O
.	POS	O
Myotonia	POS	B-NP
was	POS	O
found	POS	O
on	POS	O
clinical	POS	O
examination	POS	O
and	POS	O
EMG	POS	O
.	POS	O
The	POS	O
diagnosis	POS	O
MC	POS	O
was	POS	O
confirmed	POS	O
genetically	POS	O
.	POS	O
Neither	POS	O
the	POS	O
patient	POS	O
nor	POS	O
the	POS	O
anaesthetist	POS	O
were	POS	O
aware	POS	O
of	POS	O
the	POS	O
diagnosis	POS	O
before	POS	O
this	POS	O
potentially	POS	O
lethal	POS	O
complication	POS	O
occurred	POS	O
.	POS	O
We	POS	O
give	POS	O
a	POS	O
brief	POS	O
overview	POS	O
of	POS	O
ion	POS	O
channel	POS	O
disorders	POS	O
including	POS	O
malignant	POS	B-NP
hyperthermia	POS	I-NP
and	POS	O
their	POS	O
anaesthetic	POS	O
considerations	POS	O
.	POS	O
Respiratory	POS	O
pattern	POS	O
in	POS	O
a	POS	O
rat	POS	O
model	POS	O
of	POS	O
epilepsy	POS	B-NP
.	POS	O
PURPOSE	POS	O
:	POS	O
Apnea	POS	B-NP
is	POS	O
known	POS	O
to	POS	O
occur	POS	O
during	POS	O
seizures	POS	B-NP
,	POS	O
but	POS	O
systematic	POS	O
studies	POS	O
of	POS	O
ictal	POS	O
respiratory	POS	O
changes	POS	O
in	POS	O
adults	POS	O
are	POS	O
few	POS	O
.	POS	O
Data	POS	O
regarding	POS	O
respiratory	POS	B-NP
pattern	POS	I-NP
defects	POS	I-NP
during	POS	O
interictal	POS	O
periods	POS	O
also	POS	O
are	POS	O
scarce	POS	O
.	POS	O
Here	POS	O
we	POS	O
sought	POS	O
to	POS	O
generate	POS	O
information	POS	O
with	POS	O
regard	POS	O
to	POS	O
the	POS	O
interictal	POS	O
period	POS	O
in	POS	O
animals	POS	O
with	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
epilepsy	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Twelve	POS	O
rats	POS	O
(	POS	O
six	POS	O
chronically	POS	O
epileptic	POS	B-NP
animals	POS	O
and	POS	O
six	POS	O
controls	POS	O
)	POS	O
were	POS	O
anesthetized	POS	O
,	POS	O
given	POS	O
tracheotomies	POS	O
,	POS	O
and	POS	O
subjected	POS	O
to	POS	O
hyperventilation	POS	B-NP
or	POS	O
hypoventilation	POS	B-NP
conditions	POS	O
.	POS	O
Breathing	POS	O
movements	POS	O
caused	POS	O
changes	POS	O
in	POS	O
thoracic	POS	O
volume	POS	O
and	POS	O
forced	POS	O
air	POS	O
to	POS	O
flow	POS	O
tidally	POS	O
through	POS	O
a	POS	O
pneumotachograph	POS	O
.	POS	O
This	POS	O
flow	POS	O
was	POS	O
measured	POS	O
by	POS	O
using	POS	O
a	POS	O
differential	POS	O
pressure	POS	O
transducer	POS	O
,	POS	O
passed	POS	O
through	POS	O
a	POS	O
polygraph	POS	O
,	POS	O
and	POS	O
from	POS	O
this	POS	O
to	POS	O
a	POS	O
computer	POS	O
with	POS	O
custom	POS	O
software	POS	O
that	POS	O
derived	POS	O
ventilation	POS	O
(	POS	O
VE	POS	O
)	POS	O
,	POS	O
tidal	POS	O
volume	POS	O
(	POS	O
VT	POS	O
)	POS	O
,	POS	O
inspiratory	POS	O
time	POS	O
(	POS	O
TI	POS	O
)	POS	O
,	POS	O
expiratory	POS	O
time	POS	O
(	POS	O
TE	POS	O
)	POS	O
,	POS	O
breathing	POS	O
frequency	POS	O
(	POS	O
f	POS	O
)	POS	O
,	POS	O
and	POS	O
mean	POS	O
inspiratory	POS	O
flow	POS	O
(	POS	O
VT	POS	O
/	POS	O
TI	POS	O
)	POS	O
on	POS	O
a	POS	O
breath	POS	O
-	POS	O
by	POS	O
-	POS	O
breath	POS	O
basis	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
hyperventilation	POS	O
maneuver	POS	O
caused	POS	O
a	POS	O
decrease	POS	O
in	POS	O
spontaneous	POS	O
ventilation	POS	O
in	POS	O
pilocarpine	POS	O
-	POS	O
treated	POS	O
and	POS	O
control	POS	O
rats	POS	O
.	POS	O
Although	POS	O
VE	POS	O
had	POS	O
a	POS	O
similar	POS	O
decrease	POS	O
in	POS	O
both	POS	O
groups	POS	O
,	POS	O
in	POS	O
the	POS	O
epileptic	POS	B-NP
group	POS	O
,	POS	O
the	POS	O
decrease	POS	O
in	POS	O
VE	POS	O
was	POS	O
due	POS	O
to	POS	O
a	POS	O
significant	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
increase	POS	O
in	POS	O
TE	POS	O
peak	POS	O
in	POS	O
relation	POS	O
to	POS	O
that	POS	O
of	POS	O
the	POS	O
control	POS	O
animals	POS	O
.	POS	O
The	POS	O
hypoventilation	POS	B-NP
maneuver	POS	O
led	POS	O
to	POS	O
an	POS	O
increase	POS	O
in	POS	O
the	POS	O
arterial	POS	O
Paco2	POS	O
,	POS	O
followed	POS	O
by	POS	O
an	POS	O
increase	POS	O
in	POS	O
VE	POS	O
.	POS	O
In	POS	O
the	POS	O
epileptic	POS	B-NP
group	POS	O
,	POS	O
the	POS	O
increase	POS	O
in	POS	O
VE	POS	O
was	POS	O
mediated	POS	O
by	POS	O
a	POS	O
significant	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
decrease	POS	O
in	POS	O
TE	POS	O
peak	POS	O
compared	POS	O
with	POS	O
the	POS	O
control	POS	O
group	POS	O
.	POS	O
Systemic	POS	O
application	POS	O
of	POS	O
KCN	POS	O
,	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
effects	POS	O
of	POS	O
peripheral	POS	O
chemoreception	POS	O
activation	POS	O
on	POS	O
ventilation	POS	O
,	POS	O
led	POS	O
to	POS	O
a	POS	O
similar	POS	O
increase	POS	O
in	POS	O
VE	POS	O
for	POS	O
both	POS	O
groups	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
data	POS	O
indicate	POS	O
that	POS	O
pilocarpine	POS	O
-	POS	O
treated	POS	O
animals	POS	O
have	POS	O
an	POS	O
altered	POS	O
ability	POS	O
to	POS	O
react	POS	O
to	POS	O
(	POS	O
or	POS	O
compensate	POS	O
for	POS	O
)	POS	O
blood	POS	O
gas	POS	O
changes	POS	O
with	POS	O
changes	POS	O
in	POS	O
ventilation	POS	O
and	POS	O
suggest	POS	O
that	POS	O
it	POS	O
is	POS	O
centrally	POS	O
determined	POS	O
.	POS	O
We	POS	O
speculate	POS	O
on	POS	O
the	POS	O
possible	POS	O
relation	POS	O
of	POS	O
the	POS	O
current	POS	O
findings	POS	O
on	POS	O
treating	POS	O
different	POS	O
epilepsy	POS	B-NP
-	POS	O
associated	POS	O
conditions	POS	O
.	POS	O
Fatal	POS	O
myeloencephalopathy	POS	B-NP
due	POS	O
to	POS	O
intrathecal	POS	O
vincristine	POS	O
administration	POS	O
.	POS	O
Vincristine	POS	O
was	POS	O
accidentally	POS	O
given	POS	O
intrathecally	POS	O
to	POS	O
a	POS	O
child	POS	O
with	POS	O
leukaemia	POS	B-NP
,	POS	O
producing	POS	O
sensory	POS	O
and	POS	O
motor	POS	O
dysfunction	POS	O
followed	POS	O
by	POS	O
encephalopathy	POS	B-NP
and	POS	O
death	POS	B-NP
.	POS	O
Separate	POS	O
times	POS	O
for	POS	O
administering	POS	O
vincristine	POS	O
and	POS	O
intrathecal	POS	O
therapy	POS	O
is	POS	O
recommended	POS	O
.	POS	O
Progesterone	POS	O
potentiation	POS	O
of	POS	O
bupivacaine	POS	O
arrhythmogenicity	POS	O
in	POS	O
pentobarbital	POS	O
-	POS	O
anesthetized	POS	O
rats	POS	O
and	POS	O
beating	POS	O
rat	POS	O
heart	POS	O
cell	POS	O
cultures	POS	O
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
progesterone	POS	O
treatment	POS	O
on	POS	O
bupivacaine	POS	O
arrhythmogenicity	POS	O
in	POS	O
beating	POS	O
rat	POS	O
heart	POS	O
myocyte	POS	O
cultures	POS	O
and	POS	O
on	POS	O
anesthetized	POS	O
rats	POS	O
were	POS	O
determined	POS	O
.	POS	O
After	POS	O
determining	POS	O
the	POS	O
bupivacaine	POS	O
AD50	POS	O
(	POS	O
the	POS	O
concentration	POS	O
of	POS	O
bupivacaine	POS	O
that	POS	O
caused	POS	O
50	POS	O
%	POS	O
of	POS	O
all	POS	O
beating	POS	O
rat	POS	O
heart	POS	O
myocyte	POS	O
cultures	POS	O
to	POS	O
become	POS	O
arrhythmic	POS	O
)	POS	O
,	POS	O
we	POS	O
determined	POS	O
the	POS	O
effect	POS	O
of	POS	O
1	POS	O
-	POS	O
hour	POS	O
progesterone	POS	O
HCl	POS	O
exposure	POS	O
on	POS	O
myocyte	POS	O
contractile	POS	O
rhythm	POS	O
.	POS	O
Each	POS	O
concentration	POS	O
of	POS	O
progesterone	POS	O
(	POS	O
6	POS	O
.	POS	O
25	POS	O
,	POS	O
12	POS	O
.	POS	O
5	POS	O
,	POS	O
25	POS	O
,	POS	O
and	POS	O
50	POS	O
micrograms	POS	O
/	POS	O
ml	POS	O
)	POS	O
caused	POS	O
a	POS	O
significant	POS	O
and	POS	O
concentration	POS	O
-	POS	O
dependent	POS	O
reduction	POS	O
in	POS	O
the	POS	O
AD50	POS	O
for	POS	O
bupivacaine	POS	O
.	POS	O
Estradiol	POS	O
treatment	POS	O
also	POS	O
increased	POS	O
the	POS	O
arrhythmogenicity	POS	O
of	POS	O
bupivacaine	POS	O
in	POS	O
myocyte	POS	O
cultures	POS	O
,	POS	O
but	POS	O
was	POS	O
only	POS	O
one	POS	O
fourth	POS	O
as	POS	O
potent	POS	O
as	POS	O
progesterone	POS	O
.	POS	O
Neither	POS	O
progesterone	POS	O
nor	POS	O
estradiol	POS	O
effects	POS	O
on	POS	O
bupivacaine	POS	O
arrhythmogenicity	POS	O
were	POS	O
potentiated	POS	O
by	POS	O
epinephrine	POS	O
.	POS	O
Chronic	POS	O
progesterone	POS	O
pretreatment	POS	O
(	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
for	POS	O
21	POS	O
days	POS	O
)	POS	O
caused	POS	O
a	POS	O
significant	POS	O
increase	POS	O
in	POS	O
bupivacaine	POS	O
arrhythmogenicity	POS	O
in	POS	O
intact	POS	O
pentobarbital	POS	O
-	POS	O
anesthetized	POS	O
rats	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
significant	POS	O
decrease	POS	O
in	POS	O
the	POS	O
time	POS	O
to	POS	O
onset	POS	O
of	POS	O
arrhythmia	POS	B-NP
as	POS	O
compared	POS	O
with	POS	O
control	POS	O
nonprogesterone	POS	O
-	POS	O
treated	POS	O
rats	POS	O
(	POS	O
6	POS	O
.	POS	O
2	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
3	POS	O
vs	POS	O
.	POS	O
30	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
.	POS	O
5	POS	O
min	POS	O
,	POS	O
mean	POS	O
+	POS	O
/	POS	O
-	POS	O
SE	POS	O
)	POS	O
.	POS	O
The	POS	O
results	POS	O
of	POS	O
this	POS	O
study	POS	O
indicate	POS	O
that	POS	O
progesterone	POS	O
can	POS	O
potentiate	POS	O
bupivacaine	POS	O
arrhythmogenicity	POS	O
both	POS	O
in	POS	O
vivo	POS	O
and	POS	O
in	POS	O
vitro	POS	O
.	POS	O
Potentiation	POS	O
of	POS	O
bupivacaine	POS	O
arrhythmia	POS	B-NP
in	POS	O
myocyte	POS	O
cultures	POS	O
suggests	POS	O
that	POS	O
this	POS	O
effect	POS	O
is	POS	O
at	POS	O
least	POS	O
partly	POS	O
mediated	POS	O
at	POS	O
the	POS	O
myocyte	POS	O
level	POS	O
.	POS	O
Increased	POS	O
serum	POS	O
soluble	POS	O
Fas	POS	O
in	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
due	POS	O
to	POS	O
paracetamol	POS	O
overdose	POS	B-NP
.	POS	O
BACKGROUND	POS	O
/	POS	O
AIMS	POS	O
:	POS	O
Experimental	POS	O
studies	POS	O
have	POS	O
suggested	POS	O
that	POS	O
apoptosis	POS	O
via	POS	O
the	POS	O
Fas	POS	O
/	POS	O
Fas	POS	O
Ligand	POS	O
signaling	POS	O
system	POS	O
may	POS	O
play	POS	O
an	POS	O
important	POS	O
role	POS	O
in	POS	O
the	POS	O
development	POS	O
of	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
the	POS	O
soluble	POS	O
form	POS	O
of	POS	O
Fas	POS	O
in	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
.	POS	O
METHODOLOGY	POS	O
:	POS	O
Serum	POS	O
levels	POS	O
of	POS	O
sFas	POS	O
(	POS	O
soluble	POS	O
Fas	POS	O
)	POS	O
were	POS	O
measured	POS	O
by	POS	O
ELISA	POS	O
in	POS	O
24	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
and	POS	O
10	POS	O
normal	POS	B-NP
control	POS	O
subjects	POS	O
.	POS	O
Serum	POS	O
levels	POS	O
of	POS	O
tumor	POS	B-NP
necrosis	POS	O
factor	POS	O
-	POS	O
alpha	POS	O
and	POS	O
interferon	POS	O
-	POS	O
gamma	POS	O
were	POS	O
also	POS	O
determined	POS	O
by	POS	O
ELISA	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Serum	POS	O
sFas	POS	O
was	POS	O
significantly	POS	O
increased	POS	O
in	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
(	POS	O
median	POS	O
,	POS	O
26	POS	O
.	POS	O
8	POS	O
U	POS	O
/	POS	O
mL	POS	O
;	POS	O
range	POS	O
,	POS	O
6	POS	O
.	POS	O
9	POS	O
-	POS	O
52	POS	O
.	POS	O
7	POS	O
U	POS	O
/	POS	O
mL	POS	O
)	POS	O
compared	POS	O
to	POS	O
the	POS	O
normal	POS	O
controls	POS	O
(	POS	O
median	POS	O
,	POS	O
8	POS	O
.	POS	O
6	POS	O
U	POS	O
/	POS	O
mL	POS	O
;	POS	O
range	POS	O
,	POS	O
6	POS	O
.	POS	O
5	POS	O
-	POS	O
12	POS	O
.	POS	O
0	POS	O
U	POS	O
/	POS	O
mL	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
0001	POS	O
)	POS	O
.	POS	O
Levels	POS	O
were	POS	O
significantly	POS	O
greater	POS	O
in	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
due	POS	O
to	POS	O
paracetamol	POS	O
overdose	POS	B-NP
(	POS	O
median	POS	O
,	POS	O
28	POS	O
.	POS	O
7	POS	O
U	POS	O
/	POS	O
mL	POS	O
;	POS	O
range	POS	O
,	POS	O
12	POS	O
.	POS	O
8	POS	O
-	POS	O
52	POS	O
.	POS	O
7	POS	O
U	POS	O
/	POS	O
mL	POS	O
,	POS	O
n	POS	O
=	POS	O
17	POS	O
)	POS	O
than	POS	O
those	POS	O
due	POS	O
to	POS	O
non	POS	O
-	POS	O
A	POS	O
to	POS	O
E	POS	O
hepatitis	POS	B-NP
(	POS	O
median	POS	O
,	POS	O
12	POS	O
.	POS	O
5	POS	O
U	POS	O
/	POS	O
mL	POS	O
;	POS	O
range	POS	O
,	POS	O
6	POS	O
.	POS	O
9	POS	O
-	POS	O
46	POS	O
.	POS	O
0	POS	O
U	POS	O
/	POS	O
mL	POS	O
,	POS	O
n	POS	O
=	POS	O
7	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
relationship	POS	O
of	POS	O
sFas	POS	O
to	POS	O
eventual	POS	O
outcome	POS	O
in	POS	O
the	POS	O
patients	POS	O
.	POS	O
A	POS	O
significant	POS	O
correlation	POS	O
was	POS	O
observed	POS	O
between	POS	O
serum	POS	O
sFas	POS	O
levels	POS	O
and	POS	O
aspartate	POS	O
aminotransferase	POS	O
(	POS	O
r	POS	O
=	POS	O
0	POS	O
.	POS	O
613	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
increased	POS	O
concentration	POS	O
of	POS	O
sFas	POS	O
in	POS	O
serum	POS	O
of	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
may	POS	O
reflect	POS	O
activation	POS	O
of	POS	O
Fas	POS	O
-	POS	O
mediated	POS	O
apoptosis	POS	O
in	POS	O
the	POS	O
liver	POS	O
and	POS	O
this	POS	O
together	POS	O
with	POS	O
increased	POS	O
tumor	POS	B-NP
necrosis	POS	O
factor	POS	O
-	POS	O
alpha	POS	O
may	POS	O
be	POS	O
an	POS	O
important	POS	O
factor	POS	O
in	POS	O
liver	POS	B-NP
cell	POS	I-NP
loss	POS	I-NP
.	POS	O
Bilateral	POS	O
subthalamic	POS	O
nucleus	POS	O
stimulation	POS	O
for	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
High	POS	O
frequency	POS	O
stimulation	POS	O
of	POS	O
the	POS	O
subthalamic	POS	O
nucleus	POS	O
(	POS	O
STN	POS	O
)	POS	O
is	POS	O
known	POS	O
to	POS	O
ameliorate	POS	O
the	POS	O
signs	POS	O
and	POS	O
symptoms	POS	O
of	POS	O
advanced	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
AIM	POS	O
:	POS	O
We	POS	O
studied	POS	O
the	POS	O
effect	POS	O
of	POS	O
high	POS	O
frequency	POS	O
STN	POS	O
stimulation	POS	O
in	POS	O
23	POS	O
patients	POS	O
.	POS	O
METHOD	POS	O
:	POS	O
Twenty	POS	O
-	POS	O
three	POS	O
patients	POS	O
suffering	POS	O
from	POS	O
severe	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
(	POS	O
Stages	POS	O
III	POS	O
-	POS	O
V	POS	O
on	POS	O
Hoehn	POS	O
and	POS	O
Yahr	POS	O
scale	POS	O
)	POS	O
and	POS	O
,	POS	O
particularly	POS	O
bradykinesia	POS	B-NP
,	POS	O
rigidity	POS	B-NP
,	POS	O
and	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
underwent	POS	O
bilateral	POS	O
implantation	POS	O
of	POS	O
electrodes	POS	O
in	POS	O
the	POS	O
STN	POS	O
.	POS	O
Preoperative	POS	O
and	POS	O
postoperative	POS	O
assessments	POS	O
of	POS	O
these	POS	O
patients	POS	O
at	POS	O
1	POS	O
,	POS	O
3	POS	O
,	POS	O
6	POS	O
and	POS	O
12	POS	O
months	POS	O
follow	POS	O
-	POS	O
up	POS	O
,	POS	O
in	POS	O
"	POS	O
on	POS	O
"	POS	O
and	POS	O
"	POS	O
off	POS	O
"	POS	O
drug	POS	O
conditions	POS	O
,	POS	O
was	POS	O
carried	POS	O
out	POS	O
using	POS	O
Unified	POS	O
Parkinson	POS	O
'	POS	O
s	POS	O
Disease	POS	O
Rating	POS	O
Scale	POS	O
,	POS	O
Hoehn	POS	B-NP
and	POS	O
Yahr	POS	O
staging	POS	O
,	POS	O
England	POS	O
activities	POS	O
of	POS	O
daily	POS	O
living	POS	O
score	POS	O
and	POS	O
video	POS	O
recordings	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
After	POS	O
one	POS	O
year	POS	O
of	POS	O
electrical	POS	O
stimulation	POS	O
of	POS	O
the	POS	O
STN	POS	O
,	POS	O
the	POS	O
patients	POS	O
'	POS	O
scores	POS	O
for	POS	O
activities	POS	O
of	POS	O
daily	POS	O
living	POS	O
and	POS	O
motor	POS	O
examination	POS	O
scores	POS	O
(	POS	O
Unified	POS	O
Parkinson	POS	O
'	POS	O
s	POS	O
Disease	POS	O
Rating	POS	O
Scale	POS	O
parts	POS	O
II	POS	O
and	POS	O
III	POS	O
)	POS	O
off	POS	O
medication	POS	O
improved	POS	O
by	POS	O
62	POS	O
%	POS	O
and	POS	O
61	POS	O
%	POS	O
respectively	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
0005	POS	O
)	POS	O
.	POS	O
The	POS	O
subscores	POS	O
for	POS	O
the	POS	O
akinesia	POS	B-NP
,	POS	O
rigidity	POS	B-NP
,	POS	O
tremor	POS	B-NP
and	POS	O
gait	POS	O
also	POS	O
improved	POS	O
.	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
0005	POS	O
)	POS	O
.	POS	O
The	POS	O
average	POS	O
levodopa	POS	O
dose	POS	O
decreased	POS	O
from	POS	O
813	POS	O
mg	POS	O
to	POS	O
359	POS	O
mg	POS	O
.	POS	O
The	POS	O
cognitive	POS	O
functions	POS	O
remained	POS	O
unchanged	POS	O
.	POS	O
Two	POS	O
patients	POS	O
developed	POS	O
device	POS	O
-	POS	O
related	POS	O
complications	POS	O
and	POS	O
two	POS	O
patients	POS	O
experienced	POS	O
abnormal	POS	B-NP
weight	POS	I-NP
gain	POS	I-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
Bilateral	POS	O
subthalamic	POS	O
nucleus	POS	O
stimulation	POS	O
is	POS	O
an	POS	O
effective	POS	O
treatment	POS	O
for	POS	O
advanced	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
It	POS	O
reduces	POS	O
the	POS	O
severity	POS	O
of	POS	O
"	POS	O
off	POS	O
"	POS	O
phase	POS	O
symptoms	POS	O
,	POS	O
improves	POS	O
the	POS	O
axial	POS	O
symptoms	POS	O
and	POS	O
reduces	POS	O
levodopa	POS	O
requirements	POS	O
.	POS	O
The	POS	O
reduction	POS	O
in	POS	O
the	POS	O
levodopa	POS	O
dose	POS	O
is	POS	O
useful	POS	O
in	POS	O
controlling	POS	O
drug	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
.	POS	O
Acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
occurring	POS	O
during	POS	O
intravenous	POS	O
desferrioxamine	POS	O
therapy	POS	O
:	POS	O
recovery	POS	O
after	POS	O
haemodialysis	POS	O
.	POS	O
A	POS	O
patient	POS	O
with	POS	O
transfusion	POS	B-NP
-	POS	I-NP
dependent	POS	I-NP
thalassemia	POS	I-NP
was	POS	O
undergoing	POS	O
home	POS	O
intravenous	POS	O
desferrioxamine	POS	O
(	POS	O
DFX	POS	O
)	POS	O
treatment	POS	O
by	POS	O
means	POS	O
of	POS	O
a	POS	O
totally	POS	O
implanted	POS	O
system	POS	O
because	POS	O
of	POS	O
his	POS	O
poor	POS	O
compliance	POS	O
with	POS	O
the	POS	O
nightly	POS	O
subcutaneous	POS	O
therapy	POS	O
.	POS	O
Due	POS	O
to	POS	O
an	POS	O
accidental	POS	O
malfunctioning	POS	O
of	POS	O
the	POS	O
infusion	POS	O
pump	POS	O
,	POS	O
the	POS	O
patient	POS	O
was	POS	O
inadvertently	POS	O
administered	POS	O
a	POS	O
toxic	POS	O
dosage	POS	O
of	POS	O
the	POS	O
drug	POS	O
which	POS	O
caused	POS	O
renal	POS	B-NP
insufficiency	POS	I-NP
.	POS	O
Given	POS	O
the	POS	O
progressive	POS	O
deterioration	POS	O
of	POS	O
the	POS	O
symptoms	POS	O
and	POS	O
of	POS	O
the	POS	O
laboratory	POS	O
values	POS	O
,	POS	O
despite	POS	O
adequate	POS	O
medical	POS	O
treatment	POS	O
,	POS	O
a	POS	O
decision	POS	O
was	POS	O
made	POS	O
to	POS	O
introduce	POS	O
haemodialytical	POS	O
therapy	POS	O
in	POS	O
order	POS	O
to	POS	O
remove	POS	O
the	POS	O
drug	POS	O
and	POS	O
therapy	POS	O
reduce	POS	O
the	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
From	POS	O
the	POS	O
results	POS	O
obtained	POS	O
,	POS	O
haemodialysis	POS	O
can	POS	O
therefore	POS	O
be	POS	O
suggested	POS	O
as	POS	O
a	POS	O
useful	POS	O
therapy	POS	O
in	POS	O
rare	POS	O
cases	POS	O
of	POS	O
progressive	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
caused	POS	O
by	POS	O
desferrioxamine	POS	O
.	POS	O
Ocular	POS	B-NP
motility	POS	I-NP
changes	POS	O
after	POS	O
subtenon	POS	O
carboplatin	POS	O
chemotherapy	POS	O
for	POS	O
retinoblastoma	POS	B-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Focal	POS	O
subtenon	POS	O
carboplatin	POS	O
injections	POS	O
have	POS	O
recently	POS	O
been	POS	O
used	POS	O
as	POS	O
a	POS	O
presumably	POS	O
toxicity	POS	O
-	POS	O
free	POS	O
adjunct	POS	O
to	POS	O
systemic	POS	O
chemotherapy	POS	O
for	POS	O
intraocular	POS	B-NP
retinoblastoma	POS	I-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
report	POS	O
our	POS	O
clinical	POS	O
experience	POS	O
with	POS	O
abnormal	POS	B-NP
ocular	POS	I-NP
motility	POS	I-NP
in	POS	O
patients	POS	O
treated	POS	O
with	POS	O
subtenon	POS	O
carboplatin	POS	O
chemotherapy	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
noted	POS	O
abnormal	POS	B-NP
ocular	POS	I-NP
motility	POS	I-NP
in	POS	O
10	POS	O
consecutive	POS	O
patients	POS	O
with	POS	O
retinoblastoma	POS	B-NP
who	POS	O
had	POS	O
received	POS	O
subtenon	POS	O
carboplatin	POS	O
.	POS	O
During	POS	O
ocular	POS	O
manipulation	POS	O
under	POS	O
general	POS	O
anesthesia	POS	O
,	POS	O
we	POS	O
assessed	POS	O
their	POS	O
eyes	POS	O
by	POS	O
forced	POS	O
duction	POS	O
testing	POS	O
,	POS	O
comparing	POS	O
ocular	POS	O
motility	POS	O
after	POS	O
tumor	POS	B-NP
control	POS	O
with	POS	O
ocular	POS	B-NP
motility	POS	I-NP
at	POS	O
diagnosis	POS	O
.	POS	O
Eyes	POS	O
subsequently	POS	O
enucleated	POS	O
because	POS	O
of	POS	O
treatment	POS	O
failure	POS	O
(	POS	O
n	POS	O
=	POS	O
4	POS	O
)	POS	O
were	POS	O
examined	POS	O
histologically	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Limitation	POS	O
of	POS	O
ocular	POS	B-NP
motility	POS	I-NP
was	POS	O
detected	POS	O
in	POS	O
all	POS	O
12	POS	O
eyes	POS	O
of	POS	O
10	POS	O
patients	POS	O
treated	POS	O
for	POS	O
intraocular	POS	B-NP
retinoblastoma	POS	I-NP
with	POS	O
1	POS	O
to	POS	O
6	POS	O
injections	POS	O
of	POS	O
subtenon	POS	O
carboplatin	POS	O
as	POS	O
part	POS	O
of	POS	O
multimodality	POS	O
therapy	POS	O
.	POS	O
Histopathological	POS	O
examination	POS	O
revealed	POS	O
many	POS	O
lipophages	POS	O
in	POS	O
the	POS	O
periorbital	POS	O
fat	POS	O
surrounding	POS	O
the	POS	O
optic	POS	O
nerve	POS	O
in	POS	O
1	POS	O
eye	POS	O
,	POS	O
indicative	POS	O
of	POS	O
phagocytosis	POS	O
of	POS	O
previously	POS	O
existing	POS	O
fat	POS	O
cells	POS	O
and	POS	O
suggesting	POS	O
prior	POS	O
fat	POS	O
necrosis	POS	B-NP
.	POS	O
The	POS	O
enucleations	POS	O
were	POS	O
technically	POS	O
difficult	POS	O
and	POS	O
hazardous	POS	O
for	POS	O
globe	POS	O
rupture	POS	O
because	POS	O
of	POS	O
extensive	POS	O
orbital	POS	O
soft	POS	O
tissue	POS	O
adhesions	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Subtenon	POS	O
carboplatin	POS	O
chemotherapy	POS	O
is	POS	O
associated	POS	O
with	POS	O
significant	POS	O
fibrosis	POS	B-NP
of	POS	O
orbital	POS	O
soft	POS	O
tissues	POS	O
,	POS	O
leading	POS	O
to	POS	O
mechanical	POS	O
restriction	POS	O
of	POS	O
eye	POS	O
movements	POS	O
and	POS	O
making	POS	O
subsequent	POS	O
enucleation	POS	O
difficult	POS	O
.	POS	O
Subtenon	POS	O
carboplatin	POS	O
is	POS	O
not	POS	O
free	POS	O
of	POS	O
toxicity	POS	B-NP
,	POS	O
and	POS	O
its	POS	O
use	POS	O
is	POS	O
best	POS	O
restricted	POS	O
to	POS	O
specific	POS	O
indications	POS	O
.	POS	O
Ethambutol	POS	O
and	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
demonstrate	POS	O
the	POS	O
association	POS	O
between	POS	O
ethambutol	POS	O
and	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
.	POS	O
METHOD	POS	O
:	POS	O
Thirteen	POS	O
patients	POS	O
who	POS	O
developed	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
after	POS	O
being	POS	O
treated	POS	O
with	POS	O
ethambutol	POS	O
for	POS	O
tuberculosis	POS	B-NP
of	POS	O
the	POS	O
lung	POS	O
or	POS	O
lymph	POS	O
node	POS	O
at	POS	O
Siriraj	POS	O
Hospital	POS	O
between	POS	O
1997	POS	O
and	POS	O
2001	POS	O
were	POS	O
retrospectively	POS	O
reviewed	POS	O
.	POS	O
The	POS	O
clinical	POS	O
characteristics	POS	O
and	POS	O
initial	POS	O
and	POS	O
final	POS	O
visual	POS	O
acuity	POS	O
were	POS	O
analyzed	POS	O
to	POS	O
determine	POS	O
visual	POS	O
outcome	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
All	POS	O
patients	POS	O
had	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
between	POS	O
1	POS	O
to	POS	O
6	POS	O
months	POS	O
(	POS	O
mean	POS	O
=	POS	O
2	POS	O
.	POS	O
9	POS	O
months	POS	O
)	POS	O
after	POS	O
starting	POS	O
ethambutol	POS	O
therapy	POS	O
at	POS	O
a	POS	O
dosage	POS	O
ranging	POS	O
from	POS	O
13	POS	O
to	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
(	POS	O
mean	POS	O
=	POS	O
17	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
)	POS	O
.	POS	O
Seven	POS	O
(	POS	O
54	POS	O
%	POS	O
)	POS	O
of	POS	O
the	POS	O
13	POS	O
patients	POS	O
experienced	POS	O
visual	POS	O
recovery	POS	O
after	POS	O
stopping	POS	O
the	POS	O
drug	POS	O
.	POS	O
Of	POS	O
6	POS	O
patients	POS	O
with	POS	O
irreversible	POS	O
visual	POS	B-NP
impairment	POS	I-NP
,	POS	O
4	POS	O
patients	POS	O
had	POS	O
diabetes	POS	B-NP
mellitus	POS	I-NP
,	POS	O
glaucoma	POS	B-NP
and	POS	O
a	POS	O
history	POS	O
of	POS	O
heavy	POS	O
smoking	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Early	POS	O
recognition	POS	O
of	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
should	POS	O
be	POS	O
considered	POS	O
in	POS	O
patients	POS	O
with	POS	O
ethambutol	POS	O
therapy	POS	O
.	POS	O
A	POS	O
low	POS	O
dose	POS	O
and	POS	O
prompt	POS	O
discontinuation	POS	O
of	POS	O
the	POS	O
drug	POS	O
is	POS	O
recommended	POS	O
particularly	POS	O
in	POS	O
individuals	POS	O
with	POS	O
diabetes	POS	B-NP
mellitus	POS	I-NP
,	POS	O
glaucoma	POS	B-NP
or	POS	O
who	POS	O
are	POS	O
heavy	POS	O
smokers	POS	O
.	POS	O
Treatment	POS	O
of	POS	O
compensatory	POS	O
gustatory	POS	B-NP
hyperhidrosis	POS	I-NP
with	POS	O
topical	POS	O
glycopyrrolate	POS	O
.	POS	O
Gustatory	POS	B-NP
hyperhidrosis	POS	I-NP
is	POS	O
facial	POS	B-NP
sweating	POS	I-NP
usually	POS	O
associated	POS	O
with	POS	O
the	POS	O
eating	POS	O
of	POS	O
hot	POS	O
spicy	POS	O
food	POS	O
or	POS	O
even	POS	O
smelling	POS	O
this	POS	O
food	POS	O
.	POS	O
Current	POS	O
options	POS	O
of	POS	O
treatment	POS	O
include	POS	O
oral	POS	O
anticholinergic	POS	O
drugs	POS	O
,	POS	O
the	POS	O
topical	POS	O
application	POS	O
of	POS	O
anticholinergics	POS	O
or	POS	O
aluminum	POS	O
chloride	POS	O
,	POS	O
and	POS	O
the	POS	O
injection	POS	O
of	POS	O
botulinum	POS	O
toxin	POS	O
.	POS	O
Thirteen	POS	O
patients	POS	O
have	POS	O
been	POS	O
treated	POS	O
to	POS	O
date	POS	O
with	POS	O
1	POS	O
.	POS	O
5	POS	O
%	POS	O
or	POS	O
2	POS	O
%	POS	O
topical	POS	O
glycopyrrolate	POS	O
.	POS	O
All	POS	O
patients	POS	O
had	POS	O
gustatory	POS	B-NP
hyperhidrosis	POS	I-NP
,	POS	O
which	POS	O
interfered	POS	O
with	POS	O
their	POS	O
social	POS	O
activities	POS	O
,	POS	O
after	POS	O
transthroacic	POS	O
endoscopic	POS	O
sympathectomy	POS	O
,	POS	O
and	POS	O
which	POS	O
was	POS	O
associated	POS	O
with	POS	O
compensatory	POS	O
focal	POS	O
hyperhidrosis	POS	B-NP
.	POS	O
After	POS	O
applying	POS	O
topical	POS	O
glycopyrrolate	POS	O
,	POS	O
the	POS	O
subjective	POS	O
effect	POS	O
was	POS	O
excellent	POS	O
(	POS	O
no	POS	O
sweating	POS	O
after	POS	O
eating	POS	O
hot	POS	O
spicy	POS	O
food	POS	O
)	POS	O
in	POS	O
10	POS	O
patients	POS	O
(	POS	O
77	POS	O
%	POS	O
)	POS	O
,	POS	O
and	POS	O
fair	POS	O
(	POS	O
clearly	POS	O
reduced	POS	O
sweating	POS	O
)	POS	O
in	POS	O
3	POS	O
patients	POS	O
(	POS	O
23	POS	O
%	POS	O
)	POS	O
.	POS	O
All	POS	O
had	POS	O
reported	POS	O
incidents	POS	O
of	POS	O
being	POS	O
very	POS	O
embarrassed	POS	O
whilst	POS	O
eating	POS	O
hot	POS	O
spicy	POS	O
foods	POS	O
.	POS	O
Adverse	POS	O
effects	POS	O
included	POS	O
a	POS	O
mildly	POS	O
dry	POS	B-NP
mouth	POS	I-NP
and	POS	O
a	POS	O
sore	POS	B-NP
throat	POS	I-NP
in	POS	O
2	POS	O
patients	POS	O
(	POS	O
2	POS	O
%	POS	O
glycopyrrolate	POS	O
)	POS	O
,	POS	O
a	POS	O
light	POS	O
headache	POS	B-NP
in	POS	O
1	POS	O
patient	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
%	POS	O
glycopyrrolate	POS	O
)	POS	O
.	POS	O
The	POS	O
topical	POS	O
application	POS	O
of	POS	O
a	POS	O
glycopyrrolate	POS	O
pad	POS	O
appeared	POS	O
to	POS	O
be	POS	O
safe	POS	O
,	POS	O
efficacious	POS	O
,	POS	O
well	POS	O
tolerated	POS	O
,	POS	O
and	POS	O
a	POS	O
convenient	POS	O
method	POS	O
of	POS	O
treatment	POS	O
for	POS	O
moderate	POS	O
to	POS	O
severe	POS	O
symptoms	POS	O
of	POS	O
gustatory	POS	B-NP
hyperhidrosis	POS	I-NP
in	POS	O
post	POS	O
transthoracic	POS	O
endoscopic	POS	O
sympathectomy	POS	O
or	POS	O
sympathicotomy	POS	O
patients	POS	O
,	POS	O
with	POS	O
few	POS	O
side	POS	O
effects	POS	O
.	POS	O
Neuroleptic	POS	B-NP
-	POS	O
associated	POS	O
hyperprolactinemia	POS	B-NP
.	POS	O
Can	POS	O
it	POS	O
be	POS	O
treated	POS	O
with	POS	O
bromocriptine	POS	O
?	POS	O
Six	POS	O
stable	POS	O
psychiatric	POS	O
outpatients	POS	O
with	POS	O
hyperprolactinemia	POS	B-NP
and	POS	O
amenorrhea	POS	B-NP
/	POS	O
oligomenorrhea	POS	B-NP
associated	POS	O
with	POS	O
their	POS	O
neuroleptic	POS	O
medications	POS	O
were	POS	O
treated	POS	O
with	POS	O
bromocriptine	POS	O
.	POS	O
Daily	POS	O
dosages	POS	O
of	POS	O
5	POS	O
-	POS	O
10	POS	O
mg	POS	O
corrected	POS	O
the	POS	O
hyperprolactinemia	POS	B-NP
and	POS	O
restored	POS	O
menstruation	POS	O
in	POS	O
four	POS	O
of	POS	O
the	POS	O
six	POS	O
patients	POS	O
.	POS	O
One	POS	O
woman	POS	O
,	POS	O
however	POS	O
,	POS	O
developed	POS	O
worsened	POS	O
psychiatric	POS	B-NP
symptoms	POS	I-NP
while	POS	O
taking	POS	O
bromocriptine	POS	O
,	POS	O
and	POS	O
it	POS	O
was	POS	O
discontinued	POS	O
.	POS	O
Thus	POS	O
,	POS	O
three	POS	O
of	POS	O
six	POS	O
patients	POS	O
had	POS	O
their	POS	O
menstrual	POS	O
irregularity	POS	O
successfully	POS	O
corrected	POS	O
with	POS	O
bromocriptine	POS	O
.	POS	O
This	POS	O
suggests	POS	O
that	POS	O
bromocriptine	POS	O
should	POS	O
be	POS	O
further	POS	O
evaluated	POS	O
as	POS	O
potential	POS	O
therapy	POS	O
for	POS	O
neuroleptic	POS	O
-	POS	O
associated	POS	O
hyperprolactinemia	POS	B-NP
and	POS	O
amenorrhea	POS	B-NP
/	POS	O
galactorrhea	POS	B-NP
.	POS	O
Ethacrynic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
convulsions	POS	B-NP
and	POS	O
brain	POS	O
neurotransmitters	POS	O
in	POS	O
mice	POS	O
.	POS	O
Intracerebroventricular	POS	O
injection	POS	O
of	POS	O
ethacrynic	POS	O
acid	POS	O
(	POS	O
50	POS	O
%	POS	O
convulsive	POS	B-NP
dose	POS	O
;	POS	O
50	POS	O
micrograms	POS	O
/	POS	O
mouse	POS	O
)	POS	O
accelerated	POS	O
the	POS	O
synthesis	POS	O
/	POS	O
turnover	POS	O
of	POS	O
5	POS	O
-	POS	O
hydroxytryptamine	POS	O
(	POS	O
5	POS	O
-	POS	O
HT	POS	O
)	POS	O
but	POS	O
suppressed	POS	O
the	POS	O
synthesis	POS	O
of	POS	O
gamma	POS	O
-	POS	O
aminobutyric	POS	O
acid	POS	O
and	POS	O
acetylcholine	POS	O
in	POS	O
mouse	POS	O
brain	POS	O
.	POS	O
These	POS	O
effects	POS	O
were	POS	O
completely	POS	O
antagonized	POS	O
by	POS	O
pretreatment	POS	O
with	POS	O
a	POS	O
glutamate	POS	O
/	POS	O
N	POS	O
-	POS	O
methyl	POS	O
-	POS	O
D	POS	O
-	POS	O
aspartate	POS	O
antagonist	POS	O
,	POS	O
aminophosphonovaleric	POS	O
acid	POS	O
.	POS	O
In	POS	O
ethacrynic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
convulsions	POS	B-NP
,	POS	O
these	POS	O
neurotransmitter	POS	O
systems	POS	O
may	POS	O
be	POS	O
differentially	POS	O
modulated	POS	O
,	POS	O
probably	POS	O
through	POS	O
activation	POS	O
of	POS	O
glutaminergic	POS	O
neurons	POS	O
in	POS	O
the	POS	O
brain	POS	O
.	POS	O
Pharmacology	POS	O
of	POS	O
gamma	POS	O
-	POS	O
aminobutyric	POS	O
acidA	POS	O
receptor	POS	O
complex	POS	O
after	POS	O
the	POS	O
in	POS	O
vivo	POS	O
administration	POS	O
of	POS	O
the	POS	O
anxioselective	POS	O
and	POS	O
anticonvulsant	POS	O
beta	POS	O
-	POS	O
carboline	POS	O
derivative	POS	O
abecarnil	POS	O
.	POS	O
In	POS	O
rodents	POS	O
,	POS	O
the	POS	O
effect	POS	O
of	POS	O
the	POS	O
beta	POS	O
-	POS	O
carboline	POS	O
derivative	POS	O
isopropyl	POS	O
-	POS	O
6	POS	O
-	POS	O
benzyloxy	POS	O
-	POS	O
4	POS	O
-	POS	O
methoxymethyl	POS	O
-	POS	O
beta	POS	O
-	POS	O
carboline	POS	O
-	POS	O
3	POS	O
-	POS	O
carboxylate	POS	O
(	POS	O
abecarrnil	POS	O
)	POS	O
,	POS	O
a	POS	O
new	POS	O
ligand	POS	O
for	POS	O
benzodiazepine	POS	O
receptors	POS	O
possessing	POS	O
anxiolytic	POS	O
and	POS	O
anticonvulsant	POS	O
properties	POS	O
,	POS	O
was	POS	O
evaluated	POS	O
on	POS	O
the	POS	O
function	POS	O
of	POS	O
central	POS	O
gamma	POS	O
-	POS	O
aminobutyric	POS	O
acid	POS	O
(	POS	O
GABA	POS	O
)	POS	O
A	POS	O
receptor	POS	O
complex	POS	O
,	POS	O
both	POS	O
in	POS	O
vitro	POS	O
and	POS	O
in	POS	O
vivo	POS	O
.	POS	O
Added	POS	O
in	POS	O
vitro	POS	O
to	POS	O
rat	POS	O
cortical	POS	O
membrane	POS	O
preparation	POS	O
,	POS	O
abecarnil	POS	O
increased	POS	O
[	POS	O
3H	POS	O
]	POS	O
GABA	POS	O
binding	POS	O
,	POS	O
enhanced	POS	O
muscimol	POS	O
-	POS	O
stimulated	POS	O
36Cl	POS	O
-	POS	O
uptake	POS	O
and	POS	O
reduced	POS	O
the	POS	O
binding	POS	O
of	POS	O
t	POS	O
-	POS	O
[	POS	O
35S	POS	O
]	POS	O
butylbicyclophosphorothionate	POS	O
(	POS	O
[	POS	O
35S	POS	O
]	POS	O
TBPS	POS	O
)	POS	O
.	POS	O
These	POS	O
effects	POS	O
were	POS	O
similar	POS	O
to	POS	O
those	POS	O
induced	POS	O
by	POS	O
diazepam	POS	O
,	POS	O
whereas	POS	O
the	POS	O
partial	POS	O
agonist	POS	O
Ro	POS	O
16	POS	O
-	POS	O
6028	POS	O
(	POS	O
tert	POS	O
-	POS	O
butyl	POS	O
-	POS	O
(	POS	O
S	POS	O
)	POS	O
-	POS	O
8	POS	O
-	POS	O
bromo	POS	O
-	POS	O
11	POS	O
,	POS	O
12	POS	O
,	POS	O
13	POS	O
,	POS	O
13a	POS	O
-	POS	O
tetrahydro	POS	O
-	POS	O
9	POS	O
-	POS	O
oxo	POS	O
-	POS	O
9H	POS	O
-	POS	O
imidazo	POS	O
[	POS	O
1	POS	O
,	POS	O
5	POS	O
-	POS	O
a	POS	O
]	POS	O
-	POS	O
pyrrolo	POS	O
-	POS	O
[	POS	O
2	POS	O
,	POS	O
1	POS	O
-	POS	O
c	POS	O
]	POS	O
[	POS	O
1	POS	O
,	POS	O
4	POS	O
]	POS	O
benzodiazepine	POS	O
-	POS	O
1	POS	O
-	POS	O
carboxylate	POS	O
)	POS	O
showed	POS	O
very	POS	O
weak	POS	O
efficacy	POS	O
in	POS	O
these	POS	O
biochemical	POS	O
tests	POS	O
.	POS	O
After	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
injection	POS	O
to	POS	O
rats	POS	O
,	POS	O
abecarnil	POS	O
and	POS	O
diazepam	POS	O
decreased	POS	O
in	POS	O
a	POS	O
time	POS	O
-	POS	O
dependent	POS	O
and	POS	O
dose	POS	O
-	POS	O
related	POS	O
(	POS	O
0	POS	O
.	POS	O
25	POS	O
-	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
manner	POS	O
[	POS	O
35S	POS	O
]	POS	O
TBPS	POS	O
binding	POS	O
measured	POS	O
ex	POS	O
vivo	POS	O
in	POS	O
the	POS	O
cerebral	POS	O
cortex	POS	O
.	POS	O
Moreover	POS	O
,	POS	O
both	POS	O
drugs	POS	O
at	POS	O
the	POS	O
dose	POS	O
of	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
antagonized	POS	O
completely	POS	O
the	POS	O
convulsant	POS	O
activity	POS	O
and	POS	O
the	POS	O
increase	POS	O
of	POS	O
[	POS	O
35S	POS	O
]	POS	O
TBPS	POS	O
binding	POS	O
induced	POS	O
by	POS	O
isoniazide	POS	O
(	POS	O
350	POS	O
mg	POS	O
/	POS	O
kg	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
as	POS	O
well	POS	O
as	POS	O
the	POS	O
increase	POS	O
of	POS	O
[	POS	O
35S	POS	O
]	POS	O
TBPS	POS	O
binding	POS	O
induced	POS	O
by	POS	O
foot	POS	O
-	POS	O
shock	POS	O
stress	POS	O
.	POS	O
To	POS	O
better	POS	O
correlate	POS	O
the	POS	O
biochemical	POS	O
and	POS	O
the	POS	O
pharmacological	POS	O
effects	POS	O
,	POS	O
we	POS	O
studied	POS	O
the	POS	O
action	POS	O
of	POS	O
abecarnil	POS	O
on	POS	O
[	POS	O
35S	POS	O
]	POS	O
TBPS	POS	O
binding	POS	O
,	POS	O
exploratory	POS	O
motility	POS	O
and	POS	O
on	POS	O
isoniazid	POS	O
-	POS	O
induced	POS	O
biochemical	POS	O
and	POS	O
pharmacological	POS	O
effects	POS	O
in	POS	O
mice	POS	O
.	POS	O
In	POS	O
these	POS	O
animals	POS	O
,	POS	O
abecarnil	POS	O
produced	POS	O
a	POS	O
paralleled	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
(	POS	O
0	POS	O
.	POS	O
05	POS	O
-	POS	O
1	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
reduction	POS	O
of	POS	O
both	POS	O
motor	POS	O
behavior	POS	O
and	POS	O
cortical	POS	O
[	POS	O
35S	POS	O
]	POS	O
TBPS	POS	O
binding	POS	O
.	POS	O
Moreover	POS	O
,	POS	O
0	POS	O
.	POS	O
05	POS	O
mg	POS	O
/	POS	O
kg	POS	O
of	POS	O
this	POS	O
beta	POS	O
-	POS	O
carboline	POS	O
reduced	POS	O
markedly	POS	O
the	POS	O
increase	POS	O
of	POS	O
[	POS	O
35S	POS	O
]	POS	O
TBPS	POS	O
binding	POS	O
and	POS	O
the	POS	O
convulsions	POS	B-NP
induced	POS	O
by	POS	O
isoniazid	POS	O
(	POS	O
200	POS	O
mg	POS	O
/	POS	O
kg	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
250	POS	O
WORDS	POS	O
)	POS	O
Recurrent	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
in	POS	O
a	POS	O
postpartum	POS	O
patient	POS	O
receiving	POS	O
bromocriptine	POS	O
.	POS	O
Myocardial	POS	B-NP
infarction	POS	I-NP
in	POS	O
puerperium	POS	B-NP
is	POS	O
infrequently	POS	O
reported	POS	O
.	POS	O
Spasm	POS	B-NP
,	POS	O
coronary	POS	B-NP
dissection	POS	I-NP
,	POS	O
or	POS	O
atheromatous	POS	B-NP
etiology	POS	O
has	POS	O
been	POS	O
described	POS	O
.	POS	O
Bromocriptine	POS	O
has	POS	O
been	POS	O
implicated	POS	O
in	POS	O
several	POS	O
previous	POS	O
case	POS	O
reports	POS	O
of	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
in	POS	O
the	POS	O
puerperium	POS	O
.	POS	O
Our	POS	O
case	POS	O
(	POS	O
including	POS	O
an	POS	O
inadvertent	POS	O
rechallenge	POS	O
)	POS	O
suggests	POS	O
such	POS	O
a	POS	O
relationship	POS	O
.	POS	O
Although	POS	O
generally	POS	O
regarded	POS	O
as	POS	O
"	POS	O
safe	POS	O
,	POS	O
"	POS	O
possible	POS	O
serious	POS	O
cardiac	POS	O
effects	POS	O
of	POS	O
bromocriptine	POS	O
should	POS	O
be	POS	O
acknowledged	POS	O
.	POS	O
Asterixis	POS	B-NP
induced	POS	O
by	POS	O
carbamazepine	POS	O
therapy	POS	O
.	POS	O
There	POS	O
are	POS	O
very	POS	O
few	POS	O
reports	POS	O
about	POS	O
asterixis	POS	B-NP
as	POS	O
a	POS	O
side	POS	O
effect	POS	O
of	POS	O
treatment	POS	O
with	POS	O
psychopharmacologic	POS	O
agents	POS	O
.	POS	O
In	POS	O
this	POS	O
report	POS	O
we	POS	O
present	POS	O
four	POS	O
patients	POS	O
treated	POS	O
with	POS	O
a	POS	O
combination	POS	O
of	POS	O
different	POS	O
psychotropic	POS	O
drugs	POS	O
,	POS	O
in	POS	O
whom	POS	O
asterixis	POS	B-NP
was	POS	O
triggered	POS	O
either	POS	O
by	POS	O
adding	POS	O
carbamazepine	POS	O
(	POS	O
CBZ	POS	O
)	POS	O
to	POS	O
a	POS	O
treatment	POS	O
regimen	POS	O
,	POS	O
or	POS	O
by	POS	O
increasing	POS	O
its	POS	O
dosage	POS	O
.	POS	O
Neither	POS	O
dosage	POS	O
nor	POS	O
serum	POS	O
levels	POS	O
of	POS	O
CBZ	POS	O
were	POS	O
in	POS	O
a	POS	O
higher	POS	O
range	POS	O
.	POS	O
We	POS	O
consider	POS	O
asterixis	POS	B-NP
to	POS	O
be	POS	O
an	POS	O
easily	POS	O
overlooked	POS	O
sign	POS	O
of	POS	O
neurotoxicity	POS	B-NP
,	POS	O
which	POS	O
may	POS	O
occur	POS	O
even	POS	O
at	POS	O
low	POS	O
or	POS	O
moderate	POS	O
dosage	POS	O
levels	POS	O
,	POS	O
if	POS	O
certain	POS	O
drugs	POS	O
as	POS	O
lithium	POS	O
or	POS	O
clozapine	POS	O
are	POS	O
used	POS	O
in	POS	O
combination	POS	O
with	POS	O
CBZ	POS	O
.	POS	O
Pharmacodynamics	POS	O
of	POS	O
the	POS	O
hypotensive	POS	B-NP
effect	POS	O
of	POS	O
levodopa	POS	O
in	POS	O
parkinsonian	POS	B-NP
patients	POS	O
.	POS	O
Blood	POS	O
pressure	POS	O
effects	POS	O
of	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
levodopa	POS	O
were	POS	O
examined	POS	O
in	POS	O
parkinsonian	POS	B-NP
patients	POS	O
with	POS	O
stable	POS	O
and	POS	O
fluctuating	POS	O
responses	POS	O
to	POS	O
levodopa	POS	O
.	POS	O
The	POS	O
magnitude	POS	O
of	POS	O
the	POS	O
hypotensive	POS	B-NP
effect	POS	O
of	POS	O
levodopa	POS	O
was	POS	O
concentration	POS	O
dependent	POS	O
and	POS	O
was	POS	O
fit	POS	O
to	POS	O
an	POS	O
Emax	POS	O
model	POS	O
in	POS	O
fluctuating	POS	O
responders	POS	O
.	POS	O
Stable	POS	O
responders	POS	O
demonstrated	POS	O
a	POS	O
small	POS	O
hypotensive	POS	B-NP
response	POS	O
.	POS	O
Baseline	POS	O
blood	POS	O
pressures	POS	O
were	POS	O
higher	POS	O
in	POS	O
fluctuating	POS	O
patients	POS	O
;	POS	O
a	POS	O
higher	POS	O
baseline	POS	O
blood	POS	O
pressure	POS	O
correlated	POS	O
with	POS	O
greater	POS	O
hypotensive	POS	B-NP
effects	POS	O
.	POS	O
Antiparkinsonian	POS	O
effects	POS	O
of	POS	O
levodopa	POS	O
temporally	POS	O
correlated	POS	O
with	POS	O
blood	POS	O
pressure	POS	O
changes	POS	O
.	POS	O
Phenylalanine	POS	O
,	POS	O
a	POS	O
large	POS	O
neutral	POS	O
amino	POS	O
acid	POS	O
(	POS	O
LNAA	POS	O
)	POS	O
competing	POS	O
with	POS	O
levodopa	POS	O
for	POS	O
transport	POS	O
across	POS	O
the	POS	O
blood	POS	O
-	POS	O
brain	POS	O
barrier	POS	O
,	POS	O
reduced	POS	O
the	POS	O
hypotensive	POS	B-NP
and	POS	O
antiparkinsonian	POS	O
effects	POS	O
of	POS	O
levodopa	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
levodopa	POS	O
has	POS	O
a	POS	O
central	POS	O
hypotensive	POS	B-NP
action	POS	O
that	POS	O
parallels	POS	O
the	POS	O
motor	POS	O
effects	POS	O
in	POS	O
fluctuating	POS	O
patients	POS	O
.	POS	O
The	POS	O
hypotensive	POS	B-NP
effect	POS	O
appears	POS	O
to	POS	O
be	POS	O
related	POS	O
to	POS	O
the	POS	O
higher	POS	O
baseline	POS	O
blood	POS	O
pressure	POS	O
we	POS	O
observed	POS	O
in	POS	O
fluctuating	POS	O
patients	POS	O
relative	POS	O
to	POS	O
stable	POS	O
patients	POS	O
.	POS	O
Syndrome	POS	B-NP
of	POS	I-NP
inappropriate	POS	I-NP
secretion	POS	I-NP
of	POS	I-NP
antidiuretic	POS	I-NP
hormone	POS	I-NP
after	POS	O
infusional	POS	O
vincristine	POS	O
.	POS	O
A	POS	O
77	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
refractory	POS	O
multiple	POS	B-NP
myeloma	POS	I-NP
was	POS	O
treated	POS	O
with	POS	O
a	POS	O
4	POS	O
-	POS	O
day	POS	O
continuous	POS	O
intravenous	POS	O
infusion	POS	O
of	POS	O
vincristine	POS	O
and	POS	O
doxorubicin	POS	O
and	POS	O
4	POS	O
days	POS	O
of	POS	O
oral	POS	O
dexamethasone	POS	O
.	POS	O
Nine	POS	O
days	POS	O
after	POS	O
her	POS	O
second	POS	O
cycle	POS	O
she	POS	O
presented	POS	O
with	POS	O
lethargy	POS	B-NP
and	POS	O
weakness	POS	B-NP
associated	POS	O
with	POS	O
hyponatremia	POS	B-NP
.	POS	O
Evaluation	POS	O
revealed	POS	O
the	POS	O
syndrome	POS	O
of	POS	O
inappropriate	POS	O
secretion	POS	O
of	POS	O
antidiuretic	POS	O
hormone	POS	O
,	POS	O
which	POS	O
was	POS	O
attributed	POS	O
to	POS	O
the	POS	O
vincristine	POS	O
infusion	POS	O
.	POS	O
After	POS	O
normal	POS	O
serum	POS	O
sodium	POS	O
levels	POS	O
returned	POS	O
,	POS	O
further	POS	O
doxorubicin	POS	O
and	POS	O
dexamethasone	POS	O
chemotherapy	POS	O
without	POS	O
vincristine	POS	O
did	POS	O
not	POS	O
produce	POS	O
this	POS	O
complication	POS	O
.	POS	O
Heart	POS	B-NP
failure	POS	I-NP
:	POS	O
to	POS	O
digitalise	POS	O
or	POS	O
not	POS	O
?	POS	O
The	POS	O
view	POS	O
against	POS	O
.	POS	O
Despite	POS	O
extensive	POS	O
clinical	POS	O
experience	POS	O
the	POS	O
role	POS	O
of	POS	O
digoxin	POS	O
is	POS	O
still	POS	O
not	POS	O
well	POS	O
defined	POS	O
.	POS	O
In	POS	O
patients	POS	O
with	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
digoxin	POS	O
is	POS	O
beneficial	POS	O
for	POS	O
ventricular	POS	O
rate	POS	O
control	POS	O
.	POS	O
For	POS	O
patients	POS	O
in	POS	O
sinus	POS	O
rhythm	POS	O
and	POS	O
heart	POS	B-NP
failure	POS	I-NP
the	POS	O
situation	POS	O
is	POS	O
less	POS	O
clear	POS	O
.	POS	O
Digoxin	POS	O
has	POS	O
a	POS	O
narrow	POS	O
therapeutic	POS	O
:	POS	O
toxic	POS	O
ratio	POS	O
and	POS	O
concentrations	POS	O
are	POS	O
affected	POS	O
by	POS	O
a	POS	O
number	POS	O
of	POS	O
drugs	POS	O
.	POS	O
Also	POS	O
,	POS	O
digoxin	POS	O
has	POS	O
undesirable	POS	O
effects	POS	O
such	POS	O
as	POS	O
increasing	POS	O
peripheral	POS	O
resistance	POS	O
and	POS	O
myocardial	POS	O
demands	POS	O
,	POS	O
and	POS	O
causing	POS	O
arrhythmias	POS	B-NP
.	POS	O
There	POS	O
is	POS	O
a	POS	O
paucity	POS	O
of	POS	O
data	POS	O
from	POS	O
well	POS	O
-	POS	O
designed	POS	O
trials	POS	O
.	POS	O
The	POS	O
trials	POS	O
that	POS	O
are	POS	O
available	POS	O
are	POS	O
generally	POS	O
small	POS	O
with	POS	O
limitations	POS	O
in	POS	O
design	POS	O
and	POS	O
these	POS	O
show	POS	O
variation	POS	O
in	POS	O
patient	POS	O
benefit	POS	O
.	POS	O
More	POS	O
convincing	POS	O
evidence	POS	O
is	POS	O
required	POS	O
showing	POS	O
that	POS	O
digoxin	POS	O
improves	POS	O
symptoms	POS	O
or	POS	O
exercise	POS	O
capacity	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
no	POS	O
trial	POS	O
has	POS	O
had	POS	O
sufficient	POS	O
power	POS	O
to	POS	O
evaluate	POS	O
mortality	POS	O
.	POS	O
Pooled	POS	O
analysis	POS	O
of	POS	O
the	POS	O
effects	POS	O
of	POS	O
other	POS	O
inotropic	POS	O
drugs	POS	O
shows	POS	O
an	POS	O
excess	POS	O
mortality	POS	O
and	POS	O
there	POS	O
is	POS	O
a	POS	O
possibility	POS	O
that	POS	O
digoxin	POS	O
may	POS	O
increase	POS	O
mortality	POS	O
after	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
(	POS	O
MI	POS	B-NP
)	POS	O
.	POS	O
Angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
(	POS	O
ACE	POS	O
)	POS	O
inhibitors	POS	O
should	POS	O
be	POS	O
used	POS	O
first	POS	O
as	POS	O
they	POS	O
are	POS	O
safer	POS	O
,	POS	O
do	POS	O
not	POS	O
require	POS	O
blood	POS	O
level	POS	O
monitoring	POS	O
,	POS	O
modify	POS	O
progression	POS	O
of	POS	O
disease	POS	O
,	POS	O
relieve	POS	O
symptoms	POS	O
,	POS	O
improve	POS	O
exercise	POS	B-NP
tolerance	POS	I-NP
and	POS	O
reduce	POS	O
mortality	POS	O
.	POS	O
Caution	POS	O
should	POS	O
be	POS	O
exercised	POS	O
in	POS	O
using	POS	O
digoxin	POS	O
until	POS	O
large	POS	O
mortality	POS	O
trials	POS	O
are	POS	O
completed	POS	O
showing	POS	O
either	POS	O
benefit	POS	O
or	POS	O
harm	POS	O
.	POS	O
Until	POS	O
then	POS	O
digoxin	POS	O
should	POS	O
be	POS	O
considered	POS	O
a	POS	O
third	POS	O
-	POS	O
line	POS	O
therapy	POS	O
.	POS	O
Isradipine	POS	O
treatment	POS	O
for	POS	O
hypertension	POS	B-NP
in	POS	O
general	POS	O
practice	POS	O
in	POS	O
Hong	POS	O
Kong	POS	O
.	POS	O
A	POS	O
6	POS	O
-	POS	O
week	POS	O
open	POS	O
study	POS	O
of	POS	O
the	POS	O
introduction	POS	O
of	POS	O
isradipine	POS	O
treatment	POS	O
was	POS	O
conducted	POS	O
in	POS	O
general	POS	O
practice	POS	O
in	POS	O
Hong	POS	O
Kong	POS	O
.	POS	O
303	POS	O
Chinese	POS	O
patients	POS	O
with	POS	O
mild	POS	O
to	POS	O
moderate	POS	O
hypertension	POS	B-NP
entered	POS	O
the	POS	O
study	POS	O
.	POS	O
Side	POS	O
effects	POS	O
were	POS	O
reported	POS	O
in	POS	O
21	POS	O
%	POS	O
of	POS	O
patients	POS	O
and	POS	O
caused	POS	O
withdrawal	POS	O
from	POS	O
the	POS	O
study	POS	O
in	POS	O
3	POS	O
patients	POS	O
.	POS	O
The	POS	O
main	POS	O
side	POS	O
-	POS	O
effects	POS	O
were	POS	O
headache	POS	B-NP
,	POS	O
dizziness	POS	B-NP
,	POS	O
palpitation	POS	B-NP
and	POS	O
flushing	POS	B-NP
and	POS	O
these	POS	O
were	POS	O
not	POS	O
more	POS	O
frequent	POS	O
than	POS	O
reported	POS	O
in	POS	O
other	POS	O
studies	POS	O
with	POS	O
isradipine	POS	O
or	POS	O
with	POS	O
placebo	POS	O
.	POS	O
Supine	POS	O
blood	POS	O
pressure	POS	O
was	POS	O
reduced	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
from	POS	O
170	POS	O
+	POS	O
/	POS	O
-	POS	O
20	POS	O
/	POS	O
102	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
mmHg	POS	O
to	POS	O
153	POS	O
+	POS	O
/	POS	O
-	POS	O
19	POS	O
/	POS	O
92	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
,	POS	O
147	POS	O
+	POS	O
/	POS	O
-	POS	O
18	POS	O
/	POS	O
88	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
and	POS	O
144	POS	O
+	POS	O
/	POS	O
-	POS	O
14	POS	O
/	POS	O
87	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
mmHg	POS	O
at	POS	O
2	POS	O
,	POS	O
4	POS	O
and	POS	O
6	POS	O
weeks	POS	O
respectively	POS	O
in	POS	O
evaluable	POS	O
patients	POS	O
.	POS	O
Similar	POS	O
reductions	POS	O
occurred	POS	O
in	POS	O
standing	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
there	POS	O
was	POS	O
no	POS	O
evidence	POS	O
of	POS	O
postural	POS	B-NP
hypotension	POS	I-NP
.	POS	O
Normalization	POS	O
and	POS	O
responder	POS	O
rates	POS	O
at	POS	O
6	POS	O
weeks	POS	O
were	POS	O
86	POS	O
%	POS	O
and	POS	O
69	POS	O
%	POS	O
respectively	POS	O
.	POS	O
Dosage	POS	O
was	POS	O
increased	POS	O
from	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
b	POS	O
.	POS	O
d	POS	O
.	POS	O
to	POS	O
5	POS	O
mg	POS	O
b	POS	O
.	POS	O
d	POS	O
.	POS	O
at	POS	O
4	POS	O
weeks	POS	O
in	POS	O
patients	POS	O
with	POS	O
diastolic	POS	O
blood	POS	O
pressure	POS	O
greater	POS	O
than	POS	O
90	POS	O
mmHg	POS	O
and	POS	O
their	POS	O
further	POS	O
response	POS	O
was	POS	O
greater	POS	O
than	POS	O
those	POS	O
remaining	POS	O
on	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
b	POS	O
.	POS	O
d	POS	O
.	POS	O
Pharmacological	POS	O
characteristics	POS	O
and	POS	O
side	POS	O
effects	POS	O
of	POS	O
a	POS	O
new	POS	O
galenic	POS	O
formulation	POS	O
of	POS	O
propofol	POS	O
without	POS	O
soyabean	POS	O
oil	POS	O
.	POS	O
We	POS	O
compared	POS	O
the	POS	O
pharmacokinetics	POS	O
,	POS	O
pharmacodynamics	POS	O
and	POS	O
safety	POS	O
profile	POS	O
of	POS	O
a	POS	O
new	POS	O
galenic	POS	O
formulation	POS	O
of	POS	O
propofol	POS	O
(	POS	O
AM149	POS	O
1	POS	O
%	POS	O
)	POS	O
,	POS	O
which	POS	O
does	POS	O
not	POS	O
contain	POS	O
soyabean	POS	O
oil	POS	O
,	POS	O
with	POS	O
a	POS	O
standard	POS	O
formulation	POS	O
of	POS	O
propofol	POS	O
(	POS	O
Disoprivan	POS	O
1	POS	O
%	POS	O
)	POS	O
.	POS	O
In	POS	O
a	POS	O
randomised	POS	O
,	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
cross	POS	O
-	POS	O
over	POS	O
study	POS	O
,	POS	O
30	POS	O
healthy	POS	O
volunteers	POS	O
received	POS	O
a	POS	O
single	POS	O
intravenous	POS	O
bolus	POS	O
injection	POS	O
of	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
propofol	POS	O
.	POS	O
Plasma	POS	O
propofol	POS	O
levels	POS	O
were	POS	O
measured	POS	O
for	POS	O
48	POS	O
h	POS	O
following	POS	O
drug	POS	O
administration	POS	O
and	POS	O
evaluated	POS	O
according	POS	O
to	POS	O
a	POS	O
three	POS	O
-	POS	O
compartment	POS	O
model	POS	O
.	POS	O
The	POS	O
pharmacodynamic	POS	O
parameters	POS	O
assessed	POS	O
included	POS	O
induction	POS	O
and	POS	O
emergence	POS	O
times	POS	O
,	POS	O
respiratory	POS	O
and	POS	O
cardiovascular	POS	O
effects	POS	O
,	POS	O
and	POS	O
pain	POS	B-NP
on	POS	O
injection	POS	O
.	POS	O
Patients	POS	O
were	POS	O
monitored	POS	O
for	POS	O
side	POS	O
effects	POS	O
over	POS	O
48	POS	O
h	POS	O
.	POS	O
Owing	POS	O
to	POS	O
a	POS	O
high	POS	O
incidence	POS	O
of	POS	O
thrombophlebitis	POS	B-NP
,	POS	O
the	POS	O
study	POS	O
was	POS	O
terminated	POS	O
prematurely	POS	O
and	POS	O
only	POS	O
the	POS	O
data	POS	O
of	POS	O
the	POS	O
two	POS	O
parallel	POS	O
treatment	POS	O
groups	POS	O
(	POS	O
15	POS	O
patients	POS	O
in	POS	O
each	POS	O
group	POS	O
)	POS	O
were	POS	O
analysed	POS	O
.	POS	O
Plasma	POS	O
concentrations	POS	O
did	POS	O
not	POS	O
differ	POS	O
significantly	POS	O
between	POS	O
the	POS	O
two	POS	O
formulations	POS	O
.	POS	O
Anaesthesia	POS	B-NP
induction	POS	O
and	POS	O
emergence	POS	O
times	POS	O
,	POS	O
respiratory	POS	O
and	POS	O
cardiovascular	POS	O
variables	POS	O
showed	POS	O
no	POS	O
significant	POS	O
differences	POS	O
between	POS	O
the	POS	O
two	POS	O
treatment	POS	O
groups	POS	O
.	POS	O
Pain	POS	B-NP
on	POS	O
injection	POS	O
(	POS	O
80	POS	O
vs	POS	O
.	POS	O
20	POS	O
%	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
and	POS	O
thrombophlebitis	POS	B-NP
(	POS	O
93	POS	O
.	POS	O
3	POS	O
vs	POS	O
.	POS	O
6	POS	O
.	POS	O
6	POS	O
%	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
occurred	POS	O
more	POS	O
frequently	POS	O
with	POS	O
AM149	POS	O
than	POS	O
with	POS	O
Disoprivan	POS	O
.	POS	O
Although	POS	O
both	POS	O
formulations	POS	O
had	POS	O
similar	POS	O
pharmacokinetic	POS	O
and	POS	O
pharmacodynamic	POS	O
profiles	POS	O
the	POS	O
new	POS	O
formulation	POS	O
is	POS	O
not	POS	O
suitable	POS	O
for	POS	O
clinical	POS	O
use	POS	O
due	POS	O
to	POS	O
the	POS	O
high	POS	O
incidence	POS	O
of	POS	O
thrombophlebitis	POS	B-NP
produced	POS	O
.	POS	O
Pure	POS	B-NP
red	POS	I-NP
cell	POS	I-NP
aplasia	POS	I-NP
,	POS	O
toxic	POS	B-NP
dermatitis	POS	I-NP
and	POS	O
lymphadenopathy	POS	B-NP
in	POS	O
a	POS	O
patient	POS	O
taking	POS	O
diphenylhydantoin	POS	O
.	POS	O
A	POS	O
patient	POS	O
taking	POS	O
diphenylhydantoin	POS	O
for	POS	O
3	POS	O
weeks	POS	O
developed	POS	O
a	POS	O
generalized	POS	O
skin	POS	B-NP
rash	POS	I-NP
,	POS	O
lymphadenopathy	POS	B-NP
and	POS	O
pure	POS	B-NP
red	POS	I-NP
cell	POS	I-NP
aplasia	POS	I-NP
.	POS	O
After	POS	O
withdrawal	POS	O
of	POS	O
the	POS	O
pharmacon	POS	O
all	POS	O
symptoms	POS	O
disappeared	POS	O
spontaneously	POS	O
.	POS	O
Skin	POS	B-NP
rash	POS	I-NP
is	POS	O
a	POS	O
well	POS	O
-	POS	O
known	POS	O
complication	POS	O
of	POS	O
diphenylhydantoin	POS	O
treatment	POS	O
as	POS	O
is	POS	O
benign	POS	O
and	POS	O
malignant	POS	B-NP
lymphadenopathy	POS	I-NP
.	POS	O
Pure	POS	B-NP
red	POS	I-NP
cell	POS	I-NP
aplasia	POS	I-NP
associated	POS	O
with	POS	O
diphenylhydantoin	POS	O
medication	POS	O
has	POS	O
been	POS	O
reported	POS	O
in	POS	O
3	POS	O
patients	POS	O
.	POS	O
The	POS	O
exact	POS	O
mechanism	POS	O
by	POS	O
which	POS	O
diphenylhydantoin	POS	O
exerts	POS	O
its	POS	O
toxic	POS	O
effects	POS	O
is	POS	O
not	POS	O
known	POS	O
.	POS	O
In	POS	O
this	POS	O
patient	POS	O
the	POS	O
time	POS	O
relation	POS	O
between	POS	O
the	POS	O
ingestion	POS	O
of	POS	O
diphenylhydantoin	POS	O
and	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
the	POS	O
skin	POS	B-NP
rash	POS	I-NP
,	POS	O
lymphadenopathy	POS	B-NP
and	POS	O
pure	POS	B-NP
red	POS	I-NP
cell	POS	I-NP
aplasia	POS	I-NP
is	POS	O
very	POS	O
suggestive	POS	O
of	POS	O
a	POS	O
direct	POS	O
connection	POS	O
.	POS	O
Vinorelbine	POS	O
-	POS	O
related	POS	O
cardiac	POS	O
events	POS	O
:	POS	O
a	POS	O
meta	POS	O
-	POS	O
analysis	POS	O
of	POS	O
randomized	POS	O
clinical	POS	O
trials	POS	O
.	POS	O
Several	POS	O
cases	POS	O
of	POS	O
cardiac	POS	B-NP
adverse	POS	I-NP
reactions	POS	I-NP
related	POS	O
to	POS	O
vinorelbine	POS	O
(	POS	O
VNR	POS	O
)	POS	O
have	POS	O
been	POS	O
reported	POS	O
in	POS	O
the	POS	O
literature	POS	O
.	POS	O
In	POS	O
order	POS	O
to	POS	O
quantify	POS	O
the	POS	O
incidence	POS	O
of	POS	O
these	POS	O
cardiac	POS	O
events	POS	O
,	POS	O
we	POS	O
performed	POS	O
a	POS	O
meta	POS	O
-	POS	O
analysis	POS	O
of	POS	O
clinical	POS	O
trials	POS	O
comparing	POS	O
VNR	POS	O
with	POS	O
other	POS	O
chemotherapeutic	POS	O
agents	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
various	POS	O
malignancies	POS	B-NP
.	POS	O
Randomized	POS	O
clinical	POS	O
trials	POS	O
comparing	POS	O
VNR	POS	O
with	POS	O
other	POS	O
drugs	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
cancer	POS	B-NP
were	POS	O
searched	POS	O
in	POS	O
Medline	POS	O
,	POS	O
Embase	POS	O
,	POS	O
Evidence	POS	O
-	POS	O
based	POS	O
Medicine	POS	O
Reviews	POS	O
databases	POS	O
and	POS	O
the	POS	O
Cochrane	POS	O
library	POS	O
from	POS	O
1987	POS	O
to	POS	O
2002	POS	O
.	POS	O
Outcomes	POS	O
of	POS	O
interest	POS	O
were	POS	O
severe	POS	O
cardiac	POS	B-NP
events	POS	I-NP
,	POS	O
toxic	POS	B-NP
deaths	POS	I-NP
and	POS	O
cardiac	POS	B-NP
event	POS	I-NP
-	POS	I-NP
related	POS	I-NP
deaths	POS	I-NP
reported	POS	O
in	POS	O
each	POS	O
publication	POS	O
.	POS	O
We	POS	O
found	POS	O
19	POS	O
trials	POS	O
,	POS	O
involving	POS	O
2441	POS	O
patients	POS	O
treated	POS	O
by	POS	O
VNR	POS	O
and	POS	O
2050	POS	O
control	POS	O
patients	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
cardiac	POS	B-NP
events	POS	I-NP
with	POS	O
VNR	POS	O
was	POS	O
1	POS	O
.	POS	O
19	POS	O
%	POS	O
[	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
(	POS	O
CI	POS	O
)	POS	O
(	POS	O
0	POS	O
.	POS	O
75	POS	O
;	POS	O
1	POS	O
.	POS	O
67	POS	O
)	POS	O
]	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
difference	POS	O
in	POS	O
the	POS	O
risk	POS	O
of	POS	O
cardiac	POS	O
events	POS	O
between	POS	O
VNR	POS	O
and	POS	O
other	POS	O
drugs	POS	O
[	POS	O
odds	POS	O
ratio	POS	O
:	POS	O
0	POS	O
.	POS	O
92	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
(	POS	O
0	POS	O
.	POS	O
54	POS	O
;	POS	O
1	POS	O
.	POS	O
55	POS	O
)	POS	O
]	POS	O
.	POS	O
The	POS	O
risk	POS	O
of	POS	O
VNR	POS	O
cardiac	POS	O
events	POS	O
was	POS	O
similar	POS	O
to	POS	O
vindesine	POS	O
(	POS	O
VDS	POS	O
)	POS	O
and	POS	O
other	POS	O
cardiotoxic	POS	B-NP
drugs	POS	O
[	POS	O
fluorouracil	POS	O
,	POS	O
anthracyclines	POS	O
,	POS	O
gemcitabine	POS	O
(	POS	O
GEM	POS	O
)	POS	O
em	POS	O
leader	POS	O
]	POS	O
.	POS	O
Even	POS	O
if	POS	O
it	POS	O
did	POS	O
not	POS	O
reach	POS	O
statistical	POS	O
significance	POS	O
because	POS	O
of	POS	O
a	POS	O
few	POS	O
number	POS	O
of	POS	O
cases	POS	O
,	POS	O
the	POS	O
risk	POS	O
was	POS	O
lower	POS	O
in	POS	O
trials	POS	O
excluding	POS	O
patients	POS	O
with	POS	O
cardiac	POS	B-NP
history	POS	I-NP
,	POS	O
and	POS	O
seemed	POS	O
to	POS	O
be	POS	O
higher	POS	O
in	POS	O
trials	POS	O
including	POS	O
patients	POS	O
with	POS	O
pre	POS	O
-	POS	O
existing	POS	O
cardiac	POS	B-NP
diseases	POS	I-NP
.	POS	O
Vinorelbine	POS	O
-	POS	O
related	POS	O
cardiac	POS	O
events	POS	O
concern	POS	O
about	POS	O
1	POS	O
%	POS	O
of	POS	O
treated	POS	O
patients	POS	O
in	POS	O
clinical	POS	O
trials	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
risk	POS	O
associated	POS	O
with	POS	O
VNR	POS	O
seems	POS	O
to	POS	O
be	POS	O
similar	POS	O
to	POS	O
that	POS	O
of	POS	O
other	POS	O
chemotherapeutic	POS	O
agents	POS	O
in	POS	O
the	POS	O
same	POS	O
indications	POS	O
.	POS	O
MRI	POS	O
findings	POS	O
of	POS	O
hypoxic	POS	O
cortical	POS	O
laminar	POS	O
necrosis	POS	B-NP
in	POS	O
a	POS	O
child	POS	O
with	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
crisis	POS	O
.	POS	O
We	POS	O
present	POS	O
magnetic	POS	O
resonance	POS	O
imaging	POS	O
findings	POS	O
of	POS	O
a	POS	O
5	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
girl	POS	O
who	POS	O
had	POS	O
a	POS	O
rapidly	POS	O
installing	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
crisis	POS	O
induced	POS	O
by	POS	O
trimethoprim	POS	O
-	POS	O
sulfomethoxazole	POS	O
,	POS	O
resulting	POS	O
in	POS	O
cerebral	POS	B-NP
anoxia	POS	I-NP
leading	POS	O
to	POS	O
permanent	POS	O
damage	POS	O
.	POS	O
Magnetic	POS	O
Resonance	POS	O
imaging	POS	O
revealed	POS	O
cortical	POS	O
laminar	POS	O
necrosis	POS	B-NP
in	POS	O
arterial	POS	O
border	POS	O
zones	POS	O
in	POS	O
both	POS	O
cerebral	POS	O
hemispheres	POS	O
,	POS	O
ischemic	POS	O
changes	POS	O
in	POS	O
subcortical	POS	O
white	POS	O
matter	POS	O
of	POS	O
left	POS	O
cerebral	POS	O
hemisphere	POS	O
,	POS	O
and	POS	O
in	POS	O
the	POS	O
left	POS	O
putamen	POS	O
.	POS	O
Although	POS	O
cortical	POS	O
laminar	POS	O
necrosis	POS	B-NP
is	POS	O
a	POS	O
classic	POS	O
entity	POS	O
in	POS	O
adulthood	POS	O
related	POS	O
to	POS	O
conditions	POS	O
of	POS	O
energy	POS	O
depletions	POS	O
,	POS	O
there	POS	O
are	POS	O
few	POS	O
reports	POS	O
available	POS	O
in	POS	O
children	POS	O
.	POS	O
A	POS	O
wide	POS	O
review	POS	O
of	POS	O
the	POS	O
literature	POS	O
is	POS	O
also	POS	O
presented	POS	O
.	POS	O
The	POS	O
natural	POS	O
history	POS	O
of	POS	O
Vigabatrin	POS	B-NP
associated	POS	I-NP
visual	POS	I-NP
field	POS	I-NP
defects	POS	I-NP
in	POS	O
patients	POS	O
electing	POS	O
to	POS	O
continue	POS	O
their	POS	O
medication	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
determine	POS	O
the	POS	O
natural	POS	O
history	POS	O
of	POS	O
visual	POS	B-NP
field	POS	I-NP
defects	POS	I-NP
in	POS	O
a	POS	O
group	POS	O
of	POS	O
patients	POS	O
known	POS	O
to	POS	O
have	POS	O
Vigabatrin	POS	O
-	POS	O
associated	POS	O
changes	POS	O
who	POS	O
elected	POS	O
to	POS	O
continue	POS	O
the	POS	O
medication	POS	O
because	POS	O
of	POS	O
good	POS	O
seizure	POS	B-NP
control	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
All	POS	O
patients	POS	O
taking	POS	O
Vigabatrin	POS	O
alone	POS	O
or	POS	O
in	POS	O
combination	POS	O
with	POS	O
other	POS	O
antiepileptic	POS	O
drugs	POS	O
for	POS	O
at	POS	O
least	POS	O
5	POS	O
years	POS	O
(	POS	O
range	POS	O
5	POS	O
-	POS	O
12	POS	O
years	POS	O
)	POS	O
were	POS	O
entered	POS	O
into	POS	O
a	POS	O
visual	POS	O
surveillance	POS	O
programme	POS	O
.	POS	O
Patients	POS	O
were	POS	O
followed	POS	O
up	POS	O
at	POS	O
6	POS	O
-	POS	O
monthly	POS	O
intervals	POS	O
for	POS	O
not	POS	O
less	POS	O
than	POS	O
18	POS	O
months	POS	O
(	POS	O
range	POS	O
18	POS	O
-	POS	O
43	POS	O
months	POS	O
)	POS	O
.	POS	O
In	POS	O
all	POS	O
,	POS	O
16	POS	O
patients	POS	O
with	POS	O
unequivocal	POS	O
defects	POS	O
continued	POS	O
the	POS	O
medication	POS	O
.	POS	O
Following	POS	O
already	POS	O
published	POS	O
methodology	POS	O
(	POS	O
Eye	POS	O
2002	POS	O
;	POS	O
16	POS	O
;	POS	O
567	POS	O
-	POS	O
571	POS	O
)	POS	O
monocular	POS	O
mean	POS	O
radial	POS	O
degrees	POS	O
(	POS	O
MRDs	POS	O
)	POS	O
to	POS	O
the	POS	O
I	POS	O
/	POS	O
4e	POS	O
isopter	POS	O
on	POS	O
Goldmann	POS	O
perimetry	POS	O
was	POS	O
calculated	POS	O
for	POS	O
the	POS	O
right	POS	O
eye	POS	O
at	POS	O
the	POS	O
time	POS	O
of	POS	O
discovery	POS	O
of	POS	O
a	POS	O
visual	POS	B-NP
field	POS	I-NP
defect	POS	I-NP
and	POS	O
again	POS	O
after	POS	O
not	POS	O
less	POS	O
than	POS	O
18	POS	O
months	POS	O
follow	POS	O
-	POS	O
up	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Mean	POS	O
right	POS	O
eye	POS	O
MRD	POS	O
at	POS	O
presentation	POS	O
was	POS	O
36	POS	O
.	POS	O
98	POS	O
degrees	POS	O
(	POS	O
range	POS	O
22	POS	O
.	POS	O
25	POS	O
-	POS	O
51	POS	O
.	POS	O
0	POS	O
)	POS	O
,	POS	O
compared	POS	O
to	POS	O
38	POS	O
.	POS	O
40	POS	O
degrees	POS	O
(	POS	O
range	POS	O
22	POS	O
.	POS	O
5	POS	O
-	POS	O
49	POS	O
.	POS	O
75	POS	O
)	POS	O
after	POS	O
follow	POS	O
-	POS	O
up	POS	O
;	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
338	POS	O
unpaired	POS	O
t	POS	O
-	POS	O
test	POS	O
.	POS	O
Only	POS	O
one	POS	O
patient	POS	O
demonstrated	POS	O
a	POS	O
deterioration	POS	O
in	POS	O
visual	POS	O
field	POS	O
during	POS	O
the	POS	O
study	POS	O
period	POS	O
and	POS	O
discontinued	POS	O
treatment	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Established	POS	O
visual	POS	B-NP
field	POS	I-NP
defects	POS	I-NP
presumed	POS	O
to	POS	O
be	POS	O
due	POS	O
to	POS	O
Vigabatrin	POS	O
therapy	POS	O
did	POS	O
not	POS	O
usually	POS	O
progress	POS	O
in	POS	O
spite	POS	O
of	POS	O
continuing	POS	O
use	POS	O
of	POS	O
the	POS	O
medication	POS	O
.	POS	O
These	POS	O
data	POS	O
give	POS	O
support	POS	O
to	POS	O
the	POS	O
hypothesis	POS	O
that	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
Vigabatrin	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
visual	POS	I-NP
field	POS	I-NP
defects	POS	I-NP
may	POS	O
be	POS	O
an	POS	O
idiosyncratic	POS	O
adverse	POS	O
drug	POS	O
reaction	POS	O
rather	POS	O
than	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
toxicity	POS	B-NP
.	POS	O
Induction	POS	O
of	POS	O
rosaceiform	POS	B-NP
dermatitis	POS	I-NP
during	POS	O
treatment	POS	O
of	POS	O
facial	POS	B-NP
inflammatory	POS	I-NP
dermatoses	POS	I-NP
with	POS	O
tacrolimus	POS	O
ointment	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Tacrolimus	POS	O
ointment	POS	O
is	POS	O
increasingly	POS	O
used	POS	O
for	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
treatment	POS	O
of	POS	O
sensitive	POS	O
areas	POS	O
such	POS	O
as	POS	O
the	POS	O
face	POS	O
,	POS	O
and	POS	O
recent	POS	O
observations	POS	O
indicate	POS	O
that	POS	O
the	POS	O
treatment	POS	O
is	POS	O
effective	POS	O
in	POS	O
steroid	POS	O
-	POS	O
aggravated	POS	O
rosacea	POS	B-NP
and	POS	O
perioral	POS	B-NP
dermatitis	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
on	POS	O
rosaceiform	POS	B-NP
dermatitis	POS	I-NP
as	POS	O
a	POS	O
complication	POS	O
of	POS	O
treatment	POS	O
with	POS	O
tacrolimus	POS	O
ointment	POS	O
.	POS	O
OBSERVATIONS	POS	O
:	POS	O
Six	POS	O
adult	POS	O
patients	POS	O
with	POS	O
inflammatory	POS	B-NP
facial	POS	I-NP
dermatoses	POS	I-NP
were	POS	O
treated	POS	O
with	POS	O
tacrolimus	POS	O
ointment	POS	O
because	POS	O
of	POS	O
the	POS	O
ineffectiveness	POS	O
of	POS	O
standard	POS	O
treatments	POS	O
.	POS	O
Within	POS	O
2	POS	O
to	POS	O
3	POS	O
weeks	POS	O
of	POS	O
initially	POS	O
effective	POS	O
and	POS	O
well	POS	O
-	POS	O
tolerated	POS	O
treatment	POS	O
,	POS	O
3	POS	O
patients	POS	O
with	POS	O
a	POS	O
history	POS	O
of	POS	O
rosacea	POS	B-NP
and	POS	O
1	POS	O
with	POS	O
a	POS	O
history	POS	O
of	POS	O
acne	POS	B-NP
experienced	POS	O
sudden	POS	B-NP
worsening	POS	I-NP
with	POS	O
pustular	POS	B-NP
rosaceiform	POS	I-NP
lesions	POS	I-NP
.	POS	O
Biopsy	POS	B-NP
revealed	POS	O
an	POS	O
abundance	POS	O
of	POS	O
Demodex	POS	O
mites	POS	O
in	POS	O
2	POS	O
of	POS	O
these	POS	O
patients	POS	O
.	POS	O
In	POS	O
1	POS	O
patient	POS	O
with	POS	O
eyelid	POS	B-NP
eczema	POS	I-NP
,	POS	O
rosaceiform	POS	B-NP
periocular	POS	I-NP
dermatitis	POS	I-NP
gradually	POS	O
appeared	POS	O
after	POS	O
3	POS	O
weeks	POS	O
of	POS	O
treatment	POS	O
.	POS	O
In	POS	O
1	POS	O
patient	POS	O
with	POS	O
atopic	POS	B-NP
dermatitis	POS	I-NP
,	POS	O
telangiectatic	POS	B-NP
and	POS	O
papular	POS	B-NP
rosacea	POS	I-NP
insidiously	POS	I-NP
appeared	POS	O
after	POS	O
5	POS	O
months	POS	O
of	POS	O
treatment	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Our	POS	O
observations	POS	O
suggest	POS	O
that	POS	O
the	POS	O
spectrum	POS	O
of	POS	O
rosaceiform	POS	B-NP
dermatitis	POS	I-NP
as	POS	O
a	POS	O
complication	POS	O
of	POS	O
treatment	POS	O
with	POS	O
tacrolimus	POS	O
ointment	POS	O
is	POS	O
heterogeneous	POS	O
.	POS	O
A	POS	O
variety	POS	O
of	POS	O
factors	POS	O
,	POS	O
such	POS	O
as	POS	O
vasoactive	POS	O
properties	POS	O
of	POS	O
tacrolimus	POS	O
,	POS	O
proliferation	POS	O
of	POS	O
Demodex	POS	O
due	POS	O
to	POS	O
local	POS	O
immunosuppression	POS	O
,	POS	O
and	POS	O
the	POS	O
occlusive	POS	O
properties	POS	O
of	POS	O
the	POS	O
ointment	POS	O
,	POS	O
may	POS	O
be	POS	O
involved	POS	O
in	POS	O
the	POS	O
observed	POS	O
phenomena	POS	O
.	POS	O
Future	POS	O
studies	POS	O
are	POS	O
needed	POS	O
to	POS	O
identify	POS	O
individual	POS	O
risk	POS	O
factors	POS	O
.	POS	O
Intravascular	POS	B-NP
hemolysis	POS	I-NP
and	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
following	POS	O
intermittent	POS	O
rifampin	POS	O
therapy	POS	O
.	POS	O
Renal	POS	B-NP
failure	POS	I-NP
is	POS	O
a	POS	O
rare	POS	O
complication	POS	O
associated	POS	O
with	POS	O
the	POS	O
use	POS	O
of	POS	O
rifampin	POS	O
.	POS	O
Intravascular	POS	B-NP
hemolysis	POS	I-NP
leading	POS	O
to	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
following	POS	O
rifampin	POS	O
therapy	POS	O
is	POS	O
extremely	POS	O
rare	POS	O
.	POS	O
Two	POS	O
patients	POS	O
with	POS	O
leprosy	POS	B-NP
who	POS	O
developed	POS	O
hemolysis	POS	B-NP
and	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
following	POS	O
rifampin	POS	O
are	POS	O
reported	POS	O
.	POS	O
Structural	POS	B-NP
abnormalities	POS	I-NP
in	POS	O
the	POS	O
brains	POS	O
of	POS	O
human	POS	O
subjects	POS	O
who	POS	O
use	POS	O
methamphetamine	POS	O
.	POS	O
We	POS	O
visualize	POS	O
,	POS	O
for	POS	O
the	POS	O
first	POS	O
time	POS	O
,	POS	O
the	POS	O
profile	POS	O
of	POS	O
structural	POS	O
deficits	POS	O
in	POS	O
the	POS	O
human	POS	O
brain	POS	O
associated	POS	O
with	POS	O
chronic	POS	O
methamphetamine	POS	O
(	POS	O
MA	POS	O
)	POS	O
abuse	POS	O
.	POS	O
Studies	POS	O
of	POS	O
human	POS	O
subjects	POS	O
who	POS	O
have	POS	O
used	POS	O
MA	POS	O
chronically	POS	O
have	POS	O
revealed	POS	O
deficits	POS	O
in	POS	O
dopaminergic	POS	O
and	POS	O
serotonergic	POS	O
systems	POS	O
and	POS	O
cerebral	POS	O
metabolic	POS	O
abnormalities	POS	O
.	POS	O
Using	POS	O
magnetic	POS	O
resonance	POS	O
imaging	POS	O
(	POS	O
MRI	POS	O
)	POS	O
and	POS	O
new	POS	O
computational	POS	O
brain	POS	O
-	POS	O
mapping	POS	O
techniques	POS	O
,	POS	O
we	POS	O
determined	POS	O
the	POS	O
pattern	POS	O
of	POS	O
structural	POS	O
brain	POS	O
alterations	POS	O
associated	POS	O
with	POS	O
chronic	POS	O
MA	POS	O
abuse	POS	O
in	POS	O
human	POS	O
subjects	POS	O
and	POS	O
related	POS	O
these	POS	O
deficits	POS	O
to	POS	O
cognitive	POS	B-NP
impairment	POS	I-NP
.	POS	O
We	POS	O
used	POS	O
high	POS	O
-	POS	O
resolution	POS	O
MRI	POS	O
and	POS	O
surface	POS	O
-	POS	O
based	POS	O
computational	POS	O
image	POS	O
analyses	POS	O
to	POS	O
map	POS	O
regional	POS	O
abnormalities	POS	O
in	POS	O
the	POS	O
cortex	POS	O
,	POS	O
hippocampus	POS	O
,	POS	O
white	POS	O
matter	POS	O
,	POS	O
and	POS	O
ventricles	POS	O
in	POS	O
22	POS	O
human	POS	O
subjects	POS	O
who	POS	O
used	POS	O
MA	POS	O
and	POS	O
21	POS	O
age	POS	O
-	POS	O
matched	POS	O
,	POS	O
healthy	POS	O
controls	POS	O
.	POS	O
Cortical	POS	O
maps	POS	O
revealed	POS	O
severe	POS	O
gray	POS	B-NP
-	POS	I-NP
matter	POS	I-NP
deficits	POS	I-NP
in	POS	O
the	POS	O
cingulate	POS	O
,	POS	O
limbic	POS	O
,	POS	O
and	POS	O
paralimbic	POS	O
cortices	POS	O
of	POS	O
MA	POS	O
abusers	POS	O
(	POS	O
averaging	POS	O
11	POS	O
.	POS	O
3	POS	O
%	POS	O
below	POS	O
control	POS	O
;	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
On	POS	O
average	POS	O
,	POS	O
MA	POS	O
abusers	POS	O
had	POS	O
7	POS	O
.	POS	O
8	POS	O
%	POS	O
smaller	POS	O
hippocampal	POS	O
volumes	POS	O
than	POS	O
control	POS	O
subjects	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
;	POS	O
left	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
01	POS	O
;	POS	O
right	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
and	POS	O
significant	POS	O
white	POS	B-NP
-	POS	I-NP
matter	POS	I-NP
hypertrophy	POS	I-NP
(	POS	O
7	POS	O
.	POS	O
0	POS	O
%	POS	O
;	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Hippocampal	POS	B-NP
deficits	POS	I-NP
were	POS	O
mapped	POS	O
and	POS	O
correlated	POS	O
with	POS	O
memory	POS	O
performance	POS	O
on	POS	O
a	POS	O
word	POS	O
-	POS	O
recall	POS	O
test	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
MRI	POS	O
-	POS	O
based	POS	O
maps	POS	O
suggest	POS	O
that	POS	O
chronic	POS	O
methamphetamine	POS	O
abuse	POS	O
causes	POS	O
a	POS	O
selective	POS	O
pattern	POS	O
of	POS	O
cerebral	POS	B-NP
deterioration	POS	I-NP
that	POS	O
contributes	POS	O
to	POS	O
impaired	POS	O
memory	POS	O
performance	POS	O
.	POS	O
MA	POS	O
may	POS	O
selectively	POS	O
damage	POS	O
the	POS	O
medial	POS	O
temporal	POS	O
lobe	POS	O
and	POS	O
,	POS	O
consistent	POS	O
with	POS	O
metabolic	POS	O
studies	POS	O
,	POS	O
the	POS	O
cingulate	POS	O
-	POS	O
limbic	POS	O
cortex	POS	O
,	POS	O
inducing	POS	O
neuroadaptation	POS	O
,	POS	O
neuropil	POS	O
reduction	POS	O
,	POS	O
or	POS	O
cell	POS	O
death	POS	O
.	POS	O
Prominent	POS	O
white	POS	O
-	POS	O
matter	POS	O
hypertrophy	POS	B-NP
may	POS	O
result	POS	O
from	POS	O
altered	POS	O
myelination	POS	O
and	POS	O
adaptive	POS	O
glial	POS	O
changes	POS	O
,	POS	O
including	POS	O
gliosis	POS	B-NP
secondary	POS	O
to	POS	O
neuronal	POS	B-NP
damage	POS	I-NP
.	POS	O
These	POS	O
brain	POS	O
substrates	POS	O
may	POS	O
help	POS	O
account	POS	O
for	POS	O
the	POS	O
symptoms	POS	O
of	POS	O
MA	POS	O
abuse	POS	O
,	POS	O
providing	POS	O
therapeutic	POS	O
targets	POS	O
for	POS	O
drug	POS	O
-	POS	O
induced	POS	O
brain	POS	B-NP
injury	POS	I-NP
.	POS	O
Disruption	POS	O
of	POS	O
hepatic	POS	O
lipid	POS	O
homeostasis	POS	O
in	POS	O
mice	POS	O
after	POS	O
amiodarone	POS	O
treatment	POS	O
is	POS	O
associated	POS	O
with	POS	O
peroxisome	POS	O
proliferator	POS	O
-	POS	O
activated	POS	O
receptor	POS	O
-	POS	O
alpha	POS	O
target	POS	O
gene	POS	O
activation	POS	O
.	POS	O
Amiodarone	POS	O
,	POS	O
an	POS	O
efficacious	POS	O
and	POS	O
widely	POS	O
used	POS	O
antiarrhythmic	POS	O
agent	POS	O
,	POS	O
has	POS	O
been	POS	O
reported	POS	O
to	POS	O
cause	POS	O
hepatotoxicity	POS	B-NP
in	POS	O
some	POS	O
patients	POS	O
.	POS	O
To	POS	O
gain	POS	O
insight	POS	O
into	POS	O
the	POS	O
mechanism	POS	O
of	POS	O
this	POS	O
unwanted	POS	O
effect	POS	O
,	POS	O
mice	POS	O
were	POS	O
administered	POS	O
various	POS	O
doses	POS	O
of	POS	O
amiodarone	POS	O
and	POS	O
examined	POS	O
for	POS	O
changes	POS	O
in	POS	O
hepatic	POS	O
histology	POS	O
and	POS	O
gene	POS	O
regulation	POS	O
.	POS	O
Amiodarone	POS	O
induced	POS	O
hepatomegaly	POS	B-NP
,	POS	O
hepatocyte	POS	O
microvesicular	POS	O
lipid	POS	O
accumulation	POS	O
,	POS	O
and	POS	O
a	POS	O
significant	POS	O
decrease	POS	O
in	POS	O
serum	POS	O
triglycerides	POS	O
and	POS	O
glucose	POS	O
.	POS	O
Northern	POS	O
blot	POS	O
analysis	POS	O
of	POS	O
hepatic	POS	O
RNA	POS	O
revealed	POS	O
a	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
increase	POS	O
in	POS	O
the	POS	O
expression	POS	O
of	POS	O
a	POS	O
number	POS	O
of	POS	O
genes	POS	O
critical	POS	O
for	POS	O
fatty	POS	O
acid	POS	O
oxidation	POS	O
,	POS	O
lipoprotein	POS	O
assembly	POS	O
,	POS	O
and	POS	O
lipid	POS	O
transport	POS	O
.	POS	O
Many	POS	O
of	POS	O
these	POS	O
genes	POS	O
are	POS	O
regulated	POS	O
by	POS	O
the	POS	O
peroxisome	POS	O
proliferator	POS	O
-	POS	O
activated	POS	O
receptor	POS	O
-	POS	O
alpha	POS	O
(	POS	O
PPARalpha	POS	O
)	POS	O
,	POS	O
a	POS	O
ligand	POS	O
-	POS	O
activated	POS	O
nuclear	POS	O
hormone	POS	O
receptor	POS	O
transcription	POS	O
factor	POS	O
.	POS	O
The	POS	O
absence	POS	O
of	POS	O
induction	POS	O
of	POS	O
these	POS	O
genes	POS	O
as	POS	O
well	POS	O
as	POS	O
hepatomegaly	POS	B-NP
in	POS	O
PPARalpha	POS	O
knockout	POS	O
[	POS	O
PPARalpha	POS	O
-	POS	O
/	POS	O
-	POS	O
]	POS	O
mice	POS	O
indicated	POS	O
that	POS	O
the	POS	O
effects	POS	O
of	POS	O
amiodarone	POS	O
were	POS	O
dependent	POS	O
upon	POS	O
the	POS	O
presence	POS	O
of	POS	O
a	POS	O
functional	POS	O
PPARalpha	POS	O
gene	POS	O
.	POS	O
Compared	POS	O
to	POS	O
wild	POS	O
-	POS	O
type	POS	O
mice	POS	O
,	POS	O
treatment	POS	O
of	POS	O
PPARalpha	POS	O
-	POS	O
/	POS	O
-	POS	O
mice	POS	O
with	POS	O
amiodarone	POS	O
resulted	POS	O
in	POS	O
an	POS	O
increased	POS	O
rate	POS	O
and	POS	O
extent	POS	O
of	POS	O
total	POS	O
body	POS	O
weight	POS	O
loss	POS	O
.	POS	O
The	POS	O
inability	POS	O
of	POS	O
amiodarone	POS	O
to	POS	O
directly	POS	O
activate	POS	O
either	POS	O
human	POS	O
or	POS	O
mouse	POS	O
PPARalpha	POS	O
transiently	POS	O
expressed	POS	O
in	POS	O
human	POS	O
HepG2	POS	O
hepatoma	POS	O
cells	POS	O
indicates	POS	O
that	POS	O
the	POS	O
effects	POS	O
of	POS	O
amiodarone	POS	O
on	POS	O
the	POS	O
function	POS	O
of	POS	O
this	POS	O
receptor	POS	O
were	POS	O
indirect	POS	O
.	POS	O
Based	POS	O
upon	POS	O
these	POS	O
results	POS	O
,	POS	O
we	POS	O
conclude	POS	O
that	POS	O
amiodarone	POS	O
disrupts	POS	O
hepatic	POS	O
lipid	POS	O
homeostasis	POS	O
and	POS	O
that	POS	O
the	POS	O
increased	POS	O
expression	POS	O
of	POS	O
PPARalpha	POS	O
target	POS	O
genes	POS	O
is	POS	O
secondary	POS	O
to	POS	O
this	POS	O
toxic	POS	O
effect	POS	O
.	POS	O
These	POS	O
results	POS	O
provide	POS	O
important	POS	O
new	POS	O
mechanistic	POS	O
information	POS	O
regarding	POS	O
the	POS	O
hepatotoxic	POS	B-NP
effects	POS	O
of	POS	O
amiodarone	POS	O
and	POS	O
indicate	POS	O
that	POS	O
PPARalpha	POS	O
protects	POS	O
against	POS	O
amiodarone	POS	O
-	POS	O
induced	POS	O
hepatotoxicity	POS	B-NP
.	POS	O
Safety	POS	O
and	POS	O
compliance	POS	O
with	POS	O
once	POS	O
-	POS	O
daily	POS	O
niacin	POS	O
extended	POS	O
-	POS	O
release	POS	O
/	POS	O
lovastatin	POS	O
as	POS	O
initial	POS	O
therapy	POS	O
in	POS	O
the	POS	O
Impact	POS	O
of	POS	O
Medical	POS	O
Subspecialty	POS	O
on	POS	O
Patient	POS	O
Compliance	POS	O
to	POS	O
Treatment	POS	O
(	POS	O
IMPACT	POS	O
)	POS	O
study	POS	O
.	POS	O
Niacin	POS	O
extended	POS	O
-	POS	O
release	POS	O
/	POS	O
lovastatin	POS	O
is	POS	O
a	POS	O
new	POS	O
combination	POS	O
product	POS	O
approved	POS	O
for	POS	O
treatment	POS	O
of	POS	O
primary	POS	O
hypercholesterolemia	POS	B-NP
and	POS	O
mixed	POS	O
dyslipidemia	POS	B-NP
.	POS	O
This	POS	O
open	POS	O
-	POS	O
labeled	POS	O
,	POS	O
multicenter	POS	O
study	POS	O
evaluated	POS	O
the	POS	O
safety	POS	O
of	POS	O
bedtime	POS	O
niacin	POS	O
extended	POS	O
-	POS	O
release	POS	O
/	POS	O
lovastatin	POS	O
when	POS	O
dosed	POS	O
as	POS	O
initial	POS	O
therapy	POS	O
and	POS	O
patient	POS	O
compliance	POS	O
to	POS	O
treatment	POS	O
in	POS	O
various	POS	O
clinical	POS	O
practice	POS	O
settings	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
4	POS	O
,	POS	O
499	POS	O
patients	POS	O
with	POS	O
dyslipidemia	POS	B-NP
requiring	POS	O
drug	POS	O
intervention	POS	O
was	POS	O
enrolled	POS	O
at	POS	O
1	POS	O
,	POS	O
081	POS	O
sites	POS	O
.	POS	O
Patients	POS	O
were	POS	O
treated	POS	O
with	POS	O
1	POS	O
tablet	POS	O
(	POS	O
500	POS	O
mg	POS	O
of	POS	O
niacin	POS	O
extended	POS	O
-	POS	O
release	POS	O
/	POS	O
20	POS	O
mg	POS	O
of	POS	O
lovastatin	POS	O
)	POS	O
once	POS	O
nightly	POS	O
for	POS	O
4	POS	O
weeks	POS	O
and	POS	O
then	POS	O
2	POS	O
tablets	POS	O
for	POS	O
8	POS	O
weeks	POS	O
.	POS	O
Patients	POS	O
also	POS	O
received	POS	O
dietary	POS	O
counseling	POS	O
,	POS	O
educational	POS	O
materials	POS	O
,	POS	O
and	POS	O
reminders	POS	O
to	POS	O
call	POS	O
a	POS	O
toll	POS	O
-	POS	O
free	POS	O
number	POS	O
that	POS	O
provided	POS	O
further	POS	O
education	POS	O
about	POS	O
dyslipidemia	POS	B-NP
and	POS	O
niacin	POS	O
extended	POS	O
-	POS	O
release	POS	O
/	POS	O
lovastatin	POS	O
.	POS	O
Primary	POS	O
end	POS	O
points	POS	O
were	POS	O
study	POS	O
compliance	POS	O
,	POS	O
increases	POS	O
in	POS	O
liver	POS	O
transaminases	POS	O
to	POS	O
>	POS	O
3	POS	O
times	POS	O
the	POS	O
upper	POS	O
limit	POS	O
of	POS	O
normal	POS	O
,	POS	O
and	POS	O
clinical	POS	O
myopathy	POS	B-NP
.	POS	O
Final	POS	O
study	POS	O
status	POS	O
was	POS	O
available	POS	O
for	POS	O
4	POS	O
,	POS	O
217	POS	O
patients	POS	O
(	POS	O
94	POS	O
%	POS	O
)	POS	O
.	POS	O
Compliance	POS	O
to	POS	O
niacin	POS	O
extended	POS	O
-	POS	O
release	POS	O
/	POS	O
lovastatin	POS	O
was	POS	O
77	POS	O
%	POS	O
,	POS	O
with	POS	O
3	POS	O
,	POS	O
245	POS	O
patients	POS	O
completing	POS	O
the	POS	O
study	POS	O
.	POS	O
Patients	POS	O
in	POS	O
the	POS	O
southeast	POS	O
and	POS	O
those	POS	O
enrolled	POS	O
by	POS	O
endocrinologists	POS	O
had	POS	O
the	POS	O
lowest	POS	O
compliance	POS	O
and	POS	O
highest	POS	O
adverse	POS	O
event	POS	O
rates	POS	O
.	POS	O
Flushing	POS	O
was	POS	O
the	POS	O
most	POS	O
common	POS	O
adverse	POS	O
event	POS	O
,	POS	O
reported	POS	O
by	POS	O
18	POS	O
%	POS	O
of	POS	O
patients	POS	O
and	POS	O
leading	POS	O
to	POS	O
discontinuation	POS	O
by	POS	O
6	POS	O
%	POS	O
.	POS	O
Incidence	POS	O
of	POS	O
increased	POS	O
aspartate	POS	O
aminotransferase	POS	O
and	POS	O
/	POS	O
or	POS	O
alanine	POS	O
aminotransferase	POS	O
>	POS	O
3	POS	O
times	POS	O
the	POS	O
upper	POS	O
limit	POS	O
of	POS	O
normal	POS	O
was	POS	O
<	POS	O
0	POS	O
.	POS	O
3	POS	O
%	POS	O
.	POS	O
An	POS	O
increase	POS	O
of	POS	O
creatine	POS	O
phosphokinase	POS	O
to	POS	O
>	POS	O
5	POS	O
times	POS	O
the	POS	O
upper	POS	O
limit	POS	O
of	POS	O
normal	POS	O
occurred	POS	O
in	POS	O
0	POS	O
.	POS	O
24	POS	O
%	POS	O
of	POS	O
patients	POS	O
,	POS	O
and	POS	O
no	POS	O
cases	POS	O
of	POS	O
drug	POS	O
-	POS	O
induced	POS	O
myopathy	POS	B-NP
were	POS	O
observed	POS	O
.	POS	O
Niacin	POS	O
extended	POS	O
-	POS	O
release	POS	O
/	POS	O
lovastatin	POS	O
1	POS	O
,	POS	O
000	POS	O
/	POS	O
40	POS	O
mg	POS	O
,	POS	O
dosed	POS	O
as	POS	O
initial	POS	O
therapy	POS	O
,	POS	O
was	POS	O
associated	POS	O
with	POS	O
good	POS	O
compliance	POS	O
and	POS	O
safety	POS	O
and	POS	O
had	POS	O
very	POS	O
low	POS	O
incidences	POS	O
of	POS	O
increased	POS	O
liver	POS	O
and	POS	O
muscle	POS	O
enzymes	POS	O
.	POS	O
Protective	POS	O
effect	POS	O
of	POS	O
Terminalia	POS	O
chebula	POS	O
against	POS	O
experimental	POS	O
myocardial	POS	B-NP
injury	POS	I-NP
induced	POS	O
by	POS	O
isoproterenol	POS	O
.	POS	O
Cardioprotective	POS	O
effect	POS	O
of	POS	O
ethanolic	POS	O
extract	POS	O
of	POS	O
Terminalia	POS	O
chebula	POS	O
fruits	POS	O
(	POS	O
500	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
wt	POS	O
)	POS	O
was	POS	O
examined	POS	O
in	POS	O
isoproterenol	POS	O
(	POS	O
200	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
wt	POS	O
)	POS	O
induced	POS	O
myocardial	POS	B-NP
damage	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
In	POS	O
isoproterenol	POS	O
administered	POS	O
rats	POS	O
,	POS	O
the	POS	O
level	POS	O
of	POS	O
lipid	POS	O
peroxides	POS	O
increased	POS	O
significantly	POS	O
in	POS	O
the	POS	O
serum	POS	O
and	POS	O
heart	POS	O
.	POS	O
A	POS	O
significant	POS	O
decrease	POS	O
was	POS	O
observed	POS	O
in	POS	O
the	POS	O
activity	POS	O
of	POS	O
the	POS	O
myocardial	POS	O
marker	POS	O
enzymes	POS	O
with	POS	O
a	POS	O
concomitant	POS	O
increase	POS	O
in	POS	O
their	POS	O
activity	POS	O
in	POS	O
serum	POS	O
.	POS	O
Histopathological	POS	O
examination	POS	O
was	POS	O
carried	POS	O
out	POS	O
to	POS	O
confirm	POS	O
the	POS	O
myocardial	POS	B-NP
necrosis	POS	I-NP
.	POS	O
T	POS	O
.	POS	O
chebula	POS	O
extract	POS	O
pretreatment	POS	O
was	POS	O
found	POS	O
to	POS	O
ameliorate	POS	O
the	POS	O
effect	POS	O
of	POS	O
isoproterenol	POS	O
on	POS	O
lipid	POS	O
peroxide	POS	O
formation	POS	O
and	POS	O
retained	POS	O
the	POS	O
activities	POS	O
of	POS	O
the	POS	O
diagnostic	POS	O
marker	POS	O
enzymes	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
postoperative	POS	B-NP
anxiety	POS	I-NP
due	POS	O
to	POS	O
low	POS	O
dose	POS	O
droperidol	POS	O
used	POS	O
with	POS	O
patient	POS	O
-	POS	O
controlled	POS	O
analgesia	POS	B-NP
.	POS	O
A	POS	O
multiparous	POS	O
woman	POS	O
in	POS	O
good	POS	O
psychological	POS	O
health	POS	O
underwent	POS	O
urgent	POS	O
caesarean	POS	O
section	POS	O
in	POS	O
labour	POS	O
.	POS	O
Postoperatively	POS	O
,	POS	O
she	POS	O
was	POS	O
given	POS	O
a	POS	O
patient	POS	O
-	POS	O
controlled	POS	O
analgesia	POS	O
device	POS	O
delivering	POS	O
boluses	POS	O
of	POS	O
diamorphine	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
and	POS	O
droperidol	POS	O
0	POS	O
.	POS	O
025	POS	O
mg	POS	O
.	POS	O
Whilst	POS	O
using	POS	O
the	POS	O
device	POS	O
she	POS	O
gradually	POS	O
became	POS	O
anxious	POS	B-NP
,	POS	O
the	POS	O
feeling	POS	O
worsening	POS	O
after	POS	O
each	POS	O
bolus	POS	O
.	POS	O
The	POS	O
diagnosis	POS	O
of	POS	O
droperidol	POS	O
-	POS	O
induced	POS	O
psychological	POS	O
disturbance	POS	O
was	POS	O
not	POS	O
made	POS	O
straight	POS	O
away	POS	O
although	POS	O
on	POS	O
subsequent	POS	O
close	POS	O
questioning	POS	O
the	POS	O
patient	POS	O
gave	POS	O
a	POS	O
very	POS	O
clear	POS	O
history	POS	O
.	POS	O
After	POS	O
she	POS	O
had	POS	O
received	POS	O
a	POS	O
total	POS	O
of	POS	O
only	POS	O
0	POS	O
.	POS	O
9	POS	O
mg	POS	O
droperidol	POS	O
,	POS	O
a	POS	O
syringe	POS	O
containing	POS	O
diamorphine	POS	O
only	POS	O
was	POS	O
substituted	POS	O
and	POS	O
her	POS	O
unease	POS	O
resolved	POS	O
completely	POS	O
.	POS	O
We	POS	O
feel	POS	O
that	POS	O
,	POS	O
although	POS	O
the	POS	O
dramatic	POS	O
extrapyramidal	POS	O
side	POS	O
effects	POS	O
of	POS	O
dopaminergic	POS	O
antiemetics	POS	O
are	POS	O
well	POS	O
known	POS	O
,	POS	O
more	POS	O
subtle	POS	O
manifestations	POS	O
may	POS	O
easily	POS	O
be	POS	O
overlooked	POS	O
.	POS	O
Accurate	POS	O
patient	POS	O
history	POS	O
contributes	POS	O
to	POS	O
differentiating	POS	O
diabetes	POS	B-NP
insipidus	POS	I-NP
:	POS	O
a	POS	O
case	POS	O
study	POS	O
.	POS	O
This	POS	O
case	POS	O
study	POS	O
highlights	POS	O
the	POS	O
important	POS	O
contribution	POS	O
of	POS	O
nursing	POS	O
in	POS	O
obtaining	POS	O
an	POS	O
accurate	POS	O
health	POS	O
history	POS	O
.	POS	O
The	POS	O
case	POS	O
discussed	POS	O
herein	POS	O
initially	POS	O
appeared	POS	O
to	POS	O
be	POS	O
neurogenic	POS	B-NP
diabetes	POS	I-NP
insipidus	POS	I-NP
(	POS	O
DI	POS	B-NP
)	POS	O
secondary	POS	O
to	POS	O
a	POS	O
traumatic	POS	B-NP
brain	POS	I-NP
injury	POS	I-NP
.	POS	O
The	POS	O
nursing	POS	O
staff	POS	O
,	POS	O
by	POS	O
reviewing	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
health	POS	O
history	POS	O
with	POS	O
his	POS	O
family	POS	O
,	POS	O
discovered	POS	O
a	POS	O
history	POS	O
of	POS	O
polydipsia	POS	B-NP
and	POS	O
long	POS	O
-	POS	O
standing	POS	O
lithium	POS	O
use	POS	O
.	POS	O
Lithium	POS	O
is	POS	O
implicated	POS	O
in	POS	O
drug	POS	O
-	POS	O
induced	POS	O
nephrogenic	POS	B-NP
DI	POS	I-NP
,	POS	O
and	POS	O
because	POS	O
the	POS	O
patient	POS	O
had	POS	O
not	POS	O
received	POS	O
lithium	POS	O
since	POS	O
being	POS	O
admitted	POS	O
to	POS	O
the	POS	O
hospital	POS	O
,	POS	O
his	POS	O
treatment	POS	O
changed	POS	O
to	POS	O
focus	POS	O
on	POS	O
nephrogenic	POS	B-NP
DI	POS	I-NP
.	POS	O
By	POS	O
combining	POS	O
information	POS	O
from	POS	O
the	POS	O
patient	POS	O
history	POS	O
,	POS	O
the	POS	O
physical	POS	O
examination	POS	O
,	POS	O
and	POS	O
radiologic	POS	O
and	POS	O
laboratory	POS	O
studies	POS	O
,	POS	O
the	POS	O
critical	POS	O
care	POS	O
team	POS	O
demonstrated	POS	O
that	POS	O
the	POS	O
patient	POS	O
had	POS	O
been	POS	O
self	POS	O
-	POS	O
treating	POS	O
his	POS	O
lithium	POS	O
-	POS	O
induced	POS	O
nephrogenic	POS	B-NP
DI	POS	I-NP
and	POS	O
developed	POS	O
neurogenic	POS	O
DI	POS	O
secondary	POS	O
to	POS	O
brain	POS	B-NP
trauma	POS	I-NP
.	POS	O
Thus	POS	O
successful	POS	O
treatment	POS	O
required	POS	O
that	POS	O
nephrogenic	POS	B-NP
and	POS	O
neurogenic	POS	B-NP
DI	POS	I-NP
be	POS	O
treated	POS	O
concomitantly	POS	O
.	POS	O
Factors	POS	O
contributing	POS	O
to	POS	O
ribavirin	POS	O
-	POS	O
induced	POS	O
anemia	POS	B-NP
.	POS	O
BACKGROUND	POS	O
AND	POS	O
AIM	POS	O
:	POS	O
Interferon	POS	O
and	POS	O
ribavirin	POS	O
combination	POS	O
therapy	POS	O
for	POS	O
chronic	POS	O
hepatitis	POS	O
C	POS	O
produces	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
.	POS	O
This	POS	O
study	POS	O
was	POS	O
conducted	POS	O
to	POS	O
identify	POS	O
the	POS	O
factors	POS	O
contributing	POS	O
to	POS	O
ribavirin	POS	O
-	POS	O
induced	POS	O
anemia	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Eighty	POS	O
-	POS	O
eight	POS	O
patients	POS	O
with	POS	O
chronic	POS	B-NP
hepatitis	POS	I-NP
C	POS	I-NP
who	POS	O
received	POS	O
interferon	POS	O
-	POS	O
alpha	POS	O
-	POS	O
2b	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
6	POS	O
MU	POS	O
administered	POS	O
intramuscularly	POS	O
for	POS	O
24	POS	O
weeks	POS	O
in	POS	O
combination	POS	O
with	POS	O
ribavirin	POS	O
administered	POS	O
orally	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
600	POS	O
mg	POS	O
or	POS	O
800	POS	O
mg	POS	O
participated	POS	O
in	POS	O
the	POS	O
study	POS	O
.	POS	O
A	POS	O
hemoglobin	POS	O
concentration	POS	O
of	POS	O
<	POS	O
10	POS	O
g	POS	O
/	POS	O
dL	POS	O
was	POS	O
defined	POS	O
as	POS	O
ribavirin	POS	O
-	POS	O
induced	POS	O
anemia	POS	B-NP
.	POS	O
RESULTS	POS	O
:	POS	O
Ribavirin	POS	O
-	POS	O
induced	POS	O
anemia	POS	B-NP
occurred	POS	O
in	POS	O
18	POS	O
(	POS	O
20	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
patients	POS	O
during	POS	O
treatment	POS	O
.	POS	O
A	POS	O
2	POS	O
g	POS	O
/	POS	O
dL	POS	O
decrease	POS	O
in	POS	O
hemoglobin	POS	O
concentrations	POS	O
in	POS	O
patients	POS	O
with	POS	O
anemia	POS	B-NP
was	POS	O
observed	POS	O
at	POS	O
week	POS	O
2	POS	O
after	POS	O
the	POS	O
start	POS	O
of	POS	O
treatment	POS	O
.	POS	O
The	POS	O
hemoglobin	POS	O
concentration	POS	O
in	POS	O
patients	POS	O
with	POS	O
>	POS	O
or	POS	O
=	POS	O
2	POS	O
g	POS	O
/	POS	O
dL	POS	O
decrease	POS	O
at	POS	O
week	POS	O
2	POS	O
was	POS	O
observed	POS	O
to	POS	O
be	POS	O
significantly	POS	O
lower	POS	O
even	POS	O
after	POS	O
week	POS	O
2	POS	O
than	POS	O
in	POS	O
patients	POS	O
with	POS	O
<	POS	O
2	POS	O
g	POS	O
/	POS	O
dL	POS	O
decrease	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
A	POS	O
significant	POS	O
relationship	POS	O
was	POS	O
observed	POS	O
between	POS	O
the	POS	O
rate	POS	O
of	POS	O
reduction	POS	O
of	POS	O
hemoglobin	POS	O
concentrations	POS	O
at	POS	O
week	POS	O
2	POS	O
and	POS	O
the	POS	O
severity	POS	O
of	POS	O
anemia	POS	B-NP
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Such	POS	O
factors	POS	O
as	POS	O
sex	POS	O
(	POS	O
female	POS	O
)	POS	O
,	POS	O
age	POS	O
(	POS	O
>	POS	O
or	POS	O
=	POS	O
60	POS	O
years	POS	O
old	POS	O
)	POS	O
,	POS	O
and	POS	O
the	POS	O
ribavirin	POS	O
dose	POS	O
by	POS	O
body	POS	O
weight	POS	O
(	POS	O
12	POS	O
mg	POS	O
/	POS	O
kg	POS	O
or	POS	O
more	POS	O
)	POS	O
were	POS	O
significant	POS	O
by	POS	O
univariate	POS	O
analysis	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Careful	POS	O
administration	POS	O
is	POS	O
necessary	POS	O
in	POS	O
patients	POS	O
>	POS	O
or	POS	O
=	POS	O
60	POS	O
years	POS	O
old	POS	O
,	POS	O
in	POS	O
female	POS	O
patients	POS	O
,	POS	O
and	POS	O
in	POS	O
patients	POS	O
receiving	POS	O
a	POS	O
ribavirin	POS	O
dose	POS	O
of	POS	O
12	POS	O
mg	POS	O
/	POS	O
kg	POS	O
or	POS	O
more	POS	O
.	POS	O
Patients	POS	O
who	POS	O
experience	POS	O
a	POS	O
fall	POS	O
in	POS	O
hemoglobin	POS	O
concentrations	POS	O
of	POS	O
2	POS	O
g	POS	O
/	POS	O
dL	POS	O
or	POS	O
more	POS	O
at	POS	O
week	POS	O
2	POS	O
after	POS	O
the	POS	O
start	POS	O
of	POS	O
treatment	POS	O
should	POS	O
be	POS	O
monitored	POS	O
with	POS	O
particular	POS	O
care	POS	O
.	POS	O
Zidovudine	POS	O
-	POS	O
induced	POS	O
hepatitis	POS	B-NP
.	POS	O
A	POS	O
case	POS	O
of	POS	O
acute	POS	B-NP
hepatitis	POS	I-NP
induced	POS	O
by	POS	O
zidovudine	POS	O
in	POS	O
a	POS	O
38	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
patient	POS	O
with	POS	O
AIDS	POS	B-NP
is	POS	O
presented	POS	O
.	POS	O
The	POS	O
mechanism	POS	O
whereby	POS	O
the	POS	O
hepatitis	POS	B-NP
was	POS	O
induced	POS	O
is	POS	O
not	POS	O
known	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
patient	POS	O
tolerated	POS	O
well	POS	O
an	POS	O
alternative	POS	O
reverse	POS	O
transcriptase	POS	O
inhibitor	POS	O
,	POS	O
2	POS	O
'	POS	O
3	POS	O
'	POS	O
dideoxyinosine	POS	O
.	POS	O
Physicians	POS	O
caring	POS	O
for	POS	O
patients	POS	O
with	POS	O
AIDS	POS	B-NP
should	POS	O
be	POS	O
aware	POS	O
of	POS	O
this	POS	O
hitherto	POS	O
rarely	POS	O
reported	POS	O
complication	POS	O
.	POS	O
Oxidative	POS	O
damage	POS	O
precedes	POS	O
nitrative	POS	O
damage	POS	O
in	POS	O
adriamycin	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
mitochondrial	POS	I-NP
injury	POS	I-NP
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
if	POS	O
elevated	POS	O
reactive	POS	O
oxygen	POS	O
(	POS	O
ROS	POS	O
)	POS	O
/	POS	O
nitrogen	POS	O
species	POS	O
(	POS	O
RNS	POS	O
)	POS	O
reported	POS	O
to	POS	O
be	POS	O
present	POS	O
in	POS	O
adriamycin	POS	O
(	POS	O
ADR	POS	O
)	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
actually	POS	O
resulted	POS	O
in	POS	O
cardiomyocyte	POS	O
oxidative	POS	O
/	POS	O
nitrative	POS	O
damage	POS	O
,	POS	O
and	POS	O
to	POS	O
quantitatively	POS	O
determine	POS	O
the	POS	O
time	POS	O
course	POS	O
and	POS	O
subcellular	POS	O
localization	POS	O
of	POS	O
these	POS	O
postulated	POS	O
damage	POS	O
products	POS	O
using	POS	O
an	POS	O
in	POS	O
vivo	POS	O
approach	POS	O
.	POS	O
B6C3	POS	O
mice	POS	O
were	POS	O
treated	POS	O
with	POS	O
a	POS	O
single	POS	O
dose	POS	O
of	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
ADR	POS	O
.	POS	O
Ultrastructural	POS	O
damage	POS	O
and	POS	O
levels	POS	O
of	POS	O
4	POS	O
-	POS	O
hydroxy	POS	O
-	POS	O
2	POS	O
-	POS	O
nonenal	POS	O
(	POS	O
4HNE	POS	O
)	POS	O
-	POS	O
protein	POS	O
adducts	POS	O
and	POS	O
3	POS	O
-	POS	O
nitrotyrosine	POS	O
(	POS	O
3NT	POS	O
)	POS	O
were	POS	O
analyzed	POS	O
.	POS	O
Quantitative	POS	O
ultrastructural	POS	O
damage	POS	O
using	POS	O
computerized	POS	O
image	POS	O
techniques	POS	O
showed	POS	O
cardiomyocyte	POS	B-NP
injury	POS	I-NP
as	POS	O
early	POS	O
as	POS	O
3	POS	O
hours	POS	O
,	POS	O
with	POS	O
mitochondria	POS	O
being	POS	O
the	POS	O
most	POS	O
extensively	POS	O
and	POS	O
progressively	POS	O
injured	POS	O
subcellular	POS	O
organelle	POS	O
.	POS	O
Analysis	POS	O
of	POS	O
4HNE	POS	O
protein	POS	O
adducts	POS	O
by	POS	O
immunogold	POS	O
electron	POS	O
microscopy	POS	O
showed	POS	O
appearance	POS	O
of	POS	O
4HNE	POS	O
protein	POS	O
adducts	POS	O
in	POS	O
mitochondria	POS	O
as	POS	O
early	POS	O
as	POS	O
3	POS	O
hours	POS	O
,	POS	O
with	POS	O
a	POS	O
peak	POS	O
at	POS	O
6	POS	O
hours	POS	O
and	POS	O
subsequent	POS	O
decline	POS	O
at	POS	O
24	POS	O
hours	POS	O
.	POS	O
3NT	POS	O
levels	POS	O
were	POS	O
significantly	POS	O
increased	POS	O
in	POS	O
all	POS	O
subcellular	POS	O
compartments	POS	O
at	POS	O
6	POS	O
hours	POS	O
and	POS	O
subsequently	POS	O
declined	POS	O
at	POS	O
24	POS	O
hours	POS	O
.	POS	O
Our	POS	O
data	POS	O
showed	POS	O
ADR	POS	O
induced	POS	O
4HNE	POS	O
-	POS	O
protein	POS	O
adducts	POS	O
in	POS	O
mitochondria	POS	O
at	POS	O
the	POS	O
same	POS	O
time	POS	O
point	POS	O
as	POS	O
when	POS	O
mitochondrial	POS	B-NP
injury	POS	I-NP
initially	POS	O
appeared	POS	O
.	POS	O
These	POS	O
results	POS	O
document	POS	O
for	POS	O
the	POS	O
first	POS	O
time	POS	O
in	POS	O
vivo	POS	O
that	POS	O
mitochondrial	POS	O
oxidative	POS	O
damage	POS	O
precedes	POS	O
nitrative	POS	O
damage	POS	O
.	POS	O
The	POS	O
progressive	POS	O
nature	POS	O
of	POS	O
mitochondrial	POS	B-NP
injury	POS	I-NP
suggests	POS	O
that	POS	O
mitochondria	POS	O
,	POS	O
not	POS	O
other	POS	O
subcellular	POS	O
organelles	POS	O
,	POS	O
are	POS	O
the	POS	O
major	POS	O
site	POS	O
of	POS	O
intracellular	POS	O
injury	POS	O
.	POS	O
Sotalol	POS	O
-	POS	O
induced	POS	O
coronary	POS	B-NP
spasm	POS	I-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
dilated	POS	B-NP
cardiomyopathy	POS	I-NP
associated	POS	O
with	POS	O
sustained	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
.	POS	O
A	POS	O
54	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
with	POS	O
severe	POS	O
left	POS	B-NP
ventricular	POS	I-NP
dysfunction	POS	I-NP
due	POS	O
to	POS	O
dilated	POS	B-NP
cardiomyopathy	POS	I-NP
was	POS	O
referred	POS	O
to	POS	O
our	POS	O
hospital	POS	O
for	POS	O
symptomatic	POS	O
incessant	POS	O
sustained	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
(	POS	O
VT	POS	B-NP
)	POS	O
.	POS	O
After	POS	O
the	POS	O
administration	POS	O
of	POS	O
nifekalant	POS	O
hydrochloride	POS	O
,	POS	O
sustained	POS	O
VT	POS	B-NP
was	POS	O
terminated	POS	O
.	POS	O
An	POS	O
alternate	POS	O
class	POS	O
III	POS	O
agent	POS	O
,	POS	O
sotalol	POS	O
,	POS	O
was	POS	O
also	POS	O
effective	POS	O
for	POS	O
the	POS	O
prevention	POS	O
of	POS	O
VT	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
one	POS	O
month	POS	O
after	POS	O
switching	POS	O
over	POS	O
nifekalant	POS	O
to	POS	O
sotalol	POS	O
,	POS	O
a	POS	O
short	POS	O
duration	POS	O
of	POS	O
ST	POS	O
elevation	POS	O
was	POS	O
documented	POS	O
in	POS	O
ECG	POS	O
monitoring	POS	O
at	POS	O
almost	POS	O
the	POS	O
same	POS	O
time	POS	O
for	POS	O
three	POS	O
consecutive	POS	O
days	POS	O
.	POS	O
ST	POS	O
elevation	POS	O
with	POS	O
chest	POS	B-NP
discomfort	POS	I-NP
disappeared	POS	O
since	POS	O
he	POS	O
began	POS	O
taking	POS	O
long	POS	O
-	POS	O
acting	POS	O
diltiazem	POS	O
.	POS	O
Coronary	POS	B-NP
vasospasm	POS	I-NP
may	POS	O
be	POS	O
induced	POS	O
by	POS	O
the	POS	O
non	POS	O
-	POS	O
selective	POS	O
beta	POS	O
-	POS	O
blocking	POS	O
properties	POS	O
of	POS	O
sotalol	POS	O
.	POS	O
Effects	POS	O
of	POS	O
the	POS	O
antidepressant	POS	O
trazodone	POS	O
,	POS	O
a	POS	O
5	POS	O
-	POS	O
HT	POS	O
2A	POS	O
/	POS	O
2C	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
on	POS	O
dopamine	POS	O
-	POS	O
dependent	POS	O
behaviors	POS	O
in	POS	O
rats	POS	O
.	POS	O
RATIONALE	POS	O
:	POS	O
5	POS	O
-	POS	O
Hydroxytryptamine	POS	O
,	POS	O
via	POS	O
stimulation	POS	O
of	POS	O
5	POS	O
-	POS	O
HT	POS	O
2C	POS	O
receptors	POS	O
,	POS	O
exerts	POS	O
a	POS	O
tonic	POS	O
inhibitory	POS	O
influence	POS	O
on	POS	O
dopaminergic	POS	O
neurotransmission	POS	O
,	POS	O
whereas	POS	O
activation	POS	O
of	POS	O
5	POS	O
-	POS	O
HT	POS	O
2A	POS	O
receptors	POS	O
enhances	POS	O
stimulated	POS	O
DAergic	POS	O
neurotransmission	POS	O
.	POS	O
The	POS	O
antidepressant	POS	O
trazodone	POS	O
is	POS	O
a	POS	O
5	POS	O
-	POS	O
HT	POS	O
2A	POS	O
/	POS	O
2C	POS	O
receptor	POS	O
antagonist	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
To	POS	O
evaluate	POS	O
the	POS	O
effect	POS	O
of	POS	O
trazodone	POS	O
treatment	POS	O
on	POS	O
behaviors	POS	O
dependent	POS	O
on	POS	O
the	POS	O
functional	POS	O
status	POS	O
of	POS	O
the	POS	O
nigrostriatal	POS	O
DAergic	POS	O
system	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
The	POS	O
effect	POS	O
of	POS	O
pretreatment	POS	O
with	POS	O
trazodone	POS	O
on	POS	O
dexamphetamine	POS	O
-	POS	O
and	POS	O
apomorphine	POS	O
-	POS	O
induced	POS	O
oral	POS	O
stereotypies	POS	B-NP
,	POS	O
on	POS	O
catalepsy	POS	B-NP
induced	POS	O
by	POS	O
haloperidol	POS	O
and	POS	O
apomorphine	POS	O
(	POS	O
0	POS	O
.	POS	O
05	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
,	POS	O
on	POS	O
ergometrine	POS	O
-	POS	O
induced	POS	O
wet	POS	O
dog	POS	O
shake	POS	O
(	POS	O
WDS	POS	O
)	POS	O
behavior	POS	O
and	POS	O
fluoxetine	POS	O
-	POS	O
induced	POS	O
penile	POS	O
erections	POS	O
was	POS	O
studied	POS	O
in	POS	O
rats	POS	O
.	POS	O
We	POS	O
also	POS	O
investigated	POS	O
whether	POS	O
trazodone	POS	O
induces	POS	O
catalepsy	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Trazodone	POS	O
at	POS	O
2	POS	O
.	POS	O
5	POS	O
-	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
did	POS	O
not	POS	O
induce	POS	O
catalepsy	POS	B-NP
,	POS	O
and	POS	O
did	POS	O
not	POS	O
antagonize	POS	O
apomorphine	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
and	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
stereotypy	POS	O
and	POS	O
apomorphine	POS	O
(	POS	O
0	POS	O
.	POS	O
05	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
pretreatment	POS	O
with	POS	O
5	POS	O
,	POS	O
10	POS	O
and	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
trazodone	POS	O
enhanced	POS	O
dexamphetamine	POS	O
stereotypy	POS	B-NP
,	POS	O
and	POS	O
antagonized	POS	O
haloperidol	POS	O
catalepsy	POS	B-NP
,	POS	O
ergometrine	POS	O
-	POS	O
induced	POS	O
WDS	POS	O
behavior	POS	O
and	POS	O
fluoxetine	POS	O
-	POS	O
induced	POS	O
penile	POS	O
erections	POS	O
.	POS	O
Trazodone	POS	O
at	POS	O
30	POS	O
,	POS	O
40	POS	O
and	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
induced	POS	O
catalepsy	POS	B-NP
and	POS	O
antagonized	POS	O
apomorphine	POS	O
and	POS	O
dexamphetamine	POS	O
stereotypies	POS	B-NP
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Our	POS	O
results	POS	O
indicate	POS	O
that	POS	O
trazodone	POS	O
at	POS	O
2	POS	O
.	POS	O
5	POS	O
-	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
does	POS	O
not	POS	O
block	POS	O
pre	POS	O
-	POS	O
and	POS	O
postsynaptic	POS	O
striatal	POS	O
D2	POS	O
DA	POS	O
receptors	POS	O
,	POS	O
while	POS	O
at	POS	O
30	POS	O
,	POS	O
40	POS	O
and	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
it	POS	O
blocks	POS	O
postsynaptic	POS	O
striatal	POS	O
D2	POS	O
DA	POS	O
receptors	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
at	POS	O
5	POS	O
,	POS	O
10	POS	O
and	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
trazodone	POS	O
blocks	POS	O
5	POS	O
-	POS	O
HT	POS	O
2A	POS	O
and	POS	O
5	POS	O
-	POS	O
HT	POS	O
2C	POS	O
receptors	POS	O
.	POS	O
We	POS	O
suggest	POS	O
that	POS	O
trazodone	POS	O
(	POS	O
5	POS	O
,	POS	O
10	POS	O
and	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
by	POS	O
blocking	POS	O
the	POS	O
5	POS	O
-	POS	O
HT	POS	O
2C	POS	O
receptors	POS	O
,	POS	O
releases	POS	O
the	POS	O
nigrostriatal	POS	O
DAergic	POS	O
neurons	POS	O
from	POS	O
tonic	POS	O
inhibition	POS	O
caused	POS	O
by	POS	O
5	POS	O
-	POS	O
HT	POS	O
,	POS	O
and	POS	O
thereby	POS	O
potentiates	POS	O
dexamphetamine	POS	O
stereotypy	POS	O
and	POS	O
antagonizes	POS	O
haloperidol	POS	O
catalepsy	POS	B-NP
.	POS	O
Swallowing	POS	B-NP
abnormalities	POS	I-NP
and	POS	O
dyskinesia	POS	B-NP
in	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
Gastrointestinal	POS	B-NP
abnormalities	POS	I-NP
in	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
(	POS	O
PD	POS	B-NP
)	POS	O
have	POS	O
been	POS	O
known	POS	O
for	POS	O
almost	POS	O
two	POS	O
centuries	POS	O
,	POS	O
but	POS	O
many	POS	O
aspects	POS	O
concerning	POS	O
their	POS	O
pathophysiology	POS	O
have	POS	O
not	POS	O
been	POS	O
completely	POS	O
clarified	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
characterize	POS	O
the	POS	O
oropharyngeal	POS	O
dynamics	POS	O
in	POS	O
PD	POS	B-NP
patients	POS	O
with	POS	O
and	POS	O
without	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
dyskinesia	POS	B-NP
.	POS	O
Fifteen	POS	O
dyskinetic	POS	B-NP
,	POS	O
12	POS	O
nondyskinetic	POS	B-NP
patients	POS	O
,	POS	O
and	POS	O
a	POS	O
control	POS	O
group	POS	O
were	POS	O
included	POS	O
.	POS	O
Patients	POS	O
were	POS	O
asked	POS	O
about	POS	O
dysphagia	POS	B-NP
and	POS	O
evaluated	POS	O
with	POS	O
the	POS	O
Unified	POS	O
Parkinson	POS	O
'	POS	O
s	POS	O
Disease	POS	O
Rating	POS	O
Scale	POS	O
Parts	POS	O
II	POS	O
and	POS	O
III	POS	O
and	POS	O
the	POS	O
Hoehn	POS	B-NP
and	POS	O
Yahr	POS	O
scale	POS	O
.	POS	O
Deglutition	POS	B-NP
was	POS	O
assessed	POS	O
using	POS	O
modified	POS	O
barium	POS	O
swallow	POS	O
with	POS	O
videofluoroscopy	POS	O
.	POS	O
Nondyskinetic	POS	B-NP
patients	POS	O
,	POS	O
but	POS	O
not	POS	O
the	POS	O
dyskinetic	POS	B-NP
ones	POS	O
,	POS	O
showed	POS	O
less	POS	O
oropharyngeal	POS	O
swallowing	POS	O
efficiency	POS	O
(	POS	O
OPSE	POS	O
)	POS	O
for	POS	O
liquid	POS	O
food	POS	O
than	POS	O
controls	POS	O
(	POS	O
Dunnett	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
02	POS	O
)	POS	O
.	POS	O
Dyskinetic	POS	B-NP
patients	POS	O
tended	POS	O
to	POS	O
have	POS	O
a	POS	O
greater	POS	O
OPSE	POS	O
than	POS	O
nondyskinetic	POS	O
(	POS	O
Dunnett	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
06	POS	O
)	POS	O
.	POS	O
Patients	POS	O
who	POS	O
were	POS	O
using	POS	O
a	POS	O
higher	POS	O
dose	POS	O
of	POS	O
levodopa	POS	O
had	POS	O
a	POS	O
greater	POS	O
OPSE	POS	O
and	POS	O
a	POS	O
trend	POS	O
toward	POS	O
a	POS	O
smaller	POS	O
oral	POS	O
transit	POS	O
time	POS	O
(	POS	O
Pearson	POS	O
'	POS	O
s	POS	O
correlation	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
01	POS	O
and	POS	O
0	POS	O
.	POS	O
08	POS	O
,	POS	O
respectively	POS	O
)	POS	O
.	POS	O
Neither	POS	O
the	POS	O
report	POS	O
of	POS	O
dysphagia	POS	B-NP
nor	POS	O
any	POS	O
of	POS	O
the	POS	O
PD	POS	B-NP
severity	POS	O
parameters	POS	O
correlated	POS	O
to	POS	O
the	POS	O
videofluoroscopic	POS	O
variables	POS	O
.	POS	O
In	POS	O
the	POS	O
current	POS	O
study	POS	O
,	POS	O
dyskinetic	POS	B-NP
patients	POS	O
performed	POS	O
better	POS	O
in	POS	O
swallowing	POS	O
function	POS	O
,	POS	O
which	POS	O
could	POS	O
be	POS	O
explained	POS	O
on	POS	O
the	POS	O
basis	POS	O
of	POS	O
a	POS	O
greater	POS	O
levodopa	POS	O
dose	POS	O
.	POS	O
Our	POS	O
results	POS	O
suggest	POS	O
a	POS	O
role	POS	O
for	POS	O
levodopa	POS	O
in	POS	O
the	POS	O
oral	POS	O
phase	POS	O
of	POS	O
deglutition	POS	O
and	POS	O
confirm	POS	O
that	POS	O
dysphagia	POS	B-NP
is	POS	O
not	POS	O
a	POS	O
good	POS	O
predictor	POS	O
of	POS	O
deglutition	POS	O
alterations	POS	O
in	POS	O
PD	POS	B-NP
.	POS	O
Inhibition	POS	O
of	POS	O
nuclear	POS	O
factor	POS	O
-	POS	O
kappaB	POS	O
activation	POS	O
attenuates	POS	O
tubulointerstitial	POS	B-NP
nephritis	POS	I-NP
induced	POS	O
by	POS	O
gentamicin	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Animals	POS	O
treated	POS	O
with	POS	O
gentamicin	POS	O
can	POS	O
show	POS	O
residual	POS	O
areas	POS	O
of	POS	O
interstitial	POS	B-NP
fibrosis	POS	I-NP
in	POS	O
the	POS	O
renal	POS	O
cortex	POS	O
.	POS	O
This	POS	O
study	POS	O
investigated	POS	O
the	POS	O
expression	POS	O
of	POS	O
nuclear	POS	O
factor	POS	O
-	POS	O
kappaB	POS	O
(	POS	O
NF	POS	O
-	POS	O
kappaB	POS	O
)	POS	O
,	POS	O
mitogen	POS	O
-	POS	O
activated	POS	O
protein	POS	O
(	POS	O
MAP	POS	O
)	POS	O
kinases	POS	O
and	POS	O
macrophages	POS	O
in	POS	O
the	POS	O
renal	POS	O
cortex	POS	O
and	POS	O
structural	POS	O
and	POS	O
functional	POS	O
renal	POS	O
changes	POS	O
of	POS	O
rats	POS	O
treated	POS	O
with	POS	O
gentamicin	POS	O
or	POS	O
gentamicin	POS	O
+	POS	O
pyrrolidine	POS	O
dithiocarbamate	POS	O
(	POS	O
PDTC	POS	O
)	POS	O
,	POS	O
an	POS	O
NF	POS	O
-	POS	O
kappaB	POS	O
inhibitor	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
38	POS	O
female	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
injected	POS	O
with	POS	O
gentamicin	POS	O
,	POS	O
40	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
twice	POS	O
a	POS	O
day	POS	O
for	POS	O
9	POS	O
days	POS	O
,	POS	O
38	POS	O
with	POS	O
gentamicin	POS	O
+	POS	O
PDTC	POS	O
,	POS	O
and	POS	O
28	POS	O
with	POS	O
0	POS	O
.	POS	O
15	POS	O
M	POS	O
NaCl	POS	O
solution	POS	O
.	POS	O
The	POS	O
animals	POS	O
were	POS	O
killed	POS	O
5	POS	O
and	POS	O
30	POS	O
days	POS	O
after	POS	O
these	POS	O
injections	POS	O
and	POS	O
the	POS	O
kidneys	POS	O
were	POS	O
removed	POS	O
for	POS	O
histological	POS	O
and	POS	O
immunohistochemical	POS	O
studies	POS	O
.	POS	O
The	POS	O
results	POS	O
of	POS	O
the	POS	O
immunohistochemical	POS	O
studies	POS	O
were	POS	O
scored	POS	O
according	POS	O
to	POS	O
the	POS	O
extent	POS	O
of	POS	O
staining	POS	O
.	POS	O
The	POS	O
fractional	POS	O
interstitial	POS	O
area	POS	O
was	POS	O
determined	POS	O
by	POS	O
morphometry	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Gentamicin	POS	O
-	POS	O
treated	POS	O
rats	POS	O
presented	POS	O
a	POS	O
transitory	POS	O
increase	POS	O
in	POS	O
plasma	POS	O
creatinine	POS	O
levels	POS	O
.	POS	O
Increased	POS	O
ED	POS	O
-	POS	O
1	POS	O
,	POS	O
MAP	POS	O
kinases	POS	O
and	POS	O
NF	POS	O
-	POS	O
kappaB	POS	O
staining	POS	O
were	POS	O
also	POS	O
observed	POS	O
in	POS	O
the	POS	O
renal	POS	O
cortex	POS	O
from	POS	O
all	POS	O
gentamicin	POS	O
-	POS	O
treated	POS	O
rats	POS	O
compared	POS	O
to	POS	O
control	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
The	POS	O
animals	POS	O
killed	POS	O
on	POS	O
day	POS	O
30	POS	O
also	POS	O
presented	POS	O
fibrosis	POS	B-NP
in	POS	O
the	POS	O
renal	POS	O
cortex	POS	O
despite	POS	O
the	POS	O
recovery	POS	O
of	POS	O
renal	POS	O
function	POS	O
.	POS	O
Treatment	POS	O
with	POS	O
PDTC	POS	O
reduced	POS	O
the	POS	O
functional	POS	O
and	POS	O
structural	POS	O
changes	POS	O
induced	POS	O
by	POS	O
gentamicin	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
These	POS	O
data	POS	O
show	POS	O
that	POS	O
inhibition	POS	O
of	POS	O
NF	POS	O
-	POS	O
kappaB	POS	O
activation	POS	O
attenuates	POS	O
tubulointerstitial	POS	B-NP
nephritis	POS	I-NP
induced	POS	O
by	POS	O
gentamicin	POS	O
.	POS	O
Glucose	POS	O
metabolism	POS	O
in	POS	O
patients	POS	O
with	POS	O
schizophrenia	POS	B-NP
treated	POS	O
with	POS	O
atypical	POS	O
antipsychotic	POS	O
agents	POS	O
:	POS	O
a	POS	O
frequently	POS	O
sampled	POS	O
intravenous	POS	O
glucose	POS	O
tolerance	POS	O
test	POS	O
and	POS	O
minimal	POS	O
model	POS	O
analysis	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
While	POS	O
the	POS	O
incidence	POS	O
of	POS	O
new	POS	O
-	POS	O
onset	POS	O
diabetes	POS	B-NP
mellitus	POS	I-NP
may	POS	O
be	POS	O
increasing	POS	O
in	POS	O
patients	POS	O
with	POS	O
schizophrenia	POS	B-NP
treated	POS	O
with	POS	O
certain	POS	O
atypical	POS	O
antipsychotic	POS	O
agents	POS	O
,	POS	O
it	POS	O
remains	POS	O
unclear	POS	O
whether	POS	O
atypical	POS	O
agents	POS	O
are	POS	O
directly	POS	O
affecting	POS	O
glucose	POS	O
metabolism	POS	O
or	POS	O
simply	POS	O
increasing	POS	O
known	POS	O
risk	POS	O
factors	POS	O
for	POS	O
diabetes	POS	B-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
study	POS	O
the	POS	O
2	POS	O
drugs	POS	O
most	POS	O
clearly	POS	O
implicated	POS	O
(	POS	O
clozapine	POS	O
and	POS	O
olanzapine	POS	O
)	POS	O
and	POS	O
risperidone	POS	O
using	POS	O
a	POS	O
frequently	POS	O
sampled	POS	O
intravenous	POS	O
glucose	POS	O
tolerance	POS	O
test	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
A	POS	O
cross	POS	O
-	POS	O
sectional	POS	O
design	POS	O
in	POS	O
stable	POS	O
,	POS	O
treated	POS	O
patients	POS	O
with	POS	O
schizophrenia	POS	B-NP
evaluated	POS	O
using	POS	O
a	POS	O
frequently	POS	O
sampled	POS	O
intravenous	POS	O
glucose	POS	O
tolerance	POS	O
test	POS	O
and	POS	O
the	POS	O
Bergman	POS	O
minimal	POS	O
model	POS	O
analysis	POS	O
.	POS	O
SETTING	POS	O
:	POS	O
Subjects	POS	O
were	POS	O
recruited	POS	O
from	POS	O
an	POS	O
urban	POS	O
community	POS	O
mental	POS	O
health	POS	O
clinic	POS	O
and	POS	O
were	POS	O
studied	POS	O
at	POS	O
a	POS	O
general	POS	O
clinical	POS	O
research	POS	O
center	POS	O
.	POS	O
Patients	POS	O
Fifty	POS	O
subjects	POS	O
signed	POS	O
informed	POS	O
consent	POS	O
and	POS	O
41	POS	O
underwent	POS	O
the	POS	O
frequently	POS	O
sampled	POS	O
intravenous	POS	O
glucose	POS	O
tolerance	POS	O
test	POS	O
.	POS	O
Thirty	POS	O
-	POS	O
six	POS	O
nonobese	POS	O
subjects	POS	O
with	POS	O
schizophrenia	POS	B-NP
or	POS	O
schizoaffective	POS	B-NP
disorder	POS	I-NP
,	POS	O
matched	POS	O
by	POS	O
body	POS	O
mass	POS	O
index	POS	O
and	POS	O
treated	POS	O
with	POS	O
either	POS	O
clozapine	POS	O
,	POS	O
olanzapine	POS	O
,	POS	O
or	POS	O
risperidone	POS	O
,	POS	O
were	POS	O
included	POS	O
in	POS	O
the	POS	O
analysis	POS	O
.	POS	O
MAIN	POS	O
OUTCOME	POS	O
MEASURES	POS	O
:	POS	O
Fasting	POS	O
plasma	POS	O
glucose	POS	O
and	POS	O
fasting	POS	O
serum	POS	O
insulin	POS	O
levels	POS	O
,	POS	O
insulin	POS	O
sensitivity	POS	O
index	POS	O
,	POS	O
homeostasis	POS	O
model	POS	O
assessment	POS	O
of	POS	O
insulin	POS	B-NP
resistance	POS	I-NP
,	POS	O
and	POS	O
glucose	POS	O
effectiveness	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
mean	POS	O
+	POS	O
/	POS	O
-	POS	O
SD	POS	O
duration	POS	O
of	POS	O
treatment	POS	O
with	POS	O
the	POS	O
identified	POS	O
atypical	POS	O
antipsychotic	POS	O
agent	POS	O
was	POS	O
68	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
28	POS	O
.	POS	O
9	POS	O
months	POS	O
(	POS	O
clozapine	POS	O
)	POS	O
,	POS	O
29	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
17	POS	O
.	POS	O
5	POS	O
months	POS	O
(	POS	O
olanzapine	POS	O
)	POS	O
,	POS	O
and	POS	O
40	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
33	POS	O
.	POS	O
7	POS	O
(	POS	O
risperidone	POS	O
)	POS	O
.	POS	O
Fasting	POS	O
serum	POS	O
insulin	POS	O
concentrations	POS	O
differed	POS	O
among	POS	O
groups	POS	O
(	POS	O
F	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
3	POS	O
.	POS	O
35	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
047	POS	O
)	POS	O
(	POS	O
clozapine	POS	O
>	POS	O
olanzapine	POS	O
>	POS	O
risperidone	POS	O
)	POS	O
with	POS	O
significant	POS	O
differences	POS	O
between	POS	O
clozapine	POS	O
and	POS	O
risperidone	POS	O
(	POS	O
t	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
2	POS	O
.	POS	O
32	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
03	POS	O
)	POS	O
and	POS	O
olanzapine	POS	O
and	POS	O
risperidone	POS	O
(	POS	O
t	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
2	POS	O
.	POS	O
15	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
04	POS	O
)	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
significant	POS	O
difference	POS	O
in	POS	O
insulin	POS	O
sensitivity	POS	O
index	POS	O
among	POS	O
groups	POS	O
(	POS	O
F	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
10	POS	O
.	POS	O
66	POS	O
;	POS	O
P	POS	O
<	POS	O
.	POS	O
001	POS	O
)	POS	O
(	POS	O
clozapine	POS	O
<	POS	O
olanzapine	POS	O
<	POS	O
risperidone	POS	O
)	POS	O
,	POS	O
with	POS	O
subjects	POS	O
who	POS	O
received	POS	O
clozapine	POS	O
and	POS	O
olanzapine	POS	O
exhibiting	POS	O
significant	POS	O
insulin	POS	B-NP
resistance	POS	I-NP
compared	POS	O
with	POS	O
subjects	POS	O
who	POS	O
were	POS	O
treated	POS	O
with	POS	O
risperidone	POS	O
(	POS	O
clozapine	POS	O
vs	POS	O
risperidone	POS	O
,	POS	O
t	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
-	POS	O
4	POS	O
.	POS	O
29	POS	O
;	POS	O
P	POS	O
<	POS	O
.	POS	O
001	POS	O
;	POS	O
olanzapine	POS	O
vs	POS	O
risperidone	POS	O
,	POS	O
t	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
-	POS	O
3	POS	O
.	POS	O
62	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
001	POS	O
[	POS	O
P	POS	O
<	POS	O
.	POS	O
001	POS	O
]	POS	O
)	POS	O
.	POS	O
The	POS	O
homeostasis	POS	O
model	POS	O
assessment	POS	O
of	POS	O
insulin	POS	O
resistance	POS	O
also	POS	O
differed	POS	O
significantly	POS	O
among	POS	O
groups	POS	O
(	POS	O
F	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
4	POS	O
.	POS	O
92	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
01	POS	O
)	POS	O
(	POS	O
clozapine	POS	O
>	POS	O
olanzapine	POS	O
>	POS	O
risperidone	POS	O
)	POS	O
(	POS	O
clozapine	POS	O
vs	POS	O
risperidone	POS	O
,	POS	O
t	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
2	POS	O
.	POS	O
94	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
006	POS	O
;	POS	O
olanzapine	POS	O
vs	POS	O
risperidone	POS	O
,	POS	O
t	POS	O
(	POS	O
33	POS	O
)	POS	O
=	POS	O
2	POS	O
.	POS	O
42	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
02	POS	O
)	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
significant	POS	O
difference	POS	O
among	POS	O
groups	POS	O
in	POS	O
glucose	POS	O
effectiveness	POS	O
(	POS	O
F	POS	O
(	POS	O
30	POS	O
)	POS	O
=	POS	O
4	POS	O
.	POS	O
18	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
02	POS	O
)	POS	O
(	POS	O
clozapine	POS	O
<	POS	O
olanzapine	POS	O
<	POS	O
risperidone	POS	O
)	POS	O
with	POS	O
significant	POS	O
differences	POS	O
between	POS	O
clozapine	POS	O
and	POS	O
risperidone	POS	O
(	POS	O
t	POS	O
(	POS	O
30	POS	O
)	POS	O
=	POS	O
-	POS	O
2	POS	O
.	POS	O
59	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
02	POS	O
)	POS	O
and	POS	O
olanzapine	POS	O
and	POS	O
risperidone	POS	O
(	POS	O
t	POS	O
(	POS	O
30	POS	O
)	POS	O
=	POS	O
-	POS	O
2	POS	O
.	POS	O
34	POS	O
,	POS	O
P	POS	O
=	POS	O
.	POS	O
03	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Both	POS	O
nonobese	POS	O
clozapine	POS	O
-	POS	O
and	POS	O
olanzapine	POS	O
-	POS	O
treated	POS	O
groups	POS	O
displayed	POS	O
significant	POS	O
insulin	POS	B-NP
resistance	POS	I-NP
and	POS	O
impairment	POS	O
of	POS	O
glucose	POS	O
effectiveness	POS	O
compared	POS	O
with	POS	O
risperidone	POS	O
-	POS	O
treated	POS	O
subjects	POS	O
.	POS	O
Patients	POS	O
taking	POS	O
clozapine	POS	O
and	POS	O
olanzapine	POS	O
must	POS	O
be	POS	O
examined	POS	O
for	POS	O
insulin	POS	B-NP
resistance	POS	I-NP
and	POS	O
its	POS	O
consequences	POS	O
.	POS	O
Thoracic	POS	B-NP
hematomyelia	POS	I-NP
secondary	POS	O
to	POS	O
coumadin	POS	O
anticoagulant	POS	O
therapy	POS	O
:	POS	O
a	POS	O
case	POS	O
report	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
thoracic	POS	B-NP
hematomyelia	POS	I-NP
secondary	POS	O
to	POS	O
anticoagulant	POS	O
therapy	POS	O
is	POS	O
presented	POS	O
.	POS	O
Clinical	POS	O
features	POS	O
,	POS	O
similar	POS	O
to	POS	O
2	POS	O
other	POS	O
previously	POS	O
reported	POS	O
cases	POS	O
,	POS	O
are	POS	O
discussed	POS	O
.	POS	O
A	POS	O
high	POS	O
index	POS	O
of	POS	O
suspicion	POS	O
may	POS	O
lead	POS	O
to	POS	O
a	POS	O
quick	POS	O
diagnostic	POS	O
procedure	POS	O
and	POS	O
successful	POS	O
decompressive	POS	O
surgery	POS	O
.	POS	O
Mania	POS	B-NP
associated	POS	O
with	POS	O
fluoxetine	POS	O
treatment	POS	O
in	POS	O
adolescents	POS	O
.	POS	O
Fluoxetine	POS	O
,	POS	O
a	POS	O
selective	POS	O
serotonin	POS	O
reuptake	POS	O
inhibitor	POS	O
,	POS	O
is	POS	O
gaining	POS	O
increased	POS	O
acceptance	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
adolescent	POS	B-NP
depression	POS	I-NP
.	POS	O
Generally	POS	O
safe	POS	O
and	POS	O
well	POS	O
tolerated	POS	O
by	POS	O
adults	POS	O
,	POS	O
fluoxetine	POS	O
has	POS	O
been	POS	O
reported	POS	O
to	POS	O
induce	POS	O
mania	POS	B-NP
.	POS	O
The	POS	O
cases	POS	O
of	POS	O
five	POS	O
depressed	POS	B-NP
adolescents	POS	O
,	POS	O
14	POS	O
-	POS	O
16	POS	O
years	POS	O
of	POS	O
age	POS	O
,	POS	O
who	POS	O
developed	POS	O
mania	POS	B-NP
during	POS	O
pharmacotherapy	POS	O
with	POS	O
fluoxetine	POS	O
,	POS	O
are	POS	O
reported	POS	O
here	POS	O
.	POS	O
Apparent	POS	O
risk	POS	O
factors	POS	O
for	POS	O
the	POS	O
development	POS	O
of	POS	O
mania	POS	B-NP
or	POS	O
hypomania	POS	B-NP
during	POS	O
fluoxetine	POS	O
pharmacotherapy	POS	O
in	POS	O
this	POS	O
population	POS	O
were	POS	O
the	POS	O
combination	POS	O
of	POS	O
attention	POS	B-NP
-	POS	I-NP
deficit	POS	I-NP
hyperactivity	POS	I-NP
disorder	POS	I-NP
and	POS	O
affective	POS	B-NP
instability	POS	I-NP
;	POS	O
major	POS	B-NP
depression	POS	I-NP
with	POS	O
psychotic	POS	B-NP
features	POS	O
;	POS	O
a	POS	O
family	POS	O
history	POS	O
of	POS	O
affective	POS	B-NP
disorder	POS	I-NP
,	POS	O
especially	POS	O
bipolar	POS	B-NP
disorder	POS	I-NP
;	POS	O
and	POS	O
a	POS	O
diagnosis	POS	O
of	POS	O
bipolar	POS	B-NP
disorder	POS	I-NP
.	POS	O
Further	POS	O
study	POS	O
is	POS	O
needed	POS	O
to	POS	O
determine	POS	O
the	POS	O
optimal	POS	O
dosage	POS	O
and	POS	O
to	POS	O
identify	POS	O
risk	POS	O
factors	POS	O
that	POS	O
increase	POS	O
individual	POS	O
vulnerability	POS	O
to	POS	O
fluoxetine	POS	O
induced	POS	O
mania	POS	B-NP
in	POS	O
adolescents	POS	O
.	POS	O
Acute	POS	B-NP
renal	POS	I-NP
insufficiency	POS	I-NP
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
melphalan	POS	O
in	POS	O
patients	POS	O
with	POS	O
primary	POS	O
systemic	POS	B-NP
amyloidosis	POS	I-NP
during	POS	O
stem	POS	O
cell	POS	O
transplantation	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Patients	POS	O
with	POS	O
primary	POS	O
systemic	POS	B-NP
amyloidosis	POS	I-NP
(	POS	O
AL	POS	O
)	POS	O
have	POS	O
a	POS	O
poor	POS	O
prognosis	POS	O
.	POS	O
Median	POS	O
survival	POS	O
time	POS	O
from	POS	O
standard	POS	O
treatments	POS	O
is	POS	O
only	POS	O
17	POS	O
months	POS	O
.	POS	O
High	POS	O
-	POS	O
dose	POS	O
intravenous	POS	O
melphalan	POS	O
followed	POS	O
by	POS	O
peripheral	POS	O
blood	POS	O
stem	POS	O
cell	POS	O
transplant	POS	O
(	POS	O
PBSCT	POS	O
)	POS	O
appears	POS	O
to	POS	O
be	POS	O
the	POS	O
most	POS	O
promising	POS	O
therapy	POS	O
,	POS	O
but	POS	O
treatment	POS	O
mortality	POS	O
can	POS	O
be	POS	O
high	POS	O
.	POS	O
The	POS	O
authors	POS	O
have	POS	O
noted	POS	O
the	POS	O
development	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
insufficiency	POS	I-NP
immediately	POS	O
after	POS	O
melphalan	POS	O
conditioning	POS	O
.	POS	O
This	POS	O
study	POS	O
was	POS	O
undertaken	POS	O
to	POS	O
further	POS	O
examine	POS	O
its	POS	O
risk	POS	O
factors	POS	O
and	POS	O
impact	POS	O
on	POS	O
posttransplant	POS	O
mortality	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Consecutive	POS	O
AL	POS	O
patients	POS	O
who	POS	O
underwent	POS	O
PBSCT	POS	O
were	POS	O
studied	POS	O
retrospectively	POS	O
.	POS	O
Acute	POS	B-NP
renal	POS	I-NP
insufficiency	POS	I-NP
(	POS	O
ARI	POS	B-NP
)	POS	O
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
melphalan	POS	O
was	POS	O
defined	POS	O
by	POS	O
a	POS	O
minimum	POS	O
increase	POS	O
of	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
dL	POS	O
(	POS	O
44	POS	O
micromol	POS	O
/	POS	O
L	POS	O
)	POS	O
in	POS	O
the	POS	O
serum	POS	O
creatinine	POS	O
level	POS	O
that	POS	O
is	POS	O
greater	POS	O
than	POS	O
50	POS	O
%	POS	O
of	POS	O
baseline	POS	O
immediately	POS	O
after	POS	O
conditioning	POS	O
.	POS	O
Urine	POS	O
sediment	POS	O
score	POS	O
was	POS	O
the	POS	O
sum	POS	O
of	POS	O
the	POS	O
individual	POS	O
types	POS	O
of	POS	O
sediment	POS	O
identified	POS	O
on	POS	O
urine	POS	O
microscopy	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Of	POS	O
the	POS	O
80	POS	O
patients	POS	O
studied	POS	O
,	POS	O
ARI	POS	B-NP
developed	POS	O
in	POS	O
18	POS	O
.	POS	O
8	POS	O
%	POS	O
of	POS	O
the	POS	O
patients	POS	O
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
melphalan	POS	O
.	POS	O
Univariate	POS	O
analysis	POS	O
identified	POS	O
age	POS	O
,	POS	O
hypoalbuminemia	POS	B-NP
,	POS	O
heavy	POS	O
proteinuria	POS	B-NP
,	POS	O
diuretic	POS	O
use	POS	O
,	POS	O
and	POS	O
urine	POS	O
sediment	POS	O
score	POS	O
(	POS	O
>	POS	O
3	POS	O
)	POS	O
as	POS	O
risk	POS	O
factors	POS	O
.	POS	O
Age	POS	O
and	POS	O
urine	POS	O
sediment	POS	O
score	POS	O
remained	POS	O
independently	POS	O
significant	POS	O
risk	POS	O
factors	POS	O
in	POS	O
the	POS	O
multivariate	POS	O
analysis	POS	O
.	POS	O
Patients	POS	O
who	POS	O
had	POS	O
ARI	POS	B-NP
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
melphalan	POS	O
underwent	POS	O
dialysis	POS	O
more	POS	O
often	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
007	POS	O
)	POS	O
,	POS	O
and	POS	O
had	POS	O
a	POS	O
worse	POS	O
1	POS	O
-	POS	O
year	POS	O
survival	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
03	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
timing	POS	O
of	POS	O
renal	POS	B-NP
injury	POS	I-NP
strongly	POS	O
suggests	POS	O
melphalan	POS	O
as	POS	O
the	POS	O
causative	POS	O
agent	POS	O
.	POS	O
Ongoing	POS	O
tubular	POS	B-NP
injury	POS	I-NP
may	POS	O
be	POS	O
a	POS	O
prerequisite	POS	O
for	POS	O
renal	POS	B-NP
injury	POS	I-NP
by	POS	O
melphalan	POS	O
as	POS	O
evidenced	POS	O
by	POS	O
the	POS	O
active	POS	O
urinary	POS	O
sediment	POS	O
.	POS	O
Development	POS	O
of	POS	O
ARI	POS	O
adversely	POS	O
affected	POS	O
the	POS	O
outcome	POS	O
after	POS	O
PBSCT	POS	O
.	POS	O
Effective	POS	O
preventive	POS	O
measures	POS	O
may	POS	O
help	POS	O
decrease	POS	O
the	POS	O
treatment	POS	O
mortality	POS	O
of	POS	O
PBSCT	POS	O
in	POS	O
AL	POS	O
patients	POS	O
.	POS	O
Focal	POS	B-NP
cerebral	POS	I-NP
ischemia	POS	I-NP
in	POS	O
rats	POS	O
:	POS	O
effect	POS	O
of	POS	O
phenylephrine	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
during	POS	O
reperfusion	POS	O
.	POS	O
After	POS	O
180	POS	O
min	POS	O
of	POS	O
temporary	POS	O
middle	POS	O
cerebral	POS	B-NP
artery	POS	I-NP
occlusion	POS	I-NP
in	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
rats	POS	O
,	POS	O
the	POS	O
effect	POS	O
of	POS	O
phenylephrine	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
on	POS	O
ischemic	POS	B-NP
brain	POS	I-NP
injury	POS	I-NP
and	POS	O
blood	POS	O
-	POS	O
brain	POS	O
barrier	POS	O
permeability	POS	O
was	POS	O
determined	POS	O
.	POS	O
Blood	POS	O
pressure	POS	O
was	POS	O
manipulated	POS	O
by	POS	O
one	POS	O
of	POS	O
the	POS	O
following	POS	O
schedules	POS	O
during	POS	O
120	POS	O
min	POS	O
of	POS	O
reperfusion	POS	O
:	POS	O
Control	POS	O
,	POS	O
normotensive	POS	O
reperfusion	POS	O
;	POS	O
90	POS	O
/	POS	O
hypertension	POS	B-NP
(	POS	O
90	POS	O
/	POS	O
HTN	POS	O
)	POS	O
,	POS	O
blood	POS	O
pressure	POS	O
was	POS	O
increased	POS	O
by	POS	O
35	POS	O
mm	POS	O
Hg	POS	O
during	POS	O
the	POS	O
initial	POS	O
90	POS	O
min	POS	O
of	POS	O
reperfusion	POS	O
only	POS	O
;	POS	O
15	POS	O
/	POS	O
hypertension	POS	B-NP
(	POS	O
15	POS	O
/	POS	O
HTN	POS	O
)	POS	O
,	POS	O
normotensive	POS	O
reperfusion	POS	O
for	POS	O
30	POS	O
min	POS	O
followed	POS	O
by	POS	O
15	POS	O
min	POS	O
of	POS	O
hypertension	POS	B-NP
and	POS	O
75	POS	O
min	POS	O
of	POS	O
normotension	POS	O
.	POS	O
Part	POS	O
A	POS	O
,	POS	O
for	POS	O
eight	POS	O
rats	POS	O
in	POS	O
each	POS	O
group	POS	O
brain	POS	B-NP
injury	POS	I-NP
was	POS	O
evaluated	POS	O
by	POS	O
staining	POS	O
tissue	POS	O
using	POS	O
2	POS	O
,	POS	O
3	POS	O
,	POS	O
5	POS	O
-	POS	O
triphenyltetrazolium	POS	O
chloride	POS	O
and	POS	O
edema	POS	B-NP
was	POS	O
evaluated	POS	O
by	POS	O
microgravimetry	POS	O
.	POS	O
Part	POS	O
B	POS	O
,	POS	O
for	POS	O
eight	POS	O
different	POS	O
rats	POS	O
in	POS	O
each	POS	O
group	POS	O
blood	POS	O
-	POS	O
brain	POS	O
barrier	POS	O
permeability	POS	O
was	POS	O
evaluated	POS	O
by	POS	O
measuring	POS	O
the	POS	O
amount	POS	O
and	POS	O
extent	POS	O
of	POS	O
extravasation	POS	O
of	POS	O
Evans	POS	O
Blue	POS	O
dye	POS	O
.	POS	O
Brain	POS	O
injury	POS	O
(	POS	O
percentage	POS	O
of	POS	O
the	POS	O
ischemic	POS	O
hemisphere	POS	O
)	POS	O
was	POS	O
less	POS	O
in	POS	O
the	POS	O
15	POS	O
/	POS	O
HTN	POS	O
group	POS	O
(	POS	O
16	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
,	POS	O
mean	POS	O
+	POS	O
/	POS	O
-	POS	O
SD	POS	O
)	POS	O
versus	POS	O
the	POS	O
90	POS	O
/	POS	O
HTN	POS	O
group	POS	O
(	POS	O
30	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
)	POS	O
,	POS	O
which	POS	O
was	POS	O
in	POS	O
turn	POS	O
less	POS	O
than	POS	O
the	POS	O
control	POS	O
group	POS	O
(	POS	O
42	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
)	POS	O
.	POS	O
Specific	POS	O
gravity	POS	O
was	POS	O
greater	POS	O
in	POS	O
the	POS	O
15	POS	O
/	POS	O
HTN	POS	O
group	POS	O
(	POS	O
1	POS	O
.	POS	O
043	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
002	POS	O
)	POS	O
versus	POS	O
the	POS	O
90	POS	O
/	POS	O
HTN	POS	O
(	POS	O
1	POS	O
.	POS	O
036	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
003	POS	O
)	POS	O
and	POS	O
control	POS	O
(	POS	O
1	POS	O
.	POS	O
037	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
003	POS	O
)	POS	O
groups	POS	O
.	POS	O
Evans	POS	O
Blue	POS	O
(	POS	O
mug	POS	O
g	POS	O
-	POS	O
1	POS	O
of	POS	O
brain	POS	O
tissue	POS	O
)	POS	O
was	POS	O
greater	POS	O
in	POS	O
the	POS	O
90	POS	O
/	POS	O
HTN	POS	O
group	POS	O
(	POS	O
24	POS	O
.	POS	O
4	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
.	POS	O
0	POS	O
)	POS	O
versus	POS	O
the	POS	O
control	POS	O
group	POS	O
(	POS	O
12	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
.	POS	O
1	POS	O
)	POS	O
,	POS	O
which	POS	O
was	POS	O
in	POS	O
turn	POS	O
greater	POS	O
than	POS	O
the	POS	O
15	POS	O
/	POS	O
HTN	POS	O
group	POS	O
(	POS	O
7	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
.	POS	O
2	POS	O
)	POS	O
.	POS	O
This	POS	O
study	POS	O
supports	POS	O
a	POS	O
hypothesis	POS	O
that	POS	O
during	POS	O
reperfusion	POS	O
,	POS	O
a	POS	O
short	POS	O
interval	POS	O
of	POS	O
hypertension	POS	B-NP
decreases	POS	O
brain	POS	B-NP
injury	POS	I-NP
and	POS	O
edema	POS	B-NP
;	POS	O
and	POS	O
that	POS	O
sustained	POS	O
hypertension	POS	B-NP
increases	POS	O
the	POS	O
risk	POS	O
of	POS	O
vasogenic	POS	B-NP
edema	POS	I-NP
.	POS	O
People	POS	O
aged	POS	O
over	POS	O
75	POS	O
in	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
on	POS	O
warfarin	POS	O
:	POS	O
the	POS	O
rate	POS	O
of	POS	O
major	POS	O
hemorrhage	POS	B-NP
and	POS	O
stroke	POS	B-NP
in	POS	O
more	POS	O
than	POS	O
500	POS	O
patient	POS	O
-	POS	O
years	POS	O
of	POS	O
follow	POS	O
-	POS	O
up	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
To	POS	O
determine	POS	O
the	POS	O
incidence	POS	O
of	POS	O
major	POS	O
hemorrhage	POS	B-NP
and	POS	O
stroke	POS	B-NP
in	POS	O
people	POS	O
aged	POS	O
76	POS	O
and	POS	O
older	POS	O
with	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
on	POS	O
adjusted	POS	O
-	POS	O
dose	POS	O
warfarin	POS	O
who	POS	O
had	POS	O
been	POS	O
recently	POS	O
been	POS	O
admitted	POS	O
to	POS	O
hospital	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
A	POS	O
retrospective	POS	O
observational	POS	O
cohort	POS	O
study	POS	O
.	POS	O
SETTING	POS	O
:	POS	O
A	POS	O
major	POS	O
healthcare	POS	O
network	POS	O
involving	POS	O
four	POS	O
tertiary	POS	O
hospitals	POS	O
.	POS	O
PARTICIPANTS	POS	O
:	POS	O
Two	POS	O
hundred	POS	O
thirty	POS	O
-	POS	O
five	POS	O
patients	POS	O
aged	POS	O
76	POS	O
and	POS	O
older	POS	O
admitted	POS	O
to	POS	O
a	POS	O
major	POS	O
healthcare	POS	O
network	POS	O
between	POS	O
July	POS	O
1	POS	O
,	POS	O
2001	POS	O
,	POS	O
and	POS	O
June	POS	O
30	POS	O
,	POS	O
2002	POS	O
,	POS	O
with	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
on	POS	O
warfarin	POS	O
were	POS	O
enrolled	POS	O
.	POS	O
MEASUREMENTS	POS	O
:	POS	O
Information	POS	O
regarding	POS	O
major	POS	O
bleeding	POS	B-NP
episodes	POS	O
,	POS	O
strokes	POS	B-NP
,	POS	O
and	POS	O
warfarin	POS	O
use	POS	O
was	POS	O
obtained	POS	O
from	POS	O
patients	POS	O
,	POS	O
relatives	POS	O
,	POS	O
primary	POS	O
physicians	POS	O
,	POS	O
and	POS	O
medical	POS	O
records	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Two	POS	O
hundred	POS	O
twenty	POS	O
-	POS	O
eight	POS	O
patients	POS	O
(	POS	O
42	POS	O
%	POS	O
men	POS	O
)	POS	O
with	POS	O
a	POS	O
mean	POS	O
age	POS	O
of	POS	O
81	POS	O
.	POS	O
1	POS	O
(	POS	O
range	POS	O
76	POS	O
-	POS	O
94	POS	O
)	POS	O
were	POS	O
included	POS	O
in	POS	O
the	POS	O
analysis	POS	O
.	POS	O
Total	POS	O
follow	POS	O
-	POS	O
up	POS	O
on	POS	O
warfarin	POS	O
was	POS	O
530	POS	O
years	POS	O
(	POS	O
mean	POS	O
28	POS	O
months	POS	O
)	POS	O
.	POS	O
There	POS	O
were	POS	O
53	POS	O
major	POS	O
hemorrhages	POS	B-NP
,	POS	O
for	POS	O
an	POS	O
annual	POS	O
rate	POS	O
of	POS	O
10	POS	O
.	POS	O
0	POS	O
%	POS	O
,	POS	O
including	POS	O
24	POS	O
(	POS	O
45	POS	O
.	POS	O
3	POS	O
%	POS	O
)	POS	O
life	POS	O
-	POS	O
threatening	POS	O
and	POS	O
five	POS	O
(	POS	O
9	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
fatal	POS	O
bleeds	POS	B-NP
.	POS	O
The	POS	O
annual	POS	O
stroke	POS	B-NP
rate	POS	O
after	POS	O
initiation	POS	O
of	POS	O
warfarin	POS	O
was	POS	O
2	POS	O
.	POS	O
6	POS	O
%	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
rate	POS	O
of	POS	O
major	POS	O
hemorrhage	POS	B-NP
was	POS	O
high	POS	O
in	POS	O
this	POS	O
old	POS	O
,	POS	O
frail	POS	O
group	POS	O
,	POS	O
but	POS	O
excluding	POS	O
fatalities	POS	B-NP
,	POS	O
resulted	POS	O
in	POS	O
no	POS	O
long	POS	O
-	POS	O
term	POS	O
sequelae	POS	O
,	POS	O
and	POS	O
the	POS	O
stroke	POS	B-NP
rate	POS	O
on	POS	O
warfarin	POS	O
was	POS	O
low	POS	O
,	POS	O
demonstrating	POS	O
how	POS	O
effective	POS	O
warfarin	POS	O
treatment	POS	O
is	POS	O
.	POS	O
Safety	POS	O
of	POS	O
celecoxib	POS	O
in	POS	O
patients	POS	O
with	POS	O
adverse	POS	O
skin	POS	O
reactions	POS	O
to	POS	O
acetaminophen	POS	O
(	POS	O
paracetamol	POS	O
)	POS	O
and	POS	O
nimesulide	POS	O
associated	POS	O
or	POS	O
not	POS	O
with	POS	O
common	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Acetaminophen	POS	O
(	POS	O
paracetamol	POS	O
-	POS	O
-	POS	O
P	POS	O
)	POS	O
and	POS	O
Nimesulide	POS	O
(	POS	O
N	POS	O
)	POS	O
are	POS	O
widely	POS	O
used	POS	O
analgesic	POS	O
-	POS	O
antipyretic	POS	O
/	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
.	POS	O
The	POS	O
rate	POS	O
of	POS	O
adverse	POS	O
hypersensitivity	POS	B-NP
reactions	POS	O
to	POS	O
these	POS	O
agents	POS	O
is	POS	O
generally	POS	O
low	POS	O
.	POS	O
On	POS	O
the	POS	O
contrary	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
(	POS	O
NSAIDs	POS	O
)	POS	O
are	POS	O
commonly	POS	O
involved	POS	O
in	POS	O
such	POS	O
reactions	POS	O
.	POS	O
Celecoxib	POS	O
(	POS	O
CE	POS	O
)	POS	O
is	POS	O
a	POS	O
novel	POS	O
drug	POS	O
,	POS	O
with	POS	O
high	POS	O
selectivity	POS	O
and	POS	O
affinity	POS	O
for	POS	O
COX	POS	O
-	POS	O
2	POS	O
enzyme	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
We	POS	O
evaluated	POS	O
the	POS	O
tolerability	POS	O
of	POS	O
CE	POS	O
in	POS	O
a	POS	O
group	POS	O
of	POS	O
patients	POS	O
with	POS	O
documented	POS	O
history	POS	O
of	POS	O
adverse	POS	O
cutaneous	POS	O
reactions	POS	O
to	POS	O
P	POS	O
and	POS	O
N	POS	O
associated	POS	O
or	POS	O
not	POS	O
to	POS	O
classic	POS	O
NSAIDs	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
studied	POS	O
9	POS	O
patients	POS	O
with	POS	O
hypersensitivity	POS	B-NP
to	POS	O
P	POS	O
and	POS	O
N	POS	O
with	POS	O
or	POS	O
without	POS	O
associated	POS	O
reactions	POS	O
to	POS	O
classic	POS	O
NSAIDs	POS	O
.	POS	O
The	POS	O
diagnosis	POS	O
of	POS	O
P	POS	O
and	POS	O
N	POS	O
-	POS	O
induced	POS	O
skin	POS	O
reactions	POS	O
was	POS	O
based	POS	O
in	POS	O
vivo	POS	O
challenge	POS	O
.	POS	O
The	POS	O
placebo	POS	O
was	POS	O
blindly	POS	O
administered	POS	O
at	POS	O
the	POS	O
beginning	POS	O
of	POS	O
each	POS	O
challenge	POS	O
.	POS	O
After	POS	O
three	POS	O
days	POS	O
,	POS	O
a	POS	O
cumulative	POS	O
dosage	POS	O
of	POS	O
200	POS	O
mg	POS	O
of	POS	O
CE	POS	O
in	POS	O
refracted	POS	O
doses	POS	O
were	POS	O
given	POS	O
.	POS	O
After	POS	O
2	POS	O
-	POS	O
3	POS	O
days	POS	O
,	POS	O
a	POS	O
single	POS	O
dose	POS	O
of	POS	O
200	POS	O
mg	POS	O
was	POS	O
administered	POS	O
.	POS	O
All	POS	O
patients	POS	O
were	POS	O
observed	POS	O
for	POS	O
6	POS	O
hours	POS	O
after	POS	O
each	POS	O
challenge	POS	O
,	POS	O
and	POS	O
controlled	POS	O
again	POS	O
after	POS	O
24	POS	O
hours	POS	O
to	POS	O
exclude	POS	O
delayed	POS	O
reactions	POS	O
.	POS	O
The	POS	O
challenge	POS	O
was	POS	O
considered	POS	O
positive	POS	O
if	POS	O
one	POS	O
or	POS	O
more	POS	O
of	POS	O
the	POS	O
following	POS	O
appeared	POS	O
:	POS	O
erythema	POS	B-NP
,	POS	O
rush	POS	B-NP
or	POS	O
urticaria	POS	B-NP
-	POS	O
angioedema	POS	B-NP
.	POS	O
RESULTS	POS	O
:	POS	O
No	POS	O
reaction	POS	O
was	POS	O
observed	POS	O
with	POS	O
placebo	POS	O
and	POS	O
eight	POS	O
patients	POS	O
(	POS	O
88	POS	O
.	POS	O
8	POS	O
%	POS	O
)	POS	O
tolerated	POS	O
CE	POS	O
.	POS	O
Only	POS	O
one	POS	O
patient	POS	O
developed	POS	O
a	POS	O
moderate	POS	O
angioedema	POS	B-NP
of	POS	I-NP
the	POS	I-NP
lips	POS	I-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
Only	POS	O
one	POS	O
hypersensitivity	POS	B-NP
reaction	POS	O
to	POS	O
CE	POS	O
was	POS	O
documented	POS	O
among	POS	O
9	POS	O
P	POS	O
and	POS	O
N	POS	O
-	POS	O
highly	POS	O
NSAIDs	POS	O
intolerant	POS	O
patients	POS	O
.	POS	O
Thus	POS	O
,	POS	O
we	POS	O
conclude	POS	O
that	POS	O
CE	POS	O
is	POS	O
a	POS	O
reasonably	POS	O
safe	POS	O
alternative	POS	O
to	POS	O
be	POS	O
used	POS	O
in	POS	O
subjects	POS	O
who	POS	O
do	POS	O
not	POS	O
tolerate	POS	O
P	POS	O
and	POS	O
N	POS	O
.	POS	O
Case	POS	O
-	POS	O
control	POS	O
study	POS	O
of	POS	O
regular	POS	O
analgesic	POS	O
and	POS	O
nonsteroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
use	POS	O
and	POS	O
end	POS	O
-	POS	O
stage	POS	O
renal	POS	B-NP
disease	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Studies	POS	O
on	POS	O
the	POS	O
association	POS	O
between	POS	O
the	POS	O
long	POS	O
-	POS	O
term	POS	O
use	POS	O
of	POS	O
aspirin	POS	O
and	POS	O
other	POS	O
analgesic	POS	O
and	POS	O
nonsteroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
(	POS	O
NSAIDs	POS	O
)	POS	O
and	POS	O
end	POS	O
-	POS	O
stage	POS	O
renal	POS	B-NP
disease	POS	I-NP
(	POS	O
ESRD	POS	B-NP
)	POS	O
have	POS	O
given	POS	O
conflicting	POS	O
results	POS	O
.	POS	O
In	POS	O
order	POS	O
to	POS	O
examine	POS	O
this	POS	O
association	POS	O
,	POS	O
a	POS	O
case	POS	O
-	POS	O
control	POS	O
study	POS	O
with	POS	O
incident	POS	O
cases	POS	O
of	POS	O
ESRD	POS	B-NP
was	POS	O
carried	POS	O
out	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
The	POS	O
cases	POS	O
were	POS	O
all	POS	O
patients	POS	O
entering	POS	O
the	POS	O
local	POS	O
dialysis	POS	O
program	POS	O
because	POS	O
of	POS	O
ESRD	POS	B-NP
in	POS	O
the	POS	O
study	POS	O
area	POS	O
between	POS	O
June	POS	O
1	POS	O
,	POS	O
1995	POS	O
and	POS	O
November	POS	O
30	POS	O
,	POS	O
1997	POS	O
.	POS	O
They	POS	O
were	POS	O
classified	POS	O
according	POS	O
to	POS	O
the	POS	O
underlying	POS	O
disease	POS	O
,	POS	O
which	POS	O
had	POS	O
presumably	POS	O
led	POS	O
them	POS	O
to	POS	O
ESRD	POS	B-NP
.	POS	O
Controls	POS	O
were	POS	O
patients	POS	O
admitted	POS	O
to	POS	O
the	POS	O
same	POS	O
hospitals	POS	O
from	POS	O
where	POS	O
the	POS	O
cases	POS	O
arose	POS	O
,	POS	O
also	POS	O
matched	POS	O
by	POS	O
age	POS	O
and	POS	O
sex	POS	O
.	POS	O
Odds	POS	O
ratios	POS	O
were	POS	O
calculated	POS	O
using	POS	O
a	POS	O
conditional	POS	O
logistic	POS	O
model	POS	O
,	POS	O
including	POS	O
potential	POS	O
confounding	POS	O
factors	POS	O
,	POS	O
both	POS	O
for	POS	O
the	POS	O
whole	POS	O
study	POS	O
population	POS	O
and	POS	O
for	POS	O
the	POS	O
various	POS	O
underlying	POS	O
diseases	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Five	POS	O
hundred	POS	O
and	POS	O
eighty	POS	O
-	POS	O
three	POS	O
cases	POS	O
and	POS	O
1190	POS	O
controls	POS	O
were	POS	O
included	POS	O
in	POS	O
the	POS	O
analysis	POS	O
.	POS	O
Long	POS	O
-	POS	O
term	POS	O
use	POS	O
of	POS	O
any	POS	O
analgesic	POS	O
was	POS	O
associated	POS	O
with	POS	O
an	POS	O
overall	POS	O
odds	POS	O
ratio	POS	O
of	POS	O
1	POS	O
.	POS	O
22	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
0	POS	O
.	POS	O
89	POS	O
-	POS	O
1	POS	O
.	POS	O
66	POS	O
)	POS	O
.	POS	O
For	POS	O
specific	POS	O
groups	POS	O
of	POS	O
drugs	POS	O
,	POS	O
the	POS	O
risks	POS	O
were	POS	O
1	POS	O
.	POS	O
56	POS	O
(	POS	O
1	POS	O
.	POS	O
05	POS	O
-	POS	O
2	POS	O
.	POS	O
30	POS	O
)	POS	O
for	POS	O
aspirin	POS	O
,	POS	O
1	POS	O
.	POS	O
03	POS	O
(	POS	O
0	POS	O
.	POS	O
60	POS	O
-	POS	O
1	POS	O
.	POS	O
76	POS	O
)	POS	O
for	POS	O
pyrazolones	POS	O
,	POS	O
0	POS	O
.	POS	O
80	POS	O
(	POS	O
0	POS	O
.	POS	O
39	POS	O
-	POS	O
1	POS	O
.	POS	O
63	POS	O
)	POS	O
for	POS	O
paracetamol	POS	O
,	POS	O
and	POS	O
0	POS	O
.	POS	O
94	POS	O
(	POS	O
0	POS	O
.	POS	O
57	POS	O
-	POS	O
1	POS	O
.	POS	O
56	POS	O
)	POS	O
for	POS	O
nonaspirin	POS	O
NSAIDs	POS	O
.	POS	O
The	POS	O
risk	POS	O
of	POS	O
ESRD	POS	B-NP
associated	POS	O
with	POS	O
aspirin	POS	O
was	POS	O
related	POS	O
to	POS	O
the	POS	O
cumulated	POS	O
dose	POS	O
and	POS	O
duration	POS	O
of	POS	O
use	POS	O
,	POS	O
and	POS	O
it	POS	O
was	POS	O
particularly	POS	O
high	POS	O
among	POS	O
the	POS	O
subset	POS	O
of	POS	O
patients	POS	O
with	POS	O
vascular	POS	B-NP
nephropathy	POS	I-NP
as	POS	O
underlying	POS	O
disease	POS	O
[	POS	O
2	POS	O
.	POS	O
35	POS	O
(	POS	O
1	POS	O
.	POS	O
17	POS	O
-	POS	O
4	POS	O
.	POS	O
72	POS	O
)	POS	O
]	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Our	POS	O
data	POS	O
indicate	POS	O
that	POS	O
long	POS	O
-	POS	O
term	POS	O
use	POS	O
of	POS	O
nonaspirin	POS	O
analgesic	POS	O
drugs	POS	O
and	POS	O
NSAIDs	POS	O
is	POS	O
not	POS	O
associated	POS	O
with	POS	O
an	POS	O
increased	POS	O
risk	POS	O
of	POS	O
ESRD	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
the	POS	O
chronic	POS	O
use	POS	O
of	POS	O
aspirin	POS	O
may	POS	O
increase	POS	O
the	POS	O
risk	POS	O
of	POS	O
ESRD	POS	B-NP
.	POS	O
Two	POS	O
cases	POS	O
of	POS	O
amisulpride	POS	O
overdose	POS	B-NP
:	POS	O
a	POS	O
cause	POS	O
for	POS	O
prolonged	POS	O
QT	POS	B-NP
syndrome	POS	I-NP
.	POS	O
Two	POS	O
cases	POS	O
of	POS	O
deliberate	POS	B-NP
self	POS	I-NP
-	POS	I-NP
poisoning	POS	I-NP
with	POS	O
5	POS	O
g	POS	O
and	POS	O
3	POS	O
.	POS	O
6	POS	O
g	POS	O
of	POS	O
amisulpride	POS	O
,	POS	O
respectively	POS	O
,	POS	O
are	POS	O
reported	POS	O
.	POS	O
In	POS	O
both	POS	O
cases	POS	O
,	POS	O
QT	POS	B-NP
prolongation	POS	I-NP
and	POS	O
hypocalcaemia	POS	B-NP
were	POS	O
noted	POS	O
.	POS	O
The	POS	O
QT	POS	O
prolongation	POS	O
appeared	POS	O
to	POS	O
respond	POS	O
to	POS	O
administration	POS	O
of	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
calcium	POS	O
gluconate	POS	O
.	POS	O
Growth	POS	O
-	POS	O
associated	POS	O
protein	POS	O
43	POS	O
expression	POS	O
in	POS	O
hippocampal	POS	O
molecular	POS	O
layer	POS	O
of	POS	O
chronic	POS	O
epileptic	POS	B-NP
rats	POS	O
treated	POS	O
with	POS	O
cycloheximide	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
GAP43	POS	O
has	POS	O
been	POS	O
thought	POS	O
to	POS	O
be	POS	O
linked	POS	O
with	POS	O
mossy	POS	O
fiber	POS	O
sprouting	POS	O
(	POS	O
MFS	POS	B-NP
)	POS	O
in	POS	O
various	POS	O
experimental	POS	O
models	POS	O
of	POS	O
epilepsy	POS	B-NP
.	POS	O
To	POS	O
investigate	POS	O
how	POS	O
GAP43	POS	O
expression	POS	O
(	POS	O
GAP43	POS	O
-	POS	O
ir	POS	O
)	POS	O
correlates	POS	O
with	POS	O
MFS	POS	B-NP
,	POS	O
we	POS	O
assessed	POS	O
the	POS	O
intensity	POS	O
(	POS	O
densitometry	POS	O
)	POS	O
and	POS	O
extension	POS	O
(	POS	O
width	POS	O
)	POS	O
of	POS	O
GAP43	POS	O
-	POS	O
ir	POS	O
in	POS	O
the	POS	O
inner	POS	O
molecular	POS	O
layer	POS	O
of	POS	O
the	POS	O
dentate	POS	O
gyrus	POS	O
(	POS	O
IML	POS	O
)	POS	O
of	POS	O
rats	POS	O
subject	POS	O
to	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
induced	POS	O
by	POS	O
pilocarpine	POS	O
(	POS	O
Pilo	POS	O
)	POS	O
,	POS	O
previously	POS	O
injected	POS	O
or	POS	O
not	POS	O
with	POS	O
cycloheximide	POS	O
(	POS	O
CHX	POS	O
)	POS	O
,	POS	O
which	POS	O
has	POS	O
been	POS	O
shown	POS	O
to	POS	O
inhibit	POS	O
MFS	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
CHX	POS	O
was	POS	O
injected	POS	O
before	POS	O
the	POS	O
Pilo	POS	O
injection	POS	O
in	POS	O
adult	POS	O
Wistar	POS	O
rats	POS	O
.	POS	O
The	POS	O
Pilo	POS	O
group	POS	O
was	POS	O
injected	POS	O
with	POS	O
the	POS	O
same	POS	O
drugs	POS	O
,	POS	O
except	POS	O
for	POS	O
CHX	POS	O
.	POS	O
Animals	POS	O
were	POS	O
killed	POS	O
between	POS	O
30	POS	O
and	POS	O
60	POS	O
days	POS	O
later	POS	O
,	POS	O
and	POS	O
brain	POS	O
sections	POS	O
were	POS	O
processed	POS	O
for	POS	O
GAP43	POS	O
immunohistochemistry	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Densitometry	POS	O
showed	POS	O
no	POS	O
significant	POS	O
difference	POS	O
regarding	POS	O
GAP43	POS	O
-	POS	O
ir	POS	O
in	POS	O
the	POS	O
IML	POS	O
between	POS	O
Pilo	POS	O
,	POS	O
CHX	POS	O
+	POS	O
Pilo	POS	O
,	POS	O
and	POS	O
control	POS	O
groups	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
results	POS	O
of	POS	O
the	POS	O
width	POS	O
of	POS	O
the	POS	O
GAP43	POS	O
-	POS	O
ir	POS	O
band	POS	O
in	POS	O
the	POS	O
IML	POS	O
showed	POS	O
that	POS	O
CHX	POS	O
+	POS	O
Pilo	POS	O
and	POS	O
control	POS	O
animals	POS	O
had	POS	O
a	POS	O
significantly	POS	O
larger	POS	O
band	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
03	POS	O
)	POS	O
as	POS	O
compared	POS	O
with	POS	O
that	POS	O
in	POS	O
the	POS	O
Pilo	POS	O
group	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Our	POS	O
current	POS	O
finding	POS	O
that	POS	O
animals	POS	O
in	POS	O
the	POS	O
CHX	POS	O
+	POS	O
Pilo	POS	O
group	POS	O
have	POS	O
a	POS	O
GAP43	POS	O
-	POS	O
ir	POS	O
band	POS	O
in	POS	O
the	POS	O
IML	POS	O
,	POS	O
similar	POS	O
to	POS	O
that	POS	O
of	POS	O
controls	POS	O
,	POS	O
reinforces	POS	O
prior	POS	O
data	POS	O
on	POS	O
the	POS	O
blockade	POS	O
of	POS	O
MFS	POS	B-NP
in	POS	O
these	POS	O
animals	POS	O
.	POS	O
The	POS	O
change	POS	O
in	POS	O
GAP43	POS	O
-	POS	O
ir	POS	O
present	POS	O
in	POS	O
Pilo	POS	O
-	POS	O
treated	POS	O
animals	POS	O
was	POS	O
a	POS	O
thinning	POS	O
of	POS	O
the	POS	O
band	POS	O
to	POS	O
a	POS	O
very	POS	O
narrow	POS	O
layer	POS	O
just	POS	O
above	POS	O
the	POS	O
granule	POS	O
cell	POS	O
layer	POS	O
that	POS	O
is	POS	O
likely	POS	O
to	POS	O
be	POS	O
associated	POS	O
with	POS	O
the	POS	O
loss	POS	O
of	POS	O
hilar	POS	O
cell	POS	O
projections	POS	O
that	POS	O
express	POS	O
GAP	POS	O
-	POS	O
43	POS	O
.	POS	O
Nicotine	POS	O
antagonizes	POS	O
caffeine	POS	O
-	POS	O
but	POS	O
not	POS	O
pentylenetetrazole	POS	O
-	POS	O
induced	POS	O
anxiogenic	POS	O
effect	POS	O
in	POS	O
mice	POS	O
.	POS	O
RATIONALE	POS	O
:	POS	O
Nicotine	POS	O
and	POS	O
caffeine	POS	O
are	POS	O
widely	POS	O
consumed	POS	O
licit	POS	O
psychoactive	POS	O
drugs	POS	O
worldwide	POS	O
.	POS	O
Epidemiological	POS	O
studies	POS	O
showed	POS	O
that	POS	O
they	POS	O
were	POS	O
generally	POS	O
used	POS	O
concurrently	POS	O
.	POS	O
Although	POS	O
some	POS	O
studies	POS	O
in	POS	O
experimental	POS	O
animals	POS	O
indicate	POS	O
clear	POS	O
pharmacological	POS	O
interactions	POS	O
between	POS	O
them	POS	O
,	POS	O
no	POS	O
studies	POS	O
have	POS	O
shown	POS	O
a	POS	O
specific	POS	O
interaction	POS	O
on	POS	O
anxiety	POS	B-NP
responses	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
The	POS	O
present	POS	O
study	POS	O
investigates	POS	O
the	POS	O
effects	POS	O
of	POS	O
nicotine	POS	O
on	POS	O
anxiety	POS	B-NP
induced	POS	O
by	POS	O
caffeine	POS	O
and	POS	O
another	POS	O
anxiogenic	POS	O
drug	POS	O
,	POS	O
pentylenetetrazole	POS	O
,	POS	O
in	POS	O
mice	POS	O
.	POS	O
The	POS	O
elevated	POS	O
plus	POS	O
-	POS	O
maze	POS	O
(	POS	O
EPM	POS	O
)	POS	O
test	POS	O
was	POS	O
used	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
effects	POS	O
of	POS	O
drugs	POS	O
on	POS	O
anxiety	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Adult	POS	O
male	POS	O
Swiss	POS	O
Webster	POS	O
mice	POS	O
(	POS	O
25	POS	O
-	POS	O
32	POS	O
g	POS	O
)	POS	O
were	POS	O
given	POS	O
nicotine	POS	O
(	POS	O
0	POS	O
.	POS	O
05	POS	O
-	POS	O
0	POS	O
.	POS	O
25	POS	O
mg	POS	O
/	POS	O
kg	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
or	POS	O
saline	POS	O
10	POS	O
min	POS	O
before	POS	O
caffeine	POS	O
(	POS	O
70	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
or	POS	O
pentylenetetrazole	POS	O
(	POS	O
15	POS	O
and	POS	O
30	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
injections	POS	O
.	POS	O
After	POS	O
15	POS	O
min	POS	O
,	POS	O
mice	POS	O
were	POS	O
evaluated	POS	O
for	POS	O
their	POS	O
open	POS	O
-	POS	O
and	POS	O
closed	POS	O
-	POS	O
arm	POS	O
time	POS	O
and	POS	O
entries	POS	O
on	POS	O
the	POS	O
EPM	POS	O
for	POS	O
a	POS	O
10	POS	O
-	POS	O
min	POS	O
session	POS	O
.	POS	O
Locomotor	POS	O
activity	POS	O
was	POS	O
recorded	POS	O
for	POS	O
individual	POS	O
groups	POS	O
by	POS	O
using	POS	O
the	POS	O
same	POS	O
treatment	POS	O
protocol	POS	O
with	POS	O
the	POS	O
EPM	POS	O
test	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Nicotine	POS	O
(	POS	O
0	POS	O
.	POS	O
05	POS	O
-	POS	O
0	POS	O
.	POS	O
25	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
itself	POS	O
did	POS	O
not	POS	O
produce	POS	O
any	POS	O
significant	POS	O
effect	POS	O
in	POS	O
the	POS	O
EPM	POS	O
test	POS	O
,	POS	O
whereas	POS	O
caffeine	POS	O
(	POS	O
70	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
pentylenetetrazole	POS	O
(	POS	O
30	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
produced	POS	O
an	POS	O
anxiogenic	POS	O
effect	POS	O
,	POS	O
apparent	POS	O
with	POS	O
decreases	POS	O
in	POS	O
open	POS	O
-	POS	O
arm	POS	O
time	POS	O
and	POS	O
entry	POS	O
.	POS	O
Nicotine	POS	O
(	POS	O
0	POS	O
.	POS	O
25	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
pretreatment	POS	O
blocked	POS	O
the	POS	O
caffeine	POS	O
-	POS	O
but	POS	O
not	POS	O
pentylenetetrazole	POS	O
-	POS	O
induced	POS	O
anxiety	POS	B-NP
.	POS	O
Administration	POS	O
of	POS	O
each	POS	O
drug	POS	O
and	POS	O
their	POS	O
combinations	POS	O
did	POS	O
not	POS	O
produce	POS	O
any	POS	O
effect	POS	O
on	POS	O
locomotor	POS	O
activity	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Our	POS	O
results	POS	O
suggest	POS	O
that	POS	O
the	POS	O
antagonistic	POS	O
effect	POS	O
of	POS	O
nicotine	POS	O
on	POS	O
caffeine	POS	O
-	POS	O
induced	POS	O
anxiety	POS	B-NP
is	POS	O
specific	POS	O
to	POS	O
caffeine	POS	O
,	POS	O
instead	POS	O
of	POS	O
a	POS	O
non	POS	O
-	POS	O
specific	POS	O
anxiolytic	POS	O
effect	POS	O
.	POS	O
Thus	POS	O
,	POS	O
it	POS	O
may	POS	O
extend	POS	O
the	POS	O
current	POS	O
findings	POS	O
on	POS	O
the	POS	O
interaction	POS	O
between	POS	O
nicotine	POS	O
and	POS	O
caffeine	POS	O
.	POS	O
Long	POS	O
term	POS	O
hormone	POS	O
therapy	POS	O
for	POS	O
perimenopausal	POS	O
and	POS	O
postmenopausal	POS	O
women	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Hormone	POS	O
therapy	POS	O
(	POS	O
HT	POS	O
)	POS	O
is	POS	O
widely	POS	O
used	POS	O
for	POS	O
controlling	POS	O
menopausal	POS	O
symptoms	POS	O
.	POS	O
It	POS	O
has	POS	O
also	POS	O
been	POS	O
used	POS	O
for	POS	O
the	POS	O
management	POS	O
and	POS	O
prevention	POS	O
of	POS	O
cardiovascular	POS	B-NP
disease	POS	I-NP
,	POS	O
osteoporosis	POS	B-NP
and	POS	O
dementia	POS	B-NP
in	POS	O
older	POS	O
women	POS	O
but	POS	O
the	POS	O
evidence	POS	O
supporting	POS	O
its	POS	O
use	POS	O
for	POS	O
these	POS	O
indications	POS	O
is	POS	O
largely	POS	O
observational	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
To	POS	O
assess	POS	O
the	POS	O
effect	POS	O
of	POS	O
long	POS	O
-	POS	O
term	POS	O
HT	POS	O
on	POS	O
mortality	POS	O
,	POS	O
heart	POS	B-NP
disease	POS	I-NP
,	POS	O
venous	POS	B-NP
thromboembolism	POS	I-NP
,	POS	O
stroke	POS	B-NP
,	POS	O
transient	POS	B-NP
ischaemic	POS	I-NP
attacks	POS	I-NP
,	POS	O
breast	POS	B-NP
cancer	POS	I-NP
,	POS	O
colorectal	POS	B-NP
cancer	POS	I-NP
,	POS	O
ovarian	POS	B-NP
cancer	POS	I-NP
,	POS	O
endometrial	POS	B-NP
cancer	POS	I-NP
,	POS	O
gallbladder	POS	B-NP
disease	POS	I-NP
,	POS	O
cognitive	POS	B-NP
function	POS	I-NP
,	POS	O
dementia	POS	B-NP
,	POS	O
fractures	POS	B-NP
and	POS	O
quality	POS	O
of	POS	O
life	POS	O
.	POS	O
SEARCH	POS	O
STRATEGY	POS	O
:	POS	O
We	POS	O
searched	POS	O
the	POS	O
following	POS	O
databases	POS	O
up	POS	O
to	POS	O
November	POS	O
2004	POS	O
:	POS	O
the	POS	O
Cochrane	POS	O
Menstrual	POS	O
Disorders	POS	O
and	POS	O
Subfertility	POS	O
Group	POS	O
Trials	POS	O
Register	POS	O
,	POS	O
Cochrane	POS	O
Central	POS	O
Register	POS	O
of	POS	O
Controlled	POS	O
Trials	POS	O
(	POS	O
CENTRAL	POS	O
)	POS	O
,	POS	O
MEDLINE	POS	O
,	POS	O
EMBASE	POS	O
,	POS	O
Biological	POS	O
Abstracts	POS	O
.	POS	O
Relevant	POS	O
non	POS	O
-	POS	O
indexed	POS	O
journals	POS	O
and	POS	O
conference	POS	O
abstracts	POS	O
were	POS	O
also	POS	O
searched	POS	O
.	POS	O
SELECTION	POS	O
CRITERIA	POS	O
:	POS	O
Randomised	POS	O
double	POS	O
-	POS	O
blind	POS	O
trials	POS	O
of	POS	O
HT	POS	O
(	POS	O
oestrogens	POS	O
with	POS	O
or	POS	O
without	POS	O
progestogens	POS	O
)	POS	O
versus	POS	O
placebo	POS	O
,	POS	O
taken	POS	O
for	POS	O
at	POS	O
least	POS	O
one	POS	O
year	POS	O
by	POS	O
perimenopausal	POS	O
or	POS	O
postmenopausal	POS	O
women	POS	O
.	POS	O
DATA	POS	O
COLLECTION	POS	O
AND	POS	O
ANALYSIS	POS	O
:	POS	O
Fifteen	POS	O
RCTs	POS	O
were	POS	O
included	POS	O
.	POS	O
Trials	POS	O
were	POS	O
assessed	POS	O
for	POS	O
quality	POS	O
and	POS	O
two	POS	O
review	POS	O
authors	POS	O
extracted	POS	O
data	POS	O
independently	POS	O
.	POS	O
They	POS	O
calculated	POS	O
risk	POS	O
ratios	POS	O
for	POS	O
dichotomous	POS	O
outcomes	POS	O
and	POS	O
weighted	POS	O
mean	POS	O
differences	POS	O
for	POS	O
continuous	POS	O
outcomes	POS	O
.	POS	O
Clinical	POS	O
heterogeneity	POS	O
precluded	POS	O
meta	POS	O
-	POS	O
analysis	POS	O
for	POS	O
most	POS	O
outcomes	POS	O
.	POS	O
MAIN	POS	O
RESULTS	POS	O
:	POS	O
All	POS	O
the	POS	O
statistically	POS	O
significant	POS	O
results	POS	O
were	POS	O
derived	POS	O
from	POS	O
the	POS	O
two	POS	O
biggest	POS	O
trials	POS	O
.	POS	O
In	POS	O
relatively	POS	O
healthy	POS	O
women	POS	O
,	POS	O
combined	POS	O
continuous	POS	O
HT	POS	O
significantly	POS	O
increased	POS	O
the	POS	O
risk	POS	O
of	POS	O
venous	POS	B-NP
thromboembolism	POS	I-NP
or	POS	O
coronary	POS	B-NP
event	POS	I-NP
(	POS	O
after	POS	O
one	POS	O
year	POS	O
'	POS	O
s	POS	O
use	POS	O
)	POS	O
,	POS	O
stroke	POS	B-NP
(	POS	O
after	POS	O
3	POS	O
years	POS	O
)	POS	O
,	POS	O
breast	POS	B-NP
cancer	POS	I-NP
(	POS	O
after	POS	O
5	POS	O
years	POS	O
)	POS	O
and	POS	O
gallbladder	POS	B-NP
disease	POS	I-NP
.	POS	O
Long	POS	O
-	POS	O
term	POS	O
oestrogen	POS	O
-	POS	O
only	POS	O
HT	POS	O
also	POS	O
significantly	POS	O
increased	POS	O
the	POS	O
risk	POS	O
of	POS	O
stroke	POS	B-NP
and	POS	O
gallbladder	POS	B-NP
disease	POS	I-NP
.	POS	O
Overall	POS	O
,	POS	O
the	POS	O
only	POS	O
statistically	POS	O
significant	POS	O
benefits	POS	O
of	POS	O
HT	POS	O
were	POS	O
a	POS	O
decreased	POS	O
incidence	POS	O
of	POS	O
fractures	POS	B-NP
and	POS	O
colon	POS	B-NP
cancer	POS	I-NP
with	POS	O
long	POS	O
-	POS	O
term	POS	O
use	POS	O
.	POS	O
Among	POS	O
relatively	POS	O
healthy	POS	O
women	POS	O
over	POS	O
65	POS	O
years	POS	O
taking	POS	O
continuous	POS	O
combined	POS	O
HT	POS	O
,	POS	O
there	POS	O
was	POS	O
a	POS	O
statistically	POS	O
significant	POS	O
increase	POS	O
in	POS	O
the	POS	O
incidence	POS	O
of	POS	O
dementia	POS	B-NP
.	POS	O
Among	POS	O
women	POS	O
with	POS	O
cardiovascular	POS	B-NP
disease	POS	I-NP
,	POS	O
long	POS	O
-	POS	O
term	POS	O
use	POS	O
of	POS	O
combined	POS	O
continuous	POS	O
HT	POS	O
significantly	POS	O
increased	POS	O
the	POS	O
risk	POS	O
of	POS	O
venous	POS	B-NP
thromboembolism	POS	I-NP
.	POS	O
No	POS	O
trials	POS	O
focussed	POS	O
specifically	POS	O
on	POS	O
younger	POS	O
women	POS	O
.	POS	O
However	POS	O
,	POS	O
one	POS	O
trial	POS	O
analysed	POS	O
subgroups	POS	O
of	POS	O
2839	POS	O
relatively	POS	O
healthy	POS	O
50	POS	O
to	POS	O
59	POS	O
year	POS	O
-	POS	O
old	POS	O
women	POS	O
taking	POS	O
combined	POS	O
continuous	POS	O
HT	POS	O
and	POS	O
1637	POS	O
taking	POS	O
oestrogen	POS	O
-	POS	O
only	POS	O
HT	POS	O
,	POS	O
versus	POS	O
similar	POS	O
-	POS	O
sized	POS	O
placebo	POS	O
groups	POS	O
.	POS	O
The	POS	O
only	POS	O
significantly	POS	O
increased	POS	O
risk	POS	O
reported	POS	O
was	POS	O
for	POS	O
venous	POS	B-NP
thromboembolism	POS	I-NP
in	POS	O
women	POS	O
taking	POS	O
combined	POS	O
continuous	POS	O
HT	POS	O
;	POS	O
their	POS	O
absolute	POS	O
risk	POS	O
remained	POS	O
very	POS	O
low	POS	O
.	POS	O
AUTHORS	POS	O
'	POS	O
CONCLUSIONS	POS	O
:	POS	O
HT	POS	O
is	POS	O
not	POS	O
indicated	POS	O
for	POS	O
the	POS	O
routine	POS	O
management	POS	O
of	POS	O
chronic	POS	B-NP
disease	POS	I-NP
.	POS	O
We	POS	O
need	POS	O
more	POS	O
evidence	POS	O
on	POS	O
the	POS	O
safety	POS	O
of	POS	O
HT	POS	O
for	POS	O
menopausal	POS	O
symptom	POS	O
control	POS	O
,	POS	O
though	POS	O
short	POS	O
-	POS	O
term	POS	O
use	POS	O
appears	POS	O
to	POS	O
be	POS	O
relatively	POS	O
safe	POS	O
for	POS	O
healthy	POS	O
younger	POS	O
women	POS	O
.	POS	O
Drug	POS	O
-	POS	O
induced	POS	O
liver	POS	B-NP
injury	POS	I-NP
:	POS	O
an	POS	O
analysis	POS	O
of	POS	O
461	POS	O
incidences	POS	O
submitted	POS	O
to	POS	O
the	POS	O
Spanish	POS	O
registry	POS	O
over	POS	O
a	POS	O
10	POS	O
-	POS	O
year	POS	O
period	POS	O
.	POS	O
BACKGROUND	POS	O
&	POS	O
AIMS	POS	O
:	POS	O
Progress	POS	O
in	POS	O
the	POS	O
understanding	POS	O
of	POS	O
susceptibility	POS	O
factors	POS	O
to	POS	O
drug	POS	O
-	POS	O
induced	POS	O
liver	POS	B-NP
injury	POS	I-NP
(	POS	O
DILI	POS	B-NP
)	POS	O
and	POS	O
outcome	POS	O
predictability	POS	O
are	POS	O
hampered	POS	O
by	POS	O
the	POS	O
lack	POS	O
of	POS	O
systematic	POS	O
programs	POS	O
to	POS	O
detect	POS	O
bona	POS	O
fide	POS	O
cases	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
cooperative	POS	O
network	POS	O
was	POS	O
created	POS	O
in	POS	O
1994	POS	O
in	POS	O
Spain	POS	O
to	POS	O
identify	POS	O
all	POS	O
suspicions	POS	O
of	POS	O
DILI	POS	B-NP
following	POS	O
a	POS	O
prospective	POS	O
structured	POS	O
report	POS	O
form	POS	O
.	POS	O
The	POS	O
liver	POS	B-NP
damage	POS	I-NP
was	POS	O
characterized	POS	O
according	POS	O
to	POS	O
hepatocellular	POS	B-NP
,	POS	O
cholestatic	POS	B-NP
,	POS	O
and	POS	O
mixed	POS	O
laboratory	POS	O
criteria	POS	O
and	POS	O
to	POS	O
histologic	POS	O
criteria	POS	O
when	POS	O
available	POS	O
.	POS	O
Further	POS	O
evaluation	POS	O
of	POS	O
causality	POS	O
assessment	POS	O
was	POS	O
centrally	POS	O
performed	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Since	POS	O
April	POS	O
1994	POS	O
to	POS	O
August	POS	O
2004	POS	O
,	POS	O
461	POS	O
out	POS	O
of	POS	O
570	POS	O
submitted	POS	O
cases	POS	O
,	POS	O
involving	POS	O
505	POS	O
drugs	POS	O
,	POS	O
were	POS	O
deemed	POS	O
to	POS	O
be	POS	O
related	POS	O
to	POS	O
DILI	POS	B-NP
.	POS	O
The	POS	O
antiinfective	POS	O
group	POS	O
of	POS	O
drugs	POS	O
was	POS	O
the	POS	O
more	POS	O
frequently	POS	O
incriminated	POS	O
,	POS	O
amoxicillin	POS	O
-	POS	O
clavulanate	POS	O
accounting	POS	O
for	POS	O
the	POS	O
12	POS	O
.	POS	O
8	POS	O
%	POS	O
of	POS	O
the	POS	O
whole	POS	O
series	POS	O
.	POS	O
The	POS	O
hepatocellular	POS	O
pattern	POS	O
of	POS	O
damage	POS	O
was	POS	O
the	POS	O
most	POS	O
common	POS	O
(	POS	O
58	POS	O
%	POS	O
)	POS	O
,	POS	O
was	POS	O
inversely	POS	O
correlated	POS	O
with	POS	O
age	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
0001	POS	O
)	POS	O
,	POS	O
and	POS	O
had	POS	O
the	POS	O
worst	POS	O
outcome	POS	O
(	POS	O
Cox	POS	O
regression	POS	O
,	POS	O
P	POS	O
<	POS	O
.	POS	O
034	POS	O
)	POS	O
.	POS	O
Indeed	POS	O
,	POS	O
the	POS	O
incidence	POS	O
of	POS	O
liver	POS	O
transplantation	POS	O
and	POS	O
death	POS	O
in	POS	O
this	POS	O
group	POS	O
was	POS	O
11	POS	O
.	POS	O
7	POS	O
%	POS	O
if	POS	O
patients	POS	O
had	POS	O
jaundice	POS	B-NP
at	POS	O
presentation	POS	O
,	POS	O
whereas	POS	O
the	POS	O
corresponding	POS	O
figure	POS	O
was	POS	O
3	POS	O
.	POS	O
8	POS	O
%	POS	O
in	POS	O
nonjaundiced	POS	O
patients	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
04	POS	O
)	POS	O
.	POS	O
Factors	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
fulminant	POS	B-NP
hepatic	POS	I-NP
failure	POS	I-NP
were	POS	O
female	POS	O
sex	POS	O
(	POS	O
OR	POS	O
=	POS	O
25	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
4	POS	O
.	POS	O
1	POS	O
-	POS	O
151	POS	O
;	POS	O
P	POS	O
<	POS	O
.	POS	O
0001	POS	O
)	POS	O
,	POS	O
hepatocellular	POS	B-NP
damage	POS	I-NP
(	POS	O
OR	POS	O
=	POS	O
7	POS	O
.	POS	O
9	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
1	POS	O
.	POS	O
6	POS	O
-	POS	O
37	POS	O
;	POS	O
P	POS	O
<	POS	O
.	POS	O
009	POS	O
)	POS	O
,	POS	O
and	POS	O
higher	POS	O
baseline	POS	O
plasma	POS	O
bilirubin	POS	O
value	POS	O
(	POS	O
OR	POS	O
=	POS	O
1	POS	O
.	POS	O
15	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
1	POS	O
.	POS	O
09	POS	O
-	POS	O
1	POS	O
.	POS	O
22	POS	O
;	POS	O
P	POS	O
<	POS	O
.	POS	O
0001	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Patients	POS	O
with	POS	O
drug	POS	O
-	POS	O
induced	POS	O
hepatocellular	POS	B-NP
jaundice	POS	I-NP
have	POS	O
11	POS	O
.	POS	O
7	POS	O
%	POS	O
chance	POS	O
of	POS	O
progressing	POS	O
to	POS	O
death	POS	O
or	POS	O
transplantation	POS	O
.	POS	O
Amoxicillin	POS	O
-	POS	O
clavulanate	POS	O
stands	POS	O
out	POS	O
as	POS	O
the	POS	O
most	POS	O
common	POS	O
drug	POS	O
related	POS	O
to	POS	O
DILI	POS	B-NP
.	POS	O
Morphological	POS	O
evaluation	POS	O
of	POS	O
the	POS	O
effect	POS	O
of	POS	O
d	POS	O
-	POS	O
ribose	POS	O
on	POS	O
adriamycin	POS	O
-	POS	O
evoked	POS	O
cardiotoxicity	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
influence	POS	O
of	POS	O
d	POS	O
-	POS	O
ribose	POS	O
on	POS	O
adriamycin	POS	O
-	POS	O
induced	POS	O
myocardiopathy	POS	B-NP
in	POS	O
rats	POS	O
was	POS	O
studied	POS	O
.	POS	O
Adriamycin	POS	O
in	POS	O
the	POS	O
cumulative	POS	O
dose	POS	O
of	POS	O
25	POS	O
mg	POS	O
/	POS	O
kg	POS	O
evoked	POS	O
fully	POS	O
developed	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
.	POS	O
D	POS	O
-	POS	O
ribose	POS	O
in	POS	O
the	POS	O
multiple	POS	O
doses	POS	O
of	POS	O
200	POS	O
mg	POS	O
/	POS	O
kg	POS	O
did	POS	O
not	POS	O
influence	POS	O
ADR	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
In	POS	O
vivo	POS	O
evidences	POS	O
suggesting	POS	O
the	POS	O
role	POS	O
of	POS	O
oxidative	POS	O
stress	POS	O
in	POS	O
pathogenesis	POS	O
of	POS	O
vancomycin	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
:	POS	O
protection	POS	O
by	POS	O
erdosteine	POS	O
.	POS	O
The	POS	O
aims	POS	O
of	POS	O
this	POS	O
study	POS	O
were	POS	O
to	POS	O
examine	POS	O
vancomycin	POS	O
(	POS	O
VCM	POS	O
)	POS	O
-	POS	O
induced	POS	O
oxidative	POS	O
stress	POS	O
that	POS	O
promotes	POS	O
production	POS	O
of	POS	O
reactive	POS	O
oxygen	POS	O
species	POS	O
(	POS	O
ROS	POS	O
)	POS	O
and	POS	O
to	POS	O
investigate	POS	O
the	POS	O
role	POS	O
of	POS	O
erdosteine	POS	O
,	POS	O
an	POS	O
expectorant	POS	O
agent	POS	O
,	POS	O
which	POS	O
has	POS	O
also	POS	O
antioxidant	POS	O
properties	POS	O
,	POS	O
on	POS	O
kidney	POS	O
tissue	POS	O
against	POS	O
the	POS	O
possible	POS	O
VCM	POS	O
-	POS	O
induced	POS	O
renal	POS	B-NP
impairment	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
Rats	POS	O
were	POS	O
divided	POS	O
into	POS	O
three	POS	O
groups	POS	O
:	POS	O
sham	POS	O
,	POS	O
VCM	POS	O
and	POS	O
VCM	POS	O
plus	POS	O
erdosteine	POS	O
.	POS	O
VCM	POS	O
was	POS	O
administrated	POS	O
intraperitoneally	POS	O
(	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
with	POS	O
200mgkg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
twice	POS	O
daily	POS	O
for	POS	O
7	POS	O
days	POS	O
.	POS	O
Erdosteine	POS	O
was	POS	O
administered	POS	O
orally	POS	O
.	POS	O
VCM	POS	O
administration	POS	O
to	POS	O
control	POS	O
rats	POS	O
significantly	POS	O
increased	POS	O
renal	POS	O
malondialdehyde	POS	O
(	POS	O
MDA	POS	O
)	POS	O
and	POS	O
urinary	POS	O
N	POS	O
-	POS	O
acetyl	POS	O
-	POS	O
beta	POS	O
-	POS	O
d	POS	O
-	POS	O
glucosaminidase	POS	O
(	POS	O
NAG	POS	O
,	POS	O
a	POS	O
marker	POS	O
of	POS	O
renal	POS	B-NP
tubular	POS	I-NP
injury	POS	I-NP
)	POS	O
excretion	POS	O
but	POS	O
decreased	POS	O
superoxide	POS	O
dismutase	POS	O
(	POS	O
SOD	POS	O
)	POS	O
and	POS	O
catalase	POS	O
(	POS	O
CAT	POS	O
)	POS	O
activities	POS	O
.	POS	O
Erdosteine	POS	O
administration	POS	O
with	POS	O
VCM	POS	O
injections	POS	O
caused	POS	O
significantly	POS	O
decreased	POS	O
renal	POS	O
MDA	POS	O
and	POS	O
urinary	POS	O
NAG	POS	O
excretion	POS	O
,	POS	O
and	POS	O
increased	POS	O
SOD	POS	O
activity	POS	O
,	POS	O
but	POS	O
not	POS	O
CAT	POS	O
activity	POS	O
in	POS	O
renal	POS	O
tissue	POS	O
when	POS	O
compared	POS	O
with	POS	O
VCM	POS	O
alone	POS	O
.	POS	O
Erdosteine	POS	O
showed	POS	O
histopathological	POS	O
protection	POS	O
against	POS	O
VCM	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
There	POS	O
were	POS	O
a	POS	O
significant	POS	O
dilatation	POS	B-NP
of	POS	I-NP
tubular	POS	I-NP
lumens	POS	I-NP
,	POS	O
extensive	POS	O
epithelial	POS	O
cell	POS	O
vacuolization	POS	O
,	POS	O
atrophy	POS	B-NP
,	POS	O
desquamation	POS	B-NP
,	POS	O
and	POS	O
necrosis	POS	B-NP
in	POS	O
VCM	POS	O
-	POS	O
treated	POS	O
rats	POS	O
more	POS	O
than	POS	O
those	POS	O
of	POS	O
the	POS	O
control	POS	O
and	POS	O
the	POS	O
erdosteine	POS	O
groups	POS	O
.	POS	O
Erdosteine	POS	O
caused	POS	O
a	POS	O
marked	POS	O
reduction	POS	O
in	POS	O
the	POS	O
extent	POS	O
of	POS	O
tubular	POS	B-NP
damage	POS	I-NP
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
oxidative	POS	O
tubular	POS	O
damage	POS	O
plays	POS	O
an	POS	O
important	POS	O
role	POS	O
in	POS	O
the	POS	O
VCM	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
and	POS	O
the	POS	O
modulation	POS	O
of	POS	O
oxidative	POS	O
stress	POS	O
with	POS	O
erdosteine	POS	O
reduces	POS	O
the	POS	O
VCM	POS	O
-	POS	O
induced	POS	O
kidney	POS	O
damage	POS	O
both	POS	O
at	POS	O
the	POS	O
biochemical	POS	O
and	POS	O
histological	POS	O
levels	POS	O
.	POS	O
Gemfibrozil	POS	O
-	POS	O
lovastatin	POS	O
therapy	POS	O
for	POS	O
primary	POS	O
hyperlipoproteinemias	POS	B-NP
.	POS	O
The	POS	O
specific	POS	O
aim	POS	O
of	POS	O
this	POS	O
retrospective	POS	O
,	POS	O
observational	POS	O
study	POS	O
was	POS	O
to	POS	O
assess	POS	O
safety	POS	O
and	POS	O
efficacy	POS	O
of	POS	O
long	POS	O
-	POS	O
term	POS	O
(	POS	O
21	POS	O
months	POS	O
/	POS	O
patient	POS	O
)	POS	O
,	POS	O
open	POS	O
-	POS	O
label	POS	O
,	POS	O
gemfibrozil	POS	O
-	POS	O
lovastatin	POS	O
treatment	POS	O
in	POS	O
80	POS	O
patients	POS	O
with	POS	O
primary	POS	O
mixed	POS	O
hyperlipidemia	POS	B-NP
(	POS	O
68	POS	O
%	POS	O
of	POS	O
whom	POS	O
had	POS	O
atherosclerotic	POS	B-NP
vascular	POS	I-NP
disease	POS	I-NP
)	POS	O
.	POS	O
Because	POS	O
ideal	POS	O
lipid	POS	O
targets	POS	O
were	POS	O
not	POS	O
reached	POS	O
(	POS	O
low	POS	O
-	POS	O
density	POS	O
lipoprotein	POS	O
(	POS	O
LDL	POS	O
)	POS	O
cholesterol	POS	O
less	POS	O
than	POS	O
130	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
high	POS	O
-	POS	O
density	POS	O
lipoprotein	POS	O
(	POS	O
HDL	POS	O
)	POS	O
cholesterol	POS	O
greater	POS	O
than	POS	O
35	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
or	POS	O
total	POS	O
cholesterol	POS	O
/	POS	O
HDL	POS	O
cholesterol	POS	O
less	POS	O
than	POS	O
4	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
dl	POS	O
)	POS	O
with	POS	O
diet	POS	O
plus	POS	O
a	POS	O
single	POS	O
drug	POS	O
,	POS	O
gemfibrozil	POS	O
(	POS	O
1	POS	O
.	POS	O
2	POS	O
g	POS	O
/	POS	O
day	POS	O
)	POS	O
-	POS	O
lovastatin	POS	O
(	POS	O
primarily	POS	O
20	POS	O
or	POS	O
40	POS	O
mg	POS	O
)	POS	O
treatment	POS	O
was	POS	O
given	POS	O
.	POS	O
Follow	POS	O
-	POS	O
up	POS	O
visits	POS	O
were	POS	O
scheduled	POS	O
with	POS	O
2	POS	O
-	POS	O
drug	POS	O
therapy	POS	O
every	POS	O
6	POS	O
to	POS	O
8	POS	O
weeks	POS	O
,	POS	O
an	POS	O
average	POS	O
of	POS	O
10	POS	O
.	POS	O
3	POS	O
visits	POS	O
per	POS	O
patient	POS	O
,	POS	O
with	POS	O
741	POS	O
batteries	POS	O
of	POS	O
6	POS	O
liver	POS	O
function	POS	O
tests	POS	O
and	POS	O
714	POS	O
creatine	POS	O
phosphokinase	POS	O
levels	POS	O
measured	POS	O
.	POS	O
Only	POS	O
1	POS	O
of	POS	O
the	POS	O
4	POS	O
,	POS	O
446	POS	O
liver	POS	O
function	POS	O
tests	POS	O
(	POS	O
0	POS	O
.	POS	O
02	POS	O
%	POS	O
)	POS	O
,	POS	O
a	POS	O
gamma	POS	O
glutamyl	POS	O
transferase	POS	O
,	POS	O
was	POS	O
greater	POS	O
than	POS	O
or	POS	O
equal	POS	O
to	POS	O
3	POS	O
times	POS	O
the	POS	O
upper	POS	O
normal	POS	O
limit	POS	O
.	POS	O
Of	POS	O
the	POS	O
714	POS	O
creatine	POS	O
phosphokinase	POS	O
levels	POS	O
,	POS	O
9	POS	O
%	POS	O
were	POS	O
high	POS	O
;	POS	O
only	POS	O
1	POS	O
(	POS	O
0	POS	O
.	POS	O
1	POS	O
%	POS	O
)	POS	O
was	POS	O
greater	POS	O
than	POS	O
or	POS	O
equal	POS	O
to	POS	O
3	POS	O
times	POS	O
the	POS	O
upper	POS	O
normal	POS	O
limit	POS	O
.	POS	O
With	POS	O
2	POS	O
-	POS	O
drug	POS	O
therapy	POS	O
,	POS	O
mean	POS	O
total	POS	O
cholesterol	POS	O
decreased	POS	O
22	POS	O
%	POS	O
from	POS	O
255	POS	O
to	POS	O
200	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
triglyceride	POS	O
levels	POS	O
decreased	POS	O
35	POS	O
%	POS	O
from	POS	O
236	POS	O
to	POS	O
154	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
LDL	POS	O
cholesterol	POS	O
decreased	POS	O
26	POS	O
%	POS	O
from	POS	O
176	POS	O
to	POS	O
131	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
and	POS	O
the	POS	O
total	POS	O
cholesterol	POS	O
/	POS	O
HDL	POS	O
cholesterol	POS	O
ratio	POS	O
decreased	POS	O
24	POS	O
%	POS	O
from	POS	O
7	POS	O
.	POS	O
1	POS	O
to	POS	O
5	POS	O
.	POS	O
4	POS	O
,	POS	O
all	POS	O
p	POS	O
less	POS	O
than	POS	O
or	POS	O
equal	POS	O
to	POS	O
0	POS	O
.	POS	O
0001	POS	O
.	POS	O
Myositis	POS	B-NP
,	POS	O
attributable	POS	O
to	POS	O
the	POS	O
drug	POS	O
combination	POS	O
and	POS	O
symptomatic	POS	O
enough	POS	O
to	POS	O
discontinue	POS	O
it	POS	O
,	POS	O
occurred	POS	O
in	POS	O
3	POS	O
%	POS	O
of	POS	O
patients	POS	O
,	POS	O
and	POS	O
in	POS	O
1	POS	O
%	POS	O
with	POS	O
concurrent	POS	O
high	POS	O
creatine	POS	O
phosphokinase	POS	O
(	POS	O
769	POS	O
U	POS	O
/	POS	O
liter	POS	O
)	POS	O
;	POS	O
no	POS	O
patients	POS	O
had	POS	O
rhabdomyolysis	POS	B-NP
or	POS	O
myoglobinuria	POS	B-NP
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
250	POS	O
WORDS	POS	O
)	POS	O
Does	POS	O
domperidone	POS	O
potentiate	POS	O
mirtazapine	POS	O
-	POS	O
associated	POS	O
restless	POS	B-NP
legs	POS	I-NP
syndrome	POS	I-NP
?	POS	O
There	POS	O
is	POS	O
now	POS	O
evidence	POS	O
to	POS	O
suggest	POS	O
a	POS	O
central	POS	O
role	POS	O
for	POS	O
the	POS	O
dopaminergic	POS	O
system	POS	O
in	POS	O
restless	POS	B-NP
legs	POS	I-NP
syndrome	POS	I-NP
(	POS	O
RLS	POS	B-NP
)	POS	O
.	POS	O
For	POS	O
example	POS	O
,	POS	O
the	POS	O
symptoms	POS	O
of	POS	O
RLS	POS	B-NP
can	POS	O
be	POS	O
dramatically	POS	O
improved	POS	O
by	POS	O
levodopa	POS	O
and	POS	O
dopamine	POS	O
agonists	POS	O
,	POS	O
whereas	POS	O
central	POS	O
dopamine	POS	O
D2	POS	O
receptor	POS	O
antagonists	POS	O
can	POS	O
induce	POS	O
or	POS	O
aggravate	POS	O
RLS	POS	B-NP
symptoms	POS	O
.	POS	O
To	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
there	POS	O
is	POS	O
no	POS	O
previous	POS	O
report	POS	O
regarding	POS	O
whether	POS	O
domperidone	POS	O
,	POS	O
a	POS	O
peripheral	POS	O
dopamine	POS	O
D2	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
can	POS	O
also	POS	O
induce	POS	O
or	POS	O
aggravate	POS	O
symptoms	POS	O
of	POS	O
RLS	POS	B-NP
.	POS	O
Mirtazapine	POS	O
,	POS	O
the	POS	O
first	POS	O
noradrenergic	POS	O
and	POS	O
specific	POS	O
serotonergic	POS	O
antidepressant	POS	O
(	POS	O
NaSSA	POS	O
)	POS	O
,	POS	O
has	POS	O
been	POS	O
associated	POS	O
with	POS	O
RLS	POS	B-NP
in	POS	O
several	POS	O
recent	POS	O
publications	POS	O
.	POS	O
The	POS	O
authors	POS	O
report	POS	O
here	POS	O
a	POS	O
depressed	POS	B-NP
patient	POS	O
comorbid	POS	O
with	POS	O
postprandial	POS	B-NP
dyspepsia	POS	I-NP
who	POS	O
developed	POS	O
RLS	POS	B-NP
after	POS	O
mirtazapine	POS	O
had	POS	O
been	POS	O
added	POS	O
to	POS	O
his	POS	O
domperidone	POS	O
therapy	POS	O
.	POS	O
Our	POS	O
patient	POS	O
started	POS	O
to	POS	O
have	POS	O
symptoms	POS	O
of	POS	O
RLS	POS	B-NP
only	POS	O
after	POS	O
he	POS	O
had	POS	O
been	POS	O
treated	POS	O
with	POS	O
mirtazapine	POS	O
,	POS	O
and	POS	O
his	POS	O
RLS	POS	B-NP
symptoms	POS	O
resolved	POS	O
completely	POS	O
upon	POS	O
discontinuation	POS	O
of	POS	O
his	POS	O
mirtazapine	POS	O
.	POS	O
Such	POS	O
a	POS	O
temporal	POS	O
relationship	POS	O
between	POS	O
the	POS	O
use	POS	O
of	POS	O
mirtazapine	POS	O
and	POS	O
the	POS	O
symptoms	POS	O
of	POS	O
RLS	POS	B-NP
in	POS	O
our	POS	O
patient	POS	O
did	POS	O
not	POS	O
support	POS	O
a	POS	O
potentiating	POS	O
effect	POS	O
of	POS	O
domperione	POS	O
on	POS	O
mirtazapine	POS	O
-	POS	O
associated	POS	O
RLS	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
physicians	POS	O
should	POS	O
be	POS	O
aware	POS	O
of	POS	O
the	POS	O
possibility	POS	O
that	POS	O
mirtazapine	POS	O
can	POS	O
be	POS	O
associated	POS	O
with	POS	O
RLS	POS	B-NP
in	POS	O
some	POS	O
individuals	POS	O
,	POS	O
especially	POS	O
those	POS	O
receiving	POS	O
concomitant	POS	O
dopamine	POS	O
D2	POS	O
receptor	POS	O
antagonists	POS	O
.	POS	O
Antiandrogenic	POS	O
therapy	POS	O
can	POS	O
cause	POS	O
coronary	POS	B-NP
arterial	POS	I-NP
disease	POS	I-NP
.	POS	O
AIM	POS	O
:	POS	O
To	POS	O
study	POS	O
the	POS	O
change	POS	O
of	POS	O
lipid	POS	O
metabolism	POS	O
by	POS	O
antiandrogen	POS	O
therapy	POS	O
in	POS	O
patients	POS	O
with	POS	O
prostate	POS	B-NP
cancer	POS	I-NP
.	POS	O
MATERIALS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
studied	POS	O
with	POS	O
a	POS	O
2	POS	O
.	POS	O
5	POS	O
years	POS	O
follow	POS	O
-	POS	O
up	POS	O
the	POS	O
changes	POS	O
in	POS	O
plasma	POS	O
cholesterols	POS	O
(	POS	O
C	POS	O
)	POS	O
,	POS	O
triglycerides	POS	O
(	POS	O
TG	POS	O
)	POS	O
,	POS	O
lipoproteins	POS	O
(	POS	O
LP	POS	O
)	POS	O
,	POS	O
and	POS	O
apolipoproteins	POS	O
(	POS	O
Apo	POS	O
)	POS	O
B	POS	O
-	POS	O
100	POS	O
,	POS	O
A	POS	O
-	POS	O
I	POS	O
,	POS	O
and	POS	O
A	POS	O
-	POS	O
II	POS	O
pro	POS	O
fi	POS	O
les	POS	O
in	POS	O
24	POS	O
patients	POS	O
of	POS	O
mean	POS	O
age	POS	O
60	POS	O
years	POS	O
with	POS	O
low	POS	O
risk	POS	O
prostate	POS	B-NP
cancer	POS	I-NP
(	POS	O
stage	POS	O
:	POS	O
T1cN0M0	POS	O
,	POS	O
Gleason	POS	O
score	POS	O
:	POS	O
2	POS	O
-	POS	O
5	POS	O
)	POS	O
during	POS	O
treatment	POS	O
with	POS	O
cyproterone	POS	O
acetate	POS	O
(	POS	O
CPA	POS	O
)	POS	O
without	POS	O
surgical	POS	O
management	POS	O
or	POS	O
radiation	POS	O
therapy	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Significant	POS	O
decreases	POS	O
of	POS	O
HDL	POS	O
-	POS	O
C	POS	O
,	POS	O
Apo	POS	O
A	POS	O
-	POS	O
I	POS	O
and	POS	O
Apo	POS	O
A	POS	O
-	POS	O
II	POS	O
and	POS	O
an	POS	O
increase	POS	O
of	POS	O
triglyceride	POS	O
levels	POS	O
in	POS	O
VLDL	POS	O
were	POS	O
induced	POS	O
by	POS	O
CPA	POS	O
.	POS	O
After	POS	O
a	POS	O
period	POS	O
of	POS	O
2	POS	O
.	POS	O
5	POS	O
years	POS	O
on	POS	O
CPA	POS	O
treatment	POS	O
,	POS	O
four	POS	O
patients	POS	O
out	POS	O
of	POS	O
twenty	POS	O
-	POS	O
four	POS	O
were	POS	O
found	POS	O
to	POS	O
be	POS	O
affected	POS	O
by	POS	O
coronary	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Ischaemic	POS	B-NP
coronary	POS	I-NP
arteriosclerosis	POS	I-NP
with	POS	O
an	POS	O
incidence	POS	O
rate	POS	O
of	POS	O
16	POS	O
.	POS	O
6	POS	O
%	POS	O
as	POS	O
caused	POS	O
by	POS	O
prolonged	POS	O
CPA	POS	O
therapy	POS	O
is	POS	O
mediated	POS	O
through	POS	O
changes	POS	O
in	POS	O
HDL	POS	O
cholesterol	POS	O
,	POS	O
Apo	POS	O
A	POS	O
-	POS	O
I	POS	O
and	POS	O
Apo	POS	O
A	POS	O
-	POS	O
II	POS	O
pro	POS	O
fi	POS	O
les	POS	O
,	POS	O
other	POS	O
than	POS	O
the	POS	O
well	POS	O
-	POS	O
known	POS	O
hyperglyceridemic	POS	O
effect	POS	O
caused	POS	O
by	POS	O
estrogen	POS	O
.	POS	O
5	POS	O
-	POS	O
Fluorouracil	POS	O
cardiotoxicity	POS	B-NP
induced	POS	O
by	POS	O
alpha	POS	O
-	POS	O
fluoro	POS	O
-	POS	O
beta	POS	O
-	POS	O
alanine	POS	O
.	POS	O
Cardiotoxicity	POS	B-NP
is	POS	O
a	POS	O
rare	POS	O
complication	POS	O
occurring	POS	O
during	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
(	POS	O
5	POS	O
-	POS	O
FU	POS	O
)	POS	O
treatment	POS	O
for	POS	O
malignancies	POS	B-NP
.	POS	O
We	POS	O
herein	POS	O
report	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
70	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
with	POS	O
5	POS	O
-	POS	O
FU	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
,	POS	O
in	POS	O
whom	POS	O
a	POS	O
high	POS	O
serum	POS	O
level	POS	O
of	POS	O
alpha	POS	O
-	POS	O
fluoro	POS	O
-	POS	O
beta	POS	O
-	POS	O
alanine	POS	O
(	POS	O
FBAL	POS	O
)	POS	O
was	POS	O
observed	POS	O
.	POS	O
The	POS	O
patient	POS	O
,	POS	O
who	POS	O
had	POS	O
unresectable	POS	O
colon	POS	B-NP
cancer	POS	I-NP
metastases	POS	O
to	POS	O
the	POS	O
liver	POS	O
and	POS	O
lung	POS	O
,	POS	O
was	POS	O
referred	POS	O
to	POS	O
us	POS	O
for	POS	O
chemotherapy	POS	O
from	POS	O
an	POS	O
affiliated	POS	O
hospital	POS	O
;	POS	O
he	POS	O
had	POS	O
no	POS	O
cardiac	POS	B-NP
history	POS	I-NP
.	POS	O
After	POS	O
admission	POS	O
,	POS	O
the	POS	O
patient	POS	O
received	POS	O
a	POS	O
continuous	POS	O
intravenous	POS	O
infusion	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
(	POS	O
1000	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
,	POS	O
during	POS	O
which	POS	O
precordial	POS	B-NP
pain	POS	I-NP
with	POS	O
right	POS	B-NP
bundle	POS	I-NP
branch	POS	I-NP
block	POS	I-NP
occurred	POS	O
concomitantly	POS	O
with	POS	O
a	POS	O
high	POS	O
serum	POS	O
FBAL	POS	O
concentration	POS	O
of	POS	O
1955	POS	O
ng	POS	O
/	POS	O
ml	POS	O
.	POS	O
Both	POS	O
the	POS	O
precordial	POS	B-NP
pain	POS	I-NP
and	POS	O
the	POS	O
electrocardiographic	POS	O
changes	POS	O
disappeared	POS	O
spontaneously	POS	O
after	POS	O
the	POS	O
discontinuation	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
.	POS	O
As	POS	O
the	POS	O
precordial	POS	B-NP
pain	POS	I-NP
in	POS	O
this	POS	O
patient	POS	O
was	POS	O
considered	POS	O
to	POS	O
have	POS	O
been	POS	O
due	POS	O
to	POS	O
5	POS	O
-	POS	O
FU	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
,	POS	O
the	POS	O
administration	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
was	POS	O
abandoned	POS	O
.	POS	O
Instead	POS	O
,	POS	O
oral	POS	O
administration	POS	O
of	POS	O
S	POS	O
-	POS	O
1	POS	O
(	POS	O
a	POS	O
derivative	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
)	POS	O
,	POS	O
at	POS	O
200	POS	O
mg	POS	O
/	POS	O
day	POS	O
twice	POS	O
a	POS	O
week	POS	O
,	POS	O
was	POS	O
instituted	POS	O
,	POS	O
because	POS	O
S	POS	O
-	POS	O
1	POS	O
has	POS	O
a	POS	O
strong	POS	O
inhibitory	POS	O
effect	POS	O
on	POS	O
dihydropyrimidine	POS	O
dehydrogenase	POS	O
,	POS	O
which	POS	O
catalyzes	POS	O
the	POS	O
degradative	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
into	POS	O
FBAL	POS	O
.	POS	O
The	POS	O
serum	POS	O
FBAL	POS	O
concentration	POS	O
subsequently	POS	O
decreased	POS	O
to	POS	O
352	POS	O
ng	POS	O
/	POS	O
ml	POS	O
,	POS	O
the	POS	O
same	POS	O
as	POS	O
the	POS	O
value	POS	O
measured	POS	O
on	POS	O
the	POS	O
first	POS	O
day	POS	O
of	POS	O
S	POS	O
-	POS	O
1	POS	O
administration	POS	O
.	POS	O
Thereafter	POS	O
,	POS	O
no	POS	O
cardiac	POS	O
symptoms	POS	O
were	POS	O
observed	POS	O
.	POS	O
The	POS	O
patient	POS	O
achieved	POS	O
a	POS	O
partial	POS	O
response	POS	O
6	POS	O
months	POS	O
after	POS	O
the	POS	O
initiation	POS	O
of	POS	O
the	POS	O
S	POS	O
-	POS	O
1	POS	O
treatment	POS	O
.	POS	O
The	POS	O
experience	POS	O
of	POS	O
this	POS	O
case	POS	O
,	POS	O
together	POS	O
with	POS	O
a	POS	O
review	POS	O
of	POS	O
the	POS	O
literature	POS	O
,	POS	O
suggests	POS	O
that	POS	O
FBAL	POS	O
is	POS	O
related	POS	O
to	POS	O
5	POS	O
-	POS	O
FU	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
S	POS	O
-	POS	O
1	POS	O
may	POS	O
be	POS	O
administered	POS	O
safely	POS	O
to	POS	O
patients	POS	O
with	POS	O
5	POS	O
-	POS	O
FU	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
Hepatocellular	POS	B-NP
carcinoma	POS	I-NP
in	POS	O
Fanconi	POS	B-NP
'	POS	I-NP
s	POS	I-NP
anemia	POS	I-NP
treated	POS	O
with	POS	O
androgen	POS	O
and	POS	O
corticosteroid	POS	O
.	POS	O
The	POS	O
case	POS	O
of	POS	O
an	POS	O
11	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
boy	POS	O
is	POS	O
reported	POS	O
who	POS	O
was	POS	O
known	POS	O
to	POS	O
have	POS	O
Fanconi	POS	B-NP
'	POS	I-NP
s	POS	I-NP
anemia	POS	I-NP
for	POS	O
3	POS	O
years	POS	O
and	POS	O
was	POS	O
treated	POS	O
with	POS	O
androgens	POS	O
,	POS	O
corticosteroids	POS	O
and	POS	O
transfusions	POS	O
.	POS	O
Two	POS	O
weeks	POS	O
before	POS	O
his	POS	O
death	POS	O
he	POS	O
was	POS	O
readmitted	POS	O
because	POS	O
of	POS	O
aplastic	POS	B-NP
crisis	POS	I-NP
with	POS	O
septicemia	POS	B-NP
and	POS	O
marked	POS	O
abnormalities	POS	O
in	POS	O
liver	POS	O
function	POS	O
and	POS	O
died	POS	O
of	POS	O
hemorrhagic	POS	B-NP
bronchopneumonia	POS	I-NP
.	POS	O
At	POS	O
autopsy	POS	O
peliosis	POS	B-NP
and	POS	O
multiple	POS	B-NP
hepatic	POS	I-NP
tumors	POS	I-NP
were	POS	O
found	POS	O
which	POS	O
histologically	POS	O
proved	POS	O
to	POS	O
be	POS	O
well	POS	O
-	POS	O
differentiated	POS	O
hepatocellular	POS	O
carcinoma	POS	B-NP
.	POS	O
This	POS	O
case	POS	O
contributes	POS	O
to	POS	O
the	POS	O
previous	POS	O
observations	POS	O
that	POS	O
non	POS	B-NP
-	POS	I-NP
metastasizing	POS	I-NP
hepatic	POS	I-NP
neoplasms	POS	I-NP
and	POS	O
peliosis	POS	B-NP
can	POS	O
develop	POS	O
in	POS	O
patients	POS	O
with	POS	O
androgen	POS	O
-	POS	O
and	POS	O
corticosteroid	POS	O
-	POS	O
treated	POS	O
Fanconi	POS	B-NP
'	POS	I-NP
s	POS	I-NP
anemia	POS	I-NP
.	POS	O
The	POS	O
influence	POS	O
of	POS	O
the	POS	O
time	POS	O
interval	POS	O
between	POS	O
monoHER	POS	O
and	POS	O
doxorubicin	POS	O
administration	POS	O
on	POS	O
the	POS	O
protection	POS	O
against	POS	O
doxorubicin	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
in	POS	O
mice	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
Despite	POS	O
its	POS	O
well	POS	O
-	POS	O
known	POS	O
cardiotoxicity	POS	B-NP
,	POS	O
the	POS	O
anthracyclin	POS	O
doxorubicin	POS	O
(	POS	O
DOX	POS	O
)	POS	O
continues	POS	O
to	POS	O
be	POS	O
an	POS	O
effective	POS	O
and	POS	O
widely	POS	O
used	POS	O
chemotherapeutic	POS	O
agent	POS	O
.	POS	O
DOX	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
damage	POS	I-NP
presumably	POS	O
results	POS	O
from	POS	O
the	POS	O
formation	POS	O
of	POS	O
free	POS	O
radicals	POS	O
by	POS	O
DOX	POS	O
.	POS	O
Reactive	POS	O
oxygen	POS	O
species	POS	O
particularly	POS	O
affect	POS	O
the	POS	O
cardiac	POS	O
myocytes	POS	O
because	POS	O
these	POS	O
cells	POS	O
seem	POS	O
to	POS	O
have	POS	O
a	POS	O
relatively	POS	O
poor	POS	O
antioxidant	POS	O
defense	POS	O
system	POS	O
.	POS	O
The	POS	O
semisynthetic	POS	O
flavonoid	POS	O
monohydroxyethylrutoside	POS	O
(	POS	O
monoHER	POS	O
)	POS	O
showed	POS	O
cardioprotection	POS	O
against	POS	O
DOX	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
through	POS	O
its	POS	O
radical	POS	O
scavenging	POS	O
and	POS	O
iron	POS	O
chelating	POS	O
properties	POS	O
.	POS	O
Because	POS	O
of	POS	O
the	POS	O
relatively	POS	O
short	POS	O
final	POS	O
half	POS	O
-	POS	O
life	POS	O
of	POS	O
monoHER	POS	O
(	POS	O
about	POS	O
30	POS	O
min	POS	O
)	POS	O
,	POS	O
it	POS	O
is	POS	O
expected	POS	O
that	POS	O
the	POS	O
time	POS	O
interval	POS	O
between	POS	O
monoHER	POS	O
and	POS	O
DOX	POS	O
might	POS	O
be	POS	O
of	POS	O
influence	POS	O
on	POS	O
the	POS	O
cardioprotective	POS	O
effect	POS	O
of	POS	O
monoHER	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
the	POS	O
aim	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
this	POS	O
possible	POS	O
effect	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Six	POS	O
groups	POS	O
of	POS	O
6	POS	O
BALB	POS	O
/	POS	O
c	POS	O
mice	POS	O
were	POS	O
treated	POS	O
with	POS	O
saline	POS	O
,	POS	O
DOX	POS	O
alone	POS	O
or	POS	O
DOX	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
preceded	POS	O
by	POS	O
monoHER	POS	O
(	POS	O
500	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
with	POS	O
an	POS	O
interval	POS	O
of	POS	O
10	POS	O
,	POS	O
30	POS	O
,	POS	O
60	POS	O
or	POS	O
120	POS	O
min	POS	O
.	POS	O
After	POS	O
a	POS	O
6	POS	O
-	POS	O
week	POS	O
treatment	POS	O
period	POS	O
and	POS	O
additional	POS	O
observation	POS	O
for	POS	O
2	POS	O
weeks	POS	O
,	POS	O
the	POS	O
mice	POS	O
were	POS	O
sacrificed	POS	O
.	POS	O
Their	POS	O
cardiac	POS	O
tissues	POS	O
were	POS	O
processed	POS	O
for	POS	O
light	POS	O
microscopy	POS	O
,	POS	O
after	POS	O
which	POS	O
cardiomyocyte	POS	O
damage	POS	O
was	POS	O
evaluated	POS	O
according	POS	O
to	POS	O
Billingham	POS	O
(	POS	O
in	POS	O
Cancer	POS	O
Treat	POS	O
Rep	POS	O
62	POS	O
(	POS	O
6	POS	O
)	POS	O
:	POS	O
865	POS	O
-	POS	O
872	POS	O
,	POS	O
1978	POS	O
)	POS	O
.	POS	O
Microscopic	POS	O
evaluation	POS	O
revealed	POS	O
that	POS	O
treatment	POS	O
with	POS	O
DOX	POS	O
alone	POS	O
induced	POS	O
significant	POS	O
cardiac	POS	B-NP
damage	POS	I-NP
in	POS	O
comparison	POS	O
to	POS	O
the	POS	O
saline	POS	O
control	POS	O
group	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
number	POS	O
of	POS	O
damaged	POS	O
cardiomyocytes	POS	O
was	POS	O
9	POS	O
.	POS	O
6	POS	O
-	POS	O
fold	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
4	POS	O
.	POS	O
4	POS	O
-	POS	O
21	POS	O
.	POS	O
0	POS	O
)	POS	O
higher	POS	O
in	POS	O
mice	POS	O
treated	POS	O
with	POS	O
DOX	POS	O
alone	POS	O
than	POS	O
that	POS	O
in	POS	O
animals	POS	O
of	POS	O
the	POS	O
control	POS	O
group	POS	O
.	POS	O
The	POS	O
ratio	POS	O
of	POS	O
aberrant	POS	O
cardiomyocytes	POS	O
in	POS	O
mice	POS	O
treated	POS	O
with	POS	O
DOX	POS	O
preceded	POS	O
by	POS	O
monoHER	POS	O
and	POS	O
those	POS	O
in	POS	O
mice	POS	O
treated	POS	O
with	POS	O
saline	POS	O
ranged	POS	O
from	POS	O
1	POS	O
.	POS	O
6	POS	O
to	POS	O
2	POS	O
.	POS	O
8	POS	O
(	POS	O
mean	POS	O
2	POS	O
.	POS	O
2	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
1	POS	O
.	POS	O
2	POS	O
-	POS	O
4	POS	O
.	POS	O
1	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
019	POS	O
)	POS	O
.	POS	O
The	POS	O
mean	POS	O
protective	POS	O
effect	POS	O
by	POS	O
adding	POS	O
monoHER	POS	O
before	POS	O
DOX	POS	O
led	POS	O
to	POS	O
a	POS	O
significant	POS	O
4	POS	O
.	POS	O
4	POS	O
-	POS	O
fold	POS	O
reduction	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
2	POS	O
.	POS	O
3	POS	O
-	POS	O
8	POS	O
.	POS	O
2	POS	O
)	POS	O
of	POS	O
abnormal	POS	O
cardiomyocytes	POS	O
.	POS	O
This	POS	O
protective	POS	O
effect	POS	O
did	POS	O
not	POS	O
depend	POS	O
on	POS	O
the	POS	O
time	POS	O
interval	POS	O
between	POS	O
monoHER	POS	O
and	POS	O
DOX	POS	O
administration	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
345	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
results	POS	O
indicate	POS	O
that	POS	O
in	POS	O
an	POS	O
outpatient	POS	O
clinical	POS	O
setting	POS	O
monoHER	POS	O
may	POS	O
be	POS	O
administered	POS	O
shortly	POS	O
before	POS	O
DOX	POS	O
.	POS	O
Clinical	POS	O
evaluation	POS	O
of	POS	O
adverse	POS	O
effects	POS	O
during	POS	O
bepridil	POS	O
administration	POS	O
for	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
and	POS	O
flutter	POS	B-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Bepridil	POS	O
hydrochloride	POS	O
(	POS	O
Bpd	POS	O
)	POS	O
has	POS	O
attracted	POS	O
attention	POS	O
as	POS	O
an	POS	O
effective	POS	O
drug	POS	O
for	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
(	POS	O
AF	POS	B-NP
)	POS	O
and	POS	O
atrial	POS	B-NP
flutter	POS	I-NP
(	POS	O
AFL	POS	B-NP
)	POS	O
.	POS	O
However	POS	O
,	POS	O
serious	POS	O
adverse	POS	O
effects	POS	O
,	POS	O
including	POS	O
torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
(	POS	O
Tdp	POS	B-NP
)	POS	O
,	POS	O
have	POS	O
been	POS	O
reported	POS	O
.	POS	O
METHODS	POS	O
AND	POS	O
RESULTS	POS	O
:	POS	O
Adverse	POS	O
effects	POS	O
of	POS	O
Bpd	POS	O
requiring	POS	O
discontinuation	POS	O
of	POS	O
treatment	POS	O
were	POS	O
evaluated	POS	O
.	POS	O
Bpd	POS	O
was	POS	O
administered	POS	O
to	POS	O
459	POS	O
patients	POS	O
(	POS	O
361	POS	O
males	POS	O
,	POS	O
63	POS	O
+	POS	O
/	POS	O
-	POS	O
12	POS	O
years	POS	O
old	POS	O
)	POS	O
comprising	POS	O
378	POS	O
AF	POS	B-NP
and	POS	O
81	POS	O
AFL	POS	B-NP
cases	POS	O
.	POS	O
Mean	POS	O
left	POS	O
ventricular	POS	O
ejection	POS	O
fraction	POS	O
and	POS	O
atrial	POS	O
dimension	POS	O
(	POS	O
LAD	POS	O
)	POS	O
were	POS	O
66	POS	O
+	POS	O
/	POS	O
-	POS	O
11	POS	O
%	POS	O
and	POS	O
40	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
mm	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Adverse	POS	O
effects	POS	O
were	POS	O
observed	POS	O
in	POS	O
19	POS	O
patients	POS	O
(	POS	O
4	POS	O
%	POS	O
)	POS	O
during	POS	O
an	POS	O
average	POS	O
follow	POS	O
-	POS	O
up	POS	O
of	POS	O
20	POS	O
months	POS	O
.	POS	O
There	POS	O
was	POS	O
marked	POS	O
QT	POS	O
prolongation	POS	O
greater	POS	O
than	POS	O
0	POS	O
.	POS	O
55	POS	O
s	POS	O
in	POS	O
13	POS	O
patients	POS	O
,	POS	O
bradycardia	POS	B-NP
less	POS	O
than	POS	O
40	POS	O
beats	POS	O
/	POS	O
min	POS	O
in	POS	O
6	POS	O
patients	POS	O
,	POS	O
dizziness	POS	B-NP
and	POS	O
general	POS	B-NP
fatigue	POS	I-NP
in	POS	O
1	POS	O
patient	POS	O
each	POS	O
.	POS	O
In	POS	O
4	POS	O
of	POS	O
13	POS	O
patients	POS	O
with	POS	O
QT	POS	B-NP
prolongation	POS	I-NP
,	POS	O
Tdp	POS	B-NP
occurred	POS	O
.	POS	O
The	POS	O
major	POS	O
triggering	POS	O
factors	POS	O
of	POS	O
Tdp	POS	O
were	POS	O
hypokalemia	POS	B-NP
and	POS	O
sudden	POS	O
decrease	POS	O
in	POS	O
heart	POS	O
rate	POS	O
.	POS	O
There	POS	O
were	POS	O
no	POS	O
differences	POS	O
in	POS	O
the	POS	O
clinical	POS	O
backgrounds	POS	O
of	POS	O
the	POS	O
patients	POS	O
with	POS	O
and	POS	O
without	POS	O
Tdp	POS	O
other	POS	O
than	POS	O
LAD	POS	O
and	POS	O
age	POS	O
,	POS	O
which	POS	O
were	POS	O
larger	POS	O
and	POS	O
older	POS	O
in	POS	O
the	POS	O
patients	POS	O
with	POS	O
Tdp	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Careful	POS	O
observation	POS	O
of	POS	O
serum	POS	O
potassium	POS	O
concentration	POS	O
and	POS	O
the	POS	O
ECG	POS	O
should	POS	O
always	POS	O
be	POS	O
done	POS	O
during	POS	O
Bpd	POS	O
administration	POS	O
,	POS	O
particularly	POS	O
in	POS	O
elderly	POS	O
patients	POS	O
.	POS	O
Enhanced	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
hypertrophy	POS	I-NP
in	POS	O
transgenic	POS	O
rats	POS	O
with	POS	O
low	POS	O
brain	POS	O
angiotensinogen	POS	O
.	POS	O
We	POS	O
have	POS	O
previously	POS	O
shown	POS	O
that	POS	O
a	POS	O
permanent	POS	B-NP
deficiency	POS	I-NP
in	POS	I-NP
the	POS	I-NP
brain	POS	I-NP
renin	POS	I-NP
-	POS	I-NP
angiotensin	POS	I-NP
system	POS	I-NP
(	POS	O
RAS	POS	O
)	POS	O
may	POS	O
increase	POS	O
the	POS	O
sensitivity	POS	O
of	POS	O
the	POS	O
baroreflex	POS	O
control	POS	O
of	POS	O
heart	POS	O
rate	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
we	POS	O
aimed	POS	O
at	POS	O
studying	POS	O
the	POS	O
involvement	POS	O
of	POS	O
the	POS	O
brain	POS	O
RAS	POS	O
in	POS	O
the	POS	O
cardiac	POS	O
reactivity	POS	O
to	POS	O
the	POS	O
beta	POS	O
-	POS	O
adrenoceptor	POS	O
(	POS	O
beta	POS	O
-	POS	O
AR	POS	O
)	POS	O
agonist	POS	O
isoproterenol	POS	O
(	POS	O
Iso	POS	O
)	POS	O
.	POS	O
Transgenic	POS	O
rats	POS	O
with	POS	O
low	POS	O
brain	POS	O
angiotensinogen	POS	O
(	POS	O
TGR	POS	O
)	POS	O
were	POS	O
used	POS	O
.	POS	O
In	POS	O
isolated	POS	O
hearts	POS	O
,	POS	O
Iso	POS	O
induced	POS	O
a	POS	O
significantly	POS	O
greater	POS	O
increase	POS	O
in	POS	O
left	POS	O
ventricular	POS	O
(	POS	O
LV	POS	O
)	POS	O
pressure	POS	O
and	POS	O
maximal	POS	O
contraction	POS	O
(	POS	O
+	POS	O
dP	POS	O
/	POS	O
dt	POS	O
(	POS	O
max	POS	O
)	POS	O
)	POS	O
in	POS	O
the	POS	O
TGR	POS	O
than	POS	O
in	POS	O
the	POS	O
Sprague	POS	O
-	POS	O
Dawley	POS	O
(	POS	O
SD	POS	O
)	POS	O
rats	POS	O
.	POS	O
LV	POS	B-NP
hypertrophy	POS	I-NP
induced	POS	O
by	POS	O
Iso	POS	O
treatment	POS	O
was	POS	O
significantly	POS	O
higher	POS	O
in	POS	O
TGR	POS	O
than	POS	O
in	POS	O
SD	POS	O
rats	POS	O
(	POS	O
in	POS	O
g	POS	O
LV	POS	O
wt	POS	O
/	POS	O
100	POS	O
g	POS	O
body	POS	O
wt	POS	O
,	POS	O
0	POS	O
.	POS	O
28	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
004	POS	O
vs	POS	O
.	POS	O
0	POS	O
.	POS	O
24	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
004	POS	O
,	POS	O
respectively	POS	O
)	POS	O
.	POS	O
The	POS	O
greater	POS	O
LV	POS	B-NP
hypertrophy	POS	I-NP
in	POS	O
TGR	POS	O
rats	POS	O
was	POS	O
associated	POS	O
with	POS	O
more	POS	O
pronounced	POS	O
downregulation	POS	O
of	POS	O
beta	POS	O
-	POS	O
AR	POS	O
and	POS	O
upregulation	POS	O
of	POS	O
LV	POS	O
beta	POS	O
-	POS	O
AR	POS	O
kinase	POS	O
-	POS	O
1	POS	O
mRNA	POS	O
levels	POS	O
compared	POS	O
with	POS	O
those	POS	O
in	POS	O
SD	POS	O
rats	POS	O
.	POS	O
The	POS	O
decrease	POS	O
in	POS	O
the	POS	O
heart	POS	O
rate	POS	O
(	POS	O
HR	POS	O
)	POS	O
induced	POS	O
by	POS	O
the	POS	O
beta	POS	O
-	POS	O
AR	POS	O
antagonist	POS	O
metoprolol	POS	O
in	POS	O
conscious	POS	O
rats	POS	O
was	POS	O
significantly	POS	O
attenuated	POS	O
in	POS	O
TGR	POS	O
compared	POS	O
with	POS	O
SD	POS	O
rats	POS	O
(	POS	O
-	POS	O
9	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
7	POS	O
%	POS	O
vs	POS	O
.	POS	O
-	POS	O
18	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
,	POS	O
whereas	POS	O
the	POS	O
effect	POS	O
of	POS	O
parasympathetic	POS	O
blockade	POS	O
by	POS	O
atropine	POS	O
on	POS	O
HR	POS	O
was	POS	O
similar	POS	O
in	POS	O
both	POS	O
strains	POS	O
.	POS	O
These	POS	O
results	POS	O
indicate	POS	O
that	POS	O
TGR	POS	O
are	POS	O
more	POS	O
sensitive	POS	O
to	POS	O
beta	POS	O
-	POS	O
AR	POS	O
agonist	POS	O
-	POS	O
induced	POS	O
cardiac	POS	O
inotropic	POS	O
response	POS	O
and	POS	O
hypertrophy	POS	B-NP
,	POS	O
possibly	POS	O
due	POS	O
to	POS	O
chronically	POS	O
low	POS	O
sympathetic	POS	O
outflow	POS	O
directed	POS	O
to	POS	O
the	POS	O
heart	POS	O
.	POS	O
Drug	POS	O
-	POS	O
induced	POS	O
long	POS	O
QT	POS	B-NP
syndrome	POS	I-NP
in	POS	O
injection	POS	O
drug	POS	O
users	POS	O
receiving	POS	O
methadone	POS	O
:	POS	O
high	POS	O
frequency	POS	O
in	POS	O
hospitalized	POS	O
patients	POS	O
and	POS	O
risk	POS	O
factors	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Drug	POS	O
-	POS	O
induced	POS	O
long	POS	O
QT	POS	B-NP
syndrome	POS	I-NP
is	POS	O
a	POS	O
serious	POS	O
adverse	POS	O
drug	POS	O
reaction	POS	O
.	POS	O
Methadone	POS	O
prolongs	POS	O
the	POS	O
QT	POS	O
interval	POS	O
in	POS	O
vitro	POS	O
in	POS	O
a	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
manner	POS	O
.	POS	O
In	POS	O
the	POS	O
inpatient	POS	O
setting	POS	O
,	POS	O
the	POS	O
frequency	POS	O
of	POS	O
QT	POS	O
interval	POS	O
prolongation	POS	O
with	POS	O
methadone	POS	O
treatment	POS	O
,	POS	O
its	POS	O
dose	POS	O
dependence	POS	O
,	POS	O
and	POS	O
the	POS	O
importance	POS	O
of	POS	O
cofactors	POS	O
such	POS	O
as	POS	O
drug	POS	O
-	POS	O
drug	POS	O
interactions	POS	O
remain	POS	O
unknown	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
performed	POS	O
a	POS	O
systematic	POS	O
,	POS	O
retrospective	POS	O
study	POS	O
comparing	POS	O
active	POS	O
or	POS	O
former	POS	O
intravenous	POS	O
drug	POS	O
users	POS	O
receiving	POS	O
methadone	POS	O
and	POS	O
those	POS	O
not	POS	O
receiving	POS	O
methadone	POS	O
among	POS	O
all	POS	O
patients	POS	O
hospitalized	POS	O
over	POS	O
a	POS	O
5	POS	O
-	POS	O
year	POS	O
period	POS	O
in	POS	O
a	POS	O
tertiary	POS	O
care	POS	O
hospital	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
167	POS	O
patients	POS	O
receiving	POS	O
methadone	POS	O
fulfilled	POS	O
the	POS	O
inclusion	POS	O
criteria	POS	O
and	POS	O
were	POS	O
compared	POS	O
with	POS	O
a	POS	O
control	POS	O
group	POS	O
of	POS	O
80	POS	O
injection	POS	O
drug	POS	O
users	POS	O
not	POS	O
receiving	POS	O
methadone	POS	O
.	POS	O
In	POS	O
addition	POS	O
to	POS	O
methadone	POS	O
dose	POS	O
,	POS	O
15	POS	O
demographic	POS	O
,	POS	O
biological	POS	O
,	POS	O
and	POS	O
pharmacological	POS	O
variables	POS	O
were	POS	O
considered	POS	O
as	POS	O
potential	POS	O
risk	POS	O
factors	POS	O
for	POS	O
QT	POS	B-NP
prolongation	POS	I-NP
.	POS	O
RESULTS	POS	O
:	POS	O
Among	POS	O
167	POS	O
methadone	POS	O
maintenance	POS	O
patients	POS	O
,	POS	O
the	POS	O
prevalence	POS	O
of	POS	O
QTc	POS	O
prolongation	POS	O
to	POS	O
0	POS	O
.	POS	O
50	POS	O
second	POS	O
(	POS	O
(	POS	O
1	POS	O
/	POS	O
2	POS	O
)	POS	O
)	POS	O
or	POS	O
longer	POS	O
was	POS	O
16	POS	O
.	POS	O
2	POS	O
%	POS	O
compared	POS	O
with	POS	O
0	POS	O
%	POS	O
in	POS	O
80	POS	O
control	POS	O
subjects	POS	O
.	POS	O
Six	POS	O
patients	POS	O
(	POS	O
3	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
in	POS	O
the	POS	O
methadone	POS	O
group	POS	O
presented	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
.	POS	O
QTc	POS	O
length	POS	O
was	POS	O
weakly	POS	O
but	POS	O
significantly	POS	O
associated	POS	O
with	POS	O
methadone	POS	O
daily	POS	O
dose	POS	O
(	POS	O
Spearman	POS	O
rank	POS	O
correlation	POS	O
coefficient	POS	O
,	POS	O
0	POS	O
.	POS	O
20	POS	O
;	POS	O
P	POS	O
<	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Multivariate	POS	O
regression	POS	O
analysis	POS	O
allowed	POS	O
attribution	POS	O
of	POS	O
31	POS	O
.	POS	O
8	POS	O
%	POS	O
of	POS	O
QTc	POS	O
variability	POS	O
to	POS	O
methadone	POS	O
dose	POS	O
,	POS	O
cytochrome	POS	O
P	POS	O
-	POS	O
450	POS	O
3A4	POS	O
drug	POS	O
-	POS	O
drug	POS	O
interactions	POS	O
,	POS	O
hypokalemia	POS	B-NP
,	POS	O
and	POS	O
altered	POS	B-NP
liver	POS	I-NP
function	POS	I-NP
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
QT	POS	O
interval	POS	O
prolongation	POS	O
in	POS	O
methadone	POS	O
maintenance	POS	O
patients	POS	O
hospitalized	POS	O
in	POS	O
a	POS	O
tertiary	POS	O
care	POS	O
center	POS	O
is	POS	O
a	POS	O
frequent	POS	O
finding	POS	O
.	POS	O
Methadone	POS	O
dose	POS	O
,	POS	O
presence	POS	O
of	POS	O
cytochrome	POS	O
P	POS	O
-	POS	O
450	POS	O
3A4	POS	O
inhibitors	POS	O
,	POS	O
potassium	POS	O
level	POS	O
,	POS	O
and	POS	O
liver	POS	O
function	POS	O
contribute	POS	O
to	POS	O
QT	POS	B-NP
prolongation	POS	I-NP
.	POS	O
Long	POS	B-NP
QT	POS	I-NP
syndrome	POS	I-NP
can	POS	O
occur	POS	O
with	POS	O
low	POS	O
doses	POS	O
of	POS	O
methadone	POS	O
.	POS	O
Mechanisms	POS	O
of	POS	O
hypertension	POS	B-NP
induced	POS	O
by	POS	O
nitric	POS	O
oxide	POS	O
(	POS	O
NO	POS	O
)	POS	O
deficiency	POS	O
:	POS	O
focus	POS	O
on	POS	O
venous	POS	O
function	POS	O
.	POS	O
Loss	POS	O
of	POS	O
endothelial	POS	O
cell	POS	O
-	POS	O
derived	POS	O
nitric	POS	O
oxide	POS	O
(	POS	O
NO	POS	O
)	POS	O
in	POS	O
hypertension	POS	B-NP
is	POS	O
a	POS	O
hallmark	POS	O
of	POS	O
arterial	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
Experimental	POS	O
hypertension	POS	B-NP
created	POS	O
by	POS	O
the	POS	O
removal	POS	O
of	POS	O
NO	POS	O
,	POS	O
however	POS	O
,	POS	O
involves	POS	O
mechanisms	POS	O
in	POS	O
addition	POS	O
to	POS	O
decreased	POS	O
arterial	POS	O
vasodilator	POS	O
activity	POS	O
.	POS	O
These	POS	O
include	POS	O
augmented	POS	O
endothelin	POS	O
-	POS	O
1	POS	O
(	POS	O
ET	POS	O
-	POS	O
1	POS	O
)	POS	O
release	POS	O
,	POS	O
increased	POS	O
sympathetic	POS	O
nervous	POS	O
system	POS	O
activity	POS	O
,	POS	O
and	POS	O
elevated	POS	O
tissue	POS	O
oxidative	POS	O
stress	POS	O
.	POS	O
We	POS	O
hypothesized	POS	O
that	POS	O
increased	POS	O
venous	POS	O
smooth	POS	O
muscle	POS	O
(	POS	O
venomotor	POS	O
)	POS	O
tone	POS	O
plays	POS	O
a	POS	O
role	POS	O
in	POS	O
Nomega	POS	O
-	POS	O
nitro	POS	O
-	POS	O
L	POS	O
-	POS	O
arginine	POS	O
(	POS	O
LNNA	POS	O
)	POS	O
hypertension	POS	B-NP
through	POS	O
these	POS	O
mechanisms	POS	O
.	POS	O
Rats	POS	O
were	POS	O
treated	POS	O
with	POS	O
the	POS	O
NO	POS	O
synthase	POS	O
inhibitor	POS	O
LNNA	POS	O
(	POS	O
0	POS	O
.	POS	O
5	POS	O
g	POS	O
/	POS	O
L	POS	O
in	POS	O
drinking	POS	O
water	POS	O
)	POS	O
for	POS	O
2	POS	O
weeks	POS	O
.	POS	O
Mean	POS	O
arterial	POS	O
pressure	POS	O
of	POS	O
conscious	POS	O
rats	POS	O
was	POS	O
119	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
mm	POS	O
Hg	POS	O
in	POS	O
control	POS	O
and	POS	O
194	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
mm	POS	O
Hg	POS	O
in	POS	O
LNNA	POS	O
rats	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Carotid	POS	O
arteries	POS	O
and	POS	O
vena	POS	O
cava	POS	O
were	POS	O
removed	POS	O
for	POS	O
measurement	POS	O
of	POS	O
isometric	POS	O
contraction	POS	O
.	POS	O
Maximal	POS	O
contraction	POS	O
to	POS	O
norepinephrine	POS	O
was	POS	O
modestly	POS	O
reduced	POS	O
in	POS	O
arteries	POS	O
from	POS	O
LNNA	POS	O
compared	POS	O
with	POS	O
control	POS	O
rats	POS	O
whereas	POS	O
the	POS	O
maximum	POS	O
contraction	POS	O
to	POS	O
ET	POS	O
-	POS	O
1	POS	O
was	POS	O
significantly	POS	O
reduced	POS	O
(	POS	O
54	POS	O
%	POS	O
control	POS	O
)	POS	O
.	POS	O
Maximum	POS	O
contraction	POS	O
of	POS	O
vena	POS	O
cava	POS	O
to	POS	O
norepinephrine	POS	O
(	POS	O
37	POS	O
%	POS	O
control	POS	O
)	POS	O
also	POS	O
was	POS	O
reduced	POS	O
but	POS	O
no	POS	O
change	POS	O
in	POS	O
response	POS	O
to	POS	O
ET	POS	O
-	POS	O
1	POS	O
was	POS	O
observed	POS	O
.	POS	O
Mean	POS	O
circulatory	POS	O
filling	POS	O
pressure	POS	O
,	POS	O
an	POS	O
in	POS	O
vivo	POS	O
measure	POS	O
of	POS	O
venomotor	POS	O
tone	POS	O
,	POS	O
was	POS	O
not	POS	O
elevated	POS	O
in	POS	O
LNNA	POS	O
hypertension	POS	B-NP
at	POS	O
1	POS	O
or	POS	O
2	POS	O
weeks	POS	O
after	POS	O
LNNA	POS	O
.	POS	O
The	POS	O
superoxide	POS	O
scavenger	POS	O
tempol	POS	O
(	POS	O
30	POS	O
,	POS	O
100	POS	O
,	POS	O
and	POS	O
300	POS	O
micromol	POS	O
kg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
,	POS	O
IV	POS	O
)	POS	O
did	POS	O
not	POS	O
change	POS	O
arterial	POS	O
pressure	POS	O
in	POS	O
control	POS	O
rats	POS	O
but	POS	O
caused	POS	O
a	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
decrease	POS	O
in	POS	O
LNNA	POS	O
rats	POS	O
(	POS	O
-	POS	O
18	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
,	POS	O
-	POS	O
26	POS	O
+	POS	O
/	POS	O
-	POS	O
15	POS	O
,	POS	O
and	POS	O
-	POS	O
54	POS	O
+	POS	O
/	POS	O
-	POS	O
11	POS	O
mm	POS	O
Hg	POS	O
)	POS	O
.	POS	O
Similarly	POS	O
,	POS	O
ganglionic	POS	O
blockade	POS	O
with	POS	O
hexamethonium	POS	O
caused	POS	O
a	POS	O
significantly	POS	O
greater	POS	O
fall	POS	O
in	POS	O
LNNA	POS	O
hypertensive	POS	B-NP
rats	POS	O
(	POS	O
76	POS	O
+	POS	O
/	POS	O
-	POS	O
9	POS	O
mm	POS	O
Hg	POS	O
)	POS	O
compared	POS	O
with	POS	O
control	POS	O
rats	POS	O
(	POS	O
35	POS	O
+	POS	O
/	POS	O
-	POS	O
10	POS	O
mm	POS	O
Hg	POS	O
)	POS	O
.	POS	O
Carotid	POS	O
arteries	POS	O
,	POS	O
vena	POS	O
cava	POS	O
,	POS	O
and	POS	O
sympathetic	POS	O
ganglia	POS	O
from	POS	O
LNNA	POS	O
rats	POS	O
had	POS	O
higher	POS	O
basal	POS	O
levels	POS	O
of	POS	O
superoxide	POS	O
compared	POS	O
with	POS	O
those	POS	O
from	POS	O
control	POS	O
rats	POS	O
.	POS	O
These	POS	O
data	POS	O
suggest	POS	O
that	POS	O
while	POS	O
NO	POS	O
deficiency	POS	O
increases	POS	O
oxidative	POS	O
stress	POS	O
and	POS	O
sympathetic	POS	O
activity	POS	O
in	POS	O
both	POS	O
arterial	POS	O
and	POS	O
venous	POS	O
vessels	POS	O
,	POS	O
the	POS	O
impact	POS	O
on	POS	O
veins	POS	O
does	POS	O
not	POS	O
make	POS	O
a	POS	O
major	POS	O
contribution	POS	O
to	POS	O
this	POS	O
form	POS	O
of	POS	O
hypertension	POS	B-NP
.	POS	O
Association	POS	O
of	POS	O
DRD2	POS	O
polymorphisms	POS	O
and	POS	O
chlorpromazine	POS	O
-	POS	O
induced	POS	O
extrapyramidal	POS	B-NP
syndrome	POS	I-NP
in	POS	O
Chinese	POS	O
schizophrenic	POS	B-NP
patients	POS	O
.	POS	O
AIM	POS	B-NP
:	POS	O
Extrapyramidal	POS	B-NP
syndrome	POS	I-NP
(	POS	O
EPS	POS	B-NP
)	POS	O
is	POS	O
most	POS	O
commonly	POS	O
affected	POS	O
by	POS	O
typical	POS	O
antipsychotic	POS	O
drugs	POS	O
that	POS	O
have	POS	O
a	POS	O
high	POS	O
affinity	POS	O
with	POS	O
the	POS	O
D2	POS	O
receptor	POS	O
.	POS	O
Recently	POS	O
,	POS	O
many	POS	O
research	POS	O
groups	POS	O
have	POS	O
reported	POS	O
on	POS	O
the	POS	O
positive	POS	O
relationship	POS	O
between	POS	O
the	POS	O
genetic	POS	O
variations	POS	O
in	POS	O
the	POS	O
DRD2	POS	O
gene	POS	O
and	POS	O
the	POS	O
therapeutic	POS	O
response	POS	O
in	POS	O
schizophrenia	POS	B-NP
patients	POS	O
as	POS	O
a	POS	O
result	POS	O
of	POS	O
the	POS	O
role	POS	O
of	POS	O
variations	POS	O
in	POS	O
the	POS	O
receptor	POS	O
in	POS	O
modulating	POS	O
receptor	POS	O
expression	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
we	POS	O
evaluate	POS	O
the	POS	O
role	POS	O
DRD2	POS	O
plays	POS	O
in	POS	O
chlorpromazine	POS	O
-	POS	O
induced	POS	O
EPS	POS	B-NP
in	POS	O
schizophrenic	POS	B-NP
patients	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
identified	POS	O
seven	POS	O
SNP	POS	O
(	POS	O
single	POS	O
nucleotide	POS	O
polymorphism	POS	O
)	POS	O
(	POS	O
-	POS	O
141Cins	POS	O
>	POS	O
del	POS	O
,	POS	O
TaqIB	POS	O
,	POS	O
TaqID	POS	O
,	POS	O
Ser311Cys	POS	O
,	POS	O
rs6275	POS	O
,	POS	O
rs6277	POS	O
and	POS	O
TaqIA	POS	O
)	POS	O
in	POS	O
the	POS	O
DRD2	POS	O
gene	POS	O
in	POS	O
146	POS	O
schizophrenic	POS	B-NP
inpatients	POS	O
(	POS	O
59	POS	O
with	POS	O
EPS	POS	B-NP
and	POS	O
87	POS	O
without	POS	O
EPS	POS	B-NP
according	POS	O
to	POS	O
the	POS	O
Simpson	POS	O
-	POS	O
Angus	POS	O
Scale	POS	O
)	POS	O
treated	POS	O
with	POS	O
chlorpromazine	POS	O
after	POS	O
8	POS	O
weeks	POS	O
.	POS	O
The	POS	O
alleles	POS	O
of	POS	O
all	POS	O
loci	POS	O
were	POS	O
determined	POS	O
by	POS	O
PCR	POS	O
(	POS	O
polymerase	POS	O
chain	POS	O
reaction	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Polymorphisms	POS	O
TaqID	POS	O
,	POS	O
Ser311Cys	POS	O
and	POS	O
rs6277	POS	O
were	POS	O
not	POS	O
polymorphic	POS	O
in	POS	O
the	POS	O
population	POS	O
recruited	POS	O
in	POS	O
the	POS	O
present	POS	O
study	POS	O
.	POS	O
No	POS	O
statistical	POS	O
significance	POS	O
was	POS	O
found	POS	O
in	POS	O
the	POS	O
allele	POS	O
distribution	POS	O
of	POS	O
-	POS	O
141Cins	POS	O
>	POS	O
del	POS	O
,	POS	O
TaqIB	POS	O
,	POS	O
rs6275	POS	O
and	POS	O
TaqIA	POS	O
or	POS	O
in	POS	O
the	POS	O
estimated	POS	O
haplotypes	POS	O
(	POS	O
constituted	POS	O
by	POS	O
TaqIB	POS	O
,	POS	O
rs6275	POS	O
and	POS	O
TaqIA	POS	O
)	POS	O
in	POS	O
linkage	POS	O
disequilibrium	POS	O
between	POS	O
the	POS	O
two	POS	O
groups	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Our	POS	O
results	POS	O
did	POS	O
not	POS	O
lend	POS	O
strong	POS	O
support	POS	O
to	POS	O
the	POS	O
view	POS	O
that	POS	O
the	POS	O
genetic	POS	O
variation	POS	O
of	POS	O
the	POS	O
DRD2	POS	O
gene	POS	O
plays	POS	O
a	POS	O
major	POS	O
role	POS	O
in	POS	O
the	POS	O
individually	POS	O
variable	POS	O
adverse	POS	O
effect	POS	O
induced	POS	O
by	POS	O
chlorpromazine	POS	O
,	POS	O
at	POS	O
least	POS	O
in	POS	O
Chinese	POS	O
patients	POS	O
with	POS	O
schizophrenia	POS	B-NP
.	POS	O
Our	POS	O
results	POS	O
confirmed	POS	O
a	POS	O
previous	POS	O
study	POS	O
on	POS	O
the	POS	O
relationship	POS	O
between	POS	O
DRD2	POS	O
and	POS	O
EPS	POS	B-NP
in	POS	O
Caucasians	POS	O
.	POS	O
Physical	POS	O
training	POS	O
decreases	POS	O
susceptibility	POS	O
to	POS	O
subsequent	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
Regular	POS	O
motor	POS	O
activity	POS	O
has	POS	O
many	POS	O
benefits	POS	O
for	POS	O
mental	POS	O
and	POS	O
physical	POS	O
condition	POS	O
but	POS	O
its	POS	O
implications	POS	O
for	POS	O
epilepsy	POS	B-NP
are	POS	O
still	POS	O
controversial	POS	O
.	POS	O
In	POS	O
order	POS	O
to	POS	O
elucidate	POS	O
this	POS	O
problem	POS	O
,	POS	O
we	POS	O
have	POS	O
studied	POS	O
the	POS	O
effect	POS	O
of	POS	O
long	POS	O
-	POS	O
term	POS	O
physical	POS	O
activity	POS	O
on	POS	O
susceptibility	POS	O
to	POS	O
subsequent	POS	O
seizures	POS	B-NP
.	POS	O
Male	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
subjected	POS	O
to	POS	O
repeated	POS	O
training	POS	O
sessions	POS	O
in	POS	O
a	POS	O
treadmill	POS	O
and	POS	O
swimming	POS	O
pool	POS	O
.	POS	O
Thereafter	POS	O
,	POS	O
seizures	POS	B-NP
were	POS	O
induced	POS	O
by	POS	O
pilocarpine	POS	O
injections	POS	O
in	POS	O
trained	POS	O
and	POS	O
non	POS	O
-	POS	O
trained	POS	O
control	POS	O
groups	POS	O
.	POS	O
During	POS	O
the	POS	O
acute	POS	O
period	POS	O
of	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
,	POS	O
we	POS	O
measured	POS	O
:	POS	O
(	POS	O
1	POS	O
)	POS	O
the	POS	O
latency	POS	O
of	POS	O
the	POS	O
first	POS	O
motor	POS	O
sign	POS	O
,	POS	O
(	POS	O
2	POS	O
)	POS	O
the	POS	O
intensity	POS	O
of	POS	O
seizures	POS	B-NP
,	POS	O
(	POS	O
3	POS	O
)	POS	O
the	POS	O
time	POS	O
when	POS	O
it	POS	O
occurred	POS	O
within	POS	O
the	POS	O
6	POS	O
-	POS	O
h	POS	O
observation	POS	O
period	POS	O
,	POS	O
and	POS	O
(	POS	O
4	POS	O
)	POS	O
the	POS	O
time	POS	O
when	POS	O
the	POS	O
acute	POS	O
period	POS	O
ended	POS	O
.	POS	O
All	POS	O
these	POS	O
behavioral	POS	O
parameters	POS	O
showed	POS	O
statistically	POS	O
significant	POS	O
changes	POS	O
suggesting	POS	O
that	POS	O
regular	POS	O
physical	POS	O
exercises	POS	O
decrease	POS	O
susceptibility	POS	O
to	POS	O
subsequently	POS	O
induced	POS	O
seizures	POS	B-NP
and	POS	O
ameliorate	POS	O
the	POS	O
course	POS	O
of	POS	O
experimentally	POS	O
induced	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
.	POS	O
Tonic	POS	O
dopaminergic	POS	O
stimulation	POS	O
impairs	POS	O
associative	POS	O
learning	POS	O
in	POS	O
healthy	POS	O
subjects	POS	O
.	POS	O
Endogenous	POS	O
dopamine	POS	O
plays	POS	O
a	POS	O
central	POS	O
role	POS	O
in	POS	O
salience	POS	O
coding	POS	O
during	POS	O
associative	POS	O
learning	POS	O
.	POS	O
Administration	POS	O
of	POS	O
the	POS	O
dopamine	POS	O
precursor	POS	O
levodopa	POS	O
enhances	POS	O
learning	POS	O
in	POS	O
healthy	POS	O
subjects	POS	O
and	POS	O
stroke	POS	B-NP
patients	POS	O
.	POS	O
Because	POS	O
levodopa	POS	O
increases	POS	O
both	POS	O
phasic	POS	O
and	POS	O
tonic	POS	O
dopaminergic	POS	O
neurotransmission	POS	O
,	POS	O
the	POS	O
critical	POS	O
mechanism	POS	O
mediating	POS	O
the	POS	O
enhancement	POS	O
of	POS	O
learning	POS	O
is	POS	O
unresolved	POS	O
.	POS	O
We	POS	O
here	POS	O
probed	POS	O
how	POS	O
selective	POS	O
tonic	POS	O
dopaminergic	POS	O
stimulation	POS	O
affects	POS	O
associative	POS	O
learning	POS	O
.	POS	O
Forty	POS	O
healthy	POS	O
subjects	POS	O
were	POS	O
trained	POS	O
in	POS	O
a	POS	O
novel	POS	O
vocabulary	POS	O
of	POS	O
45	POS	O
concrete	POS	O
nouns	POS	O
over	POS	O
the	POS	O
course	POS	O
of	POS	O
5	POS	O
consecutive	POS	O
training	POS	O
days	POS	O
in	POS	O
a	POS	O
prospective	POS	O
,	POS	O
randomized	POS	O
,	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
design	POS	O
.	POS	O
Subjects	POS	O
received	POS	O
the	POS	O
tonically	POS	O
stimulating	POS	O
dopamine	POS	O
-	POS	O
receptor	POS	O
agonist	POS	O
pergolide	POS	O
(	POS	O
0	POS	O
.	POS	O
1	POS	O
mg	POS	O
)	POS	O
vs	POS	O
placebo	POS	O
120	POS	O
min	POS	O
before	POS	O
training	POS	O
on	POS	O
each	POS	O
training	POS	O
day	POS	O
.	POS	O
The	POS	O
dopamine	POS	O
agonist	POS	O
significantly	POS	O
impaired	POS	O
novel	POS	O
word	POS	O
learning	POS	O
compared	POS	O
to	POS	O
placebo	POS	O
.	POS	O
This	POS	O
learning	POS	O
decrement	POS	O
persisted	POS	O
up	POS	O
to	POS	O
the	POS	O
last	POS	O
follow	POS	O
-	POS	O
up	POS	O
4	POS	O
weeks	POS	O
post	POS	O
-	POS	O
training	POS	O
.	POS	O
Subjects	POS	O
treated	POS	O
with	POS	O
pergolide	POS	O
also	POS	O
showed	POS	O
restricted	POS	O
emotional	POS	O
responses	POS	O
compared	POS	O
to	POS	O
the	POS	O
PLACEBO	POS	O
group	POS	O
.	POS	O
The	POS	O
extent	POS	O
of	POS	O
'	POS	O
flattened	POS	O
'	POS	O
affect	POS	O
with	POS	O
pergolide	POS	O
was	POS	O
related	POS	O
to	POS	O
the	POS	O
degree	POS	O
of	POS	O
learning	POS	O
inhibition	POS	O
.	POS	O
These	POS	O
findings	POS	O
suggest	POS	O
that	POS	O
tonic	POS	O
occupation	POS	O
of	POS	O
dopamine	POS	O
receptors	POS	O
impairs	POS	O
learning	POS	O
by	POS	O
competition	POS	O
with	POS	O
phasic	POS	O
dopamine	POS	O
signals	POS	O
.	POS	O
Thus	POS	O
,	POS	O
phasic	POS	O
signaling	POS	O
seems	POS	O
to	POS	O
be	POS	O
the	POS	O
critical	POS	O
mechanism	POS	O
by	POS	O
which	POS	O
dopamine	POS	O
enhances	POS	O
associative	POS	O
learning	POS	O
in	POS	O
healthy	POS	O
subjects	POS	O
and	POS	O
stroke	POS	B-NP
patients	POS	O
.	POS	O
Minocycline	POS	O
-	POS	O
induced	POS	O
vasculitis	POS	B-NP
fulfilling	POS	O
the	POS	O
criteria	POS	O
of	POS	O
polyarteritis	POS	B-NP
nodosa	POS	I-NP
.	POS	O
A	POS	O
47	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
who	POS	O
had	POS	O
been	POS	O
taking	POS	O
minocycline	POS	O
for	POS	O
palmoplantar	POS	B-NP
pustulosis	POS	I-NP
developed	POS	O
fever	POS	B-NP
,	POS	O
myalgias	POS	B-NP
,	POS	O
polyneuropathy	POS	B-NP
,	POS	O
and	POS	O
testicular	POS	B-NP
pain	POS	I-NP
,	POS	O
with	POS	O
elevated	POS	B-NP
C	POS	I-NP
-	POS	I-NP
reactive	POS	I-NP
protein	POS	I-NP
(	POS	O
CRP	POS	O
)	POS	O
.	POS	O
Neither	POS	O
myeloperoxidase	POS	O
-	POS	O
nor	POS	O
proteinase	POS	O
-	POS	O
3	POS	O
-	POS	O
antineutrophil	POS	O
cytoplasmic	POS	O
antibody	POS	O
was	POS	O
positive	POS	O
.	POS	O
These	POS	O
manifestations	POS	O
met	POS	O
the	POS	O
American	POS	O
College	POS	O
of	POS	O
Rheumatology	POS	O
1990	POS	O
criteria	POS	O
for	POS	O
the	POS	O
classification	POS	O
of	POS	O
polyarteritis	POS	B-NP
nodosa	POS	I-NP
.	POS	O
Stopping	POS	O
minocycline	POS	O
led	POS	O
to	POS	O
amelioration	POS	O
of	POS	O
symptoms	POS	O
and	POS	O
normalization	POS	O
of	POS	O
CRP	POS	O
level	POS	O
.	POS	O
To	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
this	POS	O
is	POS	O
the	POS	O
second	POS	O
case	POS	O
of	POS	O
minocycline	POS	O
-	POS	O
induced	POS	O
vasculitis	POS	B-NP
satisfying	POS	O
the	POS	O
criteria	POS	O
.	POS	O
Differential	POS	O
diagnosis	POS	O
for	POS	O
drug	POS	O
-	POS	O
induced	POS	O
disease	POS	O
is	POS	O
invaluable	POS	O
even	POS	O
for	POS	O
patients	POS	O
with	POS	O
classical	POS	O
polyarteritis	POS	B-NP
nodosa	POS	I-NP
.	POS	O
Intramuscular	POS	B-NP
hepatitis	POS	I-NP
B	POS	I-NP
immune	POS	O
globulin	POS	O
combined	POS	O
with	POS	O
lamivudine	POS	O
in	POS	O
prevention	POS	O
of	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
recurrence	POS	O
after	POS	O
liver	POS	O
transplantation	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Combined	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
immune	POS	O
globulin	POS	O
(	POS	O
HBIg	POS	O
)	POS	O
and	POS	O
lamivudine	POS	O
in	POS	O
prophylaxis	POS	O
of	POS	O
the	POS	O
recurrence	POS	O
of	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
after	POS	O
liver	POS	O
transplantation	POS	O
has	POS	O
significantly	POS	O
improved	POS	O
the	POS	O
survival	POS	O
of	POS	O
HBsAg	POS	O
positive	POS	O
patients	POS	O
.	POS	O
This	POS	O
study	POS	O
was	POS	O
undertaken	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
outcomes	POS	O
of	POS	O
liver	POS	O
transplantation	POS	O
for	POS	O
patients	POS	O
with	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
virus	POS	O
(	POS	O
HBV	POS	O
)	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
retrospective	POS	O
chart	POS	O
analysis	POS	O
and	POS	O
a	POS	O
review	POS	O
of	POS	O
the	POS	O
organ	POS	O
transplant	POS	O
database	POS	O
identified	POS	O
51	POS	O
patients	POS	O
(	POS	O
43	POS	O
men	POS	O
and	POS	O
8	POS	O
women	POS	O
)	POS	O
transplanted	POS	O
for	POS	O
benign	POS	O
HBV	POS	O
-	POS	O
related	POS	O
cirrhotic	POS	B-NP
diseases	POS	I-NP
between	POS	O
June	POS	O
2002	POS	O
and	POS	O
December	POS	O
2004	POS	O
who	POS	O
had	POS	O
survived	POS	O
more	POS	O
than	POS	O
3	POS	O
months	POS	O
.	POS	O
HBIg	POS	O
was	POS	O
administered	POS	O
intravenously	POS	O
during	POS	O
the	POS	O
first	POS	O
week	POS	O
and	POS	O
intramuscularly	POS	O
thereafter	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
At	POS	O
a	POS	O
median	POS	O
follow	POS	O
-	POS	O
up	POS	O
of	POS	O
14	POS	O
.	POS	O
1	POS	O
months	POS	O
,	POS	O
the	POS	O
overall	POS	O
recurrence	POS	O
rate	POS	O
in	POS	O
the	POS	O
51	POS	O
patients	POS	O
was	POS	O
3	POS	O
.	POS	O
9	POS	O
%	POS	O
(	POS	O
2	POS	O
/	POS	O
51	POS	O
)	POS	O
.	POS	O
The	POS	O
overall	POS	O
patient	POS	O
survival	POS	O
was	POS	O
88	POS	O
.	POS	O
3	POS	O
%	POS	O
,	POS	O
and	POS	O
82	POS	O
.	POS	O
4	POS	O
%	POS	O
after	POS	O
1	POS	O
and	POS	O
2	POS	O
years	POS	O
,	POS	O
respectively	POS	O
.	POS	O
A	POS	O
daily	POS	O
oral	POS	O
dose	POS	O
of	POS	O
100	POS	O
mg	POS	O
lamivudine	POS	O
for	POS	O
2	POS	O
weeks	POS	O
before	POS	O
transplantation	POS	O
for	POS	O
10	POS	O
patients	POS	O
enabled	POS	O
57	POS	O
.	POS	O
1	POS	O
%	POS	O
(	POS	O
4	POS	O
/	POS	O
7	POS	O
)	POS	O
and	POS	O
62	POS	O
.	POS	O
5	POS	O
%	POS	O
(	POS	O
5	POS	O
/	POS	O
8	POS	O
)	POS	O
of	POS	O
HBV	POS	O
-	POS	O
DNA	POS	O
and	POS	O
HBeAg	POS	O
positive	POS	O
patients	POS	O
respectively	POS	O
to	POS	O
convert	POS	O
to	POS	O
be	POS	O
negative	POS	O
.	POS	O
Intramuscular	POS	O
HBIg	POS	O
was	POS	O
well	POS	O
tolerated	POS	O
in	POS	O
all	POS	O
patients	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Lamivudine	POS	O
combined	POS	O
with	POS	O
intramuscular	POS	O
HBIg	POS	O
can	POS	O
effectively	POS	O
prevent	POS	O
allograft	POS	O
from	POS	O
the	POS	O
recurrence	POS	O
of	POS	O
HBV	POS	O
after	POS	O
liver	POS	O
transplantation	POS	O
.	POS	O
Anticonvulsant	POS	O
effect	POS	O
of	POS	O
eslicarbazepine	POS	O
acetate	POS	O
(	POS	O
BIA	POS	O
2	POS	O
-	POS	O
093	POS	O
)	POS	O
on	POS	O
seizures	POS	B-NP
induced	POS	O
by	POS	O
microperfusion	POS	O
of	POS	O
picrotoxin	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
of	POS	O
freely	POS	O
moving	POS	O
rats	POS	O
.	POS	O
Eslicarbazepine	POS	O
acetate	POS	O
(	POS	O
BIA	POS	O
2	POS	O
-	POS	O
093	POS	O
,	POS	O
S	POS	O
-	POS	O
(	POS	O
-	POS	O
)	POS	O
-	POS	O
10	POS	O
-	POS	O
acetoxy	POS	O
-	POS	O
10	POS	O
,	POS	O
11	POS	O
-	POS	O
dihydro	POS	O
-	POS	O
5H	POS	O
-	POS	O
dibenzo	POS	O
/	POS	O
b	POS	O
,	POS	O
f	POS	O
/	POS	O
azepine	POS	O
-	POS	O
5	POS	O
-	POS	O
carboxamide	POS	O
)	POS	O
is	POS	O
a	POS	O
novel	POS	O
antiepileptic	POS	O
drug	POS	O
,	POS	O
now	POS	O
in	POS	O
Phase	POS	O
III	POS	O
clinical	POS	O
trials	POS	O
,	POS	O
designed	POS	O
with	POS	O
the	POS	O
aim	POS	O
of	POS	O
improving	POS	O
efficacy	POS	O
and	POS	O
safety	POS	O
in	POS	O
comparison	POS	O
with	POS	O
the	POS	O
structurally	POS	O
related	POS	O
drugs	POS	O
carbamazepine	POS	O
(	POS	O
CBZ	POS	O
)	POS	O
and	POS	O
oxcarbazepine	POS	O
(	POS	O
OXC	POS	O
)	POS	O
.	POS	O
We	POS	O
have	POS	O
studied	POS	O
the	POS	O
effects	POS	O
of	POS	O
oral	POS	O
treatment	POS	O
with	POS	O
eslicarbazepine	POS	O
acetate	POS	O
on	POS	O
a	POS	O
whole	POS	O
-	POS	O
animal	POS	O
model	POS	O
in	POS	O
which	POS	O
partial	POS	O
seizures	POS	B-NP
can	POS	O
be	POS	O
elicited	POS	O
repeatedly	POS	O
on	POS	O
different	POS	O
days	POS	O
without	POS	O
changes	POS	O
in	POS	O
threshold	POS	O
or	POS	O
seizure	POS	B-NP
patterns	POS	O
.	POS	O
In	POS	O
the	POS	O
animals	POS	O
treated	POS	O
with	POS	O
threshold	POS	O
doses	POS	O
of	POS	O
picrotoxin	POS	O
,	POS	O
the	POS	O
average	POS	O
number	POS	O
of	POS	O
seizures	POS	B-NP
was	POS	O
2	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
2	POS	O
,	POS	O
and	POS	O
average	POS	O
seizure	POS	B-NP
duration	POS	O
was	POS	O
39	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
.	POS	O
4s	POS	O
.	POS	O
Pre	POS	O
-	POS	O
treatment	POS	O
with	POS	O
a	POS	O
dose	POS	O
of	POS	O
30	POS	O
mg	POS	O
/	POS	O
kg	POS	O
2h	POS	O
before	POS	O
picrotoxin	POS	O
microperfusion	POS	O
prevented	POS	O
seizures	POS	B-NP
in	POS	O
the	POS	O
75	POS	O
%	POS	O
of	POS	O
the	POS	O
rats	POS	O
.	POS	O
Lower	POS	O
doses	POS	O
(	POS	O
3	POS	O
and	POS	O
10mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
did	POS	O
not	POS	O
suppress	POS	O
seizures	POS	B-NP
,	POS	O
however	POS	O
,	POS	O
after	POS	O
administration	POS	O
of	POS	O
10mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
significant	POS	O
reductions	POS	O
in	POS	O
seizures	POS	B-NP
duration	POS	O
(	POS	O
24	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
.	POS	O
8s	POS	O
)	POS	O
and	POS	O
seizure	POS	B-NP
number	POS	O
(	POS	O
1	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
34	POS	O
)	POS	O
were	POS	O
found	POS	O
.	POS	O
No	POS	O
adverse	POS	O
effects	POS	O
of	POS	O
eslicarbazepine	POS	O
acetate	POS	O
were	POS	O
observed	POS	O
in	POS	O
the	POS	O
behavioral	POS	O
/	POS	O
EEG	POS	O
patterns	POS	O
studied	POS	O
,	POS	O
including	POS	O
sleep	POS	O
/	POS	O
wakefulness	POS	O
cycle	POS	O
,	POS	O
at	POS	O
the	POS	O
doses	POS	O
studied	POS	O
.	POS	O
Acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
associated	POS	O
with	POS	O
prolonged	POS	O
intake	POS	O
of	POS	O
slimming	POS	O
pills	POS	O
containing	POS	O
anthraquinones	POS	O
.	POS	O
Chinese	POS	O
herbal	POS	O
medicine	POS	O
preparations	POS	O
are	POS	O
widely	POS	O
available	POS	O
and	POS	O
often	POS	O
regarded	POS	O
by	POS	O
the	POS	O
public	POS	O
as	POS	O
natural	POS	O
and	POS	O
safe	POS	O
remedies	POS	O
for	POS	O
a	POS	O
variety	POS	O
of	POS	O
medical	POS	O
conditions	POS	O
.	POS	O
Nephropathy	POS	B-NP
caused	POS	O
by	POS	O
Chinese	POS	O
herbs	POS	O
has	POS	O
previously	POS	O
been	POS	O
reported	POS	O
,	POS	O
usually	POS	O
involving	POS	O
the	POS	O
use	POS	O
of	POS	O
aristolochic	POS	O
acids	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
23	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
who	POS	O
developed	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
following	POS	O
prolonged	POS	O
use	POS	O
of	POS	O
a	POS	O
proprietary	POS	O
Chinese	POS	O
herbal	POS	O
slimming	POS	O
pill	POS	O
that	POS	O
contained	POS	O
anthraquinone	POS	O
derivatives	POS	O
,	POS	O
extracted	POS	O
from	POS	O
Rhizoma	POS	O
Rhei	POS	O
(	POS	O
rhubarb	POS	O
)	POS	O
.	POS	O
The	POS	O
renal	POS	B-NP
injury	POS	I-NP
was	POS	O
probably	POS	O
aggravated	POS	O
by	POS	O
the	POS	O
concomitant	POS	O
intake	POS	O
of	POS	O
a	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drug	POS	O
,	POS	O
diclofenac	POS	O
.	POS	O
Renal	POS	O
pathology	POS	O
was	POS	O
that	POS	O
of	POS	O
hypocellular	POS	B-NP
interstitial	POS	I-NP
fibrosis	POS	I-NP
.	POS	O
Spontaneous	POS	B-NP
renal	POS	I-NP
recovery	POS	I-NP
occurred	POS	O
upon	POS	O
cessation	POS	O
of	POS	O
the	POS	O
slimming	POS	O
pills	POS	O
,	POS	O
but	POS	O
mild	POS	O
interstitial	POS	B-NP
fibrosis	POS	I-NP
and	POS	O
tubular	POS	B-NP
atrophy	POS	I-NP
was	POS	O
still	POS	O
evident	POS	O
histologically	POS	O
4	POS	O
months	POS	O
later	POS	O
.	POS	O
Although	POS	O
a	POS	O
causal	POS	O
relationship	POS	O
between	POS	O
the	POS	O
use	POS	O
of	POS	O
an	POS	O
anthraquinone	POS	O
-	POS	O
containing	POS	O
herbal	POS	O
agent	POS	O
and	POS	O
renal	POS	B-NP
injury	POS	I-NP
remains	POS	O
to	POS	O
be	POS	O
proven	POS	O
,	POS	O
phytotherapy	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
interstitial	POS	I-NP
nephropathy	POS	I-NP
should	POS	O
be	POS	O
considered	POS	O
in	POS	O
patients	POS	O
who	POS	O
present	POS	O
with	POS	O
unexplained	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
.	POS	O
Chloroacetaldehyde	POS	O
as	POS	O
a	POS	O
sulfhydryl	POS	O
reagent	POS	O
:	POS	O
the	POS	O
role	POS	O
of	POS	O
critical	POS	O
thiol	POS	O
groups	POS	O
in	POS	O
ifosfamide	POS	O
nephropathy	POS	B-NP
.	POS	O
Chloroacetaldehyde	POS	O
(	POS	O
CAA	POS	O
)	POS	O
is	POS	O
a	POS	O
metabolite	POS	O
of	POS	O
the	POS	O
alkylating	POS	O
agent	POS	O
ifosfamide	POS	O
(	POS	O
IFO	POS	O
)	POS	O
and	POS	O
putatively	POS	O
responsible	POS	O
for	POS	O
renal	POS	O
damage	POS	O
following	POS	O
anti	POS	O
-	POS	O
tumor	POS	O
therapy	POS	O
with	POS	O
IFO	POS	O
.	POS	O
Depletion	POS	O
of	POS	O
sulfhydryl	POS	O
(	POS	O
SH	POS	O
)	POS	O
groups	POS	O
has	POS	O
been	POS	O
reported	POS	O
from	POS	O
cell	POS	O
culture	POS	O
,	POS	O
animal	POS	O
and	POS	O
clinical	POS	O
studies	POS	O
.	POS	O
In	POS	O
this	POS	O
work	POS	O
the	POS	O
effect	POS	O
of	POS	O
CAA	POS	O
on	POS	O
human	POS	O
proximal	POS	O
tubule	POS	O
cells	POS	O
in	POS	O
primary	POS	O
culture	POS	O
(	POS	O
hRPTEC	POS	O
)	POS	O
was	POS	O
investigated	POS	O
.	POS	O
Toxicity	POS	O
of	POS	O
CAA	POS	O
was	POS	O
determined	POS	O
by	POS	O
protein	POS	O
content	POS	O
,	POS	O
cell	POS	O
number	POS	O
,	POS	O
LDH	POS	O
release	POS	O
,	POS	O
trypan	POS	O
blue	POS	O
exclusion	POS	O
assay	POS	O
and	POS	O
caspase	POS	O
-	POS	O
3	POS	O
activity	POS	O
.	POS	O
Free	POS	O
thiols	POS	O
were	POS	O
measured	POS	O
by	POS	O
the	POS	O
method	POS	O
of	POS	O
Ellman	POS	O
.	POS	O
CAA	POS	O
reduced	POS	O
hRPTEC	POS	O
cell	POS	O
number	POS	O
and	POS	O
protein	POS	O
,	POS	O
induced	POS	O
a	POS	O
loss	POS	O
in	POS	O
free	POS	O
intracellular	POS	O
thiols	POS	O
and	POS	O
an	POS	O
increase	POS	O
in	POS	O
necrosis	POS	B-NP
markers	POS	O
.	POS	O
CAA	POS	O
but	POS	O
not	POS	O
acrolein	POS	O
inhibited	POS	O
the	POS	O
cysteine	POS	O
proteases	POS	O
caspase	POS	O
-	POS	O
3	POS	O
,	POS	O
caspase	POS	O
-	POS	O
8	POS	O
and	POS	O
cathepsin	POS	O
B	POS	O
.	POS	O
Caspase	POS	O
activation	POS	O
by	POS	O
cisplatin	POS	O
was	POS	O
inhibited	POS	O
by	POS	O
CAA	POS	O
.	POS	O
In	POS	O
cells	POS	O
stained	POS	O
with	POS	O
fluorescent	POS	O
dyes	POS	O
targeting	POS	O
lysosomes	POS	O
,	POS	O
CAA	POS	O
induced	POS	O
an	POS	O
increase	POS	O
in	POS	O
lysosomal	POS	O
size	POS	O
and	POS	O
lysosomal	POS	O
leakage	POS	O
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
CAA	POS	O
on	POS	O
cysteine	POS	O
protease	POS	O
activities	POS	O
and	POS	O
thiols	POS	O
could	POS	O
be	POS	O
reproduced	POS	O
in	POS	O
cell	POS	O
lysate	POS	O
.	POS	O
Acidification	POS	O
,	POS	O
which	POS	O
slowed	POS	O
the	POS	O
reaction	POS	O
of	POS	O
CAA	POS	O
with	POS	O
thiol	POS	O
donors	POS	O
,	POS	O
could	POS	O
also	POS	O
attenuate	POS	O
effects	POS	O
of	POS	O
CAA	POS	O
on	POS	O
necrosis	POS	O
markers	POS	O
,	POS	O
thiol	POS	O
depletion	POS	O
and	POS	O
cysteine	POS	O
protease	POS	O
inhibition	POS	O
in	POS	O
living	POS	O
cells	POS	O
.	POS	O
Thus	POS	O
,	POS	O
CAA	POS	O
directly	POS	O
reacts	POS	O
with	POS	O
cellular	POS	O
protein	POS	O
and	POS	O
non	POS	O
-	POS	O
protein	POS	O
thiols	POS	O
,	POS	O
mediating	POS	O
its	POS	O
toxicity	POS	O
on	POS	O
hRPTEC	POS	O
.	POS	O
This	POS	O
effect	POS	O
can	POS	O
be	POS	O
reduced	POS	O
by	POS	O
acidification	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
urinary	POS	O
acidification	POS	O
could	POS	O
be	POS	O
an	POS	O
option	POS	O
to	POS	O
prevent	POS	O
IFO	POS	O
nephropathy	POS	B-NP
in	POS	O
patients	POS	O
.	POS	O
Stereological	POS	O
methods	POS	O
reveal	POS	O
the	POS	O
robust	POS	O
size	POS	O
and	POS	O
stability	POS	O
of	POS	O
ectopic	POS	O
hilar	POS	O
granule	POS	O
cells	POS	O
after	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
in	POS	O
the	POS	O
adult	POS	O
rat	POS	O
.	POS	O
Following	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
in	POS	O
the	POS	O
rat	POS	O
,	POS	O
dentate	POS	O
granule	POS	O
cell	POS	O
neurogenesis	POS	O
increases	POS	O
greatly	POS	O
,	POS	O
and	POS	O
many	POS	O
of	POS	O
the	POS	O
new	POS	O
neurons	POS	O
appear	POS	O
to	POS	O
develop	POS	O
ectopically	POS	O
,	POS	O
in	POS	O
the	POS	O
hilar	POS	O
region	POS	O
of	POS	O
the	POS	O
hippocampal	POS	O
formation	POS	O
.	POS	O
It	POS	O
has	POS	O
been	POS	O
suggested	POS	O
that	POS	O
the	POS	O
ectopic	POS	O
hilar	POS	O
granule	POS	O
cells	POS	O
could	POS	O
contribute	POS	O
to	POS	O
the	POS	O
spontaneous	POS	O
seizures	POS	B-NP
that	POS	O
ultimately	POS	O
develop	POS	O
after	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
.	POS	O
However	POS	O
,	POS	O
the	POS	O
population	POS	O
has	POS	O
never	POS	O
been	POS	O
quantified	POS	O
,	POS	O
so	POS	O
it	POS	O
is	POS	O
unclear	POS	O
whether	POS	O
it	POS	O
is	POS	O
substantial	POS	O
enough	POS	O
to	POS	O
have	POS	O
a	POS	O
strong	POS	O
influence	POS	O
on	POS	O
epileptogenesis	POS	B-NP
.	POS	O
To	POS	O
quantify	POS	O
this	POS	O
population	POS	O
,	POS	O
the	POS	O
total	POS	O
number	POS	O
of	POS	O
ectopic	POS	O
hilar	POS	O
granule	POS	O
cells	POS	O
was	POS	O
estimated	POS	O
using	POS	O
unbiased	POS	O
stereology	POS	O
at	POS	O
different	POS	O
times	POS	O
after	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
.	POS	O
The	POS	O
number	POS	O
of	POS	O
hilar	POS	O
neurons	POS	O
immunoreactive	POS	O
for	POS	O
Prox	POS	O
-	POS	O
1	POS	O
,	POS	O
a	POS	O
granule	POS	O
-	POS	O
cell	POS	O
-	POS	O
specific	POS	O
marker	POS	O
,	POS	O
was	POS	O
estimated	POS	O
using	POS	O
the	POS	O
optical	POS	O
fractionator	POS	O
method	POS	O
.	POS	O
The	POS	O
results	POS	O
indicate	POS	O
that	POS	O
the	POS	O
size	POS	O
of	POS	O
the	POS	O
hilar	POS	O
ectopic	POS	O
granule	POS	O
cell	POS	O
population	POS	O
after	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
is	POS	O
substantial	POS	O
,	POS	O
and	POS	O
stable	POS	O
over	POS	O
time	POS	O
.	POS	O
Interestingly	POS	O
,	POS	O
the	POS	O
size	POS	O
of	POS	O
the	POS	O
population	POS	O
appears	POS	O
to	POS	O
be	POS	O
correlated	POS	O
with	POS	O
the	POS	O
frequency	POS	O
of	POS	O
behavioral	POS	O
seizures	POS	B-NP
,	POS	O
because	POS	O
animals	POS	O
with	POS	O
more	POS	O
ectopic	POS	O
granule	POS	O
cells	POS	O
in	POS	O
the	POS	O
hilus	POS	O
have	POS	O
more	POS	O
frequent	POS	O
behavioral	POS	O
seizures	POS	B-NP
.	POS	O
The	POS	O
hilar	POS	O
ectopic	POS	O
granule	POS	O
cell	POS	O
population	POS	O
does	POS	O
not	POS	O
appear	POS	O
to	POS	O
vary	POS	O
systematically	POS	O
across	POS	O
the	POS	O
septotemporal	POS	O
axis	POS	O
,	POS	O
although	POS	O
it	POS	O
is	POS	O
associated	POS	O
with	POS	O
an	POS	O
increase	POS	O
in	POS	O
volume	POS	O
of	POS	O
the	POS	O
hilus	POS	O
.	POS	O
The	POS	O
results	POS	O
provide	POS	O
new	POS	O
insight	POS	O
into	POS	O
the	POS	O
potential	POS	O
role	POS	O
of	POS	O
ectopic	POS	O
hilar	POS	O
granule	POS	O
cells	POS	O
in	POS	O
the	POS	O
pilocarpine	POS	O
model	POS	O
of	POS	O
temporal	POS	B-NP
lobe	POS	I-NP
epilepsy	POS	I-NP
.	POS	O
A	POS	O
prospective	POS	O
,	POS	O
open	POS	O
-	POS	O
label	POS	O
trial	POS	O
of	POS	O
galantamine	POS	O
in	POS	O
autistic	POS	B-NP
disorder	POS	I-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
Post	POS	O
-	POS	O
mortem	POS	O
studies	POS	O
have	POS	O
reported	POS	O
abnormalities	POS	O
of	POS	O
the	POS	O
cholinergic	POS	O
system	POS	O
in	POS	O
autism	POS	B-NP
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
assess	POS	O
the	POS	O
use	POS	O
of	POS	O
galantamine	POS	O
,	POS	O
an	POS	O
acetylcholinesterase	POS	O
inhibitor	POS	O
and	POS	O
nicotinic	POS	O
receptor	POS	O
modulator	POS	O
,	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
interfering	POS	O
behaviors	POS	O
in	POS	O
children	POS	O
with	POS	O
autism	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Thirteen	POS	O
medication	POS	O
-	POS	O
free	POS	O
children	POS	O
with	POS	O
autism	POS	B-NP
(	POS	O
mean	POS	O
age	POS	O
,	POS	O
8	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
.	POS	O
5	POS	O
years	POS	O
)	POS	O
participated	POS	O
in	POS	O
a	POS	O
12	POS	O
-	POS	O
week	POS	O
,	POS	O
open	POS	O
-	POS	O
label	POS	O
trial	POS	O
of	POS	O
galantamine	POS	O
.	POS	O
Patients	POS	O
were	POS	O
rated	POS	O
monthly	POS	O
by	POS	O
parents	POS	O
on	POS	O
the	POS	O
Aberrant	POS	O
Behavior	POS	O
Checklist	POS	O
(	POS	O
ABC	POS	O
)	POS	O
and	POS	O
the	POS	O
Conners	POS	O
'	POS	O
Parent	POS	O
Rating	POS	O
Scale	POS	O
-	POS	O
Revised	POS	O
,	POS	O
and	POS	O
by	POS	O
a	POS	O
physician	POS	O
using	POS	O
the	POS	O
Children	POS	O
'	POS	O
s	POS	O
Psychiatric	POS	O
Rating	POS	O
Scale	POS	O
and	POS	O
the	POS	O
Clinical	POS	O
Global	POS	O
Impressions	POS	O
scale	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Patients	POS	O
showed	POS	O
a	POS	O
significant	POS	O
reduction	POS	O
in	POS	O
parent	POS	O
-	POS	O
rated	POS	O
irritability	POS	B-NP
and	POS	O
social	POS	O
withdrawal	POS	O
on	POS	O
the	POS	O
ABC	POS	O
as	POS	O
well	POS	O
as	POS	O
significant	POS	O
improvements	POS	O
in	POS	O
emotional	POS	O
lability	POS	O
and	POS	O
inattention	POS	B-NP
on	POS	O
the	POS	O
Conners	POS	O
'	POS	O
Parent	POS	O
Rating	POS	O
Scale	POS	O
-	POS	O
-	POS	O
Revised	POS	O
.	POS	O
Similarly	POS	O
,	POS	O
clinician	POS	O
ratings	POS	O
showed	POS	O
reductions	POS	O
in	POS	O
the	POS	O
anger	POS	O
subscale	POS	O
of	POS	O
the	POS	O
Children	POS	O
'	POS	O
s	POS	O
Psychiatric	POS	O
Rating	POS	O
Scale	POS	O
.	POS	O
Eight	POS	O
of	POS	O
13	POS	O
participants	POS	O
were	POS	O
rated	POS	O
as	POS	O
responders	POS	O
on	POS	O
the	POS	O
basis	POS	O
of	POS	O
their	POS	O
improvement	POS	O
scores	POS	O
on	POS	O
the	POS	O
Clinical	POS	O
Global	POS	O
Impressions	POS	O
scale	POS	O
.	POS	O
Overall	POS	O
,	POS	O
galantamine	POS	O
was	POS	O
well	POS	O
-	POS	O
tolerated	POS	O
,	POS	O
with	POS	O
no	POS	O
significant	POS	O
adverse	POS	O
effects	POS	O
apart	POS	O
from	POS	O
headaches	POS	B-NP
in	POS	O
one	POS	O
patient	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
In	POS	O
this	POS	O
open	POS	O
trial	POS	O
,	POS	O
galantamine	POS	O
was	POS	O
well	POS	O
-	POS	O
tolerated	POS	O
and	POS	O
appeared	POS	O
to	POS	O
be	POS	O
beneficial	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
interfering	POS	O
behaviors	POS	O
in	POS	O
children	POS	O
with	POS	O
autism	POS	B-NP
,	POS	O
particularly	POS	O
aggression	POS	B-NP
,	POS	O
behavioral	POS	B-NP
dyscontrol	POS	I-NP
,	POS	O
and	POS	O
inattention	POS	B-NP
.	POS	O
Further	POS	O
controlled	POS	O
trials	POS	O
are	POS	O
warranted	POS	O
.	POS	O
Randomized	POS	O
comparison	POS	O
of	POS	O
olanzapine	POS	O
versus	POS	O
risperidone	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
first	POS	O
-	POS	O
episode	POS	O
schizophrenia	POS	B-NP
:	POS	O
4	POS	O
-	POS	O
month	POS	O
outcomes	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
The	POS	O
authors	POS	O
compared	POS	O
4	POS	O
-	POS	O
month	POS	O
treatment	POS	O
outcomes	POS	O
for	POS	O
olanzapine	POS	O
versus	POS	O
risperidone	POS	O
in	POS	O
patients	POS	O
with	POS	O
first	POS	O
-	POS	O
episode	POS	O
schizophrenia	POS	B-NP
spectrum	POS	O
disorders	POS	O
.	POS	O
METHOD	POS	O
:	POS	O
One	POS	O
hundred	POS	O
twelve	POS	O
subjects	POS	O
(	POS	O
70	POS	O
%	POS	O
male	POS	O
;	POS	O
mean	POS	O
age	POS	O
=	POS	O
23	POS	O
.	POS	O
3	POS	O
years	POS	O
[	POS	O
SD	POS	O
=	POS	O
5	POS	O
.	POS	O
1	POS	O
]	POS	O
)	POS	O
with	POS	O
first	POS	O
-	POS	O
episode	POS	O
schizophrenia	POS	B-NP
(	POS	O
75	POS	O
%	POS	O
)	POS	O
,	POS	O
schizophreniform	POS	B-NP
disorder	POS	I-NP
(	POS	O
17	POS	O
%	POS	O
)	POS	O
,	POS	O
or	POS	O
schizoaffective	POS	B-NP
disorder	POS	I-NP
(	POS	O
8	POS	O
%	POS	O
)	POS	O
were	POS	O
randomly	POS	O
assigned	POS	O
to	POS	O
treatment	POS	O
with	POS	O
olanzapine	POS	O
(	POS	O
2	POS	O
.	POS	O
5	POS	O
-	POS	O
20	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
or	POS	O
risperidone	POS	O
(	POS	O
1	POS	O
-	POS	O
6	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Response	POS	O
rates	POS	O
did	POS	O
not	POS	O
significantly	POS	O
differ	POS	O
between	POS	O
olanzapine	POS	O
(	POS	O
43	POS	O
.	POS	O
7	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
28	POS	O
.	POS	O
8	POS	O
%	POS	O
-	POS	O
58	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
and	POS	O
risperidone	POS	O
(	POS	O
54	POS	O
.	POS	O
3	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
39	POS	O
.	POS	O
9	POS	O
%	POS	O
-	POS	O
68	POS	O
.	POS	O
7	POS	O
%	POS	O
)	POS	O
.	POS	O
Among	POS	O
those	POS	O
responding	POS	O
to	POS	O
treatment	POS	O
,	POS	O
more	POS	O
subjects	POS	O
in	POS	O
the	POS	O
olanzapine	POS	O
group	POS	O
(	POS	O
40	POS	O
.	POS	O
9	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
16	POS	O
.	POS	O
8	POS	O
%	POS	O
-	POS	O
65	POS	O
.	POS	O
0	POS	O
%	POS	O
)	POS	O
than	POS	O
in	POS	O
the	POS	O
risperidone	POS	O
group	POS	O
(	POS	O
18	POS	O
.	POS	O
9	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
0	POS	O
%	POS	O
-	POS	O
39	POS	O
.	POS	O
2	POS	O
%	POS	O
)	POS	O
had	POS	O
subsequent	POS	O
ratings	POS	O
not	POS	O
meeting	POS	O
response	POS	O
criteria	POS	O
.	POS	O
Negative	POS	O
symptom	POS	O
outcomes	POS	O
and	POS	O
measures	POS	O
of	POS	O
parkinsonism	POS	B-NP
and	POS	O
akathisia	POS	B-NP
did	POS	O
not	POS	O
differ	POS	O
between	POS	O
medications	POS	O
.	POS	O
Extrapyramidal	POS	B-NP
symptom	POS	I-NP
severity	POS	O
scores	POS	O
were	POS	O
1	POS	O
.	POS	O
4	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
1	POS	O
.	POS	O
2	POS	O
-	POS	O
1	POS	O
.	POS	O
6	POS	O
)	POS	O
with	POS	O
risperidone	POS	O
and	POS	O
1	POS	O
.	POS	O
2	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
1	POS	O
.	POS	O
0	POS	O
-	POS	O
1	POS	O
.	POS	O
4	POS	O
)	POS	O
with	POS	O
olanzapine	POS	O
.	POS	O
Significantly	POS	O
more	POS	O
weight	POS	O
gain	POS	O
occurred	POS	O
with	POS	O
olanzapine	POS	O
than	POS	O
with	POS	O
risperidone	POS	O
:	POS	O
the	POS	O
increase	POS	O
in	POS	O
weight	POS	O
at	POS	O
4	POS	O
months	POS	O
relative	POS	O
to	POS	O
baseline	POS	O
weight	POS	O
was	POS	O
17	POS	O
.	POS	O
3	POS	O
%	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
14	POS	O
.	POS	O
2	POS	O
%	POS	O
-	POS	O
20	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
with	POS	O
olanzapine	POS	O
and	POS	O
11	POS	O
.	POS	O
3	POS	O
%	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
8	POS	O
.	POS	O
4	POS	O
%	POS	O
-	POS	O
14	POS	O
.	POS	O
3	POS	O
%	POS	O
)	POS	O
with	POS	O
risperidone	POS	O
.	POS	O
Body	POS	O
mass	POS	O
index	POS	O
at	POS	O
baseline	POS	O
and	POS	O
at	POS	O
4	POS	O
months	POS	O
was	POS	O
24	POS	O
.	POS	O
3	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
22	POS	O
.	POS	O
8	POS	O
-	POS	O
25	POS	O
.	POS	O
7	POS	O
)	POS	O
versus	POS	O
28	POS	O
.	POS	O
2	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
26	POS	O
.	POS	O
7	POS	O
-	POS	O
29	POS	O
.	POS	O
7	POS	O
)	POS	O
with	POS	O
olanzapine	POS	O
and	POS	O
23	POS	O
.	POS	O
9	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
22	POS	O
.	POS	O
5	POS	O
-	POS	O
25	POS	O
.	POS	O
3	POS	O
)	POS	O
versus	POS	O
26	POS	O
.	POS	O
7	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
25	POS	O
.	POS	O
2	POS	O
-	POS	O
28	POS	O
.	POS	O
2	POS	O
)	POS	O
with	POS	O
risperidone	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Clinical	POS	O
outcomes	POS	O
with	POS	O
risperidone	POS	O
were	POS	O
equal	POS	O
to	POS	O
those	POS	O
with	POS	O
olanzapine	POS	O
,	POS	O
and	POS	O
response	POS	O
may	POS	O
be	POS	O
more	POS	O
stable	POS	O
.	POS	O
Olanzapine	POS	O
may	POS	O
have	POS	O
an	POS	O
advantage	POS	O
for	POS	O
motor	POS	O
side	POS	O
effects	POS	O
.	POS	O
Both	POS	O
medications	POS	O
caused	POS	O
substantial	POS	O
rapid	POS	O
weight	POS	O
gain	POS	O
,	POS	O
but	POS	O
weight	POS	B-NP
gain	POS	I-NP
was	POS	O
greater	POS	O
with	POS	O
olanzapine	POS	O
.	POS	O
Early	POS	B-NP
paracentral	POS	I-NP
visual	POS	I-NP
field	POS	I-NP
loss	POS	I-NP
in	POS	O
patients	POS	O
taking	POS	O
hydroxychloroquine	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
review	POS	O
the	POS	O
natural	POS	O
history	POS	O
and	POS	O
ocular	POS	O
and	POS	O
systemic	POS	O
adverse	POS	O
effects	POS	O
of	POS	O
patients	POS	O
taking	POS	O
hydroxychloroquine	POS	O
sulfate	POS	O
who	POS	O
attended	POS	O
an	POS	O
ophthalmic	POS	O
screening	POS	O
program	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
Retrospective	POS	O
study	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Records	POS	O
of	POS	O
262	POS	O
patients	POS	O
who	POS	O
were	POS	O
taking	POS	O
hydroxychloroquine	POS	O
and	POS	O
screened	POS	O
in	POS	O
the	POS	O
Department	POS	O
of	POS	O
Ophthalmology	POS	O
were	POS	O
reviewed	POS	O
.	POS	O
Of	POS	O
the	POS	O
262	POS	O
patients	POS	O
,	POS	O
14	POS	O
(	POS	O
18	POS	O
%	POS	O
)	POS	O
of	POS	O
76	POS	O
who	POS	O
had	POS	O
stopped	POS	O
treatment	POS	O
at	POS	O
the	POS	O
time	POS	O
of	POS	O
the	POS	O
study	POS	O
experienced	POS	O
documented	POS	O
adverse	POS	O
effects	POS	O
.	POS	O
Systemic	POS	O
adverse	POS	O
effects	POS	O
occurred	POS	O
in	POS	O
8	POS	O
patients	POS	O
(	POS	O
10	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
and	POS	O
ocular	POS	O
adverse	POS	O
effects	POS	O
,	POS	O
in	POS	O
5	POS	O
(	POS	O
6	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
.	POS	O
Thirty	POS	O
-	POS	O
five	POS	O
patients	POS	O
(	POS	O
13	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
had	POS	O
visual	POS	B-NP
field	POS	I-NP
abnormalities	POS	I-NP
,	POS	O
which	POS	O
were	POS	O
attributed	POS	O
to	POS	O
hydroxychloroquine	POS	O
treatment	POS	O
in	POS	O
4	POS	O
patients	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
.	POS	O
Three	POS	O
of	POS	O
the	POS	O
4	POS	O
patients	POS	O
were	POS	O
taking	POS	O
less	POS	O
than	POS	O
6	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
per	POS	O
day	POS	O
and	POS	O
all	POS	O
patients	POS	O
had	POS	O
normal	POS	O
renal	POS	O
and	POS	O
liver	POS	O
function	POS	O
test	POS	O
results	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
current	POS	O
study	POS	O
used	POS	O
a	POS	O
protocol	POS	O
of	POS	O
visual	POS	O
acuity	POS	O
and	POS	O
color	POS	O
vision	POS	O
assessment	POS	O
,	POS	O
funduscopy	POS	O
,	POS	O
and	POS	O
Humphrey	POS	O
10	POS	O
-	POS	O
2	POS	O
visual	POS	O
field	POS	O
testing	POS	O
and	POS	O
shows	POS	O
that	POS	O
visual	POS	B-NP
field	POS	I-NP
defects	POS	I-NP
appeared	POS	O
before	POS	O
any	POS	O
corresponding	POS	O
changes	POS	O
in	POS	O
any	POS	O
other	POS	O
tested	POS	O
clinical	POS	O
parameters	POS	O
;	POS	O
the	POS	O
defects	POS	O
were	POS	O
reproducible	POS	O
and	POS	O
the	POS	O
test	POS	O
parameters	POS	O
were	POS	O
reliable	POS	O
.	POS	O
Patients	POS	O
taking	POS	O
hydroxychloroquine	POS	O
can	POS	O
demonstrate	POS	O
a	POS	O
toxic	POS	O
reaction	POS	O
in	POS	O
the	POS	O
retina	POS	O
despite	POS	O
the	POS	O
absence	POS	O
of	POS	O
known	POS	O
risk	POS	O
factors	POS	O
.	POS	O
Screening	POS	O
,	POS	O
including	POS	O
Humphrey	POS	O
10	POS	O
-	POS	O
2	POS	O
visual	POS	O
field	POS	O
assessment	POS	O
,	POS	O
is	POS	O
recommended	POS	O
2	POS	O
years	POS	O
after	POS	O
the	POS	O
initial	POS	O
baseline	POS	O
and	POS	O
yearly	POS	O
thereafter	POS	O
.	POS	O
Peri	POS	O
-	POS	O
operative	POS	O
atrioventricular	POS	B-NP
block	POS	I-NP
as	POS	O
a	POS	O
result	POS	O
of	POS	O
chemotherapy	POS	O
with	POS	O
epirubicin	POS	O
and	POS	O
paclitaxel	POS	O
.	POS	O
A	POS	O
47	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
presented	POS	O
for	POS	O
mastectomy	POS	O
and	POS	O
immediate	POS	O
latissimus	POS	O
dorsi	POS	O
flap	POS	O
reconstruction	POS	O
having	POS	O
been	POS	O
diagnosed	POS	O
with	POS	O
carcinoma	POS	B-NP
of	POS	O
the	POS	O
breast	POS	O
6	POS	O
months	POS	O
previously	POS	O
.	POS	O
In	POS	O
the	POS	O
preceding	POS	O
months	POS	O
she	POS	O
had	POS	O
received	POS	O
neo	POS	O
-	POS	O
adjuvant	POS	O
chemotherapy	POS	O
with	POS	O
epirubicin	POS	O
,	POS	O
paclitaxel	POS	O
(	POS	O
Taxol	POS	O
)	POS	O
and	POS	O
cyclophosphamide	POS	O
.	POS	O
This	POS	O
had	POS	O
been	POS	O
apparently	POS	O
uncomplicated	POS	O
and	POS	O
she	POS	O
had	POS	O
maintained	POS	O
a	POS	O
remarkably	POS	O
high	POS	O
level	POS	O
of	POS	O
physical	POS	O
activity	POS	O
.	POS	O
She	POS	O
was	POS	O
found	POS	O
to	POS	O
be	POS	O
bradycardic	POS	O
at	POS	O
pre	POS	O
-	POS	O
operative	POS	O
assessment	POS	O
but	POS	O
had	POS	O
no	POS	O
cardiac	POS	B-NP
symptoms	POS	I-NP
.	POS	O
Second	POS	O
degree	POS	O
Mobitz	POS	B-NP
type	POS	I-NP
II	POS	I-NP
atrioventricular	POS	I-NP
block	POS	I-NP
was	POS	O
diagnosed	POS	O
on	POS	O
electrocardiogram	POS	O
,	POS	O
and	POS	O
temporary	POS	O
transvenous	POS	O
ventricular	POS	O
pacing	POS	O
instituted	POS	O
in	POS	O
the	POS	O
peri	POS	O
-	POS	O
operative	POS	O
period	POS	O
.	POS	O
We	POS	O
discuss	POS	O
how	POS	O
evidence	POS	O
-	POS	O
based	POS	O
guidelines	POS	O
would	POS	O
not	POS	O
have	POS	O
been	POS	O
helpful	POS	O
in	POS	O
this	POS	O
case	POS	O
,	POS	O
and	POS	O
how	POS	O
chemotherapy	POS	O
can	POS	O
exhibit	POS	O
substantial	POS	O
cardiotoxicity	POS	B-NP
that	POS	O
may	POS	O
develop	POS	O
over	POS	O
many	POS	O
years	POS	O
.	POS	O
We	POS	O
suggest	POS	O
that	POS	O
patients	POS	O
who	POS	O
have	POS	O
received	POS	O
chemotherapy	POS	O
at	POS	O
any	POS	O
time	POS	O
should	POS	O
have	POS	O
a	POS	O
pre	POS	O
-	POS	O
operative	POS	O
electrocardiogram	POS	O
even	POS	O
if	POS	O
they	POS	O
are	POS	O
asymptomatic	POS	O
.	POS	O
Risks	POS	O
and	POS	O
benefits	POS	O
of	POS	O
COX	POS	O
-	POS	O
2	POS	O
inhibitors	POS	O
vs	POS	O
non	POS	O
-	POS	O
selective	POS	O
NSAIDs	POS	O
:	POS	O
does	POS	O
their	POS	O
cardiovascular	POS	O
risk	POS	O
exceed	POS	O
their	POS	O
gastrointestinal	POS	O
benefit	POS	O
?	POS	O
A	POS	O
retrospective	POS	O
cohort	POS	O
study	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
The	POS	O
risk	POS	O
of	POS	O
acute	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
(	POS	O
AMI	POS	B-NP
)	POS	O
with	POS	O
COX	POS	O
-	POS	O
2	POS	O
inhibitors	POS	O
may	POS	O
offset	POS	O
their	POS	O
gastrointestinal	POS	O
(	POS	O
GI	POS	O
)	POS	O
benefit	POS	O
compared	POS	O
with	POS	O
non	POS	O
-	POS	O
selective	POS	O
(	POS	O
NS	POS	O
)	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
(	POS	O
NSAIDs	POS	O
)	POS	O
.	POS	O
We	POS	O
aimed	POS	O
to	POS	O
compare	POS	O
the	POS	O
risks	POS	O
of	POS	O
hospitalization	POS	O
for	POS	O
AMI	POS	B-NP
and	POS	O
GI	POS	B-NP
bleeding	POS	I-NP
among	POS	O
elderly	POS	O
patients	POS	O
using	POS	O
COX	POS	O
-	POS	O
2	POS	O
inhibitors	POS	O
,	POS	O
NS	POS	O
-	POS	O
NSAIDs	POS	O
and	POS	O
acetaminophen	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
conducted	POS	O
a	POS	O
retrospective	POS	O
cohort	POS	O
study	POS	O
using	POS	O
administrative	POS	O
data	POS	O
of	POS	O
patients	POS	O
>	POS	O
or	POS	O
=	POS	O
65	POS	O
years	POS	O
of	POS	O
age	POS	O
who	POS	O
filled	POS	O
a	POS	O
prescription	POS	O
for	POS	O
NSAID	POS	O
or	POS	O
acetaminophen	POS	O
during	POS	O
1999	POS	O
-	POS	O
2002	POS	O
.	POS	O
Outcomes	POS	O
were	POS	O
compared	POS	O
using	POS	O
Cox	POS	O
regression	POS	O
models	POS	O
with	POS	O
time	POS	O
-	POS	O
dependent	POS	O
exposures	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Person	POS	O
-	POS	O
years	POS	O
of	POS	O
exposure	POS	O
among	POS	O
non	POS	O
-	POS	O
users	POS	O
of	POS	O
aspirin	POS	O
were	POS	O
:	POS	O
75	POS	O
,	POS	O
761	POS	O
to	POS	O
acetaminophen	POS	O
,	POS	O
42	POS	O
,	POS	O
671	POS	O
to	POS	O
rofecoxib	POS	O
65	POS	O
,	POS	O
860	POS	O
to	POS	O
celecoxib	POS	O
,	POS	O
and	POS	O
37	POS	O
,	POS	O
495	POS	O
to	POS	O
NS	POS	O
-	POS	O
NSAIDs	POS	O
.	POS	O
Among	POS	O
users	POS	O
of	POS	O
aspirin	POS	O
,	POS	O
they	POS	O
were	POS	O
:	POS	O
14	POS	O
,	POS	O
671	POS	O
to	POS	O
rofecoxib	POS	O
,	POS	O
22	POS	O
,	POS	O
875	POS	O
to	POS	O
celecoxib	POS	O
,	POS	O
9	POS	O
,	POS	O
832	POS	O
to	POS	O
NS	POS	O
-	POS	O
NSAIDs	POS	O
and	POS	O
38	POS	O
,	POS	O
048	POS	O
to	POS	O
acetaminophen	POS	O
.	POS	O
Among	POS	O
non	POS	O
-	POS	O
users	POS	O
of	POS	O
aspirin	POS	O
,	POS	O
the	POS	O
adjusted	POS	O
hazard	POS	O
ratios	POS	O
(	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
)	POS	O
of	POS	O
hospitalization	POS	O
for	POS	O
AMI	POS	B-NP
/	POS	O
GI	POS	O
vs	POS	O
the	POS	O
acetaminophen	POS	O
(	POS	O
with	POS	O
no	POS	O
aspirin	POS	O
)	POS	O
group	POS	O
were	POS	O
:	POS	O
rofecoxib	POS	O
1	POS	O
.	POS	O
27	POS	O
(	POS	O
1	POS	O
.	POS	O
13	POS	O
,	POS	O
1	POS	O
.	POS	O
42	POS	O
)	POS	O
,	POS	O
celecoxib	POS	O
0	POS	O
.	POS	O
93	POS	O
(	POS	O
0	POS	O
.	POS	O
83	POS	O
,	POS	O
1	POS	O
.	POS	O
03	POS	O
)	POS	O
,	POS	O
naproxen	POS	O
1	POS	O
.	POS	O
59	POS	O
(	POS	O
1	POS	O
.	POS	O
31	POS	O
,	POS	O
1	POS	O
.	POS	O
93	POS	O
)	POS	O
,	POS	O
diclofenac	POS	O
1	POS	O
.	POS	O
17	POS	O
(	POS	O
0	POS	O
.	POS	O
99	POS	O
,	POS	O
1	POS	O
.	POS	O
38	POS	O
)	POS	O
and	POS	O
ibuprofen	POS	O
1	POS	O
.	POS	O
05	POS	O
(	POS	O
0	POS	O
.	POS	O
74	POS	O
,	POS	O
1	POS	O
.	POS	O
51	POS	O
)	POS	O
.	POS	O
Among	POS	O
users	POS	O
of	POS	O
aspirin	POS	O
,	POS	O
they	POS	O
were	POS	O
:	POS	O
rofecoxib	POS	O
1	POS	O
.	POS	O
73	POS	O
(	POS	O
1	POS	O
.	POS	O
52	POS	O
,	POS	O
1	POS	O
.	POS	O
98	POS	O
)	POS	O
,	POS	O
celecoxib	POS	O
1	POS	O
.	POS	O
34	POS	O
(	POS	O
1	POS	O
.	POS	O
19	POS	O
,	POS	O
1	POS	O
.	POS	O
52	POS	O
)	POS	O
,	POS	O
ibuprofen	POS	O
1	POS	O
.	POS	O
51	POS	O
(	POS	O
0	POS	O
.	POS	O
95	POS	O
,	POS	O
2	POS	O
.	POS	O
41	POS	O
)	POS	O
,	POS	O
diclofenac	POS	O
1	POS	O
.	POS	O
69	POS	O
(	POS	O
1	POS	O
.	POS	O
35	POS	O
,	POS	O
2	POS	O
.	POS	O
10	POS	O
)	POS	O
,	POS	O
naproxen	POS	O
1	POS	O
.	POS	O
35	POS	O
(	POS	O
0	POS	O
.	POS	O
97	POS	O
,	POS	O
1	POS	O
.	POS	O
88	POS	O
)	POS	O
and	POS	O
acetaminophen	POS	O
1	POS	O
.	POS	O
29	POS	O
(	POS	O
1	POS	O
.	POS	O
17	POS	O
,	POS	O
1	POS	O
.	POS	O
42	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Among	POS	O
non	POS	O
-	POS	O
users	POS	O
of	POS	O
aspirin	POS	O
,	POS	O
naproxen	POS	O
seemed	POS	O
to	POS	O
carry	POS	O
the	POS	O
highest	POS	O
risk	POS	O
for	POS	O
AMI	POS	B-NP
/	POS	O
GI	POS	B-NP
bleeding	POS	I-NP
.	POS	O
The	POS	O
AMI	POS	O
/	POS	O
GI	POS	B-NP
toxicity	POS	I-NP
of	POS	O
celecoxib	POS	O
was	POS	O
similar	POS	O
to	POS	O
that	POS	O
of	POS	O
acetaminophen	POS	O
and	POS	O
seemed	POS	O
to	POS	O
be	POS	O
better	POS	O
than	POS	O
those	POS	O
of	POS	O
rofecoxib	POS	O
and	POS	O
NS	POS	O
-	POS	O
NSAIDs	POS	O
.	POS	O
Among	POS	O
users	POS	O
of	POS	O
aspirin	POS	O
,	POS	O
both	POS	O
celecoxib	POS	O
and	POS	O
naproxen	POS	O
seemed	POS	O
to	POS	O
be	POS	O
the	POS	O
least	POS	O
toxic	POS	O
.	POS	O
Quinine	POS	O
-	POS	O
induced	POS	O
arrhythmia	POS	B-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
severe	POS	O
malaria	POS	B-NP
.	POS	O
It	POS	O
was	POS	O
reported	POS	O
that	POS	O
there	POS	O
was	POS	O
a	POS	O
case	POS	O
of	POS	O
severe	POS	O
malaria	POS	B-NP
patient	POS	O
with	POS	O
jaundice	POS	B-NP
who	POS	O
presented	POS	O
with	POS	O
arrhythmia	POS	B-NP
(	POS	O
premature	POS	B-NP
ventricular	POS	I-NP
contraction	POS	I-NP
)	POS	O
while	POS	O
getting	POS	O
quinine	POS	O
infusion	POS	O
was	POS	O
reported	POS	O
.	POS	O
A	POS	O
man	POS	O
,	POS	O
25	POS	O
years	POS	O
old	POS	O
,	POS	O
was	POS	O
admitted	POS	O
to	POS	O
hospital	POS	O
with	POS	O
high	POS	B-NP
fever	POS	I-NP
,	POS	O
chill	POS	B-NP
,	POS	O
vomiting	POS	B-NP
,	POS	O
jaundice	POS	B-NP
.	POS	O
The	POS	O
patient	POS	O
was	POS	O
fully	POS	O
conscious	POS	O
,	POS	O
blood	POS	O
pressure	POS	O
120	POS	O
/	POS	O
80	POS	O
mmHg	POS	O
,	POS	O
pulse	POS	O
rate	POS	O
100	POS	O
x	POS	O
/	POS	O
minute	POS	O
,	POS	O
regular	POS	O
.	POS	O
On	POS	O
admission	POS	O
,	POS	O
laboratory	POS	O
examination	POS	O
showed	POS	O
Plasmodium	POS	O
falciparum	POS	O
(	POS	O
+	POS	O
+	POS	O
+	POS	O
+	POS	O
)	POS	O
,	POS	O
total	POS	O
bilirubin	POS	O
8	POS	O
.	POS	O
25	POS	O
mg	POS	O
/	POS	O
dL	POS	O
,	POS	O
conjugated	POS	O
bilirubin	POS	O
4	POS	O
.	POS	O
36	POS	O
mg	POS	O
/	POS	O
dL	POS	O
,	POS	O
unconjugated	POS	O
bilirubin	POS	O
3	POS	O
.	POS	O
89	POS	O
mg	POS	O
/	POS	O
dL	POS	O
,	POS	O
potassium	POS	O
3	POS	O
.	POS	O
52	POS	O
meq	POS	O
/	POS	O
L	POS	O
Patient	POS	O
was	POS	O
diagnosed	POS	O
as	POS	O
severe	POS	O
malaria	POS	B-NP
with	POS	O
jaundice	POS	B-NP
and	POS	O
got	POS	O
quinine	POS	O
infusion	POS	O
in	POS	O
dextrose	POS	O
5	POS	O
%	POS	O
500	POS	O
mg	POS	O
/	POS	O
8	POS	O
hour	POS	O
.	POS	O
On	POS	O
the	POS	O
second	POS	O
day	POS	O
the	POS	O
patient	POS	O
had	POS	O
vomitus	POS	B-NP
,	POS	O
diarrhea	POS	B-NP
,	POS	O
tinnitus	POS	B-NP
,	POS	O
loss	POS	B-NP
of	POS	I-NP
hearing	POS	I-NP
.	POS	O
After	POS	O
30	POS	O
hours	POS	O
of	POS	O
quinine	POS	O
infusion	POS	O
the	POS	O
patient	POS	O
felt	POS	O
palpitation	POS	B-NP
and	POS	O
electrocardiography	POS	O
(	POS	O
ECG	POS	O
)	POS	O
recording	POS	O
showed	POS	O
premature	POS	B-NP
ventricular	POS	I-NP
contraction	POS	I-NP
(	POS	O
PVC	POS	O
)	POS	O
>	POS	O
5	POS	O
x	POS	O
/	POS	O
minute	POS	O
,	POS	O
trigemini	POS	O
,	POS	O
constant	POS	O
type	POS	O
-	POS	O
-	POS	O
sinoatrial	POS	O
block	POS	O
,	POS	O
positive	POS	O
U	POS	O
wave	POS	O
.	POS	O
He	POS	O
was	POS	O
treated	POS	O
with	POS	O
lidocaine	POS	O
50	POS	O
mg	POS	O
intravenously	POS	O
followed	POS	O
by	POS	O
infusion	POS	O
1500	POS	O
mg	POS	O
in	POS	O
dextrose	POS	O
5	POS	O
%	POS	O
/	POS	O
24	POS	O
hour	POS	O
and	POS	O
potassium	POS	O
aspartate	POS	O
tablet	POS	O
.	POS	O
Quinine	POS	O
infusion	POS	O
was	POS	O
discontinued	POS	O
and	POS	O
changed	POS	O
with	POS	O
sulfate	POS	O
quinine	POS	O
tablets	POS	O
.	POS	O
Three	POS	O
hours	POS	O
later	POS	O
the	POS	O
patient	POS	O
felt	POS	O
better	POS	O
,	POS	O
the	POS	O
frequency	POS	O
of	POS	O
PVC	POS	O
reduced	POS	O
to	POS	O
4	POS	O
-	POS	O
5	POS	O
x	POS	O
/	POS	O
minute	POS	O
and	POS	O
on	POS	O
the	POS	O
third	POS	O
day	POS	O
ECG	POS	O
was	POS	O
normal	POS	O
,	POS	O
potassium	POS	O
level	POS	O
was	POS	O
3	POS	O
.	POS	O
34	POS	O
meq	POS	O
/	POS	O
L	POS	O
.	POS	O
He	POS	O
was	POS	O
discharged	POS	O
on	POS	O
7th	POS	O
day	POS	O
in	POS	O
good	POS	O
condition	POS	O
.	POS	O
Quinine	POS	O
,	POS	O
like	POS	O
quinidine	POS	O
,	POS	O
is	POS	O
a	POS	O
chincona	POS	O
alkaloid	POS	O
that	POS	O
has	POS	O
anti	POS	O
-	POS	O
arrhythmic	POS	O
property	POS	O
,	POS	O
although	POS	O
it	POS	O
also	POS	O
pro	POS	O
-	POS	O
arrhythmic	POS	O
that	POS	O
can	POS	O
cause	POS	O
various	POS	O
arrhythmias	POS	B-NP
,	POS	O
including	POS	O
severe	POS	O
arrhythmia	POS	B-NP
such	POS	O
as	POS	O
multiple	POS	O
PVC	POS	O
.	POS	O
Administration	POS	O
of	POS	O
parenteral	POS	O
quinine	POS	O
must	POS	O
be	POS	O
done	POS	O
carefully	POS	O
and	POS	O
with	POS	O
good	POS	O
observation	POS	O
because	POS	O
of	POS	O
its	POS	O
pro	POS	O
-	POS	O
arrhythmic	POS	O
effect	POS	O
,	POS	O
especially	POS	O
in	POS	O
older	POS	O
patients	POS	O
who	POS	O
have	POS	O
heart	POS	B-NP
diseases	POS	I-NP
or	POS	O
patients	POS	O
with	POS	O
electrolyte	POS	B-NP
disorder	POS	I-NP
(	POS	O
hypokalemia	POS	B-NP
)	POS	O
which	POS	O
frequently	POS	O
occurs	POS	O
due	POS	O
to	POS	O
vomiting	POS	B-NP
and	POS	O
or	POS	O
diarrhea	POS	B-NP
in	POS	O
malaria	POS	B-NP
cases	POS	O
.	POS	O
Penicillamine	POS	B-NP
-	POS	I-NP
related	POS	I-NP
lichenoid	POS	I-NP
dermatitis	POS	I-NP
and	POS	O
utility	POS	O
of	POS	O
zinc	POS	O
acetate	POS	O
in	POS	O
a	POS	O
Wilson	POS	B-NP
disease	POS	I-NP
patient	POS	O
with	POS	O
hepatic	POS	B-NP
presentation	POS	I-NP
,	POS	O
anxiety	POS	B-NP
and	POS	O
SPECT	POS	B-NP
abnormalities	POS	I-NP
.	POS	O
Wilson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
is	POS	O
an	POS	O
autosomal	POS	B-NP
recessive	POS	I-NP
disorder	POS	I-NP
of	POS	I-NP
hepatic	POS	I-NP
copper	POS	I-NP
metabolism	POS	I-NP
with	POS	O
consequent	POS	O
copper	POS	O
accumulation	POS	O
and	POS	O
toxicity	POS	B-NP
in	POS	O
many	POS	O
tissues	POS	O
and	POS	O
consequent	POS	O
hepatic	POS	O
,	POS	O
neurologic	POS	O
and	POS	O
psychiatric	POS	B-NP
disorders	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
Wilson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
with	POS	O
chronic	POS	B-NP
liver	POS	I-NP
disease	POS	I-NP
;	POS	O
moreover	POS	O
,	POS	O
in	POS	O
our	POS	O
patient	POS	O
,	POS	O
presenting	POS	O
also	POS	O
with	POS	O
high	POS	O
levels	POS	O
of	POS	O
state	POS	O
anxiety	POS	B-NP
without	POS	O
depression	POS	B-NP
,	POS	O
99mTc	POS	O
-	POS	O
ECD	POS	O
-	POS	O
SPECT	POS	O
showed	POS	O
cortical	POS	O
hypoperfusion	POS	O
in	POS	O
frontal	POS	O
lobes	POS	O
,	POS	O
more	POS	O
marked	POS	O
on	POS	O
the	POS	O
left	POS	O
frontal	POS	O
lobe	POS	O
.	POS	O
During	POS	O
the	POS	O
follow	POS	O
-	POS	O
up	POS	O
of	POS	O
our	POS	O
patient	POS	O
,	POS	O
penicillamine	POS	O
was	POS	O
interrupted	POS	O
after	POS	O
the	POS	O
appearance	POS	O
of	POS	O
a	POS	O
lichenoid	POS	B-NP
dermatitis	POS	I-NP
,	POS	O
and	POS	O
zinc	POS	O
acetate	POS	O
permitted	POS	O
to	POS	O
continue	POS	O
the	POS	O
successful	POS	O
treatment	POS	O
of	POS	O
the	POS	O
patient	POS	O
without	POS	O
side	POS	O
-	POS	O
effects	POS	O
.	POS	O
In	POS	O
our	POS	O
case	POS	O
the	POS	O
therapy	POS	O
with	POS	O
zinc	POS	O
acetate	POS	O
represented	POS	O
an	POS	O
effective	POS	O
treatment	POS	O
for	POS	O
a	POS	O
Wilson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
patient	POS	O
in	POS	O
which	POS	O
penicillamine	POS	O
-	POS	O
related	POS	O
side	POS	O
effects	POS	O
appeared	POS	O
.	POS	O
The	POS	O
safety	POS	O
of	POS	O
the	POS	O
zinc	POS	O
acetate	POS	O
allowed	POS	O
us	POS	O
to	POS	O
avoid	POS	O
other	POS	O
potentially	POS	O
toxic	POS	O
chelating	POS	O
drugs	POS	O
;	POS	O
this	POS	O
observation	POS	O
is	POS	O
in	POS	O
line	POS	O
with	POS	O
the	POS	O
growing	POS	O
evidence	POS	O
on	POS	O
the	POS	O
efficacy	POS	O
of	POS	O
the	POS	O
drug	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
Wilson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
Since	POS	O
most	POS	O
of	POS	O
Wilson	POS	O
'	POS	O
s	POS	O
disease	POS	O
penicillamine	POS	O
-	POS	O
treated	POS	O
patients	POS	O
do	POS	O
not	POS	O
seem	POS	O
to	POS	O
develop	POS	O
this	POS	O
skin	POS	B-NP
lesion	POS	I-NP
,	POS	O
it	POS	O
could	POS	O
be	POS	O
conceivable	POS	O
that	POS	O
a	POS	O
specific	POS	O
genetic	POS	O
factor	POS	O
is	POS	O
involved	POS	O
in	POS	O
drug	POS	O
response	POS	O
.	POS	O
Further	POS	O
studies	POS	O
are	POS	O
needed	POS	O
for	POS	O
a	POS	O
better	POS	O
clarification	POS	O
of	POS	O
Wilson	POS	O
'	POS	O
s	POS	O
disease	POS	O
therapy	POS	O
,	POS	O
and	POS	O
in	POS	O
particular	POS	O
to	POS	O
differentiate	POS	O
specific	POS	O
therapies	POS	O
for	POS	O
different	POS	O
Wilson	POS	O
'	POS	O
s	POS	O
disease	POS	O
phenotypes	POS	O
.	POS	O
A	POS	O
dramatic	POS	O
drop	POS	O
in	POS	O
blood	POS	O
pressure	POS	O
following	POS	O
prehospital	POS	O
GTN	POS	O
administration	POS	O
.	POS	O
A	POS	O
male	POS	O
in	POS	O
his	POS	O
sixties	POS	O
with	POS	O
no	POS	O
history	POS	O
of	POS	O
cardiac	POS	B-NP
chest	POS	I-NP
pain	POS	I-NP
awoke	POS	O
with	POS	O
chest	POS	B-NP
pain	POS	I-NP
following	POS	O
an	POS	O
afternoon	POS	O
sleep	POS	O
.	POS	O
The	POS	O
patient	POS	O
did	POS	O
not	POS	O
self	POS	O
medicate	POS	O
.	POS	O
The	POS	O
patient	POS	O
'	POS	O
s	POS	O
observations	POS	O
were	POS	O
within	POS	O
normal	POS	O
limits	POS	O
,	POS	O
he	POS	O
was	POS	O
administered	POS	O
oxygen	POS	O
via	POS	O
a	POS	O
face	POS	O
mask	POS	O
and	POS	O
glyceryl	POS	O
trinitrate	POS	O
(	POS	O
GTN	POS	O
)	POS	O
.	POS	O
Several	POS	O
minutes	POS	O
after	POS	O
the	POS	O
GTN	POS	O
the	POS	O
patient	POS	O
experienced	POS	O
a	POS	O
sudden	POS	O
drop	POS	O
in	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
heart	POS	O
rate	POS	O
,	POS	O
this	POS	O
was	POS	O
rectified	POS	O
by	POS	O
atropine	POS	O
sulphate	POS	O
and	POS	O
a	POS	O
fluid	POS	O
challenge	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
further	POS	O
deterioration	POS	O
in	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
condition	POS	O
during	POS	O
transport	POS	O
to	POS	O
hospital	POS	O
.	POS	O
There	POS	O
are	POS	O
very	POS	O
few	POS	O
documented	POS	O
case	POS	O
like	POS	O
this	POS	O
in	POS	O
the	POS	O
prehospital	POS	O
scientific	POS	O
literature	POS	O
.	POS	O
The	POS	O
cause	POS	O
appears	POS	O
to	POS	O
be	POS	O
the	POS	O
Bezold	POS	O
-	POS	O
Jarish	POS	O
reflex	POS	O
,	POS	O
stimulation	POS	O
of	POS	O
the	POS	O
ventricular	POS	O
walls	POS	O
which	POS	O
in	POS	O
turn	POS	O
decreases	POS	O
sympathetic	POS	O
outflow	POS	O
from	POS	O
the	POS	O
vasomotor	POS	O
centre	POS	O
.	POS	O
Prehospital	POS	O
care	POS	O
providers	POS	O
who	POS	O
are	POS	O
managing	POS	O
any	POS	O
patient	POS	O
with	POS	O
a	POS	O
syncopal	POS	B-NP
episode	POS	O
that	POS	O
fails	POS	O
to	POS	O
recover	POS	O
within	POS	O
a	POS	O
reasonable	POS	O
time	POS	O
frame	POS	O
should	POS	O
consider	POS	O
the	POS	O
Bezold	POS	O
-	POS	O
Jarisch	POS	O
reflex	POS	O
as	POS	O
the	POS	O
cause	POS	O
and	POS	O
manage	POS	O
the	POS	O
patient	POS	O
accordingly	POS	O
.	POS	O
Chronic	POS	O
lesion	POS	O
of	POS	O
rostral	POS	O
ventrolateral	POS	O
medulla	POS	O
in	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
rats	POS	O
.	POS	O
We	POS	O
studied	POS	O
the	POS	O
effects	POS	O
of	POS	O
chronic	POS	O
selective	POS	O
neuronal	POS	O
lesion	POS	O
of	POS	O
rostral	POS	O
ventrolateral	POS	O
medulla	POS	O
on	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
,	POS	O
heart	POS	O
rate	POS	O
,	POS	O
and	POS	O
neurogenic	POS	O
tone	POS	O
in	POS	O
conscious	POS	O
,	POS	O
unrestrained	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
rats	POS	O
.	POS	O
The	POS	O
lesions	POS	O
were	POS	O
placed	POS	O
via	POS	O
bilateral	POS	O
microinjections	POS	O
of	POS	O
30	POS	O
nmol	POS	O
/	POS	O
200	POS	O
nl	POS	O
N	POS	O
-	POS	O
methyl	POS	O
-	POS	O
D	POS	O
-	POS	O
aspartic	POS	O
acid	POS	O
.	POS	O
The	POS	O
restimulation	POS	O
of	POS	O
this	POS	O
area	POS	O
with	POS	O
N	POS	O
-	POS	O
methyl	POS	O
-	POS	O
D	POS	O
-	POS	O
aspartic	POS	O
acid	POS	O
15	POS	O
days	POS	O
postlesion	POS	O
failed	POS	O
to	POS	O
produce	POS	O
a	POS	O
pressor	POS	O
response	POS	O
.	POS	O
One	POS	O
day	POS	O
postlesion	POS	O
,	POS	O
the	POS	O
resting	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
was	POS	O
significantly	POS	O
decreased	POS	O
in	POS	O
lesioned	POS	O
rats	POS	O
when	POS	O
compared	POS	O
with	POS	O
sham	POS	O
rats	POS	O
(	POS	O
100	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
versus	POS	O
173	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
mm	POS	O
Hg	POS	O
,	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Fifteen	POS	O
days	POS	O
later	POS	O
,	POS	O
the	POS	O
lesioned	POS	O
group	POS	O
still	POS	O
showed	POS	O
values	POS	O
significantly	POS	O
lower	POS	O
than	POS	O
the	POS	O
sham	POS	O
group	POS	O
(	POS	O
150	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
versus	POS	O
167	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
mm	POS	O
Hg	POS	O
,	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
No	POS	O
significant	POS	O
heart	POS	O
rate	POS	O
differences	POS	O
were	POS	O
observed	POS	O
between	POS	O
the	POS	O
sham	POS	O
and	POS	O
lesioned	POS	O
groups	POS	O
.	POS	O
The	POS	O
ganglionic	POS	O
blocker	POS	O
trimethaphan	POS	O
(	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
caused	POS	O
similar	POS	O
reductions	POS	O
in	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
in	POS	O
both	POS	O
lesioned	POS	O
and	POS	O
sham	POS	O
groups	POS	O
.	POS	O
The	POS	O
trimethaphan	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
was	POS	O
accompanied	POS	O
by	POS	O
a	POS	O
significant	POS	O
bradycardia	POS	B-NP
in	POS	O
lesioned	POS	O
rats	POS	O
(	POS	O
-	POS	O
32	POS	O
+	POS	O
/	POS	O
-	POS	O
13	POS	O
beats	POS	O
per	POS	O
minute	POS	O
)	POS	O
but	POS	O
a	POS	O
tachycardia	POS	B-NP
in	POS	O
sham	POS	O
rats	POS	O
(	POS	O
+	POS	O
33	POS	O
+	POS	O
/	POS	O
-	POS	O
12	POS	O
beats	POS	O
per	POS	O
minute	POS	O
)	POS	O
1	POS	O
day	POS	O
postlesion	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
rostral	POS	O
ventrolateral	POS	O
medulla	POS	O
neurons	POS	O
appear	POS	O
to	POS	O
play	POS	O
a	POS	O
significant	POS	O
role	POS	O
in	POS	O
maintaining	POS	O
hypertension	POS	B-NP
in	POS	O
conscious	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
rats	POS	O
.	POS	O
Spinal	POS	O
or	POS	O
suprabulbar	POS	O
structures	POS	O
could	POS	O
be	POS	O
responsible	POS	O
for	POS	O
the	POS	O
gradual	POS	O
recovery	POS	O
of	POS	O
the	POS	O
hypertension	POS	B-NP
in	POS	O
the	POS	O
lesioned	POS	O
rats	POS	O
.	POS	O
Acute	POS	O
encephalopathy	POS	B-NP
and	POS	O
cerebral	POS	B-NP
vasospasm	POS	I-NP
after	POS	O
multiagent	POS	O
chemotherapy	POS	O
including	POS	O
PEG	POS	O
-	POS	O
asparaginase	POS	O
and	POS	O
intrathecal	POS	O
cytarabine	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
acute	POS	B-NP
lymphoblastic	POS	I-NP
leukemia	POS	I-NP
.	POS	O
A	POS	O
7	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
girl	POS	O
with	POS	O
an	POS	O
unusual	POS	O
reaction	POS	O
to	POS	O
induction	POS	O
chemotherapy	POS	O
for	POS	O
precursor	POS	B-NP
B	POS	I-NP
-	POS	I-NP
cell	POS	I-NP
acute	POS	I-NP
lymphoblastic	POS	I-NP
leukemia	POS	I-NP
(	POS	O
ALL	POS	B-NP
)	POS	O
is	POS	O
described	POS	O
.	POS	O
The	POS	O
patient	POS	O
developed	POS	O
acute	POS	O
encephalopathy	POS	B-NP
evidenced	POS	O
by	POS	O
behavioral	POS	O
changes	POS	O
,	POS	O
aphasia	POS	B-NP
,	POS	O
incontinence	POS	B-NP
,	POS	O
visual	POS	B-NP
hallucinations	POS	I-NP
,	POS	O
and	POS	O
right	POS	B-NP
-	POS	I-NP
sided	POS	I-NP
weakness	POS	I-NP
with	POS	O
diffuse	POS	B-NP
cerebral	POS	I-NP
vasospasm	POS	I-NP
on	POS	O
magnetic	POS	O
resonance	POS	O
angiography	POS	O
after	POS	O
the	POS	O
administration	POS	O
of	POS	O
intrathecal	POS	O
cytarabine	POS	O
.	POS	O
Vincristine	POS	O
,	POS	O
dexamethasone	POS	O
,	POS	O
and	POS	O
polyethylene	POS	O
glycol	POS	O
-	POS	O
asparaginase	POS	O
were	POS	O
also	POS	O
administered	POS	O
before	POS	O
the	POS	O
episode	POS	O
as	POS	O
part	POS	O
of	POS	O
induction	POS	O
therapy	POS	O
.	POS	O
Neurologic	POS	O
status	POS	O
returned	POS	O
to	POS	O
baseline	POS	O
within	POS	O
10	POS	O
days	POS	O
of	POS	O
the	POS	O
acute	POS	O
event	POS	O
,	POS	O
and	POS	O
magnetic	POS	O
resonance	POS	O
angiography	POS	O
findings	POS	O
returned	POS	O
to	POS	O
normal	POS	O
4	POS	O
months	POS	O
later	POS	O
.	POS	O
Comparison	POS	O
of	POS	O
valsartan	POS	O
/	POS	O
hydrochlorothiazide	POS	O
combination	POS	O
therapy	POS	O
at	POS	O
doses	POS	O
up	POS	O
to	POS	O
320	POS	O
/	POS	O
25	POS	O
mg	POS	O
versus	POS	O
monotherapy	POS	O
:	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
study	POS	O
followed	POS	O
by	POS	O
long	POS	O
-	POS	O
term	POS	O
combination	POS	O
therapy	POS	O
in	POS	O
hypertensive	POS	B-NP
adults	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
One	POS	O
third	POS	O
of	POS	O
patients	POS	O
treated	POS	O
for	POS	O
hypertension	POS	B-NP
attain	POS	O
adequate	POS	O
blood	POS	O
pressure	POS	O
(	POS	O
BP	POS	O
)	POS	O
control	POS	O
,	POS	O
and	POS	O
multidrug	POS	O
regimens	POS	O
are	POS	O
often	POS	O
required	POS	O
.	POS	O
Given	POS	O
the	POS	O
lifelong	POS	O
nature	POS	O
of	POS	O
hypertension	POS	B-NP
,	POS	O
there	POS	O
is	POS	O
a	POS	O
need	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
long	POS	O
-	POS	O
term	POS	O
efficacy	POS	O
and	POS	O
tolerability	POS	O
of	POS	O
higher	POS	O
doses	POS	O
of	POS	O
combination	POS	O
anti	POS	O
-	POS	O
hypertensive	POS	O
therapies	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
This	POS	O
study	POS	O
investigated	POS	O
the	POS	O
efficacy	POS	O
and	POS	O
tolerability	POS	O
of	POS	O
valsartan	POS	O
(	POS	O
VAL	POS	O
)	POS	O
or	POS	O
hydrochlorothiazide	POS	O
(	POS	O
HCTZ	POS	O
)	POS	O
-	POS	O
monotherapy	POS	O
and	POS	O
higher	POS	O
-	POS	O
dose	POS	O
combinations	POS	O
in	POS	O
patients	POS	O
with	POS	O
essential	POS	O
hypertension	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
The	POS	O
first	POS	O
part	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
an	POS	O
8	POS	O
-	POS	O
week	POS	O
,	POS	O
multicenter	POS	O
,	POS	O
randomized	POS	O
,	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
controlled	POS	O
,	POS	O
parallel	POS	O
-	POS	O
group	POS	O
trial	POS	O
.	POS	O
Patients	POS	O
with	POS	O
essential	POS	O
hypertension	POS	B-NP
(	POS	O
mean	POS	O
sitting	POS	O
diastolic	POS	O
BP	POS	O
[	POS	O
MSDBP	POS	O
]	POS	O
,	POS	O
>	POS	O
or	POS	O
=	POS	O
95	POS	O
mm	POS	O
Hg	POS	O
and	POS	O
<	POS	O
110	POS	O
mm	POS	O
Hg	POS	O
)	POS	O
were	POS	O
randomized	POS	O
to	POS	O
1	POS	O
of	POS	O
8	POS	O
treatment	POS	O
groups	POS	O
:	POS	O
VAL	POS	O
160	POS	O
or	POS	O
320	POS	O
mg	POS	O
;	POS	O
HCTZ	POS	O
12	POS	O
.	POS	O
5	POS	O
or	POS	O
25	POS	O
mg	POS	O
;	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
160	POS	O
/	POS	O
12	POS	O
.	POS	O
5	POS	O
,	POS	O
320	POS	O
/	POS	O
12	POS	O
.	POS	O
5	POS	O
,	POS	O
or	POS	O
320	POS	O
/	POS	O
25	POS	O
mg	POS	O
;	POS	O
or	POS	O
placebo	POS	O
.	POS	O
Mean	POS	O
changes	POS	O
in	POS	O
MSDBP	POS	O
and	POS	O
mean	POS	O
sitting	POS	O
systolic	POS	O
BP	POS	O
(	POS	O
MSSBP	POS	O
)	POS	O
were	POS	O
analyzed	POS	O
at	POS	O
the	POS	O
8	POS	O
-	POS	O
week	POS	O
core	POS	O
study	POS	O
end	POS	O
point	POS	O
.	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
320	POS	O
/	POS	O
12	POS	O
.	POS	O
5	POS	O
and	POS	O
320	POS	O
/	POS	O
25	POS	O
mg	POS	O
were	POS	O
further	POS	O
investigated	POS	O
in	POS	O
a	POS	O
54	POS	O
-	POS	O
week	POS	O
,	POS	O
open	POS	O
-	POS	O
label	POS	O
extension	POS	O
.	POS	O
Response	POS	O
was	POS	O
defined	POS	O
as	POS	O
MSDBP	POS	O
<	POS	O
90	POS	O
mm	POS	O
Hg	POS	O
or	POS	O
a	POS	O
>	POS	O
or	POS	O
=	POS	O
10	POS	O
mm	POS	O
Hg	POS	O
decrease	POS	O
compared	POS	O
to	POS	O
baseline	POS	O
.	POS	O
Control	POS	O
was	POS	O
defined	POS	O
as	POS	O
MSDBP	POS	O
<	POS	O
90	POS	O
mm	POS	O
Hg	POS	O
compared	POS	O
with	POS	O
baseline	POS	O
.	POS	O
Tolerability	POS	O
was	POS	O
assessed	POS	O
by	POS	O
monitoring	POS	O
adverse	POS	O
events	POS	O
at	POS	O
randomization	POS	O
and	POS	O
all	POS	O
subsequent	POS	O
study	POS	O
visits	POS	O
and	POS	O
regular	POS	O
evaluation	POS	O
of	POS	O
hematology	POS	O
and	POS	O
blood	POS	O
chemistry	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
1346	POS	O
patients	POS	O
were	POS	O
randomized	POS	O
into	POS	O
the	POS	O
8	POS	O
-	POS	O
week	POS	O
core	POS	O
study	POS	O
(	POS	O
734	POS	O
men	POS	O
,	POS	O
612	POS	O
women	POS	O
;	POS	O
924	POS	O
white	POS	O
,	POS	O
291	POS	O
black	POS	O
,	POS	O
23	POS	O
Asian	POS	O
,	POS	O
108	POS	O
other	POS	O
;	POS	O
mean	POS	O
age	POS	O
,	POS	O
52	POS	O
.	POS	O
7	POS	O
years	POS	O
;	POS	O
mean	POS	O
weight	POS	O
,	POS	O
92	POS	O
.	POS	O
6	POS	O
kg	POS	O
)	POS	O
.	POS	O
All	POS	O
active	POS	O
treatments	POS	O
were	POS	O
associated	POS	O
with	POS	O
significantly	POS	O
reduced	POS	O
MSSBP	POS	O
and	POS	O
MSDBP	POS	O
during	POS	O
the	POS	O
core	POS	O
8	POS	O
-	POS	O
week	POS	O
study	POS	O
,	POS	O
with	POS	O
each	POS	O
monotherapy	POS	O
significantly	POS	O
contributing	POS	O
to	POS	O
the	POS	O
overall	POS	O
effect	POS	O
of	POS	O
combination	POS	O
therapy	POS	O
(	POS	O
VAL	POS	O
and	POS	O
HCTZ	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Each	POS	O
combination	POS	O
was	POS	O
associated	POS	O
with	POS	O
significantly	POS	O
greater	POS	O
reductions	POS	O
in	POS	O
MSSBP	POS	O
and	POS	O
MSDBP	POS	O
compared	POS	O
with	POS	O
the	POS	O
monotherapies	POS	O
and	POS	O
placebo	POS	O
(	POS	O
all	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
The	POS	O
mean	POS	O
reduction	POS	O
in	POS	O
MSSBP	POS	O
/	POS	O
MSDBP	POS	O
with	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
320	POS	O
/	POS	O
25	POS	O
mg	POS	O
was	POS	O
24	POS	O
.	POS	O
7	POS	O
/	POS	O
16	POS	O
.	POS	O
6	POS	O
mm	POS	O
Hg	POS	O
,	POS	O
compared	POS	O
with	POS	O
5	POS	O
.	POS	O
9	POS	O
/	POS	O
7	POS	O
.	POS	O
0	POS	O
mm	POS	O
Hg	POS	O
with	POS	O
placebo	POS	O
.	POS	O
The	POS	O
reduction	POS	O
in	POS	O
MSSBP	POS	O
was	POS	O
significantly	POS	O
greater	POS	O
with	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
320	POS	O
/	POS	O
25	POS	O
mg	POS	O
compared	POS	O
with	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
160	POS	O
/	POS	O
12	POS	O
.	POS	O
5	POS	O
mg	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
002	POS	O
)	POS	O
.	POS	O
Rates	POS	O
of	POS	O
response	POS	O
and	POS	O
BP	POS	O
control	POS	O
were	POS	O
significantly	POS	O
higher	POS	O
in	POS	O
the	POS	O
groups	POS	O
that	POS	O
received	POS	O
combination	POS	O
treatment	POS	O
compared	POS	O
with	POS	O
those	POS	O
that	POS	O
received	POS	O
monotherapy	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
hypokalemia	POS	B-NP
was	POS	O
lower	POS	O
with	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
combinations	POS	O
(	POS	O
1	POS	O
.	POS	O
8	POS	O
%	POS	O
-	POS	O
6	POS	O
.	POS	O
1	POS	O
%	POS	O
)	POS	O
than	POS	O
with	POS	O
HCTZ	POS	O
monotherapies	POS	O
(	POS	O
7	POS	O
.	POS	O
1	POS	O
%	POS	O
-	POS	O
13	POS	O
.	POS	O
3	POS	O
%	POS	O
)	POS	O
.	POS	O
The	POS	O
majority	POS	O
of	POS	O
adverse	POS	O
events	POS	O
in	POS	O
the	POS	O
core	POS	O
study	POS	O
were	POS	O
of	POS	O
mild	POS	O
to	POS	O
moderate	POS	O
severity	POS	O
.	POS	O
The	POS	O
efficacy	POS	O
and	POS	O
tolerability	POS	O
of	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
combinations	POS	O
were	POS	O
maintained	POS	O
during	POS	O
the	POS	O
extension	POS	O
(	POS	O
797	POS	O
patients	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
In	POS	O
this	POS	O
study	POS	O
population	POS	O
,	POS	O
combination	POS	O
therapies	POS	O
with	POS	O
VAL	POS	O
/	POS	O
HCTZ	POS	O
were	POS	O
associated	POS	O
with	POS	O
significantly	POS	O
greater	POS	O
BP	POS	O
reductions	POS	O
compared	POS	O
with	POS	O
either	POS	O
monotherapy	POS	O
,	POS	O
were	POS	O
well	POS	O
tolerated	POS	O
,	POS	O
and	POS	O
were	POS	O
associated	POS	O
with	POS	O
less	POS	O
hypokalemia	POS	B-NP
than	POS	O
HCTZ	POS	O
alone	POS	O
.	POS	O
Succimer	POS	O
chelation	POS	O
improves	POS	O
learning	POS	O
,	POS	O
attention	POS	O
,	POS	O
and	POS	O
arousal	POS	O
regulation	POS	O
in	POS	O
lead	POS	O
-	POS	O
exposed	POS	O
rats	POS	O
but	POS	O
produces	POS	O
lasting	POS	O
cognitive	POS	B-NP
impairment	POS	I-NP
in	POS	O
the	POS	O
absence	POS	O
of	POS	O
lead	POS	O
exposure	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
There	POS	O
is	POS	O
growing	POS	O
pressure	POS	O
for	POS	O
clinicians	POS	O
to	POS	O
prescribe	POS	O
chelation	POS	O
therapy	POS	O
at	POS	O
only	POS	O
slightly	POS	O
elevated	POS	O
blood	POS	O
lead	POS	O
levels	POS	O
.	POS	O
However	POS	O
,	POS	O
very	POS	O
few	POS	O
studies	POS	O
have	POS	O
evaluated	POS	O
whether	POS	O
chelation	POS	O
improves	POS	O
cognitive	POS	O
outcomes	POS	O
in	POS	O
Pb	POS	O
-	POS	O
exposed	POS	O
children	POS	O
,	POS	O
or	POS	O
whether	POS	O
these	POS	O
agents	POS	O
have	POS	O
adverse	POS	O
effects	POS	O
that	POS	O
may	POS	O
affect	POS	O
brain	POS	O
development	POS	O
in	POS	O
the	POS	O
absence	POS	O
of	POS	O
Pb	POS	O
exposure	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
The	POS	O
present	POS	O
study	POS	O
was	POS	O
designed	POS	O
to	POS	O
answer	POS	O
these	POS	O
questions	POS	O
,	POS	O
using	POS	O
a	POS	O
rodent	POS	O
model	POS	O
of	POS	O
early	POS	O
childhood	POS	O
Pb	POS	O
exposure	POS	O
and	POS	O
treatment	POS	O
with	POS	O
succimer	POS	O
,	POS	O
a	POS	O
widely	POS	O
used	POS	O
chelating	POS	O
agent	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
Pb	POS	B-NP
poisoning	POS	I-NP
.	POS	O
RESULTS	POS	O
:	POS	O
Pb	POS	O
exposure	POS	O
produced	POS	O
lasting	POS	O
impairments	POS	O
in	POS	O
learning	POS	O
,	POS	O
attention	POS	O
,	POS	O
inhibitory	POS	O
control	POS	O
,	POS	O
and	POS	O
arousal	POS	O
regulation	POS	O
,	POS	O
paralleling	POS	O
the	POS	O
areas	POS	O
of	POS	O
dysfunction	POS	O
seen	POS	O
in	POS	O
Pb	POS	O
-	POS	O
exposed	POS	O
children	POS	O
.	POS	O
Succimer	POS	O
treatment	POS	O
of	POS	O
the	POS	O
Pb	POS	O
-	POS	O
exposed	POS	O
rats	POS	O
significantly	POS	O
improved	POS	O
learning	POS	O
,	POS	O
attention	POS	O
,	POS	O
and	POS	O
arousal	POS	O
regulation	POS	O
,	POS	O
although	POS	O
the	POS	O
efficacy	POS	O
of	POS	O
the	POS	O
treatment	POS	O
varied	POS	O
as	POS	O
a	POS	O
function	POS	O
of	POS	O
the	POS	O
Pb	POS	O
exposure	POS	O
level	POS	O
and	POS	O
the	POS	O
specific	POS	O
functional	POS	O
deficit	POS	O
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
succimer	POS	O
treatment	POS	O
of	POS	O
rats	POS	O
not	POS	O
previously	POS	O
exposed	POS	O
to	POS	O
Pb	POS	O
produced	POS	O
lasting	POS	O
and	POS	O
pervasive	POS	O
cognitive	POS	O
and	POS	O
affective	POS	B-NP
dysfunction	POS	I-NP
comparable	POS	O
in	POS	O
magnitude	POS	O
to	POS	O
that	POS	O
produced	POS	O
by	POS	O
the	POS	O
higher	POS	O
Pb	POS	O
exposure	POS	O
regimen	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
These	POS	O
are	POS	O
the	POS	O
first	POS	O
data	POS	O
,	POS	O
to	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
to	POS	O
show	POS	O
that	POS	O
treatment	POS	O
with	POS	O
any	POS	O
chelating	POS	O
agent	POS	O
can	POS	O
alleviate	POS	O
cognitive	POS	B-NP
deficits	POS	I-NP
due	POS	O
to	POS	O
Pb	POS	O
exposure	POS	O
.	POS	O
These	POS	O
findings	POS	O
suggest	POS	O
that	POS	O
it	POS	O
may	POS	O
be	POS	O
possible	POS	O
to	POS	O
identify	POS	O
a	POS	O
succimer	POS	O
treatment	POS	O
protocol	POS	O
that	POS	O
improves	POS	O
cognitive	POS	O
outcomes	POS	O
in	POS	O
Pb	POS	O
-	POS	O
exposed	POS	O
children	POS	O
.	POS	O
However	POS	O
,	POS	O
they	POS	O
also	POS	O
suggest	POS	O
that	POS	O
succimer	POS	O
treatment	POS	O
should	POS	O
be	POS	O
strongly	POS	O
discouraged	POS	O
for	POS	O
children	POS	O
who	POS	O
do	POS	O
not	POS	O
have	POS	O
elevated	POS	O
tissue	POS	O
levels	POS	O
of	POS	O
Pb	POS	O
or	POS	O
other	POS	O
heavy	POS	O
metals	POS	O
.	POS	O
Caffeine	POS	O
challenge	POS	O
test	POS	O
in	POS	O
panic	POS	B-NP
disorder	POS	I-NP
and	POS	O
depression	POS	B-NP
with	POS	O
panic	POS	B-NP
attacks	POS	I-NP
.	POS	O
Our	POS	O
aim	POS	O
was	POS	O
to	POS	O
observe	POS	O
if	POS	O
patients	POS	O
with	POS	O
panic	POS	B-NP
disorder	POS	I-NP
(	POS	O
PD	POS	B-NP
)	POS	O
and	POS	O
patients	POS	O
with	POS	O
major	POS	O
depression	POS	B-NP
with	POS	O
panic	POS	B-NP
attacks	POS	I-NP
(	POS	O
MDP	POS	O
)	POS	O
(	POS	O
Diagnostic	POS	O
and	POS	O
Statistical	POS	O
Manual	POS	O
of	POS	O
Mental	POS	O
Disorders	POS	O
,	POS	O
Fourth	POS	O
Edition	POS	O
criteria	POS	O
)	POS	O
respond	POS	O
in	POS	O
a	POS	O
similar	POS	O
way	POS	O
to	POS	O
the	POS	O
induction	POS	O
of	POS	O
panic	POS	B-NP
attacks	POS	I-NP
by	POS	O
an	POS	O
oral	POS	O
caffeine	POS	O
challenge	POS	O
test	POS	O
.	POS	O
We	POS	O
randomly	POS	O
selected	POS	O
29	POS	O
patients	POS	O
with	POS	O
PD	POS	B-NP
,	POS	O
27	POS	O
with	POS	O
MDP	POS	O
,	POS	O
25	POS	O
with	POS	O
major	POS	O
depression	POS	B-NP
without	POS	O
panic	POS	B-NP
attacks	POS	I-NP
(	POS	O
MD	POS	B-NP
)	POS	O
,	POS	O
and	POS	O
28	POS	O
healthy	POS	O
volunteers	POS	O
.	POS	O
The	POS	O
patients	POS	O
had	POS	O
no	POS	O
psychotropic	POS	O
drug	POS	O
for	POS	O
at	POS	O
least	POS	O
a	POS	O
4	POS	O
-	POS	O
week	POS	O
period	POS	O
.	POS	O
In	POS	O
a	POS	O
randomized	POS	O
double	POS	O
-	POS	O
blind	POS	O
experiment	POS	O
performed	POS	O
in	POS	O
2	POS	O
occasions	POS	O
7	POS	O
days	POS	O
apart	POS	O
,	POS	O
480	POS	O
mg	POS	O
caffeine	POS	O
and	POS	O
a	POS	O
caffeine	POS	O
-	POS	O
free	POS	O
(	POS	O
placebo	POS	O
)	POS	O
solution	POS	O
were	POS	O
administered	POS	O
in	POS	O
a	POS	O
coffee	POS	O
form	POS	O
and	POS	O
anxiety	POS	B-NP
scales	POS	O
were	POS	O
applied	POS	O
before	POS	O
and	POS	O
after	POS	O
each	POS	O
test	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
58	POS	O
.	POS	O
6	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
17	POS	O
)	POS	O
of	POS	O
patients	POS	O
with	POS	O
PD	POS	B-NP
,	POS	O
44	POS	O
.	POS	O
4	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
12	POS	O
)	POS	O
of	POS	O
patients	POS	O
with	POS	O
MDP	POS	O
,	POS	O
12	POS	O
.	POS	O
0	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
3	POS	O
)	POS	O
of	POS	O
patients	POS	O
with	POS	O
MD	POS	B-NP
,	POS	O
and	POS	O
7	POS	O
.	POS	O
1	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
2	POS	O
)	POS	O
of	POS	O
control	POS	O
subjects	POS	O
had	POS	O
a	POS	O
panic	POS	B-NP
attack	POS	O
after	POS	O
the	POS	O
480	POS	O
-	POS	O
mg	POS	O
caffeine	POS	O
challenge	POS	O
test	POS	O
(	POS	O
chi	POS	O
(	POS	O
2	POS	O
)	POS	O
(	POS	O
3	POS	O
)	POS	O
=	POS	O
16	POS	O
.	POS	O
22	POS	O
,	POS	O
P	POS	O
=	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
The	POS	O
patients	POS	O
with	POS	O
PD	POS	B-NP
and	POS	O
MDP	POS	O
were	POS	O
more	POS	O
sensitive	POS	O
to	POS	O
caffeine	POS	O
than	POS	O
were	POS	O
patients	POS	O
with	POS	O
MD	POS	B-NP
and	POS	O
healthy	POS	O
volunteers	POS	O
.	POS	O
No	POS	O
panic	POS	B-NP
attack	POS	O
was	POS	O
observed	POS	O
after	POS	O
the	POS	O
caffeine	POS	O
-	POS	O
free	POS	O
solution	POS	O
intake	POS	O
.	POS	O
The	POS	O
patients	POS	O
with	POS	O
MD	POS	B-NP
had	POS	O
a	POS	O
lower	POS	O
heart	POS	O
rate	POS	O
response	POS	O
to	POS	O
the	POS	O
test	POS	O
than	POS	O
all	POS	O
the	POS	O
other	POS	O
groups	POS	O
(	POS	O
2	POS	O
-	POS	O
way	POS	O
analysis	POS	O
of	POS	O
variance	POS	O
,	POS	O
group	POS	O
by	POS	O
time	POS	O
interaction	POS	O
with	POS	O
Greenhouse	POS	O
-	POS	O
Geisser	POS	O
correction	POS	O
:	POS	O
F	POS	O
(	POS	O
3	POS	O
,	POS	O
762	POS	O
)	POS	O
=	POS	O
2	POS	O
.	POS	O
85	POS	O
,	POS	O
P	POS	O
=	POS	O
.	POS	O
026	POS	O
)	POS	O
.	POS	O
Our	POS	O
data	POS	O
suggest	POS	O
that	POS	O
there	POS	O
is	POS	O
an	POS	O
association	POS	O
between	POS	O
panic	POS	B-NP
attacks	POS	I-NP
,	POS	O
no	POS	O
matter	POS	O
if	POS	O
associated	POS	O
with	POS	O
PD	POS	B-NP
or	POS	O
MDP	POS	O
,	POS	O
and	POS	O
hyperreactivity	POS	B-NP
to	POS	O
an	POS	O
oral	POS	O
caffeine	POS	O
challenge	POS	O
test	POS	O
.	POS	O
Mitral	POS	O
annuloplasty	POS	O
as	POS	O
a	POS	O
ventricular	POS	O
restoration	POS	O
method	POS	O
for	POS	O
the	POS	O
failing	POS	O
left	POS	O
ventricle	POS	O
:	POS	O
a	POS	O
pilot	POS	O
study	POS	O
.	POS	O
BACKGROUND	POS	O
AND	POS	O
AIM	POS	O
OF	POS	O
THE	POS	O
STUDY	POS	O
:	POS	O
Undersized	POS	O
mitral	POS	O
annuloplasty	POS	O
(	POS	O
MAP	POS	O
)	POS	O
is	POS	O
effective	POS	O
in	POS	O
patients	POS	O
with	POS	O
dilated	POS	B-NP
cardiomyopathy	POS	I-NP
and	POS	O
functional	POS	B-NP
mitral	POS	I-NP
regurgitation	POS	I-NP
(	POS	O
MR	POS	O
)	POS	O
since	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
addressing	POS	O
the	POS	O
MR	POS	O
,	POS	O
the	POS	O
MAP	POS	O
may	POS	O
also	POS	O
reshape	POS	O
the	POS	O
dilated	POS	O
left	POS	O
ventricular	POS	O
(	POS	O
LV	POS	O
)	POS	O
base	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
direct	POS	O
benefits	POS	O
of	POS	O
this	POS	O
possible	POS	O
reshaping	POS	O
on	POS	O
LV	POS	O
function	POS	O
in	POS	O
the	POS	O
absence	POS	O
of	POS	O
underlying	POS	O
MR	POS	O
remain	POS	O
incompletely	POS	O
understood	POS	O
.	POS	O
The	POS	O
study	POS	O
aim	POS	O
was	POS	O
to	POS	O
identify	POS	O
these	POS	O
benefits	POS	O
in	POS	O
a	POS	O
canine	POS	O
model	POS	O
of	POS	O
acute	POS	O
heart	POS	B-NP
failure	POS	I-NP
.	POS	O
METHODS	POS	O
:	POS	O
Six	POS	O
dogs	POS	O
underwent	POS	O
MAP	POS	O
with	POS	O
a	POS	O
prosthetic	POS	O
band	POS	O
on	POS	O
the	POS	O
posterior	POS	O
mitral	POS	O
annulus	POS	O
,	POS	O
using	POS	O
four	POS	O
mattress	POS	O
sutures	POS	O
.	POS	O
The	POS	O
sutures	POS	O
were	POS	O
passed	POS	O
individually	POS	O
through	POS	O
four	POS	O
tourniquets	POS	O
and	POS	O
exteriorized	POS	O
untied	POS	O
via	POS	O
the	POS	O
left	POS	O
atriotomy	POS	O
.	POS	O
Sonomicrometry	POS	O
crystals	POS	O
were	POS	O
implanted	POS	O
around	POS	O
the	POS	O
mitral	POS	O
annulus	POS	O
and	POS	O
left	POS	O
ventricle	POS	O
to	POS	O
measure	POS	O
geometry	POS	O
and	POS	O
regional	POS	O
function	POS	O
.	POS	O
Acute	POS	O
heart	POS	B-NP
failure	POS	I-NP
was	POS	O
induced	POS	O
by	POS	O
propranolol	POS	O
and	POS	O
volume	POS	O
loading	POS	O
after	POS	O
weaning	POS	O
from	POS	O
cardiopulmonary	POS	O
bypass	POS	O
;	POS	O
an	POS	O
absence	POS	O
of	POS	O
MR	POS	O
was	POS	O
confirmed	POS	O
by	POS	O
echocardiography	POS	O
.	POS	O
MAP	POS	O
was	POS	O
accomplished	POS	O
by	POS	O
cinching	POS	O
the	POS	O
tourniquets	POS	O
.	POS	O
Data	POS	O
were	POS	O
acquired	POS	O
at	POS	O
baseline	POS	O
,	POS	O
after	POS	O
induction	POS	O
of	POS	O
acute	POS	O
heart	POS	B-NP
failure	POS	I-NP
,	POS	O
and	POS	O
after	POS	O
MAP	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
MAP	POS	O
decreased	POS	O
mitral	POS	O
annular	POS	O
dimensions	POS	O
in	POS	O
both	POS	O
commissure	POS	O
-	POS	O
commissure	POS	O
and	POS	O
septal	POS	O
-	POS	O
lateral	POS	O
directions	POS	O
.	POS	O
Concomitantly	POS	O
,	POS	O
the	POS	O
diastolic	POS	O
diameter	POS	O
of	POS	O
the	POS	O
LV	POS	O
base	POS	O
and	POS	O
LV	POS	O
sphericity	POS	O
decreased	POS	O
(	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
,	POS	O
improved	POS	O
)	POS	O
from	POS	O
37	POS	O
.	POS	O
4	POS	O
+	POS	O
/	POS	O
-	POS	O
9	POS	O
.	POS	O
3	POS	O
to	POS	O
35	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
10	POS	O
mm	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
063	POS	O
)	POS	O
,	POS	O
and	POS	O
from	POS	O
67	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
18	POS	O
.	POS	O
6	POS	O
%	POS	O
to	POS	O
65	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
18	POS	O
.	POS	O
9	POS	O
%	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
016	POS	O
)	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Decreases	POS	O
were	POS	O
evident	POS	O
in	POS	O
both	POS	O
LV	POS	O
end	POS	O
-	POS	O
diastolic	POS	O
pressure	POS	O
(	POS	O
from	POS	O
17	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
to	POS	O
15	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
mmHg	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
0480	POS	O
and	POS	O
Tau	POS	O
(	POS	O
from	POS	O
48	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
to	POS	O
45	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
ms	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
while	POS	O
fractional	POS	O
shortening	POS	O
at	POS	O
the	POS	O
LV	POS	O
base	POS	O
increased	POS	O
from	POS	O
7	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
.	POS	O
5	POS	O
%	POS	O
to	POS	O
9	POS	O
.	POS	O
4	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
.	POS	O
5	POS	O
%	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
045	POS	O
)	POS	O
.	POS	O
After	POS	O
MAP	POS	O
,	POS	O
increases	POS	O
were	POS	O
identified	POS	O
in	POS	O
both	POS	O
cardiac	POS	O
output	POS	O
(	POS	O
from	POS	O
1	POS	O
.	POS	O
54	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
57	POS	O
to	POS	O
1	POS	O
.	POS	O
65	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
57	POS	O
1	POS	O
/	POS	O
min	POS	O
)	POS	O
and	POS	O
Emax	POS	O
(	POS	O
from	POS	O
1	POS	O
.	POS	O
86	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
9	POS	O
to	POS	O
2	POS	O
.	POS	O
41	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
31	POS	O
mmHg	POS	O
/	POS	O
ml	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
data	POS	O
acquired	POS	O
suggest	POS	O
that	POS	O
isolated	POS	O
MAP	POS	O
may	POS	O
have	POS	O
certain	POS	O
benefits	POS	O
on	POS	O
LV	POS	O
dimension	POS	O
/	POS	O
function	POS	O
in	POS	O
acute	POS	O
heart	POS	B-NP
failure	POS	I-NP
,	POS	O
even	POS	O
in	POS	O
the	POS	O
absence	POS	O
of	POS	O
MR	POS	O
.	POS	O
However	POS	O
,	POS	O
further	POS	O
investigations	POS	O
are	POS	O
warranted	POS	O
in	POS	O
a	POS	O
model	POS	O
of	POS	O
chronic	POS	O
heart	POS	B-NP
failure	POS	I-NP
.	POS	O
Piperacillin	POS	O
/	POS	O
tazobactam	POS	O
-	POS	O
induced	POS	O
seizure	POS	B-NP
rapidly	POS	O
reversed	POS	O
by	POS	O
high	POS	O
flux	POS	O
hemodialysis	POS	O
in	POS	O
a	POS	O
patient	POS	O
on	POS	O
peritoneal	POS	O
dialysis	POS	O
.	POS	O
Despite	POS	O
popular	POS	O
use	POS	O
of	POS	O
piperacillin	POS	O
,	POS	O
the	POS	O
dire	POS	O
neurotoxicity	POS	B-NP
associated	POS	O
with	POS	O
piperacillin	POS	O
still	POS	O
goes	POS	O
unrecognized	POS	O
,	POS	O
leading	POS	O
to	POS	O
a	POS	O
delay	POS	O
in	POS	O
appropriate	POS	O
management	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
57	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
end	POS	O
-	POS	O
stage	POS	O
renal	POS	B-NP
disease	POS	I-NP
receiving	POS	O
continuous	POS	O
ambulatory	POS	O
peritoneal	POS	O
dialysis	POS	O
(	POS	O
CAPD	POS	O
)	POS	O
,	POS	O
who	POS	O
developed	POS	O
slurred	POS	B-NP
speech	POS	I-NP
,	POS	O
tremor	POS	B-NP
,	POS	O
bizarre	POS	B-NP
behavior	POS	I-NP
,	POS	O
progressive	POS	B-NP
mental	POS	I-NP
confusion	POS	I-NP
,	POS	O
and	POS	O
2	POS	O
episodes	POS	O
of	POS	O
generalized	POS	O
tonic	POS	O
-	POS	O
clonic	POS	B-NP
seizure	POS	I-NP
(	POS	O
GTCS	POS	B-NP
)	POS	O
after	POS	O
5	POS	O
doses	POS	O
of	POS	O
piperacillin	POS	O
/	POS	O
tazobactam	POS	O
(	POS	O
2	POS	O
g	POS	O
/	POS	O
250	POS	O
mg	POS	O
)	POS	O
were	POS	O
given	POS	O
for	POS	O
bronchiectasis	POS	B-NP
with	POS	O
secondary	POS	B-NP
infection	POS	I-NP
.	POS	O
The	POS	O
laboratory	POS	O
data	POS	O
revealed	POS	O
normal	POS	O
plasma	POS	O
electrolyte	POS	O
and	POS	O
ammonia	POS	O
levels	POS	O
but	POS	O
leukocytosis	POS	B-NP
.	POS	O
Neurologic	POS	O
examinations	POS	O
showed	POS	O
dysarthria	POS	B-NP
and	POS	O
bilateral	POS	B-NP
Babinski	POS	I-NP
sign	POS	O
.	POS	O
Computed	POS	O
tomography	POS	O
of	POS	O
brain	POS	O
and	POS	O
electroencephalogram	POS	O
were	POS	O
unremarkable	POS	O
.	POS	O
Despite	POS	O
the	POS	O
use	POS	O
of	POS	O
antiepileptic	POS	O
agents	POS	O
,	POS	O
another	POS	O
GTCS	POS	B-NP
episode	POS	O
recurred	POS	O
after	POS	O
the	POS	O
sixth	POS	O
dose	POS	O
of	POS	O
piperacillin	POS	O
/	POS	O
tazobactam	POS	O
.	POS	O
Brain	POS	O
magnetic	POS	O
resonance	POS	O
imaging	POS	O
did	POS	O
not	POS	O
demonstrate	POS	O
acute	POS	B-NP
infarction	POS	I-NP
and	POS	O
organic	POS	B-NP
brain	POS	I-NP
lesions	POS	I-NP
.	POS	O
Initiation	POS	O
of	POS	O
high	POS	O
-	POS	O
flux	POS	O
hemodialysis	POS	O
rapidly	POS	O
reversed	POS	O
the	POS	O
neurologic	POS	O
symptoms	POS	O
within	POS	O
4	POS	O
hours	POS	O
.	POS	O
Piperacillin	POS	O
-	POS	O
induced	POS	O
encephalopathy	POS	B-NP
should	POS	O
be	POS	O
considered	POS	O
in	POS	O
any	POS	O
uremic	POS	B-NP
patients	POS	O
with	POS	O
unexplained	POS	O
neurological	POS	B-NP
manifestations	POS	I-NP
.	POS	O
CAPD	POS	B-NP
is	POS	O
inefficient	POS	O
in	POS	O
removing	POS	O
piperacillin	POS	O
,	POS	O
whereas	POS	O
hemodialysis	POS	O
can	POS	O
rapidly	POS	O
terminate	POS	O
the	POS	O
piperacillin	POS	O
-	POS	O
induced	POS	O
encephalopathy	POS	B-NP
.	POS	O
Frequency	POS	O
of	POS	O
transient	POS	O
ipsilateral	POS	O
vocal	POS	B-NP
cord	POS	I-NP
paralysis	POS	I-NP
in	POS	O
patients	POS	O
undergoing	POS	O
carotid	POS	O
endarterectomy	POS	O
under	POS	O
local	POS	O
anesthesia	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Especially	POS	O
because	POS	O
of	POS	O
improvements	POS	O
in	POS	O
clinical	POS	O
neurologic	POS	O
monitoring	POS	O
,	POS	O
carotid	POS	O
endarterectomy	POS	O
done	POS	O
under	POS	O
local	POS	O
anesthesia	POS	O
has	POS	O
become	POS	O
the	POS	O
technique	POS	O
of	POS	O
choice	POS	O
in	POS	O
several	POS	O
centers	POS	O
.	POS	O
Temporary	POS	O
ipsilateral	POS	O
vocal	POS	B-NP
nerve	POS	I-NP
palsies	POS	I-NP
due	POS	O
to	POS	O
local	POS	O
anesthetics	POS	O
have	POS	O
been	POS	O
described	POS	O
,	POS	O
however	POS	O
.	POS	O
Such	POS	O
complications	POS	O
are	POS	O
most	POS	O
important	POS	O
in	POS	O
situations	POS	O
where	POS	O
there	POS	O
is	POS	O
a	POS	O
pre	POS	O
-	POS	O
existing	POS	O
contralateral	POS	O
paralysis	POS	B-NP
.	POS	O
We	POS	O
therefore	POS	O
examined	POS	O
the	POS	O
effect	POS	O
of	POS	O
local	POS	O
anesthesia	POS	O
on	POS	O
vocal	POS	O
cord	POS	O
function	POS	O
to	POS	O
better	POS	O
understand	POS	O
its	POS	O
possible	POS	O
consequences	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
This	POS	O
prospective	POS	O
study	POS	O
included	POS	O
28	POS	O
patients	POS	O
undergoing	POS	O
carotid	POS	O
endarterectomy	POS	O
under	POS	O
local	POS	O
anesthesia	POS	O
.	POS	O
Vocal	POS	O
cord	POS	O
function	POS	O
was	POS	O
evaluated	POS	O
before	POS	O
,	POS	O
during	POS	O
,	POS	O
and	POS	O
after	POS	O
surgery	POS	O
(	POS	O
postoperative	POS	O
day	POS	O
1	POS	O
)	POS	O
using	POS	O
flexible	POS	O
laryngoscopy	POS	O
.	POS	O
Anesthesia	POS	O
was	POS	O
performed	POS	O
by	POS	O
injecting	POS	O
20	POS	O
to	POS	O
40	POS	O
mL	POS	O
of	POS	O
a	POS	O
mixture	POS	O
of	POS	O
long	POS	O
-	POS	O
acting	POS	O
(	POS	O
ropivacaine	POS	O
)	POS	O
and	POS	O
short	POS	O
-	POS	O
acting	POS	O
(	POS	O
prilocaine	POS	O
)	POS	O
anesthetic	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
All	POS	O
patients	POS	O
had	POS	O
normal	POS	O
vocal	POS	O
cord	POS	O
function	POS	O
preoperatively	POS	O
.	POS	O
Twelve	POS	O
patients	POS	O
(	POS	O
43	POS	O
%	POS	O
)	POS	O
were	POS	O
found	POS	O
to	POS	O
have	POS	O
intraoperative	POS	O
ipsilateral	POS	O
vocal	POS	B-NP
cord	POS	I-NP
paralysis	POS	I-NP
.	POS	O
It	POS	O
resolved	POS	O
in	POS	O
all	POS	O
cases	POS	O
<	POS	O
or	POS	O
=	POS	O
24	POS	O
hours	POS	O
.	POS	O
There	POS	O
were	POS	O
no	POS	O
significant	POS	O
differences	POS	O
in	POS	O
operating	POS	O
time	POS	O
or	POS	O
volume	POS	O
or	POS	O
frequency	POS	O
of	POS	O
anesthetic	POS	O
administration	POS	O
in	POS	O
patients	POS	O
with	POS	O
temporary	POS	O
vocal	POS	B-NP
cord	POS	I-NP
paralysis	POS	I-NP
compared	POS	O
with	POS	O
those	POS	O
without	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Local	POS	O
anesthesia	POS	O
led	POS	O
to	POS	O
temporary	POS	O
ipsilateral	POS	O
vocal	POS	B-NP
cord	POS	I-NP
paralysis	POS	I-NP
in	POS	O
almost	POS	O
half	POS	O
of	POS	O
these	POS	O
patients	POS	O
.	POS	O
Because	POS	O
pre	POS	O
-	POS	O
existing	POS	O
paralysis	POS	B-NP
is	POS	O
of	POS	O
a	POS	O
relevant	POS	O
frequency	POS	O
(	POS	O
up	POS	O
to	POS	O
3	POS	O
%	POS	O
)	POS	O
,	POS	O
a	POS	O
preoperative	POS	O
evaluation	POS	O
of	POS	O
vocal	POS	O
cord	POS	O
function	POS	O
before	POS	O
carotid	POS	O
endarterectomy	POS	O
under	POS	O
local	POS	O
anesthesia	POS	O
is	POS	O
recommended	POS	O
to	POS	O
avoid	POS	O
intraoperative	POS	B-NP
bilateral	POS	I-NP
paralysis	POS	I-NP
.	POS	O
In	POS	O
patients	POS	O
with	POS	O
preoperative	POS	B-NP
contralateral	POS	I-NP
vocal	POS	I-NP
cord	POS	I-NP
paralysis	POS	I-NP
,	POS	O
surgery	POS	O
under	POS	O
general	POS	O
anesthesia	POS	O
should	POS	O
be	POS	O
considered	POS	O
.	POS	O
Impaired	POS	O
fear	POS	O
recognition	POS	O
in	POS	O
regular	POS	O
recreational	POS	O
cocaine	POS	O
users	POS	O
.	POS	O
INTRODUCTION	POS	O
:	POS	O
The	POS	O
ability	POS	O
to	POS	O
read	POS	O
facial	POS	O
expressions	POS	O
is	POS	O
essential	POS	O
for	POS	O
normal	POS	O
human	POS	O
social	POS	O
interaction	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
conduct	POS	O
the	POS	O
first	POS	O
investigation	POS	O
of	POS	O
facial	POS	O
expression	POS	O
recognition	POS	O
performance	POS	O
in	POS	O
recreational	POS	O
cocaine	POS	O
users	POS	O
.	POS	O
MATERIALS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
Three	POS	O
groups	POS	O
,	POS	O
comprised	POS	O
of	POS	O
21	POS	O
cocaine	POS	O
naive	POS	O
participants	POS	O
(	POS	O
CN	POS	O
)	POS	O
,	POS	O
30	POS	O
occasional	POS	O
cocaine	POS	O
(	POS	O
OC	POS	O
)	POS	O
,	POS	O
and	POS	O
48	POS	O
regular	POS	O
recreational	POS	O
cocaine	POS	O
(	POS	O
RC	POS	O
)	POS	O
users	POS	O
,	POS	O
were	POS	O
compared	POS	O
.	POS	O
An	POS	O
emotional	POS	O
facial	POS	O
expression	POS	O
(	POS	O
EFE	POS	O
)	POS	O
task	POS	O
consisting	POS	O
of	POS	O
a	POS	O
male	POS	O
and	POS	O
female	POS	O
face	POS	O
expressing	POS	O
six	POS	O
basic	POS	O
emotions	POS	O
(	POS	O
happiness	POS	O
,	POS	O
surprise	POS	O
,	POS	O
sadness	POS	O
,	POS	O
anger	POS	O
,	POS	O
fear	POS	O
,	POS	O
and	POS	O
disgust	POS	O
)	POS	O
was	POS	O
administered	POS	O
.	POS	O
Mean	POS	O
percent	POS	O
accuracy	POS	O
and	POS	O
latencies	POS	O
for	POS	O
correct	POS	O
responses	POS	O
across	POS	O
eight	POS	O
presentations	POS	O
of	POS	O
each	POS	O
basic	POS	O
emotion	POS	O
were	POS	O
derived	POS	O
.	POS	O
Participants	POS	O
were	POS	O
also	POS	O
assessed	POS	O
with	POS	O
the	POS	O
"	POS	O
Eyes	POS	O
task	POS	O
"	POS	O
to	POS	O
investigate	POS	O
their	POS	O
ability	POS	O
to	POS	O
recognize	POS	O
more	POS	O
complex	POS	O
emotional	POS	O
states	POS	O
and	POS	O
the	POS	O
Symptom	POS	O
CheckList	POS	O
-	POS	O
90	POS	O
-	POS	O
Revised	POS	O
to	POS	O
measure	POS	O
psychopathology	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
There	POS	O
were	POS	O
no	POS	O
group	POS	O
differences	POS	O
in	POS	O
psychopathology	POS	O
or	POS	O
"	POS	O
eyes	POS	O
task	POS	O
"	POS	O
performance	POS	O
,	POS	O
but	POS	O
the	POS	O
RC	POS	O
group	POS	O
,	POS	O
who	POS	O
otherwise	POS	O
had	POS	O
similar	POS	O
illicit	POS	O
substance	POS	O
use	POS	O
histories	POS	O
to	POS	O
the	POS	O
OC	POS	O
group	POS	O
,	POS	O
exhibited	POS	O
impaired	POS	O
fear	POS	O
recognition	POS	O
accuracy	POS	O
compared	POS	O
to	POS	O
the	POS	O
OC	POS	O
and	POS	O
CN	POS	O
groups	POS	O
.	POS	O
The	POS	O
RC	POS	O
group	POS	O
also	POS	O
correctly	POS	O
identified	POS	O
anger	POS	O
,	POS	O
fear	POS	O
,	POS	O
happiness	POS	O
,	POS	O
and	POS	O
surprise	POS	O
,	POS	O
more	POS	O
slowly	POS	O
than	POS	O
CN	POS	O
,	POS	O
but	POS	O
not	POS	O
OC	POS	O
participants	POS	O
.	POS	O
The	POS	O
OC	POS	O
group	POS	O
was	POS	O
slower	POS	O
than	POS	O
CN	POS	O
when	POS	O
correctly	POS	O
identifying	POS	O
disgust	POS	O
.	POS	O
The	POS	O
selective	POS	O
deficit	POS	O
in	POS	O
fear	POS	O
recognition	POS	O
accuracy	POS	O
manifested	POS	O
by	POS	O
the	POS	O
RC	POS	O
group	POS	O
cannot	POS	O
be	POS	O
explained	POS	O
by	POS	O
the	POS	O
subacute	POS	O
effects	POS	O
of	POS	O
cocaine	POS	O
,	POS	O
or	POS	O
ecstasy	POS	O
,	POS	O
because	POS	O
recent	POS	O
and	POS	O
less	POS	O
recent	POS	O
users	POS	O
of	POS	O
these	POS	O
drugs	POS	O
within	POS	O
this	POS	O
group	POS	O
were	POS	O
similarly	POS	O
impaired	POS	O
.	POS	O
Possible	POS	O
parallels	POS	O
between	POS	O
RC	POS	O
users	POS	O
and	POS	O
psychopaths	POS	O
with	POS	O
respect	POS	O
to	POS	O
impaired	POS	O
fear	POS	O
recognition	POS	O
,	POS	O
amygdala	POS	B-NP
dysfunction	POS	I-NP
,	POS	O
and	POS	O
etiology	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Damage	POS	O
of	POS	O
substantia	POS	O
nigra	POS	O
pars	POS	O
reticulata	POS	O
during	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
in	POS	O
the	POS	O
rat	POS	O
:	POS	O
immunohistochemical	POS	O
study	POS	O
of	POS	O
neurons	POS	O
,	POS	O
astrocytes	POS	O
and	POS	O
serum	POS	O
-	POS	O
protein	POS	O
extravasation	POS	O
.	POS	O
The	POS	O
substantia	POS	O
nigra	POS	O
has	POS	O
a	POS	O
gating	POS	O
function	POS	O
controlling	POS	O
the	POS	O
spread	POS	O
of	POS	O
epileptic	POS	B-NP
seizure	POS	I-NP
activity	POS	O
.	POS	O
Additionally	POS	O
,	POS	O
in	POS	O
models	POS	O
of	POS	O
prolonged	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
the	POS	O
pars	POS	O
reticulata	POS	O
of	POS	O
substantia	POS	O
nigra	POS	O
(	POS	O
SNR	POS	O
)	POS	O
suffers	POS	O
from	POS	O
a	POS	O
massive	POS	O
lesion	POS	O
which	POS	O
may	POS	O
arise	POS	O
from	POS	O
a	POS	O
massive	POS	O
metabolic	POS	O
derangement	POS	O
and	POS	O
hyperexcitation	POS	B-NP
developing	POS	O
in	POS	O
the	POS	O
activated	POS	O
SNR	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
was	POS	O
induced	POS	O
by	POS	O
systemic	POS	O
injection	POS	O
of	POS	O
pilocarpine	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
neuropathology	POS	O
of	POS	O
SNR	POS	O
was	POS	O
investigated	POS	O
using	POS	O
immunohistochemical	POS	O
techniques	POS	O
with	POS	O
the	POS	O
major	POS	O
emphasis	POS	O
on	POS	O
the	POS	O
time	POS	O
-	POS	O
course	POS	O
of	POS	O
changes	POS	O
in	POS	O
neurons	POS	O
and	POS	O
astrocytes	POS	O
.	POS	O
Animals	POS	O
surviving	POS	O
20	POS	O
,	POS	O
30	POS	O
,	POS	O
40	POS	O
,	POS	O
60	POS	O
min	POS	O
,	POS	O
2	POS	O
,	POS	O
3	POS	O
,	POS	O
6	POS	O
hours	POS	O
,	POS	O
1	POS	O
,	POS	O
2	POS	O
,	POS	O
and	POS	O
3	POS	O
days	POS	O
after	POS	O
induction	POS	O
of	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
were	POS	O
perfusion	POS	O
-	POS	O
fixed	POS	O
,	POS	O
and	POS	O
brains	POS	O
processed	POS	O
for	POS	O
immunohistochemical	POS	O
staining	POS	O
of	POS	O
SNR	POS	O
.	POS	O
Nissl	POS	O
-	POS	O
staining	POS	O
and	POS	O
antibodies	POS	O
against	POS	O
the	POS	O
neuron	POS	O
-	POS	O
specific	POS	O
calcium	POS	O
-	POS	O
binding	POS	O
protein	POS	O
,	POS	O
parvalbumin	POS	O
,	POS	O
served	POS	O
to	POS	O
detect	POS	O
neuronal	POS	O
damage	POS	O
in	POS	O
SNR	POS	O
.	POS	O
Antibodies	POS	O
against	POS	O
the	POS	O
astroglia	POS	O
-	POS	O
specific	POS	O
cytoskeletal	POS	O
protein	POS	O
,	POS	O
glial	POS	O
fibrillary	POS	O
acidic	POS	O
protein	POS	O
(	POS	O
GFAP	POS	O
)	POS	O
,	POS	O
and	POS	O
against	POS	O
the	POS	O
glial	POS	O
calcium	POS	O
-	POS	O
binding	POS	O
protein	POS	O
,	POS	O
S	POS	O
-	POS	O
100	POS	O
protein	POS	O
,	POS	O
were	POS	O
used	POS	O
to	POS	O
assess	POS	O
the	POS	O
status	POS	O
of	POS	O
astrocytes	POS	O
.	POS	O
Immunohistochemical	POS	O
staining	POS	O
for	POS	O
serum	POS	O
-	POS	O
albumin	POS	O
and	POS	O
immunoglobulins	POS	O
in	POS	O
brain	POS	O
tissue	POS	O
was	POS	O
taken	POS	O
as	POS	O
indicator	POS	O
of	POS	O
blood	POS	O
-	POS	O
brain	POS	O
barrier	POS	O
disturbances	POS	O
and	POS	O
vasogenic	POS	B-NP
edema	POS	I-NP
formation	POS	O
.	POS	O
Immunohistochemical	POS	O
staining	POS	O
indicated	POS	O
loss	POS	O
of	POS	O
GFAP	POS	O
-	POS	O
staining	POS	O
already	POS	O
at	POS	O
30	POS	O
min	POS	O
after	POS	O
induction	POS	O
of	POS	O
seizures	POS	B-NP
in	POS	O
an	POS	O
oval	POS	O
focus	POS	O
situated	POS	O
in	POS	O
the	POS	O
center	POS	O
of	POS	O
SNR	POS	O
while	POS	O
sparing	POS	O
medial	POS	O
and	POS	O
lateral	POS	O
aspects	POS	O
.	POS	O
At	POS	O
1	POS	O
h	POS	O
there	POS	O
was	POS	O
additional	POS	O
vacuolation	POS	O
in	POS	O
S	POS	O
-	POS	O
100	POS	O
protein	POS	O
staining	POS	O
.	POS	O
By	POS	O
2	POS	O
hours	POS	O
,	POS	O
parvalbumin	POS	O
-	POS	O
staining	POS	O
changed	POS	O
in	POS	O
the	POS	O
central	POS	O
SNR	POS	O
indicating	POS	O
neuronal	POS	O
damage	POS	O
,	POS	O
and	POS	O
Nissl	POS	O
-	POS	O
staining	POS	O
visualized	POS	O
some	POS	O
neuronal	POS	O
distortion	POS	O
.	POS	O
Staining	POS	O
for	POS	O
serum	POS	O
-	POS	O
proteins	POS	O
occurred	POS	O
in	POS	O
a	POS	O
patchy	POS	O
manner	POS	O
throughout	POS	O
the	POS	O
forebrain	POS	O
during	POS	O
the	POS	O
first	POS	O
hours	POS	O
.	POS	O
By	POS	O
6	POS	O
h	POS	O
,	POS	O
vasogenic	POS	O
edema	POS	B-NP
covered	POS	O
the	POS	O
lesioned	POS	O
SNR	POS	O
.	POS	O
By	POS	O
24	POS	O
h	POS	O
,	POS	O
glial	POS	O
and	POS	O
neuronal	POS	O
markers	POS	O
indicated	POS	O
a	POS	O
massive	POS	O
lesion	POS	O
in	POS	O
the	POS	O
center	POS	O
of	POS	O
SNR	POS	O
.	POS	O
By	POS	O
48	POS	O
-	POS	O
72	POS	O
h	POS	O
,	POS	O
astrocytes	POS	O
surrounding	POS	O
the	POS	O
lesion	POS	O
increased	POS	O
in	POS	O
size	POS	O
,	POS	O
and	POS	O
polymorphic	POS	O
phagocytotic	POS	O
cells	POS	O
invaded	POS	O
the	POS	O
damaged	POS	O
area	POS	O
.	POS	O
In	POS	O
a	POS	O
further	POS	O
group	POS	O
of	POS	O
animals	POS	O
surviving	POS	O
1	POS	O
to	POS	O
5	POS	O
days	POS	O
,	POS	O
conventional	POS	O
paraffin	POS	O
-	POS	O
sections	POS	O
confirmed	POS	O
the	POS	O
neuronal	POS	O
and	POS	O
glial	POS	O
damage	POS	O
of	POS	O
SNR	POS	O
.	POS	O
Additional	POS	O
pathology	POS	O
of	POS	O
similar	POS	O
quality	POS	O
was	POS	O
found	POS	O
in	POS	O
the	POS	O
globus	POS	O
pallidus	POS	O
.	POS	O
Since	POS	O
astrocytes	POS	O
were	POS	O
always	POS	O
damaged	POS	O
in	POS	O
parallel	POS	O
with	POS	O
neurons	POS	O
in	POS	O
SNR	POS	O
it	POS	O
is	POS	O
proposed	POS	O
that	POS	O
the	POS	O
anatomical	POS	O
and	POS	O
functional	POS	O
interrelationship	POS	O
between	POS	O
neurons	POS	O
and	POS	O
astrocytes	POS	O
is	POS	O
particularly	POS	O
tight	POS	O
in	POS	O
SNR	POS	O
.	POS	O
Both	POS	O
cell	POS	O
elements	POS	O
may	POS	O
suffer	POS	O
in	POS	O
common	POS	O
from	POS	O
metabolic	POS	O
disturbance	POS	O
and	POS	O
neurotransmitter	POS	B-NP
dysfunction	POS	I-NP
as	POS	O
occur	POS	O
during	POS	O
massive	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
.	POS	O
Neuroprotective	POS	O
effects	POS	O
of	POS	O
melatonin	POS	O
upon	POS	O
the	POS	O
offspring	POS	O
cerebellar	POS	O
cortex	POS	O
in	POS	O
the	POS	O
rat	POS	O
model	POS	O
of	POS	O
BCNU	POS	O
-	POS	O
induced	POS	O
cortical	POS	B-NP
dysplasia	POS	I-NP
.	POS	O
Cortical	POS	B-NP
dysplasia	POS	I-NP
is	POS	O
a	POS	O
malformation	POS	B-NP
characterized	POS	O
by	POS	O
defects	POS	O
in	POS	O
proliferation	POS	O
,	POS	O
migration	POS	O
and	POS	O
maturation	POS	O
.	POS	O
This	POS	O
study	POS	O
was	POS	O
designed	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
alterations	POS	O
in	POS	O
offspring	POS	O
rat	POS	O
cerebellum	POS	O
induced	POS	O
by	POS	O
maternal	POS	O
exposure	POS	O
to	POS	O
carmustine	POS	O
-	POS	O
[	POS	O
1	POS	O
,	POS	O
3	POS	O
-	POS	O
bis	POS	O
(	POS	O
2	POS	O
-	POS	O
chloroethyl	POS	O
)	POS	O
-	POS	O
1	POS	O
-	POS	O
nitrosoure	POS	O
]	POS	O
(	POS	O
BCNU	POS	O
)	POS	O
and	POS	O
to	POS	O
investigate	POS	O
the	POS	O
effects	POS	O
of	POS	O
exogenous	POS	O
melatonin	POS	O
upon	POS	O
cerebellar	POS	O
BCNU	POS	O
-	POS	O
induced	POS	O
cortical	POS	B-NP
dysplasia	POS	I-NP
,	POS	O
using	POS	O
histological	POS	O
and	POS	O
biochemical	POS	O
analyses	POS	O
.	POS	O
Pregnant	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
assigned	POS	O
to	POS	O
five	POS	O
groups	POS	O
:	POS	O
intact	POS	O
-	POS	O
control	POS	O
,	POS	O
saline	POS	O
-	POS	O
control	POS	O
,	POS	O
melatonin	POS	O
-	POS	O
treated	POS	O
,	POS	O
BCNU	POS	O
-	POS	O
exposed	POS	O
and	POS	O
BCNU	POS	O
-	POS	O
exposed	POS	O
plus	POS	O
melatonin	POS	O
.	POS	O
Rats	POS	O
were	POS	O
exposed	POS	O
to	POS	O
BCNU	POS	O
on	POS	O
embryonic	POS	O
day	POS	O
15	POS	O
and	POS	O
melatonin	POS	O
was	POS	O
given	POS	O
until	POS	O
delivery	POS	O
.	POS	O
Immuno	POS	O
/	POS	O
histochemistry	POS	O
and	POS	O
electron	POS	O
microscopy	POS	O
were	POS	O
carried	POS	O
out	POS	O
on	POS	O
the	POS	O
offspring	POS	O
cerebellum	POS	O
,	POS	O
and	POS	O
levels	POS	O
of	POS	O
malondialdehyde	POS	O
and	POS	O
superoxide	POS	O
dismutase	POS	O
were	POS	O
determined	POS	O
.	POS	O
Histopathologically	POS	O
,	POS	O
typical	POS	O
findings	POS	O
were	POS	O
observed	POS	O
in	POS	O
the	POS	O
cerebella	POS	O
from	POS	O
the	POS	O
control	POS	O
groups	POS	O
,	POS	O
but	POS	O
the	POS	O
findings	POS	O
consistent	POS	O
with	POS	O
early	POS	O
embryonic	POS	O
development	POS	O
were	POS	O
noted	POS	O
in	POS	O
BCNU	POS	O
-	POS	O
exposed	POS	O
cortical	POS	B-NP
dysplasia	POS	I-NP
group	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
marked	POS	O
increase	POS	O
in	POS	O
the	POS	O
number	POS	O
of	POS	O
TUNEL	POS	O
positive	POS	O
cells	POS	O
and	POS	O
nestin	POS	O
positive	POS	O
cells	POS	O
in	POS	O
BCNU	POS	O
-	POS	O
exposed	POS	O
group	POS	O
,	POS	O
but	POS	O
a	POS	O
decreased	POS	O
immunoreactivity	POS	O
to	POS	O
glial	POS	O
fibrillary	POS	O
acidic	POS	O
protein	POS	O
,	POS	O
synaptophysin	POS	O
and	POS	O
transforming	POS	O
growth	POS	O
factor	POS	O
beta1	POS	O
was	POS	O
observed	POS	O
,	POS	O
indicating	POS	O
a	POS	O
delayed	POS	O
maturation	POS	O
,	POS	O
and	POS	O
melatonin	POS	O
significantly	POS	O
reversed	POS	O
these	POS	O
changes	POS	O
.	POS	O
Malondialdehyde	POS	O
level	POS	O
in	POS	O
BCNU	POS	O
-	POS	O
exposed	POS	O
group	POS	O
was	POS	O
higher	POS	O
than	POS	O
those	POS	O
in	POS	O
control	POS	O
groups	POS	O
and	POS	O
melatonin	POS	O
decreased	POS	O
malondialdehyde	POS	O
levels	POS	O
in	POS	O
BCNU	POS	O
group	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
while	POS	O
there	POS	O
were	POS	O
no	POS	O
significant	POS	O
differences	POS	O
in	POS	O
the	POS	O
superoxide	POS	O
dismutase	POS	O
levels	POS	O
between	POS	O
these	POS	O
groups	POS	O
.	POS	O
These	POS	O
data	POS	O
suggest	POS	O
that	POS	O
exposure	POS	O
of	POS	O
animals	POS	O
to	POS	O
BCNU	POS	O
during	POS	O
pregnancy	POS	O
leads	POS	O
to	POS	O
delayed	POS	O
maturation	POS	O
of	POS	O
offspring	POS	O
cerebellum	POS	O
and	POS	O
melatonin	POS	O
protects	POS	O
the	POS	O
cerebellum	POS	O
against	POS	O
the	POS	O
effects	POS	O
of	POS	O
BCNU	POS	O
.	POS	O
Reduced	POS	O
cardiotoxicity	POS	B-NP
of	POS	O
doxorubicin	POS	O
given	POS	O
in	POS	O
the	POS	O
form	POS	O
of	POS	O
N	POS	O
-	POS	O
(	POS	O
2	POS	O
-	POS	O
hydroxypropyl	POS	O
)	POS	O
methacrylamide	POS	O
conjugates	POS	O
:	POS	O
and	POS	O
experimental	POS	O
study	POS	O
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
A	POS	O
rat	POS	O
model	POS	O
was	POS	O
used	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
general	POS	O
acute	POS	B-NP
toxicity	POS	I-NP
and	POS	O
the	POS	O
late	POS	O
cardiotoxicity	POS	B-NP
of	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
doxorubicin	POS	O
(	POS	O
DOX	POS	O
)	POS	O
given	POS	O
either	POS	O
as	POS	O
free	POS	O
drug	POS	O
or	POS	O
in	POS	O
the	POS	O
form	POS	O
of	POS	O
three	POS	O
N	POS	O
-	POS	O
(	POS	O
2	POS	O
-	POS	O
hydroxypropyl	POS	O
)	POS	O
methacrylamide	POS	O
(	POS	O
HPMA	POS	O
)	POS	O
copolymer	POS	O
conjugates	POS	O
.	POS	O
In	POS	O
these	POS	O
HPMA	POS	O
copolymers	POS	O
,	POS	O
DOX	POS	O
was	POS	O
covalently	POS	O
bound	POS	O
via	POS	O
peptide	POS	O
linkages	POS	O
that	POS	O
were	POS	O
either	POS	O
non	POS	O
-	POS	O
biodegradable	POS	O
(	POS	O
Gly	POS	O
-	POS	O
Gly	POS	O
)	POS	O
or	POS	O
degradable	POS	O
by	POS	O
lysosomal	POS	O
proteinases	POS	O
(	POS	O
Gly	POS	O
-	POS	O
Phe	POS	O
-	POS	O
Leu	POS	O
-	POS	O
Gly	POS	O
)	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
one	POS	O
biodegradable	POS	O
conjugate	POS	O
containing	POS	O
galactosamine	POS	O
was	POS	O
used	POS	O
;	POS	O
this	POS	O
residue	POS	O
was	POS	O
targeted	POS	O
to	POS	O
the	POS	O
liver	POS	O
.	POS	O
Over	POS	O
the	POS	O
first	POS	O
3	POS	O
weeks	POS	O
after	POS	O
the	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
administration	POS	O
of	POS	O
free	POS	O
and	POS	O
polymer	POS	O
-	POS	O
bound	POS	O
DOX	POS	O
,	POS	O
all	POS	O
animals	POS	O
showed	POS	O
a	POS	O
transient	POS	O
reduction	POS	O
in	POS	O
body	POS	O
weight	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
maximal	POS	O
reduction	POS	O
in	POS	O
body	POS	O
weight	POS	O
seen	POS	O
in	POS	O
animals	POS	O
that	POS	O
received	POS	O
polymer	POS	O
-	POS	O
bound	POS	O
DOX	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
was	POS	O
significantly	POS	O
lower	POS	O
than	POS	O
that	POS	O
observed	POS	O
in	POS	O
those	POS	O
that	POS	O
received	POS	O
free	POS	O
DOX	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
or	POS	O
a	POS	O
mixture	POS	O
of	POS	O
the	POS	O
unmodified	POS	O
parent	POS	O
HPMA	POS	O
copolymer	POS	O
and	POS	O
free	POS	O
DOX	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
;	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Throughout	POS	O
the	POS	O
study	POS	O
(	POS	O
20	POS	O
weeks	POS	O
)	POS	O
,	POS	O
deaths	POS	O
related	POS	O
to	POS	O
cardiotoxicity	POS	B-NP
were	POS	O
observed	POS	O
only	POS	O
in	POS	O
animals	POS	O
that	POS	O
received	POS	O
either	POS	O
free	POS	O
DOX	POS	O
or	POS	O
the	POS	O
mixture	POS	O
of	POS	O
HPMA	POS	O
copolymer	POS	O
and	POS	O
free	POS	O
DOX	POS	O
;	POS	O
in	POS	O
these	POS	O
cases	POS	O
,	POS	O
histological	POS	O
investigations	POS	O
revealed	POS	O
marked	POS	O
changes	POS	O
in	POS	O
the	POS	O
heart	POS	O
that	POS	O
were	POS	O
consistent	POS	O
with	POS	O
DOX	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
Sequential	POS	O
measurements	POS	O
of	POS	O
cardiac	POS	O
output	POS	O
in	POS	O
surviving	POS	O
animals	POS	O
that	POS	O
received	POS	O
either	POS	O
free	POS	O
DOX	POS	O
or	POS	O
the	POS	O
mixture	POS	O
of	POS	O
HPMA	POS	O
copolymer	POS	O
and	POS	O
free	POS	O
DOX	POS	O
showed	POS	O
a	POS	O
reduction	POS	O
of	POS	O
approximately	POS	O
30	POS	O
%	POS	O
in	POS	O
function	POS	O
beginning	POS	O
at	POS	O
the	POS	O
4th	POS	O
week	POS	O
after	POS	O
drug	POS	O
administration	POS	O
.	POS	O
The	POS	O
heart	POS	O
rate	POS	O
in	POS	O
these	POS	O
animals	POS	O
was	POS	O
approximately	POS	O
12	POS	O
%	POS	O
lower	POS	O
than	POS	O
that	POS	O
measured	POS	O
in	POS	O
age	POS	O
-	POS	O
matched	POS	O
control	POS	O
rats	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Animals	POS	O
that	POS	O
were	POS	O
given	POS	O
the	POS	O
HPMA	POS	O
copolymer	POS	O
conjugates	POS	O
containing	POS	O
DOX	POS	O
exhibited	POS	O
no	POS	O
significant	POS	O
change	POS	O
in	POS	O
cardiac	POS	O
output	POS	O
throughout	POS	O
the	POS	O
study	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
no	POS	O
significant	POS	O
histological	POS	O
change	POS	O
was	POS	O
observed	POS	O
in	POS	O
the	POS	O
heart	POS	O
of	POS	O
animals	POS	O
that	POS	O
received	POS	O
DOX	POS	O
in	POS	O
the	POS	O
form	POS	O
of	POS	O
HPMA	POS	O
copolymer	POS	O
conjugates	POS	O
and	POS	O
were	POS	O
killed	POS	O
at	POS	O
the	POS	O
end	POS	O
of	POS	O
the	POS	O
study	POS	O
.	POS	O
However	POS	O
,	POS	O
these	POS	O
animals	POS	O
had	POS	O
shown	POS	O
a	POS	O
significant	POS	O
increase	POS	O
in	POS	O
heart	POS	O
rate	POS	O
beginning	POS	O
at	POS	O
8	POS	O
weeks	POS	O
after	POS	O
drug	POS	O
administration	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
400	POS	O
WORDS	POS	O
)	POS	O
Corneal	POS	B-NP
ulcers	POS	I-NP
associated	POS	O
with	POS	O
aerosolized	POS	O
crack	POS	O
cocaine	POS	O
use	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
We	POS	O
report	POS	O
4	POS	O
cases	POS	O
of	POS	O
corneal	POS	B-NP
ulcers	POS	I-NP
associated	POS	O
with	POS	O
drug	POS	B-NP
abuse	POS	I-NP
.	POS	O
The	POS	O
pathogenesis	POS	O
of	POS	O
these	POS	O
ulcers	POS	B-NP
and	POS	O
management	POS	O
of	POS	O
these	POS	O
patients	POS	O
are	POS	O
also	POS	O
reviewed	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Review	POS	O
of	POS	O
all	POS	O
cases	POS	O
of	POS	O
corneal	POS	B-NP
ulcers	POS	I-NP
associated	POS	O
with	POS	O
drug	POS	B-NP
abuse	POS	I-NP
seen	POS	O
at	POS	O
our	POS	O
institution	POS	O
from	POS	O
July	POS	O
2006	POS	O
to	POS	O
December	POS	O
2006	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Four	POS	O
patients	POS	O
with	POS	O
corneal	POS	B-NP
ulcers	POS	I-NP
associated	POS	O
with	POS	O
crack	POS	O
cocaine	POS	O
use	POS	O
were	POS	O
reviewed	POS	O
.	POS	O
All	POS	O
corneal	POS	B-NP
ulcers	POS	I-NP
were	POS	O
cultured	POS	O
,	POS	O
and	POS	O
the	POS	O
patients	POS	O
were	POS	O
admitted	POS	O
to	POS	O
the	POS	O
hospital	POS	O
for	POS	O
intensive	POS	O
topical	POS	O
antibiotic	POS	O
treatment	POS	O
.	POS	O
Each	POS	O
patient	POS	O
received	POS	O
comprehensive	POS	O
health	POS	O
care	POS	O
,	POS	O
including	POS	O
medical	POS	O
and	POS	O
substance	POS	O
abuse	POS	O
consultations	POS	O
.	POS	O
Streptococcal	POS	O
organisms	POS	O
were	POS	O
found	POS	O
in	POS	O
3	POS	O
cases	POS	O
and	POS	O
Capnocytophaga	POS	O
and	POS	O
Brevibacterium	POS	O
casei	POS	O
in	POS	O
1	POS	O
patient	POS	O
.	POS	O
The	POS	O
infections	POS	O
responded	POS	O
to	POS	O
antibiotic	POS	O
treatment	POS	O
.	POS	O
Two	POS	O
patients	POS	O
needed	POS	O
a	POS	O
lateral	POS	O
tarsorrhaphy	POS	O
for	POS	O
persistent	POS	O
epithelial	POS	B-NP
defects	POS	I-NP
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Aerosolized	POS	O
crack	POS	O
cocaine	POS	O
use	POS	O
can	POS	O
be	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
corneal	POS	B-NP
ulcers	POS	I-NP
.	POS	O
Drug	POS	O
abuse	POS	O
provides	POS	O
additional	POS	O
challenges	POS	O
for	POS	O
management	POS	O
.	POS	O
Not	POS	O
only	POS	O
treatment	POS	O
of	POS	O
their	POS	O
infections	POS	O
but	POS	O
also	POS	O
the	POS	O
overall	POS	O
poor	POS	O
health	POS	O
of	POS	O
the	POS	O
patients	POS	O
and	POS	O
increased	POS	O
risk	POS	O
of	POS	O
noncompliance	POS	O
need	POS	O
to	POS	O
be	POS	O
addressed	POS	O
.	POS	O
Comprehensive	POS	O
care	POS	O
may	POS	O
provide	POS	O
the	POS	O
patient	POS	O
the	POS	O
opportunity	POS	O
to	POS	O
discontinue	POS	O
their	POS	O
substance	POS	B-NP
abuse	POS	I-NP
,	POS	O
improve	POS	O
their	POS	O
overall	POS	O
health	POS	O
,	POS	O
and	POS	O
prevent	POS	O
future	POS	O
corneal	POS	B-NP
complications	POS	I-NP
.	POS	O
Topical	POS	O
0	POS	O
.	POS	O
025	POS	O
%	POS	O
capsaicin	POS	O
in	POS	O
chronic	POS	O
post	POS	O
-	POS	O
herpetic	POS	B-NP
neuralgia	POS	I-NP
:	POS	O
efficacy	POS	O
,	POS	O
predictors	POS	O
of	POS	O
response	POS	O
and	POS	O
long	POS	O
-	POS	O
term	POS	O
course	POS	O
.	POS	O
In	POS	O
order	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
efficacy	POS	O
,	POS	O
time	POS	O
-	POS	O
course	POS	O
of	POS	O
action	POS	O
and	POS	O
predictors	POS	O
of	POS	O
response	POS	O
to	POS	O
topical	POS	O
capsaicin	POS	O
,	POS	O
39	POS	O
patients	POS	O
with	POS	O
chronic	POS	B-NP
post	POS	I-NP
-	POS	I-NP
herpetic	POS	I-NP
neuralgia	POS	I-NP
(	POS	O
PHN	POS	B-NP
)	POS	O
,	POS	O
median	POS	O
duration	POS	O
24	POS	O
months	POS	O
,	POS	O
were	POS	O
treated	POS	O
with	POS	O
0	POS	O
.	POS	O
025	POS	O
%	POS	O
capsaicin	POS	O
cream	POS	O
for	POS	O
8	POS	O
weeks	POS	O
.	POS	O
During	POS	O
therapy	POS	O
the	POS	O
patients	POS	O
rated	POS	O
their	POS	O
pain	POS	B-NP
on	POS	O
a	POS	O
visual	POS	O
analogue	POS	O
scale	POS	O
(	POS	O
VAS	POS	O
)	POS	O
and	POS	O
a	POS	O
verbal	POS	O
outcome	POS	O
scale	POS	O
.	POS	O
A	POS	O
follow	POS	O
-	POS	O
up	POS	O
investigation	POS	O
was	POS	O
performed	POS	O
10	POS	O
-	POS	O
12	POS	O
months	POS	O
after	POS	O
study	POS	O
onset	POS	O
on	POS	O
the	POS	O
patients	POS	O
who	POS	O
had	POS	O
improved	POS	O
.	POS	O
Nineteen	POS	O
patients	POS	O
(	POS	O
48	POS	O
.	POS	O
7	POS	O
%	POS	O
)	POS	O
substantially	POS	O
improved	POS	O
after	POS	O
the	POS	O
8	POS	O
-	POS	O
week	POS	O
trial	POS	O
;	POS	O
5	POS	O
(	POS	O
12	POS	O
.	POS	O
8	POS	O
%	POS	O
)	POS	O
discontinued	POS	O
therapy	POS	O
due	POS	O
to	POS	O
side	POS	O
-	POS	O
effects	POS	O
such	POS	O
as	POS	O
intolerable	POS	O
capsaicin	POS	O
-	POS	O
induced	POS	O
burning	POS	O
sensations	POS	O
(	POS	O
4	POS	O
)	POS	O
or	POS	O
mastitis	POS	B-NP
(	POS	O
1	POS	O
)	POS	O
;	POS	O
15	POS	O
(	POS	O
38	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
reported	POS	O
no	POS	O
benefit	POS	O
.	POS	O
The	POS	O
decrease	POS	O
in	POS	O
VAS	POS	O
ratings	POS	O
was	POS	O
significant	POS	O
after	POS	O
2	POS	O
weeks	POS	O
of	POS	O
continuous	POS	O
application	POS	O
.	POS	O
Of	POS	O
the	POS	O
responders	POS	O
72	POS	O
.	POS	O
2	POS	O
%	POS	O
were	POS	O
still	POS	O
improved	POS	O
at	POS	O
the	POS	O
follow	POS	O
-	POS	O
up	POS	O
;	POS	O
only	POS	O
one	POS	O
-	POS	O
third	POS	O
of	POS	O
them	POS	O
had	POS	O
continued	POS	O
application	POS	O
irregularly	POS	O
.	POS	O
Treatment	POS	O
effect	POS	O
was	POS	O
not	POS	O
dependent	POS	O
on	POS	O
patient	POS	O
'	POS	O
s	POS	O
age	POS	O
,	POS	O
duration	POS	O
or	POS	O
localization	POS	O
of	POS	O
PHN	POS	B-NP
(	POS	O
trigeminal	POS	O
involvement	POS	O
was	POS	O
excluded	POS	O
)	POS	O
,	POS	O
sensory	POS	B-NP
disturbance	POS	I-NP
or	POS	O
pain	POS	B-NP
character	POS	O
.	POS	O
Treatment	POS	O
response	POS	O
was	POS	O
not	POS	O
correlated	POS	O
with	POS	O
the	POS	O
incidence	POS	O
,	POS	O
time	POS	O
-	POS	O
course	POS	O
or	POS	O
severity	POS	O
of	POS	O
capsaicin	POS	O
-	POS	O
induced	POS	O
burning	POS	O
.	POS	O
If	POS	O
confirmed	POS	O
in	POS	O
controlled	POS	O
trials	POS	O
,	POS	O
the	POS	O
long	POS	O
-	POS	O
term	POS	O
results	POS	O
of	POS	O
this	POS	O
open	POS	O
,	POS	O
non	POS	O
-	POS	O
randomized	POS	O
study	POS	O
might	POS	O
indicate	POS	O
that	POS	O
the	POS	O
analgesic	POS	O
effect	POS	O
of	POS	O
capsaicin	POS	O
in	POS	O
PHN	POS	B-NP
is	POS	O
mediated	POS	O
by	POS	O
both	POS	O
interference	POS	O
with	POS	O
neuropeptide	POS	O
metabolism	POS	O
and	POS	O
morphological	POS	O
changes	POS	O
(	POS	O
perhaps	POS	O
degeneration	POS	O
)	POS	O
of	POS	O
nociceptive	POS	O
afferents	POS	O
.	POS	O
Myo	POS	O
-	POS	O
inositol	POS	O
-	POS	O
1	POS	O
-	POS	O
phosphate	POS	O
(	POS	O
MIP	POS	O
)	POS	O
synthase	POS	O
inhibition	POS	O
:	POS	O
in	POS	O
-	POS	O
vivo	POS	O
study	POS	O
in	POS	O
rats	POS	O
.	POS	O
Lithium	POS	O
and	POS	O
valproate	POS	O
are	POS	O
the	POS	O
prototypic	POS	O
mood	POS	O
stabilizers	POS	O
and	POS	O
have	POS	O
diverse	POS	O
structures	POS	O
and	POS	O
targets	POS	O
.	POS	O
Both	POS	O
drugs	POS	O
influence	POS	O
inositol	POS	O
metabolism	POS	O
.	POS	O
Lithium	POS	O
inhibits	POS	O
IMPase	POS	O
and	POS	O
valproate	POS	O
inhibits	POS	O
MIP	POS	O
synthase	POS	O
.	POS	O
This	POS	O
study	POS	O
shows	POS	O
that	POS	O
MIP	POS	O
synthase	POS	O
inhibition	POS	O
does	POS	O
not	POS	O
replicate	POS	O
or	POS	O
augment	POS	O
the	POS	O
effects	POS	O
of	POS	O
lithium	POS	O
in	POS	O
the	POS	O
inositol	POS	O
sensitive	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
model	POS	O
.	POS	O
This	POS	O
lack	POS	O
of	POS	O
effects	POS	O
may	POS	O
stem	POS	O
from	POS	O
the	POS	O
low	POS	O
contribution	POS	O
of	POS	O
de	POS	O
-	POS	O
novo	POS	O
synthesis	POS	O
to	POS	O
cellular	POS	O
inositol	POS	O
supply	POS	O
or	POS	O
to	POS	O
the	POS	O
inhibition	POS	O
of	POS	O
the	POS	O
de	POS	O
-	POS	O
novo	POS	O
synthesis	POS	O
by	POS	O
lithium	POS	O
itself	POS	O
.	POS	O
Non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
-	POS	O
associated	POS	O
acute	POS	O
interstitial	POS	B-NP
nephritis	POS	I-NP
with	POS	O
granular	POS	B-NP
tubular	POS	I-NP
basement	POS	I-NP
membrane	POS	I-NP
deposits	POS	I-NP
.	POS	O
Acute	POS	O
tubulo	POS	O
-	POS	O
interstitial	POS	B-NP
nephritis	POS	I-NP
(	POS	O
ATIN	POS	B-NP
)	POS	O
is	POS	O
an	POS	O
important	POS	O
cause	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
resulting	POS	O
from	POS	O
a	POS	O
variety	POS	O
of	POS	O
insults	POS	O
,	POS	O
including	POS	O
immune	POS	O
complex	POS	O
-	POS	O
mediated	POS	O
tubulo	POS	O
-	POS	O
interstitial	POS	B-NP
injury	POS	I-NP
,	POS	O
but	POS	O
drugs	POS	O
such	POS	O
as	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
(	POS	O
NSAIDs	POS	O
)	POS	O
are	POS	O
a	POS	O
far	POS	O
more	POS	O
frequent	POS	O
cause	POS	O
.	POS	O
Overall	POS	O
,	POS	O
as	POS	O
an	POS	O
entity	POS	O
,	POS	O
ATIN	POS	B-NP
remains	POS	O
under	POS	O
-	POS	O
diagnosed	POS	O
,	POS	O
as	POS	O
symptoms	POS	O
resolve	POS	O
spontaneously	POS	O
if	POS	O
the	POS	O
medication	POS	O
is	POS	O
stopped	POS	O
.	POS	O
We	POS	O
report	POS	O
on	POS	O
a	POS	O
14	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
boy	POS	O
who	POS	O
developed	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
2	POS	O
weeks	POS	O
after	POS	O
aortic	POS	O
valve	POS	O
surgery	POS	O
.	POS	O
He	POS	O
was	POS	O
put	POS	O
on	POS	O
aspirin	POS	O
following	POS	O
surgery	POS	O
and	POS	O
took	POS	O
ibuprofen	POS	O
for	POS	O
fever	POS	B-NP
for	POS	O
nearly	POS	O
a	POS	O
week	POS	O
prior	POS	O
to	POS	O
presentation	POS	O
.	POS	O
He	POS	O
then	POS	O
presented	POS	O
to	POS	O
the	POS	O
emergency	POS	O
department	POS	O
feeling	POS	O
quite	POS	O
ill	POS	O
and	POS	O
was	POS	O
found	POS	O
to	POS	O
have	POS	O
a	POS	O
blood	POS	O
urea	POS	O
nitrogen	POS	O
(	POS	O
BUN	POS	O
)	POS	O
concentration	POS	O
of	POS	O
of	POS	O
147	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
creatinine	POS	O
of	POS	O
15	POS	O
.	POS	O
3	POS	O
mg	POS	O
/	POS	O
dl	POS	O
and	POS	O
serum	POS	O
potassium	POS	O
of	POS	O
8	POS	O
.	POS	O
7	POS	O
mEq	POS	O
/	POS	O
l	POS	O
.	POS	O
Dialysis	POS	O
was	POS	O
immediately	POS	O
initiated	POS	O
.	POS	O
A	POS	O
kidney	POS	O
biopsy	POS	O
showed	POS	O
inflammatory	POS	O
infiltrate	POS	O
consistent	POS	O
with	POS	O
ATIN	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
in	POS	O
the	POS	O
tubular	POS	O
basement	POS	O
membrane	POS	O
(	POS	O
TBM	POS	O
)	POS	O
,	POS	O
very	POS	O
intense	POS	O
granular	POS	O
deposits	POS	O
of	POS	O
polyclonal	POS	O
IgG	POS	O
and	POS	O
C3	POS	O
were	POS	O
noted	POS	O
.	POS	O
He	POS	O
needed	POS	O
dialysis	POS	O
for	POS	O
2	POS	O
weeks	POS	O
and	POS	O
was	POS	O
treated	POS	O
successfully	POS	O
with	POS	O
steroids	POS	O
for	POS	O
6	POS	O
months	POS	O
.	POS	O
His	POS	O
renal	POS	O
recovery	POS	O
and	POS	O
disappearance	POS	O
of	POS	O
proteinuria	POS	B-NP
took	POS	O
a	POS	O
year	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
this	POS	O
is	POS	O
a	POS	O
first	POS	O
report	POS	O
of	POS	O
NSAIDs	POS	O
-	POS	O
associated	POS	O
ATIN	POS	B-NP
,	POS	O
showing	POS	O
deposits	POS	O
of	POS	O
granular	POS	O
immune	POS	O
complex	POS	O
present	POS	O
only	POS	O
in	POS	O
the	POS	O
TBM	POS	B-NP
and	POS	O
not	POS	O
in	POS	O
the	POS	O
glomeruli	POS	O
.	POS	O
Rifampicin	POS	O
-	POS	O
associated	POS	O
segmental	POS	O
necrotizing	POS	B-NP
glomerulonephritis	POS	I-NP
in	POS	O
staphylococcal	POS	B-NP
endocarditis	POS	I-NP
.	POS	O
Segmental	POS	B-NP
necrotising	POS	I-NP
glomerulonephritis	POS	I-NP
has	POS	O
been	POS	O
reported	POS	O
as	POS	O
complication	POS	O
of	POS	O
rifampicin	POS	O
therapy	POS	O
in	POS	O
patients	POS	O
receiving	POS	O
treatment	POS	O
for	POS	O
tuberculosis	POS	B-NP
.	POS	O
Changing	POS	O
epidemiology	POS	O
of	POS	O
infections	POS	O
such	POS	O
as	POS	O
infective	POS	B-NP
endocarditis	POS	I-NP
(	POS	O
IE	POS	B-NP
)	POS	O
has	POS	O
led	POS	O
to	POS	O
an	POS	O
increase	POS	O
in	POS	O
the	POS	O
use	POS	O
of	POS	O
rifampicin	POS	O
for	POS	O
Staphylococcal	POS	B-NP
infections	POS	I-NP
.	POS	O
We	POS	O
describe	POS	O
a	POS	O
case	POS	O
of	POS	O
a	POS	O
patient	POS	O
with	POS	O
Staphylococcal	POS	B-NP
IE	POS	I-NP
who	POS	O
developed	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
secondary	POS	O
to	POS	O
a	POS	O
segmental	POS	O
necrotising	POS	B-NP
glomerulonephritis	POS	I-NP
while	POS	O
being	POS	O
treated	POS	O
with	POS	O
rifampicin	POS	O
,	POS	O
and	POS	O
review	POS	O
the	POS	O
literature	POS	O
regarding	POS	O
this	POS	O
complication	POS	O
of	POS	O
rifampicin	POS	O
therapy	POS	O
.	POS	O
Rate	POS	O
of	POS	O
YMDD	POS	O
motif	POS	O
mutants	POS	O
in	POS	O
lamivudine	POS	O
-	POS	O
untreated	POS	O
Iranian	POS	O
patients	POS	O
with	POS	O
chronic	POS	B-NP
hepatitis	POS	I-NP
B	POS	I-NP
virus	POS	I-NP
infection	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Lamivudine	POS	O
is	POS	O
used	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
chronic	POS	B-NP
hepatitis	POS	I-NP
B	POS	I-NP
patients	POS	O
.	POS	O
Recent	POS	O
studies	POS	O
show	POS	O
that	POS	O
the	POS	O
YMDD	POS	O
motif	POS	O
mutants	POS	O
(	POS	O
resistant	POS	O
hepatitis	POS	O
B	POS	O
virus	POS	O
)	POS	O
occur	POS	O
as	POS	O
natural	POS	O
genome	POS	O
variability	POS	O
in	POS	O
lamivudine	POS	O
-	POS	O
untreated	POS	O
chronic	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
patients	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
we	POS	O
aimed	POS	O
to	POS	O
determine	POS	O
the	POS	O
rate	POS	O
of	POS	O
YMDD	POS	O
motif	POS	O
mutants	POS	O
in	POS	O
lamivudine	POS	O
-	POS	O
untreated	POS	O
chronic	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
patients	POS	O
in	POS	O
Iran	POS	O
.	POS	O
PATIENTS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
77	POS	O
chronic	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
patients	POS	O
who	POS	O
had	POS	O
not	POS	O
been	POS	O
treated	POS	O
with	POS	O
lamivudine	POS	O
were	POS	O
included	POS	O
in	POS	O
the	POS	O
study	POS	O
.	POS	O
Serum	POS	O
samples	POS	O
from	POS	O
patients	POS	O
were	POS	O
tested	POS	O
by	POS	O
polymerase	POS	O
chain	POS	O
reaction	POS	O
-	POS	O
restriction	POS	O
fragment	POS	O
length	POS	O
polymorphism	POS	O
(	POS	O
PCR	POS	O
-	POS	O
RFLP	POS	O
)	POS	O
for	POS	O
detection	POS	O
of	POS	O
YMDD	POS	O
motif	POS	O
mutants	POS	O
.	POS	O
All	POS	O
patients	POS	O
were	POS	O
also	POS	O
tested	POS	O
for	POS	O
liver	POS	O
enzymes	POS	O
,	POS	O
anti	POS	O
-	POS	O
HCV	POS	O
,	POS	O
HBeAg	POS	O
,	POS	O
and	POS	O
anti	POS	O
-	POS	O
HBe	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Of	POS	O
the	POS	O
77	POS	O
patients	POS	O
enrolled	POS	O
in	POS	O
the	POS	O
study	POS	O
,	POS	O
73	POS	O
%	POS	O
were	POS	O
male	POS	O
and	POS	O
27	POS	O
%	POS	O
were	POS	O
female	POS	O
.	POS	O
Mean	POS	O
ALT	POS	O
and	POS	O
AST	POS	O
levels	POS	O
were	POS	O
124	POS	O
.	POS	O
4	POS	O
+	POS	O
/	POS	O
-	POS	O
73	POS	O
.	POS	O
4	POS	O
and	POS	O
103	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
81	POS	O
IU	POS	O
/	POS	O
l	POS	O
,	POS	O
respectively	POS	O
.	POS	O
HBeAg	POS	O
was	POS	O
positive	POS	O
in	POS	O
40	POS	O
%	POS	O
and	POS	O
anti	POS	O
-	POS	O
HBe	POS	O
in	POS	O
60	POS	O
%	POS	O
of	POS	O
the	POS	O
patients	POS	O
.	POS	O
Anti	POS	O
-	POS	O
HCV	POS	O
was	POS	O
negative	POS	O
in	POS	O
all	POS	O
of	POS	O
them	POS	O
.	POS	O
YMDD	POS	O
motif	POS	O
mutants	POS	O
were	POS	O
not	POS	O
detected	POS	O
in	POS	O
any	POS	O
of	POS	O
the	POS	O
patients	POS	O
despite	POS	O
the	POS	O
liver	POS	O
enzyme	POS	O
levels	POS	O
and	POS	O
the	POS	O
presence	POS	O
of	POS	O
HBeAg	POS	O
or	POS	O
anti	POS	O
-	POS	O
HBe	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Although	POS	O
the	POS	O
natural	POS	O
occurrence	POS	O
of	POS	O
YMDD	POS	O
motif	POS	O
mutants	POS	O
in	POS	O
lamivudine	POS	O
-	POS	O
untreated	POS	O
patients	POS	O
with	POS	O
chronic	POS	B-NP
hepatitis	POS	I-NP
B	POS	I-NP
has	POS	O
been	POS	O
reported	POS	O
,	POS	O
these	POS	O
mutants	POS	O
were	POS	O
not	POS	O
detected	POS	O
in	POS	O
Iranian	POS	O
lamivudine	POS	O
-	POS	O
untreated	POS	O
chronic	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
patients	POS	O
.	POS	O
Branch	POS	B-NP
retinal	POS	I-NP
vein	POS	I-NP
occlusion	POS	I-NP
and	POS	O
fluoxetine	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
branch	POS	O
retinal	POS	B-NP
vein	POS	I-NP
occlusion	POS	I-NP
associated	POS	O
with	POS	O
fluoxetine	POS	O
-	POS	O
induced	POS	O
secondary	POS	O
hypertension	POS	B-NP
is	POS	O
described	POS	O
.	POS	O
Although	POS	O
an	POS	O
infrequent	POS	O
complication	POS	O
of	POS	O
selective	POS	O
serotonin	POS	O
reuptake	POS	O
inhibitor	POS	O
therapy	POS	O
,	POS	O
it	POS	O
is	POS	O
important	POS	O
that	POS	O
ophthalmologists	POS	O
are	POS	O
aware	POS	O
that	POS	O
these	POS	O
agents	POS	O
can	POS	O
cause	POS	O
hypertension	POS	B-NP
because	POS	O
this	POS	O
class	POS	O
of	POS	O
drugs	POS	O
is	POS	O
widely	POS	O
prescribed	POS	O
.	POS	O
The	POS	O
differential	POS	O
effects	POS	O
of	POS	O
bupivacaine	POS	O
and	POS	O
lidocaine	POS	O
on	POS	O
prostaglandin	POS	O
E2	POS	O
release	POS	O
,	POS	O
cyclooxygenase	POS	O
gene	POS	O
expression	POS	O
and	POS	O
pain	POS	B-NP
in	POS	O
a	POS	O
clinical	POS	O
pain	POS	B-NP
model	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
In	POS	O
addition	POS	O
to	POS	O
blocking	POS	O
nociceptive	POS	O
input	POS	O
from	POS	O
surgical	POS	O
sites	POS	O
,	POS	O
long	POS	O
-	POS	O
acting	POS	O
local	POS	O
anesthetics	POS	O
might	POS	O
directly	POS	O
modulate	POS	O
inflammation	POS	B-NP
.	POS	O
In	POS	O
the	POS	O
present	POS	O
study	POS	O
,	POS	O
we	POS	O
describe	POS	O
the	POS	O
proinflammatory	POS	O
effects	POS	O
of	POS	O
bupivacaine	POS	O
on	POS	O
local	POS	O
prostaglandin	POS	O
E2	POS	O
(	POS	O
PGE2	POS	O
)	POS	O
production	POS	O
and	POS	O
cyclooxygenase	POS	O
(	POS	O
COX	POS	O
)	POS	O
gene	POS	O
expression	POS	O
that	POS	O
increases	POS	O
postoperative	POS	B-NP
pain	POS	I-NP
in	POS	O
human	POS	O
subjects	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Subjects	POS	O
(	POS	O
n	POS	O
=	POS	O
114	POS	O
)	POS	O
undergoing	POS	O
extraction	POS	O
of	POS	O
impacted	POS	O
third	POS	O
molars	POS	O
received	POS	O
either	POS	O
2	POS	O
%	POS	O
lidocaine	POS	O
or	POS	O
0	POS	O
.	POS	O
5	POS	O
%	POS	O
bupivacaine	POS	O
before	POS	O
surgery	POS	O
and	POS	O
either	POS	O
rofecoxib	POS	O
50	POS	O
mg	POS	O
or	POS	O
placebo	POS	O
orally	POS	O
90	POS	O
min	POS	O
before	POS	O
surgery	POS	O
and	POS	O
for	POS	O
the	POS	O
following	POS	O
48	POS	O
h	POS	O
.	POS	O
Oral	POS	O
mucosal	POS	O
biopsies	POS	O
were	POS	O
taken	POS	O
before	POS	O
surgery	POS	O
and	POS	O
48	POS	O
h	POS	O
after	POS	O
surgery	POS	O
.	POS	O
After	POS	O
extraction	POS	O
,	POS	O
a	POS	O
microdialysis	POS	O
probe	POS	O
was	POS	O
placed	POS	O
at	POS	O
the	POS	O
surgical	POS	O
site	POS	O
for	POS	O
PGE2	POS	O
and	POS	O
thromboxane	POS	O
B2	POS	O
(	POS	O
TXB2	POS	O
)	POS	O
measurements	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
bupivacaine	POS	O
/	POS	O
rofecoxib	POS	O
group	POS	O
reported	POS	O
significantly	POS	O
less	POS	O
pain	POS	B-NP
,	POS	O
as	POS	O
assessed	POS	O
by	POS	O
a	POS	O
visual	POS	O
analog	POS	O
scale	POS	O
,	POS	O
compared	POS	O
with	POS	O
the	POS	O
other	POS	O
three	POS	O
treatment	POS	O
groups	POS	O
over	POS	O
the	POS	O
first	POS	O
4	POS	O
h	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
bupivacaine	POS	O
/	POS	O
placebo	POS	O
group	POS	O
reported	POS	O
significantly	POS	O
more	POS	O
pain	POS	B-NP
at	POS	O
24	POS	O
h	POS	O
and	POS	O
PGE2	POS	O
levels	POS	O
during	POS	O
the	POS	O
first	POS	O
4	POS	O
h	POS	O
were	POS	O
significantly	POS	O
higher	POS	O
than	POS	O
the	POS	O
other	POS	O
three	POS	O
treatment	POS	O
groups	POS	O
.	POS	O
Moreover	POS	O
,	POS	O
bupivacaine	POS	O
significantly	POS	O
increased	POS	O
COX	POS	O
-	POS	O
2	POS	O
gene	POS	O
expression	POS	O
at	POS	O
48	POS	O
h	POS	O
as	POS	O
compared	POS	O
with	POS	O
the	POS	O
lidocaine	POS	O
/	POS	O
placebo	POS	O
group	POS	O
.	POS	O
Thromboxane	POS	O
levels	POS	O
were	POS	O
not	POS	O
significantly	POS	O
affected	POS	O
by	POS	O
any	POS	O
of	POS	O
the	POS	O
treatments	POS	O
,	POS	O
indicating	POS	O
that	POS	O
the	POS	O
effects	POS	O
seen	POS	O
were	POS	O
attributable	POS	O
to	POS	O
inhibition	POS	O
of	POS	O
COX	POS	O
-	POS	O
2	POS	O
,	POS	O
but	POS	O
not	POS	O
COX	POS	O
-	POS	O
1	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
bupivacaine	POS	O
stimulates	POS	O
COX	POS	O
-	POS	O
2	POS	O
gene	POS	O
expression	POS	O
after	POS	O
tissue	POS	O
injury	POS	O
,	POS	O
which	POS	O
is	POS	O
associated	POS	O
with	POS	O
higher	POS	O
PGE2	POS	O
production	POS	O
and	POS	O
pain	POS	B-NP
after	POS	O
the	POS	O
local	POS	O
anesthetic	POS	O
effect	POS	O
dissipates	POS	O
.	POS	O
p75NTR	POS	O
expression	POS	O
in	POS	O
rat	POS	O
urinary	POS	O
bladder	POS	O
sensory	POS	O
neurons	POS	O
and	POS	O
spinal	POS	O
cord	POS	O
with	POS	O
cyclophosphamide	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
.	POS	O
A	POS	O
role	POS	O
for	POS	O
nerve	POS	O
growth	POS	O
factor	POS	O
(	POS	O
NGF	POS	O
)	POS	O
in	POS	O
contributing	POS	O
to	POS	O
increased	POS	O
voiding	POS	O
frequency	POS	O
and	POS	O
altered	POS	O
sensation	POS	O
from	POS	O
the	POS	O
urinary	POS	O
bladder	POS	O
has	POS	O
been	POS	O
suggested	POS	O
.	POS	O
Previous	POS	O
studies	POS	O
have	POS	O
examined	POS	O
the	POS	O
expression	POS	O
and	POS	O
regulation	POS	O
of	POS	O
tyrosine	POS	O
kinase	POS	O
receptors	POS	O
(	POS	O
Trks	POS	O
)	POS	O
in	POS	O
micturition	POS	O
reflexes	POS	O
with	POS	O
urinary	POS	B-NP
bladder	POS	I-NP
inflammation	POS	I-NP
.	POS	O
The	POS	O
present	POS	O
studies	POS	O
examine	POS	O
the	POS	O
expression	POS	O
and	POS	O
regulation	POS	O
of	POS	O
another	POS	O
receptor	POS	O
known	POS	O
to	POS	O
bind	POS	O
NGF	POS	O
,	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
,	POS	O
after	POS	O
various	POS	O
durations	POS	O
of	POS	O
bladder	POS	B-NP
inflammation	POS	I-NP
induced	POS	O
by	POS	O
cyclophosphamide	POS	O
(	POS	O
CYP	POS	O
)	POS	O
.	POS	O
CYP	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
increased	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
expression	POS	O
in	POS	O
the	POS	O
superficial	POS	O
lateral	POS	O
and	POS	O
medial	POS	O
dorsal	POS	O
horn	POS	O
in	POS	O
L1	POS	O
-	POS	O
L2	POS	O
and	POS	O
L6	POS	O
-	POS	O
S1	POS	O
spinal	POS	O
segments	POS	O
.	POS	O
The	POS	O
number	POS	O
of	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
-	POS	O
immunoreactive	POS	O
(	POS	O
-	POS	O
IR	POS	O
)	POS	O
cells	POS	O
in	POS	O
the	POS	O
lumbosacral	POS	O
dorsal	POS	O
root	POS	O
ganglia	POS	O
(	POS	O
DRG	POS	O
)	POS	O
also	POS	O
increased	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
with	POS	O
CYP	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
(	POS	O
acute	POS	O
,	POS	O
intermediate	POS	O
,	POS	O
and	POS	O
chronic	POS	O
)	POS	O
.	POS	O
Quantitative	POS	O
,	POS	O
real	POS	O
-	POS	O
time	POS	O
polymerase	POS	O
chain	POS	O
reaction	POS	O
also	POS	O
demonstrated	POS	O
significant	POS	O
increases	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
in	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
mRNA	POS	O
in	POS	O
DRG	POS	O
with	POS	O
intermediate	POS	O
and	POS	O
chronic	POS	O
CYP	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
.	POS	O
Retrograde	POS	O
dye	POS	O
-	POS	O
tracing	POS	O
techniques	POS	O
with	POS	O
Fastblue	POS	O
were	POS	O
used	POS	O
to	POS	O
identify	POS	O
presumptive	POS	O
bladder	POS	O
afferent	POS	O
cells	POS	O
in	POS	O
the	POS	O
lumbosacral	POS	O
DRG	POS	O
.	POS	O
In	POS	O
bladder	POS	O
afferent	POS	O
cells	POS	O
in	POS	O
DRG	POS	O
,	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
-	POS	O
IR	POS	O
was	POS	O
also	POS	O
increased	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
with	POS	O
cystitis	POS	B-NP
.	POS	O
In	POS	O
addition	POS	O
to	POS	O
increases	POS	O
in	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
-	POS	O
IR	POS	O
in	POS	O
DRG	POS	O
cell	POS	O
bodies	POS	O
,	POS	O
increases	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
in	POS	O
pericellular	POS	O
(	POS	O
encircling	POS	O
DRG	POS	O
cells	POS	O
)	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
-	POS	O
IR	POS	O
in	POS	O
DRG	POS	O
also	POS	O
increased	POS	O
.	POS	O
Confocal	POS	O
analyses	POS	O
demonstrated	POS	O
that	POS	O
pericellular	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
-	POS	O
IR	POS	O
was	POS	O
not	POS	O
colocalized	POS	O
with	POS	O
the	POS	O
glial	POS	O
marker	POS	O
,	POS	O
glial	POS	O
fibrillary	POS	O
acidic	POS	O
protein	POS	O
(	POS	O
GFAP	POS	O
)	POS	O
.	POS	O
These	POS	O
studies	POS	O
demonstrate	POS	O
that	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
expression	POS	O
in	POS	O
micturition	POS	O
reflexes	POS	O
is	POS	O
present	POS	O
constitutively	POS	O
and	POS	O
modified	POS	O
by	POS	O
bladder	POS	B-NP
inflammation	POS	I-NP
.	POS	O
The	POS	O
functional	POS	O
significance	POS	O
of	POS	O
p75	POS	O
(	POS	O
NTR	POS	O
)	POS	O
expression	POS	O
in	POS	O
micturition	POS	B-NP
reflexes	POS	I-NP
remains	POS	O
to	POS	O
be	POS	O
determined	POS	O
.	POS	O
Azathioprine	POS	O
-	POS	O
induced	POS	O
suicidal	POS	B-NP
erythrocyte	POS	I-NP
death	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Azathioprine	POS	O
is	POS	O
widely	POS	O
used	POS	O
as	POS	O
an	POS	O
immunosuppressive	POS	O
drug	POS	O
.	POS	O
The	POS	O
side	POS	O
effects	POS	O
of	POS	O
azathioprine	POS	O
include	POS	O
anemia	POS	B-NP
,	POS	O
which	POS	O
has	POS	O
been	POS	O
attributed	POS	O
to	POS	O
bone	POS	O
marrow	POS	O
suppression	POS	O
.	POS	O
Alternatively	POS	O
,	POS	O
anemia	POS	B-NP
could	POS	O
result	POS	O
from	POS	O
accelerated	POS	O
suicidal	POS	O
erythrocyte	POS	O
death	POS	O
or	POS	O
eryptosis	POS	O
,	POS	O
which	POS	O
is	POS	O
characterized	POS	O
by	POS	O
exposure	POS	O
of	POS	O
phosphatidylserine	POS	O
(	POS	O
PS	POS	O
)	POS	O
at	POS	O
the	POS	O
erythrocyte	POS	O
surface	POS	O
and	POS	O
by	POS	O
cell	POS	O
shrinkage	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
The	POS	O
present	POS	O
experiments	POS	O
explored	POS	O
whether	POS	O
azathioprine	POS	O
influences	POS	O
eryptosis	POS	O
.	POS	O
According	POS	O
to	POS	O
annexin	POS	O
V	POS	O
binding	POS	O
,	POS	O
erythrocytes	POS	O
from	POS	O
patients	POS	O
indeed	POS	O
showed	POS	O
a	POS	O
significant	POS	O
increase	POS	O
of	POS	O
PS	POS	O
exposure	POS	O
within	POS	O
1	POS	O
week	POS	O
of	POS	O
treatment	POS	O
with	POS	O
azathioprine	POS	O
.	POS	O
In	POS	O
a	POS	O
second	POS	O
series	POS	O
,	POS	O
cytosolic	POS	O
Ca2	POS	O
+	POS	O
activity	POS	O
(	POS	O
Fluo3	POS	O
fluorescence	POS	O
)	POS	O
,	POS	O
cell	POS	O
volume	POS	O
(	POS	O
forward	POS	O
scatter	POS	O
)	POS	O
,	POS	O
and	POS	O
PS	POS	O
-	POS	O
exposure	POS	O
(	POS	O
annexin	POS	O
V	POS	O
binding	POS	O
)	POS	O
were	POS	O
determined	POS	O
by	POS	O
FACS	POS	O
analysis	POS	O
in	POS	O
erythrocytes	POS	O
from	POS	O
healthy	POS	O
volunteers	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Exposure	POS	O
to	POS	O
azathioprine	POS	O
(	POS	O
>	POS	O
or	POS	O
=	POS	O
2	POS	O
microg	POS	O
/	POS	O
mL	POS	O
)	POS	O
for	POS	O
48	POS	O
hours	POS	O
increased	POS	O
cytosolic	POS	O
Ca2	POS	O
+	POS	O
activity	POS	O
and	POS	O
annexin	POS	O
V	POS	O
binding	POS	O
and	POS	O
decreased	POS	O
forward	POS	O
scatter	POS	O
.	POS	O
The	POS	O
effect	POS	O
of	POS	O
azathioprine	POS	O
on	POS	O
both	POS	O
annexin	POS	O
V	POS	O
binding	POS	O
and	POS	O
forward	POS	O
scatter	POS	O
was	POS	O
significantly	POS	O
blunted	POS	O
in	POS	O
the	POS	O
nominal	POS	O
absence	POS	O
of	POS	O
extracellular	POS	O
Ca2	POS	O
+	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Azathioprine	POS	O
triggers	POS	O
suicidal	POS	O
erythrocyte	POS	O
death	POS	O
,	POS	O
an	POS	O
effect	POS	O
presumably	POS	O
contributing	POS	O
to	POS	O
azathioprine	POS	O
-	POS	O
induced	POS	O
anemia	POS	B-NP
.	POS	O
Levetiracetam	POS	O
as	POS	O
an	POS	O
adjunct	POS	O
to	POS	O
phenobarbital	POS	O
treatment	POS	O
in	POS	O
cats	POS	O
with	POS	O
suspected	POS	O
idiopathic	POS	B-NP
epilepsy	POS	I-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
assess	POS	O
pharmacokinetics	POS	O
,	POS	O
efficacy	POS	O
,	POS	O
and	POS	O
tolerability	POS	O
of	POS	O
oral	POS	O
levetiracetam	POS	O
administered	POS	O
as	POS	O
an	POS	O
adjunct	POS	O
to	POS	O
phenobarbital	POS	O
treatment	POS	O
in	POS	O
cats	POS	O
with	POS	O
poorly	POS	O
controlled	POS	O
suspected	POS	O
idiopathic	POS	B-NP
epilepsy	POS	I-NP
.	POS	O
DESIGN	POS	O
-	POS	O
Open	POS	O
-	POS	O
label	POS	O
,	POS	O
noncomparative	POS	O
clinical	POS	O
trial	POS	O
.	POS	O
ANIMALS	POS	O
:	POS	O
12	POS	O
cats	POS	O
suspected	POS	O
to	POS	O
have	POS	O
idiopathic	POS	B-NP
epilepsy	POS	I-NP
that	POS	O
was	POS	O
poorly	POS	O
controlled	POS	O
with	POS	O
phenobarbital	POS	O
or	POS	O
that	POS	O
had	POS	O
unacceptable	POS	O
adverse	POS	O
effects	POS	O
when	POS	O
treated	POS	O
with	POS	O
phenobarbital	POS	O
.	POS	O
PROCEDURES	POS	O
:	POS	O
Cats	POS	O
were	POS	O
treated	POS	O
with	POS	O
levetiracetam	POS	O
(	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
[	POS	O
9	POS	O
.	POS	O
1	POS	O
mg	POS	O
/	POS	O
lb	POS	O
]	POS	O
,	POS	O
PO	POS	O
,	POS	O
q	POS	O
8	POS	O
h	POS	O
)	POS	O
.	POS	O
After	POS	O
a	POS	O
minimum	POS	O
of	POS	O
1	POS	O
week	POS	O
of	POS	O
treatment	POS	O
,	POS	O
serum	POS	O
levetiracetam	POS	O
concentrations	POS	O
were	POS	O
measured	POS	O
before	POS	O
and	POS	O
2	POS	O
,	POS	O
4	POS	O
,	POS	O
and	POS	O
6	POS	O
hours	POS	O
after	POS	O
drug	POS	O
administration	POS	O
,	POS	O
and	POS	O
maximum	POS	O
and	POS	O
minimum	POS	O
serum	POS	O
concentrations	POS	O
and	POS	O
elimination	POS	O
half	POS	O
-	POS	O
life	POS	O
were	POS	O
calculated	POS	O
.	POS	O
Seizure	POS	B-NP
frequencies	POS	O
before	POS	O
and	POS	O
after	POS	O
initiation	POS	O
of	POS	O
levetiracetam	POS	O
treatment	POS	O
were	POS	O
compared	POS	O
,	POS	O
and	POS	O
adverse	POS	O
effects	POS	O
were	POS	O
recorded	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Median	POS	O
maximum	POS	O
serum	POS	O
levetiracetam	POS	O
concentration	POS	O
was	POS	O
25	POS	O
.	POS	O
5	POS	O
microg	POS	O
/	POS	O
mL	POS	O
,	POS	O
median	POS	O
minimum	POS	O
serum	POS	O
levetiracetam	POS	O
concentration	POS	O
was	POS	O
8	POS	O
.	POS	O
3	POS	O
microg	POS	O
/	POS	O
mL	POS	O
,	POS	O
and	POS	O
median	POS	O
elimination	POS	O
half	POS	O
-	POS	O
life	POS	O
was	POS	O
2	POS	O
.	POS	O
9	POS	O
hours	POS	O
.	POS	O
Median	POS	O
seizure	POS	B-NP
frequency	POS	O
prior	POS	O
to	POS	O
treatment	POS	O
with	POS	O
levetiracetam	POS	O
(	POS	O
2	POS	O
.	POS	O
1	POS	O
seizures	POS	B-NP
/	POS	O
mo	POS	O
)	POS	O
was	POS	O
significantly	POS	O
higher	POS	O
than	POS	O
median	POS	O
seizure	POS	B-NP
frequency	POS	O
after	POS	O
initiation	POS	O
of	POS	O
levetiracetam	POS	O
treatment	POS	O
(	POS	O
0	POS	O
.	POS	O
42	POS	O
seizures	POS	B-NP
/	POS	O
mo	POS	O
)	POS	O
,	POS	O
and	POS	O
7	POS	O
of	POS	O
10	POS	O
cats	POS	O
were	POS	O
classified	POS	O
as	POS	O
having	POS	O
responded	POS	O
to	POS	O
levetiracetam	POS	O
treatment	POS	O
(	POS	O
ie	POS	O
,	POS	O
reduction	POS	O
in	POS	O
seizure	POS	B-NP
frequency	POS	O
of	POS	O
>	POS	O
or	POS	O
=	POS	O
50	POS	O
%	POS	O
)	POS	O
.	POS	O
Two	POS	O
cats	POS	O
had	POS	O
transient	POS	O
lethargy	POS	B-NP
and	POS	O
inappetence	POS	B-NP
.	POS	O
CONCLUSIONS	POS	O
AND	POS	O
CLINICAL	POS	O
RELEVANCE	POS	O
:	POS	O
Results	POS	O
suggested	POS	O
that	POS	O
levetiracetam	POS	O
is	POS	O
well	POS	O
tolerated	POS	O
in	POS	O
cats	POS	O
and	POS	O
may	POS	O
be	POS	O
useful	POS	O
as	POS	O
an	POS	O
adjunct	POS	O
to	POS	O
phenobarbital	POS	O
treatment	POS	O
in	POS	O
cats	POS	O
with	POS	O
idiopathic	POS	B-NP
epilepsy	POS	I-NP
.	POS	O
Serotonin	POS	O
reuptake	POS	O
inhibitors	POS	O
,	POS	O
paranoia	POS	B-NP
,	POS	O
and	POS	O
the	POS	O
ventral	POS	O
basal	POS	O
ganglia	POS	O
.	POS	O
Antidepressants	POS	O
have	POS	O
previously	POS	O
been	POS	O
associated	POS	O
with	POS	O
paranoid	POS	O
reactions	POS	O
in	POS	O
psychiatric	POS	B-NP
patients	POS	O
.	POS	O
Five	POS	O
cases	POS	O
of	POS	O
paranoid	POS	B-NP
exacerbation	POS	I-NP
with	POS	O
the	POS	O
serotonin	POS	O
reuptake	POS	O
inhibitors	POS	O
fluoxetine	POS	O
and	POS	O
amitriptyline	POS	O
are	POS	O
reported	POS	O
here	POS	O
.	POS	O
Elements	POS	O
common	POS	O
to	POS	O
these	POS	O
cases	POS	O
included	POS	O
a	POS	O
history	POS	O
of	POS	O
paranoid	POS	O
symptomatology	POS	O
and	POS	O
the	POS	O
concomitant	POS	O
occurrence	POS	O
of	POS	O
depressive	POS	B-NP
and	POS	O
psychotic	POS	B-NP
symptoms	POS	I-NP
.	POS	O
Complicated	POS	B-NP
depressive	POS	I-NP
disorders	POS	I-NP
(	POS	O
including	POS	O
atypicality	POS	O
of	POS	O
course	POS	O
and	POS	O
symptomatology	POS	O
,	POS	O
chronicity	POS	B-NP
,	POS	O
psychosis	POS	B-NP
,	POS	O
bipolarity	POS	B-NP
,	POS	O
and	POS	O
secondary	POS	O
onset	POS	O
in	POS	O
the	POS	O
course	POS	O
of	POS	O
a	POS	O
primary	POS	O
psychosis	POS	B-NP
)	POS	O
may	POS	O
present	POS	O
particular	POS	O
vulnerability	POS	O
to	POS	O
paranoid	POS	B-NP
exacerbations	POS	I-NP
associated	POS	O
with	POS	O
serotonin	POS	O
reuptake	POS	O
inhibitors	POS	O
.	POS	O
Although	POS	O
the	POS	O
pharmacology	POS	O
and	POS	O
neurobiology	POS	O
of	POS	O
paranoia	POS	B-NP
remain	POS	O
cryptic	POS	O
,	POS	O
several	POS	O
mechanisms	POS	O
,	POS	O
including	POS	O
5HT3	POS	O
receptor	POS	O
-	POS	O
mediated	POS	O
dopamine	POS	O
release	POS	O
,	POS	O
beta	POS	O
-	POS	O
noradrenergic	POS	O
receptor	POS	O
downregulation	POS	O
,	POS	O
or	POS	O
GABAB	POS	O
receptor	POS	O
upregulation	POS	O
acting	POS	O
in	POS	O
the	POS	O
vicinity	POS	O
of	POS	O
the	POS	O
ventral	POS	O
basal	POS	O
ganglia	POS	O
(	POS	O
possibly	POS	O
in	POS	O
lateral	POS	O
orbitofrontal	POS	O
or	POS	O
anterior	POS	O
cingulate	POS	O
circuits	POS	O
)	POS	O
,	POS	O
might	POS	O
apply	POS	O
to	POS	O
this	POS	O
phenomenon	POS	O
.	POS	O
These	POS	O
cases	POS	O
call	POS	O
attention	POS	O
to	POS	O
possible	POS	O
paranoid	POS	B-NP
exacerbations	POS	I-NP
with	POS	O
serotonin	POS	O
reuptake	POS	O
blockers	POS	O
in	POS	O
select	POS	O
patients	POS	O
and	POS	O
raise	POS	O
neurobiological	POS	O
considerations	POS	O
regarding	POS	O
paranoia	POS	B-NP
.	POS	O
Clinical	POS	O
comparison	POS	O
of	POS	O
cardiorespiratory	POS	B-NP
effects	POS	I-NP
during	POS	O
unilateral	POS	O
and	POS	O
conventional	POS	O
spinal	POS	O
anaesthesia	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Spinal	POS	O
anaesthesia	POS	O
is	POS	O
widely	POS	O
employed	POS	O
in	POS	O
clinical	POS	O
practice	POS	O
but	POS	O
has	POS	O
the	POS	O
main	POS	O
drawback	POS	O
of	POS	O
post	POS	O
-	POS	O
spinal	POS	O
block	POS	O
hypotension	POS	B-NP
.	POS	O
Efforts	POS	O
must	POS	O
therefore	POS	O
continue	POS	O
to	POS	O
be	POS	O
made	POS	O
to	POS	O
obviate	POS	O
this	POS	O
setback	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
evaluate	POS	O
the	POS	O
cardiovascular	POS	O
and	POS	O
respiratory	POS	O
changes	POS	O
during	POS	O
unilateral	POS	O
and	POS	O
conventional	POS	O
spinal	POS	O
anaesthesia	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
With	POS	O
ethical	POS	O
approval	POS	O
,	POS	O
we	POS	O
studied	POS	O
74	POS	O
American	POS	O
Society	POS	O
of	POS	O
Anesthesiologists	POS	O
(	POS	O
ASA	POS	O
)	POS	O
,	POS	O
physical	POS	O
status	POS	O
class	POS	O
1	POS	O
and	POS	O
2	POS	O
patients	POS	O
scheduled	POS	O
for	POS	O
elective	POS	O
unilateral	POS	O
lower	POS	O
limb	POS	O
surgery	POS	O
.	POS	O
Patients	POS	O
were	POS	O
randomly	POS	O
allocated	POS	O
into	POS	O
one	POS	O
of	POS	O
two	POS	O
groups	POS	O
:	POS	O
lateral	POS	O
and	POS	O
conventional	POS	O
spinal	POS	O
anaesthesia	POS	O
groups	POS	O
.	POS	O
In	POS	O
the	POS	O
lateral	POS	O
position	POS	O
with	POS	O
operative	POS	O
side	POS	O
down	POS	O
,	POS	O
patients	POS	O
recived	POS	O
10	POS	O
mg	POS	O
(	POS	O
2mls	POS	O
)	POS	O
of	POS	O
0	POS	O
.	POS	O
5	POS	O
%	POS	O
hyperbaric	POS	O
bupivacaine	POS	O
through	POS	O
a	POS	O
25	POS	O
-	POS	O
gauge	POS	O
spinal	POS	O
needle	POS	O
.	POS	O
Patients	POS	O
in	POS	O
the	POS	O
unilateral	POS	O
group	POS	O
were	POS	O
maintained	POS	O
in	POS	O
the	POS	O
lateral	POS	O
position	POS	O
for	POS	O
15	POS	O
minutes	POS	O
following	POS	O
spinal	POS	O
injection	POS	O
while	POS	O
those	POS	O
in	POS	O
the	POS	O
conventional	POS	O
group	POS	O
were	POS	O
turned	POS	O
supine	POS	O
immediately	POS	O
after	POS	O
injection	POS	O
.	POS	O
Blood	POS	O
pressure	POS	O
,	POS	O
heart	POS	O
rate	POS	O
,	POS	O
respiratory	POS	O
rate	POS	O
and	POS	O
oxygen	POS	O
saturation	POS	O
were	POS	O
monitored	POS	O
over	POS	O
1	POS	O
hour	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Three	POS	O
patients	POS	O
(	POS	O
8	POS	O
.	POS	O
1	POS	O
%	POS	O
)	POS	O
in	POS	O
the	POS	O
unilateral	POS	O
group	POS	O
and	POS	O
5	POS	O
(	POS	O
13	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
in	POS	O
the	POS	O
conventional	POS	O
group	POS	O
developed	POS	O
hypotension	POS	B-NP
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
71	POS	O
.	POS	O
Four	POS	O
(	POS	O
10	POS	O
.	POS	O
8	POS	O
%	POS	O
)	POS	O
patients	POS	O
in	POS	O
the	POS	O
conventional	POS	O
group	POS	O
and	POS	O
1	POS	O
(	POS	O
2	POS	O
.	POS	O
7	POS	O
%	POS	O
)	POS	O
in	POS	O
the	POS	O
unilateral	POS	O
group	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
17	POS	O
required	POS	O
epinephrine	POS	O
infusion	POS	O
to	POS	O
treat	POS	O
hypotension	POS	B-NP
.	POS	O
Patients	POS	O
in	POS	O
the	POS	O
conventional	POS	O
group	POS	O
had	POS	O
statistically	POS	O
significant	POS	O
greater	POS	O
fall	POS	O
in	POS	O
the	POS	O
systolic	POS	O
blood	POS	O
pressures	POS	O
at	POS	O
15	POS	O
,	POS	O
30	POS	O
and	POS	O
45	POS	O
minutes	POS	O
when	POS	O
compared	POS	O
to	POS	O
the	POS	O
baseline	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
003	POS	O
,	POS	O
0	POS	O
.	POS	O
001	POS	O
and	POS	O
0	POS	O
.	POS	O
004	POS	O
)	POS	O
.	POS	O
The	POS	O
mean	POS	O
respiratory	POS	O
rate	POS	O
and	POS	O
oxygen	POS	O
saturations	POS	O
in	POS	O
the	POS	O
two	POS	O
groups	POS	O
were	POS	O
similar	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Compared	POS	O
to	POS	O
conventional	POS	O
spinal	POS	O
anaesthesia	POS	O
,	POS	O
unilateral	POS	O
spinal	POS	O
anaesthesia	POS	O
was	POS	O
associated	POS	O
with	POS	O
fewer	POS	O
cardiovascular	POS	B-NP
perturbations	POS	I-NP
.	POS	O
Also	POS	O
,	POS	O
the	POS	O
type	POS	O
of	POS	O
spinal	POS	O
block	POS	O
instituted	POS	O
affected	POS	O
neither	POS	O
the	POS	O
respiratory	POS	O
rate	POS	O
nor	POS	O
the	POS	O
arterial	POS	O
oxygen	POS	O
saturation	POS	O
.	POS	O
Spectrum	POS	O
of	POS	O
adverse	POS	O
events	POS	O
after	POS	O
generic	POS	O
HAART	POS	O
in	POS	O
southern	POS	O
Indian	POS	O
HIV	POS	O
-	POS	O
infected	POS	O
patients	POS	O
.	POS	O
To	POS	O
determine	POS	O
the	POS	O
incidence	POS	O
of	POS	O
clinically	POS	O
significant	POS	O
adverse	POS	O
events	POS	O
after	POS	O
long	POS	O
-	POS	O
term	POS	O
,	POS	O
fixed	POS	O
-	POS	O
dose	POS	O
,	POS	O
generic	POS	O
highly	POS	O
active	POS	O
antiretroviral	POS	O
therapy	POS	O
(	POS	O
HAART	POS	O
)	POS	O
use	POS	O
among	POS	O
HIV	POS	O
-	POS	O
infected	POS	O
individuals	POS	O
in	POS	O
South	POS	O
India	POS	O
,	POS	O
we	POS	O
examined	POS	O
the	POS	O
experiences	POS	O
of	POS	O
3154	POS	O
HIV	POS	O
-	POS	O
infected	POS	O
individuals	POS	O
who	POS	O
received	POS	O
a	POS	O
minimum	POS	O
of	POS	O
3	POS	O
months	POS	O
of	POS	O
generic	POS	O
HAART	POS	O
between	POS	O
February	POS	O
1996	POS	O
and	POS	O
December	POS	O
2006	POS	O
at	POS	O
a	POS	O
tertiary	POS	O
HIV	POS	O
care	POS	O
referral	POS	O
center	POS	O
in	POS	O
South	POS	O
India	POS	O
.	POS	O
The	POS	O
most	POS	O
common	POS	O
regimens	POS	O
were	POS	O
3TC	POS	O
+	POS	O
d4T	POS	O
+	POS	O
nevirapine	POS	O
(	POS	O
NVP	POS	O
)	POS	O
(	POS	O
54	POS	O
.	POS	O
8	POS	O
%	POS	O
)	POS	O
,	POS	O
zidovudine	POS	O
(	POS	O
AZT	POS	O
)	POS	O
+	POS	O
3TC	POS	O
+	POS	O
NVP	POS	O
(	POS	O
14	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
,	POS	O
3TC	POS	O
+	POS	O
d4T	POS	O
+	POS	O
efavirenz	POS	O
(	POS	O
EFV	POS	O
)	POS	O
(	POS	O
20	POS	O
.	POS	O
1	POS	O
%	POS	O
)	POS	O
,	POS	O
and	POS	O
AZT	POS	O
+	POS	O
3TC	POS	O
+	POS	O
EFV	POS	O
(	POS	O
5	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
.	POS	O
The	POS	O
most	POS	O
common	POS	O
adverse	POS	O
events	POS	O
and	POS	O
median	POS	O
CD4	POS	O
at	POS	O
time	POS	O
of	POS	O
event	POS	O
were	POS	O
rash	POS	B-NP
(	POS	O
15	POS	O
.	POS	O
2	POS	O
%	POS	O
;	POS	O
CD4	POS	O
,	POS	O
285	POS	O
cells	POS	O
/	POS	O
microL	POS	O
)	POS	O
and	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
(	POS	O
9	POS	O
.	POS	O
0	POS	O
%	POS	O
and	POS	O
348	POS	O
cells	POS	O
/	POS	O
microL	POS	O
)	POS	O
.	POS	O
Clinically	POS	O
significant	POS	O
anemia	POS	B-NP
(	POS	O
hemoglobin	POS	O
<	POS	O
7	POS	O
g	POS	O
/	POS	O
dL	POS	O
)	POS	O
was	POS	O
observed	POS	O
in	POS	O
5	POS	O
.	POS	O
4	POS	O
%	POS	O
of	POS	O
patients	POS	O
(	POS	O
CD4	POS	O
,	POS	O
165	POS	O
cells	POS	O
/	POS	O
microL	POS	O
)	POS	O
and	POS	O
hepatitis	POS	B-NP
(	POS	O
clinical	POS	O
jaundice	POS	B-NP
with	POS	O
alanine	POS	O
aminotransferase	POS	O
>	POS	O
5	POS	O
times	POS	O
upper	POS	O
limits	POS	O
of	POS	O
normal	POS	O
)	POS	O
in	POS	O
3	POS	O
.	POS	O
5	POS	O
%	POS	O
of	POS	O
patients	POS	O
(	POS	O
CD4	POS	O
,	POS	O
260	POS	O
cells	POS	O
/	POS	O
microL	POS	O
)	POS	O
.	POS	O
Women	POS	O
were	POS	O
significantly	POS	O
more	POS	O
likely	POS	O
to	POS	O
experience	POS	O
lactic	POS	B-NP
acidosis	POS	I-NP
,	POS	O
while	POS	O
men	POS	O
were	POS	O
significantly	POS	O
more	POS	O
likely	POS	O
to	POS	O
experience	POS	O
immune	POS	B-NP
reconstitution	POS	I-NP
syndrome	POS	I-NP
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Among	POS	O
the	POS	O
patients	POS	O
with	POS	O
1	POS	O
year	POS	O
of	POS	O
follow	POS	O
-	POS	O
up	POS	O
,	POS	O
NVP	POS	O
therapy	POS	O
was	POS	O
significantly	POS	O
associated	POS	O
with	POS	O
developing	POS	O
rash	POS	B-NP
and	POS	O
d4T	POS	O
therapy	POS	O
with	POS	O
developing	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Anemia	POS	B-NP
and	POS	O
hepatitis	POS	B-NP
often	POS	O
occur	POS	O
within	POS	O
12	POS	O
weeks	POS	O
of	POS	O
initiating	POS	O
generic	POS	O
HAART	POS	O
.	POS	O
Frequent	POS	O
and	POS	O
early	POS	O
monitoring	POS	O
for	POS	O
these	POS	O
toxicities	POS	B-NP
is	POS	O
warranted	POS	O
in	POS	O
developing	POS	O
countries	POS	O
where	POS	O
generic	POS	O
HAART	POS	O
is	POS	O
increasingly	POS	O
available	POS	O
.	POS	O
Thalidomide	POS	O
and	POS	O
sensory	POS	B-NP
neurotoxicity	POS	I-NP
:	POS	O
a	POS	O
neurophysiological	POS	O
study	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Recent	POS	O
studies	POS	O
confirmed	POS	O
a	POS	O
high	POS	O
incidence	POS	O
of	POS	O
sensory	POS	B-NP
axonal	POS	I-NP
neuropathy	POS	I-NP
in	POS	O
patients	POS	O
treated	POS	O
with	POS	O
different	POS	O
doses	POS	O
of	POS	O
thalidomide	POS	O
.	POS	O
The	POS	O
study	POS	O
'	POS	O
s	POS	O
aims	POS	O
were	POS	O
to	POS	O
measure	POS	O
variations	POS	O
in	POS	O
sural	POS	O
nerve	POS	O
sensory	POS	O
action	POS	O
potential	POS	O
(	POS	O
SAP	POS	O
)	POS	O
amplitude	POS	O
in	POS	O
patients	POS	O
with	POS	O
refractory	POS	O
cutaneous	POS	B-NP
lupus	POS	I-NP
erythematosus	POS	I-NP
(	POS	O
CLE	POS	B-NP
)	POS	O
treated	POS	O
with	POS	O
thalidomide	POS	O
and	POS	O
use	POS	O
these	POS	O
findings	POS	O
to	POS	O
identify	POS	O
the	POS	O
neurotoxic	POS	B-NP
potential	POS	O
of	POS	O
thalidomide	POS	O
and	POS	O
the	POS	O
recovery	POS	O
capacity	POS	O
of	POS	O
sensory	POS	O
fibres	POS	O
after	POS	O
discontinuation	POS	O
of	POS	O
treatment	POS	O
.	POS	O
PATIENTS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
Clinical	POS	O
and	POS	O
electrophysiological	POS	O
data	POS	O
in	POS	O
12	POS	O
female	POS	O
patients	POS	O
with	POS	O
CLE	POS	B-NP
during	POS	O
treatment	POS	O
with	POS	O
thalidomide	POS	O
and	POS	O
up	POS	O
to	POS	O
47	POS	O
months	POS	O
after	POS	O
discontinuation	POS	O
of	POS	O
treatment	POS	O
were	POS	O
analysed	POS	O
.	POS	O
Sural	POS	O
nerve	POS	O
SAP	POS	O
amplitude	POS	O
reduction	POS	O
>	POS	O
or	POS	O
=	POS	O
40	POS	O
%	POS	O
was	POS	O
the	POS	O
criteria	POS	O
for	POS	O
discontinuing	POS	O
therapy	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
During	POS	O
treatment	POS	O
,	POS	O
11	POS	O
patients	POS	O
showed	POS	O
a	POS	O
reduction	POS	O
in	POS	O
sural	POS	O
nerve	POS	O
SAP	POS	O
amplitude	POS	O
compared	POS	O
to	POS	O
baseline	POS	O
values	POS	O
(	POS	O
9	POS	O
with	POS	O
a	POS	O
reduction	POS	O
>	POS	O
or	POS	O
=	POS	O
50	POS	O
%	POS	O
and	POS	O
2	POS	O
<	POS	O
50	POS	O
%	POS	O
)	POS	O
.	POS	O
One	POS	O
patient	POS	O
showed	POS	O
no	POS	O
changes	POS	O
in	POS	O
SAP	POS	O
amplitude	POS	O
.	POS	O
Five	POS	O
patients	POS	O
complained	POS	O
of	POS	O
paresthesias	POS	B-NP
and	POS	O
leg	POS	B-NP
cramps	POS	I-NP
.	POS	O
After	POS	O
thalidomide	POS	O
treatment	POS	O
,	POS	O
sural	POS	O
SAP	POS	O
amplitude	POS	O
recovered	POS	O
in	POS	O
3	POS	O
patients	POS	O
.	POS	O
At	POS	O
detection	POS	O
of	POS	O
reduction	POS	O
in	POS	O
sural	POS	O
nerve	POS	O
SAP	POS	O
amplitude	POS	O
,	POS	O
the	POS	O
median	POS	O
thalidomide	POS	O
cumulative	POS	O
dose	POS	O
was	POS	O
21	POS	O
.	POS	O
4	POS	O
g	POS	O
.	POS	O
The	POS	O
threshold	POS	O
neurotoxic	POS	B-NP
dosage	POS	O
is	POS	O
lower	POS	O
than	POS	O
previously	POS	O
reported	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Sural	POS	O
nerve	POS	O
SAP	POS	O
amplitude	POS	O
reduction	POS	O
is	POS	O
a	POS	O
reliable	POS	O
and	POS	O
sensitive	POS	O
marker	POS	O
of	POS	O
degeneration	POS	O
and	POS	O
recovery	POS	O
of	POS	O
sensory	POS	O
fibres	POS	O
.	POS	O
This	POS	O
electrophysiological	POS	O
parameter	POS	O
provides	POS	O
information	POS	O
about	POS	O
subclinical	POS	O
neurotoxic	POS	B-NP
potential	POS	O
of	POS	O
thalidomide	POS	O
but	POS	O
is	POS	O
not	POS	O
helpful	POS	O
in	POS	O
predicting	POS	O
the	POS	O
appearance	POS	O
of	POS	O
sensory	POS	B-NP
symptoms	POS	I-NP
.	POS	O
Five	POS	O
cases	POS	O
of	POS	O
encephalitis	POS	B-NP
during	POS	O
treatment	POS	O
of	POS	O
loiasis	POS	B-NP
with	POS	O
diethylcarbamazine	POS	O
.	POS	O
Five	POS	O
cases	POS	O
of	POS	O
encephalitis	POS	B-NP
following	POS	O
treatment	POS	O
with	POS	O
diethylcarbamazine	POS	O
(	POS	O
DEC	POS	O
)	POS	O
were	POS	O
observed	POS	O
in	POS	O
Congolese	POS	O
patients	POS	O
with	POS	O
Loa	POS	B-NP
loa	POS	I-NP
filariasis	POS	I-NP
.	POS	O
Two	POS	O
cases	POS	O
had	POS	O
a	POS	O
fatal	POS	O
outcome	POS	O
and	POS	O
one	POS	O
resulted	POS	O
in	POS	O
severe	POS	O
sequelae	POS	O
.	POS	O
The	POS	O
notable	POS	O
fact	POS	O
was	POS	O
that	POS	O
this	POS	O
complication	POS	O
occurred	POS	O
in	POS	O
three	POS	O
patients	POS	O
hospitalized	POS	O
before	POS	O
treatment	POS	O
began	POS	O
,	POS	O
with	POS	O
whom	POS	O
particularly	POS	O
strict	POS	O
therapeutic	POS	O
precautions	POS	O
were	POS	O
taken	POS	O
,	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
,	POS	O
initial	POS	O
dose	POS	O
less	POS	O
than	POS	O
10	POS	O
mg	POS	O
of	POS	O
DEC	POS	O
,	POS	O
very	POS	O
gradual	POS	O
dose	POS	O
increases	POS	O
,	POS	O
and	POS	O
associated	POS	O
anti	POS	O
-	POS	O
allergic	POS	O
treatment	POS	O
.	POS	O
This	POS	O
type	POS	O
of	POS	O
drug	POS	O
-	POS	O
induced	POS	O
complication	POS	O
may	POS	O
not	POS	O
be	POS	O
that	POS	O
uncommon	POS	O
in	POS	O
highly	POS	O
endemic	POS	O
regions	POS	O
.	POS	O
It	POS	O
occurs	POS	O
primarily	POS	O
,	POS	O
but	POS	O
not	POS	O
exclusively	POS	O
,	POS	O
in	POS	O
subjects	POS	O
presenting	POS	O
with	POS	O
a	POS	O
high	POS	O
microfilarial	POS	O
load	POS	O
.	POS	O
The	POS	O
relationship	POS	O
between	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
encephalitis	POS	B-NP
and	POS	O
the	POS	O
decrease	POS	O
in	POS	O
microfilaremia	POS	B-NP
is	POS	O
evident	POS	O
.	POS	O
The	POS	O
pathophysiological	POS	O
mechanisms	POS	O
are	POS	O
discussed	POS	O
in	POS	O
the	POS	O
light	POS	O
of	POS	O
these	POS	O
observations	POS	O
and	POS	O
the	POS	O
few	POS	O
other	POS	O
comments	POS	O
on	POS	O
this	POS	O
subject	POS	O
published	POS	O
in	POS	O
the	POS	O
literature	POS	O
.	POS	O
Amiodarone	POS	O
-	POS	O
related	POS	O
pulmonary	POS	O
mass	POS	O
and	POS	O
unique	POS	O
membranous	POS	B-NP
glomerulonephritis	POS	I-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
valvular	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
:	POS	O
Diagnostic	POS	O
pitfall	POS	O
and	POS	O
new	POS	O
findings	POS	O
.	POS	O
Amiodarone	POS	O
is	POS	O
an	POS	O
anti	POS	O
-	POS	O
arrhythmic	POS	O
drug	POS	O
for	POS	O
life	POS	O
-	POS	O
threatening	POS	O
tachycardia	POS	B-NP
,	POS	O
but	POS	O
various	POS	O
adverse	POS	O
effects	POS	O
have	POS	O
been	POS	O
reported	POS	O
.	POS	O
Reported	POS	O
herein	POS	O
is	POS	O
an	POS	O
autopsy	POS	O
case	POS	O
of	POS	O
valvular	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
,	POS	O
in	POS	O
a	POS	O
patient	POS	O
who	POS	O
developed	POS	O
a	POS	O
lung	POS	O
mass	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
cm	POS	O
in	POS	O
diameter	POS	O
)	POS	O
and	POS	O
proteinuria	POS	B-NP
(	POS	O
2	POS	O
.	POS	O
76	POS	O
g	POS	O
/	POS	O
day	POS	O
)	POS	O
after	POS	O
treatment	POS	O
with	POS	O
amiodarone	POS	O
for	POS	O
a	POS	O
long	POS	O
time	POS	O
.	POS	O
The	POS	O
lung	POS	O
mass	POS	O
was	POS	O
highly	POS	O
suspected	POS	O
to	POS	O
be	POS	O
lung	POS	B-NP
cancer	POS	I-NP
on	POS	O
CT	POS	O
and	POS	O
positron	POS	O
emission	POS	O
tomography	POS	O
,	POS	O
but	POS	O
histologically	POS	O
the	POS	O
lesion	POS	O
was	POS	O
composed	POS	O
of	POS	O
lymphoplasmacytic	POS	O
infiltrates	POS	O
in	POS	O
alveolar	POS	O
walls	POS	O
and	POS	O
intra	POS	O
-	POS	O
alveolar	POS	O
accumulation	POS	O
of	POS	O
foamy	POS	O
macrophages	POS	O
containing	POS	O
characteristic	POS	O
myelinoid	POS	O
bodies	POS	O
,	POS	O
indicating	POS	O
that	POS	O
it	POS	O
was	POS	O
an	POS	O
amiodarone	POS	O
-	POS	O
related	POS	O
lesion	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
the	POS	O
lung	POS	O
tissue	POS	O
had	POS	O
unevenly	POS	O
distributed	POS	O
hemosiderin	POS	O
deposition	POS	O
,	POS	O
and	POS	O
abnormally	POS	O
tortuous	POS	O
capillaries	POS	O
were	POS	O
seen	POS	O
in	POS	O
the	POS	O
mass	POS	O
and	POS	O
in	POS	O
heavily	POS	O
hemosiderotic	POS	O
lung	POS	O
portions	POS	O
outside	POS	O
the	POS	O
mass	POS	O
.	POS	O
In	POS	O
the	POS	O
kidneys	POS	O
,	POS	O
glomeruli	POS	O
had	POS	O
membrane	POS	O
spikes	POS	O
,	POS	O
prominent	POS	O
swelling	POS	O
of	POS	O
podocytes	POS	O
and	POS	O
subepithelial	POS	O
deposits	POS	O
,	POS	O
which	POS	O
were	POS	O
sometimes	POS	O
large	POS	O
and	POS	O
hump	POS	O
-	POS	O
like	POS	O
.	POS	O
Autoimmune	POS	B-NP
diseases	POS	I-NP
,	POS	O
viral	POS	B-NP
hepatitis	POS	I-NP
,	POS	O
malignant	POS	B-NP
neoplasms	POS	I-NP
or	POS	O
other	POS	O
diseases	POS	O
with	POS	O
a	POS	O
known	POS	O
relationship	POS	O
to	POS	O
membranous	POS	O
glomerulonephritis	POS	B-NP
were	POS	O
not	POS	O
found	POS	O
.	POS	O
The	POS	O
present	POS	O
case	POS	O
highlights	POS	O
the	POS	O
possibility	POS	O
that	POS	O
differential	POS	O
diagnosis	POS	O
between	POS	O
an	POS	O
amiodarone	POS	O
-	POS	O
related	POS	O
pulmonary	POS	B-NP
lesion	POS	I-NP
and	POS	O
a	POS	O
neoplasm	POS	B-NP
can	POS	O
be	POS	O
very	POS	O
difficult	POS	O
radiologically	POS	O
,	POS	O
and	POS	O
suggests	POS	O
that	POS	O
membranous	POS	O
glomerulonephritis	POS	B-NP
might	POS	O
be	POS	O
another	POS	O
possible	POS	O
complication	POS	O
of	POS	O
amiodarone	POS	O
treatment	POS	O
.	POS	O
Risk	POS	O
of	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
associated	POS	O
with	POS	O
initial	POS	O
sulphonylurea	POS	O
treatment	POS	O
of	POS	O
patients	POS	O
with	POS	O
type	POS	B-NP
2	POS	I-NP
diabetes	POS	I-NP
:	POS	O
a	POS	O
matched	POS	O
case	POS	O
-	POS	O
control	POS	O
study	POS	O
.	POS	O
AIMS	POS	O
:	POS	O
This	POS	O
study	POS	O
sought	POS	O
to	POS	O
assess	POS	O
the	POS	O
risk	POS	O
of	POS	O
developing	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
(	POS	O
CAD	POS	B-NP
)	POS	O
associated	POS	O
with	POS	O
initial	POS	O
treatment	POS	O
of	POS	O
type	POS	B-NP
2	POS	I-NP
diabetes	POS	I-NP
with	POS	O
different	POS	O
sulphonylureas	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
In	POS	O
type	POS	B-NP
2	POS	I-NP
diabetic	POS	I-NP
patients	POS	O
,	POS	O
cases	POS	O
who	POS	O
developed	POS	O
CAD	POS	B-NP
were	POS	O
compared	POS	O
retrospectively	POS	O
with	POS	O
controls	POS	O
that	POS	O
did	POS	O
not	POS	O
.	POS	O
The	POS	O
20	POS	O
-	POS	O
year	POS	O
risk	POS	O
of	POS	O
CAD	POS	B-NP
at	POS	O
diagnosis	POS	O
of	POS	O
diabetes	POS	B-NP
,	POS	O
using	POS	O
the	POS	O
UKPDS	POS	B-NP
risk	POS	O
engine	POS	O
,	POS	O
was	POS	O
used	POS	O
to	POS	O
match	POS	O
cases	POS	O
with	POS	O
controls	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
76	POS	O
cases	POS	O
of	POS	O
CAD	POS	B-NP
were	POS	O
compared	POS	O
with	POS	O
152	POS	O
controls	POS	O
.	POS	O
The	POS	O
hazard	POS	O
of	POS	O
developing	POS	O
CAD	POS	B-NP
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
)	POS	O
associated	POS	O
with	POS	O
initial	POS	O
treatment	POS	O
increased	POS	O
by	POS	O
2	POS	O
.	POS	O
4	POS	O
-	POS	O
fold	POS	O
(	POS	O
1	POS	O
.	POS	O
3	POS	O
-	POS	O
4	POS	O
.	POS	O
3	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
004	POS	O
)	POS	O
with	POS	O
glibenclamide	POS	O
;	POS	O
2	POS	O
-	POS	O
fold	POS	O
(	POS	O
0	POS	O
.	POS	O
9	POS	O
-	POS	O
4	POS	O
.	POS	O
6	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
099	POS	O
)	POS	O
with	POS	O
glipizide	POS	O
;	POS	O
2	POS	O
.	POS	O
9	POS	O
-	POS	O
fold	POS	O
(	POS	O
1	POS	O
.	POS	O
6	POS	O
-	POS	O
5	POS	O
.	POS	O
1	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
000	POS	O
)	POS	O
with	POS	O
either	POS	O
,	POS	O
and	POS	O
was	POS	O
unchanged	POS	O
with	POS	O
metformin	POS	O
.	POS	O
The	POS	O
hazard	POS	O
decreased	POS	O
0	POS	O
.	POS	O
3	POS	O
-	POS	O
fold	POS	O
(	POS	O
0	POS	O
.	POS	O
7	POS	O
-	POS	O
1	POS	O
.	POS	O
7	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
385	POS	O
)	POS	O
with	POS	O
glimepiride	POS	O
,	POS	O
0	POS	O
.	POS	O
4	POS	O
-	POS	O
fold	POS	O
(	POS	O
0	POS	O
.	POS	O
7	POS	O
-	POS	O
1	POS	O
.	POS	O
3	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
192	POS	O
)	POS	O
with	POS	O
gliclazide	POS	O
,	POS	O
and	POS	O
0	POS	O
.	POS	O
4	POS	O
-	POS	O
fold	POS	O
(	POS	O
0	POS	O
.	POS	O
7	POS	O
-	POS	O
1	POS	O
.	POS	O
1	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
09	POS	O
)	POS	O
with	POS	O
either	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Initiating	POS	O
treatment	POS	O
of	POS	O
type	POS	B-NP
2	POS	I-NP
diabetes	POS	I-NP
with	POS	O
glibenclamide	POS	O
or	POS	O
glipizide	POS	O
is	POS	O
associated	POS	O
with	POS	O
increased	POS	O
risk	POS	O
of	POS	O
CAD	POS	B-NP
in	POS	O
comparison	POS	O
to	POS	O
gliclazide	POS	O
or	POS	O
glimepiride	POS	O
.	POS	O
If	POS	O
confirmed	POS	O
,	POS	O
this	POS	O
may	POS	O
be	POS	O
important	POS	O
because	POS	O
most	POS	O
Indian	POS	O
patients	POS	O
receive	POS	O
the	POS	O
cheaper	POS	O
older	POS	O
sulphonylureas	POS	O
,	POS	O
and	POS	O
present	POS	O
guidelines	POS	O
do	POS	O
not	POS	O
distinguish	POS	O
between	POS	O
individual	POS	O
agents	POS	O
.	POS	O
Reduced	POS	O
progression	POS	O
of	POS	O
adriamycin	POS	O
nephropathy	POS	B-NP
in	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
rats	POS	O
treated	POS	O
by	POS	O
losartan	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
the	POS	O
antihypertensive	POS	O
effects	POS	O
of	POS	O
angiotensin	POS	O
II	POS	O
type	POS	O
-	POS	O
1	POS	O
receptor	POS	O
blocker	POS	O
,	POS	O
losartan	POS	O
,	POS	O
and	POS	O
its	POS	O
potential	POS	O
in	POS	O
slowing	POS	O
down	POS	O
renal	POS	O
disease	POS	O
progression	POS	O
in	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
rats	POS	O
(	POS	O
SHR	POS	O
)	POS	O
with	POS	O
adriamycin	POS	O
(	POS	O
ADR	POS	O
)	POS	O
nephropathy	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Six	POS	O
-	POS	O
month	POS	O
-	POS	O
old	POS	O
female	POS	O
SHR	POS	O
were	POS	O
randomly	POS	O
selected	POS	O
in	POS	O
six	POS	O
groups	POS	O
.	POS	O
Two	POS	O
control	POS	O
groups	POS	O
(	POS	O
SH	POS	O
(	POS	O
6	POS	O
)	POS	O
,	POS	O
SH	POS	O
(	POS	O
12	POS	O
)	POS	O
)	POS	O
received	POS	O
vehicle	POS	O
.	POS	O
Groups	POS	O
ADR	POS	O
(	POS	O
6	POS	O
)	POS	O
,	POS	O
ADR	POS	O
+	POS	O
LOS	POS	O
(	POS	O
6	POS	O
)	POS	O
and	POS	O
ADR	POS	O
(	POS	O
12	POS	O
)	POS	O
,	POS	O
and	POS	O
ADR	POS	O
+	POS	O
LOS	POS	O
(	POS	O
12	POS	O
)	POS	O
received	POS	O
ADR	POS	O
(	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
b	POS	O
.	POS	O
w	POS	O
.	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
twice	POS	O
in	POS	O
a	POS	O
3	POS	O
-	POS	O
week	POS	O
interval	POS	O
.	POS	O
Group	POS	O
ADR	POS	O
+	POS	O
LOS	POS	O
(	POS	O
6	POS	O
)	POS	O
received	POS	O
losartan	POS	O
(	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
b	POS	O
.	POS	O
w	POS	O
.	POS	O
/	POS	O
day	POS	O
by	POS	O
gavages	POS	O
)	POS	O
for	POS	O
6	POS	O
weeks	POS	O
and	POS	O
group	POS	O
ADR	POS	O
+	POS	O
LOS	POS	O
(	POS	O
12	POS	O
)	POS	O
for	POS	O
12	POS	O
weeks	POS	O
after	POS	O
second	POS	O
injection	POS	O
of	POS	O
ADR	POS	O
.	POS	O
Animals	POS	O
were	POS	O
killed	POS	O
after	POS	O
6	POS	O
or	POS	O
12	POS	O
weeks	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Haemodynamic	POS	O
measurements	POS	O
were	POS	O
performed	POS	O
on	POS	O
anaesthetized	POS	O
animals	POS	O
,	POS	O
blood	POS	O
and	POS	O
urine	POS	O
samples	POS	O
were	POS	O
taken	POS	O
for	POS	O
biochemical	POS	O
analysis	POS	O
and	POS	O
the	POS	O
left	POS	O
kidney	POS	O
was	POS	O
processed	POS	O
for	POS	O
morphological	POS	O
studies	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Short	POS	O
-	POS	O
term	POS	O
losartan	POS	O
treatment	POS	O
,	POS	O
besides	POS	O
antihypertensive	POS	O
effect	POS	O
,	POS	O
improved	POS	O
glomerular	POS	O
filtration	POS	O
rate	POS	O
and	POS	O
ameliorated	POS	O
glomerulosclerosis	POS	B-NP
resulting	POS	O
in	POS	O
decreased	POS	O
proteinuria	POS	B-NP
.	POS	O
Prolonged	POS	O
treatment	POS	O
with	POS	O
losartan	POS	O
showed	POS	O
further	POS	O
reduction	POS	O
of	POS	O
glomerulosclerosis	POS	B-NP
associated	POS	O
with	POS	O
reduced	POS	O
progression	POS	O
of	POS	O
tubular	POS	B-NP
atrophy	POS	I-NP
and	POS	O
interstitial	POS	B-NP
fibrosis	POS	I-NP
,	POS	O
thus	POS	O
preventing	POS	O
heavy	POS	O
proteinuria	POS	B-NP
and	POS	O
chronic	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
.	POS	O
Losartan	POS	O
reduced	POS	O
uraemia	POS	B-NP
and	POS	O
increased	POS	O
urea	POS	O
clearance	POS	O
in	POS	O
advanced	POS	O
ADR	POS	O
nephropathy	POS	B-NP
in	POS	O
SHR	POS	O
.	POS	O
Histological	POS	O
examination	POS	O
showed	POS	O
that	POS	O
losartan	POS	O
could	POS	O
prevent	POS	O
tubular	POS	B-NP
atrophy	POS	I-NP
,	POS	O
interstitial	POS	B-NP
infiltration	POS	I-NP
and	POS	O
fibrosis	POS	B-NP
in	POS	O
ADR	POS	B-NP
nephropathy	POS	I-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
Losartan	POS	O
reduces	POS	O
the	POS	O
rate	POS	O
of	POS	O
progression	POS	O
of	POS	O
ADR	POS	O
-	POS	O
induced	POS	O
focal	POS	O
segmental	POS	O
glomerulosclerosis	POS	B-NP
to	POS	O
end	POS	O
-	POS	O
stage	POS	O
renal	POS	B-NP
disease	POS	I-NP
in	POS	O
SHR	POS	O
.	POS	O
The	POS	O
risks	POS	O
of	POS	O
aprotinin	POS	O
and	POS	O
tranexamic	POS	O
acid	POS	O
in	POS	O
cardiac	POS	O
surgery	POS	O
:	POS	O
a	POS	O
one	POS	O
-	POS	O
year	POS	O
follow	POS	O
-	POS	O
up	POS	O
of	POS	O
1188	POS	O
consecutive	POS	O
patients	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Our	POS	O
aim	POS	O
was	POS	O
to	POS	O
investigate	POS	O
postoperative	POS	B-NP
complications	POS	I-NP
and	POS	O
mortality	POS	O
after	POS	O
administration	POS	O
of	POS	O
aprotinin	POS	O
compared	POS	O
to	POS	O
tranexamic	POS	O
acid	POS	O
in	POS	O
an	POS	O
unselected	POS	O
,	POS	O
consecutive	POS	O
cohort	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Perioperative	POS	O
data	POS	O
from	POS	O
consecutive	POS	O
cardiac	POS	O
surgery	POS	O
patients	POS	O
were	POS	O
prospectively	POS	O
collected	POS	O
between	POS	O
September	POS	O
2005	POS	O
and	POS	O
June	POS	O
2006	POS	O
in	POS	O
a	POS	O
university	POS	O
-	POS	O
affiliated	POS	O
clinic	POS	O
(	POS	O
n	POS	O
=	POS	O
1188	POS	O
)	POS	O
.	POS	O
During	POS	O
the	POS	O
first	POS	O
5	POS	O
mo	POS	O
,	POS	O
596	POS	O
patients	POS	O
received	POS	O
aprotinin	POS	O
(	POS	O
Group	POS	O
A	POS	O
)	POS	O
;	POS	O
in	POS	O
the	POS	O
next	POS	O
5	POS	O
mo	POS	O
,	POS	O
592	POS	O
patients	POS	O
were	POS	O
treated	POS	O
with	POS	O
tranexamic	POS	O
acid	POS	O
(	POS	O
Group	POS	O
T	POS	O
)	POS	O
.	POS	O
Except	POS	O
for	POS	O
antifibrinolytic	POS	O
therapy	POS	O
,	POS	O
the	POS	O
anesthetic	POS	O
and	POS	O
surgical	POS	O
protocols	POS	O
remained	POS	O
unchanged	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
pre	POS	O
-	POS	O
and	POS	O
intraoperative	POS	O
variables	POS	O
were	POS	O
comparable	POS	O
between	POS	O
the	POS	O
treatment	POS	O
groups	POS	O
.	POS	O
Postoperatively	POS	O
,	POS	O
a	POS	O
significantly	POS	O
higher	POS	O
incidence	POS	O
of	POS	O
seizures	POS	B-NP
was	POS	O
found	POS	O
in	POS	O
Group	POS	O
T	POS	O
(	POS	O
4	POS	O
.	POS	O
6	POS	O
%	POS	O
vs	POS	O
1	POS	O
.	POS	O
2	POS	O
%	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
This	POS	O
difference	POS	O
was	POS	O
also	POS	O
significant	POS	O
in	POS	O
the	POS	O
primary	POS	O
valve	POS	O
surgery	POS	O
and	POS	O
the	POS	O
high	POS	O
risk	POS	O
surgery	POS	O
subgroups	POS	O
(	POS	O
7	POS	O
.	POS	O
9	POS	O
%	POS	O
vs	POS	O
1	POS	O
.	POS	O
2	POS	O
%	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
003	POS	O
;	POS	O
7	POS	O
.	POS	O
3	POS	O
%	POS	O
vs	POS	O
2	POS	O
.	POS	O
4	POS	O
%	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
035	POS	O
,	POS	O
respectively	POS	O
)	POS	O
.	POS	O
Persistent	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
(	POS	O
7	POS	O
.	POS	O
9	POS	O
%	POS	O
vs	POS	O
2	POS	O
.	POS	O
3	POS	O
%	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
020	POS	O
)	POS	O
and	POS	O
renal	POS	B-NP
failure	POS	I-NP
(	POS	O
9	POS	O
.	POS	O
7	POS	O
%	POS	O
vs	POS	O
1	POS	O
.	POS	O
7	POS	O
%	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
002	POS	O
)	POS	O
were	POS	O
also	POS	O
more	POS	O
common	POS	O
in	POS	O
Group	POS	O
T	POS	O
,	POS	O
in	POS	O
the	POS	O
primary	POS	O
valve	POS	O
surgery	POS	O
subgroup	POS	O
.	POS	O
On	POS	O
the	POS	O
contrary	POS	O
,	POS	O
among	POS	O
primary	POS	O
coronary	POS	O
artery	POS	O
bypass	POS	O
surgery	POS	O
patients	POS	O
,	POS	O
there	POS	O
were	POS	O
more	POS	O
acute	POS	O
myocardial	POS	B-NP
infarctions	POS	I-NP
and	POS	O
renal	POS	B-NP
dysfunction	POS	I-NP
in	POS	O
Group	POS	O
A	POS	O
(	POS	O
5	POS	O
.	POS	O
8	POS	O
%	POS	O
vs	POS	O
2	POS	O
.	POS	O
0	POS	O
%	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
027	POS	O
;	POS	O
22	POS	O
.	POS	O
5	POS	O
%	POS	O
vs	POS	O
15	POS	O
.	POS	O
2	POS	O
%	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
036	POS	O
,	POS	O
respectively	POS	O
)	POS	O
.	POS	O
The	POS	O
1	POS	O
-	POS	O
yr	POS	O
mortality	POS	O
was	POS	O
significantly	POS	O
higher	POS	O
after	POS	O
aprotinin	POS	O
treatment	POS	O
in	POS	O
the	POS	O
high	POS	O
risk	POS	O
surgery	POS	O
group	POS	O
(	POS	O
17	POS	O
.	POS	O
7	POS	O
%	POS	O
vs	POS	O
9	POS	O
.	POS	O
8	POS	O
%	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
034	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Both	POS	O
antifibrinolytic	POS	O
drugs	POS	O
bear	POS	O
the	POS	O
risk	POS	O
of	POS	O
adverse	POS	O
outcome	POS	O
depending	POS	O
on	POS	O
the	POS	O
type	POS	O
of	POS	O
cardiac	POS	O
surgery	POS	O
.	POS	O
Administration	POS	O
of	POS	O
aprotinin	POS	O
should	POS	O
be	POS	O
avoided	POS	O
in	POS	O
coronary	POS	O
artery	POS	O
bypass	POS	O
graft	POS	O
and	POS	O
high	POS	O
risk	POS	O
patients	POS	O
,	POS	O
whereas	POS	O
administration	POS	O
of	POS	O
tranexamic	POS	O
acid	POS	O
is	POS	O
not	POS	O
recommended	POS	O
in	POS	O
valve	POS	O
surgery	POS	O
.	POS	O
Delirium	POS	B-NP
in	POS	O
an	POS	O
elderly	POS	O
woman	POS	O
possibly	POS	O
associated	POS	O
with	POS	O
administration	POS	O
of	POS	O
misoprostol	POS	O
.	POS	O
Misoprostol	POS	O
has	POS	O
been	POS	O
associated	POS	O
with	POS	O
adverse	POS	O
reactions	POS	O
,	POS	O
including	POS	O
gastrointestinal	POS	B-NP
symptoms	POS	I-NP
,	POS	O
gynecologic	POS	B-NP
problems	POS	I-NP
,	POS	O
and	POS	O
headache	POS	B-NP
.	POS	O
Changes	POS	B-NP
in	POS	I-NP
mental	POS	I-NP
status	POS	I-NP
,	POS	O
however	POS	O
,	POS	O
have	POS	O
not	POS	O
been	POS	O
reported	POS	O
.	POS	O
We	POS	O
present	POS	O
a	POS	O
case	POS	O
in	POS	O
which	POS	O
an	POS	O
89	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
in	POS	O
a	POS	O
long	POS	O
-	POS	O
term	POS	O
care	POS	O
facility	POS	O
became	POS	O
confused	POS	O
after	POS	O
the	POS	O
initiation	POS	O
of	POS	O
misoprostol	POS	O
therapy	POS	O
.	POS	O
The	POS	O
patient	POS	O
'	POS	O
s	POS	O
change	POS	O
in	POS	O
mental	POS	O
status	POS	O
was	POS	O
first	POS	O
reported	POS	O
nine	POS	O
days	POS	O
after	POS	O
the	POS	O
initiation	POS	O
of	POS	O
therapy	POS	O
.	POS	O
Her	POS	O
delirium	POS	B-NP
significantly	POS	O
improved	POS	O
after	POS	O
misoprostol	POS	O
was	POS	O
discontinued	POS	O
and	POS	O
her	POS	O
mental	POS	O
status	POS	O
returned	POS	O
to	POS	O
normal	POS	O
within	POS	O
a	POS	O
week	POS	O
.	POS	O
Because	POS	O
no	POS	O
other	POS	O
factors	POS	O
related	POS	O
to	POS	O
this	POS	O
patient	POS	O
changed	POS	O
significantly	POS	O
,	POS	O
the	POS	O
delirium	POS	B-NP
experienced	POS	O
by	POS	O
this	POS	O
patient	POS	O
possibly	POS	O
resulted	POS	O
from	POS	O
misoprostol	POS	O
therapy	POS	O
.	POS	O
The	POS	O
biological	POS	O
properties	POS	O
of	POS	O
the	POS	O
optical	POS	O
isomers	POS	O
of	POS	O
propranolol	POS	O
and	POS	O
their	POS	O
effects	POS	O
on	POS	O
cardiac	POS	B-NP
arrhythmias	POS	I-NP
.	POS	O
1	POS	O
.	POS	O
The	POS	O
optical	POS	O
isomers	POS	O
of	POS	O
propranolol	POS	O
have	POS	O
been	POS	O
compared	POS	O
for	POS	O
their	POS	O
beta	POS	O
-	POS	O
blocking	POS	O
and	POS	O
antiarrhythmic	POS	O
activities	POS	O
.	POS	O
2	POS	O
.	POS	O
In	POS	O
blocking	POS	O
the	POS	O
positive	POS	O
inotropic	POS	O
and	POS	O
chronotropic	POS	O
responses	POS	O
to	POS	O
isoprenaline	POS	O
,	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
had	POS	O
less	POS	O
than	POS	O
one	POS	O
hundredth	POS	O
the	POS	O
potency	POS	O
of	POS	O
(	POS	O
-	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
.	POS	O
At	POS	O
dose	POS	O
levels	POS	O
of	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
which	POS	O
attenuated	POS	O
the	POS	O
responses	POS	O
to	POS	O
isoprenaline	POS	O
,	POS	O
there	POS	O
was	POS	O
a	POS	O
significant	POS	O
prolongation	POS	O
of	POS	O
the	POS	O
PR	POS	O
interval	POS	O
of	POS	O
the	POS	O
electrocardiogram	POS	O
.	POS	O
3	POS	O
.	POS	O
The	POS	O
metabolic	POS	O
responses	POS	O
to	POS	O
isoprenaline	POS	O
in	POS	O
dogs	POS	O
(	POS	O
an	POS	O
increase	POS	O
in	POS	O
circulating	POS	O
glucose	POS	O
,	POS	O
lactate	POS	O
and	POS	O
free	POS	O
fatty	POS	O
acids	POS	O
)	POS	O
were	POS	O
all	POS	O
blocked	POS	O
by	POS	O
(	POS	O
-	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
.	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
Propranolol	POS	O
had	POS	O
no	POS	O
effect	POS	O
on	POS	O
fatty	POS	O
acid	POS	O
mobilization	POS	O
but	POS	O
significantly	POS	O
reduced	POS	O
the	POS	O
increments	POS	O
in	POS	O
both	POS	O
lactate	POS	O
and	POS	O
glucose	POS	O
.	POS	O
4	POS	O
.	POS	O
Both	POS	O
isomers	POS	O
of	POS	O
propranolol	POS	O
possessed	POS	O
similar	POS	O
depressant	POS	O
potency	POS	O
on	POS	O
isolated	POS	O
atrial	POS	O
muscle	POS	O
taken	POS	O
from	POS	O
guinea	POS	O
-	POS	O
pigs	POS	O
.	POS	O
5	POS	O
.	POS	O
The	POS	O
isomers	POS	O
of	POS	O
propranolol	POS	O
exhibited	POS	O
similar	POS	O
local	POS	O
anaesthetic	POS	O
potencies	POS	O
on	POS	O
an	POS	O
isolated	POS	O
frog	POS	O
nerve	POS	O
preparation	POS	O
at	POS	O
a	POS	O
level	POS	O
approximately	POS	O
three	POS	O
times	POS	O
that	POS	O
of	POS	O
procaine	POS	O
.	POS	O
The	POS	O
racemic	POS	O
compound	POS	O
was	POS	O
significantly	POS	O
less	POS	O
potent	POS	O
than	POS	O
either	POS	O
isomer	POS	O
.	POS	O
6	POS	O
.	POS	O
Both	POS	O
isomers	POS	O
of	POS	O
propranolol	POS	O
were	POS	O
capable	POS	O
of	POS	O
preventing	POS	O
adrenaline	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
arrhythmias	POS	I-NP
in	POS	O
cats	POS	O
anaesthetized	POS	O
with	POS	O
halothane	POS	O
,	POS	O
but	POS	O
the	POS	O
mean	POS	O
dose	POS	O
of	POS	O
(	POS	O
-	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
was	POS	O
0	POS	O
.	POS	O
09	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
02	POS	O
mg	POS	O
/	POS	O
kg	POS	O
whereas	POS	O
that	POS	O
of	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
was	POS	O
4	POS	O
.	POS	O
2	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
At	POS	O
the	POS	O
effective	POS	O
dose	POS	O
level	POS	O
of	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
there	POS	O
was	POS	O
a	POS	O
significant	POS	O
prolongation	POS	O
of	POS	O
the	POS	O
PR	POS	O
interval	POS	O
of	POS	O
the	POS	O
electrocardiogram	POS	O
.	POS	O
Blockade	POS	O
of	POS	O
arrhythmias	POS	B-NP
with	POS	O
both	POS	O
isomers	POS	O
was	POS	O
surmountable	POS	O
by	POS	O
increasing	POS	O
the	POS	O
dose	POS	O
of	POS	O
adrenaline	POS	O
.	POS	O
7	POS	O
.	POS	O
Both	POS	O
isomers	POS	O
of	POS	O
propranolol	POS	O
were	POS	O
also	POS	O
capable	POS	O
of	POS	O
reversing	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
caused	POS	O
by	POS	O
ouabain	POS	O
in	POS	O
anaesthetized	POS	O
cats	POS	O
and	POS	O
dogs	POS	O
.	POS	O
The	POS	O
dose	POS	O
of	POS	O
(	POS	O
-	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
was	POS	O
significantly	POS	O
smaller	POS	O
than	POS	O
that	POS	O
of	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
propranolol	POS	O
in	POS	O
both	POS	O
species	POS	O
but	POS	O
much	POS	O
higher	POS	O
than	POS	O
that	POS	O
required	POS	O
to	POS	O
produce	POS	O
evidence	POS	O
of	POS	O
beta	POS	O
-	POS	O
blockade	POS	O
.	POS	O
8	POS	O
.	POS	O
The	POS	O
implications	POS	O
of	POS	O
these	POS	O
results	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Topotecan	POS	O
in	POS	O
combination	POS	O
with	POS	O
radiotherapy	POS	O
in	POS	O
unresectable	POS	O
glioblastoma	POS	B-NP
:	POS	O
a	POS	O
phase	POS	O
2	POS	O
study	POS	O
.	POS	O
Improving	POS	O
glioblastoma	POS	B-NP
multiforme	POS	I-NP
(	POS	O
GBM	POS	B-NP
)	POS	O
treatment	POS	O
with	POS	O
radio	POS	O
-	POS	O
chemotherapy	POS	O
remains	POS	O
a	POS	O
challenge	POS	O
.	POS	O
Topotecan	POS	O
is	POS	O
an	POS	O
attractive	POS	O
option	POS	O
as	POS	O
it	POS	O
exhibits	POS	O
growth	POS	O
inhibition	POS	O
of	POS	O
human	POS	O
glioma	POS	B-NP
as	POS	O
well	POS	O
as	POS	O
brain	POS	O
penetration	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
assessed	POS	O
the	POS	O
combination	POS	O
of	POS	O
radiotherapy	POS	O
(	POS	O
60	POS	O
Gy	POS	O
/	POS	O
30	POS	O
fractions	POS	O
/	POS	O
40	POS	O
days	POS	O
)	POS	O
and	POS	O
topotecan	POS	O
(	POS	O
0	POS	O
.	POS	O
9	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
/	POS	O
day	POS	O
on	POS	O
days	POS	O
1	POS	O
-	POS	O
5	POS	O
on	POS	O
weeks	POS	O
1	POS	O
,	POS	O
3	POS	O
and	POS	O
5	POS	O
)	POS	O
in	POS	O
50	POS	O
adults	POS	O
with	POS	O
histologically	POS	O
proven	POS	O
and	POS	O
untreated	POS	O
GBM	POS	B-NP
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
non	POS	B-NP
-	POS	I-NP
hematological	POS	I-NP
toxicities	POS	I-NP
was	POS	O
low	POS	O
and	POS	O
grade	POS	O
3	POS	O
-	POS	O
4	POS	O
hematological	POS	B-NP
toxicities	POS	I-NP
were	POS	O
reported	POS	O
in	POS	O
20	POS	O
patients	POS	O
(	POS	O
mainly	POS	O
lymphopenia	POS	B-NP
and	POS	O
neutropenia	POS	B-NP
)	POS	O
.	POS	O
Partial	POS	O
response	POS	O
and	POS	O
stabilization	POS	O
rates	POS	O
were	POS	O
2	POS	O
%	POS	O
and	POS	O
32	POS	O
%	POS	O
,	POS	O
respectively	POS	O
,	POS	O
with	POS	O
an	POS	O
overall	POS	O
time	POS	O
to	POS	O
progression	POS	O
of	POS	O
12	POS	O
weeks	POS	O
.	POS	O
One	POS	O
-	POS	O
year	POS	O
overall	POS	O
survival	POS	O
(	POS	O
OS	POS	O
)	POS	O
rate	POS	O
was	POS	O
42	POS	O
%	POS	O
,	POS	O
with	POS	O
a	POS	O
median	POS	O
OS	POS	O
of	POS	O
40	POS	O
weeks	POS	O
.	POS	O
Topotecan	POS	O
in	POS	O
combination	POS	O
with	POS	O
radiotherapy	POS	O
was	POS	O
well	POS	O
tolerated	POS	O
.	POS	O
However	POS	O
,	POS	O
while	POS	O
response	POS	O
and	POS	O
stabilization	POS	O
concerned	POS	O
one	POS	O
-	POS	O
third	POS	O
of	POS	O
the	POS	O
patients	POS	O
,	POS	O
the	POS	O
study	POS	O
did	POS	O
not	POS	O
show	POS	O
increased	POS	O
benefits	POS	O
in	POS	O
terms	POS	O
of	POS	O
survival	POS	O
in	POS	O
patients	POS	O
with	POS	O
unresectable	POS	O
GBM	POS	B-NP
.	POS	O
Long	POS	O
-	POS	O
term	POS	O
lithium	POS	O
therapy	POS	O
leading	POS	O
to	POS	O
hyperparathyroidism	POS	B-NP
:	POS	O
a	POS	O
case	POS	O
report	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
This	POS	O
paper	POS	O
reviews	POS	O
the	POS	O
effect	POS	O
of	POS	O
chronic	POS	O
lithium	POS	O
therapy	POS	O
on	POS	O
serum	POS	O
calcium	POS	O
level	POS	O
and	POS	O
parathyroid	POS	O
glands	POS	O
,	POS	O
its	POS	O
pathogenesis	POS	O
,	POS	O
and	POS	O
treatment	POS	O
options	POS	O
.	POS	O
We	POS	O
examined	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
lithium	POS	O
-	POS	O
treated	POS	O
patient	POS	O
who	POS	O
had	POS	O
recurrent	POS	O
hypercalcemia	POS	B-NP
to	POS	O
better	POS	O
understand	POS	O
the	POS	O
disease	POS	O
process	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Primary	POS	B-NP
hyperparathyroidism	POS	I-NP
is	POS	O
a	POS	O
rare	POS	O
but	POS	O
potentially	POS	O
life	POS	O
-	POS	O
threatening	POS	O
side	POS	O
effect	POS	O
of	POS	O
long	POS	O
-	POS	O
term	POS	O
lithium	POS	O
therapy	POS	O
.	POS	O
Careful	POS	O
patient	POS	O
selection	POS	O
and	POS	O
long	POS	O
-	POS	O
term	POS	O
follow	POS	O
-	POS	O
up	POS	O
can	POS	O
reduce	POS	O
morbidity	POS	O
.	POS	O
PRACTICAL	POS	O
IMPLICATIONS	POS	O
:	POS	O
As	POS	O
much	POS	O
as	POS	O
15	POS	O
%	POS	O
of	POS	O
lithium	POS	O
-	POS	O
treated	POS	O
patients	POS	O
become	POS	O
hypercalcemic	POS	B-NP
.	POS	O
By	POS	O
routinely	POS	O
monitoring	POS	O
serum	POS	O
calcium	POS	O
levels	POS	O
,	POS	O
healthcare	POS	O
providers	POS	O
can	POS	O
improve	POS	O
the	POS	O
quality	POS	O
of	POS	O
life	POS	O
of	POS	O
this	POS	O
patient	POS	O
group	POS	O
.	POS	O
Comparison	POS	O
of	POS	O
laryngeal	POS	O
mask	POS	O
with	POS	O
endotracheal	POS	O
tube	POS	O
for	POS	O
anesthesia	POS	O
in	POS	O
endoscopic	POS	O
sinus	POS	O
surgery	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
The	POS	O
purpose	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
compare	POS	O
surgical	POS	O
conditions	POS	O
,	POS	O
including	POS	O
the	POS	O
amount	POS	O
of	POS	O
intraoperative	POS	O
bleeding	POS	O
as	POS	O
well	POS	O
as	POS	O
intraoperative	POS	O
blood	POS	O
pressure	POS	O
,	POS	O
during	POS	O
functional	POS	O
endoscopic	POS	O
sinus	POS	O
surgery	POS	O
(	POS	O
FESS	POS	O
)	POS	O
using	POS	O
flexible	POS	O
reinforced	POS	O
laryngeal	POS	O
mask	POS	O
airway	POS	O
(	POS	O
FRLMA	POS	O
)	POS	O
versus	POS	O
endotracheal	POS	O
tube	POS	O
(	POS	O
ETT	POS	O
)	POS	O
in	POS	O
maintaining	POS	O
controlled	POS	O
hypotension	POS	B-NP
anesthesia	POS	O
induced	POS	O
by	POS	O
propofol	POS	O
-	POS	O
remifentanil	POS	O
total	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
anesthesia	POS	O
(	POS	O
TIVA	POS	O
)	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Sixty	POS	O
normotensive	POS	O
American	POS	O
Society	POS	O
of	POS	O
Anesthesiologists	POS	O
I	POS	O
-	POS	O
II	POS	O
adult	POS	O
patients	POS	O
undergoing	POS	O
FESS	POS	B-NP
under	POS	O
controlled	POS	O
hypotension	POS	B-NP
anesthesia	POS	O
caused	POS	O
by	POS	O
propofol	POS	O
-	POS	O
remifentanil	POS	O
-	POS	O
TIVA	POS	O
were	POS	O
randomly	POS	O
assigned	POS	O
into	POS	O
two	POS	O
groups	POS	O
:	POS	O
group	POS	O
I	POS	O
,	POS	O
FRLMA	POS	O
;	POS	O
group	POS	O
II	POS	O
,	POS	O
ETT	POS	O
.	POS	O
Hemorrhage	POS	O
was	POS	O
measured	POS	O
and	POS	O
the	POS	O
visibility	POS	O
of	POS	O
the	POS	O
operative	POS	O
field	POS	O
was	POS	O
evaluated	POS	O
according	POS	O
to	POS	O
a	POS	O
six	POS	O
-	POS	O
point	POS	O
scale	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Controlled	POS	O
hypotension	POS	B-NP
was	POS	O
achieved	POS	O
within	POS	O
a	POS	O
shorter	POS	O
period	POS	O
using	POS	O
laryngeal	POS	O
mask	POS	O
using	POS	O
lower	POS	O
rates	POS	O
of	POS	O
remifentanil	POS	O
infusion	POS	O
and	POS	O
lower	POS	O
total	POS	O
dose	POS	O
of	POS	O
remifentanil	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
In	POS	O
summary	POS	O
,	POS	O
our	POS	O
results	POS	O
indicate	POS	O
that	POS	O
airway	POS	O
management	POS	O
using	POS	O
FRLMA	POS	O
during	POS	O
controlled	POS	O
hypotension	POS	B-NP
anesthesia	POS	O
provided	POS	O
better	POS	O
surgical	POS	O
conditions	POS	O
in	POS	O
terms	POS	O
of	POS	O
quality	POS	O
of	POS	O
operative	POS	O
field	POS	O
and	POS	O
blood	POS	O
loss	POS	O
and	POS	O
allowed	POS	O
for	POS	O
convenient	POS	O
induced	POS	O
hypotension	POS	B-NP
with	POS	O
low	POS	O
doses	POS	O
of	POS	O
remifentanil	POS	O
during	POS	O
TIVA	POS	O
in	POS	O
patients	POS	O
undergoing	POS	O
FESS	POS	B-NP
.	POS	O
Nonalcoholic	POS	B-NP
fatty	POS	I-NP
liver	POS	I-NP
disease	POS	I-NP
during	POS	O
valproate	POS	O
therapy	POS	O
.	POS	O
Valproic	POS	O
acid	POS	O
(	POS	O
VPA	POS	O
)	POS	O
is	POS	O
effective	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
many	POS	O
types	POS	O
of	POS	O
epilepsy	POS	B-NP
,	POS	O
but	POS	O
its	POS	O
use	POS	O
can	POS	O
be	POS	O
associated	POS	O
with	POS	O
an	POS	O
increase	POS	O
in	POS	O
body	POS	O
weight	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
nonalcoholic	POS	B-NP
fatty	POS	I-NP
liver	POS	I-NP
disease	POS	I-NP
(	POS	O
NAFLD	POS	B-NP
)	POS	O
arising	POS	O
in	POS	O
a	POS	O
child	POS	O
who	POS	O
developed	POS	O
obesity	POS	B-NP
during	POS	O
VPA	POS	O
treatment	POS	O
.	POS	O
Laboratory	POS	O
data	POS	O
revealed	POS	O
hyperinsulinemia	POS	B-NP
with	POS	O
insulin	POS	B-NP
resistance	POS	I-NP
.	POS	O
After	POS	O
the	POS	O
withdrawal	POS	O
of	POS	O
VPA	POS	O
therapy	POS	O
,	POS	O
our	POS	O
patient	POS	O
showed	POS	O
a	POS	O
significant	POS	O
weight	POS	B-NP
loss	POS	I-NP
,	POS	O
a	POS	O
decrease	POS	O
of	POS	O
body	POS	O
mass	POS	O
index	POS	O
,	POS	O
and	POS	O
normalization	POS	O
of	POS	O
metabolic	POS	O
and	POS	O
endocrine	POS	O
parameters	POS	O
;	POS	O
moreover	POS	O
,	POS	O
ultrasound	POS	O
measurements	POS	O
showed	POS	O
a	POS	O
complete	POS	O
normalization	POS	O
.	POS	O
The	POS	O
present	POS	O
case	POS	O
suggests	POS	O
that	POS	O
obesity	POS	B-NP
,	POS	O
hyperinsulinemia	POS	B-NP
,	POS	O
insulin	POS	B-NP
resistance	POS	I-NP
,	POS	O
and	POS	O
long	POS	O
-	POS	O
term	POS	O
treatment	POS	O
with	POS	O
VPA	POS	O
may	POS	O
be	POS	O
all	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
NAFLD	POS	B-NP
;	POS	O
this	POS	O
side	POS	O
effect	POS	O
is	POS	O
reversible	POS	O
after	POS	O
VPA	POS	O
withdrawal	POS	O
.	POS	O
Carbimazole	POS	O
induced	POS	O
ANCA	POS	B-NP
positive	POS	O
vasculitis	POS	B-NP
.	POS	O
Anti	POS	O
-	POS	O
thyroid	POS	O
drugs	POS	O
,	POS	O
like	POS	O
carbimazole	POS	O
and	POS	O
propylthiouracil	POS	O
(	POS	O
PTU	POS	B-NP
)	POS	O
are	POS	O
commonly	POS	O
prescribed	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
hyperthyroidism	POS	B-NP
.	POS	O
One	POS	O
should	POS	O
be	POS	O
aware	POS	O
of	POS	O
the	POS	O
side	POS	O
effects	POS	O
of	POS	O
antithyroid	POS	O
medications	POS	O
.	POS	O
Antineutrophil	POS	O
cytoplasmic	POS	O
antibody	POS	O
(	POS	O
ANCA	POS	B-NP
)	POS	I-NP
-	POS	I-NP
-	POS	I-NP
associated	POS	I-NP
vasculitis	POS	I-NP
is	POS	O
a	POS	O
potentially	POS	O
life	POS	O
-	POS	O
threatening	POS	O
adverse	POS	O
effect	POS	O
of	POS	O
antithyroidmedications	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
patient	POS	O
with	POS	O
Graves	POS	B-NP
'	POS	I-NP
disease	POS	I-NP
who	POS	O
developed	POS	O
ANCA	POS	B-NP
positive	POS	O
carbimazole	POS	O
induced	POS	O
vasculitis	POS	B-NP
.	POS	O
The	POS	O
episode	POS	O
was	POS	O
characterized	POS	O
by	POS	O
a	POS	O
vasculitic	POS	B-NP
skin	POS	I-NP
rash	POS	I-NP
associated	POS	O
with	POS	O
large	POS	O
joint	POS	B-NP
arthritis	POS	I-NP
,	POS	O
pyrexia	POS	B-NP
and	POS	O
parotiditis	POS	B-NP
but	POS	O
no	POS	O
renal	POS	O
or	POS	O
pulmonary	POS	B-NP
involvement	POS	I-NP
.	POS	O
He	POS	O
was	POS	O
referred	POS	O
to	POS	O
us	POS	O
for	POS	O
neurological	POS	O
evaluation	POS	O
because	POS	O
he	POS	O
had	POS	O
difficulty	POS	O
in	POS	O
getting	POS	O
up	POS	O
from	POS	O
squatting	POS	O
position	POS	O
and	POS	O
was	POS	O
suspected	POS	O
to	POS	O
have	POS	O
myositis	POS	B-NP
.	POS	O
Carbimazole	POS	O
and	POS	O
methimazole	POS	O
have	POS	O
a	POS	O
lower	POS	O
incidence	POS	O
of	POS	O
reported	POS	O
ANCA	POS	B-NP
positive	POS	O
side	POS	O
effects	POS	O
than	POS	O
PUT	POS	O
.	POS	O
To	POS	O
the	POS	O
best	POS	O
of	POS	O
our	POS	O
knowledge	POS	O
this	POS	O
is	POS	O
the	POS	O
first	POS	O
ANCA	POS	B-NP
positive	POS	O
carbimazole	POS	O
induced	POS	O
vasculitis	POS	B-NP
case	POS	O
reported	POS	O
from	POS	O
India	POS	O
.	POS	O
Aspirin	POS	O
for	POS	O
the	POS	O
primary	POS	O
prevention	POS	O
of	POS	O
cardiovascular	POS	O
events	POS	O
:	POS	O
an	POS	O
update	POS	O
of	POS	O
the	POS	O
evidence	POS	O
for	POS	O
the	POS	O
U	POS	O
.	POS	O
S	POS	O
.	POS	O
Preventive	POS	O
Services	POS	O
Task	POS	O
Force	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Coronary	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
and	POS	O
cerebrovascular	POS	B-NP
disease	POS	I-NP
are	POS	O
leading	POS	O
causes	POS	O
of	POS	O
death	POS	O
in	POS	O
the	POS	O
United	POS	O
States	POS	O
.	POS	O
In	POS	O
2002	POS	O
,	POS	O
the	POS	O
U	POS	O
.	POS	O
S	POS	O
.	POS	O
Preventive	POS	O
Services	POS	O
Task	POS	O
Force	POS	O
(	POS	O
USPSTF	POS	O
)	POS	O
strongly	POS	O
recommended	POS	O
that	POS	O
clinicians	POS	O
discuss	POS	O
aspirin	POS	O
with	POS	O
adults	POS	O
who	POS	O
are	POS	O
at	POS	O
increased	POS	O
risk	POS	O
for	POS	O
coronary	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
determine	POS	O
the	POS	O
benefits	POS	O
and	POS	O
harms	POS	O
of	POS	O
taking	POS	O
aspirin	POS	O
for	POS	O
the	POS	O
primary	POS	O
prevention	POS	O
of	POS	O
myocardial	POS	B-NP
infarctions	POS	I-NP
,	POS	O
strokes	POS	B-NP
,	POS	O
and	POS	O
death	POS	O
.	POS	O
DATA	POS	O
SOURCES	POS	O
:	POS	O
MEDLINE	POS	O
and	POS	O
Cochrane	POS	O
Library	POS	O
(	POS	O
search	POS	O
dates	POS	O
,	POS	O
1	POS	O
January	POS	O
2001	POS	O
to	POS	O
28	POS	O
August	POS	O
2008	POS	O
)	POS	O
,	POS	O
recent	POS	O
systematic	POS	O
reviews	POS	O
,	POS	O
reference	POS	O
lists	POS	O
of	POS	O
retrieved	POS	O
articles	POS	O
,	POS	O
and	POS	O
suggestions	POS	O
from	POS	O
experts	POS	O
.	POS	O
STUDY	POS	O
SELECTION	POS	O
:	POS	O
English	POS	O
-	POS	O
language	POS	O
randomized	POS	O
,	POS	O
controlled	POS	O
trials	POS	O
(	POS	O
RCTs	POS	O
)	POS	O
;	POS	O
case	POS	O
-	POS	O
control	POS	O
studies	POS	O
;	POS	O
meta	POS	O
-	POS	O
analyses	POS	O
;	POS	O
and	POS	O
systematic	POS	O
reviews	POS	O
of	POS	O
aspirin	POS	O
versus	POS	O
control	POS	O
for	POS	O
the	POS	O
primary	POS	O
prevention	POS	O
of	POS	O
cardiovascular	POS	B-NP
disease	POS	I-NP
(	POS	O
CVD	POS	B-NP
)	POS	O
were	POS	O
selected	POS	O
to	POS	O
answer	POS	O
the	POS	O
following	POS	O
questions	POS	O
:	POS	O
Does	POS	O
aspirin	POS	O
decrease	POS	O
coronary	POS	B-NP
heart	POS	I-NP
events	POS	I-NP
,	POS	O
strokes	POS	B-NP
,	POS	O
death	POS	B-NP
from	POS	O
coronary	POS	B-NP
heart	POS	I-NP
events	POS	I-NP
or	POS	O
stroke	POS	B-NP
,	POS	O
or	POS	O
all	POS	O
-	POS	O
cause	POS	O
mortality	POS	O
in	POS	O
adults	POS	O
without	POS	O
known	POS	O
CVD	POS	B-NP
?	POS	O
Does	POS	O
aspirin	POS	O
increase	POS	O
gastrointestinal	POS	B-NP
bleeding	POS	I-NP
or	POS	O
hemorrhagic	POS	B-NP
strokes	POS	I-NP
?	POS	O
DATA	POS	O
EXTRACTION	POS	O
:	POS	O
All	POS	O
studies	POS	O
were	POS	O
reviewed	POS	O
,	POS	O
abstracted	POS	O
,	POS	O
and	POS	O
rated	POS	O
for	POS	O
quality	POS	O
by	POS	O
using	POS	O
predefined	POS	O
USPSTF	POS	O
criteria	POS	O
.	POS	O
DATA	POS	O
SYNTHESIS	POS	O
:	POS	O
New	POS	O
evidence	POS	O
from	POS	O
1	POS	O
good	POS	O
-	POS	O
quality	POS	O
RCT	POS	O
,	POS	O
1	POS	O
good	POS	O
-	POS	O
quality	POS	O
meta	POS	O
-	POS	O
analysis	POS	O
,	POS	O
and	POS	O
2	POS	O
fair	POS	O
-	POS	O
quality	POS	O
subanalyses	POS	O
of	POS	O
RCTs	POS	O
demonstrates	POS	O
that	POS	O
aspirin	POS	O
use	POS	O
reduces	POS	O
the	POS	O
number	POS	O
of	POS	O
CVD	POS	B-NP
events	POS	O
in	POS	O
patients	POS	O
without	POS	O
known	POS	O
CVD	POS	B-NP
.	POS	O
Men	POS	O
in	POS	O
these	POS	O
studies	POS	O
experienced	POS	O
fewer	POS	O
myocardial	POS	B-NP
infarctions	POS	I-NP
and	POS	O
women	POS	O
experienced	POS	O
fewer	POS	O
ischemic	POS	B-NP
strokes	POS	I-NP
.	POS	O
Aspirin	POS	B-NP
does	POS	O
not	POS	O
seem	POS	O
to	POS	O
affect	POS	O
CVD	POS	B-NP
mortality	POS	O
or	POS	O
all	POS	O
-	POS	O
cause	POS	O
mortality	POS	O
in	POS	O
either	POS	O
men	POS	O
or	POS	O
women	POS	O
.	POS	O
The	POS	O
use	POS	O
of	POS	O
aspirin	POS	O
for	POS	O
primary	POS	O
prevention	POS	O
increases	POS	O
the	POS	O
risk	POS	O
for	POS	O
major	POS	O
bleeding	POS	O
events	POS	O
,	POS	O
primarily	POS	O
gastrointestinal	POS	B-NP
bleeding	POS	I-NP
events	POS	O
,	POS	O
in	POS	O
both	POS	O
men	POS	O
and	POS	O
women	POS	O
.	POS	O
Men	POS	O
have	POS	O
an	POS	O
increased	POS	O
risk	POS	O
for	POS	O
hemorrhagic	POS	B-NP
strokes	POS	I-NP
with	POS	O
aspirin	POS	O
use	POS	O
.	POS	O
A	POS	O
new	POS	O
RCT	POS	O
and	POS	O
meta	POS	O
-	POS	O
analysis	POS	O
suggest	POS	O
that	POS	O
the	POS	O
risk	POS	O
for	POS	O
hemorrhagic	POS	B-NP
strokes	POS	I-NP
in	POS	O
women	POS	O
is	POS	O
not	POS	O
statistically	POS	O
significantly	POS	O
increased	POS	O
.	POS	O
LIMITATIONS	POS	O
:	POS	O
New	POS	O
evidence	POS	O
on	POS	O
aspirin	POS	O
for	POS	O
the	POS	O
primary	POS	O
prevention	POS	O
of	POS	O
CVD	POS	B-NP
is	POS	O
limited	POS	O
.	POS	O
The	POS	O
dose	POS	O
of	POS	O
aspirin	POS	O
used	POS	O
in	POS	O
the	POS	O
RCTs	POS	O
varied	POS	O
,	POS	O
which	POS	O
prevented	POS	O
the	POS	O
estimation	POS	O
of	POS	O
the	POS	O
most	POS	O
appropriate	POS	O
dose	POS	O
for	POS	O
primary	POS	O
prevention	POS	O
.	POS	O
Several	POS	O
of	POS	O
the	POS	O
RCTs	POS	O
were	POS	O
conducted	POS	O
within	POS	O
populations	POS	O
of	POS	O
health	POS	O
professionals	POS	O
,	POS	O
which	POS	O
potentially	POS	O
limits	POS	O
generalizability	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Aspirin	POS	O
reduces	POS	O
the	POS	O
risk	POS	O
for	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
in	POS	O
men	POS	O
and	POS	O
strokes	POS	B-NP
in	POS	O
women	POS	O
.	POS	O
Aspirin	POS	O
use	POS	O
increases	POS	O
the	POS	O
risk	POS	O
for	POS	O
serious	POS	O
bleeding	POS	B-NP
events	POS	O
.	POS	O
Reducing	POS	O
harm	POS	O
associated	POS	O
with	POS	O
anticoagulation	POS	O
:	POS	O
practical	POS	O
considerations	POS	O
of	POS	O
argatroban	POS	O
therapy	POS	O
in	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
.	POS	O
Argatroban	POS	O
is	POS	O
a	POS	O
hepatically	POS	O
metabolized	POS	O
,	POS	O
direct	POS	O
thrombin	POS	O
inhibitor	POS	O
used	POS	O
for	POS	O
prophylaxis	POS	O
or	POS	O
treatment	POS	O
of	POS	O
thrombosis	POS	B-NP
in	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
(	POS	O
HIT	POS	B-NP
)	POS	O
and	POS	O
for	POS	O
patients	POS	O
with	POS	O
or	POS	O
at	POS	O
risk	POS	O
of	POS	O
HIT	POS	B-NP
undergoing	POS	O
percutaneous	POS	O
coronary	POS	O
intervention	POS	O
(	POS	O
PCI	POS	O
)	POS	O
.	POS	O
The	POS	O
objective	POS	O
of	POS	O
this	POS	O
review	POS	O
is	POS	O
to	POS	O
summarize	POS	O
practical	POS	O
considerations	POS	O
of	POS	O
argatroban	POS	O
therapy	POS	O
in	POS	O
HIT	POS	B-NP
.	POS	O
The	POS	O
US	POS	O
FDA	POS	O
-	POS	O
recommended	POS	O
argatroban	POS	O
dose	POS	O
in	POS	O
HIT	POS	B-NP
is	POS	O
2	POS	O
microg	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
(	POS	O
reduced	POS	O
in	POS	O
patients	POS	O
with	POS	O
hepatic	POS	B-NP
impairment	POS	I-NP
and	POS	O
in	POS	O
paediatric	POS	O
patients	POS	O
)	POS	O
,	POS	O
adjusted	POS	O
to	POS	O
achieve	POS	O
activated	POS	O
partial	POS	O
thromboplastin	POS	O
times	POS	O
(	POS	O
aPTTs	POS	O
)	POS	O
1	POS	O
.	POS	O
5	POS	O
-	POS	O
3	POS	O
times	POS	O
baseline	POS	O
(	POS	O
not	POS	O
>	POS	O
100	POS	O
seconds	POS	O
)	POS	O
.	POS	O
Contemporary	POS	O
experiences	POS	O
indicate	POS	O
that	POS	O
reduced	POS	O
doses	POS	O
are	POS	O
also	POS	O
needed	POS	O
in	POS	O
patients	POS	O
with	POS	O
conditions	POS	O
associated	POS	O
with	POS	O
hepatic	POS	B-NP
hypoperfusion	POS	I-NP
,	POS	O
e	POS	O
.	POS	O
g	POS	O
.	POS	O
heart	POS	B-NP
failure	POS	I-NP
,	POS	O
yet	POS	O
are	POS	O
unnecessary	POS	O
for	POS	O
renal	POS	B-NP
dysfunction	POS	I-NP
,	POS	O
adult	POS	O
age	POS	O
,	POS	O
sex	POS	O
,	POS	O
race	POS	O
/	POS	O
ethnicity	POS	O
or	POS	O
obesity	POS	B-NP
.	POS	O
Argatroban	POS	O
0	POS	O
.	POS	O
5	POS	O
-	POS	O
1	POS	O
.	POS	O
2	POS	O
microg	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
typically	POS	O
supports	POS	O
therapeutic	POS	O
aPTTs	POS	O
.	POS	O
The	POS	O
FDA	POS	O
-	POS	O
recommended	POS	O
dose	POS	O
during	POS	O
PCI	POS	O
is	POS	O
25	POS	O
microg	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
(	POS	O
350	POS	O
microg	POS	O
/	POS	O
kg	POS	O
initial	POS	O
bolus	POS	O
)	POS	O
,	POS	O
adjusted	POS	O
to	POS	O
achieve	POS	O
activated	POS	O
clotting	POS	O
times	POS	O
(	POS	O
ACTs	POS	O
)	POS	O
of	POS	O
300	POS	O
-	POS	O
450	POS	O
sec	POS	O
.	POS	O
For	POS	O
PCI	POS	O
,	POS	O
argatroban	POS	O
has	POS	O
not	POS	O
been	POS	O
investigated	POS	O
in	POS	O
hepatically	POS	O
impaired	POS	O
patients	POS	O
;	POS	O
dose	POS	O
adjustment	POS	O
is	POS	O
unnecessary	POS	O
for	POS	O
adult	POS	O
age	POS	O
,	POS	O
sex	POS	O
,	POS	O
race	POS	O
/	POS	O
ethnicity	POS	O
or	POS	O
obesity	POS	B-NP
,	POS	O
and	POS	O
lesser	POS	O
doses	POS	O
may	POS	O
be	POS	O
adequate	POS	O
with	POS	O
concurrent	POS	O
glycoprotein	POS	O
IIb	POS	O
/	POS	O
IIIa	POS	O
inhibition	POS	O
.	POS	O
Argatroban	POS	O
prolongs	POS	O
the	POS	O
International	POS	O
Normalized	POS	O
Ratio	POS	O
,	POS	O
and	POS	O
published	POS	O
approaches	POS	O
for	POS	O
monitoring	POS	O
the	POS	O
argatroban	POS	O
-	POS	O
to	POS	O
-	POS	O
warfarin	POS	O
transition	POS	O
should	POS	O
be	POS	O
followed	POS	O
.	POS	O
Major	POS	O
bleeding	POS	O
with	POS	O
argatroban	POS	O
is	POS	O
0	POS	O
-	POS	O
10	POS	O
%	POS	O
in	POS	O
the	POS	O
non	POS	O
-	POS	O
interventional	POS	O
setting	POS	O
and	POS	O
0	POS	O
-	POS	O
5	POS	O
.	POS	O
8	POS	O
%	POS	O
periprocedurally	POS	O
.	POS	O
Argatroban	POS	O
has	POS	O
no	POS	O
specific	POS	O
antidote	POS	O
,	POS	O
and	POS	O
if	POS	O
excessive	POS	O
anticoagulation	POS	O
occurs	POS	O
,	POS	O
argatroban	POS	O
infusion	POS	O
should	POS	O
be	POS	O
stopped	POS	O
or	POS	O
reduced	POS	O
.	POS	O
Improved	POS	O
familiarity	POS	O
of	POS	O
healthcare	POS	O
professionals	POS	O
with	POS	O
argatroban	POS	O
therapy	POS	O
in	POS	O
HIT	POS	B-NP
,	POS	O
including	POS	O
in	POS	O
special	POS	O
populations	POS	O
and	POS	O
during	POS	O
PCI	POS	O
,	POS	O
may	POS	O
facilitate	POS	O
reduction	POS	O
of	POS	O
harm	POS	O
associated	POS	O
with	POS	O
HIT	POS	B-NP
(	POS	O
e	POS	O
.	POS	O
g	POS	O
.	POS	O
fewer	POS	O
thromboses	POS	B-NP
)	POS	O
or	POS	O
its	POS	O
treatment	POS	O
(	POS	O
e	POS	O
.	POS	O
g	POS	O
.	POS	O
fewer	POS	O
argatroban	POS	O
medication	POS	O
errors	POS	O
)	POS	O
.	POS	O
Rhabdomyolysis	POS	B-NP
and	POS	O
brain	POS	B-NP
ischemic	POS	I-NP
stroke	POS	I-NP
in	POS	O
a	POS	O
heroin	POS	O
-	POS	O
dependent	POS	O
male	POS	O
under	POS	O
methadone	POS	O
maintenance	POS	O
therapy	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
There	POS	O
are	POS	O
several	POS	O
complications	POS	O
associated	POS	O
with	POS	O
heroin	POS	B-NP
abuse	POS	I-NP
,	POS	O
some	POS	O
of	POS	O
which	POS	O
are	POS	O
life	POS	O
-	POS	O
threatening	POS	O
.	POS	O
Methadone	POS	O
may	POS	O
aggravate	POS	O
this	POS	O
problem	POS	O
.	POS	O
METHOD	POS	O
:	POS	O
A	POS	O
clinical	POS	O
case	POS	O
description	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
A	POS	O
33	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
presented	POS	O
with	POS	O
rhabdomyolysis	POS	B-NP
and	POS	O
cerebral	POS	B-NP
ischemic	POS	I-NP
stroke	POS	I-NP
after	POS	O
intravenous	POS	O
heroin	POS	O
.	POS	O
He	POS	O
had	POS	O
used	POS	O
heroin	POS	O
since	POS	O
age	POS	O
20	POS	O
,	POS	O
and	POS	O
had	POS	O
used	POS	O
150	POS	O
mg	POS	O
methadone	POS	O
daily	POS	O
for	POS	O
6	POS	O
months	POS	O
.	POS	O
He	POS	O
was	POS	O
found	POS	O
unconsciousness	POS	B-NP
at	POS	O
home	POS	O
and	POS	O
was	POS	O
sent	POS	O
to	POS	O
our	POS	O
hospital	POS	O
.	POS	O
In	POS	O
the	POS	O
ER	POS	O
,	POS	O
his	POS	O
opiate	POS	O
level	POS	O
was	POS	O
4497	POS	O
ng	POS	O
/	POS	O
ml	POS	O
.	POS	O
In	POS	O
the	POS	O
ICU	POS	O
,	POS	O
we	POS	O
found	POS	O
rhabdomyolysis	POS	B-NP
,	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
and	POS	O
acute	POS	B-NP
respiratory	POS	I-NP
failure	POS	I-NP
.	POS	O
After	POS	O
transfer	POS	O
to	POS	O
an	POS	O
internal	POS	O
ward	POS	O
,	POS	O
we	POS	O
noted	POS	O
aphasia	POS	B-NP
and	POS	O
weakness	POS	B-NP
of	POS	I-NP
his	POS	I-NP
left	POS	I-NP
limbs	POS	I-NP
.	POS	O
After	POS	O
MRI	POS	O
,	POS	O
we	POS	O
found	POS	O
cerebral	POS	B-NP
ischemic	POS	I-NP
infarction	POS	I-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
Those	POS	O
using	POS	O
methadone	POS	O
and	POS	O
heroin	POS	O
simultaneously	POS	O
may	POS	O
increase	POS	O
risk	POS	O
of	POS	O
rhabdomyolysis	POS	B-NP
and	POS	O
ischemic	POS	B-NP
stroke	POS	I-NP
.	POS	O
Patients	POS	O
under	POS	O
methadone	POS	O
maintenance	POS	O
therapy	POS	O
should	POS	O
be	POS	O
warned	POS	O
regarding	POS	O
these	POS	O
serious	POS	O
adverse	POS	O
events	POS	O
.	POS	O
Hypotheses	POS	O
of	POS	O
heroin	POS	O
-	POS	O
related	POS	O
rhabdomyolysis	POS	B-NP
and	POS	O
stroke	POS	B-NP
in	POS	O
heroin	POS	O
abusers	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Increased	POS	O
vulnerability	POS	O
to	POS	O
6	POS	O
-	POS	O
hydroxydopamine	POS	O
lesion	POS	O
and	POS	O
reduced	POS	O
development	POS	O
of	POS	O
dyskinesias	POS	B-NP
in	POS	O
mice	POS	O
lacking	POS	O
CB1	POS	O
cannabinoid	POS	O
receptors	POS	O
.	POS	O
Motor	POS	B-NP
impairment	POS	I-NP
,	POS	O
dopamine	POS	O
(	POS	O
DA	POS	O
)	POS	O
neuronal	POS	O
activity	POS	O
and	POS	O
proenkephalin	POS	O
(	POS	O
PENK	POS	O
)	POS	O
gene	POS	O
expression	POS	O
in	POS	O
the	POS	O
caudate	POS	O
-	POS	O
putamen	POS	O
(	POS	O
CPu	POS	O
)	POS	O
were	POS	O
measured	POS	O
in	POS	O
6	POS	O
-	POS	O
OHDA	POS	O
-	POS	O
lesioned	POS	O
and	POS	O
treated	POS	O
(	POS	O
L	POS	O
-	POS	O
DOPA	POS	O
+	POS	O
benserazide	POS	O
)	POS	O
CB1	POS	O
KO	POS	O
and	POS	O
WT	POS	O
mice	POS	O
.	POS	O
A	POS	O
lesion	POS	O
induced	POS	O
by	POS	O
6	POS	O
-	POS	O
OHDA	POS	O
produced	POS	O
more	POS	O
severe	POS	O
motor	POS	O
deterioration	POS	O
in	POS	O
CB1	POS	O
KO	POS	O
mice	POS	O
accompanied	POS	O
by	POS	O
more	POS	O
loss	POS	O
of	POS	O
DA	POS	O
neurons	POS	O
and	POS	O
increased	POS	O
PENK	POS	O
gene	POS	O
expression	POS	O
in	POS	O
the	POS	O
CPu	POS	O
.	POS	O
Oxidative	POS	O
/	POS	O
nitrosative	POS	O
and	POS	O
neuroinflammatory	POS	O
parameters	POS	O
were	POS	O
estimated	POS	O
in	POS	O
the	POS	O
CPu	POS	O
and	POS	O
cingulate	POS	O
cortex	POS	O
(	POS	O
Cg	POS	O
)	POS	O
.	POS	O
CB1	POS	O
KO	POS	O
mice	POS	O
exhibited	POS	O
higher	POS	O
MDA	POS	O
levels	POS	O
and	POS	O
iNOS	POS	O
protein	POS	O
expression	POS	O
in	POS	O
the	POS	O
CPu	POS	O
and	POS	O
Cg	POS	O
compared	POS	O
to	POS	O
WT	POS	O
mice	POS	O
.	POS	O
Treatment	POS	O
with	POS	O
L	POS	O
-	POS	O
DOPA	POS	O
+	POS	O
benserazide	POS	O
(	POS	O
12	POS	O
weeks	POS	O
)	POS	O
resulted	POS	O
in	POS	O
less	POS	O
severe	POS	O
dyskinesias	POS	B-NP
in	POS	O
CB1	POS	O
KO	POS	O
than	POS	O
in	POS	O
WT	POS	O
mice	POS	O
.	POS	O
The	POS	O
results	POS	O
revealed	POS	O
that	POS	O
the	POS	O
lack	POS	O
of	POS	O
cannabinoid	POS	O
CB1	POS	O
receptors	POS	O
increased	POS	O
the	POS	O
severity	POS	O
of	POS	O
motor	POS	O
impairment	POS	O
and	POS	O
DA	POS	O
lesion	POS	O
,	POS	O
and	POS	O
reduced	POS	O
L	POS	O
-	POS	O
DOPA	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
activation	POS	O
of	POS	O
CB1	POS	O
receptors	POS	O
offers	POS	O
neuroprotection	POS	O
against	POS	O
dopaminergic	POS	O
lesion	POS	O
and	POS	O
the	POS	O
development	POS	O
of	POS	O
L	POS	O
-	POS	O
DOPA	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
.	POS	O
Hepatocellular	POS	O
oxidant	POS	O
stress	POS	O
following	POS	O
intestinal	POS	B-NP
ischemia	POS	I-NP
-	POS	O
reperfusion	POS	B-NP
injury	POS	I-NP
.	POS	O
Reperfusion	POS	O
of	POS	O
ischemic	POS	O
intestine	POS	O
results	POS	O
in	POS	O
acute	POS	B-NP
liver	POS	I-NP
dysfunction	POS	I-NP
characterized	POS	O
by	POS	O
hepatocellular	POS	O
enzyme	POS	O
release	POS	O
into	POS	O
plasma	POS	O
,	POS	O
reduction	POS	O
in	POS	O
bile	POS	O
flow	POS	O
rate	POS	O
,	POS	O
and	POS	O
neutrophil	POS	O
sequestration	POS	O
within	POS	O
the	POS	O
liver	POS	O
.	POS	O
The	POS	O
pathophysiology	POS	O
underlying	POS	O
this	POS	O
acute	POS	O
hepatic	POS	B-NP
injury	POS	I-NP
is	POS	O
unknown	POS	O
.	POS	O
This	POS	O
study	POS	O
was	POS	O
undertaken	POS	O
to	POS	O
determine	POS	O
whether	POS	O
oxidants	POS	O
are	POS	O
associated	POS	O
with	POS	O
the	POS	O
hepatic	POS	B-NP
injury	POS	I-NP
and	POS	O
to	POS	O
determine	POS	O
the	POS	O
relative	POS	O
value	POS	O
of	POS	O
several	POS	O
indirect	POS	O
methods	POS	O
of	POS	O
assessing	POS	O
oxidant	POS	O
exposure	POS	O
in	POS	O
vivo	POS	O
.	POS	O
Rats	POS	O
were	POS	O
subjected	POS	O
to	POS	O
a	POS	O
standardized	POS	O
intestinal	POS	O
ischemia	POS	B-NP
-	POS	O
reperfusion	POS	B-NP
injury	POS	I-NP
.	POS	O
Hepatic	POS	O
tissue	POS	O
was	POS	O
assayed	POS	O
for	POS	O
lipid	POS	O
peroxidation	POS	O
products	POS	O
and	POS	O
oxidized	POS	O
and	POS	O
reduced	POS	O
glutathione	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
change	POS	O
in	POS	O
hepatic	POS	O
tissue	POS	O
total	POS	O
glutathione	POS	O
following	POS	O
intestinal	POS	O
ischemia	POS	B-NP
-	POS	O
reperfusion	POS	B-NP
injury	POS	I-NP
.	POS	O
Oxidized	POS	O
glutathione	POS	O
(	POS	O
GSSG	POS	O
)	POS	O
increased	POS	O
significantly	POS	O
following	POS	O
30	POS	O
and	POS	O
60	POS	O
min	POS	O
of	POS	O
reperfusion	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
increase	POS	O
in	POS	O
any	POS	O
of	POS	O
the	POS	O
products	POS	O
of	POS	O
lipid	POS	O
peroxidation	POS	O
associated	POS	O
with	POS	O
this	POS	O
injury	POS	O
.	POS	O
An	POS	O
increase	POS	O
in	POS	O
GSSG	POS	O
within	POS	O
hepatic	POS	O
tissue	POS	O
during	POS	O
intestinal	POS	O
reperfusion	POS	O
suggests	POS	O
exposure	POS	O
of	POS	O
hepatocytes	POS	O
to	POS	O
an	POS	O
oxidant	POS	O
stress	POS	O
.	POS	O
The	POS	O
lack	POS	O
of	POS	O
a	POS	O
significant	POS	O
increase	POS	O
in	POS	O
products	POS	O
of	POS	O
lipid	POS	O
peroxidation	POS	O
suggests	POS	O
that	POS	O
the	POS	O
oxidant	POS	O
stress	POS	O
is	POS	O
of	POS	O
insufficient	POS	O
magnitude	POS	O
to	POS	O
result	POS	O
in	POS	O
irreversible	POS	O
injury	POS	O
to	POS	O
hepatocyte	POS	O
cell	POS	O
membranes	POS	O
.	POS	O
These	POS	O
data	POS	O
also	POS	O
suggest	POS	O
that	POS	O
the	POS	O
measurement	POS	O
of	POS	O
tissue	POS	O
GSSG	POS	O
may	POS	O
be	POS	O
a	POS	O
more	POS	O
sensitive	POS	O
indicator	POS	O
of	POS	O
oxidant	POS	O
stress	POS	O
than	POS	O
measurement	POS	O
of	POS	O
products	POS	O
of	POS	O
lipid	POS	O
peroxidation	POS	O
.	POS	O
Animal	POS	O
model	POS	O
of	POS	O
mania	POS	B-NP
induced	POS	O
by	POS	O
ouabain	POS	O
:	POS	O
Evidence	POS	O
of	POS	O
oxidative	POS	O
stress	POS	O
in	POS	O
submitochondrial	POS	O
particles	POS	O
of	POS	O
the	POS	O
rat	POS	O
brain	POS	O
.	POS	O
The	POS	O
intracerebroventricular	POS	O
(	POS	O
ICV	POS	O
)	POS	O
administration	POS	O
of	POS	O
ouabain	POS	O
(	POS	O
a	POS	O
Na	POS	O
(	POS	O
+	POS	O
)	POS	O
/	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
ATPase	POS	O
inhibitor	POS	O
)	POS	O
in	POS	O
rats	POS	O
has	POS	O
been	POS	O
suggested	POS	O
to	POS	O
mimic	POS	O
some	POS	O
symptoms	POS	O
of	POS	O
human	POS	O
bipolar	POS	B-NP
mania	POS	I-NP
.	POS	O
Clinical	POS	O
studies	POS	O
have	POS	O
shown	POS	O
that	POS	O
bipolar	POS	B-NP
disorder	POS	I-NP
may	POS	O
be	POS	O
related	POS	O
to	POS	O
mitochondrial	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
Herein	POS	O
,	POS	O
we	POS	O
investigated	POS	O
the	POS	O
behavioral	POS	O
and	POS	O
biochemical	POS	O
effects	POS	O
induced	POS	O
by	POS	O
the	POS	O
ICV	POS	O
administration	POS	O
of	POS	O
ouabain	POS	O
in	POS	O
rats	POS	O
.	POS	O
To	POS	O
achieve	POS	O
this	POS	O
aim	POS	O
,	POS	O
the	POS	O
effects	POS	O
of	POS	O
ouabain	POS	O
injection	POS	O
immediately	POS	O
after	POS	O
and	POS	O
7	POS	O
days	POS	O
following	POS	O
a	POS	O
single	POS	O
ICV	POS	O
administration	POS	O
(	POS	O
at	POS	O
concentrations	POS	O
of	POS	O
10	POS	O
(	POS	O
-	POS	O
2	POS	O
)	POS	O
and	POS	O
10	POS	O
(	POS	O
-	POS	O
3	POS	O
)	POS	O
M	POS	O
)	POS	O
on	POS	O
locomotion	POS	O
was	POS	O
measured	POS	O
using	POS	O
the	POS	O
open	POS	O
-	POS	O
field	POS	O
test	POS	O
.	POS	O
Additionally	POS	O
,	POS	O
thiobarbituric	POS	O
acid	POS	O
reactive	POS	O
substances	POS	O
(	POS	O
TBARSs	POS	O
)	POS	O
and	POS	O
superoxide	POS	O
production	POS	O
were	POS	O
measured	POS	O
in	POS	O
submitochondrial	POS	O
particles	POS	O
of	POS	O
the	POS	O
prefrontal	POS	O
cortex	POS	O
,	POS	O
hippocampus	POS	O
,	POS	O
striatum	POS	O
and	POS	O
amygdala	POS	O
.	POS	O
Our	POS	O
findings	POS	O
demonstrated	POS	O
that	POS	O
ouabain	POS	O
at	POS	O
10	POS	O
(	POS	O
-	POS	O
2	POS	O
)	POS	O
and	POS	O
10	POS	O
(	POS	O
-	POS	O
3	POS	O
)	POS	O
M	POS	O
induced	POS	O
hyperlocomotion	POS	B-NP
in	POS	O
rats	POS	O
,	POS	O
and	POS	O
this	POS	O
response	POS	O
remained	POS	O
up	POS	O
to	POS	O
7	POS	O
days	POS	O
following	POS	O
a	POS	O
single	POS	O
ICV	POS	O
injection	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
we	POS	O
observed	POS	O
that	POS	O
the	POS	O
persistent	POS	O
increase	POS	O
in	POS	O
the	POS	O
rat	POS	O
spontaneous	POS	O
locomotion	POS	O
is	POS	O
associated	POS	O
with	POS	O
increased	POS	O
TBARS	POS	O
levels	POS	O
and	POS	O
superoxide	POS	O
generation	POS	O
in	POS	O
submitochondrial	POS	O
particles	POS	O
in	POS	O
the	POS	O
prefrontal	POS	O
cortex	POS	O
,	POS	O
striatum	POS	O
and	POS	O
amygdala	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
ouabain	POS	O
-	POS	O
induced	POS	O
mania	POS	B-NP
-	POS	O
like	POS	O
behavior	POS	O
may	POS	O
provide	POS	O
a	POS	O
useful	POS	O
animal	POS	O
model	POS	O
to	POS	O
test	POS	O
the	POS	O
hypothesis	POS	O
of	POS	O
the	POS	O
involvement	POS	O
of	POS	O
oxidative	POS	O
stress	POS	O
in	POS	O
bipolar	POS	B-NP
disorder	POS	I-NP
.	POS	O
Intraoperative	POS	O
dialysis	POS	O
during	POS	O
liver	POS	O
transplantation	POS	O
with	POS	O
citrate	POS	O
dialysate	POS	O
.	POS	O
Liver	POS	O
transplantation	POS	O
for	POS	O
acutely	POS	O
ill	POS	O
patients	POS	O
with	POS	O
fulminant	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
carries	POS	O
high	POS	O
intraoperative	POS	O
and	POS	O
immediate	POS	O
postoperative	POS	O
risks	POS	O
.	POS	O
These	POS	O
are	POS	O
increased	POS	O
with	POS	O
the	POS	O
presence	POS	O
of	POS	O
concomitant	POS	O
acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
(	POS	O
AKI	POS	B-NP
)	POS	O
and	POS	O
intraoperative	POS	O
dialysis	POS	O
is	POS	O
sometimes	POS	O
required	POS	O
to	POS	O
allow	POS	O
the	POS	O
transplant	POS	O
to	POS	O
proceed	POS	O
.	POS	O
The	POS	O
derangements	POS	O
in	POS	O
the	POS	O
procoagulant	POS	O
and	POS	O
anticoagulant	POS	O
pathways	POS	O
during	POS	O
fulminant	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
can	POS	O
lead	POS	O
to	POS	O
difficulties	POS	O
with	POS	O
anticoagulation	POS	O
during	POS	O
dialysis	POS	O
,	POS	O
especially	POS	O
when	POS	O
continued	POS	O
in	POS	O
the	POS	O
operating	POS	O
room	POS	O
.	POS	O
Systemic	POS	O
anticoagulation	POS	O
is	POS	O
unsafe	POS	O
and	POS	O
regional	POS	O
citrate	POS	O
anticoagulation	POS	O
in	POS	O
the	POS	O
absence	POS	O
of	POS	O
a	POS	O
functional	POS	O
liver	POS	O
carries	POS	O
the	POS	O
risk	POS	O
of	POS	O
citrate	POS	O
toxicity	POS	O
.	POS	O
Citrate	POS	O
dialysate	POS	O
,	POS	O
a	POS	O
new	POS	O
dialysate	POS	O
with	POS	O
citric	POS	O
acid	POS	O
can	POS	O
be	POS	O
used	POS	O
for	POS	O
anticoagulation	POS	O
in	POS	O
patients	POS	O
who	POS	O
cannot	POS	O
tolerate	POS	O
heparin	POS	O
or	POS	O
regional	POS	O
citrate	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
a	POS	O
40	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
female	POS	O
with	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
fulminant	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
with	POS	O
associated	POS	O
AKI	POS	B-NP
who	POS	O
underwent	POS	O
intraoperative	POS	O
dialytic	POS	O
support	POS	O
during	POS	O
liver	POS	O
transplantation	POS	O
anticoagulated	POS	O
with	POS	O
citrate	POS	O
dialysate	POS	O
during	POS	O
the	POS	O
entire	POS	O
procedure	POS	O
.	POS	O
The	POS	O
patient	POS	O
tolerated	POS	O
the	POS	O
procedure	POS	O
well	POS	O
without	POS	O
any	POS	O
signs	POS	O
of	POS	O
citrate	POS	O
toxicity	POS	B-NP
and	POS	O
maintained	POS	O
adequate	POS	O
anticoagulation	POS	O
for	POS	O
patency	POS	O
of	POS	O
the	POS	O
dialysis	POS	O
circuit	POS	O
.	POS	O
Citrate	POS	O
dialysate	POS	O
is	POS	O
a	POS	O
safe	POS	O
alternative	POS	O
for	POS	O
intradialytic	POS	O
support	POS	O
of	POS	O
liver	POS	O
transplantation	POS	O
in	POS	O
fulminant	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
.	POS	O
Delirium	POS	B-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
toxic	POS	O
flecainide	POS	O
plasma	POS	O
concentrations	POS	O
:	POS	O
the	POS	O
role	POS	O
of	POS	O
a	POS	O
pharmacokinetic	POS	O
drug	POS	O
interaction	POS	O
with	POS	O
paroxetine	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
describe	POS	O
a	POS	O
case	POS	O
of	POS	O
flecainide	POS	O
-	POS	O
induced	POS	O
delirium	POS	B-NP
associated	POS	O
with	POS	O
a	POS	O
pharmacokinetic	POS	O
drug	POS	O
interaction	POS	O
with	POS	O
paroxetine	POS	O
.	POS	O
CASE	POS	O
SUMMARY	POS	O
:	POS	O
A	POS	O
69	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
white	POS	O
female	POS	O
presented	POS	O
to	POS	O
the	POS	O
emergency	POS	O
department	POS	O
with	POS	O
a	POS	O
history	POS	O
of	POS	O
confusion	POS	B-NP
and	POS	O
paranoia	POS	B-NP
over	POS	O
the	POS	O
past	POS	O
several	POS	O
days	POS	O
.	POS	O
On	POS	O
admission	POS	O
the	POS	O
patient	POS	O
was	POS	O
taking	POS	O
carvedilol	POS	O
12	POS	O
mg	POS	O
twice	POS	O
daily	POS	O
,	POS	O
warfarin	POS	O
2	POS	O
mg	POS	O
/	POS	O
day	POS	O
,	POS	O
folic	POS	O
acid	POS	O
1	POS	O
mg	POS	O
/	POS	O
day	POS	O
,	POS	O
levothyroxine	POS	O
100	POS	O
microg	POS	O
/	POS	O
day	POS	O
,	POS	O
pantoprazole	POS	O
40	POS	O
mg	POS	O
/	POS	O
day	POS	O
,	POS	O
paroxetine	POS	O
40	POS	O
mg	POS	O
/	POS	O
day	POS	O
,	POS	O
and	POS	O
flecainide	POS	O
100	POS	O
mg	POS	O
twice	POS	O
daily	POS	O
.	POS	O
Flecainide	POS	O
had	POS	O
been	POS	O
started	POS	O
2	POS	O
weeks	POS	O
prior	POS	O
for	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
.	POS	O
Laboratory	POS	O
test	POS	O
findings	POS	O
on	POS	O
admission	POS	O
were	POS	O
notable	POS	O
only	POS	O
for	POS	O
a	POS	O
flecainide	POS	O
plasma	POS	O
concentration	POS	O
of	POS	O
1360	POS	O
microg	POS	O
/	POS	O
L	POS	O
(	POS	O
reference	POS	O
range	POS	O
200	POS	O
-	POS	O
1000	POS	O
)	POS	O
.	POS	O
A	POS	O
metabolic	POS	O
drug	POS	O
interaction	POS	O
between	POS	O
flecainide	POS	O
and	POS	O
paroxetine	POS	O
,	POS	O
which	POS	O
the	POS	O
patient	POS	O
had	POS	O
been	POS	O
taking	POS	O
for	POS	O
more	POS	O
than	POS	O
5	POS	O
years	POS	O
,	POS	O
was	POS	O
considered	POS	O
.	POS	O
Paroxetine	POS	O
was	POS	O
discontinued	POS	O
and	POS	O
the	POS	O
dose	POS	O
of	POS	O
flecainide	POS	O
was	POS	O
reduced	POS	O
to	POS	O
50	POS	O
mg	POS	O
twice	POS	O
daily	POS	O
.	POS	O
Her	POS	O
delirium	POS	B-NP
resolved	POS	O
3	POS	O
days	POS	O
later	POS	O
.	POS	O
DISCUSSION	POS	O
:	POS	O
Flecainide	POS	O
and	POS	O
pharmacologically	POS	O
similar	POS	O
agents	POS	O
that	POS	O
interact	POS	O
with	POS	O
sodium	POS	O
channels	POS	O
may	POS	O
cause	POS	O
delirium	POS	B-NP
in	POS	O
susceptible	POS	O
patients	POS	O
.	POS	O
A	POS	O
MEDLINE	POS	O
search	POS	O
(	POS	O
1966	POS	O
-	POS	O
January	POS	O
2009	POS	O
)	POS	O
revealed	POS	O
one	POS	O
in	POS	O
vivo	POS	O
pharmacokinetic	POS	O
study	POS	O
on	POS	O
the	POS	O
interaction	POS	O
between	POS	O
flecainide	POS	O
,	POS	O
a	POS	O
CYP2D6	POS	O
substrate	POS	O
,	POS	O
and	POS	O
paroxetine	POS	O
,	POS	O
a	POS	O
CYP2D6	POS	O
inhibitor	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
3	POS	O
case	POS	O
reports	POS	O
of	POS	O
flecainide	POS	O
-	POS	O
induced	POS	O
delirium	POS	B-NP
.	POS	O
According	POS	O
to	POS	O
the	POS	O
Naranjo	POS	O
probability	POS	O
scale	POS	O
,	POS	O
flecainide	POS	O
was	POS	O
the	POS	O
probable	POS	O
cause	POS	O
of	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
delirium	POS	B-NP
;	POS	O
the	POS	O
Horn	POS	O
Drug	POS	O
Interaction	POS	O
Probability	POS	O
Scale	POS	O
indicates	POS	O
a	POS	O
possible	POS	O
pharmacokinetic	POS	O
drug	POS	O
interaction	POS	O
between	POS	O
flecainide	POS	O
and	POS	O
paroxetine	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Supratherapeutic	POS	O
flecainide	POS	O
plasma	POS	O
concentrations	POS	O
may	POS	O
cause	POS	O
delirium	POS	B-NP
.	POS	O
Because	POS	O
toxicity	POS	B-NP
may	POS	O
occur	POS	O
when	POS	O
flecainide	POS	O
is	POS	O
prescribed	POS	O
with	POS	O
paroxetine	POS	O
and	POS	O
other	POS	O
potent	POS	O
CYP2D6	POS	O
inhibitors	POS	O
,	POS	O
flecainide	POS	O
plasma	POS	O
concentrations	POS	O
should	POS	O
be	POS	O
monitored	POS	O
closely	POS	O
with	POS	O
commencement	POS	O
of	POS	O
CYP2D6	POS	O
inhibitors	POS	O
.	POS	O
Efficacy	POS	O
of	POS	O
everolimus	POS	O
(	POS	O
RAD001	POS	O
)	POS	O
in	POS	O
patients	POS	O
with	POS	O
advanced	POS	O
NSCLC	POS	B-NP
previously	POS	O
treated	POS	O
with	POS	O
chemotherapy	POS	O
alone	POS	O
or	POS	O
with	POS	O
chemotherapy	POS	O
and	POS	O
EGFR	POS	O
inhibitors	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Treatment	POS	O
options	POS	O
are	POS	O
scarce	POS	O
in	POS	O
pretreated	POS	O
advanced	POS	O
non	POS	B-NP
-	POS	I-NP
small	POS	I-NP
-	POS	I-NP
cell	POS	I-NP
lung	POS	I-NP
cancer	POS	I-NP
(	POS	O
NSCLC	POS	B-NP
)	POS	O
patients	POS	O
.	POS	O
RAD001	POS	O
,	POS	O
an	POS	O
oral	POS	O
inhibitor	POS	O
of	POS	O
the	POS	O
mammalian	POS	O
target	POS	O
of	POS	O
rapamycin	POS	O
(	POS	O
mTOR	POS	O
)	POS	O
,	POS	O
has	POS	O
shown	POS	O
phase	POS	O
I	POS	O
efficacy	POS	O
in	POS	O
NSCLC	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Stage	POS	O
IIIb	POS	O
or	POS	O
IV	POS	O
NSCLC	POS	B-NP
patients	POS	O
,	POS	O
with	POS	O
two	POS	O
or	POS	O
fewer	POS	O
prior	POS	O
chemotherapy	POS	O
regimens	POS	O
,	POS	O
one	POS	O
platinum	POS	O
based	POS	O
(	POS	O
stratum	POS	O
1	POS	O
)	POS	O
or	POS	O
both	POS	O
chemotherapy	POS	O
and	POS	O
epidermal	POS	O
growth	POS	O
factor	POS	O
receptor	POS	O
tyrosine	POS	O
kinase	POS	O
inhibitors	POS	O
(	POS	O
stratum	POS	O
2	POS	O
)	POS	O
,	POS	O
received	POS	O
RAD001	POS	O
10	POS	O
mg	POS	O
/	POS	O
day	POS	O
until	POS	O
progression	POS	O
or	POS	O
unacceptable	POS	O
toxicity	POS	B-NP
.	POS	O
Primary	POS	O
objective	POS	O
was	POS	O
overall	POS	O
response	POS	O
rate	POS	O
(	POS	O
ORR	POS	O
)	POS	O
.	POS	O
Analyses	POS	O
of	POS	O
markers	POS	O
associated	POS	O
with	POS	O
the	POS	O
mTOR	POS	O
pathway	POS	O
were	POS	O
carried	POS	O
out	POS	O
on	POS	O
archival	POS	O
tumor	POS	B-NP
from	POS	O
a	POS	O
subgroup	POS	O
using	POS	O
immunohistochemistry	POS	O
(	POS	O
IHC	POS	O
)	POS	O
and	POS	O
direct	POS	O
mutation	POS	O
sequencing	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Eighty	POS	O
-	POS	O
five	POS	O
patients	POS	O
were	POS	O
enrolled	POS	O
,	POS	O
42	POS	O
in	POS	O
stratum	POS	O
1	POS	O
and	POS	O
43	POS	O
in	POS	O
stratum	POS	O
.	POS	O
ORR	POS	O
was	POS	O
4	POS	O
.	POS	O
7	POS	O
%	POS	O
(	POS	O
7	POS	O
.	POS	O
1	POS	O
%	POS	O
stratum	POS	O
1	POS	O
;	POS	O
2	POS	O
.	POS	O
3	POS	O
%	POS	O
stratum	POS	O
2	POS	O
)	POS	O
.	POS	O
Overall	POS	O
disease	POS	O
control	POS	O
rate	POS	O
was	POS	O
47	POS	O
.	POS	O
1	POS	O
%	POS	O
.	POS	O
Median	POS	O
progression	POS	O
-	POS	O
free	POS	O
survivals	POS	O
(	POS	O
PFSs	POS	O
)	POS	O
were	POS	O
2	POS	O
.	POS	O
6	POS	O
(	POS	O
stratum	POS	O
1	POS	O
)	POS	O
and	POS	O
2	POS	O
.	POS	O
7	POS	O
months	POS	O
(	POS	O
stratum	POS	O
2	POS	O
)	POS	O
.	POS	O
Common	POS	O
>	POS	O
or	POS	O
=	POS	O
grade	POS	O
3	POS	O
events	POS	O
were	POS	O
fatigue	POS	B-NP
,	POS	O
dyspnea	POS	B-NP
,	POS	O
stomatitis	POS	B-NP
,	POS	O
anemia	POS	B-NP
,	POS	O
and	POS	O
thrombocytopenia	POS	B-NP
.	POS	O
Pneumonitis	POS	B-NP
,	POS	O
probably	POS	O
or	POS	O
possibly	POS	O
related	POS	O
,	POS	O
mainly	POS	O
grade	POS	O
1	POS	O
/	POS	O
2	POS	O
,	POS	O
occurred	POS	O
in	POS	O
25	POS	O
%	POS	O
.	POS	O
Cox	POS	O
regression	POS	O
analysis	POS	O
of	POS	O
IHC	POS	O
scores	POS	O
found	POS	O
that	POS	O
only	POS	O
phospho	POS	O
AKT	POS	O
(	POS	O
pAKT	POS	O
)	POS	O
was	POS	O
a	POS	O
significant	POS	O
independent	POS	O
predictor	POS	O
of	POS	O
worse	POS	O
PFS	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
RAD001	POS	O
10	POS	O
mg	POS	O
/	POS	O
day	POS	O
was	POS	O
well	POS	O
tolerated	POS	O
,	POS	O
showing	POS	O
modest	POS	O
clinical	POS	O
activity	POS	O
in	POS	O
pretreated	POS	O
NSCLC	POS	B-NP
.	POS	O
Evaluation	POS	O
of	POS	O
RAD001	POS	O
plus	POS	O
standard	POS	O
therapy	POS	O
for	POS	O
metastatic	POS	O
NSCLC	POS	B-NP
continues	POS	O
.	POS	O
Posttransplant	POS	B-NP
anemia	POS	I-NP
:	POS	O
the	POS	O
role	POS	O
of	POS	O
sirolimus	POS	O
.	POS	O
Posttransplant	POS	B-NP
anemia	POS	I-NP
is	POS	O
a	POS	O
common	POS	O
problem	POS	O
that	POS	O
may	POS	O
hinder	POS	O
patients	POS	O
'	POS	O
quality	POS	O
of	POS	O
life	POS	O
.	POS	O
It	POS	O
occurs	POS	O
in	POS	O
12	POS	O
to	POS	O
76	POS	O
%	POS	O
of	POS	O
patients	POS	O
,	POS	O
and	POS	O
is	POS	O
most	POS	O
common	POS	O
in	POS	O
the	POS	O
immediate	POS	O
posttransplant	POS	O
period	POS	O
.	POS	O
A	POS	O
variety	POS	O
of	POS	O
factors	POS	O
have	POS	O
been	POS	O
identified	POS	O
that	POS	O
increase	POS	O
the	POS	O
risk	POS	O
of	POS	O
posttransplant	POS	O
anemia	POS	B-NP
,	POS	O
of	POS	O
which	POS	O
the	POS	O
level	POS	O
of	POS	O
renal	POS	O
function	POS	O
is	POS	O
most	POS	O
important	POS	O
.	POS	O
Sirolimus	POS	O
,	POS	O
a	POS	O
mammalian	POS	O
target	POS	O
of	POS	O
rapamycin	POS	O
inhibitor	POS	O
,	POS	O
has	POS	O
been	POS	O
implicated	POS	O
as	POS	O
playing	POS	O
a	POS	O
special	POS	O
role	POS	O
in	POS	O
posttransplant	POS	O
anemia	POS	B-NP
.	POS	O
This	POS	O
review	POS	O
considers	POS	O
anemia	POS	B-NP
associated	POS	O
with	POS	O
sirolimus	POS	O
,	POS	O
including	POS	O
its	POS	O
presentation	POS	O
,	POS	O
mechanisms	POS	O
,	POS	O
and	POS	O
management	POS	O
.	POS	O
Coronary	POS	O
computerized	POS	O
tomography	POS	O
angiography	POS	O
for	POS	O
rapid	POS	O
discharge	POS	O
of	POS	O
low	POS	O
-	POS	O
risk	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Most	POS	O
patients	POS	O
presenting	POS	O
to	POS	O
emergency	POS	O
departments	POS	O
(	POS	O
EDs	POS	O
)	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
are	POS	O
admitted	POS	O
for	POS	O
at	POS	O
least	POS	O
12	POS	O
hours	POS	O
and	POS	O
receive	POS	O
a	POS	O
"	POS	O
rule	POS	O
out	POS	O
acute	POS	O
coronary	POS	B-NP
syndrome	POS	I-NP
"	POS	O
protocol	POS	O
,	POS	O
often	POS	O
with	POS	O
noninvasive	POS	O
testing	POS	O
prior	POS	O
to	POS	O
discharge	POS	O
.	POS	O
In	POS	O
patients	POS	O
without	POS	O
cocaine	POS	O
use	POS	O
,	POS	O
coronary	POS	O
computerized	POS	O
tomography	POS	O
angiography	POS	O
(	POS	O
CTA	POS	O
)	POS	O
has	POS	O
been	POS	O
shown	POS	O
to	POS	O
be	POS	O
useful	POS	O
for	POS	O
identifying	POS	O
a	POS	O
group	POS	O
of	POS	O
patients	POS	O
at	POS	O
low	POS	O
risk	POS	O
for	POS	O
cardiac	POS	B-NP
events	POS	I-NP
who	POS	O
can	POS	O
be	POS	O
safely	POS	O
discharged	POS	O
.	POS	O
It	POS	O
is	POS	O
unclear	POS	O
whether	POS	O
a	POS	O
coronary	POS	O
CTA	POS	O
strategy	POS	O
would	POS	O
be	POS	O
efficacious	POS	O
in	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
,	POS	O
as	POS	O
coronary	POS	B-NP
vasospasm	POS	I-NP
may	POS	O
account	POS	O
for	POS	O
some	POS	O
of	POS	O
the	POS	O
ischemia	POS	B-NP
.	POS	O
We	POS	O
studied	POS	O
whether	POS	O
a	POS	O
negative	POS	O
coronary	POS	O
CTA	POS	O
in	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
could	POS	O
identify	POS	O
a	POS	O
subset	POS	O
safe	POS	O
for	POS	O
discharge	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
prospectively	POS	O
evaluated	POS	O
the	POS	O
safety	POS	O
of	POS	O
coronary	POS	O
CTA	POS	O
for	POS	O
low	POS	O
-	POS	O
risk	POS	O
patients	POS	O
who	POS	O
presented	POS	O
to	POS	O
the	POS	O
ED	POS	O
with	POS	O
cocaineassociated	POS	B-NP
chest	POS	I-NP
pain	POS	I-NP
(	POS	O
self	POS	O
-	POS	O
reported	POS	O
or	POS	O
positive	POS	O
urine	POS	O
test	POS	O
)	POS	O
.	POS	O
Consecutive	POS	O
patients	POS	O
received	POS	O
either	POS	O
immediate	POS	O
coronary	POS	O
CTA	POS	O
in	POS	O
the	POS	O
ED	POS	O
(	POS	O
without	POS	O
serial	POS	O
markers	POS	O
)	POS	O
or	POS	O
underwent	POS	O
coronary	POS	O
CTA	POS	O
after	POS	O
a	POS	O
brief	POS	O
observation	POS	O
period	POS	O
with	POS	O
serial	POS	O
cardiac	POS	O
marker	POS	O
measurements	POS	O
.	POS	O
Patients	POS	O
with	POS	O
negative	POS	O
coronary	POS	O
CTA	POS	O
(	POS	O
maximal	POS	O
stenosis	POS	B-NP
less	POS	O
than	POS	O
50	POS	O
%	POS	O
)	POS	O
were	POS	O
discharged	POS	O
.	POS	O
The	POS	O
main	POS	O
outcome	POS	O
was	POS	O
30	POS	O
-	POS	O
day	POS	O
cardiovascular	POS	O
death	POS	O
or	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
RESULTS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
59	POS	O
patients	POS	O
with	POS	O
cocaine	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
chest	POS	I-NP
pain	POS	I-NP
were	POS	O
evaluated	POS	O
.	POS	O
Patients	POS	O
had	POS	O
a	POS	O
mean	POS	O
age	POS	O
of	POS	O
45	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
.	POS	O
6	POS	O
yrs	POS	O
and	POS	O
were	POS	O
86	POS	O
%	POS	O
black	POS	O
,	POS	O
66	POS	O
%	POS	O
male	POS	O
.	POS	O
Seventy	POS	O
-	POS	O
nine	POS	O
percent	POS	O
had	POS	O
a	POS	O
normal	POS	O
or	POS	O
nonspecific	POS	O
ECG	POS	O
and	POS	O
85	POS	O
%	POS	O
had	POS	O
a	POS	O
TIMI	POS	B-NP
score	POS	O
<	POS	O
2	POS	O
.	POS	O
Twenty	POS	O
patients	POS	O
received	POS	O
coronary	POS	O
CTA	POS	O
immediately	POS	O
in	POS	O
the	POS	O
ED	POS	O
,	POS	O
18	POS	O
of	POS	O
whom	POS	O
were	POS	O
discharged	POS	O
following	POS	O
CTA	POS	O
(	POS	O
90	POS	O
%	POS	O
)	POS	O
.	POS	O
Thirty	POS	O
-	POS	O
nine	POS	O
received	POS	O
coronary	POS	O
CTA	POS	O
after	POS	O
a	POS	O
brief	POS	O
observation	POS	O
period	POS	O
,	POS	O
with	POS	O
37	POS	O
discharged	POS	O
home	POS	O
following	POS	O
CTA	POS	O
(	POS	O
95	POS	O
%	POS	O
)	POS	O
.	POS	O
Six	POS	O
patients	POS	O
had	POS	O
coronary	POS	B-NP
stenosis	POS	I-NP
>	POS	O
or	POS	O
=	POS	O
50	POS	O
%	POS	O
.	POS	O
During	POS	O
the	POS	O
30	POS	O
-	POS	O
day	POS	O
follow	POS	O
-	POS	O
up	POS	O
period	POS	O
,	POS	O
no	POS	O
patients	POS	O
died	POS	O
of	POS	O
a	POS	O
cardiovascular	POS	B-NP
event	POS	I-NP
(	POS	O
0	POS	O
%	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
0	POS	O
-	POS	O
6	POS	O
.	POS	O
1	POS	O
%	POS	O
)	POS	O
and	POS	O
no	POS	O
patient	POS	O
sustained	POS	O
a	POS	O
nonfatal	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
(	POS	O
0	POS	O
%	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
0	POS	O
-	POS	O
6	POS	O
.	POS	O
1	POS	O
%	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Although	POS	O
cocaine	POS	O
-	POS	O
associated	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
can	POS	O
result	POS	O
from	POS	O
coronary	POS	B-NP
vasoconstriction	POS	I-NP
,	POS	O
patients	POS	O
with	POS	O
cocaine	POS	O
associated	POS	O
chest	POS	B-NP
pain	POS	I-NP
,	POS	O
a	POS	O
non	POS	B-NP
-	POS	I-NP
ischemic	POS	I-NP
ECG	POS	I-NP
,	POS	O
and	POS	O
a	POS	O
TIMI	POS	B-NP
risk	POS	O
score	POS	O
<	POS	O
2	POS	O
may	POS	O
be	POS	O
safely	POS	O
discharged	POS	O
from	POS	O
the	POS	O
ED	POS	O
after	POS	O
a	POS	O
negative	POS	O
coronary	POS	O
CTA	POS	O
with	POS	O
a	POS	O
low	POS	O
risk	POS	O
of	POS	O
30	POS	O
-	POS	O
day	POS	O
adverse	POS	O
events	POS	O
.	POS	O
Bilateral	POS	O
haemorrhagic	POS	B-NP
infarction	POS	I-NP
of	POS	O
the	POS	O
globus	POS	O
pallidus	POS	O
after	POS	O
cocaine	POS	O
and	POS	O
alcohol	POS	B-NP
intoxication	POS	I-NP
.	POS	O
Cocaine	POS	O
is	POS	O
a	POS	O
risk	POS	O
factor	POS	O
for	POS	O
both	POS	O
ischemic	POS	B-NP
and	POS	O
haemorrhagic	POS	B-NP
stroke	POS	I-NP
.	POS	O
We	POS	O
present	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
31	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
with	POS	O
bilateral	POS	B-NP
ischemia	POS	I-NP
of	POS	O
the	POS	O
globus	POS	O
pallidus	POS	O
after	POS	O
excessive	POS	O
alcohol	POS	O
and	POS	O
intranasal	POS	O
cocaine	POS	O
use	POS	O
.	POS	O
Drug	POS	O
-	POS	O
related	POS	O
globus	POS	O
pallidus	POS	O
infarctions	POS	O
are	POS	O
most	POS	O
often	POS	O
associated	POS	O
with	POS	O
heroin	POS	O
.	POS	O
Bilateral	POS	O
basal	POS	O
ganglia	POS	O
infarcts	POS	B-NP
after	POS	O
the	POS	O
use	POS	O
of	POS	O
cocaine	POS	O
,	POS	O
without	POS	O
concurrent	POS	O
heroin	POS	O
use	POS	O
,	POS	O
have	POS	O
never	POS	O
been	POS	O
reported	POS	O
.	POS	O
In	POS	O
our	POS	O
patient	POS	O
,	POS	O
transient	POS	O
cardiac	POS	B-NP
arrhythmia	POS	I-NP
or	POS	O
respiratory	POS	B-NP
dysfunction	POS	I-NP
related	POS	O
to	POS	O
cocaine	POS	O
and	POS	O
/	POS	O
or	POS	O
ethanol	POS	O
use	POS	O
were	POS	O
the	POS	O
most	POS	O
likely	POS	O
causes	POS	O
of	POS	O
cerebral	POS	B-NP
hypoperfusion	POS	I-NP
.	POS	O
Late	POS	O
fulminant	POS	O
posterior	POS	O
reversible	POS	O
encephalopathy	POS	B-NP
syndrome	POS	I-NP
after	POS	O
liver	POS	O
transplant	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
Posterior	POS	B-NP
leukoencephalopathy	POS	I-NP
due	POS	O
to	POS	O
calcineurin	POS	O
-	POS	O
inhibitor	POS	O
-	POS	O
related	POS	O
neurotoxicity	POS	B-NP
is	POS	O
a	POS	O
rare	POS	O
but	POS	O
severe	POS	O
complication	POS	O
that	POS	O
results	POS	O
from	POS	O
treatment	POS	O
with	POS	O
immunosuppressive	POS	O
agents	POS	O
(	POS	O
primarily	POS	O
those	POS	O
administered	POS	O
after	POS	O
a	POS	O
liver	POS	O
or	POS	O
kidney	POS	O
transplant	POS	O
)	POS	O
.	POS	O
The	POS	O
pathophysiologic	POS	O
mechanisms	POS	O
of	POS	O
that	POS	O
disorder	POS	O
remain	POS	O
unknown	POS	O
.	POS	O
CASE	POS	O
:	POS	O
We	POS	O
report	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
46	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
who	POS	O
received	POS	O
a	POS	O
liver	POS	O
transplant	POS	O
in	POS	O
our	POS	O
center	POS	O
as	POS	O
treatment	POS	O
for	POS	O
alcoholic	POS	O
cirrhosis	POS	B-NP
and	POS	O
in	POS	O
whom	POS	O
either	POS	O
a	POS	O
fulminant	POS	B-NP
course	POS	O
of	POS	O
posterior	POS	B-NP
leukoencephalopathy	POS	I-NP
or	POS	O
posterior	POS	O
reversible	POS	O
encephalopathy	POS	B-NP
syndrome	POS	I-NP
developed	POS	O
110	POS	O
days	POS	O
after	POS	O
transplant	POS	O
.	POS	O
After	POS	O
an	POS	O
initially	POS	O
uneventful	POS	O
course	POS	O
after	POS	O
the	POS	O
transplant	POS	O
,	POS	O
the	POS	O
patient	POS	O
rapidly	POS	O
fell	POS	O
into	POS	O
deep	POS	O
coma	POS	B-NP
.	POS	O
RESULTS	POS	O
:	POS	O
Cerebral	POS	O
MRI	POS	O
scan	POS	O
showed	POS	O
typical	POS	O
signs	POS	O
of	POS	O
enhancement	POS	O
in	POS	O
the	POS	O
pontine	POS	O
and	POS	O
posterior	POS	O
regions	POS	O
.	POS	O
Switching	POS	O
the	POS	O
immunosuppressive	POS	O
regimen	POS	O
from	POS	O
tacrolimus	POS	O
to	POS	O
cyclosporine	POS	O
did	POS	O
not	POS	O
improve	POS	O
the	POS	O
clinical	POS	O
situation	POS	O
.	POS	O
The	POS	O
termination	POS	O
of	POS	O
treatment	POS	O
with	POS	O
any	POS	O
calcineurin	POS	O
inhibitor	POS	O
resulted	POS	O
in	POS	O
a	POS	O
complete	POS	O
resolution	POS	O
of	POS	O
that	POS	O
complication	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Posterior	POS	O
reversible	POS	O
encephalopathy	POS	B-NP
syndrome	POS	I-NP
after	POS	O
liver	POS	O
transplant	POS	O
is	POS	O
rare	POS	O
.	POS	O
We	POS	O
recommend	POS	O
a	POS	O
complete	POS	O
cessation	POS	O
of	POS	O
any	POS	O
calcineurin	POS	O
inhibitor	POS	O
rather	POS	O
than	POS	O
a	POS	O
dose	POS	O
reduction	POS	O
.	POS	O
Prolonged	POS	O
hypothermia	POS	B-NP
as	POS	O
a	POS	O
bridge	POS	O
to	POS	O
recovery	POS	O
for	POS	O
cerebral	POS	B-NP
edema	POS	I-NP
and	POS	O
intracranial	POS	B-NP
hypertension	POS	I-NP
associated	POS	O
with	POS	O
fulminant	POS	B-NP
hepatic	POS	I-NP
failure	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
To	POS	O
review	POS	O
evidence	POS	O
-	POS	O
based	POS	O
treatment	POS	O
options	POS	O
in	POS	O
patients	POS	O
with	POS	O
cerebral	POS	B-NP
edema	POS	I-NP
complicating	POS	O
fulminant	POS	B-NP
hepatic	POS	I-NP
failure	POS	I-NP
(	POS	O
FHF	POS	B-NP
)	POS	O
and	POS	O
discuss	POS	O
the	POS	O
potential	POS	O
applications	POS	O
of	POS	O
hypothermia	POS	B-NP
.	POS	O
METHOD	POS	O
:	POS	O
Case	POS	O
-	POS	O
based	POS	O
observations	POS	O
from	POS	O
a	POS	O
medical	POS	O
intensive	POS	O
care	POS	O
unit	POS	O
(	POS	O
MICU	POS	O
)	POS	O
in	POS	O
a	POS	O
tertiary	POS	O
care	POS	O
facility	POS	O
in	POS	O
a	POS	O
27	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
female	POS	O
with	POS	O
FHF	POS	B-NP
from	POS	O
acetaminophen	POS	O
and	POS	O
resultant	POS	O
cerebral	POS	B-NP
edema	POS	I-NP
.	POS	O
RESULTS	POS	O
:	POS	O
Our	POS	O
patient	POS	O
was	POS	O
admitted	POS	O
to	POS	O
the	POS	O
MICU	POS	O
after	POS	O
being	POS	O
found	POS	O
unresponsive	POS	O
with	POS	O
presumed	POS	O
toxicity	POS	B-NP
from	POS	O
acetaminophen	POS	O
which	POS	O
was	POS	O
ingested	POS	O
over	POS	O
a	POS	O
2	POS	O
-	POS	O
day	POS	O
period	POS	O
.	POS	O
The	POS	O
patient	POS	O
had	POS	O
depressed	POS	O
of	POS	O
mental	POS	O
status	POS	O
lasting	POS	O
at	POS	O
least	POS	O
24	POS	O
h	POS	O
prior	POS	O
to	POS	O
admission	POS	O
.	POS	O
Initial	POS	O
evaluation	POS	O
confirmed	POS	O
FHF	POS	B-NP
from	POS	O
acetaminophen	POS	O
and	POS	O
cerebral	POS	B-NP
edema	POS	I-NP
.	POS	O
The	POS	O
patient	POS	O
was	POS	O
treated	POS	O
with	POS	O
hyperosmolar	POS	O
therapy	POS	O
,	POS	O
hyperventilation	POS	B-NP
,	POS	O
sedation	POS	O
,	POS	O
and	POS	O
chemical	POS	O
paralysis	POS	B-NP
.	POS	O
Her	POS	O
intracranial	POS	O
pressure	POS	O
remained	POS	O
elevated	POS	O
despite	POS	O
maximal	POS	O
medical	POS	O
therapy	POS	O
.	POS	O
We	POS	O
then	POS	O
initiated	POS	O
therapeutic	POS	O
hypothermia	POS	B-NP
which	POS	O
was	POS	O
continued	POS	O
for	POS	O
5	POS	O
days	POS	O
.	POS	O
At	POS	O
re	POS	O
-	POS	O
warming	POS	O
,	POS	O
patient	POS	O
had	POS	O
resolution	POS	O
of	POS	O
her	POS	O
cerebral	POS	B-NP
edema	POS	I-NP
and	POS	O
intracranial	POS	B-NP
hypertension	POS	I-NP
.	POS	O
At	POS	O
discharge	POS	O
,	POS	O
she	POS	O
had	POS	O
complete	POS	O
recovery	POS	O
of	POS	O
neurological	POS	O
and	POS	O
hepatic	POS	O
functions	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
In	POS	O
patients	POS	O
with	POS	O
FHF	POS	B-NP
and	POS	O
cerebral	POS	B-NP
edema	POS	I-NP
from	POS	O
acetaminophen	POS	O
overdose	POS	B-NP
,	POS	O
prolonged	POS	O
therapeutic	POS	O
hypothermia	POS	B-NP
could	POS	O
potentially	POS	O
be	POS	O
used	POS	O
as	POS	O
a	POS	O
life	POS	O
saving	POS	O
therapy	POS	O
and	POS	O
a	POS	O
bridge	POS	O
to	POS	O
hepatic	POS	O
and	POS	O
neurological	POS	O
recovery	POS	O
.	POS	O
A	POS	O
clinical	POS	O
trial	POS	O
of	POS	O
hypothermia	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
this	POS	O
condition	POS	O
is	POS	O
warranted	POS	O
.	POS	O
Binasal	POS	B-NP
visual	POS	I-NP
field	POS	I-NP
defects	POS	I-NP
are	POS	O
not	POS	O
specific	POS	O
to	POS	O
vigabatrin	POS	O
.	POS	O
This	POS	O
study	POS	O
investigated	POS	O
the	POS	O
visual	POS	B-NP
defects	POS	I-NP
associated	POS	O
with	POS	O
the	POS	O
antiepileptic	POS	O
drug	POS	O
vigabatrin	POS	O
(	POS	O
VGB	POS	O
)	POS	O
.	POS	O
Two	POS	O
hundred	POS	O
four	POS	O
people	POS	O
with	POS	O
epilepsy	POS	B-NP
were	POS	O
grouped	POS	O
on	POS	O
the	POS	O
basis	POS	O
of	POS	O
antiepileptic	POS	O
drug	POS	O
therapy	POS	O
(	POS	O
current	POS	O
,	POS	O
previous	POS	O
,	POS	O
or	POS	O
no	POS	O
exposure	POS	O
to	POS	O
VGB	POS	O
)	POS	O
.	POS	O
Groups	POS	O
were	POS	O
matched	POS	O
with	POS	O
respect	POS	O
to	POS	O
age	POS	O
,	POS	O
gender	POS	O
,	POS	O
and	POS	O
seizure	POS	B-NP
frequency	POS	O
.	POS	O
All	POS	O
patients	POS	O
underwent	POS	O
objective	POS	O
assessment	POS	O
of	POS	O
electrophysiological	POS	O
function	POS	O
(	POS	O
wide	POS	O
-	POS	O
field	POS	O
multifocal	POS	O
electroretinography	POS	O
)	POS	O
and	POS	O
conventional	POS	O
visual	POS	O
field	POS	O
testing	POS	O
(	POS	O
static	POS	O
perimetry	POS	O
)	POS	O
.	POS	O
Bilateral	POS	B-NP
visual	POS	I-NP
field	POS	I-NP
constriction	POS	I-NP
was	POS	O
observed	POS	O
in	POS	O
59	POS	O
%	POS	O
of	POS	O
patients	POS	O
currently	POS	O
taking	POS	O
VGB	POS	O
,	POS	O
43	POS	O
%	POS	O
of	POS	O
patients	POS	O
who	POS	O
previously	POS	O
took	POS	O
VGB	POS	O
,	POS	O
and	POS	O
24	POS	O
%	POS	O
of	POS	O
patients	POS	O
with	POS	O
no	POS	O
exposure	POS	O
to	POS	O
VGB	POS	O
.	POS	O
Assessment	POS	O
of	POS	O
retinal	POS	O
function	POS	O
revealed	POS	O
abnormal	POS	O
responses	POS	O
in	POS	O
48	POS	O
%	POS	O
of	POS	O
current	POS	O
VGB	POS	O
users	POS	O
and	POS	O
22	POS	O
%	POS	O
of	POS	O
prior	POS	O
VGB	POS	O
users	POS	O
,	POS	O
but	POS	O
in	POS	O
none	POS	O
of	POS	O
the	POS	O
patients	POS	O
without	POS	O
previous	POS	O
exposure	POS	O
to	POS	O
VGB	POS	B-NP
.	POS	O
Bilateral	POS	B-NP
visual	POS	I-NP
field	POS	I-NP
abnormalities	POS	I-NP
are	POS	O
common	POS	O
in	POS	O
the	POS	O
treated	POS	O
epilepsy	POS	B-NP
population	POS	O
,	POS	O
irrespective	POS	O
of	POS	O
drug	POS	O
history	POS	O
.	POS	O
Assessment	POS	O
by	POS	O
conventional	POS	O
static	POS	O
perimetry	POS	O
may	POS	O
neither	POS	O
be	POS	O
sufficiently	POS	O
sensitive	POS	O
nor	POS	O
specific	POS	O
to	POS	O
reliably	POS	O
identify	POS	O
retinal	POS	B-NP
toxicity	POS	I-NP
associated	POS	O
with	POS	O
VGB	POS	B-NP
.	POS	O
Smoking	POS	O
of	POS	O
crack	POS	O
cocaine	POS	O
as	POS	O
a	POS	O
risk	POS	O
factor	POS	O
for	POS	O
HIV	POS	B-NP
infection	POS	I-NP
among	POS	O
people	POS	O
who	POS	O
use	POS	O
injection	POS	O
drugs	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Little	POS	O
is	POS	O
known	POS	O
about	POS	O
the	POS	O
possible	POS	O
role	POS	O
that	POS	O
smoking	POS	O
crack	POS	O
cocaine	POS	O
has	POS	O
on	POS	O
the	POS	O
incidence	POS	O
of	POS	O
HIV	POS	B-NP
infection	POS	I-NP
.	POS	O
Given	POS	O
the	POS	O
increasing	POS	O
use	POS	O
of	POS	O
crack	POS	O
cocaine	POS	O
,	POS	O
we	POS	O
sought	POS	O
to	POS	O
examine	POS	O
whether	POS	O
use	POS	O
of	POS	O
this	POS	O
illicit	POS	O
drug	POS	O
has	POS	O
become	POS	O
a	POS	O
risk	POS	O
factor	POS	O
for	POS	O
HIV	POS	B-NP
infection	POS	I-NP
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
included	POS	O
data	POS	O
from	POS	O
people	POS	O
participating	POS	O
in	POS	O
the	POS	O
Vancouver	POS	O
Injection	POS	O
Drug	POS	O
Users	POS	O
Study	POS	O
who	POS	O
reported	POS	O
injecting	POS	O
illicit	POS	O
drugs	POS	O
at	POS	O
least	POS	O
once	POS	O
in	POS	O
the	POS	O
month	POS	O
before	POS	O
enrolment	POS	O
,	POS	O
lived	POS	O
in	POS	O
the	POS	O
greater	POS	O
Vancouver	POS	O
area	POS	O
,	POS	O
were	POS	O
HIV	POS	O
-	POS	O
negative	POS	O
at	POS	O
enrolment	POS	O
and	POS	O
completed	POS	O
at	POS	O
least	POS	O
1	POS	O
follow	POS	O
-	POS	O
up	POS	O
study	POS	O
visit	POS	O
.	POS	O
To	POS	O
determine	POS	O
whether	POS	O
the	POS	O
risk	POS	O
of	POS	O
HIV	POS	B-NP
seroconversion	POS	I-NP
among	POS	O
daily	POS	O
smokers	POS	O
of	POS	O
crack	POS	O
cocaine	POS	O
changed	POS	O
over	POS	O
time	POS	O
,	POS	O
we	POS	O
used	POS	O
Cox	POS	O
proportional	POS	O
hazards	POS	O
regression	POS	O
and	POS	O
divided	POS	O
the	POS	O
study	POS	O
into	POS	O
3	POS	O
periods	POS	O
:	POS	O
May	POS	O
1	POS	O
,	POS	O
1996	POS	O
-	POS	O
Nov	POS	O
.	POS	O
30	POS	O
,	POS	O
1999	POS	O
(	POS	O
period	POS	O
1	POS	O
)	POS	O
,	POS	O
Dec	POS	O
.	POS	O
1	POS	O
,	POS	O
1999	POS	O
-	POS	O
Nov	POS	O
.	POS	O
30	POS	O
,	POS	O
2002	POS	O
(	POS	O
period	POS	O
2	POS	O
)	POS	O
,	POS	O
and	POS	O
Dec	POS	O
.	POS	O
1	POS	O
,	POS	O
2002	POS	O
-	POS	O
Dec	POS	O
.	POS	O
30	POS	O
,	POS	O
2005	POS	O
(	POS	O
period	POS	O
3	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Overall	POS	O
,	POS	O
1048	POS	O
eligible	POS	O
injection	POS	O
drug	POS	O
users	POS	O
were	POS	O
included	POS	O
in	POS	O
our	POS	O
study	POS	O
.	POS	O
Of	POS	O
these	POS	O
,	POS	O
137	POS	O
acquired	POS	O
HIV	POS	B-NP
infection	POS	I-NP
during	POS	O
follow	POS	O
-	POS	O
up	POS	O
.	POS	O
The	POS	O
mean	POS	O
proportion	POS	O
of	POS	O
participants	POS	O
who	POS	O
reported	POS	O
daily	POS	O
smoking	POS	O
of	POS	O
crack	POS	O
cocaine	POS	O
increased	POS	O
from	POS	O
11	POS	O
.	POS	O
6	POS	O
%	POS	O
in	POS	O
period	POS	O
1	POS	O
to	POS	O
39	POS	O
.	POS	O
7	POS	O
%	POS	O
in	POS	O
period	POS	O
3	POS	O
.	POS	O
After	POS	O
adjusting	POS	O
for	POS	O
potential	POS	O
confounders	POS	O
,	POS	O
we	POS	O
found	POS	O
that	POS	O
the	POS	O
risk	POS	O
of	POS	O
HIV	POS	B-NP
seroconversion	POS	I-NP
among	POS	O
participants	POS	O
who	POS	O
were	POS	O
daily	POS	O
smokers	POS	O
of	POS	O
crack	POS	O
cocaine	POS	O
increased	POS	O
over	POS	O
time	POS	O
(	POS	O
period	POS	O
1	POS	O
:	POS	O
hazard	POS	O
ratio	POS	O
[	POS	O
HR	POS	O
]	POS	O
1	POS	O
.	POS	O
03	POS	O
,	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
[	POS	O
CI	POS	O
]	POS	O
0	POS	O
.	POS	O
57	POS	O
-	POS	O
1	POS	O
.	POS	O
85	POS	O
;	POS	O
period	POS	O
2	POS	O
:	POS	O
HR	POS	O
1	POS	O
.	POS	O
68	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
1	POS	O
.	POS	O
01	POS	O
-	POS	O
2	POS	O
.	POS	O
80	POS	O
;	POS	O
and	POS	O
period	POS	O
3	POS	O
:	POS	O
HR	POS	O
2	POS	O
.	POS	O
74	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
1	POS	O
.	POS	O
06	POS	O
-	POS	O
7	POS	O
.	POS	O
11	POS	O
)	POS	O
.	POS	O
INTERPRETATION	POS	O
:	POS	O
Smoking	POS	O
of	POS	O
crack	POS	O
cocaine	POS	O
was	POS	O
found	POS	O
to	POS	O
be	POS	O
an	POS	O
independent	POS	O
risk	POS	O
factor	POS	O
for	POS	O
HIV	POS	B-NP
seroconversion	POS	I-NP
among	POS	O
people	POS	O
who	POS	O
were	POS	O
injection	POS	O
drug	POS	O
users	POS	O
.	POS	O
This	POS	O
finding	POS	O
points	POS	O
to	POS	O
the	POS	O
urgent	POS	O
need	POS	O
for	POS	O
evidence	POS	O
-	POS	O
based	POS	O
public	POS	O
health	POS	O
initiatives	POS	O
targeted	POS	O
at	POS	O
people	POS	O
who	POS	O
smoke	POS	O
crack	POS	O
cocaine	POS	O
.	POS	O
Fluoxetine	POS	O
improves	POS	O
the	POS	O
memory	POS	B-NP
deficits	POS	I-NP
caused	POS	O
by	POS	O
the	POS	O
chemotherapy	POS	O
agent	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
.	POS	O
Cancer	POS	B-NP
patients	POS	O
who	POS	O
have	POS	O
been	POS	O
treated	POS	O
with	POS	O
systemic	POS	O
adjuvant	POS	O
chemotherapy	POS	O
have	POS	O
described	POS	O
experiencing	POS	O
deteriorations	POS	O
in	POS	O
cognition	POS	O
.	POS	O
A	POS	O
widely	POS	O
used	POS	O
chemotherapeutic	POS	O
agent	POS	O
,	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
(	POS	O
5	POS	O
-	POS	O
FU	POS	O
)	POS	O
,	POS	O
readily	POS	O
crosses	POS	O
the	POS	O
blood	POS	O
-	POS	O
brain	POS	O
barrier	POS	O
and	POS	O
so	POS	O
could	POS	O
have	POS	O
a	POS	O
direct	POS	O
effect	POS	O
on	POS	O
brain	POS	O
function	POS	O
.	POS	O
In	POS	O
particular	POS	O
this	POS	O
anti	POS	O
mitotic	POS	O
drug	POS	O
could	POS	O
reduce	POS	O
cell	POS	O
proliferation	POS	O
in	POS	O
the	POS	O
neurogenic	POS	O
regions	POS	O
of	POS	O
the	POS	O
adult	POS	O
brain	POS	O
.	POS	O
In	POS	O
contrast	POS	O
reports	POS	O
indicate	POS	O
that	POS	O
hippocampal	POS	O
dependent	POS	O
neurogenesis	POS	O
and	POS	O
cognition	POS	O
are	POS	O
enhanced	POS	O
by	POS	O
the	POS	O
SSRI	POS	O
antidepressant	POS	O
Fluoxetine	POS	O
.	POS	O
In	POS	O
this	POS	O
investigation	POS	O
the	POS	O
behavioural	POS	O
effects	POS	O
of	POS	O
chronic	POS	O
(	POS	O
two	POS	O
week	POS	O
)	POS	O
treatment	POS	O
with	POS	O
5	POS	O
-	POS	O
FU	POS	O
and	POS	O
(	POS	O
three	POS	O
weeks	POS	O
)	POS	O
with	POS	O
Fluoxetine	POS	O
either	POS	O
separately	POS	O
or	POS	O
in	POS	O
combination	POS	O
with	POS	O
5	POS	O
-	POS	O
FU	POS	O
were	POS	O
tested	POS	O
on	POS	O
adult	POS	O
Lister	POS	O
hooded	POS	O
rats	POS	O
.	POS	O
Behavioural	POS	O
effects	POS	O
were	POS	O
tested	POS	O
using	POS	O
a	POS	O
context	POS	O
dependent	POS	O
conditioned	POS	O
emotional	POS	O
response	POS	O
test	POS	O
(	POS	O
CER	POS	O
)	POS	O
which	POS	O
showed	POS	O
that	POS	O
animals	POS	O
treated	POS	O
with	POS	O
5	POS	O
-	POS	O
FU	POS	O
had	POS	O
a	POS	O
significant	POS	O
reduction	POS	O
in	POS	O
freezing	POS	O
time	POS	O
compared	POS	O
to	POS	O
controls	POS	O
.	POS	O
A	POS	O
separate	POS	O
group	POS	O
of	POS	O
animals	POS	O
was	POS	O
tested	POS	O
using	POS	O
a	POS	O
hippocampal	POS	O
dependent	POS	O
spatial	POS	O
working	POS	O
memory	POS	O
test	POS	O
,	POS	O
the	POS	O
object	POS	O
location	POS	O
recognition	POS	O
test	POS	O
(	POS	O
OLR	POS	O
)	POS	O
.	POS	O
Animals	POS	O
treated	POS	O
only	POS	O
with	POS	O
5	POS	O
-	POS	O
FU	POS	O
showed	POS	O
significant	POS	O
deficits	POS	O
in	POS	O
their	POS	O
ability	POS	O
to	POS	O
carry	POS	O
out	POS	O
the	POS	O
OLR	POS	O
task	POS	O
but	POS	O
co	POS	O
administration	POS	O
of	POS	O
Fluoxetine	POS	O
improved	POS	O
their	POS	O
performance	POS	O
.	POS	O
5	POS	O
-	POS	O
FU	POS	O
chemotherapy	POS	O
caused	POS	O
a	POS	O
significant	POS	O
reduction	POS	O
in	POS	O
the	POS	O
number	POS	O
of	POS	O
proliferating	POS	O
cells	POS	O
in	POS	O
the	POS	O
sub	POS	O
granular	POS	O
zone	POS	O
of	POS	O
the	POS	O
dentate	POS	O
gyrus	POS	O
compared	POS	O
to	POS	O
controls	POS	O
.	POS	O
This	POS	O
reduction	POS	O
was	POS	O
eliminated	POS	O
when	POS	O
Fluoxetine	POS	O
was	POS	O
co	POS	O
administered	POS	O
with	POS	O
5	POS	O
-	POS	O
FU	POS	O
.	POS	O
Fluoxetine	POS	O
on	POS	O
its	POS	O
own	POS	O
had	POS	O
no	POS	O
effect	POS	O
on	POS	O
proliferating	POS	O
cell	POS	O
number	POS	O
or	POS	O
behaviour	POS	O
.	POS	O
These	POS	O
findings	POS	O
suggest	POS	O
that	POS	O
5	POS	O
-	POS	O
FU	POS	O
can	POS	O
negatively	POS	O
affect	POS	O
both	POS	O
cell	POS	O
proliferation	POS	O
and	POS	O
hippocampal	POS	O
dependent	POS	O
working	POS	O
memory	POS	O
and	POS	O
that	POS	O
these	POS	O
deficits	POS	O
can	POS	O
be	POS	O
reversed	POS	O
by	POS	O
the	POS	O
simultaneous	POS	O
administration	POS	O
of	POS	O
the	POS	O
antidepressant	POS	O
Fluoxetine	POS	O
.	POS	O
Liver	POS	O
-	POS	O
specific	POS	O
ablation	POS	O
of	POS	O
integrin	POS	O
-	POS	O
linked	POS	O
kinase	POS	O
in	POS	O
mice	POS	O
results	POS	O
in	POS	O
enhanced	POS	O
and	POS	O
prolonged	POS	O
cell	POS	O
proliferation	POS	O
and	POS	O
hepatomegaly	POS	B-NP
after	POS	O
phenobarbital	POS	O
administration	POS	O
.	POS	O
We	POS	O
have	POS	O
recently	POS	O
demonstrated	POS	O
that	POS	O
disruption	POS	O
of	POS	O
extracellular	POS	O
matrix	POS	O
(	POS	O
ECM	POS	O
)	POS	O
/	POS	O
integrin	POS	O
signaling	POS	O
via	POS	O
elimination	POS	O
of	POS	O
integrin	POS	O
-	POS	O
linked	POS	O
kinase	POS	O
(	POS	O
ILK	POS	O
)	POS	O
in	POS	O
hepatocytes	POS	O
interferes	POS	O
with	POS	O
signals	POS	O
leading	POS	O
to	POS	O
termination	POS	O
of	POS	O
liver	POS	O
regeneration	POS	O
.	POS	O
This	POS	O
study	POS	O
investigates	POS	O
the	POS	O
role	POS	O
of	POS	O
ILK	POS	O
in	POS	O
liver	POS	B-NP
enlargement	POS	I-NP
induced	POS	O
by	POS	O
phenobarbital	POS	O
(	POS	O
PB	POS	O
)	POS	O
.	POS	O
Wild	POS	O
-	POS	O
type	POS	O
(	POS	O
WT	POS	O
)	POS	O
and	POS	O
ILK	POS	O
:	POS	O
liver	POS	O
-	POS	O
/	POS	O
-	POS	O
mice	POS	O
were	POS	O
given	POS	O
PB	POS	O
(	POS	O
0	POS	O
.	POS	O
1	POS	O
%	POS	O
in	POS	O
drinking	POS	O
water	POS	O
)	POS	O
for	POS	O
10	POS	O
days	POS	O
.	POS	O
Livers	POS	O
were	POS	O
harvested	POS	O
on	POS	O
2	POS	O
,	POS	O
5	POS	O
,	POS	O
and	POS	O
10	POS	O
days	POS	O
during	POS	O
PB	POS	O
administration	POS	O
.	POS	O
In	POS	O
the	POS	O
hepatocyte	POS	O
-	POS	O
specific	POS	O
ILK	POS	O
/	POS	O
liver	POS	O
-	POS	O
/	POS	O
-	POS	O
mice	POS	O
,	POS	O
the	POS	O
liver	POS	O
:	POS	O
body	POS	O
weight	POS	O
ratio	POS	O
was	POS	O
more	POS	O
than	POS	O
double	POS	O
as	POS	O
compared	POS	O
to	POS	O
0	POS	O
h	POS	O
at	POS	O
day	POS	O
2	POS	O
(	POS	O
2	POS	O
.	POS	O
5	POS	O
times	POS	O
)	POS	O
,	POS	O
while	POS	O
at	POS	O
days	POS	O
5	POS	O
and	POS	O
10	POS	O
,	POS	O
it	POS	O
was	POS	O
enlarged	POS	O
three	POS	O
times	POS	O
.	POS	O
In	POS	O
the	POS	O
WT	POS	O
mice	POS	O
,	POS	O
the	POS	O
increase	POS	O
was	POS	O
as	POS	O
expected	POS	O
from	POS	O
previous	POS	O
literature	POS	O
(	POS	O
1	POS	O
.	POS	O
8	POS	O
times	POS	O
)	POS	O
and	POS	O
seems	POS	O
to	POS	O
have	POS	O
leveled	POS	O
off	POS	O
after	POS	O
day	POS	O
2	POS	O
.	POS	O
There	POS	O
were	POS	O
slightly	POS	O
increased	POS	O
proliferating	POS	O
cell	POS	O
nuclear	POS	O
antigen	POS	O
-	POS	O
positive	POS	O
cells	POS	O
in	POS	O
the	POS	O
ILK	POS	O
/	POS	O
liver	POS	O
-	POS	O
/	POS	O
-	POS	O
animals	POS	O
at	POS	O
day	POS	O
2	POS	O
as	POS	O
compared	POS	O
to	POS	O
WT	POS	O
after	POS	O
PB	POS	O
administration	POS	O
.	POS	O
In	POS	O
the	POS	O
WT	POS	O
animals	POS	O
,	POS	O
the	POS	O
proliferative	POS	O
response	POS	O
had	POS	O
come	POS	O
back	POS	O
to	POS	O
normal	POS	O
by	POS	O
days	POS	O
5	POS	O
and	POS	O
10	POS	O
.	POS	O
Hepatocytes	POS	O
of	POS	O
the	POS	O
ILK	POS	O
/	POS	O
liver	POS	O
-	POS	O
/	POS	O
-	POS	O
mice	POS	O
continued	POS	O
to	POS	O
proliferate	POS	O
up	POS	O
until	POS	O
day	POS	O
10	POS	O
.	POS	O
ILK	POS	O
/	POS	O
liver	POS	O
-	POS	O
/	POS	O
-	POS	O
mice	POS	O
also	POS	O
showed	POS	O
increased	POS	O
expression	POS	O
of	POS	O
key	POS	O
genes	POS	O
involved	POS	O
in	POS	O
hepatocyte	POS	O
proliferation	POS	O
at	POS	O
different	POS	O
time	POS	O
points	POS	O
during	POS	O
PB	POS	O
administration	POS	O
.	POS	O
In	POS	O
summary	POS	O
,	POS	O
ECM	POS	O
proteins	POS	O
communicate	POS	O
with	POS	O
the	POS	O
signaling	POS	O
machinery	POS	O
of	POS	O
dividing	POS	O
cells	POS	O
via	POS	O
ILK	POS	O
to	POS	O
regulate	POS	O
hepatocyte	POS	O
proliferation	POS	O
and	POS	O
termination	POS	O
of	POS	O
the	POS	O
proliferative	POS	O
response	POS	O
.	POS	O
Lack	POS	O
of	POS	O
ILK	POS	O
in	POS	O
the	POS	O
hepatocytes	POS	O
imparts	POS	O
prolonged	POS	O
proliferative	POS	O
response	POS	O
not	POS	O
only	POS	O
to	POS	O
stimuli	POS	O
related	POS	O
to	POS	O
liver	POS	O
regeneration	POS	O
but	POS	O
also	POS	O
to	POS	O
xenobiotic	POS	O
chemical	POS	O
mitogens	POS	O
,	POS	O
such	POS	O
as	POS	O
PB	POS	O
.	POS	O
Decreased	POS	O
Expression	POS	O
of	POS	O
Na	POS	O
/	POS	O
K	POS	O
-	POS	O
ATPase	POS	O
,	POS	O
NHE3	POS	O
,	POS	O
NBC1	POS	O
,	POS	O
AQP1	POS	O
and	POS	O
OAT	POS	O
in	POS	O
Gentamicin	POS	O
-	POS	O
induced	POS	O
Nephropathy	POS	B-NP
.	POS	O
The	POS	O
present	POS	O
study	POS	O
was	POS	O
aimed	POS	O
to	POS	O
determine	POS	O
whether	POS	O
there	POS	O
is	POS	O
an	POS	O
altered	POS	O
regulation	POS	O
of	POS	O
tubular	POS	O
transporters	POS	O
in	POS	O
gentamicin	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
.	POS	O
Sprague	POS	O
-	POS	O
Dawley	POS	O
male	POS	O
rats	POS	O
(	POS	O
200	POS	O
~	POS	O
250	POS	O
g	POS	O
)	POS	O
were	POS	O
subcutaneously	POS	O
injected	POS	O
with	POS	O
gentamicin	POS	O
(	POS	O
100	POS	O
mg	POS	O
/	POS	O
kg	POS	O
per	POS	O
day	POS	O
)	POS	O
for	POS	O
7	POS	O
days	POS	O
,	POS	O
and	POS	O
the	POS	O
expression	POS	O
of	POS	O
tubular	POS	O
transporters	POS	O
was	POS	O
determined	POS	O
by	POS	O
immunoblotting	POS	O
and	POS	O
immunohistochemistry	POS	O
.	POS	O
The	POS	O
mRNA	POS	O
and	POS	O
protein	POS	O
expression	POS	O
of	POS	O
OAT	POS	O
was	POS	O
also	POS	O
determined	POS	O
.	POS	O
Gentamicin	POS	O
-	POS	O
treated	POS	O
rats	POS	O
exhibited	POS	O
significantly	POS	O
decreased	POS	O
creatinine	POS	O
clearance	POS	O
along	POS	O
with	POS	O
increased	POS	O
plasma	POS	O
creatinine	POS	O
levels	POS	O
.	POS	O
Accordingly	POS	O
,	POS	O
the	POS	O
fractional	POS	O
excretion	POS	O
of	POS	O
sodium	POS	O
increased	POS	O
.	POS	O
Urine	POS	O
volume	POS	O
was	POS	O
increased	POS	O
,	POS	O
while	POS	O
urine	POS	O
osmolality	POS	O
and	POS	O
free	POS	O
water	POS	O
reabsorption	POS	O
were	POS	O
decreased	POS	O
.	POS	O
Immunoblotting	POS	O
and	POS	O
immunohistochemistry	POS	O
revealed	POS	O
decreased	POS	O
expression	POS	O
of	POS	O
Na	POS	O
(	POS	O
+	POS	O
)	POS	O
/	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
ATPase	POS	O
,	POS	O
NHE3	POS	O
,	POS	O
NBC1	POS	O
,	POS	O
and	POS	O
AQP1	POS	O
in	POS	O
the	POS	O
kidney	POS	O
of	POS	O
gentamicin	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
The	POS	O
expression	POS	O
of	POS	O
OAT1	POS	O
and	POS	O
OAT3	POS	O
was	POS	O
also	POS	O
decreased	POS	O
.	POS	O
Gentamicin	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
may	POS	O
at	POS	O
least	POS	O
in	POS	O
part	POS	O
be	POS	O
causally	POS	O
related	POS	O
with	POS	O
a	POS	O
decreased	POS	O
expression	POS	O
of	POS	O
Na	POS	O
(	POS	O
+	POS	O
)	POS	O
/	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
-	POS	O
ATPase	POS	O
,	POS	O
NHE3	POS	O
,	POS	O
NBC1	POS	O
,	POS	O
AQP1	POS	O
and	POS	O
OAT	POS	O
.	POS	O
Acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
methotrexate	POS	O
therapy	POS	O
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
ileostomy	POS	O
.	POS	O
High	POS	O
-	POS	O
dose	POS	O
methotrexate	POS	O
(	POS	O
HD	POS	B-NP
-	POS	O
MTX	POS	O
)	POS	O
is	POS	O
an	POS	O
important	POS	O
treatment	POS	O
for	POS	O
Burkitt	POS	B-NP
lymphoma	POS	I-NP
,	POS	O
but	POS	O
can	POS	O
cause	POS	O
hepatic	POS	B-NP
and	POS	I-NP
renal	POS	I-NP
toxicity	POS	I-NP
when	POS	O
its	POS	O
clearance	POS	O
is	POS	O
delayed	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
after	POS	O
HD	POS	B-NP
-	POS	O
MTX	POS	O
therapy	POS	O
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
ileostomy	POS	O
,	POS	O
The	POS	O
patient	POS	O
was	POS	O
a	POS	O
3	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
boy	POS	O
who	POS	O
had	POS	O
received	POS	O
a	POS	O
living	POS	O
-	POS	O
related	POS	O
liver	POS	O
transplantation	POS	O
for	POS	O
congenital	POS	B-NP
biliary	POS	I-NP
atresia	POS	I-NP
.	POS	O
At	POS	O
day	POS	O
833	POS	O
after	POS	O
the	POS	O
transplantation	POS	O
,	POS	O
he	POS	O
was	POS	O
diagnosed	POS	O
with	POS	O
PTLD	POS	B-NP
(	POS	O
post	POS	B-NP
-	POS	I-NP
transplantation	POS	I-NP
lymphoproliferative	POS	I-NP
disorder	POS	I-NP
,	POS	O
Burkitt	POS	B-NP
-	POS	I-NP
type	POS	I-NP
malignant	POS	I-NP
lymphoma	POS	I-NP
)	POS	O
.	POS	O
During	POS	O
induction	POS	O
therapy	POS	O
,	POS	O
he	POS	O
suffered	POS	O
ileal	POS	B-NP
perforation	POS	I-NP
and	POS	O
ileostomy	POS	B-NP
was	POS	O
performed	POS	O
.	POS	O
Subsequent	POS	O
HD	POS	B-NP
-	POS	O
MTX	POS	O
therapy	POS	O
caused	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
that	POS	O
required	POS	O
continuous	POS	O
hemodialysis	POS	O
.	POS	O
We	POS	O
supposed	POS	O
that	POS	O
intravascular	POS	B-NP
hypovolemia	POS	I-NP
due	POS	O
to	POS	O
substantial	POS	O
drainage	POS	O
from	POS	O
the	POS	O
ileostoma	POS	B-NP
caused	POS	O
acute	POS	B-NP
prerenal	POS	I-NP
failure	POS	I-NP
.	POS	O
After	POS	O
recovery	POS	O
of	POS	O
his	POS	O
renal	POS	O
function	POS	O
,	POS	O
we	POS	O
could	POS	O
safely	POS	O
treat	POS	O
the	POS	O
patient	POS	O
with	POS	O
HD	POS	B-NP
-	POS	O
MTX	POS	O
therapy	POS	O
by	POS	O
controlling	POS	O
drainage	POS	O
from	POS	O
ileostoma	POS	B-NP
with	POS	O
total	POS	O
parenteral	POS	O
nutrition	POS	O
.	POS	O
Longitudinal	POS	O
association	POS	O
of	POS	O
alcohol	POS	O
use	POS	O
with	POS	O
HIV	POS	B-NP
disease	POS	I-NP
progression	POS	O
and	POS	O
psychological	POS	O
health	POS	O
of	POS	O
women	POS	O
with	POS	O
HIV	POS	B-NP
.	POS	O
We	POS	O
evaluated	POS	O
the	POS	O
association	POS	O
of	POS	O
alcohol	POS	O
consumption	POS	O
and	POS	O
depression	POS	B-NP
,	POS	O
and	POS	O
their	POS	O
effects	POS	O
on	POS	O
HIV	POS	B-NP
disease	POS	I-NP
progression	POS	O
among	POS	O
women	POS	O
with	POS	O
HIV	POS	B-NP
.	POS	O
The	POS	O
study	POS	O
included	POS	O
871	POS	O
women	POS	O
with	POS	O
HIV	POS	B-NP
who	POS	O
were	POS	O
recruited	POS	O
from	POS	O
1993	POS	O
-	POS	O
1995	POS	O
in	POS	O
four	POS	O
US	POS	O
cities	POS	O
.	POS	O
The	POS	O
participants	POS	O
had	POS	O
physical	POS	O
examination	POS	O
,	POS	O
medical	POS	O
record	POS	O
extraction	POS	O
,	POS	O
and	POS	O
venipuncture	POS	O
,	POS	O
CD4	POS	O
+	POS	O
T	POS	O
-	POS	O
cell	POS	O
counts	POS	O
determination	POS	O
,	POS	O
measurement	POS	O
of	POS	O
depression	POS	B-NP
symptoms	POS	O
(	POS	O
using	POS	O
the	POS	O
self	POS	O
-	POS	O
report	POS	O
Center	POS	O
for	POS	O
Epidemiological	POS	O
Studies	POS	O
-	POS	O
Depression	POS	O
Scale	POS	O
)	POS	O
,	POS	O
and	POS	O
alcohol	POS	O
use	POS	O
assessment	POS	O
at	POS	O
enrollment	POS	O
,	POS	O
and	POS	O
semiannually	POS	O
until	POS	O
March	POS	O
2000	POS	O
.	POS	O
Multilevel	POS	O
random	POS	O
coefficient	POS	O
ordinal	POS	O
models	POS	O
as	POS	O
well	POS	O
as	POS	O
multilevel	POS	O
models	POS	O
with	POS	O
joint	POS	O
responses	POS	O
were	POS	O
used	POS	O
in	POS	O
the	POS	O
analysis	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
significant	POS	O
association	POS	O
between	POS	O
level	POS	O
of	POS	O
alcohol	POS	O
use	POS	O
and	POS	O
CD4	POS	O
+	POS	O
T	POS	O
-	POS	O
cell	POS	O
counts	POS	O
.	POS	O
When	POS	O
participants	POS	O
were	POS	O
stratified	POS	O
by	POS	O
antiretroviral	POS	O
therapy	POS	O
(	POS	O
ART	POS	O
)	POS	O
use	POS	O
,	POS	O
the	POS	O
association	POS	O
between	POS	O
alcohol	POS	O
and	POS	O
CD4	POS	O
+	POS	O
T	POS	O
-	POS	O
cell	POS	O
did	POS	O
not	POS	O
reach	POS	O
statistical	POS	O
significance	POS	O
.	POS	O
The	POS	O
association	POS	O
between	POS	O
alcohol	POS	O
consumption	POS	O
and	POS	O
depression	POS	B-NP
was	POS	O
significant	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Depression	POS	B-NP
had	POS	O
a	POS	O
significant	POS	O
negative	POS	O
effect	POS	O
on	POS	O
CD4	POS	O
+	POS	O
T	POS	O
-	POS	O
cell	POS	O
counts	POS	O
over	POS	O
time	POS	O
regardless	POS	O
of	POS	O
ART	POS	O
use	POS	O
.	POS	O
Our	POS	O
findings	POS	O
suggest	POS	O
that	POS	O
alcohol	POS	O
consumption	POS	O
has	POS	O
a	POS	O
direct	POS	O
association	POS	O
with	POS	O
depression	POS	B-NP
.	POS	O
Moreover	POS	O
,	POS	O
depression	POS	B-NP
is	POS	O
associated	POS	O
with	POS	O
HIV	POS	B-NP
disease	POS	I-NP
progression	POS	O
.	POS	O
Our	POS	O
findings	POS	O
have	POS	O
implications	POS	O
for	POS	O
the	POS	O
provision	POS	O
of	POS	O
alcohol	POS	O
use	POS	O
interventions	POS	O
and	POS	O
psychological	POS	O
resources	POS	O
to	POS	O
improve	POS	O
the	POS	O
health	POS	O
of	POS	O
women	POS	O
with	POS	O
HIV	POS	O
.	POS	O
Chemokine	POS	O
CCL2	POS	O
and	POS	O
its	POS	O
receptor	POS	O
CCR2	POS	O
are	POS	O
increased	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
following	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Neuroinflammation	POS	O
occurs	POS	O
after	POS	O
seizures	POS	B-NP
and	POS	O
is	POS	O
implicated	POS	O
in	POS	O
epileptogenesis	POS	B-NP
.	POS	O
CCR2	POS	O
is	POS	O
a	POS	O
chemokine	POS	O
receptor	POS	O
for	POS	O
CCL2	POS	O
and	POS	O
their	POS	O
interaction	POS	O
mediates	POS	O
monocyte	POS	O
infiltration	POS	O
in	POS	O
the	POS	O
neuroinflammatory	POS	O
cascade	POS	O
triggered	POS	O
in	POS	O
different	POS	O
brain	POS	B-NP
pathologies	POS	I-NP
.	POS	O
In	POS	O
this	POS	O
work	POS	O
CCR2	POS	O
and	POS	O
CCL2	POS	O
expression	POS	O
were	POS	O
examined	POS	O
following	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
(	POS	O
SE	POS	B-NP
)	POS	O
induced	POS	O
by	POS	O
pilocarpine	POS	O
injection	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
SE	POS	B-NP
was	POS	O
induced	POS	O
by	POS	O
pilocarpine	POS	O
injection	POS	O
.	POS	O
Control	POS	O
rats	POS	O
were	POS	O
injected	POS	O
with	POS	O
saline	POS	O
instead	POS	O
of	POS	O
pilocarpine	POS	O
.	POS	O
Five	POS	O
days	POS	O
after	POS	O
SE	POS	O
,	POS	O
CCR2	POS	O
staining	POS	O
in	POS	O
neurons	POS	O
and	POS	O
glial	POS	O
cells	POS	O
was	POS	O
examined	POS	O
using	POS	O
imunohistochemical	POS	O
analyses	POS	O
.	POS	O
The	POS	O
number	POS	O
of	POS	O
CCR2	POS	O
positive	POS	O
cells	POS	O
was	POS	O
determined	POS	O
using	POS	O
stereology	POS	O
probes	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
.	POS	O
CCL2	POS	O
expression	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
was	POS	O
examined	POS	O
by	POS	O
molecular	POS	O
assay	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Increased	POS	O
CCR2	POS	O
was	POS	O
observed	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
after	POS	O
SE	POS	B-NP
.	POS	O
Seizures	POS	B-NP
also	POS	O
resulted	POS	O
in	POS	O
alterations	POS	O
to	POS	O
the	POS	O
cell	POS	O
types	POS	O
expressing	POS	O
CCR2	POS	O
.	POS	O
Increased	POS	O
numbers	POS	O
of	POS	O
neurons	POS	O
that	POS	O
expressed	POS	O
CCR2	POS	O
was	POS	O
observed	POS	O
following	POS	O
SE	POS	B-NP
.	POS	O
Microglial	POS	O
cells	POS	O
were	POS	O
more	POS	O
closely	POS	O
apposed	POS	O
to	POS	O
the	POS	O
CCR2	POS	O
-	POS	O
labeled	POS	O
cells	POS	O
in	POS	O
SE	POS	O
rats	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
rats	POS	O
that	POS	O
experienced	POS	O
SE	POS	O
exhibited	POS	O
CCR2	POS	O
-	POS	O
labeling	POS	O
in	POS	O
populations	POS	O
of	POS	O
hypertrophied	POS	O
astrocytes	POS	O
,	POS	O
especially	POS	O
in	POS	O
CA1	POS	O
and	POS	O
dentate	POS	O
gyrus	POS	O
.	POS	O
These	POS	O
CCR2	POS	O
+	POS	O
astroctytes	POS	O
were	POS	O
not	POS	O
observed	POS	O
in	POS	O
control	POS	O
rats	POS	O
.	POS	O
Examination	POS	O
of	POS	O
CCL2	POS	O
expression	POS	O
showed	POS	O
that	POS	O
it	POS	O
was	POS	O
elevated	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
following	POS	O
SE	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
data	POS	O
show	POS	O
that	POS	O
CCR2	POS	O
and	POS	O
CCL2	POS	O
are	POS	O
up	POS	O
-	POS	O
regulated	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
after	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
SE	POS	B-NP
.	POS	O
Seizures	POS	B-NP
also	POS	O
result	POS	O
in	POS	O
changes	POS	O
to	POS	O
CCR2	POS	O
receptor	POS	O
expression	POS	O
in	POS	O
neurons	POS	O
and	POS	O
astrocytes	POS	O
.	POS	O
These	POS	O
changes	POS	O
might	POS	O
be	POS	O
involved	POS	O
in	POS	O
detrimental	POS	O
neuroplasticity	POS	O
and	POS	O
neuroinflammatory	POS	O
changes	POS	O
that	POS	O
occur	POS	O
following	POS	O
seizures	POS	B-NP
.	POS	O
Metallothionein	POS	O
induction	POS	O
reduces	POS	O
caspase	POS	O
-	POS	O
3	POS	O
activity	POS	O
and	POS	O
TNFalpha	POS	O
levels	POS	O
with	POS	O
preservation	POS	O
of	POS	O
cognitive	POS	O
function	POS	O
and	POS	O
intact	POS	O
hippocampal	POS	O
neurons	POS	O
in	POS	O
carmustine	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
Hippocampal	POS	O
integrity	POS	O
is	POS	O
essential	POS	O
for	POS	O
cognitive	POS	O
functions	POS	O
.	POS	O
On	POS	O
the	POS	O
other	POS	O
hand	POS	O
,	POS	O
induction	POS	O
of	POS	O
metallothionein	POS	O
(	POS	O
MT	POS	O
)	POS	O
by	POS	O
ZnSO	POS	O
(	POS	O
4	POS	O
)	POS	O
and	POS	O
its	POS	O
role	POS	O
in	POS	O
neuroprotection	POS	O
has	POS	O
been	POS	O
documented	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
aimed	POS	O
to	POS	O
explore	POS	O
the	POS	O
effect	POS	O
of	POS	O
MT	POS	O
induction	POS	O
on	POS	O
carmustine	POS	O
(	POS	O
BCNU	POS	O
)	POS	O
-	POS	O
induced	POS	O
hippocampal	POS	B-NP
cognitive	POS	I-NP
dysfunction	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
60	POS	O
male	POS	O
Wistar	POS	O
albino	POS	O
rats	POS	O
were	POS	O
randomly	POS	O
divided	POS	O
into	POS	O
four	POS	O
groups	POS	O
(	POS	O
15	POS	O
/	POS	O
group	POS	O
)	POS	O
:	POS	O
The	POS	O
control	POS	O
group	POS	O
injected	POS	O
with	POS	O
single	POS	O
doses	POS	O
of	POS	O
normal	POS	O
saline	POS	O
(	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
)	POS	O
followed	POS	O
24	POS	O
h	POS	O
later	POS	O
by	POS	O
BCNU	POS	O
solvent	POS	O
(	POS	O
i	POS	O
.	POS	O
v	POS	O
)	POS	O
.	POS	O
The	POS	O
second	POS	O
group	POS	O
administered	POS	O
ZnSO	POS	O
(	POS	O
4	POS	O
)	POS	O
(	POS	O
0	POS	O
.	POS	O
1	POS	O
micromol	POS	O
/	POS	O
10	POS	O
microl	POS	O
normal	POS	O
saline	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
,	POS	O
once	POS	O
)	POS	O
then	POS	O
BCNU	POS	O
solvent	POS	O
(	POS	O
i	POS	O
.	POS	O
v	POS	O
)	POS	O
after	POS	O
24	POS	O
h	POS	O
.	POS	O
Third	POS	O
group	POS	O
received	POS	O
BCNU	POS	O
(	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
v	POS	O
,	POS	O
once	POS	O
)	POS	O
24	POS	O
h	POS	O
after	POS	O
injection	POS	O
with	POS	O
normal	POS	O
saline	POS	O
(	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
)	POS	O
.	POS	O
Fourth	POS	O
group	POS	O
received	POS	O
a	POS	O
single	POS	O
dose	POS	O
of	POS	O
ZnSO	POS	O
(	POS	O
4	POS	O
)	POS	O
(	POS	O
0	POS	O
.	POS	O
1	POS	O
micromol	POS	O
/	POS	O
10	POS	O
microl	POS	O
normal	POS	O
saline	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
)	POS	O
then	POS	O
BCNU	POS	O
(	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
v	POS	O
,	POS	O
once	POS	O
)	POS	O
after	POS	O
24	POS	O
h	POS	O
.	POS	O
The	POS	O
obtained	POS	O
data	POS	O
revealed	POS	O
that	POS	O
BCNU	POS	O
administration	POS	O
resulted	POS	O
in	POS	O
deterioration	POS	O
of	POS	O
learning	POS	O
and	POS	O
short	POS	O
-	POS	O
term	POS	O
memory	POS	O
(	POS	O
STM	POS	O
)	POS	O
,	POS	O
as	POS	O
measured	POS	O
by	POS	O
using	POS	O
radial	POS	O
arm	POS	O
water	POS	O
maze	POS	O
,	POS	O
accompanied	POS	O
with	POS	O
decreased	POS	O
hippocampal	POS	O
glutathione	POS	O
reductase	POS	O
(	POS	O
GR	POS	O
)	POS	O
activity	POS	O
and	POS	O
reduced	POS	O
glutathione	POS	O
(	POS	O
GSH	POS	O
)	POS	O
content	POS	O
.	POS	O
Also	POS	O
,	POS	O
BCNU	POS	O
administration	POS	O
increased	POS	O
serum	POS	O
tumor	POS	O
necrosis	POS	O
factor	POS	O
-	POS	O
alpha	POS	O
(	POS	O
TNFalpha	POS	O
)	POS	O
,	POS	O
hippocampal	POS	O
MT	POS	O
and	POS	O
malondialdehyde	POS	O
(	POS	O
MDA	POS	O
)	POS	O
contents	POS	O
as	POS	O
well	POS	O
as	POS	O
caspase	POS	O
-	POS	O
3	POS	O
activity	POS	O
in	POS	O
addition	POS	O
to	POS	O
histological	POS	O
alterations	POS	O
.	POS	O
ZnSO	POS	O
(	POS	O
4	POS	O
)	POS	O
pretreatment	POS	O
counteracted	POS	O
BCNU	POS	O
-	POS	O
induced	POS	O
inhibition	POS	O
of	POS	O
GR	POS	O
and	POS	O
depletion	POS	O
of	POS	O
GSH	POS	O
and	POS	O
resulted	POS	O
in	POS	O
significant	POS	O
reduction	POS	O
in	POS	O
the	POS	O
levels	POS	O
of	POS	O
MDA	POS	O
and	POS	O
TNFalpha	POS	O
as	POS	O
well	POS	O
as	POS	O
the	POS	O
activity	POS	O
of	POS	O
caspase	POS	O
-	POS	O
3	POS	O
.	POS	O
The	POS	O
histological	POS	O
features	POS	O
were	POS	O
improved	POS	O
in	POS	O
hippocampus	POS	O
of	POS	O
rats	POS	O
treated	POS	O
with	POS	O
ZnSO	POS	O
(	POS	O
4	POS	O
)	POS	O
+	POS	O
BCNU	POS	O
compared	POS	O
to	POS	O
only	POS	O
BCNU	POS	O
-	POS	O
treated	POS	O
animals	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
MT	POS	O
induction	POS	O
halts	POS	O
BCNU	POS	O
-	POS	O
induced	POS	O
hippocampal	POS	B-NP
toxicity	POS	I-NP
as	POS	O
it	POS	O
prevented	POS	O
GR	POS	O
inhibition	POS	O
and	POS	O
GSH	POS	O
depletion	POS	O
and	POS	O
counteracted	POS	O
the	POS	O
increased	POS	O
levels	POS	O
of	POS	O
TNFalpha	POS	O
,	POS	O
MDA	POS	O
and	POS	O
caspase	POS	O
-	POS	O
3	POS	O
activity	POS	O
with	POS	O
subsequent	POS	O
preservation	POS	O
of	POS	O
cognition	POS	O
.	POS	O
Fatal	POS	O
carbamazepine	POS	O
induced	POS	O
fulminant	POS	B-NP
eosinophilic	POS	I-NP
(	POS	O
hypersensitivity	POS	B-NP
)	POS	O
myocarditis	POS	B-NP
:	POS	O
emphasis	POS	O
on	POS	O
anatomical	POS	O
and	POS	O
histological	POS	O
characteristics	POS	O
,	POS	O
mechanisms	POS	O
and	POS	O
genetics	POS	O
of	POS	O
drug	POS	O
hypersensitivity	POS	B-NP
and	POS	O
differential	POS	O
diagnosis	POS	O
.	POS	O
The	POS	O
most	POS	O
severe	POS	O
adverse	POS	O
reactions	POS	O
to	POS	O
carbamazepine	POS	O
have	POS	O
been	POS	O
observed	POS	O
in	POS	O
the	POS	O
haemopoietic	POS	O
system	POS	O
,	POS	O
the	POS	O
liver	POS	O
and	POS	O
the	POS	O
cardiovascular	POS	O
system	POS	O
.	POS	O
A	POS	O
frequently	POS	O
fatal	POS	O
,	POS	O
although	POS	O
exceptionally	POS	O
rare	POS	O
side	POS	O
effect	POS	O
of	POS	O
carbamazepine	POS	O
is	POS	O
necrotizing	POS	B-NP
eosinophilic	POS	I-NP
(	POS	O
hypersensitivity	POS	B-NP
)	POS	O
myocarditis	POS	B-NP
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
hypersensitivity	POS	B-NP
myocarditis	POS	I-NP
secondary	POS	O
to	POS	O
administration	POS	O
of	POS	O
carbamazepine	POS	O
.	POS	O
Acute	POS	O
hypersensitivity	POS	B-NP
myocarditis	POS	I-NP
was	POS	O
not	POS	O
suspected	POS	O
clinically	POS	O
,	POS	O
and	POS	O
the	POS	O
diagnosis	POS	O
was	POS	O
made	POS	O
post	POS	O
-	POS	O
mortem	POS	O
.	POS	O
Histology	POS	O
revealed	POS	O
diffuse	POS	O
infiltration	POS	O
of	POS	O
the	POS	O
myocardium	POS	O
by	POS	O
eosinophils	POS	O
and	POS	O
lymphocytes	POS	O
with	POS	O
myocyte	POS	B-NP
damage	POS	I-NP
.	POS	O
Clinically	POS	O
,	POS	O
death	POS	B-NP
was	POS	O
due	POS	O
to	POS	O
cardiogenic	POS	B-NP
shock	POS	I-NP
.	POS	O
To	POS	O
best	POS	O
of	POS	O
our	POS	O
knowledge	POS	O
this	POS	O
is	POS	O
the	POS	O
second	POS	O
case	POS	O
of	POS	O
fatal	POS	O
carbamazepine	POS	O
induced	POS	O
myocarditis	POS	B-NP
reported	POS	O
in	POS	O
English	POS	O
literature	POS	O
.	POS	O
Neuropsychiatric	POS	O
behaviors	POS	O
in	POS	O
the	POS	O
MPTP	POS	O
marmoset	POS	O
model	POS	O
of	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
OBJECTIVES	POS	O
:	POS	O
Neuropsychiatric	POS	B-NP
symptoms	POS	I-NP
are	POS	O
increasingly	POS	O
recognised	POS	O
as	POS	O
a	POS	O
significant	POS	O
problem	POS	O
in	POS	O
patients	POS	O
with	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
(	POS	O
PD	POS	B-NP
)	POS	O
.	POS	O
These	POS	O
symptoms	POS	O
may	POS	O
be	POS	O
due	POS	O
to	POS	O
'	POS	O
sensitisation	POS	O
'	POS	O
following	POS	O
repeated	POS	O
levodopa	POS	O
treatment	POS	O
or	POS	O
a	POS	O
direct	POS	O
effect	POS	O
of	POS	O
dopamine	POS	O
on	POS	O
the	POS	O
disease	POS	O
state	POS	O
.	POS	O
The	POS	O
levodopa	POS	O
-	POS	O
treated	POS	O
MPTP	POS	O
-	POS	O
lesioned	POS	O
marmoset	POS	O
was	POS	O
used	POS	O
as	POS	O
a	POS	O
model	POS	O
of	POS	O
neuropsychiatric	POS	B-NP
symptoms	POS	I-NP
in	POS	O
PD	POS	B-NP
patients	POS	O
.	POS	O
Here	POS	O
we	POS	O
compare	POS	O
the	POS	O
time	POS	O
course	POS	O
of	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
motor	POS	O
fluctuations	POS	O
and	POS	O
neuropsychiatric	POS	O
-	POS	O
like	POS	O
behaviors	POS	O
to	POS	O
determine	POS	O
the	POS	O
relationship	POS	O
between	POS	O
duration	POS	O
of	POS	O
treatment	POS	O
and	POS	O
onset	POS	O
of	POS	O
symptoms	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Marmosets	POS	O
were	POS	O
administered	POS	O
1	POS	O
-	POS	O
methyl	POS	O
-	POS	O
4	POS	O
-	POS	O
phenyl	POS	O
-	POS	O
1	POS	O
,	POS	O
2	POS	O
,	POS	O
3	POS	O
,	POS	O
6	POS	O
-	POS	O
tetrahydropyridine	POS	O
(	POS	O
2	POS	O
.	POS	O
0	POS	O
mg	POS	O
/	POS	O
kg	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
for	POS	O
five	POS	O
days	POS	O
,	POS	O
resulting	POS	O
in	POS	O
stable	POS	O
parkinsonism	POS	B-NP
.	POS	O
Levodopa	POS	O
(	POS	O
15	POS	O
mg	POS	O
/	POS	O
kg	POS	O
and	POS	O
benserazide	POS	O
,	POS	O
3	POS	O
.	POS	O
75	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
p	POS	O
.	POS	O
o	POS	O
.	POS	O
b	POS	O
.	POS	O
i	POS	O
.	POS	O
d	POS	O
,	POS	O
was	POS	O
administered	POS	O
for	POS	O
30	POS	O
days	POS	O
.	POS	O
Animals	POS	O
were	POS	O
evaluated	POS	O
for	POS	O
parkinsonian	POS	B-NP
disability	POS	I-NP
,	POS	O
dyskinesia	POS	B-NP
and	POS	O
on	POS	O
-	POS	O
time	POS	O
(	POS	O
motor	POS	O
fluctuations	POS	O
)	POS	O
and	POS	O
neuropsychiatric	POS	O
-	POS	O
like	POS	O
behaviors	POS	O
on	POS	O
Day	POS	O
0	POS	O
(	POS	O
prior	POS	O
to	POS	O
levodopa	POS	O
)	POS	O
and	POS	O
on	POS	O
Days	POS	O
1	POS	O
,	POS	O
7	POS	O
,	POS	O
13	POS	O
,	POS	O
27	POS	O
and	POS	O
30	POS	O
of	POS	O
treatment	POS	O
using	POS	O
post	POS	O
hoc	POS	O
DVD	POS	O
analysis	POS	O
by	POS	O
a	POS	O
trained	POS	O
rater	POS	O
,	POS	O
blind	POS	O
to	POS	O
the	POS	O
treatment	POS	O
day	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
neuropsychiatric	POS	O
-	POS	O
like	POS	O
behavior	POS	O
rating	POS	O
scale	POS	O
demonstrated	POS	O
high	POS	O
interrater	POS	O
reliability	POS	O
between	POS	O
three	POS	O
trained	POS	O
raters	POS	O
of	POS	O
differing	POS	O
professional	POS	O
backgrounds	POS	O
.	POS	O
As	POS	O
anticipated	POS	O
,	POS	O
animals	POS	O
exhibited	POS	O
a	POS	O
progressive	POS	O
increase	POS	O
in	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
motor	POS	O
fluctuations	POS	O
,	POS	O
dyskinesia	POS	B-NP
and	POS	O
wearing	POS	O
-	POS	O
off	POS	O
,	POS	O
that	POS	O
correlated	POS	O
with	POS	O
the	POS	O
duration	POS	O
of	POS	O
levodopa	POS	O
therapy	POS	O
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
neuropsychiatric	POS	B-NP
-	POS	I-NP
like	POS	I-NP
behaviors	POS	I-NP
were	POS	O
present	POS	O
on	POS	O
Day	POS	O
1	POS	O
of	POS	O
levodopa	POS	O
treatment	POS	O
and	POS	O
their	POS	O
severity	POS	O
did	POS	O
not	POS	O
correlate	POS	O
with	POS	O
duration	POS	O
of	POS	O
treatment	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
data	POS	O
suggest	POS	O
that	POS	O
neuropsychiatric	POS	B-NP
disorders	POS	I-NP
in	POS	O
PD	POS	B-NP
are	POS	O
more	POS	O
likely	POS	O
an	POS	O
interaction	POS	O
between	POS	O
levodopa	POS	O
and	POS	O
the	POS	O
disease	POS	O
state	POS	O
than	POS	O
a	POS	O
consequence	POS	O
of	POS	O
sensitisation	POS	O
to	POS	O
repeated	POS	O
dopaminergic	POS	O
therapy	POS	O
.	POS	O
Contrast	POS	O
medium	POS	O
nephrotoxicity	POS	B-NP
after	POS	O
renal	POS	O
artery	POS	O
and	POS	O
coronary	POS	B-NP
angioplasty	POS	I-NP
.	POS	O
BACKGROUND	POS	O
:	POS	O
Renal	POS	B-NP
dysfunction	POS	I-NP
induced	POS	O
by	POS	O
iodinated	POS	O
contrast	POS	O
medium	POS	O
(	POS	O
CM	POS	O
)	POS	O
administration	POS	O
can	POS	O
minimize	POS	O
the	POS	O
benefit	POS	O
of	POS	O
the	POS	O
interventional	POS	O
procedure	POS	O
in	POS	O
patients	POS	O
undergoing	POS	O
renal	POS	O
angioplasty	POS	O
(	POS	O
PTRA	POS	O
)	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
compare	POS	O
the	POS	O
susceptibility	POS	O
to	POS	O
nephrotoxic	POS	B-NP
effect	POS	O
of	POS	O
CM	POS	B-NP
in	POS	O
patients	POS	O
undergoing	POS	O
PTRA	POS	O
with	POS	O
that	POS	O
of	POS	O
patients	POS	O
submitted	POS	O
to	POS	O
percutaneous	POS	O
coronary	POS	O
intervention	POS	O
(	POS	O
PCI	POS	O
)	POS	O
.	POS	O
MATERIAL	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
33	POS	O
patients	POS	O
successfully	POS	O
treated	POS	O
with	POS	O
PTRA	POS	O
(	POS	O
PTRA	POS	O
group	POS	O
,	POS	O
mean	POS	O
age	POS	O
70	POS	O
+	POS	O
/	POS	O
-	POS	O
12	POS	O
years	POS	O
,	POS	O
23	POS	O
female	POS	O
,	POS	O
basal	POS	O
creatinine	POS	O
1	POS	O
.	POS	O
46	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
79	POS	O
,	POS	O
range	POS	O
0	POS	O
.	POS	O
7	POS	O
-	POS	O
4	POS	O
.	POS	O
9	POS	O
mg	POS	O
/	POS	O
dl	POS	O
)	POS	O
were	POS	O
compared	POS	O
with	POS	O
33	POS	O
patients	POS	O
undergoing	POS	O
successful	POS	O
PCI	POS	O
(	POS	O
PCI	POS	O
group	POS	O
)	POS	O
,	POS	O
matched	POS	O
for	POS	O
basal	POS	O
creatinine	POS	O
(	POS	O
1	POS	O
.	POS	O
44	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
6	POS	O
,	POS	O
range	POS	O
0	POS	O
.	POS	O
7	POS	O
-	POS	O
3	POS	O
.	POS	O
4	POS	O
mg	POS	O
/	POS	O
dl	POS	O
)	POS	O
,	POS	O
gender	POS	O
,	POS	O
and	POS	O
age	POS	O
.	POS	O
In	POS	O
both	POS	O
groups	POS	O
postprocedural	POS	O
(	POS	O
48	POS	O
h	POS	O
)	POS	O
serum	POS	O
creatinine	POS	O
was	POS	O
measured	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Postprocedural	POS	O
creatinine	POS	O
level	POS	O
decreased	POS	O
nonsignificantly	POS	O
in	POS	O
the	POS	O
PTRA	POS	O
group	POS	O
(	POS	O
1	POS	O
.	POS	O
46	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
8	POS	O
vs	POS	O
.	POS	O
1	POS	O
.	POS	O
34	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
P	POS	O
=	POS	O
NS	POS	O
)	POS	O
and	POS	O
increased	POS	O
significantly	POS	O
in	POS	O
the	POS	O
PCI	POS	O
group	POS	O
(	POS	O
1	POS	O
.	POS	O
44	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
6	POS	O
vs	POS	O
.	POS	O
1	POS	O
.	POS	O
57	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
mg	POS	O
/	POS	O
dl	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
02	POS	O
)	POS	O
.	POS	O
Changes	POS	O
in	POS	O
serum	POS	O
creatinine	POS	O
after	POS	O
intervention	POS	O
(	POS	O
after	POS	O
-	POS	O
before	POS	O
)	POS	O
were	POS	O
significantly	POS	O
different	POS	O
between	POS	O
the	POS	O
PTRA	POS	O
and	POS	O
PCI	POS	O
groups	POS	O
(	POS	O
-	POS	O
0	POS	O
.	POS	O
12	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
5	POS	O
vs	POS	O
.	POS	O
0	POS	O
.	POS	O
13	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
3	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
014	POS	O
)	POS	O
.	POS	O
This	POS	O
difference	POS	O
was	POS	O
not	POS	O
related	POS	O
to	POS	O
either	POS	O
a	POS	O
different	POS	O
clinical	POS	O
risk	POS	O
profile	POS	O
or	POS	O
to	POS	O
the	POS	O
volume	POS	O
of	POS	O
CM	POS	O
administered	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
In	POS	O
this	POS	O
preliminary	POS	O
study	POS	O
patients	POS	O
submitted	POS	O
to	POS	O
PTRA	POS	O
showed	POS	O
a	POS	O
lower	POS	O
susceptibility	POS	O
to	POS	O
renal	POS	B-NP
damage	POS	I-NP
induced	POS	O
by	POS	O
CM	POS	O
administration	POS	O
than	POS	O
PCI	POS	O
patients	POS	O
.	POS	O
The	POS	O
effectiveness	POS	O
of	POS	O
PTRA	POS	O
on	POS	O
renal	POS	O
function	POS	O
seems	POS	O
to	POS	O
be	POS	O
barely	POS	O
influenced	POS	O
by	POS	O
CM	POS	B-NP
toxicity	POS	I-NP
.	POS	O
Diphenhydramine	POS	O
prevents	POS	O
the	POS	O
haemodynamic	POS	O
changes	POS	O
of	POS	O
cimetidine	POS	O
in	POS	O
ICU	POS	O
patients	POS	O
.	POS	O
Cimetidine	POS	O
,	POS	O
a	POS	O
histamine	POS	O
2	POS	O
(	POS	O
H2	POS	O
)	POS	O
antagonist	POS	O
,	POS	O
produces	POS	O
a	POS	O
decrease	POS	O
in	POS	O
arterial	POS	O
pressure	POS	O
due	POS	O
to	POS	O
vasodilatation	POS	O
,	POS	O
especially	POS	O
in	POS	O
critically	POS	O
ill	POS	O
patients	POS	O
.	POS	O
This	POS	O
may	POS	O
be	POS	O
because	POS	O
cimetidine	POS	O
acts	POS	O
as	POS	O
a	POS	O
histamine	POS	O
agonist	POS	O
.	POS	O
We	POS	O
,	POS	O
therefore	POS	O
,	POS	O
investigated	POS	O
the	POS	O
effects	POS	O
of	POS	O
the	POS	O
histamine	POS	O
1	POS	O
(	POS	O
H1	POS	O
)	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
diphenhydramine	POS	O
,	POS	O
on	POS	O
the	POS	O
haemodynamic	POS	O
changes	POS	O
observed	POS	O
after	POS	O
cimetidine	POS	O
in	POS	O
ICU	POS	O
patients	POS	O
.	POS	O
Each	POS	O
patient	POS	O
was	POS	O
studied	POS	O
on	POS	O
two	POS	O
separate	POS	O
days	POS	O
.	POS	O
In	POS	O
a	POS	O
random	POS	O
fashion	POS	O
,	POS	O
they	POS	O
received	POS	O
cimetidine	POS	O
200	POS	O
mg	POS	O
iv	POS	O
on	POS	O
one	POS	O
day	POS	O
,	POS	O
and	POS	O
on	POS	O
the	POS	O
other	POS	O
,	POS	O
a	POS	O
pretreatment	POS	O
of	POS	O
diphenhydramine	POS	O
40	POS	O
mg	POS	O
iv	POS	O
with	POS	O
cimetidine	POS	O
200	POS	O
mg	POS	O
iv	POS	O
.	POS	O
In	POS	O
the	POS	O
non	POS	O
-	POS	O
pretreatment	POS	O
group	POS	O
,	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
(	POS	O
MAP	POS	O
)	POS	O
decreased	POS	O
from	POS	O
107	POS	O
.	POS	O
4	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
.	POS	O
4	POS	O
mmHg	POS	O
to	POS	O
86	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
11	POS	O
.	POS	O
4	POS	O
mmHg	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
two	POS	O
minutes	POS	O
after	POS	O
cimetidine	POS	O
.	POS	O
Also	POS	O
,	POS	O
systemic	POS	O
vascular	POS	O
resistance	POS	O
(	POS	O
SVR	POS	O
)	POS	O
decreased	POS	O
during	POS	O
the	POS	O
eight	POS	O
-	POS	O
minute	POS	O
observation	POS	O
period	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
in	POS	O
the	POS	O
pretreatment	POS	O
group	POS	O
,	POS	O
little	POS	O
haemodynamic	POS	O
change	POS	O
was	POS	O
seen	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
an	POS	O
H1	POS	O
antagonist	POS	O
may	POS	O
be	POS	O
useful	POS	O
in	POS	O
preventing	POS	O
hypotension	POS	B-NP
caused	POS	O
by	POS	O
iv	POS	O
cimetidine	POS	O
,	POS	O
since	POS	O
the	POS	O
vasodilating	POS	O
activity	POS	O
of	POS	O
cimetidine	POS	O
is	POS	O
mediated	POS	O
,	POS	O
in	POS	O
part	POS	O
,	POS	O
through	POS	O
the	POS	O
H1	POS	O
receptor	POS	O
.	POS	O
Medical	POS	O
and	POS	O
psychiatric	POS	O
outcomes	POS	O
for	POS	O
patients	POS	O
transplanted	POS	O
for	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
:	POS	O
a	POS	O
case	POS	O
-	POS	O
control	POS	O
study	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Acetaminophen	POS	O
-	POS	O
induced	POS	O
hepatotoxicity	POS	B-NP
is	POS	O
the	POS	O
most	POS	O
common	POS	O
cause	POS	O
of	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
(	POS	O
ALF	POS	B-NP
)	POS	O
in	POS	O
the	POS	O
UK	POS	O
.	POS	O
Patients	POS	O
often	POS	O
consume	POS	O
the	POS	O
drug	POS	O
with	POS	O
suicidal	POS	O
intent	POS	O
or	POS	O
with	POS	O
a	POS	O
background	POS	O
of	POS	O
substance	POS	O
dependence	POS	O
.	POS	O
AIMS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
compared	POS	O
the	POS	O
severity	POS	O
of	POS	O
pretransplant	POS	B-NP
illness	POS	I-NP
,	POS	O
psychiatric	POS	O
co	POS	O
-	POS	O
morbidity	POS	O
,	POS	O
medical	POS	O
and	POS	O
psychosocial	POS	O
outcomes	POS	O
of	POS	O
all	POS	O
patients	POS	O
who	POS	O
had	POS	O
undergone	POS	O
liver	POS	O
transplantation	POS	O
(	POS	O
LT	POS	O
)	POS	O
emergently	POS	O
between	POS	O
1999	POS	O
-	POS	O
2004	POS	O
for	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
(	POS	O
n	POS	O
=	POS	O
36	POS	O
)	POS	O
with	POS	O
age	POS	O
-	POS	O
and	POS	O
sex	POS	O
-	POS	O
matched	POS	O
patients	POS	O
undergoing	POS	O
emergent	POS	O
LT	POS	O
for	POS	O
non	POS	O
-	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
(	POS	O
n	POS	O
=	POS	O
35	POS	O
)	POS	O
and	POS	O
elective	POS	O
LT	POS	O
for	POS	O
chronic	POS	B-NP
liver	POS	I-NP
disease	POS	I-NP
(	POS	O
CLD	POS	B-NP
,	POS	O
n	POS	O
=	POS	O
34	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
patients	POS	O
undergoing	POS	O
LT	POS	O
had	POS	O
a	POS	O
greater	POS	O
severity	POS	O
of	POS	O
pre	POS	O
-	POS	O
LT	POS	O
illness	POS	O
reflected	POS	O
by	POS	O
higher	POS	O
Acute	POS	O
Physiology	POS	O
and	POS	O
Chronic	POS	O
Health	POS	O
Evaluation	POS	O
II	POS	O
scores	POS	O
and	POS	O
requirement	POS	O
for	POS	O
organ	POS	O
support	POS	O
compared	POS	O
with	POS	O
the	POS	O
other	POS	O
two	POS	O
groups	POS	O
.	POS	O
Twenty	POS	O
(	POS	O
56	POS	O
%	POS	O
)	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
patients	POS	O
had	POS	O
a	POS	O
formal	POS	O
psychiatric	POS	O
diagnosis	POS	O
before	POS	O
LT	POS	O
(	POS	O
non	POS	O
-	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
=	POS	O
0	POS	O
/	POS	O
35	POS	O
,	POS	O
CLD	POS	B-NP
=	POS	O
2	POS	O
/	POS	O
34	POS	O
;	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
for	POS	O
all	POS	O
)	POS	O
and	POS	O
nine	POS	O
(	POS	O
25	POS	O
%	POS	O
)	POS	O
had	POS	O
a	POS	O
previous	POS	O
suicide	POS	O
attempt	POS	O
.	POS	O
During	POS	O
follow	POS	O
-	POS	O
up	POS	O
(	POS	O
median	POS	O
5	POS	O
years	POS	O
)	POS	O
,	POS	O
there	POS	O
were	POS	O
no	POS	O
significant	POS	O
differences	POS	O
in	POS	O
rejection	POS	O
(	POS	O
acute	POS	O
and	POS	O
chronic	POS	O
)	POS	O
,	POS	O
graft	POS	B-NP
failure	POS	I-NP
or	POS	O
survival	POS	O
between	POS	O
the	POS	O
groups	POS	O
(	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
1	POS	O
year	POS	O
87	POS	O
%	POS	O
,	POS	O
5	POS	O
years	POS	O
75	POS	O
%	POS	O
;	POS	O
non	POS	O
-	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
88	POS	O
%	POS	O
,	POS	O
78	POS	O
%	POS	O
;	POS	O
CLD	POS	B-NP
93	POS	O
%	POS	O
,	POS	O
82	POS	O
%	POS	O
:	POS	O
P	POS	O
>	POS	O
0	POS	O
.	POS	O
6	POS	O
log	POS	O
rank	POS	O
)	POS	O
.	POS	O
Two	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
patients	POS	O
reattempted	POS	O
suicide	POS	O
post	POS	O
-	POS	O
LT	POS	O
(	POS	O
one	POS	O
died	POS	O
8	POS	O
years	POS	O
post	POS	O
-	POS	O
LT	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Despite	POS	O
a	POS	O
high	POS	O
prevalence	POS	O
of	POS	O
psychiatric	POS	B-NP
disturbance	POS	I-NP
,	POS	O
outcomes	POS	O
for	POS	O
patients	POS	O
transplanted	POS	O
emergently	POS	O
for	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
were	POS	O
comparable	POS	O
to	POS	O
those	POS	O
transplanted	POS	O
for	POS	O
non	POS	O
-	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
ALF	POS	B-NP
and	POS	O
electively	POS	O
for	POS	O
CLD	POS	B-NP
.	POS	O
Multidisciplinary	POS	O
approaches	POS	O
with	POS	O
long	POS	O
-	POS	O
term	POS	O
psychiatric	POS	O
follow	POS	O
-	POS	O
up	POS	O
may	POS	O
contribute	POS	O
to	POS	O
low	POS	O
post	POS	O
-	POS	O
transplant	POS	O
suicide	POS	O
rates	POS	O
seen	POS	O
and	POS	O
low	POS	O
rates	POS	O
of	POS	O
graft	POS	B-NP
loss	POS	I-NP
because	POS	O
of	POS	O
non	POS	O
-	POS	O
compliance	POS	O
.	POS	O
Antithrombotic	POS	O
drug	POS	O
use	POS	O
,	POS	O
cerebral	POS	B-NP
microbleeds	POS	I-NP
,	POS	O
and	POS	O
intracerebral	POS	B-NP
hemorrhage	POS	I-NP
:	POS	O
a	POS	O
systematic	POS	O
review	POS	O
of	POS	O
published	POS	O
and	POS	O
unpublished	POS	O
studies	POS	O
.	POS	O
BACKGROUND	POS	O
AND	POS	O
PURPOSE	POS	O
:	POS	O
Cerebral	POS	B-NP
microbleeds	POS	I-NP
(	POS	O
MB	POS	B-NP
)	POS	O
are	POS	O
potential	POS	O
risk	POS	O
factors	POS	O
for	POS	O
intracerebral	POS	B-NP
hemorrhage	POS	I-NP
(	POS	O
ICH	POS	B-NP
)	POS	O
,	POS	O
but	POS	O
it	POS	O
is	POS	O
unclear	POS	O
if	POS	O
they	POS	O
are	POS	O
a	POS	O
contraindication	POS	O
to	POS	O
using	POS	O
antithrombotic	POS	O
drugs	POS	O
.	POS	O
Insights	POS	O
could	POS	O
be	POS	O
gained	POS	O
by	POS	O
pooling	POS	O
data	POS	O
on	POS	O
MB	POS	B-NP
frequency	POS	O
stratified	POS	O
by	POS	O
antithrombotic	POS	O
use	POS	O
in	POS	O
cohorts	POS	O
with	POS	O
ICH	POS	B-NP
and	POS	O
ischemic	POS	B-NP
stroke	POS	I-NP
(	POS	O
IS	POS	O
)	POS	O
/	POS	O
transient	POS	O
ischemic	POS	B-NP
attack	POS	I-NP
(	POS	O
TIA	POS	B-NP
)	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
performed	POS	O
a	POS	O
systematic	POS	O
review	POS	O
of	POS	O
published	POS	O
and	POS	O
unpublished	POS	O
data	POS	O
from	POS	O
cohorts	POS	O
with	POS	O
stroke	POS	B-NP
or	POS	O
TIA	POS	B-NP
to	POS	O
compare	POS	O
the	POS	O
presence	POS	O
of	POS	O
MB	POS	B-NP
in	POS	O
:	POS	O
(	POS	O
1	POS	O
)	POS	O
antithrombotic	POS	O
users	POS	O
vs	POS	O
nonantithrombotic	POS	O
users	POS	O
with	POS	O
ICH	POS	B-NP
;	POS	O
(	POS	O
2	POS	O
)	POS	O
antithrombotic	POS	O
users	POS	O
vs	POS	O
nonusers	POS	O
with	POS	O
IS	POS	O
/	POS	O
TIA	POS	B-NP
;	POS	O
and	POS	O
(	POS	O
3	POS	O
)	POS	O
ICH	POS	B-NP
vs	POS	O
ischemic	POS	B-NP
events	POS	O
stratified	POS	O
by	POS	O
antithrombotic	POS	O
use	POS	O
.	POS	O
We	POS	O
also	POS	O
analyzed	POS	O
published	POS	O
and	POS	O
unpublished	POS	O
follow	POS	O
-	POS	O
up	POS	O
data	POS	O
to	POS	O
determine	POS	O
the	POS	O
risk	POS	O
of	POS	O
ICH	POS	B-NP
in	POS	O
antithrombotic	POS	O
users	POS	O
with	POS	O
MB	POS	B-NP
.	POS	O
RESULTS	POS	O
:	POS	O
In	POS	O
a	POS	O
pooled	POS	O
analysis	POS	O
of	POS	O
1460	POS	O
ICH	POS	B-NP
and	POS	O
3817	POS	O
IS	POS	O
/	POS	O
TIA	POS	B-NP
,	POS	O
MB	POS	B-NP
were	POS	O
more	POS	O
frequent	POS	O
in	POS	O
ICH	POS	B-NP
vs	POS	O
IS	POS	O
/	POS	O
TIA	POS	B-NP
in	POS	O
all	POS	O
treatment	POS	O
groups	POS	O
,	POS	O
but	POS	O
the	POS	O
excess	POS	O
increased	POS	O
from	POS	O
2	POS	O
.	POS	O
8	POS	O
(	POS	O
odds	POS	O
ratio	POS	O
;	POS	O
range	POS	O
,	POS	O
2	POS	O
.	POS	O
3	POS	O
-	POS	O
3	POS	O
.	POS	O
5	POS	O
)	POS	O
in	POS	O
nonantithrombotic	POS	O
users	POS	O
to	POS	O
5	POS	O
.	POS	O
7	POS	O
(	POS	O
range	POS	O
,	POS	O
3	POS	O
.	POS	O
4	POS	O
-	POS	O
9	POS	O
.	POS	O
7	POS	O
)	POS	O
in	POS	O
antiplatelet	POS	O
users	POS	O
and	POS	O
8	POS	O
.	POS	O
0	POS	O
(	POS	O
range	POS	O
,	POS	O
3	POS	O
.	POS	O
5	POS	O
-	POS	O
17	POS	O
.	POS	O
8	POS	O
)	POS	O
in	POS	O
warfarin	POS	O
users	POS	O
(	POS	O
P	POS	O
difference	POS	O
=	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
There	POS	O
was	POS	O
also	POS	O
an	POS	O
excess	POS	O
of	POS	O
MB	POS	B-NP
in	POS	O
warfarin	POS	O
users	POS	O
vs	POS	O
nonusers	POS	O
with	POS	O
ICH	POS	B-NP
(	POS	O
OR	POS	O
,	POS	O
2	POS	O
.	POS	O
7	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
1	POS	O
.	POS	O
6	POS	O
-	POS	O
4	POS	O
.	POS	O
4	POS	O
;	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
but	POS	O
none	POS	O
in	POS	O
warfarin	POS	O
users	POS	O
with	POS	O
IS	POS	O
/	POS	O
TIA	POS	B-NP
(	POS	O
OR	POS	O
,	POS	O
1	POS	O
.	POS	O
3	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
0	POS	O
.	POS	O
9	POS	O
-	POS	O
1	POS	O
.	POS	O
7	POS	O
;	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
33	POS	O
;	POS	O
P	POS	O
difference	POS	O
=	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
smaller	POS	O
excess	POS	O
of	POS	O
MB	POS	B-NP
in	POS	O
antiplatelet	POS	O
users	POS	O
vs	POS	O
nonusers	POS	O
with	POS	O
ICH	POS	B-NP
(	POS	O
OR	POS	O
,	POS	O
1	POS	O
.	POS	O
7	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
1	POS	O
.	POS	O
3	POS	O
-	POS	O
2	POS	O
.	POS	O
3	POS	O
;	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
but	POS	O
findings	POS	O
were	POS	O
similar	POS	O
for	POS	O
antiplatelet	POS	O
users	POS	O
with	POS	O
IS	POS	O
/	POS	O
TIA	POS	B-NP
(	POS	O
OR	POS	O
,	POS	O
1	POS	O
.	POS	O
4	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
1	POS	O
.	POS	O
2	POS	O
-	POS	O
1	POS	O
.	POS	O
7	POS	O
;	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
;	POS	O
P	POS	O
difference	POS	O
=	POS	O
0	POS	O
.	POS	O
25	POS	O
)	POS	O
.	POS	O
In	POS	O
pooled	POS	O
follow	POS	O
-	POS	O
up	POS	O
data	POS	O
for	POS	O
768	POS	O
antithrombotic	POS	O
users	POS	O
,	POS	O
presence	POS	O
of	POS	O
MB	POS	B-NP
at	POS	O
baseline	POS	O
was	POS	O
associated	POS	O
with	POS	O
a	POS	O
substantially	POS	O
increased	POS	O
risk	POS	O
of	POS	O
subsequent	POS	O
ICH	POS	B-NP
(	POS	O
OR	POS	O
,	POS	O
12	POS	O
.	POS	O
1	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
3	POS	O
.	POS	O
4	POS	O
-	POS	O
42	POS	O
.	POS	O
5	POS	O
;	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
excess	POS	O
of	POS	O
MB	POS	B-NP
in	POS	O
warfarin	POS	O
users	POS	O
with	POS	O
ICH	POS	B-NP
compared	POS	O
to	POS	O
other	POS	O
groups	POS	O
suggests	POS	O
that	POS	O
MB	POS	B-NP
increase	POS	O
the	POS	O
risk	POS	O
of	POS	O
warfarin	POS	O
-	POS	O
associated	POS	O
ICH	POS	B-NP
.	POS	O
Limited	POS	O
prospective	POS	O
data	POS	O
corroborate	POS	O
these	POS	O
findings	POS	O
,	POS	O
but	POS	O
larger	POS	O
prospective	POS	O
studies	POS	O
are	POS	O
urgently	POS	O
required	POS	O
.	POS	O
Studies	POS	O
of	POS	O
synergy	POS	O
between	POS	O
morphine	POS	O
and	POS	O
a	POS	O
novel	POS	O
sodium	POS	O
channel	POS	O
blocker	POS	O
,	POS	O
CNSB002	POS	O
,	POS	O
in	POS	O
rat	POS	O
models	POS	O
of	POS	O
inflammatory	POS	O
and	POS	O
neuropathic	POS	B-NP
pain	POS	I-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
This	POS	O
study	POS	O
determined	POS	O
the	POS	O
antihyperalgesic	POS	O
effect	POS	O
of	POS	O
CNSB002	POS	O
,	POS	O
a	POS	O
sodium	POS	O
channel	POS	O
blocker	POS	O
with	POS	O
antioxidant	POS	O
properties	POS	O
given	POS	O
alone	POS	O
and	POS	O
in	POS	O
combinations	POS	O
with	POS	O
morphine	POS	O
in	POS	O
rat	POS	O
models	POS	O
of	POS	O
inflammatory	POS	O
and	POS	O
neuropathic	POS	B-NP
pain	POS	I-NP
.	POS	O
DESIGN	POS	O
:	POS	O
Dose	POS	O
response	POS	O
curves	POS	O
for	POS	O
nonsedating	POS	O
doses	POS	O
of	POS	O
morphine	POS	O
and	POS	O
CNSB002	POS	O
given	POS	O
intraperitoneally	POS	O
alone	POS	O
and	POS	O
together	POS	O
in	POS	O
combinations	POS	O
were	POS	O
constructed	POS	O
for	POS	O
antihyperalgesic	POS	O
effect	POS	O
using	POS	O
paw	POS	O
withdrawal	POS	O
from	POS	O
noxious	POS	O
heat	POS	O
in	POS	O
two	POS	O
rat	POS	O
pain	POS	B-NP
models	POS	O
:	POS	O
carrageenan	POS	O
-	POS	O
induced	POS	O
paw	POS	O
inflammation	POS	B-NP
and	POS	O
streptozotocin	POS	O
(	POS	O
STZ	POS	O
)	POS	O
-	POS	O
induced	POS	O
diabetic	POS	B-NP
neuropathy	POS	I-NP
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
maximum	POS	O
nonsedating	POS	O
doses	POS	O
were	POS	O
:	POS	O
morphine	POS	O
,	POS	O
3	POS	O
.	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
;	POS	O
CNSB002	POS	O
10	POS	O
.	POS	O
0	POS	O
mg	POS	O
/	POS	O
kg	POS	O
;	POS	O
5	POS	O
.	POS	O
0	POS	O
mg	POS	O
/	POS	O
kg	POS	O
CNSB002	POS	O
with	POS	O
morphine	POS	O
3	POS	O
.	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
in	POS	O
combination	POS	O
.	POS	O
The	POS	O
doses	POS	O
calculated	POS	O
to	POS	O
cause	POS	O
50	POS	O
%	POS	O
reversal	POS	O
of	POS	O
hyperalgesia	POS	B-NP
(	POS	O
ED50	POS	O
)	POS	O
were	POS	O
7	POS	O
.	POS	O
54	POS	O
(	POS	O
1	POS	O
.	POS	O
81	POS	O
)	POS	O
and	POS	O
4	POS	O
.	POS	O
83	POS	O
(	POS	O
1	POS	O
.	POS	O
54	POS	O
)	POS	O
in	POS	O
the	POS	O
carrageenan	POS	O
model	POS	O
and	POS	O
44	POS	O
.	POS	O
18	POS	O
(	POS	O
1	POS	O
.	POS	O
37	POS	O
)	POS	O
and	POS	O
9	POS	O
.	POS	O
14	POS	O
(	POS	O
1	POS	O
.	POS	O
24	POS	O
)	POS	O
in	POS	O
the	POS	O
STZ	POS	O
-	POS	O
induced	POS	O
neuropathy	POS	B-NP
model	POS	O
for	POS	O
CNSB002	POS	O
and	POS	O
morphine	POS	O
,	POS	O
respectively	POS	O
(	POS	O
mg	POS	O
/	POS	O
kg	POS	O
;	POS	O
mean	POS	O
,	POS	O
SEM	POS	O
)	POS	O
.	POS	O
These	POS	O
values	POS	O
were	POS	O
greater	POS	O
than	POS	O
the	POS	O
maximum	POS	O
nonsedating	POS	O
doses	POS	O
.	POS	O
The	POS	O
ED50	POS	O
values	POS	O
for	POS	O
morphine	POS	O
when	POS	O
given	POS	O
in	POS	O
combination	POS	O
with	POS	O
CNSB002	POS	O
(	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
were	POS	O
less	POS	O
than	POS	O
the	POS	O
maximum	POS	O
nonsedating	POS	O
dose	POS	O
:	POS	O
0	POS	O
.	POS	O
56	POS	O
(	POS	O
1	POS	O
.	POS	O
55	POS	O
)	POS	O
in	POS	O
the	POS	O
carrageenan	POS	O
model	POS	O
and	POS	O
1	POS	O
.	POS	O
37	POS	O
(	POS	O
1	POS	O
.	POS	O
23	POS	O
)	POS	O
in	POS	O
the	POS	O
neuropathy	POS	B-NP
model	POS	O
(	POS	O
mg	POS	O
/	POS	O
kg	POS	O
;	POS	O
mean	POS	O
,	POS	O
SEM	POS	O
)	POS	O
.	POS	O
The	POS	O
antinociception	POS	O
after	POS	O
morphine	POS	O
(	POS	O
3	POS	O
.	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
was	POS	O
increased	POS	O
by	POS	O
co	POS	O
-	POS	O
administration	POS	O
with	POS	O
CNSB002	POS	O
from	POS	O
28	POS	O
.	POS	O
0	POS	O
and	POS	O
31	POS	O
.	POS	O
7	POS	O
%	POS	O
to	POS	O
114	POS	O
.	POS	O
6	POS	O
and	POS	O
56	POS	O
.	POS	O
9	POS	O
%	POS	O
reversal	POS	O
of	POS	O
hyperalgesia	POS	B-NP
in	POS	O
the	POS	O
inflammatory	POS	O
and	POS	O
neuropathic	POS	B-NP
models	POS	O
,	POS	O
respectively	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
;	POS	O
one	POS	O
-	POS	O
way	POS	O
analysis	POS	O
of	POS	O
variance	POS	O
-	POS	O
significantly	POS	O
greater	POS	O
than	POS	O
either	POS	O
drug	POS	O
given	POS	O
alone	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
maximum	POS	O
antihyperalgesic	POS	O
effect	POS	O
achievable	POS	O
with	POS	O
nonsedating	POS	O
doses	POS	O
of	POS	O
morphine	POS	O
may	POS	O
be	POS	O
increased	POS	O
significantly	POS	O
when	POS	O
the	POS	O
drug	POS	O
is	POS	O
used	POS	O
in	POS	O
combination	POS	O
with	POS	O
CNSB002	POS	O
.	POS	O
Heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
:	POS	O
a	POS	O
practical	POS	O
review	POS	O
.	POS	O
Heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
(	POS	O
HIT	POS	B-NP
)	POS	O
remains	POS	O
under	POS	O
-	POS	O
recognized	POS	O
despite	POS	O
its	POS	O
potentially	POS	O
devastating	POS	O
outcomes	POS	O
.	POS	O
It	POS	O
begins	POS	O
when	POS	O
heparin	POS	O
exposure	POS	O
stimulates	POS	O
the	POS	O
formation	POS	O
of	POS	O
heparin	POS	O
-	POS	O
platelet	POS	O
factor	POS	O
4	POS	O
antibodies	POS	O
,	POS	O
which	POS	O
in	POS	O
turn	POS	O
triggers	POS	O
the	POS	O
release	POS	O
of	POS	O
procoagulant	POS	O
platelet	POS	O
particles	POS	O
.	POS	O
Thrombosis	POS	B-NP
and	POS	O
thrombocytopenia	POS	B-NP
that	POS	O
follow	POS	O
comprise	POS	O
the	POS	O
2	POS	O
hallmark	POS	O
traits	POS	O
of	POS	O
HIT	POS	B-NP
,	POS	O
with	POS	O
the	POS	O
former	POS	O
largely	POS	O
responsible	POS	O
for	POS	O
significant	POS	O
vascular	POS	B-NP
complications	POS	I-NP
.	POS	O
The	POS	O
prevalence	POS	O
of	POS	O
HIT	POS	B-NP
varies	POS	O
among	POS	O
several	POS	O
subgroups	POS	O
,	POS	O
with	POS	O
greater	POS	O
incidence	POS	O
in	POS	O
surgical	POS	O
as	POS	O
compared	POS	O
with	POS	O
medical	POS	O
populations	POS	O
.	POS	O
HIT	POS	B-NP
must	POS	O
be	POS	O
acknowledged	POS	O
for	POS	O
its	POS	O
intense	POS	O
predilection	POS	O
for	POS	O
thrombosis	POS	B-NP
and	POS	O
suspected	POS	O
whenever	POS	O
thrombosis	POS	B-NP
occurs	POS	O
after	POS	O
heparin	POS	O
exposure	POS	O
.	POS	O
Early	POS	O
recognition	POS	O
that	POS	O
incorporates	POS	O
the	POS	O
clinical	POS	O
and	POS	O
serologic	POS	O
clues	POS	O
is	POS	O
paramount	POS	O
to	POS	O
timely	POS	O
institution	POS	O
of	POS	O
treatment	POS	O
,	POS	O
as	POS	O
its	POS	O
delay	POS	O
may	POS	O
result	POS	O
in	POS	O
catastrophic	POS	O
outcomes	POS	O
.	POS	O
The	POS	O
treatment	POS	O
of	POS	O
HIT	POS	B-NP
mandates	POS	O
an	POS	O
immediate	POS	O
cessation	POS	O
of	POS	O
all	POS	O
heparin	POS	O
exposure	POS	O
and	POS	O
the	POS	O
institution	POS	O
of	POS	O
an	POS	O
antithrombotic	POS	O
therapy	POS	O
,	POS	O
most	POS	O
commonly	POS	O
using	POS	O
a	POS	O
direct	POS	O
thrombin	POS	O
inhibitor	POS	O
.	POS	O
Current	POS	O
"	POS	O
diagnostic	POS	O
"	POS	O
tests	POS	O
,	POS	O
which	POS	O
primarily	POS	O
include	POS	O
functional	POS	O
and	POS	O
antigenic	POS	O
assays	POS	O
,	POS	O
have	POS	O
more	POS	O
of	POS	O
a	POS	O
confirmatory	POS	O
than	POS	O
diagnostic	POS	O
role	POS	O
in	POS	O
the	POS	O
management	POS	O
of	POS	O
HIT	POS	B-NP
.	POS	O
Special	POS	O
attention	POS	O
must	POS	O
be	POS	O
paid	POS	O
to	POS	O
cardiac	POS	O
patients	POS	O
who	POS	O
are	POS	O
often	POS	O
exposed	POS	O
to	POS	O
heparin	POS	O
multiple	POS	O
times	POS	O
during	POS	O
their	POS	O
course	POS	O
of	POS	O
treatment	POS	O
.	POS	O
Direct	POS	O
thrombin	POS	O
inhibitors	POS	O
are	POS	O
appropriate	POS	O
,	POS	O
evidence	POS	O
-	POS	O
based	POS	O
alternatives	POS	O
to	POS	O
heparin	POS	O
in	POS	O
patients	POS	O
with	POS	O
a	POS	O
history	POS	O
of	POS	O
HIT	POS	B-NP
,	POS	O
who	POS	O
need	POS	O
to	POS	O
undergo	POS	O
percutaneous	POS	O
coronary	POS	O
intervention	POS	O
.	POS	O
As	POS	O
heparin	POS	O
remains	POS	O
one	POS	O
of	POS	O
the	POS	O
most	POS	O
frequently	POS	O
used	POS	O
medications	POS	O
today	POS	O
with	POS	O
potential	POS	O
for	POS	O
HIT	POS	B-NP
with	POS	O
every	POS	O
heparin	POS	O
exposure	POS	O
,	POS	O
a	POS	O
close	POS	O
vigilance	POS	O
of	POS	O
platelet	POS	O
counts	POS	O
must	POS	O
be	POS	O
practiced	POS	O
whenever	POS	O
heparin	POS	O
is	POS	O
initiated	POS	O
.	POS	O
Abductor	POS	B-NP
paralysis	POS	I-NP
after	POS	O
botox	POS	O
injection	POS	O
for	POS	O
adductor	POS	B-NP
spasmodic	POS	I-NP
dysphonia	POS	I-NP
.	POS	O
OBJECTIVES	POS	O
/	POS	O
HYPOTHESIS	POS	O
:	POS	O
Botulinum	POS	O
toxin	POS	O
(	POS	O
Botox	POS	O
)	POS	O
injections	POS	O
into	POS	O
the	POS	O
thyroarytenoid	POS	O
muscles	POS	O
are	POS	O
the	POS	O
current	POS	O
standard	POS	O
of	POS	O
care	POS	O
for	POS	O
adductor	POS	B-NP
spasmodic	POS	I-NP
dysphonia	POS	I-NP
(	POS	O
ADSD	POS	B-NP
)	POS	O
.	POS	O
Reported	POS	O
adverse	POS	O
effects	POS	O
include	POS	O
a	POS	O
period	POS	O
of	POS	O
breathiness	POS	B-NP
,	POS	O
throat	POS	B-NP
pain	POS	I-NP
,	POS	O
and	POS	O
difficulty	POS	O
with	POS	O
swallowing	POS	O
liquids	POS	O
.	POS	O
Here	POS	O
we	POS	O
report	POS	O
multiple	POS	O
cases	POS	O
of	POS	O
bilateral	POS	B-NP
abductor	POS	I-NP
paralysis	POS	I-NP
following	POS	O
Botox	POS	O
injections	POS	O
for	POS	O
ADSD	POS	B-NP
,	POS	O
a	POS	O
complication	POS	O
previously	POS	O
unreported	POS	O
.	POS	O
STUDY	POS	O
DESIGN	POS	O
:	POS	O
Retrospective	POS	O
case	POS	O
series	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Patients	POS	O
that	POS	O
received	POS	O
Botox	POS	O
injections	POS	O
for	POS	O
spasmodic	POS	B-NP
dysphonia	POS	I-NP
between	POS	O
January	POS	O
2000	POS	O
and	POS	O
October	POS	O
2009	POS	O
were	POS	O
evaluated	POS	O
.	POS	O
Patients	POS	O
with	POS	O
ADSD	POS	B-NP
were	POS	O
identified	POS	O
.	POS	O
The	POS	O
number	POS	O
of	POS	O
treatments	POS	O
received	POS	O
and	POS	O
adverse	POS	O
effects	POS	O
were	POS	O
noted	POS	O
.	POS	O
For	POS	O
patients	POS	O
with	POS	O
bilateral	POS	B-NP
abductor	POS	I-NP
paralysis	POS	I-NP
,	POS	O
age	POS	O
,	POS	O
sex	POS	O
,	POS	O
paralytic	POS	B-NP
Botox	POS	I-NP
dose	POS	O
,	POS	O
prior	POS	O
Botox	POS	O
dose	POS	O
,	POS	O
and	POS	O
course	POS	O
following	POS	O
paralysis	POS	B-NP
were	POS	O
noted	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
From	POS	O
a	POS	O
database	POS	O
of	POS	O
452	POS	O
patients	POS	O
receiving	POS	O
Botox	POS	O
,	POS	O
352	POS	O
patients	POS	O
had	POS	O
been	POS	O
diagnosed	POS	O
with	POS	O
ADSD	POS	B-NP
.	POS	O
Of	POS	O
these	POS	O
352	POS	O
patients	POS	O
,	POS	O
eight	POS	O
patients	POS	O
suffered	POS	O
bilateral	POS	B-NP
abductor	POS	I-NP
paralysis	POS	I-NP
,	POS	O
and	POS	O
two	POS	O
suffered	POS	O
this	POS	O
complication	POS	O
twice	POS	O
.	POS	O
All	POS	O
affected	POS	B-NP
patients	POS	O
were	POS	O
females	POS	O
over	POS	O
the	POS	O
age	POS	O
of	POS	O
50	POS	O
years	POS	O
.	POS	O
Most	POS	O
patients	POS	O
had	POS	O
received	POS	O
treatments	POS	O
prior	POS	O
to	POS	O
abductor	POS	B-NP
paralysis	POS	I-NP
and	POS	O
continued	POS	O
receiving	POS	O
after	POS	O
paralysis	POS	B-NP
.	POS	O
Seven	POS	O
patients	POS	O
recovered	POS	O
after	POS	O
a	POS	O
brief	POS	O
period	POS	O
of	POS	O
activity	POS	O
restrictions	POS	O
,	POS	O
and	POS	O
one	POS	O
underwent	POS	O
a	POS	O
tracheotomy	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
abductor	POS	B-NP
paralysis	POS	I-NP
after	POS	O
Botox	POS	O
injection	POS	O
for	POS	O
ADSD	POS	B-NP
was	POS	O
0	POS	O
.	POS	O
34	POS	O
%	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Bilateral	POS	O
abductor	POS	B-NP
paralysis	POS	I-NP
is	POS	O
a	POS	O
rare	POS	O
complication	POS	O
of	POS	O
Botox	POS	O
injections	POS	O
for	POS	O
ADSD	POS	B-NP
,	POS	O
causing	POS	O
difficulty	POS	O
with	POS	O
breathing	POS	B-NP
upon	POS	I-NP
exertion	POS	I-NP
.	POS	O
The	POS	O
likely	POS	O
mechanism	POS	O
of	POS	O
paralysis	POS	B-NP
is	POS	O
diffusion	POS	O
of	POS	O
Botox	POS	O
around	POS	O
the	POS	O
muscular	POS	O
process	POS	O
of	POS	O
the	POS	O
arytenoid	POS	O
to	POS	O
the	POS	O
posterior	POS	O
cricoarytenoid	POS	O
muscles	POS	O
.	POS	O
The	POS	O
paralysis	POS	B-NP
is	POS	O
temporary	POS	O
,	POS	O
and	POS	O
watchful	POS	O
waiting	POS	O
with	POS	O
restriction	POS	O
of	POS	O
activity	POS	O
is	POS	O
the	POS	O
recommended	POS	O
management	POS	O
.	POS	O
Mitochondrial	POS	B-NP
impairment	POS	I-NP
contributes	POS	O
to	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
dysfunction	POS	I-NP
:	POS	O
Prevention	POS	O
by	POS	O
the	POS	O
targeted	POS	O
antioxidant	POS	O
MitoQ	POS	O
.	POS	O
The	POS	O
goal	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
assess	POS	O
mitochondrial	POS	O
function	POS	O
and	POS	O
ROS	POS	O
production	POS	O
in	POS	O
an	POS	O
experimental	POS	O
model	POS	O
of	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
We	POS	O
hypothesized	POS	O
that	POS	O
cocaine	POS	B-NP
abuse	POS	I-NP
may	POS	O
lead	POS	O
to	POS	O
altered	POS	O
mitochondrial	POS	O
function	POS	O
that	POS	O
in	POS	O
turn	POS	O
may	POS	O
cause	POS	O
left	POS	O
ventricular	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
Seven	POS	O
days	POS	O
of	POS	O
cocaine	POS	O
administration	POS	O
to	POS	O
rats	POS	O
led	POS	O
to	POS	O
an	POS	O
increased	POS	O
oxygen	POS	O
consumption	POS	O
detected	POS	O
in	POS	O
cardiac	POS	O
fibers	POS	O
,	POS	O
specifically	POS	O
through	POS	O
complex	POS	O
I	POS	O
and	POS	O
complex	POS	O
III	POS	O
.	POS	O
ROS	POS	O
levels	POS	O
were	POS	O
increased	POS	O
,	POS	O
specifically	POS	O
in	POS	O
interfibrillar	POS	O
mitochondria	POS	O
.	POS	O
In	POS	O
parallel	POS	O
there	POS	O
was	POS	O
a	POS	O
decrease	POS	O
in	POS	O
ATP	POS	O
synthesis	POS	O
,	POS	O
whereas	POS	O
no	POS	O
difference	POS	O
was	POS	O
observed	POS	O
in	POS	O
subsarcolemmal	POS	O
mitochondria	POS	O
.	POS	O
This	POS	O
uncoupling	POS	O
effect	POS	O
on	POS	O
oxidative	POS	O
phosphorylation	POS	O
was	POS	O
not	POS	O
detectable	POS	O
after	POS	O
short	POS	O
-	POS	O
term	POS	O
exposure	POS	O
to	POS	O
cocaine	POS	O
,	POS	O
suggesting	POS	O
that	POS	O
these	POS	O
mitochondrial	POS	B-NP
abnormalities	POS	I-NP
were	POS	O
a	POS	O
late	POS	O
rather	POS	O
than	POS	O
a	POS	O
primary	POS	O
event	POS	O
in	POS	O
the	POS	O
pathological	POS	O
response	POS	O
to	POS	O
cocaine	POS	O
.	POS	O
MitoQ	POS	O
,	POS	O
a	POS	O
mitochondrial	POS	O
-	POS	O
targeted	POS	O
antioxidant	POS	O
,	POS	O
was	POS	O
shown	POS	O
to	POS	O
completely	POS	O
prevent	POS	O
these	POS	O
mitochondrial	POS	O
abnormalities	POS	O
as	POS	O
well	POS	O
as	POS	O
cardiac	POS	B-NP
dysfunction	POS	I-NP
characterized	POS	O
here	POS	O
by	POS	O
a	POS	O
diastolic	POS	B-NP
dysfunction	POS	I-NP
studied	POS	O
with	POS	O
a	POS	O
conductance	POS	O
catheter	POS	O
to	POS	O
obtain	POS	O
pressure	POS	O
-	POS	O
volume	POS	O
data	POS	O
.	POS	O
Taken	POS	O
together	POS	O
,	POS	O
these	POS	O
results	POS	O
extend	POS	O
previous	POS	O
studies	POS	O
and	POS	O
demonstrate	POS	O
that	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
dysfunction	POS	I-NP
may	POS	O
be	POS	O
due	POS	O
to	POS	O
a	POS	O
mitochondrial	POS	B-NP
defect	POS	I-NP
.	POS	O
Trimethoprim	POS	O
-	POS	O
induced	POS	O
immune	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
in	POS	O
a	POS	O
pediatric	POS	O
oncology	POS	O
patient	POS	O
presenting	POS	O
as	POS	O
an	POS	O
acute	POS	B-NP
hemolytic	POS	I-NP
transfusion	POS	I-NP
reaction	POS	I-NP
.	POS	O
A	POS	O
10	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
with	POS	O
acute	POS	B-NP
leukemia	POS	I-NP
presented	POS	O
with	POS	O
post	POS	O
-	POS	O
chemotherapy	POS	O
anemia	POS	B-NP
.	POS	O
During	POS	O
red	POS	O
cell	POS	O
transfusion	POS	O
,	POS	O
he	POS	O
developed	POS	O
hemoglobinuria	POS	B-NP
.	POS	O
Transfusion	POS	O
reaction	POS	O
workup	POS	O
was	POS	O
negative	POS	O
.	POS	O
Drug	POS	O
-	POS	O
induced	POS	O
immune	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
was	POS	O
suspected	POS	O
because	POS	O
of	POS	O
positive	POS	O
direct	POS	O
antiglobulin	POS	O
test	POS	O
,	POS	O
negative	POS	O
eluate	POS	O
,	POS	O
and	POS	O
microspherocytes	POS	O
on	POS	O
smear	POS	O
pre	POS	O
-	POS	O
and	POS	O
post	POS	O
-	POS	O
transfusion	POS	O
.	POS	O
Drug	POS	O
studies	POS	O
using	POS	O
the	POS	O
indirect	POS	O
antiglobulin	POS	O
test	POS	O
were	POS	O
strongly	POS	O
positive	POS	O
with	POS	O
trimethoprim	POS	O
and	POS	O
trimethoprim	POS	O
-	POS	O
sulfamethoxazole	POS	O
but	POS	O
negative	POS	O
with	POS	O
sulfamethoxazole	POS	O
.	POS	O
The	POS	O
patient	POS	O
recovered	POS	O
after	POS	O
discontinuing	POS	O
the	POS	O
drug	POS	O
,	POS	O
with	POS	O
no	POS	O
recurrence	POS	O
in	POS	O
2	POS	O
years	POS	O
.	POS	O
Other	POS	O
causes	POS	O
of	POS	O
anemia	POS	B-NP
should	POS	O
be	POS	O
considered	POS	O
in	POS	O
patients	POS	O
with	POS	O
worse	POS	O
-	POS	O
than	POS	O
-	POS	O
expected	POS	O
anemia	POS	B-NP
after	POS	O
chemotherapy	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
hemolysis	POS	B-NP
during	POS	O
transfusion	POS	O
is	POS	O
not	POS	O
always	POS	O
a	POS	O
transfusion	POS	O
reaction	POS	O
.	POS	O
Verapamil	POS	O
stimulation	POS	O
test	POS	O
in	POS	O
hyperprolactinemia	POS	B-NP
:	POS	O
loss	POS	O
of	POS	O
prolactin	POS	O
response	POS	O
in	POS	O
anatomic	POS	O
or	POS	O
functional	POS	O
stalk	POS	O
effect	POS	O
.	POS	O
AIM	POS	O
:	POS	O
Verapamil	POS	O
stimulation	POS	O
test	POS	O
was	POS	O
previously	POS	O
investigated	POS	O
as	POS	O
a	POS	O
tool	POS	O
for	POS	O
differential	POS	O
diagnosis	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
,	POS	O
but	POS	O
with	POS	O
conflicting	POS	O
results	POS	O
.	POS	O
Macroprolactinemia	POS	B-NP
was	POS	O
never	POS	O
considered	POS	O
in	POS	O
those	POS	O
previous	POS	O
studies	POS	O
.	POS	O
Here	POS	O
,	POS	O
we	POS	O
aimed	POS	O
to	POS	O
re	POS	O
-	POS	O
investigate	POS	O
the	POS	O
diagnostic	POS	O
value	POS	O
of	POS	O
verapamil	POS	O
in	POS	O
a	POS	O
population	POS	O
who	POS	O
were	POS	O
all	POS	O
screened	POS	O
for	POS	O
macroprolactinemia	POS	B-NP
.	POS	O
Prolactin	POS	O
responses	POS	O
to	POS	O
verapamil	POS	O
in	POS	O
65	POS	O
female	POS	O
patients	POS	O
(	POS	O
age	POS	O
:	POS	O
29	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
.	POS	O
1	POS	O
years	POS	O
)	POS	O
with	POS	O
hyperprolactinemia	POS	B-NP
were	POS	O
tested	POS	O
in	POS	O
a	POS	O
descriptive	POS	O
,	POS	O
matched	POS	O
case	POS	O
-	POS	O
control	POS	O
study	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Verapamil	POS	O
80	POS	O
mg	POS	O
,	POS	O
p	POS	O
.	POS	O
o	POS	O
.	POS	O
was	POS	O
administered	POS	O
,	POS	O
and	POS	O
then	POS	O
PRL	POS	O
levels	POS	O
were	POS	O
measured	POS	O
at	POS	O
8th	POS	O
and	POS	O
16th	POS	O
hours	POS	O
,	POS	O
by	POS	O
immunometric	POS	O
chemiluminescence	POS	O
.	POS	O
Verapamil	POS	O
responsiveness	POS	O
was	POS	O
determined	POS	O
by	POS	O
peak	POS	O
percent	POS	O
change	POS	O
in	POS	O
basal	POS	O
prolactin	POS	O
levels	POS	O
(	POS	O
PRL	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Verapamil	POS	O
significantly	POS	O
increased	POS	O
PRL	POS	O
levels	POS	O
in	POS	O
healthy	POS	O
controls	POS	O
(	POS	O
N	POS	O
.	POS	O
8	POS	O
,	POS	O
PRL	POS	O
:	POS	O
183	POS	O
%	POS	O
)	POS	O
,	POS	O
macroprolactinoma	POS	B-NP
(	POS	O
N	POS	O
.	POS	O
8	POS	O
,	POS	O
PRL	POS	O
:	POS	O
7	POS	O
%	POS	O
)	POS	O
,	POS	O
microprolactinoma	POS	B-NP
(	POS	O
N	POS	O
.	POS	O
19	POS	O
,	POS	O
PRL	POS	O
:	POS	O
21	POS	O
%	POS	O
)	POS	O
,	POS	O
macroprolactinemia	POS	B-NP
(	POS	O
N	POS	O
.	POS	O
23	POS	O
,	POS	O
PRL	POS	O
:	POS	O
126	POS	O
%	POS	O
)	POS	O
,	POS	O
but	POS	O
not	POS	O
in	POS	O
pseudoprolactinoma	POS	B-NP
(	POS	O
N	POS	O
.	POS	O
8	POS	O
,	POS	O
PRL	POS	O
:	POS	O
0	POS	O
.	POS	O
8	POS	O
%	POS	O
)	POS	O
,	POS	O
and	POS	O
risperidone	POS	O
-	POS	O
induced	POS	O
hyperprolactinemia	POS	B-NP
(	POS	O
N	POS	O
.	POS	O
7	POS	O
,	POS	O
PRL	POS	O
:	POS	O
3	POS	O
%	POS	O
)	POS	O
.	POS	O
ROC	POS	O
curve	POS	O
analysis	POS	O
revealed	POS	O
that	POS	O
unresponsiveness	POS	O
to	POS	O
verapamil	POS	O
defined	POS	O
as	POS	O
PRL	POS	O
<	POS	O
7	POS	O
%	POS	O
,	POS	O
discriminated	POS	O
anatomical	POS	O
or	POS	O
functional	POS	O
stalk	POS	O
effect	POS	O
(	POS	O
sensitivity	POS	O
:	POS	O
74	POS	O
%	POS	O
,	POS	O
specificity	POS	O
:	POS	O
73	POS	O
%	POS	O
,	POS	O
AUC	POS	O
:	POS	O
0	POS	O
.	POS	O
855	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
04	POS	O
,	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
,	POS	O
CI	POS	O
:	POS	O
0	POS	O
.	POS	O
768	POS	O
-	POS	O
0	POS	O
.	POS	O
942	POS	O
)	POS	O
associated	POS	O
with	POS	O
pseudoprolactinoma	POS	O
or	POS	O
risperidone	POS	O
-	POS	O
induced	POS	O
hyperprolactinemia	POS	B-NP
,	POS	O
respectively	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Verapamil	POS	O
responsiveness	POS	O
is	POS	O
not	POS	O
a	POS	O
reliable	POS	O
finding	POS	O
for	POS	O
the	POS	O
differential	POS	O
diagnosis	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
verapamil	POS	O
unresponsiveness	POS	O
discriminates	POS	O
stalk	POS	O
effect	POS	O
(	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
,	POS	O
anatomically	POS	O
or	POS	O
functionally	POS	O
inhibited	POS	O
dopaminergic	POS	O
tonus	POS	O
)	POS	O
from	POS	O
other	POS	O
causes	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
with	POS	O
varying	POS	O
degrees	POS	O
of	POS	O
responsiveness	POS	O
.	POS	O
Blockade	POS	O
of	POS	O
endothelial	POS	O
-	POS	O
mesenchymal	POS	O
transition	POS	O
by	POS	O
a	POS	O
Smad3	POS	O
inhibitor	POS	O
delays	POS	O
the	POS	O
early	POS	O
development	POS	O
of	POS	O
streptozotocin	POS	O
-	POS	O
induced	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
A	POS	O
multicenter	POS	O
,	POS	O
controlled	POS	O
trial	POS	O
showed	POS	O
that	POS	O
early	POS	O
blockade	POS	O
of	POS	O
the	POS	O
renin	POS	O
-	POS	O
angiotensin	POS	O
system	POS	O
in	POS	O
patients	POS	O
with	POS	O
type	POS	B-NP
1	POS	I-NP
diabetes	POS	I-NP
and	POS	O
normoalbuminuria	POS	B-NP
did	POS	O
not	POS	O
retard	POS	O
the	POS	O
progression	POS	O
of	POS	O
nephropathy	POS	B-NP
,	POS	O
suggesting	POS	O
that	POS	O
other	POS	O
mechanism	POS	O
(	POS	O
s	POS	O
)	POS	O
are	POS	O
involved	POS	O
in	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
early	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
(	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
)	POS	O
.	POS	O
We	POS	O
have	POS	O
previously	POS	O
demonstrated	POS	O
that	POS	O
endothelial	POS	O
-	POS	O
mesenchymal	POS	O
-	POS	O
transition	POS	O
(	POS	O
EndoMT	POS	O
)	POS	O
contributes	POS	O
to	POS	O
the	POS	O
early	POS	O
development	POS	O
of	POS	O
renal	POS	B-NP
interstitial	POS	I-NP
fibrosis	POS	I-NP
independently	POS	O
of	POS	O
microalbuminuria	POS	B-NP
in	POS	O
mice	POS	O
with	POS	O
streptozotocin	POS	O
(	POS	O
STZ	POS	O
)	POS	O
-	POS	O
induced	POS	O
diabetes	POS	B-NP
.	POS	O
In	POS	O
the	POS	O
present	POS	O
study	POS	O
,	POS	O
we	POS	O
hypothesized	POS	O
that	POS	O
blocking	POS	O
EndoMT	POS	O
reduces	POS	O
the	POS	O
early	POS	O
development	POS	O
of	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
.	POS	O
RESEARCH	POS	O
DESIGN	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
EndoMT	POS	O
was	POS	O
induced	POS	O
in	POS	O
a	POS	O
mouse	POS	O
pancreatic	POS	O
microvascular	POS	O
endothelial	POS	O
cell	POS	O
line	POS	O
(	POS	O
MMEC	POS	O
)	POS	O
in	POS	O
the	POS	O
presence	POS	O
of	POS	O
advanced	POS	O
glycation	POS	O
end	POS	O
products	POS	O
(	POS	O
AGEs	POS	O
)	POS	O
and	POS	O
in	POS	O
the	POS	O
endothelial	POS	O
lineage	POS	O
-	POS	O
traceble	POS	O
mouse	POS	O
line	POS	O
Tie2	POS	O
-	POS	O
Cre	POS	O
;	POS	O
Loxp	POS	O
-	POS	O
EGFP	POS	O
by	POS	O
administration	POS	O
of	POS	O
AGEs	POS	O
,	POS	O
with	POS	O
nonglycated	POS	O
mouse	POS	O
albumin	POS	O
serving	POS	O
as	POS	O
a	POS	O
control	POS	O
.	POS	O
Phosphorylated	POS	O
Smad3	POS	O
was	POS	O
detected	POS	O
by	POS	O
immunoprecipitation	POS	O
/	POS	O
Western	POS	O
blotting	POS	O
and	POS	O
confocal	POS	O
microscopy	POS	O
.	POS	O
Blocking	POS	O
studies	POS	O
using	POS	O
receptor	POS	O
for	POS	O
AGE	POS	O
siRNA	POS	O
and	POS	O
a	POS	O
specific	POS	O
inhibitor	POS	O
of	POS	O
Smad3	POS	O
(	POS	O
SIS3	POS	O
)	POS	O
were	POS	O
performed	POS	O
in	POS	O
MMECs	POS	O
and	POS	O
in	POS	O
STZ	POS	O
-	POS	O
induced	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
in	POS	O
Tie2	POS	O
-	POS	O
Cre	POS	O
;	POS	O
Loxp	POS	O
-	POS	O
EGFP	POS	O
mice	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Confocal	POS	O
microscopy	POS	O
and	POS	O
real	POS	O
-	POS	O
time	POS	O
PCR	POS	O
demonstrated	POS	O
that	POS	O
AGEs	POS	O
induced	POS	O
EndoMT	POS	O
in	POS	O
MMECs	POS	O
and	POS	O
in	POS	O
Tie2	POS	O
-	POS	O
Cre	POS	O
;	POS	O
Loxp	POS	O
-	POS	O
EGFP	POS	O
mice	POS	O
.	POS	O
Immunoprecipitation	POS	O
/	POS	O
Western	POS	O
blotting	POS	O
showed	POS	O
that	POS	O
Smad3	POS	O
was	POS	O
activated	POS	O
by	POS	O
AGEs	POS	O
but	POS	O
was	POS	O
inhibited	POS	O
by	POS	O
SIS3	POS	O
in	POS	O
MMECs	POS	O
and	POS	O
in	POS	O
STZ	POS	O
-	POS	O
induced	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
.	POS	O
Confocal	POS	O
microscopy	POS	O
and	POS	O
real	POS	O
-	POS	O
time	POS	O
PCR	POS	O
further	POS	O
demonstrated	POS	O
that	POS	O
SIS3	POS	O
abrogated	POS	O
EndoMT	POS	O
,	POS	O
reduced	POS	O
renal	POS	B-NP
fibrosis	POS	I-NP
,	POS	O
and	POS	O
retarded	POS	O
progression	POS	O
of	POS	O
nephropathy	POS	B-NP
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
EndoMT	POS	O
is	POS	O
a	POS	O
novel	POS	O
pathway	POS	O
leading	POS	O
to	POS	O
early	POS	O
development	POS	O
of	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
.	POS	O
Blockade	POS	O
of	POS	O
EndoMT	POS	O
by	POS	O
SIS3	POS	O
may	POS	O
provide	POS	O
a	POS	O
new	POS	O
strategy	POS	O
to	POS	O
retard	POS	O
the	POS	O
progression	POS	O
of	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
and	POS	O
other	POS	O
diabetes	POS	B-NP
complications	POS	O
.	POS	O
Cytostatic	POS	O
and	POS	O
anti	POS	O
-	POS	O
angiogenic	POS	O
effects	POS	O
of	POS	O
temsirolimus	POS	O
in	POS	O
refractory	POS	O
mantle	POS	B-NP
cell	POS	I-NP
lymphoma	POS	I-NP
.	POS	O
Mantle	POS	B-NP
cell	POS	I-NP
lymphoma	POS	I-NP
(	POS	O
MCL	POS	B-NP
)	POS	O
is	POS	O
a	POS	O
rare	POS	O
and	POS	O
aggressive	POS	B-NP
type	POS	I-NP
of	POS	I-NP
B	POS	I-NP
-	POS	I-NP
cell	POS	I-NP
non	POS	I-NP
-	POS	I-NP
Hodgkin	POS	I-NP
'	POS	I-NP
s	POS	I-NP
lymphoma	POS	I-NP
.	POS	O
Patients	POS	O
become	POS	O
progressively	POS	O
refractory	POS	O
to	POS	O
conventional	POS	O
chemotherapy	POS	O
,	POS	O
and	POS	O
their	POS	O
prognosis	POS	O
is	POS	O
poor	POS	O
.	POS	O
However	POS	O
,	POS	O
a	POS	O
38	POS	O
%	POS	O
remission	POS	O
rate	POS	O
has	POS	O
been	POS	O
recently	POS	O
reported	POS	O
in	POS	O
refractory	POS	O
MCL	POS	O
treated	POS	O
with	POS	O
temsirolimus	POS	O
,	POS	O
a	POS	O
mTOR	POS	O
inhibitor	POS	O
.	POS	O
Here	POS	O
we	POS	O
had	POS	O
the	POS	O
opportunity	POS	O
to	POS	O
study	POS	O
a	POS	O
case	POS	O
of	POS	O
refractory	POS	O
MCL	POS	B-NP
who	POS	O
had	POS	O
tumor	POS	B-NP
regression	POS	O
two	POS	O
months	POS	O
after	POS	O
temsirolimus	POS	O
treatment	POS	O
,	POS	O
and	POS	O
a	POS	O
progression	POS	O
-	POS	O
free	POS	O
survival	POS	O
of	POS	O
10	POS	O
months	POS	O
.	POS	O
In	POS	O
this	POS	O
case	POS	O
,	POS	O
lymph	POS	O
node	POS	O
biopsies	POS	O
were	POS	O
performed	POS	O
before	POS	O
and	POS	O
six	POS	O
months	POS	O
after	POS	O
temsirolimus	POS	O
therapy	POS	O
.	POS	O
Comparison	POS	O
of	POS	O
the	POS	O
two	POS	O
biopsies	POS	O
showed	POS	O
that	POS	O
temsirolimus	POS	O
inhibited	POS	O
tumor	POS	B-NP
cell	POS	I-NP
proliferation	POS	I-NP
through	POS	I-NP
cell	POS	I-NP
cycle	POS	I-NP
arrest	POS	I-NP
,	POS	O
but	POS	O
did	POS	O
not	POS	O
induce	POS	O
any	POS	O
change	POS	O
in	POS	O
the	POS	O
number	POS	O
of	POS	O
apoptotic	POS	O
tumor	POS	B-NP
cells	POS	O
.	POS	O
Apart	POS	O
from	POS	O
this	POS	O
cytostatic	POS	O
effect	POS	O
,	POS	O
temsirolimus	POS	O
had	POS	O
an	POS	O
antiangiogenic	POS	O
effect	POS	O
with	POS	O
decrease	POS	O
of	POS	O
tumor	POS	B-NP
microvessel	POS	O
density	POS	O
and	POS	O
of	POS	O
VEGF	POS	O
expression	POS	O
.	POS	O
Moreover	POS	O
,	POS	O
numerous	POS	O
patchy	POS	O
,	POS	O
well	POS	O
-	POS	O
limited	POS	O
fibrotic	POS	O
areas	POS	O
,	POS	O
compatible	POS	O
with	POS	O
post	POS	O
-	POS	O
necrotic	POS	O
tissue	POS	O
repair	POS	O
,	POS	O
were	POS	O
found	POS	O
after	POS	O
6	POS	O
-	POS	O
month	POS	O
temsirolimus	POS	O
therapy	POS	O
.	POS	O
Thus	POS	O
,	POS	O
temsirolimus	POS	O
reduced	POS	O
tumor	POS	B-NP
burden	POS	O
through	POS	O
associated	POS	O
cytostatic	POS	O
and	POS	O
anti	POS	O
-	POS	O
angiogenic	POS	O
effects	POS	O
.	POS	O
This	POS	O
dual	POS	O
effect	POS	O
of	POS	O
temsirolimus	POS	O
on	POS	O
tumor	POS	B-NP
tissue	POS	O
could	POS	O
contribute	POS	O
to	POS	O
its	POS	O
recently	POS	O
reported	POS	O
efficiency	POS	O
in	POS	O
refractory	POS	O
MCL	POS	B-NP
resistant	POS	O
to	POS	O
conventional	POS	O
chemotherapy	POS	O
.	POS	O
Acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
due	POS	O
to	POS	O
rifampicin	POS	O
.	POS	O
A	POS	O
23	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
patient	POS	O
with	POS	O
bacteriologically	POS	O
proven	POS	O
pulmonary	POS	B-NP
tuberculosis	POS	I-NP
was	POS	O
treated	POS	O
with	POS	O
the	POS	O
various	POS	O
regimens	POS	O
of	POS	O
antituberculosis	POS	O
drugs	POS	O
for	POS	O
nearly	POS	O
15	POS	O
months	POS	O
.	POS	O
Rifampicin	POS	O
was	POS	O
administered	POS	O
thrice	POS	O
as	POS	O
one	POS	O
of	POS	O
the	POS	O
3	POS	O
-	POS	O
4	POS	O
drug	POS	O
regimen	POS	O
and	POS	O
each	POS	O
time	POS	O
he	POS	O
developed	POS	O
untoward	POS	O
side	POS	O
effects	POS	O
like	POS	O
nausea	POS	B-NP
,	POS	O
vomiting	POS	B-NP
and	POS	O
fever	POS	B-NP
with	POS	O
chills	POS	B-NP
and	POS	O
rigors	POS	B-NP
.	POS	O
The	POS	O
last	POS	O
such	POS	O
episode	POS	O
was	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
at	POS	O
which	POS	O
stage	POS	O
the	POS	O
patient	POS	O
was	POS	O
seen	POS	O
by	POS	O
the	POS	O
authors	POS	O
of	POS	O
this	POS	O
report	POS	O
.	POS	O
The	POS	O
patient	POS	O
,	POS	O
however	POS	O
,	POS	O
made	POS	O
a	POS	O
full	POS	O
recovery	POS	O
.	POS	O
Syncope	POS	B-NP
caused	POS	O
by	POS	O
hyperkalemia	POS	B-NP
during	POS	O
use	POS	O
of	POS	O
a	POS	O
combined	POS	O
therapy	POS	O
with	POS	O
the	POS	O
angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
inhibitor	POS	O
and	POS	O
spironolactone	POS	O
.	POS	O
A	POS	O
76	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
a	POS	O
history	POS	O
of	POS	O
coronary	POS	O
artery	POS	O
bypass	POS	O
grafting	POS	O
and	POS	O
prior	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
was	POS	O
transferred	POS	O
to	POS	O
the	POS	O
emergency	POS	O
room	POS	O
with	POS	O
loss	POS	O
of	POS	O
consciousness	POS	O
due	POS	O
to	POS	O
marked	POS	O
bradycardia	POS	B-NP
caused	POS	O
by	POS	O
hyperkalemia	POS	B-NP
.	POS	O
The	POS	O
concentration	POS	O
of	POS	O
serum	POS	O
potassium	POS	O
was	POS	O
high	POS	O
,	POS	O
and	POS	O
normal	POS	O
sinus	POS	O
rhythm	POS	O
was	POS	O
restored	POS	O
after	POS	O
correction	POS	O
of	POS	O
the	POS	O
serum	POS	O
potassium	POS	O
level	POS	O
.	POS	O
The	POS	O
cause	POS	O
of	POS	O
hyperkalemia	POS	B-NP
was	POS	O
considered	POS	O
to	POS	O
be	POS	O
several	POS	O
doses	POS	O
of	POS	O
spiranolactone	POS	O
,	POS	O
an	POS	O
aldosterone	POS	O
antagonist	POS	O
,	POS	O
in	POS	O
addition	POS	O
to	POS	O
the	POS	O
long	POS	O
-	POS	O
term	POS	O
intake	POS	O
of	POS	O
ramipril	POS	O
,	POS	O
an	POS	O
ACE	POS	O
inhibitor	POS	O
.	POS	O
This	POS	O
case	POS	O
is	POS	O
a	POS	O
good	POS	O
example	POS	O
of	POS	O
electrolyte	POS	O
imbalance	POS	O
causing	POS	O
acute	POS	O
life	POS	O
-	POS	O
threatening	POS	O
cardiac	POS	O
events	POS	O
.	POS	O
Clinicians	POS	O
should	POS	O
be	POS	O
alert	POS	O
to	POS	O
the	POS	O
possibility	POS	O
of	POS	O
hyperkalemia	POS	B-NP
,	POS	O
especially	POS	O
in	POS	O
elderly	POS	O
patients	POS	O
using	POS	O
ACE	POS	O
/	POS	O
ARB	POS	O
in	POS	O
combination	POS	O
with	POS	O
potassium	POS	O
sparing	POS	O
agents	POS	O
and	POS	O
who	POS	O
have	POS	O
mild	POS	O
renal	POS	B-NP
disturbance	POS	I-NP
.	POS	O
Diffuse	POS	B-NP
skeletal	POS	I-NP
pain	POS	I-NP
after	POS	O
administration	POS	O
of	POS	O
alendronate	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Osteoporosis	POS	B-NP
is	POS	O
caused	POS	O
by	POS	O
bone	POS	O
resorption	POS	O
in	POS	O
excess	POS	O
of	POS	O
bone	POS	O
formation	POS	O
,	POS	O
and	POS	O
bisphosphonates	POS	O
,	POS	O
are	POS	O
used	POS	O
to	POS	O
inhibit	POS	O
bone	POS	O
resorption	POS	O
.	POS	O
Alendronate	POS	O
,	POS	O
a	POS	O
biphosphonate	POS	O
,	POS	O
is	POS	O
effective	POS	O
for	POS	O
both	POS	O
the	POS	O
treatment	POS	O
and	POS	O
prevention	POS	O
of	POS	O
osteoporosis	POS	B-NP
in	POS	O
postmenopausal	POS	O
women	POS	O
.	POS	O
Side	POS	O
effects	POS	O
are	POS	O
relatively	POS	O
few	POS	O
and	POS	O
prominently	POS	O
gastrointestinal	POS	O
.	POS	O
Musculoskeletal	POS	B-NP
pain	POS	I-NP
may	POS	O
be	POS	O
an	POS	O
important	POS	O
side	POS	O
effect	POS	O
in	POS	O
these	POS	O
patients	POS	O
.	POS	O
We	POS	O
presented	POS	O
a	POS	O
patient	POS	O
admitted	POS	O
to	POS	O
our	POS	O
out	POS	O
-	POS	O
patient	POS	O
clinic	POS	O
with	POS	O
diffuse	POS	O
skeletal	POS	B-NP
pain	POS	I-NP
after	POS	O
three	POS	O
consecutive	POS	O
administration	POS	O
of	POS	O
alendronate	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
We	POS	O
conclude	POS	O
that	POS	O
patients	POS	O
with	POS	O
osteoporosis	POS	B-NP
can	POS	O
report	POS	O
pain	POS	B-NP
,	POS	O
and	POS	O
bisphosphonate	POS	B-NP
-	POS	I-NP
related	POS	I-NP
pain	POS	I-NP
should	POS	O
also	POS	O
be	POS	O
considered	POS	O
before	POS	O
ascribing	POS	O
this	POS	O
complaint	POS	O
to	POS	O
osteoporosis	POS	B-NP
.	POS	O
Cerebrospinal	POS	O
fluid	POS	O
penetration	POS	O
of	POS	O
high	POS	O
-	POS	O
dose	POS	O
daptomycin	POS	O
in	POS	O
suspected	POS	O
Staphylococcus	POS	O
aureus	POS	O
meningitis	POS	B-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
methicillin	POS	O
-	POS	O
sensitive	POS	O
Staphylococcus	POS	O
aureus	POS	O
(	POS	O
MSSA	POS	O
)	POS	O
bacteremia	POS	B-NP
with	POS	O
suspected	POS	O
MSSA	POS	B-NP
meningitis	POS	I-NP
treated	POS	O
with	POS	O
high	POS	O
-	POS	O
dose	POS	O
daptomycin	POS	O
assessed	POS	O
with	POS	O
concurrent	POS	O
serum	POS	O
and	POS	O
cerebrospinal	POS	O
fluid	POS	O
(	POS	O
CSF	POS	O
)	POS	O
concentrations	POS	O
.	POS	O
CASE	POS	O
SUMMARY	POS	O
:	POS	O
A	POS	O
54	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
presented	POS	O
to	POS	O
the	POS	O
emergency	POS	O
department	POS	O
with	POS	O
generalized	POS	B-NP
weakness	POS	I-NP
and	POS	O
presumed	POS	O
health	POS	O
-	POS	O
care	POS	O
-	POS	O
associated	POS	O
pneumonia	POS	B-NP
shown	POS	O
on	POS	O
chest	POS	O
radiograph	POS	O
.	POS	O
Treatment	POS	O
was	POS	O
empirically	POS	O
initiated	POS	O
with	POS	O
vancomycin	POS	O
,	POS	O
levofloxacin	POS	O
,	POS	O
and	POS	O
piperacillin	POS	O
/	POS	O
tazobactam	POS	O
.	POS	O
Blood	POS	O
cultures	POS	O
revealed	POS	O
S	POS	O
.	POS	O
aureus	POS	O
susceptible	POS	O
to	POS	O
oxacillin	POS	O
.	POS	O
Empiric	POS	O
antibiotic	POS	O
treatment	POS	O
was	POS	O
narrowed	POS	O
to	POS	O
nafcillin	POS	O
on	POS	O
day	POS	O
4	POS	O
.	POS	O
On	POS	O
day	POS	O
8	POS	O
,	POS	O
the	POS	O
patient	POS	O
developed	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
(	POS	O
serum	POS	O
creatinine	POS	O
1	POS	O
.	POS	O
9	POS	O
mg	POS	O
/	POS	O
dL	POS	O
,	POS	O
increased	POS	O
from	POS	O
1	POS	O
.	POS	O
2	POS	O
mg	POS	O
/	POS	O
dL	POS	O
the	POS	O
previous	POS	O
day	POS	O
and	POS	O
0	POS	O
.	POS	O
8	POS	O
mg	POS	O
/	POS	O
dL	POS	O
on	POS	O
admission	POS	O
)	POS	O
.	POS	O
The	POS	O
patient	POS	O
'	POS	O
s	POS	O
Glasgow	POS	O
Coma	POS	B-NP
Score	POS	O
was	POS	O
3	POS	O
,	POS	O
with	POS	O
normal	POS	O
findings	POS	O
shown	POS	O
on	POS	O
computed	POS	O
tomography	POS	O
scan	POS	O
of	POS	O
the	POS	O
head	POS	O
72	POS	O
hours	POS	O
following	POS	O
an	POS	O
episode	POS	O
of	POS	O
cardiac	POS	B-NP
arrest	POS	I-NP
on	POS	O
day	POS	O
10	POS	O
.	POS	O
The	POS	O
patient	POS	O
experienced	POS	O
relapsing	POS	O
MSSA	POS	B-NP
bacteremia	POS	B-NP
on	POS	O
day	POS	O
9	POS	O
,	POS	O
increasing	POS	O
the	POS	O
suspicion	POS	O
for	POS	O
a	POS	O
central	POS	B-NP
nervous	POS	I-NP
system	POS	I-NP
(	POS	I-NP
CNS	POS	I-NP
)	POS	I-NP
infection	POS	I-NP
.	POS	O
Nafcillin	POS	O
was	POS	O
discontinued	POS	O
and	POS	O
daptomycin	POS	O
9	POS	O
mg	POS	O
/	POS	O
kg	POS	O
daily	POS	O
was	POS	O
initiated	POS	O
for	POS	O
suspected	POS	O
meningitis	POS	B-NP
and	POS	O
was	POS	O
continued	POS	O
until	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
death	POS	O
on	POS	O
day	POS	O
16	POS	O
.	POS	O
Daptomycin	POS	O
serum	POS	O
and	POS	O
CSF	POS	O
trough	POS	O
concentrations	POS	O
were	POS	O
11	POS	O
.	POS	O
21	POS	O
ug	POS	O
/	POS	O
mL	POS	O
and	POS	O
0	POS	O
.	POS	O
52	POS	O
ug	POS	O
/	POS	O
mL	POS	O
,	POS	O
respectively	POS	O
,	POS	O
prior	POS	O
to	POS	O
the	POS	O
third	POS	O
dose	POS	O
.	POS	O
Lumbar	POS	O
puncture	POS	O
results	POS	O
were	POS	O
inconclusive	POS	O
and	POS	O
no	POS	O
further	POS	O
blood	POS	O
cultures	POS	O
were	POS	O
positive	POS	O
for	POS	O
MSSA	POS	O
.	POS	O
Creatine	POS	O
kinase	POS	O
levels	POS	O
were	POS	O
normal	POS	O
prior	POS	O
to	POS	O
daptomycin	POS	O
therapy	POS	O
and	POS	O
were	POS	O
not	POS	O
reassessed	POS	O
.	POS	O
DISCUSSION	POS	O
:	POS	O
Daptomycin	POS	O
was	POS	O
initiated	POS	O
in	POS	O
our	POS	O
patient	POS	O
secondary	POS	O
to	POS	O
possible	POS	O
nafcillin	POS	O
-	POS	O
induced	POS	O
acute	POS	O
interstitial	POS	B-NP
nephritis	POS	I-NP
and	POS	O
relapsing	POS	B-NP
bacteremia	POS	I-NP
.	POS	O
At	POS	O
a	POS	O
dose	POS	O
of	POS	O
9	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
resultant	POS	O
penetration	POS	O
of	POS	O
5	POS	O
%	POS	O
was	POS	O
higher	POS	O
than	POS	O
in	POS	O
previous	POS	O
reports	POS	O
,	POS	O
more	POS	O
consistent	POS	O
with	POS	O
inflamed	POS	O
meninges	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
High	POS	O
-	POS	O
dose	POS	O
daptomycin	POS	O
may	POS	O
be	POS	O
an	POS	O
alternative	POS	O
option	POS	O
for	POS	O
MSSA	POS	O
bacteremia	POS	B-NP
with	POS	O
or	POS	O
without	POS	O
a	POS	O
CNS	POS	O
source	POS	O
in	POS	O
patients	POS	O
who	POS	O
have	POS	O
failed	POS	O
or	POS	O
cannot	POS	O
tolerate	POS	O
standard	POS	O
therapy	POS	O
.	POS	O
Further	POS	O
clinical	POS	O
evaluation	POS	O
in	POS	O
patients	POS	O
with	POS	O
confirmed	POS	O
meningitis	POS	B-NP
is	POS	O
warranted	POS	O
.	POS	O
The	POS	O
role	POS	O
of	POS	O
nitric	POS	O
oxide	POS	O
in	POS	O
convulsions	POS	B-NP
induced	POS	O
by	POS	O
lindane	POS	O
in	POS	O
rats	POS	O
.	POS	O
Lindane	POS	O
is	POS	O
an	POS	O
organochloride	POS	O
pesticide	POS	O
and	POS	O
scabicide	POS	O
.	POS	O
It	POS	O
evokes	POS	O
convulsions	POS	B-NP
mainly	POS	O
trough	POS	O
the	POS	O
blockage	POS	O
of	POS	O
GABA	POS	O
(	POS	O
A	POS	O
)	POS	O
receptors	POS	O
.	POS	O
Nitric	POS	O
oxide	POS	O
(	POS	O
NO	POS	O
)	POS	O
,	POS	O
gaseous	POS	O
neurotransmitter	POS	O
,	POS	O
has	POS	O
contradictor	POS	O
role	POS	O
in	POS	O
epileptogenesis	POS	B-NP
due	POS	O
to	POS	O
opposite	POS	O
effects	POS	O
of	POS	O
L	POS	O
-	POS	O
arginine	POS	O
,	POS	O
precursor	POS	O
of	POS	O
NO	POS	O
syntheses	POS	O
(	POS	O
NOS	POS	O
)	POS	O
,	POS	O
and	POS	O
L	POS	O
-	POS	O
NAME	POS	O
(	POS	O
NOS	POS	O
inhibitor	POS	O
)	POS	O
observed	POS	O
in	POS	O
different	POS	O
epilepsy	POS	B-NP
models	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
current	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
the	POS	O
effects	POS	O
of	POS	O
NO	POS	O
on	POS	O
the	POS	O
behavioral	POS	O
and	POS	O
EEG	POS	O
characteristics	POS	O
of	POS	O
lindane	POS	O
-	POS	O
induced	POS	O
epilepsy	POS	B-NP
in	POS	O
male	POS	O
Wistar	POS	O
albino	POS	O
rats	POS	O
.	POS	O
The	POS	O
administration	POS	O
of	POS	O
L	POS	O
-	POS	O
arginine	POS	O
(	POS	O
600	POS	O
,	POS	O
800	POS	O
and	POS	O
1000	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
in	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
manner	POS	O
significantly	POS	O
increased	POS	O
convulsion	POS	B-NP
incidence	POS	O
and	POS	O
severity	POS	O
and	POS	O
shortened	POS	O
latency	POS	O
time	POS	O
to	POS	O
first	POS	O
convulsion	POS	B-NP
elicited	POS	O
by	POS	O
lower	POS	O
lindane	POS	O
dose	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
.	POS	O
On	POS	O
the	POS	O
contrary	POS	O
,	POS	O
pretreatment	POS	O
with	POS	O
L	POS	O
-	POS	O
NAME	POS	O
(	POS	O
500	POS	O
,	POS	O
700	POS	O
and	POS	O
900	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
decreased	POS	O
convulsion	POS	B-NP
incidence	POS	O
and	POS	O
severity	POS	O
and	POS	O
prolonged	POS	O
latency	POS	O
time	POS	O
to	POS	O
convulsion	POS	B-NP
following	POS	O
injection	POS	O
with	POS	O
a	POS	O
convulsive	POS	B-NP
dose	POS	O
of	POS	O
lindane	POS	O
(	POS	O
8	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
.	POS	O
EEG	POS	O
analyses	POS	O
showed	POS	O
increase	POS	O
of	POS	O
number	POS	O
and	POS	O
duration	POS	O
of	POS	O
ictal	POS	O
periods	POS	O
in	POS	O
EEG	POS	O
of	POS	O
rats	POS	O
receiving	POS	O
l	POS	O
-	POS	O
arginine	POS	O
prior	POS	O
to	POS	O
lindane	POS	O
and	POS	O
decrease	POS	O
of	POS	O
this	POS	O
number	POS	O
in	POS	O
rats	POS	O
pretreated	POS	O
with	POS	O
L	POS	O
-	POS	O
NAME	POS	O
.	POS	O
These	POS	O
results	POS	O
support	POS	O
the	POS	O
conclusion	POS	O
that	POS	O
NO	POS	O
plays	POS	O
a	POS	O
role	POS	O
of	POS	O
endogenous	POS	O
convulsant	POS	O
in	POS	O
rat	POS	O
model	POS	O
of	POS	O
lindane	POS	O
seizures	POS	B-NP
.	POS	O
Severe	POS	B-NP
polyneuropathy	POS	I-NP
and	POS	O
motor	POS	B-NP
loss	POS	I-NP
after	POS	O
intrathecal	POS	O
thiotepa	POS	O
combination	POS	O
chemotherapy	POS	O
:	POS	O
description	POS	O
of	POS	O
two	POS	O
cases	POS	O
.	POS	O
Two	POS	O
cases	POS	O
of	POS	O
severe	POS	O
delayed	POS	O
neurologic	POS	B-NP
toxicity	POS	I-NP
related	POS	O
to	POS	O
the	POS	O
administration	POS	O
of	POS	O
intrathecal	POS	O
(	POS	O
IT	POS	O
)	POS	O
combination	POS	O
chemotherapy	POS	O
including	POS	O
thiotepa	POS	O
(	POS	O
TSPA	POS	O
)	POS	O
are	POS	O
presented	POS	O
.	POS	O
Both	POS	O
cases	POS	O
developed	POS	O
axonal	POS	B-NP
neuropathy	POS	I-NP
with	POS	O
motor	POS	O
predominance	POS	O
in	POS	O
the	POS	O
lower	POS	O
extremities	POS	O
1	POS	O
and	POS	O
6	POS	O
months	POS	O
after	POS	O
IT	POS	O
chemotherapy	POS	O
was	POS	O
administered	POS	O
.	POS	O
Neurologic	POS	B-NP
toxicities	POS	I-NP
have	POS	O
been	POS	O
described	POS	O
with	POS	O
IT	POS	O
-	POS	O
methotrexate	POS	O
,	POS	O
IT	POS	O
-	POS	O
cytosine	POS	O
arabinoside	POS	O
and	POS	O
IT	POS	O
-	POS	O
TSPA	POS	O
.	POS	O
To	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
however	POS	O
,	POS	O
axonal	POS	B-NP
neuropathy	POS	I-NP
following	POS	O
administration	POS	O
of	POS	O
these	POS	O
three	POS	O
agents	POS	O
has	POS	O
not	POS	O
been	POS	O
previously	POS	O
described	POS	O
.	POS	O
In	POS	O
spite	POS	O
of	POS	O
the	POS	O
fact	POS	O
that	POS	O
TSPA	POS	O
is	POS	O
a	POS	O
useful	POS	O
IT	POS	O
agent	POS	O
,	POS	O
its	POS	O
combination	POS	O
with	POS	O
MTX	POS	O
,	POS	O
ara	POS	O
-	POS	O
C	POS	O
and	POS	O
radiotherapy	POS	O
could	POS	O
cause	POS	O
severe	POS	O
neurotoxicity	POS	B-NP
.	POS	O
This	POS	O
unexpected	POS	O
complication	POS	O
indicates	POS	O
the	POS	O
need	POS	O
for	POS	O
further	POS	O
toxicology	POS	O
research	POS	O
on	POS	O
IT	POS	O
-	POS	O
TSPA	POS	O
.	POS	O
Effects	POS	O
of	POS	O
cromakalim	POS	O
and	POS	O
pinacidil	POS	O
on	POS	O
large	POS	O
epicardial	POS	O
and	POS	O
small	POS	O
coronary	POS	O
arteries	POS	O
in	POS	O
conscious	POS	O
dogs	POS	O
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
bolus	POS	O
administration	POS	O
of	POS	O
cromakalim	POS	O
(	POS	O
1	POS	O
-	POS	O
10	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
pinacidil	POS	O
(	POS	O
3	POS	O
-	POS	O
100	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
)	POS	O
on	POS	O
large	POS	O
(	POS	O
circumflex	POS	O
artery	POS	O
)	POS	O
and	POS	O
small	POS	O
coronary	POS	O
arteries	POS	O
and	POS	O
on	POS	O
systemic	POS	O
hemodynamics	POS	O
were	POS	O
investigated	POS	O
in	POS	O
chronically	POS	O
instrumented	POS	O
conscious	POS	O
dogs	POS	O
and	POS	O
compared	POS	O
to	POS	O
those	POS	O
of	POS	O
nitroglycerin	POS	O
(	POS	O
0	POS	O
.	POS	O
03	POS	O
-	POS	O
10	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
)	POS	O
.	POS	O
Nitroglycerin	POS	O
,	POS	O
up	POS	O
to	POS	O
0	POS	O
.	POS	O
3	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
,	POS	O
selectively	POS	O
increased	POS	O
circumflex	POS	O
artery	POS	O
diameter	POS	O
(	POS	O
CxAD	POS	O
)	POS	O
without	POS	O
simultaneously	POS	O
affecting	POS	O
any	POS	O
other	POS	O
cardiac	POS	O
or	POS	O
systemic	POS	O
hemodynamic	POS	O
parameter	POS	O
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
cromakalim	POS	O
and	POS	O
pinacidil	POS	O
at	POS	O
all	POS	O
doses	POS	O
and	POS	O
nitroglycerin	POS	O
at	POS	O
doses	POS	O
higher	POS	O
than	POS	O
0	POS	O
.	POS	O
3	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
simultaneously	POS	O
and	POS	O
dose	POS	O
-	POS	O
dependently	POS	O
increased	POS	O
CxAD	POS	O
,	POS	O
coronary	POS	O
blood	POS	O
flow	POS	O
and	POS	O
heart	POS	O
rate	POS	O
and	POS	O
decreased	POS	O
coronary	POS	O
vascular	POS	O
resistance	POS	O
and	POS	O
aortic	POS	O
pressure	POS	O
.	POS	O
Cromakalim	POS	O
was	POS	O
approximately	POS	O
8	POS	O
-	POS	O
to	POS	O
9	POS	O
.	POS	O
5	POS	O
-	POS	O
fold	POS	O
more	POS	O
potent	POS	O
than	POS	O
pinacidil	POS	O
in	POS	O
increasing	POS	O
CxAD	POS	O
.	POS	O
Vasodilation	POS	O
of	POS	O
large	POS	O
and	POS	O
small	POS	O
coronary	POS	O
vessels	POS	O
and	POS	O
hypotension	POS	B-NP
induced	POS	O
by	POS	O
cromakalim	POS	O
and	POS	O
pinacidil	POS	O
were	POS	O
not	POS	O
affected	POS	O
by	POS	O
prior	POS	O
combined	POS	O
beta	POS	O
adrenergic	POS	O
and	POS	O
muscarinic	POS	O
receptors	POS	O
blockade	POS	O
but	POS	O
drug	POS	O
-	POS	O
induced	POS	O
tachycardia	POS	B-NP
was	POS	O
abolished	POS	O
.	POS	O
When	POS	O
circumflex	POS	O
artery	POS	O
blood	POS	O
flow	POS	O
was	POS	O
maintained	POS	O
constant	POS	O
,	POS	O
the	POS	O
increases	POS	O
in	POS	O
CxAD	POS	O
induced	POS	O
by	POS	O
cromakalim	POS	O
(	POS	O
10	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
pinacidil	POS	O
(	POS	O
30	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
nitroglycerin	POS	O
(	POS	O
10	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
)	POS	O
were	POS	O
reduced	POS	O
by	POS	O
68	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
,	POS	O
54	POS	O
+	POS	O
/	POS	O
-	POS	O
9	POS	O
and	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
%	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Thus	POS	O
,	POS	O
whereas	POS	O
nitroglycerin	POS	O
preferentially	POS	O
and	POS	O
flow	POS	O
-	POS	O
independently	POS	O
dilates	POS	O
large	POS	O
coronary	POS	O
arteries	POS	O
,	POS	O
cromakalim	POS	O
and	POS	O
pinacidil	POS	O
dilate	POS	O
both	POS	O
large	POS	O
and	POS	O
small	POS	O
coronary	POS	O
arteries	POS	O
and	POS	O
this	POS	O
effect	POS	O
is	POS	O
not	POS	O
dependent	POS	O
upon	POS	O
the	POS	O
simultaneous	POS	O
beta	POS	O
adrenoceptors	POS	O
-	POS	O
mediated	POS	O
rise	POS	O
in	POS	O
myocardial	POS	O
metabolic	POS	O
demand	POS	O
.	POS	O
Finally	POS	O
,	POS	O
two	POS	O
mechanisms	POS	O
at	POS	O
least	POS	O
,	POS	O
direct	POS	O
vasodilation	POS	O
and	POS	O
flow	POS	O
dependency	POS	O
,	POS	O
are	POS	O
involved	POS	O
in	POS	O
the	POS	O
cromakalim	POS	O
-	POS	O
and	POS	O
pinacidil	POS	O
-	POS	O
induced	POS	O
increase	POS	O
in	POS	O
CxAD	POS	O
.	POS	O
Mefenamic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
neutropenia	POS	B-NP
and	POS	O
renal	POS	B-NP
failure	POS	I-NP
in	POS	O
elderly	POS	O
females	POS	O
with	POS	O
hypothyroidism	POS	B-NP
.	POS	O
We	POS	O
report	POS	O
mefenamic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
non	POS	B-NP
-	POS	I-NP
oliguric	POS	I-NP
renal	POS	I-NP
failure	POS	I-NP
and	POS	O
severe	POS	O
neutropenia	POS	B-NP
occurring	POS	O
simultaneously	POS	O
in	POS	O
two	POS	O
elderly	POS	O
females	POS	O
.	POS	O
The	POS	O
neutropenia	POS	B-NP
was	POS	O
due	POS	O
to	POS	O
maturation	POS	O
arrest	POS	O
of	POS	O
the	POS	O
myeloid	POS	O
series	POS	O
in	POS	O
one	POS	O
patient	POS	O
.	POS	O
Both	POS	O
patients	POS	O
were	POS	O
also	POS	O
hypothyroid	POS	B-NP
,	POS	O
but	POS	O
it	POS	O
is	POS	O
not	POS	O
clear	POS	O
whether	POS	O
this	POS	O
was	POS	O
a	POS	O
predisposing	POS	O
factor	POS	O
to	POS	O
the	POS	O
development	POS	O
of	POS	O
these	POS	O
adverse	POS	O
reactions	POS	O
.	POS	O
However	POS	O
,	POS	O
it	POS	O
would	POS	O
seem	POS	O
prudent	POS	O
not	POS	O
to	POS	O
use	POS	O
mefenamic	POS	O
acid	POS	O
in	POS	O
hypothyroid	POS	B-NP
patients	POS	O
until	POS	O
the	POS	O
hypothyroidism	POS	B-NP
has	POS	O
been	POS	O
corrected	POS	O
.	POS	O
Etiology	POS	O
of	POS	O
hypercalcemia	POS	B-NP
in	POS	O
hemodialysis	POS	B-NP
patients	POS	O
on	POS	O
calcium	POS	O
carbonate	POS	O
therapy	POS	O
.	POS	O
Fourteen	POS	O
of	POS	O
39	POS	O
dialysis	POS	O
patients	POS	O
(	POS	O
36	POS	O
%	POS	O
)	POS	O
became	POS	O
hypercalcemic	POS	B-NP
after	POS	O
switching	POS	O
to	POS	O
calcium	POS	O
carbonate	POS	O
as	POS	O
their	POS	O
principal	POS	O
phosphate	POS	O
binder	POS	O
.	POS	O
In	POS	O
order	POS	O
to	POS	O
identify	POS	O
risk	POS	O
factors	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
hypercalcemia	POS	B-NP
,	POS	O
indirect	POS	O
parameters	POS	O
of	POS	O
intestinal	POS	O
calcium	POS	O
reabsorption	POS	O
and	POS	O
bone	POS	O
turnover	POS	O
rate	POS	O
in	POS	O
these	POS	O
14	POS	O
patients	POS	O
were	POS	O
compared	POS	O
with	POS	O
results	POS	O
in	POS	O
14	POS	O
eucalcemic	POS	O
patients	POS	O
matched	POS	O
for	POS	O
age	POS	O
,	POS	O
sex	POS	O
,	POS	O
length	POS	O
of	POS	O
time	POS	O
on	POS	O
dialysis	POS	O
,	POS	O
and	POS	O
etiology	POS	O
of	POS	O
renal	POS	B-NP
disease	POS	I-NP
.	POS	O
In	POS	O
addition	POS	O
to	POS	O
experiencing	POS	O
hypercalcemic	POS	B-NP
episodes	POS	O
with	POS	O
peak	POS	O
calcium	POS	O
values	POS	O
of	POS	O
2	POS	O
.	POS	O
7	POS	O
to	POS	O
3	POS	O
.	POS	O
8	POS	O
mmol	POS	O
/	POS	O
L	POS	O
(	POS	O
10	POS	O
.	POS	O
7	POS	O
to	POS	O
15	POS	O
.	POS	O
0	POS	O
mg	POS	O
/	POS	O
dL	POS	O
)	POS	O
,	POS	O
patients	POS	O
in	POS	O
the	POS	O
hypercalcemic	POS	B-NP
group	POS	O
exhibited	POS	O
a	POS	O
significant	POS	O
increase	POS	O
in	POS	O
the	POS	O
mean	POS	O
calcium	POS	O
concentration	POS	O
obtained	POS	O
during	POS	O
6	POS	O
months	POS	O
before	POS	O
the	POS	O
switch	POS	O
,	POS	O
compared	POS	O
with	POS	O
the	POS	O
mean	POS	O
value	POS	O
obtained	POS	O
during	POS	O
the	POS	O
7	POS	O
months	POS	O
of	POS	O
observation	POS	O
after	POS	O
the	POS	O
switch	POS	O
(	POS	O
2	POS	O
.	POS	O
4	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
03	POS	O
to	POS	O
2	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
03	POS	O
mmol	POS	O
/	POS	O
L	POS	O
[	POS	O
9	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
2	POS	O
to	POS	O
10	POS	O
.	POS	O
2	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
1	POS	O
mg	POS	O
/	POS	O
dL	POS	O
]	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
006	POS	O
)	POS	O
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
eucalcemic	POS	O
patients	POS	O
exhibited	POS	O
no	POS	O
change	POS	O
in	POS	O
mean	POS	O
calcium	POS	O
values	POS	O
over	POS	O
the	POS	O
same	POS	O
time	POS	O
period	POS	O
(	POS	O
2	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
05	POS	O
to	POS	O
2	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
05	POS	O
mmol	POS	O
/	POS	O
L	POS	O
[	POS	O
9	POS	O
.	POS	O
2	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
2	POS	O
to	POS	O
9	POS	O
.	POS	O
2	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
2	POS	O
mg	POS	O
/	POS	O
dL	POS	O
]	POS	O
)	POS	O
.	POS	O
CaCO3	POS	O
dosage	POS	O
,	POS	O
calculated	POS	O
dietary	POS	O
calcium	POS	O
intake	POS	O
,	POS	O
and	POS	O
circulating	POS	O
levels	POS	O
of	POS	O
vitamin	POS	O
D	POS	O
metabolites	POS	O
were	POS	O
similar	POS	O
in	POS	O
both	POS	O
groups	POS	O
.	POS	O
Physical	POS	O
activity	POS	O
index	POS	O
and	POS	O
predialysis	POS	O
serum	POS	O
bicarbonate	POS	O
levels	POS	O
also	POS	O
were	POS	O
similar	POS	O
in	POS	O
both	POS	O
groups	POS	O
.	POS	O
However	POS	O
,	POS	O
there	POS	O
was	POS	O
a	POS	O
significant	POS	O
difference	POS	O
in	POS	O
parameters	POS	O
reflecting	POS	O
bone	POS	O
turnover	POS	O
rates	POS	O
between	POS	O
groups	POS	O
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
250	POS	O
WORDS	POS	O
)	POS	O
Late	POS	O
-	POS	O
onset	POS	O
scleroderma	POS	B-NP
renal	POS	I-NP
crisis	POS	I-NP
induced	POS	O
by	POS	O
tacrolimus	POS	O
and	POS	O
prednisolone	POS	O
:	POS	O
a	POS	O
case	POS	O
report	POS	O
.	POS	O
Scleroderma	POS	B-NP
renal	POS	I-NP
crisis	POS	I-NP
(	POS	O
SRC	POS	B-NP
)	POS	O
is	POS	O
a	POS	O
rare	POS	O
complication	POS	O
of	POS	O
systemic	POS	B-NP
sclerosis	POS	I-NP
(	POS	O
SSc	POS	B-NP
)	POS	O
but	POS	O
can	POS	O
be	POS	O
severe	POS	O
enough	POS	O
to	POS	O
require	POS	O
temporary	POS	O
or	POS	O
permanent	POS	O
renal	POS	O
replacement	POS	O
therapy	POS	O
.	POS	O
Moderate	POS	O
to	POS	O
high	POS	O
dose	POS	O
corticosteroid	POS	O
use	POS	O
is	POS	O
recognized	POS	O
as	POS	O
a	POS	O
major	POS	O
risk	POS	O
factor	POS	O
for	POS	O
SRC	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
there	POS	O
have	POS	O
been	POS	O
reports	POS	O
of	POS	O
thrombotic	POS	B-NP
microangiopathy	POS	I-NP
precipitated	POS	O
by	POS	O
cyclosporine	POS	O
in	POS	O
patients	POS	O
with	POS	O
SSc	POS	B-NP
.	POS	O
In	POS	O
this	POS	O
article	POS	O
,	POS	O
we	POS	O
report	POS	O
a	POS	O
patient	POS	O
with	POS	O
SRC	POS	B-NP
induced	POS	O
by	POS	O
tacrolimus	POS	O
and	POS	O
corticosteroids	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
work	POS	O
is	POS	O
to	POS	O
call	POS	O
attention	POS	O
to	POS	O
the	POS	O
risk	POS	O
of	POS	O
tacrolimus	POS	O
use	POS	O
in	POS	O
patients	POS	O
with	POS	O
SSc	POS	B-NP
.	POS	O
Methyldopa	POS	O
-	POS	O
induced	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
in	POS	O
a	POS	O
15	POS	O
year	POS	O
old	POS	O
presenting	POS	O
as	POS	O
near	POS	B-NP
-	POS	I-NP
syncope	POS	I-NP
.	POS	O
Methyldopa	POS	B-NP
is	POS	O
an	POS	O
antihypertensive	POS	O
medication	POS	O
which	POS	O
is	POS	O
available	POS	O
generically	POS	O
and	POS	O
under	POS	O
the	POS	O
trade	POS	O
name	POS	O
Aldomet	POS	O
that	POS	O
is	POS	O
widely	POS	O
prescribed	POS	O
in	POS	O
the	POS	O
adult	POS	O
population	POS	O
and	POS	O
infrequently	POS	O
used	POS	O
in	POS	O
children	POS	O
.	POS	O
Methyldopa	POS	B-NP
causes	POS	O
an	POS	O
autoimmune	POS	B-NP
hemolytic	POS	I-NP
anemia	POS	I-NP
in	POS	O
a	POS	O
small	POS	O
percentage	POS	O
of	POS	O
patients	POS	O
who	POS	O
take	POS	O
the	POS	O
drug	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
methyldopa	POS	O
-	POS	O
induced	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
in	POS	O
a	POS	O
15	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
boy	POS	O
who	POS	O
presented	POS	O
to	POS	O
the	POS	O
emergency	POS	O
department	POS	O
with	POS	O
near	POS	O
-	POS	O
syncope	POS	B-NP
.	POS	O
The	POS	O
boy	POS	O
had	POS	O
been	POS	O
treated	POS	O
with	POS	O
intravenous	POS	O
methyldopa	POS	O
during	POS	O
a	POS	O
trauma	POS	B-NP
admission	POS	O
seven	POS	O
weeks	POS	O
prior	POS	O
to	POS	O
presentation	POS	O
.	POS	O
Evaluation	POS	O
revealed	POS	O
a	POS	O
hemoglobin	POS	O
of	POS	O
three	POS	O
grams	POS	O
,	POS	O
3	POS	O
+	POS	O
Coombs	POS	O
'	POS	O
test	POS	O
with	POS	O
polyspecific	POS	O
anti	POS	O
-	POS	O
human	POS	O
globulin	POS	O
and	POS	O
monospecific	POS	O
IgG	POS	O
reagents	POS	O
,	POS	O
and	POS	O
a	POS	O
warm	POS	O
reacting	POS	O
autoantibody	POS	O
.	POS	O
Transfusion	POS	O
and	POS	O
corticosteroid	POS	O
therapy	POS	O
resulted	POS	O
in	POS	O
a	POS	O
complete	POS	O
recovery	POS	O
of	POS	O
the	POS	O
patient	POS	O
.	POS	O
Emergency	POS	O
physicians	POS	O
treating	POS	O
children	POS	O
must	POS	O
be	POS	O
aware	POS	O
of	POS	O
this	POS	O
syndrome	POS	O
in	POS	O
order	POS	O
to	POS	O
diagnose	POS	O
and	POS	O
treat	POS	O
it	POS	O
correctly	POS	O
.	POS	O
A	POS	O
brief	POS	O
review	POS	O
of	POS	O
autoimmune	POS	O
and	POS	O
drug	POS	O
-	POS	O
induced	POS	O
hemolytic	POS	B-NP
anemias	POS	I-NP
is	POS	O
provided	POS	O
.	POS	O
The	POS	O
risk	POS	O
and	POS	O
associated	POS	O
factors	POS	O
of	POS	O
methamphetamine	POS	O
psychosis	POS	B-NP
in	POS	O
methamphetamine	POS	O
-	POS	O
dependent	POS	O
patients	POS	O
in	POS	O
Malaysia	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
The	POS	O
objective	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
the	POS	O
risk	POS	O
of	POS	O
lifetime	POS	O
and	POS	O
current	POS	O
methamphetamine	POS	O
-	POS	O
induced	POS	O
psychosis	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
methamphetamine	POS	O
dependence	POS	O
.	POS	O
The	POS	O
association	POS	O
between	POS	O
psychiatric	POS	O
co	POS	O
-	POS	O
morbidity	POS	O
and	POS	O
methamphetamine	POS	O
-	POS	O
induced	POS	O
psychosis	POS	B-NP
was	POS	O
also	POS	O
studied	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
This	POS	O
was	POS	O
a	POS	O
cross	POS	O
-	POS	O
sectional	POS	O
study	POS	O
conducted	POS	O
concurrently	POS	O
at	POS	O
a	POS	O
teaching	POS	O
hospital	POS	O
and	POS	O
a	POS	O
drug	POS	O
rehabilitation	POS	O
center	POS	O
in	POS	O
Malaysia	POS	O
.	POS	O
Patients	POS	O
with	POS	O
the	POS	O
diagnosis	POS	O
of	POS	O
methamphetamine	POS	O
based	POS	O
on	POS	O
DSM	POS	O
-	POS	O
IV	POS	O
were	POS	O
interviewed	POS	O
using	POS	O
the	POS	O
Mini	POS	O
International	POS	O
Neuropsychiatric	POS	O
Interview	POS	O
(	POS	O
M	POS	O
.	POS	O
I	POS	O
.	POS	O
N	POS	O
.	POS	O
I	POS	O
.	POS	O
)	POS	O
for	POS	O
methamphetamine	POS	O
-	POS	O
induced	POS	O
psychosis	POS	B-NP
and	POS	O
other	POS	O
Axis	POS	B-NP
I	POS	I-NP
psychiatric	POS	I-NP
disorders	POS	I-NP
.	POS	O
The	POS	O
information	POS	O
on	POS	O
sociodemographic	POS	O
background	POS	O
and	POS	O
drug	POS	O
use	POS	O
history	POS	O
was	POS	O
obtained	POS	O
from	POS	O
interview	POS	O
or	POS	O
medical	POS	O
records	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Of	POS	O
292	POS	O
subjects	POS	O
,	POS	O
47	POS	O
.	POS	O
9	POS	O
%	POS	O
of	POS	O
the	POS	O
subjects	POS	O
had	POS	O
a	POS	O
past	POS	O
history	POS	O
of	POS	O
psychotic	POS	B-NP
symptoms	POS	I-NP
and	POS	O
13	POS	O
.	POS	O
0	POS	O
%	POS	O
of	POS	O
the	POS	O
patients	POS	O
were	POS	O
having	POS	O
current	POS	O
psychotic	POS	B-NP
symptoms	POS	I-NP
.	POS	O
Co	POS	O
-	POS	O
morbid	POS	O
major	POS	O
depressive	POS	B-NP
disorder	POS	I-NP
(	POS	O
OR	POS	O
=	POS	O
7	POS	O
.	POS	O
18	POS	O
,	POS	O
95	POS	O
CI	POS	O
=	POS	O
2	POS	O
.	POS	O
612	POS	O
-	POS	O
19	POS	O
.	POS	O
708	POS	O
)	POS	O
,	POS	O
bipolar	POS	B-NP
disorder	POS	I-NP
(	POS	O
OR	POS	O
=	POS	O
13	POS	O
.	POS	O
807	POS	O
,	POS	O
95	POS	O
CI	POS	O
=	POS	O
5	POS	O
.	POS	O
194	POS	O
-	POS	O
36	POS	O
.	POS	O
706	POS	O
)	POS	O
,	POS	O
antisocial	POS	B-NP
personality	POS	I-NP
disorder	POS	I-NP
(	POS	O
OR	POS	O
=	POS	O
12	POS	O
.	POS	O
619	POS	O
,	POS	O
95	POS	O
CI	POS	O
=	POS	O
6	POS	O
.	POS	O
702	POS	O
-	POS	O
23	POS	O
.	POS	O
759	POS	O
)	POS	O
and	POS	O
heavy	POS	O
methamphetamine	POS	O
uses	POS	O
were	POS	O
significantly	POS	O
associated	POS	O
with	POS	O
lifetime	POS	O
methamphetamine	POS	O
-	POS	O
induced	POS	O
psychosis	POS	B-NP
after	POS	O
adjusted	POS	O
for	POS	O
other	POS	O
factors	POS	O
.	POS	O
Major	POS	O
depressive	POS	B-NP
disorder	POS	I-NP
(	POS	O
OR	POS	O
=	POS	O
2	POS	O
.	POS	O
870	POS	O
,	POS	O
CI	POS	O
=	POS	O
1	POS	O
.	POS	O
154	POS	O
-	POS	O
7	POS	O
.	POS	O
142	POS	O
)	POS	O
and	POS	O
antisocial	POS	B-NP
personality	POS	I-NP
disorder	POS	I-NP
(	POS	O
OR	POS	O
=	POS	O
3	POS	O
.	POS	O
299	POS	O
,	POS	O
95	POS	O
CI	POS	O
=	POS	O
1	POS	O
.	POS	O
375	POS	O
-	POS	O
7	POS	O
.	POS	O
914	POS	O
)	POS	O
were	POS	O
the	POS	O
only	POS	O
factors	POS	O
associated	POS	O
with	POS	O
current	POS	O
psychosis	POS	B-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
There	POS	O
was	POS	O
a	POS	O
high	POS	O
risk	POS	O
of	POS	O
psychosis	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
methamphetamine	POS	B-NP
dependence	POS	I-NP
.	POS	O
It	POS	O
was	POS	O
associated	POS	O
with	POS	O
co	POS	B-NP
-	POS	I-NP
morbid	POS	I-NP
affective	POS	I-NP
disorder	POS	I-NP
,	POS	O
antisocial	POS	B-NP
personality	POS	I-NP
,	POS	O
and	POS	O
heavy	POS	O
methamphetamine	POS	O
use	POS	O
.	POS	O
It	POS	O
is	POS	O
recommended	POS	O
that	POS	O
all	POS	O
cases	POS	O
of	POS	O
methamphetamine	POS	O
dependence	POS	O
should	POS	O
be	POS	O
screened	POS	O
for	POS	O
psychotic	POS	B-NP
symptoms	POS	I-NP
.	POS	O
Cerebellar	POS	O
sensory	POS	O
processing	POS	O
alterations	POS	O
impact	POS	O
motor	POS	O
cortical	POS	O
plasticity	POS	O
in	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
:	POS	O
clues	POS	O
from	POS	O
dyskinetic	POS	B-NP
patients	POS	O
.	POS	O
The	POS	O
plasticity	POS	O
of	POS	O
primary	POS	O
motor	POS	O
cortex	POS	O
(	POS	O
M1	POS	O
)	POS	O
in	POS	O
patients	POS	O
with	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
(	POS	O
PD	POS	B-NP
)	POS	O
and	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
(	POS	O
LIDs	POS	B-NP
)	POS	O
is	POS	O
severely	POS	O
impaired	POS	O
.	POS	O
We	POS	O
recently	POS	O
reported	POS	O
in	POS	O
young	POS	O
healthy	POS	O
subjects	POS	O
that	POS	O
inhibitory	POS	O
cerebellar	POS	O
stimulation	POS	O
enhanced	POS	O
the	POS	O
sensorimotor	POS	O
plasticity	POS	O
of	POS	O
M1	POS	O
that	POS	O
was	POS	O
induced	POS	O
by	POS	O
paired	POS	O
associative	POS	O
stimulation	POS	O
(	POS	O
PAS	POS	O
)	POS	O
.	POS	O
This	POS	O
study	POS	O
demonstrates	POS	O
that	POS	O
the	POS	O
deficient	POS	O
sensorimotor	POS	O
M1	POS	O
plasticity	POS	O
in	POS	O
16	POS	O
patients	POS	O
with	POS	O
LIDs	POS	B-NP
could	POS	O
be	POS	O
reinstated	POS	O
by	POS	O
a	POS	O
single	POS	O
session	POS	O
of	POS	O
real	POS	O
inhibitory	POS	O
cerebellar	POS	O
stimulation	POS	O
but	POS	O
not	POS	O
sham	POS	O
stimulation	POS	O
.	POS	O
This	POS	O
was	POS	O
evident	POS	O
only	POS	O
when	POS	O
a	POS	O
sensory	POS	O
component	POS	O
was	POS	O
involved	POS	O
in	POS	O
the	POS	O
induction	POS	O
of	POS	O
plasticity	POS	O
,	POS	O
indicating	POS	O
that	POS	O
cerebellar	POS	O
sensory	POS	O
processing	POS	O
function	POS	O
is	POS	O
involved	POS	O
in	POS	O
the	POS	O
resurgence	POS	O
of	POS	O
M1	POS	O
plasticity	POS	O
.	POS	O
The	POS	O
benefit	POS	O
of	POS	O
inhibitory	POS	O
cerebellar	POS	O
stimulation	POS	O
on	POS	O
LIDs	POS	B-NP
is	POS	O
known	POS	O
.	POS	O
To	POS	O
explore	POS	O
whether	POS	O
this	POS	O
benefit	POS	O
is	POS	O
linked	POS	O
to	POS	O
the	POS	O
restoration	POS	O
of	POS	O
sensorimotor	POS	O
plasticity	POS	O
of	POS	O
M1	POS	O
,	POS	O
we	POS	O
conducted	POS	O
an	POS	O
additional	POS	O
study	POS	O
looking	POS	O
at	POS	O
changes	POS	O
in	POS	O
LIDs	POS	B-NP
and	POS	O
PAS	POS	O
-	POS	O
induced	POS	O
plasticity	POS	O
after	POS	O
10	POS	O
sessions	POS	O
of	POS	O
either	POS	O
bilateral	POS	O
,	POS	O
real	POS	O
inhibitory	POS	O
cerebellar	POS	O
stimulation	POS	O
or	POS	O
sham	POS	O
stimulation	POS	O
.	POS	O
Only	POS	O
real	POS	O
and	POS	O
not	POS	O
sham	POS	O
stimulation	POS	O
had	POS	O
an	POS	O
antidyskinetic	POS	O
effect	POS	O
and	POS	O
it	POS	O
was	POS	O
paralleled	POS	O
by	POS	O
a	POS	O
resurgence	POS	O
in	POS	O
the	POS	O
sensorimotor	POS	O
plasticity	POS	O
of	POS	O
M1	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
alterations	POS	O
in	POS	O
cerebellar	POS	O
sensory	POS	O
processing	POS	O
function	POS	O
,	POS	O
occurring	POS	O
secondary	POS	O
to	POS	O
abnormal	POS	O
basal	POS	O
ganglia	POS	O
signals	POS	O
reaching	POS	O
it	POS	O
,	POS	O
may	POS	O
be	POS	O
an	POS	O
important	POS	O
element	POS	O
contributing	POS	O
to	POS	O
the	POS	O
maladaptive	POS	O
sensorimotor	POS	O
plasticity	POS	O
of	POS	O
M1	POS	O
and	POS	O
the	POS	O
emergence	POS	O
of	POS	O
abnormal	POS	B-NP
involuntary	POS	I-NP
movements	POS	I-NP
.	POS	O
The	POS	O
long	POS	O
-	POS	O
term	POS	O
safety	POS	O
of	POS	O
danazol	POS	O
in	POS	O
women	POS	O
with	POS	O
hereditary	POS	B-NP
angioedema	POS	I-NP
.	POS	O
Although	POS	O
the	POS	O
short	POS	O
-	POS	O
term	POS	O
safety	POS	O
(	POS	O
less	POS	O
than	POS	O
or	POS	O
equal	POS	O
to	POS	O
6	POS	O
months	POS	O
)	POS	O
of	POS	O
danazol	POS	O
has	POS	O
been	POS	O
established	POS	O
in	POS	O
a	POS	O
variety	POS	O
of	POS	O
settings	POS	O
,	POS	O
no	POS	O
information	POS	O
exists	POS	O
as	POS	O
to	POS	O
its	POS	O
long	POS	O
-	POS	O
term	POS	O
safety	POS	O
.	POS	O
We	POS	O
therefore	POS	O
investigated	POS	O
the	POS	O
long	POS	O
-	POS	O
term	POS	O
safety	POS	O
of	POS	O
danazol	POS	O
by	POS	O
performing	POS	O
a	POS	O
retrospective	POS	O
chart	POS	O
review	POS	O
of	POS	O
60	POS	O
female	POS	O
patients	POS	O
with	POS	O
hereditary	POS	B-NP
angioedema	POS	I-NP
treated	POS	O
with	POS	O
danazol	POS	O
for	POS	O
a	POS	O
continuous	POS	O
period	POS	O
of	POS	O
6	POS	O
months	POS	O
or	POS	O
longer	POS	O
.	POS	O
The	POS	O
mean	POS	O
age	POS	O
of	POS	O
the	POS	O
patients	POS	O
was	POS	O
35	POS	O
.	POS	O
2	POS	O
years	POS	O
and	POS	O
the	POS	O
mean	POS	O
duration	POS	O
of	POS	O
therapy	POS	O
was	POS	O
59	POS	O
.	POS	O
7	POS	O
months	POS	O
.	POS	O
Virtually	POS	O
all	POS	O
patients	POS	O
experienced	POS	O
one	POS	O
or	POS	O
more	POS	O
adverse	POS	O
reactions	POS	O
.	POS	O
Menstrual	POS	B-NP
abnormalities	POS	I-NP
(	POS	O
79	POS	O
%	POS	O
)	POS	O
,	POS	O
weight	POS	B-NP
gain	POS	I-NP
(	POS	O
60	POS	O
%	POS	O
)	POS	O
,	POS	O
muscle	POS	B-NP
cramps	POS	I-NP
/	POS	O
myalgias	POS	B-NP
(	POS	O
40	POS	O
%	POS	O
)	POS	O
,	POS	O
and	POS	O
transaminase	POS	O
elevations	POS	O
(	POS	O
40	POS	O
%	POS	O
)	POS	O
were	POS	O
the	POS	O
most	POS	O
common	POS	O
adverse	POS	O
reactions	POS	O
.	POS	O
The	POS	O
drug	POS	O
was	POS	O
discontinued	POS	O
due	POS	O
to	POS	O
adverse	POS	O
reactions	POS	O
in	POS	O
8	POS	O
patients	POS	O
.	POS	O
No	POS	O
patient	POS	O
has	POS	O
died	POS	O
or	POS	O
suffered	POS	O
any	POS	O
apparent	POS	O
long	POS	O
-	POS	O
term	POS	O
sequelae	POS	O
that	POS	O
were	POS	O
directly	POS	O
attributable	POS	O
to	POS	O
the	POS	O
drug	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
,	POS	O
despite	POS	O
a	POS	O
relatively	POS	O
high	POS	O
incidence	POS	O
of	POS	O
adverse	POS	O
reactions	POS	O
,	POS	O
danazol	POS	O
has	POS	O
proven	POS	O
to	POS	O
be	POS	O
remarkably	POS	O
safe	POS	O
over	POS	O
the	POS	O
long	POS	O
-	POS	O
term	POS	O
in	POS	O
this	POS	O
group	POS	O
of	POS	O
patients	POS	O
.	POS	O
The	POS	O
function	POS	O
of	POS	O
P2X3	POS	O
receptor	POS	O
and	POS	O
NK1	POS	O
receptor	POS	O
antagonists	POS	O
on	POS	O
cyclophosphamide	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
The	POS	O
purpose	POS	O
of	POS	O
the	POS	O
study	POS	O
is	POS	O
to	POS	O
explore	POS	O
the	POS	O
function	POS	O
of	POS	O
P2X3	POS	O
and	POS	O
NK1	POS	O
receptors	POS	O
antagonists	POS	O
on	POS	O
cyclophosphamide	POS	O
(	POS	O
CYP	POS	O
)	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Sixty	POS	O
female	POS	O
Sprague	POS	O
-	POS	O
Dawley	POS	O
(	POS	O
SD	POS	O
)	POS	O
rats	POS	O
were	POS	O
randomly	POS	O
divided	POS	O
into	POS	O
three	POS	O
groups	POS	O
.	POS	O
The	POS	O
rats	POS	O
in	POS	O
the	POS	O
control	POS	O
group	POS	O
were	POS	O
intraperitoneally	POS	O
(	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
injected	POS	O
with	POS	O
0	POS	O
.	POS	O
9	POS	O
%	POS	O
saline	POS	O
(	POS	O
4	POS	O
ml	POS	O
/	POS	O
kg	POS	O
)	POS	O
;	POS	O
the	POS	O
rats	POS	O
in	POS	O
the	POS	O
model	POS	O
group	POS	O
were	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
injected	POS	O
with	POS	O
CYP	POS	O
(	POS	O
150	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
;	POS	O
and	POS	O
the	POS	O
rats	POS	O
in	POS	O
the	POS	O
intervention	POS	O
group	POS	O
were	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
injected	POS	O
with	POS	O
CYP	POS	O
with	POS	O
subsequently	POS	O
perfusion	POS	O
of	POS	O
bladder	POS	O
with	POS	O
P2X3	POS	O
and	POS	O
NK1	POS	O
receptors	POS	O
'	POS	O
antagonists	POS	O
,	POS	O
Suramin	POS	O
and	POS	O
GR	POS	O
82334	POS	O
.	POS	O
Spontaneous	POS	O
pain	POS	O
behaviors	POS	O
following	POS	O
the	POS	O
administration	POS	O
of	POS	O
CYP	POS	O
were	POS	O
observed	POS	O
.	POS	O
Urodynamic	POS	O
parameters	POS	O
,	POS	O
bladder	POS	O
pressure	POS	O
-	POS	O
volume	POS	O
curve	POS	O
,	POS	O
maximum	POS	O
voiding	POS	O
pressure	POS	O
(	POS	O
MVP	POS	O
)	POS	O
,	POS	O
and	POS	O
maximum	POS	O
cystometric	POS	O
capacity	POS	O
(	POS	O
MCC	POS	O
)	POS	O
,	POS	O
were	POS	O
recorded	POS	O
.	POS	O
Pathological	POS	O
changes	POS	O
in	POS	O
bladder	POS	O
tissue	POS	O
were	POS	O
observed	POS	O
.	POS	O
Immunofluorescence	POS	O
was	POS	O
used	POS	O
to	POS	O
detect	POS	O
the	POS	O
expression	POS	O
of	POS	O
P2X3	POS	O
and	POS	O
NK1	POS	O
receptors	POS	O
in	POS	O
bladder	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Cyclophosphamide	POS	O
treatment	POS	O
increased	POS	O
the	POS	O
spontaneous	POS	O
pain	POS	B-NP
behaviors	POS	O
scores	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
bladder	POS	B-NP
instability	POS	I-NP
during	POS	O
urine	POS	O
storage	POS	O
period	POS	O
of	POS	O
model	POS	O
group	POS	O
was	POS	O
significantly	POS	O
higher	POS	O
than	POS	O
intervention	POS	O
group	POS	O
(	POS	O
X	POS	O
(	POS	O
2	POS	O
)	POS	O
=	POS	O
7	POS	O
.	POS	O
619	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
007	POS	O
)	POS	O
and	POS	O
control	POS	O
group	POS	O
(	POS	O
X	POS	O
(	POS	O
2	POS	O
)	POS	O
=	POS	O
13	POS	O
.	POS	O
755	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
000	POS	O
)	POS	O
.	POS	O
MCC	POS	O
in	POS	O
the	POS	O
model	POS	O
group	POS	O
was	POS	O
lower	POS	O
than	POS	O
the	POS	O
control	POS	O
and	POS	O
intervention	POS	O
groups	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Histological	POS	O
changes	POS	O
evident	POS	O
in	POS	O
model	POS	O
and	POS	O
intervention	POS	O
groups	POS	O
rats	POS	O
'	POS	O
bladder	POS	O
included	POS	O
edema	POS	B-NP
,	POS	O
vasodilation	POS	B-NP
,	POS	O
and	POS	O
infiltration	POS	O
of	POS	O
inflammatory	POS	O
cells	POS	O
.	POS	O
In	POS	O
model	POS	O
group	POS	O
,	POS	O
the	POS	O
expression	POS	O
of	POS	O
P2X3	POS	O
receptor	POS	O
increased	POS	O
in	POS	O
urothelium	POS	O
and	POS	O
suburothelium	POS	O
,	POS	O
and	POS	O
NK1	POS	O
receptor	POS	O
increased	POS	O
in	POS	O
suburothelium	POS	O
,	POS	O
while	POS	O
the	POS	O
expression	POS	O
of	POS	O
them	POS	O
in	POS	O
intervention	POS	O
group	POS	O
was	POS	O
lower	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
In	POS	O
CYP	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
,	POS	O
the	POS	O
expression	POS	O
of	POS	O
P2X3	POS	O
and	POS	O
NK1	POS	O
receptors	POS	O
increased	POS	O
in	POS	O
urothelium	POS	O
and	POS	O
/	POS	O
or	POS	O
suburothelium	POS	O
.	POS	O
Perfusion	POS	O
of	POS	O
bladder	POS	O
with	POS	O
P2X3	POS	O
and	POS	O
NK1	POS	O
receptors	POS	O
antagonists	POS	O
ameliorated	POS	O
the	POS	O
bladder	POS	O
function	POS	O
.	POS	O
Patient	POS	O
tolerance	POS	O
study	POS	O
of	POS	O
topical	POS	O
chlorhexidine	POS	O
diphosphanilate	POS	O
:	POS	O
a	POS	O
new	POS	O
topical	POS	O
agent	POS	O
for	POS	O
burns	POS	O
.	POS	O
Effective	POS	O
topical	POS	O
antimicrobial	POS	O
agents	POS	O
decrease	POS	O
infection	POS	O
and	POS	O
mortality	POS	O
in	POS	O
burn	POS	O
patients	POS	O
.	POS	O
Chlorhexidine	POS	O
phosphanilate	POS	O
(	POS	O
CHP	POS	O
)	POS	O
,	POS	O
a	POS	O
new	POS	O
broad	POS	O
-	POS	O
spectrum	POS	O
antimicrobial	POS	O
agent	POS	O
,	POS	O
has	POS	O
been	POS	O
evaluated	POS	O
as	POS	O
a	POS	O
topical	POS	O
burn	POS	O
wound	POS	O
dressing	POS	O
in	POS	O
cream	POS	O
form	POS	O
,	POS	O
but	POS	O
preliminary	POS	O
clinical	POS	O
trials	POS	O
reported	POS	O
that	POS	O
it	POS	O
was	POS	O
painful	POS	O
upon	POS	O
application	POS	O
.	POS	O
This	POS	O
study	POS	O
compared	POS	O
various	POS	O
concentrations	POS	O
of	POS	O
CHP	POS	O
to	POS	O
determine	POS	O
if	POS	O
a	POS	O
tolerable	POS	O
concentration	POS	O
could	POS	O
be	POS	O
identified	POS	O
with	POS	O
retention	POS	O
of	POS	O
antimicrobial	POS	O
efficacy	POS	O
.	POS	O
Twenty	POS	O
-	POS	O
nine	POS	O
burn	POS	B-NP
patients	POS	O
,	POS	O
each	POS	O
with	POS	O
two	POS	O
similar	POS	O
burns	POS	B-NP
which	POS	O
could	POS	O
be	POS	O
separately	POS	O
treated	POS	O
,	POS	O
were	POS	O
given	POS	O
pairs	POS	O
of	POS	O
treatments	POS	O
at	POS	O
successive	POS	O
12	POS	O
-	POS	O
h	POS	O
intervals	POS	O
over	POS	O
a	POS	O
3	POS	O
-	POS	O
day	POS	O
period	POS	O
.	POS	O
One	POS	O
burn	POS	O
site	POS	O
was	POS	O
treated	POS	O
with	POS	O
each	POS	O
of	POS	O
four	POS	O
different	POS	O
CHP	POS	O
concentrations	POS	O
,	POS	O
from	POS	O
0	POS	O
.	POS	O
25	POS	O
per	POS	O
cent	POS	O
to	POS	O
2	POS	O
per	POS	O
cent	POS	O
,	POS	O
their	POS	O
vehicle	POS	O
,	POS	O
and	POS	O
1	POS	O
per	POS	O
cent	POS	O
silver	POS	O
sulphadiazine	POS	O
(	POS	O
AgSD	POS	O
)	POS	O
cream	POS	O
,	POS	O
an	POS	O
antimicrobial	POS	O
agent	POS	O
frequently	POS	O
used	POS	O
for	POS	O
topical	POS	O
treatment	POS	O
of	POS	O
burn	POS	B-NP
wounds	POS	I-NP
.	POS	O
The	POS	O
other	POS	O
site	POS	O
was	POS	O
always	POS	O
treated	POS	O
with	POS	O
AgSD	POS	O
cream	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
direct	POS	O
relationship	POS	O
between	POS	O
CHP	POS	O
concentration	POS	O
and	POS	O
patients	POS	O
'	POS	O
ratings	POS	O
of	POS	O
pain	POS	B-NP
on	POS	O
an	POS	O
analogue	POS	O
scale	POS	O
.	POS	O
The	POS	O
0	POS	O
.	POS	O
25	POS	O
per	POS	O
cent	POS	O
CHP	POS	O
cream	POS	O
was	POS	O
closest	POS	O
to	POS	O
AgSD	POS	O
in	POS	O
pain	POS	B-NP
tolerance	POS	I-NP
;	POS	O
however	POS	O
,	POS	O
none	POS	O
of	POS	O
the	POS	O
treatments	POS	O
differed	POS	O
statistically	POS	O
from	POS	O
AgSD	POS	B-NP
or	POS	O
from	POS	O
each	POS	O
other	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
ease	POS	O
of	POS	O
application	POS	O
of	POS	O
CHP	POS	O
creams	POS	O
was	POS	O
less	POS	O
satisfactory	POS	O
than	POS	O
that	POS	O
of	POS	O
AgSD	POS	B-NP
.	POS	O
It	POS	O
was	POS	O
concluded	POS	O
that	POS	O
formulations	POS	O
at	POS	O
or	POS	O
below	POS	O
0	POS	O
.	POS	O
5	POS	O
per	POS	O
cent	POS	O
CHP	POS	O
may	POS	O
prove	POS	O
acceptable	POS	O
for	POS	O
wound	POS	O
care	POS	O
,	POS	O
but	POS	O
the	POS	O
vehicle	POS	O
system	POS	O
needs	POS	O
pharmaceutical	POS	O
improvement	POS	O
to	POS	O
render	POS	O
it	POS	O
more	POS	O
tolerable	POS	O
and	POS	O
easier	POS	O
to	POS	O
use	POS	O
.	POS	O
Acute	POS	O
hepatitis	POS	B-NP
associated	POS	O
with	POS	O
clopidogrel	POS	O
:	POS	O
a	POS	O
case	POS	O
report	POS	O
and	POS	O
review	POS	O
of	POS	O
the	POS	O
literature	POS	O
.	POS	O
Drug	POS	O
-	POS	O
induced	POS	O
hepatotoxicity	POS	B-NP
is	POS	O
a	POS	O
common	POS	O
cause	POS	O
of	POS	O
acute	POS	B-NP
hepatitis	POS	I-NP
,	POS	O
and	POS	O
the	POS	O
recognition	POS	O
of	POS	O
the	POS	O
responsible	POS	O
drug	POS	O
may	POS	O
be	POS	O
difficult	POS	O
.	POS	O
We	POS	O
describe	POS	O
a	POS	O
case	POS	O
of	POS	O
clopidogrel	POS	O
-	POS	O
related	POS	O
acute	POS	O
hepatitis	POS	B-NP
.	POS	O
The	POS	O
diagnosis	POS	O
is	POS	O
strongly	POS	O
suggested	POS	O
by	POS	O
an	POS	O
accurate	POS	O
medical	POS	O
history	POS	O
and	POS	O
liver	POS	O
biopsy	POS	O
.	POS	O
Reports	POS	O
about	POS	O
cases	POS	O
of	POS	O
hepatotoxicity	POS	B-NP
due	POS	O
to	POS	O
clopidogrel	POS	O
are	POS	O
increasing	POS	O
in	POS	O
the	POS	O
last	POS	O
few	POS	O
years	POS	O
,	POS	O
after	POS	O
the	POS	O
increased	POS	O
use	POS	O
of	POS	O
this	POS	O
drug	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
we	POS	O
believe	POS	O
that	POS	O
physicians	POS	O
should	POS	O
carefully	POS	O
consider	POS	O
the	POS	O
risk	POS	O
of	POS	O
drug	POS	O
-	POS	O
induced	POS	O
hepatic	POS	B-NP
injury	POS	I-NP
when	POS	O
clopidogrel	POS	O
is	POS	O
prescribed	POS	O
.	POS	O
Bortezomib	POS	O
and	POS	O
dexamethasone	POS	O
as	POS	O
salvage	POS	O
therapy	POS	O
in	POS	O
patients	POS	O
with	POS	O
relapsed	POS	B-NP
/	POS	I-NP
refractory	POS	I-NP
multiple	POS	I-NP
myeloma	POS	I-NP
:	POS	O
analysis	POS	O
of	POS	O
long	POS	O
-	POS	O
term	POS	O
clinical	POS	O
outcomes	POS	O
.	POS	O
Bortezomib	POS	O
(	POS	O
bort	POS	O
)	POS	O
-	POS	O
dexamethasone	POS	O
(	POS	O
dex	POS	O
)	POS	O
is	POS	O
an	POS	O
effective	POS	O
therapy	POS	O
for	POS	O
relapsed	POS	B-NP
/	POS	I-NP
refractory	POS	I-NP
(	POS	I-NP
R	POS	I-NP
/	POS	I-NP
R	POS	I-NP
)	POS	I-NP
multiple	POS	I-NP
myeloma	POS	I-NP
(	POS	O
MM	POS	B-NP
)	POS	O
.	POS	O
This	POS	O
retrospective	POS	O
study	POS	O
investigated	POS	O
the	POS	O
combination	POS	O
of	POS	O
bort	POS	O
(	POS	O
1	POS	O
.	POS	O
3	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
on	POS	O
days	POS	O
1	POS	O
,	POS	O
4	POS	O
,	POS	O
8	POS	O
,	POS	O
and	POS	O
11	POS	O
every	POS	O
3	POS	O
weeks	POS	O
)	POS	O
and	POS	O
dex	POS	O
(	POS	O
20	POS	O
mg	POS	O
on	POS	O
the	POS	O
day	POS	O
of	POS	O
and	POS	O
the	POS	O
day	POS	O
after	POS	O
bort	POS	O
)	POS	O
as	POS	O
salvage	POS	O
treatment	POS	O
in	POS	O
85	POS	O
patients	POS	O
with	POS	O
R	POS	O
/	POS	O
R	POS	O
MM	POS	O
after	POS	O
prior	POS	O
autologous	POS	O
stem	POS	O
cell	POS	O
transplantation	POS	O
or	POS	O
conventional	POS	O
chemotherapy	POS	O
.	POS	O
The	POS	O
median	POS	O
number	POS	O
of	POS	O
prior	POS	O
lines	POS	O
of	POS	O
therapy	POS	O
was	POS	O
2	POS	O
.	POS	O
Eighty	POS	O
-	POS	O
seven	POS	O
percent	POS	O
of	POS	O
the	POS	O
patients	POS	O
had	POS	O
received	POS	O
immunomodulatory	POS	O
drugs	POS	O
included	POS	O
in	POS	O
some	POS	O
line	POS	O
of	POS	O
therapy	POS	O
before	POS	O
bort	POS	O
-	POS	O
dex	POS	O
.	POS	O
The	POS	O
median	POS	O
number	POS	O
of	POS	O
bort	POS	O
-	POS	O
dex	POS	O
cycles	POS	O
was	POS	O
6	POS	O
,	POS	O
up	POS	O
to	POS	O
a	POS	O
maximum	POS	O
of	POS	O
12	POS	O
cycles	POS	O
.	POS	O
On	POS	O
an	POS	O
intention	POS	O
-	POS	O
to	POS	O
-	POS	O
treat	POS	O
basis	POS	O
,	POS	O
55	POS	O
%	POS	O
of	POS	O
the	POS	O
patients	POS	O
achieved	POS	O
at	POS	O
least	POS	O
partial	POS	O
response	POS	O
,	POS	O
including	POS	O
19	POS	O
%	POS	O
CR	POS	O
and	POS	O
35	POS	O
%	POS	O
achieved	POS	O
at	POS	O
least	POS	O
very	POS	O
good	POS	O
partial	POS	O
response	POS	O
.	POS	O
Median	POS	O
durations	POS	O
of	POS	O
response	POS	O
,	POS	O
time	POS	O
to	POS	O
next	POS	O
therapy	POS	O
and	POS	O
treatment	POS	O
-	POS	O
free	POS	O
interval	POS	O
were	POS	O
8	POS	O
,	POS	O
11	POS	O
.	POS	O
2	POS	O
,	POS	O
and	POS	O
5	POS	O
.	POS	O
1	POS	O
months	POS	O
,	POS	O
respectively	POS	O
.	POS	O
The	POS	O
most	POS	O
relevant	POS	O
adverse	POS	O
event	POS	O
was	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
,	POS	O
which	POS	O
occurred	POS	O
in	POS	O
78	POS	O
%	POS	O
of	POS	O
the	POS	O
patients	POS	O
(	POS	O
grade	POS	O
II	POS	O
,	POS	O
38	POS	O
%	POS	O
;	POS	O
grade	POS	O
III	POS	O
,	POS	O
21	POS	O
%	POS	O
)	POS	O
and	POS	O
led	POS	O
to	POS	O
treatment	POS	O
discontinuation	POS	O
in	POS	O
6	POS	O
%	POS	O
.	POS	O
With	POS	O
a	POS	O
median	POS	O
follow	POS	O
up	POS	O
of	POS	O
22	POS	O
months	POS	O
,	POS	O
median	POS	O
time	POS	O
to	POS	O
progression	POS	O
,	POS	O
progression	POS	O
-	POS	O
free	POS	O
survival	POS	O
(	POS	O
PFS	POS	O
)	POS	O
and	POS	O
overall	POS	O
survival	POS	O
(	POS	O
OS	POS	O
)	POS	O
were	POS	O
8	POS	O
.	POS	O
9	POS	O
,	POS	O
8	POS	O
.	POS	O
7	POS	O
,	POS	O
and	POS	O
22	POS	O
months	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Prolonged	POS	O
PFS	POS	O
and	POS	O
OS	POS	O
were	POS	O
observed	POS	O
in	POS	O
patients	POS	O
achieving	POS	O
CR	POS	O
and	POS	O
receiving	POS	O
bort	POS	O
-	POS	O
dex	POS	O
a	POS	O
single	POS	O
line	POS	O
of	POS	O
prior	POS	O
therapy	POS	O
.	POS	O
Bort	POS	O
-	POS	O
dex	POS	O
was	POS	O
an	POS	O
effective	POS	O
salvage	POS	O
treatment	POS	O
for	POS	O
MM	POS	B-NP
patients	POS	O
,	POS	O
particularly	POS	O
for	POS	O
those	POS	O
in	POS	O
first	POS	O
relapse	POS	O
.	POS	O
Pubertal	POS	O
exposure	POS	O
to	POS	O
Bisphenol	POS	O
A	POS	O
increases	POS	O
anxiety	POS	B-NP
-	POS	O
like	POS	O
behavior	POS	O
and	POS	O
decreases	POS	O
acetylcholinesterase	POS	O
activity	POS	O
of	POS	O
hippocampus	POS	O
in	POS	O
adult	POS	O
male	POS	O
mice	POS	O
.	POS	O
The	POS	O
negative	POS	O
effects	POS	O
of	POS	O
Bisphenol	POS	O
A	POS	O
(	POS	O
BPA	POS	O
)	POS	O
on	POS	O
neurodevelopment	POS	O
and	POS	O
behaviors	POS	O
have	POS	O
been	POS	O
well	POS	O
established	POS	O
.	POS	O
Acetylcholinesterase	POS	O
(	POS	O
AChE	POS	O
)	POS	O
is	POS	O
a	POS	O
regulatory	POS	O
enzyme	POS	O
which	POS	O
is	POS	O
involved	POS	O
in	POS	O
anxiety	POS	B-NP
-	POS	O
like	POS	O
behavior	POS	O
.	POS	O
This	POS	O
study	POS	O
investigated	POS	O
behavioral	POS	O
phenotypes	POS	O
and	POS	O
AChE	POS	O
activity	POS	O
in	POS	O
male	POS	O
mice	POS	O
following	POS	O
BPA	POS	O
exposure	POS	O
during	POS	O
puberty	POS	B-NP
.	POS	O
On	POS	O
postnatal	POS	O
day	POS	O
(	POS	O
PND	POS	O
)	POS	O
35	POS	O
,	POS	O
male	POS	O
mice	POS	O
were	POS	O
exposed	POS	O
to	POS	O
50mg	POS	O
BPA	POS	O
/	POS	O
kg	POS	O
diet	POS	O
per	POS	O
day	POS	O
for	POS	O
a	POS	O
period	POS	O
of	POS	O
35	POS	O
days	POS	O
.	POS	O
On	POS	O
PND71	POS	O
,	POS	O
a	POS	O
behavioral	POS	O
assay	POS	O
was	POS	O
performed	POS	O
using	POS	O
the	POS	O
elevated	POS	O
plus	POS	O
maze	POS	O
(	POS	O
EPM	POS	O
)	POS	O
and	POS	O
the	POS	O
light	POS	O
/	POS	O
dark	POS	O
test	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
AChE	POS	O
activity	POS	O
was	POS	O
measured	POS	O
in	POS	O
the	POS	O
prefrontal	POS	O
cortex	POS	O
,	POS	O
hypothalamus	POS	O
,	POS	O
cerebellum	POS	O
and	POS	O
hippocampus	POS	O
.	POS	O
Results	POS	O
from	POS	O
our	POS	O
behavioral	POS	O
phenotyping	POS	O
indicated	POS	O
that	POS	O
anxiety	POS	B-NP
-	POS	O
like	POS	O
behavior	POS	O
was	POS	O
increased	POS	O
in	POS	O
mice	POS	O
exposed	POS	O
to	POS	O
BPA	POS	O
.	POS	O
AChE	POS	O
activity	POS	O
was	POS	O
significantly	POS	O
decreased	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
of	POS	O
mice	POS	O
with	POS	O
BPA	POS	O
compared	POS	O
to	POS	O
control	POS	O
mice	POS	O
,	POS	O
whereas	POS	O
no	POS	O
difference	POS	O
was	POS	O
found	POS	O
in	POS	O
the	POS	O
prefrontal	POS	O
cortex	POS	O
,	POS	O
hypothalamus	POS	O
and	POS	O
cerebellum	POS	O
.	POS	O
Our	POS	O
findings	POS	O
showed	POS	O
that	POS	O
pubertal	POS	O
BPA	POS	O
exposure	POS	O
increased	POS	O
anxiety	POS	B-NP
-	POS	O
like	POS	O
behavior	POS	O
,	POS	O
which	POS	O
may	POS	O
be	POS	O
associated	POS	O
with	POS	O
decreased	POS	O
AChE	POS	O
activity	POS	O
of	POS	O
the	POS	O
hippocampus	POS	O
in	POS	O
adult	POS	O
male	POS	O
mice	POS	O
.	POS	O
Further	POS	O
studies	POS	O
are	POS	O
necessary	POS	O
to	POS	O
investigate	POS	O
the	POS	O
cholinergic	POS	O
signaling	POS	O
of	POS	O
the	POS	O
hippocampus	POS	O
in	POS	O
PBE	POS	O
induced	POS	O
anxiety	POS	B-NP
-	POS	O
like	POS	O
behaviors	POS	O
.	POS	O
Biochemical	POS	O
effects	POS	O
of	POS	O
Solidago	POS	O
virgaurea	POS	O
extract	POS	O
on	POS	O
experimental	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
Cardiovascular	POS	B-NP
diseases	POS	I-NP
(	POS	O
CVDs	POS	B-NP
)	POS	O
are	POS	O
the	POS	O
major	POS	O
health	POS	O
problem	POS	O
of	POS	O
advanced	POS	O
as	POS	O
well	POS	O
as	POS	O
developing	POS	O
countries	POS	O
of	POS	O
the	POS	O
world	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
the	POS	O
protective	POS	O
effect	POS	O
of	POS	O
the	POS	O
Solidago	POS	O
virgaurea	POS	O
extract	POS	O
on	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
subcutaneous	POS	O
injection	POS	O
of	POS	O
isoproterenol	POS	O
(	POS	O
30	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
into	POS	O
rats	POS	O
twice	POS	O
at	POS	O
an	POS	O
interval	POS	O
of	POS	O
24	POS	O
h	POS	O
,	POS	O
for	POS	O
two	POS	O
consecutive	POS	O
days	POS	O
,	POS	O
led	POS	O
to	POS	O
a	POS	O
significant	POS	O
increase	POS	O
in	POS	O
serum	POS	O
lactate	POS	O
dehydrogenase	POS	O
,	POS	O
creatine	POS	O
phosphokinase	POS	O
,	POS	O
alanine	POS	O
transaminase	POS	O
,	POS	O
aspartate	POS	O
transaminase	POS	O
,	POS	O
and	POS	O
angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
activities	POS	O
,	POS	O
total	POS	O
cholesterol	POS	O
,	POS	O
triglycerides	POS	O
,	POS	O
free	POS	O
serum	POS	O
fatty	POS	O
acid	POS	O
,	POS	O
cardiac	POS	O
tissue	POS	O
malondialdehyde	POS	O
(	POS	O
MDA	POS	O
)	POS	O
,	POS	O
and	POS	O
nitric	POS	O
oxide	POS	O
levels	POS	O
and	POS	O
a	POS	O
significant	POS	O
decrease	POS	O
in	POS	O
levels	POS	O
of	POS	O
glutathione	POS	O
and	POS	O
superoxide	POS	O
dismutase	POS	O
in	POS	O
cardiac	POS	O
tissue	POS	O
as	POS	O
compared	POS	O
to	POS	O
the	POS	O
normal	POS	O
control	POS	O
group	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Pretreatment	POS	O
with	POS	O
S	POS	O
.	POS	O
virgaurea	POS	O
extract	POS	O
for	POS	O
5	POS	O
weeks	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
250	POS	O
mg	POS	O
/	POS	O
kg	POS	O
followed	POS	O
by	POS	O
isoproterenol	POS	O
injection	POS	O
significantly	POS	O
prevented	POS	O
the	POS	O
observed	POS	O
alterations	POS	O
.	POS	O
Captopril	POS	O
(	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
,	POS	O
given	POS	O
orally	POS	O
)	POS	O
,	POS	O
an	POS	O
inhibitor	POS	O
of	POS	O
angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
used	POS	O
as	POS	O
a	POS	O
standard	POS	O
cardioprotective	POS	O
drug	POS	O
,	POS	O
was	POS	O
used	POS	O
as	POS	O
a	POS	O
positive	POS	O
control	POS	O
in	POS	O
this	POS	O
study	POS	O
.	POS	O
The	POS	O
data	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
suggest	POS	O
that	POS	O
S	POS	O
.	POS	O
virgaurea	POS	O
extract	POS	O
exerts	POS	O
its	POS	O
protective	POS	O
effect	POS	O
by	POS	O
decreasing	POS	O
MDA	POS	O
level	POS	O
and	POS	O
increasing	POS	O
the	POS	O
antioxidant	POS	O
status	POS	O
in	POS	O
isoproterenol	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
The	POS	O
study	POS	O
emphasizes	POS	O
the	POS	O
beneficial	POS	O
action	POS	O
of	POS	O
S	POS	O
.	POS	O
virgaurea	POS	O
extract	POS	O
as	POS	O
a	POS	O
cardioprotective	POS	O
agent	POS	O
.	POS	O
"	POS	O
Real	POS	O
-	POS	O
world	POS	O
"	POS	O
data	POS	O
on	POS	O
the	POS	O
efficacy	POS	O
and	POS	O
safety	POS	O
of	POS	O
lenalidomide	POS	O
and	POS	O
dexamethasone	POS	O
in	POS	O
patients	POS	O
with	POS	O
relapsed	POS	B-NP
/	POS	I-NP
refractory	POS	I-NP
multiple	POS	I-NP
myeloma	POS	I-NP
who	POS	O
were	POS	O
treated	POS	O
according	POS	O
to	POS	O
the	POS	O
standard	POS	O
clinical	POS	O
practice	POS	O
:	POS	O
a	POS	O
study	POS	O
of	POS	O
the	POS	O
Greek	POS	O
Myeloma	POS	B-NP
Study	POS	O
Group	POS	O
.	POS	O
Lenalidomide	POS	O
and	POS	O
dexamethasone	POS	O
(	POS	O
RD	POS	O
)	POS	O
is	POS	O
a	POS	O
standard	POS	O
of	POS	O
care	POS	O
for	POS	O
relapsed	POS	B-NP
/	POS	I-NP
refractory	POS	I-NP
multiple	POS	I-NP
myeloma	POS	I-NP
(	POS	O
RRMM	POS	O
)	POS	O
,	POS	O
but	POS	O
there	POS	O
is	POS	O
limited	POS	O
published	POS	O
data	POS	O
on	POS	O
its	POS	O
efficacy	POS	O
and	POS	O
safety	POS	O
in	POS	O
the	POS	O
"	POS	O
real	POS	O
world	POS	O
"	POS	O
(	POS	O
RW	POS	O
)	POS	O
,	POS	O
according	POS	O
to	POS	O
the	POS	O
International	POS	O
Society	POS	O
of	POS	O
Pharmacoeconomics	POS	O
and	POS	O
Outcomes	POS	O
Research	POS	O
definition	POS	O
.	POS	O
We	POS	O
studied	POS	O
212	POS	O
RRMM	POS	O
patients	POS	O
who	POS	O
received	POS	O
RD	POS	O
in	POS	O
RW	POS	O
.	POS	O
Objective	POS	O
response	POS	O
(	POS	O
>	POS	O
PR	POS	O
(	POS	O
partial	POS	O
response	POS	O
)	POS	O
)	POS	O
rate	POS	O
was	POS	O
77	POS	O
.	POS	O
4	POS	O
%	POS	O
(	POS	O
complete	POS	O
response	POS	O
(	POS	O
CR	POS	O
)	POS	O
,	POS	O
20	POS	O
.	POS	O
2	POS	O
%	POS	O
)	POS	O
.	POS	O
Median	POS	O
time	POS	O
to	POS	O
first	POS	O
and	POS	O
best	POS	O
response	POS	O
was	POS	O
2	POS	O
and	POS	O
5	POS	O
months	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Median	POS	O
time	POS	O
to	POS	O
CR	POS	O
when	POS	O
RD	POS	O
was	POS	O
given	POS	O
as	POS	O
2nd	POS	O
or	POS	O
>	POS	O
2	POS	O
(	POS	O
nd	POS	O
)	POS	O
-	POS	O
line	POS	O
treatment	POS	O
at	POS	O
4	POS	O
and	POS	O
11	POS	O
months	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Quality	POS	O
of	POS	O
response	POS	O
was	POS	O
independent	POS	O
of	POS	O
previous	POS	O
lines	POS	O
of	POS	O
therapies	POS	O
or	POS	O
previous	POS	O
exposure	POS	O
to	POS	O
thalidomide	POS	O
or	POS	O
bortezomib	POS	O
.	POS	O
Median	POS	O
duration	POS	O
of	POS	O
response	POS	O
was	POS	O
34	POS	O
.	POS	O
4	POS	O
months	POS	O
,	POS	O
and	POS	O
it	POS	O
was	POS	O
higher	POS	O
in	POS	O
patients	POS	O
who	POS	O
received	POS	O
RD	POS	B-NP
until	POS	O
progression	POS	O
(	POS	O
not	POS	O
reached	POS	O
versus	POS	O
19	POS	O
months	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Improvement	POS	O
of	POS	O
humoral	POS	O
immunity	POS	O
occurred	POS	O
in	POS	O
60	POS	O
%	POS	O
of	POS	O
responders	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
and	POS	O
in	POS	O
the	POS	O
majority	POS	O
of	POS	O
patients	POS	O
who	POS	O
achieved	POS	O
stable	POS	O
disease	POS	O
.	POS	O
Adverse	POS	O
events	POS	O
were	POS	O
reported	POS	O
in	POS	O
68	POS	O
.	POS	O
9	POS	O
%	POS	O
of	POS	O
patients	POS	O
(	POS	O
myelosuppression	POS	B-NP
in	POS	O
49	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
and	POS	O
12	POS	O
.	POS	O
7	POS	O
%	POS	O
of	POS	O
patients	POS	O
needed	POS	O
hospitalization	POS	O
.	POS	O
Peripheral	POS	B-NP
neuropathy	POS	I-NP
was	POS	O
observed	POS	O
only	POS	O
in	POS	O
2	POS	O
.	POS	O
5	POS	O
%	POS	O
of	POS	O
patients	POS	O
and	POS	O
deep	POS	O
vein	POS	B-NP
thrombosis	POS	I-NP
in	POS	O
5	POS	O
.	POS	O
7	POS	O
%	POS	O
.	POS	O
Dose	POS	O
reductions	POS	O
were	POS	O
needed	POS	O
in	POS	O
31	POS	O
%	POS	O
of	POS	O
patients	POS	O
and	POS	O
permanent	POS	O
discontinuation	POS	O
in	POS	O
38	POS	O
.	POS	O
9	POS	O
%	POS	O
.	POS	O
Median	POS	O
time	POS	O
to	POS	O
treatment	POS	O
discontinuation	POS	O
was	POS	O
16	POS	O
.	POS	O
8	POS	O
months	POS	O
.	POS	O
Performance	POS	O
status	POS	O
(	POS	O
PS	POS	O
)	POS	O
and	POS	O
initial	POS	O
lenalidomide	POS	O
dose	POS	O
predicted	POS	O
for	POS	O
treatment	POS	O
discontinuation	POS	O
.	POS	O
Extra	POS	B-NP
-	POS	I-NP
medullary	POS	I-NP
relapses	POS	I-NP
occurred	POS	O
in	POS	O
3	POS	O
.	POS	O
8	POS	O
%	POS	O
of	POS	O
patients	POS	O
.	POS	O
Our	POS	O
study	POS	O
confirms	POS	O
that	POS	O
RD	POS	O
is	POS	O
effective	POS	O
and	POS	O
safe	POS	O
in	POS	O
RRMM	POS	O
in	POS	O
the	POS	O
RW	POS	O
;	POS	O
it	POS	O
produces	POS	O
durable	POS	O
responses	POS	O
especially	POS	O
in	POS	O
patients	POS	O
who	POS	O
continue	POS	O
on	POS	O
treatment	POS	O
till	POS	O
progression	POS	O
and	POS	O
improves	POS	O
humoral	POS	O
immunity	POS	O
even	POS	O
in	POS	O
patients	POS	O
with	POS	O
stable	POS	O
disease	POS	O
.	POS	O
The	POS	O
cytogenetic	POS	O
action	POS	O
of	POS	O
ifosfamide	POS	O
,	POS	O
mesna	POS	O
,	POS	O
and	POS	O
their	POS	O
combination	POS	O
on	POS	O
peripheral	POS	O
rabbit	POS	O
lymphocytes	POS	O
:	POS	O
an	POS	O
in	POS	O
vivo	POS	O
/	POS	O
in	POS	O
vitro	POS	O
cytogenetic	POS	O
study	POS	O
.	POS	O
Ifosfamide	POS	O
(	POS	O
IFO	POS	O
)	POS	O
is	POS	O
an	POS	O
alkylating	POS	O
nitrogen	POS	O
mustard	POS	O
,	POS	O
administrated	POS	O
as	POS	O
an	POS	O
antineoplasmic	POS	O
agent	POS	O
.	POS	O
It	POS	O
is	POS	O
characterized	POS	O
by	POS	O
its	POS	O
intense	POS	O
urotoxic	POS	O
action	POS	O
,	POS	O
leading	POS	O
to	POS	O
hemorrhagic	POS	B-NP
cystitis	POS	I-NP
.	POS	O
This	POS	O
side	POS	O
effect	POS	O
of	POS	O
IFO	POS	O
raises	POS	O
the	POS	O
requirement	POS	O
for	POS	O
the	POS	O
co	POS	O
-	POS	O
administration	POS	O
with	POS	O
sodium	POS	O
2	POS	O
-	POS	O
sulfanylethanesulfonate	POS	O
(	POS	O
Mesna	POS	O
)	POS	O
aiming	POS	O
to	POS	O
avoid	POS	O
or	POS	O
minimize	POS	O
this	POS	O
effect	POS	O
.	POS	O
IFO	POS	O
and	POS	O
Mesna	POS	O
were	POS	O
administrated	POS	O
separately	POS	O
on	POS	O
rabbit	POS	O
'	POS	O
s	POS	O
lymphocytes	POS	O
in	POS	O
vivo	POS	O
,	POS	O
which	POS	O
were	POS	O
later	POS	O
developed	POS	O
in	POS	O
vitro	POS	O
.	POS	O
Cytogenetic	POS	O
markers	POS	O
for	POS	O
sister	POS	O
chromatid	POS	O
exchanges	POS	O
(	POS	O
SCEs	POS	O
)	POS	O
,	POS	O
proliferation	POS	O
rate	POS	O
index	POS	O
(	POS	O
PRI	POS	O
)	POS	O
and	POS	O
Mitotic	POS	O
Index	POS	O
were	POS	O
recorded	POS	O
.	POS	O
Mesna	POS	O
'	POS	O
s	POS	O
action	POS	O
,	POS	O
in	POS	O
conjunction	POS	O
with	POS	O
IFO	POS	O
reduces	POS	O
the	POS	O
frequency	POS	O
of	POS	O
SCEs	POS	O
,	POS	O
in	POS	O
comparison	POS	O
with	POS	O
the	POS	O
SCEs	POS	O
recordings	POS	O
obtained	POS	O
when	POS	O
IFO	POS	O
is	POS	O
administered	POS	O
alone	POS	O
.	POS	O
In	POS	O
addition	POS	O
to	POS	O
this	POS	O
,	POS	O
when	POS	O
high	POS	O
concentrations	POS	O
of	POS	O
Mesna	POS	O
were	POS	O
administered	POS	O
alone	POS	O
significant	POS	O
reductions	POS	O
of	POS	O
the	POS	O
PRI	POS	O
were	POS	O
noted	POS	O
,	POS	O
than	POS	O
with	POS	O
IFO	POS	O
acting	POS	O
at	POS	O
the	POS	O
same	POS	O
concentration	POS	O
on	POS	O
the	POS	O
lymphocytes	POS	O
.	POS	O
Mesna	POS	O
significantly	POS	O
reduces	POS	O
IFO	POS	O
'	POS	O
s	POS	O
genotoxicity	POS	B-NP
,	POS	O
while	POS	O
when	POS	O
administered	POS	O
in	POS	O
high	POS	O
concentrations	POS	O
it	POS	O
acts	POS	O
in	POS	O
an	POS	O
inhibitory	POS	O
fashion	POS	O
on	POS	O
the	POS	O
cytostatic	POS	O
action	POS	O
of	POS	O
the	POS	O
drug	POS	O
.	POS	O
Risk	POS	O
factors	POS	O
and	POS	O
predictors	POS	O
of	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
dyskinesia	POS	B-NP
among	POS	O
multiethnic	POS	O
Malaysians	POS	O
with	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
Chronic	POS	O
pulsatile	POS	O
levodopa	POS	O
therapy	POS	O
for	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
(	POS	O
PD	POS	B-NP
)	POS	O
leads	POS	O
to	POS	O
the	POS	O
development	POS	O
of	POS	O
motor	POS	O
fluctuations	POS	O
and	POS	O
dyskinesia	POS	B-NP
.	POS	O
We	POS	O
studied	POS	O
the	POS	O
prevalence	POS	O
and	POS	O
predictors	POS	O
of	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
dyskinesia	POS	B-NP
among	POS	O
multiethnic	POS	O
Malaysian	POS	O
patients	POS	O
with	POS	O
PD	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
This	POS	O
is	POS	O
a	POS	O
cross	POS	O
-	POS	O
sectional	POS	O
study	POS	O
involving	POS	O
95	POS	O
patients	POS	O
with	POS	O
PD	POS	B-NP
on	POS	O
uninterrupted	POS	O
levodopa	POS	O
therapy	POS	O
for	POS	O
at	POS	O
least	POS	O
6	POS	O
months	POS	O
.	POS	O
The	POS	O
instrument	POS	O
used	POS	O
was	POS	O
the	POS	O
UPDRS	POS	O
questionnaires	POS	O
.	POS	O
The	POS	O
predictors	POS	O
of	POS	O
dyskinesia	POS	B-NP
were	POS	O
determined	POS	O
using	POS	O
multivariate	POS	O
logistic	POS	O
regression	POS	O
analysis	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
mean	POS	O
age	POS	O
was	POS	O
65	POS	O
.	POS	O
6	POS	O
+	POS	O
8	POS	O
.	POS	O
5	POS	O
years	POS	O
.	POS	O
The	POS	O
mean	POS	O
onset	POS	O
age	POS	O
was	POS	O
58	POS	O
.	POS	O
5	POS	O
+	POS	O
9	POS	O
.	POS	O
8	POS	O
years	POS	O
.	POS	O
The	POS	O
median	POS	O
disease	POS	O
duration	POS	O
was	POS	O
6	POS	O
(	POS	O
7	POS	O
)	POS	O
years	POS	O
.	POS	O
Dyskinesia	POS	B-NP
was	POS	O
present	POS	O
in	POS	O
44	POS	O
%	POS	O
(	POS	O
n	POS	O
=	POS	O
42	POS	O
)	POS	O
with	POS	O
median	POS	O
levodopa	POS	O
therapy	POS	O
of	POS	O
3	POS	O
years	POS	O
.	POS	O
There	POS	O
were	POS	O
64	POS	O
.	POS	O
3	POS	O
%	POS	O
Chinese	POS	O
,	POS	O
31	POS	O
%	POS	O
Malays	POS	O
,	POS	O
and	POS	O
3	POS	O
.	POS	O
7	POS	O
%	POS	O
Indians	POS	O
and	POS	O
other	POS	O
ethnic	POS	O
groups	POS	O
.	POS	O
Eighty	POS	O
-	POS	O
one	POS	O
percent	POS	O
of	POS	O
patients	POS	O
with	POS	O
dyskinesia	POS	B-NP
had	POS	O
clinical	POS	O
fluctuations	POS	O
.	POS	O
Patients	POS	O
with	POS	O
dyskinesia	POS	B-NP
had	POS	O
lower	POS	O
onset	POS	O
age	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
longer	POS	O
duration	POS	O
of	POS	O
levodopa	POS	O
therapy	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
longer	POS	O
disease	POS	O
duration	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
higher	POS	O
total	POS	O
daily	POS	O
levodopa	POS	O
dose	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
and	POS	O
higher	POS	O
total	POS	O
UPDRS	POS	O
scores	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
005	POS	O
)	POS	O
than	POS	O
patients	POS	O
without	POS	O
dyskinesia	POS	B-NP
.	POS	O
The	POS	O
three	POS	O
significant	POS	O
predictors	POS	O
of	POS	O
dyskinesia	POS	B-NP
were	POS	O
duration	POS	O
of	POS	O
levodopa	POS	O
therapy	POS	O
,	POS	O
onset	POS	O
age	POS	O
,	POS	O
and	POS	O
total	POS	O
daily	POS	O
levodopa	POS	O
dose	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
prevalence	POS	O
of	POS	O
levodopa	POS	O
-	POS	O
induced	POS	O
dyskinesia	POS	B-NP
in	POS	O
our	POS	O
patients	POS	O
was	POS	O
44	POS	O
%	POS	O
.	POS	O
The	POS	O
most	POS	O
significant	POS	O
predictors	POS	O
were	POS	O
duration	POS	O
of	POS	O
levodopa	POS	O
therapy	POS	O
,	POS	O
total	POS	O
daily	POS	O
levodopa	POS	O
dose	POS	O
,	POS	O
and	POS	O
onset	POS	O
age	POS	O
.	POS	O
Dose	POS	O
-	POS	O
dependent	POS	O
neurotoxicity	POS	B-NP
of	POS	O
high	POS	O
-	POS	O
dose	POS	O
busulfan	POS	O
in	POS	O
children	POS	O
:	POS	O
a	POS	O
clinical	POS	O
and	POS	O
pharmacological	POS	O
study	POS	O
.	POS	O
Busulfan	POS	O
is	POS	O
known	POS	O
to	POS	O
be	POS	O
neurotoxic	POS	B-NP
in	POS	O
animals	POS	O
and	POS	O
humans	POS	O
,	POS	O
but	POS	O
its	POS	O
acute	POS	O
neurotoxicity	POS	B-NP
remains	POS	O
poorly	POS	O
characterized	POS	O
in	POS	O
children	POS	O
.	POS	O
We	POS	O
report	POS	O
here	POS	O
a	POS	O
retrospective	POS	O
study	POS	O
of	POS	O
123	POS	O
children	POS	O
(	POS	O
median	POS	O
age	POS	O
,	POS	O
6	POS	O
.	POS	O
5	POS	O
years	POS	O
)	POS	O
receiving	POS	O
high	POS	O
-	POS	O
dose	POS	O
busulfan	POS	O
in	POS	O
combined	POS	O
chemotherapy	POS	O
before	POS	O
bone	POS	O
marrow	POS	O
transplantation	POS	O
for	POS	O
malignant	POS	B-NP
solid	POS	I-NP
tumors	POS	I-NP
,	POS	O
brain	POS	B-NP
tumors	POS	I-NP
excluded	POS	O
.	POS	O
Busulfan	POS	O
was	POS	O
given	POS	O
p	POS	O
.	POS	O
o	POS	O
.	POS	O
,	POS	O
every	POS	O
6	POS	O
hours	POS	O
for	POS	O
16	POS	O
doses	POS	O
over	POS	O
4	POS	O
days	POS	O
.	POS	O
Two	POS	O
total	POS	O
doses	POS	O
were	POS	O
consecutively	POS	O
used	POS	O
:	POS	O
16	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
then	POS	O
600	POS	O
mg	POS	O
/	POS	O
m2	POS	O
.	POS	O
The	POS	O
dose	POS	O
calculation	POS	O
on	POS	O
the	POS	O
basis	POS	O
of	POS	O
body	POS	O
surface	POS	O
area	POS	O
results	POS	O
in	POS	O
higher	POS	O
doses	POS	O
in	POS	O
young	POS	O
children	POS	O
than	POS	O
in	POS	O
older	POS	O
patients	POS	O
(	POS	O
16	POS	O
to	POS	O
28	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
.	POS	O
Ninety	POS	O
-	POS	O
six	POS	O
patients	POS	O
were	POS	O
not	POS	O
given	POS	O
anticonvulsive	POS	O
prophylaxis	POS	B-NP
;	POS	O
7	POS	O
(	POS	O
7	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
developed	POS	O
seizures	POS	B-NP
during	POS	O
the	POS	O
4	POS	O
days	POS	O
of	POS	O
the	POS	O
busulfan	POS	O
course	POS	O
or	POS	O
within	POS	O
24	POS	O
h	POS	O
after	POS	O
the	POS	O
last	POS	O
dosing	POS	O
.	POS	O
When	POS	O
the	POS	O
total	POS	O
busulfan	POS	O
dose	POS	O
was	POS	O
taken	POS	O
into	POS	O
account	POS	O
,	POS	O
there	POS	O
was	POS	O
a	POS	O
significant	POS	O
difference	POS	O
in	POS	O
terms	POS	O
of	POS	O
neurotoxicity	POS	B-NP
incidence	POS	O
among	POS	O
patients	POS	O
under	POS	O
16	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
1	POS	O
of	POS	O
57	POS	O
,	POS	O
1	POS	O
.	POS	O
7	POS	O
%	POS	O
)	POS	O
and	POS	O
patients	POS	O
under	POS	O
600	POS	O
mg	POS	O
/	POS	O
m2	POS	O
(	POS	O
6	POS	O
of	POS	O
39	POS	O
,	POS	O
15	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
02	POS	O
)	POS	O
.	POS	O
Twenty	POS	O
-	POS	O
seven	POS	O
patients	POS	O
were	POS	O
given	POS	O
a	POS	O
600	POS	O
-	POS	O
mg	POS	O
/	POS	O
m2	POS	O
busulfan	POS	O
total	POS	O
dose	POS	O
with	POS	O
continuous	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
infusion	POS	O
of	POS	O
clonazepam	POS	O
;	POS	O
none	POS	O
had	POS	O
any	POS	O
neurological	POS	O
symptoms	POS	O
.	POS	O
Busulfan	POS	O
levels	POS	O
were	POS	O
measured	POS	O
by	POS	O
a	POS	O
gas	POS	O
chromatographic	POS	O
-	POS	O
mass	POS	O
spectrometry	POS	O
assay	POS	O
in	POS	O
the	POS	O
plasma	POS	O
and	POS	O
cerebrospinal	POS	O
fluid	POS	O
of	POS	O
9	POS	O
children	POS	O
without	POS	O
central	POS	O
nervous	POS	O
system	POS	O
disease	POS	O
under	POS	O
600	POS	O
mg	POS	O
/	POS	O
m2	POS	O
busulfan	POS	O
with	POS	O
clonazepam	POS	O
:	POS	O
busulfan	POS	O
cerebrospinal	POS	O
fluid	POS	O
:	POS	O
plasma	POS	O
ratio	POS	O
was	POS	O
1	POS	O
.	POS	O
39	POS	O
.	POS	O
This	POS	O
was	POS	O
significantly	POS	O
different	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
02	POS	O
)	POS	O
from	POS	O
the	POS	O
cerebrospinal	POS	O
fluid	POS	O
:	POS	O
plasma	POS	O
ratio	POS	O
previously	POS	O
defined	POS	O
in	POS	O
children	POS	O
receiving	POS	O
a	POS	O
16	POS	O
-	POS	O
mg	POS	O
/	POS	O
kg	POS	O
total	POS	O
dose	POS	O
of	POS	O
busulfan	POS	O
.	POS	O
This	POS	O
study	POS	O
shows	POS	O
that	POS	O
busulfan	POS	O
neurotoxicity	POS	B-NP
is	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
in	POS	O
children	POS	O
and	POS	O
efficiently	POS	O
prevented	POS	O
by	POS	O
clonazepam	POS	O
.	POS	O
A	POS	O
busulfan	POS	O
dose	POS	O
calculated	POS	O
on	POS	O
the	POS	O
basis	POS	O
of	POS	O
body	POS	O
surface	POS	O
area	POS	O
,	POS	O
resulting	POS	O
in	POS	O
higher	POS	O
doses	POS	O
in	POS	O
young	POS	O
children	POS	O
,	POS	O
was	POS	O
followed	POS	O
by	POS	O
increased	POS	O
neurotoxicity	POS	B-NP
,	POS	O
close	POS	O
to	POS	O
neurotoxicity	POS	B-NP
incidence	POS	O
observed	POS	O
in	POS	O
adults	POS	O
.	POS	O
Since	POS	O
plasma	POS	O
pharmacokinetic	POS	O
studies	POS	O
showed	POS	O
a	POS	O
faster	POS	O
busulfan	POS	O
clearance	POS	O
in	POS	O
children	POS	O
than	POS	O
in	POS	O
adults	POS	O
,	POS	O
this	POS	O
new	POS	O
dose	POS	O
may	POS	O
approximate	POS	O
more	POS	O
closely	POS	O
the	POS	O
adult	POS	O
systemic	POS	O
exposure	POS	O
obtained	POS	O
after	POS	O
the	POS	O
usual	POS	O
16	POS	O
-	POS	O
mg	POS	O
/	POS	O
kg	POS	O
total	POS	O
dose	POS	O
,	POS	O
with	POS	O
potential	POS	O
inferences	POS	O
in	POS	O
terms	POS	O
of	POS	O
anticancer	POS	O
or	POS	O
myeloablative	POS	O
effects	POS	O
.	POS	O
The	POS	O
busulfan	POS	O
dose	POS	O
in	POS	O
children	POS	O
and	POS	O
infants	POS	O
undergoing	POS	O
bone	POS	O
marrow	POS	O
transplantation	POS	O
should	POS	O
be	POS	O
reconsidered	POS	O
on	POS	O
the	POS	O
basis	POS	O
of	POS	O
pharmacokinetic	POS	O
studies	POS	O
.	POS	O
An	POS	O
unexpected	POS	O
diagnosis	POS	O
in	POS	O
a	POS	O
renal	POS	O
-	POS	O
transplant	POS	O
patient	POS	O
with	POS	O
proteinuria	POS	B-NP
treated	POS	O
with	POS	O
everolimus	POS	O
:	POS	O
AL	POS	O
amyloidosis	POS	B-NP
.	POS	O
Proteinuria	POS	B-NP
is	POS	O
an	POS	O
expected	POS	O
complication	POS	O
in	POS	O
transplant	POS	O
patients	POS	O
treated	POS	O
with	POS	O
mammalian	POS	O
target	POS	O
of	POS	O
rapamycin	POS	O
inhibitors	POS	O
(	POS	O
mTOR	POS	O
-	POS	O
i	POS	O
)	POS	O
.	POS	O
However	POS	O
,	POS	O
clinical	POS	O
suspicion	POS	O
should	POS	O
always	POS	O
be	POS	O
supported	POS	O
by	POS	O
histological	POS	O
evidence	POS	O
in	POS	O
order	POS	O
to	POS	O
investigate	POS	O
potential	POS	O
alternate	POS	O
diagnoses	POS	O
such	POS	O
as	POS	O
acute	POS	O
or	POS	O
chronic	POS	B-NP
rejection	POS	I-NP
,	POS	O
interstitial	POS	B-NP
fibrosis	POS	I-NP
and	POS	O
tubular	POS	B-NP
atrophy	POS	I-NP
,	POS	O
or	POS	O
recurrent	POS	O
or	POS	O
de	POS	O
novo	POS	O
glomerulopathy	POS	B-NP
.	POS	O
In	POS	O
this	POS	O
case	POS	O
we	POS	O
report	POS	O
the	POS	O
unexpected	POS	O
diagnosis	POS	O
of	POS	O
amyloidosis	POS	B-NP
in	POS	O
a	POS	O
renal	POS	O
-	POS	O
transplant	POS	O
patient	POS	O
with	POS	O
pre	POS	O
-	POS	O
transplant	POS	O
monoclonal	POS	O
gammapathy	POS	O
of	POS	O
undetermined	POS	O
significance	POS	O
who	POS	O
developed	POS	O
proteinuria	POS	B-NP
after	POS	O
conversion	POS	O
from	POS	O
tacrolimus	POS	O
to	POS	O
everolimus	POS	O
.	POS	O
Long	POS	O
-	POS	O
term	POS	O
oral	POS	O
galactose	POS	O
treatment	POS	O
prevents	POS	O
cognitive	POS	B-NP
deficits	POS	I-NP
in	POS	O
male	POS	O
Wistar	POS	O
rats	POS	O
treated	POS	O
intracerebroventricularly	POS	O
with	POS	O
streptozotocin	POS	O
.	POS	O
Basic	POS	O
and	POS	O
clinical	POS	O
research	POS	O
has	POS	O
demonstrated	POS	O
that	POS	O
dementia	POS	B-NP
of	POS	O
sporadic	POS	O
Alzheimer	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
(	POS	O
sAD	POS	B-NP
)	POS	O
type	POS	O
is	POS	O
associated	POS	O
with	POS	O
dysfunction	POS	O
of	POS	O
the	POS	O
insulin	POS	O
-	POS	O
receptor	POS	O
(	POS	O
IR	POS	O
)	POS	O
system	POS	O
followed	POS	O
by	POS	O
decreased	POS	O
glucose	POS	O
transport	POS	O
via	POS	O
glucose	POS	O
transporter	POS	O
GLUT4	POS	O
and	POS	O
decreased	POS	O
glucose	POS	O
metabolism	POS	O
in	POS	O
brain	POS	O
cells	POS	O
.	POS	O
An	POS	O
alternative	POS	O
source	POS	O
of	POS	O
energy	POS	O
is	POS	O
d	POS	O
-	POS	O
galactose	POS	O
(	POS	O
the	POS	O
C	POS	O
-	POS	O
4	POS	O
-	POS	O
epimer	POS	O
of	POS	O
d	POS	O
-	POS	O
glucose	POS	O
)	POS	O
which	POS	O
is	POS	O
transported	POS	O
into	POS	O
the	POS	O
brain	POS	O
by	POS	O
insulin	POS	O
-	POS	O
independent	POS	O
GLUT3	POS	O
transporter	POS	O
where	POS	O
it	POS	O
might	POS	O
be	POS	O
metabolized	POS	O
to	POS	O
glucose	POS	O
via	POS	O
the	POS	O
Leloir	POS	O
pathway	POS	O
.	POS	O
Exclusively	POS	O
parenteral	POS	O
daily	POS	O
injections	POS	O
of	POS	O
galactose	POS	O
induce	POS	O
memory	POS	O
deterioration	POS	O
in	POS	O
rodents	POS	O
and	POS	O
are	POS	O
used	POS	O
to	POS	O
generate	POS	O
animal	POS	O
aging	POS	O
model	POS	O
,	POS	O
but	POS	O
the	POS	O
effects	POS	O
of	POS	O
oral	POS	O
galactose	POS	O
treatment	POS	O
on	POS	O
cognitive	POS	O
functions	POS	O
have	POS	O
never	POS	O
been	POS	O
tested	POS	O
.	POS	O
We	POS	O
have	POS	O
investigated	POS	O
the	POS	O
effects	POS	O
of	POS	O
continuous	POS	O
daily	POS	O
oral	POS	O
galactose	POS	O
(	POS	O
200	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
)	POS	O
treatment	POS	O
on	POS	O
cognitive	POS	B-NP
deficits	POS	I-NP
in	POS	O
streptozotocin	POS	O
-	POS	O
induced	POS	O
(	POS	O
STZ	POS	O
-	POS	O
icv	POS	O
)	POS	O
rat	POS	O
model	POS	O
of	POS	O
sAD	POS	O
,	POS	O
tested	POS	O
by	POS	O
Morris	POS	O
Water	POS	O
Maze	POS	O
and	POS	O
Passive	POS	O
Avoidance	POS	O
test	POS	O
,	POS	O
respectively	POS	O
.	POS	O
One	POS	O
month	POS	O
of	POS	O
oral	POS	O
galactose	POS	O
treatment	POS	O
initiated	POS	O
immediately	POS	O
after	POS	O
the	POS	O
STZ	POS	O
-	POS	O
icv	POS	O
administration	POS	O
,	POS	O
successfully	POS	O
prevented	POS	O
development	POS	O
of	POS	O
the	POS	O
STZ	POS	O
-	POS	O
icv	POS	O
-	POS	O
induced	POS	O
cognitive	POS	B-NP
deficits	POS	I-NP
.	POS	O
Beneficial	POS	O
effect	POS	O
of	POS	O
oral	POS	O
galactose	POS	O
was	POS	O
independent	POS	O
of	POS	O
the	POS	O
rat	POS	O
age	POS	O
and	POS	O
of	POS	O
the	POS	O
galactose	POS	O
dose	POS	O
ranging	POS	O
from	POS	O
100	POS	O
to	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
.	POS	O
Additionally	POS	O
,	POS	O
oral	POS	O
galactose	POS	O
administration	POS	O
led	POS	O
to	POS	O
the	POS	O
appearance	POS	O
of	POS	O
galactose	POS	O
in	POS	O
the	POS	O
blood	POS	O
.	POS	O
The	POS	O
increase	POS	O
of	POS	O
galactose	POS	O
concentration	POS	O
in	POS	O
the	POS	O
cerebrospinal	POS	O
fluid	POS	O
was	POS	O
several	POS	O
times	POS	O
lower	POS	O
after	POS	O
oral	POS	O
than	POS	O
after	POS	O
parenteral	POS	O
administration	POS	O
of	POS	O
the	POS	O
same	POS	O
galactose	POS	O
dose	POS	O
.	POS	O
Oral	POS	O
galactose	POS	O
exposure	POS	O
might	POS	O
have	POS	O
beneficial	POS	O
effects	POS	O
on	POS	O
learning	POS	O
and	POS	O
memory	POS	O
ability	POS	O
and	POS	O
could	POS	O
be	POS	O
worth	POS	O
investigating	POS	O
for	POS	O
improvement	POS	O
of	POS	O
cognitive	POS	B-NP
deficits	POS	I-NP
associated	POS	O
with	POS	O
glucose	POS	B-NP
hypometabolism	POS	I-NP
in	POS	O
AD	POS	B-NP
.	POS	O
An	POS	O
investigation	POS	O
of	POS	O
the	POS	O
pattern	POS	O
of	POS	O
kidney	POS	B-NP
injury	POS	I-NP
in	POS	O
HIV	POS	O
-	POS	O
positive	POS	O
persons	POS	O
exposed	POS	O
to	POS	O
tenofovir	POS	O
disoproxil	POS	O
fumarate	POS	O
:	POS	O
an	POS	O
examination	POS	O
of	POS	O
a	POS	O
large	POS	O
population	POS	O
database	POS	O
(	POS	O
MHRA	POS	O
database	POS	O
)	POS	O
.	POS	O
The	POS	O
potential	POS	O
for	POS	O
tenofovir	POS	O
to	POS	O
cause	POS	O
a	POS	O
range	POS	O
of	POS	O
kidney	POS	B-NP
syndromes	POS	I-NP
has	POS	O
been	POS	O
established	POS	O
from	POS	O
mechanistic	POS	O
and	POS	O
randomised	POS	O
clinical	POS	O
trials	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
exact	POS	O
pattern	POS	O
of	POS	O
kidney	POS	O
involvement	POS	O
is	POS	O
still	POS	O
uncertain	POS	O
.	POS	O
We	POS	O
undertook	POS	O
a	POS	O
descriptive	POS	O
analysis	POS	O
of	POS	O
Yellow	POS	O
Card	POS	O
records	POS	O
of	POS	O
407	POS	O
HIV	POS	O
-	POS	O
positive	POS	O
persons	POS	O
taking	POS	O
tenofovir	POS	O
disoproxil	POS	O
fumarate	POS	O
(	POS	O
TDF	POS	O
)	POS	O
as	POS	O
part	POS	O
of	POS	O
their	POS	O
antiretroviral	POS	O
therapy	POS	O
regimen	POS	O
and	POS	O
submitted	POS	O
to	POS	O
the	POS	O
Medicines	POS	O
and	POS	O
Healthcare	POS	O
Products	POS	O
Regulatory	POS	O
Agency	POS	O
(	POS	O
MHRA	POS	O
)	POS	O
with	POS	O
suspected	POS	O
kidney	POS	O
adverse	POS	O
effects	POS	O
.	POS	O
Reports	POS	O
that	POS	O
satisfy	POS	O
defined	POS	O
criteria	POS	O
were	POS	O
classified	POS	O
as	POS	O
acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
,	POS	O
kidney	POS	B-NP
tubular	POS	I-NP
dysfunction	POS	I-NP
and	POS	O
Fanconi	POS	B-NP
syndrome	POS	I-NP
.	POS	O
Of	POS	O
the	POS	O
407	POS	O
Yellow	POS	O
Card	POS	O
records	POS	O
analysed	POS	O
,	POS	O
106	POS	O
satisfied	POS	O
criteria	POS	O
for	POS	O
TDF	POS	O
-	POS	O
related	POS	O
kidney	POS	B-NP
disease	POS	I-NP
,	POS	O
of	POS	O
which	POS	O
53	POS	O
(	POS	O
50	POS	O
%	POS	O
)	POS	O
had	POS	O
features	POS	O
of	POS	O
kidney	POS	B-NP
tubular	POS	I-NP
dysfunction	POS	I-NP
,	POS	O
35	POS	O
(	POS	O
33	POS	O
%	POS	O
)	POS	O
were	POS	O
found	POS	O
to	POS	O
have	POS	O
features	POS	O
of	POS	O
glomerular	POS	B-NP
dysfunction	POS	I-NP
and	POS	O
18	POS	O
(	POS	O
17	POS	O
%	POS	O
)	POS	O
had	POS	O
Fanconi	POS	B-NP
syndrome	POS	I-NP
.	POS	O
The	POS	O
median	POS	O
TDF	POS	O
exposure	POS	O
was	POS	O
316	POS	O
days	POS	O
(	POS	O
interquartile	POS	O
range	POS	O
120	POS	O
-	POS	O
740	POS	O
)	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
hospitalisation	POS	O
for	POS	O
TDF	POS	O
kidney	POS	O
adverse	POS	O
effects	POS	O
was	POS	O
high	POS	O
,	POS	O
particularly	POS	O
amongst	POS	O
patients	POS	O
with	POS	O
features	POS	O
of	POS	O
Fanconi	POS	B-NP
syndrome	POS	I-NP
.	POS	O
The	POS	O
pattern	POS	O
of	POS	O
kidney	POS	B-NP
syndromes	POS	I-NP
in	POS	O
this	POS	O
population	POS	O
series	POS	O
mirrors	POS	O
that	POS	O
reported	POS	O
in	POS	O
randomised	POS	O
clinical	POS	O
trials	POS	O
.	POS	O
Cessation	POS	O
of	POS	O
TDF	POS	O
was	POS	O
associated	POS	O
with	POS	O
complete	POS	O
restoration	POS	O
of	POS	O
kidney	POS	O
function	POS	O
in	POS	O
up	POS	O
half	POS	O
of	POS	O
the	POS	O
patients	POS	O
in	POS	O
this	POS	O
report	POS	O
.	POS	O
Incidence	POS	O
of	POS	O
postoperative	POS	B-NP
delirium	POS	I-NP
is	POS	O
high	POS	O
even	POS	O
in	POS	O
a	POS	O
population	POS	O
without	POS	O
known	POS	O
risk	POS	O
factors	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
Postoperative	POS	O
delirium	POS	B-NP
is	POS	O
a	POS	O
recognized	POS	O
complication	POS	O
in	POS	O
populations	POS	O
at	POS	O
risk	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
is	POS	O
to	POS	O
assess	POS	O
the	POS	O
prevalence	POS	O
of	POS	O
early	POS	O
postoperative	POS	B-NP
delirium	POS	I-NP
in	POS	O
a	POS	O
population	POS	O
without	POS	O
known	POS	O
risk	POS	O
factors	POS	O
admitted	POS	O
to	POS	O
the	POS	O
ICU	POS	O
for	POS	O
postoperative	POS	O
monitoring	POS	O
after	POS	O
elective	POS	O
major	POS	O
surgery	POS	O
.	POS	O
The	POS	O
secondary	POS	O
outcome	POS	O
investigated	POS	O
is	POS	O
to	POS	O
identify	POS	O
eventual	POS	O
independent	POS	O
risk	POS	O
factors	POS	O
among	POS	O
demographic	POS	O
data	POS	O
and	POS	O
anesthetic	POS	O
drugs	POS	O
used	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
An	POS	O
observational	POS	O
,	POS	O
prospective	POS	O
study	POS	O
was	POS	O
conducted	POS	O
on	POS	O
a	POS	O
consecutive	POS	O
cohort	POS	O
of	POS	O
patients	POS	O
admitted	POS	O
to	POS	O
our	POS	O
ICU	POS	O
within	POS	O
and	POS	O
for	POS	O
at	POS	O
least	POS	O
24	POS	O
h	POS	O
after	POS	O
major	POS	O
surgical	POS	O
procedures	POS	O
.	POS	O
Exclusion	POS	O
criteria	POS	O
were	POS	O
any	POS	O
preexisting	POS	O
predisposing	POS	O
factor	POS	O
for	POS	O
delirium	POS	B-NP
or	POS	O
other	POS	O
potentially	POS	O
confounding	POS	O
neurological	POS	B-NP
dysfunctions	POS	I-NP
.	POS	O
Patients	POS	O
were	POS	O
assessed	POS	O
daily	POS	O
using	POS	O
the	POS	O
confusion	POS	B-NP
assessment	POS	O
method	POS	O
for	POS	O
the	POS	O
ICU	POS	O
scale	POS	O
for	POS	O
3	POS	O
days	POS	O
after	POS	O
the	POS	O
surgical	POS	O
procedure	POS	O
.	POS	O
Early	POS	O
postoperative	POS	B-NP
delirium	POS	I-NP
incidence	POS	O
risk	POS	O
factors	POS	O
were	POS	O
then	POS	O
assessed	POS	O
through	POS	O
three	POS	O
different	POS	O
multiple	POS	O
regression	POS	O
models	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
According	POS	O
to	POS	O
the	POS	O
confusion	POS	B-NP
assessment	POS	O
method	POS	O
for	POS	O
the	POS	O
ICU	POS	O
scale	POS	O
,	POS	O
28	POS	O
%	POS	O
of	POS	O
patients	POS	O
were	POS	O
diagnosed	POS	O
with	POS	O
early	POS	O
postoperative	POS	B-NP
delirium	POS	I-NP
.	POS	O
The	POS	O
use	POS	O
of	POS	O
thiopentone	POS	O
was	POS	O
significantly	POS	O
associated	POS	O
with	POS	O
an	POS	O
eight	POS	O
-	POS	O
fold	POS	O
-	POS	O
higher	POS	O
risk	POS	O
for	POS	O
delirium	POS	B-NP
compared	POS	O
to	POS	O
propofol	POS	O
(	POS	O
57	POS	O
.	POS	O
1	POS	O
%	POS	O
vs	POS	O
.	POS	O
7	POS	O
.	POS	O
1	POS	O
%	POS	O
,	POS	O
RR	POS	O
=	POS	O
8	POS	O
.	POS	O
0	POS	O
,	POS	O
X2	POS	O
=	POS	O
4	POS	O
.	POS	O
256	POS	O
;	POS	O
df	POS	O
=	POS	O
1	POS	O
;	POS	O
0	POS	O
.	POS	O
05	POS	O
<	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
02	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
In	POS	O
this	POS	O
study	POS	O
early	POS	O
postoperative	POS	B-NP
delirium	POS	I-NP
was	POS	O
found	POS	O
to	POS	O
be	POS	O
a	POS	O
very	POS	O
common	POS	O
complication	POS	O
after	POS	O
major	POS	O
surgery	POS	O
,	POS	O
even	POS	O
in	POS	O
a	POS	O
population	POS	O
without	POS	O
known	POS	O
risk	POS	O
factors	POS	O
.	POS	O
Thiopentone	POS	O
was	POS	O
independently	POS	O
associated	POS	O
with	POS	O
an	POS	O
increase	POS	O
in	POS	O
its	POS	O
relative	POS	O
risk	POS	O
.	POS	O
A	POS	O
single	POS	O
neurotoxic	POS	B-NP
dose	POS	O
of	POS	O
methamphetamine	POS	O
induces	POS	O
a	POS	O
long	POS	O
-	POS	O
lasting	POS	O
depressive	POS	O
-	POS	O
like	POS	O
behaviour	POS	O
in	POS	O
mice	POS	O
.	POS	O
Methamphetamine	POS	O
(	POS	O
METH	POS	O
)	POS	O
triggers	POS	O
a	POS	O
disruption	POS	O
of	POS	O
the	POS	O
monoaminergic	POS	O
system	POS	O
and	POS	O
METH	POS	O
abuse	POS	O
leads	POS	O
to	POS	O
negative	POS	O
emotional	POS	O
states	POS	O
including	POS	O
depressive	POS	B-NP
symptoms	POS	I-NP
during	POS	O
drug	POS	O
withdrawal	POS	O
.	POS	O
However	POS	O
,	POS	O
it	POS	O
is	POS	O
currently	POS	O
unknown	POS	O
if	POS	O
the	POS	O
acute	POS	O
toxic	POS	O
dosage	POS	O
of	POS	O
METH	POS	O
also	POS	O
causes	POS	O
a	POS	O
long	POS	O
-	POS	O
lasting	POS	O
depressive	POS	B-NP
phenotype	POS	O
and	POS	O
persistent	POS	O
monoaminergic	POS	B-NP
deficits	POS	I-NP
.	POS	O
Thus	POS	O
,	POS	O
we	POS	O
now	POS	O
assessed	POS	O
the	POS	O
depressive	POS	O
-	POS	O
like	POS	O
behaviour	POS	O
in	POS	O
mice	POS	O
at	POS	O
early	POS	O
and	POS	O
long	POS	O
-	POS	O
term	POS	O
periods	POS	O
following	POS	O
a	POS	O
single	POS	O
high	POS	O
METH	POS	O
dose	POS	O
(	POS	O
30	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
.	POS	O
METH	POS	O
did	POS	O
not	POS	O
alter	POS	O
the	POS	O
motor	POS	O
function	POS	O
and	POS	O
procedural	POS	O
memory	POS	O
of	POS	O
mice	POS	O
as	POS	O
assessed	POS	O
by	POS	O
swimming	POS	O
speed	POS	O
and	POS	O
escape	POS	O
latency	POS	O
to	POS	O
find	POS	O
the	POS	O
platform	POS	O
in	POS	O
a	POS	O
cued	POS	O
version	POS	O
of	POS	O
the	POS	O
water	POS	O
maze	POS	O
task	POS	O
.	POS	O
However	POS	O
,	POS	O
METH	POS	O
significantly	POS	O
increased	POS	O
the	POS	O
immobility	POS	O
time	POS	O
in	POS	O
the	POS	O
tail	POS	O
suspension	POS	O
test	POS	O
at	POS	O
3	POS	O
and	POS	O
49	POS	O
days	POS	O
post	POS	O
-	POS	O
administration	POS	O
.	POS	O
This	POS	O
depressive	POS	O
-	POS	O
like	POS	O
profile	POS	O
induced	POS	O
by	POS	O
METH	POS	O
was	POS	O
accompanied	POS	O
by	POS	O
a	POS	O
marked	POS	O
depletion	POS	O
of	POS	O
frontostriatal	POS	O
dopaminergic	POS	O
and	POS	O
serotonergic	POS	O
neurotransmission	POS	O
,	POS	O
indicated	POS	O
by	POS	O
a	POS	O
reduction	POS	O
in	POS	O
the	POS	O
levels	POS	O
of	POS	O
dopamine	POS	O
,	POS	O
DOPAC	POS	O
and	POS	O
HVA	POS	O
,	POS	O
tyrosine	POS	O
hydroxylase	POS	O
and	POS	O
serotonin	POS	O
,	POS	O
observed	POS	O
at	POS	O
both	POS	O
3	POS	O
and	POS	O
49	POS	O
days	POS	O
post	POS	O
-	POS	O
administration	POS	O
.	POS	O
In	POS	O
parallel	POS	O
,	POS	O
another	POS	O
neurochemical	POS	O
feature	POS	O
of	POS	O
depression	POS	B-NP
-	POS	O
-	POS	O
astroglial	POS	O
dysfunction	POS	O
-	POS	O
-	POS	O
was	POS	O
unaffected	POS	O
in	POS	O
the	POS	O
cortex	POS	O
and	POS	O
the	POS	O
striatal	POS	O
levels	POS	O
of	POS	O
the	POS	O
astrocytic	POS	O
protein	POS	O
marker	POS	O
,	POS	O
glial	POS	O
fibrillary	POS	O
acidic	POS	O
protein	POS	O
,	POS	O
were	POS	O
only	POS	O
transiently	POS	O
increased	POS	O
at	POS	O
3	POS	O
days	POS	O
.	POS	O
These	POS	O
findings	POS	O
demonstrate	POS	O
for	POS	O
the	POS	O
first	POS	O
time	POS	O
that	POS	O
a	POS	O
single	POS	O
high	POS	O
dose	POS	O
of	POS	O
METH	POS	O
induces	POS	O
long	POS	O
-	POS	O
lasting	POS	O
depressive	POS	O
-	POS	O
like	POS	O
behaviour	POS	O
in	POS	O
mice	POS	O
associated	POS	O
with	POS	O
a	POS	O
persistent	POS	O
disruption	POS	O
of	POS	O
frontostriatal	POS	O
dopaminergic	POS	O
and	POS	O
serotonergic	POS	O
homoeostasis	POS	O
.	POS	O
Linezolid	POS	O
-	POS	O
induced	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
.	POS	O
Many	POS	O
systemic	POS	O
antimicrobials	POS	O
have	POS	O
been	POS	O
implicated	POS	O
to	POS	O
cause	POS	O
ocular	POS	O
adverse	POS	O
effects	POS	O
.	POS	O
This	POS	O
is	POS	O
especially	POS	O
relevant	POS	O
in	POS	O
multidrug	POS	O
therapy	POS	O
where	POS	O
more	POS	O
than	POS	O
one	POS	O
drug	POS	O
can	POS	O
cause	POS	O
a	POS	O
similar	POS	O
ocular	POS	O
adverse	POS	O
effect	POS	O
.	POS	O
We	POS	O
describe	POS	O
a	POS	O
case	POS	O
of	POS	O
progressive	POS	O
loss	POS	O
of	POS	O
vision	POS	O
associated	POS	O
with	POS	O
linezolid	POS	O
therapy	POS	O
.	POS	O
A	POS	O
45	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
patient	POS	O
who	POS	O
was	POS	O
on	POS	O
treatment	POS	O
with	POS	O
multiple	POS	O
second	POS	O
-	POS	O
line	POS	O
anti	POS	O
-	POS	O
tuberculous	POS	O
drugs	POS	O
including	POS	O
linezolid	POS	O
and	POS	O
ethambutol	POS	O
for	POS	O
extensively	POS	O
drug	POS	O
-	POS	O
resistant	POS	O
tuberculosis	POS	B-NP
(	POS	O
XDR	POS	O
-	POS	O
TB	POS	O
)	POS	O
presented	POS	O
to	POS	O
us	POS	O
with	POS	O
painless	POS	O
progressive	POS	O
loss	POS	O
of	POS	O
vision	POS	O
in	POS	O
both	POS	O
eyes	POS	O
.	POS	O
Color	POS	B-NP
vision	POS	I-NP
was	POS	O
defective	POS	O
and	POS	O
fundus	POS	O
examination	POS	O
revealed	POS	O
optic	POS	B-NP
disc	POS	I-NP
edema	POS	I-NP
in	POS	O
both	POS	O
eyes	POS	O
.	POS	O
Ethambutol	POS	O
-	POS	O
induced	POS	O
toxic	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
was	POS	O
suspected	POS	O
and	POS	O
tablet	POS	O
ethambutol	POS	O
was	POS	O
withdrawn	POS	O
.	POS	O
Deterioration	POS	B-NP
of	POS	I-NP
vision	POS	I-NP
occurred	POS	O
despite	POS	O
withdrawal	POS	O
of	POS	O
ethambutol	POS	O
.	POS	O
Discontinuation	POS	O
of	POS	O
linezolid	POS	O
resulted	POS	O
in	POS	O
marked	POS	O
improvement	POS	O
of	POS	O
vision	POS	O
.	POS	O
Our	POS	O
report	POS	O
emphasizes	POS	O
the	POS	O
need	POS	O
for	POS	O
monitoring	POS	O
of	POS	O
visual	POS	O
function	POS	O
in	POS	O
patients	POS	O
on	POS	O
long	POS	O
-	POS	O
term	POS	O
linezolid	POS	O
treatment	POS	O
.	POS	O
Resuscitation	POS	O
with	POS	O
lipid	POS	O
,	POS	O
epinephrine	POS	O
,	POS	O
or	POS	O
both	POS	O
in	POS	O
levobupivacaine	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
in	POS	O
newborn	POS	O
piglets	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
The	POS	O
optimal	POS	O
dosing	POS	O
regimens	POS	O
of	POS	O
lipid	POS	O
emulsion	POS	O
,	POS	O
epinephrine	POS	O
,	POS	O
or	POS	O
both	POS	O
are	POS	O
not	POS	O
yet	POS	O
determined	POS	O
in	POS	O
neonates	POS	O
in	POS	O
cases	POS	O
of	POS	O
local	POS	O
anaesthetic	POS	O
systemic	POS	B-NP
toxicity	POS	I-NP
(	POS	O
LAST	POS	O
)	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Newborn	POS	O
piglets	POS	O
received	POS	O
levobupivacaine	POS	O
until	POS	O
cardiovascular	POS	B-NP
collapse	POS	I-NP
occurred	POS	O
.	POS	O
Standard	POS	O
cardiopulmonary	POS	O
resuscitation	POS	O
was	POS	O
started	POS	O
and	POS	O
electrocardiogram	POS	O
(	POS	O
ECG	POS	O
)	POS	O
was	POS	O
monitored	POS	O
for	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
,	POS	O
fibrillation	POS	B-NP
,	POS	O
or	POS	O
QRS	POS	B-NP
prolongation	POS	I-NP
.	POS	O
Piglets	POS	O
were	POS	O
then	POS	O
randomly	POS	O
allocated	POS	O
to	POS	O
four	POS	O
groups	POS	O
:	POS	O
control	POS	O
(	POS	O
saline	POS	O
)	POS	O
,	POS	O
Intralipid	POS	O
(	POS	O
)	POS	O
alone	POS	O
,	POS	O
epinephrine	POS	O
alone	POS	O
,	POS	O
or	POS	O
a	POS	O
combination	POS	O
of	POS	O
Intralipd	POS	O
plus	POS	O
epinephrine	POS	O
.	POS	O
Resuscitation	POS	O
continued	POS	O
for	POS	O
30	POS	O
min	POS	O
or	POS	O
until	POS	O
there	POS	O
was	POS	O
a	POS	O
return	POS	O
of	POS	O
spontaneous	POS	O
circulation	POS	O
(	POS	O
ROSC	POS	O
)	POS	O
accompanied	POS	O
by	POS	O
a	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
at	POS	O
or	POS	O
superior	POS	O
to	POS	O
the	POS	O
baseline	POS	O
pressure	POS	O
and	POS	O
normal	POS	O
sinus	POS	O
rhythm	POS	O
for	POS	O
a	POS	O
period	POS	O
of	POS	O
30	POS	O
min	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
ROSC	POS	O
was	POS	O
achieved	POS	O
in	POS	O
only	POS	O
one	POS	O
of	POS	O
the	POS	O
control	POS	O
piglets	POS	O
compared	POS	O
with	POS	O
most	POS	O
of	POS	O
the	POS	O
treated	POS	O
piglets	POS	O
.	POS	O
Mortality	POS	O
was	POS	O
not	POS	O
significantly	POS	O
different	POS	O
between	POS	O
the	POS	O
three	POS	O
treatment	POS	O
groups	POS	O
,	POS	O
but	POS	O
was	POS	O
significantly	POS	O
lower	POS	O
in	POS	O
all	POS	O
the	POS	O
treatment	POS	O
groups	POS	O
compared	POS	O
with	POS	O
control	POS	O
.	POS	O
The	POS	O
number	POS	O
of	POS	O
ECG	POS	B-NP
abnormalities	POS	I-NP
was	POS	O
zero	POS	O
in	POS	O
the	POS	O
Intralipid	POS	O
only	POS	O
group	POS	O
,	POS	O
but	POS	O
14	POS	O
and	POS	O
17	POS	O
,	POS	O
respectively	POS	O
,	POS	O
in	POS	O
the	POS	O
epinephrine	POS	O
and	POS	O
epinephrine	POS	O
plus	POS	O
lipid	POS	O
groups	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Lipid	POS	O
emulsion	POS	O
with	POS	O
or	POS	O
without	POS	O
epinephrine	POS	O
,	POS	O
or	POS	O
epinephrine	POS	O
alone	POS	O
were	POS	O
equally	POS	O
effective	POS	O
in	POS	O
achieving	POS	O
a	POS	O
return	POS	O
to	POS	O
spontaneous	POS	O
circulation	POS	O
in	POS	O
this	POS	O
model	POS	O
of	POS	O
LAST	POS	O
.	POS	O
Epinephrine	POS	O
alone	POS	O
or	POS	O
in	POS	O
combination	POS	O
with	POS	O
lipid	POS	O
was	POS	O
associated	POS	O
with	POS	O
an	POS	O
increased	POS	O
number	POS	O
of	POS	O
ECG	POS	B-NP
abnormalities	POS	I-NP
compared	POS	O
with	POS	O
lipid	POS	O
emulsion	POS	O
alone	POS	O
.	POS	O
Incidence	POS	O
of	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
type	POS	O
II	POS	O
and	POS	O
postoperative	POS	O
recovery	POS	O
of	POS	O
platelet	POS	O
count	POS	O
in	POS	O
liver	POS	O
graft	POS	O
recipients	POS	O
:	POS	O
a	POS	O
retrospective	POS	O
cohort	POS	O
analysis	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Thrombocytopenia	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
end	POS	O
-	POS	O
stage	POS	O
liver	POS	B-NP
disease	POS	I-NP
is	POS	O
a	POS	O
common	POS	O
disorder	POS	O
caused	POS	O
mainly	POS	O
by	POS	O
portal	POS	O
hypertension	POS	B-NP
,	POS	O
low	POS	O
levels	POS	O
of	POS	O
thrombopoetin	POS	O
,	POS	O
and	POS	O
endotoxemia	POS	B-NP
.	POS	O
The	POS	O
impact	POS	O
of	POS	O
immune	POS	O
-	POS	O
mediated	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
type	POS	O
II	POS	O
(	POS	O
HIT	POS	B-NP
type	POS	O
II	POS	O
)	POS	O
as	POS	O
a	POS	O
cause	POS	O
of	POS	O
thrombocytopenia	POS	B-NP
after	POS	O
liver	POS	O
transplantation	POS	O
is	POS	O
not	POS	O
yet	POS	O
understood	POS	O
,	POS	O
with	POS	O
few	POS	O
literature	POS	O
citations	POS	O
reporting	POS	O
contradictory	POS	O
results	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
our	POS	O
study	POS	O
was	POS	O
to	POS	O
demonstrate	POS	O
the	POS	O
perioperative	POS	O
course	POS	O
of	POS	O
thrombocytopenia	POS	B-NP
after	POS	O
liver	POS	O
transplantation	POS	O
and	POS	O
determine	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
clinical	POS	O
HIT	POS	B-NP
type	POS	O
II	POS	O
.	POS	O
METHOD	POS	O
:	POS	O
We	POS	O
retrospectively	POS	O
evaluated	POS	O
the	POS	O
medical	POS	O
records	POS	O
of	POS	O
205	POS	O
consecutive	POS	O
adult	POS	O
patients	POS	O
who	POS	O
underwent	POS	O
full	POS	O
-	POS	O
size	POS	O
liver	POS	O
transplantation	POS	O
between	POS	O
January	POS	O
2006	POS	O
and	POS	O
December	POS	O
2010	POS	O
due	POS	O
to	POS	O
end	POS	O
-	POS	O
stage	POS	O
or	POS	O
malignant	POS	B-NP
liver	POS	I-NP
disease	POS	I-NP
.	POS	O
Preoperative	POS	O
platelet	POS	O
count	POS	O
,	POS	O
postoperative	POS	O
course	POS	O
of	POS	O
platelets	POS	O
,	POS	O
and	POS	O
clinical	POS	O
signs	POS	O
of	POS	O
HIT	POS	B-NP
type	POS	O
II	POS	O
were	POS	O
analyzed	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
155	POS	O
(	POS	O
75	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
of	POS	O
205	POS	O
patients	POS	O
had	POS	O
thrombocytopenia	POS	B-NP
before	POS	O
transplantation	POS	O
,	POS	O
significantly	POS	O
influenced	POS	O
by	POS	O
Model	POS	O
of	POS	O
End	POS	O
-	POS	O
Stage	POS	O
Liver	POS	O
Disease	POS	O
score	POS	O
and	POS	O
liver	POS	B-NP
cirrhosis	POS	I-NP
.	POS	O
The	POS	O
platelet	POS	O
count	POS	O
exceeded	POS	O
100	POS	O
,	POS	O
000	POS	O
/	POS	O
uL	POS	O
in	POS	O
most	POS	O
of	POS	O
the	POS	O
patients	POS	O
(	POS	O
n	POS	O
=	POS	O
193	POS	O
)	POS	O
at	POS	O
a	POS	O
medium	POS	O
of	POS	O
7	POS	O
d	POS	O
.	POS	O
Regarding	POS	O
HIT	POS	B-NP
II	POS	O
,	POS	O
there	POS	O
were	POS	O
four	POS	O
(	POS	O
1	POS	O
.	POS	O
95	POS	O
%	POS	O
)	POS	O
patients	POS	O
with	POS	O
a	POS	O
background	POS	O
of	POS	O
HIT	POS	B-NP
type	POS	O
II	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
incidence	POS	O
of	POS	O
HIT	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
end	POS	O
-	POS	O
stage	POS	O
hepatic	POS	B-NP
failure	POS	I-NP
is	POS	O
,	POS	O
with	POS	O
about	POS	O
1	POS	O
.	POS	O
95	POS	O
%	POS	O
,	POS	O
rare	POS	O
.	POS	O
For	POS	O
further	POS	O
reduction	POS	O
of	POS	O
HIT	POS	B-NP
type	POS	O
II	POS	O
,	POS	O
the	POS	O
use	POS	O
of	POS	O
intravenous	POS	O
heparin	POS	O
should	POS	O
be	POS	O
avoided	POS	O
and	POS	O
the	POS	O
prophylactic	POS	O
anticoagulation	POS	O
should	POS	O
be	POS	O
performed	POS	O
with	POS	O
low	POS	O
-	POS	O
molecular	POS	O
-	POS	O
weight	POS	O
heparin	POS	O
after	POS	O
normalization	POS	O
of	POS	O
platelet	POS	O
count	POS	O
.	POS	O
Takotsubo	POS	B-NP
syndrome	POS	I-NP
(	POS	O
or	POS	O
apical	POS	B-NP
ballooning	POS	I-NP
syndrome	POS	I-NP
)	POS	O
secondary	POS	O
to	POS	O
Zolmitriptan	POS	O
.	POS	O
Takotsubo	POS	B-NP
syndrome	POS	I-NP
(	POS	O
TS	POS	B-NP
)	POS	O
,	POS	O
also	POS	O
known	POS	O
as	POS	O
broken	POS	O
heart	POS	B-NP
syndrome	POS	I-NP
,	POS	O
is	POS	O
characterized	POS	O
by	POS	O
left	POS	B-NP
ventricle	POS	I-NP
apical	POS	I-NP
ballooning	POS	I-NP
with	POS	O
elevated	POS	O
cardiac	POS	O
biomarkers	POS	O
and	POS	O
electrocardiographic	POS	O
changes	POS	O
suggestive	POS	O
of	POS	O
an	POS	O
acute	POS	O
coronary	POS	B-NP
syndrome	POS	I-NP
(	POS	O
ie	POS	O
,	POS	O
ST	POS	B-NP
-	POS	I-NP
segment	POS	I-NP
elevation	POS	I-NP
,	POS	O
T	POS	O
wave	POS	O
inversions	POS	O
,	POS	O
and	POS	O
pathologic	POS	O
Q	POS	O
waves	POS	O
)	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
54	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
medical	POS	O
history	POS	O
of	POS	O
mitral	POS	B-NP
valve	POS	I-NP
prolapse	POS	I-NP
and	POS	O
migraines	POS	B-NP
,	POS	O
who	POS	O
was	POS	O
admitted	POS	O
to	POS	O
the	POS	O
hospital	POS	O
for	POS	O
substernal	POS	B-NP
chest	POS	I-NP
pain	POS	I-NP
and	POS	O
electrocardiogram	POS	O
demonstrated	POS	O
1	POS	O
/	POS	O
2	POS	O
mm	POS	O
ST	POS	O
-	POS	O
segment	POS	O
elevation	POS	O
in	POS	O
leads	POS	O
II	POS	O
,	POS	O
III	POS	O
,	POS	O
aVF	POS	O
,	POS	O
V5	POS	O
,	POS	O
and	POS	O
V6	POS	O
and	POS	O
positive	POS	O
troponin	POS	O
I	POS	O
.	POS	O
Emergent	POS	O
coronary	POS	O
angiogram	POS	O
revealed	POS	O
normal	POS	O
coronary	POS	O
arteries	POS	O
with	POS	O
moderately	POS	O
reduced	POS	O
left	POS	O
ventricular	POS	O
ejection	POS	O
fraction	POS	O
with	POS	O
wall	POS	O
motion	POS	O
abnormalities	POS	O
consistent	POS	O
with	POS	O
TS	POS	B-NP
.	POS	O
Detailed	POS	O
history	POS	O
obtained	POS	O
retrospectively	POS	O
revealed	POS	O
that	POS	O
the	POS	O
patient	POS	O
took	POS	O
zolmitriptan	POS	O
sparingly	POS	O
only	POS	O
when	POS	O
she	POS	O
had	POS	O
migraines	POS	B-NP
.	POS	O
But	POS	O
before	POS	O
this	POS	O
event	POS	O
,	POS	O
she	POS	O
was	POS	O
taking	POS	O
zolmitriptan	POS	O
2	POS	O
-	POS	O
3	POS	O
times	POS	O
daily	POS	O
for	POS	O
several	POS	O
days	POS	O
because	POS	O
of	POS	O
a	POS	O
persistent	POS	O
migraine	POS	B-NP
headache	POS	I-NP
.	POS	O
She	POS	O
otherwise	POS	O
reported	POS	O
that	POS	O
she	POS	O
is	POS	O
quite	POS	O
active	POS	O
,	POS	O
rides	POS	O
horses	POS	O
,	POS	O
and	POS	O
does	POS	O
show	POS	O
jumping	POS	O
without	POS	O
any	POS	O
limitations	POS	O
in	POS	O
her	POS	O
physical	POS	O
activity	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
evidence	POS	O
of	POS	O
any	POS	O
recent	POS	O
stress	POS	O
or	POS	O
status	POS	B-NP
migrainosus	POS	I-NP
.	POS	O
Extensive	POS	O
literature	POS	O
search	POS	O
revealed	POS	O
multiple	POS	O
cases	POS	O
of	POS	O
coronary	POS	B-NP
artery	POS	I-NP
vasospasm	POS	I-NP
secondary	POS	O
to	POS	O
zolmitriptan	POS	O
,	POS	O
but	POS	O
none	POS	O
of	POS	O
the	POS	O
cases	POS	O
were	POS	O
associated	POS	O
with	POS	O
TS	POS	B-NP
.	POS	O
Depression	POS	B-NP
,	POS	O
impulsiveness	POS	B-NP
,	POS	O
sleep	POS	O
,	POS	O
and	POS	O
memory	POS	O
in	POS	O
past	POS	O
and	POS	O
present	POS	O
polydrug	POS	O
users	POS	O
of	POS	O
3	POS	O
,	POS	O
4	POS	O
-	POS	O
methylenedioxymethamphetamine	POS	O
(	POS	O
MDMA	POS	O
,	POS	O
ecstasy	POS	O
)	POS	O
.	POS	O
RATIONALE	POS	O
:	POS	O
Ecstasy	POS	O
(	POS	O
3	POS	O
,	POS	O
4	POS	O
-	POS	O
methylenedioxymethamphetamine	POS	O
,	POS	O
MDMA	POS	O
)	POS	O
is	POS	O
a	POS	O
worldwide	POS	O
recreational	POS	O
drug	POS	O
of	POS	O
abuse	POS	O
.	POS	O
Unfortunately	POS	O
,	POS	O
the	POS	O
results	POS	O
from	POS	O
human	POS	O
research	POS	O
investigating	POS	O
its	POS	O
psychological	POS	O
effects	POS	O
have	POS	O
been	POS	O
inconsistent	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
The	POS	O
present	POS	O
study	POS	O
aimed	POS	O
to	POS	O
be	POS	O
the	POS	O
largest	POS	O
to	POS	O
date	POS	O
in	POS	O
sample	POS	O
size	POS	O
and	POS	O
5HT	POS	O
-	POS	O
related	POS	O
behaviors	POS	O
;	POS	O
the	POS	O
first	POS	O
to	POS	O
compare	POS	O
present	POS	O
ecstasy	POS	O
users	POS	O
with	POS	O
past	POS	O
users	POS	O
after	POS	O
an	POS	O
abstinence	POS	O
of	POS	O
4	POS	O
or	POS	O
more	POS	O
years	POS	O
,	POS	O
and	POS	O
the	POS	O
first	POS	O
to	POS	O
include	POS	O
robust	POS	O
controls	POS	O
for	POS	O
other	POS	O
recreational	POS	O
substances	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
sample	POS	O
of	POS	O
997	POS	O
participants	POS	O
(	POS	O
52	POS	O
%	POS	O
male	POS	O
)	POS	O
was	POS	O
recruited	POS	O
to	POS	O
four	POS	O
control	POS	O
groups	POS	O
(	POS	O
non	POS	O
-	POS	O
drug	POS	O
(	POS	O
ND	POS	O
)	POS	O
,	POS	O
alcohol	POS	O
/	POS	O
nicotine	POS	O
(	POS	O
AN	POS	O
)	POS	O
,	POS	O
cannabis	POS	O
/	POS	O
alcohol	POS	O
/	POS	O
nicotine	POS	O
(	POS	O
CAN	POS	O
)	POS	O
,	POS	O
non	POS	B-NP
-	POS	I-NP
ecstasy	POS	I-NP
polydrug	POS	I-NP
(	POS	O
PD	POS	B-NP
)	POS	O
)	POS	O
,	POS	O
and	POS	O
two	POS	O
ecstasy	POS	O
polydrug	POS	O
groups	POS	O
(	POS	O
present	POS	O
(	POS	O
MDMA	POS	O
)	POS	O
and	POS	O
past	POS	O
users	POS	O
(	POS	O
EX	POS	O
-	POS	O
MDMA	POS	O
)	POS	O
.	POS	O
Participants	POS	O
completed	POS	O
a	POS	O
drug	POS	O
history	POS	O
questionnaire	POS	O
,	POS	O
Beck	POS	O
Depression	POS	O
Inventory	POS	O
,	POS	O
Barratt	POS	O
Impulsiveness	POS	O
Scale	POS	O
,	POS	O
Pittsburgh	POS	O
Sleep	POS	O
Quality	POS	O
Index	POS	O
,	POS	O
and	POS	O
Wechsler	POS	O
Memory	POS	O
Scale	POS	O
-	POS	O
Revised	POS	O
which	POS	O
,	POS	O
in	POS	O
total	POS	O
,	POS	O
provided	POS	O
13	POS	O
psychometric	POS	O
measures	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
While	POS	O
the	POS	O
CAN	POS	O
and	POS	O
PD	POS	B-NP
groups	POS	O
tended	POS	O
to	POS	O
record	POS	O
greater	POS	O
deficits	POS	O
than	POS	O
the	POS	O
non	POS	O
-	POS	O
drug	POS	O
controls	POS	O
,	POS	O
the	POS	O
MDMA	POS	O
and	POS	O
EX	POS	O
-	POS	O
MDMA	POS	O
groups	POS	O
recorded	POS	O
greater	POS	O
deficits	POS	O
than	POS	O
all	POS	O
the	POS	O
control	POS	O
groups	POS	O
on	POS	O
ten	POS	O
of	POS	O
the	POS	O
13	POS	O
psychometric	POS	O
measures	POS	O
.	POS	O
Strikingly	POS	O
,	POS	O
despite	POS	O
prolonged	POS	O
abstinence	POS	O
(	POS	O
mean	POS	O
,	POS	O
4	POS	O
.	POS	O
98	POS	O
;	POS	O
range	POS	O
,	POS	O
4	POS	O
-	POS	O
9	POS	O
years	POS	O
)	POS	O
,	POS	O
past	POS	O
ecstasy	POS	O
users	POS	O
showed	POS	O
few	POS	O
signs	POS	O
of	POS	O
recovery	POS	O
.	POS	O
Compared	POS	O
with	POS	O
present	POS	O
ecstasy	POS	O
users	POS	O
,	POS	O
the	POS	O
past	POS	O
users	POS	O
showed	POS	O
no	POS	O
change	POS	O
for	POS	O
ten	POS	O
measures	POS	O
,	POS	O
increased	POS	O
impairment	POS	O
for	POS	O
two	POS	O
measures	POS	O
,	POS	O
and	POS	O
improvement	POS	O
on	POS	O
just	POS	O
one	POS	O
measure	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Given	POS	O
this	POS	O
record	POS	O
of	POS	O
impaired	POS	B-NP
memory	POS	I-NP
and	POS	O
clinically	POS	O
significant	POS	O
levels	POS	O
of	POS	O
depression	POS	B-NP
,	POS	O
impulsiveness	POS	B-NP
,	POS	O
and	POS	O
sleep	POS	B-NP
disturbance	POS	I-NP
,	POS	O
the	POS	O
prognosis	POS	O
for	POS	O
the	POS	O
current	POS	O
generation	POS	O
of	POS	O
ecstasy	POS	O
users	POS	O
is	POS	O
a	POS	O
major	POS	O
cause	POS	O
for	POS	O
concern	POS	O
.	POS	O
Association	POS	O
of	POS	O
common	POS	O
genetic	POS	O
variants	POS	O
of	POS	O
HOMER1	POS	O
gene	POS	O
with	POS	O
levodopa	POS	O
adverse	POS	O
effects	POS	O
in	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
patients	POS	O
.	POS	O
Levodopa	POS	B-NP
is	POS	O
the	POS	O
most	POS	O
effective	POS	O
symptomatic	POS	O
therapy	POS	O
for	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
,	POS	O
but	POS	O
its	POS	O
chronic	POS	O
use	POS	O
could	POS	O
lead	POS	O
to	POS	O
chronic	POS	O
adverse	POS	O
outcomes	POS	O
,	POS	O
such	POS	O
as	POS	O
motor	POS	O
fluctuations	POS	O
,	POS	O
dyskinesia	POS	B-NP
and	POS	O
visual	POS	B-NP
hallucinations	POS	I-NP
.	POS	O
HOMER1	POS	O
is	POS	O
a	POS	O
protein	POS	O
with	POS	O
pivotal	POS	O
function	POS	O
in	POS	O
glutamate	POS	O
transmission	POS	O
,	POS	O
which	POS	O
has	POS	O
been	POS	O
related	POS	O
to	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
these	POS	O
complications	POS	O
.	POS	O
This	POS	O
study	POS	O
investigates	POS	O
whether	POS	O
polymorphisms	POS	O
in	POS	O
the	POS	O
HOMER1	POS	O
gene	POS	O
promoter	POS	O
region	POS	O
are	POS	O
associated	POS	O
with	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
the	POS	O
chronic	POS	O
complications	POS	O
of	POS	O
levodopa	POS	O
therapy	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
205	POS	O
patients	POS	O
with	POS	O
idiopathic	POS	B-NP
Parkinson	POS	I-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
were	POS	O
investigated	POS	O
.	POS	O
Patients	POS	O
were	POS	O
genotyped	POS	O
for	POS	O
rs4704559	POS	O
,	POS	O
rs10942891	POS	O
and	POS	O
rs4704560	POS	O
by	POS	O
allelic	POS	O
discrimination	POS	O
with	POS	O
Taqman	POS	O
assays	POS	O
.	POS	O
The	POS	O
rs4704559	POS	O
G	POS	O
allele	POS	O
was	POS	O
associated	POS	O
with	POS	O
a	POS	O
lower	POS	O
prevalence	POS	O
of	POS	O
dyskinesia	POS	B-NP
(	POS	O
prevalence	POS	O
ratio	POS	O
(	POS	O
PR	POS	O
)	POS	O
=	POS	O
0	POS	O
.	POS	O
615	POS	O
,	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
(	POS	O
CI	POS	O
)	POS	O
0	POS	O
.	POS	O
426	POS	O
-	POS	O
0	POS	O
.	POS	O
887	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
009	POS	O
)	POS	O
and	POS	O
visual	POS	B-NP
hallucinations	POS	I-NP
(	POS	O
PR	POS	O
=	POS	O
0	POS	O
.	POS	O
515	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
0	POS	O
.	POS	O
295	POS	O
-	POS	O
0	POS	O
.	POS	O
899	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
020	POS	O
)	POS	O
.	POS	O
Our	POS	O
data	POS	O
suggest	POS	O
that	POS	O
HOMER1	POS	O
rs4704559	POS	O
G	POS	O
allele	POS	O
has	POS	O
a	POS	O
protective	POS	O
role	POS	O
for	POS	O
the	POS	O
development	POS	O
of	POS	O
levodopa	POS	O
adverse	POS	O
effects	POS	O
.	POS	O
Crocin	POS	O
improves	POS	O
lipid	POS	O
dysregulation	POS	O
in	POS	O
subacute	POS	O
diazinon	POS	O
exposure	POS	O
through	POS	O
ERK1	POS	O
/	POS	O
2	POS	O
pathway	POS	O
in	POS	O
rat	POS	O
liver	POS	O
.	POS	O
INTRODUCTION	POS	O
:	POS	O
Diazinon	POS	O
Yis	POS	O
one	POS	O
of	POS	O
the	POS	O
most	POS	O
broadly	POS	O
used	POS	O
organophosphorus	POS	O
insecticides	POS	O
in	POS	O
agriculture	POS	O
.	POS	O
It	POS	O
has	POS	O
been	POS	O
shown	POS	O
that	POS	O
exposure	POS	O
to	POS	O
diazinon	POS	O
may	POS	O
interfere	POS	O
with	POS	O
lipid	POS	O
metabolism	POS	O
.	POS	O
Moreover	POS	O
,	POS	O
the	POS	O
hypolipidemic	POS	O
effect	POS	O
of	POS	O
crocin	POS	O
has	POS	O
been	POS	O
established	POS	O
.	POS	O
Earlier	POS	O
studies	POS	O
revealed	POS	O
the	POS	O
major	POS	O
role	POS	O
of	POS	O
Extracellular	POS	O
signal	POS	O
-	POS	O
regulated	POS	O
kinase	POS	O
(	POS	O
ERK	POS	O
)	POS	O
pathways	POS	O
in	POS	O
low	POS	O
-	POS	O
density	POS	O
lipoprotein	POS	O
receptor	POS	O
(	POS	O
LDLr	POS	O
)	POS	O
expression	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
evaluate	POS	O
changes	POS	O
in	POS	O
the	POS	O
regulation	POS	O
of	POS	O
lipid	POS	O
metabolism	POS	O
,	POS	O
ERK	POS	O
and	POS	O
LDLr	POS	O
expression	POS	O
in	POS	O
the	POS	O
liver	POS	O
of	POS	O
rats	POS	O
exposed	POS	O
to	POS	O
subacute	POS	O
diazinon	POS	O
.	POS	O
Furthermore	POS	O
ameliorating	POS	O
effect	POS	O
of	POS	O
crocin	POS	O
on	POS	O
diazinon	POS	O
induced	POS	O
disturbed	POS	O
cholesterol	POS	O
homeostasis	POS	O
was	POS	O
studied	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
24	POS	O
Rats	POS	O
were	POS	O
divided	POS	O
into	POS	O
4	POS	O
groups	POS	O
and	POS	O
received	POS	O
following	POS	O
treatments	POS	O
for	POS	O
4	POS	O
weeks	POS	O
;	POS	O
Corn	POS	O
oil	POS	O
(	POS	O
control	POS	O
)	POS	O
,	POS	O
diazinon	POS	O
(	POS	O
15mg	POS	O
/	POS	O
kg	POS	O
per	POS	O
day	POS	O
,	POS	O
orally	POS	O
)	POS	O
and	POS	O
crocin	POS	O
(	POS	O
12	POS	O
.	POS	O
5	POS	O
and	POS	O
25mg	POS	O
/	POS	O
kg	POS	O
per	POS	O
day	POS	O
,	POS	O
intraperitoneally	POS	O
)	POS	O
in	POS	O
combination	POS	O
with	POS	O
diazinon	POS	O
(	POS	O
15	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
.	POS	O
The	POS	O
levels	POS	O
of	POS	O
cholesterol	POS	O
,	POS	O
triglyceride	POS	O
and	POS	O
LDL	POS	O
in	POS	O
blood	POS	O
of	POS	O
rats	POS	O
were	POS	O
analyzed	POS	O
.	POS	O
Moreover	POS	O
mRNA	POS	O
levels	POS	O
of	POS	O
LDLr	POS	O
and	POS	O
ERK1	POS	O
/	POS	O
2	POS	O
as	POS	O
well	POS	O
as	POS	O
protein	POS	O
levels	POS	O
of	POS	O
total	POS	O
and	POS	O
activated	POS	O
forms	POS	O
of	POS	O
ERK1	POS	O
/	POS	O
2	POS	O
in	POS	O
rat	POS	O
liver	POS	O
were	POS	O
evaluated	POS	O
by	POS	O
Western	POS	O
blotting	POS	O
and	POS	O
quantitative	POS	O
real	POS	O
time	POS	O
polymerase	POS	O
chain	POS	O
reaction	POS	O
analysis	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Our	POS	O
data	POS	O
showed	POS	O
that	POS	O
subacute	POS	O
exposure	POS	O
to	POS	O
diazinon	POS	O
significantly	POS	O
increased	POS	O
concentrations	POS	O
of	POS	O
cholesterol	POS	O
,	POS	O
triglyceride	POS	O
and	POS	O
LDL	POS	O
.	POS	O
Moreover	POS	O
diazinon	POS	O
decreased	POS	O
ERK1	POS	O
/	POS	O
2	POS	O
protein	POS	O
phosphorylation	POS	O
and	POS	O
LDLr	POS	O
transcript	POS	O
.	POS	O
Crocin	POS	O
reduced	POS	O
inhibition	POS	O
of	POS	O
ERK	POS	O
activation	POS	O
and	POS	O
diazinon	POS	O
-	POS	O
induced	POS	O
hyperlipemia	POS	B-NP
and	POS	O
increased	POS	O
levels	POS	O
of	POS	O
LDLr	POS	O
transcript	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Crocin	POS	O
may	POS	O
be	POS	O
considered	POS	O
as	POS	O
a	POS	O
novel	POS	O
protective	POS	O
agent	POS	O
in	POS	O
diazinon	POS	O
-	POS	O
induced	POS	O
hyperlipemia	POS	B-NP
through	POS	O
modulating	POS	O
of	POS	O
ERK	POS	O
pathway	POS	O
and	POS	O
increase	POS	O
of	POS	O
LDLr	POS	O
expression	POS	O
.	POS	O
GEM	POS	O
-	POS	O
P	POS	O
chemotherapy	POS	O
is	POS	O
active	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
relapsed	POS	B-NP
Hodgkin	POS	I-NP
lymphoma	POS	I-NP
.	POS	O
Hodgkin	POS	B-NP
lymphoma	POS	I-NP
(	POS	O
HL	POS	B-NP
)	POS	O
is	POS	O
a	POS	O
relatively	POS	O
chemosensitive	POS	B-NP
malignancy	POS	I-NP
.	POS	O
However	POS	O
,	POS	O
for	POS	O
those	POS	O
who	POS	O
relapse	POS	O
,	POS	O
high	POS	O
-	POS	O
dose	POS	O
chemotherapy	POS	O
with	POS	O
autologous	POS	O
stem	POS	O
cell	POS	O
transplant	POS	O
is	POS	O
the	POS	O
treatment	POS	O
of	POS	O
choice	POS	O
which	POS	O
relies	POS	O
on	POS	O
adequate	POS	O
disease	POS	O
control	POS	O
with	POS	O
salvage	POS	O
chemotherapy	POS	O
.	POS	O
Regimens	POS	O
commonly	POS	O
used	POS	O
often	POS	O
require	POS	O
inpatient	POS	O
administration	POS	O
and	POS	O
can	POS	O
be	POS	O
difficult	POS	O
to	POS	O
deliver	POS	O
due	POS	O
to	POS	O
toxicity	POS	B-NP
.	POS	O
Gemcitabine	POS	O
and	POS	O
cisplatin	POS	O
have	POS	O
activity	POS	O
in	POS	O
HL	POS	B-NP
,	POS	O
non	POS	B-NP
-	POS	I-NP
overlapping	POS	I-NP
toxicity	POS	I-NP
with	POS	O
first	POS	O
-	POS	O
line	POS	O
chemotherapeutics	POS	O
,	POS	O
and	POS	O
may	POS	O
be	POS	O
delivered	POS	O
in	POS	O
an	POS	O
outpatient	POS	O
setting	POS	O
.	POS	O
In	POS	O
this	POS	O
retrospective	POS	O
single	POS	O
-	POS	O
centre	POS	O
analysis	POS	O
,	POS	O
patients	POS	O
with	POS	O
relapsed	POS	O
or	POS	O
refractory	POS	O
HL	POS	B-NP
treated	POS	O
with	POS	O
gemcitabine	POS	O
1	POS	O
,	POS	O
000	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
day	POS	O
(	POS	O
D	POS	O
)	POS	O
1	POS	O
,	POS	O
D8	POS	O
and	POS	O
D15	POS	O
;	POS	O
methylprednisolone	POS	O
1	POS	O
,	POS	O
000	POS	O
mg	POS	O
D1	POS	O
-	POS	O
5	POS	O
;	POS	O
and	POS	O
cisplatin	POS	O
100	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
D15	POS	O
,	POS	O
every	POS	O
28	POS	O
days	POS	O
(	POS	O
GEM	POS	O
-	POS	O
P	POS	O
)	POS	O
were	POS	O
included	POS	O
.	POS	O
Demographic	POS	O
,	POS	O
survival	POS	O
,	POS	O
response	POS	O
and	POS	O
toxicity	POS	B-NP
data	POS	O
were	POS	O
recorded	POS	O
.	POS	O
Forty	POS	O
-	POS	O
one	POS	O
eligible	POS	O
patients	POS	O
were	POS	O
identified	POS	O
:	POS	O
median	POS	O
age	POS	O
27	POS	O
.	POS	O
One	POS	O
hundred	POS	O
and	POS	O
twenty	POS	O
-	POS	O
two	POS	O
cycles	POS	O
of	POS	O
GEM	POS	O
-	POS	O
P	POS	O
were	POS	O
administered	POS	O
in	POS	O
total	POS	O
(	POS	O
median	POS	O
3	POS	O
cycles	POS	O
;	POS	O
range	POS	O
1	POS	O
-	POS	O
6	POS	O
)	POS	O
.	POS	O
Twenty	POS	O
of	POS	O
41	POS	O
(	POS	O
48	POS	O
%	POS	O
)	POS	O
patients	POS	O
received	POS	O
GEM	POS	O
-	POS	O
P	POS	O
as	POS	O
second	POS	O
-	POS	O
line	POS	O
treatment	POS	O
and	POS	O
11	POS	O
/	POS	O
41	POS	O
(	POS	O
27	POS	O
%	POS	O
)	POS	O
as	POS	O
third	POS	O
-	POS	O
line	POS	O
therapy	POS	O
.	POS	O
Overall	POS	O
response	POS	O
rate	POS	O
(	POS	O
ORR	POS	O
)	POS	O
to	POS	O
GEM	POS	O
-	POS	O
P	POS	O
in	POS	O
the	POS	O
entire	POS	O
cohort	POS	O
was	POS	O
80	POS	O
%	POS	O
(	POS	O
complete	POS	O
response	POS	O
(	POS	O
CR	POS	O
)	POS	O
37	POS	O
%	POS	O
,	POS	O
partial	POS	O
response	POS	O
44	POS	O
%	POS	O
)	POS	O
with	POS	O
14	POS	O
/	POS	O
15	POS	O
CR	POS	O
confirmed	POS	O
as	POS	O
a	POS	O
metabolic	POS	O
CR	POS	O
on	POS	O
PET	POS	O
and	POS	O
ORR	POS	O
of	POS	O
85	POS	O
%	POS	O
in	POS	O
the	POS	O
20	POS	O
second	POS	O
-	POS	O
line	POS	O
patients	POS	O
.	POS	O
The	POS	O
most	POS	O
common	POS	O
grade	POS	O
3	POS	O
/	POS	O
4	POS	O
toxicities	POS	B-NP
were	POS	O
haematological	POS	B-NP
:	POS	O
neutropenia	POS	B-NP
54	POS	O
%	POS	O
and	POS	O
thrombocytopenia	POS	B-NP
51	POS	O
%	POS	O
.	POS	O
Median	POS	O
follow	POS	O
-	POS	O
up	POS	O
from	POS	O
the	POS	O
start	POS	O
of	POS	O
GEM	POS	O
-	POS	O
P	POS	O
was	POS	O
4	POS	O
.	POS	O
5	POS	O
years	POS	O
.	POS	O
Following	POS	O
GEM	POS	O
-	POS	O
P	POS	O
,	POS	O
5	POS	O
-	POS	O
year	POS	O
progression	POS	O
-	POS	O
free	POS	O
survival	POS	O
was	POS	O
46	POS	O
%	POS	O
(	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
(	POS	O
CI	POS	O
)	POS	O
,	POS	O
30	POS	O
-	POS	O
62	POS	O
%	POS	O
)	POS	O
and	POS	O
5	POS	O
-	POS	O
year	POS	O
overall	POS	O
survival	POS	O
was	POS	O
59	POS	O
%	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
,	POS	O
43	POS	O
-	POS	O
74	POS	O
%	POS	O
)	POS	O
.	POS	O
Fourteen	POS	O
of	POS	O
41	POS	O
patients	POS	O
proceeded	POS	O
directly	POS	O
to	POS	O
autologous	POS	O
transplant	POS	O
.	POS	O
GEM	POS	O
-	POS	O
P	POS	O
is	POS	O
a	POS	O
salvage	POS	O
chemotherapy	POS	O
with	POS	O
relatively	POS	O
high	POS	O
response	POS	O
rates	POS	O
,	POS	O
leading	POS	O
to	POS	O
successful	POS	O
transplantation	POS	O
in	POS	O
appropriate	POS	O
patients	POS	O
,	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
relapsed	POS	O
or	POS	O
refractory	POS	O
HL	POS	B-NP
.	POS	O
Basal	POS	B-NP
functioning	POS	I-NP
of	POS	I-NP
the	POS	I-NP
hypothalamic	POS	I-NP
-	POS	I-NP
pituitary	POS	I-NP
-	POS	I-NP
adrenal	POS	I-NP
(	POS	I-NP
HPA	POS	I-NP
)	POS	I-NP
axis	POS	I-NP
and	POS	I-NP
psychological	POS	I-NP
distress	POS	I-NP
in	POS	O
recreational	POS	O
ecstasy	POS	O
polydrug	POS	O
users	POS	O
.	POS	O
RATIONALE	POS	O
:	POS	O
Ecstasy	POS	O
(	POS	O
MDMA	POS	O
)	POS	O
is	POS	O
a	POS	O
psychostimulant	POS	O
drug	POS	O
which	POS	O
is	POS	O
increasingly	POS	O
associated	POS	O
with	POS	O
psychobiological	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
While	POS	O
some	POS	O
recent	POS	O
studies	POS	O
suggest	POS	O
acute	POS	O
changes	POS	O
in	POS	O
neuroendocrine	POS	O
function	POS	O
,	POS	O
less	POS	O
is	POS	O
known	POS	O
about	POS	O
long	POS	O
-	POS	O
term	POS	O
changes	POS	O
in	POS	O
HPA	POS	O
functionality	POS	O
in	POS	O
recreational	POS	O
users	POS	O
.	POS	O
OBJECTIVES	POS	O
:	POS	O
The	POS	O
current	POS	O
study	POS	O
is	POS	O
the	POS	O
first	POS	O
to	POS	O
explore	POS	O
the	POS	O
effects	POS	O
of	POS	O
ecstasy	POS	O
-	POS	O
polydrug	POS	O
use	POS	O
on	POS	O
psychological	POS	O
distress	POS	O
and	POS	O
basal	POS	O
functioning	POS	O
of	POS	O
the	POS	O
HPA	POS	O
axis	POS	O
through	POS	O
assessing	POS	O
the	POS	O
secretion	POS	O
of	POS	O
cortisol	POS	O
across	POS	O
the	POS	O
diurnal	POS	O
period	POS	O
.	POS	O
METHOD	POS	O
:	POS	O
Seventy	POS	O
-	POS	O
six	POS	O
participants	POS	O
(	POS	O
21	POS	O
nonusers	POS	O
,	POS	O
29	POS	O
light	POS	O
ecstasy	POS	O
-	POS	O
polydrug	POS	O
users	POS	O
,	POS	O
26	POS	O
heavy	POS	O
ecstasy	POS	O
-	POS	O
polydrug	POS	O
users	POS	O
)	POS	O
completed	POS	O
a	POS	O
substance	POS	O
use	POS	O
inventory	POS	O
and	POS	O
measures	POS	O
of	POS	O
psychological	POS	O
distress	POS	O
at	POS	O
baseline	POS	O
,	POS	O
then	POS	O
two	POS	O
consecutive	POS	O
days	POS	O
of	POS	O
cortisol	POS	O
sampling	POS	O
(	POS	O
on	POS	O
awakening	POS	O
,	POS	O
30	POS	O
min	POS	O
post	POS	O
awakening	POS	O
,	POS	O
between	POS	O
1400	POS	O
and	POS	O
1600	POS	O
hours	POS	O
and	POS	O
pre	POS	O
bedtime	POS	O
)	POS	O
.	POS	O
On	POS	O
day	POS	O
2	POS	O
,	POS	O
participants	POS	O
also	POS	O
attended	POS	O
the	POS	O
laboratory	POS	O
to	POS	O
complete	POS	O
a	POS	O
20	POS	O
-	POS	O
min	POS	O
multitasking	POS	O
stressor	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Both	POS	O
user	POS	O
groups	POS	O
exhibited	POS	O
significantly	POS	O
greater	POS	O
levels	POS	O
of	POS	O
anxiety	POS	B-NP
and	POS	O
depression	POS	B-NP
than	POS	O
nonusers	POS	O
.	POS	O
On	POS	O
day	POS	O
1	POS	O
,	POS	O
all	POS	O
participants	POS	O
exhibited	POS	O
a	POS	O
typical	POS	O
cortisol	POS	O
profile	POS	O
,	POS	O
though	POS	O
light	POS	O
users	POS	O
had	POS	O
significantly	POS	O
elevated	POS	O
levels	POS	O
pre	POS	O
-	POS	O
bed	POS	O
.	POS	O
On	POS	O
day	POS	O
2	POS	O
,	POS	O
heavy	POS	O
users	POS	O
demonstrated	POS	O
elevated	POS	O
levels	POS	O
upon	POS	O
awakening	POS	O
and	POS	O
all	POS	O
ecstasy	POS	O
-	POS	O
polydrug	POS	O
users	POS	O
demonstrated	POS	O
elevated	POS	O
pre	POS	O
-	POS	O
bed	POS	O
levels	POS	O
compared	POS	O
to	POS	O
non	POS	O
-	POS	O
users	POS	O
.	POS	O
Significant	POS	O
between	POS	O
group	POS	O
differences	POS	O
were	POS	O
also	POS	O
observed	POS	O
in	POS	O
afternoon	POS	O
cortisol	POS	O
levels	POS	O
and	POS	O
in	POS	O
overall	POS	O
cortisol	POS	O
secretion	POS	O
across	POS	O
the	POS	O
day	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
increases	POS	O
in	POS	O
anxiety	POS	B-NP
and	POS	O
depression	POS	B-NP
are	POS	O
in	POS	O
line	POS	O
with	POS	O
previous	POS	O
observations	POS	O
in	POS	O
recreational	POS	O
ecstasy	POS	O
-	POS	O
polydrug	POS	O
users	POS	O
.	POS	O
Dysregulated	POS	O
diurnal	POS	O
cortisol	POS	O
may	POS	O
be	POS	O
indicative	POS	O
of	POS	O
inappropriate	POS	O
anticipation	POS	O
of	POS	O
forthcoming	POS	O
demands	POS	O
and	POS	O
hypersecretion	POS	B-NP
may	POS	O
lead	POS	O
to	POS	O
the	POS	O
increased	POS	O
psychological	POS	O
and	POS	O
physical	POS	O
morbidity	POS	O
associated	POS	O
with	POS	O
heavy	POS	O
recreational	POS	O
use	POS	O
of	POS	O
ecstasy	POS	O
.	POS	O
Ifosfamide	POS	O
related	POS	O
encephalopathy	POS	B-NP
:	POS	O
the	POS	O
need	POS	O
for	POS	O
a	POS	O
timely	POS	O
EEG	POS	O
evaluation	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Ifosfamide	POS	O
is	POS	O
an	POS	O
alkylating	POS	O
agent	POS	O
useful	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
a	POS	O
wide	POS	O
range	POS	O
of	POS	O
cancers	POS	B-NP
including	POS	O
sarcomas	POS	B-NP
,	POS	O
lymphoma	POS	B-NP
,	POS	O
gynecologic	POS	B-NP
and	POS	O
testicular	POS	B-NP
cancers	POS	I-NP
.	POS	O
Encephalopathy	POS	B-NP
has	POS	O
been	POS	O
reported	POS	O
in	POS	O
10	POS	O
-	POS	O
40	POS	O
%	POS	O
of	POS	O
patients	POS	O
receiving	POS	O
high	POS	O
-	POS	O
dose	POS	O
IV	POS	O
ifosfamide	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
highlight	POS	O
the	POS	O
role	POS	O
of	POS	O
electroencephalogram	POS	O
(	POS	O
EEG	POS	O
)	POS	O
in	POS	O
the	POS	O
early	POS	O
detection	POS	O
and	POS	O
management	POS	O
of	POS	O
ifosfamide	POS	O
related	POS	O
encephalopathy	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Retrospective	POS	O
chart	POS	O
review	POS	O
including	POS	O
clinical	POS	O
data	POS	O
and	POS	O
EEG	POS	O
recordings	POS	O
was	POS	O
done	POS	O
on	POS	O
five	POS	O
patients	POS	O
,	POS	O
admitted	POS	O
to	POS	O
MD	POS	O
Anderson	POS	O
Cancer	POS	O
Center	POS	O
between	POS	O
years	POS	O
2009	POS	O
and	POS	O
2012	POS	O
,	POS	O
who	POS	O
developed	POS	O
ifosfamide	POS	O
related	POS	O
acute	POS	B-NP
encephalopathy	POS	I-NP
.	POS	O
RESULTS	POS	O
:	POS	O
All	POS	O
five	POS	O
patients	POS	O
experienced	POS	O
symptoms	POS	O
of	POS	O
encephalopathy	POS	B-NP
soon	POS	O
after	POS	O
(	POS	O
within	POS	O
12	POS	O
h	POS	O
-	POS	O
2	POS	O
days	POS	O
)	POS	O
receiving	POS	O
ifosfamide	POS	O
.	POS	O
Two	POS	O
patients	POS	O
developed	POS	O
generalized	POS	O
convulsions	POS	B-NP
while	POS	O
one	POS	O
patient	POS	O
developed	POS	O
continuous	POS	O
non	POS	O
-	POS	O
convulsive	POS	B-NP
status	POS	I-NP
epilepticus	POS	I-NP
(	POS	O
NCSE	POS	B-NP
)	POS	O
that	POS	O
required	POS	O
ICU	POS	O
admission	POS	O
and	POS	O
intubation	POS	O
.	POS	O
Initial	POS	O
EEG	POS	O
showed	POS	O
epileptiform	POS	O
discharges	POS	O
in	POS	O
three	POS	O
patients	POS	O
;	POS	O
run	POS	O
of	POS	O
triphasic	POS	O
waves	POS	O
in	POS	O
one	POS	O
patient	POS	O
and	POS	O
moderate	POS	O
degree	POS	O
diffuse	POS	O
generalized	POS	O
slowing	POS	O
.	POS	O
Mixed	POS	O
pattern	POS	O
with	POS	O
the	POS	O
presence	POS	O
of	POS	O
both	POS	O
sharps	POS	O
and	POS	O
triphasic	POS	O
waves	POS	O
were	POS	O
also	POS	O
noted	POS	O
.	POS	O
Repeat	POS	O
EEGs	POS	O
within	POS	O
24	POS	O
_	POS	O
h	POS	O
of	POS	O
symptom	POS	O
onset	POS	O
showed	POS	O
marked	POS	O
improvement	POS	O
that	POS	O
was	POS	O
correlated	POS	O
with	POS	O
clinical	POS	O
improvement	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Severity	POS	O
of	POS	O
ifosfamide	POS	O
related	POS	O
encephalopathy	POS	B-NP
correlates	POS	O
with	POS	O
EEG	POS	O
changes	POS	O
.	POS	O
We	POS	O
suggest	POS	O
a	POS	O
timely	POS	O
EEG	POS	O
evaluation	POS	O
for	POS	O
patients	POS	O
receiving	POS	O
ifosfamide	POS	O
who	POS	O
develop	POS	O
features	POS	O
of	POS	O
encephalopathy	POS	B-NP
.	POS	O
Incidence	POS	O
of	POS	O
contrast	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
in	POS	O
hospitalised	POS	O
patients	POS	O
with	POS	O
cancer	POS	B-NP
.	POS	O
OBJECTIVES	POS	O
:	POS	O
To	POS	O
determine	POS	O
the	POS	O
frequency	POS	O
of	POS	O
and	POS	O
possible	POS	O
factors	POS	O
related	POS	O
to	POS	O
contrast	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
(	POS	O
CIN	POS	B-NP
)	POS	O
in	POS	O
hospitalised	POS	O
patients	POS	O
with	POS	O
cancer	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Ninety	POS	O
adult	POS	O
patients	POS	O
were	POS	O
enrolled	POS	O
.	POS	O
Patients	POS	O
with	POS	O
risk	POS	O
factors	POS	O
for	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
were	POS	O
excluded	POS	O
.	POS	O
Blood	POS	O
samples	POS	O
were	POS	O
examined	POS	O
the	POS	O
day	POS	O
before	POS	O
contrast	POS	O
-	POS	O
enhanced	POS	O
computed	POS	O
tomography	POS	O
(	POS	O
CT	POS	O
)	POS	O
and	POS	O
serially	POS	O
for	POS	O
3	POS	O
days	POS	O
thereafter	POS	O
.	POS	O
CIN	POS	B-NP
was	POS	O
defined	POS	O
as	POS	O
an	POS	O
increase	POS	O
in	POS	O
serum	POS	O
creatinine	POS	O
(	POS	O
Cr	POS	O
)	POS	O
of	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
dl	POS	O
or	POS	O
more	POS	O
,	POS	O
or	POS	O
elevation	POS	O
of	POS	O
Cr	POS	O
to	POS	O
25	POS	O
%	POS	O
over	POS	O
baseline	POS	O
.	POS	O
Relationships	POS	O
between	POS	O
CIN	POS	B-NP
and	POS	O
possible	POS	O
risk	POS	O
factors	POS	O
were	POS	O
investigated	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
CIN	POS	B-NP
was	POS	O
detected	POS	O
in	POS	O
18	POS	O
/	POS	O
90	POS	O
(	POS	O
20	POS	O
%	POS	O
)	POS	O
patients	POS	O
.	POS	O
CIN	POS	B-NP
developed	POS	O
in	POS	O
25	POS	O
.	POS	O
5	POS	O
%	POS	O
patients	POS	O
who	POS	O
underwent	POS	O
chemotherapy	POS	O
and	POS	O
in	POS	O
11	POS	O
%	POS	O
patients	POS	O
who	POS	O
did	POS	O
not	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
1	POS	O
)	POS	O
.	POS	O
CIN	POS	B-NP
more	POS	O
frequently	POS	O
developed	POS	O
in	POS	O
patients	POS	O
who	POS	O
had	POS	O
undergone	POS	O
CT	POS	O
within	POS	O
45	POS	O
days	POS	O
after	POS	O
the	POS	O
last	POS	O
chemotherapy	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
005	POS	O
)	POS	O
;	POS	O
it	POS	O
was	POS	O
also	POS	O
an	POS	O
independent	POS	O
risk	POS	O
factor	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
017	POS	O
)	POS	O
.	POS	O
CIN	POS	B-NP
was	POS	O
significantly	POS	O
more	POS	O
after	POS	O
treatment	POS	O
with	POS	O
bevacizumab	POS	O
/	POS	O
irinotecan	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
021	POS	O
)	POS	O
and	POS	O
in	POS	O
patients	POS	O
with	POS	O
hypertension	POS	B-NP
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
044	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
incidence	POS	O
of	POS	O
CIN	POS	B-NP
after	POS	O
CT	POS	O
in	POS	O
hospitalised	POS	O
oncological	POS	O
patients	POS	O
was	POS	O
20	POS	O
%	POS	O
.	POS	O
CIN	POS	B-NP
developed	POS	O
4	POS	O
.	POS	O
5	POS	O
-	POS	O
times	POS	O
more	POS	O
frequently	POS	O
in	POS	O
patients	POS	O
with	POS	O
cancer	POS	B-NP
who	POS	O
had	POS	O
undergone	POS	O
recent	POS	O
chemotherapy	POS	O
.	POS	O
Hypertension	POS	B-NP
and	POS	O
the	POS	O
combination	POS	O
of	POS	O
bevacizumab	POS	O
/	POS	O
irinotecan	POS	O
may	POS	O
be	POS	O
additional	POS	O
risk	POS	O
factors	POS	O
for	POS	O
CIN	POS	B-NP
development	POS	O
.	POS	O
KEY	POS	O
POINTS	POS	O
:	POS	O
.	POS	O
Contrast	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
(	POS	O
CIN	POS	B-NP
)	POS	O
is	POS	O
a	POS	O
concern	POS	O
for	POS	O
oncological	POS	O
patients	POS	O
undergoing	POS	O
CT	POS	O
.	POS	O
.	POS	O
CIN	POS	B-NP
occurs	POS	O
more	POS	O
often	POS	O
when	POS	O
CT	POS	O
is	POS	O
performed	POS	O
<	POS	O
45	POS	O
days	POS	O
after	POS	O
chemotherapy	POS	O
.	POS	O
.	POS	O
Hypertension	POS	B-NP
and	POS	O
treatment	POS	O
with	POS	O
bevacizumab	POS	O
appear	POS	O
to	POS	O
be	POS	O
additional	POS	O
risk	POS	O
factors	POS	O
.	POS	O
Syndrome	POS	B-NP
of	POS	I-NP
inappropriate	POS	I-NP
antidiuretic	POS	I-NP
hormone	POS	I-NP
secretion	POS	I-NP
associated	POS	O
with	POS	O
desvenlafaxine	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
syndrome	POS	O
of	POS	O
inappropriate	POS	O
anti	POS	O
-	POS	O
diuretic	POS	O
hormone	POS	O
(	POS	O
SIADH	POS	B-NP
)	POS	O
secretion	POS	O
associated	POS	O
with	POS	O
desvenlafaxine	POS	O
.	POS	O
CASE	POS	O
SUMMARY	POS	O
:	POS	O
A	POS	O
57	POS	O
-	POS	O
year	POS	O
old	POS	O
female	POS	O
with	POS	O
hyponatraemia	POS	B-NP
.	POS	O
Her	POS	O
medications	POS	O
included	POS	O
desvenlafaxine	POS	O
,	POS	O
and	POS	O
symptoms	POS	O
included	POS	O
nausea	POS	B-NP
,	POS	O
anxiety	POS	B-NP
and	POS	O
confusion	POS	B-NP
.	POS	O
The	POS	O
serum	POS	O
sodium	POS	O
at	POS	O
this	POS	O
time	POS	O
was	POS	O
120	POS	O
mmol	POS	O
/	POS	O
L	POS	O
,	POS	O
serum	POS	O
osmolality	POS	O
was	POS	O
263	POS	O
mosmol	POS	O
/	POS	O
kg	POS	O
,	POS	O
urine	POS	O
osmolality	POS	O
410	POS	O
mosmol	POS	O
/	POS	O
kg	POS	O
and	POS	O
urine	POS	O
sodium	POS	O
63	POS	O
mmol	POS	O
/	POS	O
L	POS	O
,	POS	O
consistent	POS	O
with	POS	O
a	POS	O
diagnosis	POS	O
of	POS	O
SIADH	POS	B-NP
.	POS	O
Desvenlafaxine	POS	O
was	POS	O
ceased	POS	O
and	POS	O
fluid	POS	O
restriction	POS	O
implemented	POS	O
.	POS	O
After	POS	O
4	POS	O
days	POS	O
the	POS	O
sodium	POS	O
increased	POS	O
to	POS	O
128	POS	O
mmol	POS	O
/	POS	O
L	POS	O
and	POS	O
fluid	POS	O
restriction	POS	O
was	POS	O
relaxed	POS	O
.	POS	O
During	POS	O
her	POS	O
further	POS	O
3	POS	O
weeks	POS	O
inpatient	POS	O
admission	POS	O
the	POS	O
serum	POS	O
sodium	POS	O
ranged	POS	O
from	POS	O
134	POS	O
to	POS	O
137	POS	O
mmol	POS	O
/	POS	O
L	POS	O
during	POS	O
treatment	POS	O
with	POS	O
mirtazapine	POS	O
.	POS	O
DISCUSSION	POS	O
:	POS	O
SIADH	POS	B-NP
has	POS	O
been	POS	O
widely	POS	O
reported	POS	O
with	POS	O
a	POS	O
range	POS	O
of	POS	O
antidepressants	POS	O
.	POS	O
This	POS	O
case	POS	O
report	POS	O
suggests	POS	O
that	POS	O
desvenlafaxine	POS	O
might	POS	O
cause	POS	O
clinically	POS	O
significant	POS	O
hyponatremia	POS	B-NP
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Clinicians	POS	O
should	POS	O
be	POS	O
aware	POS	O
of	POS	O
the	POS	O
potential	POS	O
for	POS	O
antidepressants	POS	O
to	POS	O
cause	POS	O
hyponatremia	POS	B-NP
,	POS	O
and	POS	O
take	POS	O
appropriate	POS	O
corrective	POS	O
action	POS	O
where	POS	O
necessary	POS	O
.	POS	O
Oxidative	POS	O
stress	POS	O
on	POS	O
cardiotoxicity	POS	B-NP
after	POS	O
treatment	POS	O
with	POS	O
single	POS	O
and	POS	O
multiple	POS	O
doses	POS	O
of	POS	O
doxorubicin	POS	O
.	POS	O
The	POS	O
mechanism	POS	O
of	POS	O
doxorubicin	POS	O
(	POS	O
DOX	POS	O
)	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
remains	POS	O
controversial	POS	O
.	POS	O
Wistar	POS	O
rats	POS	O
(	POS	O
n	POS	O
=	POS	O
66	POS	O
)	POS	O
received	POS	O
DOX	POS	O
injections	POS	O
intraperitoneally	POS	O
and	POS	O
were	POS	O
randomly	POS	O
assigned	POS	O
to	POS	O
2	POS	O
experimental	POS	O
protocols	POS	O
:	POS	O
(	POS	O
1	POS	O
)	POS	O
rats	POS	O
were	POS	O
killed	POS	O
before	POS	O
(	POS	O
-	POS	O
24	POS	O
h	POS	O
,	POS	O
n	POS	O
=	POS	O
8	POS	O
)	POS	O
and	POS	O
24	POS	O
h	POS	O
after	POS	O
(	POS	O
+	POS	O
24	POS	O
h	POS	O
,	POS	O
n	POS	O
=	POS	O
8	POS	O
)	POS	O
a	POS	O
single	POS	O
dose	POS	O
of	POS	O
DOX	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
weight	POS	O
)	POS	O
to	POS	O
determine	POS	O
the	POS	O
DOX	POS	O
acute	POS	O
effect	POS	O
and	POS	O
(	POS	O
2	POS	O
)	POS	O
rats	POS	O
(	POS	O
n	POS	O
=	POS	O
58	POS	O
)	POS	O
received	POS	O
4	POS	O
injections	POS	O
of	POS	O
DOX	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
weight	POS	O
/	POS	O
week	POS	O
)	POS	O
and	POS	O
were	POS	O
killed	POS	O
before	POS	O
the	POS	O
first	POS	O
injection	POS	O
(	POS	O
M0	POS	O
)	POS	O
and	POS	O
1	POS	O
week	POS	O
after	POS	O
each	POS	O
injection	POS	O
(	POS	O
M1	POS	O
,	POS	O
M2	POS	O
,	POS	O
M3	POS	O
,	POS	O
and	POS	O
M4	POS	O
)	POS	O
to	POS	O
determine	POS	O
the	POS	O
chronological	POS	O
effects	POS	O
.	POS	O
Animals	POS	O
used	POS	O
at	POS	O
M0	POS	O
(	POS	O
n	POS	O
=	POS	O
8	POS	O
)	POS	O
were	POS	O
also	POS	O
used	POS	O
at	POS	O
moment	POS	O
-	POS	O
24	POS	O
h	POS	O
of	POS	O
acute	POS	O
study	POS	O
.	POS	O
Cardiac	POS	O
total	POS	O
antioxidant	POS	O
performance	POS	O
(	POS	O
TAP	POS	O
)	POS	O
,	POS	O
DNA	POS	O
damage	POS	O
,	POS	O
and	POS	O
morphology	POS	O
analyses	POS	O
were	POS	O
carried	POS	O
out	POS	O
at	POS	O
each	POS	O
time	POS	O
point	POS	O
.	POS	O
Single	POS	O
dose	POS	O
of	POS	O
DOX	POS	O
was	POS	O
associated	POS	O
with	POS	O
increased	POS	O
cardiac	POS	B-NP
disarrangement	POS	I-NP
,	POS	O
necrosis	POS	B-NP
,	POS	O
and	POS	O
DNA	POS	O
damage	POS	O
(	POS	O
strand	POS	O
breaks	POS	O
(	POS	O
SBs	POS	O
)	POS	O
and	POS	O
oxidized	POS	O
pyrimidines	POS	O
)	POS	O
and	POS	O
decreased	POS	O
TAP	POS	O
.	POS	O
The	POS	O
chronological	POS	O
study	POS	O
showed	POS	O
an	POS	O
effect	POS	O
of	POS	O
a	POS	O
cumulative	POS	O
dose	POS	O
on	POS	O
body	POS	O
weight	POS	O
(	POS	O
R	POS	O
=	POS	O
-	POS	O
0	POS	O
.	POS	O
99	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
011	POS	O
)	POS	O
,	POS	O
necrosis	POS	B-NP
(	POS	O
R	POS	O
=	POS	O
1	POS	O
.	POS	O
00	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
004	POS	O
)	POS	O
,	POS	O
TAP	POS	O
(	POS	O
R	POS	O
=	POS	O
0	POS	O
.	POS	O
95	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
049	POS	O
)	POS	O
,	POS	O
and	POS	O
DNA	POS	O
SBs	POS	O
(	POS	O
R	POS	O
=	POS	O
-	POS	O
0	POS	O
.	POS	O
95	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
049	POS	O
)	POS	O
.	POS	O
DNA	POS	O
SBs	POS	O
damage	POS	O
was	POS	O
negatively	POS	O
associated	POS	O
with	POS	O
TAP	POS	O
(	POS	O
R	POS	O
=	POS	O
-	POS	O
0	POS	O
.	POS	O
98	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
018	POS	O
)	POS	O
,	POS	O
and	POS	O
necrosis	POS	B-NP
(	POS	O
R	POS	O
=	POS	O
-	POS	O
0	POS	O
.	POS	O
97	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
027	POS	O
)	POS	O
.	POS	O
Our	POS	O
results	POS	O
suggest	POS	O
that	POS	O
oxidative	POS	O
damage	POS	O
is	POS	O
associated	POS	O
with	POS	O
acute	POS	O
cardiotoxicity	POS	B-NP
induced	POS	O
by	POS	O
a	POS	O
single	POS	O
dose	POS	O
of	POS	O
DOX	POS	O
only	POS	O
.	POS	O
Increased	POS	O
resistance	POS	O
to	POS	O
the	POS	O
oxidative	POS	O
stress	POS	O
is	POS	O
plausible	POS	O
for	POS	O
the	POS	O
multiple	POS	O
dose	POS	O
of	POS	O
DOX	POS	O
.	POS	O
Thus	POS	O
,	POS	O
different	POS	O
mechanisms	POS	O
may	POS	O
be	POS	O
involved	POS	O
in	POS	O
acute	POS	B-NP
toxicity	POS	I-NP
versus	POS	O
chronic	POS	B-NP
toxicity	POS	I-NP
.	POS	O
Tacrolimus	POS	O
-	POS	O
related	POS	O
seizure	POS	B-NP
after	POS	O
pediatric	POS	O
liver	POS	O
transplantation	POS	O
-	POS	O
-	POS	O
a	POS	O
single	POS	O
-	POS	O
center	POS	O
experience	POS	O
.	POS	O
To	POS	O
identify	POS	O
the	POS	O
risk	POS	O
factors	POS	O
for	POS	O
new	POS	O
-	POS	O
onset	POS	O
seizures	POS	B-NP
after	POS	O
pediatric	POS	O
LT	POS	O
and	POS	O
to	POS	O
assess	POS	O
their	POS	O
clinical	POS	O
implications	POS	O
and	POS	O
long	POS	O
-	POS	O
term	POS	O
prognosis	POS	O
.	POS	O
The	POS	O
clinical	POS	O
and	POS	O
laboratory	POS	O
data	POS	O
of	POS	O
27	POS	O
consecutive	POS	O
children	POS	O
who	POS	O
underwent	POS	O
LT	POS	O
from	POS	O
January	POS	O
2007	POS	O
to	POS	O
December	POS	O
2010	POS	O
in	POS	O
our	POS	O
center	POS	O
were	POS	O
analyzed	POS	O
retrospectively	POS	O
.	POS	O
Patients	POS	O
were	POS	O
divided	POS	O
into	POS	O
seizures	POS	B-NP
group	POS	O
and	POS	O
a	POS	O
non	POS	O
-	POS	O
seizures	POS	B-NP
group	POS	O
.	POS	O
Pre	POS	O
-	POS	O
operative	POS	O
,	POS	O
intra	POS	O
-	POS	O
operative	POS	O
,	POS	O
and	POS	O
post	POS	O
-	POS	O
operative	POS	O
data	POS	O
were	POS	O
collected	POS	O
.	POS	O
Seizures	POS	B-NP
occurred	POS	O
in	POS	O
four	POS	O
children	POS	O
,	POS	O
an	POS	O
incidence	POS	O
of	POS	O
14	POS	O
.	POS	O
8	POS	O
%	POS	O
.	POS	O
All	POS	O
exhibited	POS	O
generalized	POS	O
tonic	POS	O
-	POS	O
clonic	POS	B-NP
seizures	POS	B-NP
within	POS	O
the	POS	O
first	POS	O
two	POS	O
wk	POS	O
after	POS	O
LT	POS	O
.	POS	O
Univariate	POS	O
analysis	POS	O
showed	POS	O
that	POS	O
the	POS	O
risk	POS	O
factors	POS	O
associated	POS	O
with	POS	O
seizures	POS	B-NP
after	POS	O
pediatric	POS	O
LT	POS	O
included	POS	O
gender	POS	O
,	POS	O
pediatric	POS	B-NP
end	POS	I-NP
-	POS	I-NP
stage	POS	I-NP
liver	POS	I-NP
disease	POS	I-NP
score	POS	O
before	POS	O
surgery	POS	O
,	POS	O
Child	POS	O
-	POS	O
Pugh	POS	O
score	POS	O
before	POS	O
surgery	POS	O
,	POS	O
serum	POS	O
total	POS	O
bilirubin	POS	O
after	POS	O
surgery	POS	O
,	POS	O
and	POS	O
trough	POS	O
TAC	POS	O
level	POS	O
.	POS	O
Multivariate	POS	O
analysis	POS	O
showed	POS	O
that	POS	O
trough	POS	O
TAC	POS	O
level	POS	O
was	POS	O
the	POS	O
only	POS	O
independent	POS	O
risk	POS	O
factor	POS	O
associated	POS	O
with	POS	O
the	POS	O
seizures	POS	B-NP
.	POS	O
All	POS	O
children	POS	O
who	POS	O
experienced	POS	O
seizures	POS	B-NP
survived	POS	O
with	POS	O
good	POS	O
graft	POS	O
function	POS	O
and	POS	O
remained	POS	O
seizure	POS	B-NP
-	POS	O
free	POS	O
without	POS	O
anti	POS	O
-	POS	O
epileptic	POS	B-NP
drugs	POS	O
over	POS	O
a	POS	O
mean	POS	O
follow	POS	O
-	POS	O
up	POS	O
period	POS	O
of	POS	O
33	POS	O
.	POS	O
7	POS	O
+	POS	O
14	POS	O
.	POS	O
6	POS	O
months	POS	O
.	POS	O
High	POS	O
trough	POS	O
TAC	POS	O
level	POS	O
was	POS	O
the	POS	O
predominant	POS	O
factor	POS	O
that	POS	O
contributed	POS	O
to	POS	O
seizures	POS	B-NP
in	POS	O
the	POS	O
early	POS	O
post	POS	O
-	POS	O
operative	POS	O
period	POS	O
after	POS	O
pediatric	POS	O
LT	POS	O
.	POS	O
High	POS	O
PELD	POS	O
and	POS	O
Child	POS	O
-	POS	O
Pugh	POS	O
scores	POS	O
before	POS	O
LT	POS	O
and	POS	O
high	POS	O
post	POS	O
-	POS	O
operative	POS	O
serum	POS	O
Tbil	POS	O
may	POS	O
be	POS	O
contributory	POS	O
risk	POS	O
factors	POS	O
for	POS	O
TAC	POS	O
-	POS	O
related	POS	O
seizures	POS	B-NP
.	POS	O
The	POS	O
flavonoid	POS	O
apigenin	POS	O
delays	POS	O
forgetting	POS	O
of	POS	O
passive	POS	O
avoidance	POS	O
conditioning	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
present	POS	O
experiments	POS	O
were	POS	O
performed	POS	O
to	POS	O
study	POS	O
the	POS	O
effect	POS	O
of	POS	O
the	POS	O
flavonoid	POS	O
apigenin	POS	O
(	POS	O
20	POS	O
mg	POS	O
/	POS	O
kg	POS	O
intraperitoneally	POS	O
(	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
,	POS	O
1	POS	O
h	POS	O
before	POS	O
acquisition	POS	O
)	POS	O
,	POS	O
on	POS	O
24	POS	O
h	POS	O
retention	POS	O
performance	POS	O
and	POS	O
forgetting	POS	O
of	POS	O
a	POS	O
step	POS	O
-	POS	O
through	POS	O
passive	POS	O
avoidance	POS	O
task	POS	O
,	POS	O
in	POS	O
young	POS	O
male	POS	O
Wistar	POS	O
rats	POS	O
.	POS	O
There	POS	O
were	POS	O
no	POS	O
differences	POS	O
between	POS	O
saline	POS	O
-	POS	O
and	POS	O
apigenin	POS	O
-	POS	O
treated	POS	O
groups	POS	O
in	POS	O
the	POS	O
24	POS	O
h	POS	O
retention	POS	O
trial	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
apigenin	POS	O
did	POS	O
not	POS	O
prevent	POS	O
the	POS	O
amnesia	POS	B-NP
induced	POS	O
by	POS	O
scopolamine	POS	O
(	POS	O
1mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
,	POS	O
30	POS	O
min	POS	O
before	POS	O
the	POS	O
acquisition	POS	O
)	POS	O
.	POS	O
The	POS	O
saline	POS	O
-	POS	O
and	POS	O
apigenin	POS	O
-	POS	O
treated	POS	O
rats	POS	O
that	POS	O
did	POS	O
not	POS	O
step	POS	O
through	POS	O
into	POS	O
the	POS	O
dark	POS	O
compartment	POS	O
during	POS	O
the	POS	O
cut	POS	O
-	POS	O
off	POS	O
time	POS	O
(	POS	O
540	POS	O
s	POS	O
)	POS	O
were	POS	O
retested	POS	O
weekly	POS	O
for	POS	O
up	POS	O
to	POS	O
eight	POS	O
weeks	POS	O
.	POS	O
In	POS	O
the	POS	O
saline	POS	O
treated	POS	O
group	POS	O
,	POS	O
the	POS	O
first	POS	O
significant	POS	O
decline	POS	O
in	POS	O
passive	POS	O
avoidance	POS	O
response	POS	O
was	POS	O
observed	POS	O
at	POS	O
four	POS	O
weeks	POS	O
,	POS	O
and	POS	O
complete	POS	O
memory	POS	B-NP
loss	POS	I-NP
was	POS	O
found	POS	O
five	POS	O
weeks	POS	O
after	POS	O
the	POS	O
acquisition	POS	O
of	POS	O
the	POS	O
passive	POS	O
avoidance	POS	O
task	POS	O
.	POS	O
At	POS	O
the	POS	O
end	POS	O
of	POS	O
the	POS	O
experimental	POS	O
period	POS	O
,	POS	O
60	POS	O
%	POS	O
of	POS	O
the	POS	O
animals	POS	O
treated	POS	O
with	POS	O
apigenin	POS	O
still	POS	O
did	POS	O
not	POS	O
step	POS	O
through	POS	O
.	POS	O
These	POS	O
data	POS	O
suggest	POS	O
that	POS	O
1	POS	O
)	POS	O
apigenin	POS	O
delays	POS	O
the	POS	O
long	POS	O
-	POS	O
term	POS	O
forgetting	POS	O
but	POS	O
did	POS	O
not	POS	O
modulate	POS	O
the	POS	O
24	POS	O
h	POS	O
retention	POS	O
of	POS	O
fear	POS	O
memory	POS	O
and	POS	O
2	POS	O
)	POS	O
the	POS	O
obtained	POS	O
beneficial	POS	O
effect	POS	O
of	POS	O
apigenin	POS	O
on	POS	O
the	POS	O
passive	POS	O
avoidance	POS	O
conditioning	POS	O
is	POS	O
mediated	POS	O
by	POS	O
mechanisms	POS	O
that	POS	O
do	POS	O
not	POS	O
implicate	POS	O
its	POS	O
action	POS	O
on	POS	O
the	POS	O
muscarinic	POS	O
cholinergic	POS	O
system	POS	O
.	POS	O
Histamine	POS	O
antagonists	POS	O
and	POS	O
d	POS	O
-	POS	O
tubocurarine	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
in	POS	O
cardiac	POS	O
surgical	POS	O
patients	POS	O
.	POS	O
Hemodynamic	POS	O
effects	POS	O
and	POS	O
histamine	POS	O
release	POS	O
by	POS	O
bolus	POS	O
injection	POS	O
of	POS	O
0	POS	O
.	POS	O
35	POS	O
mg	POS	O
/	POS	O
kg	POS	O
of	POS	O
d	POS	O
-	POS	O
tubocurarine	POS	O
were	POS	O
studied	POS	O
in	POS	O
24	POS	O
patients	POS	O
.	POS	O
H1	POS	O
-	POS	O
and	POS	O
H2	POS	O
-	POS	O
histamine	POS	O
antagonists	POS	O
or	POS	O
placebo	POS	O
were	POS	O
given	POS	O
before	POS	O
dosing	POS	O
with	POS	O
d	POS	O
-	POS	O
tubocurarine	POS	O
in	POS	O
a	POS	O
randomized	POS	O
double	POS	O
-	POS	O
blind	POS	O
fashion	POS	O
to	POS	O
four	POS	O
groups	POS	O
:	POS	O
group	POS	O
1	POS	O
-	POS	O
-	POS	O
placebo	POS	O
;	POS	O
group	POS	O
2	POS	O
-	POS	O
-	POS	O
cimetidine	POS	O
,	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
plus	POS	O
placebo	POS	O
;	POS	O
group	POS	O
3	POS	O
-	POS	O
-	POS	O
chlorpheniramine	POS	O
,	POS	O
0	POS	O
.	POS	O
1	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
plus	POS	O
placebo	POS	O
;	POS	O
and	POS	O
group	POS	O
4	POS	O
-	POS	O
-	POS	O
cimetidine	POS	O
plus	POS	O
chlorpheniramine	POS	O
.	POS	O
Histamine	POS	O
release	POS	O
occurred	POS	O
in	POS	O
most	POS	O
patients	POS	O
,	POS	O
the	POS	O
highest	POS	O
level	POS	O
2	POS	O
minutes	POS	O
after	POS	O
d	POS	O
-	POS	O
tubocurarine	POS	O
dosing	POS	O
.	POS	O
Group	POS	O
1	POS	O
had	POS	O
a	POS	O
moderate	POS	O
negative	POS	O
correlation	POS	O
between	POS	O
plasma	POS	O
histamine	POS	O
change	POS	O
and	POS	O
systemic	POS	O
vascular	POS	O
resistance	POS	O
(	POS	O
r	POS	O
=	POS	O
0	POS	O
.	POS	O
58	POS	O
;	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
not	POS	O
present	POS	O
in	POS	O
group	POS	O
4	POS	O
.	POS	O
Prior	POS	O
dosing	POS	O
with	POS	O
antagonists	POS	O
partially	POS	O
prevented	POS	O
the	POS	O
fall	POS	O
in	POS	O
systemic	POS	O
vascular	POS	O
resistance	POS	O
.	POS	O
These	POS	O
data	POS	O
demonstrate	POS	O
that	POS	O
the	POS	O
hemodynamic	POS	O
changes	POS	O
associated	POS	O
with	POS	O
d	POS	O
-	POS	O
tubocurarine	POS	O
dosing	POS	O
are	POS	O
only	POS	O
partially	POS	O
explained	POS	O
by	POS	O
histamine	POS	O
release	POS	O
.	POS	O
Thus	POS	O
prior	POS	O
dosing	POS	O
with	POS	O
H1	POS	O
-	POS	O
and	POS	O
H2	POS	O
-	POS	O
antagonists	POS	O
provides	POS	O
only	POS	O
partial	POS	O
protection	POS	O
.	POS	O
Cholecystokinin	POS	O
-	POS	O
octapeptide	POS	O
restored	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
hippocampal	POS	O
long	POS	O
-	POS	O
term	POS	O
potentiation	POS	O
impairment	POS	O
in	POS	O
rats	POS	O
.	POS	O
Cholecystokinin	POS	O
-	POS	O
octapeptide	POS	O
(	POS	O
CCK	POS	O
-	POS	O
8	POS	O
)	POS	O
,	POS	O
which	POS	O
is	POS	O
a	POS	O
typical	POS	O
brain	POS	O
-	POS	O
gut	POS	O
peptide	POS	O
,	POS	O
exerts	POS	O
a	POS	O
wide	POS	O
range	POS	O
of	POS	O
biological	POS	O
activities	POS	O
on	POS	O
the	POS	O
central	POS	O
nervous	POS	O
system	POS	O
.	POS	O
We	POS	O
have	POS	O
previously	POS	O
reported	POS	O
that	POS	O
CCK	POS	O
-	POS	O
8	POS	O
significantly	POS	O
alleviated	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
amnesia	POS	B-NP
and	POS	O
reversed	POS	O
spine	POS	O
density	POS	O
decreases	POS	O
in	POS	O
the	POS	O
CA1	POS	O
region	POS	O
of	POS	O
the	POS	O
hippocampus	POS	O
in	POS	O
morphine	POS	O
-	POS	O
treated	POS	O
animals	POS	O
.	POS	O
Here	POS	O
,	POS	O
we	POS	O
investigated	POS	O
the	POS	O
effects	POS	O
of	POS	O
CCK	POS	O
-	POS	O
8	POS	O
on	POS	O
long	POS	O
-	POS	O
term	POS	O
potentiation	POS	O
(	POS	O
LTP	POS	O
)	POS	O
in	POS	O
the	POS	O
lateral	POS	O
perforant	POS	O
path	POS	O
(	POS	O
LPP	POS	O
)	POS	O
-	POS	O
granule	POS	O
cell	POS	O
synapse	POS	O
of	POS	O
rat	POS	O
dentate	POS	O
gyrus	POS	O
(	POS	O
DG	POS	O
)	POS	O
in	POS	O
acute	POS	O
saline	POS	O
or	POS	O
morphine	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
Population	POS	O
spikes	POS	O
(	POS	O
PS	POS	O
)	POS	O
,	POS	O
which	POS	O
were	POS	O
evoked	POS	O
by	POS	O
stimulation	POS	O
of	POS	O
the	POS	O
LPP	POS	O
,	POS	O
were	POS	O
recorded	POS	O
in	POS	O
the	POS	O
DG	POS	O
region	POS	O
.	POS	O
Acute	POS	O
morphine	POS	O
(	POS	O
30mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
treatment	POS	O
significantly	POS	O
attenuated	POS	O
hippocampal	POS	O
LTP	POS	O
and	POS	O
CCK	POS	O
-	POS	O
8	POS	O
(	POS	O
1ug	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
restored	POS	O
the	POS	O
amplitude	POS	O
of	POS	O
PS	POS	O
that	POS	O
was	POS	O
attenuated	POS	O
by	POS	O
morphine	POS	O
injection	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
microinjection	POS	O
of	POS	O
CCK	POS	O
-	POS	O
8	POS	O
(	POS	O
0	POS	O
.	POS	O
1	POS	O
and	POS	O
1ug	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
also	POS	O
significantly	POS	O
augmented	POS	O
hippocampal	POS	O
LTP	POS	O
in	POS	O
saline	POS	O
-	POS	O
treated	POS	O
(	POS	O
1ml	POS	O
/	POS	O
kg	POS	O
,	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
rats	POS	O
.	POS	O
Pre	POS	O
-	POS	O
treatment	POS	O
of	POS	O
the	POS	O
CCK2	POS	O
receptor	POS	O
antagonist	POS	O
L	POS	O
-	POS	O
365	POS	O
,	POS	O
260	POS	O
(	POS	O
10ug	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
)	POS	O
reversed	POS	O
the	POS	O
effects	POS	O
of	POS	O
CCK	POS	O
-	POS	O
8	POS	O
,	POS	O
but	POS	O
the	POS	O
CCK1	POS	O
receptor	POS	O
antagonist	POS	O
L	POS	O
-	POS	O
364	POS	O
,	POS	O
718	POS	O
(	POS	O
10ug	POS	O
,	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
v	POS	O
)	POS	O
did	POS	O
not	POS	O
.	POS	O
The	POS	O
present	POS	O
results	POS	O
demonstrate	POS	O
that	POS	O
CCK	POS	O
-	POS	O
8	POS	O
attenuates	POS	O
the	POS	O
effect	POS	O
of	POS	O
morphine	POS	O
on	POS	O
hippocampal	POS	O
LTP	POS	O
through	POS	O
CCK2	POS	O
receptors	POS	O
and	POS	O
suggest	POS	O
an	POS	O
ameliorative	POS	O
function	POS	O
of	POS	O
CCK	POS	O
-	POS	O
8	POS	O
on	POS	O
morphine	POS	O
-	POS	O
induced	POS	O
memory	POS	B-NP
impairment	POS	I-NP
.	POS	O
Glial	POS	O
activation	POS	O
and	POS	O
post	POS	O
-	POS	O
synaptic	POS	O
neurotoxicity	POS	B-NP
:	POS	O
the	POS	O
key	POS	O
events	POS	O
in	POS	O
Streptozotocin	POS	O
(	POS	O
ICV	POS	O
)	POS	O
induced	POS	O
memory	POS	B-NP
impairment	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
In	POS	O
the	POS	O
present	POS	O
study	POS	O
the	POS	O
role	POS	O
of	POS	O
glial	POS	O
activation	POS	O
and	POS	O
post	POS	O
synaptic	POS	B-NP
toxicity	POS	I-NP
in	POS	O
ICV	POS	O
Streptozotocin	POS	O
(	POS	O
STZ	POS	O
)	POS	O
induced	POS	O
memory	POS	O
impaired	POS	O
rats	POS	O
was	POS	O
explored	POS	O
.	POS	O
In	POS	O
experiment	POS	O
set	POS	O
up	POS	O
1	POS	O
:	POS	O
Memory	POS	B-NP
deficit	POS	I-NP
was	POS	O
found	POS	O
in	POS	O
Morris	POS	O
water	POS	O
maze	POS	O
test	POS	O
on	POS	O
14	POS	O
-	POS	O
16	POS	O
days	POS	O
after	POS	O
STZ	POS	O
(	POS	O
ICV	POS	O
;	POS	O
3mg	POS	O
/	POS	O
Kg	POS	O
)	POS	O
administration	POS	O
.	POS	O
STZ	POS	O
causes	POS	O
increased	POS	O
expression	POS	O
of	POS	O
GFAP	POS	O
,	POS	O
CD11b	POS	O
and	POS	O
TNF	POS	O
-	POS	O
a	POS	O
indicating	POS	O
glial	POS	O
activation	POS	O
and	POS	O
neuroinflammation	POS	O
.	POS	O
STZ	POS	O
also	POS	O
significantly	POS	O
increased	POS	O
the	POS	O
level	POS	O
of	POS	O
ROS	POS	O
,	POS	O
nitrite	POS	O
,	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
and	POS	O
reduced	POS	O
the	POS	O
mitochondrial	POS	O
activity	POS	O
in	POS	O
synaptosomal	POS	O
preparation	POS	O
illustrating	POS	O
free	POS	O
radical	POS	O
generation	POS	O
and	POS	O
excitotoxicity	POS	O
.	POS	O
Increased	POS	O
expression	POS	O
and	POS	O
activity	POS	O
of	POS	O
Caspase	POS	O
-	POS	O
3	POS	O
was	POS	O
also	POS	O
observed	POS	O
in	POS	O
STZ	POS	O
treated	POS	O
rat	POS	O
which	POS	O
specify	POS	O
apoptotic	POS	O
cell	POS	O
death	POS	O
in	POS	O
hippocampus	POS	O
and	POS	O
cortex	POS	O
.	POS	O
STZ	POS	O
treatment	POS	O
showed	POS	O
decrease	POS	O
expression	POS	O
of	POS	O
post	POS	O
synaptic	POS	O
markers	POS	O
CaMKIIa	POS	O
and	POS	O
PSD	POS	O
-	POS	O
95	POS	O
,	POS	O
while	POS	O
,	POS	O
expression	POS	O
of	POS	O
pre	POS	O
synaptic	POS	O
markers	POS	O
(	POS	O
synaptophysin	POS	O
and	POS	O
SNAP	POS	O
-	POS	O
25	POS	O
)	POS	O
remains	POS	O
unaltered	POS	O
indicating	POS	O
selective	POS	O
post	POS	O
synaptic	POS	O
neurotoxicity	POS	B-NP
.	POS	O
Oral	POS	O
treatment	POS	O
with	POS	O
Memantine	POS	O
(	POS	O
10mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
Ibuprofen	POS	O
(	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
daily	POS	O
for	POS	O
13	POS	O
days	POS	O
attenuated	POS	O
STZ	POS	O
induced	POS	O
glial	POS	O
activation	POS	O
,	POS	O
apoptotic	POS	O
cell	POS	O
death	POS	O
and	POS	O
post	POS	O
synaptic	POS	O
neurotoxicity	POS	B-NP
in	POS	O
rat	POS	O
brain	POS	O
.	POS	O
Further	POS	O
,	POS	O
in	POS	O
experiment	POS	O
set	POS	O
up	POS	O
2	POS	O
:	POS	O
where	POS	O
memory	POS	O
function	POS	O
was	POS	O
not	POS	O
affected	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
7	POS	O
-	POS	O
9	POS	O
days	POS	O
after	POS	O
STZ	POS	O
treatment	POS	O
.	POS	O
The	POS	O
level	POS	O
of	POS	O
GFAP	POS	O
,	POS	O
CD11b	POS	O
,	POS	O
TNF	POS	O
-	POS	O
a	POS	O
,	POS	O
ROS	POS	O
and	POS	O
nitrite	POS	O
levels	POS	O
were	POS	O
increased	POS	O
.	POS	O
On	POS	O
the	POS	O
other	POS	O
hand	POS	O
,	POS	O
apoptotic	POS	O
marker	POS	O
,	POS	O
synaptic	POS	O
markers	POS	O
,	POS	O
mitochondrial	POS	O
activity	POS	O
and	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
levels	POS	O
remained	POS	O
unaffected	POS	B-NP
.	POS	O
Collective	POS	O
data	POS	O
indicates	POS	O
that	POS	O
neuroinflammatory	POS	O
process	POS	O
and	POS	O
oxidative	POS	O
stress	POS	O
occurs	POS	O
earlier	POS	O
to	POS	O
apoptosis	POS	O
and	POS	O
does	POS	O
not	POS	O
affect	POS	O
memory	POS	O
function	POS	O
.	POS	O
Present	POS	O
study	POS	O
clearly	POS	O
suggests	POS	O
that	POS	O
glial	POS	O
activation	POS	O
and	POS	O
post	POS	O
synaptic	POS	O
neurotoxicity	POS	B-NP
are	POS	O
the	POS	O
key	POS	O
factors	POS	O
in	POS	O
STZ	POS	O
induced	POS	O
memory	POS	B-NP
impairment	POS	I-NP
and	POS	O
neuronal	POS	B-NP
cell	POS	I-NP
death	POS	I-NP
.	POS	O
Comparison	POS	O
of	POS	O
effects	POS	O
of	POS	O
isotonic	POS	O
sodium	POS	O
chloride	POS	O
with	POS	O
diltiazem	POS	O
in	POS	O
prevention	POS	O
of	POS	O
contrast	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
.	POS	O
INTRODUCTION	POS	O
AND	POS	O
OBJECTIVE	POS	O
:	POS	O
Contrast	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
(	POS	O
CIN	POS	B-NP
)	POS	O
significantly	POS	O
increases	POS	O
the	POS	O
morbidity	POS	O
and	POS	O
mortality	POS	O
of	POS	O
patients	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
is	POS	O
to	POS	O
investigate	POS	O
and	POS	O
compare	POS	O
the	POS	O
protective	POS	O
effects	POS	O
of	POS	O
isotonic	POS	O
sodium	POS	O
chloride	POS	O
with	POS	O
sodium	POS	O
bicarbonate	POS	O
infusion	POS	O
and	POS	O
isotonic	POS	O
sodium	POS	O
chloride	POS	O
infusion	POS	O
with	POS	O
diltiazem	POS	O
,	POS	O
a	POS	O
calcium	POS	O
channel	POS	O
blocker	POS	O
,	POS	O
in	POS	O
preventing	POS	O
CIN	POS	O
.	POS	O
MATERIALS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
Our	POS	O
study	POS	O
included	POS	O
patients	POS	O
who	POS	O
were	POS	O
administered	POS	O
30	POS	O
-	POS	O
60	POS	O
mL	POS	O
of	POS	O
iodinated	POS	O
contrast	POS	O
agent	POS	O
for	POS	O
percutaneous	POS	O
coronary	POS	O
angiography	POS	O
(	POS	O
PCAG	POS	O
)	POS	O
,	POS	O
all	POS	O
with	POS	O
creatinine	POS	O
values	POS	O
between	POS	O
1	POS	O
.	POS	O
1	POS	O
and	POS	O
3	POS	O
.	POS	O
1	POS	O
mg	POS	O
/	POS	O
dL	POS	O
.	POS	O
Patients	POS	O
were	POS	O
divided	POS	O
into	POS	O
three	POS	O
groups	POS	O
and	POS	O
each	POS	O
group	POS	O
had	POS	O
20	POS	O
patients	POS	O
.	POS	O
The	POS	O
first	POS	O
group	POS	O
of	POS	O
patients	POS	O
was	POS	O
administered	POS	O
isotonic	POS	O
sodium	POS	O
chloride	POS	O
;	POS	O
the	POS	O
second	POS	O
group	POS	O
was	POS	O
administered	POS	O
a	POS	O
solution	POS	O
that	POS	O
of	POS	O
5	POS	O
%	POS	O
dextrose	POS	O
and	POS	O
sodium	POS	O
bicarbonate	POS	O
,	POS	O
while	POS	O
the	POS	O
third	POS	O
group	POS	O
was	POS	O
administered	POS	O
isotonic	POS	O
sodium	POS	O
chloride	POS	O
before	POS	O
and	POS	O
after	POS	O
the	POS	O
contrast	POS	O
injection	POS	O
.	POS	O
The	POS	O
third	POS	O
group	POS	O
received	POS	O
an	POS	O
additional	POS	O
injection	POS	O
of	POS	O
diltiazem	POS	O
the	POS	O
day	POS	O
before	POS	O
and	POS	O
first	POS	O
2	POS	O
days	POS	O
after	POS	O
the	POS	O
contrast	POS	O
injection	POS	O
.	POS	O
All	POS	O
of	POS	O
the	POS	O
patients	POS	O
'	POS	O
plasma	POS	O
blood	POS	O
urea	POS	O
nitrogen	POS	O
(	POS	O
BUN	POS	O
)	POS	O
and	POS	O
creatinine	POS	O
levels	POS	O
were	POS	O
measured	POS	O
on	POS	O
the	POS	O
second	POS	O
and	POS	O
seventh	POS	O
day	POS	O
after	POS	O
the	POS	O
administration	POS	O
of	POS	O
intravenous	POS	O
contrast	POS	O
material	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
basal	POS	O
creatinine	POS	O
levels	POS	O
were	POS	O
similar	POS	O
for	POS	O
all	POS	O
three	POS	O
groups	POS	O
(	POS	O
p	POS	O
>	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Among	POS	O
a	POS	O
total	POS	O
of	POS	O
60	POS	O
patients	POS	O
included	POS	O
in	POS	O
the	POS	O
study	POS	O
,	POS	O
16	POS	O
patients	POS	O
developed	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
(	POS	O
ARF	POS	B-NP
)	POS	O
on	POS	O
the	POS	O
second	POS	O
day	POS	O
after	POS	O
contrast	POS	O
material	POS	O
was	POS	O
injected	POS	O
(	POS	O
26	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
.	POS	O
The	POS	O
number	POS	O
of	POS	O
patients	POS	O
who	POS	O
developed	POS	O
ARF	POS	B-NP
on	POS	O
the	POS	O
second	POS	O
day	POS	O
after	POS	O
the	POS	O
injection	POS	O
in	POS	O
the	POS	O
first	POS	O
group	POS	O
was	POS	O
five	POS	O
(	POS	O
25	POS	O
%	POS	O
)	POS	O
,	POS	O
in	POS	O
the	POS	O
second	POS	O
group	POS	O
was	POS	O
six	POS	O
(	POS	O
30	POS	O
%	POS	O
)	POS	O
and	POS	O
the	POS	O
third	POS	O
group	POS	O
was	POS	O
five	POS	O
(	POS	O
25	POS	O
%	POS	O
)	POS	O
(	POS	O
p	POS	O
>	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
There	POS	O
was	POS	O
no	POS	O
significant	POS	O
difference	POS	O
between	POS	O
isotonic	POS	O
sodium	POS	O
chloride	POS	O
,	POS	O
sodium	POS	O
bicarbonate	POS	O
and	POS	O
isotonic	POS	O
sodium	POS	O
chloride	POS	O
with	POS	O
diltiazem	POS	O
application	POS	O
in	POS	O
prevention	POS	O
of	POS	O
CIN	POS	B-NP
.	POS	O
Neurocognitive	POS	O
and	POS	O
neuroradiologic	POS	O
central	POS	O
nervous	POS	O
system	POS	O
late	POS	O
effects	POS	O
in	POS	O
children	POS	O
treated	POS	O
on	POS	O
Pediatric	POS	O
Oncology	POS	O
Group	POS	O
(	POS	O
POG	POS	O
)	POS	O
P9605	POS	O
(	POS	O
standard	POS	O
risk	POS	O
)	POS	O
and	POS	O
P9201	POS	O
(	POS	O
lesser	POS	O
risk	POS	O
)	POS	O
acute	POS	B-NP
lymphoblastic	POS	I-NP
leukemia	POS	I-NP
protocols	POS	O
(	POS	O
ACCL0131	POS	O
)	POS	O
:	POS	O
a	POS	O
methotrexate	POS	O
consequence	POS	O
?	POS	O
A	POS	O
report	POS	O
from	POS	O
the	POS	O
Children	POS	O
'	POS	O
s	POS	O
Oncology	POS	O
Group	POS	O
.	POS	O
Concerns	POS	O
about	POS	O
long	POS	O
-	POS	O
term	POS	O
methotrexate	POS	O
(	POS	O
MTX	POS	O
)	POS	O
neurotoxicity	POS	B-NP
in	POS	O
the	POS	O
1990s	POS	O
led	POS	O
to	POS	O
modifications	POS	O
in	POS	O
intrathecal	POS	O
(	POS	O
IT	POS	O
)	POS	O
therapy	POS	O
,	POS	O
leucovorin	POS	O
rescue	POS	O
,	POS	O
and	POS	O
frequency	POS	O
of	POS	O
systemic	POS	O
MTX	POS	O
administration	POS	O
in	POS	O
children	POS	O
with	POS	O
acute	POS	B-NP
lymphoblastic	POS	I-NP
leukemia	POS	I-NP
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
neurocognitive	POS	O
outcomes	POS	O
and	POS	O
neuroradiologic	POS	O
evidence	POS	O
of	POS	O
leukoencephalopathy	POS	B-NP
were	POS	O
compared	POS	O
in	POS	O
children	POS	O
treated	POS	O
with	POS	O
intense	POS	B-NP
central	POS	I-NP
nervous	POS	I-NP
system	POS	I-NP
(	POS	O
CNS	POS	O
)	POS	O
-	POS	O
directed	POS	O
therapy	POS	O
(	POS	O
P9605	POS	O
)	POS	O
versus	POS	O
those	POS	O
receiving	POS	O
fewer	POS	O
CNS	POS	O
-	POS	O
directed	POS	O
treatment	POS	O
days	POS	O
during	POS	O
intensive	POS	O
consolidation	POS	O
(	POS	O
P9201	POS	O
)	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
66	POS	O
children	POS	O
from	POS	O
16	POS	O
Pediatric	POS	O
Oncology	POS	O
Group	POS	O
institutions	POS	O
with	POS	O
"	POS	O
standard	POS	O
-	POS	O
risk	POS	O
"	POS	O
acute	POS	B-NP
lymphoblastic	POS	I-NP
leukemia	POS	I-NP
,	POS	O
1	POS	O
.	POS	O
00	POS	O
to	POS	O
9	POS	O
.	POS	O
99	POS	O
years	POS	O
at	POS	O
diagnosis	POS	O
,	POS	O
without	POS	O
evidence	POS	O
of	POS	O
CNS	POS	B-NP
leukemia	POS	I-NP
at	POS	O
diagnosis	POS	O
were	POS	O
enrolled	POS	O
on	POS	O
ACCL0131	POS	O
:	POS	O
28	POS	O
from	POS	O
P9201	POS	O
and	POS	O
38	POS	O
from	POS	O
P9605	POS	O
.	POS	O
Magnetic	POS	O
resonance	POS	O
imaging	POS	O
scans	POS	O
and	POS	O
standard	POS	O
neuropsychological	POS	O
tests	POS	O
were	POS	O
performed	POS	O
>	POS	O
2	POS	O
.	POS	O
6	POS	O
years	POS	O
after	POS	O
the	POS	O
end	POS	O
of	POS	O
treatment	POS	O
.	POS	O
Significantly	POS	O
more	POS	O
P9605	POS	O
patients	POS	O
developed	POS	O
leukoencephalopathy	POS	B-NP
compared	POS	O
with	POS	O
P9201	POS	O
patients	POS	O
(	POS	O
68	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
49	POS	O
%	POS	O
-	POS	O
83	POS	O
%	POS	O
vs	POS	O
.	POS	O
22	POS	O
%	POS	O
,	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
5	POS	O
%	POS	O
-	POS	O
44	POS	O
%	POS	O
;	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
identified	POS	O
as	POS	O
late	POS	O
as	POS	O
7	POS	O
.	POS	O
7	POS	O
years	POS	O
after	POS	O
the	POS	O
end	POS	O
of	POS	O
treatment	POS	O
.	POS	O
Overall	POS	O
,	POS	O
40	POS	O
%	POS	O
of	POS	O
patients	POS	O
scored	POS	O
<	POS	O
85	POS	O
on	POS	O
either	POS	O
Verbal	POS	O
or	POS	O
Performance	POS	O
IQ	POS	O
.	POS	O
Children	POS	O
on	POS	O
both	POS	O
studies	POS	O
had	POS	O
significant	POS	O
attention	POS	B-NP
problems	POS	I-NP
,	POS	O
but	POS	O
P9605	POS	O
children	POS	O
scored	POS	O
below	POS	O
average	POS	O
on	POS	O
more	POS	O
neurocognitive	POS	O
measures	POS	O
than	POS	O
those	POS	O
treated	POS	O
on	POS	O
P9201	POS	O
(	POS	O
82	POS	O
%	POS	O
,	POS	O
14	POS	O
/	POS	O
17	POS	O
measures	POS	O
vs	POS	O
.	POS	O
24	POS	O
%	POS	O
,	POS	O
4	POS	O
/	POS	O
17	POS	O
measures	POS	O
)	POS	O
.	POS	O
This	POS	O
supports	POS	O
ongoing	POS	O
concerns	POS	O
about	POS	O
intensive	POS	O
MTX	POS	O
exposure	POS	O
as	POS	O
a	POS	O
major	POS	O
contributor	POS	O
to	POS	O
CNS	POS	O
late	POS	O
effects	POS	O
.	POS	O
Tranexamic	POS	O
acid	POS	O
overdosage	POS	O
-	POS	O
induced	POS	O
generalized	POS	O
seizure	POS	B-NP
in	POS	O
renal	POS	B-NP
failure	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
a	POS	O
45	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
lady	POS	O
with	POS	O
chronic	POS	B-NP
kidney	POS	I-NP
disease	POS	I-NP
stage	POS	O
4	POS	O
due	POS	O
to	POS	O
chronic	POS	O
tubulointerstial	POS	B-NP
disease	POS	I-NP
.	POS	O
She	POS	O
was	POS	O
admitted	POS	O
to	POS	O
our	POS	O
center	POS	O
for	POS	O
severe	POS	O
anemia	POS	B-NP
due	POS	O
to	POS	O
menorrhagia	POS	B-NP
and	POS	O
deterioration	POS	B-NP
of	POS	I-NP
renal	POS	I-NP
function	POS	I-NP
.	POS	O
She	POS	O
was	POS	O
infused	POS	O
three	POS	O
units	POS	O
of	POS	O
packed	POS	O
cells	POS	O
during	POS	O
a	POS	O
session	POS	O
of	POS	O
hemodialysis	POS	O
.	POS	O
Tranexamic	POS	O
acid	POS	O
(	POS	O
TNA	POS	O
)	POS	O
1	POS	O
g	POS	O
8	POS	O
-	POS	O
hourly	POS	O
was	POS	O
administered	POS	O
to	POS	O
her	POS	O
to	POS	O
control	POS	O
bleeding	POS	O
per	POS	O
vaginum	POS	O
.	POS	O
Two	POS	O
hours	POS	O
after	POS	O
the	POS	O
sixth	POS	O
dose	POS	O
of	POS	O
TNA	POS	O
,	POS	O
she	POS	O
had	POS	O
an	POS	O
episode	POS	O
of	POS	O
generalized	POS	O
tonic	POS	O
clonic	POS	B-NP
convulsions	POS	B-NP
.	POS	O
TNA	POS	O
was	POS	O
discontinued	POS	O
.	POS	O
Investigations	POS	O
of	POS	O
the	POS	O
patient	POS	O
revealed	POS	O
no	POS	O
biochemical	POS	O
or	POS	O
structural	POS	O
central	POS	O
nervous	POS	O
system	POS	O
abnormalities	POS	O
that	POS	O
could	POS	O
have	POS	O
provoked	POS	O
the	POS	O
convulsions	POS	B-NP
.	POS	O
She	POS	O
did	POS	O
not	POS	O
require	POS	O
any	POS	O
further	POS	O
dialytic	POS	O
support	POS	O
.	POS	O
She	POS	O
had	POS	O
no	POS	O
further	POS	O
episodes	POS	O
of	POS	O
convulsion	POS	B-NP
till	POS	O
dis	POS	O
-	POS	O
charge	POS	O
and	POS	O
during	POS	O
the	POS	O
two	POS	O
months	POS	O
of	POS	O
follow	POS	O
-	POS	O
up	POS	O
.	POS	O
Thus	POS	O
,	POS	O
the	POS	O
precipitating	POS	O
cause	POS	O
of	POS	O
convulsions	POS	B-NP
was	POS	O
believed	POS	O
to	POS	O
be	POS	O
an	POS	O
overdose	POS	B-NP
of	POS	O
TNA	POS	O
.	POS	O
Pre	POS	O
-	POS	O
treatment	POS	O
of	POS	O
bupivacaine	POS	O
-	POS	O
induced	POS	O
cardiovascular	POS	B-NP
depression	POS	I-NP
using	POS	O
different	POS	O
lipid	POS	O
formulations	POS	O
of	POS	O
propofol	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Pre	POS	O
-	POS	O
treatment	POS	O
with	POS	O
lipid	POS	O
emulsions	POS	O
has	POS	O
been	POS	O
shown	POS	O
to	POS	O
increase	POS	O
lethal	POS	O
doses	POS	O
of	POS	O
bupivacaine	POS	O
,	POS	O
and	POS	O
the	POS	O
lipid	POS	O
content	POS	O
of	POS	O
propofol	POS	O
may	POS	O
alleviate	POS	O
bupivacaine	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
is	POS	O
to	POS	O
investigate	POS	O
the	POS	O
effects	POS	O
of	POS	O
propofol	POS	O
in	POS	O
intralipid	POS	O
or	POS	O
medialipid	POS	O
emulsions	POS	O
on	POS	O
bupivacaine	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Rats	POS	O
were	POS	O
anaesthetised	POS	O
with	POS	O
ketamine	POS	O
and	POS	O
were	POS	O
given	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
propofol	POS	O
in	POS	O
intralipid	POS	O
(	POS	O
Group	POS	O
P	POS	O
)	POS	O
,	POS	O
propofol	POS	O
in	POS	O
medialipid	POS	O
(	POS	O
Group	POS	O
L	POS	O
)	POS	O
,	POS	O
or	POS	O
saline	POS	O
(	POS	O
Group	POS	O
C	POS	O
)	POS	O
over	POS	O
20	POS	O
min	POS	O
.	POS	O
Thereafter	POS	O
,	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
bupivacaine	POS	O
0	POS	O
.	POS	O
5	POS	O
%	POS	O
was	POS	O
infused	POS	O
.	POS	O
We	POS	O
recorded	POS	O
time	POS	O
to	POS	O
first	POS	O
dysrhythmia	POS	B-NP
occurrence	POS	O
,	POS	O
respective	POS	O
times	POS	O
to	POS	O
25	POS	O
%	POS	O
and	POS	O
50	POS	O
%	POS	O
reduction	POS	O
of	POS	O
the	POS	O
heart	POS	O
rate	POS	O
(	POS	O
HR	POS	O
)	POS	O
and	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
,	POS	O
and	POS	O
time	POS	O
to	POS	O
asystole	POS	B-NP
and	POS	O
total	POS	O
amount	POS	O
of	POS	O
bupivacaine	POS	O
consumption	POS	O
.	POS	O
Blood	POS	O
and	POS	O
tissue	POS	O
samples	POS	O
were	POS	O
collected	POS	O
following	POS	O
asystole	POS	B-NP
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
time	POS	O
to	POS	O
first	POS	O
dysrhythmia	POS	B-NP
occurrence	POS	O
,	POS	O
time	POS	O
to	POS	O
25	POS	O
%	POS	O
and	POS	O
50	POS	O
%	POS	O
reductions	POS	O
in	POS	O
HR	POS	O
,	POS	O
and	POS	O
time	POS	O
to	POS	O
asystole	POS	B-NP
were	POS	O
longer	POS	O
in	POS	O
Group	POS	O
P	POS	O
than	POS	O
the	POS	O
other	POS	O
groups	POS	O
.	POS	O
The	POS	O
cumulative	POS	O
bupivacaine	POS	O
dose	POS	O
given	POS	O
at	POS	O
those	POS	O
time	POS	O
points	POS	O
was	POS	O
higher	POS	O
in	POS	O
Group	POS	O
P	POS	O
.	POS	O
Plasma	POS	O
bupivacaine	POS	O
levels	POS	O
were	POS	O
significantly	POS	O
lower	POS	O
in	POS	O
Group	POS	O
P	POS	O
than	POS	O
in	POS	O
Group	POS	O
C	POS	O
.	POS	O
Bupivacaine	POS	O
levels	POS	O
in	POS	O
the	POS	O
brain	POS	O
and	POS	O
heart	POS	O
were	POS	O
significantly	POS	O
lower	POS	O
in	POS	O
Group	POS	O
P	POS	O
and	POS	O
Group	POS	O
L	POS	O
than	POS	O
in	POS	O
Group	POS	O
C	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
We	POS	O
conclude	POS	O
that	POS	O
pre	POS	O
-	POS	O
treatment	POS	O
with	POS	O
propofol	POS	O
in	POS	O
intralipid	POS	O
,	POS	O
compared	POS	O
with	POS	O
propofol	POS	O
in	POS	O
medialipid	POS	O
or	POS	O
saline	POS	O
,	POS	O
delayed	POS	O
the	POS	O
onset	POS	O
of	POS	O
bupivacaine	POS	O
-	POS	O
induced	POS	O
cardiotoxic	POS	B-NP
effects	POS	O
as	POS	O
well	POS	O
as	POS	O
reduced	POS	O
plasma	POS	O
bupivacaine	POS	O
levels	POS	O
.	POS	O
Further	POS	O
studies	POS	O
are	POS	O
needed	POS	O
to	POS	O
explore	POS	O
tissue	POS	O
bupivacaine	POS	O
levels	POS	O
of	POS	O
propofol	POS	O
in	POS	O
medialipid	POS	O
and	POS	O
adapt	POS	O
these	POS	O
results	POS	O
to	POS	O
clinical	POS	O
practice	POS	O
.	POS	O
Drug	POS	O
-	POS	O
Induced	POS	O
Acute	POS	O
Liver	POS	B-NP
Injury	POS	I-NP
Within	POS	O
12	POS	O
Hours	POS	O
After	POS	O
Fluvastatin	POS	O
Therapy	POS	O
.	POS	O
Although	POS	O
statins	POS	O
are	POS	O
generally	POS	O
well	POS	O
-	POS	O
tolerated	POS	O
drugs	POS	O
,	POS	O
recent	POS	O
cases	POS	O
of	POS	O
drug	POS	O
-	POS	O
induced	POS	O
liver	POS	B-NP
injury	POS	I-NP
associated	POS	O
with	POS	O
their	POS	O
use	POS	O
have	POS	O
been	POS	O
reported	POS	O
.	POS	O
A	POS	O
52	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
Chinese	POS	O
man	POS	O
reported	POS	O
with	POS	O
liver	POS	B-NP
damage	POS	I-NP
,	POS	O
which	POS	O
appeared	POS	O
12	POS	O
hours	POS	O
after	POS	O
beginning	POS	O
treatment	POS	O
with	POS	O
fluvastatin	POS	O
.	POS	O
Patient	POS	O
presented	POS	O
with	POS	O
complaints	POS	O
of	POS	O
increasing	POS	O
nausea	POS	B-NP
,	POS	O
anorexia	POS	B-NP
,	POS	O
and	POS	O
upper	POS	B-NP
abdominal	POS	I-NP
pain	POS	I-NP
.	POS	O
His	POS	O
laboratory	POS	O
values	POS	O
showed	POS	O
elevated	POS	O
creatine	POS	O
kinase	POS	O
and	POS	O
transaminases	POS	O
.	POS	O
Testing	POS	O
for	POS	O
autoantibodies	POS	O
was	POS	O
also	POS	O
negative	POS	O
.	POS	O
The	POS	O
liver	POS	O
biochemistries	POS	O
eventually	POS	O
normalized	POS	O
within	POS	O
3	POS	O
weeks	POS	O
of	POS	O
stopping	POS	O
the	POS	O
fluvastatin	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
when	POS	O
prescribing	POS	O
statins	POS	O
,	POS	O
the	POS	O
possibility	POS	O
of	POS	O
hepatic	POS	B-NP
damage	POS	I-NP
should	POS	O
be	POS	O
taken	POS	O
into	POS	O
account	POS	O
.	POS	O
Fluconazole	POS	O
associated	POS	O
agranulocytosis	POS	B-NP
and	POS	O
thrombocytopenia	POS	B-NP
.	POS	O
CASE	POS	O
:	POS	O
We	POS	O
describe	POS	O
a	POS	O
second	POS	O
case	POS	O
of	POS	O
fluconazole	POS	O
associated	POS	O
agranulocytosis	POS	B-NP
with	POS	O
thrombocytopenia	POS	B-NP
and	POS	O
recovery	POS	O
upon	POS	O
discontinuation	POS	O
of	POS	O
therapy	POS	O
.	POS	O
The	POS	O
patient	POS	O
began	POS	O
to	POS	O
have	POS	O
changes	POS	O
in	POS	O
white	POS	O
blood	POS	O
cells	POS	O
and	POS	O
platelets	POS	O
within	POS	O
48	POS	O
h	POS	O
of	POS	O
administration	POS	O
of	POS	O
fluconazole	POS	O
and	POS	O
began	POS	O
to	POS	O
recover	POS	O
with	POS	O
48	POS	O
h	POS	O
of	POS	O
discontinuation	POS	O
.	POS	O
This	POS	O
case	POS	O
highlights	POS	O
that	POS	O
drug	POS	O
-	POS	O
induced	POS	O
blood	POS	B-NP
dyscrasias	POS	I-NP
can	POS	O
occur	POS	O
unexpectedly	POS	O
as	POS	O
a	POS	O
result	POS	O
of	POS	O
treatment	POS	O
with	POS	O
a	POS	O
commonly	POS	O
used	POS	O
drug	POS	O
thought	POS	O
to	POS	O
be	POS	O
"	POS	O
safe	POS	O
"	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
According	POS	O
to	POS	O
Naranjo	POS	O
'	POS	O
s	POS	O
algorithm	POS	O
the	POS	O
likelihood	POS	O
that	POS	O
our	POS	O
patient	POS	O
'	POS	O
s	POS	O
agranulocytosis	POS	B-NP
and	POS	O
thrombocytopenia	POS	B-NP
occurred	POS	O
as	POS	O
a	POS	O
result	POS	O
of	POS	O
therapy	POS	O
with	POS	O
fluconazole	POS	O
is	POS	O
probable	POS	O
,	POS	O
with	POS	O
a	POS	O
total	POS	O
of	POS	O
six	POS	O
points	POS	O
.	POS	O
We	POS	O
feel	POS	O
that	POS	O
the	POS	O
weight	POS	O
of	POS	O
the	POS	O
overall	POS	O
evidence	POS	O
of	POS	O
this	POS	O
evidence	POS	O
is	POS	O
strong	POS	O
.	POS	O
In	POS	O
particular	POS	O
the	POS	O
temporal	POS	O
relationship	POS	O
of	POS	O
bone	POS	O
marrow	POS	O
suppression	POS	O
to	POS	O
the	POS	O
initiation	POS	O
of	POS	O
fluconazole	POS	O
and	POS	O
the	POS	O
abatement	POS	O
of	POS	O
symptoms	POS	O
that	POS	O
rapidly	POS	O
reversed	POS	O
immediately	POS	O
following	POS	O
discontinuation	POS	O
.	POS	O
Two	POS	O
-	POS	O
dimensional	POS	O
speckle	POS	O
tracking	POS	O
echocardiography	POS	O
combined	POS	O
with	POS	O
high	POS	O
-	POS	O
sensitive	POS	O
cardiac	POS	O
troponin	POS	O
T	POS	O
in	POS	O
early	POS	O
detection	POS	O
and	POS	O
prediction	POS	O
of	POS	O
cardiotoxicity	POS	B-NP
during	POS	O
epirubicine	POS	O
-	POS	O
based	POS	O
chemotherapy	POS	O
.	POS	O
AIMS	POS	O
:	POS	O
To	POS	O
investigate	POS	O
whether	POS	O
alterations	POS	O
of	POS	O
myocardial	POS	O
strain	POS	O
and	POS	O
high	POS	O
-	POS	O
sensitive	POS	O
cardiac	POS	O
troponin	POS	O
T	POS	O
(	POS	O
cTnT	POS	O
)	POS	O
could	POS	O
predict	POS	O
future	POS	O
cardiac	POS	B-NP
dysfunction	POS	I-NP
in	POS	O
patients	POS	O
after	POS	O
epirubicin	POS	O
exposure	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Seventy	POS	O
-	POS	O
five	POS	O
patients	POS	O
with	POS	O
non	POS	B-NP
-	POS	I-NP
Hodgkin	POS	I-NP
lymphoma	POS	I-NP
treated	POS	O
with	POS	O
epirubicin	POS	O
were	POS	O
studied	POS	O
.	POS	O
Blood	POS	O
collection	POS	O
and	POS	O
echocardiography	POS	O
were	POS	O
performed	POS	O
at	POS	O
baseline	POS	O
,	POS	O
1	POS	O
day	POS	O
after	POS	O
the	POS	O
third	POS	O
cycle	POS	O
,	POS	O
and	POS	O
1	POS	O
day	POS	O
after	POS	O
completion	POS	O
of	POS	O
chemotherapy	POS	O
.	POS	O
Patients	POS	O
were	POS	O
studied	POS	O
using	POS	O
echocardiography	POS	O
during	POS	O
follow	POS	O
-	POS	O
up	POS	O
.	POS	O
Global	POS	O
longitudinal	POS	O
(	POS	O
GLS	POS	O
)	POS	O
,	POS	O
circumferential	POS	O
(	POS	O
GCS	POS	O
)	POS	O
,	POS	O
and	POS	O
radial	POS	O
strain	POS	O
(	POS	O
GRS	POS	O
)	POS	O
were	POS	O
calculated	POS	O
using	POS	O
speckle	POS	O
tracking	POS	O
echocardiography	POS	O
.	POS	O
Left	POS	O
ventricular	POS	O
ejection	POS	O
fraction	POS	O
was	POS	O
analysed	POS	O
by	POS	O
real	POS	O
-	POS	O
time	POS	O
3D	POS	O
echocardiography	POS	O
.	POS	O
Cardiotoxicity	POS	B-NP
was	POS	O
defined	POS	O
as	POS	O
a	POS	O
reduction	POS	O
of	POS	O
the	POS	O
LVEF	POS	O
of	POS	O
>	POS	O
5	POS	O
%	POS	O
to	POS	O
<	POS	O
55	POS	O
%	POS	O
with	POS	O
symptoms	POS	O
of	POS	O
heart	POS	B-NP
failure	POS	I-NP
or	POS	O
an	POS	O
asymptomatic	POS	O
reduction	POS	O
of	POS	O
the	POS	O
LVEF	POS	O
of	POS	O
>	POS	O
10	POS	O
%	POS	O
to	POS	O
<	POS	O
55	POS	O
%	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Fourteen	POS	O
patients	POS	O
(	POS	O
18	POS	O
.	POS	O
67	POS	O
%	POS	O
)	POS	O
developed	POS	O
cardiotoxicity	POS	B-NP
after	POS	O
treatment	POS	O
.	POS	O
GLS	POS	O
(	POS	O
-	POS	O
18	POS	O
.	POS	O
48	POS	O
+	POS	O
1	POS	O
.	POS	O
72	POS	O
%	POS	O
vs	POS	O
.	POS	O
-	POS	O
15	POS	O
.	POS	O
96	POS	O
+	POS	O
1	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
,	POS	O
GCS	POS	B-NP
(	POS	O
-	POS	O
20	POS	O
.	POS	O
93	POS	O
+	POS	O
2	POS	O
.	POS	O
86	POS	O
%	POS	O
vs	POS	O
.	POS	O
-	POS	O
19	POS	O
.	POS	O
20	POS	O
+	POS	O
3	POS	O
.	POS	O
21	POS	O
%	POS	O
)	POS	O
,	POS	O
and	POS	O
GRS	POS	O
(	POS	O
39	POS	O
.	POS	O
23	POS	O
+	POS	O
6	POS	O
.	POS	O
44	POS	O
%	POS	O
vs	POS	O
.	POS	O
34	POS	O
.	POS	O
98	POS	O
+	POS	O
6	POS	O
.	POS	O
2	POS	O
%	POS	O
)	POS	O
were	POS	O
markedly	POS	O
reduced	POS	O
and	POS	O
cTnT	POS	O
was	POS	O
elevated	POS	O
from	POS	O
0	POS	O
.	POS	O
0010	POS	O
+	POS	O
0	POS	O
.	POS	O
0020	POS	O
to	POS	O
0	POS	O
.	POS	O
0073	POS	O
+	POS	O
0	POS	O
.	POS	O
0038	POS	O
ng	POS	O
/	POS	O
mL	POS	O
(	POS	O
P	POS	O
all	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
at	POS	O
the	POS	O
completion	POS	O
of	POS	O
chemotherapy	POS	O
compared	POS	O
with	POS	O
baseline	POS	O
values	POS	O
.	POS	O
A	POS	O
>	POS	O
15	POS	O
.	POS	O
9	POS	O
%	POS	O
decrease	POS	O
in	POS	O
GLS	POS	O
[	POS	O
sensitivity	POS	O
,	POS	O
86	POS	O
%	POS	O
;	POS	O
specificity	POS	O
,	POS	O
75	POS	O
%	POS	O
;	POS	O
area	POS	O
under	POS	O
the	POS	O
curve	POS	O
(	POS	O
AUC	POS	O
)	POS	O
=	POS	O
0	POS	O
.	POS	O
815	POS	O
;	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
001	POS	O
]	POS	O
and	POS	O
a	POS	O
>	POS	O
0	POS	O
.	POS	O
004	POS	O
ng	POS	O
/	POS	O
mL	POS	O
elevation	POS	O
in	POS	O
cTnT	POS	O
(	POS	O
sensitivity	POS	O
,	POS	O
79	POS	O
%	POS	O
;	POS	O
specificity	POS	O
,	POS	O
64	POS	O
%	POS	O
;	POS	O
AUC	POS	O
=	POS	O
0	POS	O
.	POS	O
757	POS	O
;	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
005	POS	O
)	POS	O
from	POS	O
baseline	POS	O
to	POS	O
the	POS	O
third	POS	O
cycle	POS	O
of	POS	O
chemotherapy	POS	O
predicted	POS	O
later	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
The	POS	O
decrease	POS	O
in	POS	O
GLS	POS	O
remained	POS	O
the	POS	O
only	POS	O
independent	POS	O
predictor	POS	O
of	POS	O
cardiotoxicity	POS	B-NP
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
000	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
GLS	POS	O
combined	POS	O
with	POS	O
cTnT	POS	O
may	POS	O
provide	POS	O
a	POS	O
reliable	POS	O
and	POS	O
non	POS	O
-	POS	O
invasive	POS	O
method	POS	O
to	POS	O
predict	POS	O
cardiac	POS	B-NP
dysfunction	POS	I-NP
in	POS	O
patients	POS	O
receiving	POS	O
anthracycline	POS	O
-	POS	O
based	POS	O
chemotherapy	POS	O
.	POS	O
Prevention	POS	O
of	POS	O
etomidate	POS	O
-	POS	O
induced	POS	O
myoclonus	POS	B-NP
:	POS	O
which	POS	O
is	POS	O
superior	POS	O
:	POS	O
Fentanyl	POS	O
,	POS	O
midazolam	POS	O
,	POS	O
or	POS	O
a	POS	O
combination	POS	O
?	POS	O
A	POS	O
Retrospective	POS	O
comparative	POS	O
study	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
In	POS	O
this	POS	O
retrospective	POS	O
comparative	POS	O
study	POS	O
,	POS	O
we	POS	O
aimed	POS	O
to	POS	O
compare	POS	O
the	POS	O
effectiveness	POS	O
of	POS	O
fentanyl	POS	O
,	POS	O
midazolam	POS	O
,	POS	O
and	POS	O
a	POS	O
combination	POS	O
of	POS	O
fentanyl	POS	O
and	POS	O
midazolam	POS	O
to	POS	O
prevent	POS	O
etomidate	POS	O
-	POS	O
induced	POS	O
myoclonus	POS	B-NP
.	POS	O
MATERIAL	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
This	POS	O
study	POS	O
was	POS	O
performed	POS	O
based	POS	O
on	POS	O
anesthesia	POS	O
records	POS	O
.	POS	O
Depending	POS	O
on	POS	O
the	POS	O
drugs	POS	O
that	POS	O
would	POS	O
be	POS	O
given	POS	O
before	POS	O
the	POS	O
induction	POS	O
of	POS	O
anesthesia	POS	O
with	POS	O
etomidate	POS	O
,	POS	O
the	POS	O
patients	POS	O
were	POS	O
separated	POS	O
into	POS	O
4	POS	O
groups	POS	O
:	POS	O
no	POS	O
pretreatment	POS	O
(	POS	O
Group	POS	O
NP	POS	O
)	POS	O
,	POS	O
fentanyl	POS	O
1	POS	O
ug	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
(	POS	O
Group	POS	O
F	POS	O
)	POS	O
,	POS	O
midazolam	POS	O
0	POS	O
.	POS	O
03	POS	O
mg	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
(	POS	O
Group	POS	O
M	POS	O
)	POS	O
,	POS	O
and	POS	O
midazolam	POS	O
0	POS	O
.	POS	O
015	POS	O
mg	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
+	POS	O
fentanyl	POS	O
0	POS	O
.	POS	O
5	POS	O
ug	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
(	POS	O
Group	POS	O
FM	POS	O
)	POS	O
.	POS	O
Patients	POS	O
who	POS	O
received	POS	O
the	POS	O
same	POS	O
anesthetic	POS	O
procedure	POS	O
were	POS	O
selected	POS	O
:	POS	O
2	POS	O
minutes	POS	O
after	POS	O
intravenous	POS	O
injections	POS	O
of	POS	O
the	POS	O
pretreatment	POS	O
drugs	POS	O
,	POS	O
anesthesia	POS	O
is	POS	O
induced	POS	O
with	POS	O
0	POS	O
.	POS	O
3	POS	O
mg	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
etomidate	POS	O
injected	POS	O
intravenously	POS	O
over	POS	O
a	POS	O
period	POS	O
of	POS	O
20	POS	O
-	POS	O
30	POS	O
seconds	POS	O
.	POS	O
Myoclonic	POS	B-NP
movements	POS	I-NP
are	POS	O
evaluated	POS	O
,	POS	O
which	POS	O
were	POS	O
observed	POS	O
and	POS	O
graded	POS	O
according	POS	O
to	POS	O
clinical	POS	O
severity	POS	O
during	POS	O
the	POS	O
2	POS	O
minutes	POS	O
after	POS	O
etomidate	POS	O
injection	POS	O
.	POS	O
The	POS	O
severity	POS	O
of	POS	O
pain	POS	B-NP
due	POS	O
to	POS	O
etomidate	POS	O
injection	POS	O
,	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
,	POS	O
heart	POS	O
rate	POS	O
,	POS	O
and	POS	O
adverse	POS	O
effects	POS	O
were	POS	O
also	POS	O
evaluated	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Study	POS	O
results	POS	O
showed	POS	O
that	POS	O
myoclonus	POS	B-NP
incidence	POS	O
was	POS	O
85	POS	O
%	POS	O
,	POS	O
40	POS	O
%	POS	O
,	POS	O
70	POS	O
%	POS	O
,	POS	O
and	POS	O
25	POS	O
%	POS	O
in	POS	O
Group	POS	O
NP	POS	O
,	POS	O
Group	POS	O
F	POS	O
,	POS	O
Group	POS	O
M	POS	O
,	POS	O
and	POS	O
Group	POS	O
FM	POS	O
,	POS	O
respectively	POS	O
,	POS	O
and	POS	O
were	POS	O
significantly	POS	O
lower	POS	O
in	POS	O
Group	POS	O
F	POS	O
and	POS	O
Group	POS	O
FM	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
We	POS	O
conclude	POS	O
that	POS	O
pretreatment	POS	O
with	POS	O
fentanyl	POS	O
or	POS	O
combination	POS	O
of	POS	O
fentanyl	POS	O
and	POS	O
midazolam	POS	O
was	POS	O
effective	POS	O
in	POS	O
preventing	POS	O
etomidate	POS	O
-	POS	O
induced	POS	O
myoclonus	POS	B-NP
.	POS	O
Convulsant	POS	O
effect	POS	O
of	POS	O
lindane	POS	O
and	POS	O
regional	POS	O
brain	POS	O
concentration	POS	O
of	POS	O
GABA	POS	O
and	POS	O
dopamine	POS	O
.	POS	O
Lindane	POS	O
(	POS	O
gamma	POS	O
-	POS	O
hexachlorocyclohexane	POS	O
)	POS	O
is	POS	O
an	POS	O
organochlorine	POS	O
insecticide	POS	O
with	POS	O
known	POS	O
neurotoxic	POS	B-NP
effects	POS	O
.	POS	O
Its	POS	O
mechanism	POS	O
of	POS	O
action	POS	O
is	POS	O
not	POS	O
well	POS	O
understood	POS	O
although	POS	O
it	POS	O
has	POS	O
been	POS	O
proposed	POS	O
that	POS	O
lindane	POS	O
acts	POS	O
as	POS	O
a	POS	O
non	POS	O
-	POS	O
competitive	POS	O
antagonist	POS	O
at	POS	O
the	POS	O
gamma	POS	O
-	POS	O
aminobutyric	POS	O
acid	POS	O
(	POS	O
GABA	POS	O
)	POS	O
-	POS	O
A	POS	O
receptor	POS	O
.	POS	O
We	POS	O
studied	POS	O
the	POS	O
effect	POS	O
of	POS	O
lindane	POS	O
(	POS	O
150	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
on	POS	O
the	POS	O
GABAergic	POS	O
and	POS	O
dopaminergic	POS	O
systems	POS	O
by	POS	O
measuring	POS	O
the	POS	O
concentration	POS	O
of	POS	O
GABA	POS	O
,	POS	O
dopamine	POS	O
and	POS	O
its	POS	O
metabolites	POS	O
in	POS	O
7	POS	O
brain	POS	O
areas	POS	O
at	POS	O
the	POS	O
onset	POS	O
of	POS	O
seizures	POS	B-NP
.	POS	O
All	POS	O
animals	POS	O
suffered	POS	O
tonic	POS	O
convulsions	POS	B-NP
at	POS	O
18	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
4	POS	O
min	POS	O
after	POS	O
lindane	POS	O
administration	POS	O
.	POS	O
The	POS	O
concentration	POS	O
of	POS	O
GABA	POS	O
was	POS	O
only	POS	O
slightly	POS	O
but	POS	O
significantly	POS	O
decreased	POS	O
in	POS	O
the	POS	O
colliculi	POS	O
without	POS	O
modifications	POS	O
in	POS	O
the	POS	O
other	POS	O
areas	POS	O
.	POS	O
The	POS	O
concentration	POS	O
of	POS	O
dopamine	POS	O
was	POS	O
increased	POS	O
in	POS	O
the	POS	O
mesencephalon	POS	O
and	POS	O
that	POS	O
of	POS	O
its	POS	O
metabolite	POS	O
DOPAC	POS	O
was	POS	O
also	POS	O
increased	POS	O
in	POS	O
the	POS	O
mesencephalon	POS	O
and	POS	O
the	POS	O
striatum	POS	O
.	POS	O
Cholestatic	POS	O
presentation	POS	O
of	POS	O
yellow	POS	O
phosphorus	POS	O
poisoning	POS	O
.	POS	O
Yellow	POS	O
phosphorus	POS	O
,	POS	O
a	POS	O
component	POS	O
of	POS	O
certain	POS	O
pesticide	POS	O
pastes	POS	O
and	POS	O
fireworks	POS	O
,	POS	O
is	POS	O
well	POS	O
known	POS	O
to	POS	O
cause	POS	O
hepatotoxicity	POS	B-NP
.	POS	O
Poisoning	POS	O
with	POS	O
yellow	POS	O
phosphorus	POS	O
classically	POS	O
manifests	POS	O
with	POS	O
acute	POS	B-NP
hepatitis	POS	I-NP
leading	POS	O
to	POS	O
acute	POS	B-NP
liver	POS	I-NP
failure	POS	I-NP
which	POS	O
may	POS	O
need	POS	O
liver	POS	O
transplantation	POS	O
.	POS	O
We	POS	O
present	POS	O
a	POS	O
case	POS	O
of	POS	O
yellow	POS	O
phosphorus	POS	O
poisoning	POS	B-NP
in	POS	O
which	POS	O
a	POS	O
patient	POS	O
presented	POS	O
with	POS	O
florid	POS	O
clinical	POS	O
features	POS	O
of	POS	O
cholestasis	POS	B-NP
highlighting	POS	O
the	POS	O
fact	POS	O
that	POS	O
cholestasis	POS	B-NP
can	POS	O
rarely	POS	O
be	POS	O
a	POS	O
presenting	POS	O
feature	POS	O
of	POS	O
yellow	POS	O
phosphorus	POS	O
hepatotoxicity	POS	B-NP
.	POS	O
Vasovagal	POS	B-NP
syncope	POS	I-NP
and	POS	O
severe	POS	O
bradycardia	POS	B-NP
following	POS	O
intranasal	POS	O
dexmedetomidine	POS	O
for	POS	O
pediatric	POS	O
procedural	POS	O
sedation	POS	O
.	POS	O
We	POS	O
report	POS	O
syncope	POS	B-NP
and	POS	O
bradycardia	POS	B-NP
in	POS	O
an	POS	O
11	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
girl	POS	O
following	POS	O
administration	POS	O
of	POS	O
intranasal	POS	O
dexmedetomidine	POS	O
for	POS	O
sedation	POS	O
for	POS	O
a	POS	O
voiding	POS	O
cystourethrogram	POS	O
.	POS	O
Following	POS	O
successful	POS	O
completion	POS	O
of	POS	O
VCUG	POS	O
and	POS	O
a	POS	O
60	POS	O
-	POS	O
min	POS	O
recovery	POS	O
period	POS	O
,	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
level	POS	O
of	POS	O
consciousness	POS	O
and	POS	O
vital	POS	O
signs	POS	O
returned	POS	O
to	POS	O
presedation	POS	O
levels	POS	O
.	POS	O
Upon	POS	O
leaving	POS	O
the	POS	O
sedation	POS	O
area	POS	O
,	POS	O
the	POS	O
patient	POS	O
collapsed	POS	O
,	POS	O
with	POS	O
no	POS	O
apparent	POS	O
inciting	POS	O
event	POS	O
.	POS	O
The	POS	O
patient	POS	O
quickly	POS	O
regained	POS	O
consciousness	POS	O
and	POS	O
no	POS	O
injury	POS	O
occurred	POS	O
.	POS	O
The	POS	O
primary	POS	O
abnormality	POS	O
found	POS	O
was	POS	O
persistent	POS	O
bradycardia	POS	B-NP
,	POS	O
and	POS	O
she	POS	O
was	POS	O
admitted	POS	O
to	POS	O
the	POS	O
hospital	POS	O
for	POS	O
telemetric	POS	O
observation	POS	O
.	POS	O
The	POS	O
bradycardia	POS	B-NP
lasted	POS	O
~	POS	O
2	POS	O
h	POS	O
,	POS	O
and	POS	O
further	POS	O
cardiac	POS	O
workup	POS	O
revealed	POS	O
no	POS	O
underlying	POS	O
abnormality	POS	O
.	POS	O
Unanticipated	POS	O
and	POS	O
previously	POS	O
unreported	POS	O
outcomes	POS	O
may	POS	O
be	POS	O
witnessed	POS	O
as	POS	O
we	POS	O
expand	POS	O
the	POS	O
use	POS	O
of	POS	O
certain	POS	O
sedatives	POS	O
to	POS	O
alternative	POS	O
routes	POS	O
of	POS	O
administration	POS	O
.	POS	O
Paradoxical	POS	O
severe	POS	O
agitation	POS	B-NP
induced	POS	O
by	POS	O
add	POS	O
-	POS	O
on	POS	O
high	POS	O
-	POS	O
doses	POS	O
quetiapine	POS	O
in	POS	O
schizo	POS	B-NP
-	POS	I-NP
affective	POS	I-NP
disorder	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
35	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
patient	POS	O
suffering	POS	O
from	POS	O
schizo	POS	B-NP
-	POS	I-NP
affective	POS	I-NP
disorder	POS	I-NP
since	POS	O
the	POS	O
age	POS	O
of	POS	O
19	POS	O
years	POS	O
,	POS	O
treated	POS	O
by	POS	O
a	POS	O
combination	POS	O
of	POS	O
first	POS	O
-	POS	O
generation	POS	O
antipsychotics	POS	O
,	POS	O
zuclopenthixol	POS	O
(	POS	O
100	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
and	POS	O
lithium	POS	O
(	POS	O
1200	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
(	POS	O
serum	POS	O
lithium	POS	O
=	POS	O
0	POS	O
.	POS	O
85	POS	O
mEq	POS	O
/	POS	O
l	POS	O
)	POS	O
.	POS	O
This	POS	O
patient	POS	O
had	POS	O
no	POS	O
associated	POS	O
personality	POS	B-NP
disorder	POS	I-NP
(	POS	O
particularly	POS	O
no	POS	O
antisocial	POS	B-NP
disorder	POS	I-NP
)	POS	O
and	POS	O
no	POS	O
substance	POS	B-NP
abuse	POS	I-NP
disorder	POS	I-NP
.	POS	O
Within	POS	O
the	POS	O
48	POS	O
h	POS	O
following	POS	O
the	POS	O
gradual	POS	O
introduction	POS	O
of	POS	O
quetiapine	POS	O
(	POS	O
up	POS	O
to	POS	O
600	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
,	POS	O
the	POS	O
patient	POS	O
presented	POS	O
severe	POS	O
agitation	POS	B-NP
without	POS	O
an	POS	O
environmental	POS	O
explanation	POS	O
,	POS	O
contrasting	POS	O
with	POS	O
the	POS	O
absence	POS	O
of	POS	O
a	POS	O
history	POS	O
of	POS	O
aggressiveness	POS	B-NP
or	POS	O
personality	POS	B-NP
disorder	POS	I-NP
.	POS	O
The	POS	O
diagnoses	POS	O
of	POS	O
manic	POS	B-NP
shift	POS	O
and	POS	O
akathisia	POS	B-NP
were	POS	O
dismissed	POS	O
.	POS	O
The	POS	O
withdrawal	POS	O
and	POS	O
the	POS	O
gradual	POS	O
reintroduction	POS	O
of	POS	O
quetiapine	POS	O
2	POS	O
weeks	POS	O
later	POS	O
,	POS	O
which	POS	O
led	POS	O
to	POS	O
another	POS	O
severe	POS	O
agitation	POS	B-NP
,	POS	O
enabled	POS	O
us	POS	O
to	POS	O
attribute	POS	O
the	POS	O
agitation	POS	B-NP
specifically	POS	O
to	POS	O
quetiapine	POS	O
.	POS	O
Antioxidant	POS	O
effects	POS	O
of	POS	O
bovine	POS	O
lactoferrin	POS	O
on	POS	O
dexamethasone	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
in	POS	O
rat	POS	O
.	POS	O
Dexamethasone	POS	O
-	POS	O
(	POS	O
Dex	POS	O
-	POS	O
)	POS	O
induced	POS	O
hypertension	POS	B-NP
is	POS	O
associated	POS	O
with	POS	O
enhanced	POS	O
oxidative	POS	O
stress	POS	O
.	POS	O
Lactoferrin	POS	O
(	POS	O
LF	POS	O
)	POS	O
is	POS	O
an	POS	O
iron	POS	O
-	POS	O
binding	POS	O
glycoprotein	POS	O
with	POS	O
antihypertensive	POS	O
properties	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
we	POS	O
investigated	POS	O
the	POS	O
effect	POS	O
of	POS	O
chronic	POS	O
administration	POS	O
of	POS	O
LF	POS	O
on	POS	O
oxidative	POS	O
stress	POS	O
and	POS	O
hypertension	POS	B-NP
upon	POS	O
Dex	POS	O
administration	POS	O
.	POS	O
Male	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
treated	POS	O
by	POS	O
Dex	POS	O
(	POS	O
30	POS	O
u	POS	O
g	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
subcutaneously	POS	O
)	POS	O
or	POS	O
saline	POS	O
for	POS	O
14	POS	O
days	POS	O
.	POS	O
Oral	POS	O
bovine	POS	O
LF	POS	O
(	POS	O
30	POS	O
,	POS	O
100	POS	O
,	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
was	POS	O
given	POS	O
from	POS	O
day	POS	O
8	POS	O
to	POS	O
14	POS	O
in	POS	O
a	POS	O
reversal	POS	O
study	POS	O
.	POS	O
In	POS	O
a	POS	O
prevention	POS	O
study	POS	O
,	POS	O
rats	POS	O
received	POS	O
4	POS	O
days	POS	O
of	POS	O
LF	POS	O
treatment	POS	O
followed	POS	O
by	POS	O
Dex	POS	O
and	POS	O
continued	POS	O
during	POS	O
the	POS	O
test	POS	O
period	POS	O
.	POS	O
Systolic	POS	O
blood	POS	O
pressure	POS	O
(	POS	O
SBP	POS	O
)	POS	O
was	POS	O
measured	POS	O
using	POS	O
tail	POS	O
-	POS	O
cuff	POS	O
method	POS	O
.	POS	O
Thymus	POS	O
weight	POS	O
was	POS	O
used	POS	O
as	POS	O
a	POS	O
marker	POS	O
of	POS	O
glucocorticoid	POS	O
activity	POS	O
.	POS	O
Plasma	POS	O
hydrogen	POS	O
peroxide	POS	O
(	POS	O
H2O2	POS	O
)	POS	O
concentration	POS	O
and	POS	O
ferric	POS	O
reducing	POS	O
antioxidant	POS	O
power	POS	O
(	POS	O
FRAP	POS	O
)	POS	O
value	POS	O
were	POS	O
determined	POS	O
.	POS	O
Dexamethasone	POS	O
significantly	POS	O
increased	POS	O
SBP	POS	O
and	POS	O
plasma	POS	O
H2O2	POS	O
level	POS	O
and	POS	O
decreased	POS	O
thymus	POS	O
and	POS	O
body	POS	O
weights	POS	O
.	POS	O
LF	POS	O
lowered	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
and	POS	O
dose	POS	O
dependently	POS	O
prevented	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
Dex	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
.	POS	O
LF	POS	O
prevented	POS	O
body	POS	O
weight	POS	O
loss	POS	O
and	POS	O
significantly	POS	O
reduced	POS	O
the	POS	O
elevated	POS	O
plasma	POS	O
H2O2	POS	O
and	POS	O
increased	POS	O
FRAP	POS	O
values	POS	O
.	POS	O
Chronic	POS	O
administration	POS	O
of	POS	O
LF	POS	O
strongly	POS	O
reduced	POS	O
the	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
production	POS	O
of	POS	O
ROS	POS	O
and	POS	O
improved	POS	O
antioxidant	POS	O
capacity	POS	O
in	POS	O
Dex	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
,	POS	O
suggesting	POS	O
the	POS	O
role	POS	O
of	POS	O
inhibition	POS	O
of	POS	O
oxidative	POS	O
stress	POS	O
as	POS	O
another	POS	O
mechanism	POS	O
of	POS	O
antihypertensive	POS	O
action	POS	O
of	POS	O
LF	POS	O
.	POS	O
The	POS	O
association	POS	O
between	POS	O
tranexamic	POS	O
acid	POS	O
and	POS	O
convulsive	POS	B-NP
seizures	POS	I-NP
after	POS	O
cardiac	POS	O
surgery	POS	O
:	POS	O
a	POS	O
multivariate	POS	O
analysis	POS	O
in	POS	O
11	POS	O
529	POS	O
patients	POS	O
.	POS	O
Because	POS	O
of	POS	O
a	POS	O
lack	POS	O
of	POS	O
contemporary	POS	O
data	POS	O
regarding	POS	O
seizures	POS	B-NP
after	POS	O
cardiac	POS	O
surgery	POS	O
,	POS	O
we	POS	O
undertook	POS	O
a	POS	O
retrospective	POS	O
analysis	POS	O
of	POS	O
prospectively	POS	O
collected	POS	O
data	POS	O
from	POS	O
11	POS	O
529	POS	O
patients	POS	O
in	POS	O
whom	POS	O
cardiopulmonary	POS	O
bypass	POS	O
was	POS	O
used	POS	O
from	POS	O
January	POS	O
2004	POS	O
to	POS	O
December	POS	O
2010	POS	O
.	POS	O
A	POS	O
convulsive	POS	O
seizure	POS	B-NP
was	POS	O
defined	POS	O
as	POS	O
a	POS	O
transient	POS	O
episode	POS	O
of	POS	O
disturbed	POS	O
brain	POS	O
function	POS	O
characterised	POS	O
by	POS	O
abnormal	POS	B-NP
involuntary	POS	I-NP
motor	POS	I-NP
movements	POS	I-NP
.	POS	O
Multivariate	POS	O
regression	POS	O
analysis	POS	O
was	POS	O
performed	POS	O
to	POS	O
identify	POS	O
independent	POS	O
predictors	POS	O
of	POS	O
postoperative	POS	B-NP
seizures	POS	I-NP
.	POS	O
A	POS	O
total	POS	O
of	POS	O
100	POS	O
(	POS	O
0	POS	O
.	POS	O
9	POS	O
%	POS	O
)	POS	O
patients	POS	O
developed	POS	O
postoperative	POS	B-NP
convulsive	POS	I-NP
seizures	POS	I-NP
.	POS	O
Generalised	POS	O
and	POS	O
focal	POS	O
seizures	POS	B-NP
were	POS	O
identified	POS	O
in	POS	O
68	POS	O
and	POS	O
32	POS	O
patients	POS	O
,	POS	O
respectively	POS	O
.	POS	O
The	POS	O
median	POS	O
(	POS	O
IQR	POS	O
[	POS	O
range	POS	O
]	POS	O
)	POS	O
time	POS	O
after	POS	O
surgery	POS	O
when	POS	O
the	POS	O
seizure	POS	B-NP
occurred	POS	O
was	POS	O
7	POS	O
(	POS	O
6	POS	O
-	POS	O
12	POS	O
[	POS	O
1	POS	O
-	POS	O
216	POS	O
]	POS	O
)	POS	O
h	POS	O
and	POS	O
8	POS	O
(	POS	O
6	POS	O
-	POS	O
11	POS	O
[	POS	O
4	POS	O
-	POS	O
18	POS	O
]	POS	O
)	POS	O
h	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Epileptiform	POS	O
findings	POS	O
on	POS	O
electroencephalography	POS	O
were	POS	O
seen	POS	O
in	POS	O
19	POS	O
patients	POS	O
.	POS	O
Independent	POS	O
predictors	POS	O
of	POS	O
postoperative	POS	O
seizures	POS	B-NP
included	POS	O
age	POS	O
,	POS	O
female	POS	O
sex	POS	O
,	POS	O
redo	POS	O
cardiac	POS	O
surgery	POS	O
,	POS	O
calcification	POS	B-NP
of	POS	I-NP
ascending	POS	I-NP
aorta	POS	I-NP
,	POS	O
congestive	POS	B-NP
heart	POS	I-NP
failure	POS	I-NP
,	POS	O
deep	POS	O
hypothermic	POS	B-NP
circulatory	POS	I-NP
arrest	POS	I-NP
,	POS	O
duration	POS	O
of	POS	O
aortic	POS	O
cross	POS	O
-	POS	O
clamp	POS	O
and	POS	O
tranexamic	POS	O
acid	POS	O
.	POS	O
When	POS	O
tested	POS	O
in	POS	O
a	POS	O
multivariate	POS	O
regression	POS	O
analysis	POS	O
,	POS	O
tranexamic	POS	O
acid	POS	O
was	POS	O
a	POS	O
strong	POS	O
independent	POS	O
predictor	POS	O
of	POS	O
seizures	POS	B-NP
(	POS	O
OR	POS	O
14	POS	O
.	POS	O
3	POS	O
,	POS	O
95	POS	O
%	POS	O
CI	POS	O
5	POS	O
.	POS	O
5	POS	O
-	POS	O
36	POS	O
.	POS	O
7	POS	O
;	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Patients	POS	O
with	POS	O
convulsive	POS	B-NP
seizures	POS	I-NP
had	POS	O
2	POS	O
.	POS	O
5	POS	O
times	POS	O
higher	POS	O
in	POS	O
-	POS	O
hospital	POS	O
mortality	POS	O
rates	POS	O
and	POS	O
twice	POS	O
the	POS	O
length	POS	O
of	POS	O
hospital	POS	O
stay	POS	O
compared	POS	O
with	POS	O
patients	POS	O
without	POS	O
convulsive	POS	B-NP
seizures	POS	I-NP
.	POS	O
Mean	POS	O
(	POS	O
IQR	POS	O
[	POS	O
range	POS	O
]	POS	O
)	POS	O
length	POS	O
of	POS	O
stay	POS	O
in	POS	O
the	POS	O
intensive	POS	O
care	POS	O
unit	POS	O
was	POS	O
115	POS	O
(	POS	O
49	POS	O
-	POS	O
228	POS	O
[	POS	O
32	POS	O
-	POS	O
481	POS	O
]	POS	O
)	POS	O
h	POS	O
in	POS	O
patients	POS	O
with	POS	O
convulsive	POS	B-NP
seizures	POS	I-NP
compared	POS	O
with	POS	O
26	POS	O
(	POS	O
22	POS	O
-	POS	O
69	POS	O
[	POS	O
14	POS	O
-	POS	O
1080	POS	O
]	POS	O
)	POS	O
h	POS	O
in	POS	O
patients	POS	O
without	POS	O
seizures	POS	B-NP
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Convulsive	POS	B-NP
seizures	POS	I-NP
are	POS	O
a	POS	O
serious	POS	O
postoperative	POS	O
complication	POS	O
after	POS	O
cardiac	POS	O
surgery	POS	O
.	POS	O
As	POS	O
tranexamic	POS	O
acid	POS	O
is	POS	O
the	POS	O
only	POS	O
modifiable	POS	O
factor	POS	O
,	POS	O
its	POS	O
administration	POS	O
,	POS	O
particularly	POS	O
in	POS	O
doses	POS	O
exceeding	POS	O
80	POS	O
mg	POS	O
.	POS	O
kg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
,	POS	O
should	POS	O
be	POS	O
weighed	POS	O
against	POS	O
the	POS	O
risk	POS	O
of	POS	O
postoperative	POS	B-NP
seizures	POS	I-NP
.	POS	O
Dysfunctional	POS	O
overnight	POS	O
memory	POS	O
consolidation	POS	O
in	POS	O
ecstasy	POS	O
users	POS	O
.	POS	O
Sleep	POS	O
plays	POS	O
an	POS	O
important	POS	O
role	POS	O
in	POS	O
the	POS	O
consolidation	POS	O
and	POS	O
integration	POS	O
of	POS	O
memory	POS	O
in	POS	O
a	POS	O
process	POS	O
called	POS	O
overnight	POS	O
memory	POS	O
consolidation	POS	O
.	POS	O
Previous	POS	O
studies	POS	O
indicate	POS	O
that	POS	O
ecstasy	POS	O
users	POS	O
have	POS	O
marked	POS	O
and	POS	O
persistent	POS	O
neurocognitive	POS	O
and	POS	O
sleep	POS	B-NP
-	POS	I-NP
related	POS	I-NP
impairments	POS	I-NP
.	POS	O
We	POS	O
extend	POS	O
past	POS	O
research	POS	O
by	POS	O
examining	POS	O
overnight	POS	O
memory	POS	O
consolidation	POS	O
among	POS	O
regular	POS	O
ecstasy	POS	O
users	POS	O
(	POS	O
n	POS	O
=	POS	O
12	POS	O
)	POS	O
and	POS	O
drug	POS	O
naive	POS	O
healthy	POS	O
controls	POS	O
(	POS	O
n	POS	O
=	POS	O
26	POS	O
)	POS	O
.	POS	O
Memory	POS	O
recall	POS	O
of	POS	O
word	POS	O
pairs	POS	O
was	POS	O
evaluated	POS	O
before	POS	O
and	POS	O
after	POS	O
a	POS	O
period	POS	O
of	POS	O
sleep	POS	O
,	POS	O
with	POS	O
and	POS	O
without	POS	O
interference	POS	O
prior	POS	O
to	POS	O
testing	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
we	POS	O
assessed	POS	O
neurocognitive	POS	O
performances	POS	O
across	POS	O
tasks	POS	O
of	POS	O
learning	POS	O
,	POS	O
memory	POS	O
and	POS	O
executive	POS	O
functioning	POS	O
.	POS	O
Ecstasy	POS	O
users	POS	O
demonstrated	POS	O
impaired	POS	O
overnight	POS	O
memory	POS	O
consolidation	POS	O
,	POS	O
a	POS	O
finding	POS	O
that	POS	O
was	POS	O
more	POS	O
pronounced	POS	O
following	POS	O
associative	POS	O
interference	POS	O
.	POS	O
Additionally	POS	O
,	POS	O
ecstasy	POS	O
users	POS	O
demonstrated	POS	O
impairments	POS	O
on	POS	O
tasks	POS	O
recruiting	POS	O
frontostriatal	POS	O
and	POS	O
hippocampal	POS	O
neural	POS	O
circuitry	POS	O
,	POS	O
in	POS	O
the	POS	O
domains	POS	O
of	POS	O
proactive	POS	O
interference	POS	O
memory	POS	O
,	POS	O
long	POS	O
-	POS	O
term	POS	O
memory	POS	O
,	POS	O
encoding	POS	O
,	POS	O
working	POS	O
memory	POS	O
and	POS	O
complex	POS	O
planning	POS	O
.	POS	O
We	POS	O
suggest	POS	O
that	POS	O
ecstasy	POS	O
-	POS	O
associated	POS	O
dysfunction	POS	O
in	POS	O
fronto	POS	O
-	POS	O
temporal	POS	O
circuitry	POS	O
may	POS	O
underlie	POS	O
overnight	POS	O
consolidation	POS	O
memory	POS	B-NP
impairments	POS	I-NP
in	POS	O
regular	POS	O
ecstasy	POS	O
users	POS	O
.	POS	O
Normoammonemic	POS	B-NP
encephalopathy	POS	I-NP
:	POS	O
solely	POS	O
valproate	POS	O
induced	POS	O
or	POS	O
multiple	POS	O
mechanisms	POS	O
?	POS	O
A	POS	O
77	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
presented	POS	O
with	POS	O
subacute	POS	O
onset	POS	O
progressive	POS	O
confusion	POS	B-NP
,	POS	O
aggression	POS	B-NP
,	POS	O
auditory	POS	B-NP
hallucinations	POS	I-NP
and	POS	O
delusions	POS	B-NP
.	POS	O
In	POS	O
the	POS	O
preceding	POS	O
months	POS	O
,	POS	O
the	POS	O
patient	POS	O
had	POS	O
a	POS	O
number	POS	O
of	POS	O
admissions	POS	O
with	POS	O
transient	POS	O
unilateral	POS	B-NP
hemiparesis	POS	I-NP
with	POS	O
facial	POS	B-NP
droop	POS	I-NP
,	POS	O
and	POS	O
had	POS	O
been	POS	O
started	POS	O
on	POS	O
valproate	POS	O
for	POS	O
presumed	POS	O
hemiplegic	POS	B-NP
migraine	POS	I-NP
.	POS	O
Valproate	POS	B-NP
was	POS	O
withdrawn	POS	O
soon	POS	O
after	POS	O
admission	POS	O
and	POS	O
her	POS	O
cognitive	POS	O
abilities	POS	O
have	POS	O
gradually	POS	O
improved	POS	O
over	POS	O
3	POS	O
months	POS	O
of	POS	O
follow	POS	O
-	POS	O
up	POS	O
.	POS	O
Valproate	POS	O
levels	POS	O
taken	POS	O
prior	POS	O
to	POS	O
withdrawal	POS	O
were	POS	O
subtherapeutic	POS	O
and	POS	O
the	POS	O
patient	POS	O
was	POS	O
normoammonaemic	POS	O
.	POS	O
EEG	POS	O
undertaken	POS	O
during	POS	O
inpatient	POS	O
stay	POS	O
showed	POS	O
changes	POS	O
consistent	POS	O
with	POS	O
encephalopathy	POS	B-NP
,	POS	O
and	POS	O
low	POS	O
titre	POS	O
N	POS	O
-	POS	O
methyl	POS	O
-	POS	O
D	POS	O
-	POS	O
aspartate	POS	O
(	POS	O
NMDA	POS	O
)	POS	O
receptor	POS	O
antibodies	POS	O
were	POS	O
present	POS	O
in	POS	O
this	POS	O
patient	POS	O
.	POS	O
The	POS	O
possible	POS	O
aetiologies	POS	O
of	POS	O
valproate	POS	O
-	POS	O
induced	POS	O
encephalopathy	POS	B-NP
and	POS	O
NMDA	POS	O
receptor	POS	O
-	POS	O
associated	POS	O
encephalitis	POS	B-NP
present	POS	O
a	POS	O
diagnostic	POS	O
dilemma	POS	O
.	POS	O
We	POS	O
present	POS	O
a	POS	O
putative	POS	O
combinatorial	POS	O
hypothesis	POS	O
to	POS	O
explain	POS	O
this	POS	O
patient	POS	O
'	POS	O
s	POS	O
symptoms	POS	O
.	POS	O
Cerebellar	POS	O
and	POS	O
oculomotor	POS	B-NP
dysfunction	POS	I-NP
induced	POS	O
by	POS	O
rapid	POS	O
infusion	POS	O
of	POS	O
pethidine	POS	O
.	POS	O
Pethidine	POS	O
is	POS	O
an	POS	O
opioid	POS	O
that	POS	O
gains	POS	O
its	POS	O
popularity	POS	O
for	POS	O
the	POS	O
effective	POS	O
pain	POS	B-NP
control	POS	O
through	POS	O
acting	POS	O
on	POS	O
the	POS	O
opioid	POS	O
-	POS	O
receptors	POS	O
.	POS	O
However	POS	O
,	POS	O
rapid	POS	O
pain	POS	B-NP
relief	POS	O
sometimes	POS	O
brings	POS	O
about	POS	O
unfavourable	POS	O
side	POS	O
effects	POS	O
that	POS	O
largely	POS	O
limit	POS	O
its	POS	O
clinical	POS	O
utility	POS	O
.	POS	O
Common	POS	O
side	POS	O
effects	POS	O
include	POS	O
nausea	POS	B-NP
,	POS	O
vomiting	POS	B-NP
and	POS	O
hypotension	POS	B-NP
.	POS	O
In	POS	O
patients	POS	O
with	POS	O
impaired	POS	B-NP
renal	POS	I-NP
and	POS	I-NP
liver	POS	I-NP
function	POS	I-NP
,	POS	O
and	POS	O
those	POS	O
who	POS	O
need	POS	O
long	POS	O
-	POS	O
term	POS	O
pain	POS	B-NP
control	POS	O
,	POS	O
pethidine	POS	O
may	POS	O
cause	POS	O
excitatory	POS	O
central	POS	O
nervous	POS	O
system	POS	O
(	POS	O
CNS	POS	O
)	POS	O
effects	POS	O
through	POS	O
its	POS	O
neurotoxic	POS	O
metabolite	POS	O
,	POS	O
norpethidine	POS	O
,	POS	O
resulting	POS	O
in	POS	O
irritability	POS	B-NP
and	POS	O
seizure	POS	B-NP
attack	POS	O
.	POS	O
On	POS	O
the	POS	O
contrary	POS	O
,	POS	O
though	POS	O
not	POS	O
clinically	POS	O
apparent	POS	O
,	POS	O
pethidine	POS	O
potentially	POS	O
causes	POS	O
inhibitory	POS	O
impacts	POS	O
on	POS	O
the	POS	O
CNS	POS	O
and	POS	O
impairs	POS	O
normal	POS	O
cerebellar	POS	O
and	POS	O
oculomotor	POS	O
function	POS	O
in	POS	O
the	POS	O
short	POS	O
term	POS	O
.	POS	O
In	POS	O
this	POS	O
case	POS	O
report	POS	O
,	POS	O
we	POS	O
highlight	POS	O
opioid	POS	O
'	POS	O
s	POS	O
inhibitory	POS	O
side	POS	O
effects	POS	O
on	POS	O
the	POS	O
cerebellar	POS	O
structure	POS	O
that	POS	O
causes	POS	O
dysmetria	POS	B-NP
,	POS	O
dysarthria	POS	B-NP
,	POS	O
reduced	POS	O
smooth	POS	O
pursuit	POS	O
gain	POS	O
and	POS	O
decreased	POS	O
saccadic	POS	O
velocity	POS	O
.	POS	O
Baboon	POS	B-NP
syndrome	POS	I-NP
induced	POS	O
by	POS	O
ketoconazole	POS	O
.	POS	O
A	POS	O
27	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
patient	POS	O
presented	POS	O
with	POS	O
a	POS	O
maculopapular	POS	B-NP
eruption	POS	I-NP
on	POS	O
the	POS	O
flexural	POS	O
areas	POS	O
and	POS	O
buttocks	POS	O
after	POS	O
using	POS	O
oral	POS	O
ketoconazole	POS	O
.	POS	O
The	POS	O
patient	POS	O
was	POS	O
diagnosed	POS	O
with	POS	O
drug	POS	O
-	POS	O
induced	POS	O
baboon	POS	B-NP
syndrome	POS	I-NP
based	POS	O
on	POS	O
his	POS	O
history	POS	O
,	POS	O
which	POS	O
included	POS	O
prior	POS	O
sensitivity	POS	O
to	POS	O
topical	POS	O
ketoconazole	POS	O
,	POS	O
a	POS	O
physical	POS	O
examination	POS	O
,	POS	O
and	POS	O
histopathological	POS	O
findings	POS	O
.	POS	O
Baboon	POS	B-NP
syndrome	POS	I-NP
is	POS	O
a	POS	O
drug	POS	O
-	POS	O
or	POS	O
contact	POS	O
allergen	POS	O
-	POS	O
related	POS	O
maculopapular	POS	B-NP
eruption	POS	I-NP
that	POS	O
typically	POS	O
involves	POS	O
the	POS	O
flexural	POS	O
and	POS	O
gluteal	POS	O
areas	POS	O
.	POS	O
To	POS	O
the	POS	O
best	POS	O
of	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
this	POS	O
is	POS	O
the	POS	O
first	POS	O
reported	POS	O
case	POS	O
of	POS	O
ketoconazole	POS	O
-	POS	O
induced	POS	O
baboon	POS	B-NP
syndrome	POS	I-NP
in	POS	O
the	POS	O
English	POS	O
literature	POS	O
.	POS	O
A	POS	O
Case	POS	O
of	POS	O
Sudden	POS	B-NP
Cardiac	POS	I-NP
Death	POS	I-NP
due	POS	O
to	POS	O
Pilsicainide	POS	O
-	POS	O
Induced	POS	O
Torsades	POS	O
de	POS	O
Pointes	POS	B-NP
.	POS	O
An	POS	O
84	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
received	POS	O
oral	POS	O
pilsicainide	POS	O
,	POS	O
a	POS	O
pure	POS	O
sodium	POS	O
channel	POS	O
blocker	POS	O
with	POS	O
slow	POS	O
recovery	POS	O
kinetics	POS	O
,	POS	O
to	POS	O
convert	POS	O
his	POS	O
paroxysmal	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
to	POS	O
a	POS	O
sinus	POS	O
rhythm	POS	O
;	POS	O
the	POS	O
patient	POS	O
developed	POS	O
sudden	POS	O
cardiac	POS	B-NP
death	POS	I-NP
two	POS	O
days	POS	O
later	POS	O
.	POS	O
The	POS	O
Holter	POS	O
electrocardiogram	POS	O
,	POS	O
which	POS	O
was	POS	O
worn	POS	O
by	POS	O
chance	POS	O
,	POS	O
revealed	POS	O
torsade	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
with	POS	O
gradually	POS	O
prolonged	POS	O
QT	POS	O
intervals	POS	O
.	POS	O
This	POS	O
drug	POS	O
is	POS	O
rapidly	POS	O
absorbed	POS	O
from	POS	O
the	POS	O
gastrointestinal	POS	O
tract	POS	O
,	POS	O
and	POS	O
most	POS	O
of	POS	O
it	POS	O
is	POS	O
excreted	POS	O
from	POS	O
the	POS	O
kidney	POS	O
.	POS	O
Although	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
renal	POS	O
function	POS	O
was	POS	O
not	POS	O
highly	POS	O
impaired	POS	O
and	POS	O
the	POS	O
dose	POS	O
of	POS	O
pilsicainide	POS	O
was	POS	O
low	POS	O
,	POS	O
the	POS	O
plasma	POS	O
concentration	POS	O
of	POS	O
pilsicainide	POS	O
may	POS	O
have	POS	O
been	POS	O
high	POS	O
,	POS	O
which	POS	O
can	POS	O
produce	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
in	POS	O
the	POS	O
octogenarian	POS	O
.	POS	O
Although	POS	O
the	POS	O
oral	POS	O
administration	POS	O
of	POS	O
class	POS	O
IC	POS	O
drugs	POS	O
,	POS	O
including	POS	O
pilsicainide	POS	O
,	POS	O
is	POS	O
effective	POS	O
to	POS	O
terminate	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
,	POS	O
careful	POS	O
consideration	POS	O
must	POS	O
be	POS	O
taken	POS	O
before	POS	O
giving	POS	O
these	POS	O
drugs	POS	O
to	POS	O
octogenarians	POS	O
.	POS	O
All	POS	O
-	POS	O
trans	POS	O
retinoic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
inflammatory	POS	B-NP
myositis	POS	I-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
acute	POS	B-NP
promyelocytic	POS	I-NP
leukemia	POS	I-NP
.	POS	O
All	POS	O
-	POS	O
trans	POS	O
retinoic	POS	O
acid	POS	O
(	POS	O
ATRA	POS	O
)	POS	O
,	POS	O
a	POS	O
component	POS	O
of	POS	O
standard	POS	O
therapy	POS	O
for	POS	O
acute	POS	B-NP
promyelocytic	POS	I-NP
leukemia	POS	I-NP
(	POS	O
APL	POS	B-NP
)	POS	O
,	POS	O
is	POS	O
associated	POS	O
with	POS	O
potentially	POS	O
serious	POS	O
but	POS	O
treatable	POS	O
adverse	POS	O
effects	POS	O
involving	POS	O
numerous	POS	O
organ	POS	O
systems	POS	O
,	POS	O
including	POS	O
rare	POS	O
skeletal	POS	O
muscle	POS	O
involvement	POS	O
.	POS	O
Only	POS	O
a	POS	O
handful	POS	O
of	POS	O
cases	POS	O
of	POS	O
ATRA	POS	O
-	POS	O
induced	POS	O
myositis	POS	B-NP
in	POS	O
children	POS	O
have	POS	O
been	POS	O
reported	POS	O
,	POS	O
and	POS	O
none	POS	O
in	POS	O
the	POS	O
radiology	POS	O
literature	POS	O
.	POS	O
We	POS	O
present	POS	O
such	POS	O
a	POS	O
case	POS	O
in	POS	O
a	POS	O
15	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
boy	POS	O
with	POS	O
APL	POS	B-NP
,	POS	O
where	POS	O
recognition	POS	O
of	POS	O
imaging	POS	O
findings	POS	O
played	POS	O
a	POS	O
crucial	POS	O
role	POS	O
in	POS	O
making	POS	O
the	POS	O
diagnosis	POS	O
and	POS	O
facilitated	POS	O
prompt	POS	O
,	POS	O
effective	POS	O
treatment	POS	O
.	POS	O
Tolerability	POS	O
of	POS	O
lomustine	POS	O
in	POS	O
combination	POS	O
with	POS	O
cyclophosphamide	POS	O
in	POS	O
dogs	POS	O
with	POS	O
lymphoma	POS	B-NP
.	POS	O
This	POS	O
retrospective	POS	O
study	POS	O
describes	POS	O
toxicity	POS	B-NP
associated	POS	O
with	POS	O
a	POS	O
protocol	POS	O
of	POS	O
lomustine	POS	O
(	POS	O
CCNU	POS	O
)	POS	O
and	POS	O
cyclophosphamide	POS	O
(	POS	O
CTX	POS	O
)	POS	O
in	POS	O
dogs	POS	O
with	POS	O
lymphoma	POS	B-NP
.	POS	O
CCNU	POS	O
was	POS	O
administered	POS	O
per	POS	O
os	POS	O
(	POS	O
PO	POS	O
)	POS	O
at	POS	O
a	POS	O
targeted	POS	O
dosage	POS	O
of	POS	O
60	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
body	POS	O
surface	POS	O
area	POS	O
on	POS	O
day	POS	O
0	POS	O
,	POS	O
CTX	POS	O
was	POS	O
administered	POS	O
PO	POS	O
at	POS	O
a	POS	O
targeted	POS	O
dosage	POS	O
of	POS	O
250	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
divided	POS	O
over	POS	O
days	POS	O
0	POS	O
through	POS	O
4	POS	O
,	POS	O
and	POS	O
all	POS	O
dogs	POS	O
received	POS	O
prophylactic	POS	O
antibiotics	POS	O
.	POS	O
Ninety	POS	O
treatments	POS	O
were	POS	O
given	POS	O
to	POS	O
the	POS	O
57	POS	O
dogs	POS	O
included	POS	O
in	POS	O
the	POS	O
study	POS	O
.	POS	O
Neutropenia	POS	B-NP
was	POS	O
the	POS	O
principal	POS	O
toxic	POS	O
effect	POS	O
,	POS	O
and	POS	O
the	POS	O
overall	POS	O
frequency	POS	O
of	POS	O
grade	POS	O
4	POS	O
neutropenia	POS	B-NP
after	POS	O
the	POS	O
first	POS	O
treatment	POS	O
of	POS	O
CCNU	POS	O
/	POS	O
CTX	POS	B-NP
was	POS	O
30	POS	O
%	POS	O
(	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
,	POS	O
19	POS	O
-	POS	O
43	POS	O
%	POS	O
)	POS	O
.	POS	O
The	POS	O
mean	POS	O
body	POS	O
weight	POS	O
of	POS	O
dogs	POS	O
with	POS	O
grade	POS	O
4	POS	O
neutropenia	POS	B-NP
(	POS	O
19	POS	O
.	POS	O
7	POS	O
kg	POS	O
+	POS	O
13	POS	O
.	POS	O
4	POS	O
kg	POS	O
)	POS	O
was	POS	O
significantly	POS	O
less	POS	O
than	POS	O
the	POS	O
mean	POS	O
body	POS	O
weight	POS	O
of	POS	O
dogs	POS	O
that	POS	O
did	POS	O
not	POS	O
develop	POS	O
grade	POS	O
4	POS	O
neutropenia	POS	B-NP
(	POS	O
31	POS	O
.	POS	O
7	POS	O
kg	POS	O
+	POS	O
12	POS	O
.	POS	O
4	POS	O
kg	POS	O
;	POS	O
P	POS	O
=	POS	O
.	POS	O
005	POS	O
)	POS	O
.	POS	O
One	POS	O
dog	POS	O
(	POS	O
3	POS	O
%	POS	O
)	POS	O
developed	POS	O
hematologic	POS	O
changes	POS	O
suggestive	POS	O
of	POS	O
hepatotoxicity	POS	B-NP
.	POS	O
No	POS	O
dogs	POS	O
had	POS	O
evidence	POS	O
of	POS	O
either	POS	O
renal	POS	B-NP
toxicity	POS	I-NP
or	POS	O
hemorrhagic	POS	B-NP
cystitis	POS	I-NP
.	POS	O
Adverse	POS	O
gastrointestinal	POS	O
effects	POS	O
were	POS	O
uncommon	POS	O
.	POS	O
On	POS	O
the	POS	O
basis	POS	O
of	POS	O
the	POS	O
findings	POS	O
reported	POS	O
herein	POS	O
,	POS	O
a	POS	O
dose	POS	O
of	POS	O
60	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
of	POS	O
CCNU	POS	O
combined	POS	O
with	POS	O
250	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
of	POS	O
CTX	POS	B-NP
(	POS	O
divided	POS	O
over	POS	O
5	POS	O
days	POS	O
)	POS	O
q	POS	O
4	POS	O
wk	POS	O
is	POS	O
tolerable	POS	O
in	POS	O
tumor	POS	B-NP
-	POS	O
bearing	POS	O
dogs	POS	O
.	POS	O
Nelarabine	POS	O
neurotoxicity	POS	B-NP
with	POS	O
concurrent	POS	O
intrathecal	POS	O
chemotherapy	POS	O
:	POS	O
Case	POS	O
report	POS	O
and	POS	O
review	POS	O
of	POS	O
literature	POS	O
.	POS	O
Severe	POS	O
nelarabine	POS	O
neurotoxicity	POS	B-NP
in	POS	O
a	POS	O
patient	POS	O
who	POS	O
received	POS	O
concurrent	POS	O
intrathecal	POS	O
(	POS	O
IT	POS	O
)	POS	O
chemotherapy	POS	O
is	POS	O
reported	POS	O
.	POS	O
A	POS	O
37	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
Caucasian	POS	O
woman	POS	O
with	POS	O
a	POS	O
history	POS	O
of	POS	O
T	POS	B-NP
-	POS	I-NP
cell	POS	I-NP
lymphoblastic	POS	I-NP
lymphoma	POS	I-NP
was	POS	O
admitted	POS	O
for	POS	O
relapsed	POS	B-NP
disease	POS	I-NP
.	POS	O
She	POS	O
was	POS	O
originally	POS	O
treated	POS	O
with	POS	O
induction	POS	O
chemotherapy	POS	O
followed	POS	O
by	POS	O
an	POS	O
autologous	POS	O
transplant	POS	O
.	POS	O
She	POS	O
developed	POS	O
relapsed	POS	B-NP
disease	POS	I-NP
10	POS	O
months	POS	O
later	POS	O
with	POS	O
leukemic	POS	B-NP
involvement	POS	I-NP
.	POS	O
She	POS	O
was	POS	O
re	POS	O
-	POS	O
induced	POS	O
with	POS	O
nelarabine	POS	O
1500	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
on	POS	O
days	POS	O
1	POS	O
,	POS	O
3	POS	O
,	POS	O
and	POS	O
5	POS	O
with	POS	O
1	POS	O
dose	POS	O
of	POS	O
IT	POS	O
cytarabine	POS	O
100	POS	O
mg	POS	O
on	POS	O
day	POS	O
2	POS	O
as	POS	O
central	POS	O
nervous	POS	O
system	POS	O
(	POS	O
CNS	POS	O
)	POS	O
prophylaxis	POS	O
.	POS	O
At	POS	O
the	POS	O
time	POS	O
of	POS	O
treatment	POS	O
,	POS	O
she	POS	O
was	POS	O
on	POS	O
continuous	POS	O
renal	POS	O
replacement	POS	O
therapy	POS	O
due	POS	O
to	POS	O
sequelae	POS	O
of	POS	O
tumor	POS	B-NP
lysis	POS	I-NP
syndrome	POS	I-NP
(	POS	O
TLS	POS	O
)	POS	O
.	POS	O
She	POS	O
tolerated	POS	O
therapy	POS	O
well	POS	O
,	POS	O
entered	POS	O
a	POS	O
complete	POS	O
remission	POS	O
,	POS	O
and	POS	O
recovered	POS	O
her	POS	O
renal	POS	O
function	POS	O
.	POS	O
She	POS	O
received	POS	O
a	POS	O
second	POS	O
cycle	POS	O
of	POS	O
nelarabine	POS	O
without	POS	O
additional	POS	O
IT	POS	O
prophylaxis	POS	O
one	POS	O
month	POS	O
later	POS	O
.	POS	O
A	POS	O
week	POS	O
after	POS	O
this	POS	O
second	POS	O
cycle	POS	O
,	POS	O
she	POS	O
noted	POS	O
numbness	POS	B-NP
in	POS	O
her	POS	O
lower	POS	O
extremities	POS	O
.	POS	O
Predominantly	POS	O
sensory	POS	O
,	POS	O
though	POS	O
also	POS	O
motor	POS	O
and	POS	O
autonomic	POS	O
,	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
started	POS	O
in	POS	O
her	POS	O
feet	POS	O
,	POS	O
ascended	POS	O
proximally	POS	O
to	POS	O
the	POS	O
mid	POS	O
-	POS	O
thoracic	POS	O
region	POS	O
,	POS	O
and	POS	O
eventually	POS	O
included	POS	O
her	POS	O
distal	POS	O
upper	POS	O
extremities	POS	O
.	POS	O
A	POS	O
magnetic	POS	O
resonance	POS	O
imaging	POS	O
(	POS	O
MRI	POS	O
)	POS	O
of	POS	O
her	POS	O
spine	POS	O
demonstrated	POS	O
changes	POS	O
from	POS	O
C2	POS	O
to	POS	O
C6	POS	O
consistent	POS	O
with	POS	O
subacute	POS	O
combined	POS	O
degeneration	POS	O
.	POS	O
Nelarabine	POS	O
was	POS	O
felt	POS	O
to	POS	O
be	POS	O
the	POS	O
cause	POS	O
of	POS	O
her	POS	O
symptoms	POS	O
.	POS	O
Her	POS	B-NP
neuropathy	POS	I-NP
stabilized	POS	O
and	POS	O
showed	POS	O
slight	POS	O
improvement	POS	O
and	POS	O
ultimately	POS	O
received	POS	O
an	POS	O
unrelated	POS	O
,	POS	O
reduced	POS	O
-	POS	O
intensity	POS	O
allogeneic	POS	O
transplant	POS	O
while	POS	O
in	POS	O
complete	POS	O
remission	POS	O
,	POS	O
but	POS	O
relapsed	POS	B-NP
disease	POS	I-NP
10	POS	O
weeks	POS	O
later	POS	O
.	POS	O
She	POS	O
is	POS	O
currently	POS	O
being	POS	O
treated	POS	O
with	POS	O
best	POS	O
supportive	POS	O
care	POS	O
.	POS	O
To	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
this	POS	O
is	POS	O
the	POS	O
first	POS	O
published	POS	O
case	POS	O
report	POS	O
of	POS	O
severe	POS	O
neurotoxicity	POS	B-NP
caused	POS	O
by	POS	O
nelarabine	POS	O
in	POS	O
a	POS	O
patient	POS	O
who	POS	O
received	POS	O
concurrent	POS	O
IT	POS	O
chemotherapy	POS	O
.	POS	O
Valproate	POS	O
-	POS	O
induced	POS	O
hyperammonemic	POS	B-NP
encephalopathy	POS	I-NP
in	POS	O
a	POS	O
renal	POS	O
transplanted	POS	O
patient	POS	O
.	POS	O
Neurological	POS	B-NP
complications	POS	I-NP
after	POS	O
renal	POS	O
transplantation	POS	O
constitute	POS	O
an	POS	O
important	POS	O
cause	POS	O
of	POS	O
morbidity	POS	O
and	POS	O
mortality	POS	O
.	POS	O
Their	POS	O
differential	POS	O
diagnosis	POS	O
is	POS	O
difficult	POS	O
and	POS	O
essential	POS	O
for	POS	O
subsequent	POS	O
patient	POS	O
'	POS	O
s	POS	O
management	POS	O
.	POS	O
Valproate	POS	O
-	POS	O
induced	POS	O
hyperammonemic	POS	B-NP
encephalopathy	POS	I-NP
is	POS	O
an	POS	O
uncommon	POS	O
but	POS	O
serious	POS	O
effect	POS	O
of	POS	O
valproate	POS	O
treatment	POS	O
.	POS	O
Here	POS	O
,	POS	O
we	POS	O
describe	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
15	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
girl	POS	O
who	POS	O
was	POS	O
on	POS	O
a	POS	O
long	POS	O
-	POS	O
term	POS	O
therapy	POS	O
with	POS	O
valproate	POS	O
due	POS	O
to	POS	O
epilepsy	POS	B-NP
and	POS	O
revealed	POS	O
impaired	POS	B-NP
consciousness	POS	I-NP
with	POS	O
hyperammonemia	POS	B-NP
12	POS	O
days	POS	O
after	POS	O
renal	POS	O
transplantation	POS	O
.	POS	O
After	POS	O
withdraw	POS	O
of	POS	O
valproate	POS	O
,	POS	O
patients	POS	O
'	POS	O
symptoms	POS	O
resolved	POS	O
within	POS	O
24	POS	O
h	POS	O
.	POS	O
Clinicians	POS	O
should	POS	O
increase	POS	O
their	POS	O
awareness	POS	O
for	POS	O
potential	POS	O
complication	POS	O
of	POS	O
valproate	POS	O
,	POS	O
especially	POS	O
in	POS	O
transplanted	POS	O
patients	POS	O
.	POS	O
Necrotising	POS	B-NP
fasciitis	POS	I-NP
after	POS	O
bortezomib	POS	O
and	POS	O
dexamethasone	POS	O
-	POS	O
containing	POS	O
regimen	POS	O
in	POS	O
an	POS	O
elderly	POS	O
patient	POS	O
of	POS	O
Waldenstrom	POS	B-NP
macroglobulinaemia	POS	I-NP
.	POS	O
Bortezomib	POS	O
and	POS	O
high	POS	O
-	POS	O
dose	POS	O
dexamethasone	POS	O
-	POS	O
containing	POS	O
regimens	POS	O
are	POS	O
considered	POS	O
to	POS	O
be	POS	O
generally	POS	O
tolerable	POS	O
with	POS	O
few	POS	O
severe	POS	O
bacterial	POS	B-NP
infections	POS	I-NP
in	POS	O
patients	POS	O
with	POS	O
B	POS	B-NP
-	POS	I-NP
cell	POS	I-NP
malignancies	POS	I-NP
.	POS	O
However	POS	O
,	POS	O
information	POS	O
is	POS	O
limited	POS	O
concerning	POS	O
the	POS	O
safety	POS	O
of	POS	O
the	POS	O
regimen	POS	O
in	POS	O
elderly	POS	O
patients	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
a	POS	O
76	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
with	POS	O
Waldenstrom	POS	B-NP
macroglobulinaemia	POS	I-NP
who	POS	O
suffered	POS	O
necrotising	POS	B-NP
fasciitis	POS	I-NP
without	POS	O
neutropenia	POS	B-NP
after	POS	O
the	POS	O
combination	POS	O
treatment	POS	O
with	POS	O
bortezomib	POS	O
,	POS	O
high	POS	O
-	POS	O
dose	POS	O
dexamethasone	POS	O
and	POS	O
rituximab	POS	O
.	POS	O
Despite	POS	O
immediate	POS	O
intravenous	POS	O
antimicrobial	POS	O
therapy	POS	O
,	POS	O
he	POS	O
succumbed	POS	O
23	POS	O
h	POS	O
after	POS	O
the	POS	O
onset	POS	O
.	POS	O
Physicians	POS	O
should	POS	O
recognise	POS	O
the	POS	O
possibility	POS	O
of	POS	O
fatal	POS	O
bacterial	POS	B-NP
infections	POS	I-NP
related	POS	O
to	POS	O
bortezomib	POS	O
plus	POS	O
high	POS	O
-	POS	O
dose	POS	O
dexamethasone	POS	O
in	POS	O
elderly	POS	O
patients	POS	O
,	POS	O
and	POS	O
we	POS	O
believe	POS	O
this	POS	O
case	POS	O
warrants	POS	O
further	POS	O
investigation	POS	O
.	POS	O
An	POS	O
integrated	POS	O
characterization	POS	O
of	POS	O
serological	POS	O
,	POS	O
pathological	POS	O
,	POS	O
and	POS	O
functional	POS	O
events	POS	O
in	POS	O
doxorubicin	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
Many	POS	O
efficacious	POS	O
cancer	POS	B-NP
treatments	POS	O
cause	POS	O
significant	POS	O
cardiac	POS	B-NP
morbidity	POS	I-NP
,	POS	O
yet	POS	O
biomarkers	POS	O
or	POS	O
functional	POS	O
indices	POS	O
of	POS	O
early	POS	O
damage	POS	O
,	POS	O
which	POS	O
would	POS	O
allow	POS	O
monitoring	POS	O
and	POS	O
intervention	POS	O
,	POS	O
are	POS	O
lacking	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
we	POS	O
have	POS	O
utilized	POS	O
a	POS	O
rat	POS	O
model	POS	O
of	POS	O
progressive	POS	O
doxorubicin	POS	O
(	POS	O
DOX	POS	O
)	POS	O
-	POS	O
induced	POS	O
cardiomyopathy	POS	B-NP
,	POS	O
applying	POS	O
multiple	POS	O
approaches	POS	O
,	POS	O
including	POS	O
cardiac	POS	O
magnetic	POS	O
resonance	POS	O
imaging	POS	O
(	POS	O
MRI	POS	O
)	POS	O
,	POS	O
to	POS	O
provide	POS	O
the	POS	O
most	POS	O
comprehensive	POS	O
characterization	POS	O
to	POS	O
date	POS	O
of	POS	O
the	POS	O
timecourse	POS	O
of	POS	O
serological	POS	O
,	POS	O
pathological	POS	O
,	POS	O
and	POS	O
functional	POS	O
events	POS	O
underlying	POS	O
this	POS	O
toxicity	POS	B-NP
.	POS	O
Hannover	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
dosed	POS	O
with	POS	O
1	POS	O
.	POS	O
25	POS	O
mg	POS	O
/	POS	O
kg	POS	O
DOX	POS	O
weekly	POS	O
for	POS	O
8	POS	O
weeks	POS	O
followed	POS	O
by	POS	O
a	POS	O
4	POS	O
week	POS	O
off	POS	O
-	POS	O
dosing	POS	O
"	POS	O
recovery	POS	O
"	POS	O
period	POS	O
.	POS	O
Electron	POS	O
microscopy	POS	O
of	POS	O
the	POS	O
myocardium	POS	O
revealed	POS	O
subcellular	POS	O
degeneration	POS	O
and	POS	O
marked	POS	O
mitochondrial	POS	O
changes	POS	O
after	POS	O
a	POS	O
single	POS	O
dose	POS	O
.	POS	O
Histopathological	POS	O
analysis	POS	O
revealed	POS	O
progressive	POS	O
cardiomyocyte	POS	B-NP
degeneration	POS	I-NP
,	POS	O
hypertrophy	POS	B-NP
/	POS	I-NP
cytomegaly	POS	I-NP
,	POS	O
and	POS	O
extensive	POS	O
vacuolation	POS	O
after	POS	O
two	POS	O
doses	POS	O
.	POS	O
Extensive	POS	O
replacement	POS	O
fibrosis	POS	B-NP
(	POS	O
quantified	POS	O
by	POS	O
Sirius	POS	O
red	POS	O
staining	POS	O
)	POS	O
developed	POS	O
during	POS	O
the	POS	O
off	POS	O
-	POS	O
dosing	POS	O
period	POS	O
.	POS	O
Functional	POS	O
indices	POS	O
assessed	POS	O
by	POS	O
cardiac	POS	O
MRI	POS	O
(	POS	O
including	POS	O
left	POS	O
ventricular	POS	O
ejection	POS	O
fraction	POS	O
(	POS	O
LVEF	POS	O
)	POS	O
,	POS	O
cardiac	POS	O
output	POS	O
,	POS	O
and	POS	O
E	POS	O
/	POS	O
A	POS	O
ratio	POS	O
)	POS	O
declined	POS	O
progressively	POS	O
,	POS	O
reaching	POS	O
statistical	POS	O
significance	POS	O
after	POS	O
two	POS	O
doses	POS	O
and	POS	O
culminating	POS	O
in	POS	O
"	POS	O
clinical	POS	O
"	POS	O
LV	POS	B-NP
dysfunction	POS	I-NP
by	POS	O
12	POS	O
weeks	POS	O
.	POS	O
Significant	POS	O
increases	POS	O
in	POS	O
peak	POS	O
myocardial	POS	O
contrast	POS	O
enhancement	POS	O
and	POS	O
serological	POS	O
cardiac	POS	O
troponin	POS	O
I	POS	O
(	POS	O
cTnI	POS	O
)	POS	O
emerged	POS	O
after	POS	O
eight	POS	O
doses	POS	O
,	POS	O
importantly	POS	O
preceding	POS	O
the	POS	O
LVEF	POS	O
decline	POS	O
to	POS	O
<	POS	O
50	POS	O
%	POS	O
.	POS	O
Troponin	POS	O
I	POS	O
levels	POS	O
positively	POS	O
correlated	POS	O
with	POS	O
delayed	POS	O
and	POS	O
peak	POS	O
gadolinium	POS	O
contrast	POS	O
enhancement	POS	O
,	POS	O
histopathological	POS	O
grading	POS	O
,	POS	O
and	POS	O
diastolic	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
In	POS	O
summary	POS	O
,	POS	O
subcellular	POS	O
cardiomyocyte	POS	B-NP
degeneration	POS	I-NP
was	POS	O
the	POS	O
earliest	POS	O
marker	POS	O
,	POS	O
followed	POS	O
by	POS	O
progressive	POS	O
functional	POS	O
decline	POS	O
and	POS	O
histopathological	POS	O
manifestations	POS	O
.	POS	O
Myocardial	POS	O
contrast	POS	O
enhancement	POS	O
and	POS	O
elevations	POS	O
in	POS	O
cTnI	POS	O
occurred	POS	O
later	POS	O
.	POS	O
However	POS	O
,	POS	O
all	POS	O
indices	POS	O
predated	POS	O
"	POS	O
clinical	POS	O
"	POS	O
LV	POS	B-NP
dysfunction	POS	I-NP
and	POS	O
thus	POS	O
warrant	POS	O
further	POS	O
evaluation	POS	O
as	POS	O
predictive	POS	O
biomarkers	POS	O
.	POS	O
Intradermal	POS	O
glutamate	POS	O
and	POS	O
capsaicin	POS	O
injections	POS	O
:	POS	O
intra	POS	O
-	POS	O
and	POS	O
interindividual	POS	O
variability	POS	O
of	POS	O
provoked	POS	O
hyperalgesia	POS	B-NP
and	POS	O
allodynia	POS	B-NP
.	POS	O
Intradermal	POS	O
injections	POS	O
of	POS	O
glutamate	POS	O
and	POS	O
capsaicin	POS	O
are	POS	O
attractive	POS	O
to	POS	O
use	POS	O
in	POS	O
human	POS	O
experimental	POS	O
pain	POS	B-NP
models	POS	O
because	POS	O
hyperalgesia	POS	B-NP
and	POS	O
allodynia	POS	B-NP
mimic	POS	O
isolated	POS	O
aspects	POS	O
of	POS	O
clinical	POS	O
pain	POS	B-NP
disorders	POS	I-NP
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
the	POS	O
reproducibility	POS	O
of	POS	O
these	POS	O
models	POS	O
.	POS	O
Twenty	POS	O
healthy	POS	O
male	POS	O
volunteers	POS	O
(	POS	O
mean	POS	O
age	POS	O
24	POS	O
years	POS	O
;	POS	O
range	POS	O
18	POS	O
-	POS	O
38	POS	O
years	POS	O
)	POS	O
received	POS	O
intradermal	POS	O
injections	POS	O
of	POS	O
glutamate	POS	O
and	POS	O
capsaicin	POS	O
in	POS	O
the	POS	O
volar	POS	O
forearm	POS	O
.	POS	O
Magnitudes	POS	O
of	POS	O
secondary	POS	O
pinprick	POS	O
hyperalgesia	POS	B-NP
and	POS	O
brush	POS	O
-	POS	O
evoked	POS	O
allodynia	POS	B-NP
were	POS	O
investigated	POS	O
using	POS	O
von	POS	O
Frey	POS	O
filaments	POS	O
(	POS	O
gauges	POS	O
10	POS	O
,	POS	O
15	POS	O
,	POS	O
60	POS	O
and	POS	O
100	POS	O
g	POS	O
)	POS	O
and	POS	O
brush	POS	O
strokes	POS	B-NP
.	POS	O
Areas	POS	O
of	POS	O
secondary	POS	O
hyperalgesia	POS	B-NP
and	POS	O
allodynia	POS	B-NP
were	POS	O
quantified	POS	O
immediately	POS	O
after	POS	O
injection	POS	O
and	POS	O
after	POS	O
15	POS	O
,	POS	O
30	POS	O
and	POS	O
60	POS	O
min	POS	O
.	POS	O
Two	POS	O
identical	POS	O
experiments	POS	O
separated	POS	O
by	POS	O
at	POS	O
least	POS	O
7	POS	O
days	POS	O
were	POS	O
performed	POS	O
.	POS	O
Reproducibility	POS	O
across	POS	O
and	POS	O
within	POS	O
volunteers	POS	O
(	POS	O
inter	POS	O
-	POS	O
and	POS	O
intra	POS	O
-	POS	O
individual	POS	O
variation	POS	O
,	POS	O
respectively	POS	O
)	POS	O
was	POS	O
assessed	POS	O
using	POS	O
intraclass	POS	O
correlation	POS	O
coefficient	POS	O
(	POS	O
ICC	POS	O
)	POS	O
and	POS	O
coefficient	POS	O
of	POS	O
variation	POS	O
(	POS	O
CV	POS	O
)	POS	O
.	POS	O
Secondary	POS	B-NP
pinprick	POS	I-NP
hyperalgesia	POS	I-NP
was	POS	O
observed	POS	O
as	POS	O
a	POS	O
marked	POS	O
increase	POS	O
in	POS	O
the	POS	O
visual	POS	O
analogue	POS	O
scale	POS	O
(	POS	O
VAS	POS	O
)	POS	O
response	POS	O
to	POS	O
von	POS	O
Frey	POS	O
gauges	POS	O
60	POS	O
and	POS	O
100	POS	O
g	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
after	POS	O
glutamate	POS	O
injection	POS	O
.	POS	O
For	POS	O
capsaicin	POS	O
,	POS	O
secondary	POS	O
pinprick	POS	O
hyperalgesia	POS	B-NP
was	POS	O
detected	POS	O
with	POS	O
all	POS	O
von	POS	O
Frey	POS	O
gauges	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Glutamate	POS	O
evoked	POS	O
reproducible	POS	O
VAS	POS	O
response	POS	O
to	POS	O
all	POS	O
von	POS	O
Frey	POS	O
gauges	POS	O
(	POS	O
ICC	POS	O
>	POS	O
0	POS	O
.	POS	O
60	POS	O
)	POS	O
and	POS	O
brush	POS	O
strokes	POS	B-NP
(	POS	O
ICC	POS	O
>	POS	O
0	POS	O
.	POS	O
83	POS	O
)	POS	O
.	POS	O
Capsaicin	POS	O
injection	POS	O
was	POS	O
reproducible	POS	O
for	POS	O
secondary	POS	O
hyperalgesia	POS	B-NP
(	POS	O
ICC	POS	O
>	POS	O
0	POS	O
.	POS	O
70	POS	O
)	POS	O
and	POS	O
allodynia	POS	B-NP
(	POS	O
ICC	POS	O
>	POS	O
0	POS	O
.	POS	O
71	POS	O
)	POS	O
.	POS	O
Intra	POS	O
-	POS	O
individual	POS	O
variability	POS	O
was	POS	O
generally	POS	O
lower	POS	O
for	POS	O
the	POS	O
VAS	POS	O
response	POS	O
to	POS	O
von	POS	O
Frey	POS	O
and	POS	O
brush	POS	O
compared	POS	O
with	POS	O
areas	POS	O
of	POS	O
secondary	POS	O
hyperalgesia	POS	B-NP
and	POS	O
allodynia	POS	B-NP
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
glutamate	POS	O
and	POS	O
capsaicin	POS	O
yield	POS	O
reproducible	POS	O
hyperalgesic	POS	B-NP
and	POS	O
allodynic	POS	O
responses	POS	O
,	POS	O
and	POS	O
the	POS	O
present	POS	O
model	POS	O
is	POS	O
well	POS	O
suited	POS	O
for	POS	O
basic	POS	O
research	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
for	POS	O
assessing	POS	O
the	POS	O
modulation	POS	O
of	POS	O
central	POS	O
phenomena	POS	O
.	POS	O
Ocular	POS	O
-	POS	O
specific	POS	O
ER	POS	O
stress	POS	O
reduction	POS	O
rescues	POS	O
glaucoma	POS	B-NP
in	POS	O
murine	POS	O
glucocorticoid	POS	O
-	POS	O
induced	POS	O
glaucoma	POS	B-NP
.	POS	O
Administration	POS	O
of	POS	O
glucocorticoids	POS	O
induces	POS	O
ocular	POS	O
hypertension	POS	B-NP
in	POS	O
some	POS	O
patients	POS	O
.	POS	O
If	POS	O
untreated	POS	O
,	POS	O
these	POS	O
patients	POS	O
can	POS	O
develop	POS	O
a	POS	O
secondary	POS	O
glaucoma	POS	B-NP
that	POS	O
resembles	POS	O
primary	POS	O
open	POS	O
-	POS	O
angle	POS	O
glaucoma	POS	B-NP
(	POS	O
POAG	POS	B-NP
)	POS	O
.	POS	O
The	POS	O
underlying	POS	O
pathology	POS	O
of	POS	O
glucocorticoid	POS	O
-	POS	O
induced	POS	O
glaucoma	POS	B-NP
is	POS	O
not	POS	O
fully	POS	O
understood	POS	O
,	POS	O
due	POS	O
in	POS	O
part	POS	O
to	POS	O
lack	POS	O
of	POS	O
an	POS	O
appropriate	POS	O
animal	POS	O
model	POS	O
.	POS	O
Here	POS	O
,	POS	O
we	POS	O
developed	POS	O
a	POS	O
murine	POS	O
model	POS	O
of	POS	O
glucocorticoid	POS	O
-	POS	O
induced	POS	O
glaucoma	POS	B-NP
that	POS	O
exhibits	POS	O
glaucoma	POS	B-NP
features	POS	O
that	POS	O
are	POS	O
observed	POS	O
in	POS	O
patients	POS	O
.	POS	O
Treatment	POS	O
of	POS	O
WT	POS	O
mice	POS	O
with	POS	O
topical	POS	O
ocular	POS	O
0	POS	O
.	POS	O
1	POS	O
%	POS	O
dexamethasone	POS	O
led	POS	O
to	POS	O
elevation	POS	O
of	POS	O
intraocular	POS	O
pressure	POS	O
(	POS	O
IOP	POS	O
)	POS	O
,	POS	O
functional	POS	O
and	POS	O
structural	POS	O
loss	POS	O
of	POS	O
retinal	POS	O
ganglion	POS	O
cells	POS	O
,	POS	O
and	POS	O
axonal	POS	B-NP
degeneration	POS	I-NP
,	POS	O
resembling	POS	O
glucocorticoid	POS	O
-	POS	O
induced	POS	O
glaucoma	POS	B-NP
in	POS	O
human	POS	O
patients	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
dexamethasone	POS	O
-	POS	O
induced	POS	O
ocular	POS	O
hypertension	POS	B-NP
was	POS	O
associated	POS	O
with	POS	O
chronic	POS	O
ER	POS	O
stress	POS	O
of	POS	O
the	POS	O
trabecular	POS	O
meshwork	POS	O
(	POS	O
TM	POS	O
)	POS	O
.	POS	O
Similar	POS	O
to	POS	O
patients	POS	O
,	POS	O
withdrawal	POS	O
of	POS	O
dexamethasone	POS	O
treatment	POS	O
reduced	POS	O
elevated	POS	O
IOP	POS	O
and	POS	O
ER	POS	O
stress	POS	O
in	POS	O
this	POS	O
animal	POS	O
model	POS	O
.	POS	O
Dexamethasone	POS	O
induced	POS	O
the	POS	O
transcriptional	POS	O
factor	POS	O
CHOP	POS	O
,	POS	O
a	POS	O
marker	POS	O
for	POS	O
chronic	POS	O
ER	POS	O
stress	POS	O
,	POS	O
in	POS	O
the	POS	O
anterior	POS	O
segment	POS	O
tissues	POS	O
,	POS	O
and	POS	O
Chop	POS	O
deletion	POS	O
reduced	POS	O
ER	POS	O
stress	POS	O
in	POS	O
these	POS	O
tissues	POS	O
and	POS	O
prevented	POS	O
dexamethasone	POS	O
-	POS	O
induced	POS	O
ocular	POS	O
hypertension	POS	B-NP
.	POS	O
Furthermore	POS	O
,	POS	O
reduction	POS	B-NP
of	POS	I-NP
ER	POS	I-NP
stress	POS	I-NP
in	POS	O
the	POS	O
TM	POS	O
with	POS	O
sodium	POS	O
4	POS	O
-	POS	O
phenylbutyrate	POS	O
prevented	POS	O
dexamethasone	POS	O
-	POS	O
induced	POS	O
ocular	POS	O
hypertension	POS	B-NP
in	POS	O
WT	POS	O
mice	POS	O
.	POS	O
Our	POS	O
data	POS	O
indicate	POS	O
that	POS	O
ER	POS	O
stress	POS	O
contributes	POS	O
to	POS	O
glucocorticoid	POS	O
-	POS	O
induced	POS	O
ocular	POS	O
hypertension	POS	B-NP
and	POS	O
suggest	POS	O
that	POS	O
reducing	POS	O
ER	POS	O
stress	POS	O
has	POS	O
potential	POS	O
as	POS	O
a	POS	O
therapeutic	POS	O
strategy	POS	O
for	POS	O
treating	POS	O
glucocorticoid	POS	O
-	POS	O
induced	POS	O
glaucoma	POS	B-NP
.	POS	O
Effects	POS	O
of	POS	O
ginsenosides	POS	O
on	POS	O
opioid	POS	O
-	POS	O
induced	POS	O
hyperalgesia	POS	B-NP
in	POS	O
mice	POS	O
.	POS	O
Opioid	POS	O
-	POS	O
induced	POS	O
hyperalgesia	POS	B-NP
(	POS	O
OIH	POS	O
)	POS	O
is	POS	O
characterized	POS	O
by	POS	O
nociceptive	POS	O
sensitization	POS	O
caused	POS	O
by	POS	O
the	POS	O
cessation	POS	O
of	POS	O
chronic	POS	O
opioid	POS	O
use	POS	O
.	POS	O
OIH	POS	O
can	POS	O
limit	POS	O
the	POS	O
clinical	POS	O
use	POS	O
of	POS	O
opioid	POS	O
analgesics	POS	O
and	POS	O
complicate	POS	O
withdrawal	POS	O
from	POS	O
opioid	POS	O
addiction	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
we	POS	O
investigated	POS	O
the	POS	O
effects	POS	O
of	POS	O
Re	POS	O
,	POS	O
Rg1	POS	O
,	POS	O
and	POS	O
Rb1	POS	O
ginsenosides	POS	O
,	POS	O
the	POS	O
bioactive	POS	O
components	POS	O
of	POS	O
ginseng	POS	O
,	POS	O
on	POS	O
OIH	POS	O
.	POS	O
OIH	POS	O
was	POS	O
achieved	POS	O
in	POS	O
mice	POS	O
after	POS	O
subcutaneous	POS	O
administration	POS	O
of	POS	O
morphine	POS	O
for	POS	O
7	POS	O
consecutive	POS	O
days	POS	O
three	POS	O
times	POS	O
per	POS	O
day	POS	O
.	POS	O
During	POS	O
withdrawal	POS	O
(	POS	O
days	POS	O
8	POS	O
and	POS	O
9	POS	O
)	POS	O
,	POS	O
these	POS	O
mice	POS	O
were	POS	O
administered	POS	O
Re	POS	O
,	POS	O
Rg1	POS	O
,	POS	O
or	POS	O
Rb1	POS	O
intragastrically	POS	O
two	POS	O
times	POS	O
per	POS	O
day	POS	O
.	POS	O
On	POS	O
the	POS	O
test	POS	O
day	POS	O
(	POS	O
day	POS	O
10	POS	O
)	POS	O
,	POS	O
mice	POS	O
were	POS	O
subjected	POS	O
to	POS	O
the	POS	O
thermal	POS	O
sensitivity	POS	O
test	POS	O
and	POS	O
the	POS	O
acetic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
writhing	POS	O
test	POS	O
.	POS	O
Re	POS	O
(	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
inhibited	POS	O
OIH	POS	O
in	POS	O
both	POS	O
the	POS	O
thermal	POS	O
sensitivity	POS	O
test	POS	O
and	POS	O
the	POS	O
acetic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
writhing	POS	O
test	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
Rg1	POS	O
and	POS	O
Rb1	POS	O
ginsenosides	POS	O
failed	POS	O
to	POS	O
prevent	POS	O
OIH	POS	O
in	POS	O
either	POS	O
test	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
Rg1	POS	O
showed	POS	O
a	POS	O
tendency	POS	O
to	POS	O
aggravate	POS	O
OIH	POS	O
in	POS	O
the	POS	O
acetic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
writhing	POS	O
test	POS	O
.	POS	O
Our	POS	O
data	POS	O
suggested	POS	O
that	POS	O
the	POS	O
ginsenoside	POS	O
Re	POS	O
,	POS	O
but	POS	O
not	POS	O
Rg1	POS	O
or	POS	O
Rb1	POS	O
,	POS	O
may	POS	O
contribute	POS	O
toward	POS	O
reversal	POS	O
of	POS	O
OIH	POS	O
.	POS	O
A	POS	O
comparison	POS	O
of	POS	O
severe	POS	O
hemodynamic	POS	B-NP
disturbances	POS	I-NP
between	POS	O
dexmedetomidine	POS	O
and	POS	O
propofol	POS	O
for	POS	O
sedation	POS	O
in	POS	O
neurocritical	POS	O
care	POS	O
patients	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
Dexmedetomidine	POS	O
and	POS	O
propofol	POS	O
are	POS	O
commonly	POS	O
used	POS	O
sedatives	POS	O
in	POS	O
neurocritical	POS	O
care	POS	O
as	POS	O
they	POS	O
allow	POS	O
for	POS	O
frequent	POS	O
neurologic	POS	O
examinations	POS	O
.	POS	O
However	POS	O
,	POS	O
both	POS	O
agents	POS	O
are	POS	O
associated	POS	O
with	POS	O
significant	POS	O
hemodynamic	POS	O
side	POS	O
effects	POS	O
.	POS	O
The	POS	O
primary	POS	O
objective	POS	O
of	POS	O
this	POS	O
study	POS	O
is	POS	O
to	POS	O
compare	POS	O
the	POS	O
prevalence	POS	O
of	POS	O
severe	POS	O
hemodynamic	POS	O
effects	POS	O
in	POS	O
neurocritical	POS	O
care	POS	O
patients	POS	O
receiving	POS	O
dexmedetomidine	POS	O
and	POS	O
propofol	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
Multicenter	POS	O
,	POS	O
retrospective	POS	O
,	POS	O
propensity	POS	O
-	POS	O
matched	POS	O
cohort	POS	O
study	POS	O
.	POS	O
SETTING	POS	O
:	POS	O
Neurocritical	POS	O
care	POS	O
units	POS	O
at	POS	O
two	POS	O
academic	POS	O
medical	POS	O
centers	POS	O
with	POS	O
dedicated	POS	O
neurocritical	POS	O
care	POS	O
teams	POS	O
and	POS	O
board	POS	O
-	POS	O
certified	POS	O
neurointensivists	POS	O
.	POS	O
PATIENTS	POS	O
:	POS	O
Neurocritical	POS	O
care	POS	O
patients	POS	O
admitted	POS	O
between	POS	O
July	POS	O
2009	POS	O
and	POS	O
September	POS	O
2012	POS	O
were	POS	O
evaluated	POS	O
and	POS	O
then	POS	O
matched	POS	O
1	POS	O
:	POS	O
1	POS	O
based	POS	O
on	POS	O
propensity	POS	O
scoring	POS	O
of	POS	O
baseline	POS	O
characteristics	POS	O
.	POS	O
INTERVENTIONS	POS	O
:	POS	O
Continuous	POS	O
sedation	POS	O
with	POS	O
dexmedetomidine	POS	O
or	POS	O
propofol	POS	O
.	POS	O
MEASUREMENTS	POS	O
AND	POS	O
MAIN	POS	O
RESULTS	POS	O
:	POS	O
A	POS	O
total	POS	O
of	POS	O
342	POS	O
patients	POS	O
(	POS	O
105	POS	O
dexmedetomidine	POS	O
and	POS	O
237	POS	O
propofol	POS	O
)	POS	O
were	POS	O
included	POS	O
in	POS	O
the	POS	O
analysis	POS	O
,	POS	O
with	POS	O
190	POS	O
matched	POS	O
(	POS	O
95	POS	O
in	POS	O
each	POS	O
group	POS	O
)	POS	O
by	POS	O
propensity	POS	O
score	POS	O
.	POS	O
The	POS	O
primary	POS	O
outcome	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
a	POS	O
composite	POS	O
of	POS	O
severe	POS	O
hypotension	POS	B-NP
(	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
<	POS	O
60	POS	O
mm	POS	O
Hg	POS	O
)	POS	O
and	POS	O
bradycardia	POS	B-NP
(	POS	O
heart	POS	O
rate	POS	O
<	POS	O
50	POS	O
beats	POS	O
/	POS	O
min	POS	O
)	POS	O
during	POS	O
sedative	POS	O
infusion	POS	O
.	POS	O
No	POS	O
difference	POS	O
in	POS	O
the	POS	O
primary	POS	O
composite	POS	O
outcome	POS	O
in	POS	O
both	POS	O
the	POS	O
unmatched	POS	O
(	POS	O
30	POS	O
%	POS	O
vs	POS	O
30	POS	O
%	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
94	POS	O
)	POS	O
or	POS	O
matched	POS	O
cohorts	POS	O
(	POS	O
28	POS	O
%	POS	O
vs	POS	O
34	POS	O
%	POS	O
,	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
35	POS	O
)	POS	O
could	POS	O
be	POS	O
found	POS	O
.	POS	O
When	POS	O
analyzed	POS	O
separately	POS	O
,	POS	O
no	POS	O
differences	POS	O
could	POS	O
be	POS	O
found	POS	O
in	POS	O
the	POS	O
prevalence	POS	O
of	POS	O
severe	POS	O
hypotension	POS	B-NP
or	POS	O
bradycardia	POS	B-NP
in	POS	O
either	POS	O
the	POS	O
unmatched	POS	O
or	POS	O
matched	POS	O
cohorts	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Severe	POS	O
hypotension	POS	B-NP
and	POS	O
bradycardia	POS	B-NP
occur	POS	O
at	POS	O
similar	POS	O
prevalence	POS	O
in	POS	O
neurocritical	POS	O
care	POS	O
patients	POS	O
who	POS	O
receive	POS	O
dexmedetomidine	POS	O
or	POS	O
propofol	POS	O
.	POS	O
Providers	POS	O
should	POS	O
similarly	POS	O
consider	POS	O
the	POS	O
likelihood	POS	O
of	POS	O
hypotension	POS	B-NP
or	POS	O
bradycardia	POS	B-NP
before	POS	O
starting	POS	O
either	POS	O
sedative	POS	O
.	POS	O
Hydroxytyrosol	POS	O
ameliorates	POS	O
oxidative	POS	O
stress	POS	O
and	POS	O
mitochondrial	POS	B-NP
dysfunction	POS	I-NP
in	POS	O
doxorubicin	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
in	POS	O
rats	POS	O
with	POS	O
breast	POS	B-NP
cancer	POS	I-NP
.	POS	O
Oxidative	POS	O
stress	POS	O
is	POS	O
involved	POS	O
in	POS	O
several	POS	O
processes	POS	O
including	POS	O
cancer	POS	B-NP
,	POS	O
aging	POS	O
and	POS	O
cardiovascular	POS	B-NP
disease	POS	I-NP
,	POS	O
and	POS	O
has	POS	O
been	POS	O
shown	POS	O
to	POS	O
potentiate	POS	O
the	POS	O
therapeutic	POS	O
effect	POS	O
of	POS	O
drugs	POS	O
such	POS	O
as	POS	O
doxorubicin	POS	O
.	POS	O
Doxorubicin	POS	O
causes	POS	O
significant	POS	O
cardiotoxicity	POS	B-NP
characterized	POS	O
by	POS	O
marked	POS	O
increases	POS	O
in	POS	O
oxidative	POS	O
stress	POS	O
and	POS	O
mitochondrial	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
Herein	POS	O
,	POS	O
we	POS	O
investigate	POS	O
whether	POS	O
doxorubicin	POS	O
-	POS	O
associated	POS	O
chronic	POS	O
cardiac	POS	B-NP
toxicity	POS	I-NP
can	POS	O
be	POS	O
ameliorated	POS	O
with	POS	O
the	POS	O
antioxidant	POS	O
hydroxytyrosol	POS	O
in	POS	O
rats	POS	O
with	POS	O
breast	POS	B-NP
cancer	POS	I-NP
.	POS	O
Thirty	POS	O
-	POS	O
six	POS	O
rats	POS	O
bearing	POS	O
breast	POS	B-NP
tumors	POS	I-NP
induced	POS	O
chemically	POS	O
were	POS	O
divided	POS	O
into	POS	O
4	POS	O
groups	POS	O
:	POS	O
control	POS	O
,	POS	O
hydroxytyrosol	POS	O
(	POS	O
0	POS	O
.	POS	O
5mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
5days	POS	O
/	POS	O
week	POS	O
)	POS	O
,	POS	O
doxorubicin	POS	O
(	POS	O
1mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
week	POS	O
)	POS	O
,	POS	O
and	POS	O
doxorubicin	POS	O
plus	POS	O
hydroxytyrosol	POS	O
.	POS	O
Cardiac	POS	O
disturbances	POS	O
at	POS	O
the	POS	O
cellular	POS	O
and	POS	O
mitochondrial	POS	O
level	POS	O
,	POS	O
mitochondrial	POS	O
electron	POS	O
transport	POS	O
chain	POS	O
complexes	POS	O
I	POS	O
-	POS	O
IV	POS	O
and	POS	O
apoptosis	POS	O
-	POS	O
inducing	POS	O
factor	POS	O
,	POS	O
and	POS	O
oxidative	POS	O
stress	POS	O
markers	POS	O
have	POS	O
been	POS	O
analyzed	POS	O
.	POS	O
Hydroxytyrosol	POS	O
improved	POS	O
the	POS	O
cardiac	POS	B-NP
disturbances	POS	I-NP
enhanced	POS	O
by	POS	O
doxorubicin	POS	O
by	POS	O
significantly	POS	O
reducing	POS	O
the	POS	O
percentage	POS	O
of	POS	O
altered	POS	O
mitochondria	POS	O
and	POS	O
oxidative	POS	O
damage	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
hydroxytyrosol	POS	O
improve	POS	O
the	POS	O
mitochondrial	POS	O
electron	POS	O
transport	POS	O
chain	POS	O
.	POS	O
This	POS	O
study	POS	O
demonstrates	POS	O
that	POS	O
hydroxytyrosol	POS	O
protect	POS	O
rat	POS	O
heart	POS	O
damage	POS	O
provoked	POS	O
by	POS	O
doxorubicin	POS	O
decreasing	POS	O
oxidative	POS	O
damage	POS	O
and	POS	O
mitochondrial	POS	O
alterations	POS	O
.	POS	O
Amiodarone	POS	O
-	POS	O
induced	POS	O
myxoedema	POS	B-NP
coma	POS	I-NP
.	POS	O
A	POS	O
62	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
was	POS	O
found	POS	O
to	POS	O
have	POS	O
bradycardia	POS	B-NP
,	POS	O
hypothermia	POS	B-NP
and	POS	O
respiratory	POS	B-NP
failure	POS	I-NP
3	POS	O
weeks	POS	O
after	POS	O
initiation	POS	O
of	POS	O
amiodarone	POS	O
therapy	POS	O
for	POS	O
atrial	POS	B-NP
fibrillation	POS	I-NP
.	POS	O
Thyroid	POS	O
-	POS	O
stimulating	POS	O
hormone	POS	O
was	POS	O
found	POS	O
to	POS	O
be	POS	O
168	POS	O
uIU	POS	O
/	POS	O
mL	POS	O
(	POS	O
nl	POS	O
.	POS	O
0	POS	O
.	POS	O
3	POS	O
-	POS	O
5	POS	O
uIU	POS	O
/	POS	O
mL	POS	O
)	POS	O
and	POS	O
free	POS	O
thyroxine	POS	O
(	POS	O
FT4	POS	O
)	POS	O
was	POS	O
<	POS	O
0	POS	O
.	POS	O
2	POS	O
ng	POS	O
/	POS	O
dL	POS	O
(	POS	O
nl	POS	O
.	POS	O
0	POS	O
.	POS	O
8	POS	O
-	POS	O
1	POS	O
.	POS	O
8	POS	O
ng	POS	O
/	POS	O
dL	POS	O
)	POS	O
.	POS	O
He	POS	O
received	POS	O
intravenous	POS	O
fluids	POS	O
,	POS	O
vasopressor	POS	O
therapy	POS	O
and	POS	O
stress	POS	O
dose	POS	O
steroids	POS	O
;	POS	O
he	POS	O
was	POS	O
intubated	POS	O
and	POS	O
admitted	POS	O
to	POS	O
the	POS	O
intensive	POS	O
care	POS	O
unit	POS	O
.	POS	O
He	POS	O
received	POS	O
500	POS	O
ug	POS	O
of	POS	O
intravenous	POS	O
levothyroxine	POS	O
in	POS	O
the	POS	O
first	POS	O
18	POS	O
h	POS	O
of	POS	O
therapy	POS	O
,	POS	O
and	POS	O
150	POS	O
ug	POS	O
intravenous	POS	O
daily	POS	O
thereafter	POS	O
.	POS	O
Haemodynamic	POS	O
improvement	POS	O
,	POS	O
along	POS	O
with	POS	O
complete	POS	O
recovery	POS	O
of	POS	O
mental	POS	O
status	POS	O
,	POS	O
occurred	POS	O
after	POS	O
48	POS	O
h	POS	O
.	POS	O
Twelve	POS	O
hours	POS	O
after	POS	O
the	POS	O
initiation	POS	O
of	POS	O
therapy	POS	O
,	POS	O
FT4	POS	O
was	POS	O
0	POS	O
.	POS	O
96	POS	O
ng	POS	O
/	POS	O
dL	POS	O
.	POS	O
The	POS	O
patient	POS	O
was	POS	O
maintained	POS	O
on	POS	O
levothyroxine	POS	O
175	POS	O
(	POS	O
g	POS	O
POorally	POS	O
daily	POS	O
.	POS	O
A	POS	O
thyroid	POS	O
ultrasound	POS	O
showed	POS	O
diffuse	POS	O
heterogeneity	POS	O
.	POS	O
The	POS	O
24	POS	O
hour	POS	O
excretion	POS	O
of	POS	O
iodine	POS	O
was	POS	O
3657	POS	O
(	POS	O
mcg	POS	O
(	POS	O
25	POS	O
-	POS	O
756	POS	O
(	POS	O
mcg	POS	O
)	POS	O
.	POS	O
The	POS	O
only	POS	O
two	POS	O
cases	POS	O
of	POS	O
amiodarone	POS	O
-	POS	O
induced	POS	O
myxoedema	POS	B-NP
coma	POS	I-NP
in	POS	O
the	POS	O
literature	POS	O
report	POS	O
patient	POS	O
death	POS	B-NP
despite	POS	O
supportive	POS	O
therapy	POS	O
and	POS	O
thyroid	POS	O
hormone	POS	O
replacement	POS	O
.	POS	O
This	POS	O
case	POS	O
represents	POS	O
the	POS	O
most	POS	O
thoroughly	POS	O
investigated	POS	O
case	POS	O
of	POS	O
amiodarone	POS	O
-	POS	O
induced	POS	O
myxoedema	POS	B-NP
coma	POS	I-NP
with	POS	O
a	POS	O
history	POS	O
significant	POS	O
for	POS	O
subclinical	POS	B-NP
thyroid	POS	I-NP
disease	POS	I-NP
.	POS	O
Use	POS	O
of	POS	O
argatroban	POS	O
and	POS	O
catheter	POS	O
-	POS	O
directed	POS	O
thrombolysis	POS	B-NP
with	POS	O
alteplase	POS	O
in	POS	O
an	POS	O
oncology	POS	O
patient	POS	O
with	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
with	POS	O
thrombosis	POS	B-NP
.	POS	O
PURPOSE	POS	O
:	POS	O
The	POS	O
case	POS	O
of	POS	O
an	POS	O
oncology	POS	O
patient	POS	O
who	POS	O
developed	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
with	POS	O
thrombosis	POS	B-NP
(	POS	O
HITT	POS	B-NP
)	POS	O
and	POS	O
was	POS	O
treated	POS	O
with	POS	O
argatroban	POS	O
plus	POS	O
catheter	POS	O
-	POS	O
directed	POS	O
thrombolysis	POS	B-NP
(	POS	O
CDT	POS	O
)	POS	O
with	POS	O
alteplase	POS	O
is	POS	O
presented	POS	O
.	POS	O
SUMMARY	POS	O
:	POS	O
A	POS	O
63	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
Caucasian	POS	O
man	POS	O
with	POS	O
renal	POS	B-NP
amyloidosis	POS	I-NP
undergoing	POS	O
peripheral	POS	O
blood	POS	O
stem	POS	O
cell	POS	O
collection	POS	O
for	POS	O
an	POS	O
autologous	POS	O
stem	POS	O
cell	POS	O
transplant	POS	O
developed	POS	O
extensive	POS	O
bilateral	POS	B-NP
upper	POS	I-NP
-	POS	I-NP
extremity	POS	I-NP
deep	POS	I-NP
venous	POS	I-NP
thrombosis	POS	I-NP
(	POS	O
DVT	POS	B-NP
)	POS	O
and	POS	O
pulmonary	POS	B-NP
embolism	POS	I-NP
secondary	POS	O
to	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
.	POS	O
A	POS	O
continuous	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
infusion	POS	O
of	POS	O
argatroban	POS	O
was	POS	O
initiated	POS	O
,	POS	O
and	POS	O
the	POS	O
patient	POS	O
was	POS	O
managed	POS	O
on	POS	O
the	POS	O
general	POS	O
medical	POS	O
floor	POS	O
.	POS	O
After	POS	O
one	POS	O
week	POS	O
of	POS	O
therapy	POS	O
,	POS	O
he	POS	O
was	POS	O
transferred	POS	O
to	POS	O
the	POS	O
intensive	POS	O
care	POS	O
unit	POS	O
with	POS	O
cardiopulmonary	POS	O
compromise	POS	O
related	POS	O
to	POS	O
superior	POS	B-NP
vena	POS	I-NP
cava	POS	I-NP
(	POS	I-NP
SVC	POS	I-NP
)	POS	I-NP
syndrome	POS	I-NP
.	POS	O
A	POS	O
percutaneous	POS	O
mechanical	POS	O
thrombectomy	POS	O
and	POS	O
CDT	POS	O
with	POS	O
alteplase	POS	O
were	POS	O
attempted	POS	O
,	POS	O
but	POS	O
the	POS	O
procedure	POS	O
was	POS	O
aborted	POS	O
due	POS	O
to	POS	O
epistaxis	POS	B-NP
.	POS	O
The	POS	O
epistaxis	POS	B-NP
resolved	POS	O
the	POS	O
next	POS	O
day	POS	O
,	POS	O
and	POS	O
the	POS	O
patient	POS	O
was	POS	O
restarted	POS	O
on	POS	O
argatroban	POS	O
.	POS	O
A	POS	O
second	POS	O
percutaneous	POS	O
mechanical	POS	O
thrombectomy	POS	O
was	POS	O
performed	POS	O
six	POS	O
days	POS	O
later	POS	O
and	POS	O
resulted	POS	O
in	POS	O
partial	POS	O
revascularization	POS	O
of	POS	O
the	POS	O
SVC	POS	O
and	POS	O
central	POS	O
veins	POS	O
.	POS	O
Postthrombectomy	POS	O
continuous	POS	O
CDT	POS	O
with	POS	O
alteplase	POS	O
was	POS	O
commenced	POS	O
while	POS	O
argatroban	POS	O
was	POS	O
withheld	POS	O
,	POS	O
and	POS	O
complete	POS	O
patency	POS	O
of	POS	O
the	POS	O
SVC	POS	O
and	POS	O
central	POS	O
veins	POS	O
was	POS	O
achieved	POS	O
after	POS	O
three	POS	O
days	POS	O
of	POS	O
therapy	POS	O
.	POS	O
Alteplase	POS	O
was	POS	O
discontinued	POS	O
,	POS	O
and	POS	O
the	POS	O
patient	POS	O
was	POS	O
reinitiated	POS	O
on	POS	O
argatroban	POS	O
;	POS	O
ultimately	POS	O
,	POS	O
he	POS	O
was	POS	O
transitioned	POS	O
to	POS	O
warfarin	POS	O
for	POS	O
long	POS	O
-	POS	O
term	POS	O
anticoagulation	POS	O
.	POS	O
Although	POS	O
the	POS	O
patient	POS	O
recovered	POS	O
,	POS	O
he	POS	O
experienced	POS	O
permanent	POS	O
vision	POS	O
and	POS	O
hearing	POS	B-NP
loss	POS	I-NP
,	POS	O
as	POS	O
well	POS	O
as	POS	O
end	POS	O
-	POS	O
stage	POS	O
renal	POS	B-NP
disease	POS	I-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
A	POS	O
63	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
with	POS	O
renal	POS	B-NP
amyloidosis	POS	I-NP
and	POS	O
SVC	POS	B-NP
syndrome	POS	I-NP
secondary	POS	O
to	POS	O
HITT	POS	B-NP
was	POS	O
successfully	POS	O
treated	POS	O
with	POS	O
argatroban	POS	O
and	POS	O
CDT	POS	O
with	POS	O
alteplase	POS	O
.	POS	O
Effects	POS	O
of	POS	O
dehydroepiandrosterone	POS	O
in	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
schizophrenia	POS	B-NP
models	POS	O
in	POS	O
mice	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
examine	POS	O
the	POS	O
effects	POS	O
of	POS	O
dehydroepiandrosterone	POS	O
(	POS	O
DHEA	POS	O
)	POS	O
on	POS	O
animal	POS	O
models	POS	O
of	POS	O
schizophrenia	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
Seventy	POS	O
Swiss	POS	O
albino	POS	O
female	POS	O
mice	POS	O
(	POS	O
25	POS	O
-	POS	O
35	POS	O
g	POS	O
)	POS	O
were	POS	O
divided	POS	O
into	POS	O
4	POS	O
groups	POS	O
:	POS	O
amphetamine	POS	O
-	POS	O
free	POS	O
(	POS	O
control	POS	O
)	POS	O
,	POS	O
amphetamine	POS	O
,	POS	O
50	POS	O
,	POS	O
and	POS	O
100	POS	O
mg	POS	O
/	POS	O
kg	POS	O
DHEA	POS	O
.	POS	O
The	POS	O
DHEA	POS	O
was	POS	O
administered	POS	O
intraperitoneally	POS	O
(	POS	O
ip	POS	O
)	POS	O
for	POS	O
5	POS	O
days	POS	O
.	POS	O
Amphetamine	POS	O
(	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
ip	POS	O
)	POS	O
induced	POS	O
hyper	POS	O
locomotion	POS	O
,	POS	O
apomorphine	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
subcutaneously	POS	O
[	POS	O
sc	POS	O
]	POS	O
)	POS	O
induced	POS	O
climbing	POS	O
,	POS	O
and	POS	O
haloperidol	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
sc	POS	O
)	POS	O
induced	POS	O
catalepsy	POS	B-NP
tests	POS	O
were	POS	O
used	POS	O
as	POS	O
animal	POS	O
models	POS	O
of	POS	O
schizophrenia	POS	B-NP
.	POS	O
The	POS	O
study	POS	O
was	POS	O
conducted	POS	O
at	POS	O
the	POS	O
Animal	POS	O
Experiment	POS	O
Laboratories	POS	O
,	POS	O
Department	POS	O
of	POS	O
Pharmacology	POS	O
,	POS	O
Medical	POS	O
School	POS	O
,	POS	O
Eskisehir	POS	O
Osmangazi	POS	O
University	POS	O
,	POS	O
Eskisehir	POS	O
,	POS	O
Turkey	POS	O
between	POS	O
March	POS	O
and	POS	O
May	POS	O
2012	POS	O
.	POS	O
Statistical	POS	O
analysis	POS	O
was	POS	O
carried	POS	O
out	POS	O
using	POS	O
Kruskal	POS	O
-	POS	O
Wallis	POS	O
test	POS	O
for	POS	O
hyper	POS	O
locomotion	POS	O
,	POS	O
and	POS	O
one	POS	O
-	POS	O
way	POS	O
ANOVA	POS	O
for	POS	O
climbing	POS	O
and	POS	O
catalepsy	POS	B-NP
tests	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
In	POS	O
the	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
locomotion	POS	O
test	POS	O
,	POS	O
there	POS	O
were	POS	O
significant	POS	O
increases	POS	O
in	POS	O
all	POS	O
movements	POS	O
compared	POS	O
with	POS	O
the	POS	O
amphetamine	POS	O
-	POS	O
free	POS	O
group	POS	O
.	POS	O
Both	POS	O
DHEA	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
,	POS	O
and	POS	O
100	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
significantly	POS	O
decreased	POS	O
all	POS	O
movements	POS	O
compared	POS	O
with	POS	O
the	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
locomotion	POS	O
group	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
significant	POS	O
difference	POS	O
between	POS	O
groups	POS	O
in	POS	O
the	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
test	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
significant	POS	O
difference	POS	O
between	POS	O
groups	POS	O
in	POS	O
terms	POS	O
of	POS	O
total	POS	O
climbing	POS	O
time	POS	O
in	POS	O
the	POS	O
apomorphine	POS	O
-	POS	O
induced	POS	O
climbing	POS	O
test	POS	O
(	POS	O
p	POS	O
>	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
We	POS	O
observed	POS	O
that	POS	O
DHEA	POS	O
reduced	POS	O
locomotor	POS	O
activity	POS	O
and	POS	O
increased	POS	O
catalepsy	POS	B-NP
at	POS	O
both	POS	O
doses	POS	O
,	POS	O
while	POS	O
it	POS	O
had	POS	O
no	POS	O
effect	POS	O
on	POS	O
climbing	POS	O
behavior	POS	O
.	POS	O
We	POS	O
suggest	POS	O
that	POS	O
DHEA	POS	O
displays	POS	O
typical	POS	O
neuroleptic	POS	O
-	POS	O
like	POS	O
effects	POS	O
,	POS	O
and	POS	O
may	POS	O
be	POS	O
used	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
schizophrenia	POS	B-NP
.	POS	O
Availability	POS	O
of	POS	O
human	POS	O
induced	POS	O
pluripotent	POS	O
stem	POS	O
cell	POS	O
-	POS	O
derived	POS	O
cardiomyocytes	POS	O
in	POS	O
assessment	POS	O
of	POS	O
drug	POS	O
potential	POS	O
for	POS	O
QT	POS	O
prolongation	POS	O
.	POS	O
Field	POS	O
potential	POS	O
duration	POS	O
(	POS	O
FPD	POS	O
)	POS	O
in	POS	O
human	POS	O
-	POS	O
induced	POS	O
pluripotent	POS	O
stem	POS	O
cell	POS	O
-	POS	O
derived	POS	O
cardiomyocytes	POS	O
(	POS	O
hiPS	POS	O
-	POS	O
CMs	POS	O
)	POS	O
,	POS	O
which	POS	O
can	POS	O
express	POS	O
QT	POS	O
interval	POS	O
in	POS	O
an	POS	O
electrocardiogram	POS	O
,	POS	O
is	POS	O
reported	POS	O
to	POS	O
be	POS	O
a	POS	O
useful	POS	O
tool	POS	O
to	POS	O
predict	POS	O
K	POS	O
(	POS	O
+	POS	O
)	POS	O
channel	POS	O
and	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
channel	POS	O
blocker	POS	O
effects	POS	O
on	POS	O
QT	POS	O
interval	POS	O
.	POS	O
However	POS	O
,	POS	O
there	POS	O
is	POS	O
no	POS	O
report	POS	O
showing	POS	O
that	POS	O
this	POS	O
technique	POS	O
can	POS	O
be	POS	O
used	POS	O
to	POS	O
predict	POS	O
multichannel	POS	O
blocker	POS	O
potential	POS	O
for	POS	O
QT	POS	O
prolongation	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
is	POS	O
to	POS	O
show	POS	O
that	POS	O
FPD	POS	O
from	POS	O
MEA	POS	O
(	POS	O
Multielectrode	POS	O
array	POS	O
)	POS	O
of	POS	O
hiPS	POS	O
-	POS	O
CMs	POS	O
can	POS	O
detect	POS	O
QT	POS	O
prolongation	POS	O
induced	POS	O
by	POS	O
multichannel	POS	O
blockers	POS	O
.	POS	O
hiPS	POS	O
-	POS	O
CMs	POS	O
were	POS	O
seeded	POS	O
onto	POS	O
MEA	POS	O
and	POS	O
FPD	POS	O
was	POS	O
measured	POS	O
for	POS	O
2min	POS	O
every	POS	O
10min	POS	O
for	POS	O
30min	POS	O
after	POS	O
drug	POS	O
exposure	POS	O
for	POS	O
the	POS	O
vehicle	POS	O
and	POS	O
each	POS	O
drug	POS	O
concentration	POS	O
.	POS	O
IKr	POS	O
and	POS	O
IKs	POS	O
blockers	POS	O
concentration	POS	O
-	POS	O
dependently	POS	O
prolonged	POS	O
corrected	POS	O
FPD	POS	O
(	POS	O
FPDc	POS	O
)	POS	O
,	POS	O
whereas	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
channel	POS	O
blockers	POS	O
concentration	POS	O
-	POS	O
dependently	POS	O
shortened	POS	O
FPDc	POS	O
.	POS	O
Also	POS	O
,	POS	O
the	POS	O
multichannel	POS	O
blockers	POS	O
Amiodarone	POS	O
,	POS	O
Paroxetine	POS	O
,	POS	O
Terfenadine	POS	O
and	POS	O
Citalopram	POS	O
prolonged	POS	O
FPDc	POS	O
in	POS	O
a	POS	O
concentration	POS	O
dependent	POS	O
manner	POS	O
.	POS	O
Finally	POS	O
,	POS	O
the	POS	O
IKr	POS	O
blockers	POS	O
,	POS	O
Terfenadine	POS	O
and	POS	O
Citalopram	POS	O
,	POS	O
which	POS	O
are	POS	O
reported	POS	O
to	POS	O
cause	POS	O
Torsade	POS	B-NP
de	POS	I-NP
Pointes	POS	I-NP
(	POS	O
TdP	POS	B-NP
)	POS	O
in	POS	O
clinical	POS	O
practice	POS	O
,	POS	O
produced	POS	O
early	POS	O
afterdepolarization	POS	B-NP
(	POS	O
EAD	POS	B-NP
)	POS	O
.	POS	O
hiPS	POS	O
-	POS	O
CMs	POS	O
using	POS	O
MEA	POS	O
system	POS	O
and	POS	O
FPDc	POS	O
can	POS	O
predict	POS	O
the	POS	O
effects	POS	O
of	POS	O
drug	POS	O
candidates	POS	O
on	POS	O
QT	POS	O
interval	POS	O
.	POS	O
This	POS	O
study	POS	O
also	POS	O
shows	POS	O
that	POS	O
this	POS	O
assay	POS	O
can	POS	O
help	POS	O
detect	POS	O
EAD	POS	B-NP
for	POS	O
drugs	POS	O
with	POS	O
TdP	POS	B-NP
potential	POS	O
.	POS	O
Dermal	POS	B-NP
developmental	POS	I-NP
toxicity	POS	I-NP
of	POS	O
N	POS	O
-	POS	O
phenylimide	POS	O
herbicides	POS	O
in	POS	O
rats	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
S	POS	O
-	POS	O
53482	POS	O
and	POS	O
S	POS	O
-	POS	O
23121	POS	O
are	POS	O
N	POS	O
-	POS	O
phenylimide	POS	O
herbicides	POS	O
and	POS	O
produced	POS	O
embryolethality	POS	B-NP
,	POS	O
teratogenicity	POS	B-NP
(	POS	O
mainly	POS	O
ventricular	POS	B-NP
septal	POS	I-NP
defects	POS	I-NP
and	POS	O
wavy	POS	O
ribs	POS	O
)	POS	O
,	POS	O
and	POS	O
growth	POS	B-NP
retardation	POS	I-NP
in	POS	O
rats	POS	O
in	POS	O
conventional	POS	O
oral	POS	O
developmental	POS	O
toxicity	POS	B-NP
studies	POS	O
.	POS	O
Our	POS	O
objective	POS	O
in	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
whether	POS	O
the	POS	O
compounds	POS	O
induce	POS	O
developmental	POS	O
toxicity	POS	O
via	POS	O
the	POS	O
dermal	POS	O
route	POS	O
,	POS	O
which	POS	O
is	POS	O
more	POS	O
relevant	POS	O
to	POS	O
occupational	POS	O
exposure	POS	O
,	POS	O
hence	POS	O
better	POS	O
addressing	POS	O
human	POS	O
health	POS	O
risks	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
S	POS	O
-	POS	O
53482	POS	O
was	POS	O
administered	POS	O
dermally	POS	O
to	POS	O
rats	POS	O
at	POS	O
30	POS	O
,	POS	O
100	POS	O
,	POS	O
and	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
during	POS	O
organogenesis	POS	O
,	POS	O
and	POS	O
S	POS	O
-	POS	O
23121	POS	O
was	POS	O
administered	POS	O
at	POS	O
200	POS	O
,	POS	O
400	POS	O
,	POS	O
and	POS	O
800	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
the	POS	O
maximum	POS	O
applicable	POS	O
dose	POS	O
level	POS	O
)	POS	O
.	POS	O
Fetuses	POS	O
were	POS	O
obtained	POS	O
by	POS	O
a	POS	O
Cesarean	POS	O
section	POS	O
and	POS	O
examined	POS	O
for	POS	O
external	POS	O
,	POS	O
visceral	POS	O
,	POS	O
and	POS	O
skeletal	POS	O
alterations	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Dermal	POS	O
exposure	POS	O
of	POS	O
rats	POS	O
to	POS	O
S	POS	O
-	POS	O
53482	POS	O
at	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
produced	POS	O
patterns	POS	O
of	POS	O
developmental	POS	O
toxicity	POS	B-NP
similar	POS	O
to	POS	O
those	POS	O
resulting	POS	O
from	POS	O
oral	POS	O
exposure	POS	O
.	POS	O
Toxicity	POS	O
included	POS	O
embryolethality	POS	B-NP
,	POS	O
teratogenicity	POS	B-NP
,	POS	O
and	POS	O
growth	POS	B-NP
retardation	POS	I-NP
.	POS	O
Dermal	POS	O
administration	POS	O
of	POS	O
S	POS	O
-	POS	O
23121	POS	O
at	POS	O
800	POS	O
mg	POS	O
/	POS	O
kg	POS	O
resulted	POS	O
in	POS	O
an	POS	O
increased	POS	O
incidence	POS	O
of	POS	O
embryonic	POS	B-NP
death	POS	I-NP
and	POS	O
ventricular	POS	B-NP
septal	POS	I-NP
defect	POS	I-NP
,	POS	O
but	POS	O
retarded	POS	O
fetal	POS	O
growth	POS	O
was	POS	O
not	POS	O
observed	POS	O
as	POS	O
it	POS	O
was	POS	O
following	POS	O
oral	POS	O
exposure	POS	O
to	POS	O
S	POS	O
-	POS	O
23121	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Based	POS	O
on	POS	O
the	POS	O
results	POS	O
,	POS	O
S	POS	O
-	POS	O
53482	POS	O
and	POS	O
S	POS	O
-	POS	O
23121	POS	O
were	POS	O
teratogenic	POS	O
when	POS	O
administered	POS	O
dermally	POS	O
to	POS	O
pregnant	POS	O
rats	POS	O
as	POS	O
were	POS	O
the	POS	O
compounds	POS	O
administered	POS	O
orally	POS	O
.	POS	O
Thus	POS	O
,	POS	O
investigation	POS	O
of	POS	O
the	POS	O
mechanism	POS	O
and	POS	O
its	POS	O
human	POS	O
relevancy	POS	O
become	POS	O
more	POS	O
important	POS	O
.	POS	O
Rates	POS	O
of	POS	O
Renal	POS	O
Toxicity	POS	O
in	POS	O
Cancer	POS	O
Patients	POS	O
Receiving	POS	O
Cisplatin	POS	O
With	POS	O
and	POS	O
Without	POS	O
Mannitol	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Cisplatin	POS	O
is	POS	O
a	POS	O
widely	POS	O
used	POS	O
antineoplastic	POS	O
.	POS	O
One	POS	O
of	POS	O
the	POS	O
major	POS	O
complications	POS	O
of	POS	O
cisplatin	POS	O
use	POS	O
is	POS	O
dose	POS	O
-	POS	O
limiting	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
There	POS	O
are	POS	O
many	POS	O
strategies	POS	O
to	POS	O
prevent	POS	O
this	POS	O
toxicity	POS	B-NP
,	POS	O
including	POS	O
the	POS	O
use	POS	O
of	POS	O
mannitol	POS	O
as	POS	O
a	POS	O
nephroprotectant	POS	O
in	POS	O
combination	POS	O
with	POS	O
hydration	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
We	POS	O
aimed	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
rates	POS	O
of	POS	O
cisplatin	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
in	POS	O
cancer	POS	B-NP
patients	POS	O
receiving	POS	O
single	POS	O
-	POS	O
agent	POS	O
cisplatin	POS	O
with	POS	O
and	POS	O
without	POS	O
mannitol	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
This	POS	O
single	POS	O
-	POS	O
center	POS	O
retrospective	POS	O
analysis	POS	O
was	POS	O
a	POS	O
quasi	POS	O
experiment	POS	O
created	POS	O
by	POS	O
the	POS	O
national	POS	O
mannitol	POS	O
shortage	POS	O
.	POS	O
Data	POS	O
were	POS	O
collected	POS	O
on	POS	O
adult	POS	O
cancer	POS	B-NP
patients	POS	O
receiving	POS	O
single	POS	O
-	POS	O
agent	POS	O
cisplatin	POS	O
as	POS	O
an	POS	O
outpatient	POS	O
from	POS	O
January	POS	O
2011	POS	O
to	POS	O
September	POS	O
2012	POS	O
.	POS	O
The	POS	O
primary	POS	O
outcome	POS	O
was	POS	O
acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
(	POS	O
AKI	POS	B-NP
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
We	POS	O
evaluated	POS	O
143	POS	O
patients	POS	O
who	POS	O
received	POS	O
single	POS	O
-	POS	O
agent	POS	O
cisplatin	POS	O
;	POS	O
97	POS	O
.	POS	O
2	POS	O
%	POS	O
of	POS	O
patients	POS	O
had	POS	O
head	POS	B-NP
and	POS	I-NP
neck	POS	I-NP
cancer	POS	I-NP
as	POS	O
their	POS	O
primary	POS	B-NP
malignancy	POS	I-NP
.	POS	O
Patients	POS	O
who	POS	O
did	POS	O
not	POS	O
receive	POS	O
mannitol	POS	O
were	POS	O
more	POS	O
likely	POS	O
to	POS	O
develop	POS	O
nephrotoxicity	POS	B-NP
:	POS	O
odds	POS	O
ratio	POS	O
[	POS	O
OR	POS	O
]	POS	O
=	POS	O
2	POS	O
.	POS	O
646	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
1	POS	O
.	POS	O
008	POS	O
,	POS	O
6	POS	O
.	POS	O
944	POS	O
;	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
048	POS	O
)	POS	O
.	POS	O
Patients	POS	O
who	POS	O
received	POS	O
the	POS	O
100	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
dosing	POS	O
and	POS	O
patients	POS	O
who	POS	O
had	POS	O
a	POS	O
history	POS	O
of	POS	O
hypertension	POS	B-NP
also	POS	O
had	POS	O
a	POS	O
higher	POS	O
likelihood	POS	O
of	POS	O
developing	POS	O
nephrotoxicity	POS	B-NP
:	POS	O
OR	POS	O
=	POS	O
11	POS	O
.	POS	O
494	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
4	POS	O
.	POS	O
149	POS	O
,	POS	O
32	POS	O
.	POS	O
258	POS	O
;	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
0001	POS	O
)	POS	O
and	POS	O
OR	POS	O
=	POS	O
3	POS	O
.	POS	O
219	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
=	POS	O
1	POS	O
.	POS	O
228	POS	O
,	POS	O
8	POS	O
.	POS	O
439	POS	O
;	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
017	POS	O
)	POS	O
,	POS	O
respectively	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
When	POS	O
limited	POS	O
quantities	POS	O
of	POS	O
mannitol	POS	O
are	POS	O
available	POS	O
,	POS	O
it	POS	O
should	POS	O
preferentially	POS	O
be	POS	O
given	POS	O
to	POS	O
patients	POS	O
at	POS	O
particularly	POS	O
high	POS	O
risk	POS	O
of	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
Our	POS	O
analysis	POS	O
suggests	POS	O
that	POS	O
those	POS	O
patients	POS	O
receiving	POS	O
the	POS	O
dosing	POS	O
schedule	POS	O
of	POS	O
100	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
cisplatin	POS	O
every	POS	O
3	POS	O
weeks	POS	O
and	POS	O
those	POS	O
with	POS	O
hypertension	POS	B-NP
are	POS	O
at	POS	O
the	POS	O
greatest	POS	O
risk	POS	O
of	POS	O
nephrotoxicity	POS	B-NP
and	POS	O
would	POS	O
benefit	POS	O
from	POS	O
the	POS	O
addition	POS	O
of	POS	O
mannitol	POS	O
.	POS	O
Metformin	POS	O
protects	POS	O
against	POS	O
seizures	POS	B-NP
,	POS	O
learning	POS	B-NP
and	POS	I-NP
memory	POS	I-NP
impairments	POS	I-NP
and	POS	O
oxidative	POS	O
damage	POS	O
induced	POS	O
by	POS	O
pentylenetetrazole	POS	O
-	POS	O
induced	POS	O
kindling	POS	O
in	POS	O
mice	POS	O
.	POS	O
Cognitive	POS	B-NP
impairment	POS	I-NP
,	POS	O
the	POS	O
most	POS	O
common	POS	O
and	POS	O
severe	POS	O
comorbidity	POS	O
of	POS	O
epilepsy	POS	B-NP
,	POS	O
greatly	POS	O
diminishes	POS	O
the	POS	O
quality	POS	O
of	POS	O
life	POS	O
.	POS	O
However	POS	O
,	POS	O
current	POS	O
therapeutic	POS	O
interventions	POS	O
for	POS	O
epilepsy	POS	B-NP
can	POS	O
also	POS	O
cause	POS	O
untoward	POS	O
cognitive	POS	O
effects	POS	O
.	POS	O
Thus	POS	O
,	POS	O
there	POS	O
is	POS	O
an	POS	O
urgent	POS	O
need	POS	O
for	POS	O
new	POS	O
kinds	POS	O
of	POS	O
agents	POS	O
targeting	POS	O
both	POS	O
seizures	POS	B-NP
and	POS	O
cognition	POS	B-NP
deficits	POS	I-NP
.	POS	O
Oxidative	POS	O
stress	POS	O
is	POS	O
considered	POS	O
to	POS	O
play	POS	O
an	POS	O
important	POS	O
role	POS	O
in	POS	O
epileptogenesis	POS	B-NP
and	POS	O
cognitive	POS	B-NP
deficits	POS	I-NP
,	POS	O
and	POS	O
antioxidants	POS	O
have	POS	O
a	POS	O
putative	POS	O
antiepileptic	POS	O
potential	POS	O
.	POS	O
Metformin	POS	O
,	POS	O
the	POS	O
most	POS	O
commonly	POS	O
prescribed	POS	O
antidiabetic	POS	O
oral	POS	O
drug	POS	O
,	POS	O
has	POS	O
antioxidant	POS	O
properties	POS	O
.	POS	O
This	POS	O
study	POS	O
was	POS	O
designed	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
ameliorative	POS	O
effects	POS	O
of	POS	O
metformin	POS	O
on	POS	O
seizures	POS	B-NP
,	POS	O
cognitive	POS	B-NP
impairment	POS	I-NP
and	POS	O
brain	POS	O
oxidative	POS	O
stress	POS	O
markers	POS	O
observed	POS	O
in	POS	O
pentylenetetrazole	POS	O
-	POS	O
induced	POS	O
kindling	POS	O
animals	POS	O
.	POS	O
Male	POS	O
C57BL	POS	O
/	POS	O
6	POS	O
mice	POS	O
were	POS	O
administered	POS	O
with	POS	O
subconvulsive	POS	O
dose	POS	O
of	POS	O
pentylenetetrazole	POS	O
(	POS	O
37	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
every	POS	O
other	POS	O
day	POS	O
for	POS	O
14	POS	O
injections	POS	O
.	POS	O
Metformin	POS	O
was	POS	O
injected	POS	O
intraperitoneally	POS	O
in	POS	O
dose	POS	O
of	POS	O
200mg	POS	O
/	POS	O
kg	POS	O
along	POS	O
with	POS	O
alternate	POS	O
-	POS	O
day	POS	O
PTZ	POS	O
.	POS	O
We	POS	O
found	POS	O
that	POS	O
metformin	POS	O
suppressed	POS	O
the	POS	O
progression	POS	O
of	POS	O
kindling	POS	O
,	POS	O
ameliorated	POS	O
the	POS	O
cognitive	POS	B-NP
impairment	POS	I-NP
and	POS	O
decreased	POS	O
brain	POS	O
oxidative	POS	O
stress	POS	O
.	POS	O
Thus	POS	O
the	POS	O
present	POS	O
study	POS	O
concluded	POS	O
that	POS	O
metformin	POS	O
may	POS	O
be	POS	O
a	POS	O
potential	POS	O
agent	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
epilepsy	POS	B-NP
as	POS	O
well	POS	O
as	POS	O
a	POS	O
protective	POS	O
medicine	POS	O
against	POS	O
cognitive	POS	B-NP
impairment	POS	I-NP
induced	POS	O
by	POS	O
seizures	POS	B-NP
.	POS	O
P53	POS	O
inhibition	POS	O
exacerbates	POS	O
late	POS	O
-	POS	O
stage	POS	O
anthracycline	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
AIMS	POS	O
:	POS	O
Doxorubicin	POS	O
(	POS	O
DOX	POS	O
)	POS	O
is	POS	O
an	POS	O
effective	POS	O
anti	POS	O
-	POS	O
cancer	POS	O
therapeutic	POS	O
,	POS	O
but	POS	O
is	POS	O
associated	POS	O
with	POS	O
both	POS	O
acute	POS	O
and	POS	O
late	POS	O
-	POS	O
stage	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
Children	POS	O
are	POS	O
particularly	POS	O
sensitive	POS	O
to	POS	O
DOX	POS	O
-	POS	O
induced	POS	O
heart	POS	B-NP
failure	POS	I-NP
.	POS	O
Here	POS	O
,	POS	O
the	POS	O
impact	POS	O
of	POS	O
p53	POS	O
inhibition	POS	O
on	POS	O
acute	POS	O
vs	POS	O
.	POS	O
late	POS	O
-	POS	O
stage	POS	O
DOX	POS	O
cardiotoxicity	POS	B-NP
was	POS	O
examined	POS	O
in	POS	O
a	POS	O
juvenile	POS	O
model	POS	O
.	POS	O
METHODS	POS	O
AND	POS	O
RESULTS	POS	O
:	POS	O
Two	POS	O
-	POS	O
week	POS	O
-	POS	O
old	POS	O
MHC	POS	O
-	POS	O
CB7	POS	O
mice	POS	O
(	POS	O
which	POS	O
express	POS	O
dominant	POS	O
-	POS	O
interfering	POS	O
p53	POS	O
in	POS	O
cardiomyocytes	POS	O
)	POS	O
and	POS	O
their	POS	O
non	POS	O
-	POS	O
transgenic	POS	O
(	POS	O
NON	POS	O
-	POS	O
TXG	POS	O
)	POS	O
littermates	POS	O
received	POS	O
weekly	POS	O
DOX	POS	O
injections	POS	O
for	POS	O
5	POS	O
weeks	POS	O
(	POS	O
25	POS	O
mg	POS	O
/	POS	O
kg	POS	O
cumulative	POS	O
dose	POS	O
)	POS	O
.	POS	O
One	POS	O
week	POS	O
after	POS	O
the	POS	O
last	POS	O
DOX	POS	O
treatment	POS	O
(	POS	O
acute	POS	O
stage	POS	O
)	POS	O
,	POS	O
MHC	POS	O
-	POS	O
CB7	POS	O
mice	POS	O
exhibited	POS	O
improved	POS	O
cardiac	POS	O
function	POS	O
and	POS	O
lower	POS	O
levels	POS	O
of	POS	O
cardiomyocyte	POS	O
apoptosis	POS	O
when	POS	O
compared	POS	O
with	POS	O
the	POS	O
NON	POS	O
-	POS	O
TXG	POS	O
mice	POS	O
.	POS	O
Surprisingly	POS	O
,	POS	O
by	POS	O
13	POS	O
weeks	POS	O
following	POS	O
the	POS	O
last	POS	O
DOX	POS	O
treatment	POS	O
(	POS	O
late	POS	O
stage	POS	O
)	POS	O
,	POS	O
MHC	POS	O
-	POS	O
CB7	POS	O
exhibited	POS	O
a	POS	O
progressive	POS	O
decrease	POS	O
in	POS	O
cardiac	POS	O
function	POS	O
and	POS	O
higher	POS	O
rates	POS	O
of	POS	O
cardiomyocyte	POS	O
apoptosis	POS	O
when	POS	O
compared	POS	O
with	POS	O
NON	POS	O
-	POS	O
TXG	POS	O
mice	POS	O
.	POS	O
p53	POS	O
inhibition	POS	O
blocked	POS	O
transient	POS	O
DOX	POS	O
-	POS	O
induced	POS	O
STAT3	POS	O
activation	POS	O
in	POS	O
MHC	POS	O
-	POS	O
CB7	POS	O
mice	POS	O
,	POS	O
which	POS	O
was	POS	O
associated	POS	O
with	POS	O
enhanced	POS	O
induction	POS	O
of	POS	O
the	POS	O
DNA	POS	O
repair	POS	O
proteins	POS	O
Ku70	POS	O
and	POS	O
Ku80	POS	O
.	POS	O
Mice	POS	O
with	POS	O
cardiomyocyte	POS	O
-	POS	O
restricted	POS	O
deletion	POS	O
of	POS	O
STAT3	POS	O
exhibited	POS	O
worse	POS	O
cardiac	POS	O
function	POS	O
,	POS	O
higher	POS	O
levels	POS	O
of	POS	O
cardiomyocyte	POS	O
apoptosis	POS	O
,	POS	O
and	POS	O
a	POS	O
greater	POS	O
induction	POS	O
of	POS	O
Ku70	POS	O
and	POS	O
Ku80	POS	O
in	POS	O
response	POS	O
to	POS	O
DOX	POS	O
treatment	POS	O
during	POS	O
the	POS	O
acute	POS	O
stage	POS	O
when	POS	O
compared	POS	O
with	POS	O
control	POS	O
animals	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
These	POS	O
data	POS	O
support	POS	O
a	POS	O
model	POS	O
wherein	POS	O
a	POS	O
p53	POS	O
-	POS	O
dependent	POS	O
cardioprotective	POS	O
pathway	POS	O
,	POS	O
mediated	POS	O
via	POS	O
STAT3	POS	O
activation	POS	O
,	POS	O
mitigates	POS	O
DOX	POS	O
-	POS	O
induced	POS	O
myocardial	POS	O
stress	POS	O
during	POS	O
drug	POS	O
delivery	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
these	POS	O
data	POS	O
suggest	POS	O
an	POS	O
explanation	POS	O
as	POS	O
to	POS	O
how	POS	O
p53	POS	O
inhibition	POS	O
can	POS	O
result	POS	O
in	POS	O
cardioprotection	POS	O
during	POS	O
drug	POS	O
treatment	POS	O
and	POS	O
,	POS	O
paradoxically	POS	O
,	POS	O
enhanced	POS	O
cardiotoxicity	POS	B-NP
long	POS	O
after	POS	O
the	POS	O
cessation	POS	O
of	POS	O
drug	POS	O
treatment	POS	O
.	POS	O
Metronidazole	POS	O
-	POS	O
induced	POS	O
encephalopathy	POS	B-NP
:	POS	O
an	POS	O
uncommon	POS	O
scenario	POS	O
.	POS	O
Metronidazole	POS	O
can	POS	O
produce	POS	O
neurological	POS	B-NP
complications	POS	I-NP
although	POS	O
it	POS	O
is	POS	O
not	POS	O
a	POS	O
common	POS	O
scenario	POS	O
.	POS	O
We	POS	O
present	POS	O
a	POS	O
case	POS	O
where	POS	O
a	POS	O
patient	POS	O
developed	POS	O
features	POS	O
of	POS	O
encephalopathy	POS	B-NP
following	POS	O
prolonged	POS	O
metronidazole	POS	O
intake	POS	O
.	POS	O
Magnetic	POS	O
resonance	POS	O
imaging	POS	O
(	POS	O
MRI	POS	O
)	POS	O
brain	POS	O
showed	POS	O
abnormal	POS	O
signal	POS	O
intensity	POS	O
involving	POS	O
both	POS	O
dentate	POS	O
nuclei	POS	O
of	POS	O
cerebellum	POS	O
and	POS	O
splenium	POS	O
of	POS	O
corpus	POS	O
callosum	POS	O
.	POS	O
The	POS	O
diagnosis	POS	O
of	POS	O
metronidazole	POS	O
toxicity	POS	B-NP
was	POS	O
made	POS	O
by	POS	O
the	POS	O
MRI	POS	O
findings	POS	O
and	POS	O
supported	POS	O
clinically	POS	O
.	POS	O
Aconitine	POS	O
-	POS	O
induced	POS	O
Ca2	POS	O
+	POS	O
overload	POS	O
causes	POS	O
arrhythmia	POS	B-NP
and	POS	O
triggers	POS	O
apoptosis	POS	O
through	POS	O
p38	POS	O
MAPK	POS	O
signaling	POS	O
pathway	POS	O
in	POS	O
rats	POS	O
.	POS	O
Aconitine	POS	O
is	POS	O
a	POS	O
major	POS	O
bioactive	POS	O
diterpenoid	POS	O
alkaloid	POS	O
with	POS	O
high	POS	O
content	POS	O
derived	POS	O
from	POS	O
herbal	POS	O
aconitum	POS	O
plants	POS	O
.	POS	O
Emerging	POS	O
evidence	POS	O
indicates	POS	O
that	POS	O
voltage	POS	O
-	POS	O
dependent	POS	O
Na	POS	O
(	POS	O
+	POS	O
)	POS	O
channels	POS	O
have	POS	O
pivotal	POS	O
roles	POS	O
in	POS	O
the	POS	O
cardiotoxicity	POS	B-NP
of	POS	O
aconitine	POS	O
.	POS	O
However	POS	O
,	POS	O
no	POS	O
reports	POS	O
are	POS	O
available	POS	O
on	POS	O
the	POS	O
role	POS	O
of	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
in	POS	O
aconitine	POS	B-NP
poisoning	POS	I-NP
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
we	POS	O
explored	POS	O
the	POS	O
importance	POS	O
of	POS	O
pathological	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
signaling	POS	O
in	POS	O
aconitine	POS	O
poisoning	POS	B-NP
in	POS	O
vitro	POS	O
and	POS	O
in	POS	O
vivo	POS	O
.	POS	O
We	POS	O
found	POS	O
that	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
overload	POS	O
lead	POS	O
to	POS	O
accelerated	POS	O
beating	POS	O
rhythm	POS	O
in	POS	O
adult	POS	O
rat	POS	O
ventricular	POS	O
myocytes	POS	O
and	POS	O
caused	POS	O
arrhythmia	POS	B-NP
in	POS	O
conscious	POS	O
freely	POS	O
moving	POS	O
rats	POS	O
.	POS	O
To	POS	O
investigate	POS	O
effects	POS	O
of	POS	O
aconitine	POS	O
on	POS	O
myocardial	POS	B-NP
injury	POS	I-NP
,	POS	O
we	POS	O
performed	POS	O
cytotoxicity	POS	B-NP
assay	POS	O
in	POS	O
neonatal	POS	O
rat	POS	O
ventricular	POS	O
myocytes	POS	O
(	POS	O
NRVMs	POS	O
)	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
measured	POS	O
lactate	POS	O
dehydrogenase	POS	O
level	POS	O
in	POS	O
the	POS	O
culture	POS	O
medium	POS	O
of	POS	O
NRVMs	POS	O
and	POS	O
activities	POS	O
of	POS	O
serum	POS	O
cardiac	POS	O
enzymes	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
results	POS	O
showed	POS	O
that	POS	O
aconitine	POS	O
resulted	POS	O
in	POS	O
myocardial	POS	B-NP
injury	POS	I-NP
and	POS	O
reduced	POS	O
NRVMs	POS	O
viability	POS	O
dose	POS	O
-	POS	O
dependently	POS	O
.	POS	O
To	POS	O
confirm	POS	O
the	POS	O
pro	POS	O
-	POS	O
apoptotic	POS	O
effects	POS	O
,	POS	O
we	POS	O
performed	POS	O
flow	POS	O
cytometric	POS	O
detection	POS	O
,	POS	O
cardiac	POS	O
histology	POS	O
,	POS	O
transmission	POS	O
electron	POS	O
microscopy	POS	O
and	POS	O
terminal	POS	O
deoxynucleotidyl	POS	O
transferase	POS	O
-	POS	O
mediated	POS	O
dUTP	POS	O
-	POS	O
biotin	POS	O
nick	POS	O
end	POS	O
labeling	POS	O
assay	POS	O
.	POS	O
The	POS	O
results	POS	O
showed	POS	O
that	POS	O
aconitine	POS	O
stimulated	POS	O
apoptosis	POS	O
time	POS	O
-	POS	O
dependently	POS	O
.	POS	O
The	POS	O
expression	POS	O
analysis	POS	O
of	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
handling	POS	O
proteins	POS	O
demonstrated	POS	O
that	POS	O
aconitine	POS	O
promoted	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
overload	POS	O
through	POS	O
the	POS	O
expression	POS	O
regulation	POS	O
of	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
handling	POS	O
proteins	POS	O
.	POS	O
The	POS	O
expression	POS	O
analysis	POS	O
of	POS	O
apoptosis	POS	O
-	POS	O
related	POS	O
proteins	POS	O
revealed	POS	O
that	POS	O
pro	POS	O
-	POS	O
apoptotic	POS	O
protein	POS	O
expression	POS	O
was	POS	O
upregulated	POS	O
,	POS	O
and	POS	O
anti	POS	O
-	POS	O
apoptotic	POS	O
protein	POS	O
BCL	POS	O
-	POS	O
2	POS	O
expression	POS	O
was	POS	O
downregulated	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
increased	POS	O
phosphorylation	POS	O
of	POS	O
MAPK	POS	O
family	POS	O
members	POS	O
,	POS	O
especially	POS	O
the	POS	O
P	POS	O
-	POS	O
P38	POS	O
/	POS	O
P38	POS	O
ratio	POS	O
was	POS	O
found	POS	O
in	POS	O
cardiac	POS	O
tissues	POS	O
.	POS	O
Hence	POS	O
,	POS	O
our	POS	O
results	POS	O
suggest	POS	O
that	POS	O
aconitine	POS	O
significantly	POS	O
aggravates	POS	O
Ca	POS	O
(	POS	O
2	POS	O
+	POS	O
)	POS	O
overload	POS	O
and	POS	O
causes	POS	O
arrhythmia	POS	B-NP
and	POS	O
finally	POS	O
promotes	POS	O
apoptotic	POS	O
development	POS	O
via	POS	O
phosphorylation	POS	O
of	POS	O
P38	POS	O
mitogen	POS	O
-	POS	O
activated	POS	O
protein	POS	O
kinase	POS	O
.	POS	O
Chronic	POS	O
treatment	POS	O
with	POS	O
metformin	POS	O
suppresses	POS	O
toll	POS	O
-	POS	O
like	POS	O
receptor	POS	O
4	POS	O
signaling	POS	O
and	POS	O
attenuates	POS	O
left	POS	O
ventricular	POS	B-NP
dysfunction	POS	I-NP
following	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
Acute	POS	O
treatment	POS	O
with	POS	O
metformin	POS	O
has	POS	O
a	POS	O
protective	POS	O
effect	POS	O
in	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
by	POS	O
suppression	POS	O
of	POS	O
inflammatory	POS	O
responses	POS	O
due	POS	O
to	POS	O
activation	POS	O
of	POS	O
AMP	POS	O
-	POS	O
activated	POS	O
protein	POS	O
kinase	POS	O
(	POS	O
AMPK	POS	O
)	POS	O
.	POS	O
In	POS	O
the	POS	O
present	POS	O
study	POS	O
,	POS	O
the	POS	O
effect	POS	O
of	POS	O
chronic	POS	O
pre	POS	O
-	POS	O
treatment	POS	O
with	POS	O
metformin	POS	O
on	POS	O
cardiac	POS	B-NP
dysfunction	POS	I-NP
and	POS	O
toll	POS	O
-	POS	O
like	POS	O
receptor	POS	O
4	POS	O
(	POS	O
TLR4	POS	O
)	POS	O
activities	POS	O
following	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
and	POS	O
their	POS	O
relation	POS	O
with	POS	O
AMPK	POS	O
were	POS	O
assessed	POS	O
.	POS	O
Male	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
randomly	POS	O
assigned	POS	O
to	POS	O
one	POS	O
of	POS	O
5	POS	O
groups	POS	O
(	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
:	POS	O
normal	POS	O
control	POS	O
and	POS	O
groups	POS	O
were	POS	O
injected	POS	O
isoproterenol	POS	O
after	POS	O
chronic	POS	O
pre	POS	O
-	POS	O
treatment	POS	O
with	POS	O
0	POS	O
,	POS	O
25	POS	O
,	POS	O
50	POS	O
,	POS	O
or	POS	O
100mg	POS	O
/	POS	O
kg	POS	O
of	POS	O
metformin	POS	O
twice	POS	O
daily	POS	O
for	POS	O
14	POS	O
days	POS	O
.	POS	O
Isoproterenol	POS	O
(	POS	O
100mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
was	POS	O
injected	POS	O
subcutaneously	POS	O
on	POS	O
the	POS	O
13th	POS	O
and	POS	O
14th	POS	O
days	POS	O
to	POS	O
induce	POS	O
acute	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
Isoproterenol	POS	O
alone	POS	O
decreased	POS	O
left	POS	O
ventricular	POS	O
systolic	POS	O
pressure	POS	O
and	POS	O
myocardial	POS	O
contractility	POS	O
indexed	POS	O
as	POS	O
LVdp	POS	O
/	POS	O
dtmax	POS	O
and	POS	O
LVdp	POS	O
/	POS	O
dtmin	POS	O
.	POS	O
The	POS	O
left	POS	O
ventricular	POS	B-NP
dysfunction	POS	I-NP
was	POS	O
significantly	POS	O
lower	POS	O
in	POS	O
the	POS	O
groups	POS	O
treated	POS	O
with	POS	O
25	POS	O
and	POS	O
50mg	POS	O
/	POS	O
kg	POS	O
of	POS	O
metformin	POS	O
.	POS	O
Metfromin	POS	O
markedly	POS	O
lowered	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
elevation	POS	O
in	POS	O
the	POS	O
levels	POS	O
of	POS	O
TLR4	POS	O
mRNA	POS	O
,	POS	O
myeloid	POS	O
differentiation	POS	O
protein	POS	O
88	POS	O
(	POS	O
MyD88	POS	O
)	POS	O
,	POS	O
tumor	POS	B-NP
necrosis	POS	I-NP
factor	POS	O
-	POS	O
alpha	POS	O
(	POS	O
TNF	POS	O
-	POS	O
a	POS	O
)	POS	O
,	POS	O
and	POS	O
interleukin	POS	O
6	POS	O
(	POS	O
IL	POS	O
-	POS	O
6	POS	O
)	POS	O
in	POS	O
the	POS	O
heart	POS	O
tissues	POS	O
.	POS	O
Similar	POS	O
changes	POS	O
were	POS	O
also	POS	O
seen	POS	O
in	POS	O
the	POS	O
serum	POS	O
levels	POS	O
of	POS	O
TNF	POS	O
-	POS	O
a	POS	O
and	POS	O
IL	POS	O
-	POS	O
6	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
lower	POS	O
doses	POS	O
of	POS	O
25	POS	O
and	POS	O
50mg	POS	O
/	POS	O
kg	POS	O
were	POS	O
more	POS	O
effective	POS	O
than	POS	O
100mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
Phosphorylated	POS	O
AMPKa	POS	O
(	POS	O
p	POS	O
-	POS	O
AMPK	POS	O
)	POS	O
in	POS	O
the	POS	O
myocardium	POS	O
was	POS	O
significantly	POS	O
elevated	POS	O
by	POS	O
25mg	POS	O
/	POS	O
kg	POS	O
of	POS	O
metformin	POS	O
,	POS	O
slightly	POS	O
by	POS	O
50mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
but	POS	O
not	POS	O
by	POS	O
100mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
Chronic	POS	O
pre	POS	O
-	POS	O
treatment	POS	O
with	POS	O
metformin	POS	O
reduces	POS	O
post	POS	O
-	POS	O
myocardial	POS	O
infarction	POS	O
cardiac	POS	O
dysfunction	POS	O
and	POS	O
suppresses	POS	O
inflammatory	POS	O
responses	POS	O
,	POS	O
possibly	POS	O
through	POS	O
inhibition	POS	O
of	POS	O
TLR4	POS	O
activities	POS	O
.	POS	O
This	POS	O
mechanism	POS	O
can	POS	O
be	POS	O
considered	POS	O
as	POS	O
a	POS	O
target	POS	O
to	POS	O
protect	POS	O
infarcted	POS	O
myocardium	POS	O
.	POS	O
Unusual	POS	O
complications	POS	O
of	POS	O
antithyroid	POS	O
drug	POS	O
therapy	POS	O
:	POS	O
four	POS	O
case	POS	O
reports	POS	O
and	POS	O
review	POS	O
of	POS	O
literature	POS	O
.	POS	O
Two	POS	O
cases	POS	O
of	POS	O
propylthiouracil	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
acute	POS	I-NP
hepatitis	POS	I-NP
,	POS	O
one	POS	O
case	POS	O
of	POS	O
fatal	POS	O
methimazole	POS	O
-	POS	O
associated	POS	O
hepatocellular	POS	B-NP
necrosis	POS	I-NP
and	POS	O
one	POS	O
case	POS	O
of	POS	O
propylthiouracil	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
lupus	POS	I-NP
-	POS	I-NP
like	POS	I-NP
syndrome	POS	I-NP
are	POS	O
described	POS	O
.	POS	O
The	POS	O
literature	POS	O
related	POS	O
to	POS	O
antithyroid	POS	O
drug	POS	O
side	POS	O
effects	POS	O
and	POS	O
the	POS	O
mechanisms	POS	O
for	POS	O
their	POS	O
occurrence	POS	O
are	POS	O
reviewed	POS	O
and	POS	O
the	POS	O
efficacy	POS	O
and	POS	O
complications	POS	O
of	POS	O
thyroidectomy	POS	O
and	POS	O
radioiodine	POS	O
compared	POS	O
to	POS	O
those	POS	O
of	POS	O
antithyroid	POS	O
drugs	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
in	POS	O
most	POS	O
circumstances	POS	O
131I	POS	O
is	POS	O
the	POS	O
therapy	POS	O
of	POS	O
choice	POS	O
for	POS	O
hyperthyroidism	POS	B-NP
.	POS	O
Neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
induced	POS	O
by	POS	O
combination	POS	O
therapy	POS	O
with	POS	O
tetrabenazine	POS	O
and	POS	O
tiapride	POS	O
in	POS	O
a	POS	O
Japanese	POS	O
patient	POS	O
with	POS	O
Huntington	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
at	POS	O
the	POS	O
terminal	POS	O
stage	POS	O
of	POS	O
recurrent	POS	O
breast	POS	B-NP
cancer	POS	I-NP
.	POS	O
We	POS	O
herein	POS	O
describe	POS	O
the	POS	O
case	POS	O
of	POS	O
an	POS	O
81	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
Japanese	POS	O
woman	POS	O
with	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
that	POS	O
occurred	POS	O
36	POS	O
days	POS	O
after	POS	O
the	POS	O
initiation	POS	O
of	POS	O
combination	POS	O
therapy	POS	O
with	POS	O
tiapride	POS	O
(	POS	O
75	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
and	POS	O
tetrabenazine	POS	O
(	POS	O
12	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
for	POS	O
Huntington	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
The	POS	O
patient	POS	O
had	POS	O
been	POS	O
treated	POS	O
with	POS	O
tiapride	POS	O
or	POS	O
tetrabenazine	POS	O
alone	POS	O
without	POS	O
any	POS	O
adverse	POS	O
effects	POS	O
before	POS	O
the	POS	O
administration	POS	O
of	POS	O
the	POS	O
combination	POS	O
therapy	POS	O
.	POS	O
She	POS	O
also	POS	O
had	POS	O
advanced	POS	O
breast	POS	B-NP
cancer	POS	I-NP
when	POS	O
the	POS	O
combination	POS	O
therapy	POS	O
was	POS	O
initiated	POS	O
.	POS	O
To	POS	O
the	POS	O
best	POS	O
of	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
due	POS	O
to	POS	O
combination	POS	O
therapy	POS	O
with	POS	O
tetrabenazine	POS	O
and	POS	O
tiapride	POS	O
has	POS	O
not	POS	O
been	POS	O
previously	POS	O
reported	POS	O
.	POS	O
Tetrabenazine	POS	O
should	POS	O
be	POS	O
administered	POS	O
very	POS	O
carefully	POS	O
in	POS	O
combination	POS	O
with	POS	O
other	POS	O
neuroleptic	POS	O
drugs	POS	O
,	POS	O
particularly	POS	O
in	POS	O
patients	POS	O
with	POS	O
a	POS	O
worsening	POS	O
general	POS	O
condition	POS	O
.	POS	O
A	POS	O
metoprolol	POS	O
-	POS	O
terbinafine	POS	O
combination	POS	O
induced	POS	O
bradycardia	POS	B-NP
.	POS	O
To	POS	O
report	POS	O
a	POS	O
sinus	POS	B-NP
bradycardia	POS	I-NP
induced	POS	O
by	POS	O
metoprolol	POS	O
and	POS	O
terbinafine	POS	O
drug	POS	O
-	POS	O
drug	POS	O
interaction	POS	O
and	POS	O
its	POS	O
management	POS	O
.	POS	O
A	POS	O
63	POS	O
year	POS	O
-	POS	O
old	POS	O
Caucasian	POS	O
man	POS	O
on	POS	O
metoprolol	POS	O
200	POS	O
mg	POS	O
/	POS	O
day	POS	O
for	POS	O
stable	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
was	POS	O
prescribed	POS	O
a	POS	O
90	POS	O
-	POS	O
day	POS	O
course	POS	O
of	POS	O
oral	POS	O
terbinafine	POS	O
250	POS	O
mg	POS	O
/	POS	O
day	POS	O
for	POS	O
onychomycosis	POS	B-NP
.	POS	O
On	POS	O
the	POS	O
49th	POS	O
day	POS	O
of	POS	O
terbinafine	POS	O
therapy	POS	O
,	POS	O
he	POS	O
was	POS	O
brought	POS	O
to	POS	O
the	POS	O
emergency	POS	O
room	POS	O
for	POS	O
a	POS	O
decrease	POS	O
of	POS	O
his	POS	O
global	POS	O
health	POS	O
status	POS	O
,	POS	O
confusion	POS	B-NP
and	POS	O
falls	POS	O
.	POS	O
The	POS	O
electrocardiogram	POS	O
revealed	POS	O
a	POS	O
37	POS	O
beats	POS	O
/	POS	O
min	POS	O
sinus	POS	O
bradycardia	POS	B-NP
.	POS	O
A	POS	O
score	POS	O
of	POS	O
7	POS	O
on	POS	O
the	POS	O
Naranjo	POS	O
adverse	POS	O
drug	POS	O
reaction	POS	O
probability	POS	O
scale	POS	O
indicates	POS	O
a	POS	O
probable	POS	O
relationship	POS	O
between	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
sinus	POS	O
bradycardia	POS	B-NP
and	POS	O
the	POS	O
drug	POS	O
interaction	POS	O
between	POS	O
metoprolol	POS	O
and	POS	O
terbinafine	POS	O
.	POS	O
The	POS	O
heart	POS	O
rate	POS	O
ameliorated	POS	O
first	POS	O
with	POS	O
a	POS	O
decrease	POS	O
in	POS	O
the	POS	O
dose	POS	O
of	POS	O
metoprolol	POS	O
.	POS	O
It	POS	O
was	POS	O
subsequently	POS	O
changed	POS	O
to	POS	O
bisoprolol	POS	O
and	POS	O
the	POS	O
heart	POS	O
rate	POS	O
remained	POS	O
normal	POS	O
.	POS	O
By	POS	O
inhibiting	POS	O
the	POS	O
cytochrome	POS	O
P450	POS	O
2D6	POS	O
,	POS	O
terbinafine	POS	O
had	POS	O
decreased	POS	O
metoprolol	POS	O
'	POS	O
s	POS	O
clearance	POS	O
,	POS	O
leading	POS	O
in	POS	O
metoprolol	POS	O
accumulation	POS	O
which	POS	O
has	POS	O
resulted	POS	O
in	POS	O
clinically	POS	O
significant	POS	O
sinus	POS	B-NP
bradycardia	POS	I-NP
.	POS	O
Optochiasmatic	POS	B-NP
and	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
due	POS	O
to	POS	O
ethambutol	POS	O
overtreatment	POS	O
.	POS	O
Ethambutol	POS	O
is	POS	O
known	POS	O
to	POS	O
cause	POS	O
optic	POS	B-NP
neuropathy	POS	I-NP
and	POS	O
,	POS	O
more	POS	O
rarely	POS	O
,	POS	O
axonal	POS	B-NP
polyneuropathy	POS	I-NP
.	POS	O
We	POS	O
characterize	POS	O
the	POS	O
clinical	POS	O
,	POS	O
neurophysiological	POS	O
,	POS	O
and	POS	O
neuroimaging	POS	O
findings	POS	O
in	POS	O
a	POS	O
72	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
who	POS	O
developed	POS	O
visual	POS	B-NP
loss	POS	I-NP
and	POS	O
paresthesias	POS	B-NP
after	POS	O
11	POS	O
weeks	POS	O
of	POS	O
exposure	POS	O
to	POS	O
a	POS	O
supratherapeutic	POS	O
dose	POS	O
of	POS	O
ethambutol	POS	O
.	POS	O
This	POS	O
case	POS	O
demonstrates	POS	O
the	POS	O
selective	POS	O
vulnerability	POS	O
of	POS	O
the	POS	O
anterior	POS	O
visual	POS	O
pathways	POS	O
and	POS	O
peripheral	POS	O
nerves	POS	O
to	POS	O
ethambutol	POS	O
toxicity	POS	B-NP
.	POS	O
Testosterone	POS	O
ameliorates	POS	O
streptozotocin	POS	O
-	POS	O
induced	POS	O
memory	POS	B-NP
impairment	POS	I-NP
in	POS	O
male	POS	O
rats	POS	O
.	POS	O
AIM	POS	O
:	POS	O
To	POS	O
study	POS	O
the	POS	O
effects	POS	O
of	POS	O
testosterone	POS	O
on	POS	O
streptozotocin	POS	O
(	POS	O
STZ	POS	O
)	POS	O
-	POS	O
induced	POS	O
memory	POS	B-NP
impairment	POS	I-NP
in	POS	O
male	POS	O
rats	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Adult	POS	O
male	POS	O
Wistar	POS	O
rats	POS	O
were	POS	O
intracerebroventricularly	POS	O
(	POS	O
icv	POS	O
)	POS	O
infused	POS	O
with	POS	O
STZ	POS	O
(	POS	O
750	POS	O
ug	POS	O
)	POS	O
on	POS	O
d	POS	O
1	POS	O
and	POS	O
d	POS	O
3	POS	O
,	POS	O
and	POS	O
a	POS	O
passive	POS	O
avoidance	POS	O
task	POS	O
was	POS	O
assessed	POS	O
2	POS	O
weeks	POS	O
after	POS	O
the	POS	O
first	POS	O
injection	POS	O
of	POS	O
STZ	POS	O
.	POS	O
Castration	POS	O
surgery	POS	O
was	POS	O
performed	POS	O
in	POS	O
another	POS	O
group	POS	O
of	POS	O
rats	POS	O
,	POS	O
and	POS	O
the	POS	O
passive	POS	O
avoidance	POS	O
task	POS	O
was	POS	O
assessed	POS	O
4	POS	O
weeks	POS	O
after	POS	O
the	POS	O
operation	POS	O
.	POS	O
Testosterone	POS	O
(	POS	O
1	POS	O
mg	POS	O
.	POS	O
kg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
.	POS	O
d	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
,	POS	O
sc	POS	O
)	POS	O
,	POS	O
the	POS	O
androgen	POS	O
receptor	POS	O
antagonist	POS	O
flutamide	POS	O
(	POS	O
10	POS	O
mg	POS	O
.	POS	O
kg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
.	POS	O
d	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
,	POS	O
ip	POS	O
)	POS	O
,	POS	O
the	POS	O
estrogen	POS	O
receptor	POS	O
antagonist	POS	O
tamoxifen	POS	O
(	POS	O
1	POS	O
mg	POS	O
.	POS	O
kg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
.	POS	O
d	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
,	POS	O
ip	POS	O
)	POS	O
or	POS	O
the	POS	O
aromatase	POS	O
inhibitor	POS	O
letrozole	POS	O
(	POS	O
4	POS	O
mg	POS	O
.	POS	O
kg	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
.	POS	O
d	POS	O
(	POS	O
-	POS	O
1	POS	O
)	POS	O
,	POS	O
ip	POS	O
)	POS	O
were	POS	O
administered	POS	O
for	POS	O
6	POS	O
d	POS	O
after	POS	O
the	POS	O
first	POS	O
injection	POS	O
of	POS	O
STZ	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
STZ	POS	O
administration	POS	O
and	POS	O
castration	POS	O
markedly	POS	O
decreased	POS	O
both	POS	O
STL1	POS	O
(	POS	O
the	POS	O
short	POS	O
memory	POS	O
)	POS	O
and	POS	O
STL2	POS	O
(	POS	O
the	POS	O
long	POS	O
memory	POS	O
)	POS	O
in	POS	O
passive	POS	O
avoidance	POS	O
tests	POS	O
.	POS	O
Testosterone	POS	O
replacement	POS	O
almost	POS	O
restored	POS	O
the	POS	O
STL1	POS	O
and	POS	O
STL2	POS	O
in	POS	O
castrated	POS	O
rats	POS	O
,	POS	O
and	POS	O
significantly	POS	O
prolonged	POS	O
the	POS	O
STL1	POS	O
and	POS	O
STL2	POS	O
in	POS	O
STZ	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
Administration	POS	O
of	POS	O
flutamide	POS	O
,	POS	O
letrozole	POS	O
or	POS	O
tamoxifen	POS	O
significantly	POS	O
impaired	POS	O
the	POS	O
memory	POS	O
in	POS	O
intact	POS	O
rats	POS	O
,	POS	O
and	POS	O
significantly	POS	O
attenuated	POS	O
the	POS	O
testosterone	POS	O
replacement	POS	O
in	POS	O
improving	POS	O
STZ	POS	O
-	POS	O
and	POS	O
castration	POS	O
-	POS	O
induced	POS	O
memory	POS	B-NP
impairment	POS	I-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
Testosterone	POS	O
administration	POS	O
ameliorates	POS	O
STZ	POS	O
-	POS	O
and	POS	O
castration	POS	O
-	POS	O
induced	POS	O
memory	POS	B-NP
impairment	POS	I-NP
in	POS	O
male	POS	O
Wistar	POS	O
rats	POS	O
.	POS	O
Behavioral	POS	O
and	POS	O
neurochemical	POS	O
studies	POS	O
in	POS	O
mice	POS	O
pretreated	POS	O
with	POS	O
garcinielliptone	POS	O
FC	POS	O
in	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
.	POS	O
Garcinielliptone	POS	O
FC	POS	O
(	POS	O
GFC	POS	O
)	POS	O
isolated	POS	O
from	POS	O
hexanic	POS	O
fraction	POS	O
seed	POS	O
extract	POS	O
of	POS	O
species	POS	O
Platonia	POS	O
insignis	POS	O
Mart	POS	O
.	POS	O
It	POS	O
is	POS	O
widely	POS	O
used	POS	O
in	POS	O
folk	POS	O
medicine	POS	O
to	POS	O
treat	POS	O
skin	POS	B-NP
diseases	POS	I-NP
in	POS	O
both	POS	O
humans	POS	O
and	POS	O
animals	POS	O
as	POS	O
well	POS	O
as	POS	O
the	POS	O
seed	POS	O
decoction	POS	O
has	POS	O
been	POS	O
used	POS	O
to	POS	O
treat	POS	O
diarrheas	POS	B-NP
and	POS	O
inflammatory	POS	B-NP
diseases	POS	I-NP
.	POS	O
However	POS	O
,	POS	O
there	POS	O
is	POS	O
no	POS	O
research	POS	O
on	POS	O
GFC	POS	O
effects	POS	O
in	POS	O
the	POS	O
central	POS	O
nervous	POS	O
system	POS	O
of	POS	O
rodents	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
aimed	POS	O
to	POS	O
evaluate	POS	O
the	POS	O
GFC	POS	O
effects	POS	O
at	POS	O
doses	POS	O
of	POS	O
25	POS	O
,	POS	O
50	POS	O
or	POS	O
75	POS	O
mg	POS	O
/	POS	O
kg	POS	O
on	POS	O
seizure	POS	B-NP
parameters	POS	O
to	POS	O
determine	POS	O
their	POS	O
anticonvulsant	POS	O
activity	POS	O
and	POS	O
its	POS	O
effects	POS	O
on	POS	O
amino	POS	O
acid	POS	O
(	POS	O
r	POS	O
-	POS	O
aminobutyric	POS	O
acid	POS	O
(	POS	O
GABA	POS	O
)	POS	O
,	POS	O
glutamine	POS	O
,	POS	O
aspartate	POS	O
and	POS	O
glutathione	POS	O
)	POS	O
levels	POS	O
as	POS	O
well	POS	O
as	POS	O
on	POS	O
acetylcholinesterase	POS	O
(	POS	O
AChE	POS	O
)	POS	O
activity	POS	O
in	POS	O
mice	POS	O
hippocampus	POS	O
after	POS	O
seizures	POS	B-NP
.	POS	O
GFC	POS	O
produced	POS	O
an	POS	O
increased	POS	O
latency	POS	O
to	POS	O
first	POS	O
seizure	POS	B-NP
,	POS	O
at	POS	O
doses	POS	O
25mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
20	POS	O
.	POS	O
12	POS	O
+	POS	O
2	POS	O
.	POS	O
20	POS	O
min	POS	O
)	POS	O
,	POS	O
50mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
20	POS	O
.	POS	O
95	POS	O
+	POS	O
2	POS	O
.	POS	O
21	POS	O
min	POS	O
)	POS	O
or	POS	O
75	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
23	POS	O
.	POS	O
43	POS	O
+	POS	O
1	POS	O
.	POS	O
99	POS	O
min	POS	O
)	POS	O
when	POS	O
compared	POS	O
with	POS	O
seized	POS	O
mice	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
GABA	POS	O
content	POS	O
of	POS	O
mice	POS	O
hippocampus	POS	O
treated	POS	O
with	POS	O
GFC75	POS	O
plus	POS	O
P400	POS	O
showed	POS	O
an	POS	O
increase	POS	O
of	POS	O
46	POS	O
.	POS	O
90	POS	O
%	POS	O
when	POS	O
compared	POS	O
with	POS	O
seized	POS	O
mice	POS	O
.	POS	O
In	POS	O
aspartate	POS	O
,	POS	O
glutamine	POS	O
and	POS	O
glutamate	POS	O
levels	POS	O
detected	POS	O
a	POS	O
decrease	POS	O
of	POS	O
5	POS	O
.	POS	O
21	POS	O
%	POS	O
,	POS	O
13	POS	O
.	POS	O
55	POS	O
%	POS	O
and	POS	O
21	POS	O
.	POS	O
80	POS	O
%	POS	O
,	POS	O
respectively	POS	O
in	POS	O
mice	POS	O
hippocampus	POS	O
treated	POS	O
with	POS	O
GFC75	POS	O
plus	POS	O
P400	POS	O
when	POS	O
compared	POS	O
with	POS	O
seized	POS	O
mice	POS	O
.	POS	O
Hippocampus	POS	O
mice	POS	O
treated	POS	O
with	POS	O
GFC75	POS	O
plus	POS	O
P400	POS	O
showed	POS	O
an	POS	O
increase	POS	O
in	POS	O
AChE	POS	O
activity	POS	O
(	POS	O
63	POS	O
.	POS	O
30	POS	O
%	POS	O
)	POS	O
when	POS	O
compared	POS	O
with	POS	O
seized	POS	O
mice	POS	O
.	POS	O
The	POS	O
results	POS	O
indicate	POS	O
that	POS	O
GFC	POS	O
can	POS	O
exert	POS	O
anticonvulsant	POS	O
activity	POS	O
and	POS	O
reduce	POS	O
the	POS	O
frequency	POS	O
of	POS	O
installation	POS	O
of	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
,	POS	O
as	POS	O
demonstrated	POS	O
by	POS	O
increase	POS	O
in	POS	O
latency	POS	O
to	POS	O
first	POS	O
seizure	POS	B-NP
and	POS	O
decrease	POS	O
in	POS	O
mortality	POS	O
rate	POS	O
of	POS	O
animals	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
our	POS	O
data	POS	O
suggest	POS	O
that	POS	O
GFC	POS	O
may	POS	O
influence	POS	O
in	POS	O
epileptogenesis	POS	B-NP
and	POS	O
promote	POS	O
anticonvulsant	POS	O
actions	POS	O
in	POS	O
pilocarpine	POS	O
model	POS	O
by	POS	O
modulating	POS	O
the	POS	O
GABA	POS	O
and	POS	O
glutamate	POS	O
contents	POS	O
and	POS	O
of	POS	O
AChE	POS	O
activity	POS	O
in	POS	O
seized	POS	O
mice	POS	O
hippocampus	POS	O
.	POS	O
This	POS	O
compound	POS	O
may	POS	O
be	POS	O
useful	POS	O
to	POS	O
produce	POS	O
neuronal	POS	O
protection	POS	O
and	POS	O
it	POS	O
can	POS	O
be	POS	O
considered	POS	O
as	POS	O
an	POS	O
anticonvulsant	POS	O
agent	POS	O
.	POS	O
Standard	POS	O
operating	POS	O
procedures	POS	O
for	POS	O
antibiotic	POS	O
therapy	POS	O
and	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
:	POS	O
a	POS	O
prospective	POS	O
,	POS	O
clinical	POS	O
,	POS	O
non	POS	O
-	POS	O
interventional	POS	O
,	POS	O
observational	POS	O
study	POS	O
.	POS	O
INTRODUCTION	POS	O
:	POS	O
Acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
(	POS	O
AKI	POS	B-NP
)	POS	O
occurs	POS	O
in	POS	O
7	POS	O
%	POS	O
of	POS	O
hospitalized	POS	O
and	POS	O
66	POS	O
%	POS	O
of	POS	O
Intensive	POS	O
Care	POS	O
Unit	POS	O
(	POS	O
ICU	POS	O
)	POS	O
patients	POS	O
.	POS	O
It	POS	O
increases	POS	O
mortality	POS	O
,	POS	O
hospital	POS	O
length	POS	O
of	POS	O
stay	POS	O
,	POS	O
and	POS	O
costs	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
,	POS	O
whether	POS	O
there	POS	O
is	POS	O
an	POS	O
association	POS	O
between	POS	O
adherence	POS	O
to	POS	O
guidelines	POS	O
(	POS	O
standard	POS	O
operating	POS	O
procedures	POS	O
(	POS	O
SOP	POS	O
)	POS	O
)	POS	O
for	POS	O
potentially	POS	O
nephrotoxic	POS	B-NP
antibiotics	POS	O
and	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
AKI	POS	B-NP
.	POS	O
METHODS	POS	O
:	POS	O
This	POS	O
study	POS	O
was	POS	O
carried	POS	O
out	POS	O
as	POS	O
a	POS	O
prospective	POS	O
,	POS	O
clinical	POS	O
,	POS	O
non	POS	O
-	POS	O
interventional	POS	O
,	POS	O
observational	POS	O
study	POS	O
.	POS	O
Data	POS	O
collection	POS	O
was	POS	O
performed	POS	O
over	POS	O
a	POS	O
total	POS	O
of	POS	O
170	POS	O
days	POS	O
in	POS	O
three	POS	O
ICUs	POS	O
at	POS	O
Charite	POS	O
-	POS	O
Universitaetsmedizin	POS	O
Berlin	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
675	POS	O
patients	POS	O
were	POS	O
included	POS	O
;	POS	O
163	POS	O
of	POS	O
these	POS	O
had	POS	O
therapy	POS	O
with	POS	O
vancomycin	POS	O
,	POS	O
gentamicin	POS	O
,	POS	O
or	POS	O
tobramycin	POS	O
;	POS	O
were	POS	O
>	POS	O
18	POS	O
years	POS	O
;	POS	O
and	POS	O
treated	POS	O
in	POS	O
the	POS	O
ICU	POS	O
for	POS	O
>	POS	O
24	POS	O
hours	POS	O
.	POS	O
Patients	POS	O
with	POS	O
an	POS	O
adherence	POS	O
to	POS	O
SOP	POS	O
>	POS	O
70	POS	O
%	POS	O
were	POS	O
classified	POS	O
into	POS	O
the	POS	O
high	POS	O
adherence	POS	O
group	POS	O
(	POS	O
HAG	POS	O
)	POS	O
and	POS	O
patients	POS	O
with	POS	O
an	POS	O
adherence	POS	O
of	POS	O
<	POS	O
70	POS	O
%	POS	O
into	POS	O
the	POS	O
low	POS	O
adherence	POS	O
group	POS	O
(	POS	O
LAG	POS	O
)	POS	O
.	POS	O
AKI	POS	B-NP
was	POS	O
defined	POS	O
according	POS	O
to	POS	O
RIFLE	POS	O
criteria	POS	O
.	POS	O
Adherence	POS	O
to	POS	O
SOPs	POS	O
was	POS	O
evaluated	POS	O
by	POS	O
retrospective	POS	O
expert	POS	O
audit	POS	O
.	POS	O
Development	POS	O
of	POS	O
AKI	POS	B-NP
was	POS	O
compared	POS	O
between	POS	O
groups	POS	O
with	POS	O
exact	POS	O
Chi2	POS	O
-	POS	O
test	POS	O
and	POS	O
multivariate	POS	O
logistic	POS	O
regression	POS	O
analysis	POS	O
(	POS	O
two	POS	O
-	POS	O
sided	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
LAG	POS	O
consisted	POS	O
of	POS	O
75	POS	O
patients	POS	O
(	POS	O
46	POS	O
%	POS	O
)	POS	O
versus	POS	O
88	POS	O
HAG	POS	O
patients	POS	O
(	POS	O
54	POS	O
%	POS	O
)	POS	O
.	POS	O
AKI	POS	B-NP
occurred	POS	O
significantly	POS	O
more	POS	O
often	POS	O
in	POS	O
LAG	POS	O
with	POS	O
36	POS	O
%	POS	O
versus	POS	O
21	POS	O
%	POS	O
in	POS	O
HAG	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
035	POS	O
)	POS	O
.	POS	O
Basic	POS	O
characteristics	POS	O
were	POS	O
comparable	POS	O
,	POS	O
except	POS	O
an	POS	O
increased	POS	O
rate	POS	O
of	POS	O
soft	POS	B-NP
tissue	POS	I-NP
infections	POS	I-NP
in	POS	O
LAG	POS	O
.	POS	O
Multivariate	POS	O
analysis	POS	O
revealed	POS	O
an	POS	O
odds	POS	O
ratio	POS	O
of	POS	O
2	POS	O
.	POS	O
5	POS	O
-	POS	O
fold	POS	O
for	POS	O
LAG	POS	O
to	POS	O
develop	POS	O
AKI	POS	B-NP
compared	POS	O
with	POS	O
HAG	POS	O
(	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
1	POS	O
.	POS	O
195	POS	O
to	POS	O
5	POS	O
.	POS	O
124	POS	O
,	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
039	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Low	POS	O
adherence	POS	O
to	POS	O
SOPs	POS	O
for	POS	O
potentially	POS	O
nephrotoxic	POS	B-NP
antibiotics	POS	O
was	POS	O
associated	POS	O
with	POS	O
a	POS	O
higher	POS	O
occurrence	POS	O
of	POS	O
AKI	POS	B-NP
.	POS	O
TRIAL	POS	O
REGISTRATION	POS	O
:	POS	O
Current	POS	O
Controlled	POS	O
Trials	POS	O
ISRCTN54598675	POS	O
.	POS	O
Registered	POS	O
17	POS	O
August	POS	O
2007	POS	O
.	POS	O
Rhabdomyolysis	POS	B-NP
in	POS	O
a	POS	O
hepatitis	POS	B-NP
C	POS	I-NP
virus	POS	I-NP
infected	POS	I-NP
patient	POS	O
treated	POS	O
with	POS	O
telaprevir	POS	O
and	POS	O
simvastatin	POS	O
.	POS	O
A	POS	O
46	POS	O
-	POS	O
year	POS	O
old	POS	O
man	POS	O
with	POS	O
a	POS	O
chronic	POS	B-NP
hepatitis	POS	I-NP
C	POS	I-NP
virus	POS	I-NP
infection	POS	I-NP
received	POS	O
triple	POS	O
therapy	POS	O
with	POS	O
ribavirin	POS	O
,	POS	O
pegylated	POS	O
interferon	POS	O
and	POS	O
telaprevir	POS	O
.	POS	O
The	POS	O
patient	POS	O
also	POS	O
received	POS	O
simvastatin	POS	O
.	POS	O
One	POS	O
month	POS	O
after	POS	O
starting	POS	O
the	POS	O
antiviral	POS	O
therapy	POS	O
,	POS	O
the	POS	O
patient	POS	O
was	POS	O
admitted	POS	O
to	POS	O
the	POS	O
hospital	POS	O
because	POS	O
he	POS	O
developed	POS	O
rhabdomyolysis	POS	B-NP
.	POS	O
At	POS	O
admission	POS	O
simvastatin	POS	O
and	POS	O
all	POS	O
antiviral	POS	O
drugs	POS	O
were	POS	O
discontinued	POS	O
because	POS	O
toxicity	POS	B-NP
due	POS	O
to	POS	O
a	POS	O
drug	POS	O
-	POS	O
drug	POS	O
interaction	POS	O
was	POS	O
suspected	POS	O
.	POS	O
The	POS	O
creatine	POS	O
kinase	POS	O
peaked	POS	O
at	POS	O
62	POS	O
,	POS	O
246	POS	O
IU	POS	O
/	POS	O
L	POS	O
and	POS	O
the	POS	O
patient	POS	O
was	POS	O
treated	POS	O
with	POS	O
intravenous	POS	O
normal	POS	O
saline	POS	O
.	POS	O
The	POS	O
patient	POS	O
'	POS	O
s	POS	O
renal	POS	O
function	POS	O
remained	POS	O
unaffected	POS	B-NP
.	POS	O
Fourteen	POS	O
days	POS	O
after	POS	O
hospitalization	POS	O
,	POS	O
creatine	POS	O
kinase	POS	O
level	POS	O
had	POS	O
returned	POS	O
to	POS	O
230	POS	O
IU	POS	O
/	POS	O
L	POS	O
and	POS	O
the	POS	O
patient	POS	O
was	POS	O
discharged	POS	O
.	POS	O
Telaprevir	POS	O
was	POS	O
considered	POS	O
the	POS	O
probable	POS	O
causative	POS	O
agent	POS	O
of	POS	O
an	POS	O
interaction	POS	O
with	POS	O
simvastatin	POS	O
according	POS	O
to	POS	O
the	POS	O
Drug	POS	O
Interaction	POS	O
Probability	POS	O
Scale	POS	O
.	POS	O
The	POS	O
interaction	POS	O
is	POS	O
due	POS	O
to	POS	O
inhibition	POS	O
of	POS	O
CYP3A4	POS	O
-	POS	O
mediated	POS	O
simvastatin	POS	O
clearance	POS	O
.	POS	O
Simvastatin	POS	O
plasma	POS	O
concentration	POS	O
increased	POS	O
30	POS	O
times	POS	O
in	POS	O
this	POS	O
patient	POS	O
and	POS	O
statin	POS	O
induced	POS	O
muscle	POS	B-NP
toxicity	POS	I-NP
is	POS	O
related	POS	O
to	POS	O
the	POS	O
concentration	POS	O
of	POS	O
the	POS	O
statin	POS	O
in	POS	O
blood	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
with	POS	O
this	POS	O
case	POS	O
we	POS	O
illustrate	POS	O
that	POS	O
telaprevir	POS	O
as	POS	O
well	POS	O
as	POS	O
statins	POS	O
are	POS	O
susceptible	POS	O
to	POS	O
clinical	POS	O
relevant	POS	O
drug	POS	O
-	POS	O
drug	POS	O
interactions	POS	O
.	POS	O
Combination	POS	O
of	POS	O
bortezomib	POS	O
,	POS	O
thalidomide	POS	O
,	POS	O
and	POS	O
dexamethasone	POS	O
(	POS	O
VTD	POS	O
)	POS	O
as	POS	O
a	POS	O
consolidation	POS	O
therapy	POS	O
after	POS	O
autologous	POS	O
stem	POS	O
cell	POS	O
transplantation	POS	O
for	POS	O
symptomatic	POS	O
multiple	POS	O
myeloma	POS	B-NP
in	POS	O
Japanese	POS	O
patients	POS	O
.	POS	O
Consolidation	POS	O
therapy	POS	O
for	POS	O
patients	POS	O
with	POS	O
multiple	POS	B-NP
myeloma	POS	I-NP
(	POS	O
MM	POS	B-NP
)	POS	O
has	POS	O
been	POS	O
widely	POS	O
adopted	POS	O
to	POS	O
improve	POS	O
treatment	POS	O
response	POS	O
following	POS	O
autologous	POS	O
stem	POS	O
cell	POS	O
transplantation	POS	O
.	POS	O
In	POS	O
this	POS	O
study	POS	O
,	POS	O
we	POS	O
retrospectively	POS	O
analyzed	POS	O
the	POS	O
safety	POS	O
and	POS	O
efficacy	POS	O
of	POS	O
combination	POS	O
regimen	POS	O
of	POS	O
bortezomib	POS	O
,	POS	O
thalidomide	POS	O
,	POS	O
and	POS	O
dexamethasone	POS	O
(	POS	O
VTD	POS	O
)	POS	O
as	POS	O
consolidation	POS	O
therapy	POS	O
in	POS	O
24	POS	O
Japanese	POS	O
patients	POS	O
with	POS	O
newly	POS	O
diagnosed	POS	O
MM	POS	B-NP
.	POS	O
VTD	POS	B-NP
consisted	POS	O
of	POS	O
bortezomib	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
1	POS	O
.	POS	O
3	POS	O
mg	POS	O
/	POS	O
m	POS	O
(	POS	O
2	POS	O
)	POS	O
and	POS	O
dexamethasone	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
40	POS	O
mg	POS	O
/	POS	O
day	POS	O
on	POS	O
days	POS	O
1	POS	O
,	POS	O
8	POS	O
,	POS	O
15	POS	O
,	POS	O
and	POS	O
22	POS	O
of	POS	O
a	POS	O
35	POS	O
-	POS	O
day	POS	O
cycle	POS	O
,	POS	O
with	POS	O
daily	POS	O
oral	POS	O
thalidomide	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
100	POS	O
mg	POS	O
/	POS	O
day	POS	O
.	POS	O
Grade	POS	O
3	POS	O
-	POS	O
4	POS	O
neutropenia	POS	B-NP
and	POS	O
thrombocytopenia	POS	B-NP
were	POS	O
documented	POS	O
in	POS	O
four	POS	O
and	POS	O
three	POS	O
patients	POS	O
(	POS	O
17	POS	O
and	POS	O
13	POS	O
%	POS	O
)	POS	O
,	POS	O
respectively	POS	O
,	POS	O
but	POS	O
drug	POS	O
dose	POS	O
reduction	POS	O
due	POS	O
to	POS	O
cytopenia	POS	B-NP
was	POS	O
not	POS	O
required	POS	O
in	POS	O
any	POS	O
case	POS	O
.	POS	O
Peripheral	POS	B-NP
neuropathy	POS	I-NP
was	POS	O
common	POS	O
(	POS	O
63	POS	O
%	POS	O
)	POS	O
,	POS	O
but	POS	O
severe	POS	O
grade	POS	O
3	POS	O
-	POS	O
4	POS	O
peripheral	POS	B-NP
neuropathy	POS	I-NP
was	POS	O
not	POS	O
observed	POS	O
.	POS	O
Very	POS	O
good	POS	O
partial	POS	O
response	POS	O
or	POS	O
better	POS	O
response	POS	O
(	POS	O
>	POS	O
VGPR	POS	O
)	POS	O
rates	POS	O
before	POS	O
and	POS	O
after	POS	O
consolidation	POS	O
therapy	POS	O
were	POS	O
54	POS	O
and	POS	O
79	POS	O
%	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Patients	POS	O
had	POS	O
a	POS	O
significant	POS	O
probability	POS	O
of	POS	O
improving	POS	O
from	POS	O
<	POS	O
VGPR	POS	O
before	POS	O
consolidation	POS	O
therapy	POS	O
to	POS	O
>	POS	O
VGPR	POS	O
after	POS	O
consolidation	POS	O
therapy	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
041	POS	O
)	POS	O
.	POS	O
The	POS	O
VTD	POS	O
regimen	POS	O
may	POS	O
be	POS	O
safe	POS	O
and	POS	O
effective	POS	O
as	POS	O
a	POS	O
consolidation	POS	O
therapy	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
MM	POS	B-NP
in	POS	O
Japanese	POS	O
population	POS	O
.	POS	O
Conversion	POS	O
to	POS	O
sirolimus	POS	O
ameliorates	POS	O
cyclosporine	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
in	POS	O
the	POS	O
rat	POS	O
:	POS	O
focus	POS	O
on	POS	O
serum	POS	O
,	POS	O
urine	POS	O
,	POS	O
gene	POS	O
,	POS	O
and	POS	O
protein	POS	O
renal	POS	O
expression	POS	O
biomarkers	POS	O
.	POS	O
Protocols	POS	O
of	POS	O
conversion	POS	O
from	POS	O
cyclosporin	POS	O
A	POS	O
(	POS	O
CsA	POS	O
)	POS	O
to	POS	O
sirolimus	POS	O
(	POS	O
SRL	POS	O
)	POS	O
have	POS	O
been	POS	O
widely	POS	O
used	POS	O
in	POS	O
immunotherapy	POS	O
after	POS	O
transplantation	POS	O
to	POS	O
prevent	POS	O
CsA	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
,	POS	O
but	POS	O
the	POS	O
molecular	POS	O
mechanisms	POS	O
underlying	POS	O
these	POS	O
protocols	POS	O
remain	POS	O
nuclear	POS	O
.	POS	O
This	POS	O
study	POS	O
aimed	POS	O
to	POS	O
identify	POS	O
the	POS	O
molecular	POS	O
pathways	POS	O
and	POS	O
putative	POS	O
biomarkers	POS	O
of	POS	O
CsA	POS	O
-	POS	O
to	POS	O
-	POS	O
SRL	POS	O
conversion	POS	O
in	POS	O
a	POS	O
rat	POS	O
model	POS	O
.	POS	O
Four	POS	O
animal	POS	O
groups	POS	O
(	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
were	POS	O
tested	POS	O
during	POS	O
9	POS	O
weeks	POS	O
:	POS	O
control	POS	O
,	POS	O
CsA	POS	O
,	POS	O
SRL	POS	O
,	POS	O
and	POS	O
conversion	POS	O
(	POS	O
CsA	POS	O
for	POS	O
3	POS	O
weeks	POS	O
followed	POS	O
by	POS	O
SRL	POS	O
for	POS	O
6	POS	O
weeks	POS	O
)	POS	O
.	POS	O
Classical	POS	O
and	POS	O
emergent	POS	O
serum	POS	O
,	POS	O
urinary	POS	O
,	POS	O
and	POS	O
kidney	POS	O
tissue	POS	O
(	POS	O
gene	POS	O
and	POS	O
protein	POS	O
expression	POS	O
)	POS	O
markers	POS	O
were	POS	O
assessed	POS	O
.	POS	O
Renal	POS	B-NP
lesions	POS	I-NP
were	POS	O
analyzed	POS	O
in	POS	O
hematoxylin	POS	O
and	POS	O
eosin	POS	O
,	POS	O
periodic	POS	O
acid	POS	O
-	POS	O
Schiff	POS	O
,	POS	O
and	POS	O
Masson	POS	O
'	POS	O
s	POS	O
trichrome	POS	O
stains	POS	O
.	POS	O
SRL	POS	O
-	POS	O
treated	POS	O
rats	POS	O
presented	POS	O
proteinuria	POS	B-NP
and	POS	O
NGAL	POS	O
(	POS	O
serum	POS	O
and	POS	O
urinary	POS	O
)	POS	O
as	POS	O
the	POS	O
best	POS	O
markers	POS	O
of	POS	O
renal	POS	B-NP
impairment	POS	I-NP
.	POS	O
Short	POS	O
CsA	POS	O
treatment	POS	O
presented	POS	O
slight	POS	O
or	POS	O
even	POS	O
absent	POS	O
kidney	POS	O
lesions	POS	O
and	POS	O
TGF	POS	O
-	POS	O
b	POS	O
,	POS	O
NF	POS	O
-	POS	O
kb	POS	O
,	POS	O
mTOR	POS	O
,	POS	O
PCNA	POS	O
,	POS	O
TP53	POS	O
,	POS	O
KIM	POS	O
-	POS	O
1	POS	O
,	POS	O
and	POS	O
CTGF	POS	O
as	POS	O
relevant	POS	O
gene	POS	O
and	POS	O
protein	POS	O
changes	POS	O
.	POS	O
Prolonged	POS	O
CsA	POS	O
exposure	POS	O
aggravated	POS	O
renal	POS	B-NP
damage	POS	I-NP
,	POS	O
without	POS	O
clear	POS	O
changes	POS	O
on	POS	O
the	POS	O
traditional	POS	O
markers	POS	O
,	POS	O
but	POS	O
with	POS	O
changes	POS	O
in	POS	O
serums	POS	O
TGF	POS	O
-	POS	O
b	POS	O
and	POS	O
IL	POS	O
-	POS	O
7	POS	O
,	POS	O
TBARs	POS	O
clearance	POS	O
,	POS	O
and	POS	O
kidney	POS	O
TGF	POS	O
-	POS	O
b	POS	O
and	POS	O
mTOR	POS	O
.	POS	O
Conversion	POS	O
to	POS	O
SRL	POS	O
prevented	POS	O
CsA	POS	O
-	POS	O
induced	POS	O
renal	POS	O
damage	POS	O
evolution	POS	O
(	POS	O
absent	POS	O
/	POS	O
mild	POS	O
grade	POS	O
lesions	POS	B-NP
)	POS	O
,	POS	O
while	POS	O
NGAL	POS	O
(	POS	O
serum	POS	O
versus	POS	O
urine	POS	O
)	POS	O
seems	POS	O
to	POS	O
be	POS	O
a	POS	O
feasible	POS	O
biomarker	POS	O
of	POS	O
CsA	POS	O
replacement	POS	O
to	POS	O
SRL	POS	O
.	POS	O
Kinin	POS	O
B2	POS	O
receptor	POS	O
deletion	POS	O
and	POS	O
blockage	POS	O
ameliorates	POS	O
cisplatin	POS	O
-	POS	O
induced	POS	O
acute	POS	B-NP
renal	POS	I-NP
injury	POS	I-NP
.	POS	O
Cisplatin	POS	O
treatment	POS	O
has	POS	O
been	POS	O
adopted	POS	O
in	POS	O
some	POS	O
chemotherapies	POS	O
;	POS	O
however	POS	O
,	POS	O
this	POS	O
drug	POS	O
can	POS	O
induce	POS	O
acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
due	POS	O
its	POS	O
ability	POS	O
to	POS	O
negatively	POS	O
affect	POS	O
renal	POS	O
function	POS	O
,	POS	O
augment	POS	O
serum	POS	O
levels	POS	O
of	POS	O
creatinine	POS	O
and	POS	O
urea	POS	O
,	POS	O
increase	POS	O
the	POS	O
acute	POS	O
tubular	POS	O
necrosis	POS	O
score	POS	O
and	POS	O
up	POS	O
-	POS	O
regulate	POS	O
cytokines	POS	O
(	POS	O
e	POS	O
.	POS	O
g	POS	O
.	POS	O
,	POS	O
IL	POS	O
-	POS	O
1b	POS	O
and	POS	O
TNF	POS	O
-	POS	O
a	POS	O
)	POS	O
.	POS	O
The	POS	O
kinin	POS	O
B2	POS	O
receptor	POS	O
has	POS	O
been	POS	O
associated	POS	O
with	POS	O
the	POS	O
inflammation	POS	O
process	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
the	POS	O
regulation	POS	O
of	POS	O
cytokine	POS	O
expression	POS	O
,	POS	O
and	POS	O
its	POS	O
deletion	POS	O
resulted	POS	O
in	POS	O
an	POS	O
improvement	POS	O
in	POS	O
the	POS	O
diabetic	POS	B-NP
nephropathy	POS	I-NP
status	POS	O
.	POS	O
To	POS	O
examine	POS	O
the	POS	O
role	POS	O
of	POS	O
the	POS	O
kinin	POS	O
B2	POS	O
receptor	POS	O
in	POS	O
cisplatin	POS	O
-	POS	O
induced	POS	O
acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
,	POS	O
kinin	POS	O
B2	POS	O
receptor	POS	O
knockout	POS	O
mice	POS	O
were	POS	O
challenged	POS	O
with	POS	O
cisplatin	POS	O
.	POS	O
Additionally	POS	O
,	POS	O
WT	POS	O
mice	POS	O
were	POS	O
treated	POS	O
with	POS	O
a	POS	O
B2	POS	O
receptor	POS	O
antagonist	POS	O
after	POS	O
cisplatin	POS	O
administration	POS	O
.	POS	O
B2	POS	O
receptor	POS	O
-	POS	O
deficient	POS	O
mice	POS	O
were	POS	O
less	POS	O
sensitive	POS	O
to	POS	O
this	POS	O
drug	POS	O
than	POS	O
the	POS	O
WT	POS	O
mice	POS	O
,	POS	O
as	POS	O
shown	POS	O
by	POS	O
reduced	POS	O
weight	POS	O
loss	POS	O
,	POS	O
better	POS	O
preservation	POS	O
of	POS	O
kidney	POS	O
function	POS	O
,	POS	O
down	POS	O
regulation	POS	O
of	POS	O
inflammatory	POS	O
cytokines	POS	O
and	POS	O
less	POS	O
acute	POS	O
tubular	POS	O
necrosis	POS	B-NP
.	POS	O
Moreover	POS	O
,	POS	O
treatment	POS	O
with	POS	O
the	POS	O
kinin	POS	O
B2	POS	O
receptor	POS	O
antagonist	POS	O
effectively	POS	O
reduced	POS	O
the	POS	O
levels	POS	O
of	POS	O
serum	POS	O
creatinine	POS	O
and	POS	O
blood	POS	O
urea	POS	O
after	POS	O
cisplatin	POS	O
administration	POS	O
.	POS	O
Thus	POS	O
,	POS	O
our	POS	O
data	POS	O
suggest	POS	O
that	POS	O
the	POS	O
kinin	POS	O
B2	POS	O
receptor	POS	O
is	POS	O
involved	POS	O
in	POS	O
cisplatin	POS	O
-	POS	O
induced	POS	O
acute	POS	B-NP
kidney	POS	I-NP
injury	POS	I-NP
by	POS	O
mediating	POS	O
the	POS	O
necrotic	POS	O
process	POS	O
and	POS	O
the	POS	O
expression	POS	O
of	POS	O
inflammatory	POS	O
cytokines	POS	O
,	POS	O
thus	POS	O
resulting	POS	O
in	POS	O
declined	POS	O
renal	POS	O
function	POS	O
.	POS	O
These	POS	O
results	POS	O
highlight	POS	O
the	POS	O
kinin	POS	O
B2	POS	O
receptor	POS	O
antagonist	POS	O
treatment	POS	O
in	POS	O
amelioration	POS	O
of	POS	O
nephrotoxicity	POS	B-NP
induced	POS	O
by	POS	O
cisplatin	POS	O
therapy	POS	O
.	POS	O
Safety	POS	O
and	POS	O
efficacy	POS	O
of	POS	O
fluocinolone	POS	O
acetonide	POS	O
intravitreal	POS	O
implant	POS	O
(	POS	O
0	POS	O
.	POS	O
59	POS	O
mg	POS	O
)	POS	O
in	POS	O
birdshot	POS	B-NP
retinochoroidopathy	POS	I-NP
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
report	POS	O
the	POS	O
treatment	POS	O
outcomes	POS	O
of	POS	O
the	POS	O
fluocinolone	POS	O
acetonide	POS	O
intravitreal	POS	O
implant	POS	O
(	POS	O
0	POS	O
.	POS	O
59	POS	O
mg	POS	O
)	POS	O
in	POS	O
patients	POS	O
with	POS	O
birdshot	POS	B-NP
retinochoroidopathy	POS	I-NP
whose	POS	I-NP
disease	POS	I-NP
is	POS	O
refractory	POS	O
or	POS	O
intolerant	POS	O
to	POS	O
conventional	POS	O
immunomodulatory	POS	O
therapy	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
A	POS	O
retrospective	POS	O
case	POS	O
series	POS	O
involving	POS	O
11	POS	O
birdshot	POS	O
retinochoroidopathy	POS	B-NP
patients	POS	O
(	POS	O
11	POS	O
eyes	POS	O
)	POS	O
.	POS	O
Eleven	POS	O
patients	POS	O
(	POS	O
11	POS	O
eyes	POS	O
)	POS	O
underwent	POS	O
surgery	POS	O
for	POS	O
fluocinolone	POS	O
acetonide	POS	O
implant	POS	O
(	POS	O
0	POS	O
.	POS	O
59	POS	O
mg	POS	O
)	POS	O
.	POS	O
Treatment	POS	O
outcomes	POS	O
of	POS	O
interest	POS	O
were	POS	O
noted	POS	O
at	POS	O
baseline	POS	O
,	POS	O
before	POS	O
fluocinolone	POS	O
acetonide	POS	O
implant	POS	O
,	POS	O
and	POS	O
then	POS	O
at	POS	O
6	POS	O
months	POS	O
,	POS	O
1	POS	O
year	POS	O
,	POS	O
2	POS	O
years	POS	O
,	POS	O
3	POS	O
years	POS	O
,	POS	O
and	POS	O
beyond	POS	O
3	POS	O
years	POS	O
.	POS	O
Disease	POS	O
activity	POS	O
markers	POS	O
,	POS	O
including	POS	O
signs	POS	O
of	POS	O
ocular	POS	B-NP
inflammation	POS	I-NP
,	POS	O
evidence	POS	O
of	POS	O
retinal	POS	B-NP
vasculitis	POS	I-NP
,	POS	O
Swedish	POS	O
interactive	POS	O
threshold	POS	O
algorithm	POS	O
-	POS	O
short	POS	O
wavelength	POS	O
automated	POS	O
perimetry	POS	O
Humphrey	POS	O
visual	POS	O
field	POS	O
analysis	POS	O
,	POS	O
electroretinographic	POS	O
parameters	POS	O
,	POS	O
and	POS	O
optical	POS	O
coherence	POS	O
tomography	POS	O
were	POS	O
recorded	POS	O
.	POS	O
Data	POS	O
on	POS	O
occurrence	POS	O
of	POS	O
cataract	POS	B-NP
and	POS	O
raised	POS	O
intraocular	POS	O
pressure	POS	O
were	POS	O
collected	POS	O
in	POS	O
all	POS	O
eyes	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Intraocular	POS	B-NP
inflammation	POS	I-NP
was	POS	O
present	POS	O
in	POS	O
54	POS	O
.	POS	O
5	POS	O
,	POS	O
9	POS	O
.	POS	O
9	POS	O
,	POS	O
11	POS	O
.	POS	O
1	POS	O
,	POS	O
and	POS	O
0	POS	O
%	POS	O
of	POS	O
patients	POS	O
at	POS	O
baseline	POS	O
,	POS	O
6	POS	O
months	POS	O
,	POS	O
1	POS	O
year	POS	O
,	POS	O
2	POS	O
years	POS	O
,	POS	O
3	POS	O
years	POS	O
,	POS	O
and	POS	O
beyond	POS	O
3	POS	O
years	POS	O
after	POS	O
receiving	POS	O
the	POS	O
implant	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Active	POS	O
vasculitis	POS	B-NP
was	POS	O
noted	POS	O
in	POS	O
36	POS	O
.	POS	O
3	POS	O
%	POS	O
patients	POS	O
at	POS	O
baseline	POS	O
and	POS	O
0	POS	O
%	POS	O
at	POS	O
3	POS	O
years	POS	O
of	POS	O
follow	POS	O
-	POS	O
up	POS	O
.	POS	O
More	POS	O
than	POS	O
20	POS	O
%	POS	O
(	POS	O
47	POS	O
.	POS	O
61	POS	O
-	POS	O
67	POS	O
.	POS	O
2	POS	O
%	POS	O
)	POS	O
reduction	POS	O
in	POS	O
central	POS	O
retinal	POS	O
thickness	POS	O
was	POS	O
noted	POS	O
in	POS	O
all	POS	O
patients	POS	O
with	POS	O
cystoid	POS	B-NP
macular	POS	I-NP
edema	POS	I-NP
at	POS	O
6	POS	O
months	POS	O
,	POS	O
1	POS	O
year	POS	O
,	POS	O
2	POS	O
years	POS	O
,	POS	O
and	POS	O
3	POS	O
years	POS	O
postimplant	POS	O
.	POS	O
At	POS	O
baseline	POS	O
,	POS	O
54	POS	O
.	POS	O
5	POS	O
%	POS	O
patients	POS	O
were	POS	O
on	POS	O
immunomodulatory	POS	O
agents	POS	O
.	POS	O
This	POS	O
percentage	POS	O
decreased	POS	O
to	POS	O
45	POS	O
.	POS	O
45	POS	O
,	POS	O
44	POS	O
.	POS	O
4	POS	O
,	POS	O
and	POS	O
14	POS	O
.	POS	O
28	POS	O
%	POS	O
at	POS	O
1	POS	O
year	POS	O
,	POS	O
2	POS	O
years	POS	O
,	POS	O
and	POS	O
3	POS	O
years	POS	O
postimplant	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Adverse	POS	O
events	POS	O
included	POS	O
increased	POS	O
intraocular	POS	O
pressure	POS	O
(	POS	O
54	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
and	POS	O
cataract	POS	B-NP
formation	POS	O
(	POS	O
100	POS	O
%	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
data	POS	O
suggest	POS	O
that	POS	O
fluocinolone	POS	O
acetonide	POS	O
implant	POS	O
(	POS	O
0	POS	O
.	POS	O
59	POS	O
mg	POS	O
)	POS	O
helps	POS	O
to	POS	O
control	POS	O
inflammation	POS	B-NP
in	POS	O
otherwise	POS	O
treatment	POS	O
-	POS	O
refractory	POS	O
cases	POS	O
of	POS	O
birdshot	POS	B-NP
retinochoroidopathy	POS	I-NP
.	POS	O
It	POS	O
is	POS	O
associated	POS	O
with	POS	O
significant	POS	O
side	POS	O
effects	POS	O
of	POS	O
cataract	POS	B-NP
and	POS	O
ocular	POS	B-NP
hypertension	POS	I-NP
requiring	POS	O
treatment	POS	O
.	POS	O
Optimal	POS	O
precurarizing	POS	O
dose	POS	O
of	POS	O
rocuronium	POS	O
to	POS	O
decrease	POS	O
fasciculation	POS	B-NP
and	POS	O
myalgia	POS	B-NP
following	POS	O
succinylcholine	POS	O
administration	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Succinylcholine	POS	O
commonly	POS	O
produces	POS	O
frequent	POS	O
adverse	POS	O
effects	POS	O
,	POS	O
including	POS	O
muscle	POS	B-NP
fasciculation	POS	I-NP
and	POS	O
myalgia	POS	B-NP
.	POS	O
The	POS	O
current	POS	O
study	POS	O
identified	POS	O
the	POS	O
optimal	POS	O
dose	POS	O
of	POS	O
rocuronium	POS	O
to	POS	O
prevent	POS	O
succinylcholine	POS	O
-	POS	O
induced	POS	O
fasciculation	POS	B-NP
and	POS	O
myalgia	POS	B-NP
and	POS	O
evaluated	POS	O
the	POS	O
influence	POS	O
of	POS	O
rocuronium	POS	O
on	POS	O
the	POS	O
speed	POS	O
of	POS	O
onset	POS	O
produced	POS	O
by	POS	O
succinylcholine	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
This	POS	O
randomized	POS	O
,	POS	O
double	POS	O
-	POS	O
blinded	POS	O
study	POS	O
was	POS	O
conducted	POS	O
in	POS	O
100	POS	O
patients	POS	O
randomly	POS	O
allocated	POS	O
into	POS	O
five	POS	O
groups	POS	O
of	POS	O
20	POS	O
patients	POS	O
each	POS	O
.	POS	O
Patients	POS	O
were	POS	O
randomized	POS	O
to	POS	O
receive	POS	O
0	POS	O
.	POS	O
02	POS	O
,	POS	O
0	POS	O
.	POS	O
03	POS	O
,	POS	O
0	POS	O
.	POS	O
04	POS	O
,	POS	O
0	POS	O
.	POS	O
05	POS	O
and	POS	O
0	POS	O
.	POS	O
06	POS	O
mg	POS	O
/	POS	O
kg	POS	O
rocuronium	POS	O
as	POS	O
a	POS	O
precurarizing	POS	O
dose	POS	O
.	POS	O
Neuromuscular	POS	O
monitoring	POS	O
after	POS	O
each	POS	O
precurarizing	POS	O
dose	POS	O
was	POS	O
recorded	POS	O
from	POS	O
the	POS	O
adductor	POS	O
pollicis	POS	O
muscle	POS	O
using	POS	O
acceleromyography	POS	O
with	POS	O
train	POS	O
-	POS	O
of	POS	O
-	POS	O
four	POS	O
stimulation	POS	O
of	POS	O
the	POS	O
ulnar	POS	O
nerve	POS	O
.	POS	O
All	POS	O
patients	POS	O
received	POS	O
succinylcholine	POS	O
1	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
at	POS	O
2	POS	O
minutes	POS	O
after	POS	O
the	POS	O
precurarization	POS	O
,	POS	O
and	POS	O
were	POS	O
assessed	POS	O
the	POS	O
incidence	POS	O
and	POS	O
severity	POS	O
of	POS	O
fasciculations	POS	B-NP
,	POS	O
while	POS	O
myalgia	POS	B-NP
was	POS	O
assessed	POS	O
at	POS	O
24	POS	O
hours	POS	O
after	POS	O
surgery	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
incidence	POS	O
and	POS	O
severity	POS	O
of	POS	O
visible	POS	O
muscle	POS	B-NP
fasciculation	POS	I-NP
was	POS	O
significantly	POS	O
less	POS	O
with	POS	O
increasing	POS	O
the	POS	O
amount	POS	O
of	POS	O
precurarizing	POS	O
dose	POS	O
of	POS	O
rocuronium	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Those	POS	O
of	POS	O
myalgia	POS	B-NP
tend	POS	O
to	POS	O
decrease	POS	O
according	POS	O
to	POS	O
increasing	POS	O
the	POS	O
amount	POS	O
of	POS	O
precurarizing	POS	O
dose	POS	O
of	POS	O
rocuronium	POS	O
,	POS	O
but	POS	O
there	POS	O
was	POS	O
no	POS	O
significance	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
072	POS	O
)	POS	O
.	POS	O
The	POS	O
onset	POS	O
time	POS	O
of	POS	O
succinylcholine	POS	O
was	POS	O
significantly	POS	O
longer	POS	O
with	POS	O
increasing	POS	O
the	POS	O
amount	POS	O
of	POS	O
precurarizing	POS	O
dose	POS	O
of	POS	O
rocuronium	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Precurarization	POS	O
with	POS	O
0	POS	O
.	POS	O
04	POS	O
mg	POS	O
/	POS	O
kg	POS	O
rocuronium	POS	O
was	POS	O
the	POS	O
optimal	POS	O
dose	POS	O
considering	POS	O
the	POS	O
reduction	POS	O
in	POS	O
the	POS	O
incidence	POS	O
and	POS	O
severity	POS	O
of	POS	O
fasciculation	POS	B-NP
and	POS	O
myalgia	POS	B-NP
with	POS	O
acceptable	POS	O
onset	POS	O
time	POS	O
,	POS	O
and	POS	O
the	POS	O
safe	POS	O
and	POS	O
effective	POS	O
precurarization	POS	O
.	POS	O
Absence	POS	O
of	POS	O
PKC	POS	O
-	POS	O
alpha	POS	O
attenuates	POS	O
lithium	POS	O
-	POS	O
induced	POS	O
nephrogenic	POS	B-NP
diabetes	POS	I-NP
insipidus	POS	I-NP
.	POS	O
Lithium	POS	B-NP
,	POS	O
an	POS	O
effective	POS	O
antipsychotic	POS	O
,	POS	O
induces	POS	O
nephrogenic	POS	B-NP
diabetes	POS	I-NP
insipidus	POS	I-NP
(	POS	O
NDI	POS	B-NP
)	POS	O
in	POS	O
40	POS	O
%	POS	O
of	POS	O
patients	POS	O
.	POS	O
The	POS	O
decreased	POS	O
capacity	POS	O
to	POS	O
concentrate	POS	O
urine	POS	O
is	POS	O
likely	POS	O
due	POS	O
to	POS	O
lithium	POS	O
acutely	POS	O
disrupting	POS	O
the	POS	O
cAMP	POS	O
pathway	POS	O
and	POS	O
chronically	POS	O
reducing	POS	O
urea	POS	O
transporter	POS	O
(	POS	O
UT	POS	O
-	POS	O
A1	POS	O
)	POS	O
and	POS	O
water	POS	O
channel	POS	O
(	POS	O
AQP2	POS	O
)	POS	O
expression	POS	O
in	POS	O
the	POS	O
inner	POS	O
medulla	POS	O
.	POS	O
Targeting	POS	O
an	POS	O
alternative	POS	O
signaling	POS	O
pathway	POS	O
,	POS	O
such	POS	O
as	POS	O
PKC	POS	O
-	POS	O
mediated	POS	O
signaling	POS	O
,	POS	O
may	POS	O
be	POS	O
an	POS	O
effective	POS	O
method	POS	O
of	POS	O
treating	POS	O
lithium	POS	O
-	POS	O
induced	POS	O
polyuria	POS	B-NP
.	POS	O
PKC	POS	O
-	POS	O
alpha	POS	O
null	POS	O
mice	POS	O
(	POS	O
PKCa	POS	O
KO	POS	O
)	POS	O
and	POS	O
strain	POS	O
-	POS	O
matched	POS	O
wild	POS	O
type	POS	O
(	POS	O
WT	POS	O
)	POS	O
controls	POS	O
were	POS	O
treated	POS	O
with	POS	O
lithium	POS	O
for	POS	O
0	POS	O
,	POS	O
3	POS	O
or	POS	O
5	POS	O
days	POS	O
.	POS	O
WT	POS	O
mice	POS	O
had	POS	O
increased	POS	O
urine	POS	O
output	POS	O
and	POS	O
lowered	POS	O
urine	POS	O
osmolality	POS	O
after	POS	O
3	POS	O
and	POS	O
5	POS	O
days	POS	O
of	POS	O
treatment	POS	O
whereas	POS	O
PKCa	POS	O
KO	POS	O
mice	POS	O
had	POS	O
no	POS	O
change	POS	O
in	POS	O
urine	POS	O
output	POS	O
or	POS	O
concentration	POS	O
.	POS	O
Western	POS	O
blot	POS	O
analysis	POS	O
revealed	POS	O
that	POS	O
AQP2	POS	O
expression	POS	O
in	POS	O
medullary	POS	O
tissues	POS	O
was	POS	O
lowered	POS	O
after	POS	O
3	POS	O
and	POS	O
5	POS	O
days	POS	O
in	POS	O
WT	POS	O
mice	POS	O
;	POS	O
however	POS	O
,	POS	O
AQP2	POS	O
was	POS	O
unchanged	POS	O
in	POS	O
PKCa	POS	O
KO	POS	O
.	POS	O
Similar	POS	O
results	POS	O
were	POS	O
observed	POS	O
with	POS	O
UT	POS	O
-	POS	O
A1	POS	O
expression	POS	O
.	POS	O
Animals	POS	O
were	POS	O
also	POS	O
treated	POS	O
with	POS	O
lithium	POS	O
for	POS	O
6	POS	O
weeks	POS	O
.	POS	O
Lithium	POS	O
-	POS	O
treated	POS	O
WT	POS	O
mice	POS	O
had	POS	O
19	POS	O
-	POS	O
fold	POS	O
increased	POS	O
urine	POS	O
output	POS	O
whereas	POS	O
treated	POS	O
PKCa	POS	O
KO	POS	O
animals	POS	O
had	POS	O
a	POS	O
4	POS	O
-	POS	O
fold	POS	O
increase	POS	O
in	POS	O
output	POS	O
.	POS	O
AQP2	POS	O
and	POS	O
UT	POS	O
-	POS	O
A1	POS	O
expression	POS	O
was	POS	O
lowered	POS	O
in	POS	O
6	POS	O
week	POS	O
lithium	POS	O
-	POS	O
treated	POS	O
WT	POS	O
animals	POS	O
whereas	POS	O
in	POS	O
treated	POS	O
PKCa	POS	O
KO	POS	O
mice	POS	O
,	POS	O
AQP2	POS	O
was	POS	O
only	POS	O
reduced	POS	O
by	POS	O
2	POS	O
-	POS	O
fold	POS	O
and	POS	O
UT	POS	O
-	POS	O
A1	POS	O
expression	POS	O
was	POS	O
unaffected	POS	O
.	POS	O
Urinary	POS	O
sodium	POS	O
,	POS	O
potassium	POS	O
and	POS	O
calcium	POS	O
were	POS	O
elevated	POS	O
in	POS	O
lithium	POS	O
-	POS	O
fed	POS	O
WT	POS	O
but	POS	O
not	POS	O
in	POS	O
lithium	POS	O
-	POS	O
fed	POS	O
PKCa	POS	O
KO	POS	O
mice	POS	O
.	POS	O
Our	POS	O
data	POS	O
show	POS	O
that	POS	O
ablation	POS	O
of	POS	O
PKCa	POS	O
preserves	POS	O
AQP2	POS	O
and	POS	O
UT	POS	O
-	POS	O
A1	POS	O
protein	POS	O
expression	POS	O
and	POS	O
localization	POS	O
in	POS	O
lithium	POS	O
-	POS	O
induced	POS	O
NDI	POS	O
,	POS	O
and	POS	O
prevents	POS	O
the	POS	O
development	POS	O
of	POS	O
the	POS	O
severe	POS	O
polyuria	POS	B-NP
associated	POS	O
with	POS	O
lithium	POS	O
therapy	POS	O
.	POS	O
Is	POS	O
Dysguesia	POS	B-NP
Going	POS	O
to	POS	O
be	POS	O
a	POS	O
Rare	POS	O
or	POS	O
a	POS	O
Common	POS	O
Side	POS	O
-	POS	O
effect	POS	O
of	POS	O
Amlodipine	POS	O
?	POS	O
A	POS	O
very	POS	O
rare	POS	O
side	POS	O
-	POS	O
effect	POS	O
of	POS	O
amlodipine	POS	O
is	POS	O
dysguesia	POS	B-NP
.	POS	O
A	POS	O
review	POS	O
of	POS	O
the	POS	O
literature	POS	O
produced	POS	O
only	POS	O
one	POS	O
case	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
about	POS	O
a	POS	O
female	POS	O
with	POS	O
essential	POS	O
hypertension	POS	B-NP
on	POS	O
drug	POS	O
treatment	POS	O
with	POS	O
amlodipine	POS	O
developed	POS	O
loss	POS	B-NP
of	POS	I-NP
taste	POS	I-NP
sensation	POS	I-NP
.	POS	O
Condition	POS	O
moderately	POS	O
improved	POS	O
on	POS	O
stoppage	POS	O
of	POS	O
the	POS	O
drug	POS	O
for	POS	O
25	POS	O
days	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
amlodipine	POS	O
can	POS	O
cause	POS	O
dysguesia	POS	B-NP
.	POS	O
Here	POS	O
,	POS	O
we	POS	O
describe	POS	O
the	POS	O
clinical	POS	O
presentation	POS	O
and	POS	O
review	POS	O
the	POS	O
relevant	POS	O
literature	POS	O
on	POS	O
amlodipine	POS	O
and	POS	O
dysguesia	POS	B-NP
.	POS	O
Rhabdomyolysis	POS	B-NP
in	POS	O
association	POS	O
with	POS	O
simvastatin	POS	O
and	POS	O
dosage	POS	O
increment	POS	O
in	POS	O
clarithromycin	POS	O
.	POS	O
Clarithromycin	POS	O
is	POS	O
the	POS	O
most	POS	O
documented	POS	O
cytochrome	POS	O
P450	POS	O
3A4	POS	O
(	POS	O
CYP3A4	POS	O
)	POS	O
inhibitor	POS	O
to	POS	O
cause	POS	O
an	POS	O
adverse	POS	O
interaction	POS	O
with	POS	O
simvastatin	POS	O
.	POS	O
This	POS	O
particular	POS	O
case	POS	O
is	POS	O
of	POS	O
interest	POS	O
as	POS	O
rhabdomyolysis	POS	B-NP
only	POS	O
occurred	POS	O
after	POS	O
an	POS	O
increase	POS	O
in	POS	O
the	POS	O
dose	POS	O
of	POS	O
clarithromycin	POS	O
.	POS	O
The	POS	O
patient	POS	O
developed	POS	O
raised	POS	O
cardiac	POS	O
biomarkers	POS	O
without	POS	O
any	POS	O
obvious	POS	O
cardiac	POS	O
issues	POS	O
,	POS	O
a	POS	O
phenomenon	POS	O
that	POS	O
has	POS	O
been	POS	O
linked	POS	O
to	POS	O
rhabdomyolysis	POS	B-NP
previously	POS	O
.	POS	O
To	POS	O
date	POS	O
,	POS	O
there	POS	O
has	POS	O
been	POS	O
no	POS	O
reported	POS	O
effect	POS	O
of	POS	O
rhabdomyolysis	POS	B-NP
on	POS	O
the	POS	O
structure	POS	O
and	POS	O
function	POS	O
of	POS	O
cardiac	POS	O
muscle	POS	O
.	POS	O
Clinicians	POS	O
need	POS	O
to	POS	O
be	POS	O
aware	POS	O
of	POS	O
prescribing	POS	O
concomitant	POS	O
medications	POS	O
that	POS	O
increase	POS	O
the	POS	O
risk	POS	O
of	POS	O
myopathy	POS	B-NP
or	POS	O
inhibit	POS	O
the	POS	O
CYP3A4	POS	O
enzyme	POS	O
.	POS	O
Our	POS	O
case	POS	O
suggests	POS	O
that	POS	O
troponin	POS	O
elevation	POS	O
could	POS	O
be	POS	O
associated	POS	O
with	POS	O
statin	POS	O
induced	POS	O
rhabdomyolysis	POS	B-NP
,	POS	O
which	POS	O
may	POS	O
warrant	POS	O
further	POS	O
studies	POS	O
.	POS	O
Characterization	POS	O
of	POS	O
a	POS	O
novel	POS	O
BCHE	POS	O
"	POS	O
silent	POS	O
"	POS	O
allele	POS	O
:	POS	O
point	POS	O
mutation	POS	O
(	POS	O
p	POS	O
.	POS	O
Val204Asp	POS	O
)	POS	O
causes	POS	O
loss	POS	O
of	POS	O
activity	POS	O
and	POS	O
prolonged	POS	O
apnea	POS	B-NP
with	POS	O
suxamethonium	POS	O
.	POS	O
Butyrylcholinesterase	POS	B-NP
deficiency	POS	I-NP
is	POS	O
characterized	POS	O
by	POS	O
prolonged	POS	O
apnea	POS	B-NP
after	POS	O
the	POS	O
use	POS	O
of	POS	O
muscle	POS	O
relaxants	POS	O
(	POS	O
suxamethonium	POS	O
or	POS	O
mivacurium	POS	O
)	POS	O
in	POS	O
patients	POS	O
who	POS	O
have	POS	O
mutations	POS	O
in	POS	O
the	POS	O
BCHE	POS	O
gene	POS	O
.	POS	O
Here	POS	O
,	POS	O
we	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
prolonged	POS	O
neuromuscular	POS	B-NP
block	POS	I-NP
after	POS	O
administration	POS	O
of	POS	O
suxamethonium	POS	O
leading	POS	O
to	POS	O
the	POS	O
discovery	POS	O
of	POS	O
a	POS	O
novel	POS	O
BCHE	POS	O
variant	POS	O
(	POS	O
c	POS	O
.	POS	O
695T	POS	O
>	POS	O
A	POS	O
,	POS	O
p	POS	O
.	POS	O
Val204Asp	POS	O
)	POS	O
.	POS	O
Inhibition	POS	O
studies	POS	O
,	POS	O
kinetic	POS	O
analysis	POS	O
and	POS	O
molecular	POS	O
dynamics	POS	O
were	POS	O
undertaken	POS	O
to	POS	O
understand	POS	O
how	POS	O
this	POS	O
mutation	POS	O
disrupts	POS	O
the	POS	O
catalytic	POS	O
triad	POS	O
and	POS	O
determines	POS	O
a	POS	O
"	POS	O
silent	POS	O
"	POS	O
phenotype	POS	O
.	POS	O
Low	POS	O
activity	POS	O
of	POS	O
patient	POS	O
plasma	POS	O
butyrylcholinesterase	POS	O
with	POS	O
butyrylthiocholine	POS	O
(	POS	O
BTC	POS	O
)	POS	O
and	POS	O
benzoylcholine	POS	O
,	POS	O
and	POS	O
values	POS	O
of	POS	O
dibucaine	POS	O
and	POS	O
fluoride	POS	O
numbers	POS	O
fit	POS	O
with	POS	O
heterozygous	POS	O
atypical	POS	O
silent	POS	O
genotype	POS	O
.	POS	O
Electrophoretic	POS	O
analysis	POS	O
of	POS	O
plasma	POS	O
BChE	POS	O
of	POS	O
the	POS	O
proband	POS	O
and	POS	O
his	POS	O
mother	POS	O
showed	POS	O
that	POS	O
patient	POS	O
has	POS	O
a	POS	O
reduced	POS	O
amount	POS	O
of	POS	O
tetrameric	POS	O
enzyme	POS	O
in	POS	O
plasma	POS	O
and	POS	O
that	POS	O
minor	POS	O
fast	POS	O
-	POS	O
moving	POS	O
BChE	POS	O
components	POS	O
:	POS	O
monomer	POS	O
,	POS	O
dimer	POS	O
,	POS	O
and	POS	O
monomer	POS	O
-	POS	O
albumin	POS	O
conjugate	POS	O
are	POS	O
missing	POS	O
.	POS	O
Kinetic	POS	O
analysis	POS	O
showed	POS	O
that	POS	O
the	POS	O
p	POS	O
.	POS	O
Val204Asp	POS	O
/	POS	O
p	POS	O
.	POS	O
Asp70Gly	POS	O
-	POS	O
p	POS	O
.	POS	O
Ala539Thr	POS	O
BChE	POS	O
displays	POS	O
a	POS	O
pure	POS	O
Michaelian	POS	O
behavior	POS	O
with	POS	O
BTC	POS	O
as	POS	O
the	POS	O
substrate	POS	O
.	POS	O
Both	POS	O
catalytic	POS	O
parameters	POS	O
Km	POS	O
=	POS	O
265	POS	O
uM	POS	O
for	POS	O
BTC	POS	O
,	POS	O
two	POS	O
times	POS	O
higher	POS	O
than	POS	O
that	POS	O
of	POS	O
the	POS	O
atypical	POS	O
enzyme	POS	O
,	POS	O
and	POS	O
a	POS	O
low	POS	O
Vmax	POS	O
are	POS	O
consistent	POS	O
with	POS	O
the	POS	O
absence	POS	O
of	POS	O
activity	POS	O
against	POS	O
suxamethonium	POS	O
.	POS	O
Molecular	POS	O
dynamic	POS	O
(	POS	O
MD	POS	O
)	POS	O
simulations	POS	O
showed	POS	O
that	POS	O
the	POS	O
overall	POS	O
effect	POS	O
of	POS	O
the	POS	O
mutation	POS	O
p	POS	O
.	POS	O
Val204Asp	POS	O
is	POS	O
disruption	POS	O
of	POS	O
hydrogen	POS	O
bonding	POS	O
between	POS	O
Gln223	POS	O
and	POS	O
Glu441	POS	O
,	POS	O
leading	POS	O
Ser198	POS	O
and	POS	O
His438	POS	O
to	POS	O
move	POS	O
away	POS	O
from	POS	O
each	POS	O
other	POS	O
with	POS	O
subsequent	POS	O
disruption	POS	O
of	POS	O
the	POS	O
catalytic	POS	O
triad	POS	O
functionality	POS	O
regardless	POS	O
of	POS	O
the	POS	O
type	POS	O
of	POS	O
substrate	POS	O
.	POS	O
MD	POS	O
also	POS	O
showed	POS	O
that	POS	O
the	POS	O
enzyme	POS	O
volume	POS	O
is	POS	O
increased	POS	O
,	POS	O
suggesting	POS	O
a	POS	O
pre	POS	O
-	POS	O
denaturation	POS	O
state	POS	O
.	POS	O
This	POS	O
fits	POS	O
with	POS	O
the	POS	O
reduced	POS	O
concentration	POS	O
of	POS	O
p	POS	O
.	POS	O
Ala204Asp	POS	O
/	POS	O
p	POS	O
.	POS	O
Asp70Gly	POS	O
-	POS	O
p	POS	O
.	POS	O
Ala539Thr	POS	O
tetrameric	POS	O
enzyme	POS	O
in	POS	O
the	POS	O
plasma	POS	O
and	POS	O
non	POS	O
-	POS	O
detectable	POS	O
fast	POS	O
moving	POS	O
-	POS	O
bands	POS	O
on	POS	O
electrophoresis	POS	O
gels	POS	O
.	POS	O
Delayed	POS	O
anemia	POS	B-NP
after	POS	O
treatment	POS	O
with	POS	O
injectable	POS	O
artesunate	POS	O
in	POS	O
the	POS	O
Democratic	POS	O
Republic	POS	O
of	POS	O
the	POS	O
Congo	POS	O
:	POS	O
a	POS	O
manageable	POS	O
issue	POS	O
.	POS	O
Cases	POS	O
of	POS	O
delayed	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
have	POS	O
been	POS	O
described	POS	O
after	POS	O
treatment	POS	O
with	POS	O
injectable	POS	O
artesunate	POS	O
,	POS	O
the	POS	O
current	POS	O
World	POS	O
Health	POS	O
Organization	POS	O
(	POS	O
WHO	POS	O
)	POS	O
-	POS	O
recommended	POS	O
first	POS	O
-	POS	O
line	POS	O
drug	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
severe	POS	O
malaria	POS	B-NP
.	POS	O
A	POS	O
total	POS	O
of	POS	O
350	POS	O
patients	POS	O
(	POS	O
215	POS	O
[	POS	O
61	POS	O
.	POS	O
4	POS	O
%	POS	O
]	POS	O
<	POS	O
5	POS	O
years	POS	O
of	POS	O
age	POS	O
and	POS	O
135	POS	O
[	POS	O
38	POS	O
.	POS	O
6	POS	O
%	POS	O
]	POS	O
>	POS	O
5	POS	O
years	POS	O
of	POS	O
age	POS	O
)	POS	O
were	POS	O
followed	POS	O
-	POS	O
up	POS	O
after	POS	O
treatment	POS	O
with	POS	O
injectable	POS	O
artesunate	POS	O
for	POS	O
severe	POS	O
malaria	POS	B-NP
in	POS	O
hospitals	POS	O
and	POS	O
health	POS	O
centers	POS	O
of	POS	O
the	POS	O
Democratic	POS	O
Republic	POS	O
of	POS	O
the	POS	O
Congo	POS	O
.	POS	O
Complete	POS	O
series	POS	O
of	POS	O
hemoglobin	POS	O
(	POS	O
Hb	POS	O
)	POS	O
measurements	POS	O
were	POS	O
available	POS	O
for	POS	O
201	POS	O
patients	POS	O
.	POS	O
A	POS	O
decrease	POS	O
in	POS	O
Hb	POS	O
levels	POS	O
between	POS	O
2	POS	O
and	POS	O
5	POS	O
g	POS	O
/	POS	O
dL	POS	O
was	POS	O
detected	POS	O
in	POS	O
23	POS	O
(	POS	O
11	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
patients	POS	O
during	POS	O
the	POS	O
follow	POS	O
-	POS	O
up	POS	O
period	POS	O
.	POS	O
For	POS	O
five	POS	O
patients	POS	O
,	POS	O
Hb	POS	O
levels	POS	O
decreased	POS	O
below	POS	O
5	POS	O
g	POS	O
/	POS	O
dL	POS	O
during	POS	O
at	POS	O
least	POS	O
one	POS	O
follow	POS	O
-	POS	O
up	POS	O
visit	POS	O
.	POS	O
All	POS	O
cases	POS	O
of	POS	O
delayed	POS	O
anemia	POS	B-NP
were	POS	O
clinically	POS	O
manageable	POS	O
and	POS	O
resolved	POS	O
within	POS	O
one	POS	O
month	POS	O
.	POS	O
Regulation	POS	O
of	POS	O
signal	POS	O
transducer	POS	O
and	POS	O
activator	POS	O
of	POS	O
transcription	POS	O
3	POS	O
and	POS	O
apoptotic	POS	O
pathways	POS	O
by	POS	O
betaine	POS	O
attenuates	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
acute	POS	O
myocardial	POS	B-NP
injury	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
was	POS	O
designed	POS	O
to	POS	O
investigate	POS	O
the	POS	O
cardioprotective	POS	O
effects	POS	O
of	POS	O
betaine	POS	O
on	POS	O
acute	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
induced	POS	O
experimentally	POS	O
in	POS	O
rats	POS	O
focusing	POS	O
on	POS	O
regulation	POS	O
of	POS	O
signal	POS	O
transducer	POS	O
and	POS	O
activator	POS	O
of	POS	O
transcription	POS	O
3	POS	O
(	POS	O
STAT3	POS	O
)	POS	O
and	POS	O
apoptotic	POS	O
pathways	POS	O
as	POS	O
the	POS	O
potential	POS	O
mechanism	POS	O
underlying	POS	O
the	POS	O
drug	POS	O
effect	POS	O
.	POS	O
Male	POS	O
Sprague	POS	O
Dawley	POS	O
rats	POS	O
were	POS	O
treated	POS	O
with	POS	O
betaine	POS	O
(	POS	O
100	POS	O
,	POS	O
200	POS	O
,	POS	O
and	POS	O
400	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
orally	POS	O
for	POS	O
40	POS	O
days	POS	O
.	POS	O
Acute	POS	O
myocardial	POS	B-NP
ischemic	POS	I-NP
injury	POS	I-NP
was	POS	O
induced	POS	O
in	POS	O
rats	POS	O
by	POS	O
subcutaneous	POS	O
injection	POS	O
of	POS	O
isoproterenol	POS	O
(	POS	O
85	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
for	POS	O
two	POS	O
consecutive	POS	O
days	POS	O
.	POS	O
Serum	POS	O
cardiac	POS	O
marker	POS	O
enzyme	POS	O
,	POS	O
histopathological	POS	O
variables	POS	O
and	POS	O
expression	POS	O
of	POS	O
protein	POS	O
levels	POS	O
were	POS	O
analyzed	POS	O
.	POS	O
Oral	POS	O
administration	POS	O
of	POS	O
betaine	POS	O
(	POS	O
200	POS	O
and	POS	O
400	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
significantly	POS	O
reduced	POS	O
the	POS	O
level	POS	O
of	POS	O
cardiac	POS	O
marker	POS	O
enzyme	POS	O
in	POS	O
the	POS	O
serum	POS	O
and	POS	O
prevented	POS	O
left	POS	O
ventricular	POS	O
remodeling	POS	O
.	POS	O
Western	POS	O
blot	POS	O
analysis	POS	O
showed	POS	O
that	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
phosphorylation	POS	O
of	POS	O
STAT3	POS	O
was	POS	O
maintained	POS	O
or	POS	O
further	POS	O
enhanced	POS	O
by	POS	O
betaine	POS	O
treatment	POS	O
in	POS	O
myocardium	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
betaine	POS	O
(	POS	O
200	POS	O
and	POS	O
400	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
treatment	POS	O
increased	POS	O
the	POS	O
ventricular	POS	O
expression	POS	O
of	POS	O
Bcl	POS	O
-	POS	O
2	POS	O
and	POS	O
reduced	POS	O
the	POS	O
level	POS	O
of	POS	O
Bax	POS	O
,	POS	O
therefore	POS	O
causing	POS	O
a	POS	O
significant	POS	O
increase	POS	O
in	POS	O
the	POS	O
ratio	POS	O
of	POS	O
Bcl	POS	O
-	POS	O
2	POS	O
/	POS	O
Bax	POS	O
.	POS	O
The	POS	O
protective	POS	O
role	POS	O
of	POS	O
betaine	POS	O
on	POS	O
myocardial	POS	B-NP
damage	POS	I-NP
was	POS	O
further	POS	O
confirmed	POS	O
by	POS	O
histopathological	POS	O
examination	POS	O
.	POS	O
In	POS	O
summary	POS	O
,	POS	O
our	POS	O
results	POS	O
showed	POS	O
that	POS	O
betaine	POS	O
pretreatment	POS	O
attenuated	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
acute	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
via	POS	O
the	POS	O
regulation	POS	O
of	POS	O
STAT3	POS	O
and	POS	O
apoptotic	POS	O
pathways	POS	O
.	POS	O
Quetiapine	POS	O
-	POS	O
induced	POS	O
neutropenia	POS	B-NP
in	POS	O
a	POS	O
bipolar	POS	O
patient	POS	O
with	POS	O
hepatocellular	POS	B-NP
carcinoma	POS	I-NP
.	POS	O
OBJECTIVE	POS	O
:	POS	O
Quetiapine	POS	O
is	POS	O
a	POS	O
dibenzothiazepine	POS	O
derivative	POS	O
,	POS	O
similar	POS	O
to	POS	O
clozapine	POS	O
,	POS	O
which	POS	O
has	POS	O
the	POS	O
highest	POS	O
risk	POS	O
of	POS	O
causing	POS	O
blood	POS	B-NP
dyscrasias	POS	I-NP
,	POS	O
especially	POS	O
neutropenia	POS	B-NP
.	POS	O
There	POS	O
are	POS	O
some	POS	O
case	POS	O
reports	POS	O
about	POS	O
this	POS	O
side	POS	O
effect	POS	O
of	POS	O
quetiapine	POS	O
,	POS	O
but	POS	O
possible	POS	O
risk	POS	O
factors	POS	O
are	POS	O
seldom	POS	O
discussed	POS	O
and	POS	O
identified	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
a	POS	O
patient	POS	O
with	POS	O
hepatocellular	POS	B-NP
carcinoma	POS	I-NP
that	POS	O
developed	POS	O
neutropenia	POS	B-NP
after	POS	O
treatment	POS	O
with	POS	O
quetiapine	POS	O
is	POS	O
described	POS	O
here	POS	O
.	POS	O
CASE	POS	O
REPORT	POS	O
:	POS	O
A	POS	O
62	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
Taiwanese	POS	O
widow	POS	O
with	POS	O
bipolar	POS	B-NP
disorder	POS	I-NP
was	POS	O
diagnosed	POS	O
with	POS	O
hepatocellular	POS	B-NP
carcinoma	POS	I-NP
at	POS	O
age	POS	O
60	POS	O
.	POS	O
She	POS	O
developed	POS	O
leucopenia	POS	B-NP
after	POS	O
being	POS	O
treated	POS	O
with	POS	O
quetiapine	POS	O
.	POS	O
After	POS	O
quetiapine	POS	O
was	POS	O
discontinued	POS	O
,	POS	O
her	POS	O
white	POS	O
blood	POS	O
cell	POS	O
count	POS	O
returned	POS	O
to	POS	O
normal	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Although	POS	O
neutropenia	POS	B-NP
is	POS	O
not	POS	O
a	POS	O
common	POS	O
side	POS	O
effect	POS	O
of	POS	O
quetiapine	POS	O
,	POS	O
physicians	POS	O
should	POS	O
be	POS	O
cautious	POS	O
about	POS	O
its	POS	O
presentation	POS	O
and	POS	O
associated	POS	O
risk	POS	O
factors	POS	O
.	POS	O
Hepatic	POS	B-NP
dysfunction	POS	I-NP
may	POS	O
be	POS	O
one	POS	O
of	POS	O
the	POS	O
possible	POS	O
risk	POS	O
factors	POS	O
,	POS	O
and	POS	O
concomitant	POS	O
fever	POS	B-NP
may	POS	O
be	POS	O
a	POS	O
diagnostic	POS	O
marker	POS	O
for	POS	O
adverse	POS	O
reaction	POS	O
to	POS	O
quetiapine	POS	O
.	POS	O
Lateral	POS	B-NP
antebrachial	POS	I-NP
cutaneous	POS	I-NP
neuropathy	POS	I-NP
after	POS	O
steroid	POS	O
injection	POS	O
at	POS	O
lateral	POS	O
epicondyle	POS	O
.	POS	O
BACKGROUND	POS	O
AND	POS	O
OBJECTIVES	POS	O
:	POS	O
This	POS	O
report	POS	O
aimed	POS	O
to	POS	O
present	POS	O
a	POS	O
case	POS	O
of	POS	O
lateral	POS	B-NP
antebrachial	POS	I-NP
cutaneous	POS	I-NP
neuropathy	POS	I-NP
(	POS	O
LACNP	POS	B-NP
)	POS	O
that	POS	O
occurred	POS	O
after	POS	O
a	POS	O
steroid	POS	O
injection	POS	O
in	POS	O
the	POS	O
lateral	POS	O
epicondyle	POS	O
to	POS	O
treat	POS	O
lateral	POS	B-NP
epicondylitis	POS	I-NP
in	POS	O
a	POS	O
40	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
.	POS	O
MATERIAL	POS	O
AND	POS	O
METHOD	POS	O
:	POS	O
A	POS	O
40	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
presented	POS	O
with	POS	O
decreased	POS	B-NP
sensation	POS	I-NP
and	POS	O
paresthesia	POS	B-NP
over	POS	O
her	POS	O
right	POS	O
lateral	POS	O
forearm	POS	O
;	POS	O
the	POS	O
paresthesia	POS	B-NP
had	POS	O
occurred	POS	O
after	POS	O
a	POS	O
steroid	POS	O
injection	POS	O
in	POS	O
the	POS	O
right	POS	O
lateral	POS	O
epicondyle	POS	O
3	POS	O
months	POS	O
before	POS	O
.	POS	O
Her	POS	O
sensation	POS	O
of	POS	O
light	POS	O
touch	POS	O
and	POS	O
pain	POS	B-NP
was	POS	O
diminished	POS	O
over	POS	O
the	POS	O
lateral	POS	O
side	POS	O
of	POS	O
the	POS	O
right	POS	O
forearm	POS	O
and	POS	O
wrist	POS	O
area	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
The	POS	O
sensory	POS	O
action	POS	O
potential	POS	O
amplitude	POS	O
of	POS	O
the	POS	O
right	POS	O
lateral	POS	O
antebrachial	POS	O
cutaneous	POS	O
nerve	POS	O
(	POS	O
LACN	POS	O
)	POS	O
(	POS	O
6	POS	O
.	POS	O
2	POS	O
uV	POS	O
)	POS	O
was	POS	O
lower	POS	O
than	POS	O
that	POS	O
of	POS	O
the	POS	O
left	POS	O
(	POS	O
13	POS	O
.	POS	O
1	POS	O
uV	POS	O
)	POS	O
.	POS	O
The	POS	O
difference	POS	O
of	POS	O
amplitude	POS	O
between	POS	O
both	POS	O
sides	POS	O
was	POS	O
significant	POS	O
because	POS	O
there	POS	O
was	POS	O
more	POS	O
than	POS	O
a	POS	O
50	POS	O
%	POS	O
reduction	POS	O
.	POS	O
She	POS	O
was	POS	O
diagnosed	POS	O
with	POS	O
right	POS	O
LACNP	POS	O
(	POS	O
mainly	POS	O
axonal	POS	O
involvement	POS	O
)	POS	O
on	POS	O
the	POS	O
basis	POS	O
of	POS	O
the	POS	O
clinical	POS	O
manifestation	POS	O
and	POS	O
the	POS	O
electrodiagnostic	POS	O
findings	POS	O
.	POS	O
Her	POS	O
symptoms	POS	O
improved	POS	O
through	POS	O
physical	POS	O
therapy	POS	O
but	POS	O
persisted	POS	O
to	POS	O
some	POS	O
degree	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
This	POS	O
report	POS	O
describes	POS	O
the	POS	O
case	POS	O
of	POS	O
a	POS	O
woman	POS	O
with	POS	O
LACNP	POS	B-NP
that	POS	O
developed	POS	O
after	POS	O
a	POS	O
steroid	POS	O
injection	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
lateral	POS	B-NP
epicondylitis	POS	I-NP
.	POS	O
An	POS	O
electrodiagnostic	POS	O
study	POS	O
,	POS	O
including	POS	O
a	POS	O
nerve	POS	O
conduction	POS	O
study	POS	O
of	POS	O
the	POS	O
LACN	POS	O
,	POS	O
was	POS	O
helpful	POS	O
to	POS	O
diagnose	POS	O
right	POS	O
LACNP	POS	O
and	POS	O
to	POS	O
find	POS	O
the	POS	O
passage	POS	O
of	POS	O
the	POS	O
LACN	POS	O
on	POS	O
the	POS	O
lateral	POS	O
epicondyle	POS	O
.	POS	O
Curcumin	POS	O
prevents	POS	O
maleate	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
:	POS	O
relation	POS	O
to	POS	O
hemodynamic	POS	O
alterations	POS	O
,	POS	O
oxidative	POS	O
stress	POS	O
,	POS	O
mitochondrial	POS	O
oxygen	POS	O
consumption	POS	O
and	POS	O
activity	POS	O
of	POS	O
respiratory	POS	O
complex	POS	O
I	POS	O
.	POS	O
The	POS	O
potential	POS	O
protective	POS	O
effect	POS	O
of	POS	O
the	POS	O
dietary	POS	O
antioxidant	POS	O
curcumin	POS	O
(	POS	O
120	POS	O
mg	POS	O
/	POS	O
Kg	POS	O
/	POS	O
day	POS	O
for	POS	O
6	POS	O
days	POS	O
)	POS	O
against	POS	O
the	POS	O
renal	POS	B-NP
injury	POS	I-NP
induced	POS	O
by	POS	O
maleate	POS	O
was	POS	O
evaluated	POS	O
.	POS	O
Tubular	POS	O
proteinuria	POS	B-NP
and	POS	O
oxidative	POS	O
stress	POS	O
were	POS	O
induced	POS	O
by	POS	O
a	POS	O
single	POS	O
injection	POS	O
of	POS	O
maleate	POS	O
(	POS	O
400	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
in	POS	O
rats	POS	O
.	POS	O
Maleate	POS	O
-	POS	O
induced	POS	O
renal	POS	B-NP
injury	POS	I-NP
included	POS	O
increase	POS	B-NP
in	POS	I-NP
renal	POS	I-NP
vascular	POS	I-NP
resistance	POS	I-NP
and	POS	O
in	POS	O
the	POS	O
urinary	POS	O
excretion	POS	O
of	POS	O
total	POS	O
protein	POS	O
,	POS	O
glucose	POS	O
,	POS	O
sodium	POS	O
,	POS	O
neutrophil	POS	O
gelatinase	POS	O
-	POS	O
associated	POS	O
lipocalin	POS	O
(	POS	O
NGAL	POS	O
)	POS	O
and	POS	O
N	POS	O
-	POS	O
acetyl	POS	O
b	POS	O
-	POS	O
D	POS	O
-	POS	O
glucosaminidase	POS	O
(	POS	O
NAG	POS	O
)	POS	O
,	POS	O
upregulation	POS	O
of	POS	O
kidney	POS	O
injury	POS	O
molecule	POS	O
(	POS	O
KIM	POS	O
)	POS	O
-	POS	O
1	POS	O
,	POS	O
decrease	POS	O
in	POS	O
renal	POS	O
blood	POS	O
flow	POS	O
and	POS	O
claudin	POS	O
-	POS	O
2	POS	O
expression	POS	O
besides	POS	O
of	POS	O
necrosis	POS	B-NP
and	POS	O
apoptosis	POS	O
of	POS	O
tubular	POS	O
cells	POS	O
on	POS	O
24	POS	O
h	POS	O
.	POS	O
Oxidative	POS	O
stress	POS	O
was	POS	O
determined	POS	O
by	POS	O
measuring	POS	O
the	POS	O
oxidation	POS	O
of	POS	O
lipids	POS	O
and	POS	O
proteins	POS	O
and	POS	O
diminution	POS	O
in	POS	O
renal	POS	O
Nrf2	POS	O
levels	POS	O
.	POS	O
Studies	POS	O
were	POS	O
also	POS	O
conducted	POS	O
in	POS	O
renal	POS	O
epithelial	POS	O
LLC	POS	O
-	POS	O
PK1	POS	O
cells	POS	O
and	POS	O
in	POS	O
mitochondria	POS	O
isolated	POS	O
from	POS	O
kidneys	POS	O
of	POS	O
all	POS	O
the	POS	O
experimental	POS	O
groups	POS	O
.	POS	O
Maleate	POS	O
induced	POS	O
cell	POS	O
damage	POS	O
and	POS	O
reactive	POS	O
oxygen	POS	O
species	POS	O
(	POS	O
ROS	POS	O
)	POS	O
production	POS	O
in	POS	O
LLC	POS	O
-	POS	O
PK1	POS	O
cells	POS	O
in	POS	O
culture	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
maleate	POS	O
treatment	POS	O
reduced	POS	O
oxygen	POS	O
consumption	POS	O
in	POS	O
ADP	POS	O
-	POS	O
stimulated	POS	O
mitochondria	POS	O
and	POS	O
diminished	POS	O
respiratory	POS	O
control	POS	O
index	POS	O
when	POS	O
using	POS	O
malate	POS	O
/	POS	O
glutamate	POS	O
as	POS	O
substrate	POS	O
.	POS	O
The	POS	O
activities	POS	O
of	POS	O
both	POS	O
complex	POS	O
I	POS	O
and	POS	O
aconitase	POS	O
were	POS	O
also	POS	O
diminished	POS	O
.	POS	O
All	POS	O
the	POS	O
above	POS	O
-	POS	O
described	POS	O
alterations	POS	O
were	POS	O
prevented	POS	O
by	POS	O
curcumin	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
curcumin	POS	O
is	POS	O
able	POS	O
to	POS	O
attenuate	POS	O
in	POS	O
vivo	POS	O
maleate	POS	O
-	POS	O
induced	POS	O
nephropathy	POS	B-NP
and	POS	O
in	POS	O
vitro	POS	O
cell	POS	O
damage	POS	O
.	POS	O
The	POS	O
in	POS	O
vivo	POS	O
protection	POS	O
was	POS	O
associated	POS	O
to	POS	O
the	POS	O
prevention	POS	O
of	POS	O
oxidative	POS	O
stress	POS	O
and	POS	O
preservation	POS	O
of	POS	O
mitochondrial	POS	O
oxygen	POS	O
consumption	POS	O
and	POS	O
activity	POS	O
of	POS	O
respiratory	POS	O
complex	POS	O
I	POS	O
,	POS	O
and	POS	O
the	POS	O
in	POS	O
vitro	POS	O
protection	POS	O
was	POS	O
associated	POS	O
to	POS	O
the	POS	O
prevention	POS	O
of	POS	O
ROS	POS	O
production	POS	O
.	POS	O
Anticonvulsant	POS	O
actions	POS	O
of	POS	O
MK	POS	O
-	POS	O
801	POS	O
on	POS	O
the	POS	O
lithium	POS	O
-	POS	O
pilocarpine	POS	O
model	POS	O
of	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
MK	POS	O
-	POS	O
801	POS	O
,	POS	O
a	POS	O
noncompetitive	POS	O
N	POS	O
-	POS	O
methyl	POS	O
-	POS	O
D	POS	O
-	POS	O
aspartate	POS	O
(	POS	O
NMDA	POS	O
)	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
was	POS	O
tested	POS	O
for	POS	O
anticonvulsant	POS	O
effects	POS	O
in	POS	O
rats	POS	O
using	POS	O
two	POS	O
seizure	POS	B-NP
models	POS	O
,	POS	O
coadministration	POS	O
of	POS	O
lithium	POS	O
and	POS	O
pilocarpine	POS	O
and	POS	O
administration	POS	O
of	POS	O
a	POS	O
high	POS	O
dose	POS	O
of	POS	O
pilocarpine	POS	O
alone	POS	O
.	POS	O
Three	POS	O
major	POS	O
results	POS	O
are	POS	O
reported	POS	O
.	POS	O
First	POS	O
,	POS	O
pretreatment	POS	O
with	POS	O
MK	POS	O
-	POS	O
801	POS	O
produced	POS	O
an	POS	O
effective	POS	O
and	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
anticonvulsant	POS	O
action	POS	O
with	POS	O
the	POS	O
lithium	POS	O
-	POS	O
pilocarpine	POS	O
model	POS	O
but	POS	O
not	POS	O
with	POS	O
rats	POS	O
treated	POS	O
with	POS	O
pilocarpine	POS	O
alone	POS	O
,	POS	O
suggesting	POS	O
that	POS	O
different	POS	O
biochemical	POS	O
mechanisms	POS	O
control	POS	O
seizures	POS	B-NP
in	POS	O
these	POS	O
two	POS	O
models	POS	O
.	POS	O
Second	POS	O
,	POS	O
the	POS	O
anticonvulsant	POS	O
effect	POS	O
of	POS	O
MK	POS	O
-	POS	O
801	POS	O
in	POS	O
the	POS	O
lithium	POS	O
-	POS	O
pilocarpine	POS	O
model	POS	O
only	POS	O
occurred	POS	O
after	POS	O
initial	POS	O
periods	POS	O
of	POS	O
seizure	POS	B-NP
activity	POS	O
.	POS	O
This	POS	O
observation	POS	O
is	POS	O
suggested	POS	O
to	POS	O
be	POS	O
an	POS	O
in	POS	O
vivo	POS	O
demonstration	POS	O
of	POS	O
the	POS	O
conclusion	POS	O
derived	POS	O
from	POS	O
in	POS	O
vitro	POS	O
experiments	POS	O
that	POS	O
MK	POS	O
-	POS	O
801	POS	O
binding	POS	O
requires	POS	O
agonist	POS	O
-	POS	O
induced	POS	O
opening	POS	O
of	POS	O
the	POS	O
channel	POS	O
sites	POS	O
of	POS	O
the	POS	O
NMDA	POS	O
receptor	POS	O
.	POS	O
Third	POS	O
,	POS	O
although	POS	O
it	POS	O
is	POS	O
relatively	POS	O
easy	POS	O
to	POS	O
block	POS	O
seizures	POS	B-NP
induced	POS	O
by	POS	O
lithium	POS	O
and	POS	O
pilocarpine	POS	O
by	POS	O
administration	POS	O
of	POS	O
anticonvulsants	POS	O
prior	POS	O
to	POS	O
pilocarpine	POS	O
,	POS	O
it	POS	O
is	POS	O
more	POS	O
difficult	POS	O
to	POS	O
terminate	POS	O
ongoing	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
and	POS	O
block	POS	O
the	POS	O
lethality	POS	O
of	POS	O
the	POS	O
seizures	POS	B-NP
.	POS	O
Administration	POS	O
of	POS	O
MK	POS	O
-	POS	O
801	POS	O
30	POS	O
or	POS	O
60	POS	O
min	POS	O
after	POS	O
pilocarpine	POS	O
,	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
,	POS	O
during	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
,	POS	O
gradually	POS	O
reduced	POS	O
electrical	POS	O
and	POS	O
behavioral	POS	O
seizure	POS	B-NP
activity	POS	O
and	POS	O
greatly	POS	O
enhanced	POS	O
the	POS	O
survival	POS	O
rate	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
activation	POS	O
of	POS	O
NMDA	POS	O
receptors	POS	O
plays	POS	O
an	POS	O
important	POS	O
role	POS	O
in	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
and	POS	O
brain	POS	B-NP
damage	POS	I-NP
in	POS	O
the	POS	O
lithium	POS	O
-	POS	O
pilocarpine	POS	O
model	POS	O
.	POS	O
This	POS	O
was	POS	O
further	POS	O
supported	POS	O
by	POS	O
results	POS	O
showing	POS	O
that	POS	O
nonconvulsive	POS	B-NP
doses	POS	O
of	POS	O
NMDA	POS	O
and	POS	O
pilocarpine	POS	O
were	POS	O
synergistic	POS	O
,	POS	O
resulting	POS	O
in	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
and	POS	O
subsequent	POS	O
mortality	POS	O
.	POS	O
Continuous	POS	O
infusion	POS	O
tobramycin	POS	O
combined	POS	O
with	POS	O
carbenicillin	POS	O
for	POS	O
infections	POS	O
in	POS	O
cancer	POS	B-NP
patients	POS	O
.	POS	O
The	POS	O
cure	POS	O
rate	POS	O
of	POS	O
infections	POS	B-NP
in	POS	O
cancer	POS	B-NP
patients	POS	O
is	POS	O
adversely	POS	O
affected	POS	O
by	POS	O
neutropenia	POS	B-NP
(	POS	O
less	POS	O
than	POS	O
1	POS	O
,	POS	O
000	POS	O
/	POS	O
mm3	POS	O
)	POS	O
.	POS	O
In	POS	O
particular	POS	O
,	POS	O
patients	POS	O
with	POS	O
severe	POS	O
neutropenia	POS	B-NP
(	POS	O
less	POS	O
than	POS	O
100	POS	O
/	POS	O
mm3	POS	O
)	POS	O
have	POS	O
shown	POS	O
a	POS	O
poor	POS	O
response	POS	O
to	POS	O
antibiotics	POS	O
.	POS	O
To	POS	O
overcome	POS	O
the	POS	O
adverse	POS	O
effects	POS	O
of	POS	O
neutropenia	POS	B-NP
,	POS	O
tobramycin	POS	O
was	POS	O
given	POS	O
by	POS	O
continuous	POS	O
infusion	POS	O
and	POS	O
combined	POS	O
with	POS	O
intermittent	POS	O
carbenicillin	POS	O
.	POS	O
Tobramycin	POS	O
was	POS	O
given	POS	O
to	POS	O
a	POS	O
total	POS	O
daily	POS	O
dose	POS	O
of	POS	O
300	POS	O
mg	POS	O
/	POS	O
m2	POS	O
and	POS	O
carbenicillin	POS	O
was	POS	O
given	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
5	POS	O
gm	POS	O
every	POS	O
four	POS	O
hours	POS	O
.	POS	O
There	POS	O
were	POS	O
125	POS	O
infectious	POS	O
episodes	POS	O
in	POS	O
116	POS	O
cancer	POS	B-NP
patients	POS	O
receiving	POS	O
myelosuppressive	POS	O
chemotherapy	POS	O
.	POS	O
The	POS	O
overall	POS	O
cure	POS	O
rate	POS	O
was	POS	O
70	POS	O
%	POS	O
.	POS	O
Pneumonia	POS	B-NP
was	POS	O
the	POS	O
most	POS	O
common	POS	O
infection	POS	O
and	POS	O
61	POS	O
%	POS	O
of	POS	O
59	POS	O
episodes	POS	O
were	POS	O
cured	POS	O
.	POS	O
Gram	POS	O
-	POS	O
negative	POS	O
bacilli	POS	O
were	POS	O
the	POS	O
most	POS	O
common	POS	O
causative	POS	O
organisms	POS	O
and	POS	O
69	POS	O
%	POS	O
of	POS	O
these	POS	O
infections	POS	B-NP
were	POS	O
cured	POS	O
.	POS	O
The	POS	O
most	POS	O
common	POS	O
pathogen	POS	O
was	POS	O
Klebsiella	POS	O
pneumoniae	POS	O
and	POS	O
this	POS	O
,	POS	O
together	POS	O
with	POS	O
Escherichia	POS	O
coli	POS	O
and	POS	O
Pseudomonas	POS	O
aeruginosa	POS	O
,	POS	O
accounted	POS	O
for	POS	O
74	POS	O
%	POS	O
of	POS	O
all	POS	O
gram	POS	O
-	POS	O
negative	POS	O
bacillary	POS	B-NP
infections	POS	I-NP
.	POS	O
Response	POS	O
was	POS	O
not	POS	O
influenced	POS	O
by	POS	O
the	POS	O
initial	POS	O
neutrophil	POS	O
count	POS	O
,	POS	O
with	POS	O
a	POS	O
62	POS	O
%	POS	O
cure	POS	O
rate	POS	O
for	POS	O
39	POS	O
episodes	POS	O
associated	POS	O
with	POS	O
severe	POS	O
neutropenia	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
failure	POS	O
of	POS	O
the	POS	O
neutrophil	POS	O
count	POS	O
to	POS	O
increase	POS	O
during	POS	O
therapy	POS	O
adversely	POS	O
affected	POS	O
response	POS	O
.	POS	O
Azotemia	POS	B-NP
was	POS	O
the	POS	O
major	POS	O
side	POS	O
effect	POS	O
recognized	POS	O
,	POS	O
and	POS	O
it	POS	O
occurred	POS	O
in	POS	O
11	POS	O
%	POS	O
of	POS	O
episodes	POS	O
.	POS	O
Major	POS	O
azotemia	POS	B-NP
(	POS	O
serum	POS	O
creatinine	POS	O
greater	POS	O
than	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
dl	POS	O
or	POS	O
BUN	POS	O
greater	POS	O
than	POS	O
50	POS	O
mg	POS	O
/	POS	O
dl	POS	O
)	POS	O
occurred	POS	O
in	POS	O
only	POS	O
2	POS	O
%	POS	O
.	POS	O
Azotemia	POS	B-NP
was	POS	O
not	POS	O
related	POS	O
to	POS	O
duration	POS	O
of	POS	O
therapy	POS	O
or	POS	O
serum	POS	O
tobramycin	POS	O
concentration	POS	O
.	POS	O
This	POS	O
antibiotic	POS	O
regimen	POS	O
showed	POS	O
both	POS	O
therapeutic	POS	O
efficacy	POS	O
and	POS	O
acceptable	POS	O
renal	POS	B-NP
toxicity	POS	I-NP
for	POS	O
these	POS	O
patients	POS	O
.	POS	O
Incidence	POS	O
of	POS	O
solid	POS	O
tumours	POS	B-NP
among	POS	O
pesticide	POS	O
applicators	POS	O
exposed	POS	O
to	POS	O
the	POS	O
organophosphate	POS	O
insecticide	POS	O
diazinon	POS	O
in	POS	O
the	POS	O
Agricultural	POS	O
Health	POS	O
Study	POS	O
:	POS	O
an	POS	O
updated	POS	O
analysis	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
Diazinon	POS	O
,	POS	O
a	POS	O
common	POS	O
organophosphate	POS	O
insecticide	POS	O
with	POS	O
genotoxic	POS	O
properties	POS	O
,	POS	O
was	POS	O
previously	POS	O
associated	POS	O
with	POS	O
lung	POS	B-NP
cancer	POS	I-NP
in	POS	O
the	POS	O
Agricultural	POS	O
Health	POS	O
Study	POS	O
(	POS	O
AHS	POS	O
)	POS	O
cohort	POS	O
,	POS	O
but	POS	O
few	POS	O
other	POS	O
epidemiological	POS	O
studies	POS	O
have	POS	O
examined	POS	O
diazinon	POS	O
-	POS	O
associated	POS	O
cancer	POS	B-NP
risk	POS	O
.	POS	O
We	POS	O
used	POS	O
updated	POS	O
diazinon	POS	O
exposure	POS	O
and	POS	O
cancer	POS	B-NP
incidence	POS	O
information	POS	O
to	POS	O
evaluate	POS	O
solid	POS	O
tumour	POS	B-NP
risk	POS	O
in	POS	O
the	POS	O
AHS	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
Male	POS	O
pesticide	POS	O
applicators	POS	O
in	POS	O
Iowa	POS	O
and	POS	O
North	POS	O
Carolina	POS	O
reported	POS	O
lifetime	POS	O
diazinon	POS	O
use	POS	O
at	POS	O
enrolment	POS	O
(	POS	O
1993	POS	O
-	POS	O
1997	POS	O
)	POS	O
and	POS	O
follow	POS	O
-	POS	O
up	POS	O
(	POS	O
1998	POS	O
-	POS	O
2005	POS	O
)	POS	O
;	POS	O
cancer	POS	B-NP
incidence	POS	O
was	POS	O
assessed	POS	O
through	POS	O
2010	POS	O
(	POS	O
North	POS	O
Carolina	POS	O
)	POS	O
/	POS	O
2011	POS	O
(	POS	O
Iowa	POS	O
)	POS	O
.	POS	O
Among	POS	O
applicators	POS	O
with	POS	O
usage	POS	O
information	POS	O
sufficient	POS	O
to	POS	O
evaluate	POS	O
exposure	POS	O
-	POS	O
response	POS	O
patterns	POS	O
,	POS	O
we	POS	O
used	POS	O
Poisson	POS	O
regression	POS	O
to	POS	O
estimate	POS	O
adjusted	POS	O
rate	POS	O
ratios	POS	O
(	POS	O
RRs	POS	O
)	POS	O
and	POS	O
95	POS	O
%	POS	O
CI	POS	O
for	POS	O
cancer	POS	B-NP
sites	POS	O
with	POS	O
>	POS	O
10	POS	O
exposed	POS	O
cases	POS	O
for	POS	O
both	POS	O
lifetime	POS	O
(	POS	O
LT	POS	O
)	POS	O
exposure	POS	O
days	POS	O
and	POS	O
intensity	POS	O
-	POS	O
weighted	POS	O
(	POS	O
IW	POS	O
)	POS	O
lifetime	POS	O
exposure	POS	O
days	POS	O
(	POS	O
accounting	POS	O
for	POS	O
factors	POS	O
impacting	POS	O
exposure	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
We	POS	O
observed	POS	O
elevated	POS	O
lung	POS	B-NP
cancer	POS	I-NP
risks	POS	O
(	POS	O
N	POS	O
=	POS	O
283	POS	O
)	POS	O
among	POS	O
applicators	POS	O
with	POS	O
the	POS	O
greatest	POS	O
number	POS	O
of	POS	O
LT	POS	O
(	POS	O
RR	POS	O
=	POS	O
1	POS	O
.	POS	O
60	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
1	POS	O
.	POS	O
11	POS	O
to	POS	O
2	POS	O
.	POS	O
31	POS	O
;	POS	O
Ptrend	POS	O
=	POS	O
0	POS	O
.	POS	O
02	POS	O
)	POS	O
and	POS	O
IW	POS	O
days	POS	O
of	POS	O
diazinon	POS	O
use	POS	O
(	POS	O
RR	POS	O
=	POS	O
1	POS	O
.	POS	O
41	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
0	POS	O
.	POS	O
98	POS	O
to	POS	O
2	POS	O
.	POS	O
04	POS	O
;	POS	O
Ptrend	POS	O
=	POS	O
0	POS	O
.	POS	O
08	POS	O
)	POS	O
.	POS	O
Kidney	POS	B-NP
cancer	POS	I-NP
(	POS	O
N	POS	O
=	POS	O
94	POS	O
)	POS	O
risks	POS	O
were	POS	O
non	POS	O
-	POS	O
significantly	POS	O
elevated	POS	O
(	POS	O
RRLT	POS	O
days	POS	O
=	POS	O
1	POS	O
.	POS	O
77	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
0	POS	O
.	POS	O
90	POS	O
to	POS	O
3	POS	O
.	POS	O
51	POS	O
;	POS	O
Ptrend	POS	O
=	POS	O
0	POS	O
.	POS	O
09	POS	O
;	POS	O
RRIW	POS	O
days	POS	O
1	POS	O
.	POS	O
37	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
0	POS	O
.	POS	O
64	POS	O
to	POS	O
2	POS	O
.	POS	O
92	POS	O
;	POS	O
Ptrend	POS	O
=	POS	O
0	POS	O
.	POS	O
50	POS	O
)	POS	O
,	POS	O
as	POS	O
were	POS	O
risks	POS	O
for	POS	O
aggressive	POS	O
prostate	POS	B-NP
cancer	POS	I-NP
(	POS	O
N	POS	O
=	POS	O
656	POS	O
)	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Our	POS	O
updated	POS	O
evaluation	POS	O
of	POS	O
diazinon	POS	O
provides	POS	O
additional	POS	O
evidence	POS	O
of	POS	O
an	POS	O
association	POS	O
with	POS	O
lung	POS	B-NP
cancer	POS	I-NP
risk	POS	O
.	POS	O
Newly	POS	O
identified	POS	O
links	POS	O
to	POS	O
kidney	POS	B-NP
cancer	POS	I-NP
and	POS	O
associations	POS	O
with	POS	O
aggressive	POS	O
prostate	POS	B-NP
cancer	POS	I-NP
require	POS	O
further	POS	O
evaluation	POS	O
.	POS	O
Associations	POS	O
of	POS	O
Ozone	POS	O
and	POS	O
PM2	POS	O
.	POS	O
5	POS	O
Concentrations	POS	O
With	POS	O
Parkinson	POS	O
'	POS	O
s	POS	O
Disease	POS	O
Among	POS	O
Participants	POS	O
in	POS	O
the	POS	O
Agricultural	POS	O
Health	POS	O
Study	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
This	POS	O
study	POS	O
describes	POS	O
associations	POS	O
of	POS	O
ozone	POS	O
and	POS	O
fine	POS	O
particulate	POS	O
matter	POS	O
with	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
observed	POS	O
among	POS	O
farmers	POS	O
in	POS	O
North	POS	O
Carolina	POS	O
and	POS	O
Iowa	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
used	POS	O
logistic	POS	O
regression	POS	O
to	POS	O
determine	POS	O
the	POS	O
associations	POS	O
of	POS	O
these	POS	O
pollutants	POS	O
with	POS	O
self	POS	O
-	POS	O
reported	POS	O
,	POS	O
doctor	POS	O
-	POS	O
diagnosed	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
Daily	POS	O
predicted	POS	O
pollutant	POS	O
concentrations	POS	O
were	POS	O
used	POS	O
to	POS	O
derive	POS	O
surrogates	POS	O
of	POS	O
long	POS	O
-	POS	O
term	POS	O
exposure	POS	O
and	POS	O
link	POS	O
them	POS	O
to	POS	O
study	POS	O
participants	POS	O
'	POS	O
geocoded	POS	O
addresses	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
We	POS	O
observed	POS	O
positive	POS	O
associations	POS	O
of	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
with	POS	O
ozone	POS	O
(	POS	O
odds	POS	O
ratio	POS	O
=	POS	O
1	POS	O
.	POS	O
39	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
0	POS	O
.	POS	O
98	POS	O
to	POS	O
1	POS	O
.	POS	O
98	POS	O
)	POS	O
and	POS	O
fine	POS	O
particulate	POS	O
matter	POS	O
(	POS	O
odds	POS	O
ratio	POS	O
=	POS	O
1	POS	O
.	POS	O
34	POS	O
;	POS	O
95	POS	O
%	POS	O
CI	POS	O
:	POS	O
0	POS	O
.	POS	O
93	POS	O
to	POS	O
1	POS	O
.	POS	O
93	POS	O
)	POS	O
in	POS	O
North	POS	O
Carolina	POS	O
but	POS	O
not	POS	O
in	POS	O
Iowa	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
The	POS	O
plausibility	POS	O
of	POS	O
an	POS	O
effect	POS	O
of	POS	O
ambient	POS	O
concentrations	POS	O
of	POS	O
these	POS	O
pollutants	POS	O
on	POS	O
Parkinson	POS	O
'	POS	O
s	POS	O
disease	POS	O
risk	POS	O
is	POS	O
supported	POS	O
by	POS	O
experimental	POS	O
data	POS	O
demonstrating	POS	O
damage	POS	O
to	POS	O
dopaminergic	POS	O
neurons	POS	O
at	POS	O
relevant	POS	O
concentrations	POS	O
.	POS	O
Additional	POS	O
studies	POS	O
are	POS	O
needed	POS	O
to	POS	O
address	POS	O
uncertainties	POS	O
related	POS	O
to	POS	O
confounding	POS	O
and	POS	O
to	POS	O
examine	POS	O
temporal	POS	O
aspects	POS	O
of	POS	O
the	POS	O
associations	POS	O
we	POS	O
observed	POS	O
.	POS	O
Low	POS	O
functional	POS	O
programming	POS	O
of	POS	O
renal	POS	O
AT2R	POS	O
mediates	POS	O
the	POS	O
developmental	POS	O
origin	POS	O
of	POS	O
glomerulosclerosis	POS	B-NP
in	POS	O
adult	POS	O
offspring	POS	O
induced	POS	O
by	POS	O
prenatal	POS	O
caffeine	POS	O
exposure	POS	O
.	POS	O
UNASSIGNED	POS	O
:	POS	O
Our	POS	O
previous	POS	O
study	POS	O
has	POS	O
indicated	POS	O
that	POS	O
prenatal	POS	O
caffeine	POS	O
exposure	POS	O
(	POS	O
PCE	POS	O
)	POS	O
could	POS	O
induce	POS	O
intrauterine	POS	B-NP
growth	POS	I-NP
retardation	POS	I-NP
(	POS	O
IUGR	POS	B-NP
)	POS	O
of	POS	O
offspring	POS	O
.	POS	O
Recent	POS	O
research	POS	O
suggested	POS	O
that	POS	O
IUGR	POS	B-NP
is	POS	O
a	POS	O
risk	POS	O
factor	POS	O
for	POS	O
glomerulosclerosis	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
whether	POS	O
PCE	POS	O
could	POS	O
induce	POS	O
glomerulosclerosis	POS	B-NP
and	POS	O
its	POS	O
underlying	POS	O
mechanisms	POS	O
remain	POS	O
unknown	POS	O
.	POS	O
This	POS	O
study	POS	O
aimed	POS	O
to	POS	O
demonstrate	POS	O
the	POS	O
induction	POS	O
to	POS	O
glomerulosclerosis	POS	B-NP
in	POS	O
adult	POS	O
offspring	POS	O
by	POS	O
PCE	POS	O
and	POS	O
its	POS	O
intrauterine	POS	O
programming	POS	O
mechanisms	POS	O
.	POS	O
A	POS	O
rat	POS	O
model	POS	O
of	POS	O
IUGR	POS	B-NP
was	POS	O
established	POS	O
by	POS	O
PCE	POS	O
,	POS	O
male	POS	O
fetuses	POS	O
and	POS	O
adult	POS	O
offspring	POS	O
at	POS	O
the	POS	O
age	POS	O
of	POS	O
postnatal	POS	O
week	POS	O
24	POS	O
were	POS	O
euthanized	POS	O
.	POS	O
The	POS	O
results	POS	O
revealed	POS	O
that	POS	O
the	POS	O
adult	POS	O
offspring	POS	O
kidneys	POS	O
in	POS	O
the	POS	O
PCE	POS	O
group	POS	O
exhibited	POS	O
glomerulosclerosis	POS	B-NP
as	POS	O
well	POS	O
as	POS	O
interstitial	POS	B-NP
fibrosis	POS	I-NP
,	POS	O
accompanied	POS	O
by	POS	O
elevated	POS	O
levels	POS	O
of	POS	O
serum	POS	O
creatinine	POS	O
and	POS	O
urine	POS	O
protein	POS	O
.	POS	O
Renal	POS	O
angiotensin	POS	O
II	POS	O
receptor	POS	O
type	POS	O
2	POS	O
(	POS	O
AT2R	POS	O
)	POS	O
gene	POS	O
expression	POS	O
in	POS	O
adult	POS	O
offspring	POS	O
was	POS	O
reduced	POS	O
by	POS	O
PCE	POS	O
,	POS	O
whereas	POS	O
the	POS	O
renal	POS	O
angiotensin	POS	O
II	POS	O
receptor	POS	O
type	POS	O
1a	POS	O
(	POS	O
AT1aR	POS	O
)	POS	O
/	POS	O
AT2R	POS	O
expression	POS	O
ratio	POS	O
was	POS	O
increased	POS	O
.	POS	O
The	POS	O
fetal	POS	O
kidneys	POS	O
in	POS	O
the	POS	O
PCE	POS	O
group	POS	O
displayed	POS	O
an	POS	O
enlarged	POS	O
Bowman	POS	O
'	POS	O
s	POS	O
space	POS	O
and	POS	O
a	POS	O
shrunken	POS	O
glomerular	POS	O
tuft	POS	O
,	POS	O
accompanied	POS	O
by	POS	O
a	POS	O
reduced	POS	O
cortex	POS	O
width	POS	O
and	POS	O
an	POS	O
increase	POS	O
in	POS	O
the	POS	O
nephrogenic	POS	O
zone	POS	O
/	POS	O
cortical	POS	O
zone	POS	O
ratio	POS	O
.	POS	O
Observation	POS	O
by	POS	O
electronic	POS	O
microscope	POS	O
revealed	POS	O
structural	POS	O
damage	POS	O
of	POS	O
podocytes	POS	O
;	POS	O
the	POS	O
reduced	POS	O
expression	POS	O
level	POS	O
of	POS	O
podocyte	POS	O
marker	POS	O
genes	POS	O
,	POS	O
nephrin	POS	O
and	POS	O
podocin	POS	O
,	POS	O
was	POS	O
also	POS	O
detected	POS	O
by	POS	O
q	POS	O
-	POS	O
PCR	POS	O
.	POS	O
Moreover	POS	O
,	POS	O
AT2R	POS	O
gene	POS	O
and	POS	O
protein	POS	O
expressions	POS	O
in	POS	O
fetal	POS	O
kidneys	POS	O
were	POS	O
inhibited	POS	O
by	POS	O
PCE	POS	O
,	POS	O
associated	POS	O
with	POS	O
the	POS	O
repression	POS	O
of	POS	O
the	POS	O
gene	POS	O
expression	POS	O
of	POS	O
glial	POS	O
-	POS	O
cell	POS	O
-	POS	O
line	POS	O
-	POS	O
derived	POS	O
neurotrophic	POS	O
factor	POS	O
(	POS	O
GDNF	POS	O
)	POS	O
/	POS	O
tyrosine	POS	O
kinase	POS	O
receptor	POS	O
(	POS	O
c	POS	O
-	POS	O
Ret	POS	O
)	POS	O
signaling	POS	O
pathway	POS	O
.	POS	O
These	POS	O
results	POS	O
demonstrated	POS	O
that	POS	O
PCE	POS	O
could	POS	O
induce	POS	O
dysplasia	POS	B-NP
of	POS	O
fetal	POS	O
kidneys	POS	O
as	POS	O
well	POS	O
as	POS	O
glomerulosclerosis	POS	B-NP
of	POS	O
adult	POS	O
offspring	POS	O
,	POS	O
and	POS	O
the	POS	O
low	POS	O
functional	POS	O
programming	POS	O
of	POS	O
renal	POS	O
AT2R	POS	O
might	POS	O
mediate	POS	O
the	POS	O
developmental	POS	O
origin	POS	O
of	POS	O
adult	POS	O
glomerulosclerosis	POS	B-NP
.	POS	O
1	POS	O
,	POS	O
3	POS	O
-	POS	O
Butadiene	POS	O
,	POS	O
CML	POS	B-NP
and	POS	O
the	POS	O
t	POS	O
(	POS	O
9	POS	O
:	POS	O
22	POS	O
)	POS	O
translocation	POS	O
:	POS	O
A	POS	O
reality	POS	O
check	POS	O
.	POS	O
UNASSIGNED	POS	O
:	POS	O
Epidemiological	POS	O
studies	POS	O
of	POS	O
1	POS	O
,	POS	O
3	POS	O
-	POS	O
butadiene	POS	O
have	POS	O
suggest	POS	O
that	POS	O
exposures	POS	O
to	POS	O
humans	POS	O
are	POS	O
associated	POS	O
with	POS	O
chronic	POS	B-NP
myeloid	POS	I-NP
leukemia	POS	I-NP
(	POS	O
CML	POS	B-NP
)	POS	O
.	POS	O
CML	POS	B-NP
has	POS	O
a	POS	O
well	POS	O
-	POS	O
documented	POS	O
association	POS	O
with	POS	O
ionizing	POS	O
radiation	POS	O
,	POS	O
but	POS	O
reports	POS	O
of	POS	O
associations	POS	O
with	POS	O
chemical	POS	O
exposures	POS	O
have	POS	O
been	POS	O
questioned	POS	O
.	POS	O
Ionizing	POS	O
radiation	POS	O
is	POS	O
capable	POS	O
of	POS	O
inducing	POS	O
the	POS	O
requisite	POS	O
CML	POS	O
-	POS	O
associated	POS	O
t	POS	O
(	POS	O
9	POS	O
:	POS	O
22	POS	O
)	POS	O
translocation	POS	O
(	POS	O
Philadelphia	POS	O
chromosome	POS	O
)	POS	O
in	POS	O
appropriate	POS	O
cells	POS	O
in	POS	O
vitro	POS	O
but	POS	O
,	POS	O
thus	POS	O
far	POS	O
,	POS	O
chemicals	POS	O
have	POS	O
not	POS	O
shown	POS	O
this	POS	O
capacity	POS	O
.	POS	O
We	POS	O
have	POS	O
proposed	POS	O
that	POS	O
1	POS	O
,	POS	O
3	POS	O
-	POS	O
butadiene	POS	O
metabolites	POS	O
be	POS	O
so	POS	O
tested	POS	O
as	POS	O
a	POS	O
reality	POS	O
check	POS	O
on	POS	O
the	POS	O
epidemiological	POS	O
reports	POS	O
.	POS	O
In	POS	O
order	POS	O
to	POS	O
conduct	POS	O
reliable	POS	O
testing	POS	O
in	POS	O
this	POS	O
regard	POS	O
,	POS	O
it	POS	O
is	POS	O
essential	POS	O
that	POS	O
a	POS	O
positive	POS	O
control	POS	O
for	POS	O
induction	POS	O
be	POS	O
available	POS	O
.	POS	O
We	POS	O
have	POS	O
used	POS	O
ionizing	POS	O
radiation	POS	O
to	POS	O
develop	POS	O
such	POS	O
a	POS	O
control	POS	O
.	POS	O
Results	POS	O
described	POS	O
here	POS	O
demonstrate	POS	O
that	POS	O
this	POS	O
agent	POS	O
does	POS	O
in	POS	O
fact	POS	O
induce	POS	O
pathogenic	POS	O
t	POS	O
(	POS	O
9	POS	O
:	POS	O
22	POS	O
)	POS	O
translocations	POS	O
in	POS	O
a	POS	O
human	POS	O
myeloid	POS	O
cell	POS	O
line	POS	O
in	POS	O
vitro	POS	O
,	POS	O
but	POS	O
does	POS	O
so	POS	O
at	POS	O
low	POS	O
frequencies	POS	O
.	POS	O
Conditions	POS	O
that	POS	O
will	POS	O
be	POS	O
required	POS	O
for	POS	O
studies	POS	O
of	POS	O
1	POS	O
,	POS	O
3	POS	O
-	POS	O
butadiene	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Cancer	POS	O
incidence	POS	O
and	POS	O
metolachlor	POS	O
use	POS	O
in	POS	O
the	POS	O
Agricultural	POS	O
Health	POS	O
Study	POS	O
:	POS	O
An	POS	O
update	POS	O
.	POS	O
UNASSIGNED	POS	O
:	POS	O
Metolachlor	POS	O
,	POS	O
a	POS	O
widely	POS	O
used	POS	O
herbicide	POS	O
,	POS	O
is	POS	O
classified	POS	O
as	POS	O
a	POS	O
Group	POS	O
C	POS	O
carcinogen	POS	O
by	POS	O
the	POS	O
U	POS	O
.	POS	O
S	POS	O
.	POS	O
Environmental	POS	O
Protection	POS	O
Agency	POS	O
based	POS	O
on	POS	O
increased	POS	O
liver	POS	B-NP
neoplasms	POS	I-NP
in	POS	O
female	POS	O
rats	POS	O
.	POS	O
Epidemiologic	POS	O
studies	POS	O
of	POS	O
the	POS	O
health	POS	O
effects	POS	O
of	POS	O
metolachlor	POS	O
have	POS	O
been	POS	O
limited	POS	O
.	POS	O
The	POS	O
Agricultural	POS	O
Health	POS	O
Study	POS	O
(	POS	O
AHS	POS	O
)	POS	O
is	POS	O
a	POS	O
prospective	POS	O
cohort	POS	O
study	POS	O
including	POS	O
licensed	POS	O
private	POS	O
and	POS	O
commercial	POS	O
pesticide	POS	O
applicators	POS	O
in	POS	O
Iowa	POS	O
and	POS	O
North	POS	O
Carolina	POS	O
enrolled	POS	O
1993	POS	O
-	POS	O
1997	POS	O
.	POS	O
We	POS	O
evaluated	POS	O
cancer	POS	B-NP
incidence	POS	O
through	POS	O
2010	POS	O
/	POS	O
2011	POS	O
(	POS	O
NC	POS	O
/	POS	O
IA	POS	O
)	POS	O
for	POS	O
49	POS	O
,	POS	O
616	POS	O
applicators	POS	O
,	POS	O
53	POS	O
%	POS	O
of	POS	O
whom	POS	O
reported	POS	O
ever	POS	O
using	POS	O
metolachlor	POS	O
.	POS	O
We	POS	O
used	POS	O
Poisson	POS	O
regression	POS	O
to	POS	O
evaluate	POS	O
relations	POS	O
between	POS	O
two	POS	O
metrics	POS	O
of	POS	O
metolachlor	POS	O
use	POS	O
(	POS	O
lifetime	POS	O
days	POS	O
,	POS	O
intensity	POS	O
-	POS	O
weighted	POS	O
lifetime	POS	O
days	POS	O
)	POS	O
and	POS	O
cancer	POS	B-NP
incidence	POS	O
.	POS	O
We	POS	O
saw	POS	O
no	POS	O
association	POS	O
between	POS	O
metolachlor	POS	O
use	POS	O
and	POS	O
incidence	POS	O
of	POS	O
all	POS	O
cancers	POS	B-NP
combined	POS	O
(	POS	O
n	POS	O
=	POS	O
5	POS	O
,	POS	O
701	POS	O
with	POS	O
a	POS	O
5	POS	O
-	POS	O
year	POS	O
lag	POS	O
)	POS	O
or	POS	O
most	POS	O
site	POS	O
-	POS	O
specific	POS	O
cancers	POS	B-NP
.	POS	O
For	POS	O
liver	POS	B-NP
cancer	POS	I-NP
,	POS	O
in	POS	O
analyses	POS	O
restricted	POS	O
to	POS	O
exposed	POS	O
workers	POS	O
,	POS	O
elevations	POS	O
observed	POS	O
at	POS	O
higher	POS	O
categories	POS	O
of	POS	O
use	POS	O
were	POS	O
not	POS	O
statistically	POS	O
significant	POS	O
.	POS	O
However	POS	O
,	POS	O
trends	POS	O
for	POS	O
both	POS	O
lifetime	POS	O
and	POS	O
intensity	POS	O
-	POS	O
weighted	POS	O
lifetime	POS	O
days	POS	O
of	POS	O
metolachor	POS	O
use	POS	O
were	POS	O
positive	POS	O
and	POS	O
statistically	POS	O
significant	POS	O
with	POS	O
an	POS	O
unexposed	POS	O
reference	POS	O
group	POS	O
.	POS	O
A	POS	O
similar	POS	O
pattern	POS	O
was	POS	O
observed	POS	O
for	POS	O
follicular	POS	B-NP
cell	POS	I-NP
lymphoma	POS	I-NP
,	POS	O
but	POS	O
no	POS	O
other	POS	O
lymphoma	POS	B-NP
subtypes	POS	O
.	POS	O
An	POS	O
earlier	POS	O
suggestion	POS	O
of	POS	O
increased	POS	O
lung	POS	B-NP
cancer	POS	I-NP
risk	POS	O
at	POS	O
high	POS	O
levels	POS	O
of	POS	O
metolachlor	POS	O
use	POS	O
in	POS	O
this	POS	O
cohort	POS	O
was	POS	O
not	POS	O
confirmed	POS	O
in	POS	O
this	POS	O
update	POS	O
.	POS	O
This	POS	O
suggestion	POS	O
of	POS	O
an	POS	O
association	POS	O
between	POS	O
metolachlor	POS	O
and	POS	O
liver	POS	B-NP
cancer	POS	I-NP
among	POS	O
pesticide	POS	O
applicators	POS	O
is	POS	O
a	POS	O
novel	POS	O
finding	POS	O
and	POS	O
echoes	POS	O
observation	POS	O
of	POS	O
increased	POS	O
liver	POS	B-NP
neoplasms	POS	I-NP
in	POS	O
some	POS	O
animal	POS	O
studies	POS	O
.	POS	O
However	POS	O
,	POS	O
our	POS	O
findings	POS	O
for	POS	O
both	POS	O
liver	POS	B-NP
cancer	POS	I-NP
and	POS	O
follicular	POS	B-NP
cell	POS	I-NP
lymphoma	POS	I-NP
warrant	POS	O
follow	POS	O
-	POS	O
up	POS	O
to	POS	O
better	POS	O
differentiate	POS	O
effects	POS	O
of	POS	O
metolachlor	POS	O
use	POS	O
from	POS	O
other	POS	O
factors	POS	O
.	POS	O
Mechanisms	POS	O
Underlying	POS	O
Latent	POS	O
Disease	POS	O
Risk	POS	O
Associated	POS	O
with	POS	O
Early	POS	O
-	POS	O
Life	POS	O
Arsenic	POS	O
Exposure	POS	O
:	POS	O
Current	POS	O
Research	POS	O
Trends	POS	O
and	POS	O
Scientific	POS	O
Gaps	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Millions	POS	O
of	POS	O
individuals	POS	O
worldwide	POS	O
,	POS	O
particularly	POS	O
those	POS	O
living	POS	O
in	POS	O
rural	POS	O
and	POS	O
developing	POS	O
areas	POS	O
,	POS	O
are	POS	O
exposed	POS	O
to	POS	O
harmful	POS	O
levels	POS	O
of	POS	O
inorganic	POS	O
arsenic	POS	O
(	POS	O
iAs	POS	O
)	POS	O
in	POS	O
their	POS	O
drinking	POS	O
water	POS	O
.	POS	O
Inorganic	POS	O
As	POS	O
exposure	POS	O
during	POS	O
key	POS	O
developmental	POS	O
periods	POS	O
is	POS	O
associated	POS	O
with	POS	O
a	POS	O
variety	POS	O
of	POS	O
adverse	POS	O
health	POS	O
effects	POS	O
including	POS	O
those	POS	O
that	POS	O
are	POS	O
evident	POS	O
in	POS	O
adulthood	POS	O
.	POS	O
There	POS	O
is	POS	O
considerable	POS	O
interest	POS	O
in	POS	O
identifying	POS	O
the	POS	O
molecular	POS	O
mechanisms	POS	O
that	POS	O
relate	POS	O
early	POS	O
-	POS	O
life	POS	O
iAs	POS	O
exposure	POS	O
to	POS	O
the	POS	O
development	POS	O
of	POS	O
these	POS	O
latent	POS	B-NP
diseases	POS	I-NP
,	POS	O
particularly	POS	O
in	POS	O
relationship	POS	O
to	POS	O
cancer	POS	B-NP
.	POS	O
OBJECTIVES	POS	O
:	POS	O
This	POS	O
work	POS	O
summarizes	POS	O
research	POS	O
on	POS	O
the	POS	O
molecular	POS	O
mechanisms	POS	O
that	POS	O
underlie	POS	O
the	POS	O
increased	POS	O
risk	POS	O
of	POS	O
cancer	POS	B-NP
development	POS	O
in	POS	O
adulthood	POS	O
that	POS	O
is	POS	O
associated	POS	O
with	POS	O
early	POS	O
-	POS	O
life	POS	O
iAs	POS	O
exposure	POS	O
.	POS	O
DISCUSSION	POS	O
:	POS	O
Epigenetic	POS	O
reprogramming	POS	O
that	POS	O
imparts	POS	O
functional	POS	O
changes	POS	O
in	POS	O
gene	POS	O
expression	POS	O
,	POS	O
the	POS	O
development	POS	O
of	POS	O
cancer	POS	B-NP
stem	POS	O
cells	POS	O
,	POS	O
and	POS	O
immunomodulation	POS	O
are	POS	O
plausible	POS	O
underlying	POS	O
mechanisms	POS	O
by	POS	O
which	POS	O
early	POS	O
-	POS	O
life	POS	O
iAs	POS	O
exposure	POS	O
elicits	POS	O
latent	POS	O
carcinogenic	POS	O
effects	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Evidence	POS	O
is	POS	O
mounting	POS	O
that	POS	O
relates	POS	O
early	POS	O
-	POS	O
life	POS	O
iAs	POS	O
exposure	POS	O
and	POS	O
cancer	POS	B-NP
development	POS	O
later	POS	O
in	POS	O
life	POS	O
.	POS	O
Future	POS	O
research	POS	O
should	POS	O
include	POS	O
animal	POS	O
studies	POS	O
that	POS	O
address	POS	O
mechanistic	POS	O
hypotheses	POS	O
and	POS	O
studies	POS	O
of	POS	O
human	POS	O
populations	POS	O
that	POS	O
integrate	POS	O
early	POS	O
-	POS	O
life	POS	O
exposure	POS	O
,	POS	O
molecular	POS	O
alterations	POS	O
,	POS	O
and	POS	O
latent	POS	O
disease	POS	O
outcomes	POS	O
.	POS	O
Nifedipine	POS	O
induced	POS	O
bradycardia	POS	B-NP
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
autonomic	POS	B-NP
neuropathy	POS	I-NP
.	POS	O
An	POS	O
80	POS	O
year	POS	O
old	POS	O
diabetic	POS	O
male	POS	O
with	POS	O
evidence	POS	O
of	POS	O
peripheral	POS	O
and	POS	O
autonomic	POS	B-NP
neuropathy	POS	I-NP
was	POS	O
admitted	POS	O
with	POS	O
chest	POS	B-NP
pain	POS	I-NP
.	POS	O
He	POS	O
was	POS	O
found	POS	O
to	POS	O
have	POS	O
atrial	POS	B-NP
flutter	POS	I-NP
at	POS	O
a	POS	O
ventricular	POS	O
rate	POS	O
of	POS	O
70	POS	O
/	POS	O
min	POS	O
which	POS	O
slowed	POS	O
down	POS	O
to	POS	O
30	POS	O
-	POS	O
40	POS	O
/	POS	O
min	POS	O
when	POS	O
nifedipine	POS	O
(	POS	O
60	POS	O
mg	POS	O
)	POS	O
in	POS	O
3	POS	O
divided	POS	O
doses	POS	O
,	POS	O
during	POS	O
which	POS	O
he	POS	O
was	POS	O
paced	POS	O
at	POS	O
a	POS	O
rate	POS	O
of	POS	O
70	POS	O
/	POS	O
min	POS	O
.	POS	O
This	POS	O
is	POS	O
inconsistent	POS	O
with	POS	O
the	POS	O
well	POS	O
-	POS	O
established	POS	O
finding	POS	O
that	POS	O
nifedipine	POS	O
induces	POS	O
tachycardia	POS	B-NP
in	POS	O
normally	POS	O
innervated	POS	O
hearts	POS	O
.	POS	O
However	POS	O
,	POS	O
in	POS	O
hearts	POS	O
deprived	POS	O
of	POS	O
compensatory	POS	O
sympathetic	POS	O
drive	POS	O
,	POS	O
it	POS	O
may	POS	O
lead	POS	O
to	POS	O
bradycardia	POS	B-NP
.	POS	O
The	POS	O
effect	POS	O
of	POS	O
haloperidol	POS	O
in	POS	O
cocaine	POS	O
and	POS	O
amphetamine	POS	O
intoxication	POS	O
.	POS	O
The	POS	O
effectiveness	POS	O
of	POS	O
haloperidol	POS	O
pretreatment	POS	O
in	POS	O
preventing	POS	O
the	POS	O
toxic	POS	O
effects	POS	O
of	POS	O
high	POS	O
doses	POS	O
of	POS	O
amphetamine	POS	O
and	POS	O
cocaine	POS	O
was	POS	O
studied	POS	O
in	POS	O
rats	POS	O
.	POS	O
In	POS	O
this	POS	O
model	POS	O
,	POS	O
toxic	POS	O
effects	POS	O
were	POS	O
induced	POS	O
by	POS	O
intraperitoneal	POS	O
(	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
injection	POS	O
of	POS	O
amphetamine	POS	O
75	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
100	POS	O
%	POS	O
death	POS	O
rate	POS	O
)	POS	O
or	POS	O
cocaine	POS	O
70	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
82	POS	O
%	POS	O
death	POS	O
rate	POS	O
)	POS	O
.	POS	O
Haloperidol	POS	O
failed	POS	O
to	POS	O
prevent	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
,	POS	O
but	POS	O
did	POS	O
lower	POS	O
the	POS	O
mortality	POS	O
rate	POS	O
at	POS	O
most	POS	O
doses	POS	O
tested	POS	O
.	POS	O
Haloperidol	POS	O
decreased	POS	O
the	POS	O
incidence	POS	O
of	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
at	POS	O
the	POS	O
two	POS	O
highest	POS	O
doses	POS	O
,	POS	O
but	POS	O
the	POS	O
lowering	POS	O
of	POS	O
the	POS	O
mortality	POS	O
rate	POS	O
did	POS	O
not	POS	O
reach	POS	O
statistical	POS	O
significance	POS	O
at	POS	O
any	POS	O
dose	POS	O
.	POS	O
These	POS	O
data	POS	O
suggest	POS	O
a	POS	O
protective	POS	O
role	POS	O
for	POS	O
the	POS	O
central	POS	O
dopamine	POS	O
blocker	POS	O
haloperidol	POS	O
against	POS	O
death	POS	O
from	POS	O
high	POS	O
-	POS	O
dose	POS	O
amphetamine	POS	O
exposure	POS	O
without	POS	O
reducing	POS	O
the	POS	O
incidence	POS	O
of	POS	O
seizures	POS	B-NP
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
haloperidol	POS	O
demonstrated	POS	O
an	POS	O
ability	POS	O
to	POS	O
reduce	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
without	POS	O
significantly	POS	O
reducing	POS	O
mortality	POS	O
.	POS	O
Autoradiographic	POS	O
evidence	POS	O
of	POS	O
estrogen	POS	O
binding	POS	O
sites	POS	O
in	POS	O
nuclei	POS	O
of	POS	O
diethylstilbesterol	POS	O
induced	POS	O
hamster	POS	B-NP
renal	POS	I-NP
carcinomas	POS	I-NP
.	POS	O
Estrogen	POS	O
binding	POS	O
sites	POS	O
were	POS	O
demonstrated	POS	O
by	POS	O
autoradiography	POS	O
in	POS	O
one	POS	O
transplantable	POS	O
and	POS	O
five	POS	O
primary	POS	O
diethylstilbesterol	POS	O
induced	POS	O
renal	POS	B-NP
carcinomas	POS	I-NP
in	POS	O
three	POS	O
hamsters	POS	O
.	POS	O
Radiolabelling	POS	O
,	POS	O
following	POS	O
the	POS	O
in	POS	O
vivo	POS	O
injection	POS	O
of	POS	O
3H	POS	O
-	POS	O
17	POS	O
beta	POS	O
estradiol	POS	O
,	POS	O
was	POS	O
increased	POS	O
only	POS	O
over	POS	O
the	POS	O
nuclei	POS	O
of	POS	O
tumor	POS	B-NP
cells	POS	O
;	POS	O
stereologic	POS	O
analysis	POS	O
revealed	POS	O
a	POS	O
4	POS	O
.	POS	O
5	POS	O
-	POS	O
to	POS	O
6	POS	O
.	POS	O
7	POS	O
-	POS	O
times	POS	O
higher	POS	O
concentration	POS	O
of	POS	O
reduced	POS	O
silver	POS	O
grains	POS	O
over	POS	O
nuclei	POS	O
than	POS	O
cytoplasm	POS	O
of	POS	O
these	POS	O
cells	POS	O
.	POS	O
Despite	POS	O
rapid	POS	O
tubular	POS	O
excretion	POS	O
of	POS	O
estradiol	POS	O
which	POS	O
peaked	POS	O
in	POS	O
less	POS	O
than	POS	O
1	POS	O
h	POS	O
,	POS	O
the	POS	O
normal	POS	O
cells	POS	O
did	POS	O
not	POS	O
appear	POS	O
to	POS	O
bind	POS	O
the	POS	O
ligand	POS	O
.	POS	O
This	POS	O
is	POS	O
the	POS	O
first	POS	O
published	POS	O
report	POS	O
documenting	POS	O
the	POS	O
preferential	POS	O
in	POS	O
vivo	POS	O
binding	POS	O
of	POS	O
estrogen	POS	O
to	POS	O
nuclei	POS	O
of	POS	O
cells	POS	O
in	POS	O
estrogen	POS	O
induced	POS	O
hamster	POS	O
renal	POS	O
carcinomas	POS	B-NP
.	POS	O
Bradycardia	POS	B-NP
due	POS	O
to	POS	O
biperiden	POS	O
.	POS	O
In	POS	O
a	POS	O
38	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
patient	POS	O
suffering	POS	O
from	POS	O
a	POS	O
severe	POS	O
postzosteric	POS	O
trigeminal	POS	B-NP
neuralgia	POS	I-NP
,	POS	O
intravenous	POS	O
application	POS	O
of	POS	O
10	POS	O
mg	POS	O
biperiden	POS	O
lactate	POS	O
led	POS	O
to	POS	O
a	POS	O
long	POS	O
-	POS	O
lasting	POS	O
paradoxical	POS	O
reaction	POS	O
characterized	POS	O
by	POS	O
considerable	POS	O
bradycardia	POS	B-NP
,	POS	O
dysarthria	POS	B-NP
,	POS	O
and	POS	O
dysphagia	POS	B-NP
.	POS	O
The	POS	O
heart	POS	O
rate	POS	O
was	POS	O
back	POS	O
to	POS	O
normal	POS	O
within	POS	O
12	POS	O
hours	POS	O
upon	POS	O
administration	POS	O
of	POS	O
orciprenaline	POS	O
under	POS	O
cardiac	POS	O
monitoring	POS	O
in	POS	O
an	POS	O
intensive	POS	O
care	POS	O
unit	POS	O
.	POS	O
Bradycardia	POS	B-NP
induced	POS	O
by	POS	O
biperiden	POS	O
is	POS	O
attributed	POS	O
to	POS	O
the	POS	O
speed	POS	O
of	POS	O
injection	POS	O
and	POS	O
to	POS	O
a	POS	O
dose	POS	O
-	POS	O
related	POS	O
dual	POS	O
effect	POS	O
of	POS	O
atropine	POS	O
-	POS	O
like	POS	O
drugs	POS	O
on	POS	O
muscarine	POS	O
receptors	POS	O
.	POS	O
Deliberate	POS	O
hypotension	POS	B-NP
induced	POS	O
by	POS	O
labetalol	POS	O
with	POS	O
halothane	POS	O
,	POS	O
enflurane	POS	O
or	POS	O
isoflurane	POS	O
for	POS	O
middle	POS	O
-	POS	O
ear	POS	O
surgery	POS	O
.	POS	O
The	POS	O
feasibility	POS	O
of	POS	O
using	POS	O
labetalol	POS	O
,	POS	O
an	POS	O
alpha	POS	O
-	POS	O
and	POS	O
beta	POS	O
-	POS	O
adrenergic	POS	O
blocking	POS	O
agent	POS	O
,	POS	O
as	POS	O
a	POS	O
hypotensive	POS	B-NP
agent	POS	O
in	POS	O
combination	POS	O
with	POS	O
inhalation	POS	O
anaesthetics	POS	O
(	POS	O
halothane	POS	O
,	POS	O
enflurane	POS	O
or	POS	O
isoflurane	POS	O
)	POS	O
was	POS	O
studied	POS	O
in	POS	O
23	POS	O
adult	POS	O
patients	POS	O
undergoing	POS	O
middle	POS	O
-	POS	O
ear	POS	O
surgery	POS	O
.	POS	O
The	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
was	POS	O
decreased	POS	O
from	POS	O
86	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
(	POS	O
s	POS	O
.	POS	O
e	POS	O
.	POS	O
mean	POS	O
)	POS	O
mmHg	POS	O
to	POS	O
52	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
mmHg	POS	O
(	POS	O
11	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
to	POS	O
6	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
1	POS	O
kPa	POS	O
)	POS	O
for	POS	O
98	POS	O
+	POS	O
/	POS	O
-	POS	O
10	POS	O
min	POS	O
in	POS	O
the	POS	O
halothane	POS	O
(	POS	O
H	POS	O
)	POS	O
group	POS	O
,	POS	O
from	POS	O
79	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
to	POS	O
53	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
mmHg	POS	O
(	POS	O
10	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
to	POS	O
7	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
1	POS	O
kPa	POS	O
)	POS	O
for	POS	O
129	POS	O
+	POS	O
/	POS	O
-	POS	O
11	POS	O
min	POS	O
in	POS	O
the	POS	O
enflurane	POS	O
(	POS	O
E	POS	O
)	POS	O
group	POS	O
,	POS	O
and	POS	O
from	POS	O
80	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
to	POS	O
49	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
mmHg	POS	O
(	POS	O
10	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
5	POS	O
to	POS	O
6	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
1	POS	O
kPa	POS	O
)	POS	O
for	POS	O
135	POS	O
+	POS	O
/	POS	O
-	POS	O
15	POS	O
min	POS	O
in	POS	O
the	POS	O
isoflurane	POS	O
(	POS	O
I	POS	O
)	POS	O
group	POS	O
.	POS	O
The	POS	O
mean	POS	O
H	POS	O
concentration	POS	O
during	POS	O
hypotension	POS	B-NP
in	POS	O
the	POS	O
inspiratory	POS	O
gas	POS	O
was	POS	O
0	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
1	POS	O
vol	POS	O
%	POS	O
,	POS	O
the	POS	O
mean	POS	O
E	POS	O
concentration	POS	O
1	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
2	POS	O
vol	POS	O
%	POS	O
,	POS	O
and	POS	O
the	POS	O
mean	POS	O
I	POS	O
concentration	POS	O
1	POS	O
.	POS	O
0	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
1	POS	O
vol	POS	O
%	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
the	POS	O
patients	POS	O
received	POS	O
fentanyl	POS	O
and	POS	O
d	POS	O
-	POS	O
tubocurarine	POS	O
.	POS	O
The	POS	O
initial	POS	O
dose	POS	O
of	POS	O
labetalol	POS	O
for	POS	O
lowering	POS	O
blood	POS	O
pressure	POS	O
was	POS	O
similar	POS	O
,	POS	O
0	POS	O
.	POS	O
52	POS	O
-	POS	O
0	POS	O
.	POS	O
59	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
in	POS	O
all	POS	O
the	POS	O
groups	POS	O
.	POS	O
During	POS	O
hypotension	POS	B-NP
,	POS	O
the	POS	O
heart	POS	O
rate	POS	O
was	POS	O
stable	POS	O
without	POS	O
tachy	POS	O
-	POS	O
or	POS	O
bradycardia	POS	B-NP
.	POS	O
The	POS	O
operating	POS	O
conditions	POS	O
regarding	POS	O
bleeding	POS	B-NP
were	POS	O
estimated	POS	O
in	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
manner	POS	O
,	POS	O
and	POS	O
did	POS	O
not	POS	O
differ	POS	O
significantly	POS	O
between	POS	O
the	POS	O
groups	POS	O
.	POS	O
During	POS	O
hypotension	POS	B-NP
,	POS	O
the	POS	O
serum	POS	O
creatinine	POS	O
concentration	POS	O
rose	POS	O
significantly	POS	O
in	POS	O
all	POS	O
groups	POS	O
from	POS	O
the	POS	O
values	POS	O
before	POS	O
hypotension	POS	B-NP
and	POS	O
returned	POS	O
postoperatively	POS	O
to	POS	O
the	POS	O
initial	POS	O
level	POS	O
in	POS	O
the	POS	O
other	POS	O
groups	POS	O
,	POS	O
except	POS	O
the	POS	O
isoflurane	POS	O
group	POS	O
.	POS	O
After	POS	O
hypotension	POS	B-NP
there	POS	O
was	POS	O
no	POS	O
rebound	POS	O
phenomenon	POS	O
in	POS	O
either	POS	O
blood	POS	O
pressure	POS	O
or	POS	O
heart	POS	O
rate	POS	O
.	POS	O
These	POS	O
results	POS	O
indicate	POS	O
that	POS	O
labetalol	POS	O
induces	POS	O
easily	POS	O
adjustable	POS	O
hypotension	POS	B-NP
without	POS	O
compensatory	POS	O
tachycardia	POS	B-NP
and	POS	O
rebound	POS	O
hypertension	POS	B-NP
.	POS	O
Convulsion	POS	B-NP
following	POS	O
intravenous	POS	O
fluorescein	POS	O
angiography	POS	O
.	POS	O
Tonic	POS	O
-	POS	O
clonic	POS	O
seizures	POS	B-NP
followed	POS	O
intravenous	POS	O
fluorescein	POS	O
injection	POS	O
for	POS	O
fundus	POS	O
angiography	POS	O
in	POS	O
a	POS	O
47	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
male	POS	O
.	POS	O
Despite	POS	O
precautions	POS	O
this	POS	O
adverse	POS	O
reaction	POS	O
recurred	POS	O
on	POS	O
re	POS	O
-	POS	O
exposure	POS	O
to	POS	O
intravenous	POS	O
fluorescein	POS	O
.	POS	O
Pharmacology	POS	O
of	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
(	POS	O
phenytoin	POS	O
prodrug	POS	O
)	POS	O
.	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
,	POS	O
the	POS	O
disodium	POS	O
phosphate	POS	O
ester	POS	O
of	POS	O
3	POS	O
-	POS	O
hydroxymethyl	POS	O
-	POS	O
5	POS	O
,	POS	O
5	POS	O
-	POS	O
diphenylhydantoin	POS	O
,	POS	O
is	POS	O
a	POS	O
prodrug	POS	O
of	POS	O
phenytoin	POS	O
with	POS	O
advantageous	POS	O
physicochemical	POS	O
properties	POS	O
.	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
is	POS	O
rapidly	POS	O
converted	POS	O
enzymatically	POS	O
to	POS	O
phenytoin	POS	O
in	POS	O
vivo	POS	O
.	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
and	POS	O
phenytoin	POS	O
sodium	POS	O
have	POS	O
equivalent	POS	O
anticonvulsant	POS	O
activity	POS	O
against	POS	O
seizures	POS	B-NP
induced	POS	O
by	POS	O
maximal	POS	O
electroshock	POS	O
(	POS	O
MES	POS	O
)	POS	O
in	POS	O
mice	POS	O
following	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
,	POS	O
oral	POS	O
,	POS	O
or	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
administration	POS	O
.	POS	O
The	POS	O
ED50	POS	O
doses	POS	O
were	POS	O
16	POS	O
mg	POS	O
/	POS	O
kg	POS	O
for	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
and	POS	O
8	POS	O
mg	POS	O
/	POS	O
kg	POS	O
for	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
phenytoin	POS	O
sodium	POS	O
.	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
and	POS	O
phenytoin	POS	O
sodium	POS	O
have	POS	O
similar	POS	O
antiarrhythmic	POS	O
activity	POS	O
against	POS	O
ouabain	POS	O
-	POS	O
induced	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
in	POS	O
anesthetized	POS	O
dogs	POS	O
.	POS	O
The	POS	O
total	POS	O
doses	POS	O
of	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
or	POS	O
phenytoin	POS	O
sodium	POS	O
necessary	POS	O
to	POS	O
convert	POS	O
the	POS	O
arrhythmia	POS	B-NP
to	POS	O
a	POS	O
normal	POS	O
sinus	POS	O
rhythm	POS	O
were	POS	O
24	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
and	POS	O
14	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Only	POS	O
phenytoin	POS	O
sodium	POS	O
displayed	POS	O
in	POS	O
vitro	POS	O
antiarrhythmic	POS	O
activity	POS	O
against	POS	O
strophanthidin	POS	O
-	POS	O
induced	POS	O
arrhythmias	POS	B-NP
in	POS	O
guinea	POS	O
pig	POS	O
right	POS	O
atria	POS	O
.	POS	O
In	POS	O
anesthetized	POS	O
dogs	POS	O
,	POS	O
a	POS	O
high	POS	O
dose	POS	O
of	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
(	POS	O
31	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
was	POS	O
infused	POS	O
over	POS	O
15	POS	O
,	POS	O
20	POS	O
,	POS	O
and	POS	O
30	POS	O
min	POS	O
and	POS	O
the	POS	O
responses	POS	O
were	POS	O
compared	POS	O
to	POS	O
an	POS	O
equimolar	POS	O
dose	POS	O
of	POS	O
phenytoin	POS	O
sodium	POS	O
(	POS	O
21	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
.	POS	O
The	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
and	POS	O
phenytoin	POS	O
sodium	POS	O
treatments	POS	O
produced	POS	O
similar	POS	O
marked	POS	O
reductions	POS	O
in	POS	O
diastolic	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
contractile	POS	O
force	POS	O
(	POS	O
LVdP	POS	O
/	POS	O
dt	POS	O
)	POS	O
.	POS	O
The	POS	O
maximum	POS	O
effects	POS	O
of	POS	O
each	POS	O
treatment	POS	O
occurred	POS	O
at	POS	O
the	POS	O
time	POS	O
of	POS	O
maximum	POS	O
phenytoin	POS	O
sodium	POS	O
levels	POS	O
.	POS	O
Acute	POS	B-NP
toxicity	POS	I-NP
studies	POS	O
of	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
and	POS	O
phenytoin	POS	O
sodium	POS	O
were	POS	O
carried	POS	O
out	POS	O
in	POS	O
mice	POS	O
,	POS	O
rats	POS	O
,	POS	O
rabbits	POS	O
,	POS	O
and	POS	O
dogs	POS	O
by	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
,	POS	O
i	POS	O
.	POS	O
m	POS	O
.	POS	O
,	POS	O
and	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
routes	POS	O
of	POS	O
administration	POS	O
.	POS	O
The	POS	O
systemic	POS	O
toxic	POS	O
signs	POS	O
of	POS	O
both	POS	O
agents	POS	O
were	POS	O
similar	POS	O
and	POS	O
occurred	POS	O
at	POS	O
approximately	POS	O
equivalent	POS	O
doses	POS	O
.	POS	O
Importantly	POS	O
,	POS	O
the	POS	O
local	POS	O
irritation	POS	O
of	POS	O
ACC	POS	O
-	POS	O
9653	POS	O
was	POS	O
markedly	POS	O
less	POS	O
than	POS	O
phenytoin	POS	O
sodium	POS	O
following	POS	O
i	POS	O
.	POS	O
m	POS	O
.	POS	O
administration	POS	O
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
250	POS	O
WORDS	POS	O
)	POS	O
Tachyphylaxis	POS	O
to	POS	O
systemic	POS	O
but	POS	O
not	POS	O
to	POS	O
airway	POS	O
responses	POS	O
during	POS	O
prolonged	POS	O
therapy	POS	O
with	POS	O
high	POS	O
dose	POS	O
inhaled	POS	O
salbutamol	POS	O
in	POS	O
asthmatics	POS	O
.	POS	O
High	POS	O
doses	POS	O
of	POS	O
inhaled	POS	O
salbutamol	POS	O
produce	POS	O
substantial	POS	O
improvements	POS	O
in	POS	O
airway	POS	O
response	POS	O
in	POS	O
patients	POS	O
with	POS	O
asthma	POS	B-NP
,	POS	O
and	POS	O
are	POS	O
associated	POS	O
with	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
systemic	POS	O
beta	POS	O
-	POS	O
adrenoceptor	POS	O
responses	POS	O
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
investigate	POS	O
whether	POS	O
tachyphylaxis	POS	B-NP
occurs	POS	O
during	POS	O
prolonged	POS	O
treatment	POS	O
with	POS	O
high	POS	O
dose	POS	O
inhaled	POS	O
salbutamol	POS	O
.	POS	O
Twelve	POS	O
asthmatic	POS	B-NP
patients	POS	O
(	POS	O
FEV1	POS	O
,	POS	O
81	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
%	POS	O
predicted	POS	O
)	POS	O
,	POS	O
requiring	POS	O
only	POS	O
occasional	POS	O
inhaled	POS	O
beta	POS	O
-	POS	O
agonists	POS	O
as	POS	O
their	POS	O
sole	POS	O
therapy	POS	O
,	POS	O
were	POS	O
given	POS	O
a	POS	O
14	POS	O
-	POS	O
day	POS	O
treatment	POS	O
with	POS	O
high	POS	O
dose	POS	O
inhaled	POS	O
salbutamol	POS	O
(	POS	O
HDS	POS	O
)	POS	O
,	POS	O
4	POS	O
,	POS	O
000	POS	O
micrograms	POS	O
daily	POS	O
,	POS	O
low	POS	O
dose	POS	O
inhaled	POS	O
salbutamol	POS	O
(	POS	O
LDS	POS	O
)	POS	O
,	POS	O
800	POS	O
micrograms	POS	O
daily	POS	O
,	POS	O
or	POS	O
placebo	POS	O
(	POS	O
PI	POS	O
)	POS	O
by	POS	O
metered	POS	O
-	POS	O
dose	POS	O
inhaler	POS	O
in	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
randomized	POS	O
crossover	POS	O
design	POS	O
.	POS	O
During	POS	O
the	POS	O
14	POS	O
-	POS	O
day	POS	O
run	POS	O
-	POS	O
in	POS	O
and	POS	O
during	POS	O
washout	POS	O
periods	POS	O
,	POS	O
inhaled	POS	O
beta	POS	O
-	POS	O
agonists	POS	O
were	POS	O
withheld	POS	O
and	POS	O
ipratropium	POS	O
bromide	POS	O
was	POS	O
substituted	POS	O
for	POS	O
rescue	POS	O
purposes	POS	O
.	POS	O
At	POS	O
the	POS	O
end	POS	O
of	POS	O
each	POS	O
14	POS	O
-	POS	O
day	POS	O
treatment	POS	O
,	POS	O
a	POS	O
dose	POS	O
-	POS	O
response	POS	O
curve	POS	O
(	POS	O
DRC	POS	O
)	POS	O
was	POS	O
performed	POS	O
,	POS	O
and	POS	O
airway	POS	O
(	POS	O
FEV1	POS	O
,	POS	O
FEF25	POS	O
-	POS	O
75	POS	O
)	POS	O
chronotropic	POS	O
(	POS	O
HR	POS	O
)	POS	O
,	POS	O
tremor	POS	B-NP
,	POS	O
and	POS	O
metabolic	POS	O
(	POS	O
K	POS	O
,	POS	O
Glu	POS	O
)	POS	O
responses	POS	O
were	POS	O
measured	POS	O
at	POS	O
each	POS	O
step	POS	O
(	POS	O
from	POS	O
100	POS	O
to	POS	O
4	POS	O
,	POS	O
000	POS	O
micrograms	POS	O
)	POS	O
.	POS	O
Treatment	POS	O
had	POS	O
no	POS	O
significant	POS	O
effect	POS	O
on	POS	O
baseline	POS	O
values	POS	O
.	POS	O
There	POS	O
were	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
increases	POS	O
in	POS	O
FEV1	POS	O
and	POS	O
FEF25	POS	O
-	POS	O
75	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
and	POS	O
pretreatment	POS	O
with	POS	O
HDS	POS	O
did	POS	O
not	POS	O
displace	POS	O
the	POS	O
DRC	POS	O
to	POS	O
the	POS	O
right	POS	O
.	POS	O
DRC	POS	O
for	POS	O
HR	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
K	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
and	POS	O
Glu	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
005	POS	O
)	POS	O
were	POS	O
attenuated	POS	O
after	POS	O
treatment	POS	O
with	POS	O
HDS	POS	B-NP
compared	POS	O
with	POS	O
PI	POS	O
.	POS	O
There	POS	O
were	POS	O
also	POS	O
differences	POS	O
between	POS	O
HDS	POS	O
and	POS	O
LDS	POS	O
for	POS	O
HR	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
and	POS	O
Glu	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
responses	POS	O
.	POS	O
Frequency	POS	O
and	POS	O
severity	POS	O
of	POS	O
subjective	POS	O
adverse	POS	O
effects	POS	O
were	POS	O
also	POS	O
reduced	POS	O
after	POS	O
HDS	POS	B-NP
:	POS	O
tremor	POS	B-NP
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
palpitations	POS	B-NP
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
250	POS	O
WORDS	POS	O
)	POS	O
Phenytoin	POS	O
induced	POS	O
fatal	POS	O
hepatic	POS	B-NP
injury	POS	I-NP
.	POS	O
A	POS	O
61	POS	O
year	POS	O
old	POS	O
female	POS	O
developed	POS	O
fatal	POS	O
hepatic	POS	B-NP
failure	POS	I-NP
after	POS	O
phenytoin	POS	O
administration	POS	O
.	POS	O
A	POS	O
typical	POS	O
multisystem	POS	O
clinical	POS	O
pattern	POS	O
precedes	POS	O
the	POS	O
manifestations	POS	O
of	POS	O
hepatic	POS	B-NP
injury	POS	I-NP
.	POS	O
The	POS	O
hematologic	POS	O
,	POS	O
biochemical	POS	O
and	POS	O
pathologic	POS	O
features	POS	O
indicate	POS	O
a	POS	O
mixed	POS	O
hepatocellular	POS	B-NP
damage	POS	I-NP
due	POS	O
to	POS	O
drug	POS	O
hypersensitivity	POS	B-NP
.	POS	O
In	POS	O
a	POS	O
patient	POS	O
receiving	POS	O
phenytoin	POS	O
who	POS	O
presents	POS	O
a	POS	O
viral	POS	B-NP
-	POS	I-NP
like	POS	I-NP
illness	POS	I-NP
,	POS	O
early	POS	O
recognition	POS	O
and	POS	O
discontinuation	POS	O
of	POS	O
the	POS	O
drug	POS	O
are	POS	O
mandatory	POS	O
.	POS	O
Treatment	POS	O
of	POS	O
lethal	POS	O
pertussis	POS	O
vaccine	POS	O
reaction	POS	O
with	POS	O
histamine	POS	O
H1	POS	O
antagonists	POS	O
.	POS	O
We	POS	O
studied	POS	O
mortality	POS	O
after	POS	O
pertussis	POS	O
immunization	POS	O
in	POS	O
the	POS	O
mouse	POS	O
.	POS	O
Without	POS	O
treatment	POS	O
,	POS	O
73	POS	O
of	POS	O
92	POS	O
animals	POS	O
(	POS	O
80	POS	O
%	POS	O
)	POS	O
died	POS	O
after	POS	O
injection	POS	O
of	POS	O
bovine	POS	O
serum	POS	O
albumin	POS	O
(	POS	O
BSA	POS	O
)	POS	O
on	POS	O
day	POS	O
+	POS	O
7	POS	O
of	POS	O
pertussis	POS	O
immunization	POS	O
.	POS	O
After	POS	O
pretreatment	POS	O
with	POS	O
3	POS	O
mg	POS	O
of	POS	O
cyproheptadine	POS	O
,	POS	O
2	POS	O
mg	POS	O
mianserin	POS	O
,	POS	O
or	POS	O
2	POS	O
mg	POS	O
chlorpheniramine	POS	O
,	POS	O
only	POS	O
5	POS	O
of	POS	O
105	POS	O
animals	POS	O
(	POS	O
5	POS	O
%	POS	O
)	POS	O
died	POS	O
after	POS	O
receiving	POS	O
BSA	POS	O
on	POS	O
day	POS	O
+	POS	O
7	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Blockade	POS	O
of	POS	O
histamine	POS	O
H1	POS	O
receptors	POS	O
may	POS	O
reduce	POS	O
mortality	POS	O
in	POS	O
pertussis	POS	O
immunization	POS	O
-	POS	O
induced	POS	O
encephalopathy	POS	B-NP
in	POS	O
mice	POS	O
.	POS	O
Support	POS	O
for	POS	O
adrenaline	POS	O
-	POS	O
hypertension	POS	B-NP
hypothesis	POS	O
:	POS	O
18	POS	O
hour	POS	O
pressor	POS	O
effect	POS	O
after	POS	O
6	POS	O
hours	POS	O
adrenaline	POS	O
infusion	POS	O
.	POS	O
In	POS	O
a	POS	O
double	POS	O
blind	POS	O
,	POS	O
crossover	POS	O
study	POS	O
6	POS	O
h	POS	O
infusions	POS	O
of	POS	O
adrenaline	POS	O
(	POS	O
15	POS	O
ng	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
;	POS	O
1	POS	O
ng	POS	O
=	POS	O
5	POS	O
.	POS	O
458	POS	O
pmol	POS	O
)	POS	O
,	POS	O
noradrenaline	POS	O
(	POS	O
30	POS	O
ng	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
;	POS	O
1	POS	O
ng	POS	O
=	POS	O
5	POS	O
.	POS	O
911	POS	O
pmol	POS	O
)	POS	O
,	POS	O
and	POS	O
a	POS	O
5	POS	O
%	POS	O
dextrose	POS	O
solution	POS	O
(	POS	O
5	POS	O
.	POS	O
4	POS	O
ml	POS	O
/	POS	O
h	POS	O
)	POS	O
,	POS	O
were	POS	O
given	POS	O
to	POS	O
ten	POS	O
healthy	POS	O
volunteers	POS	O
in	POS	O
random	POS	O
order	POS	O
2	POS	O
weeks	POS	O
apart	POS	O
.	POS	O
By	POS	O
means	POS	O
of	POS	O
intra	POS	O
-	POS	O
arterial	POS	O
ambulatory	POS	O
monitoring	POS	O
the	POS	O
haemodynamic	POS	O
effects	POS	O
were	POS	O
followed	POS	O
for	POS	O
18	POS	O
h	POS	O
after	POS	O
the	POS	O
infusions	POS	O
were	POS	O
stopped	POS	O
.	POS	O
Adrenaline	POS	O
,	POS	O
but	POS	O
not	POS	O
noradrenaline	POS	O
,	POS	O
caused	POS	O
a	POS	O
delayed	POS	O
and	POS	O
protracted	POS	O
pressor	POS	O
effect	POS	O
.	POS	O
Over	POS	O
the	POS	O
total	POS	O
postinfusion	POS	O
period	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
arterial	POS	O
pressure	POS	O
were	POS	O
6	POS	O
(	POS	O
SEM	POS	O
2	POS	O
)	POS	O
%	POS	O
and	POS	O
7	POS	O
(	POS	O
2	POS	O
)	POS	O
%	POS	O
,	POS	O
respectively	POS	O
,	POS	O
higher	POS	O
than	POS	O
after	POS	O
dextrose	POS	O
infusion	POS	O
(	POS	O
ANOVA	POS	O
,	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
.	POS	O
Thus	POS	O
,	POS	O
"	POS	O
stress	POS	O
"	POS	O
levels	POS	O
of	POS	O
adrenaline	POS	O
(	POS	O
230	POS	O
pg	POS	O
/	POS	O
ml	POS	O
)	POS	O
for	POS	O
6	POS	O
h	POS	O
cause	POS	O
a	POS	O
delayed	POS	O
and	POS	O
protracted	POS	O
pressor	POS	O
effect	POS	O
.	POS	O
These	POS	O
findings	POS	O
are	POS	O
strong	POS	O
support	POS	O
for	POS	O
the	POS	O
adrenaline	POS	O
-	POS	O
hypertension	POS	B-NP
hypothesis	POS	O
in	POS	O
man	POS	O
.	POS	O
Effect	POS	O
of	POS	O
alkylxanthines	POS	O
on	POS	O
gentamicin	POS	O
-	POS	O
induced	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
Adenosine	POS	O
antagonists	POS	O
have	POS	O
been	POS	O
previously	POS	O
shown	POS	O
to	POS	O
be	POS	O
of	POS	O
benefit	POS	O
in	POS	O
some	POS	O
ischaemic	POS	B-NP
and	POS	O
nephrotoxic	POS	B-NP
models	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
(	POS	O
ARF	POS	B-NP
)	POS	O
.	POS	O
In	POS	O
the	POS	O
present	POS	O
study	POS	O
,	POS	O
the	POS	O
effects	POS	O
of	POS	O
three	POS	O
alkylxanthines	POS	O
with	POS	O
different	POS	O
potencies	POS	O
as	POS	O
adenosine	POS	O
antagonists	POS	O
8	POS	O
-	POS	O
phenyltheophylline	POS	O
,	POS	O
theophylline	POS	O
and	POS	O
enprofylline	POS	O
,	POS	O
were	POS	O
examined	POS	O
in	POS	O
rats	POS	O
developing	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
after	POS	O
4	POS	O
daily	POS	O
injections	POS	O
of	POS	O
gentamicin	POS	O
(	POS	O
200	POS	O
mg	POS	O
kg	POS	O
-	POS	O
1	POS	O
)	POS	O
.	POS	O
Renal	POS	O
function	POS	O
was	POS	O
assessed	POS	O
by	POS	O
biochemical	POS	O
(	POS	O
plasma	POS	O
urea	POS	O
and	POS	O
creatinine	POS	O
)	POS	O
,	POS	O
functional	POS	O
(	POS	O
urine	POS	O
analysis	POS	O
and	POS	O
[	POS	O
3H	POS	O
]	POS	O
inulin	POS	O
and	POS	O
[	POS	O
14C	POS	O
]	POS	O
p	POS	O
-	POS	O
aminohippuric	POS	O
acid	POS	O
clearances	POS	O
)	POS	O
and	POS	O
morphological	POS	O
(	POS	O
degree	POS	O
of	POS	O
necrosis	POS	B-NP
)	POS	O
indices	POS	O
.	POS	O
The	POS	O
various	POS	O
drug	POS	O
treatments	POS	O
produced	POS	O
improvements	POS	O
in	POS	O
some	POS	O
,	POS	O
but	POS	O
not	POS	O
all	POS	O
,	POS	O
measurements	POS	O
of	POS	O
renal	POS	O
function	POS	O
.	POS	O
However	POS	O
,	POS	O
any	POS	O
improvement	POS	O
produced	POS	O
by	POS	O
drug	POS	O
treatment	POS	O
was	POS	O
largely	POS	O
a	POS	O
result	POS	O
of	POS	O
a	POS	O
beneficial	POS	O
effect	POS	O
exerted	POS	O
by	POS	O
its	POS	O
vehicle	POS	O
(	POS	O
polyethylene	POS	O
glycol	POS	O
and	POS	O
NaOH	POS	O
)	POS	O
.	POS	O
The	POS	O
lack	POS	O
of	POS	O
any	POS	O
consistent	POS	O
protective	POS	O
effect	POS	O
noted	POS	O
with	POS	O
the	POS	O
alkylxanthines	POS	O
tested	POS	O
in	POS	O
the	POS	O
present	POS	O
study	POS	O
indicates	POS	O
that	POS	O
adenosine	POS	O
plays	POS	O
little	POS	O
,	POS	O
if	POS	O
any	POS	O
,	POS	O
pathophysiological	POS	O
role	POS	O
in	POS	O
gentamicin	POS	O
-	POS	O
induced	POS	O
ARF	POS	B-NP
.	POS	O
Adverse	POS	O
ocular	POS	O
reactions	POS	O
possibly	POS	O
associated	POS	O
with	POS	O
isotretinoin	POS	O
.	POS	O
A	POS	O
total	POS	O
of	POS	O
261	POS	O
adverse	POS	O
ocular	POS	B-NP
reactions	POS	I-NP
occurred	POS	O
in	POS	O
237	POS	O
patients	POS	O
who	POS	O
received	POS	O
isotretinoin	POS	O
,	POS	O
a	POS	O
commonly	POS	O
used	POS	O
drug	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
severe	POS	O
cystic	POS	B-NP
acne	POS	I-NP
.	POS	O
Blepharoconjunctivitis	POS	B-NP
,	POS	O
subjective	POS	O
complaints	POS	O
of	POS	O
dry	POS	B-NP
eyes	POS	I-NP
,	POS	O
blurred	POS	B-NP
vision	POS	I-NP
,	POS	O
contact	POS	B-NP
lens	POS	I-NP
intolerance	POS	I-NP
,	POS	O
and	POS	O
photodermatitis	POS	B-NP
are	POS	O
reversible	POS	O
side	POS	O
effects	POS	O
.	POS	O
More	POS	O
serious	POS	O
ocular	POS	O
adverse	POS	O
reactions	POS	O
include	POS	O
papilledema	POS	B-NP
,	POS	O
pseudotumor	POS	B-NP
cerebri	POS	I-NP
,	POS	O
and	POS	O
white	POS	O
or	POS	O
gray	POS	O
subepithelial	POS	O
corneal	POS	O
opacities	POS	O
;	POS	O
all	POS	O
of	POS	O
these	POS	O
are	POS	O
reversible	POS	O
if	POS	O
the	POS	O
drug	POS	O
is	POS	O
discontinued	POS	O
.	POS	O
Reported	POS	O
cases	POS	O
of	POS	O
decreased	POS	O
dark	POS	O
adaptation	POS	O
are	POS	O
under	POS	O
investigation	POS	O
.	POS	O
Isotretinoin	POS	O
is	POS	O
contraindicated	POS	O
in	POS	O
pregnancy	POS	O
because	POS	O
of	POS	O
the	POS	O
many	POS	O
reported	POS	O
congenital	POS	B-NP
abnormalities	POS	I-NP
after	POS	O
maternal	POS	O
use	POS	O
(	POS	O
including	POS	O
microphthalmos	POS	B-NP
,	POS	O
orbital	POS	B-NP
hypertelorism	POS	I-NP
,	POS	O
and	POS	O
optic	POS	B-NP
nerve	POS	I-NP
hypoplasia	POS	I-NP
)	POS	O
.	POS	O
Procaterol	POS	O
and	POS	O
terbutaline	POS	O
in	POS	O
bronchial	POS	B-NP
asthma	POS	I-NP
.	POS	O
A	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
,	POS	O
cross	POS	O
-	POS	O
over	POS	O
study	POS	O
.	POS	O
Procaterol	POS	O
,	POS	O
a	POS	O
new	POS	O
beta	POS	O
-	POS	O
2	POS	O
adrenoceptor	POS	O
stimulant	POS	O
,	POS	O
was	POS	O
studied	POS	O
in	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
,	POS	O
cross	POS	O
-	POS	O
over	POS	O
trial	POS	O
in	POS	O
patients	POS	O
with	POS	O
bronchial	POS	B-NP
asthma	POS	I-NP
.	POS	O
Oral	POS	O
procaterol	POS	O
50	POS	O
micrograms	POS	O
b	POS	O
.	POS	O
d	POS	O
.	POS	O
,	POS	O
procaterol	POS	O
100	POS	O
micrograms	POS	O
b	POS	O
.	POS	O
d	POS	O
.	POS	O
,	POS	O
and	POS	O
terbutaline	POS	O
5	POS	O
mg	POS	O
t	POS	O
.	POS	O
i	POS	O
.	POS	O
d	POS	O
.	POS	O
,	POS	O
were	POS	O
compared	POS	O
when	POS	O
given	POS	O
randomly	POS	O
in	POS	O
1	POS	O
-	POS	O
week	POS	O
treatment	POS	O
periods	POS	O
.	POS	O
The	POS	O
best	POS	O
clinical	POS	O
effect	POS	O
was	POS	O
found	POS	O
with	POS	O
terbutaline	POS	O
.	POS	O
Both	POS	O
anti	POS	O
-	POS	O
asthmatic	POS	O
and	POS	O
tremorgenic	POS	O
effects	POS	O
of	POS	O
procaterol	POS	O
were	POS	O
dose	POS	O
-	POS	O
related	POS	O
.	POS	O
Procaterol	POS	O
appeared	POS	O
effective	POS	O
in	POS	O
the	POS	O
doses	POS	O
tested	POS	O
,	POS	O
and	POS	O
a	POS	O
twice	POS	O
daily	POS	O
regimen	POS	O
would	POS	O
appear	POS	O
to	POS	O
be	POS	O
suitable	POS	O
with	POS	O
this	POS	O
drug	POS	O
.	POS	O
Subacute	POS	O
effects	POS	O
of	POS	O
propranolol	POS	O
and	POS	O
B	POS	O
24	POS	O
/	POS	O
76	POS	O
on	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
rat	POS	O
heart	POS	B-NP
hypertrophy	POS	I-NP
in	POS	O
correlation	POS	O
with	POS	O
blood	POS	O
pressure	POS	O
.	POS	O
We	POS	O
compared	POS	O
the	POS	O
potential	POS	O
beta	POS	O
-	POS	O
receptor	POS	O
blocker	POS	O
,	POS	O
B	POS	O
24	POS	O
/	POS	O
76	POS	O
i	POS	O
.	POS	O
e	POS	O
.	POS	O
1	POS	O
-	POS	O
(	POS	O
2	POS	O
,	POS	O
4	POS	O
-	POS	O
dichlorophenoxy	POS	O
)	POS	O
-	POS	O
3	POS	O
[	POS	O
2	POS	O
-	POS	O
3	POS	O
,	POS	O
4	POS	O
-	POS	O
dimethoxyphenyl	POS	O
)	POS	O
ethanolamino	POS	O
]	POS	O
-	POS	O
prop	POS	O
an	POS	O
-	POS	O
2	POS	O
-	POS	O
ol	POS	O
,	POS	O
which	POS	O
is	POS	O
characterized	POS	O
by	POS	O
beta	POS	O
1	POS	O
-	POS	O
adrenoceptor	POS	O
blocking	POS	O
and	POS	O
beta	POS	O
2	POS	O
-	POS	O
adrenoceptor	POS	O
stimulating	POS	O
properties	POS	O
with	POS	O
propranolol	POS	O
.	POS	O
The	POS	O
studies	POS	O
were	POS	O
performed	POS	O
using	POS	O
an	POS	O
experimental	POS	O
model	POS	O
of	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
heart	POS	B-NP
hypertrophy	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
A	POS	O
correlation	POS	O
of	POS	O
the	POS	O
blood	POS	O
pressure	POS	O
was	POS	O
neither	POS	O
found	POS	O
in	POS	O
the	POS	O
development	POS	O
nor	POS	O
in	POS	O
the	POS	O
attempt	POS	O
to	POS	O
suppress	POS	O
the	POS	O
development	POS	O
of	POS	O
heart	POS	B-NP
hypertrophy	POS	I-NP
with	POS	O
the	POS	O
two	POS	O
beta	POS	O
-	POS	O
receptor	POS	O
blockers	POS	O
.	POS	O
Both	POS	O
beta	POS	O
-	POS	O
blockers	POS	O
influenced	POS	O
the	POS	O
development	POS	O
of	POS	O
hypertrophy	POS	B-NP
to	POS	O
a	POS	O
different	POS	O
,	POS	O
but	POS	O
not	POS	O
reproducible	POS	O
extent	POS	O
.	POS	O
It	POS	O
was	POS	O
possible	POS	O
to	POS	O
suppress	POS	O
the	POS	O
increased	POS	O
ornithine	POS	O
decarboxylase	POS	O
activity	POS	O
with	POS	O
both	POS	O
beta	POS	O
-	POS	O
blockers	POS	O
in	POS	O
hypertrophied	POS	O
hearts	POS	O
,	POS	O
but	POS	O
there	POS	O
was	POS	O
no	POS	O
effect	POS	O
on	POS	O
the	POS	O
heart	POS	O
mass	POS	O
.	POS	O
Neither	POS	O
propranolol	POS	O
nor	POS	O
B	POS	O
24	POS	O
/	POS	O
76	POS	O
could	POS	O
stop	POS	O
the	POS	O
changes	POS	O
in	POS	O
the	POS	O
characteristic	POS	O
myosin	POS	O
isoenzyme	POS	O
pattern	POS	O
of	POS	O
the	POS	O
hypertrophied	POS	O
rat	POS	O
heart	POS	O
.	POS	O
Thus	POS	O
,	POS	O
the	POS	O
investigations	POS	O
did	POS	O
not	POS	O
provide	POS	O
any	POS	O
evidence	POS	O
that	POS	O
the	POS	O
beta	POS	O
-	POS	O
receptor	POS	O
blockers	POS	O
propranolol	POS	O
and	POS	O
B	POS	O
24	POS	O
/	POS	O
76	POS	O
have	POS	O
the	POS	O
potency	POS	O
to	POS	O
prevent	POS	O
isoproterenol	POS	O
from	POS	O
producing	POS	O
heart	POS	B-NP
hypertrophy	POS	I-NP
.	POS	O
Increased	POS	O
anxiogenic	POS	O
effects	POS	O
of	POS	O
caffeine	POS	O
in	POS	O
panic	POS	B-NP
disorders	POS	I-NP
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
oral	POS	O
administration	POS	O
of	POS	O
caffeine	POS	O
(	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
on	POS	O
behavioral	POS	O
ratings	POS	O
,	POS	O
somatic	POS	O
symptoms	POS	O
,	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
plasma	POS	O
levels	POS	O
of	POS	O
3	POS	O
-	POS	O
methoxy	POS	O
-	POS	O
4	POS	O
-	POS	O
hydroxyphenethyleneglycol	POS	O
(	POS	O
MHPG	POS	O
)	POS	O
and	POS	O
cortisol	POS	O
were	POS	O
determined	POS	O
in	POS	O
17	POS	O
healthy	POS	O
subjects	POS	O
and	POS	O
21	POS	O
patients	POS	O
meeting	POS	O
DSM	POS	O
-	POS	O
III	POS	O
criteria	POS	O
for	POS	O
agoraphobia	POS	B-NP
with	POS	O
panic	POS	B-NP
attacks	POS	I-NP
or	POS	O
panic	POS	B-NP
disorder	POS	I-NP
.	POS	O
Caffeine	POS	O
produced	POS	O
significantly	POS	O
greater	POS	O
increases	POS	O
in	POS	O
subject	POS	O
-	POS	O
rated	POS	O
anxiety	POS	B-NP
,	POS	O
nervousness	POS	B-NP
,	POS	O
fear	POS	B-NP
,	POS	O
nausea	POS	B-NP
,	POS	O
palpitations	POS	B-NP
,	POS	O
restlessness	POS	B-NP
,	POS	O
and	POS	O
tremors	POS	B-NP
in	POS	O
the	POS	O
patients	POS	O
compared	POS	O
with	POS	O
healthy	POS	O
subjects	POS	O
.	POS	O
In	POS	O
the	POS	O
patients	POS	O
,	POS	O
but	POS	O
not	POS	O
the	POS	O
healthy	POS	O
subjects	POS	O
,	POS	O
these	POS	O
symptoms	POS	O
were	POS	O
significantly	POS	O
correlated	POS	O
with	POS	O
plasma	POS	O
caffeine	POS	O
levels	POS	O
.	POS	O
Seventy	POS	O
-	POS	O
one	POS	O
percent	POS	O
of	POS	O
the	POS	O
patients	POS	O
reported	POS	O
that	POS	O
the	POS	O
behavioral	POS	O
effects	POS	O
of	POS	O
caffeine	POS	O
were	POS	O
similar	POS	O
to	POS	O
those	POS	O
experienced	POS	O
during	POS	O
panic	POS	B-NP
attacks	POS	I-NP
.	POS	O
Caffeine	POS	O
did	POS	O
not	POS	O
alter	POS	O
plasma	POS	O
MHPG	POS	O
levels	POS	O
in	POS	O
either	POS	O
the	POS	O
healthy	POS	O
subjects	POS	O
or	POS	O
patients	POS	O
.	POS	O
Caffeine	POS	O
increased	POS	O
plasma	POS	O
cortisol	POS	O
levels	POS	O
equally	POS	O
in	POS	O
the	POS	O
patient	POS	O
and	POS	O
healthy	POS	O
groups	POS	O
.	POS	O
Because	POS	O
caffeine	POS	O
is	POS	O
an	POS	O
adenosine	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
these	POS	O
results	POS	O
suggest	POS	O
that	POS	O
some	POS	O
panic	POS	B-NP
disorder	POS	I-NP
patients	POS	O
may	POS	O
have	POS	O
abnormalities	POS	O
in	POS	O
neuronal	POS	O
systems	POS	O
involving	POS	O
adenosine	POS	O
.	POS	O
Patients	POS	O
with	POS	O
anxiety	POS	B-NP
disorders	POS	I-NP
may	POS	O
benefit	POS	O
by	POS	O
avoiding	POS	O
caffeine	POS	O
-	POS	O
containing	POS	O
foods	POS	O
and	POS	O
beverages	POS	O
.	POS	O
Comparison	POS	O
of	POS	O
the	POS	O
effect	POS	O
of	POS	O
oxitropium	POS	O
bromide	POS	O
and	POS	O
of	POS	O
slow	POS	O
-	POS	O
release	POS	O
theophylline	POS	O
on	POS	O
nocturnal	POS	O
asthma	POS	B-NP
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
a	POS	O
new	POS	O
inhaled	POS	O
antimuscarinic	POS	O
drug	POS	O
,	POS	O
oxitropium	POS	O
bromide	POS	O
,	POS	O
and	POS	O
of	POS	O
a	POS	O
slow	POS	O
-	POS	O
release	POS	O
theophylline	POS	O
preparation	POS	O
upon	POS	O
nocturnal	POS	O
asthma	POS	B-NP
were	POS	O
compared	POS	O
in	POS	O
a	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
double	POS	O
-	POS	O
blind	POS	O
study	POS	O
.	POS	O
Two	POS	O
samples	POS	O
were	POS	O
studied	POS	O
:	POS	O
12	POS	O
patients	POS	O
received	POS	O
oxitropium	POS	O
at	POS	O
600	POS	O
micrograms	POS	O
(	POS	O
6	POS	O
subjects	POS	O
)	POS	O
or	POS	O
at	POS	O
400	POS	O
micrograms	POS	O
t	POS	O
.	POS	O
i	POS	O
.	POS	O
d	POS	O
.	POS	O
(	POS	O
6	POS	O
subjects	POS	O
)	POS	O
whereas	POS	O
11	POS	O
received	POS	O
theophylline	POS	O
at	POS	O
300	POS	O
mg	POS	O
b	POS	O
.	POS	O
i	POS	O
.	POS	O
d	POS	O
.	POS	O
Morning	POS	O
dipping	POS	O
,	POS	O
assessed	POS	O
by	POS	O
the	POS	O
fall	POS	O
in	POS	O
peak	POS	O
flow	POS	O
overnight	POS	O
,	POS	O
was	POS	O
significantly	POS	O
reduced	POS	O
in	POS	O
the	POS	O
periods	POS	O
when	POS	O
either	POS	O
active	POS	O
drug	POS	O
was	POS	O
taken	POS	O
,	POS	O
whereas	POS	O
no	POS	O
difference	POS	O
was	POS	O
noticed	POS	O
during	POS	O
the	POS	O
placebo	POS	O
administration	POS	O
.	POS	O
No	POS	O
significant	POS	O
difference	POS	O
was	POS	O
noticed	POS	O
between	POS	O
results	POS	O
obtained	POS	O
with	POS	O
either	POS	O
active	POS	O
drug	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
with	POS	O
either	POS	O
dosage	POS	O
of	POS	O
oxitropium	POS	O
.	POS	O
No	POS	O
subject	POS	O
reported	POS	O
side	POS	O
effects	POS	O
of	POS	O
oxitropium	POS	O
,	POS	O
as	POS	O
compared	POS	O
to	POS	O
three	POS	O
subjects	POS	O
reporting	POS	O
nausea	POS	B-NP
,	POS	O
vomiting	POS	B-NP
and	POS	O
tremors	POS	B-NP
after	POS	O
theophylline	POS	O
.	POS	O
Oxitropium	POS	O
proves	POS	O
to	POS	O
be	POS	O
a	POS	O
valuable	POS	O
alternative	POS	O
to	POS	O
theophylline	POS	O
in	POS	O
nocturnal	POS	B-NP
asthma	POS	I-NP
,	POS	O
since	POS	O
it	POS	O
is	POS	O
equally	POS	O
potent	POS	O
,	POS	O
safer	POS	O
and	POS	O
does	POS	O
not	POS	O
require	POS	O
the	POS	O
titration	POS	O
of	POS	O
dosage	POS	O
.	POS	O
Penicillin	POS	O
anaphylaxis	POS	B-NP
.	POS	O
A	POS	O
case	POS	O
of	POS	O
oral	POS	O
penicillin	POS	O
anaphylaxis	POS	B-NP
is	POS	O
described	POS	O
,	POS	O
and	POS	O
the	POS	O
terminology	POS	O
,	POS	O
occurrence	POS	O
,	POS	O
clinical	POS	O
manifestations	POS	O
,	POS	O
pathogenesis	POS	O
,	POS	O
prevention	POS	O
,	POS	O
and	POS	O
treatment	POS	O
of	POS	O
anaphylaxis	POS	B-NP
are	POS	O
reviewed	POS	O
.	POS	O
Emergency	POS	O
physicians	POS	O
should	POS	O
be	POS	O
aware	POS	O
of	POS	O
oral	POS	O
penicillin	POS	O
anaphylaxis	POS	B-NP
in	POS	O
order	POS	O
to	POS	O
prevent	POS	O
its	POS	O
occurrence	POS	O
by	POS	O
prescribing	POS	O
the	POS	O
antibiotic	POS	O
judiciously	POS	O
and	POS	O
knowledgeably	POS	O
and	POS	O
to	POS	O
offer	POS	O
optimal	POS	O
medical	POS	O
therapy	POS	O
once	POS	O
this	POS	O
life	POS	O
-	POS	O
threatening	POS	O
reaction	POS	O
has	POS	O
begun	POS	O
.	POS	O
Reversible	POS	O
valproic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
dementia	POS	B-NP
:	POS	O
a	POS	O
case	POS	O
report	POS	O
.	POS	O
Reversible	POS	O
valproic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
dementia	POS	B-NP
was	POS	O
documented	POS	O
in	POS	O
a	POS	O
21	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
with	POS	O
epilepsy	POS	B-NP
who	POS	O
had	POS	O
a	POS	O
3	POS	O
-	POS	O
year	POS	O
history	POS	O
of	POS	O
insidious	POS	O
progressive	POS	O
decline	POS	O
in	POS	O
global	POS	O
cognitive	POS	O
abilities	POS	O
documented	POS	O
by	POS	O
serial	POS	O
neuropsychological	POS	O
studies	POS	O
.	POS	O
Repeat	POS	O
neuropsychological	POS	O
testing	POS	O
7	POS	O
weeks	POS	O
after	POS	O
discontinuation	POS	O
of	POS	O
the	POS	O
drug	POS	O
revealed	POS	O
dramatic	POS	O
improvement	POS	O
in	POS	O
IQ	POS	O
,	POS	O
memory	POS	O
,	POS	O
naming	POS	O
,	POS	O
and	POS	O
other	POS	O
tasks	POS	O
commensurate	POS	O
with	POS	O
clinical	POS	O
recovery	POS	O
in	POS	O
his	POS	O
intellectual	POS	O
capacity	POS	O
.	POS	O
Possible	POS	O
pathophysiological	POS	O
mechanisms	POS	O
which	POS	O
may	POS	O
have	POS	O
been	POS	O
operative	POS	O
in	POS	O
this	POS	O
case	POS	O
include	POS	O
:	POS	O
a	POS	O
direct	POS	O
central	POS	O
nervous	POS	O
system	POS	O
(	POS	O
CNS	POS	O
)	POS	O
toxic	POS	O
effect	POS	O
of	POS	O
valproic	POS	O
acid	POS	O
;	POS	O
a	POS	O
paradoxical	POS	O
epileptogenic	POS	O
effect	POS	O
secondary	POS	O
to	POS	O
the	POS	O
drug	POS	O
;	POS	O
and	POS	O
an	POS	O
indirect	POS	O
CNS	POS	O
toxic	POS	O
effect	POS	O
mediated	POS	O
through	POS	O
valproic	POS	O
acid	POS	O
-	POS	O
induced	POS	O
hyperammonemia	POS	B-NP
.	POS	O
Reversal	POS	O
of	POS	O
scopolamine	POS	O
-	POS	O
induced	POS	O
amnesia	POS	B-NP
of	POS	O
passive	POS	O
avoidance	POS	O
by	POS	O
pre	POS	O
-	POS	O
and	POS	O
post	POS	O
-	POS	O
training	POS	O
naloxone	POS	O
.	POS	O
In	POS	O
a	POS	O
series	POS	O
of	POS	O
five	POS	O
experiments	POS	O
,	POS	O
the	POS	O
modulating	POS	O
role	POS	O
of	POS	O
naloxone	POS	O
on	POS	O
a	POS	O
scopolamine	POS	O
-	POS	O
induced	POS	O
retention	POS	O
deficit	POS	O
in	POS	O
a	POS	O
passive	POS	O
avoidance	POS	O
paradigm	POS	O
was	POS	O
investigated	POS	O
in	POS	O
mice	POS	O
.	POS	O
Scopolamine	POS	O
,	POS	O
but	POS	O
not	POS	O
methyl	POS	O
scopolamine	POS	O
(	POS	O
1	POS	O
and	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
induced	POS	O
an	POS	O
amnesia	POS	B-NP
as	POS	O
measured	POS	O
by	POS	O
latency	POS	O
and	POS	O
duration	POS	O
parameters	POS	O
.	POS	O
Naloxone	POS	O
(	POS	O
0	POS	O
.	POS	O
3	POS	O
,	POS	O
1	POS	O
,	POS	O
3	POS	O
,	POS	O
and	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
injected	POS	O
prior	POS	O
to	POS	O
training	POS	O
attenuated	POS	O
the	POS	O
retention	POS	O
deficit	POS	O
with	POS	O
a	POS	O
peak	POS	O
of	POS	O
activity	POS	O
at	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
The	POS	O
effect	POS	O
of	POS	O
naloxone	POS	O
could	POS	O
be	POS	O
antagonized	POS	O
with	POS	O
morphine	POS	O
(	POS	O
1	POS	O
,	POS	O
3	POS	O
,	POS	O
and	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
,	POS	O
demonstrating	POS	O
the	POS	O
opioid	POS	O
specificity	POS	O
of	POS	O
the	POS	O
naloxone	POS	O
effect	POS	O
.	POS	O
Post	POS	O
-	POS	O
training	POS	O
administration	POS	O
of	POS	O
naloxone	POS	O
(	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
as	POS	O
a	POS	O
single	POS	O
or	POS	O
as	POS	O
a	POS	O
split	POS	O
dose	POS	O
also	POS	O
attenuated	POS	O
the	POS	O
scopolamine	POS	O
-	POS	O
induced	POS	O
amnesia	POS	B-NP
.	POS	O
Control	POS	O
experiments	POS	O
indicated	POS	O
that	POS	O
neither	POS	O
an	POS	O
increase	POS	O
in	POS	O
pain	POS	B-NP
sensitivity	POS	O
(	POS	O
pre	POS	O
-	POS	O
training	POS	O
naloxone	POS	O
)	POS	O
nor	POS	O
an	POS	O
induced	POS	O
aversive	POS	O
state	POS	O
(	POS	O
post	POS	O
-	POS	O
training	POS	O
naloxone	POS	O
)	POS	O
appear	POS	O
to	POS	O
be	POS	O
responsible	POS	O
for	POS	O
the	POS	O
influence	POS	O
of	POS	O
naloxone	POS	O
on	POS	O
the	POS	O
scopolamine	POS	O
-	POS	O
induced	POS	O
retention	POS	B-NP
deficit	POS	I-NP
.	POS	O
These	POS	O
results	POS	O
extend	POS	O
previous	POS	O
findings	POS	O
implicating	POS	O
a	POS	O
cholinergic	POS	O
-	POS	O
opioid	POS	O
interaction	POS	O
in	POS	O
memory	POS	O
processes	POS	O
.	POS	O
A	POS	O
possible	POS	O
mechanism	POS	O
for	POS	O
this	POS	O
interaction	POS	O
involving	POS	O
the	POS	O
septo	POS	O
-	POS	O
hippocampal	POS	O
cholinergic	POS	O
pathway	POS	O
is	POS	O
discussed	POS	O
.	POS	O
Electron	POS	O
microscopic	POS	O
investigations	POS	O
of	POS	O
the	POS	O
cyclophosphamide	POS	O
-	POS	O
induced	POS	O
lesions	POS	O
of	POS	O
the	POS	O
urinary	POS	O
bladder	POS	O
of	POS	O
the	POS	O
rat	POS	O
and	POS	O
their	POS	O
prevention	POS	O
by	POS	O
mesna	POS	O
.	POS	O
Fully	POS	O
developed	POS	O
cyclophosphamide	POS	O
-	POS	O
induced	POS	O
cystitis	POS	B-NP
is	POS	O
characterized	POS	O
by	POS	O
nearly	POS	O
complete	POS	O
detachment	POS	B-NP
of	POS	I-NP
the	POS	I-NP
urothelium	POS	I-NP
,	POS	O
severe	POS	O
submucosal	POS	B-NP
edema	POS	I-NP
owing	POS	O
to	POS	O
damage	POS	O
to	POS	O
the	POS	O
microvascular	POS	O
bed	POS	O
and	POS	O
focal	POS	O
muscle	POS	B-NP
necroses	POS	I-NP
.	POS	O
The	POS	O
initial	POS	O
response	POS	O
to	POS	O
the	POS	O
primary	POS	O
attack	POS	O
by	POS	O
the	POS	O
cyclophosphamide	POS	O
metabolites	POS	O
seems	POS	O
to	POS	O
be	POS	O
fragmentation	POS	O
of	POS	O
the	POS	O
luminal	POS	O
membrane	POS	O
.	POS	O
This	POS	O
damages	POS	O
the	POS	O
cellular	POS	O
barrier	POS	O
against	POS	O
the	POS	O
hypertonic	POS	O
urine	POS	O
.	POS	O
Subsequent	POS	O
breaks	POS	O
in	POS	O
the	POS	O
lateral	POS	O
cell	POS	O
membranes	POS	O
of	POS	O
the	POS	O
superficial	POS	O
cells	POS	O
and	POS	O
in	POS	O
all	POS	O
the	POS	O
plasma	POS	O
membranes	POS	O
of	POS	O
the	POS	O
intermediate	POS	O
and	POS	O
basal	POS	O
cells	POS	O
,	POS	O
intercellular	POS	O
and	POS	O
intracellular	POS	O
edema	POS	B-NP
and	POS	O
disintegration	POS	O
of	POS	O
the	POS	O
desmosomes	POS	O
and	POS	O
hemidesmosomes	POS	O
lead	POS	O
to	POS	O
progressive	POS	O
degeneration	POS	O
and	POS	O
detachment	POS	O
of	POS	O
the	POS	O
epithelial	POS	O
cells	POS	O
with	POS	O
exposure	POS	O
and	POS	O
splitting	POS	O
of	POS	O
the	POS	O
basal	POS	O
membrane	POS	O
.	POS	O
The	POS	O
morphological	POS	O
changes	POS	O
of	POS	O
the	POS	O
endothelial	POS	O
cells	POS	O
,	POS	O
which	POS	O
become	POS	O
more	POS	O
pronounced	POS	O
in	POS	O
the	POS	O
later	POS	O
stages	POS	O
of	POS	O
the	POS	O
experiment	POS	O
,	POS	O
the	POS	O
involvement	POS	O
of	POS	O
blood	POS	O
vessels	POS	O
regardless	POS	O
of	POS	O
their	POS	O
diameter	POS	O
and	POS	O
the	POS	O
location	POS	O
-	POS	O
dependent	POS	O
extent	POS	O
of	POS	O
the	POS	O
damage	POS	O
indicate	POS	O
a	POS	O
direct	POS	O
type	POS	O
of	POS	O
damage	POS	O
which	POS	O
is	POS	O
preceded	POS	O
by	POS	O
a	POS	O
mediator	POS	O
-	POS	O
induced	POS	O
increase	POS	O
in	POS	O
permeability	POS	O
,	POS	O
the	POS	O
morphological	POS	O
correlate	POS	O
of	POS	O
which	POS	O
is	POS	O
the	POS	O
formation	POS	O
of	POS	O
gaps	POS	O
in	POS	O
the	POS	O
interendothelial	POS	O
cell	POS	O
connections	POS	O
on	POS	O
the	POS	O
venules	POS	O
.	POS	O
These	POS	O
changes	POS	O
can	POS	O
be	POS	O
effectively	POS	O
prevented	POS	O
by	POS	O
mesna	POS	O
.	POS	O
The	POS	O
only	POS	O
sign	POS	O
of	POS	O
a	POS	O
possible	POS	O
involvement	POS	O
is	POS	O
the	POS	O
increase	POS	O
in	POS	O
the	POS	O
number	POS	O
of	POS	O
specific	POS	O
granules	POS	O
with	POS	O
a	POS	O
presumed	POS	O
lysosomal	POS	O
function	POS	O
in	POS	O
the	POS	O
superficial	POS	O
cells	POS	O
.	POS	O
Increase	POS	O
in	POS	O
intragastric	POS	O
pressure	POS	O
during	POS	O
suxamethonium	POS	O
-	POS	O
induced	POS	O
muscle	POS	B-NP
fasciculations	POS	I-NP
in	POS	O
children	POS	O
:	POS	O
inhibition	POS	O
by	POS	O
alfentanil	POS	O
.	POS	O
Changes	POS	O
in	POS	O
intragastric	POS	O
pressure	POS	O
after	POS	O
the	POS	O
administration	POS	O
of	POS	O
suxamethonium	POS	O
1	POS	O
.	POS	O
5	POS	O
mg	POS	O
kg	POS	O
-	POS	O
1	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
were	POS	O
studied	POS	O
in	POS	O
32	POS	O
children	POS	O
(	POS	O
mean	POS	O
age	POS	O
6	POS	O
.	POS	O
9	POS	O
yr	POS	O
)	POS	O
pretreated	POS	O
with	POS	O
either	POS	O
physiological	POS	O
saline	POS	O
or	POS	O
alfentanil	POS	O
50	POS	O
micrograms	POS	O
kg	POS	O
-	POS	O
1	POS	O
.	POS	O
Anaesthesia	POS	B-NP
was	POS	O
induced	POS	O
with	POS	O
thiopentone	POS	O
5	POS	O
mg	POS	O
kg	POS	O
-	POS	O
1	POS	O
.	POS	O
The	POS	O
incidence	POS	O
and	POS	O
intensity	POS	O
of	POS	O
muscle	POS	B-NP
fasciculations	POS	I-NP
caused	POS	O
by	POS	O
suxamethonium	POS	O
were	POS	O
significantly	POS	O
greater	POS	O
in	POS	O
the	POS	O
control	POS	O
than	POS	O
in	POS	O
the	POS	O
alfentanil	POS	O
group	POS	O
.	POS	O
The	POS	O
intragastric	POS	O
pressure	POS	O
during	POS	O
muscle	POS	B-NP
fasciculations	POS	I-NP
was	POS	O
significantly	POS	O
higher	POS	O
in	POS	O
the	POS	O
control	POS	O
group	POS	O
(	POS	O
16	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
(	POS	O
SEM	POS	O
)	POS	O
cm	POS	O
H2O	POS	O
)	POS	O
than	POS	O
in	POS	O
the	POS	O
alfentanil	POS	O
group	POS	O
(	POS	O
7	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
5	POS	O
(	POS	O
SEM	POS	O
)	POS	O
cm	POS	O
H2O	POS	O
)	POS	O
.	POS	O
The	POS	O
increase	POS	O
in	POS	O
intragastric	POS	O
pressure	POS	O
was	POS	O
directly	POS	O
related	POS	O
to	POS	O
the	POS	O
intensity	POS	O
of	POS	O
muscle	POS	B-NP
fasciculations	POS	I-NP
(	POS	O
regression	POS	O
line	POS	O
:	POS	O
y	POS	O
=	POS	O
0	POS	O
.	POS	O
5	POS	O
+	POS	O
4	POS	O
.	POS	O
78x	POS	O
with	POS	O
r	POS	O
of	POS	O
0	POS	O
.	POS	O
78	POS	O
)	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
intragastric	POS	O
pressure	POS	O
increases	POS	O
significantly	POS	O
during	POS	O
muscle	POS	B-NP
fasciculations	POS	I-NP
caused	POS	O
by	POS	O
suxamethonium	POS	O
in	POS	O
healthy	POS	O
children	POS	O
.	POS	O
Alfentanil	POS	O
50	POS	O
micrograms	POS	O
kg	POS	O
-	POS	O
1	POS	O
effectively	POS	O
inhibits	POS	O
the	POS	O
incidence	POS	O
and	POS	O
intensity	POS	O
of	POS	O
suxamethonium	POS	O
-	POS	O
induced	POS	O
muscle	POS	B-NP
fasciculations	POS	I-NP
;	POS	O
moreover	POS	O
,	POS	O
intragastric	POS	O
pressure	POS	O
remains	POS	O
at	POS	O
its	POS	O
control	POS	O
value	POS	O
.	POS	O
Acute	POS	O
insulin	POS	O
treatment	POS	O
normalizes	POS	O
the	POS	O
resistance	POS	O
to	POS	O
the	POS	O
cardiotoxic	POS	B-NP
effect	POS	O
of	POS	O
isoproterenol	POS	O
in	POS	O
streptozotocin	POS	O
diabetic	POS	O
rats	POS	O
.	POS	O
A	POS	O
morphometric	POS	O
study	POS	O
of	POS	O
isoproterenol	POS	O
induced	POS	O
myocardial	POS	B-NP
fibrosis	POS	I-NP
.	POS	O
The	POS	O
acute	POS	O
effect	POS	O
of	POS	O
insulin	POS	O
treatment	POS	O
on	POS	O
the	POS	O
earlier	POS	O
reported	POS	O
protective	POS	O
effect	POS	O
of	POS	O
streptozotocin	POS	O
diabetes	POS	B-NP
against	POS	O
the	POS	O
cardiotoxic	POS	B-NP
effect	POS	O
of	POS	O
high	POS	O
doses	POS	O
of	POS	O
isoproterenol	POS	O
(	POS	O
ISO	POS	O
)	POS	O
was	POS	O
investigated	POS	O
in	POS	O
rats	POS	O
.	POS	O
Thirty	POS	O
to	POS	O
135	POS	O
min	POS	O
after	POS	O
the	POS	O
injection	POS	O
of	POS	O
crystalline	POS	O
insulin	POS	O
,	POS	O
ISO	POS	O
was	POS	O
given	POS	O
subcutaneously	POS	O
and	POS	O
when	POS	O
ISO	POS	O
induced	POS	O
fibrosis	POS	B-NP
in	POS	O
the	POS	O
myocardium	POS	O
was	POS	O
morphometrically	POS	O
analyzed	POS	O
7	POS	O
days	POS	O
later	POS	O
,	POS	O
a	POS	O
highly	POS	O
significant	POS	O
correlation	POS	O
(	POS	O
r	POS	O
=	POS	O
0	POS	O
.	POS	O
83	POS	O
,	POS	O
2	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
006	POS	O
)	POS	O
to	POS	O
the	POS	O
slope	POS	O
of	POS	O
the	POS	O
fall	POS	O
in	POS	O
blood	POS	O
glucose	POS	O
after	POS	O
insulin	POS	O
treatment	POS	O
appeared	POS	O
.	POS	O
The	POS	O
myocardial	POS	O
content	POS	O
of	POS	O
catecholamines	POS	O
was	POS	O
estimated	POS	O
in	POS	O
these	POS	O
8	POS	O
day	POS	O
diabetic	POS	O
rats	POS	O
.	POS	O
The	POS	O
norepinephrine	POS	O
content	POS	O
was	POS	O
significantly	POS	O
increased	POS	O
while	POS	O
epinephrine	POS	O
remained	POS	O
unchanged	POS	O
.	POS	O
An	POS	O
enhanced	POS	O
sympathetic	POS	O
nervous	POS	O
system	POS	O
activity	POS	O
with	POS	O
a	POS	O
consequent	POS	O
down	POS	O
regulation	POS	O
of	POS	O
the	POS	O
myocardial	POS	O
beta	POS	O
-	POS	O
adrenergic	POS	O
receptors	POS	O
could	POS	O
,	POS	O
therefore	POS	O
,	POS	O
explain	POS	O
this	POS	O
catecholamine	POS	O
resistance	POS	O
.	POS	O
The	POS	O
rapid	POS	O
reversion	POS	O
after	POS	O
insulin	POS	O
treatment	POS	O
excludes	POS	O
the	POS	O
possibility	POS	O
that	POS	O
streptozotocin	POS	O
in	POS	O
itself	POS	O
causes	POS	O
the	POS	O
ISO	POS	O
resistance	POS	O
and	POS	O
points	POS	O
towards	POS	O
a	POS	O
direct	POS	O
insulin	POS	O
effect	POS	O
on	POS	O
myocardial	POS	O
catecholamine	POS	O
sensitivity	POS	O
in	POS	O
diabetic	POS	O
rats	POS	O
.	POS	O
The	POS	O
phenomenon	POS	O
described	POS	O
might	POS	O
elucidate	POS	O
pathogenetic	POS	O
mechanisms	POS	O
behind	POS	O
toxic	POS	O
myocardial	POS	B-NP
cell	POS	I-NP
degeneration	POS	I-NP
and	POS	O
may	POS	O
possibly	POS	O
have	POS	O
relevance	POS	O
for	POS	O
acute	POS	O
cardiovascular	POS	O
complications	POS	O
in	POS	O
diabetic	POS	B-NP
patients	POS	O
.	POS	O
Differential	POS	O
effects	POS	O
of	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
on	POS	O
seizures	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
muscarinic	POS	O
cholinergic	POS	O
agonist	POS	O
pilocarpine	POS	O
induces	POS	O
in	POS	O
rats	POS	O
seizures	POS	B-NP
and	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
followed	POS	O
by	POS	O
widespread	POS	O
damage	POS	O
to	POS	O
the	POS	O
forebrain	POS	O
.	POS	O
The	POS	O
present	POS	O
study	POS	O
was	POS	O
designed	POS	O
to	POS	O
investigate	POS	O
the	POS	O
effect	POS	O
of	POS	O
5	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
,	POS	O
sodium	POS	O
salicylate	POS	O
,	POS	O
phenylbutazone	POS	O
,	POS	O
indomethacin	POS	O
,	POS	O
ibuprofen	POS	O
and	POS	O
mefenamic	POS	O
acid	POS	O
,	POS	O
on	POS	O
seizures	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
.	POS	O
Pretreatment	POS	O
of	POS	O
rats	POS	O
with	POS	O
sodium	POS	O
salicylate	POS	O
,	POS	O
ED50	POS	O
103	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
60	POS	O
-	POS	O
174	POS	O
)	POS	O
,	POS	O
and	POS	O
phenylbutazone	POS	O
,	POS	O
59	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
50	POS	O
-	POS	O
70	POS	O
)	POS	O
converted	POS	O
the	POS	O
non	POS	O
-	POS	O
convulsant	POS	O
dose	POS	O
of	POS	O
pilocarpine	POS	O
,	POS	O
200	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
to	POS	O
a	POS	O
convulsant	POS	O
one	POS	O
.	POS	O
Indomethacin	POS	O
,	POS	O
1	POS	O
-	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
and	POS	O
ibuprofen	POS	O
,	POS	O
10	POS	O
-	POS	O
100	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
failed	POS	O
to	POS	O
modulate	POS	O
seizures	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
.	POS	O
Mefenamic	POS	O
acid	POS	O
,	POS	O
26	POS	O
(	POS	O
22	POS	O
-	POS	O
30	POS	O
)	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
prevented	POS	O
seizures	POS	B-NP
and	POS	O
protected	POS	O
rats	POS	O
from	POS	O
seizure	POS	B-NP
-	POS	O
related	POS	O
brain	POS	B-NP
damage	POS	I-NP
induced	POS	O
by	POS	O
pilocarpine	POS	O
,	POS	O
380	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
These	POS	O
results	POS	O
indicate	POS	O
that	POS	O
non	POS	O
-	POS	O
steroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drugs	POS	O
differentially	POS	O
modulate	POS	O
the	POS	O
threshold	POS	O
for	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
.	POS	O
Acute	POS	B-NP
neurologic	POS	I-NP
dysfunction	POS	I-NP
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
etoposide	POS	O
therapy	POS	O
for	POS	O
malignant	POS	B-NP
glioma	POS	I-NP
.	POS	O
Etoposide	POS	O
(	POS	O
VP	POS	O
-	POS	O
16	POS	O
-	POS	O
213	POS	O
)	POS	O
has	POS	O
been	POS	O
used	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
many	POS	O
solid	POS	O
tumors	POS	B-NP
and	POS	O
hematologic	POS	B-NP
malignancies	POS	I-NP
.	POS	O
When	POS	O
used	POS	O
in	POS	O
high	POS	O
doses	POS	O
and	POS	O
in	POS	O
conjunction	POS	O
with	POS	O
autologous	POS	O
bone	POS	O
marrow	POS	O
transplantation	POS	O
,	POS	O
this	POS	O
agent	POS	O
has	POS	O
activity	POS	O
against	POS	O
several	POS	O
treatment	POS	O
-	POS	O
resistant	POS	O
cancers	POS	B-NP
including	POS	O
malignant	POS	B-NP
glioma	POS	I-NP
.	POS	O
In	POS	O
six	POS	O
of	POS	O
eight	POS	O
patients	POS	O
(	POS	O
75	POS	O
%	POS	O
)	POS	O
who	POS	O
we	POS	O
treated	POS	O
for	POS	O
recurrent	POS	O
or	POS	O
resistant	POS	O
glioma	POS	B-NP
,	POS	O
sudden	POS	O
severe	POS	O
neurologic	POS	B-NP
deterioration	POS	I-NP
occurred	POS	O
.	POS	O
This	POS	O
developed	POS	O
a	POS	O
median	POS	O
of	POS	O
9	POS	O
days	POS	O
after	POS	O
initiation	POS	O
of	POS	O
high	POS	O
-	POS	O
dose	POS	O
etoposide	POS	O
therapy	POS	O
.	POS	O
Significant	POS	O
clinical	POS	O
manifestations	POS	O
have	POS	O
included	POS	O
confusion	POS	B-NP
,	POS	O
papilledema	POS	B-NP
,	POS	O
somnolence	POS	B-NP
,	POS	O
exacerbation	POS	B-NP
of	POS	I-NP
motor	POS	I-NP
deficits	POS	I-NP
,	POS	O
and	POS	O
sharp	POS	O
increase	POS	O
in	POS	O
seizure	POS	B-NP
activity	POS	O
.	POS	O
These	POS	O
abnormalities	POS	O
resolved	POS	O
rapidly	POS	O
after	POS	O
initiation	POS	O
of	POS	O
high	POS	O
-	POS	O
dose	POS	O
intravenous	POS	O
dexamethasone	POS	O
therapy	POS	O
.	POS	O
In	POS	O
all	POS	O
patients	POS	O
,	POS	O
computerized	POS	O
tomographic	POS	O
(	POS	O
CT	POS	O
)	POS	O
brain	POS	O
scans	POS	O
demonstrated	POS	O
stability	POS	O
in	POS	O
tumor	POS	B-NP
size	POS	O
and	POS	O
peritumor	POS	B-NP
edema	POS	I-NP
when	POS	O
compared	POS	O
with	POS	O
pretransplant	POS	O
scans	POS	O
.	POS	O
This	POS	O
complication	POS	O
appears	POS	O
to	POS	O
represent	POS	O
a	POS	O
significant	POS	O
new	POS	O
toxicity	POS	B-NP
of	POS	O
high	POS	O
-	POS	O
dose	POS	O
etoposide	POS	O
therapy	POS	O
for	POS	O
malignant	POS	B-NP
glioma	POS	I-NP
.	POS	O
Progressive	POS	B-NP
bile	POS	I-NP
duct	POS	I-NP
injury	POS	I-NP
after	POS	O
thiabendazole	POS	O
administration	POS	O
.	POS	O
A	POS	O
27	POS	O
-	POS	O
yr	POS	O
-	POS	O
old	POS	O
man	POS	O
developed	POS	O
jaundice	POS	B-NP
2	POS	O
wk	POS	O
after	POS	O
exposure	POS	O
to	POS	O
thiabendazole	POS	O
.	POS	O
Cholestasis	POS	B-NP
persisted	POS	O
for	POS	O
3	POS	O
yr	POS	O
,	POS	O
at	POS	O
which	POS	O
time	POS	O
a	POS	O
liver	POS	O
transplant	POS	O
was	POS	O
performed	POS	O
.	POS	O
Two	POS	O
liver	POS	O
biopsy	POS	O
specimens	POS	O
and	POS	O
the	POS	O
hepatectomy	POS	O
specimen	POS	O
were	POS	O
remarkable	POS	O
for	POS	O
almost	POS	O
complete	POS	O
disappearance	POS	O
of	POS	O
interlobular	POS	O
bile	POS	O
ducts	POS	O
.	POS	O
Prominent	POS	O
fibrosis	POS	B-NP
and	POS	O
hepatocellular	POS	B-NP
regeneration	POS	I-NP
were	POS	O
also	POS	O
present	POS	O
;	POS	O
however	POS	O
,	POS	O
the	POS	O
lobular	POS	O
architecture	POS	O
was	POS	O
preserved	POS	O
.	POS	O
This	POS	O
case	POS	O
represents	POS	O
an	POS	O
example	POS	O
of	POS	O
"	POS	O
idiosyncratic	POS	O
"	POS	O
drug	POS	O
-	POS	O
induced	POS	O
liver	POS	B-NP
damage	POS	I-NP
in	POS	O
which	POS	O
the	POS	O
primary	POS	O
target	POS	O
of	POS	O
injury	POS	O
is	POS	O
the	POS	O
bile	POS	O
duct	POS	O
.	POS	O
An	POS	O
autoimmune	POS	O
pathogenesis	POS	O
of	POS	O
the	POS	O
bile	POS	O
duct	POS	O
destruction	POS	O
is	POS	O
suggested	POS	O
.	POS	O
Differential	POS	O
effects	POS	O
of	POS	O
1	POS	O
,	POS	O
4	POS	O
-	POS	O
dihydropyridine	POS	O
calcium	POS	O
channel	POS	O
blockers	POS	O
:	POS	O
therapeutic	POS	O
implications	POS	O
.	POS	O
Increasing	POS	O
recognition	POS	O
of	POS	O
the	POS	O
importance	POS	O
of	POS	O
calcium	POS	O
in	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
cardiovascular	POS	B-NP
disease	POS	I-NP
has	POS	O
stimulated	POS	O
research	POS	O
into	POS	O
the	POS	O
use	POS	O
of	POS	O
calcium	POS	O
channel	POS	O
blocking	POS	O
agents	POS	O
for	POS	O
treatment	POS	O
of	POS	O
a	POS	O
variety	POS	O
of	POS	O
cardiovascular	POS	B-NP
diseases	POS	I-NP
.	POS	O
The	POS	O
favorable	POS	O
efficacy	POS	O
and	POS	O
tolerability	POS	O
profiles	POS	O
of	POS	O
these	POS	O
agents	POS	O
make	POS	O
them	POS	O
attractive	POS	O
therapeutic	POS	O
modalities	POS	O
.	POS	O
Clinical	POS	O
applications	POS	O
of	POS	O
calcium	POS	O
channel	POS	O
blockers	POS	O
parallel	POS	O
their	POS	O
tissue	POS	O
selectivity	POS	O
.	POS	O
In	POS	O
contrast	POS	O
to	POS	O
verapamil	POS	O
and	POS	O
diltiazem	POS	O
,	POS	O
which	POS	O
are	POS	O
roughly	POS	O
equipotent	POS	O
in	POS	O
their	POS	O
actions	POS	O
on	POS	O
the	POS	O
heart	POS	O
and	POS	O
vascular	POS	O
smooth	POS	O
muscle	POS	O
,	POS	O
the	POS	O
dihydropyridine	POS	O
calcium	POS	O
channel	POS	O
blockers	POS	O
are	POS	O
a	POS	O
group	POS	O
of	POS	O
potent	POS	O
peripheral	POS	O
vasodilator	POS	O
agents	POS	O
that	POS	O
exert	POS	O
minimal	POS	O
electrophysiologic	POS	O
effects	POS	O
on	POS	O
cardiac	POS	O
nodal	POS	O
or	POS	O
conduction	POS	O
tissue	POS	O
.	POS	O
As	POS	O
the	POS	O
first	POS	O
dihydropyridine	POS	O
available	POS	O
for	POS	O
use	POS	O
in	POS	O
the	POS	O
United	POS	O
States	POS	O
,	POS	O
nifedipine	POS	O
controls	POS	O
angina	POS	B-NP
and	POS	O
hypertension	POS	B-NP
with	POS	O
minimal	POS	O
depression	POS	B-NP
of	POS	O
cardiac	POS	B-NP
function	POS	I-NP
.	POS	O
Additional	POS	O
members	POS	O
of	POS	O
this	POS	O
group	POS	O
of	POS	O
calcium	POS	O
channel	POS	O
blockers	POS	O
have	POS	O
been	POS	O
studied	POS	O
for	POS	O
a	POS	O
variety	POS	O
of	POS	O
indications	POS	O
for	POS	O
which	POS	O
they	POS	O
may	POS	O
offer	POS	O
advantages	POS	O
over	POS	O
current	POS	O
therapy	POS	O
.	POS	O
Once	POS	O
or	POS	O
twice	POS	O
daily	POS	O
dosage	POS	O
possible	POS	O
with	POS	O
nitrendipine	POS	O
and	POS	O
nisoldipine	POS	O
offers	POS	O
a	POS	O
convenient	POS	O
administration	POS	O
schedule	POS	O
,	POS	O
which	POS	O
encourages	POS	O
patient	POS	O
compliance	POS	O
in	POS	O
long	POS	O
-	POS	O
term	POS	O
therapy	POS	O
of	POS	O
hypertension	POS	B-NP
.	POS	O
The	POS	O
coronary	POS	O
vasodilating	POS	O
properties	POS	O
of	POS	O
nisoldipine	POS	O
have	POS	O
led	POS	O
to	POS	O
the	POS	O
investigation	POS	O
of	POS	O
this	POS	O
agent	POS	O
for	POS	O
use	POS	O
in	POS	O
angina	POS	B-NP
.	POS	O
Selectivity	POS	O
for	POS	O
the	POS	O
cerebrovascular	POS	O
bed	POS	O
makes	POS	O
nimodipine	POS	O
potentially	POS	O
useful	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
subarachnoid	POS	B-NP
hemorrhage	POS	I-NP
,	POS	O
migraine	POS	B-NP
headache	POS	I-NP
,	POS	O
dementia	POS	B-NP
,	POS	O
and	POS	O
stroke	POS	B-NP
.	POS	O
In	POS	O
general	POS	O
,	POS	O
the	POS	O
dihydropyridine	POS	O
calcium	POS	O
channel	POS	O
blockers	POS	O
are	POS	O
usually	POS	O
well	POS	O
tolerated	POS	O
,	POS	O
with	POS	O
headache	POS	B-NP
,	POS	O
facial	POS	B-NP
flushing	POS	I-NP
,	POS	O
palpitations	POS	B-NP
,	POS	O
edema	POS	B-NP
,	POS	O
nausea	POS	B-NP
,	POS	O
anorexia	POS	B-NP
,	POS	O
and	POS	O
dizziness	POS	B-NP
being	POS	O
the	POS	O
more	POS	O
common	POS	O
adverse	POS	O
effects	POS	O
.	POS	O
The	POS	O
enhancement	POS	O
of	POS	O
aminonucleoside	POS	O
nephrosis	POS	B-NP
by	POS	O
the	POS	O
co	POS	O
-	POS	O
administration	POS	O
of	POS	O
protamine	POS	O
.	POS	O
An	POS	O
experimental	POS	O
model	POS	O
of	POS	O
focal	POS	O
segmental	POS	O
glomerular	POS	B-NP
sclerosis	POS	I-NP
(	POS	O
FSGS	POS	B-NP
)	POS	O
was	POS	O
developed	POS	O
in	POS	O
rats	POS	O
by	POS	O
the	POS	O
combined	POS	O
administration	POS	O
of	POS	O
puromycin	POS	O
-	POS	O
aminonucleoside	POS	O
(	POS	O
AMNS	POS	O
)	POS	O
and	POS	O
protamine	POS	O
sulfate	POS	O
(	POS	O
PS	POS	O
)	POS	O
.	POS	O
Male	POS	O
Sprague	POS	O
-	POS	O
Dawley	POS	O
rats	POS	O
,	POS	O
uninephrectomized	POS	O
three	POS	O
weeks	POS	O
before	POS	O
,	POS	O
received	POS	O
daily	POS	O
injections	POS	O
of	POS	O
subcutaneous	POS	O
AMNS	POS	O
(	POS	O
1	POS	O
mg	POS	O
/	POS	O
100	POS	O
g	POS	O
body	POS	O
wt	POS	O
)	POS	O
and	POS	O
intravenous	POS	O
PS	POS	O
(	POS	O
2	POS	O
separated	POS	O
doses	POS	O
of	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
100	POS	O
g	POS	O
body	POS	O
wt	POS	O
)	POS	O
for	POS	O
four	POS	O
days	POS	O
.	POS	O
The	POS	O
series	POS	O
of	POS	O
injections	POS	O
were	POS	O
repeated	POS	O
another	POS	O
three	POS	O
times	POS	O
at	POS	O
10	POS	O
day	POS	O
intervals	POS	O
.	POS	O
The	POS	O
animals	POS	O
were	POS	O
sacrificed	POS	O
on	POS	O
days	POS	O
24	POS	O
,	POS	O
52	POS	O
,	POS	O
and	POS	O
80	POS	O
.	POS	O
They	POS	O
developed	POS	O
nephrotic	POS	B-NP
syndrome	POS	I-NP
and	POS	O
finally	POS	O
renal	POS	B-NP
failure	POS	I-NP
.	POS	O
The	POS	O
time	POS	O
-	POS	O
course	POS	O
curve	POS	O
of	POS	O
creatinine	POS	O
clearance	POS	O
dropped	POS	O
and	POS	O
showed	POS	O
significant	POS	O
difference	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
from	POS	O
that	POS	O
of	POS	O
each	POS	O
control	POS	O
group	POS	O
,	POS	O
such	POS	O
as	POS	O
,	POS	O
AMNS	POS	O
alone	POS	O
,	POS	O
PS	POS	O
alone	POS	O
or	POS	O
saline	POS	O
injected	POS	O
.	POS	O
Their	POS	O
glomeruli	POS	O
showed	POS	O
changes	POS	O
of	POS	O
progressive	POS	O
FSGS	POS	B-NP
.	POS	O
The	POS	O
ultrastructural	POS	O
studies	POS	O
in	POS	O
the	POS	O
initial	POS	O
stage	POS	O
revealed	POS	O
significant	POS	O
lack	POS	O
of	POS	O
particles	POS	O
of	POS	O
perfused	POS	O
ruthenium	POS	O
red	POS	O
on	POS	O
the	POS	O
lamina	POS	O
rara	POS	O
externa	POS	O
and	POS	O
marked	POS	O
changes	POS	O
in	POS	O
epithelial	POS	O
cell	POS	O
cytoplasm	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
it	POS	O
is	POS	O
suggested	POS	O
that	POS	O
the	POS	O
administration	POS	O
of	POS	O
PS	POS	O
enhances	POS	O
the	POS	O
toxicity	POS	O
of	POS	O
AMNS	POS	O
on	POS	O
the	POS	O
glomerulus	POS	O
and	POS	O
readily	POS	O
produces	POS	O
progressive	POS	O
FSGS	POS	B-NP
in	POS	O
rats	POS	O
resulting	POS	O
in	POS	O
the	POS	O
end	POS	O
-	POS	O
stage	POS	O
renal	POS	B-NP
disease	POS	I-NP
.	POS	O
Theophylline	POS	O
neurotoxicity	POS	B-NP
in	POS	O
pregnant	POS	O
rats	POS	O
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
this	POS	O
investigation	POS	O
was	POS	O
to	POS	O
determine	POS	O
whether	POS	O
the	POS	O
neurotoxicity	POS	B-NP
of	POS	O
theophylline	POS	O
is	POS	O
altered	POS	O
in	POS	O
advanced	POS	O
pregnancy	POS	O
.	POS	O
Sprague	POS	O
-	POS	O
Dawley	POS	O
rats	POS	O
that	POS	O
were	POS	O
20	POS	O
days	POS	O
pregnant	POS	O
and	POS	O
nonpregnant	POS	O
rats	POS	O
of	POS	O
the	POS	O
same	POS	O
age	POS	O
and	POS	O
strain	POS	O
received	POS	O
infusions	POS	O
of	POS	O
aminophylline	POS	O
until	POS	O
onset	POS	O
of	POS	O
maximal	POS	O
seizures	POS	B-NP
which	POS	O
occurred	POS	O
after	POS	O
28	POS	O
and	POS	O
30	POS	O
minutes	POS	O
respectively	POS	O
.	POS	O
Theophylline	POS	O
concentrations	POS	O
at	POS	O
this	POS	O
endpoint	POS	O
in	POS	O
serum	POS	O
(	POS	O
total	POS	O
)	POS	O
and	POS	O
CSF	POS	O
were	POS	O
similar	POS	O
but	POS	O
serum	POS	O
(	POS	O
free	POS	O
)	POS	O
and	POS	O
brain	POS	O
concentrations	POS	O
were	POS	O
slightly	POS	O
different	POS	O
in	POS	O
pregnant	POS	O
rats	POS	O
.	POS	O
Theophylline	POS	O
serum	POS	O
protein	POS	O
binding	POS	O
determined	POS	O
by	POS	O
equilibrium	POS	O
dialysis	POS	O
was	POS	O
lower	POS	O
in	POS	O
pregnant	POS	O
rats	POS	O
.	POS	O
Fetal	POS	O
serum	POS	O
concentrations	POS	O
at	POS	O
onset	POS	O
of	POS	O
seizures	POS	B-NP
in	POS	O
the	POS	O
mother	POS	O
were	POS	O
similar	POS	O
to	POS	O
maternal	POS	O
brain	POS	O
and	POS	O
CSF	POS	O
concentrations	POS	O
and	POS	O
correlated	POS	O
significantly	POS	O
with	POS	O
the	POS	O
former	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
advanced	POS	O
pregnancy	POS	O
has	POS	O
a	POS	O
negligible	POS	O
effect	POS	O
on	POS	O
the	POS	O
neurotoxic	POS	B-NP
response	POS	O
to	POS	O
theophylline	POS	O
in	POS	O
rats	POS	O
.	POS	O
Hyperkalemia	POS	B-NP
induced	POS	O
by	POS	O
indomethacin	POS	O
and	POS	O
naproxen	POS	O
and	POS	O
reversed	POS	O
by	POS	O
fludrocortisone	POS	O
.	POS	O
We	POS	O
have	POS	O
described	POS	O
a	POS	O
patient	POS	O
with	POS	O
severe	POS	O
rheumatoid	POS	B-NP
arthritis	POS	I-NP
and	POS	O
a	POS	O
history	POS	O
of	POS	O
mefenamic	POS	O
acid	POS	O
nephropathy	POS	B-NP
in	POS	O
whom	POS	O
hyperkalemia	POS	B-NP
and	POS	O
inappropriate	POS	O
hypoaldosteronism	POS	B-NP
were	POS	O
caused	POS	O
by	POS	O
both	POS	O
indomethacin	POS	O
and	POS	O
naproxen	POS	O
,	POS	O
without	POS	O
major	POS	O
decline	POS	O
in	POS	O
renal	POS	O
function	POS	O
.	POS	O
It	POS	O
is	POS	O
likely	POS	O
that	POS	O
preexisting	POS	O
renal	POS	B-NP
disease	POS	I-NP
predisposed	POS	O
this	POS	O
patient	POS	O
to	POS	O
type	POS	B-NP
IV	POS	I-NP
renal	POS	I-NP
tubular	POS	I-NP
acidosis	POS	I-NP
with	POS	O
prostaglandin	POS	O
synthetase	POS	O
inhibitors	POS	O
.	POS	O
Because	POS	O
he	POS	O
was	POS	O
unable	POS	O
to	POS	O
discontinue	POS	O
nonsteroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
drug	POS	O
therapy	POS	O
,	POS	O
fludrocortisone	POS	O
was	POS	O
added	POS	O
,	POS	O
correcting	POS	O
the	POS	O
hyperkalemia	POS	B-NP
and	POS	O
allowing	POS	O
indomethacin	POS	O
therapy	POS	O
to	POS	O
be	POS	O
continued	POS	O
safely	POS	O
.	POS	O
Hypotension	POS	B-NP
as	POS	O
a	POS	O
manifestation	POS	O
of	POS	O
cardiotoxicity	POS	B-NP
in	POS	O
three	POS	O
patients	POS	O
receiving	POS	O
cisplatin	POS	O
and	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
.	POS	O
Cardiac	POS	B-NP
symptoms	POS	I-NP
,	POS	O
including	POS	O
hypotension	POS	B-NP
,	POS	O
developed	POS	O
in	POS	O
three	POS	O
patients	POS	O
with	POS	O
advanced	POS	O
colorectal	POS	B-NP
carcinoma	POS	B-NP
while	POS	O
being	POS	O
treated	POS	O
with	POS	O
cisplatin	POS	O
(	POS	O
CDDP	POS	O
)	POS	O
and	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
(	POS	O
5	POS	O
-	POS	O
FU	POS	O
)	POS	O
.	POS	O
In	POS	O
two	POS	O
patients	POS	O
,	POS	O
hypotension	POS	B-NP
was	POS	O
associated	POS	O
with	POS	O
severe	POS	O
left	POS	O
ventricular	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
All	POS	O
three	POS	O
patients	POS	O
required	POS	O
therapy	POS	O
discontinuation	POS	O
.	POS	O
Cardiac	POS	O
enzymes	POS	O
remained	POS	O
normal	POS	O
despite	POS	O
transient	POS	O
electrocardiographic	POS	O
(	POS	O
EKG	POS	O
)	POS	O
changes	POS	O
.	POS	O
The	POS	O
presentation	POS	O
and	POS	O
cardiac	POS	O
evaluation	POS	O
(	POS	O
hemodynamic	POS	O
,	POS	O
echocardiographic	POS	O
,	POS	O
and	POS	O
scintigraphic	POS	O
)	POS	O
of	POS	O
these	POS	O
patients	POS	O
suggest	POS	O
new	POS	O
manifestations	POS	O
of	POS	O
5	POS	O
-	POS	O
FU	POS	O
cardiotoxicity	POS	B-NP
that	POS	O
may	POS	O
be	POS	O
influenced	POS	O
by	POS	O
CDDP	POS	O
.	POS	O
The	POS	O
possible	POS	O
pathophysiologic	POS	O
mechanisms	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Fatal	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
in	POS	O
a	POS	O
patient	POS	O
treated	POS	O
with	POS	O
carbamazepine	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
fatal	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
due	POS	O
to	POS	O
carbamazepine	POS	O
treatment	POS	O
in	POS	O
an	POS	O
epileptic	POS	B-NP
woman	POS	O
is	POS	O
reported	POS	O
.	POS	O
Despite	POS	O
concerns	POS	O
of	POS	O
fatal	POS	O
bone	POS	B-NP
marrow	POS	I-NP
toxicity	POS	I-NP
due	POS	O
to	POS	O
carbamazepine	POS	O
,	POS	O
this	POS	O
is	POS	O
only	POS	O
the	POS	O
fourth	POS	O
documented	POS	O
and	POS	O
published	POS	O
report	POS	O
.	POS	O
Carbamazepine	POS	O
is	POS	O
a	POS	O
safe	POS	O
drug	POS	O
,	POS	O
but	POS	O
physicians	POS	O
and	POS	O
patients	POS	O
should	POS	O
be	POS	O
aware	POS	O
of	POS	O
the	POS	O
exceedingly	POS	O
rare	POS	O
but	POS	O
potentially	POS	O
fatal	POS	O
side	POS	O
effects	POS	O
,	POS	O
better	POS	O
prevented	POS	O
by	POS	O
clinical	POS	O
than	POS	O
by	POS	O
laboratory	POS	O
monitoring	POS	O
.	POS	O
Participation	POS	O
of	POS	O
a	POS	O
bulbospinal	POS	O
serotonergic	POS	O
pathway	POS	O
in	POS	O
the	POS	O
rat	POS	O
brain	POS	O
in	POS	O
clonidine	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
and	POS	O
bradycardia	POS	B-NP
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
microinjection	POS	O
of	POS	O
clonidine	POS	O
(	POS	O
1	POS	O
-	POS	O
10	POS	O
micrograms	POS	O
in	POS	O
1	POS	O
microliter	POS	O
)	POS	O
into	POS	O
a	POS	O
region	POS	O
adjacent	POS	O
to	POS	O
the	POS	O
ventrolateral	POS	O
surface	POS	O
of	POS	O
the	POS	O
medulla	POS	O
oblongata	POS	O
on	POS	O
cardiovascular	POS	O
function	POS	O
were	POS	O
assessed	POS	O
in	POS	O
urethane	POS	O
-	POS	O
anesthetized	POS	O
rats	POS	O
.	POS	O
Intramedullary	POS	O
administration	POS	O
of	POS	O
clonidine	POS	O
,	POS	O
but	POS	O
not	POS	O
saline	POS	O
vehicle	POS	O
,	POS	O
caused	POS	O
a	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
decrease	POS	O
in	POS	O
both	POS	O
the	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
and	POS	O
the	POS	O
heart	POS	O
rate	POS	O
.	POS	O
The	POS	O
clonidine	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
was	POS	O
antagonized	POS	O
by	POS	O
prior	POS	O
spinal	POS	O
transection	POS	O
,	POS	O
but	POS	O
not	POS	O
bilateral	POS	O
vagotomy	POS	O
.	POS	O
On	POS	O
the	POS	O
other	POS	O
hand	POS	O
,	POS	O
the	POS	O
clonidine	POS	O
-	POS	O
induced	POS	O
bradycardia	POS	B-NP
was	POS	O
antagonized	POS	O
by	POS	O
prior	POS	O
bilateral	POS	O
vagotomy	POS	O
,	POS	O
but	POS	O
not	POS	O
spinal	POS	O
transection	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
selective	POS	O
destruction	POS	O
of	POS	O
the	POS	O
spinal	POS	O
5	POS	O
-	POS	O
HT	POS	O
nerves	POS	O
,	POS	O
produced	POS	O
by	POS	O
bilateral	POS	O
spinal	POS	O
injection	POS	O
of	POS	O
5	POS	O
,	POS	O
7	POS	O
-	POS	O
dihydroxytryptamine	POS	O
,	POS	O
reduced	POS	O
the	POS	O
magnitude	POS	O
of	POS	O
the	POS	O
vasodepressor	POS	O
or	POS	O
the	POS	O
bradycardiac	POS	O
responses	POS	O
to	POS	O
clonidine	POS	O
microinjected	POS	O
into	POS	O
the	POS	O
area	POS	O
near	POS	O
the	POS	O
ventrolateral	POS	O
surface	POS	O
of	POS	O
the	POS	O
medulla	POS	O
oblongata	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
data	POS	O
indicate	POS	O
that	POS	O
a	POS	O
bulbospinal	POS	O
serotonergic	POS	O
pathway	POS	O
is	POS	O
involved	POS	O
in	POS	O
development	POS	O
of	POS	O
clonidine	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
and	POS	O
bradycardia	POS	B-NP
.	POS	O
The	POS	O
induced	POS	O
hypotension	POS	B-NP
is	POS	O
brought	POS	O
about	POS	O
by	POS	O
a	POS	O
decrease	POS	O
in	POS	O
sympathetic	POS	O
efferent	POS	O
activity	POS	O
,	POS	O
whereas	POS	O
the	POS	O
induced	POS	O
bradycardia	POS	B-NP
was	POS	O
due	POS	O
to	POS	O
an	POS	O
increase	POS	O
in	POS	O
vagal	POS	O
efferent	POS	O
activity	POS	O
.	POS	O
Hypertension	POS	B-NP
in	POS	O
neuroblastoma	POS	B-NP
induced	POS	O
by	POS	O
imipramine	POS	O
.	POS	O
Hypertension	POS	B-NP
is	POS	O
a	POS	O
well	POS	O
-	POS	O
known	POS	O
finding	POS	O
in	POS	O
some	POS	O
patients	POS	O
with	POS	O
neuroblastoma	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
it	POS	O
has	POS	O
not	POS	O
previously	POS	O
been	POS	O
described	POS	O
in	POS	O
association	POS	O
with	POS	O
the	POS	O
use	POS	O
of	POS	O
Imipramine	POS	O
.	POS	O
We	POS	O
report	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
severe	POS	O
hypertension	POS	B-NP
(	POS	O
blood	POS	O
pressure	POS	O
190	POS	O
/	POS	O
160	POS	O
)	POS	O
in	POS	O
a	POS	O
4	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
girl	POS	O
with	POS	O
neuroblastoma	POS	B-NP
who	POS	O
was	POS	O
given	POS	O
Imipramine	POS	O
to	POS	O
control	POS	O
a	POS	O
behavior	POS	B-NP
disorder	POS	I-NP
.	POS	O
It	POS	O
was	POS	O
determined	POS	O
later	POS	O
that	POS	O
this	POS	O
patient	POS	O
'	POS	O
s	POS	O
tumor	POS	B-NP
was	POS	O
recurring	POS	O
at	POS	O
the	POS	O
time	POS	O
of	POS	O
her	POS	O
hypertensive	POS	B-NP
episode	POS	O
.	POS	O
Since	POS	O
she	POS	O
had	POS	O
no	POS	O
blood	POS	O
pressure	POS	O
elevation	POS	O
at	POS	O
initial	POS	O
diagnosis	POS	O
and	POS	O
none	POS	O
following	POS	O
discontinuation	POS	O
of	POS	O
the	POS	O
Imipramine	POS	O
(	POS	O
when	POS	O
she	POS	O
was	POS	O
in	POS	O
florid	POS	O
relapse	POS	O
)	POS	O
,	POS	O
we	POS	O
believe	POS	O
that	POS	O
this	POS	O
drug	POS	O
rather	POS	O
than	POS	O
her	POS	O
underlying	POS	O
disease	POS	O
alone	POS	O
caused	POS	O
her	POS	O
hypertension	POS	B-NP
.	POS	O
The	POS	O
mechanism	POS	O
for	POS	O
this	POS	O
reaction	POS	O
is	POS	O
believed	POS	O
to	POS	O
be	POS	O
increased	POS	O
levels	POS	O
of	POS	O
vasoactive	POS	O
catecholamines	POS	O
due	POS	O
to	POS	O
interference	POS	O
of	POS	O
their	POS	O
physiologic	POS	O
inactivation	POS	O
by	POS	O
Imipramine	POS	O
.	POS	O
From	POS	O
this	POS	O
experience	POS	O
,	POS	O
we	POS	O
urge	POS	O
extreme	POS	O
caution	POS	O
in	POS	O
the	POS	O
use	POS	O
of	POS	O
tricyclic	POS	O
antidepressants	POS	O
in	POS	O
children	POS	O
with	POS	O
active	POS	O
neuroblastoma	POS	B-NP
.	POS	O
Rechallenge	POS	O
of	POS	O
patients	POS	O
who	POS	O
developed	POS	O
oral	POS	O
candidiasis	POS	B-NP
or	POS	O
hoarseness	POS	B-NP
with	POS	O
beclomethasone	POS	O
dipropionate	POS	O
.	POS	O
Of	POS	O
158	POS	O
asthmatic	POS	B-NP
patients	POS	O
who	POS	O
were	POS	O
placed	POS	O
on	POS	O
inhaled	POS	O
beclomethasone	POS	O
,	POS	O
15	POS	O
(	POS	O
9	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
developed	POS	O
either	POS	O
hoarseness	POS	B-NP
(	POS	O
8	POS	O
)	POS	O
,	POS	O
oral	POS	O
thrush	POS	B-NP
(	POS	O
6	POS	O
)	POS	O
,	POS	O
or	POS	O
both	POS	O
(	POS	O
1	POS	O
)	POS	O
.	POS	O
When	POS	O
their	POS	O
adverse	POS	O
reactions	POS	O
subsided	POS	O
,	POS	O
seven	POS	O
of	POS	O
these	POS	O
15	POS	O
patients	POS	O
were	POS	O
rechallenged	POS	O
with	POS	O
inhaled	POS	O
beclomethasone	POS	O
.	POS	O
These	POS	O
included	POS	O
five	POS	O
cases	POS	O
who	POS	O
developed	POS	O
hoarseness	POS	B-NP
and	POS	O
three	POS	O
who	POS	O
developed	POS	O
Candidiasis	POS	B-NP
.	POS	O
One	POS	O
patient	POS	O
had	POS	O
both	POS	O
.	POS	O
Oral	POS	O
thrush	POS	B-NP
did	POS	O
not	POS	O
recur	POS	O
,	POS	O
but	POS	O
60	POS	O
%	POS	O
(	POS	O
3	POS	O
/	POS	O
5	POS	O
)	POS	O
of	POS	O
patients	POS	O
with	POS	O
hoarseness	POS	B-NP
had	POS	O
recurrence	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
patients	POS	O
may	POS	O
be	POS	O
restarted	POS	O
on	POS	O
inhaled	POS	O
beclomethasone	POS	O
when	POS	O
clinically	POS	O
indicated	POS	O
;	POS	O
however	POS	O
,	POS	O
because	POS	O
of	POS	O
the	POS	O
high	POS	O
recurrence	POS	O
rate	POS	O
,	POS	O
patients	POS	O
who	POS	O
develop	POS	O
hoarseness	POS	B-NP
should	POS	O
not	POS	O
be	POS	O
re	POS	O
-	POS	O
challenged	POS	O
.	POS	O
Concomitant	POS	O
use	POS	O
of	POS	O
oral	POS	O
prednisone	POS	O
and	POS	O
topical	POS	O
beclomethasone	POS	O
may	POS	O
increase	POS	O
the	POS	O
risk	POS	O
of	POS	O
developing	POS	O
hoarseness	POS	B-NP
or	POS	O
candidiasis	POS	B-NP
.	POS	O
Cyclophosphamide	POS	B-NP
cardiotoxicity	POS	I-NP
:	POS	O
an	POS	O
analysis	POS	O
of	POS	O
dosing	POS	O
as	POS	O
a	POS	O
risk	POS	O
factor	POS	O
.	POS	O
Patients	POS	O
who	POS	O
undergo	POS	O
bone	POS	O
marrow	POS	O
transplantation	POS	O
are	POS	O
generally	POS	O
immunosuppressed	POS	O
with	POS	O
a	POS	O
dose	POS	O
of	POS	O
cyclophosphamide	POS	O
(	POS	O
CYA	POS	O
)	POS	O
which	POS	O
is	POS	O
usually	POS	O
calculated	POS	O
based	POS	O
on	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
weight	POS	O
.	POS	O
At	POS	O
these	POS	O
high	POS	O
doses	POS	O
of	POS	O
CYA	POS	O
,	POS	O
serious	POS	O
cardiotoxicity	POS	B-NP
may	POS	O
occur	POS	O
,	POS	O
but	POS	O
definitive	POS	O
risk	POS	O
factors	POS	O
for	POS	O
the	POS	O
development	POS	O
of	POS	O
such	POS	O
cardiotoxicity	POS	B-NP
have	POS	O
not	POS	O
been	POS	O
described	POS	O
.	POS	O
Since	POS	O
chemotherapeutic	POS	O
agent	POS	O
toxicity	POS	B-NP
generally	POS	O
correlates	POS	O
with	POS	O
dose	POS	O
per	POS	O
body	POS	O
surface	POS	O
area	POS	O
,	POS	O
we	POS	O
retrospectively	POS	O
calculated	POS	O
the	POS	O
dose	POS	O
of	POS	O
CYA	POS	O
in	POS	O
patients	POS	O
transplanted	POS	O
at	POS	O
our	POS	O
institution	POS	O
to	POS	O
determine	POS	O
whether	POS	O
the	POS	O
incidence	POS	O
of	POS	O
CYA	POS	O
cardiotoxicity	POS	B-NP
correlated	POS	O
with	POS	O
the	POS	O
dose	POS	O
per	POS	O
body	POS	O
surface	POS	O
area	POS	O
.	POS	O
Eighty	POS	O
patients	POS	O
who	POS	O
were	POS	O
to	POS	O
receive	POS	O
CYA	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
d	POS	O
for	POS	O
four	POS	O
days	POS	O
as	POS	O
preparation	POS	O
for	POS	O
marrow	POS	O
grafting	POS	O
underwent	POS	O
a	POS	O
total	POS	O
of	POS	O
84	POS	O
transplants	POS	O
for	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
,	POS	O
Wiskott	POS	B-NP
-	POS	I-NP
Aldrich	POS	I-NP
syndrome	POS	I-NP
,	POS	O
or	POS	O
severe	POS	O
combined	POS	O
immunodeficiency	POS	B-NP
syndrome	POS	I-NP
.	POS	O
Fourteen	POS	O
of	POS	O
84	POS	O
(	POS	O
17	POS	O
%	POS	O
)	POS	O
patients	POS	O
had	POS	O
symptoms	POS	O
and	POS	O
signs	POS	O
consistent	POS	O
with	POS	O
CYA	POS	O
cardiotoxicity	POS	B-NP
within	POS	O
ten	POS	O
days	POS	O
of	POS	O
receiving	POS	O
1	POS	O
to	POS	O
4	POS	O
doses	POS	O
of	POS	O
CYA	POS	O
.	POS	O
Six	POS	O
of	POS	O
the	POS	O
14	POS	O
patients	POS	O
died	POS	O
with	POS	O
congestive	POS	B-NP
heart	POS	I-NP
failure	POS	I-NP
.	POS	O
The	POS	O
dose	POS	O
of	POS	O
CYA	POS	O
per	POS	O
body	POS	O
surface	POS	O
area	POS	O
was	POS	O
calculated	POS	O
for	POS	O
all	POS	O
patients	POS	O
and	POS	O
the	POS	O
patients	POS	O
were	POS	O
divided	POS	O
into	POS	O
two	POS	O
groups	POS	O
based	POS	O
on	POS	O
daily	POS	O
CYA	POS	O
dose	POS	O
:	POS	O
Group	POS	O
1	POS	O
,	POS	O
CYA	POS	O
less	POS	O
than	POS	O
or	POS	O
equal	POS	O
to	POS	O
1	POS	O
.	POS	O
55	POS	O
g	POS	O
/	POS	O
m2	POS	O
/	POS	O
d	POS	O
;	POS	O
Group	POS	O
2	POS	O
,	POS	O
CYA	POS	O
greater	POS	O
than	POS	O
1	POS	O
.	POS	O
55	POS	O
g	POS	O
/	POS	O
m2	POS	O
/	POS	O
d	POS	O
.	POS	O
Cardiotoxicity	POS	B-NP
that	POS	O
was	POS	O
thought	POS	O
to	POS	O
be	POS	O
related	POS	O
to	POS	O
CYA	POS	O
occurred	POS	O
in	POS	O
1	POS	O
/	POS	O
32	POS	O
(	POS	O
3	POS	O
%	POS	O
)	POS	O
of	POS	O
patients	POS	O
in	POS	O
Group	POS	O
1	POS	O
and	POS	O
in	POS	O
13	POS	O
/	POS	O
52	POS	O
(	POS	O
25	POS	O
%	POS	O
)	POS	O
patients	POS	O
in	POS	O
Group	POS	O
2	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
025	POS	O
)	POS	O
.	POS	O
Congestive	POS	B-NP
heart	POS	I-NP
failure	POS	I-NP
caused	POS	O
or	POS	O
contributed	POS	O
to	POS	O
death	POS	O
in	POS	O
0	POS	O
/	POS	O
32	POS	O
patients	POS	O
in	POS	O
Group	POS	O
1	POS	O
v	POS	O
6	POS	O
/	POS	O
52	POS	O
(	POS	O
12	POS	O
%	POS	O
)	POS	O
of	POS	O
patients	POS	O
in	POS	O
Group	POS	O
2	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
25	POS	O
)	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
difference	POS	O
in	POS	O
the	POS	O
rate	POS	O
of	POS	O
engraftment	POS	O
of	POS	O
evaluable	POS	O
patients	POS	O
in	POS	O
the	POS	O
two	POS	O
groups	POS	O
(	POS	O
P	POS	O
greater	POS	O
than	POS	O
0	POS	O
.	POS	O
5	POS	O
)	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
the	POS	O
CYA	POS	O
cardiotoxicity	POS	B-NP
correlates	POS	O
with	POS	O
CYA	POS	O
dosage	POS	O
as	POS	O
calculated	POS	O
by	POS	O
body	POS	O
surface	POS	O
area	POS	O
,	POS	O
and	POS	O
that	POS	O
patients	POS	O
with	POS	O
aplastic	POS	B-NP
anemia	POS	I-NP
and	POS	O
immunodeficiencies	POS	B-NP
can	POS	O
be	POS	O
effectively	POS	O
prepared	POS	O
for	POS	O
bone	POS	O
marrow	POS	O
grafting	POS	O
at	POS	O
a	POS	O
CYA	POS	O
dose	POS	O
of	POS	O
1	POS	O
.	POS	O
55	POS	O
g	POS	O
/	POS	O
m2	POS	O
/	POS	O
d	POS	O
for	POS	O
four	POS	O
days	POS	O
with	POS	O
a	POS	O
lower	POS	O
incidence	POS	O
of	POS	O
cardiotoxicity	POS	B-NP
than	POS	O
patients	POS	O
whose	POS	O
CYA	POS	O
dosage	POS	O
is	POS	O
calculated	POS	O
based	POS	O
on	POS	O
weight	POS	O
.	POS	O
This	POS	O
study	POS	O
reaffirms	POS	O
the	POS	O
principle	POS	O
that	POS	O
drug	POS	O
toxicity	POS	B-NP
correlates	POS	O
with	POS	O
dose	POS	O
per	POS	O
body	POS	O
surface	POS	O
area	POS	O
.	POS	O
Studies	POS	O
of	POS	O
risk	POS	O
factors	POS	O
for	POS	O
aminoglycoside	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
The	POS	O
epidemiology	POS	O
of	POS	O
aminoglycoside	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
is	POS	O
not	POS	O
fully	POS	O
understood	POS	O
.	POS	O
Experimental	POS	O
studies	POS	O
in	POS	O
healthy	POS	O
human	POS	O
volunteers	POS	O
indicate	POS	O
aminoglycosides	POS	O
cause	POS	O
proximal	POS	O
tubular	POS	B-NP
damage	POS	I-NP
in	POS	O
most	POS	O
patients	POS	O
,	POS	O
but	POS	O
rarely	POS	O
,	POS	O
if	POS	O
ever	POS	O
,	POS	O
cause	POS	O
glomerular	POS	B-NP
or	POS	I-NP
tubular	POS	I-NP
dysfunction	POS	I-NP
.	POS	O
Clinical	POS	O
trials	POS	O
of	POS	O
aminoglycosides	POS	O
in	POS	O
seriously	POS	O
ill	POS	O
patients	POS	O
indicate	POS	O
that	POS	O
the	POS	O
relative	POS	O
risk	POS	O
for	POS	O
developing	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
during	POS	O
therapy	POS	O
ranges	POS	O
from	POS	O
8	POS	O
to	POS	O
10	POS	O
and	POS	O
that	POS	O
the	POS	O
attributable	POS	O
risk	POS	O
is	POS	O
70	POS	O
%	POS	O
to	POS	O
80	POS	O
%	POS	O
.	POS	O
Further	POS	O
analysis	POS	O
of	POS	O
these	POS	O
data	POS	O
suggests	POS	O
that	POS	O
the	POS	O
duration	POS	O
of	POS	O
therapy	POS	O
,	POS	O
plasma	POS	O
aminoglycoside	POS	O
levels	POS	O
,	POS	O
liver	POS	B-NP
disease	POS	I-NP
,	POS	O
advanced	POS	O
age	POS	O
,	POS	O
high	POS	O
initial	POS	O
estimated	POS	O
creatinine	POS	O
clearance	POS	O
and	POS	O
,	POS	O
possibly	POS	O
,	POS	O
female	POS	O
gender	POS	O
all	POS	O
increase	POS	O
the	POS	O
risk	POS	O
for	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
Other	POS	O
causes	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
,	POS	O
such	POS	O
as	POS	O
shock	POS	B-NP
,	POS	O
appear	POS	O
to	POS	O
have	POS	O
an	POS	O
additive	POS	O
effect	POS	O
.	POS	O
Predictive	POS	O
models	POS	O
have	POS	O
been	POS	O
developed	POS	O
from	POS	O
these	POS	O
analyses	POS	O
that	POS	O
should	POS	O
be	POS	O
useful	POS	O
for	POS	O
identifying	POS	O
patients	POS	O
at	POS	O
high	POS	O
risk	POS	O
.	POS	O
These	POS	O
models	POS	O
may	POS	O
also	POS	O
be	POS	O
useful	POS	O
in	POS	O
developing	POS	O
insights	POS	O
into	POS	O
the	POS	O
pathophysiology	POS	O
of	POS	O
aminoglycoside	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
Central	POS	O
action	POS	O
of	POS	O
narcotic	POS	O
analgesics	POS	O
.	POS	O
Part	POS	O
IV	POS	O
.	POS	O
Noradrenergic	POS	O
influences	POS	O
on	POS	O
the	POS	O
activity	POS	O
of	POS	O
analgesics	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
effect	POS	O
of	POS	O
clonidine	POS	O
,	POS	O
naphazoline	POS	O
and	POS	O
xylometazoline	POS	O
on	POS	O
analgesia	POS	O
induced	POS	O
by	POS	O
morphine	POS	O
,	POS	O
codeine	POS	O
,	POS	O
fentanyl	POS	O
and	POS	O
pentazocine	POS	O
,	POS	O
and	POS	O
on	POS	O
cataleptic	POS	O
effect	POS	O
of	POS	O
morphine	POS	O
,	POS	O
codine	POS	O
and	POS	O
fentanyl	POS	O
was	POS	O
studied	POS	O
in	POS	O
rats	POS	O
.	POS	O
The	POS	O
biochemical	POS	O
assays	POS	O
on	POS	O
the	POS	O
influence	POS	O
of	POS	O
four	POS	O
analgesics	POS	O
on	POS	O
the	POS	O
brain	POS	O
concentration	POS	O
and	POS	O
turnover	POS	O
of	POS	O
noradrenaline	POS	O
(	POS	O
NA	POS	O
)	POS	O
were	POS	O
also	POS	O
performed	POS	O
.	POS	O
It	POS	O
was	POS	O
found	POS	O
that	POS	O
three	POS	O
drugs	POS	O
stimulating	POS	O
central	POS	O
NA	POS	O
receptors	POS	O
failed	POS	O
to	POS	O
affect	POS	O
the	POS	O
analgesic	POS	O
ED50	POS	O
of	POS	O
all	POS	O
antinociceptive	POS	O
agents	POS	O
and	POS	O
they	POS	O
enhanced	POS	O
catalepsy	POS	B-NP
induced	POS	O
by	POS	O
morphine	POS	O
and	POS	O
fentanyl	POS	O
.	POS	O
Codeine	POS	O
catalepsy	POS	B-NP
was	POS	O
increased	POS	O
by	POS	O
clonidine	POS	O
and	POS	O
decreased	POS	O
by	POS	O
naphazoline	POS	O
and	POS	O
xylometazoline	POS	O
.	POS	O
The	POS	O
brain	POS	O
concentration	POS	O
of	POS	O
NA	POS	O
was	POS	O
not	POS	O
changed	POS	O
by	POS	O
morphine	POS	O
and	POS	O
fentanyl	POS	O
,	POS	O
but	POS	O
one	POS	O
of	POS	O
the	POS	O
doses	POS	O
of	POS	O
codeine	POS	O
(	POS	O
45	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
slightly	POS	O
enhanced	POS	O
it	POS	O
.	POS	O
Pentazocine	POS	O
dose	POS	O
-	POS	O
dependently	POS	O
decreased	POS	O
the	POS	O
brain	POS	O
level	POS	O
of	POS	O
NA	POS	O
.	POS	O
The	POS	O
rate	POS	O
of	POS	O
NA	POS	O
turnover	POS	O
was	POS	O
not	POS	O
altered	POS	O
by	POS	O
analgesics	POS	O
except	POS	O
for	POS	O
the	POS	O
higher	POS	O
dose	POS	O
of	POS	O
fentanyl	POS	O
(	POS	O
0	POS	O
.	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
following	POS	O
which	POS	O
the	POS	O
disappearance	POS	O
of	POS	O
NA	POS	O
from	POS	O
the	POS	O
brain	POS	O
was	POS	O
diminished	POS	O
.	POS	O
The	POS	O
results	POS	O
are	POS	O
discussed	POS	O
in	POS	O
the	POS	O
light	POS	O
of	POS	O
various	POS	O
and	POS	O
non	POS	O
-	POS	O
uniform	POS	O
data	POS	O
from	POS	O
the	POS	O
literature	POS	O
.	POS	O
It	POS	O
is	POS	O
suggested	POS	O
that	POS	O
in	POS	O
rats	POS	O
the	POS	O
brain	POS	O
NA	POS	O
plays	POS	O
a	POS	O
less	POS	O
important	POS	O
function	POS	O
than	POS	O
the	POS	O
other	POS	O
monoamines	POS	O
in	POS	O
the	POS	O
behavioural	POS	O
activity	POS	O
of	POS	O
potent	POS	O
analgesics	POS	O
.	POS	O
Flurothyl	POS	O
seizure	POS	B-NP
thresholds	POS	O
in	POS	O
mice	POS	O
treated	POS	O
neonatally	POS	O
with	POS	O
a	POS	O
single	POS	O
injection	POS	O
of	POS	O
monosodium	POS	O
glutamate	POS	O
(	POS	O
MSG	POS	O
)	POS	O
:	POS	O
evaluation	POS	O
of	POS	O
experimental	POS	O
parameters	POS	O
in	POS	O
flurothyl	POS	O
seizure	POS	B-NP
testing	POS	O
.	POS	O
Monosodium	POS	O
glutamate	POS	O
(	POS	O
MSG	POS	O
)	POS	O
administration	POS	O
to	POS	O
neonatal	POS	O
rodents	POS	O
produces	POS	O
convulsions	POS	B-NP
and	POS	O
results	POS	O
in	POS	O
numerous	POS	O
biochemical	POS	O
and	POS	O
behavioral	POS	B-NP
deficits	POS	I-NP
.	POS	O
These	POS	O
studies	POS	O
were	POS	O
undertaken	POS	O
to	POS	O
determine	POS	O
if	POS	O
neonatal	POS	O
administration	POS	O
of	POS	O
MSG	POS	O
produced	POS	O
permanent	POS	O
alterations	POS	O
in	POS	O
seizure	POS	B-NP
susceptibility	POS	O
,	POS	O
since	POS	O
previous	POS	O
investigations	POS	O
were	POS	O
inconclusive	POS	O
.	POS	O
A	POS	O
flurothyl	POS	O
ether	POS	O
seizure	POS	B-NP
screening	POS	O
technique	POS	O
was	POS	O
used	POS	O
to	POS	O
evaluate	POS	O
seizure	POS	B-NP
susceptibility	POS	O
in	POS	O
adult	POS	O
mice	POS	O
that	POS	O
received	POS	O
neonatal	POS	O
injections	POS	O
of	POS	O
MSG	POS	O
(	POS	O
4	POS	O
mg	POS	O
/	POS	O
g	POS	O
and	POS	O
1	POS	O
mg	POS	O
/	POS	O
g	POS	O
)	POS	O
.	POS	O
MSG	POS	O
treatment	POS	O
resulted	POS	O
in	POS	O
significant	POS	O
reductions	POS	O
in	POS	O
whole	POS	O
brain	POS	O
weight	POS	O
but	POS	O
did	POS	O
not	POS	O
alter	POS	O
seizure	POS	B-NP
threshold	POS	O
.	POS	O
A	POS	O
naloxone	POS	O
(	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
challenge	POS	O
was	POS	O
also	POS	O
ineffective	POS	O
in	POS	O
altering	POS	O
the	POS	O
seizure	POS	B-NP
thresholds	POS	O
of	POS	O
either	POS	O
control	POS	O
of	POS	O
MSG	POS	O
-	POS	O
treated	POS	O
mice	POS	O
.	POS	O
Flurothyl	POS	O
ether	POS	O
produced	POS	O
hypothermia	POS	B-NP
which	POS	O
was	POS	O
correlated	POS	O
with	POS	O
the	POS	O
duration	POS	O
of	POS	O
flurothyl	POS	O
exposure	POS	O
;	POS	O
however	POS	O
,	POS	O
the	POS	O
relationship	POS	O
of	POS	O
hypothermia	POS	B-NP
to	POS	O
seizure	POS	B-NP
induction	POS	O
was	POS	O
unclear	POS	O
.	POS	O
Flurothyl	POS	O
seizure	POS	B-NP
testing	POS	O
proved	POS	O
to	POS	O
be	POS	O
a	POS	O
rapid	POS	O
and	POS	O
reliable	POS	O
technique	POS	O
with	POS	O
which	POS	O
to	POS	O
evaluate	POS	O
seizure	POS	B-NP
susceptibility	POS	O
.	POS	O
Susceptibility	POS	O
to	POS	O
seizures	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
in	POS	O
rats	POS	O
after	POS	O
microinjection	POS	O
of	POS	O
isoniazid	POS	O
or	POS	O
gamma	POS	O
-	POS	O
vinyl	POS	O
-	POS	O
GABA	POS	O
into	POS	O
the	POS	O
substantia	POS	O
nigra	POS	O
.	POS	O
Pilocarpine	POS	O
,	POS	O
given	POS	O
intraperitoneally	POS	O
to	POS	O
rats	POS	O
,	POS	O
reproduces	POS	O
the	POS	O
neuropathological	POS	O
sequelae	POS	O
of	POS	O
temporal	POS	B-NP
lobe	POS	I-NP
epilepsy	POS	I-NP
and	POS	O
provides	POS	O
a	POS	O
relevant	POS	O
animal	POS	O
model	POS	O
for	POS	O
studying	POS	O
mechanisms	POS	O
of	POS	O
buildup	POS	O
of	POS	O
convulsive	POS	B-NP
activity	POS	O
and	POS	O
pathways	POS	O
operative	POS	O
in	POS	O
the	POS	O
generalization	POS	O
and	POS	O
propagation	POS	O
of	POS	O
seizures	POS	B-NP
within	POS	O
the	POS	O
forebrain	POS	O
.	POS	O
In	POS	O
the	POS	O
present	POS	O
study	POS	O
,	POS	O
the	POS	O
effects	POS	O
of	POS	O
manipulating	POS	O
the	POS	O
activity	POS	O
of	POS	O
the	POS	O
gamma	POS	O
-	POS	O
aminobutyric	POS	O
acid	POS	O
(	POS	O
GABA	POS	O
)	POS	O
-	POS	O
mediated	POS	O
synaptic	POS	O
inhibition	POS	O
within	POS	O
the	POS	O
substantia	POS	O
nigra	POS	O
on	POS	O
seizures	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
in	POS	O
rats	POS	O
,	POS	O
were	POS	O
investigated	POS	O
.	POS	O
In	POS	O
animals	POS	O
pretreated	POS	O
with	POS	O
microinjections	POS	O
of	POS	O
isoniazid	POS	O
,	POS	O
150	POS	O
micrograms	POS	O
,	POS	O
an	POS	O
inhibitor	POS	O
of	POS	O
activity	POS	O
of	POS	O
the	POS	O
GABA	POS	O
-	POS	O
synthesizing	POS	O
enzyme	POS	O
,	POS	O
L	POS	O
-	POS	O
glutamic	POS	O
acid	POS	O
decarboxylase	POS	O
,	POS	O
into	POS	O
the	POS	O
substantia	POS	O
nigra	POS	O
pars	POS	O
reticulata	POS	O
(	POS	O
SNR	POS	O
)	POS	O
,	POS	O
bilaterally	POS	O
,	POS	O
non	POS	O
-	POS	O
convulsant	POS	O
doses	POS	O
of	POS	O
pilocarpine	POS	O
,	POS	O
100	POS	O
and	POS	O
200	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
resulted	POS	O
in	POS	O
severe	POS	O
motor	POS	B-NP
limbic	POS	I-NP
seizures	POS	I-NP
and	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
.	POS	O
Electroencephalographic	POS	O
and	POS	O
behavioral	POS	O
monitoring	POS	O
revealed	POS	O
a	POS	O
profound	POS	O
reduction	POS	O
of	POS	O
the	POS	O
threshold	POS	O
for	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
convulsions	POS	B-NP
.	POS	O
Morphological	POS	O
analysis	POS	O
of	POS	O
frontal	POS	O
forebrain	POS	O
sections	POS	O
with	POS	O
light	POS	O
microscopy	POS	O
revealed	POS	O
seizure	POS	B-NP
-	POS	O
related	POS	O
damage	POS	O
to	POS	O
the	POS	O
hippocampal	POS	O
formation	POS	O
,	POS	O
thalamus	POS	O
,	POS	O
amygdala	POS	O
,	POS	O
olfactory	POS	O
cortex	POS	O
,	POS	O
substantia	POS	O
nigra	POS	O
and	POS	O
neocortex	POS	O
,	POS	O
which	POS	O
is	POS	O
typically	POS	O
observed	POS	O
with	POS	O
pilocarpine	POS	O
in	POS	O
doses	POS	O
exceeding	POS	O
350	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
Bilateral	POS	O
intrastriatal	POS	O
injections	POS	O
of	POS	O
isoniazid	POS	O
did	POS	O
not	POS	O
augment	POS	O
seizures	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
,	POS	O
200	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
Application	POS	O
of	POS	O
an	POS	O
irreversible	POS	O
inhibitor	POS	O
of	POS	O
GABA	POS	O
transaminase	POS	O
,	POS	O
gamma	POS	O
-	POS	O
vinyl	POS	O
-	POS	O
GABA	POS	O
(	POS	O
D	POS	O
,	POS	O
L	POS	O
-	POS	O
4	POS	O
-	POS	O
amino	POS	O
-	POS	O
hex	POS	O
-	POS	O
5	POS	O
-	POS	O
enoic	POS	O
acid	POS	O
)	POS	O
,	POS	O
5	POS	O
micrograms	POS	O
,	POS	O
into	POS	O
the	POS	O
SNR	POS	O
,	POS	O
bilaterally	POS	O
,	POS	O
suppressed	POS	O
the	POS	O
appearance	POS	O
of	POS	O
electrographic	POS	O
and	POS	O
behavioral	POS	O
seizures	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
,	POS	O
380	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
This	POS	O
treatment	POS	O
was	POS	O
also	POS	O
sufficient	POS	O
to	POS	O
protect	POS	O
animals	POS	O
from	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
brain	POS	O
damage	POS	O
.	POS	O
Microinjections	POS	O
of	POS	O
gamma	POS	O
-	POS	O
vinyl	POS	O
-	POS	O
GABA	POS	O
,	POS	O
5	POS	O
micrograms	POS	O
,	POS	O
into	POS	O
the	POS	O
dorsal	POS	O
striatum	POS	O
,	POS	O
bilaterally	POS	O
,	POS	O
failed	POS	O
to	POS	O
prevent	POS	O
the	POS	O
development	POS	O
of	POS	O
convulsions	POS	B-NP
produced	POS	O
by	POS	O
pilocarpine	POS	O
,	POS	O
380	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
The	POS	O
results	POS	O
demonstrate	POS	O
that	POS	O
the	POS	O
threshold	POS	O
for	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
in	POS	O
rats	POS	O
is	POS	O
subjected	POS	O
to	POS	O
the	POS	O
regulation	POS	O
of	POS	O
the	POS	O
GABA	POS	O
-	POS	O
mediated	POS	O
synaptic	POS	O
inhibition	POS	O
within	POS	O
the	POS	O
substantia	POS	O
nigra	POS	O
.	POS	O
Human	POS	O
and	POS	O
canine	POS	O
ventricular	POS	O
vasoactive	POS	O
intestinal	POS	O
polypeptide	POS	O
:	POS	O
decrease	POS	O
with	POS	O
heart	POS	B-NP
failure	POS	I-NP
.	POS	O
Vasoactive	POS	O
intestinal	POS	O
polypeptide	POS	O
(	POS	O
VIP	POS	O
)	POS	O
is	POS	O
a	POS	O
systemic	POS	O
and	POS	O
coronary	POS	O
vasodilator	POS	O
that	POS	O
may	POS	O
have	POS	O
positive	POS	O
inotropic	POS	O
properties	POS	O
.	POS	O
Myocardial	POS	O
levels	POS	O
of	POS	O
VIP	POS	O
were	POS	O
assayed	POS	O
before	POS	O
and	POS	O
after	POS	O
the	POS	O
development	POS	O
of	POS	O
heart	POS	B-NP
failure	POS	I-NP
in	POS	O
two	POS	O
canine	POS	O
models	POS	O
.	POS	O
In	POS	O
the	POS	O
first	POS	O
,	POS	O
cobalt	POS	O
cardiomyopathy	POS	B-NP
was	POS	O
induced	POS	O
in	POS	O
eight	POS	O
dogs	POS	O
;	POS	O
VIP	POS	O
(	POS	O
by	POS	O
radioimmunoassay	POS	O
)	POS	O
decreased	POS	O
from	POS	O
35	POS	O
+	POS	O
/	POS	O
-	POS	O
11	POS	O
pg	POS	O
/	POS	O
mg	POS	O
protein	POS	O
(	POS	O
mean	POS	O
+	POS	O
/	POS	O
-	POS	O
SD	POS	O
)	POS	O
to	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
pg	POS	O
/	POS	O
mg	POS	O
protein	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
In	POS	O
six	POS	O
dogs	POS	O
with	POS	O
doxorubicin	POS	O
-	POS	O
induced	POS	O
heart	POS	B-NP
failure	POS	I-NP
,	POS	O
VIP	POS	O
decreased	POS	O
from	POS	O
31	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
to	POS	O
11	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
pg	POS	O
/	POS	O
mg	POS	O
protein	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
VIP	POS	O
content	POS	O
of	POS	O
left	POS	O
ventricular	POS	O
muscle	POS	O
of	POS	O
resected	POS	O
failing	POS	O
hearts	POS	O
in	POS	O
10	POS	O
patients	POS	O
receiving	POS	O
a	POS	O
heart	POS	O
transplant	POS	O
was	POS	O
compared	POS	O
with	POS	O
the	POS	O
papillary	POS	O
muscles	POS	O
in	POS	O
14	POS	O
patients	POS	O
(	POS	O
five	POS	O
with	POS	O
rheumatic	POS	B-NP
disease	POS	I-NP
,	POS	O
nine	POS	O
with	POS	O
myxomatous	POS	B-NP
degeneration	POS	I-NP
)	POS	O
receiving	POS	O
mitral	POS	B-NP
valve	POS	I-NP
prostheses	POS	I-NP
.	POS	O
The	POS	O
lowest	POS	O
myocardial	POS	O
VIP	POS	O
concentration	POS	O
was	POS	O
found	POS	O
in	POS	O
the	POS	O
hearts	POS	O
of	POS	O
patients	POS	O
with	POS	O
coronary	POS	B-NP
disease	POS	I-NP
(	POS	O
one	POS	O
patient	POS	O
receiving	POS	O
a	POS	O
transplant	POS	O
and	POS	O
three	POS	O
receiving	POS	O
mitral	POS	O
prostheses	POS	O
)	POS	O
(	POS	O
6	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
9	POS	O
pg	POS	O
/	POS	O
mg	POS	O
protein	POS	O
)	POS	O
.	POS	O
The	POS	O
other	POS	O
patients	POS	O
undergoing	POS	O
transplantation	POS	O
had	POS	O
an	POS	O
average	POS	O
ejection	POS	O
fraction	POS	O
of	POS	O
17	POS	O
%	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
%	POS	O
and	POS	O
a	POS	O
VIP	POS	O
level	POS	O
of	POS	O
8	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
.	POS	O
9	POS	O
pg	POS	O
/	POS	O
mg	POS	O
protein	POS	O
.	POS	O
The	POS	O
hearts	POS	O
without	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
(	POS	O
average	POS	O
ejection	POS	O
fraction	POS	O
of	POS	O
this	POS	O
group	POS	O
62	POS	O
%	POS	O
+	POS	O
/	POS	O
-	POS	O
10	POS	O
%	POS	O
)	POS	O
had	POS	O
a	POS	O
VIP	POS	O
concentration	POS	O
of	POS	O
14	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
.	POS	O
9	POS	O
pg	POS	O
/	POS	O
mg	POS	O
protein	POS	O
,	POS	O
and	POS	O
this	POS	O
was	POS	O
greater	POS	O
than	POS	O
in	POS	O
hearts	POS	O
of	POS	O
the	POS	O
patients	POS	O
with	POS	O
coronary	POS	B-NP
disease	POS	I-NP
and	POS	O
the	POS	O
hearts	POS	O
of	POS	O
patients	POS	O
receiving	POS	O
a	POS	O
transplant	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Myocardial	POS	O
catecholamines	POS	O
were	POS	O
also	POS	O
determined	POS	O
in	POS	O
14	POS	O
subjects	POS	O
;	POS	O
a	POS	O
weak	POS	O
correlation	POS	O
(	POS	O
r	POS	O
=	POS	O
0	POS	O
.	POS	O
57	POS	O
,	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
between	POS	O
the	POS	O
tissue	POS	O
concentrations	POS	O
of	POS	O
VIP	POS	O
and	POS	O
norepinephrine	POS	O
was	POS	O
noted	POS	O
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
250	POS	O
WORDS	POS	O
)	POS	O
Non	POS	O
-	POS	O
invasive	POS	O
detection	POS	O
of	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
by	POS	O
body	POS	O
surface	POS	O
electrocardiographic	POS	O
mapping	POS	O
after	POS	O
dipyridamole	POS	O
infusion	POS	O
.	POS	O
Electrocardiographic	POS	O
changes	POS	O
after	POS	O
dipyridamole	POS	O
infusion	POS	O
(	POS	O
0	POS	O
.	POS	O
568	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
4	POS	O
min	POS	O
)	POS	O
were	POS	O
studied	POS	O
in	POS	O
41	POS	O
patients	POS	O
with	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
and	POS	O
compared	POS	O
with	POS	O
those	POS	O
after	POS	O
submaximal	POS	O
treadmill	POS	O
exercise	POS	O
by	POS	O
use	POS	O
of	POS	O
the	POS	O
body	POS	O
surface	POS	O
mapping	POS	O
technique	POS	O
.	POS	O
Patients	POS	O
were	POS	O
divided	POS	O
into	POS	O
three	POS	O
groups	POS	O
;	POS	O
19	POS	O
patients	POS	O
without	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
(	POS	O
non	POS	B-NP
-	POS	I-NP
MI	POS	I-NP
group	POS	O
)	POS	O
,	POS	O
14	POS	O
with	POS	O
anterior	POS	B-NP
infarction	POS	I-NP
(	POS	O
ANT	POS	B-NP
-	POS	I-NP
MI	POS	I-NP
)	POS	O
and	POS	O
eight	POS	O
with	POS	O
inferior	POS	B-NP
infarction	POS	I-NP
(	POS	O
INF	POS	B-NP
-	POS	I-NP
MI	POS	I-NP
)	POS	O
.	POS	O
Eighty	POS	O
-	POS	O
seven	POS	O
unipolar	POS	O
electrocardiograms	POS	O
(	POS	O
ECGs	POS	O
)	POS	O
distributed	POS	O
over	POS	O
the	POS	O
entire	POS	O
thoracic	POS	O
surface	POS	O
were	POS	O
simultaneously	POS	O
recorded	POS	O
.	POS	O
After	POS	O
dipyridamole	POS	O
,	POS	O
ischemic	POS	B-NP
ST	POS	I-NP
-	POS	I-NP
segment	POS	I-NP
depression	POS	I-NP
(	POS	O
0	POS	O
.	POS	O
05	POS	O
mV	POS	O
or	POS	O
more	POS	O
)	POS	O
was	POS	O
observed	POS	O
in	POS	O
84	POS	O
%	POS	O
of	POS	O
the	POS	O
non	POS	O
-	POS	O
MI	POS	B-NP
group	POS	O
,	POS	O
29	POS	O
%	POS	O
of	POS	O
the	POS	O
ANT	POS	O
-	POS	O
MI	POS	B-NP
group	POS	O
,	POS	O
63	POS	O
%	POS	O
of	POS	O
the	POS	O
INF	POS	O
-	POS	O
MI	POS	B-NP
group	POS	O
and	POS	O
61	POS	O
%	POS	O
of	POS	O
the	POS	O
total	POS	O
population	POS	O
.	POS	O
Exercise	POS	O
-	POS	O
induced	POS	O
ST	POS	B-NP
depression	POS	I-NP
was	POS	O
observed	POS	O
in	POS	O
84	POS	O
%	POS	O
of	POS	O
the	POS	O
non	POS	O
-	POS	O
MI	POS	B-NP
group	POS	O
,	POS	O
43	POS	O
%	POS	O
of	POS	O
the	POS	O
ANT	POS	O
-	POS	O
MI	POS	B-NP
group	POS	O
,	POS	O
38	POS	O
%	POS	O
of	POS	O
the	POS	O
INF	POS	O
-	POS	O
MI	POS	B-NP
group	POS	O
and	POS	O
61	POS	O
%	POS	O
of	POS	O
the	POS	O
total	POS	O
.	POS	O
For	POS	O
individual	POS	O
patients	POS	O
,	POS	O
there	POS	O
were	POS	O
no	POS	O
obvious	POS	O
differences	POS	O
between	POS	O
the	POS	O
body	POS	O
surface	POS	O
distribution	POS	O
of	POS	O
ST	POS	O
depression	POS	B-NP
in	POS	O
both	POS	O
tests	POS	O
.	POS	O
The	POS	O
increase	POS	O
in	POS	O
pressure	POS	O
rate	POS	O
product	POS	O
after	POS	O
dipyridamole	POS	O
was	POS	O
significantly	POS	O
less	POS	O
than	POS	O
that	POS	O
during	POS	O
the	POS	O
treadmill	POS	O
exercise	POS	O
.	POS	O
The	POS	O
data	POS	O
suggest	POS	O
that	POS	O
the	POS	O
dipyridamole	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
is	POS	O
caused	POS	O
by	POS	O
the	POS	O
inhomogenous	POS	O
distribution	POS	O
of	POS	O
myocardial	POS	O
blood	POS	O
flow	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
the	POS	O
dipyridamole	POS	O
ECG	POS	O
test	POS	O
is	POS	O
as	POS	O
useful	POS	O
as	POS	O
the	POS	O
exercise	POS	O
ECG	POS	O
test	POS	O
for	POS	O
the	POS	O
assessment	POS	O
of	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
.	POS	O
Bradycardia	POS	B-NP
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
intravenous	POS	O
methylprednisolone	POS	O
therapy	POS	O
.	POS	O
In	POS	O
5	POS	O
consecutive	POS	O
patients	POS	O
with	POS	O
rheumatoid	POS	B-NP
arthritis	POS	I-NP
who	POS	O
received	POS	O
intravenous	POS	O
high	POS	O
-	POS	O
dose	POS	O
methylprednisolone	POS	O
(	POS	O
MP	POS	O
)	POS	O
therapy	POS	O
(	POS	O
1	POS	O
g	POS	O
daily	POS	O
for	POS	O
2	POS	O
or	POS	O
3	POS	O
consecutive	POS	O
days	POS	O
)	POS	O
,	POS	O
a	POS	O
decline	POS	O
in	POS	O
pulse	POS	O
rate	POS	O
was	POS	O
observed	POS	O
,	POS	O
most	POS	O
pronounced	POS	O
on	POS	O
day	POS	O
4	POS	O
.	POS	O
In	POS	O
one	POS	O
of	POS	O
the	POS	O
5	POS	O
patients	POS	O
the	POS	O
bradycardia	POS	B-NP
was	POS	O
associated	POS	O
with	POS	O
complaints	POS	O
of	POS	O
substernal	POS	O
pressure	POS	O
.	POS	O
Reversal	POS	O
to	POS	O
normal	POS	O
heart	POS	O
rate	POS	O
was	POS	O
found	POS	O
on	POS	O
day	POS	O
7	POS	O
.	POS	O
Electrocardiographic	POS	O
registrations	POS	O
showed	POS	O
sinus	POS	B-NP
bradycardia	POS	I-NP
in	POS	O
all	POS	O
cases	POS	O
.	POS	O
No	POS	O
significant	POS	O
changes	POS	O
in	POS	O
plasma	POS	O
concentrations	POS	O
of	POS	O
electrolytes	POS	O
were	POS	O
found	POS	O
.	POS	O
Careful	POS	O
observation	POS	O
of	POS	O
patients	POS	O
receiving	POS	O
high	POS	O
-	POS	O
dose	POS	O
MP	POS	O
is	POS	O
recommended	POS	O
.	POS	O
High	POS	O
-	POS	O
dose	POS	O
MP	POS	O
may	POS	O
be	POS	O
contraindicated	POS	O
in	POS	O
patients	POS	O
with	POS	O
known	POS	O
heart	POS	B-NP
disease	POS	I-NP
.	POS	O
Two	POS	O
cases	POS	O
of	POS	O
downbeat	POS	B-NP
nystagmus	POS	I-NP
and	POS	O
oscillopsia	POS	B-NP
associated	POS	O
with	POS	O
carbamazepine	POS	O
.	POS	O
Downbeat	POS	B-NP
nystagmus	POS	I-NP
is	POS	O
often	POS	O
associated	POS	O
with	POS	O
structural	POS	O
lesions	POS	O
at	POS	O
the	POS	O
craniocervical	POS	O
junction	POS	O
,	POS	O
but	POS	O
has	POS	O
occasionally	POS	O
been	POS	O
reported	POS	O
as	POS	O
a	POS	O
manifestation	POS	O
of	POS	O
metabolic	POS	O
imbalance	POS	O
or	POS	O
drug	POS	O
intoxication	POS	O
.	POS	O
We	POS	O
recorded	POS	O
the	POS	O
eye	POS	O
movements	POS	O
of	POS	O
two	POS	O
patients	POS	O
with	POS	O
reversible	POS	O
downbeat	POS	B-NP
nystagmus	POS	I-NP
related	POS	O
to	POS	O
carbamazepine	POS	O
therapy	POS	O
.	POS	O
The	POS	O
nystagmus	POS	B-NP
of	POS	O
both	POS	O
patients	POS	O
resolved	POS	O
after	POS	O
reduction	POS	O
of	POS	O
the	POS	O
serum	POS	O
carbamazepine	POS	O
levels	POS	O
.	POS	O
Neuroradiologic	POS	O
investigations	POS	O
including	POS	O
magnetic	POS	O
resonance	POS	O
imaging	POS	O
scans	POS	O
in	POS	O
both	POS	O
patients	POS	O
showed	POS	O
no	POS	O
evidence	POS	O
of	POS	O
intracranial	POS	B-NP
abnormality	POS	I-NP
.	POS	O
In	POS	O
patients	POS	O
with	POS	O
downbeat	POS	B-NP
nystagmus	POS	I-NP
who	POS	O
are	POS	O
taking	POS	O
anticonvulsant	POS	O
medications	POS	O
,	POS	O
consideration	POS	O
should	POS	O
be	POS	O
given	POS	O
to	POS	O
reduction	POS	O
in	POS	O
dose	POS	O
before	POS	O
further	POS	O
investigation	POS	O
is	POS	O
undertaken	POS	O
.	POS	O
Improvement	POS	O
by	POS	O
denopamine	POS	O
(	POS	O
TA	POS	O
-	POS	O
064	POS	O
)	POS	O
of	POS	O
pentobarbital	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
failure	POS	I-NP
in	POS	O
the	POS	O
dog	POS	O
heart	POS	O
-	POS	O
lung	POS	O
preparation	POS	O
.	POS	O
The	POS	O
efficacy	POS	O
of	POS	O
denopamine	POS	O
,	POS	O
an	POS	O
orally	POS	O
active	POS	O
beta	POS	O
1	POS	O
-	POS	O
adrenoceptor	POS	O
agonist	POS	O
,	POS	O
in	POS	O
improving	POS	O
cardiac	POS	B-NP
failure	POS	I-NP
was	POS	O
assessed	POS	O
in	POS	O
dog	POS	O
heart	POS	O
-	POS	O
lung	POS	O
preparations	POS	O
.	POS	O
Cardiac	POS	O
functions	POS	O
depressed	POS	O
by	POS	O
pentobarbital	POS	O
(	POS	O
118	POS	O
+	POS	O
/	POS	O
-	POS	O
28	POS	O
mg	POS	O
;	POS	O
mean	POS	O
value	POS	O
+	POS	O
/	POS	O
-	POS	O
SD	POS	O
)	POS	O
such	POS	O
that	POS	O
cardiac	POS	O
output	POS	O
and	POS	O
maximum	POS	O
rate	POS	O
of	POS	O
rise	POS	O
of	POS	O
left	POS	O
ventricular	POS	O
pressure	POS	O
(	POS	O
LV	POS	O
dP	POS	O
/	POS	O
dt	POS	O
max	POS	O
)	POS	O
had	POS	O
been	POS	O
reduced	POS	O
by	POS	O
about	POS	O
35	POS	O
%	POS	O
and	POS	O
26	POS	O
%	POS	O
of	POS	O
the	POS	O
respective	POS	O
controls	POS	O
were	POS	O
improved	POS	O
by	POS	O
denopamine	POS	O
(	POS	O
10	POS	O
-	POS	O
300	POS	O
micrograms	POS	O
)	POS	O
in	POS	O
a	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
manner	POS	O
.	POS	O
With	POS	O
100	POS	O
micrograms	POS	O
denopamine	POS	O
,	POS	O
almost	POS	O
complete	POS	O
restoration	POS	O
of	POS	O
cardiac	POS	O
performance	POS	O
was	POS	O
attained	POS	O
,	POS	O
associated	POS	O
with	POS	O
a	POS	O
slight	POS	O
increase	POS	O
in	POS	O
heart	POS	O
rate	POS	O
.	POS	O
No	POS	O
arrhythmias	POS	B-NP
were	POS	O
induced	POS	O
by	POS	O
these	POS	O
doses	POS	O
of	POS	O
denopamine	POS	O
.	POS	O
The	POS	O
results	POS	O
warrant	POS	O
clinical	POS	O
trials	POS	O
of	POS	O
denopamine	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
cardiac	POS	B-NP
failure	POS	I-NP
.	POS	O
Clonazepam	POS	O
monotherapy	POS	O
for	POS	O
epilepsy	POS	B-NP
in	POS	O
childhood	POS	O
.	POS	O
Sixty	POS	O
patients	POS	O
(	POS	O
age	POS	O
-	POS	O
range	POS	O
one	POS	O
month	POS	O
to	POS	O
14	POS	O
years	POS	O
)	POS	O
with	POS	O
other	POS	O
types	POS	O
of	POS	O
epilepsy	POS	B-NP
than	POS	O
infantile	POS	B-NP
spasms	POS	I-NP
were	POS	O
treated	POS	O
with	POS	O
clonazepam	POS	O
.	POS	O
Disappearance	POS	O
of	POS	O
seizures	POS	B-NP
and	POS	O
normalization	POS	O
of	POS	O
abnormal	POS	O
EEG	POS	O
with	POS	O
disappearance	POS	O
of	POS	O
seizures	POS	B-NP
were	POS	O
recognized	POS	O
in	POS	O
77	POS	O
%	POS	O
and	POS	O
50	POS	O
%	POS	O
,	POS	O
respectively	POS	O
.	POS	O
Seizures	POS	B-NP
disappeared	POS	O
in	POS	O
71	POS	O
%	POS	O
of	POS	O
the	POS	O
patients	POS	O
with	POS	O
generalized	POS	O
seizures	POS	B-NP
and	POS	O
89	POS	O
%	POS	O
of	POS	O
partial	POS	O
seizures	POS	B-NP
.	POS	O
Improvement	POS	O
of	POS	O
abnormal	POS	O
EEG	POS	O
was	POS	O
noticed	POS	O
in	POS	O
76	POS	O
%	POS	O
of	POS	O
diffuse	POS	O
paroxysms	POS	B-NP
and	POS	O
in	POS	O
67	POS	O
%	POS	O
of	POS	O
focal	POS	O
paroxysms	POS	B-NP
.	POS	O
In	POS	O
excellent	POS	O
cases	POS	O
,	POS	O
mean	POS	O
effective	POS	O
dosages	POS	O
were	POS	O
0	POS	O
.	POS	O
086	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
021	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
in	POS	O
infants	POS	O
and	POS	O
0	POS	O
.	POS	O
057	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
022	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
day	POS	O
in	POS	O
schoolchildren	POS	O
,	POS	O
this	POS	O
difference	POS	O
was	POS	O
statistically	POS	O
significant	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
005	POS	O
)	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
side	POS	O
effects	POS	O
such	POS	O
as	POS	O
drowsiness	POS	B-NP
and	POS	O
ataxia	POS	B-NP
was	POS	O
only	POS	O
5	POS	O
%	POS	O
.	POS	O
Postmarketing	POS	O
study	POS	O
of	POS	O
timolol	POS	O
-	POS	O
hydrochlorothiazide	POS	O
antihypertensive	POS	O
therapy	POS	O
.	POS	O
A	POS	O
postmarketing	POS	O
surveillance	POS	O
study	POS	O
was	POS	O
conducted	POS	O
to	POS	O
determine	POS	O
the	POS	O
safety	POS	O
and	POS	O
efficacy	POS	O
of	POS	O
a	POS	O
fixed	POS	O
-	POS	O
ratio	POS	O
combination	POS	O
containing	POS	O
10	POS	O
mg	POS	O
of	POS	O
timolol	POS	O
maleate	POS	O
and	POS	O
25	POS	O
mg	POS	O
of	POS	O
hydrochlorothiazide	POS	O
,	POS	O
administered	POS	O
twice	POS	O
daily	POS	O
for	POS	O
one	POS	O
month	POS	O
to	POS	O
hypertensive	POS	B-NP
patients	POS	O
.	POS	O
Data	POS	O
on	POS	O
9	POS	O
,	POS	O
037	POS	O
patients	POS	O
were	POS	O
collected	POS	O
by	POS	O
1	POS	O
,	POS	O
455	POS	O
participating	POS	O
physicians	POS	O
.	POS	O
Mean	POS	O
systolic	POS	O
blood	POS	O
pressure	POS	O
decreased	POS	O
25	POS	O
mmHg	POS	O
and	POS	O
mean	POS	O
diastolic	POS	O
blood	POS	O
pressure	POS	O
declined	POS	O
15	POS	O
mmHg	POS	O
after	POS	O
one	POS	O
month	POS	O
of	POS	O
timolol	POS	O
-	POS	O
hydrochlorothiazide	POS	O
therapy	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
,	POS	O
both	POS	O
comparisons	POS	O
)	POS	O
.	POS	O
Age	POS	O
,	POS	O
race	POS	O
,	POS	O
and	POS	O
sex	POS	O
appeared	POS	O
to	POS	O
have	POS	O
no	POS	O
influence	POS	O
on	POS	O
the	POS	O
decrease	POS	O
in	POS	O
blood	POS	O
pressure	POS	O
.	POS	O
The	POS	O
antihypertensive	POS	O
effect	POS	O
of	POS	O
the	POS	O
drug	POS	O
was	POS	O
greater	POS	O
in	POS	O
patients	POS	O
with	POS	O
more	POS	O
severe	POS	O
hypertension	POS	B-NP
.	POS	O
Overall	POS	O
,	POS	O
1	POS	O
,	POS	O
453	POS	O
patients	POS	O
experienced	POS	O
a	POS	O
total	POS	O
of	POS	O
2	POS	O
,	POS	O
658	POS	O
adverse	POS	O
events	POS	O
,	POS	O
the	POS	O
most	POS	O
common	POS	O
being	POS	O
fatigue	POS	B-NP
,	POS	O
dizziness	POS	B-NP
,	POS	O
and	POS	O
weakness	POS	B-NP
.	POS	O
Treatment	POS	O
in	POS	O
590	POS	O
patients	POS	O
was	POS	O
discontinued	POS	O
because	POS	O
of	POS	O
adverse	POS	O
events	POS	O
.	POS	O
Salicylate	POS	O
nephropathy	POS	B-NP
in	POS	O
the	POS	O
Gunn	POS	O
rat	POS	O
:	POS	O
potential	POS	O
role	POS	O
of	POS	O
prostaglandins	POS	O
.	POS	O
We	POS	O
examined	POS	O
the	POS	O
potential	POS	O
role	POS	O
of	POS	O
prostaglandins	POS	O
in	POS	O
the	POS	O
development	POS	O
of	POS	O
analgesic	POS	O
nephropathy	POS	B-NP
in	POS	O
the	POS	O
Gunn	POS	O
strain	POS	O
of	POS	O
rat	POS	O
.	POS	O
The	POS	O
homozygous	POS	O
Gunn	POS	O
rats	POS	O
have	POS	O
unconjugated	POS	O
hyperbilirubinemia	POS	B-NP
due	POS	O
to	POS	O
the	POS	O
absence	POS	O
of	POS	O
glucuronyl	POS	O
transferase	POS	O
,	POS	O
leading	POS	O
to	POS	O
marked	POS	O
bilirubin	POS	O
deposition	POS	O
in	POS	O
renal	POS	O
medulla	POS	O
and	POS	O
papilla	POS	O
.	POS	O
These	POS	O
rats	POS	O
are	POS	O
also	POS	O
highly	POS	O
susceptible	POS	O
to	POS	O
develop	POS	O
papillary	POS	B-NP
necrosis	POS	I-NP
with	POS	O
analgesic	POS	O
administration	POS	O
.	POS	O
We	POS	O
used	POS	O
homozygous	POS	O
(	POS	O
jj	POS	O
)	POS	O
and	POS	O
phenotypically	POS	O
normal	POS	B-NP
heterozygous	POS	O
(	POS	O
jJ	POS	O
)	POS	O
animals	POS	O
.	POS	O
Four	POS	O
groups	POS	O
of	POS	O
rats	POS	O
(	POS	O
n	POS	O
=	POS	O
7	POS	O
)	POS	O
were	POS	O
studied	POS	O
:	POS	O
jj	POS	O
and	POS	O
jJ	POS	O
rats	POS	O
treated	POS	O
either	POS	O
with	POS	O
aspirin	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
every	POS	O
other	POS	O
day	POS	O
or	POS	O
sham	POS	O
-	POS	O
treated	POS	O
.	POS	O
After	POS	O
one	POS	O
week	POS	O
,	POS	O
slices	POS	O
of	POS	O
cortex	POS	O
,	POS	O
outer	POS	O
and	POS	O
inner	POS	O
medulla	POS	O
from	POS	O
one	POS	O
kidney	POS	O
were	POS	O
incubated	POS	O
in	POS	O
buffer	POS	O
and	POS	O
prostaglandin	POS	O
synthesis	POS	O
was	POS	O
determined	POS	O
by	POS	O
radioimmunoassay	POS	O
.	POS	O
The	POS	O
other	POS	O
kidney	POS	O
was	POS	O
examined	POS	O
histologically	POS	O
.	POS	O
A	POS	O
marked	POS	O
corticomedullary	POS	O
gradient	POS	O
of	POS	O
prostaglandin	POS	O
synthesis	POS	O
was	POS	O
observed	POS	O
in	POS	O
all	POS	O
groups	POS	O
.	POS	O
PGE2	POS	O
synthesis	POS	O
was	POS	O
significantly	POS	O
higher	POS	O
in	POS	O
outer	POS	O
medulla	POS	O
,	POS	O
but	POS	O
not	POS	O
cortex	POS	O
or	POS	O
inner	POS	O
medulla	POS	O
,	POS	O
of	POS	O
jj	POS	O
(	POS	O
38	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
ng	POS	O
/	POS	O
mg	POS	O
prot	POS	O
)	POS	O
than	POS	O
jJ	POS	O
rats	POS	O
(	POS	O
15	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
)	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
Aspirin	POS	O
treatment	POS	O
reduced	POS	O
PGE2	POS	O
synthesis	POS	O
in	POS	O
all	POS	O
regions	POS	O
,	POS	O
but	POS	O
outer	POS	O
medullary	POS	O
PGE2	POS	O
remained	POS	O
higher	POS	O
in	POS	O
jj	POS	O
(	POS	O
18	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
)	POS	O
than	POS	O
jJ	POS	O
rats	POS	O
(	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
)	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
PGF2	POS	O
alpha	POS	O
was	POS	O
also	POS	O
significantly	POS	O
higher	POS	O
in	POS	O
the	POS	O
outer	POS	O
medulla	POS	O
of	POS	O
jj	POS	O
rats	POS	O
with	POS	O
and	POS	O
without	POS	O
aspirin	POS	O
administration	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
The	POS	O
changes	POS	O
in	POS	O
renal	POS	O
prostaglandin	POS	O
synthesis	POS	O
were	POS	O
accompanied	POS	O
by	POS	O
evidence	POS	O
of	POS	O
renal	POS	B-NP
damage	POS	I-NP
in	POS	O
aspirin	POS	O
-	POS	O
treated	POS	O
jj	POS	O
but	POS	O
not	POS	O
jJ	POS	O
rats	POS	O
as	POS	O
evidenced	POS	O
by	POS	O
:	POS	O
increased	POS	O
incidence	POS	O
and	POS	O
severity	POS	O
of	POS	O
hematuria	POS	B-NP
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
;	POS	O
increased	POS	O
serum	POS	O
creatinine	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
;	POS	O
and	POS	O
increase	POS	O
in	POS	O
outer	POS	O
medullary	POS	O
histopathologic	POS	O
lesions	POS	B-NP
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
005	POS	O
compared	POS	O
to	POS	O
either	POS	O
sham	POS	O
-	POS	O
treated	POS	O
jj	POS	O
or	POS	O
aspirin	POS	O
-	POS	O
treated	POS	O
jJ	POS	O
)	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
enhanced	POS	O
prostaglandin	POS	O
synthesis	POS	O
contributes	POS	O
to	POS	O
maintenance	POS	O
of	POS	O
renal	POS	O
function	POS	O
and	POS	O
morphological	POS	O
integrity	POS	O
,	POS	O
and	POS	O
that	POS	O
inhibition	POS	O
of	POS	O
prostaglandin	POS	O
synthesis	POS	O
may	POS	O
lead	POS	O
to	POS	O
pathological	POS	O
renal	POS	B-NP
medullary	POS	I-NP
lesions	POS	I-NP
and	POS	O
deterioration	POS	B-NP
of	POS	I-NP
renal	POS	I-NP
function	POS	I-NP
.	POS	O
Prophylactic	POS	O
lidocaine	POS	O
in	POS	O
the	POS	O
early	POS	O
phase	POS	O
of	POS	O
suspected	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
Four	POS	O
hundred	POS	O
two	POS	O
patients	POS	O
with	POS	O
suspected	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
seen	POS	O
within	POS	O
6	POS	O
hours	POS	O
of	POS	O
the	POS	O
onset	POS	O
of	POS	O
symptoms	POS	O
entered	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
randomized	POS	O
trial	POS	O
of	POS	O
lidocaine	POS	O
vs	POS	O
placebo	POS	O
.	POS	O
During	POS	O
the	POS	O
1	POS	O
hour	POS	O
after	POS	O
administration	POS	O
of	POS	O
the	POS	O
drug	POS	O
the	POS	O
incidence	POS	O
of	POS	O
ventricular	POS	B-NP
fibrillation	POS	I-NP
or	POS	O
sustained	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
among	POS	O
the	POS	O
204	POS	O
patients	POS	O
with	POS	O
acute	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
was	POS	O
low	POS	O
,	POS	O
1	POS	O
.	POS	O
5	POS	O
%	POS	O
.	POS	O
Lidocaine	POS	O
,	POS	O
given	POS	O
in	POS	O
a	POS	O
300	POS	O
mg	POS	O
dose	POS	O
intramuscularly	POS	O
followed	POS	O
by	POS	O
100	POS	O
mg	POS	O
intravenously	POS	O
,	POS	O
did	POS	O
not	POS	O
prevent	POS	O
sustained	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
,	POS	O
although	POS	O
there	POS	O
was	POS	O
a	POS	O
significant	POS	O
reduction	POS	O
in	POS	O
the	POS	O
number	POS	O
of	POS	O
patients	POS	O
with	POS	O
warning	POS	O
arrhythmias	POS	B-NP
between	POS	O
15	POS	O
and	POS	O
45	POS	O
minutes	POS	O
after	POS	O
the	POS	O
administration	POS	O
of	POS	O
lidocaine	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
The	POS	O
average	POS	O
plasma	POS	O
lidocaine	POS	O
level	POS	O
10	POS	O
minutes	POS	O
after	POS	O
administration	POS	O
for	POS	O
patients	POS	O
without	POS	O
a	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
was	POS	O
significantly	POS	O
higher	POS	O
than	POS	O
that	POS	O
for	POS	O
patients	POS	O
with	POS	O
an	POS	O
acute	POS	B-NP
infarction	POS	I-NP
.	POS	O
The	POS	O
mean	POS	O
plasma	POS	O
lidocaine	POS	O
level	POS	O
of	POS	O
patients	POS	O
on	POS	O
beta	POS	O
-	POS	O
blocking	POS	O
agents	POS	O
was	POS	O
no	POS	O
different	POS	O
from	POS	O
that	POS	O
in	POS	O
patients	POS	O
not	POS	O
on	POS	O
beta	POS	O
blocking	POS	O
agents	POS	O
.	POS	O
During	POS	O
the	POS	O
1	POS	O
-	POS	O
hour	POS	O
study	POS	O
period	POS	O
,	POS	O
the	POS	O
incidence	POS	O
of	POS	O
central	POS	O
nervous	POS	O
system	POS	O
side	POS	O
effects	POS	O
was	POS	O
significantly	POS	O
greater	POS	O
in	POS	O
the	POS	O
lidocaine	POS	O
group	POS	O
,	POS	O
hypotension	POS	B-NP
occurred	POS	O
in	POS	O
11	POS	O
patients	POS	O
,	POS	O
nine	POS	O
of	POS	O
whom	POS	O
had	POS	O
received	POS	O
lidocaine	POS	O
,	POS	O
and	POS	O
four	POS	O
patients	POS	O
died	POS	O
from	POS	O
asystole	POS	B-NP
,	POS	O
three	POS	O
of	POS	O
whom	POS	O
had	POS	O
had	POS	O
lidocaine	POS	O
.	POS	O
We	POS	O
cannot	POS	O
advocate	POS	O
the	POS	O
administration	POS	O
of	POS	O
lidocaine	POS	O
prophylactically	POS	O
in	POS	O
the	POS	O
early	POS	O
hours	POS	O
of	POS	O
suspected	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
Evidence	POS	O
for	POS	O
a	POS	O
cholinergic	POS	O
role	POS	O
in	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
.	POS	O
Experiments	POS	O
in	POS	O
mice	POS	O
tested	POS	O
previous	POS	O
evidence	POS	O
that	POS	O
activation	POS	O
of	POS	O
cholinergic	POS	O
systems	POS	O
promotes	POS	O
catalepsy	POS	B-NP
and	POS	O
that	POS	O
cholinergic	POS	O
mechanisms	POS	O
need	POS	O
to	POS	O
be	POS	O
intact	POS	O
for	POS	O
full	POS	O
expression	POS	O
of	POS	O
neuroleptic	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
.	POS	O
Large	POS	O
doses	POS	O
of	POS	O
the	POS	O
cholinomimetic	POS	O
,	POS	O
pilocarpine	POS	O
,	POS	O
could	POS	O
induce	POS	O
catalepsy	POS	B-NP
when	POS	O
peripheral	POS	O
cholinergic	POS	O
receptors	POS	O
were	POS	O
blocked	POS	O
.	POS	O
Low	POS	O
doses	POS	O
of	POS	O
pilocarpine	POS	O
caused	POS	O
a	POS	O
pronounced	POS	O
enhancement	POS	O
of	POS	O
the	POS	O
catalepsy	POS	B-NP
that	POS	O
was	POS	O
induced	POS	O
by	POS	O
the	POS	O
dopaminergic	POS	O
blocker	POS	O
,	POS	O
haloperidol	POS	O
.	POS	O
A	POS	O
muscarinic	POS	O
receptor	POS	O
blocker	POS	O
,	POS	O
atropine	POS	O
,	POS	O
disrupted	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
catalepsy	POS	B-NP
.	POS	O
Intracranial	POS	O
injection	POS	O
of	POS	O
an	POS	O
acetylcholine	POS	O
-	POS	O
synthesis	POS	O
inhibitor	POS	O
,	POS	O
hemicholinium	POS	O
,	POS	O
prevented	POS	O
the	POS	O
catalepsy	POS	B-NP
that	POS	O
is	POS	O
usually	POS	O
induced	POS	O
by	POS	O
haloperidol	POS	O
.	POS	O
These	POS	O
findings	POS	O
suggest	POS	O
the	POS	O
hypothesis	POS	O
that	POS	O
the	POS	O
catalepsy	POS	B-NP
that	POS	O
is	POS	O
produced	POS	O
by	POS	O
neuroleptics	POS	O
such	POS	O
as	POS	O
haloperidol	POS	O
is	POS	O
actually	POS	O
mediated	POS	O
by	POS	O
intrinsic	POS	O
central	POS	O
cholinergic	POS	O
systems	POS	O
.	POS	O
Alternatively	POS	O
,	POS	O
activation	POS	O
of	POS	O
central	POS	O
cholinergic	POS	O
systems	POS	O
could	POS	O
promote	POS	O
catalepsy	POS	B-NP
by	POS	O
suppression	POS	O
of	POS	O
dopaminergic	POS	O
systems	POS	O
.	POS	O
Cardiovascular	POS	B-NP
dysfunction	POS	I-NP
and	POS	O
hypersensitivity	POS	B-NP
to	POS	O
sodium	POS	O
pentobarbital	POS	O
induced	POS	O
by	POS	O
chronic	POS	O
barium	POS	O
chloride	POS	O
ingestion	POS	O
.	POS	O
Barium	POS	O
-	POS	O
supplemented	POS	O
Long	POS	O
-	POS	O
Evans	POS	O
hooded	POS	O
rats	POS	O
were	POS	O
characterized	POS	O
by	POS	O
a	POS	O
persistent	POS	O
hypertension	POS	B-NP
that	POS	O
was	POS	O
evident	POS	O
after	POS	O
1	POS	O
month	POS	O
of	POS	O
barium	POS	O
(	POS	O
100	POS	O
micrograms	POS	O
/	POS	O
ml	POS	O
mineral	POS	O
fortified	POS	O
water	POS	O
)	POS	O
treatment	POS	O
.	POS	O
Analysis	POS	O
of	POS	O
in	POS	O
vivo	POS	O
myocardial	POS	O
excitability	POS	O
,	POS	O
contractility	POS	O
,	POS	O
and	POS	O
metabolic	POS	O
characteristics	POS	O
at	POS	O
16	POS	O
months	POS	O
revealed	POS	O
other	POS	O
significant	POS	O
barium	POS	O
-	POS	O
induced	POS	O
disturbances	POS	O
within	POS	O
the	POS	O
cardiovascular	POS	O
system	POS	O
.	POS	O
The	POS	O
most	POS	O
distinctive	POS	O
aspect	POS	O
of	POS	O
the	POS	O
barium	POS	O
effect	POS	O
was	POS	O
a	POS	O
demonstrated	POS	O
hypersensitivity	POS	B-NP
of	POS	I-NP
the	POS	I-NP
cardiovascular	POS	I-NP
system	POS	I-NP
to	POS	O
sodium	POS	O
pentobarbital	POS	O
.	POS	O
Under	POS	O
barbiturate	POS	O
anesthesia	POS	O
,	POS	O
virtually	POS	O
all	POS	O
of	POS	O
the	POS	O
myocardial	POS	O
contractile	POS	O
indices	POS	O
were	POS	O
depressed	POS	O
significantly	POS	O
in	POS	O
barium	POS	O
-	POS	O
exposed	POS	O
rats	POS	O
relative	POS	O
to	POS	O
the	POS	O
corresponding	POS	O
control	POS	O
-	POS	O
fed	POS	O
rats	POS	O
.	POS	O
The	POS	O
lack	POS	O
of	POS	O
a	POS	O
similar	POS	O
response	POS	O
to	POS	O
ketamine	POS	O
and	POS	O
xylazine	POS	O
anesthesia	POS	O
revealed	POS	O
that	POS	O
the	POS	O
cardiovascular	POS	O
actions	POS	O
of	POS	O
sodium	POS	O
pentobarbital	POS	O
in	POS	O
barium	POS	O
-	POS	O
treated	POS	O
rats	POS	O
were	POS	O
linked	POS	O
specifically	POS	O
to	POS	O
this	POS	O
anesthetic	POS	O
,	POS	O
and	POS	O
were	POS	O
not	POS	O
representative	POS	O
of	POS	O
a	POS	O
generalized	POS	O
anesthetic	POS	O
response	POS	O
.	POS	O
Other	POS	O
myocardial	POS	O
pathophysiologic	POS	O
and	POS	O
metabolic	POS	O
changes	POS	O
induced	POS	O
by	POS	O
barium	POS	O
were	POS	O
manifest	POS	O
,	POS	O
irrespective	POS	O
of	POS	O
the	POS	O
anesthetic	POS	O
employed	POS	O
.	POS	O
The	POS	O
contractile	POS	O
element	POS	O
shortening	POS	O
velocity	POS	O
of	POS	O
the	POS	O
cardiac	POS	O
muscle	POS	O
fibers	POS	O
was	POS	O
significantly	POS	O
slower	POS	O
in	POS	O
both	POS	O
groups	POS	O
of	POS	O
barium	POS	O
-	POS	O
treated	POS	O
rats	POS	O
relative	POS	O
to	POS	O
the	POS	O
control	POS	O
groups	POS	O
,	POS	O
irrespective	POS	O
of	POS	O
the	POS	O
anesthetic	POS	O
regimen	POS	O
.	POS	O
Similarly	POS	O
,	POS	O
significant	POS	O
disturbances	POS	O
in	POS	O
myocardial	POS	O
energy	POS	O
metabolism	POS	O
were	POS	O
detected	POS	O
in	POS	O
the	POS	O
barium	POS	O
-	POS	O
exposed	POS	O
rats	POS	O
which	POS	O
were	POS	O
consistent	POS	O
with	POS	O
the	POS	O
reduced	POS	O
contractile	POS	O
element	POS	O
shortening	POS	O
velocity	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
the	POS	O
excitability	POS	O
of	POS	O
the	POS	O
cardiac	POS	O
conduction	POS	O
system	POS	O
was	POS	O
depressed	POS	O
preferentially	POS	O
in	POS	O
the	POS	O
atrioventricular	POS	O
nodal	POS	O
region	POS	O
of	POS	O
hearts	POS	O
from	POS	O
barium	POS	O
-	POS	O
exposed	POS	O
rats	POS	O
.	POS	O
Overall	POS	O
,	POS	O
the	POS	O
altered	POS	O
cardiac	POS	O
contractility	POS	O
and	POS	O
excitability	POS	O
characteristics	POS	O
,	POS	O
the	POS	O
myocardial	POS	B-NP
metabolic	POS	I-NP
disturbances	POS	I-NP
,	POS	O
and	POS	O
the	POS	O
hypersensitivity	POS	B-NP
of	POS	O
the	POS	O
cardiovascular	POS	O
system	POS	O
to	POS	O
sodium	POS	O
pentobarbital	POS	O
suggest	POS	O
the	POS	O
existence	POS	O
of	POS	O
a	POS	O
heretofore	POS	O
undescribed	POS	O
cardiomyopathic	POS	B-NP
disorder	POS	I-NP
induced	POS	O
by	POS	O
chronic	POS	O
barium	POS	O
exposure	POS	O
.	POS	O
These	POS	O
experimental	POS	O
findings	POS	O
represent	POS	O
the	POS	O
first	POS	O
indication	POS	O
that	POS	O
life	POS	O
-	POS	O
long	POS	O
barium	POS	O
ingestion	POS	O
may	POS	O
have	POS	O
significant	POS	O
adverse	POS	O
effects	POS	O
on	POS	O
the	POS	O
mammalian	POS	O
cardiovascular	POS	O
system	POS	O
.	POS	O
Propranolol	POS	O
antagonism	POS	O
of	POS	O
phenylpropanolamine	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
.	POS	O
Phenylpropanolamine	POS	B-NP
(	POS	O
PPA	POS	O
)	POS	O
overdose	POS	B-NP
can	POS	O
cause	POS	O
severe	POS	O
hypertension	POS	B-NP
,	POS	O
intracerebral	POS	B-NP
hemorrhage	POS	I-NP
,	POS	O
and	POS	O
death	POS	B-NP
.	POS	O
We	POS	O
studied	POS	O
the	POS	O
efficacy	POS	O
and	POS	O
safety	POS	O
of	POS	O
propranolol	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
PPA	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
.	POS	O
Subjects	POS	O
received	POS	O
propranolol	POS	O
either	POS	O
by	POS	O
mouth	POS	O
for	POS	O
48	POS	O
hours	POS	O
before	POS	O
PPA	POS	O
or	POS	O
as	POS	O
a	POS	O
rapid	POS	O
intravenous	POS	O
infusion	POS	O
after	POS	O
PPA	POS	O
.	POS	O
PPA	POS	O
,	POS	O
75	POS	O
mg	POS	O
alone	POS	O
,	POS	O
increased	POS	O
blood	POS	O
pressure	POS	O
(	POS	O
31	POS	O
+	POS	O
/	POS	O
-	POS	O
14	POS	O
mm	POS	O
Hg	POS	O
systolic	POS	O
,	POS	O
20	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
mm	POS	O
Hg	POS	O
diastolic	POS	O
)	POS	O
,	POS	O
and	POS	O
propranolol	POS	O
pretreatment	POS	O
antagonized	POS	O
this	POS	O
increase	POS	O
(	POS	O
12	POS	O
+	POS	O
/	POS	O
-	POS	O
10	POS	O
mm	POS	O
Hg	POS	O
systolic	POS	O
,	POS	O
10	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
mm	POS	O
Hg	POS	O
diastolic	POS	O
)	POS	O
.	POS	O
Intravenous	POS	O
propranolol	POS	O
after	POS	O
PPA	POS	O
also	POS	O
decreased	POS	O
blood	POS	O
pressure	POS	O
.	POS	O
Left	POS	O
ventricular	POS	O
function	POS	O
(	POS	O
assessed	POS	O
by	POS	O
echocardiography	POS	O
)	POS	O
showed	POS	O
that	POS	O
PPA	POS	O
increased	POS	O
the	POS	O
stroke	POS	B-NP
volume	POS	O
30	POS	O
%	POS	O
(	POS	O
from	POS	O
62	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
20	POS	O
.	POS	O
9	POS	O
to	POS	O
80	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
22	POS	O
.	POS	O
4	POS	O
ml	POS	O
)	POS	O
,	POS	O
the	POS	O
ejection	POS	O
fraction	POS	O
9	POS	O
%	POS	O
(	POS	O
from	POS	O
64	POS	O
%	POS	O
+	POS	O
/	POS	O
-	POS	O
10	POS	O
%	POS	O
to	POS	O
70	POS	O
%	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
%	POS	O
)	POS	O
,	POS	O
and	POS	O
cardiac	POS	O
output	POS	O
14	POS	O
%	POS	O
(	POS	O
from	POS	O
3	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
6	POS	O
to	POS	O
4	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
0	POS	O
L	POS	O
/	POS	O
min	POS	O
)	POS	O
.	POS	O
Intravenous	POS	O
propranolol	POS	O
reversed	POS	O
these	POS	O
effects	POS	O
.	POS	O
Systemic	POS	O
vascular	POS	O
resistance	POS	O
was	POS	O
increased	POS	O
by	POS	O
PPA	POS	O
28	POS	O
%	POS	O
(	POS	O
from	POS	O
1710	POS	O
+	POS	O
/	POS	O
-	POS	O
200	POS	O
to	POS	O
2190	POS	O
+	POS	O
/	POS	O
-	POS	O
700	POS	O
dyne	POS	O
X	POS	O
sec	POS	O
/	POS	O
cm5	POS	O
)	POS	O
and	POS	O
was	POS	O
further	POS	O
increased	POS	O
by	POS	O
propranolol	POS	O
22	POS	O
%	POS	O
(	POS	O
to	POS	O
2660	POS	O
+	POS	O
/	POS	O
-	POS	O
1200	POS	O
dyne	POS	O
X	POS	O
sec	POS	O
/	POS	O
cm5	POS	O
)	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
PPA	POS	O
increases	POS	O
blood	POS	O
pressure	POS	O
by	POS	O
increasing	POS	O
systemic	POS	O
vascular	POS	O
resistance	POS	O
and	POS	O
cardiac	POS	O
output	POS	O
,	POS	O
and	POS	O
that	POS	O
propranolol	POS	O
antagonizes	POS	O
this	POS	O
increase	POS	O
by	POS	O
reversing	POS	O
the	POS	O
effect	POS	O
of	POS	O
PPA	POS	O
on	POS	O
cardiac	POS	O
output	POS	O
.	POS	O
That	POS	O
propranolol	POS	O
antagonizes	POS	O
the	POS	O
pressor	POS	O
effect	POS	O
of	POS	O
PPA	POS	O
is	POS	O
in	POS	O
contrast	POS	O
to	POS	O
the	POS	O
interaction	POS	O
in	POS	O
which	POS	O
propranolol	POS	O
enhances	POS	O
the	POS	O
pressor	POS	O
effect	POS	O
of	POS	O
norepinephrine	POS	O
.	POS	O
This	POS	O
is	POS	O
probably	POS	O
because	POS	O
PPA	POS	O
has	POS	O
less	POS	O
beta	POS	O
2	POS	O
activity	POS	O
than	POS	O
does	POS	O
norepinephrine	POS	O
.	POS	O
Mesangial	POS	O
function	POS	O
and	POS	O
glomerular	POS	B-NP
sclerosis	POS	I-NP
in	POS	O
rats	POS	O
with	POS	O
aminonucleoside	POS	O
nephrosis	POS	B-NP
.	POS	O
The	POS	O
possible	POS	O
relationship	POS	O
between	POS	O
mesangial	POS	B-NP
dysfunction	POS	I-NP
and	POS	O
development	POS	O
of	POS	O
glomerular	POS	B-NP
sclerosis	POS	I-NP
was	POS	O
studied	POS	O
in	POS	O
the	POS	O
puromycin	POS	O
aminonucleoside	POS	O
(	POS	O
PAN	POS	O
)	POS	O
model	POS	O
.	POS	O
Five	POS	O
male	POS	O
Wistar	POS	O
rats	POS	O
received	POS	O
repeated	POS	O
subcutaneous	POS	O
PAN	POS	O
injections	POS	O
;	POS	O
five	POS	O
controls	POS	O
received	POS	O
saline	POS	O
only	POS	O
.	POS	O
After	POS	O
4	POS	O
weeks	POS	O
the	POS	O
PAN	POS	O
rats	POS	O
were	POS	O
severely	POS	O
proteinuric	POS	O
(	POS	O
190	POS	O
+	POS	O
/	POS	O
-	POS	O
80	POS	O
mg	POS	O
/	POS	O
24	POS	O
hr	POS	O
)	POS	O
,	POS	O
and	POS	O
all	POS	O
rats	POS	O
were	POS	O
given	POS	O
colloidal	POS	O
carbon	POS	O
(	POS	O
CC	POS	O
)	POS	O
intravenously	POS	O
.	POS	O
At	POS	O
5	POS	O
months	POS	O
glomerular	POS	B-NP
sclerosis	POS	I-NP
was	POS	O
found	POS	O
in	POS	O
7	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
.	POS	O
4	POS	O
%	POS	O
of	POS	O
the	POS	O
glomeruli	POS	O
of	POS	O
PAN	POS	O
rats	POS	O
;	POS	O
glomeruli	POS	O
of	POS	O
the	POS	O
controls	POS	O
were	POS	O
normal	POS	O
.	POS	O
Glomeruli	POS	O
of	POS	O
PAN	POS	O
rats	POS	O
contained	POS	O
significantly	POS	O
more	POS	O
CC	POS	O
than	POS	O
glomeruli	POS	O
of	POS	O
controls	POS	O
.	POS	O
Glomeruli	POS	O
with	POS	O
sclerosis	POS	B-NP
contained	POS	O
significantly	POS	O
more	POS	O
CC	POS	O
than	POS	O
non	POS	O
-	POS	O
sclerotic	POS	O
glomeruli	POS	O
in	POS	O
the	POS	O
same	POS	O
kidneys	POS	O
.	POS	O
CC	POS	O
was	POS	O
preferentially	POS	O
localized	POS	O
within	POS	O
the	POS	O
sclerotic	POS	O
areas	POS	O
of	POS	O
the	POS	O
affected	POS	O
glomeruli	POS	O
.	POS	O
Since	POS	O
mesangial	POS	O
CC	POS	O
clearance	POS	O
from	POS	O
the	POS	O
mesangium	POS	O
did	POS	O
not	POS	O
change	POS	O
during	POS	O
chronic	POS	O
PAN	POS	O
treatment	POS	O
,	POS	O
we	POS	O
conclude	POS	O
that	POS	O
this	POS	O
preferential	POS	O
CC	POS	O
localization	POS	O
within	POS	O
the	POS	O
lesions	POS	B-NP
is	POS	O
caused	POS	O
by	POS	O
an	POS	O
increased	POS	O
CC	POS	O
uptake	POS	O
shortly	POS	O
after	POS	O
injection	POS	O
in	POS	O
apparent	POS	O
vulnerable	POS	O
areas	POS	O
where	POS	O
sclerosis	POS	B-NP
will	POS	O
develop	POS	O
subsequently	POS	O
.	POS	O
Cluster	POS	O
analysis	POS	O
showed	POS	O
a	POS	O
random	POS	O
distribution	POS	O
of	POS	O
lesions	POS	B-NP
in	POS	O
the	POS	O
PAN	POS	O
glomeruli	POS	O
in	POS	O
concordance	POS	O
with	POS	O
the	POS	O
random	POS	O
localization	POS	O
of	POS	O
mesangial	POS	O
areas	POS	O
with	POS	O
dysfunction	POS	O
in	POS	O
this	POS	O
model	POS	O
.	POS	O
Similar	POS	O
to	POS	O
the	POS	O
remnant	POS	O
kidney	POS	O
model	POS	O
in	POS	O
PAN	POS	O
nephrosis	POS	B-NP
the	POS	O
development	POS	O
of	POS	O
glomerular	POS	B-NP
sclerosis	POS	I-NP
may	POS	O
be	POS	O
related	POS	O
to	POS	O
"	POS	O
mesangial	POS	O
overloading	POS	O
.	POS	O
"	POS	O
Relationship	POS	O
between	POS	O
nicotine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
and	POS	O
hippocampal	POS	O
nicotinic	POS	O
receptors	POS	O
.	POS	O
A	POS	O
controversy	POS	O
has	POS	O
existed	POS	O
for	POS	O
several	POS	O
years	POS	O
concerning	POS	O
the	POS	O
physiological	POS	O
relevance	POS	O
of	POS	O
the	POS	O
nicotinic	POS	O
receptor	POS	O
measured	POS	O
by	POS	O
alpha	POS	O
-	POS	O
bungarotoxin	POS	O
binding	POS	O
.	POS	O
Using	POS	O
mice	POS	O
derived	POS	O
from	POS	O
a	POS	O
classical	POS	O
F2	POS	O
and	POS	O
backcross	POS	O
genetic	POS	O
design	POS	O
,	POS	O
a	POS	O
relationship	POS	O
between	POS	O
nicotine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
and	POS	O
alpha	POS	O
-	POS	O
bungarotoxin	POS	O
nicotinic	POS	O
receptor	POS	O
concentration	POS	O
was	POS	O
found	POS	O
.	POS	O
Mice	POS	O
sensitive	POS	O
to	POS	O
the	POS	O
convulsant	POS	O
effects	POS	O
of	POS	O
nicotine	POS	O
had	POS	O
greater	POS	O
alpha	POS	O
-	POS	O
bungarotoxin	POS	O
binding	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
than	POS	O
seizure	POS	B-NP
insensitive	POS	O
mice	POS	O
.	POS	O
The	POS	O
binding	POS	O
sites	POS	O
from	POS	O
seizure	POS	B-NP
sensitive	POS	O
and	POS	O
resistant	POS	O
mice	POS	O
were	POS	O
equally	POS	O
affected	POS	O
by	POS	O
treatment	POS	O
with	POS	O
dithiothreitol	POS	O
,	POS	O
trypsin	POS	O
or	POS	O
heat	POS	O
.	POS	O
Thus	POS	O
it	POS	O
appears	POS	O
that	POS	O
the	POS	O
difference	POS	O
between	POS	O
seizure	POS	B-NP
sensitive	POS	O
and	POS	O
insensitive	POS	O
animals	POS	O
may	POS	O
be	POS	O
due	POS	O
to	POS	O
a	POS	O
difference	POS	O
in	POS	O
hippocampal	POS	O
nicotinic	POS	O
receptor	POS	O
concentration	POS	O
as	POS	O
measured	POS	O
with	POS	O
alpha	POS	O
-	POS	O
bungarotoxin	POS	O
binding	POS	O
.	POS	O
The	POS	O
role	POS	O
of	POS	O
p	POS	O
-	POS	O
aminophenol	POS	O
in	POS	O
acetaminophen	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
:	POS	O
effect	POS	O
of	POS	O
bis	POS	O
(	POS	O
p	POS	O
-	POS	O
nitrophenyl	POS	O
)	POS	O
phosphate	POS	O
on	POS	O
acetaminophen	POS	O
and	POS	O
p	POS	O
-	POS	O
aminophenol	POS	O
nephrotoxicity	POS	B-NP
and	POS	O
metabolism	POS	O
in	POS	O
Fischer	POS	O
344	POS	O
rats	POS	O
.	POS	O
Acetaminophen	POS	O
(	POS	O
APAP	POS	O
)	POS	O
produces	POS	O
proximal	POS	O
tubular	POS	O
necrosis	POS	B-NP
in	POS	O
Fischer	POS	O
344	POS	O
(	POS	O
F344	POS	O
)	POS	O
rats	POS	O
.	POS	O
Recently	POS	O
,	POS	O
p	POS	O
-	POS	O
aminophenol	POS	O
(	POS	O
PAP	POS	O
)	POS	O
,	POS	O
a	POS	O
known	POS	O
potent	POS	O
nephrotoxicant	POS	O
,	POS	O
was	POS	O
identified	POS	O
as	POS	O
a	POS	O
metabolite	POS	O
of	POS	O
APAP	POS	O
in	POS	O
F344	POS	O
rats	POS	O
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
if	POS	O
PAP	POS	O
formation	POS	O
is	POS	O
a	POS	O
requisite	POS	O
step	POS	O
in	POS	O
APAP	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
Therefore	POS	O
,	POS	O
the	POS	O
effect	POS	O
of	POS	O
bis	POS	O
(	POS	O
p	POS	O
-	POS	O
nitrophenyl	POS	O
)	POS	O
phosphate	POS	O
(	POS	O
BNPP	POS	O
)	POS	O
,	POS	O
an	POS	O
acylamidase	POS	O
inhibitor	POS	O
,	POS	O
on	POS	O
APAP	POS	O
and	POS	O
PAP	POS	O
nephrotoxicity	POS	B-NP
and	POS	O
metabolism	POS	O
was	POS	O
determined	POS	O
.	POS	O
BNPP	POS	O
(	POS	O
1	POS	O
to	POS	O
8	POS	O
mM	POS	O
)	POS	O
reduced	POS	O
APAP	POS	O
deacetylation	POS	O
and	POS	O
covalent	POS	O
binding	POS	O
in	POS	O
F344	POS	O
renal	POS	O
cortical	POS	O
homogenates	POS	O
in	POS	O
a	POS	O
concentration	POS	O
-	POS	O
dependent	POS	O
manner	POS	O
.	POS	O
Pretreatment	POS	O
of	POS	O
animals	POS	O
with	POS	O
BNPP	POS	O
prior	POS	O
to	POS	O
APAP	POS	O
or	POS	O
PAP	POS	O
administration	POS	O
resulted	POS	O
in	POS	O
marked	POS	O
reduction	POS	O
of	POS	O
APAP	POS	O
(	POS	O
900	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
nephrotoxicity	POS	B-NP
but	POS	O
not	POS	O
PAP	POS	O
nephrotoxicity	POS	B-NP
.	POS	O
This	POS	O
result	POS	O
was	POS	O
not	POS	O
due	POS	O
to	POS	O
altered	POS	O
disposition	POS	O
of	POS	O
either	POS	O
APAP	POS	O
or	POS	O
acetylated	POS	O
metabolites	POS	O
in	POS	O
plasma	POS	O
or	POS	O
renal	POS	O
cortical	POS	O
and	POS	O
hepatic	POS	O
tissue	POS	O
.	POS	O
Rather	POS	O
,	POS	O
BNPP	POS	O
pretreatment	POS	O
reduced	POS	O
the	POS	O
fraction	POS	O
of	POS	O
APAP	POS	O
excreted	POS	O
as	POS	O
PAP	POS	O
by	POS	O
64	POS	O
and	POS	O
75	POS	O
%	POS	O
after	POS	O
APAP	POS	O
doses	POS	O
of	POS	O
750	POS	O
and	POS	O
900	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
BNPP	POS	O
did	POS	O
not	POS	O
alter	POS	O
the	POS	O
excretion	POS	O
of	POS	O
APAP	POS	O
or	POS	O
any	POS	O
of	POS	O
its	POS	O
non	POS	O
-	POS	O
deacetylated	POS	O
metabolites	POS	O
nor	POS	O
did	POS	O
BNPP	POS	O
alter	POS	O
excretion	POS	O
of	POS	O
PAP	POS	O
or	POS	O
its	POS	O
metabolites	POS	O
after	POS	O
PAP	POS	O
doses	POS	O
of	POS	O
150	POS	O
and	POS	O
300	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
Therefore	POS	O
,	POS	O
the	POS	O
BNPP	POS	O
-	POS	O
induced	POS	O
reduction	POS	O
in	POS	O
APAP	POS	O
-	POS	O
induced	POS	O
nephrotoxicity	POS	B-NP
appears	POS	O
to	POS	O
be	POS	O
due	POS	O
to	POS	O
inhibition	POS	O
of	POS	O
APAP	POS	O
deacetylation	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
PAP	POS	O
formation	POS	O
,	POS	O
in	POS	O
vivo	POS	O
,	POS	O
accounts	POS	O
,	POS	O
at	POS	O
least	POS	O
in	POS	O
part	POS	O
,	POS	O
for	POS	O
APAP	POS	O
-	POS	O
induced	POS	O
renal	POS	B-NP
tubular	POS	I-NP
necrosis	POS	I-NP
.	POS	O
Morphine	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
in	POS	O
newborn	POS	O
infants	POS	O
.	POS	O
Two	POS	O
neonates	POS	O
suffered	POS	O
from	POS	O
generalized	POS	O
seizures	POS	B-NP
during	POS	O
the	POS	O
course	POS	O
of	POS	O
intravenous	POS	O
morphine	POS	O
sulfate	POS	O
for	POS	O
post	POS	O
-	POS	O
operative	POS	O
analgesia	POS	O
.	POS	O
They	POS	O
received	POS	O
morphine	POS	O
in	POS	O
doses	POS	O
of	POS	O
32	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
hr	POS	O
and	POS	O
40	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
hr	POS	O
larger	POS	O
than	POS	O
a	POS	O
group	POS	O
of	POS	O
10	POS	O
neonates	POS	O
who	POS	O
received	POS	O
6	POS	O
-	POS	O
24	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
hr	POS	O
and	POS	O
had	POS	O
no	POS	O
seizures	POS	B-NP
.	POS	O
Plasma	POS	O
concentrations	POS	O
of	POS	O
morphine	POS	O
in	POS	O
these	POS	O
neonates	POS	O
was	POS	O
excessive	POS	O
(	POS	O
60	POS	O
and	POS	O
90	POS	O
mg	POS	O
/	POS	O
ml	POS	O
)	POS	O
.	POS	O
Other	POS	O
known	POS	O
reasons	POS	O
for	POS	O
seizures	POS	B-NP
were	POS	O
ruled	POS	O
out	POS	O
and	POS	O
the	POS	O
convulsions	POS	B-NP
stopped	POS	O
a	POS	O
few	POS	O
hours	POS	O
after	POS	O
cessation	POS	O
of	POS	O
morphine	POS	O
and	POS	O
did	POS	O
not	POS	O
reoccur	POS	O
in	POS	O
the	POS	O
subsequent	POS	O
8	POS	O
months	POS	O
.	POS	O
It	POS	O
is	POS	O
suggested	POS	O
that	POS	O
post	POS	O
-	POS	O
operative	POS	O
intravenous	POS	O
morphine	POS	O
should	POS	O
not	POS	O
exceed	POS	O
20	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
ml	POS	O
in	POS	O
neonates	POS	O
.	POS	O
Indomethacin	POS	O
induced	POS	O
hypotension	POS	B-NP
in	POS	O
sodium	POS	O
and	POS	O
volume	POS	O
depleted	POS	O
rats	POS	O
.	POS	O
After	POS	O
a	POS	O
single	POS	O
oral	POS	O
dose	POS	O
of	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
indomethacin	POS	O
(	POS	O
IDM	POS	O
)	POS	O
to	POS	O
sodium	POS	O
and	POS	O
volume	POS	O
depleted	POS	O
rats	POS	O
plasma	POS	O
renin	POS	O
activity	POS	O
(	POS	O
PRA	POS	O
)	POS	O
and	POS	O
systolic	POS	O
blood	POS	O
pressure	POS	O
fell	POS	O
significantly	POS	O
within	POS	O
four	POS	O
hours	POS	O
.	POS	O
In	POS	O
sodium	POS	O
repleted	POS	O
animals	POS	O
indomethacin	POS	O
did	POS	O
not	POS	O
change	POS	O
systolic	POS	O
blood	POS	O
pressure	POS	O
(	POS	O
BP	POS	O
)	POS	O
although	POS	O
plasma	POS	O
renin	POS	O
activity	POS	O
was	POS	O
decreased	POS	O
.	POS	O
Thus	POS	O
,	POS	O
indomethacin	POS	O
by	POS	O
inhibition	POS	O
of	POS	O
prostaglandin	POS	O
synthesis	POS	O
may	POS	O
diminish	POS	O
the	POS	O
blood	POS	O
pressure	POS	O
maintaining	POS	O
effect	POS	O
of	POS	O
the	POS	O
stimulated	POS	O
renin	POS	O
-	POS	O
angiotensin	POS	O
system	POS	O
in	POS	O
sodium	POS	O
and	POS	O
volume	POS	O
depletion	POS	O
.	POS	O
On	POS	O
the	POS	O
antiarrhythmic	POS	O
activity	POS	O
of	POS	O
one	POS	O
N	POS	O
-	POS	O
substituted	POS	O
piperazine	POS	O
derivative	POS	O
of	POS	O
trans	POS	O
-	POS	O
2	POS	O
-	POS	O
amino	POS	O
-	POS	O
3	POS	O
-	POS	O
hydroxy	POS	O
-	POS	O
1	POS	O
,	POS	O
2	POS	O
,	POS	O
3	POS	O
,	POS	O
4	POS	O
-	POS	O
tetrahydroanaphthalene	POS	O
.	POS	O
The	POS	O
antiarrhythmic	POS	O
activity	POS	O
of	POS	O
the	POS	O
compound	POS	O
N	POS	O
-	POS	O
(	POS	O
trans	POS	O
-	POS	O
3	POS	O
-	POS	O
hydroxy	POS	O
-	POS	O
1	POS	O
,	POS	O
2	POS	O
,	POS	O
3	POS	O
,	POS	O
4	POS	O
-	POS	O
tetrahydro	POS	O
-	POS	O
2	POS	O
-	POS	O
naphthyl	POS	O
)	POS	O
-	POS	O
N	POS	O
-	POS	O
(	POS	O
3	POS	O
-	POS	O
oxo	POS	O
-	POS	O
3	POS	O
-	POS	O
phenyl	POS	O
-	POS	O
2	POS	O
-	POS	O
methylpropyl	POS	O
)	POS	O
-	POS	O
piperazine	POS	O
hydrochloride	POS	O
,	POS	O
referred	POS	O
to	POS	O
as	POS	O
P11	POS	O
,	POS	O
is	POS	O
studied	POS	O
on	POS	O
anaesthesized	POS	O
cats	POS	O
and	POS	O
Wistar	POS	O
albino	POS	O
rats	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
on	POS	O
non	POS	O
-	POS	O
anaesthesized	POS	O
rabbits	POS	O
.	POS	O
Four	POS	O
types	POS	O
of	POS	O
experimental	POS	O
arrhythmia	POS	B-NP
are	POS	O
used	POS	O
-	POS	O
-	POS	O
with	POS	O
BaCl2	POS	O
,	POS	O
with	POS	O
chloroform	POS	O
-	POS	O
adrenaline	POS	O
,	POS	O
with	POS	O
strophantine	POS	O
G	POS	O
and	POS	O
with	POS	O
aconitine	POS	O
.	POS	O
The	POS	O
compound	POS	O
P11	POS	O
is	POS	O
introduced	POS	O
in	POS	O
doses	POS	O
of	POS	O
0	POS	O
.	POS	O
25	POS	O
and	POS	O
0	POS	O
.	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
intravenously	POS	O
and	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
orally	POS	O
.	POS	O
The	POS	O
compound	POS	O
manifests	POS	O
antiarrhythmic	POS	O
activity	POS	O
in	POS	O
all	POS	O
models	POS	O
of	POS	O
experimental	POS	O
arrhythmia	POS	B-NP
used	POS	O
,	POS	O
causing	POS	O
greatest	POS	O
inhibition	POS	O
on	POS	O
the	POS	O
arrhythmia	POS	B-NP
induced	POS	O
by	POS	O
chloroform	POS	O
-	POS	O
adrenaline	POS	O
(	POS	O
in	POS	O
90	POS	O
per	POS	O
cent	POS	O
)	POS	O
and	POS	O
with	POS	O
BaCl2	POS	O
(	POS	O
in	POS	O
84	POS	O
per	POS	O
cent	POS	O
)	POS	O
.	POS	O
The	POS	O
results	POS	O
obtained	POS	O
are	POS	O
associated	POS	O
with	POS	O
the	POS	O
beta	POS	O
-	POS	O
adrenoblocking	POS	O
and	POS	O
with	POS	O
the	POS	O
membrane	POS	O
-	POS	O
stabilizing	POS	O
action	POS	O
of	POS	O
the	POS	O
compound	POS	O
.	POS	O
Recurrent	POS	O
subarachnoid	POS	B-NP
hemorrhage	POS	I-NP
associated	POS	O
with	POS	O
aminocaproic	POS	O
acid	POS	O
therapy	POS	O
and	POS	O
acute	POS	B-NP
renal	POS	I-NP
artery	POS	I-NP
thrombosis	POS	I-NP
.	POS	O
Case	POS	O
report	POS	O
.	POS	O
Epsilon	POS	O
aminocaproic	POS	O
acid	POS	O
(	POS	O
EACA	POS	O
)	POS	O
has	POS	O
been	POS	O
used	POS	O
to	POS	O
prevent	POS	O
rebleeding	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
subarachnoid	POS	B-NP
hemorrhage	POS	I-NP
(	POS	O
SAH	POS	B-NP
)	POS	O
.	POS	O
Although	POS	O
this	POS	O
agent	POS	O
does	POS	O
decrease	POS	O
the	POS	O
frequency	POS	O
of	POS	O
rebleeding	POS	B-NP
,	POS	O
several	POS	O
reports	POS	O
have	POS	O
described	POS	O
thrombotic	POS	B-NP
complications	POS	O
of	POS	O
EACA	POS	O
therapy	POS	O
.	POS	O
These	POS	O
complications	POS	O
have	POS	O
included	POS	O
clinical	POS	O
deterioration	POS	O
and	POS	O
intracranial	POS	B-NP
vascular	POS	I-NP
thrombosis	POS	I-NP
in	POS	O
patients	POS	O
with	POS	O
SAH	POS	B-NP
,	POS	O
arteriolar	POS	O
and	POS	O
capillary	POS	O
fibrin	POS	O
thrombi	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
fibrinolytic	POS	B-NP
syndromes	POS	I-NP
treated	POS	O
with	POS	O
EACA	POS	O
,	POS	O
or	POS	O
other	POS	O
thromboembolic	POS	B-NP
phenomena	POS	I-NP
.	POS	O
Since	POS	O
intravascular	POS	O
fibrin	POS	O
thrombi	POS	B-NP
are	POS	O
often	POS	O
observed	POS	O
in	POS	O
patients	POS	O
with	POS	O
fibrinolytic	POS	B-NP
disorders	POS	I-NP
,	POS	O
EACA	POS	O
should	POS	O
not	POS	O
be	POS	O
implicated	POS	O
in	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
fibrin	POS	O
thrombi	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
disseminated	POS	B-NP
intravascular	POS	I-NP
coagulation	POS	I-NP
or	POS	O
other	POS	O
"	POS	O
consumption	POS	O
coagulopathies	POS	B-NP
.	POS	O
"	POS	O
This	POS	O
report	POS	O
describes	POS	O
subtotal	POS	O
infarction	POS	O
of	POS	O
the	POS	O
kidney	POS	O
due	POS	O
to	POS	O
thrombosis	POS	B-NP
of	POS	O
a	POS	O
normal	POS	B-NP
renal	POS	I-NP
artery	POS	I-NP
.	POS	O
This	POS	O
occlusion	POS	O
occurred	POS	O
after	POS	O
EACA	POS	O
therapy	POS	O
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
SAH	POS	B-NP
and	POS	O
histopathological	POS	O
documentation	POS	O
of	POS	O
recurrent	POS	O
SAH	POS	B-NP
.	POS	O
The	POS	O
corresponding	POS	O
clinical	POS	O
event	POS	O
was	POS	O
characterized	POS	O
by	POS	O
marked	POS	O
hypertension	POS	B-NP
and	POS	O
abrupt	POS	O
neurological	POS	B-NP
deterioration	POS	I-NP
.	POS	O
Effect	POS	O
of	POS	O
vincristine	POS	O
sulfate	POS	O
on	POS	O
Pseudomonas	POS	O
infections	POS	O
in	POS	O
monkeys	POS	O
.	POS	O
In	POS	O
rhesus	POS	O
monkeys	POS	O
,	POS	O
intravenous	POS	O
challenge	POS	O
with	POS	O
0	POS	O
.	POS	O
6	POS	O
x	POS	O
10	POS	O
(	POS	O
10	POS	O
)	POS	O
to	POS	O
2	POS	O
.	POS	O
2	POS	O
x	POS	O
10	POS	O
(	POS	O
10	POS	O
)	POS	O
Pseudomonas	POS	O
aeruginosa	POS	O
organisms	POS	O
caused	POS	O
acute	POS	B-NP
illness	POS	I-NP
of	POS	O
4	POS	O
to	POS	O
5	POS	O
days	POS	O
'	POS	O
duration	POS	O
with	POS	O
spontaneous	POS	O
recovery	POS	O
in	POS	O
13	POS	O
of	POS	O
15	POS	O
monkeys	POS	O
;	POS	O
blood	POS	O
cultures	POS	O
became	POS	O
negative	POS	O
3	POS	O
to	POS	O
17	POS	O
days	POS	O
after	POS	O
challenge	POS	O
.	POS	O
Leukocytosis	POS	B-NP
was	POS	O
observed	POS	O
in	POS	O
all	POS	O
monkeys	POS	O
.	POS	O
Intravenous	POS	O
or	POS	O
intratracheal	POS	O
inoculation	POS	O
of	POS	O
2	POS	O
.	POS	O
0	POS	O
to	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
of	POS	O
vincristine	POS	O
sulfate	POS	O
was	POS	O
followed	POS	O
by	POS	O
leukopenia	POS	B-NP
in	POS	O
4	POS	O
to	POS	O
5	POS	O
days	POS	O
.	POS	O
Intravenous	POS	O
inoculation	POS	O
of	POS	O
4	POS	O
.	POS	O
2	POS	O
x	POS	O
10	POS	O
(	POS	O
10	POS	O
)	POS	O
to	POS	O
7	POS	O
.	POS	O
8	POS	O
x	POS	O
10	POS	O
(	POS	O
10	POS	O
)	POS	O
pyocin	POS	O
type	POS	O
6	POS	O
Pseudomonas	POS	O
organisms	POS	O
in	POS	O
monkeys	POS	O
given	POS	O
vincristine	POS	O
sulfate	POS	O
4	POS	O
days	POS	O
previously	POS	O
resulted	POS	O
in	POS	O
fatal	POS	O
infection	POS	B-NP
in	POS	O
11	POS	O
of	POS	O
14	POS	O
monkeys	POS	O
,	POS	O
whereas	POS	O
none	POS	O
of	POS	O
four	POS	O
receiving	POS	O
Pseudomonas	POS	O
alone	POS	O
died	POS	O
.	POS	O
These	POS	O
studies	POS	O
suggest	POS	O
that	POS	O
an	POS	O
antimetabolite	POS	O
-	POS	O
induced	POS	O
leukopenia	POS	B-NP
predisposes	POS	O
to	POS	O
severe	POS	O
Pseudomonas	POS	B-NP
sepsis	POS	I-NP
and	POS	O
that	POS	O
such	POS	O
monkeys	POS	O
may	POS	O
serve	POS	O
as	POS	O
a	POS	O
biological	POS	O
model	POS	O
for	POS	O
study	POS	O
of	POS	O
comparative	POS	O
efficacy	POS	O
of	POS	O
antimicrobial	POS	O
agents	POS	O
.	POS	O
Modification	POS	O
by	POS	O
propranolol	POS	O
of	POS	O
cardiovascular	POS	O
effects	POS	O
of	POS	O
induced	POS	O
hypoglycaemia	POS	B-NP
.	POS	O
The	POS	O
cardiovascular	POS	O
effects	POS	O
of	POS	O
hypoglycaemia	POS	B-NP
,	POS	O
with	POS	O
and	POS	O
without	POS	O
beta	POS	O
-	POS	O
blockade	POS	O
,	POS	O
were	POS	O
compared	POS	O
in	POS	O
fourteen	POS	O
healthy	POS	O
men	POS	O
.	POS	O
Eight	POS	O
received	POS	O
insulin	POS	O
alone	POS	O
,	POS	O
and	POS	O
eight	POS	O
,	POS	O
including	POS	O
two	POS	O
of	POS	O
the	POS	O
original	POS	O
insulin	POS	O
-	POS	O
only	POS	O
group	POS	O
,	POS	O
were	POS	O
given	POS	O
propranolol	POS	O
and	POS	O
insulin	POS	O
.	POS	O
In	POS	O
the	POS	O
insulin	POS	O
-	POS	O
group	POS	O
the	POS	O
period	POS	O
of	POS	O
hypoglycaemia	POS	B-NP
was	POS	O
associated	POS	O
with	POS	O
an	POS	O
increase	POS	O
in	POS	O
heart	POS	O
-	POS	O
rate	POS	O
and	POS	O
a	POS	O
fall	POS	O
in	POS	O
diastolic	POS	O
blood	POS	O
-	POS	O
pressure	POS	O
.	POS	O
In	POS	O
the	POS	O
propranolol	POS	O
-	POS	O
insulin	POS	O
group	POS	O
there	POS	O
was	POS	O
a	POS	O
significant	POS	O
fall	POS	O
in	POS	O
heart	POS	O
-	POS	O
rate	POS	O
in	POS	O
most	POS	O
subjects	POS	O
and	POS	O
an	POS	O
increase	POS	O
in	POS	O
diastolic	POS	O
pressure	POS	O
.	POS	O
Typical	POS	O
S	POS	O
-	POS	O
T	POS	O
/	POS	O
T	POS	O
changes	POS	O
occurred	POS	O
in	POS	O
the	POS	O
insulin	POS	O
-	POS	O
group	POS	O
but	POS	O
in	POS	O
none	POS	O
of	POS	O
the	POS	O
propranolol	POS	O
-	POS	O
insulin	POS	O
group	POS	O
.	POS	O
Hypertension	POS	B-NP
in	POS	O
diabetics	POS	O
prone	POS	O
to	POS	O
hypoglycaemia	POS	B-NP
attacks	POS	O
should	POS	O
not	POS	O
be	POS	O
treated	POS	O
with	POS	O
beta	POS	O
-	POS	O
blockers	POS	O
because	POS	O
these	POS	O
drugs	POS	O
may	POS	O
cause	POS	O
a	POS	O
sharp	POS	O
rise	POS	O
in	POS	O
blood	POS	O
-	POS	O
pressure	POS	O
in	POS	O
such	POS	O
patients	POS	O
.	POS	O
Long	POS	O
-	POS	O
term	POS	O
propranolol	POS	O
therapy	POS	O
in	POS	O
pregnancy	POS	O
:	POS	O
maternal	POS	O
and	POS	O
fetal	POS	O
outcome	POS	O
.	POS	O
Propranolol	POS	O
,	POS	O
a	POS	O
beta	POS	O
-	POS	O
adrenergic	POS	O
blocking	POS	O
agent	POS	O
,	POS	O
has	POS	O
found	POS	O
an	POS	O
important	POS	O
position	POS	O
in	POS	O
the	POS	O
practice	POS	O
of	POS	O
medicine	POS	O
.	POS	O
Its	POS	O
use	POS	O
in	POS	O
pregnancy	POS	O
,	POS	O
however	POS	O
,	POS	O
is	POS	O
an	POS	O
open	POS	O
question	POS	O
as	POS	O
a	POS	O
number	POS	O
of	POS	O
detrimental	POS	O
side	POS	O
effects	POS	O
have	POS	O
been	POS	O
reported	POS	O
in	POS	O
the	POS	O
fetus	POS	O
and	POS	O
neonate	POS	O
.	POS	O
Ten	POS	O
patients	POS	O
and	POS	O
12	POS	O
pregnancies	POS	O
are	POS	O
reported	POS	O
where	POS	O
chronic	POS	O
propranolol	POS	O
has	POS	O
been	POS	O
administered	POS	O
.	POS	O
Five	POS	O
patients	POS	O
with	POS	O
serial	POS	O
pregnancies	POS	O
with	POS	O
and	POS	O
without	POS	O
propranolol	POS	O
therapy	POS	O
are	POS	O
also	POS	O
examined	POS	O
.	POS	O
Maternal	POS	O
,	POS	O
fetal	POS	O
,	POS	O
and	POS	O
neonatal	POS	B-NP
complications	POS	I-NP
are	POS	O
examined	POS	O
.	POS	O
An	POS	O
attempt	POS	O
is	POS	O
made	POS	O
to	POS	O
differentiate	POS	O
drug	POS	O
-	POS	O
related	POS	O
complications	POS	O
from	POS	O
maternal	POS	O
disease	POS	O
-	POS	O
-	POS	O
related	POS	O
complications	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
previously	POS	O
reported	POS	O
hypoglycemia	POS	B-NP
,	POS	O
hyperbilirubinemia	POS	B-NP
,	POS	O
polycythemia	POS	B-NP
,	POS	O
neonatal	POS	B-NP
apnea	POS	I-NP
,	POS	O
and	POS	O
bradycardia	POS	B-NP
are	POS	O
not	POS	O
invariable	POS	O
and	POS	O
cannot	POS	O
be	POS	O
statistically	POS	O
correlated	POS	O
with	POS	O
chronic	POS	O
propranolol	POS	O
therapy	POS	O
.	POS	O
Growth	POS	B-NP
retardation	POS	I-NP
,	POS	O
however	POS	O
,	POS	O
appears	POS	O
to	POS	O
be	POS	O
significant	POS	O
in	POS	O
both	POS	O
of	POS	O
our	POS	O
series	POS	O
.	POS	O
Central	POS	O
excitatory	POS	O
actions	POS	O
of	POS	O
flurazepam	POS	O
.	POS	O
Toxic	POS	O
actions	POS	O
of	POS	O
flurazepam	POS	O
(	POS	O
FZP	POS	O
)	POS	O
were	POS	O
studied	POS	O
in	POS	O
cats	POS	O
,	POS	O
mice	POS	O
and	POS	O
rats	POS	O
.	POS	O
High	POS	O
doses	POS	O
caused	POS	O
an	POS	O
apparent	POS	O
central	POS	O
excitation	POS	O
,	POS	O
most	POS	O
clearly	POS	O
seen	POS	O
as	POS	O
clonic	POS	B-NP
convulsions	POS	B-NP
,	POS	O
superimposed	POS	O
on	POS	O
general	POS	O
depression	POS	B-NP
.	POS	O
Following	POS	O
a	POS	O
lethal	POS	O
dose	POS	O
,	POS	O
death	POS	B-NP
was	POS	O
always	POS	O
associated	POS	O
with	POS	O
convulsions	POS	B-NP
.	POS	O
Comparing	POS	O
the	POS	O
relative	POS	O
sensitivity	POS	O
to	POS	O
central	POS	O
depression	POS	B-NP
and	POS	O
excitation	POS	O
revealed	POS	O
that	POS	O
rats	POS	O
were	POS	O
least	POS	O
likely	POS	O
to	POS	O
have	POS	O
convulsions	POS	B-NP
at	POS	O
doses	POS	O
that	POS	O
did	POS	O
not	POS	O
first	POS	O
cause	POS	O
loss	POS	B-NP
of	POS	I-NP
consciousness	POS	I-NP
,	POS	O
while	POS	O
cats	POS	O
most	POS	O
clearly	POS	O
showed	POS	O
marked	POS	O
central	POS	O
excitatory	POS	O
actions	POS	O
.	POS	O
Signs	POS	O
of	POS	O
FZP	POS	O
toxocity	POS	O
in	POS	O
cats	POS	O
included	POS	O
excessive	POS	O
salivation	POS	B-NP
,	POS	O
extreme	POS	O
apprehensive	POS	O
behavior	POS	O
,	POS	O
retching	POS	B-NP
,	POS	O
muscle	POS	B-NP
tremors	POS	I-NP
and	POS	O
convulsions	POS	B-NP
.	POS	O
An	POS	O
interaction	POS	O
between	POS	O
FZP	POS	O
and	POS	O
pentylenetetrazol	POS	O
(	POS	O
PTZ	POS	O
)	POS	O
was	POS	O
shown	POS	O
by	POS	O
pretreating	POS	O
mice	POS	O
with	POS	O
FZP	POS	O
before	POS	O
PTZ	POS	O
challenge	POS	O
.	POS	O
As	POS	O
a	POS	O
function	POS	O
of	POS	O
dose	POS	O
,	POS	O
FZP	POS	O
first	POS	O
protected	POS	O
against	POS	O
convulsions	POS	B-NP
and	POS	O
death	POS	B-NP
.	POS	O
At	POS	O
higher	POS	O
doses	POS	O
,	POS	O
however	POS	O
,	POS	O
convulsions	POS	B-NP
again	POS	O
emerged	POS	O
.	POS	O
These	POS	O
doses	POS	O
of	POS	O
FZP	POS	O
were	POS	O
lower	POS	O
than	POS	O
those	POS	O
that	POS	O
would	POS	O
alone	POS	O
cause	POS	O
convulsions	POS	B-NP
.	POS	O
These	POS	O
results	POS	O
may	POS	O
be	POS	O
relevant	POS	O
to	POS	O
the	POS	O
use	POS	O
of	POS	O
FZP	POS	O
in	POS	O
clinical	POS	O
situations	POS	O
in	POS	O
which	POS	O
there	POS	O
is	POS	O
increased	POS	O
neural	POS	O
excitability	POS	O
,	POS	O
such	POS	O
as	POS	O
epilepsy	POS	B-NP
or	POS	O
sedative	POS	O
-	POS	O
hypnotic	POS	O
drug	POS	O
withdrawal	POS	O
.	POS	O
Use	POS	O
of	POS	O
propranolol	POS	O
in	POS	O
the	POS	O
treatment	POS	O
of	POS	O
idiopathic	POS	B-NP
orthostatic	POS	I-NP
hypotension	POS	I-NP
.	POS	O
Five	POS	O
patients	POS	O
with	POS	O
idiopathic	POS	B-NP
orthostatic	POS	I-NP
hypotension	POS	I-NP
who	POS	O
had	POS	O
physiologic	POS	O
and	POS	O
biochemical	POS	O
evidence	POS	O
of	POS	O
severe	POS	O
autonomic	POS	B-NP
dysfunction	POS	I-NP
were	POS	O
included	POS	O
in	POS	O
the	POS	O
study	POS	O
.	POS	O
They	POS	O
all	POS	O
exhibited	POS	O
markedly	POS	O
reduced	POS	O
plasma	POS	O
catecholamines	POS	O
and	POS	O
plasma	POS	O
renin	POS	O
activity	POS	O
in	POS	O
both	POS	O
recumbent	POS	O
and	POS	O
upright	POS	O
positions	POS	O
and	POS	O
had	POS	O
marked	POS	O
hypersensitivity	POS	B-NP
to	POS	O
the	POS	O
pressor	POS	O
effects	POS	O
of	POS	O
infused	POS	O
norepinephrine	POS	O
.	POS	O
Treatment	POS	O
with	POS	O
propanolol	POS	O
administered	POS	O
intravenously	POS	O
(	POS	O
1	POS	O
-	POS	O
5	POS	O
mg	POS	O
)	POS	O
produced	POS	O
increases	POS	O
in	POS	O
supine	POS	O
and	POS	O
upright	POS	O
blood	POS	O
pressure	POS	O
in	POS	O
4	POS	O
of	POS	O
the	POS	O
5	POS	O
individuals	POS	O
with	POS	O
rises	POS	O
ranging	POS	O
from	POS	O
11	POS	O
/	POS	O
6	POS	O
to	POS	O
22	POS	O
/	POS	O
11	POS	O
mmHg	POS	O
.	POS	O
Chronic	POS	O
oral	POS	O
administration	POS	O
of	POS	O
propranolol	POS	O
(	POS	O
40	POS	O
-	POS	O
160	POS	O
mg	POS	O
/	POS	O
day	POS	O
)	POS	O
also	POS	O
elevated	POS	O
the	POS	O
blood	POS	O
pressures	POS	O
of	POS	O
these	POS	O
individuals	POS	O
with	POS	O
increases	POS	O
in	POS	O
the	POS	O
order	POS	O
of	POS	O
20	POS	O
-	POS	O
35	POS	O
/	POS	O
15	POS	O
-	POS	O
25	POS	O
mmg	POS	O
being	POS	O
observed	POS	O
.	POS	O
In	POS	O
1	POS	O
patient	POS	O
,	POS	O
marked	POS	O
hypertension	POS	B-NP
was	POS	O
induced	POS	O
by	POS	O
propranolol	POS	O
and	POS	O
the	POS	O
drug	POS	O
had	POS	O
to	POS	O
be	POS	O
withdrawn	POS	O
.	POS	O
It	POS	O
otherwise	POS	O
was	POS	O
well	POS	O
tolerated	POS	O
and	POS	O
no	POS	O
important	POS	O
side	POS	O
effects	POS	O
were	POS	O
observed	POS	O
.	POS	O
Treatment	POS	O
has	POS	O
been	POS	O
continued	POS	O
in	POS	O
3	POS	O
individuals	POS	O
for	POS	O
6	POS	O
-	POS	O
13	POS	O
months	POS	O
with	POS	O
persistence	POS	O
of	POS	O
the	POS	O
pressor	POS	O
effect	POS	O
,	POS	O
although	POS	O
there	POS	O
appears	POS	O
to	POS	O
have	POS	O
been	POS	O
some	POS	O
decrease	POS	O
in	POS	O
the	POS	O
degree	POS	O
of	POS	O
response	POS	O
with	POS	O
time	POS	O
.	POS	O
Hemodynamic	POS	O
measurements	POS	O
in	POS	O
1	POS	O
of	POS	O
the	POS	O
patients	POS	O
demonstrated	POS	O
an	POS	O
increase	POS	O
in	POS	O
total	POS	O
peripheral	POS	O
resistance	POS	O
and	POS	O
essentially	POS	O
no	POS	O
change	POS	O
in	POS	O
cardiac	POS	O
output	POS	O
following	POS	O
propranolol	POS	O
therapy	POS	O
.	POS	O
The	POS	O
studies	POS	O
suggest	POS	O
that	POS	O
propranolol	POS	O
is	POS	O
a	POS	O
useful	POS	O
drug	POS	O
in	POS	O
selected	POS	O
patients	POS	O
with	POS	O
severe	POS	O
idiopathic	POS	B-NP
orthostatic	POS	I-NP
hypotension	POS	I-NP
.	POS	O
Total	POS	O
intravenous	POS	O
anesthesia	POS	O
with	POS	O
etomidate	POS	O
.	POS	O
III	POS	O
.	POS	O
Some	POS	O
observations	POS	O
in	POS	O
adults	POS	O
.	POS	O
An	POS	O
investigation	POS	O
was	POS	O
undertaken	POS	O
to	POS	O
determine	POS	O
the	POS	O
dosage	POS	O
of	POS	O
etomidate	POS	O
required	POS	O
to	POS	O
maintain	POS	O
sleep	POS	O
in	POS	O
adults	POS	O
undergoing	POS	O
surgery	POS	O
under	POS	O
regional	POS	O
local	POS	O
anesthesia	POS	O
.	POS	O
Premedication	POS	O
of	POS	O
diazepam	POS	O
10	POS	O
mg	POS	O
and	POS	O
atropine	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
was	POS	O
given	POS	O
,	POS	O
and	POS	O
sleep	POS	O
was	POS	O
induced	POS	O
and	POS	O
maintained	POS	O
by	POS	O
intermittent	POS	O
intravenous	POS	O
injections	POS	O
of	POS	O
etomidate	POS	O
0	POS	O
.	POS	O
1	POS	O
/	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
given	POS	O
whenever	POS	O
the	POS	O
patient	POS	O
would	POS	O
open	POS	O
his	POS	O
eyes	POS	O
on	POS	O
request	POS	O
.	POS	O
A	POS	O
mean	POS	O
overall	POS	O
dose	POS	O
of	POS	O
etomidate	POS	O
17	POS	O
.	POS	O
4	POS	O
microgram	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
.	POS	O
was	POS	O
required	POS	O
to	POS	O
maintain	POS	O
sleep	POS	O
,	POS	O
but	POS	O
great	POS	O
individual	POS	O
variation	POS	O
occurred	POS	O
,	POS	O
with	POS	O
older	POS	O
patients	POS	O
requiring	POS	O
less	POS	O
drug	POS	O
.	POS	O
The	POS	O
investigation	POS	O
was	POS	O
discontinued	POS	O
after	POS	O
18	POS	O
patients	POS	O
because	POS	O
of	POS	O
the	POS	O
frequency	POS	O
and	POS	O
intensity	POS	O
of	POS	O
side	POS	O
-	POS	O
effects	POS	O
,	POS	O
particularly	POS	O
pain	POS	B-NP
and	POS	O
myoclonia	POS	B-NP
,	POS	O
which	POS	O
caused	POS	O
the	POS	O
technique	POS	O
to	POS	O
be	POS	O
abandoned	POS	O
in	POS	O
two	POS	O
cases	POS	O
.	POS	O
It	POS	O
is	POS	O
considered	POS	O
unlikely	POS	O
that	POS	O
etomidate	POS	O
will	POS	O
prove	POS	O
to	POS	O
be	POS	O
the	POS	O
hypnotic	POS	O
of	POS	O
choice	POS	O
for	POS	O
a	POS	O
totally	POS	O
intravenous	POS	O
anesthetic	POS	O
technique	POS	O
in	POS	O
adults	POS	O
because	POS	O
of	POS	O
the	POS	O
high	POS	O
incidence	POS	O
of	POS	O
myoclonia	POS	B-NP
after	POS	O
prolonged	POS	O
administration	POS	O
.	POS	O
In	POS	O
several	POS	O
patients	POS	O
uncontrollable	POS	O
muscle	POS	B-NP
movements	POS	I-NP
persisted	POS	O
for	POS	O
many	POS	O
minutes	POS	O
after	POS	O
complete	POS	O
recovery	POS	O
of	POS	O
consciousness	POS	O
.	POS	O
Evidence	POS	O
for	POS	O
cardiac	POS	O
beta	POS	O
2	POS	O
-	POS	O
adrenoceptors	POS	O
in	POS	O
man	POS	O
.	POS	O
We	POS	O
compared	POS	O
the	POS	O
effects	POS	O
of	POS	O
single	POS	O
doses	POS	O
of	POS	O
50	POS	O
mg	POS	O
atenolol	POS	O
(	POS	O
cardioselective	POS	O
)	POS	O
,	POS	O
40	POS	O
mg	POS	O
propranolol	POS	O
(	POS	O
nonselective	POS	O
)	POS	O
,	POS	O
and	POS	O
placebo	POS	O
on	POS	O
both	POS	O
exercise	POS	O
-	POS	O
and	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
tachycardia	POS	B-NP
in	POS	O
two	POS	O
experiments	POS	O
involving	POS	O
nine	POS	O
normal	POS	O
subjects	POS	O
.	POS	O
Maximal	POS	O
exercise	POS	O
heart	POS	O
rate	POS	O
was	POS	O
reduced	POS	O
from	POS	O
187	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
(	POS	O
SEM	POS	O
)	POS	O
after	POS	O
placebo	POS	O
to	POS	O
146	POS	O
+	POS	O
/	POS	O
-	POS	O
7	POS	O
bpm	POS	O
after	POS	O
atenolol	POS	O
and	POS	O
138	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
bpm	POS	O
after	POS	O
propranolol	POS	O
,	POS	O
but	POS	O
there	POS	O
were	POS	O
no	POS	O
differences	POS	O
between	POS	O
the	POS	O
drugs	POS	O
.	POS	O
The	POS	O
effects	POS	O
on	POS	O
isoproterenol	POS	O
tachycardia	POS	B-NP
were	POS	O
determined	POS	O
before	POS	O
and	POS	O
after	POS	O
atropine	POS	O
(	POS	O
0	POS	O
.	POS	O
04	POS	O
mg	POS	O
/	POS	O
kg	POS	O
IV	POS	O
)	POS	O
.	POS	O
Isoproterenol	POS	O
sensitivity	POS	O
was	POS	O
determined	POS	O
as	POS	O
the	POS	O
intravenous	POS	O
dose	POS	O
that	POS	O
increased	POS	O
heart	POS	O
rate	POS	O
by	POS	O
25	POS	O
bpm	POS	O
(	POS	O
CD25	POS	O
)	POS	O
and	POS	O
this	POS	O
was	POS	O
increased	POS	O
from	POS	O
1	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
3	POS	O
micrograms	POS	O
after	POS	O
placebo	POS	O
to	POS	O
38	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
.	POS	O
3	POS	O
micrograms	POS	O
after	POS	O
propranolol	POS	O
and	POS	O
8	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
7	POS	O
micrograms	POS	O
after	POS	O
atenolol	POS	O
.	POS	O
The	POS	O
difference	POS	O
in	POS	O
the	POS	O
effects	POS	O
of	POS	O
the	POS	O
two	POS	O
was	POS	O
significant	POS	O
.	POS	O
After	POS	O
atropine	POS	O
the	POS	O
CD25	POS	O
was	POS	O
unchanged	POS	O
after	POS	O
placebo	POS	O
(	POS	O
2	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
3	POS	O
micrograms	POS	O
)	POS	O
and	POS	O
atenolol	POS	O
(	POS	O
7	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
3	POS	O
micrograms	POS	O
)	POS	O
;	POS	O
it	POS	O
was	POS	O
reduced	POS	O
after	POS	O
propranolol	POS	O
(	POS	O
24	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
.	POS	O
0	POS	O
micrograms	POS	O
)	POS	O
,	POS	O
but	POS	O
remained	POS	O
different	POS	O
from	POS	O
atenolol	POS	O
.	POS	O
This	POS	O
change	POS	O
with	POS	O
propranolol	POS	O
sensitivity	POS	O
was	POS	O
calculated	POS	O
as	POS	O
the	POS	O
apparent	POS	O
Ka	POS	O
,	POS	O
this	POS	O
was	POS	O
unchanged	POS	O
by	POS	O
atropine	POS	O
(	POS	O
11	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
.	POS	O
1	POS	O
and	POS	O
10	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
.	POS	O
5	POS	O
ml	POS	O
/	POS	O
ng	POS	O
)	POS	O
.	POS	O
These	POS	O
data	POS	O
are	POS	O
consistent	POS	O
with	POS	O
the	POS	O
hypothesis	POS	O
that	POS	O
exercise	POS	O
-	POS	O
induced	POS	O
tachycardia	POS	B-NP
results	POS	O
largely	POS	O
from	POS	O
beta	POS	O
1	POS	O
-	POS	O
receptor	POS	O
activation	POS	O
that	POS	O
is	POS	O
blocked	POS	O
by	POS	O
both	POS	O
cardioselective	POS	O
and	POS	O
nonselective	POS	O
drugs	POS	O
,	POS	O
whereas	POS	O
isoproterenol	POS	O
activates	POS	O
both	POS	O
beta	POS	O
1	POS	O
-	POS	O
and	POS	O
beta	POS	O
2	POS	O
-	POS	O
receptors	POS	O
so	POS	O
that	POS	O
after	POS	O
cardioselective	POS	O
blockade	POS	O
there	POS	O
remains	POS	O
a	POS	O
beta	POS	O
2	POS	O
-	POS	O
component	POS	O
that	POS	O
can	POS	O
be	POS	O
blocked	POS	O
with	POS	O
a	POS	O
nonselective	POS	O
drug	POS	O
.	POS	O
While	POS	O
there	POS	O
appear	POS	O
to	POS	O
be	POS	O
beta	POS	O
2	POS	O
-	POS	O
receptors	POS	O
in	POS	O
the	POS	O
human	POS	O
heart	POS	O
,	POS	O
their	POS	O
physiologic	POS	O
or	POS	O
pathologic	POS	O
roles	POS	O
remain	POS	O
to	POS	O
be	POS	O
defined	POS	O
.	POS	O
Hormones	POS	O
and	POS	O
risk	POS	O
of	POS	O
breast	POS	B-NP
cancer	POS	I-NP
.	POS	O
This	POS	O
paper	POS	O
reports	POS	O
the	POS	O
results	POS	O
of	POS	O
a	POS	O
study	POS	O
of	POS	O
50	POS	O
menopausal	POS	O
women	POS	O
receiving	POS	O
hormonal	POS	O
replacement	POS	O
therapy	POS	O
.	POS	O
The	POS	O
majority	POS	O
(	POS	O
29	POS	O
)	POS	O
had	POS	O
surgical	POS	O
menopause	POS	O
;	POS	O
their	POS	O
mean	POS	O
age	POS	O
was	POS	O
45	POS	O
.	POS	O
7	POS	O
years	POS	O
.	POS	O
It	POS	O
was	POS	O
hypothesized	POS	O
that	POS	O
progestins	POS	O
could	POS	O
equilibrate	POS	O
the	POS	O
effects	POS	O
of	POS	O
the	POS	O
estrogenic	POS	O
stimulation	POS	O
on	POS	O
the	POS	O
mammary	POS	O
and	POS	O
endometrial	POS	O
target	POS	O
tissues	POS	O
of	POS	O
women	POS	O
on	POS	O
hormonal	POS	O
replacement	POS	O
therapy	POS	O
.	POS	O
The	POS	O
treatment	POS	O
schedule	POS	O
consisted	POS	O
of	POS	O
conjugated	POS	O
estrogens	POS	O
(	POS	O
Premarin	POS	O
)	POS	O
1	POS	O
.	POS	O
25	POS	O
mg	POS	O
/	POS	O
day	POS	O
for	POS	O
21	POS	O
days	POS	O
and	POS	O
Medroxyprogesterone	POS	O
acetate	POS	O
10	POS	O
mg	POS	O
/	POS	O
day	POS	O
for	POS	O
10	POS	O
days	POS	O
in	POS	O
each	POS	O
month	POS	O
.	POS	O
The	POS	O
mean	POS	O
treatment	POS	O
period	POS	O
was	POS	O
18	POS	O
months	POS	O
.	POS	O
During	POS	O
the	POS	O
follow	POS	O
-	POS	O
up	POS	O
period	POS	O
,	POS	O
attention	POS	O
was	POS	O
paid	POS	O
to	POS	O
breast	POS	O
modifications	POS	O
as	POS	O
evidenced	POS	O
by	POS	O
symptomatology	POS	O
,	POS	O
physical	POS	O
examination	POS	O
,	POS	O
and	POS	O
plate	POS	O
thermography	POS	O
.	POS	O
Mastodynia	POS	B-NP
was	POS	O
reported	POS	O
by	POS	O
21	POS	O
patients	POS	O
,	POS	O
and	POS	O
physical	POS	O
examination	POS	O
revealed	POS	O
a	POS	O
light	POS	O
increase	POS	O
in	POS	O
breast	POS	O
firmness	POS	O
in	POS	O
12	POS	O
women	POS	O
and	POS	O
a	POS	O
moderate	POS	O
increase	POS	O
in	POS	O
breast	POS	B-NP
nodularity	POS	I-NP
in	POS	O
2	POS	O
women	POS	O
.	POS	O
Themography	POS	B-NP
confirmed	POS	O
the	POS	O
existence	POS	O
of	POS	O
an	POS	O
excessive	POS	O
breast	POS	O
stimulation	POS	O
in	POS	O
1	POS	O
women	POS	O
who	POS	O
complained	POS	O
of	POS	O
moderate	POS	O
mastodynia	POS	B-NP
and	POS	O
in	POS	O
5	POS	O
of	POS	O
the	POS	O
7	POS	O
women	POS	O
who	POS	O
complained	POS	O
of	POS	O
severe	POS	O
mastodynia	POS	B-NP
.	POS	O
Normalization	POS	O
was	POS	O
obtained	POS	O
by	POS	O
halving	POS	O
the	POS	O
estrogen	POS	O
dose	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
hormonal	POS	O
replacement	POS	O
therapy	POS	O
can	POS	O
be	POS	O
safely	POS	O
prescribed	POS	O
if	POS	O
the	POS	O
following	POS	O
criteria	POS	O
are	POS	O
satisfied	POS	O
:	POS	O
1	POS	O
)	POS	O
preliminary	POS	O
evaluation	POS	O
of	POS	O
patients	POS	O
from	POS	O
a	POS	O
clinical	POS	O
,	POS	O
metabolic	POS	O
,	POS	O
cytologic	POS	O
,	POS	O
and	POS	O
mammographic	POS	O
perspective	POS	O
;	POS	O
2	POS	O
)	POS	O
cyclic	POS	O
treatment	POS	O
schedule	POS	O
,	POS	O
with	POS	O
a	POS	O
progestative	POS	O
phase	POS	O
of	POS	O
10	POS	O
days	POS	O
;	POS	O
and	POS	O
3	POS	O
)	POS	O
periodic	POS	O
complete	POS	O
follow	POS	O
-	POS	O
up	POS	O
,	POS	O
with	POS	O
accurate	POS	O
thermographic	POS	O
evaluation	POS	O
of	POS	O
the	POS	O
breast	POS	O
target	POS	O
tissues	POS	O
.	POS	O
Early	POS	O
infections	POS	O
in	POS	O
kidney	POS	O
,	POS	O
heart	POS	O
,	POS	O
and	POS	O
liver	POS	O
transplant	POS	O
recipients	POS	O
on	POS	O
cyclosporine	POS	O
.	POS	O
Eighty	POS	O
-	POS	O
one	POS	O
renal	POS	O
,	POS	O
seventeen	POS	O
heart	POS	O
,	POS	O
and	POS	O
twenty	POS	O
-	POS	O
four	POS	O
liver	POS	O
transplant	POS	O
patients	POS	O
were	POS	O
followed	POS	O
for	POS	O
infection	POS	O
.	POS	O
Seventeen	POS	O
renal	POS	O
patients	POS	O
received	POS	O
azathioprine	POS	O
(	POS	O
Aza	POS	O
)	POS	O
and	POS	O
prednisone	POS	O
as	POS	O
part	POS	O
of	POS	O
a	POS	O
randomized	POS	O
trial	POS	O
of	POS	O
immunosuppression	POS	O
with	POS	O
21	POS	O
cyclosporine	POS	O
-	POS	O
and	POS	O
-	POS	O
prednisone	POS	O
-	POS	O
treated	POS	O
renal	POS	O
transplant	POS	O
patients	POS	O
.	POS	O
All	POS	O
others	POS	O
received	POS	O
cyclosporine	POS	O
and	POS	O
prednisone	POS	O
.	POS	O
The	POS	O
randomized	POS	O
Aza	POS	O
patients	POS	O
had	POS	O
more	POS	O
overall	POS	O
infections	POS	B-NP
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
and	POS	O
more	POS	O
nonviral	POS	B-NP
infections	POS	I-NP
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
02	POS	O
)	POS	O
than	POS	O
the	POS	O
randomized	POS	O
cyclosporine	POS	O
patients	POS	O
.	POS	O
Heart	POS	O
and	POS	O
liver	POS	O
patients	POS	O
had	POS	O
more	POS	O
infections	POS	O
than	POS	O
cyclosporine	POS	O
renal	POS	O
patients	POS	O
but	POS	O
fewer	POS	O
infections	POS	B-NP
than	POS	O
the	POS	O
Aza	POS	O
renal	POS	O
patients	POS	O
.	POS	O
There	POS	O
were	POS	O
no	POS	O
infectious	POS	B-NP
deaths	POS	I-NP
in	POS	O
renal	POS	O
transplant	POS	O
patients	POS	O
on	POS	O
cyclosporine	POS	O
or	POS	O
Aza	POS	O
,	POS	O
but	POS	O
infection	POS	O
played	POS	O
a	POS	O
major	POS	O
role	POS	O
in	POS	O
3	POS	O
out	POS	O
of	POS	O
6	POS	O
cardiac	POS	O
transplant	POS	O
deaths	POS	O
and	POS	O
in	POS	O
8	POS	O
out	POS	O
of	POS	O
9	POS	O
liver	POS	B-NP
transplant	POS	I-NP
deaths	POS	I-NP
.	POS	O
Renal	POS	O
patients	POS	O
on	POS	O
cyclosporine	POS	O
had	POS	O
the	POS	O
fewest	POS	O
bacteremias	POS	B-NP
.	POS	O
Analysis	POS	O
of	POS	O
site	POS	O
of	POS	O
infection	POS	O
showed	POS	O
a	POS	O
preponderance	POS	O
of	POS	O
abdominal	POS	B-NP
infections	POS	I-NP
in	POS	O
liver	POS	O
patients	POS	O
,	POS	O
intrathoracic	POS	B-NP
infections	POS	I-NP
in	POS	O
heart	POS	O
patients	POS	O
,	POS	O
and	POS	O
urinary	POS	B-NP
tract	POS	I-NP
infections	POS	I-NP
in	POS	O
renal	POS	O
patients	POS	O
.	POS	O
Pulmonary	POS	B-NP
infections	POS	I-NP
were	POS	O
less	POS	O
common	POS	O
in	POS	O
cyclosporine	POS	O
-	POS	O
treated	POS	O
renal	POS	O
patients	POS	O
than	POS	O
in	POS	O
Aza	POS	O
-	POS	O
treated	POS	O
patients	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
Aza	POS	O
patients	POS	O
had	POS	O
significantly	POS	O
more	POS	O
staphylococcal	POS	B-NP
infections	POS	I-NP
than	POS	O
all	POS	O
other	POS	O
transplant	POS	O
groups	POS	O
(	POS	O
P	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
005	POS	O
)	POS	O
,	POS	O
and	POS	O
systemic	POS	B-NP
fungal	POS	I-NP
infections	POS	I-NP
occurred	POS	O
only	POS	O
in	POS	O
the	POS	O
liver	POS	O
transplant	POS	O
group	POS	O
.	POS	O
Cytomegalovirus	POS	O
(	POS	O
CMV	POS	O
)	POS	O
shedding	POS	O
or	POS	O
serological	POS	O
rises	POS	O
in	POS	O
antibody	POS	O
titer	POS	O
,	POS	O
or	POS	O
both	POS	O
occurred	POS	O
in	POS	O
78	POS	O
%	POS	O
of	POS	O
cyclosporine	POS	O
patients	POS	O
and	POS	O
76	POS	O
%	POS	O
of	POS	O
Aza	POS	O
patients	POS	O
.	POS	O
Of	POS	O
the	POS	O
cyclosporine	POS	O
patients	POS	O
,	POS	O
15	POS	O
%	POS	O
had	POS	O
symptoms	POS	O
related	POS	O
to	POS	O
CMV	POS	B-NP
infection	POS	I-NP
.	POS	O
Serological	POS	O
evidence	POS	O
for	POS	O
Epstein	POS	B-NP
Barr	POS	I-NP
Virus	POS	I-NP
infection	POS	I-NP
was	POS	O
found	POS	O
in	POS	O
20	POS	O
%	POS	O
of	POS	O
65	POS	O
cyclosporine	POS	O
patients	POS	O
studied	POS	O
.	POS	O
Three	POS	O
had	POS	O
associated	POS	O
symptoms	POS	O
,	POS	O
and	POS	O
one	POS	O
developed	POS	O
a	POS	O
lymphoma	POS	B-NP
.	POS	O
Structure	POS	O
-	POS	O
activity	POS	O
and	POS	O
dose	POS	O
-	POS	O
effect	POS	O
relationships	POS	O
of	POS	O
the	POS	O
antagonism	POS	O
of	POS	O
picrotoxin	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
by	POS	O
cholecystokinin	POS	O
,	POS	O
fragments	POS	O
and	POS	O
analogues	POS	O
of	POS	O
cholecystokinin	POS	O
in	POS	O
mice	POS	O
.	POS	O
Intraperitoneal	POS	O
administration	POS	O
of	POS	O
cholecystokinin	POS	O
octapeptide	POS	O
sulphate	POS	O
ester	POS	O
(	POS	O
CCK	POS	O
-	POS	O
8	POS	O
-	POS	O
SE	POS	O
)	POS	O
and	POS	O
nonsulphated	POS	O
cholecystokinin	POS	O
octapeptide	POS	O
(	POS	O
CCK	POS	O
-	POS	O
8	POS	O
-	POS	O
NS	POS	O
)	POS	O
enhanced	POS	O
the	POS	O
latency	POS	O
of	POS	O
seizures	POS	B-NP
induced	POS	O
by	POS	O
picrotoxin	POS	O
in	POS	O
mice	POS	O
.	POS	O
Experiments	POS	O
with	POS	O
N	POS	O
-	POS	O
and	POS	O
C	POS	O
-	POS	O
terminal	POS	O
fragments	POS	O
revealed	POS	O
that	POS	O
the	POS	O
C	POS	O
-	POS	O
terminal	POS	O
tetrapeptide	POS	O
(	POS	O
CCK	POS	O
-	POS	O
5	POS	O
-	POS	O
8	POS	O
)	POS	O
was	POS	O
the	POS	O
active	POS	O
centre	POS	O
of	POS	O
the	POS	O
CCK	POS	O
octapeptide	POS	O
molecule	POS	O
.	POS	O
The	POS	O
analogues	POS	O
CCK	POS	O
-	POS	O
8	POS	O
-	POS	O
SE	POS	O
and	POS	O
CCK	POS	O
-	POS	O
8	POS	O
-	POS	O
NS	POS	O
(	POS	O
dose	POS	O
range	POS	O
0	POS	O
.	POS	O
2	POS	O
-	POS	O
6	POS	O
.	POS	O
4	POS	O
mumol	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
caerulein	POS	O
dose	POS	O
range	POS	O
0	POS	O
.	POS	O
1	POS	O
-	POS	O
0	POS	O
.	POS	O
8	POS	O
mumol	POS	O
/	POS	O
kg	POS	O
)	POS	O
showed	POS	O
bell	POS	O
-	POS	O
shaped	POS	O
dose	POS	O
-	POS	O
effect	POS	O
curves	POS	O
,	POS	O
with	POS	O
the	POS	O
greatest	POS	O
maximum	POS	O
inhibition	POS	O
for	POS	O
CCK	POS	O
-	POS	O
8	POS	O
-	POS	O
NS	POS	O
.	POS	O
The	POS	O
peptide	POS	O
CCK	POS	O
-	POS	O
5	POS	O
-	POS	O
8	POS	O
had	POS	O
weak	POS	O
anticonvulsant	POS	O
activity	POS	O
in	POS	O
comparison	POS	O
to	POS	O
the	POS	O
octapeptides	POS	O
,	POS	O
3	POS	O
.	POS	O
2	POS	O
mumol	POS	O
/	POS	O
kg	POS	O
and	POS	O
larger	POS	O
doses	POS	O
of	POS	O
the	POS	O
reference	POS	O
drug	POS	O
,	POS	O
diazepam	POS	O
,	POS	O
totally	POS	O
prevented	POS	O
picrotoxin	POS	O
-	POS	O
induced	POS	O
seizures	POS	B-NP
and	POS	O
mortality	POS	O
.	POS	O
The	POS	O
maximum	POS	O
effect	POS	O
of	POS	O
the	POS	O
peptides	POS	O
tested	POS	O
was	POS	O
less	POS	O
than	POS	O
that	POS	O
of	POS	O
diazepam	POS	O
.	POS	O
Experiments	POS	O
with	POS	O
analogues	POS	O
and	POS	O
derivatives	POS	O
of	POS	O
CCK	POS	O
-	POS	O
5	POS	O
-	POS	O
8	POS	O
demonstrated	POS	O
that	POS	O
the	POS	O
effectiveness	POS	O
of	POS	O
the	POS	O
beta	POS	O
-	POS	O
alanyl	POS	O
derivatives	POS	O
of	POS	O
CCK	POS	O
-	POS	O
5	POS	O
-	POS	O
8	POS	O
were	POS	O
enhanced	POS	O
and	POS	O
that	POS	O
they	POS	O
were	POS	O
equipotent	POS	O
with	POS	O
CCK	POS	O
-	POS	O
8	POS	O
-	POS	O
SE	POS	O
.	POS	O
Of	POS	O
the	POS	O
CCK	POS	O
-	POS	O
2	POS	O
-	POS	O
8	POS	O
analogues	POS	O
,	POS	O
Ser	POS	O
(	POS	O
SO3H	POS	O
)	POS	O
7	POS	O
-	POS	O
Ac	POS	O
-	POS	O
CCK	POS	O
-	POS	O
2	POS	O
-	POS	O
8	POS	O
-	POS	O
SE	POS	O
and	POS	O
Thr	POS	O
(	POS	O
SO3H	POS	O
)	POS	O
7	POS	O
-	POS	O
Ac	POS	O
-	POS	O
CCK	POS	O
-	POS	O
2	POS	O
-	POS	O
8	POS	O
-	POS	O
SE	POS	O
and	POS	O
Hyp	POS	O
(	POS	O
SO3H	POS	O
)	POS	O
-	POS	O
Ac	POS	O
-	POS	O
CCK	POS	O
-	POS	O
2	POS	O
-	POS	O
8	POS	O
-	POS	O
SE	POS	O
were	POS	O
slightly	POS	O
more	POS	O
active	POS	O
than	POS	O
CCK	POS	O
-	POS	O
8	POS	O
-	POS	O
SE	POS	O
.	POS	O
Vasopressin	POS	O
as	POS	O
a	POS	O
possible	POS	O
contributor	POS	O
to	POS	O
hypertension	POS	B-NP
.	POS	O
The	POS	O
role	POS	O
of	POS	O
vasopressin	POS	O
as	POS	O
a	POS	O
pressor	POS	O
agent	POS	O
to	POS	O
the	POS	O
hypertensive	POS	B-NP
process	POS	O
was	POS	O
examined	POS	O
.	POS	O
Vasopressin	POS	O
plays	POS	O
a	POS	O
major	POS	O
role	POS	O
in	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
DOCA	POS	O
-	POS	O
salt	POS	O
hypertension	POS	B-NP
,	POS	O
since	POS	O
the	POS	O
elevation	POS	O
of	POS	O
blood	POS	O
pressure	POS	O
was	POS	O
not	POS	O
substantial	POS	O
in	POS	O
the	POS	O
rats	POS	O
with	POS	O
lithium	POS	O
-	POS	O
treated	POS	O
diabetes	POS	B-NP
insipidus	POS	I-NP
after	POS	O
DOCA	POS	O
-	POS	O
salt	POS	O
treatment	POS	O
.	POS	O
Administration	POS	O
of	POS	O
DDAVP	POS	O
which	POS	O
has	POS	O
antidiuretic	POS	O
action	POS	O
but	POS	O
minimal	POS	O
vasopressor	POS	O
effect	POS	O
failed	POS	O
to	POS	O
increase	POS	O
blood	POS	O
pressure	POS	O
to	POS	O
the	POS	O
levels	POS	O
observed	POS	O
after	POS	O
administration	POS	O
of	POS	O
AVP	POS	O
.	POS	O
Furthermore	POS	O
,	POS	O
the	POS	O
pressor	POS	O
action	POS	O
of	POS	O
vasopressin	POS	O
appears	POS	O
to	POS	O
be	POS	O
important	POS	O
in	POS	O
the	POS	O
development	POS	O
of	POS	O
this	POS	O
model	POS	O
of	POS	O
hypertension	POS	B-NP
,	POS	O
since	POS	O
the	POS	O
enhanced	POS	O
pressor	POS	O
responsiveness	POS	O
to	POS	O
the	POS	O
hormone	POS	O
was	POS	O
observed	POS	O
in	POS	O
the	POS	O
initial	POS	O
stage	POS	O
of	POS	O
hypertension	POS	B-NP
.	POS	O
Increased	POS	O
secretion	POS	O
of	POS	O
vasopressin	POS	O
from	POS	O
neurohypophysis	POS	O
also	POS	O
promotes	POS	O
the	POS	O
function	POS	O
of	POS	O
the	POS	O
hormone	POS	O
as	POS	O
a	POS	O
pathogenetic	POS	O
factor	POS	O
in	POS	O
hypertension	POS	B-NP
.	POS	O
An	POS	O
unproportional	POS	O
release	POS	O
of	POS	O
vasopressin	POS	O
compared	POS	O
to	POS	O
plasma	POS	O
osmolality	POS	O
may	POS	O
be	POS	O
induced	POS	O
by	POS	O
the	POS	O
absence	POS	O
of	POS	O
an	POS	O
adjusting	POS	O
control	POS	O
of	POS	O
angiotensin	POS	O
II	POS	O
forming	POS	O
and	POS	O
receptor	POS	O
binding	POS	O
capacity	POS	O
for	POS	O
sodium	POS	O
balance	POS	O
in	POS	O
the	POS	O
brain	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
role	POS	O
of	POS	O
vasopressin	POS	O
remains	POS	O
to	POS	O
be	POS	O
determined	POS	O
in	POS	O
human	POS	O
essential	POS	O
hypertension	POS	B-NP
.	POS	O
Toxic	POS	B-NP
hepatitis	POS	I-NP
induced	POS	O
by	POS	O
disulfiram	POS	O
in	POS	O
a	POS	O
non	POS	O
-	POS	O
alcoholic	POS	O
.	POS	O
A	POS	O
reversible	POS	O
toxic	POS	B-NP
liver	POS	I-NP
damage	POS	I-NP
was	POS	O
observed	POS	O
in	POS	O
a	POS	O
non	POS	O
-	POS	O
alcoholic	POS	O
woman	POS	O
treated	POS	O
with	POS	O
disulfiram	POS	O
.	POS	O
The	POS	O
causative	POS	O
relationship	POS	O
was	POS	O
proven	POS	O
by	POS	O
challenge	POS	O
.	POS	O
Atrial	POS	B-NP
thrombosis	POS	I-NP
involving	POS	O
the	POS	O
heart	POS	O
of	POS	O
F	POS	O
-	POS	O
344	POS	O
rats	POS	O
ingesting	POS	O
quinacrine	POS	O
hydrochloride	POS	O
.	POS	O
Quinacrine	POS	O
hydrochloride	POS	O
is	POS	O
toxic	POS	O
for	POS	O
the	POS	O
heart	POS	O
of	POS	O
F	POS	O
-	POS	O
344	POS	O
rats	POS	O
.	POS	O
Rats	POS	O
treated	POS	O
with	POS	O
500	POS	O
ppm	POS	O
quinacrine	POS	O
hydrochloride	POS	O
in	POS	O
the	POS	O
diet	POS	O
all	POS	O
developed	POS	O
a	POS	O
high	POS	O
incidence	POS	O
of	POS	O
left	POS	O
atrial	POS	B-NP
thrombosis	POS	I-NP
.	POS	O
The	POS	O
lesion	POS	O
was	POS	O
associated	POS	O
with	POS	O
cardiac	POS	B-NP
hypertrophy	POS	I-NP
and	POS	O
dilatation	POS	O
and	POS	O
focal	POS	O
myocardial	POS	B-NP
degeneration	POS	I-NP
.	POS	O
Rats	POS	O
died	POS	O
from	POS	O
cardiac	POS	B-NP
hypertrophy	POS	I-NP
with	POS	O
severe	POS	O
acute	POS	O
and	POS	O
chronic	POS	O
congestion	POS	O
of	POS	O
the	POS	O
lungs	POS	O
,	POS	O
liver	POS	O
,	POS	O
and	POS	O
other	POS	O
organs	POS	O
.	POS	O
Seventy	POS	O
percent	POS	O
of	POS	O
rats	POS	O
given	POS	O
250	POS	O
ppm	POS	O
quinacrine	POS	O
hydrochloride	POS	O
and	POS	O
1	POS	O
,	POS	O
000	POS	O
ppm	POS	O
sodium	POS	O
nitrite	POS	O
simultaneously	POS	O
in	POS	O
the	POS	O
diet	POS	O
had	POS	O
thrombosis	POS	B-NP
of	POS	O
the	POS	O
atria	POS	O
of	POS	O
the	POS	O
heart	POS	O
,	POS	O
while	POS	O
untreated	POS	O
control	POS	O
rats	POS	O
in	POS	O
this	POS	O
laboratory	POS	O
did	POS	O
not	POS	O
have	POS	O
atrial	POS	B-NP
thrombosis	POS	I-NP
.	POS	O
Sodium	POS	O
nitrite	POS	O
in	POS	O
combination	POS	O
with	POS	O
quinacrine	POS	O
hydrochloride	POS	O
appeared	POS	O
to	POS	O
have	POS	O
no	POS	O
additional	POS	O
effect	POS	O
.	POS	O
Alternating	POS	O
sinus	POS	O
rhythm	POS	O
and	POS	O
intermittent	POS	O
sinoatrial	POS	B-NP
block	POS	I-NP
induced	POS	O
by	POS	O
propranolol	POS	O
.	POS	O
Alternating	POS	O
sinus	POS	O
rhythm	POS	O
and	POS	O
intermittent	POS	O
sinoatrial	POS	O
(	POS	O
S	POS	O
-	POS	O
A	POS	O
)	POS	O
block	POS	O
was	POS	O
observed	POS	O
in	POS	O
a	POS	O
57	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
,	POS	O
under	POS	O
treatment	POS	O
for	POS	O
angina	POS	B-NP
with	POS	O
80	POS	O
mg	POS	O
propranolol	POS	O
daily	POS	O
.	POS	O
The	POS	O
electrocardiogram	POS	O
showed	POS	O
alternation	POS	O
of	POS	O
long	POS	O
and	POS	O
short	POS	O
P	POS	O
-	POS	O
P	POS	O
intervals	POS	O
and	POS	O
occasional	POS	O
pauses	POS	O
.	POS	O
These	POS	O
pauses	POS	O
were	POS	O
always	POS	O
preceded	POS	O
by	POS	O
the	POS	O
short	POS	O
P	POS	O
-	POS	O
P	POS	O
intervals	POS	O
and	POS	O
were	POS	O
usually	POS	O
followed	POS	O
by	POS	O
one	POS	O
or	POS	O
two	POS	O
P	POS	O
-	POS	O
P	POS	O
intervals	POS	O
of	POS	O
0	POS	O
.	POS	O
92	POS	O
-	POS	O
0	POS	O
.	POS	O
95	POS	O
s	POS	O
representing	POS	O
the	POS	O
basic	POS	O
sinus	POS	O
cycle	POS	O
.	POS	O
Following	POS	O
these	POS	O
basic	POS	O
sinus	POS	O
cycles	POS	O
,	POS	O
alternating	POS	O
rhythm	POS	O
started	POS	O
with	POS	O
the	POS	O
longer	POS	O
P	POS	O
-	POS	O
P	POS	O
interval	POS	O
.	POS	O
The	POS	O
long	POS	O
P	POS	O
-	POS	O
P	POS	O
intervals	POS	O
ranged	POS	O
between	POS	O
1	POS	O
.	POS	O
04	POS	O
-	POS	O
1	POS	O
.	POS	O
12	POS	O
s	POS	O
and	POS	O
the	POS	O
short	POS	O
P	POS	O
-	POS	O
P	POS	O
intervals	POS	O
between	POS	O
0	POS	O
.	POS	O
80	POS	O
-	POS	O
0	POS	O
.	POS	O
84	POS	O
s	POS	O
,	POS	O
respectively	POS	O
.	POS	O
The	POS	O
duration	POS	O
of	POS	O
the	POS	O
pauses	POS	O
were	POS	O
equal	POS	O
or	POS	O
almost	POS	O
equal	POS	O
to	POS	O
one	POS	O
short	POS	O
plus	POS	O
one	POS	O
long	POS	O
P	POS	O
-	POS	O
P	POS	O
interval	POS	O
or	POS	O
to	POS	O
twice	POS	O
the	POS	O
basic	POS	O
sinus	POS	O
cycle	POS	O
.	POS	O
In	POS	O
one	POS	O
recording	POS	O
a	POS	O
short	POS	O
period	POS	O
of	POS	O
regular	POS	O
sinus	POS	O
rhythm	POS	O
with	POS	O
intermittent	POS	O
2	POS	O
/	POS	O
1	POS	O
S	POS	O
-	POS	O
A	POS	O
block	POS	O
was	POS	O
observed	POS	O
.	POS	O
This	POS	O
short	POS	O
period	POS	O
of	POS	O
sinus	POS	O
rhythm	POS	O
was	POS	O
interrupted	POS	O
by	POS	O
sudden	POS	O
prolongation	POS	O
of	POS	O
the	POS	O
P	POS	O
-	POS	O
P	POS	O
interval	POS	O
starting	POS	O
the	POS	O
alternative	POS	O
rhythm	POS	O
.	POS	O
There	POS	O
were	POS	O
small	POS	O
changes	POS	O
in	POS	O
the	POS	O
shape	POS	O
of	POS	O
the	POS	O
P	POS	O
waves	POS	O
and	POS	O
P	POS	O
-	POS	O
R	POS	O
intervals	POS	O
.	POS	O
S	POS	O
-	POS	O
A	POS	O
conduction	POS	O
through	POS	O
two	POS	O
pathways	POS	O
,	POS	O
the	POS	O
first	POS	O
with	POS	O
2	POS	O
/	POS	O
1	POS	O
block	POS	O
the	POS	O
second	POS	O
having	POS	O
0	POS	O
.	POS	O
12	POS	O
-	POS	O
0	POS	O
.	POS	O
14	POS	O
s	POS	O
longer	POS	O
conduction	POS	O
time	POS	O
and	POS	O
with	POS	O
occasional	POS	O
2	POS	O
/	POS	O
1	POS	O
block	POS	O
was	POS	O
proposed	POS	O
for	POS	O
the	POS	O
explanation	POS	O
of	POS	O
the	POS	O
alternating	POS	O
P	POS	O
-	POS	O
P	POS	O
interval	POS	O
and	POS	O
other	POS	O
electrocardiographic	POS	O
features	POS	O
seen	POS	O
.	POS	O
Atropine	POS	O
1	POS	O
mg	POS	O
given	POS	O
intravenously	POS	O
resulted	POS	O
in	POS	O
shortening	POS	O
of	POS	O
all	POS	O
P	POS	O
-	POS	O
P	POS	O
intervals	POS	O
without	POS	O
changing	POS	O
the	POS	O
rhythm	POS	O
.	POS	O
The	POS	O
abnormal	POS	O
rhythm	POS	O
disappeared	POS	O
with	POS	O
the	POS	O
withdrawal	POS	O
of	POS	O
propranolol	POS	O
and	POS	O
when	POS	O
the	POS	O
drug	POS	O
was	POS	O
restarted	POS	O
a	POS	O
2	POS	O
/	POS	O
1	POS	O
S	POS	O
-	POS	O
A	POS	O
block	POS	O
was	POS	O
seen	POS	O
.	POS	O
This	POS	O
was	POS	O
accepted	POS	O
as	POS	O
evidence	POS	O
for	POS	O
propranolol	POS	O
being	POS	O
the	POS	O
cause	POS	O
of	POS	O
this	POS	O
conduction	POS	O
disorder	POS	O
.	POS	O
Antitumor	POS	B-NP
effect	POS	I-NP
,	POS	O
cardiotoxicity	POS	B-NP
,	POS	O
and	POS	O
nephrotoxicity	POS	B-NP
of	POS	O
doxorubicin	POS	O
in	POS	O
the	POS	O
IgM	POS	O
solid	POS	O
immunocytoma	POS	O
-	POS	O
bearing	POS	O
LOU	POS	O
/	POS	O
M	POS	O
/	POS	O
WSL	POS	O
rat	POS	O
.	POS	O
Antitumor	POS	O
activity	POS	O
,	POS	O
cardiotoxicity	POS	B-NP
,	POS	O
and	POS	O
nephrotoxicity	POS	B-NP
induced	POS	O
by	POS	O
doxorubicin	POS	O
were	POS	O
studied	POS	O
in	POS	O
LOU	POS	O
/	POS	O
M	POS	O
/	POS	O
WSL	POS	O
inbred	POS	O
rats	POS	O
each	POS	O
bearing	POS	O
a	POS	O
transplantable	POS	O
solid	POS	O
IgM	POS	O
immunocytoma	POS	B-NP
.	POS	O
Animals	POS	O
with	POS	O
a	POS	O
tumor	POS	B-NP
(	POS	O
diameter	POS	O
,	POS	O
15	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
.	POS	O
3	POS	O
mm	POS	O
)	POS	O
were	POS	O
treated	POS	O
with	POS	O
iv	POS	O
injections	POS	O
of	POS	O
doxorubicin	POS	O
on	POS	O
5	POS	O
consecutive	POS	O
days	POS	O
,	POS	O
followed	POS	O
by	POS	O
1	POS	O
weekly	POS	O
injection	POS	O
for	POS	O
7	POS	O
weeks	POS	O
(	POS	O
dose	POS	O
range	POS	O
,	POS	O
0	POS	O
.	POS	O
015	POS	O
-	POS	O
4	POS	O
.	POS	O
0	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
wt	POS	O
)	POS	O
.	POS	O
Tumor	POS	B-NP
regression	POS	O
was	POS	O
observed	POS	O
with	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
doxorubicin	POS	O
/	POS	O
kg	POS	O
.	POS	O
Complete	POS	O
disappearance	POS	O
of	POS	O
the	POS	O
tumor	POS	B-NP
was	POS	O
induced	POS	O
with	POS	O
1	POS	O
.	POS	O
0	POS	O
mg	POS	O
doxorubicin	POS	O
/	POS	O
kg	POS	O
.	POS	O
Histologic	POS	O
evidence	POS	O
of	POS	O
cardiotoxicity	POS	B-NP
scored	POS	O
as	POS	O
grade	POS	O
III	POS	O
was	POS	O
only	POS	O
observed	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
1	POS	O
.	POS	O
0	POS	O
mg	POS	O
doxorubicin	POS	O
/	POS	O
kg	POS	O
.	POS	O
Light	POS	O
microscopic	POS	O
evidence	POS	O
of	POS	O
renal	POS	B-NP
damage	POS	I-NP
was	POS	O
seen	POS	O
above	POS	O
a	POS	O
dose	POS	O
of	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
doxorubicin	POS	O
/	POS	O
kg	POS	O
,	POS	O
which	POS	O
resulted	POS	O
in	POS	O
albuminuria	POS	B-NP
and	POS	O
very	POS	O
low	POS	O
serum	POS	O
albumin	POS	O
levels	POS	O
.	POS	O
In	POS	O
the	POS	O
group	POS	O
that	POS	O
received	POS	O
1	POS	O
.	POS	O
0	POS	O
mg	POS	O
doxorubicin	POS	O
/	POS	O
kg	POS	O
,	POS	O
the	POS	O
serum	POS	O
albumin	POS	O
level	POS	O
decreased	POS	O
from	POS	O
33	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
.	POS	O
1	POS	O
to	POS	O
1	POS	O
.	POS	O
5	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
5	POS	O
g	POS	O
/	POS	O
liter	POS	O
.	POS	O
Ascites	POS	O
and	POS	O
hydrothorax	POS	B-NP
were	POS	O
observed	POS	O
simultaneously	POS	O
.	POS	O
The	POS	O
same	POS	O
experiments	POS	O
were	POS	O
performed	POS	O
with	POS	O
non	POS	O
-	POS	O
tumor	POS	O
-	POS	O
bearing	POS	O
rats	POS	O
,	POS	O
in	POS	O
which	POS	O
no	POS	O
major	POS	O
differences	POS	O
were	POS	O
observed	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
antitumor	POS	O
activity	POS	O
,	POS	O
cardiotoxicity	POS	B-NP
,	POS	O
and	POS	O
nephrotoxicity	POS	B-NP
were	POS	O
studied	POS	O
simultaneously	POS	O
in	POS	O
the	POS	O
same	POS	O
LOU	POS	O
/	POS	O
M	POS	O
/	POS	O
WSL	POS	O
rat	POS	O
.	POS	O
Albuminuria	POS	B-NP
due	POS	O
to	POS	O
renal	POS	B-NP
damage	POS	I-NP
led	POS	O
to	POS	O
extremely	POS	O
low	POS	O
serum	POS	O
albumin	POS	O
levels	POS	O
,	POS	O
so	POS	O
ascites	POS	B-NP
and	POS	O
hydrothorax	POS	B-NP
were	POS	O
not	POS	O
necessarily	POS	O
a	POS	O
consequence	POS	O
of	POS	O
the	POS	O
observed	POS	O
cardiomyopathy	POS	B-NP
.	POS	O
Intraoperative	POS	B-NP
bradycardia	POS	I-NP
and	POS	O
hypotension	POS	B-NP
associated	POS	O
with	POS	O
timolol	POS	O
and	POS	O
pilocarpine	POS	O
eye	POS	O
drops	POS	O
.	POS	O
A	POS	O
69	POS	O
-	POS	O
yr	POS	O
-	POS	O
old	POS	O
man	POS	O
,	POS	O
who	POS	O
was	POS	O
concurrently	POS	O
being	POS	O
treated	POS	O
with	POS	O
pilocarpine	POS	O
nitrate	POS	O
and	POS	O
timolol	POS	O
maleate	POS	O
eye	POS	O
drops	POS	O
,	POS	O
developed	POS	O
a	POS	O
bradycardia	POS	B-NP
and	POS	O
became	POS	O
hypotensive	POS	B-NP
during	POS	O
halothane	POS	O
anaesthesia	POS	O
.	POS	O
Both	POS	O
timolol	POS	O
and	POS	O
pilocarpine	POS	O
were	POS	O
subsequently	POS	O
identified	POS	O
in	POS	O
a	POS	O
24	POS	O
-	POS	O
h	POS	O
collection	POS	O
of	POS	O
urine	POS	O
.	POS	O
Timolol	POS	O
(	POS	O
but	POS	O
not	POS	O
pilocarpine	POS	O
)	POS	O
was	POS	O
detected	POS	O
in	POS	O
a	POS	O
sample	POS	O
of	POS	O
plasma	POS	O
removed	POS	O
during	POS	O
surgery	POS	O
;	POS	O
the	POS	O
plasma	POS	O
concentration	POS	O
of	POS	O
timolol	POS	O
(	POS	O
2	POS	O
.	POS	O
6	POS	O
ng	POS	O
ml	POS	O
-	POS	O
1	POS	O
)	POS	O
was	POS	O
consistent	POS	O
with	POS	O
partial	POS	O
beta	POS	O
-	POS	O
adrenoceptor	POS	O
blockade	POS	O
.	POS	O
It	POS	O
is	POS	O
postulated	POS	O
that	POS	O
this	POS	O
action	POS	O
may	POS	O
have	POS	O
been	POS	O
enhanced	POS	O
during	POS	O
halothane	POS	O
anaesthesia	POS	O
with	POS	O
resultant	POS	O
bradycardia	POS	B-NP
and	POS	O
hypotension	POS	B-NP
.	POS	O
Pilocarpine	POS	O
may	POS	O
have	POS	O
had	POS	O
a	POS	O
contributory	POS	O
effect	POS	O
.	POS	O
Succinylcholine	POS	O
apnoea	POS	B-NP
:	POS	O
attempted	POS	O
reversal	POS	O
with	POS	O
anticholinesterases	POS	O
.	POS	O
Anticholinesterases	POS	O
were	POS	O
administered	POS	O
in	POS	O
an	POS	O
attempt	POS	O
to	POS	O
antagonize	POS	O
prolonged	POS	O
neuromuscular	POS	O
blockade	POS	O
following	POS	O
the	POS	O
administration	POS	O
of	POS	O
succinylcholine	POS	O
in	POS	O
a	POS	O
patient	POS	O
later	POS	O
found	POS	O
to	POS	O
be	POS	O
homozygous	POS	O
for	POS	O
atypical	POS	O
plasma	POS	O
cholinesterase	POS	O
.	POS	O
Edrophonium	POS	O
10	POS	O
mg	POS	O
,	POS	O
given	POS	O
74	POS	O
min	POS	O
after	POS	O
succinylcholine	POS	O
,	POS	O
when	POS	O
train	POS	O
-	POS	O
of	POS	O
-	POS	O
four	POS	O
stimulation	POS	O
was	POS	O
characteristic	POS	O
of	POS	O
phase	POS	O
II	POS	O
block	POS	O
,	POS	O
produced	POS	O
partial	POS	O
antagonism	POS	O
which	POS	O
was	POS	O
not	POS	O
sustained	POS	O
.	POS	O
Repeated	POS	O
doses	POS	O
of	POS	O
edrophonium	POS	O
to	POS	O
70	POS	O
mg	POS	O
and	POS	O
neostigmine	POS	O
to	POS	O
2	POS	O
.	POS	O
5	POS	O
mg	POS	O
did	POS	O
not	POS	O
antagonize	POS	O
or	POS	O
augment	POS	O
the	POS	O
block	POS	O
.	POS	O
Spontaneous	POS	O
respiration	POS	O
recommenced	POS	O
200	POS	O
min	POS	O
after	POS	O
succinylcholine	POS	O
administration	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
anticholinesterases	POS	O
are	POS	O
only	POS	O
partially	POS	O
effective	POS	O
in	POS	O
restoring	POS	O
neuromuscular	POS	O
function	POS	O
in	POS	O
succinylcholine	POS	O
apnoea	POS	B-NP
despite	POS	O
muscle	POS	O
twitch	POS	O
activity	POS	O
typical	POS	O
of	POS	O
phase	POS	O
II	POS	O
block	POS	O
.	POS	O
Effect	POS	O
of	POS	O
doxorubicin	POS	O
on	POS	O
[	POS	O
omega	POS	O
-	POS	O
I	POS	O
-	POS	O
131	POS	O
]	POS	O
heptadecanoic	POS	O
acid	POS	O
myocardial	POS	O
scintigraphy	POS	O
and	POS	O
echocardiography	POS	O
in	POS	O
dogs	POS	O
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
serial	POS	O
treatment	POS	O
with	POS	O
doxorubicin	POS	O
on	POS	O
dynamic	POS	O
myocardial	POS	O
scintigraphy	POS	O
with	POS	O
[	POS	O
omega	POS	O
-	POS	O
I	POS	O
-	POS	O
131	POS	O
]	POS	O
heptadecanoic	POS	O
acid	POS	O
(	POS	O
I	POS	O
-	POS	O
131	POS	O
HA	POS	O
)	POS	O
,	POS	O
and	POS	O
on	POS	O
global	POS	O
left	POS	O
-	POS	O
ventricular	POS	O
function	POS	O
determined	POS	O
echocardiographically	POS	O
,	POS	O
were	POS	O
studied	POS	O
in	POS	O
a	POS	O
group	POS	O
of	POS	O
nine	POS	O
mongrel	POS	O
dogs	POS	O
.	POS	O
Total	POS	O
extractable	POS	O
myocardial	POS	O
lipid	POS	O
was	POS	O
compared	POS	O
postmortem	POS	O
between	POS	O
a	POS	O
group	POS	O
of	POS	O
control	POS	O
dogs	POS	O
and	POS	O
doxorubicin	POS	O
-	POS	O
treated	POS	O
dogs	POS	O
.	POS	O
A	POS	O
significant	POS	O
and	POS	O
then	POS	O
progressive	POS	O
fall	POS	O
in	POS	O
global	POS	O
LV	POS	O
function	POS	O
was	POS	O
observed	POS	O
at	POS	O
a	POS	O
cumulative	POS	O
doxorubicin	POS	O
dose	POS	O
of	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
A	POS	O
significant	POS	O
increase	POS	O
in	POS	O
the	POS	O
myocardial	POS	O
t1	POS	O
/	POS	O
2	POS	O
of	POS	O
the	POS	O
I	POS	O
-	POS	O
131	POS	O
HA	POS	O
was	POS	O
observed	POS	O
only	POS	O
at	POS	O
a	POS	O
higher	POS	O
cumulative	POS	O
dose	POS	O
,	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
No	POS	O
significant	POS	O
alteration	POS	O
in	POS	O
total	POS	O
extractable	POS	O
myocardial	POS	O
lipids	POS	O
was	POS	O
observed	POS	O
between	POS	O
control	POS	O
dogs	POS	O
and	POS	O
those	POS	O
treated	POS	O
with	POS	O
doxorubicin	POS	O
.	POS	O
Our	POS	O
findings	POS	O
suggest	POS	O
that	POS	O
the	POS	O
changes	POS	O
leading	POS	O
to	POS	O
an	POS	O
alteration	POS	O
of	POS	O
myocardial	POS	O
dynamic	POS	O
imaging	POS	O
with	POS	O
I	POS	O
-	POS	O
131	POS	O
HA	POS	O
are	POS	O
not	POS	O
the	POS	O
initiating	POS	O
factor	POS	O
in	POS	O
doxorubicin	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
Hemodynamics	POS	O
and	POS	O
myocardial	POS	O
metabolism	POS	O
under	POS	O
deliberate	POS	O
hypotension	POS	B-NP
.	POS	O
An	POS	O
experimental	POS	O
study	POS	O
in	POS	O
dogs	POS	O
.	POS	O
Coronary	POS	O
blood	POS	O
flow	POS	O
,	POS	O
cardiac	POS	O
work	POS	O
and	POS	O
metabolism	POS	O
were	POS	O
studied	POS	O
in	POS	O
dogs	POS	O
under	POS	O
sodium	POS	O
nitroprusside	POS	O
(	POS	O
SNP	POS	O
)	POS	O
and	POS	O
trimetaphan	POS	O
(	POS	O
TMP	POS	O
)	POS	O
deliberate	POS	O
hypotension	POS	B-NP
(	POS	O
20	POS	O
%	POS	O
and	POS	O
40	POS	O
%	POS	O
mean	POS	O
pressure	POS	O
decrease	POS	O
from	POS	O
baseline	POS	O
)	POS	O
.	POS	O
Regarding	POS	O
the	POS	O
effects	POS	O
of	POS	O
drug	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
on	POS	O
coronary	POS	O
blood	POS	O
flow	POS	O
,	POS	O
aortic	POS	O
and	POS	O
coronary	POS	O
sinus	POS	O
metabolic	POS	O
data	POS	O
(	POS	O
pH	POS	O
,	POS	O
pO2	POS	O
,	POS	O
pCO2	POS	O
)	POS	O
we	POS	O
could	POS	O
confirm	POS	O
that	POS	O
nitroprusside	POS	O
hypotension	POS	B-NP
could	POS	O
be	POS	O
safely	POS	O
used	POS	O
to	POS	O
30	POS	O
%	POS	O
mean	POS	O
blood	POS	O
pressure	POS	O
decrease	POS	O
from	POS	O
control	POS	O
,	POS	O
trimetaphan	POS	O
hypotension	POS	B-NP
to	POS	O
20	POS	O
%	POS	O
mean	POS	O
blood	POS	O
pressure	POS	O
decrease	POS	O
.	POS	O
Cardiac	POS	O
work	POS	O
was	POS	O
significantly	POS	O
reduced	POS	O
during	POS	O
SNP	POS	O
hypotension	POS	B-NP
.	POS	O
Myocardial	POS	O
O2	POS	O
consumption	POS	O
and	POS	O
O2	POS	O
availability	POS	O
were	POS	O
directly	POS	O
dependent	POS	O
on	POS	O
the	POS	O
coronary	POS	O
perfusion	POS	O
.	POS	O
Careful	POS	O
invasive	POS	O
monitoring	POS	O
of	POS	O
the	POS	O
blood	POS	O
pressure	POS	O
,	POS	O
blood	POS	O
gases	POS	O
and	POS	O
of	POS	O
the	POS	O
ECG	POS	O
ST	POS	O
-	POS	O
T	POS	O
segment	POS	O
is	POS	O
mandatory	POS	O
.	POS	O
Evidence	POS	O
for	POS	O
a	POS	O
selective	POS	O
brain	POS	O
noradrenergic	POS	O
involvement	POS	O
in	POS	O
the	POS	O
locomotor	POS	O
stimulant	POS	O
effects	POS	O
of	POS	O
amphetamine	POS	O
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
Male	POS	O
rats	POS	O
received	POS	O
the	POS	O
noradrenaline	POS	O
neurotoxin	POS	O
DSP4	POS	O
(	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
7	POS	O
days	POS	O
prior	POS	O
to	POS	O
injection	POS	O
of	POS	O
D	POS	O
-	POS	O
amphetamine	POS	O
(	POS	O
10	POS	O
or	POS	O
40	POS	O
mumol	POS	O
/	POS	O
kg	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
.	POS	O
The	POS	O
hyperactivity	POS	B-NP
induced	POS	O
by	POS	O
D	POS	O
-	POS	O
amphetamine	POS	O
(	POS	O
10	POS	O
mumol	POS	O
/	POS	O
kg	POS	O
)	POS	O
was	POS	O
significantly	POS	O
reduced	POS	O
by	POS	O
DSP4	POS	O
pretreatment	POS	O
.	POS	O
However	POS	O
,	POS	O
the	POS	O
increased	POS	O
rearings	POS	O
and	POS	O
the	POS	O
amphetamine	POS	O
-	POS	O
induced	POS	O
stereotypies	POS	B-NP
were	POS	O
not	POS	O
blocked	POS	O
by	POS	O
pretreatment	POS	O
with	POS	O
DSP4	POS	O
.	POS	O
The	POS	O
reduction	POS	O
of	POS	O
amphetamine	POS	O
hyperactivity	POS	B-NP
induced	POS	O
by	POS	O
DSP4	POS	O
was	POS	O
blocked	POS	O
by	POS	O
pretreatment	POS	O
with	POS	O
the	POS	O
noradrenaline	POS	O
-	POS	O
uptake	POS	O
blocking	POS	O
agent	POS	O
,	POS	O
desipramine	POS	O
,	POS	O
which	POS	O
prevents	POS	O
the	POS	O
neurotoxic	POS	B-NP
action	POS	O
of	POS	O
DSP4	POS	O
.	POS	O
The	POS	O
present	POS	O
results	POS	O
suggest	POS	O
a	POS	O
selective	POS	O
involvement	POS	O
of	POS	O
central	POS	O
noradrenergic	POS	O
neurones	POS	O
in	POS	O
the	POS	O
locomotor	POS	O
stimulant	POS	O
effect	POS	O
of	POS	O
amphetamine	POS	O
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
Accelerated	POS	O
junctional	POS	O
rhythms	POS	O
during	POS	O
oral	POS	O
verapamil	POS	O
therapy	POS	O
.	POS	O
This	POS	O
study	POS	O
examined	POS	O
the	POS	O
frequency	POS	O
of	POS	O
atrioventricular	POS	O
(	POS	O
AV	POS	O
)	POS	O
dissociation	POS	O
and	POS	O
accelerated	POS	O
junctional	POS	O
rhythms	POS	O
in	POS	O
59	POS	O
patients	POS	O
receiving	POS	O
oral	POS	O
verapamil	POS	O
.	POS	O
Accelerated	POS	O
junctional	POS	O
rhythms	POS	O
and	POS	O
AV	POS	O
dissociation	POS	O
were	POS	O
frequent	POS	O
in	POS	O
patients	POS	O
with	POS	O
supraventricular	POS	B-NP
tachyarrhythmias	POS	I-NP
,	POS	O
particularly	POS	O
AV	POS	B-NP
nodal	POS	I-NP
reentry	POS	I-NP
.	POS	O
Verapamil	POS	O
administration	POS	O
to	POS	O
these	POS	O
patients	POS	O
led	POS	O
to	POS	O
an	POS	O
asymptomatic	POS	O
increase	POS	O
in	POS	O
activity	POS	O
of	POS	O
these	POS	O
junctional	POS	O
pacemakers	POS	O
.	POS	O
In	POS	O
patients	POS	O
with	POS	O
various	POS	O
chest	POS	B-NP
pain	POS	I-NP
syndromes	POS	I-NP
,	POS	O
verapamil	POS	O
neither	POS	O
increased	POS	O
the	POS	O
frequency	POS	O
of	POS	O
junctional	POS	O
rhythms	POS	O
nor	POS	O
suppressed	POS	O
their	POS	O
role	POS	O
as	POS	O
escape	POS	O
rhythms	POS	O
under	POS	O
physiologically	POS	O
appropriate	POS	O
circumstances	POS	O
.	POS	O
Interstrain	POS	O
variation	POS	O
in	POS	O
acute	POS	O
toxic	POS	O
response	POS	O
to	POS	O
caffeine	POS	O
among	POS	O
inbred	POS	O
mice	POS	O
.	POS	O
Acute	POS	O
toxic	POS	O
dosage	POS	O
-	POS	O
dependent	POS	O
behavioral	POS	O
effects	POS	O
of	POS	O
caffeine	POS	O
were	POS	O
compared	POS	O
in	POS	O
adult	POS	O
males	POS	O
from	POS	O
seven	POS	O
inbred	POS	O
mouse	POS	O
strains	POS	O
(	POS	O
A	POS	O
/	POS	O
J	POS	O
,	POS	O
BALB	POS	O
/	POS	O
cJ	POS	O
,	POS	O
CBA	POS	O
/	POS	O
J	POS	O
,	POS	O
C3H	POS	O
/	POS	O
HeJ	POS	O
,	POS	O
C57BL	POS	O
/	POS	O
6J	POS	O
,	POS	O
DBA	POS	O
/	POS	O
2J	POS	O
,	POS	O
SWR	POS	O
/	POS	O
J	POS	O
)	POS	O
.	POS	O
C57BL	POS	O
/	POS	O
6J	POS	O
,	POS	O
chosen	POS	O
as	POS	O
a	POS	O
"	POS	O
prototypic	POS	O
"	POS	O
mouse	POS	O
strain	POS	O
,	POS	O
was	POS	O
used	POS	O
to	POS	O
determine	POS	O
behavioral	POS	O
responses	POS	O
to	POS	O
a	POS	O
broad	POS	O
range	POS	O
(	POS	O
5	POS	O
-	POS	O
500	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
of	POS	O
caffeine	POS	O
doses	POS	O
.	POS	O
Five	POS	O
phenotypic	POS	O
characteristics	POS	O
-	POS	O
-	POS	O
locomotor	POS	O
activity	POS	O
,	POS	O
righting	POS	O
ability	POS	O
,	POS	O
clonic	POS	O
seizure	POS	B-NP
induction	POS	O
,	POS	O
stress	POS	B-NP
-	POS	I-NP
induced	POS	I-NP
lethality	POS	I-NP
,	POS	O
death	POS	B-NP
without	POS	O
external	POS	O
stress	POS	O
-	POS	O
-	POS	O
were	POS	O
scored	POS	O
at	POS	O
various	POS	O
caffeine	POS	O
doses	POS	O
in	POS	O
drug	POS	O
-	POS	O
naive	POS	O
animals	POS	O
under	POS	O
empirically	POS	O
optimized	POS	O
,	POS	O
rigidly	POS	O
constant	POS	O
experimental	POS	O
conditions	POS	O
.	POS	O
Mice	POS	O
(	POS	O
n	POS	O
=	POS	O
12	POS	O
for	POS	O
each	POS	O
point	POS	O
)	POS	O
received	POS	O
single	POS	O
IP	POS	O
injections	POS	O
of	POS	O
a	POS	O
fixed	POS	O
volume	POS	O
/	POS	O
g	POS	O
body	POS	O
weight	POS	O
of	POS	O
physiological	POS	O
saline	POS	O
carrier	POS	O
with	POS	O
or	POS	O
without	POS	O
caffeine	POS	O
in	POS	O
doses	POS	O
ranging	POS	O
from	POS	O
125	POS	O
-	POS	O
500	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
Loss	POS	O
of	POS	O
righting	POS	O
ability	POS	O
was	POS	O
scored	POS	O
at	POS	O
1	POS	O
,	POS	O
3	POS	O
,	POS	O
5	POS	O
min	POS	O
post	POS	O
dosing	POS	O
and	POS	O
at	POS	O
5	POS	O
min	POS	O
intervals	POS	O
thereafter	POS	O
for	POS	O
20	POS	O
min	POS	O
.	POS	O
In	POS	O
the	POS	O
same	POS	O
animals	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
clonic	POS	B-NP
seizures	POS	B-NP
was	POS	O
scored	POS	O
as	POS	O
to	POS	O
time	POS	O
of	POS	O
onset	POS	O
and	POS	O
severity	POS	O
for	POS	O
20	POS	O
min	POS	O
after	POS	O
drug	POS	O
administration	POS	O
.	POS	O
When	POS	O
these	POS	O
proceeded	POS	O
to	POS	O
tonic	POS	O
seizures	POS	B-NP
,	POS	O
death	POS	B-NP
occurred	POS	O
in	POS	O
less	POS	O
than	POS	O
20	POS	O
min	POS	O
.	POS	O
Animals	POS	O
surviving	POS	O
for	POS	O
20	POS	O
min	POS	O
were	POS	O
immediately	POS	O
stressed	POS	O
by	POS	O
a	POS	O
swim	POS	O
test	POS	O
in	POS	O
25	POS	O
degrees	POS	O
C	POS	O
water	POS	O
,	POS	O
and	POS	O
death	POS	O
-	POS	O
producing	POS	O
tonic	POS	O
seizures	POS	B-NP
were	POS	O
scored	POS	O
for	POS	O
2	POS	O
min	POS	O
.	POS	O
In	POS	O
other	POS	O
animals	POS	O
locomotor	POS	O
activity	POS	O
was	POS	O
measured	POS	O
15	POS	O
or	POS	O
60	POS	O
min	POS	O
after	POS	O
caffeine	POS	O
administration	POS	O
.	POS	O
By	POS	O
any	POS	O
single	POS	O
behavioral	POS	O
criterion	POS	O
or	POS	O
a	POS	O
combination	POS	O
of	POS	O
these	POS	O
criteria	POS	O
,	POS	O
marked	POS	O
differences	POS	O
in	POS	O
response	POS	O
to	POS	O
toxic	POS	O
caffeine	POS	O
doses	POS	O
were	POS	O
observed	POS	O
between	POS	O
strains	POS	O
.	POS	O
These	POS	O
results	POS	O
indicate	POS	O
that	POS	O
behavioral	POS	B-NP
toxicity	POS	I-NP
testing	POS	O
of	POS	O
alkylxanthines	POS	O
in	POS	O
a	POS	O
single	POS	O
mouse	POS	O
strain	POS	O
may	POS	O
be	POS	O
misleading	POS	O
and	POS	O
suggest	POS	O
that	POS	O
toxic	POS	O
responses	POS	O
of	POS	O
the	POS	O
central	POS	O
nervous	POS	O
system	POS	O
to	POS	O
this	POS	O
class	POS	O
of	POS	O
compounds	POS	O
are	POS	O
genetically	POS	O
influenced	POS	O
in	POS	O
mammals	POS	O
.	POS	O
Treatment	POS	O
of	POS	O
ovarian	POS	B-NP
cancer	POS	I-NP
with	POS	O
a	POS	O
combination	POS	O
of	POS	O
cis	POS	O
-	POS	O
platinum	POS	O
,	POS	O
adriamycin	POS	O
,	POS	O
cyclophosphamide	POS	O
and	POS	O
hexamethylmelamine	POS	O
.	POS	O
During	POS	O
the	POS	O
last	POS	O
2	POS	O
1	POS	O
/	POS	O
2	POS	O
years	POS	O
,	POS	O
38	POS	O
patients	POS	O
with	POS	O
ovarian	POS	B-NP
cancer	POS	I-NP
were	POS	O
treated	POS	O
with	POS	O
a	POS	O
combination	POS	O
of	POS	O
cisplatinum	POS	O
(	POS	O
CPDD	POS	O
)	POS	O
,	POS	O
50	POS	O
mg	POS	O
/	POS	O
m2	POS	O
,	POS	O
adriamycin	POS	O
,	POS	O
30	POS	O
mg	POS	O
/	POS	O
m2	POS	O
,	POS	O
cyclophosphamide	POS	O
,	POS	O
300	POS	O
mg	POS	O
/	POS	O
m2	POS	O
,	POS	O
on	POS	O
day	POS	O
1	POS	O
;	POS	O
and	POS	O
hexamethylmelamine	POS	O
(	POS	O
HMM	POS	O
)	POS	O
,	POS	O
6	POS	O
mg	POS	O
/	POS	O
kg	POS	O
daily	POS	O
,	POS	O
for	POS	O
14	POS	O
days	POS	O
.	POS	O
Each	POS	O
course	POS	O
was	POS	O
repeated	POS	O
monthly	POS	O
.	POS	O
2	POS	O
patients	POS	O
had	POS	O
stage	POS	O
II	POS	O
,	POS	O
14	POS	O
stage	POS	O
III	POS	O
and	POS	O
22	POS	O
stage	POS	O
IV	POS	O
disease	POS	O
.	POS	O
14	POS	O
of	POS	O
the	POS	O
38	POS	O
patients	POS	O
were	POS	O
previously	POS	O
treated	POS	O
with	POS	O
chemotherapy	POS	O
,	POS	O
1	POS	O
with	POS	O
radiation	POS	O
,	POS	O
6	POS	O
with	POS	O
both	POS	O
chemotherapy	POS	O
and	POS	O
radiation	POS	O
,	POS	O
and	POS	O
17	POS	O
did	POS	O
not	POS	O
have	POS	O
any	POS	O
treatment	POS	O
before	POS	O
CPDD	POS	B-NP
combination	POS	O
.	POS	O
31	POS	O
of	POS	O
the	POS	O
38	POS	O
cases	POS	O
(	POS	O
81	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
demonstrated	POS	O
objective	POS	O
responses	POS	O
lasting	POS	O
for	POS	O
2	POS	O
months	POS	O
or	POS	O
more	POS	O
.	POS	O
These	POS	O
responses	POS	O
were	POS	O
partial	POS	O
in	POS	O
19	POS	O
and	POS	O
complete	POS	O
in	POS	O
12	POS	O
cases	POS	O
.	POS	O
Hematologic	POS	B-NP
toxicity	POS	I-NP
was	POS	O
moderate	POS	O
and	POS	O
with	POS	O
reversible	POS	O
anemia	POS	B-NP
developing	POS	O
in	POS	O
71	POS	O
%	POS	O
of	POS	O
patients	POS	O
.	POS	O
Gastrointestinal	POS	B-NP
side	POS	I-NP
effects	POS	I-NP
from	POS	O
CPDD	POS	B-NP
were	POS	O
universal	POS	O
.	POS	O
HMM	POS	O
gastrointestinal	POS	B-NP
toxicity	POS	I-NP
necessitated	POS	O
discontinuation	POS	O
of	POS	O
the	POS	O
drug	POS	O
in	POS	O
5	POS	O
patients	POS	O
.	POS	O
Severe	POS	O
nephrotoxicity	POS	B-NP
was	POS	O
observed	POS	O
in	POS	O
2	POS	O
patients	POS	O
but	POS	O
was	POS	O
reversible	POS	O
.	POS	O
There	POS	O
were	POS	O
no	POS	O
drug	POS	O
-	POS	O
related	POS	O
deaths	POS	O
.	POS	O
Nontraumatic	POS	B-NP
dissecting	POS	I-NP
aneurysm	POS	I-NP
of	POS	I-NP
the	POS	I-NP
basilar	POS	I-NP
artery	POS	I-NP
.	POS	O
A	POS	O
case	POS	O
of	POS	O
nontraumatic	POS	O
dissecting	POS	O
aneurysm	POS	B-NP
of	POS	O
the	POS	O
basilar	POS	O
artery	POS	O
in	POS	O
association	POS	O
with	POS	O
hypertension	POS	B-NP
,	POS	O
smoke	POS	O
,	POS	O
and	POS	O
oral	POS	O
contraceptives	POS	O
is	POS	O
reported	POS	O
in	POS	O
a	POS	O
young	POS	O
female	POS	O
patient	POS	O
with	POS	O
a	POS	O
locked	POS	O
-	POS	O
in	POS	O
syndrome	POS	O
.	POS	O
A	POS	O
method	POS	O
for	POS	O
the	POS	O
measurement	POS	O
of	POS	O
tremor	POS	B-NP
,	POS	O
and	POS	O
a	POS	O
comparison	POS	O
of	POS	O
the	POS	O
effects	POS	O
of	POS	O
tocolytic	POS	O
beta	POS	O
-	POS	O
mimetics	POS	O
.	POS	O
A	POS	O
method	POS	O
permitting	POS	O
measurement	POS	O
of	POS	O
finger	POS	O
tremor	POS	O
as	POS	O
a	POS	O
displacement	POS	O
-	POS	O
time	POS	O
curve	POS	O
is	POS	O
described	POS	O
,	POS	O
using	POS	O
a	POS	O
test	POS	O
system	POS	O
with	POS	O
simple	POS	O
amplitude	POS	O
calibration	POS	O
.	POS	O
The	POS	O
coordinates	POS	O
of	POS	O
the	POS	O
inversion	POS	O
points	POS	O
of	POS	O
the	POS	O
displacement	POS	O
-	POS	O
time	POS	O
curves	POS	O
were	POS	O
transferred	POS	O
through	POS	O
graphical	POS	O
input	POS	O
equipment	POS	O
to	POS	O
punched	POS	O
tape	POS	O
.	POS	O
By	POS	O
means	POS	O
of	POS	O
a	POS	O
computer	POS	O
program	POS	O
,	POS	O
periods	POS	O
and	POS	O
amplitudes	POS	O
of	POS	O
tremor	POS	B-NP
oscillations	POS	O
were	POS	O
calculated	POS	O
and	POS	O
classified	POS	O
.	POS	O
The	POS	O
event	POS	O
frequency	POS	O
for	POS	O
each	POS	O
class	POS	O
of	POS	O
periods	POS	O
and	POS	O
amplitudes	POS	O
was	POS	O
determined	POS	O
.	POS	O
The	POS	O
actions	POS	O
of	POS	O
fenoterol	POS	O
-	POS	O
hydrobromide	POS	O
,	POS	O
ritodrin	POS	O
-	POS	O
HCl	POS	O
and	POS	O
placebo	POS	O
given	POS	O
to	POS	O
10	POS	O
healthy	POS	O
subjects	POS	O
by	POS	O
intravenous	POS	O
infusion	POS	O
in	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
crossover	POS	O
study	POS	O
were	POS	O
tested	POS	O
by	POS	O
this	POS	O
method	POS	O
.	POS	O
At	POS	O
therapeutic	POS	O
doses	POS	O
both	POS	O
substances	POS	O
raised	POS	O
the	POS	O
mean	POS	O
tremor	POS	B-NP
amplitude	POS	O
to	POS	O
about	POS	O
three	POS	O
times	POS	O
the	POS	O
control	POS	O
level	POS	O
.	POS	O
At	POS	O
the	POS	O
same	POS	O
time	POS	O
,	POS	O
the	POS	O
mean	POS	O
period	POS	O
within	POS	O
each	POS	O
class	POS	O
of	POS	O
amplitudes	POS	O
shortened	POS	O
by	POS	O
10	POS	O
-	POS	O
-	POS	O
20	POS	O
ms	POS	O
,	POS	O
whereas	POS	O
the	POS	O
mean	POS	O
periods	POS	O
calculated	POS	O
from	POS	O
all	POS	O
oscillations	POS	O
together	POS	O
did	POS	O
not	POS	O
change	POS	O
significantly	POS	O
.	POS	O
After	POS	O
the	POS	O
end	POS	O
of	POS	O
fenoterol	POS	O
-	POS	O
hydrobromide	POS	O
infusion	POS	O
,	POS	O
tremor	POS	B-NP
amplitudes	POS	O
decreased	POS	O
significantly	POS	O
faster	POS	O
than	POS	O
those	POS	O
following	POS	O
ritodrin	POS	O
-	POS	O
HCl	POS	O
infusion	POS	O
.	POS	O
Propylthiouracil	POS	O
-	POS	O
induced	POS	O
hepatic	POS	B-NP
damage	POS	I-NP
.	POS	O
Two	POS	O
cases	POS	O
of	POS	O
propylthiouracil	POS	O
-	POS	O
induced	POS	O
liver	POS	B-NP
damage	POS	I-NP
have	POS	O
been	POS	O
observed	POS	O
.	POS	O
The	POS	O
first	POS	O
case	POS	O
is	POS	O
of	POS	O
an	POS	O
acute	POS	O
type	POS	O
of	POS	O
damage	POS	O
,	POS	O
proven	POS	O
by	POS	O
rechallenge	POS	O
;	POS	O
the	POS	O
second	POS	O
presents	POS	O
a	POS	O
clinical	POS	O
and	POS	O
histologic	POS	O
picture	POS	O
resembling	POS	O
chronic	POS	O
active	POS	O
hepatitis	POS	B-NP
,	POS	O
with	POS	O
spontaneous	POS	O
remission	POS	O
.	POS	O
Studies	POS	O
on	POS	O
the	POS	O
bradycardia	POS	B-NP
induced	POS	O
by	POS	O
bepridil	POS	O
.	POS	O
Bepridil	POS	O
,	POS	O
a	POS	O
novel	POS	O
active	POS	O
compound	POS	O
for	POS	O
prophylactic	POS	O
treatment	POS	O
of	POS	O
anginal	POS	B-NP
attacks	POS	I-NP
,	POS	O
induced	POS	O
persistent	POS	O
bradycardia	POS	B-NP
and	POS	O
a	POS	O
non	POS	O
-	POS	O
specific	POS	O
anti	POS	O
-	POS	O
tachycardial	POS	O
effect	POS	O
,	POS	O
the	POS	O
mechanisms	POS	O
of	POS	O
which	POS	O
were	POS	O
investigated	POS	O
in	POS	O
vitro	POS	O
and	POS	O
in	POS	O
vivo	POS	O
.	POS	O
In	POS	O
vitro	POS	O
perfusion	POS	O
of	POS	O
bepridil	POS	O
in	POS	O
the	POS	O
life	POS	O
-	POS	O
support	POS	O
medium	POS	O
for	POS	O
isolated	POS	O
sino	POS	O
-	POS	O
atrial	POS	O
tissue	POS	O
from	POS	O
rabbit	POS	O
heart	POS	O
,	POS	O
caused	POS	O
a	POS	O
reduction	POS	O
in	POS	O
action	POS	O
potential	POS	O
(	POS	O
AP	POS	O
)	POS	O
spike	POS	O
frequency	POS	O
(	POS	O
recorded	POS	O
by	POS	O
KCl	POS	O
microelectrodes	POS	O
)	POS	O
starting	POS	O
at	POS	O
doses	POS	O
of	POS	O
5	POS	O
X	POS	O
10	POS	O
(	POS	O
-	POS	O
6	POS	O
)	POS	O
M	POS	O
.	POS	O
This	POS	O
effect	POS	O
was	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
up	POS	O
to	POS	O
concentrations	POS	O
of	POS	O
5	POS	O
X	POS	O
10	POS	O
(	POS	O
-	POS	O
5	POS	O
)	POS	O
M	POS	O
,	POS	O
whereupon	POS	O
blockade	POS	O
of	POS	O
sinus	POS	O
activity	POS	O
set	POS	O
in	POS	O
.	POS	O
Bepridil	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
5	POS	O
X	POS	O
10	POS	O
(	POS	O
-	POS	O
6	POS	O
)	POS	O
M	POS	O
,	POS	O
induced	POS	O
a	POS	O
concomitant	POS	O
reduction	POS	O
in	POS	O
AP	POS	O
amplitude	POS	O
(	POS	O
falling	POS	O
from	POS	O
71	POS	O
+	POS	O
/	POS	O
-	POS	O
8	POS	O
mV	POS	O
to	POS	O
47	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
mV	POS	O
)	POS	O
,	POS	O
maximum	POS	O
systolic	POS	O
depolarization	POS	O
velocity	POS	O
(	POS	O
phase	POS	O
0	POS	O
)	POS	O
which	POS	O
fell	POS	O
from	POS	O
1	POS	O
.	POS	O
85	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
35	POS	O
V	POS	O
/	POS	O
s	POS	O
to	POS	O
0	POS	O
.	POS	O
84	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
28	POS	O
V	POS	O
/	POS	O
s	POS	O
,	POS	O
together	POS	O
with	POS	O
maximum	POS	O
diastolic	POS	O
depolarization	POS	O
velocity	POS	O
(	POS	O
phase	POS	O
4	POS	O
)	POS	O
which	POS	O
fell	POS	O
from	POS	O
38	POS	O
+	POS	O
/	POS	O
-	POS	O
3	POS	O
mV	POS	O
/	POS	O
s	POS	O
to	POS	O
24	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
mV	POS	O
/	POS	O
s	POS	O
.	POS	O
In	POS	O
vivo	POS	O
injection	POS	O
of	POS	O
bepridil	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
(	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
into	POS	O
6	POS	O
anaesthetized	POS	O
dogs	POS	O
which	POS	O
had	POS	O
undergone	POS	O
ablation	POS	O
of	POS	O
all	POS	O
the	POS	O
extrinsic	POS	O
cardiac	POS	O
afferent	POS	O
nerve	POS	O
supply	POS	O
,	POS	O
together	POS	O
with	POS	O
a	POS	O
bilateral	POS	O
medullo	POS	O
-	POS	O
adrenalectomy	POS	O
,	POS	O
caused	POS	O
a	POS	O
marked	POS	O
reduction	POS	O
in	POS	O
heart	POS	O
rate	POS	O
which	POS	O
fell	POS	O
from	POS	O
98	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
.	POS	O
2	POS	O
beats	POS	O
/	POS	O
min	POS	O
to	POS	O
76	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
.	POS	O
3	POS	O
beats	POS	O
/	POS	O
min	POS	O
sustained	POS	O
for	POS	O
more	POS	O
than	POS	O
45	POS	O
min	POS	O
.	POS	O
It	POS	O
is	POS	O
concluded	POS	O
that	POS	O
bepridil	POS	O
reduces	POS	O
heart	POS	O
rate	POS	O
by	POS	O
acting	POS	O
directly	POS	O
on	POS	O
the	POS	O
sinus	POS	O
node	POS	O
.	POS	O
This	POS	O
effect	POS	O
,	POS	O
which	POS	O
results	POS	O
in	POS	O
a	POS	O
flattening	POS	O
of	POS	O
the	POS	O
phase	POS	O
0	POS	O
and	POS	O
phase	POS	O
4	POS	O
slope	POS	O
,	POS	O
together	POS	O
with	POS	O
a	POS	O
longer	POS	O
AP	POS	O
duration	POS	O
,	POS	O
may	POS	O
be	POS	O
due	POS	O
to	POS	O
an	POS	O
increase	POS	O
in	POS	O
the	POS	O
time	POS	O
constants	POS	O
of	POS	O
slow	POS	O
inward	POS	O
ionic	POS	O
currents	POS	O
(	POS	O
already	POS	O
demonstrated	POS	O
elsewhere	POS	O
)	POS	O
,	POS	O
but	POS	O
also	POS	O
to	POS	O
an	POS	O
increased	POS	O
time	POS	O
constant	POS	O
for	POS	O
deactivation	POS	O
of	POS	O
the	POS	O
outward	POS	O
potassium	POS	O
current	POS	O
(	POS	O
Ip	POS	O
)	POS	O
.	POS	O
Hepatitis	POS	B-NP
and	POS	I-NP
renal	POS	I-NP
tubular	POS	I-NP
acidosis	POS	I-NP
after	POS	O
anesthesia	POS	O
with	POS	O
methoxyflurane	POS	O
.	POS	O
A	POS	O
69	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
operated	POS	O
for	POS	O
acute	POS	B-NP
cholecystitis	POS	I-NP
under	POS	O
methoxyflurane	POS	O
anesthesia	POS	O
developed	POS	O
postoperatively	POS	O
a	POS	O
hepatic	POS	B-NP
insufficiency	POS	I-NP
syndrome	POS	I-NP
and	POS	O
renal	POS	B-NP
tubular	POS	I-NP
acidosis	POS	I-NP
.	POS	O
Massive	POS	B-NP
bleeding	POS	I-NP
appeared	POS	O
during	POS	O
surgery	POS	O
which	POS	O
lasted	POS	O
for	POS	O
six	POS	O
hours	POS	O
.	POS	O
Postoperative	POS	O
evolution	POS	O
under	POS	O
supportive	POS	O
therapy	POS	O
was	POS	O
favourable	POS	O
.	POS	O
Complete	POS	O
recovery	POS	O
was	POS	O
confirmed	POS	O
by	POS	O
repeated	POS	O
controls	POS	O
performed	POS	O
over	POS	O
a	POS	O
period	POS	O
of	POS	O
one	POS	O
year	POS	O
after	POS	O
surgery	POS	O
.	POS	O
Pituitary	POS	O
response	POS	O
to	POS	O
luteinizing	POS	O
hormone	POS	O
-	POS	O
releasing	POS	O
hormone	POS	O
during	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
hyperprolactinemia	POS	B-NP
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
a	POS	O
6	POS	O
-	POS	O
hour	POS	O
infusion	POS	O
with	POS	O
haloperidol	POS	O
on	POS	O
serum	POS	O
prolactin	POS	O
and	POS	O
luteinizing	POS	O
hormone	POS	O
(	POS	O
LH	POS	O
)	POS	O
levels	POS	O
was	POS	O
studied	POS	O
in	POS	O
a	POS	O
group	POS	O
of	POS	O
male	POS	O
subjects	POS	O
.	POS	O
Five	POS	O
hours	POS	O
after	POS	O
starting	POS	O
the	POS	O
infusions	POS	O
,	POS	O
a	POS	O
study	POS	O
of	POS	O
the	POS	O
pituitary	POS	O
responses	POS	O
to	POS	O
LH	POS	O
-	POS	O
releasing	POS	O
hormone	POS	O
(	POS	O
LH	POS	O
-	POS	O
RH	POS	O
)	POS	O
was	POS	O
carried	POS	O
out	POS	O
.	POS	O
Control	POS	O
patients	POS	O
received	POS	O
infusions	POS	O
of	POS	O
0	POS	O
.	POS	O
9	POS	O
%	POS	O
NaCl	POS	O
solution	POS	O
.	POS	O
During	POS	O
the	POS	O
course	POS	O
of	POS	O
haloperidol	POS	O
infusions	POS	O
,	POS	O
significant	POS	O
hyperprolactinemia	POS	B-NP
was	POS	O
found	POS	O
,	POS	O
together	POS	O
with	POS	O
an	POS	O
abolished	POS	O
pituitary	POS	O
response	POS	O
to	POS	O
LH	POS	O
-	POS	O
RH	POS	O
,	POS	O
as	POS	O
compared	POS	O
with	POS	O
responses	POS	O
of	POS	O
control	POS	O
subjects	POS	O
.	POS	O
Antirifampicin	POS	O
antibodies	POS	O
in	POS	O
acute	POS	O
rifampicin	POS	O
-	POS	O
associated	POS	O
renal	POS	B-NP
failure	POS	I-NP
.	POS	O
5	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
(	POS	O
3	POS	O
with	POS	O
thrombopenia	POS	B-NP
and	POS	O
hemolysis	POS	B-NP
)	POS	O
induced	POS	O
by	POS	O
the	POS	O
reintroduction	POS	O
of	POS	O
rifampicin	POS	O
are	POS	O
described	POS	O
.	POS	O
No	POS	O
correlation	POS	O
was	POS	O
found	POS	O
between	POS	O
the	POS	O
severity	POS	O
of	POS	O
clinical	POS	O
manifestations	POS	O
and	POS	O
the	POS	O
total	POS	O
dose	POS	O
taken	POS	O
by	POS	O
the	POS	O
patients	POS	O
.	POS	O
In	POS	O
all	POS	O
but	POS	O
1	POS	O
patient	POS	O
,	POS	O
antirifampicin	POS	O
antibodies	POS	O
were	POS	O
detected	POS	O
.	POS	O
Antibodies	POS	O
suggested	POS	O
to	POS	O
be	POS	O
of	POS	O
the	POS	O
IgM	POS	O
class	POS	O
were	POS	O
detected	POS	O
in	POS	O
all	POS	O
3	POS	O
patients	POS	O
with	POS	O
hematological	POS	B-NP
disorders	POS	I-NP
.	POS	O
The	POS	O
pattern	POS	O
of	POS	O
non	POS	O
-	POS	O
specific	POS	O
acute	POS	O
tubular	POS	O
necrosis	POS	B-NP
found	POS	O
in	POS	O
the	POS	O
2	POS	O
biopsied	POS	O
patients	POS	O
,	POS	O
indistinguishable	POS	O
from	POS	O
that	POS	O
of	POS	O
ischemic	POS	O
origin	POS	O
,	POS	O
raised	POS	O
the	POS	O
possibility	POS	O
of	POS	O
a	POS	O
vascular	POS	B-NP
-	POS	I-NP
mediated	POS	I-NP
damage	POS	I-NP
.	POS	O
In	POS	O
3	POS	O
patients	POS	O
,	POS	O
the	POS	O
possibility	POS	O
of	POS	O
a	POS	O
triggering	POS	O
immunoallergic	POS	O
mechanism	POS	O
is	POS	O
discussed	POS	O
.	POS	O
Cardiovascular	POS	O
effects	POS	O
of	POS	O
hypotension	POS	B-NP
induced	POS	O
by	POS	O
adenosine	POS	O
triphosphate	POS	O
and	POS	O
sodium	POS	O
nitroprusside	POS	O
on	POS	O
dogs	POS	O
with	POS	O
denervated	POS	O
hearts	POS	O
.	POS	O
Adenosine	POS	O
triphosphate	POS	O
(	POS	O
ATP	POS	O
)	POS	O
and	POS	O
sodium	POS	O
nitroprusside	POS	O
(	POS	O
SNP	POS	O
)	POS	O
are	POS	O
administered	POS	O
to	POS	O
patients	POS	O
to	POS	O
induce	POS	O
and	POS	O
control	POS	O
hypotension	POS	B-NP
during	POS	O
anesthesia	POS	O
.	POS	O
SNP	POS	O
is	POS	O
authorized	POS	O
for	POS	O
clinical	POS	O
use	POS	O
in	POS	O
USA	POS	O
and	POS	O
UK	POS	O
,	POS	O
and	POS	O
ATP	POS	O
is	POS	O
clinically	POS	O
used	POS	O
in	POS	O
other	POS	O
countries	POS	O
such	POS	O
as	POS	O
Japan	POS	O
.	POS	O
We	POS	O
investigated	POS	O
how	POS	O
these	POS	O
two	POS	O
drugs	POS	O
act	POS	O
on	POS	O
the	POS	O
cardiovascular	POS	O
systems	POS	O
of	POS	O
20	POS	O
dogs	POS	O
whose	POS	O
hearts	POS	O
had	POS	O
been	POS	O
denervated	POS	O
by	POS	O
a	POS	O
procedure	POS	O
we	POS	O
had	POS	O
devised	POS	O
.	POS	O
ATP	POS	O
(	POS	O
10	POS	O
dogs	POS	O
)	POS	O
or	POS	O
SNP	POS	O
(	POS	O
10	POS	O
dogs	POS	O
)	POS	O
was	POS	O
administered	POS	O
to	POS	O
reduce	POS	O
mean	POS	O
arterial	POS	O
pressure	POS	O
by	POS	O
30	POS	O
%	POS	O
to	POS	O
70	POS	O
%	POS	O
of	POS	O
control	POS	O
.	POS	O
Before	POS	O
,	POS	O
during	POS	O
and	POS	O
after	POS	O
induced	POS	O
hypotension	POS	B-NP
,	POS	O
we	POS	O
measured	POS	O
major	POS	O
cardiovascular	POS	O
parameters	POS	O
.	POS	O
Hypotension	POS	B-NP
induced	POS	O
by	POS	O
ATP	POS	O
was	POS	O
accompanied	POS	O
by	POS	O
significant	POS	O
decreases	POS	O
in	POS	O
mean	POS	O
pulmonary	POS	O
arterial	POS	O
pressure	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
central	POS	O
venous	POS	O
pressure	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
left	POS	O
ventricular	POS	O
end	POS	O
-	POS	O
diastolic	POS	O
pressure	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
total	POS	O
peripheral	POS	O
resistance	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
rate	POS	O
pressure	POS	O
product	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
total	POS	O
body	POS	O
oxygen	POS	O
consumption	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
,	POS	O
and	POS	O
heart	POS	O
rate	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
;	POS	O
all	POS	O
these	POS	O
variables	POS	O
returned	POS	O
normal	POS	O
within	POS	O
30	POS	O
min	POS	O
after	POS	O
ATP	POS	O
was	POS	O
stopped	POS	O
.	POS	O
Cardiac	POS	O
output	POS	O
did	POS	O
not	POS	O
change	POS	O
.	POS	O
During	POS	O
hypotension	POS	B-NP
produced	POS	O
by	POS	O
SNP	POS	O
similar	POS	O
decreases	POS	O
were	POS	O
observed	POS	O
in	POS	O
mean	POS	O
pulmonary	POS	O
arterial	POS	O
pressure	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
central	POS	O
venous	POS	O
pressure	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
left	POS	O
ventricular	POS	O
end	POS	O
-	POS	O
diastolic	POS	O
pressure	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
total	POS	O
peripheral	POS	O
resistance	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
rate	POS	O
pressure	POS	O
product	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
,	POS	O
and	POS	O
oxygen	POS	O
content	POS	O
difference	POS	O
between	POS	O
arterial	POS	O
and	POS	O
mixed	POS	O
venous	POS	O
blood	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
,	POS	O
while	POS	O
heart	POS	O
rate	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
001	POS	O
)	POS	O
and	POS	O
cardiac	POS	O
output	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
were	POS	O
increased	POS	O
.	POS	O
Recoveries	POS	O
of	POS	O
heart	POS	O
rate	POS	O
and	POS	O
left	POS	O
ventricular	POS	O
end	POS	O
-	POS	O
diastolic	POS	O
pressure	POS	O
were	POS	O
not	POS	O
shown	POS	O
within	POS	O
60	POS	O
min	POS	O
after	POS	O
SNP	POS	O
had	POS	O
been	POS	O
stopped	POS	O
.	POS	O
Both	POS	O
ATP	POS	O
and	POS	O
SNP	POS	O
should	POS	O
act	POS	O
on	POS	O
the	POS	O
pacemaker	POS	O
tissue	POS	O
of	POS	O
the	POS	O
heart	POS	O
.	POS	O
Comparative	POS	O
study	POS	O
:	POS	O
Endografine	POS	O
(	POS	O
diatrizoate	POS	O
)	POS	O
,	POS	O
Vasurix	POS	O
polyvidone	POS	O
(	POS	O
acetrizoate	POS	O
)	POS	O
,	POS	O
Dimer	POS	O
-	POS	O
X	POS	O
(	POS	O
iocarmate	POS	O
)	POS	O
and	POS	O
Hexabrix	POS	O
(	POS	O
ioxaglate	POS	O
)	POS	O
in	POS	O
hysterosalpingography	POS	O
.	POS	O
Side	POS	O
effects	POS	O
of	POS	O
hysterosalpingography	POS	O
with	POS	O
Dimer	POS	O
-	POS	O
X	POS	O
,	POS	O
Hexabrix	POS	O
,	POS	O
Vasurix	POS	O
polyvidone	POS	O
and	POS	O
Endografine	POS	O
in	POS	O
142	POS	O
consecutive	POS	O
patients	POS	O
,	POS	O
receiving	POS	O
one	POS	O
of	POS	O
the	POS	O
four	POS	O
tested	POS	O
media	POS	O
were	POS	O
evaluated	POS	O
from	POS	O
replies	POS	O
to	POS	O
postal	POS	O
questionnaires	POS	O
.	POS	O
The	POS	O
Dimer	POS	O
-	POS	O
X	POS	O
group	POS	O
had	POS	O
a	POS	O
higher	POS	O
incidence	POS	O
of	POS	O
nausea	POS	B-NP
and	POS	O
dizziness	POS	B-NP
.	POS	O
The	POS	O
Endografine	POS	O
group	POS	O
had	POS	O
a	POS	O
higher	POS	O
incidence	POS	O
of	POS	O
abdominal	POS	B-NP
pain	POS	I-NP
.	POS	O
These	POS	O
differences	POS	O
occur	POS	O
especially	POS	O
in	POS	O
the	POS	O
age	POS	O
groups	POS	O
under	POS	O
30	POS	O
years	POS	O
.	POS	O
Hexabrix	POS	O
and	POS	O
Vasurix	POS	O
polyvidone	POS	O
are	POS	O
considered	POS	O
the	POS	O
best	POS	O
contrast	POS	O
media	POS	O
for	POS	O
hysterosalpingography	POS	O
and	POS	O
perhaps	POS	O
because	POS	O
of	POS	O
its	POS	O
low	POS	O
toxicity	POS	O
Hexabrix	POS	O
should	POS	O
be	POS	O
preferred	POS	O
.	POS	O
Post	POS	O
-	POS	O
suxamethonium	POS	O
pains	POS	O
in	POS	O
Nigerian	POS	O
surgical	POS	O
patients	POS	O
.	POS	O
Contrary	POS	O
to	POS	O
an	POS	O
earlier	POS	O
report	POS	O
by	POS	O
Coxon	POS	O
,	POS	O
scoline	POS	O
pain	POS	B-NP
occurs	POS	O
in	POS	O
African	POS	O
negroes	POS	O
.	POS	O
Its	POS	O
incidence	POS	O
was	POS	O
determined	POS	O
in	POS	O
a	POS	O
prospective	POS	O
study	POS	O
involving	POS	O
a	POS	O
total	POS	O
of	POS	O
100	POS	O
Nigerian	POS	O
patients	POS	O
(	POS	O
50	POS	O
out	POS	O
-	POS	O
patients	POS	O
and	POS	O
50	POS	O
in	POS	O
-	POS	O
patients	POS	O
)	POS	O
.	POS	O
About	POS	O
62	POS	O
%	POS	O
of	POS	O
the	POS	O
out	POS	O
-	POS	O
patients	POS	O
developed	POS	O
scoline	POS	B-NP
pain	POS	I-NP
as	POS	O
compared	POS	O
with	POS	O
about	POS	O
26	POS	O
%	POS	O
among	POS	O
the	POS	O
in	POS	O
-	POS	O
patients	POS	O
.	POS	O
The	POS	O
abolition	POS	O
of	POS	O
muscle	POS	B-NP
fasciculations	POS	I-NP
(	POS	O
by	POS	O
0	POS	O
.	POS	O
075mg	POS	O
/	POS	O
kg	POS	O
dose	POS	O
of	POS	O
Fazadinium	POS	O
)	POS	O
did	POS	O
not	POS	O
influence	POS	O
the	POS	O
occurrence	POS	O
of	POS	O
scoline	POS	O
pain	POS	B-NP
.	POS	O
Neither	POS	O
the	POS	O
type	POS	O
of	POS	O
induction	POS	O
agent	POS	O
(	POS	O
Althesin	POS	O
or	POS	O
Thiopentone	POS	O
)	POS	O
nor	POS	O
the	POS	O
salt	POS	O
preparation	POS	O
of	POS	O
suxamethonium	POS	O
used	POS	O
(	POS	O
chloride	POS	O
or	POS	O
bromide	POS	O
)	POS	O
,	POS	O
affected	POS	O
the	POS	O
incidence	POS	O
of	POS	O
scoline	POS	B-NP
pain	POS	I-NP
.	POS	O
Invasive	POS	B-NP
carcinoma	POS	I-NP
of	POS	I-NP
the	POS	I-NP
renal	POS	I-NP
pelvis	POS	I-NP
following	POS	O
cyclophosphamide	POS	O
therapy	POS	O
for	POS	O
nonmalignant	POS	B-NP
disease	POS	I-NP
.	POS	O
A	POS	O
47	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
right	POS	O
hydroureteronephrosis	POS	B-NP
due	POS	O
to	POS	O
ureterovesical	POS	B-NP
junction	POS	I-NP
obstruction	POS	I-NP
had	POS	O
gross	POS	O
hematuria	POS	B-NP
after	POS	O
being	POS	O
treated	POS	O
for	POS	O
five	POS	O
years	POS	O
wtih	POS	O
cyclophosphamide	POS	O
for	POS	O
cerebral	POS	B-NP
vasculitis	POS	I-NP
.	POS	O
A	POS	O
right	POS	O
nephroureterectomy	POS	O
was	POS	O
required	POS	O
for	POS	O
control	POS	O
of	POS	O
bleeding	POS	B-NP
.	POS	O
The	POS	O
pathology	POS	O
specimen	POS	O
contained	POS	O
clinically	POS	O
occult	POS	O
invasive	POS	O
carcinoma	POS	B-NP
of	POS	I-NP
the	POS	I-NP
renal	POS	I-NP
pelvis	POS	I-NP
.	POS	O
Although	POS	O
the	POS	O
ability	POS	O
of	POS	O
cyclophosphamide	POS	O
to	POS	O
cause	POS	O
hemorrhagic	POS	B-NP
cystitis	POS	I-NP
and	POS	O
urine	POS	O
cytologic	POS	O
abnormalities	POS	O
indistinguishable	POS	O
from	POS	O
high	POS	O
grade	POS	O
carcinoma	POS	B-NP
is	POS	O
well	POS	O
known	POS	O
,	POS	O
it	POS	O
is	POS	O
less	POS	O
widely	POS	O
appreciated	POS	O
that	POS	O
it	POS	O
is	POS	O
also	POS	O
associated	POS	O
with	POS	O
carcinoma	POS	B-NP
of	POS	I-NP
the	POS	I-NP
urinary	POS	I-NP
tract	POS	I-NP
.	POS	O
Twenty	POS	O
carcinomas	POS	B-NP
of	POS	O
the	POS	O
urinary	POS	O
bladder	POS	O
and	POS	O
one	POS	O
carcinoma	POS	B-NP
of	POS	O
the	POS	O
prostate	POS	O
have	POS	O
been	POS	O
reported	POS	O
in	POS	O
association	POS	O
with	POS	O
its	POS	O
use	POS	O
.	POS	O
The	POS	O
present	POS	O
case	POS	O
is	POS	O
the	POS	O
first	POS	O
carcinoma	POS	B-NP
of	POS	I-NP
the	POS	I-NP
renal	POS	I-NP
pelvis	POS	I-NP
reported	POS	O
in	POS	O
association	POS	O
with	POS	O
cyclophosphamide	POS	O
treatment	POS	O
.	POS	O
It	POS	O
is	POS	O
the	POS	O
third	POS	O
urinary	POS	B-NP
tract	POS	I-NP
cancer	POS	I-NP
reported	POS	O
in	POS	O
association	POS	O
with	POS	O
cyclophosphamide	POS	O
treatment	POS	O
for	POS	O
nonmalignant	POS	B-NP
disease	POS	I-NP
.	POS	O
The	POS	O
association	POS	O
of	POS	O
the	POS	O
tumor	POS	B-NP
with	POS	O
preexisting	POS	O
hydroureteronephrosis	POS	B-NP
suggests	POS	O
that	POS	O
stasis	POS	O
prolonged	POS	O
and	POS	O
intensified	POS	O
exposure	POS	O
of	POS	O
upper	POS	O
urinary	POS	O
tract	POS	O
epithelium	POS	O
to	POS	O
cyclophosphamide	POS	O
.	POS	O
Patients	POS	O
who	POS	O
are	POS	O
candidates	POS	O
for	POS	O
long	POS	O
-	POS	O
term	POS	O
cyclophosphamide	POS	O
treatment	POS	O
should	POS	O
be	POS	O
routinely	POS	O
evaluated	POS	O
for	POS	O
obstructive	POS	B-NP
uropathy	POS	I-NP
.	POS	O
Medial	POS	O
changes	POS	O
in	POS	O
arterial	POS	B-NP
spasm	POS	I-NP
induced	POS	O
by	POS	O
L	POS	O
-	POS	O
norepinephrine	POS	O
.	POS	O
In	POS	O
normal	POS	O
rats	POS	O
,	POS	O
the	POS	O
media	POS	O
of	POS	O
small	POS	O
arteries	POS	O
(	POS	O
0	POS	O
.	POS	O
4	POS	O
-	POS	O
-	POS	O
0	POS	O
.	POS	O
2	POS	O
mm	POS	O
in	POS	O
diameter	POS	O
)	POS	O
previously	POS	O
was	POS	O
shown	POS	O
to	POS	O
contain	POS	O
intracellular	POS	O
vacuoles	POS	O
,	POS	O
identified	POS	O
ultrastructurally	POS	O
as	POS	O
herniations	POS	O
of	POS	O
one	POS	O
smooth	POS	O
muscle	POS	O
cell	POS	O
into	POS	O
another	POS	O
.	POS	O
The	POS	O
hypothesis	POS	O
that	POS	O
intense	POS	O
vasoconstriction	POS	O
would	POS	O
increase	POS	O
the	POS	O
number	POS	O
of	POS	O
such	POS	O
vacuoles	POS	O
has	POS	O
been	POS	O
tested	POS	O
.	POS	O
In	POS	O
the	POS	O
media	POS	O
of	POS	O
the	POS	O
saphenous	POS	O
artery	POS	O
and	POS	O
its	POS	O
distal	POS	O
branch	POS	O
,	POS	O
vasoconstriction	POS	O
induced	POS	O
by	POS	O
L	POS	O
-	POS	O
norepinephrine	POS	O
produced	POS	O
many	POS	O
cell	POS	O
-	POS	O
to	POS	O
-	POS	O
cell	POS	O
hernias	POS	O
within	POS	O
15	POS	O
minutes	POS	O
.	POS	O
At	POS	O
1	POS	O
day	POS	O
their	POS	O
number	POS	O
was	POS	O
reduced	POS	O
to	POS	O
about	POS	O
1	POS	O
/	POS	O
10	POS	O
of	POS	O
the	POS	O
original	POS	O
number	POS	O
.	POS	O
By	POS	O
7	POS	O
days	POS	O
the	POS	O
vessel	POS	O
was	POS	O
almost	POS	O
restored	POS	O
to	POS	O
normal	POS	O
.	POS	O
Triple	POS	O
stimulation	POS	O
over	POS	O
1	POS	O
day	POS	O
induced	POS	O
more	POS	O
severe	POS	O
changes	POS	O
in	POS	O
the	POS	O
media	POS	O
.	POS	O
These	POS	O
findings	POS	O
suggest	POS	O
that	POS	O
smooth	POS	O
muscle	POS	O
cells	POS	O
are	POS	O
susceptible	POS	O
to	POS	O
damage	POS	O
in	POS	O
the	POS	O
course	POS	O
of	POS	O
their	POS	O
specific	POS	O
function	POS	O
.	POS	O
The	POS	O
experimental	POS	O
data	POS	O
are	POS	O
discussed	POS	O
in	POS	O
relation	POS	O
to	POS	O
medial	POS	O
changes	POS	O
observed	POS	O
in	POS	O
other	POS	O
instances	POS	O
of	POS	O
arterial	POS	B-NP
spasm	POS	I-NP
.	POS	O
Endothelial	POS	O
changes	POS	O
that	POS	O
developed	POS	O
in	POS	O
the	POS	O
same	POS	O
experimental	POS	O
model	POS	O
were	POS	O
described	POS	O
in	POS	O
a	POS	O
previous	POS	O
paper	POS	O
.	POS	O
Bilateral	POS	O
retinal	POS	O
artery	POS	O
and	POS	O
choriocapillaris	POS	B-NP
occlusion	POS	I-NP
following	POS	O
the	POS	O
injection	POS	O
of	POS	O
long	POS	O
-	POS	O
acting	POS	O
corticosteroid	POS	O
suspensions	POS	O
in	POS	O
combination	POS	O
with	POS	O
other	POS	O
drugs	POS	O
:	POS	O
I	POS	O
.	POS	O
Clinical	POS	O
studies	POS	O
.	POS	O
Two	POS	O
well	POS	O
-	POS	O
documented	POS	O
cases	POS	O
of	POS	O
bilateral	POS	O
retinal	POS	O
artery	POS	O
and	POS	O
choriocapillaris	POS	B-NP
occlusions	POS	I-NP
with	POS	O
blindness	POS	B-NP
following	POS	O
head	POS	O
and	POS	O
neck	POS	O
soft	POS	O
-	POS	O
tissue	POS	O
injection	POS	O
with	POS	O
methylprednisolone	POS	O
acetate	POS	O
in	POS	O
combination	POS	O
with	POS	O
lidocaine	POS	O
,	POS	O
epinephrine	POS	O
,	POS	O
or	POS	O
penicillin	POS	O
are	POS	O
reported	POS	O
.	POS	O
One	POS	O
case	POS	O
had	POS	O
only	POS	O
a	POS	O
unilateral	POS	O
injection	POS	O
.	POS	O
The	POS	O
acute	POS	O
observations	POS	O
included	POS	O
hazy	POS	B-NP
sensorium	POS	I-NP
,	POS	O
superior	POS	B-NP
gaze	POS	I-NP
palsy	POS	I-NP
,	POS	O
pupillary	POS	B-NP
abnormalities	POS	I-NP
,	POS	O
and	POS	O
conjunctival	POS	B-NP
hemorrhages	POS	I-NP
with	POS	O
edema	POS	B-NP
.	POS	O
Follow	POS	O
-	POS	O
up	POS	O
changes	POS	O
showed	POS	O
marked	POS	O
visual	POS	B-NP
loss	POS	I-NP
,	POS	O
constricted	POS	O
visual	POS	O
fields	POS	O
,	POS	O
optic	POS	B-NP
nerve	POS	I-NP
pallor	POS	I-NP
,	POS	O
vascular	POS	B-NP
attenuation	POS	I-NP
,	POS	O
and	POS	O
chorioretinal	POS	B-NP
atrophy	POS	I-NP
.	POS	O
The	POS	O
literature	POS	O
is	POS	O
reviewed	POS	O
,	POS	O
and	POS	O
possible	POS	O
causes	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Abnormalities	POS	O
of	POS	O
the	POS	O
pupil	POS	O
and	POS	O
visual	POS	O
-	POS	O
evoked	POS	O
potential	POS	O
in	POS	O
quinine	POS	O
amblyopia	POS	B-NP
.	POS	O
Total	POS	B-NP
blindness	POS	I-NP
with	POS	O
a	POS	O
transient	POS	O
tonic	POS	O
pupillary	POS	O
response	POS	O
,	POS	O
denervation	POS	O
supersensitivity	POS	O
,	POS	O
and	POS	O
abnormal	POS	O
visual	POS	O
-	POS	O
evoked	POS	O
potentials	POS	O
developed	POS	O
in	POS	O
a	POS	O
54	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
after	POS	O
the	POS	O
use	POS	O
of	POS	O
quinine	POS	O
sulfate	POS	O
for	POS	O
leg	POS	B-NP
cramps	POS	I-NP
.	POS	O
He	POS	O
later	POS	O
recovered	POS	O
normal	POS	O
visual	POS	O
acuity	POS	O
.	POS	O
A	POS	O
transient	POS	O
tonic	POS	O
pupillary	POS	O
response	POS	O
,	POS	O
denervation	POS	O
supersensitivity	POS	O
,	POS	O
and	POS	O
abnormal	POS	O
visual	POS	O
-	POS	O
evoked	POS	O
potentials	POS	O
in	POS	O
quinine	POS	O
toxicity	POS	B-NP
,	POS	O
to	POS	O
our	POS	O
knowledge	POS	O
,	POS	O
have	POS	O
not	POS	O
been	POS	O
previously	POS	O
reported	POS	O
.	POS	O
Suxamethonium	POS	B-NP
-	POS	I-NP
induced	POS	I-NP
jaw	POS	I-NP
stiffness	POS	I-NP
and	POS	O
myalgia	POS	B-NP
associated	POS	O
with	POS	O
atypical	POS	O
cholinesterase	POS	O
:	POS	O
case	POS	O
report	POS	O
.	POS	O
An	POS	O
11	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
boy	POS	O
was	POS	O
given	POS	O
halothane	POS	O
,	POS	O
nitrous	POS	O
oxide	POS	O
and	POS	O
oxygen	POS	O
,	POS	O
pancuronium	POS	O
0	POS	O
.	POS	O
4	POS	O
mg	POS	O
and	POS	O
suxamethonium	POS	O
100	POS	O
mg	POS	O
for	POS	O
induction	POS	O
of	POS	O
anaesthesia	POS	O
.	POS	O
In	POS	O
response	POS	O
to	POS	O
this	POS	O
a	POS	O
marked	POS	O
jaw	POS	B-NP
stiffness	POS	I-NP
occurred	POS	O
which	POS	O
lasted	POS	O
for	POS	O
two	POS	O
minutes	POS	O
and	POS	O
the	POS	O
anaesthesia	POS	O
were	POS	O
terminated	POS	O
.	POS	O
Four	POS	O
hours	POS	O
of	POS	O
apnoea	POS	B-NP
ensued	POS	O
and	POS	O
he	POS	O
suffered	POS	O
generalized	POS	O
severe	POS	O
myalgia	POS	B-NP
lasting	POS	O
for	POS	O
one	POS	O
week	POS	O
.	POS	O
He	POS	O
was	POS	O
found	POS	O
to	POS	O
have	POS	O
atypical	POS	O
plasma	POS	O
cholinesterase	POS	O
with	POS	O
a	POS	O
dibucaine	POS	O
number	POS	O
of	POS	O
12	POS	O
,	POS	O
indicating	POS	O
homozygocity	POS	O
.	POS	O
This	POS	O
was	POS	O
verified	POS	O
by	POS	O
study	POS	O
of	POS	O
the	POS	O
family	POS	O
.	POS	O
The	POS	O
case	POS	O
shows	POS	O
that	POS	O
prolonged	POS	O
jaw	POS	B-NP
rigidity	POS	I-NP
and	POS	O
myalgia	POS	B-NP
may	POS	O
occur	POS	O
after	POS	O
suxamethonium	POS	O
in	POS	O
patients	POS	O
with	POS	O
atypical	POS	O
cholinesterase	POS	O
despite	POS	O
pretreatment	POS	O
with	POS	O
pancuronium	POS	O
.	POS	O
Indomethacin	POS	O
-	POS	O
induced	POS	O
hyperkalemia	POS	B-NP
in	POS	O
three	POS	O
patients	POS	O
with	POS	O
gouty	POS	B-NP
arthritis	POS	I-NP
.	POS	O
We	POS	O
describe	POS	O
three	POS	O
patients	POS	O
in	POS	O
whom	POS	O
severe	POS	O
,	POS	O
life	POS	O
-	POS	O
threatening	POS	O
hyperkalemia	POS	B-NP
and	POS	O
renal	POS	B-NP
insufficiency	POS	I-NP
developed	POS	O
after	POS	O
treatment	POS	O
of	POS	O
acute	POS	O
gouty	POS	B-NP
arthritis	POS	I-NP
with	POS	O
indomethacin	POS	O
.	POS	O
This	POS	O
complication	POS	O
may	POS	O
result	POS	O
from	POS	O
an	POS	O
inhibition	POS	O
of	POS	O
prostaglandin	POS	O
synthesis	POS	O
and	POS	O
consequent	POS	O
hyporeninemic	POS	B-NP
hypoaidosteronism	POS	I-NP
.	POS	O
Careful	POS	O
attention	POS	O
to	POS	O
renal	POS	O
function	POS	O
and	POS	O
potassium	POS	O
balance	POS	O
in	POS	O
patients	POS	O
receiving	POS	O
indomethacin	POS	O
or	POS	O
other	POS	O
nonsteroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
agents	POS	O
,	POS	O
particularly	POS	O
in	POS	O
those	POS	O
patients	POS	O
with	POS	O
diabetes	POS	B-NP
mellitus	POS	I-NP
or	POS	O
preexisting	POS	B-NP
renal	POS	I-NP
disease	POS	I-NP
,	POS	O
will	POS	O
help	POS	O
prevent	POS	O
this	POS	O
potentially	POS	O
serious	POS	O
complication	POS	O
.	POS	O
Etomidate	POS	O
:	POS	O
a	POS	O
foreshortened	POS	O
clinical	POS	O
trial	POS	O
.	POS	O
A	POS	O
clinical	POS	O
evaluation	POS	O
of	POS	O
etomidate	POS	O
for	POS	O
outpatient	POS	O
cystoscopy	POS	O
was	POS	O
embarked	POS	O
upon	POS	O
.	POS	O
Unpremedicated	POS	O
patients	POS	O
were	POS	O
given	POS	O
fentanyl	POS	O
1	POS	O
microgram	POS	O
/	POS	O
kg	POS	O
followed	POS	O
by	POS	O
etomidate	POS	O
0	POS	O
.	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
.	POS	O
Anaesthesia	POS	O
was	POS	O
maintained	POS	O
with	POS	O
intermittent	POS	O
etomidate	POS	O
in	POS	O
2	POS	O
-	POS	O
4	POS	O
mg	POS	O
doses	POS	O
.	POS	O
Patients	POS	O
were	POS	O
interviewed	POS	O
personally	POS	O
later	POS	O
the	POS	O
same	POS	O
day	POS	O
,	POS	O
and	POS	O
by	POS	O
questionnaire	POS	O
three	POS	O
to	POS	O
four	POS	O
weeks	POS	O
later	POS	O
.	POS	O
The	POS	O
trial	POS	O
was	POS	O
discontinued	POS	O
after	POS	O
20	POS	O
cases	POS	O
because	POS	O
of	POS	O
an	POS	O
unacceptable	POS	O
incidence	POS	O
of	POS	O
side	POS	O
effects	POS	O
.	POS	O
Venous	POS	B-NP
pain	POS	I-NP
occurred	POS	O
in	POS	O
68	POS	O
%	POS	O
of	POS	O
patients	POS	O
and	POS	O
50	POS	O
%	POS	O
had	POS	O
redness	POS	B-NP
,	POS	O
pain	POS	B-NP
or	POS	O
swelling	POS	B-NP
related	POS	O
to	POS	O
the	POS	O
injection	POS	O
site	POS	O
,	POS	O
in	POS	O
some	POS	O
cases	POS	O
lasting	POS	O
up	POS	O
to	POS	O
three	POS	O
weeks	POS	O
after	POS	O
anaesthesia	POS	O
.	POS	O
Skeletal	POS	B-NP
movements	POS	I-NP
occurred	POS	O
in	POS	O
50	POS	O
%	POS	O
of	POS	O
patients	POS	O
;	POS	O
30	POS	O
%	POS	O
experienced	POS	O
respiratory	POS	B-NP
upset	POS	I-NP
,	POS	O
one	POS	O
sufficiently	POS	O
severe	POS	O
to	POS	O
necessitate	POS	O
abandoning	POS	O
the	POS	O
technique	POS	O
.	POS	O
Nausea	POS	B-NP
and	POS	O
vomiting	POS	B-NP
occurred	POS	O
in	POS	O
40	POS	O
%	POS	O
and	POS	O
25	POS	O
%	POS	O
had	POS	O
disturbing	POS	O
emergence	POS	O
psychoses	POS	B-NP
.	POS	O
Levodopa	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
are	POS	O
improved	POS	O
by	POS	O
fluoxetine	POS	O
.	POS	O
We	POS	O
evaluated	POS	O
the	POS	O
severity	POS	O
of	POS	O
motor	POS	B-NP
disability	POS	I-NP
and	POS	O
dyskinesias	POS	B-NP
in	POS	O
seven	POS	O
levodopa	POS	O
-	POS	O
responsive	POS	O
patients	POS	O
with	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
after	POS	O
an	POS	O
acute	POS	O
challenge	POS	O
with	POS	O
the	POS	O
mixed	POS	O
dopamine	POS	O
agonist	POS	O
,	POS	O
apomorphine	POS	O
,	POS	O
before	POS	O
and	POS	O
after	POS	O
the	POS	O
administration	POS	O
of	POS	O
fluoxetine	POS	O
(	POS	O
20	POS	O
mg	POS	O
twice	POS	O
per	POS	O
day	POS	O
)	POS	O
for	POS	O
11	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
days	POS	O
.	POS	O
After	POS	O
fluoxetine	POS	O
treatment	POS	O
,	POS	O
there	POS	O
was	POS	O
a	POS	O
significant	POS	O
47	POS	O
%	POS	O
improvement	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
of	POS	O
apomorphine	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
without	POS	O
modification	POS	O
of	POS	O
parkinsonian	POS	B-NP
motor	POS	I-NP
disability	POS	I-NP
.	POS	O
The	POS	O
dyskinesias	POS	B-NP
were	POS	O
reduced	POS	O
predominantly	POS	O
in	POS	O
the	POS	O
lower	POS	O
limbs	POS	O
during	POS	O
the	POS	O
onset	POS	O
and	POS	O
disappearance	POS	O
of	POS	O
dystonic	POS	B-NP
dyskinesias	POS	I-NP
(	POS	O
onset	POS	O
-	POS	O
and	POS	O
end	POS	O
-	POS	O
of	POS	O
-	POS	O
dose	POS	O
dyskinesias	POS	B-NP
)	POS	O
and	POS	O
in	POS	O
the	POS	O
upper	POS	O
limbs	POS	O
during	POS	O
choreic	POS	B-NP
mid	POS	O
-	POS	O
dose	POS	O
dyskinesias	POS	B-NP
.	POS	O
The	POS	O
results	POS	O
suggest	POS	O
that	POS	O
increased	POS	O
brain	POS	O
serotoninergic	POS	O
transmission	POS	O
with	POS	O
fluoxetine	POS	O
may	POS	O
reduce	POS	O
levodopa	POS	O
-	POS	O
or	POS	O
dopamine	POS	O
agonist	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
without	POS	O
aggravating	POS	O
parkinsonian	POS	B-NP
motor	POS	I-NP
disability	POS	I-NP
.	POS	O
A	POS	O
large	POS	O
population	POS	O
-	POS	O
based	POS	O
follow	POS	O
-	POS	O
up	POS	O
study	POS	O
of	POS	O
trimethoprim	POS	O
-	POS	O
sulfamethoxazole	POS	O
,	POS	O
trimethoprim	POS	O
,	POS	O
and	POS	O
cephalexin	POS	O
for	POS	O
uncommon	POS	O
serious	POS	O
drug	POS	B-NP
toxicity	POS	I-NP
.	POS	O
We	POS	O
conducted	POS	O
a	POS	O
population	POS	O
-	POS	O
based	POS	O
45	POS	O
-	POS	O
day	POS	O
follow	POS	O
-	POS	O
up	POS	O
study	POS	O
of	POS	O
232	POS	O
,	POS	O
390	POS	O
people	POS	O
who	POS	O
were	POS	O
prescribed	POS	O
trimethoprim	POS	O
-	POS	O
sulfamethoxazole	POS	O
(	POS	O
TMP	POS	O
-	POS	O
SMZ	POS	O
)	POS	O
,	POS	O
266	POS	O
,	POS	O
951	POS	O
prescribed	POS	O
trimethoprim	POS	O
alone	POS	O
,	POS	O
and	POS	O
196	POS	O
,	POS	O
397	POS	O
prescribed	POS	O
cephalexin	POS	O
,	POS	O
to	POS	O
estimate	POS	O
the	POS	O
risk	POS	O
of	POS	O
serious	POS	O
liver	POS	O
,	POS	O
blood	POS	O
,	POS	O
skin	POS	O
,	POS	O
and	POS	O
renal	POS	B-NP
disorders	POS	I-NP
resulting	POS	O
in	POS	O
referral	POS	O
or	POS	O
hospitalization	POS	O
associated	POS	O
with	POS	O
these	POS	O
drugs	POS	O
.	POS	O
The	POS	O
results	POS	O
were	POS	O
based	POS	O
on	POS	O
information	POS	O
recorded	POS	O
on	POS	O
office	POS	O
computers	POS	O
by	POS	O
selected	POS	O
general	POS	O
practitioners	POS	O
in	POS	O
the	POS	O
United	POS	O
Kingdom	POS	O
,	POS	O
together	POS	O
with	POS	O
a	POS	O
review	POS	O
of	POS	O
clinical	POS	O
records	POS	O
.	POS	O
The	POS	O
risk	POS	O
of	POS	O
clinically	POS	O
important	POS	O
idiopathic	POS	B-NP
liver	POS	I-NP
disease	POS	I-NP
was	POS	O
similar	POS	O
for	POS	O
persons	POS	O
prescribed	POS	O
TMP	POS	O
-	POS	O
SMZ	POS	O
(	POS	O
5	POS	O
.	POS	O
2	POS	O
/	POS	O
100	POS	O
,	POS	O
000	POS	O
)	POS	O
and	POS	O
those	POS	O
prescribed	POS	O
trimethoprim	POS	O
alone	POS	O
(	POS	O
3	POS	O
.	POS	O
8	POS	O
/	POS	O
100	POS	O
,	POS	O
000	POS	O
)	POS	O
.	POS	O
The	POS	O
risk	POS	O
for	POS	O
those	POS	O
prescribed	POS	O
cephalexin	POS	O
was	POS	O
somewhat	POS	O
lower	POS	O
(	POS	O
2	POS	O
.	POS	O
0	POS	O
/	POS	O
100	POS	O
,	POS	O
000	POS	O
)	POS	O
.	POS	O
Only	POS	O
five	POS	O
patients	POS	O
experienced	POS	O
blood	POS	B-NP
disorders	POS	I-NP
,	POS	O
one	POS	O
of	POS	O
whom	POS	O
was	POS	O
exposed	POS	O
to	POS	O
TMP	POS	O
-	POS	O
SMZ	POS	O
;	POS	O
of	POS	O
seven	POS	O
with	POS	O
erythema	POS	B-NP
multiforme	POS	I-NP
and	POS	O
Stevens	POS	B-NP
-	POS	I-NP
Johnson	POS	I-NP
syndrome	POS	I-NP
,	POS	O
four	POS	O
were	POS	O
exposed	POS	O
to	POS	O
TMP	POS	O
-	POS	O
SMZ	POS	O
.	POS	O
The	POS	O
one	POS	O
case	POS	O
of	POS	O
toxic	POS	O
epidermal	POS	B-NP
necrolysis	POS	I-NP
occurred	POS	O
in	POS	O
a	POS	O
patient	POS	O
who	POS	O
took	POS	O
cephalexin	POS	O
.	POS	O
Finally	POS	O
,	POS	O
only	POS	O
five	POS	O
cases	POS	O
of	POS	O
acute	POS	O
parenchymal	POS	B-NP
renal	POS	I-NP
disease	POS	I-NP
occurred	POS	O
,	POS	O
none	POS	O
likely	POS	O
to	POS	O
be	POS	O
caused	POS	O
by	POS	O
a	POS	O
study	POS	O
drug	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
the	POS	O
risk	POS	O
of	POS	O
the	POS	O
serious	POS	O
diseases	POS	O
studied	POS	O
is	POS	O
small	POS	O
for	POS	O
the	POS	O
three	POS	O
agents	POS	O
,	POS	O
and	POS	O
compares	POS	O
reasonably	POS	O
with	POS	O
the	POS	O
risk	POS	O
for	POS	O
many	POS	O
other	POS	O
antibiotics	POS	O
.	POS	O
Clinical	POS	O
safety	POS	O
of	POS	O
lidocaine	POS	O
in	POS	O
patients	POS	O
with	POS	O
cocaine	POS	O
-	POS	O
associated	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
STUDY	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
evaluate	POS	O
the	POS	O
safety	POS	O
of	POS	O
lidocaine	POS	O
in	POS	O
the	POS	O
setting	POS	O
of	POS	O
cocaine	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
(	POS	O
MI	POS	B-NP
)	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
A	POS	O
retrospective	POS	O
,	POS	O
multicenter	POS	O
study	POS	O
.	POS	O
SETTING	POS	O
:	POS	O
Twenty	POS	O
-	POS	O
nine	POS	O
university	POS	O
,	POS	O
university	POS	O
-	POS	O
affiliated	POS	O
,	POS	O
or	POS	O
community	POS	O
hospitals	POS	O
during	POS	O
a	POS	O
6	POS	O
-	POS	O
year	POS	O
period	POS	O
(	POS	O
total	POS	O
of	POS	O
117	POS	O
cumulative	POS	O
hospital	POS	O
-	POS	O
years	POS	O
)	POS	O
.	POS	O
PARTICIPANTS	POS	O
:	POS	O
Patients	POS	O
with	POS	O
cocaine	POS	O
-	POS	O
associated	POS	O
MI	POS	B-NP
who	POS	O
received	POS	O
lidocaine	POS	O
in	POS	O
the	POS	O
emergency	POS	O
department	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
Of	POS	O
29	POS	O
patients	POS	O
who	POS	O
received	POS	O
lidocaine	POS	O
in	POS	O
the	POS	O
setting	POS	O
of	POS	O
cocaine	POS	O
-	POS	O
associated	POS	O
MI	POS	B-NP
,	POS	O
no	POS	O
patient	POS	O
died	POS	O
;	POS	O
exhibited	POS	O
bradydysrhythmias	POS	B-NP
,	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
,	POS	O
or	POS	O
ventricular	POS	B-NP
fibrillation	POS	I-NP
;	POS	O
or	POS	O
experienced	POS	O
seizures	POS	B-NP
after	POS	O
administration	POS	O
of	POS	O
lidocaine	POS	O
(	POS	O
95	POS	O
%	POS	O
confidence	POS	O
interval	POS	O
,	POS	O
0	POS	O
%	POS	O
to	POS	O
11	POS	O
%	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Despite	POS	O
theoretical	POS	O
concerns	POS	O
that	POS	O
lidocaine	POS	O
may	POS	O
enhance	POS	O
cocaine	POS	B-NP
toxicity	POS	I-NP
,	POS	O
the	POS	O
use	POS	O
of	POS	O
lidocaine	POS	O
in	POS	O
patients	POS	O
with	POS	O
cocaine	POS	O
-	POS	O
associated	POS	O
MI	POS	B-NP
was	POS	O
not	POS	O
associated	POS	O
with	POS	O
significant	POS	O
cardiovascular	POS	B-NP
or	POS	I-NP
central	POS	I-NP
nervous	POS	I-NP
system	POS	I-NP
toxicity	POS	I-NP
.	POS	O
Experimental	POS	O
progressive	POS	O
muscular	POS	B-NP
dystrophy	POS	I-NP
and	POS	O
its	POS	O
treatment	POS	O
with	POS	O
high	POS	O
doses	POS	O
anabolizing	POS	O
agents	POS	O
.	POS	O
We	POS	O
are	POS	O
still	POS	O
a	POS	O
long	POS	O
way	POS	O
from	POS	O
discovering	POS	O
an	POS	O
unequivocal	POS	O
pathogenetic	POS	O
interpretation	POS	O
of	POS	O
progressive	POS	O
muscular	POS	B-NP
dystrophy	POS	I-NP
in	POS	O
man	POS	O
.	POS	O
Noteworthy	POS	O
efforts	POS	O
have	POS	O
been	POS	O
made	POS	O
in	POS	O
the	POS	O
experimental	POS	O
field	POS	O
;	POS	O
a	POS	O
recessive	POS	B-NP
autosomic	POS	I-NP
form	POS	O
found	POS	O
in	POS	O
the	POS	O
mouse	POS	O
seems	POS	O
to	POS	O
bear	POS	O
the	POS	O
closest	POS	O
resemblance	POS	O
to	POS	O
the	POS	O
human	POS	O
form	POS	O
from	POS	O
the	POS	O
genetic	POS	O
point	POS	O
of	POS	O
view	POS	O
.	POS	O
Myopathy	POS	B-NP
due	POS	O
to	POS	O
lack	POS	O
of	POS	O
vitamin	POS	O
E	POS	O
and	POS	O
myopathy	POS	B-NP
induced	POS	O
by	POS	O
certain	POS	O
viruses	POS	O
have	POS	O
much	POS	O
in	POS	O
common	POS	O
anatomically	POS	O
and	POS	O
pathologically	POS	O
with	POS	O
the	POS	O
human	POS	O
form	POS	O
.	POS	O
The	POS	O
authors	POS	O
induced	POS	O
myodystrophy	POS	B-NP
in	POS	O
the	POS	O
rat	POS	O
by	POS	O
giving	POS	O
it	POS	O
a	POS	O
diet	POS	O
lacking	POS	O
in	POS	O
vitamin	POS	O
E	POS	O
.	POS	O
The	POS	O
pharmacological	POS	O
characteristics	POS	O
of	POS	O
vitamin	POS	O
E	POS	O
and	POS	O
the	POS	O
degenerative	POS	O
changes	POS	O
brought	POS	O
about	POS	O
by	POS	O
its	POS	O
deficiency	POS	O
,	POS	O
especially	POS	O
in	POS	O
the	POS	O
muscles	POS	O
,	POS	O
are	POS	O
illustrated	POS	O
.	POS	O
It	POS	O
is	POS	O
thus	POS	O
confirmed	POS	O
that	POS	O
the	POS	O
histological	POS	O
characteristics	POS	O
of	POS	O
myopathic	POS	O
rat	POS	O
muscle	POS	O
induced	POS	O
experimentally	POS	O
are	POS	O
extraordinarily	POS	O
similar	POS	O
to	POS	O
those	POS	O
of	POS	O
human	POS	O
myopathy	POS	B-NP
as	POS	O
confirmed	POS	O
during	POS	O
biopsies	POS	O
performed	POS	O
at	POS	O
the	POS	O
Orthopaedic	POS	O
Traumatological	POS	O
Centre	POS	O
,	POS	O
Florence	POS	O
.	POS	O
The	POS	O
encouraging	POS	O
results	POS	O
obtained	POS	O
in	POS	O
various	POS	O
authoratative	POS	O
departments	POS	O
in	POS	O
myopathic	POS	B-NP
patients	POS	O
by	POS	O
using	POS	O
anabolizing	POS	O
steroids	POS	O
have	POS	O
encouraged	POS	O
the	POS	O
authors	POS	O
to	POS	O
investigate	POS	O
the	POS	O
beneficial	POS	O
effects	POS	O
of	POS	O
one	POS	O
anabolizing	POS	O
agent	POS	O
(	POS	O
Dianabol	POS	O
,	POS	O
CIBA	POS	O
)	POS	O
at	POS	O
high	POS	O
doses	POS	O
in	POS	O
rats	POS	O
rendered	POS	O
myopathic	POS	B-NP
by	POS	O
a	POS	O
diet	POS	O
deficient	POS	O
in	POS	O
vitamin	POS	O
E	POS	O
.	POS	O
In	POS	O
this	POS	O
way	POS	O
they	POS	O
obtained	POS	O
appreciable	POS	O
changes	POS	O
in	POS	O
body	POS	O
weight	POS	O
(	POS	O
increased	POS	O
from	POS	O
50	POS	O
to	POS	O
70	POS	O
g	POS	O
after	POS	O
forty	POS	O
days	POS	O
at	POS	O
a	POS	O
dose	POS	O
of	POS	O
5	POS	O
mg	POS	O
per	POS	O
day	POS	O
of	POS	O
anabolizing	POS	O
agent	POS	O
)	POS	O
,	POS	O
but	POS	O
most	POS	O
of	POS	O
all	POS	O
they	POS	O
found	POS	O
histological	POS	O
changes	POS	O
due	POS	O
to	POS	O
"	POS	O
regenerative	POS	O
"	POS	O
changes	POS	O
in	POS	O
the	POS	O
muscle	POS	O
tissue	POS	O
,	POS	O
which	POS	O
however	POS	O
maintained	POS	O
its	POS	O
myopathic	POS	B-NP
characteristics	POS	O
in	POS	O
the	POS	O
control	POS	O
animals	POS	O
that	POS	O
were	POS	O
not	POS	O
treated	POS	O
with	POS	O
the	POS	O
anabolizing	POS	O
agent	POS	O
.	POS	O
The	POS	O
authors	POS	O
conclude	POS	O
by	POS	O
affirming	POS	O
the	POS	O
undoubted	POS	O
efficacy	POS	O
of	POS	O
the	POS	O
anabolizing	POS	O
steroids	POS	O
in	POS	O
experimental	POS	O
myopathic	POS	B-NP
disease	POS	I-NP
,	POS	O
but	POS	O
they	POS	O
have	POS	O
reservations	POS	O
as	POS	O
to	POS	O
the	POS	O
transfer	POS	O
of	POS	O
the	POS	O
results	POS	O
into	POS	O
the	POS	O
human	POS	O
field	POS	O
,	POS	O
where	POS	O
high	POS	O
dosage	POS	O
cannot	POS	O
be	POS	O
carried	POS	O
out	POS	O
continuously	POS	O
because	POS	O
of	POS	O
the	POS	O
effects	POS	O
of	POS	O
the	POS	O
drug	POS	O
on	POS	O
virility	POS	O
;	POS	O
because	POS	O
the	POS	O
tissue	POS	O
injury	POS	O
too	POS	O
often	POS	O
occurs	POS	O
at	POS	O
an	POS	O
irreversible	POS	O
stage	POS	O
vis	POS	O
-	POS	O
a	POS	O
-	POS	O
vis	POS	O
the	POS	O
"	POS	O
regeneration	POS	O
"	POS	O
of	POS	O
the	POS	O
muscle	POS	O
tissue	POS	O
;	POS	O
and	POS	O
finally	POS	O
because	POS	O
the	POS	O
dystrophic	POS	O
injurious	POS	O
agent	POS	O
is	POS	O
certainly	POS	O
not	POS	O
the	POS	O
lack	POS	O
of	POS	O
vitamin	POS	O
E	POS	O
but	POS	O
something	POS	O
as	POS	O
yet	POS	O
unknown	POS	O
.	POS	O
Paclitaxel	POS	O
3	POS	O
-	POS	O
hour	POS	O
infusion	POS	O
given	POS	O
alone	POS	O
and	POS	O
combined	POS	O
with	POS	O
carboplatin	POS	O
:	POS	O
preliminary	POS	O
results	POS	O
of	POS	O
dose	POS	O
-	POS	O
escalation	POS	O
trials	POS	O
.	POS	O
Paclitaxel	POS	O
(	POS	O
Taxol	POS	O
;	POS	O
Bristol	POS	O
-	POS	O
Myers	POS	O
Squibb	POS	O
Company	POS	O
,	POS	O
Princeton	POS	O
,	POS	O
NJ	POS	O
)	POS	O
by	POS	O
3	POS	O
-	POS	O
hour	POS	O
infusion	POS	O
was	POS	O
combined	POS	O
with	POS	O
carboplatin	POS	O
in	POS	O
a	POS	O
phase	POS	O
I	POS	O
/	POS	O
II	POS	O
study	POS	O
directed	POS	O
to	POS	O
patients	POS	O
with	POS	O
non	POS	B-NP
-	POS	I-NP
small	POS	I-NP
cell	POS	I-NP
lung	POS	I-NP
cancer	POS	I-NP
.	POS	O
Carboplatin	POS	O
was	POS	O
given	POS	O
at	POS	O
a	POS	O
fixed	POS	O
target	POS	O
area	POS	O
under	POS	O
the	POS	O
concentration	POS	O
-	POS	O
time	POS	O
curve	POS	O
of	POS	O
6	POS	O
.	POS	O
0	POS	O
by	POS	O
the	POS	O
Calvert	POS	O
formula	POS	O
,	POS	O
whereas	POS	O
paclitaxel	POS	O
was	POS	O
escalated	POS	O
in	POS	O
patient	POS	O
cohorts	POS	O
from	POS	O
150	POS	O
mg	POS	O
/	POS	O
m2	POS	O
(	POS	O
dose	POS	O
level	POS	O
I	POS	O
)	POS	O
to	POS	O
175	POS	O
,	POS	O
200	POS	O
,	POS	O
225	POS	O
,	POS	O
and	POS	O
250	POS	O
mg	POS	O
/	POS	O
m2	POS	O
.	POS	O
The	POS	O
225	POS	O
mg	POS	O
/	POS	O
m2	POS	O
level	POS	O
was	POS	O
expanded	POS	O
for	POS	O
the	POS	O
phase	POS	O
II	POS	O
study	POS	O
since	POS	O
the	POS	O
highest	POS	O
level	POS	O
achieved	POS	O
(	POS	O
250	POS	O
mg	POS	O
/	POS	O
m2	POS	O
)	POS	O
required	POS	O
modification	POS	O
because	POS	O
of	POS	O
nonhematologic	POS	O
toxicities	POS	B-NP
(	POS	O
arthralgia	POS	B-NP
and	POS	O
sensory	POS	B-NP
neuropathy	POS	I-NP
)	POS	O
.	POS	O
Therapeutic	POS	O
effects	POS	O
were	POS	O
noted	POS	O
at	POS	O
all	POS	O
dose	POS	O
levels	POS	O
,	POS	O
with	POS	O
objective	POS	O
responses	POS	O
in	POS	O
17	POS	O
(	POS	O
two	POS	O
complete	POS	O
and	POS	O
15	POS	O
partial	POS	O
regressions	POS	O
)	POS	O
of	POS	O
41	POS	O
previously	POS	O
untreated	POS	O
patients	POS	O
.	POS	O
Toxicities	POS	B-NP
were	POS	O
compared	POS	O
with	POS	O
a	POS	O
cohort	POS	O
of	POS	O
patients	POS	O
in	POS	O
a	POS	O
phase	POS	O
I	POS	O
trial	POS	O
of	POS	O
paclitaxel	POS	O
alone	POS	O
at	POS	O
identical	POS	O
dose	POS	O
levels	POS	O
.	POS	O
Carboplatin	POS	O
did	POS	O
not	POS	O
appear	POS	O
to	POS	O
add	POS	O
to	POS	O
the	POS	O
hematologic	POS	O
toxicities	POS	B-NP
observed	POS	O
,	POS	O
and	POS	O
the	POS	O
paclitaxel	POS	O
/	POS	O
carboplatin	POS	O
combination	POS	O
could	POS	O
be	POS	O
dosed	POS	O
every	POS	O
3	POS	O
weeks	POS	O
.	POS	O
The	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
effect	POS	O
of	POS	O
misoprostol	POS	O
on	POS	O
indomethacin	POS	O
-	POS	O
induced	POS	O
renal	POS	B-NP
dysfunction	POS	I-NP
in	POS	O
well	POS	O
compensated	POS	O
cirrhosis	POS	B-NP
.	POS	O
Misoprostol	POS	O
(	POS	O
200	POS	O
micrograms	POS	O
)	POS	O
has	POS	O
been	POS	O
shown	POS	O
to	POS	O
acutely	POS	O
counteract	POS	O
the	POS	O
indomethacin	POS	O
-	POS	O
induced	POS	O
renal	POS	B-NP
dysfunction	POS	I-NP
in	POS	O
well	POS	O
compensated	POS	O
cirrhotic	POS	B-NP
patients	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
determine	POS	O
if	POS	O
the	POS	O
prophylactic	POS	O
value	POS	O
of	POS	O
misoprostol	POS	O
was	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
.	POS	O
Parameters	POS	O
of	POS	O
renal	POS	O
hemodynamics	POS	O
and	POS	O
tubular	POS	O
sodium	POS	O
and	POS	O
water	POS	O
handling	POS	O
were	POS	O
assessed	POS	O
by	POS	O
clearance	POS	O
techniques	POS	O
in	POS	O
26	POS	O
well	POS	O
compensated	POS	O
cirrhotic	POS	B-NP
patients	POS	O
before	POS	O
and	POS	O
after	POS	O
an	POS	O
oral	POS	O
combination	POS	O
of	POS	O
50	POS	O
mg	POS	O
of	POS	O
indomethacin	POS	O
and	POS	O
various	POS	O
doses	POS	O
of	POS	O
misoprostol	POS	O
.	POS	O
The	POS	O
200	POS	O
-	POS	O
micrograms	POS	O
dose	POS	O
was	POS	O
able	POS	O
to	POS	O
totally	POS	O
abolish	POS	O
the	POS	O
deleterious	POS	O
renal	POS	O
effects	POS	O
of	POS	O
indomethacin	POS	O
,	POS	O
whereas	POS	O
the	POS	O
800	POS	O
-	POS	O
micrograms	POS	O
dose	POS	O
resulted	POS	O
in	POS	O
significant	POS	O
worsening	POS	O
of	POS	O
renal	POS	O
hemodynamics	POS	O
and	POS	O
sodium	POS	O
retention	POS	O
.	POS	O
These	POS	O
changes	POS	O
were	POS	O
maximal	POS	O
in	POS	O
the	POS	O
hour	POS	O
immediately	POS	O
after	POS	O
medications	POS	O
and	POS	O
slowly	POS	O
returned	POS	O
toward	POS	O
base	POS	O
-	POS	O
line	POS	O
levels	POS	O
thereafter	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
the	POS	O
renal	POS	O
protective	POS	O
effects	POS	O
of	POS	O
misoprostol	POS	O
is	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
.	POS	O
However	POS	O
,	POS	O
until	POS	O
this	POS	O
apparent	POS	O
ability	POS	O
of	POS	O
200	POS	O
micrograms	POS	O
of	POS	O
misoprostol	POS	O
to	POS	O
prevent	POS	O
the	POS	O
adverse	POS	O
effects	POS	O
of	POS	O
indomethacin	POS	O
on	POS	O
renal	POS	O
function	POS	O
is	POS	O
confirmed	POS	O
with	POS	O
chronic	POS	O
frequent	POS	O
dosing	POS	O
,	POS	O
it	POS	O
would	POS	O
be	POS	O
prudent	POS	O
to	POS	O
avoid	POS	O
nonsteroidal	POS	O
anti	POS	O
-	POS	O
inflammatory	POS	O
therapy	POS	O
in	POS	O
patients	POS	O
with	POS	O
cirrhosis	POS	B-NP
.	POS	O
Increased	POS	O
frequency	POS	O
and	POS	O
severity	POS	O
of	POS	O
angio	POS	B-NP
-	POS	I-NP
oedema	POS	I-NP
related	POS	O
to	POS	O
long	POS	O
-	POS	O
term	POS	O
therapy	POS	O
with	POS	O
angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
inhibitor	POS	O
in	POS	O
two	POS	O
patients	POS	O
.	POS	O
Adverse	POS	O
reactions	POS	O
to	POS	O
drugs	POS	O
are	POS	O
well	POS	O
recognized	POS	O
as	POS	O
a	POS	O
cause	POS	O
of	POS	O
acute	POS	O
or	POS	O
chronic	POS	O
urticaria	POS	B-NP
,	POS	O
and	POS	O
angio	POS	B-NP
-	POS	I-NP
oedema	POS	I-NP
.	POS	O
Angiotensin	POS	O
-	POS	O
converting	POS	O
enzyme	POS	O
(	POS	O
ACE	POS	O
)	POS	O
inhibitors	POS	O
,	POS	O
used	POS	O
to	POS	O
treat	POS	O
hypertension	POS	B-NP
and	POS	O
congestive	POS	B-NP
heart	POS	I-NP
failure	POS	I-NP
,	POS	O
were	POS	O
introduced	POS	O
in	POS	O
Europe	POS	O
in	POS	O
the	POS	O
middle	POS	O
of	POS	O
the	POS	O
eighties	POS	O
,	POS	O
and	POS	O
the	POS	O
use	POS	O
of	POS	O
these	POS	O
drugs	POS	O
has	POS	O
increased	POS	O
progressively	POS	O
.	POS	O
Soon	POS	O
after	POS	O
the	POS	O
introduction	POS	O
of	POS	O
ACE	POS	O
inhibitors	POS	O
,	POS	O
acute	POS	O
bouts	POS	O
of	POS	O
angio	POS	B-NP
-	POS	I-NP
oedema	POS	I-NP
were	POS	O
reported	POS	O
in	POS	O
association	POS	O
with	POS	O
the	POS	O
use	POS	O
of	POS	O
these	POS	O
drugs	POS	O
.	POS	O
We	POS	O
wish	POS	O
to	POS	O
draw	POS	O
attention	POS	O
to	POS	O
the	POS	O
possibility	POS	O
of	POS	O
adverse	POS	O
reactions	POS	O
to	POS	O
ACE	POS	O
inhibitors	POS	O
after	POS	O
long	POS	O
-	POS	O
term	POS	O
use	POS	O
and	POS	O
in	POS	O
patients	POS	O
with	POS	O
pre	POS	O
-	POS	O
existing	POS	O
angio	POS	O
-	POS	O
oedema	POS	B-NP
.	POS	O
Myoclonus	POS	B-NP
associated	POS	O
with	POS	O
lorazepam	POS	O
therapy	POS	O
in	POS	O
very	POS	O
-	POS	O
low	POS	O
-	POS	O
birth	POS	O
-	POS	O
weight	POS	O
infants	POS	O
.	POS	O
Lorazepam	POS	O
is	POS	O
being	POS	O
used	POS	O
with	POS	O
increasing	POS	O
frequency	POS	O
as	POS	O
a	POS	O
sedative	POS	O
in	POS	O
the	POS	O
newborn	POS	O
and	POS	O
the	POS	O
young	POS	O
infant	POS	O
.	POS	O
Concern	POS	O
has	POS	O
been	POS	O
raised	POS	O
with	POS	O
regard	POS	O
to	POS	O
the	POS	O
safety	POS	O
of	POS	O
lorazepam	POS	O
in	POS	O
this	POS	O
age	POS	O
group	POS	O
,	POS	O
especially	POS	O
in	POS	O
very	POS	O
-	POS	O
low	POS	O
-	POS	O
birth	POS	O
-	POS	O
weight	POS	O
(	POS	O
VLBW	POS	O
;	POS	O
<	POS	O
1	POS	O
,	POS	O
500	POS	O
g	POS	O
)	POS	O
infants	POS	O
.	POS	O
Three	POS	O
young	POS	O
infants	POS	O
,	POS	O
all	POS	O
of	POS	O
birth	POS	O
weight	POS	O
<	POS	O
1	POS	O
,	POS	O
500	POS	O
g	POS	O
,	POS	O
experienced	POS	O
myoclonus	POS	B-NP
following	POS	O
the	POS	O
intravenous	POS	O
administration	POS	O
of	POS	O
lorazepam	POS	O
.	POS	O
The	POS	O
potential	POS	O
neurotoxic	POS	B-NP
effects	POS	O
of	POS	O
the	POS	O
drug	POS	O
(	POS	O
and	POS	O
its	POS	O
vehicle	POS	O
)	POS	O
in	POS	O
this	POS	O
population	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Injectable	POS	O
lorazepam	POS	O
should	POS	O
be	POS	O
used	POS	O
with	POS	O
caution	POS	O
in	POS	O
VLBW	POS	O
infants	POS	O
.	POS	O
Transvenous	POS	O
right	POS	O
ventricular	POS	O
pacing	POS	O
during	POS	O
cardiopulmonary	POS	O
resuscitation	POS	O
of	POS	O
pediatric	POS	O
patients	POS	O
with	POS	O
acute	POS	B-NP
cardiomyopathy	POS	I-NP
.	POS	O
We	POS	O
describe	POS	O
the	POS	O
cardiopulmonary	POS	O
resuscitation	POS	O
efforts	POS	O
on	POS	O
five	POS	O
patients	POS	O
who	POS	O
presented	POS	O
in	POS	O
acute	POS	B-NP
circulatory	POS	I-NP
failure	POS	I-NP
from	POS	O
myocardial	POS	B-NP
dysfunction	POS	I-NP
.	POS	O
Three	POS	O
patients	POS	O
had	POS	O
acute	POS	O
viral	POS	O
myocarditis	POS	B-NP
,	POS	O
one	POS	O
had	POS	O
a	POS	O
carbamazepine	POS	O
-	POS	O
induced	POS	O
acute	POS	O
eosinophilic	POS	B-NP
myocarditis	POS	I-NP
,	POS	O
and	POS	O
one	POS	O
had	POS	O
cardiac	POS	B-NP
hemosiderosis	POS	I-NP
resulting	POS	O
in	POS	O
acute	POS	B-NP
cardiogenic	POS	I-NP
shock	POS	I-NP
.	POS	O
All	POS	O
patients	POS	O
were	POS	O
continuously	POS	O
monitored	POS	O
with	POS	O
central	POS	O
venous	POS	O
and	POS	O
arterial	POS	O
catheters	POS	O
in	POS	O
addition	POS	O
to	POS	O
routine	POS	O
noninvasive	POS	O
monitoring	POS	O
.	POS	O
An	POS	O
introducer	POS	O
sheath	POS	O
,	POS	O
a	POS	O
pacemaker	POS	O
,	POS	O
and	POS	O
sterile	POS	O
pacing	POS	O
wires	POS	O
were	POS	O
made	POS	O
readily	POS	O
available	POS	O
for	POS	O
the	POS	O
patients	POS	O
,	POS	O
should	POS	O
the	POS	O
need	POS	O
arise	POS	O
to	POS	O
terminate	POS	O
resistant	POS	O
cardiac	POS	B-NP
dysrhythmias	POS	I-NP
.	POS	O
All	POS	O
patients	POS	O
developed	POS	O
cardiocirculatory	POS	B-NP
arrest	POS	I-NP
associated	POS	O
with	POS	O
extreme	POS	O
hypotension	POS	B-NP
and	POS	O
dysrhythmias	POS	B-NP
within	POS	O
the	POS	O
first	POS	O
48	POS	O
hours	POS	O
of	POS	O
their	POS	O
admission	POS	O
to	POS	O
the	POS	O
pediatric	POS	O
intensive	POS	O
care	POS	O
unit	POS	O
(	POS	O
PICU	POS	O
)	POS	O
.	POS	O
Right	POS	O
ventricular	POS	O
pacemaker	POS	O
wires	POS	O
were	POS	O
inserted	POS	O
in	POS	O
all	POS	O
of	POS	O
them	POS	O
during	POS	O
cardiopulmonary	POS	O
resuscitation	POS	O
(	POS	O
CPR	POS	O
)	POS	O
.	POS	O
In	POS	O
four	POS	O
patients	POS	O
,	POS	O
cardiac	POS	O
pacing	POS	O
was	POS	O
used	POS	O
,	POS	O
resulting	POS	O
in	POS	O
a	POS	O
temporary	POS	O
captured	POS	O
rhythm	POS	O
and	POS	O
restoration	POS	O
of	POS	O
their	POS	O
cardiac	POS	O
output	POS	O
.	POS	O
These	POS	O
patients	POS	O
had	POS	O
a	POS	O
second	POS	O
event	POS	O
of	POS	O
cardiac	POS	B-NP
arrest	POS	I-NP
,	POS	O
resulting	POS	O
in	POS	O
death	POS	O
,	POS	O
within	POS	O
10	POS	O
to	POS	O
60	POS	O
minutes	POS	O
.	POS	O
In	POS	O
one	POS	O
patient	POS	O
,	POS	O
cardiac	POS	O
pacing	POS	O
was	POS	O
not	POS	O
used	POS	O
,	POS	O
because	POS	O
he	POS	O
converted	POS	O
to	POS	O
normal	POS	O
sinus	POS	O
rhythm	POS	O
by	POS	O
electrical	POS	O
defibrillation	POS	O
within	POS	O
three	POS	O
minutes	POS	O
of	POS	O
initiating	POS	O
CPR	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
cardiac	POS	O
pacing	POS	O
during	POS	O
resuscitative	POS	O
efforts	POS	O
in	POS	O
pediatric	POS	O
patients	POS	O
suffering	POS	O
from	POS	O
acute	POS	O
myocardial	POS	B-NP
dysfunction	POS	I-NP
may	POS	O
not	POS	O
have	POS	O
long	POS	O
-	POS	O
term	POS	O
value	POS	O
in	POS	O
and	POS	O
of	POS	O
itself	POS	O
;	POS	O
however	POS	O
,	POS	O
if	POS	O
temporary	POS	O
hemodynamic	POS	O
stability	POS	O
is	POS	O
achieved	POS	O
by	POS	O
this	POS	O
procedure	POS	O
,	POS	O
it	POS	O
may	POS	O
provide	POS	O
additional	POS	O
time	POS	O
needed	POS	O
to	POS	O
institute	POS	O
other	POS	O
therapeutic	POS	O
modalities	POS	O
.	POS	O
Efficacy	POS	O
and	POS	O
safety	POS	O
of	POS	O
granisetron	POS	O
,	POS	O
a	POS	O
selective	POS	O
5	POS	O
-	POS	O
hydroxytryptamine	POS	O
-	POS	O
3	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
in	POS	O
the	POS	O
prevention	POS	O
of	POS	O
nausea	POS	B-NP
and	POS	O
vomiting	POS	B-NP
induced	POS	O
by	POS	O
high	POS	O
-	POS	O
dose	POS	O
cisplatin	POS	O
.	POS	O
PURPOSE	POS	O
:	POS	O
To	POS	O
assess	POS	O
the	POS	O
antiemetic	POS	O
effects	POS	O
and	POS	O
safety	POS	O
profile	POS	O
of	POS	O
four	POS	O
different	POS	O
doses	POS	O
of	POS	O
granisetron	POS	O
(	POS	O
Kytril	POS	O
;	POS	O
SmithKline	POS	O
Beecham	POS	O
Pharmaceuticals	POS	O
,	POS	O
Philadelphia	POS	O
,	POS	O
PA	POS	O
)	POS	O
when	POS	O
administered	POS	O
as	POS	O
a	POS	O
single	POS	O
intravenous	POS	O
(	POS	O
IV	POS	O
)	POS	O
dose	POS	O
for	POS	O
prophylaxis	POS	O
of	POS	O
cisplatin	POS	O
-	POS	O
induced	POS	O
nausea	POS	B-NP
and	POS	O
vomiting	POS	B-NP
.	POS	O
PATIENTS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
One	POS	O
hundred	POS	O
eighty	POS	O
-	POS	O
four	POS	O
chemotherapy	POS	O
-	POS	O
naive	POS	O
patients	POS	O
receiving	POS	O
high	POS	O
-	POS	O
dose	POS	O
cisplatin	POS	O
(	POS	O
81	POS	O
to	POS	O
120	POS	O
mg	POS	O
/	POS	O
m2	POS	O
)	POS	O
were	POS	O
randomized	POS	O
to	POS	O
receive	POS	O
one	POS	O
of	POS	O
four	POS	O
granisetron	POS	O
doses	POS	O
(	POS	O
5	POS	O
,	POS	O
10	POS	O
,	POS	O
20	POS	O
,	POS	O
or	POS	O
40	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
)	POS	O
administered	POS	O
before	POS	O
chemotherapy	POS	O
.	POS	O
Patients	POS	O
were	POS	O
observed	POS	O
on	POS	O
an	POS	O
inpatient	POS	O
basis	POS	O
for	POS	O
18	POS	O
to	POS	O
24	POS	O
hours	POS	O
,	POS	O
and	POS	O
vital	POS	O
signs	POS	O
,	POS	O
nausea	POS	B-NP
,	POS	O
vomiting	POS	B-NP
,	POS	O
retching	POS	B-NP
,	POS	O
and	POS	O
appetite	POS	B-NP
were	POS	O
assessed	POS	O
.	POS	O
Safety	POS	O
analyses	POS	O
included	POS	O
incidence	POS	O
of	POS	O
adverse	POS	O
experiences	POS	O
and	POS	O
laboratory	POS	O
parameter	POS	O
changes	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
After	POS	O
granisetron	POS	O
doses	POS	O
of	POS	O
5	POS	O
,	POS	O
10	POS	O
,	POS	O
20	POS	O
,	POS	O
and	POS	O
40	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
,	POS	O
a	POS	O
major	POS	O
response	POS	O
(	POS	O
<	POS	O
or	POS	O
=	POS	O
two	POS	O
vomiting	POS	B-NP
or	POS	O
retching	POS	B-NP
episodes	POS	O
,	POS	O
and	POS	O
no	POS	O
antiemetic	POS	O
rescue	POS	O
)	POS	O
was	POS	O
recorded	POS	O
in	POS	O
23	POS	O
%	POS	O
,	POS	O
57	POS	O
%	POS	O
,	POS	O
58	POS	O
%	POS	O
,	POS	O
and	POS	O
60	POS	O
%	POS	O
of	POS	O
patients	POS	O
,	POS	O
respectively	POS	O
,	POS	O
and	POS	O
a	POS	O
complete	POS	O
response	POS	O
(	POS	O
no	POS	O
vomiting	POS	B-NP
or	POS	O
retching	POS	B-NP
,	POS	O
and	POS	O
no	POS	O
antiemetic	POS	O
rescue	POS	O
)	POS	O
in	POS	O
18	POS	O
%	POS	O
,	POS	O
41	POS	O
%	POS	O
,	POS	O
40	POS	O
%	POS	O
,	POS	O
and	POS	O
47	POS	O
%	POS	O
of	POS	O
patients	POS	O
,	POS	O
respectively	POS	O
.	POS	O
There	POS	O
was	POS	O
a	POS	O
statistically	POS	O
longer	POS	O
time	POS	O
to	POS	O
first	POS	O
episode	POS	O
of	POS	O
nausea	POS	B-NP
(	POS	O
P	POS	O
=	POS	O
.	POS	O
0015	POS	O
)	POS	O
and	POS	O
vomiting	POS	B-NP
(	POS	O
P	POS	O
=	POS	O
.	POS	O
0001	POS	O
)	POS	O
,	POS	O
and	POS	O
fewer	POS	O
patients	POS	O
were	POS	O
administered	POS	O
additional	POS	O
antiemetic	POS	O
medication	POS	O
in	POS	O
the	POS	O
10	POS	O
-	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
dosing	POS	O
groups	POS	O
than	POS	O
in	POS	O
the	POS	O
5	POS	O
-	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
dosing	POS	O
group	POS	O
.	POS	O
As	POS	O
granisetron	POS	O
dose	POS	O
increased	POS	O
,	POS	O
appetite	POS	O
return	POS	O
increased	POS	O
(	POS	O
P	POS	O
=	POS	O
.	POS	O
040	POS	O
)	POS	O
.	POS	O
Headache	POS	B-NP
was	POS	O
the	POS	O
most	POS	O
frequently	POS	O
reported	POS	O
adverse	POS	O
event	POS	O
(	POS	O
20	POS	O
%	POS	O
)	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
A	POS	O
single	POS	O
10	POS	O
-	POS	O
,	POS	O
20	POS	O
-	POS	O
,	POS	O
or	POS	O
40	POS	O
-	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
dose	POS	O
of	POS	O
granisetron	POS	O
was	POS	O
effective	POS	O
in	POS	O
controlling	POS	O
vomiting	POS	B-NP
in	POS	O
57	POS	O
%	POS	O
to	POS	O
60	POS	O
%	POS	O
of	POS	O
patients	POS	O
who	POS	O
received	POS	O
cisplatin	POS	O
at	POS	O
doses	POS	O
greater	POS	O
than	POS	O
81	POS	O
mg	POS	O
/	POS	O
m2	POS	O
and	POS	O
totally	POS	O
prevented	POS	O
vomiting	POS	B-NP
in	POS	O
40	POS	O
%	POS	O
to	POS	O
47	POS	O
%	POS	O
of	POS	O
patients	POS	O
.	POS	O
There	POS	O
were	POS	O
no	POS	O
statistically	POS	O
significant	POS	O
differences	POS	O
in	POS	O
efficacy	POS	O
between	POS	O
the	POS	O
10	POS	O
-	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
dose	POS	O
and	POS	O
the	POS	O
20	POS	O
-	POS	O
and	POS	O
40	POS	O
-	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
doses	POS	O
.	POS	O
Granisetron	POS	O
was	POS	O
well	POS	O
tolerated	POS	O
at	POS	O
all	POS	O
doses	POS	O
.	POS	O
Adverse	POS	O
interaction	POS	O
between	POS	O
clonidine	POS	O
and	POS	O
verapamil	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
report	POS	O
two	POS	O
cases	POS	O
of	POS	O
a	POS	O
possible	POS	O
adverse	POS	O
interaction	POS	O
between	POS	O
clonidine	POS	O
and	POS	O
verapamil	POS	O
resulting	POS	O
in	POS	O
atrioventricular	POS	B-NP
(	POS	I-NP
AV	POS	I-NP
)	POS	I-NP
block	POS	I-NP
in	POS	O
both	POS	O
patients	POS	O
and	POS	O
severe	POS	O
hypotension	POS	B-NP
in	POS	O
one	POS	O
patient	POS	O
.	POS	O
CASE	POS	O
SUMMARIES	POS	O
:	POS	O
A	POS	O
54	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
hyperaldosteronism	POS	B-NP
was	POS	O
treated	POS	O
with	POS	O
verapamil	POS	O
480	POS	O
mg	POS	O
/	POS	O
d	POS	O
and	POS	O
spironolactone	POS	O
100	POS	O
mg	POS	O
/	POS	O
d	POS	O
.	POS	O
After	POS	O
the	POS	O
addition	POS	O
of	POS	O
a	POS	O
minimal	POS	O
dose	POS	O
of	POS	O
clonidine	POS	O
(	POS	O
0	POS	O
.	POS	O
15	POS	O
mg	POS	O
bid	POS	O
)	POS	O
,	POS	O
she	POS	O
developed	POS	O
complete	POS	O
AV	POS	B-NP
block	POS	I-NP
and	POS	O
severe	POS	O
hypotension	POS	B-NP
,	POS	O
which	POS	O
resolved	POS	O
upon	POS	O
cessation	POS	O
of	POS	O
all	POS	O
medications	POS	O
.	POS	O
A	POS	O
65	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
was	POS	O
treated	POS	O
with	POS	O
extended	POS	O
-	POS	O
release	POS	O
verapamil	POS	O
240	POS	O
mg	POS	O
/	POS	O
d	POS	O
.	POS	O
After	POS	O
the	POS	O
addition	POS	O
of	POS	O
clonidine	POS	O
0	POS	O
.	POS	O
15	POS	O
mg	POS	O
bid	POS	O
she	POS	O
developed	POS	O
complete	POS	O
AV	POS	B-NP
block	POS	I-NP
,	POS	O
which	POS	O
resolved	POS	O
after	POS	O
all	POS	O
therapy	POS	O
was	POS	O
stopped	POS	O
.	POS	O
DISCUSSION	POS	O
:	POS	O
An	POS	O
adverse	POS	O
interaction	POS	O
between	POS	O
clonidine	POS	O
and	POS	O
verapamil	POS	O
has	POS	O
not	POS	O
been	POS	O
reported	POS	O
previously	POS	O
.	POS	O
We	POS	O
describe	POS	O
two	POS	O
such	POS	O
cases	POS	O
and	POS	O
discuss	POS	O
the	POS	O
various	POS	O
mechanisms	POS	O
that	POS	O
might	POS	O
cause	POS	O
such	POS	O
an	POS	O
interaction	POS	O
.	POS	O
Clinicians	POS	O
should	POS	O
be	POS	O
acquainted	POS	O
with	POS	O
this	POS	O
possibly	POS	O
fatal	POS	O
interaction	POS	O
between	POS	O
two	POS	O
commonly	POS	O
used	POS	O
antihypertensive	POS	O
drugs	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
Caution	POS	O
is	POS	O
recommended	POS	O
in	POS	O
combining	POS	O
clonidine	POS	O
and	POS	O
verapamil	POS	O
therapy	POS	O
,	POS	O
even	POS	O
in	POS	O
patients	POS	O
who	POS	O
do	POS	O
not	POS	O
have	POS	O
sinus	POS	O
or	POS	O
AV	POS	B-NP
node	POS	I-NP
dysfunction	POS	I-NP
.	POS	O
The	POS	O
two	POS	O
drugs	POS	O
may	POS	O
act	POS	O
synergistically	POS	O
on	POS	O
both	POS	O
the	POS	O
AV	POS	O
node	POS	O
and	POS	O
the	POS	O
peripheral	POS	O
circulation	POS	O
.	POS	O
Pharmacological	POS	O
studies	POS	O
on	POS	O
a	POS	O
new	POS	O
dihydrothienopyridine	POS	O
calcium	POS	O
antagonist	POS	O
,	POS	O
S	POS	O
-	POS	O
312	POS	O
-	POS	O
d	POS	O
.	POS	O
5th	POS	O
communication	POS	O
:	POS	O
anticonvulsant	POS	O
effects	POS	O
in	POS	O
mice	POS	O
.	POS	O
S	POS	O
-	POS	O
312	POS	O
,	POS	O
S	POS	O
-	POS	O
312	POS	O
-	POS	O
d	POS	O
,	POS	O
but	POS	O
not	POS	O
S	POS	O
-	POS	O
312	POS	O
-	POS	O
l	POS	O
,	POS	O
L	POS	O
-	POS	O
type	POS	O
calcium	POS	O
channel	POS	O
antagonists	POS	O
,	POS	O
showed	POS	O
anticonvulsant	POS	O
effects	POS	O
on	POS	O
the	POS	O
audiogenic	POS	O
tonic	POS	O
convulsions	POS	B-NP
in	POS	O
DBA	POS	O
/	POS	O
2	POS	O
mice	POS	O
;	POS	O
and	POS	O
their	POS	O
ED50	POS	O
values	POS	O
were	POS	O
18	POS	O
.	POS	O
4	POS	O
(	POS	O
12	POS	O
.	POS	O
8	POS	O
-	POS	O
27	POS	O
.	POS	O
1	POS	O
)	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
p	POS	O
.	POS	O
o	POS	O
.	POS	O
and	POS	O
15	POS	O
.	POS	O
0	POS	O
(	POS	O
10	POS	O
.	POS	O
2	POS	O
-	POS	O
23	POS	O
.	POS	O
7	POS	O
)	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
p	POS	O
.	POS	O
o	POS	O
.	POS	O
,	POS	O
respectively	POS	O
,	POS	O
while	POS	O
that	POS	O
of	POS	O
flunarizine	POS	O
was	POS	O
34	POS	O
.	POS	O
0	POS	O
(	POS	O
26	POS	O
.	POS	O
0	POS	O
-	POS	O
44	POS	O
.	POS	O
8	POS	O
)	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
p	POS	O
.	POS	O
o	POS	O
.	POS	O
Although	POS	O
moderate	POS	O
anticonvulsant	POS	O
effects	POS	O
of	POS	O
S	POS	O
-	POS	O
312	POS	O
-	POS	O
d	POS	O
in	POS	O
higher	POS	O
doses	POS	O
were	POS	O
observed	POS	O
against	POS	O
the	POS	O
clonic	POS	O
convulsions	POS	B-NP
induced	POS	O
by	POS	O
pentylenetetrazole	POS	O
(	POS	O
85	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
or	POS	O
bemegride	POS	O
(	POS	O
40	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
s	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
,	POS	O
no	POS	O
effects	POS	O
were	POS	O
observed	POS	O
in	POS	O
convulsions	POS	B-NP
induced	POS	O
by	POS	O
N	POS	O
-	POS	O
methyl	POS	O
-	POS	O
D	POS	O
-	POS	O
aspartate	POS	O
,	POS	O
picrotoxin	POS	O
,	POS	O
or	POS	O
electroshock	POS	O
in	POS	O
Slc	POS	O
:	POS	O
ddY	POS	O
mice	POS	O
.	POS	O
S	POS	O
-	POS	O
312	POS	O
-	POS	O
d	POS	O
may	POS	O
be	POS	O
useful	POS	O
in	POS	O
the	POS	O
therapy	POS	O
of	POS	O
certain	POS	O
types	POS	O
of	POS	O
human	POS	O
epilepsy	POS	B-NP
.	POS	O
Transmural	POS	B-NP
myocardial	POS	I-NP
infarction	POS	I-NP
with	POS	O
sumatriptan	POS	O
.	POS	O
For	POS	O
sumatriptan	POS	O
,	POS	O
tightness	POS	B-NP
in	POS	O
the	POS	O
chest	POS	O
caused	POS	O
by	POS	O
an	POS	O
unknown	POS	O
mechanism	POS	O
has	POS	O
been	POS	O
reported	POS	O
in	POS	O
3	POS	O
-	POS	O
5	POS	O
%	POS	O
of	POS	O
users	POS	O
.	POS	O
We	POS	O
describe	POS	O
a	POS	O
47	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
an	POS	O
acute	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
after	POS	O
administration	POS	O
of	POS	O
sumatriptan	POS	O
6	POS	O
mg	POS	O
subcutaneously	POS	O
for	POS	O
cluster	POS	B-NP
headache	POS	I-NP
.	POS	O
The	POS	O
patient	POS	O
had	POS	O
no	POS	O
history	POS	O
of	POS	O
underlying	POS	O
ischaemic	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
or	POS	O
Prinzmetal	POS	B-NP
'	POS	I-NP
s	POS	I-NP
angina	POS	I-NP
.	POS	O
She	POS	O
recovered	POS	O
without	POS	O
complications	POS	O
.	POS	O
Flumazenil	POS	O
induces	POS	O
seizures	POS	B-NP
and	POS	O
death	POS	B-NP
in	POS	O
mixed	POS	O
cocaine	POS	O
-	POS	O
diazepam	POS	O
intoxications	POS	O
.	POS	O
STUDY	POS	O
HYPOTHESIS	POS	O
:	POS	O
Administration	POS	O
of	POS	O
the	POS	O
benzodiazepine	POS	O
antagonist	POS	O
flumazenil	POS	O
may	POS	O
unmask	POS	O
seizures	POS	B-NP
in	POS	O
mixed	POS	O
cocaine	POS	O
-	POS	O
benzodiazepine	POS	O
intoxication	POS	O
.	POS	O
DESIGN	POS	O
:	POS	O
Male	POS	O
Sprague	POS	O
-	POS	O
Dawley	POS	O
rats	POS	O
received	POS	O
100	POS	O
mg	POS	O
/	POS	O
kg	POS	O
cocaine	POS	O
IP	POS	O
alone	POS	O
,	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
diazepam	POS	O
alone	POS	O
,	POS	O
or	POS	O
a	POS	O
combination	POS	O
of	POS	O
diazepam	POS	O
and	POS	O
cocaine	POS	O
.	POS	O
Three	POS	O
minutes	POS	O
later	POS	O
,	POS	O
groups	POS	O
were	POS	O
challenged	POS	O
with	POS	O
vehicle	POS	O
or	POS	O
flumazenil	POS	O
5	POS	O
or	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
IP	POS	O
.	POS	O
Animal	POS	O
behavior	POS	O
,	POS	O
seizures	POS	B-NP
(	POS	O
time	POS	O
to	POS	O
and	POS	O
incidence	POS	O
)	POS	O
,	POS	O
death	POS	B-NP
(	POS	O
time	POS	O
to	POS	O
and	POS	O
incidence	POS	O
)	POS	O
,	POS	O
and	POS	O
cortical	POS	O
EEG	POS	O
tracings	POS	O
were	POS	O
recorded	POS	O
.	POS	O
INTERVENTIONS	POS	O
:	POS	O
Administration	POS	O
of	POS	O
flumazenil	POS	O
to	POS	O
animals	POS	O
after	POS	O
they	POS	O
had	POS	O
received	POS	O
a	POS	O
combination	POS	O
dose	POS	O
of	POS	O
cocaine	POS	O
and	POS	O
diazepam	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
In	POS	O
group	POS	O
1	POS	O
,	POS	O
animals	POS	O
received	POS	O
cocaine	POS	O
followed	POS	O
by	POS	O
vehicle	POS	O
.	POS	O
This	POS	O
resulted	POS	O
in	POS	O
100	POS	O
%	POS	O
developing	POS	O
seizures	POS	B-NP
and	POS	O
death	POS	B-NP
.	POS	O
Group	POS	O
2	POS	O
received	POS	O
diazepam	POS	O
alone	POS	O
followed	POS	O
by	POS	O
vehicle	POS	O
.	POS	O
Animals	POS	O
became	POS	O
somnolent	POS	O
and	POS	O
none	POS	O
died	POS	O
.	POS	O
Group	POS	O
3	POS	O
received	POS	O
diazepam	POS	O
followed	POS	O
by	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
flumazenil	POS	O
.	POS	O
Animals	POS	O
became	POS	O
somnolent	POS	O
after	POS	O
diazepam	POS	O
and	POS	O
then	POS	O
active	POS	O
after	POS	O
flumazenil	POS	O
administration	POS	O
.	POS	O
In	POS	O
group	POS	O
4	POS	O
,	POS	O
a	POS	O
combination	POS	O
of	POS	O
cocaine	POS	O
and	POS	O
diazepam	POS	O
was	POS	O
administered	POS	O
simultaneously	POS	O
.	POS	O
This	POS	O
resulted	POS	O
in	POS	O
no	POS	O
overt	POS	O
or	POS	O
EEG	POS	O
-	POS	O
detectable	POS	O
seizures	POS	B-NP
and	POS	O
a	POS	O
50	POS	O
%	POS	O
incidence	POS	O
of	POS	O
death	POS	B-NP
.	POS	O
Group	POS	O
5	POS	O
received	POS	O
a	POS	O
similar	POS	O
combination	POS	O
of	POS	O
cocaine	POS	O
and	POS	O
diazepam	POS	O
,	POS	O
followed	POS	O
later	POS	O
by	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
flumazenil	POS	O
.	POS	O
This	POS	O
resulted	POS	O
in	POS	O
an	POS	O
increased	POS	O
incidence	POS	O
of	POS	O
seizures	POS	B-NP
,	POS	O
90	POS	O
%	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
and	POS	O
death	POS	O
,	POS	O
100	POS	O
%	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
compared	POS	O
with	POS	O
group	POS	O
4	POS	O
.	POS	O
Group	POS	O
6	POS	O
received	POS	O
cocaine	POS	O
and	POS	O
diazepam	POS	O
followed	POS	O
by	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
flumazenil	POS	O
.	POS	O
This	POS	O
also	POS	O
resulted	POS	O
in	POS	O
an	POS	O
increased	POS	O
incidence	POS	O
of	POS	O
seizures	POS	B-NP
,	POS	O
90	POS	O
%	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
.	POS	O
01	POS	O
)	POS	O
,	POS	O
and	POS	O
death	POS	O
,	POS	O
90	POS	O
%	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
.	POS	O
05	POS	O
)	POS	O
,	POS	O
compared	POS	O
with	POS	O
group	POS	O
4	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
Flumazenil	POS	O
can	POS	O
unmask	POS	O
seizures	POS	B-NP
and	POS	O
increase	POS	O
the	POS	O
incidence	POS	O
of	POS	O
death	POS	B-NP
in	POS	O
a	POS	O
model	POS	O
of	POS	O
combined	POS	O
cocaine	POS	O
-	POS	O
diazepam	POS	O
intoxications	POS	O
.	POS	O
Mechanisms	POS	O
for	POS	O
protective	POS	O
effects	POS	O
of	POS	O
free	POS	O
radical	POS	O
scavengers	POS	O
on	POS	O
gentamicin	POS	O
-	POS	O
mediated	POS	O
nephropathy	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
Studies	POS	O
were	POS	O
performed	POS	O
to	POS	O
examine	POS	O
the	POS	O
mechanisms	POS	O
for	POS	O
the	POS	O
protective	POS	O
effects	POS	O
of	POS	O
free	POS	O
radical	POS	O
scavengers	POS	O
on	POS	O
gentamicin	POS	O
(	POS	O
GM	POS	O
)	POS	O
-	POS	O
mediated	POS	O
nephropathy	POS	B-NP
.	POS	O
Administration	POS	O
of	POS	O
GM	POS	O
at	POS	O
40	POS	O
mg	POS	O
/	POS	O
kg	POS	O
sc	POS	O
for	POS	O
13	POS	O
days	POS	O
to	POS	O
rats	POS	O
induced	POS	O
a	POS	O
significant	POS	O
reduction	POS	O
in	POS	O
renal	POS	O
blood	POS	O
flow	POS	O
(	POS	O
RBF	POS	O
)	POS	O
and	POS	O
inulin	POS	O
clearance	POS	O
(	POS	O
CIn	POS	O
)	POS	O
as	POS	O
well	POS	O
as	POS	O
marked	POS	O
tubular	POS	O
damage	POS	O
.	POS	O
A	POS	O
significant	POS	O
reduction	POS	O
in	POS	O
urinary	POS	O
guanosine	POS	O
3	POS	O
'	POS	O
,	POS	O
5	POS	O
'	POS	O
-	POS	O
cyclic	POS	O
monophosphate	POS	O
(	POS	O
cGMP	POS	O
)	POS	O
excretion	POS	O
and	POS	O
a	POS	O
significant	POS	O
increase	POS	O
in	POS	O
renal	POS	O
cortical	POS	O
renin	POS	O
and	POS	O
endothelin	POS	O
-	POS	O
1	POS	O
contents	POS	O
were	POS	O
also	POS	O
observed	POS	O
in	POS	O
GM	POS	O
-	POS	O
mediated	POS	O
nephropathy	POS	B-NP
.	POS	O
Superoxide	POS	O
dismutase	POS	O
(	POS	O
SOD	POS	O
)	POS	O
or	POS	O
dimethylthiourea	POS	O
(	POS	O
DMTU	POS	O
)	POS	O
significantly	POS	O
lessened	POS	O
the	POS	O
GM	POS	O
-	POS	O
induced	POS	O
decrement	POS	O
in	POS	O
CIn	POS	O
.	POS	O
The	POS	O
SOD	POS	O
-	POS	O
induced	POS	O
increase	POS	O
in	POS	O
glomerular	POS	O
filtration	POS	O
rate	POS	O
was	POS	O
associated	POS	O
with	POS	O
a	POS	O
marked	POS	O
improvement	POS	O
in	POS	O
RBF	POS	O
,	POS	O
an	POS	O
increase	POS	O
in	POS	O
urinary	POS	O
cGMP	POS	O
excretion	POS	O
,	POS	O
and	POS	O
a	POS	O
decrease	POS	O
in	POS	O
renal	POS	O
renin	POS	O
and	POS	O
endothelin	POS	O
-	POS	O
1	POS	O
content	POS	O
.	POS	O
SOD	POS	O
did	POS	O
not	POS	O
attenuate	POS	O
the	POS	O
tubular	POS	O
damage	POS	O
.	POS	O
In	POS	O
contrast	POS	O
,	POS	O
DMTU	POS	O
significantly	POS	O
reduced	POS	O
the	POS	O
tubular	POS	O
damage	POS	O
and	POS	O
lipid	POS	O
peroxidation	POS	O
,	POS	O
but	POS	O
it	POS	O
did	POS	O
not	POS	O
affect	POS	O
renal	POS	O
hemodynamics	POS	O
and	POS	O
vasoactive	POS	O
substances	POS	O
.	POS	O
Neither	POS	O
SOD	POS	O
nor	POS	O
DMTU	POS	O
affected	POS	O
the	POS	O
renal	POS	O
cortical	POS	O
GM	POS	O
content	POS	O
in	POS	O
GM	POS	O
-	POS	O
treated	POS	O
rats	POS	O
.	POS	O
These	POS	O
results	POS	O
suggest	POS	O
that	POS	O
1	POS	O
)	POS	O
both	POS	O
SOD	POS	O
and	POS	O
DMTU	POS	O
have	POS	O
protective	POS	O
effects	POS	O
on	POS	O
GM	POS	O
-	POS	O
mediated	POS	O
nephropathy	POS	B-NP
,	POS	O
2	POS	O
)	POS	O
the	POS	O
mechanisms	POS	O
for	POS	O
the	POS	O
protective	POS	O
effects	POS	O
differ	POS	O
for	POS	O
SOD	POS	O
and	POS	O
DMTU	POS	O
,	POS	O
and	POS	O
3	POS	O
)	POS	O
superoxide	POS	O
anions	POS	O
play	POS	O
a	POS	O
critical	POS	O
role	POS	O
in	POS	O
GM	POS	O
-	POS	O
induced	POS	O
renal	POS	O
vasoconstriction	POS	O
.	POS	O
Cephalothin	POS	O
-	POS	O
induced	POS	O
immune	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
.	POS	O
A	POS	O
patient	POS	O
with	POS	O
renal	POS	B-NP
disease	POS	I-NP
developed	POS	O
Coombs	POS	B-NP
-	POS	O
positive	POS	O
hemolytic	POS	B-NP
anemia	POS	I-NP
while	POS	O
receiving	POS	O
cephalothin	POS	O
therapy	POS	O
.	POS	O
An	POS	O
anti	POS	O
-	POS	O
cephalothin	POS	O
IgG	POS	O
antibody	POS	O
was	POS	O
detected	POS	O
in	POS	O
the	POS	O
patient	POS	O
'	POS	O
s	POS	O
serum	POS	O
and	POS	O
in	POS	O
the	POS	O
eluates	POS	O
from	POS	O
her	POS	O
erythrocytes	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
nonimmunologic	POS	O
binding	POS	O
of	POS	O
normal	POS	O
and	POS	O
patient	POS	O
'	POS	O
s	POS	O
serum	POS	O
proteins	POS	O
to	POS	O
her	POS	O
own	POS	O
and	POS	O
cephalothin	POS	O
-	POS	O
coated	POS	O
normal	POS	O
red	POS	O
cells	POS	O
was	POS	O
demonstrated	POS	O
.	POS	O
Skin	POS	O
tests	POS	O
and	POS	O
in	POS	O
vitro	POS	O
lymphocyte	POS	O
stimulation	POS	O
revealed	POS	O
that	POS	O
the	POS	O
patient	POS	O
was	POS	O
sensitized	POS	O
to	POS	O
cephalothin	POS	O
and	POS	O
also	POS	O
to	POS	O
ampicillin	POS	O
.	POS	O
Careful	POS	O
investigation	POS	O
of	POS	O
drug	POS	O
-	POS	O
induced	POS	O
hemolytic	POS	B-NP
anemias	POS	I-NP
reveals	POS	O
the	POS	O
complexity	POS	O
of	POS	O
the	POS	O
immune	POS	O
mechanisms	POS	O
involved	POS	O
.	POS	O
Assessment	POS	O
of	POS	O
cardiomyocyte	POS	O
DNA	POS	O
synthesis	POS	O
during	POS	O
hypertrophy	POS	B-NP
in	POS	O
adult	POS	O
mice	POS	O
.	POS	O
The	POS	O
ability	POS	O
of	POS	O
cardiomyocytes	POS	O
to	POS	O
synthesize	POS	O
DNA	POS	O
in	POS	O
response	POS	O
to	POS	O
experimentally	POS	O
induced	POS	O
cardiac	POS	B-NP
hypertrophy	POS	I-NP
was	POS	O
assessed	POS	O
in	POS	O
adult	POS	O
mice	POS	O
.	POS	O
Isoproterenol	POS	O
delivered	POS	O
by	POS	O
osmotic	POS	O
minipump	POS	O
implantation	POS	O
in	POS	O
adult	POS	O
C3Heb	POS	O
/	POS	O
FeJ	POS	O
mice	POS	O
resulted	POS	O
in	POS	O
a	POS	O
46	POS	O
%	POS	O
increase	POS	O
in	POS	O
heart	POS	O
weight	POS	O
and	POS	O
a	POS	O
19	POS	O
.	POS	O
3	POS	O
%	POS	O
increase	POS	O
in	POS	O
cardiomyocyte	POS	O
area	POS	O
.	POS	O
No	POS	O
DNA	POS	O
synthesis	POS	O
,	POS	O
as	POS	O
assessed	POS	O
by	POS	O
autoradiographic	POS	O
analysis	POS	O
of	POS	O
isolated	POS	O
cardiomyocytes	POS	O
,	POS	O
was	POS	O
observed	POS	O
in	POS	O
control	POS	O
or	POS	O
hypertrophic	POS	O
hearts	POS	O
.	POS	O
A	POS	O
survey	POS	O
of	POS	O
15	POS	O
independent	POS	O
inbred	POS	O
strains	POS	O
of	POS	O
mice	POS	O
revealed	POS	O
that	POS	O
ventricular	POS	O
cardiomyocyte	POS	O
nuclear	POS	O
number	POS	O
ranged	POS	O
from	POS	O
3	POS	O
to	POS	O
13	POS	O
%	POS	O
mononucleate	POS	O
,	POS	O
suggesting	POS	O
that	POS	O
cardiomyocyte	POS	O
terminal	POS	O
differentiation	POS	O
is	POS	O
influenced	POS	O
directly	POS	O
or	POS	O
indirectly	POS	O
by	POS	O
genetic	POS	O
background	POS	O
.	POS	O
To	POS	O
determine	POS	O
whether	POS	O
the	POS	O
capacity	POS	O
for	POS	O
reactive	POS	O
DNA	POS	O
synthesis	POS	O
was	POS	O
also	POS	O
subject	POS	O
to	POS	O
genetic	POS	O
regulation	POS	O
,	POS	O
cardiac	POS	B-NP
hypertrophy	POS	I-NP
was	POS	O
induced	POS	O
in	POS	O
the	POS	O
strains	POS	O
of	POS	O
mice	POS	O
comprising	POS	O
the	POS	O
extremes	POS	O
of	POS	O
the	POS	O
nuclear	POS	O
number	POS	O
survey	POS	O
.	POS	O
These	POS	O
data	POS	O
indicate	POS	O
that	POS	O
adult	POS	O
mouse	POS	O
atrial	POS	O
and	POS	O
ventricular	POS	O
cardiomyocytes	POS	O
do	POS	O
not	POS	O
synthesize	POS	O
DNA	POS	O
in	POS	O
response	POS	O
to	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
hypertrophy	POS	I-NP
.	POS	O
Central	POS	O
cardiovascular	POS	O
effects	POS	O
of	POS	O
AVP	POS	O
and	POS	O
ANP	POS	O
in	POS	O
normotensive	POS	O
and	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
rats	POS	O
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
the	POS	O
present	POS	O
study	POS	O
was	POS	O
to	POS	O
compare	POS	O
influence	POS	O
of	POS	O
central	POS	O
arginine	POS	O
vasopressin	POS	O
(	POS	O
AVP	POS	O
)	POS	O
and	POS	O
of	POS	O
atrial	POS	O
natriuretic	POS	O
peptide	POS	O
(	POS	O
ANP	POS	O
)	POS	O
on	POS	O
control	POS	O
of	POS	O
arterial	POS	O
blood	POS	O
pressure	POS	O
(	POS	O
MAP	POS	O
)	POS	O
and	POS	O
heart	POS	O
rate	POS	O
(	POS	O
HR	POS	O
)	POS	O
in	POS	O
normotensive	POS	O
(	POS	O
WKY	POS	O
)	POS	O
and	POS	O
spontaneously	POS	O
hypertensive	POS	B-NP
(	POS	O
SHR	POS	O
)	POS	O
rats	POS	O
.	POS	O
Three	POS	O
series	POS	O
of	POS	O
experiments	POS	O
were	POS	O
performed	POS	O
on	POS	O
30	POS	O
WKY	POS	O
and	POS	O
30	POS	O
SHR	POS	O
,	POS	O
chronically	POS	O
instrumented	POS	O
with	POS	O
guide	POS	O
tubes	POS	O
in	POS	O
the	POS	O
lateral	POS	O
ventricle	POS	O
(	POS	O
LV	POS	O
)	POS	O
and	POS	O
arterial	POS	O
and	POS	O
venous	POS	O
catheters	POS	O
.	POS	O
MAP	POS	O
and	POS	O
HR	POS	O
were	POS	O
monitored	POS	O
before	POS	O
and	POS	O
after	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
injections	POS	O
of	POS	O
either	POS	O
vehicle	POS	O
or	POS	O
1	POS	O
,	POS	O
10	POS	O
and	POS	O
50	POS	O
ng	POS	O
of	POS	O
AVP	POS	O
and	POS	O
25	POS	O
,	POS	O
125	POS	O
and	POS	O
500	POS	O
ng	POS	O
of	POS	O
ANP	POS	O
.	POS	O
Sensitivity	POS	O
of	POS	O
cardiac	POS	O
component	POS	O
of	POS	O
baroreflex	POS	O
(	POS	O
CCB	POS	O
)	POS	O
,	POS	O
expressed	POS	O
as	POS	O
a	POS	O
slope	POS	O
of	POS	O
the	POS	O
regression	POS	O
line	POS	O
was	POS	O
determined	POS	O
from	POS	O
relationships	POS	O
between	POS	O
systolic	POS	O
arterial	POS	O
pressure	POS	O
(	POS	O
SAP	POS	O
)	POS	O
and	POS	O
HR	POS	O
period	POS	O
(	POS	O
HRp	POS	O
)	POS	O
during	POS	O
phenylephrine	POS	O
(	POS	O
Phe	POS	O
)	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
and	POS	O
sodium	POS	O
nitroprusside	POS	O
(	POS	O
SN	POS	O
)	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
.	POS	O
CCB	POS	O
was	POS	O
measured	POS	O
before	POS	O
and	POS	O
after	POS	O
administration	POS	O
of	POS	O
either	POS	O
vehicle	POS	O
,	POS	O
AVP	POS	O
,	POS	O
ANP	POS	O
,	POS	O
or	POS	O
both	POS	O
peptides	POS	O
together	POS	O
.	POS	O
Increases	POS	O
of	POS	O
MAP	POS	O
occurred	POS	O
after	POS	O
LV	POS	O
administration	POS	O
of	POS	O
1	POS	O
,	POS	O
10	POS	O
and	POS	O
50	POS	O
ng	POS	O
of	POS	O
AVP	POS	O
in	POS	O
WKY	POS	O
and	POS	O
of	POS	O
10	POS	O
and	POS	O
50	POS	O
ng	POS	O
in	POS	O
SHR	POS	O
.	POS	O
ANP	POS	O
did	POS	O
not	POS	O
cause	POS	O
significant	POS	O
changes	POS	O
in	POS	O
MAP	POS	O
in	POS	O
both	POS	O
strains	POS	O
as	POS	O
compared	POS	O
to	POS	O
vehicle	POS	O
,	POS	O
but	POS	O
it	POS	O
abolished	POS	O
AVP	POS	O
-	POS	O
induced	POS	O
MAP	POS	O
increase	POS	O
in	POS	O
WKY	POS	O
and	POS	O
SHR	POS	O
.	POS	O
CCB	POS	O
was	POS	O
reduced	POS	O
in	POS	O
WKY	POS	O
and	POS	O
SHR	POS	O
after	POS	O
LV	POS	O
administration	POS	O
of	POS	O
AVP	POS	O
during	POS	O
SN	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
.	POS	O
In	POS	O
SHR	POS	O
but	POS	O
not	POS	O
in	POS	O
WKY	POS	O
administration	POS	O
of	POS	O
ANP	POS	O
,	POS	O
AVP	POS	O
and	POS	O
ANP	POS	O
+	POS	O
AVP	POS	O
decreased	POS	O
CCB	POS	O
during	POS	O
Phe	POS	O
-	POS	O
induced	POS	O
MAP	POS	O
elevation	POS	O
.	POS	O
The	POS	O
results	POS	O
indicate	POS	O
that	POS	O
centrally	POS	O
applied	POS	O
AVP	POS	O
and	POS	O
ANP	POS	O
exert	POS	O
differential	POS	O
effects	POS	O
on	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
baroreflex	POS	O
control	POS	O
of	POS	O
heart	POS	O
rate	POS	O
in	POS	O
WKY	POS	O
and	POS	O
SHR	POS	O
and	POS	O
suggest	POS	O
interaction	POS	O
of	POS	O
these	POS	O
two	POS	O
peptides	POS	O
in	POS	O
blood	POS	O
pressure	POS	O
regulation	POS	O
at	POS	O
the	POS	O
level	POS	O
of	POS	O
central	POS	O
nervous	POS	O
system	POS	O
.	POS	O
Cutaneous	POS	O
exposure	POS	O
to	POS	O
warfarin	POS	O
-	POS	O
like	POS	O
anticoagulant	POS	O
causing	POS	O
an	POS	O
intracerebral	POS	B-NP
hemorrhage	POS	I-NP
:	POS	O
a	POS	O
case	POS	O
report	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
intercerebral	POS	O
hematoma	POS	B-NP
due	POS	O
to	POS	O
warfarin	POS	O
-	POS	O
induced	POS	O
coagulopathy	POS	B-NP
is	POS	O
presented	POS	O
.	POS	O
The	POS	O
39	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
had	POS	O
spread	POS	O
a	POS	O
warfarin	POS	O
-	POS	O
type	POS	O
rat	POS	O
poison	POS	O
around	POS	O
her	POS	O
house	POS	O
weekly	POS	O
using	POS	O
her	POS	O
bare	POS	O
hands	POS	O
,	POS	O
with	POS	O
no	POS	O
washing	POS	O
post	POS	O
application	POS	O
.	POS	O
Percutaneous	POS	O
absorption	POS	O
of	POS	O
warfarin	POS	O
causing	POS	O
coagulopathy	POS	B-NP
,	POS	O
reported	POS	O
three	POS	O
times	POS	O
in	POS	O
the	POS	O
past	POS	O
,	POS	O
is	POS	O
a	POS	O
significant	POS	O
risk	POS	O
if	POS	O
protective	POS	O
measures	POS	O
,	POS	O
such	POS	O
as	POS	O
gloves	POS	O
,	POS	O
are	POS	O
not	POS	O
used	POS	O
.	POS	O
An	POS	O
adverse	POS	O
drug	POS	O
interaction	POS	O
with	POS	O
piroxicam	POS	O
,	POS	O
which	POS	O
she	POS	O
took	POS	O
occasionally	POS	O
,	POS	O
may	POS	O
have	POS	O
exacerbated	POS	O
the	POS	O
coagulopathy	POS	B-NP
.	POS	O
Pediatric	POS	O
heart	POS	O
transplantation	POS	O
without	POS	O
chronic	POS	O
maintenance	POS	O
steroids	POS	O
.	POS	O
From	POS	O
1986	POS	O
to	POS	O
February	POS	O
1993	POS	O
,	POS	O
40	POS	O
children	POS	O
aged	POS	O
2	POS	O
months	POS	O
to	POS	O
18	POS	O
years	POS	O
(	POS	O
average	POS	O
age	POS	O
10	POS	O
.	POS	O
4	POS	O
+	POS	O
/	POS	O
-	POS	O
5	POS	O
.	POS	O
8	POS	O
years	POS	O
)	POS	O
underwent	POS	O
heart	POS	O
transplantation	POS	O
.	POS	O
Indications	POS	O
for	POS	O
transplantation	POS	O
were	POS	O
idiopathic	POS	B-NP
cardiomyopathy	POS	I-NP
(	POS	O
52	POS	O
%	POS	O
)	POS	O
,	POS	O
congenital	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
(	POS	O
35	POS	O
%	POS	O
)	POS	O
with	POS	O
and	POS	O
without	POS	O
prior	POS	O
repair	POS	O
(	POS	O
71	POS	O
%	POS	O
and	POS	O
29	POS	O
%	POS	O
,	POS	O
respectively	POS	O
)	POS	O
,	POS	O
hypertrophic	POS	B-NP
cardiomyopathy	POS	I-NP
(	POS	O
5	POS	O
%	POS	O
)	POS	O
,	POS	O
valvular	POS	B-NP
heart	POS	I-NP
disease	POS	I-NP
(	POS	O
3	POS	O
%	POS	O
)	POS	O
,	POS	O
and	POS	O
doxorubicin	POS	O
cardiomyopathy	POS	B-NP
(	POS	O
5	POS	O
%	POS	O
)	POS	O
.	POS	O
Patients	POS	O
were	POS	O
managed	POS	O
with	POS	O
cyclosporine	POS	O
and	POS	O
azathioprine	POS	O
.	POS	O
No	POS	O
prophylaxis	POS	O
with	POS	O
antilymphocyte	POS	O
globulin	POS	O
was	POS	O
used	POS	O
.	POS	O
Steroids	POS	O
were	POS	O
given	POS	O
to	POS	O
39	POS	O
%	POS	O
of	POS	O
patients	POS	O
for	POS	O
refractory	POS	O
rejection	POS	O
,	POS	O
but	POS	O
weaning	POS	O
was	POS	O
always	POS	O
attempted	POS	O
and	POS	O
generally	POS	O
successful	POS	O
(	POS	O
64	POS	O
%	POS	O
)	POS	O
.	POS	O
Five	POS	O
patients	POS	O
(	POS	O
14	POS	O
%	POS	O
)	POS	O
received	POS	O
maintenance	POS	O
steroids	POS	O
.	POS	O
Four	POS	O
patients	POS	O
died	POS	O
in	POS	O
the	POS	O
perioperative	POS	O
period	POS	O
and	POS	O
one	POS	O
died	POS	O
4	POS	O
months	POS	O
later	POS	O
.	POS	O
There	POS	O
have	POS	O
been	POS	O
no	POS	O
deaths	POS	O
related	POS	O
to	POS	O
rejection	POS	O
or	POS	O
infection	POS	O
.	POS	O
Average	POS	O
follow	POS	O
-	POS	O
up	POS	O
was	POS	O
36	POS	O
+	POS	O
/	POS	O
-	POS	O
19	POS	O
months	POS	O
(	POS	O
range	POS	O
1	POS	O
to	POS	O
65	POS	O
months	POS	O
)	POS	O
.	POS	O
Cumulative	POS	O
survival	POS	O
is	POS	O
88	POS	O
%	POS	O
at	POS	O
5	POS	O
years	POS	O
.	POS	O
In	POS	O
patients	POS	O
less	POS	O
than	POS	O
7	POS	O
years	POS	O
of	POS	O
age	POS	O
,	POS	O
rejection	POS	O
was	POS	O
monitored	POS	O
noninvasively	POS	O
.	POS	O
In	POS	O
the	POS	O
first	POS	O
postoperative	POS	O
month	POS	O
,	POS	O
89	POS	O
%	POS	O
of	POS	O
patients	POS	O
were	POS	O
treated	POS	O
for	POS	O
rejection	POS	O
.	POS	O
Freedom	POS	O
from	POS	O
serious	POS	O
infections	POS	B-NP
was	POS	O
83	POS	O
%	POS	O
at	POS	O
1	POS	O
month	POS	O
and	POS	O
65	POS	O
%	POS	O
at	POS	O
1	POS	O
year	POS	O
.	POS	O
Cytomegalovirus	POS	B-NP
infections	POS	I-NP
were	POS	O
treated	POS	O
successfully	POS	O
with	POS	O
ganciclovir	POS	O
in	POS	O
11	POS	O
patients	POS	O
.	POS	O
No	POS	O
impairment	POS	O
of	POS	O
growth	POS	O
was	POS	O
observed	POS	O
in	POS	O
children	POS	O
who	POS	O
underwent	POS	O
transplantation	POS	O
compared	POS	O
with	POS	O
a	POS	O
control	POS	O
population	POS	O
.	POS	O
Twenty	POS	O
-	POS	O
one	POS	O
patients	POS	O
(	POS	O
60	POS	O
%	POS	O
)	POS	O
have	POS	O
undergone	POS	O
annual	POS	O
catheterizations	POS	O
and	POS	O
no	POS	O
sign	POS	O
of	POS	O
graft	POS	O
atherosclerosis	POS	B-NP
has	POS	O
been	POS	O
observed	POS	O
.	POS	O
Seizures	POS	B-NP
occurred	POS	O
in	POS	O
five	POS	O
patients	POS	O
(	POS	O
14	POS	O
%	POS	O
)	POS	O
and	POS	O
hypertension	POS	B-NP
was	POS	O
treated	POS	O
in	POS	O
10	POS	O
patients	POS	O
(	POS	O
28	POS	O
%	POS	O
)	POS	O
.	POS	O
No	POS	O
patient	POS	O
was	POS	O
disabled	POS	O
and	POS	O
no	POS	O
lymphoproliferative	POS	B-NP
disorder	POS	I-NP
was	POS	O
observed	POS	O
.	POS	O
(	POS	O
ABSTRACT	POS	O
TRUNCATED	POS	O
AT	POS	O
250	POS	O
WORDS	POS	O
)	POS	O
Delirium	POS	B-NP
during	POS	O
fluoxetine	POS	O
treatment	POS	O
.	POS	O
A	POS	O
case	POS	O
report	POS	O
.	POS	O
The	POS	O
correlation	POS	O
between	POS	O
high	POS	O
serum	POS	O
tricyclic	POS	O
antidepressant	POS	O
concentrations	POS	O
and	POS	O
central	POS	O
nervous	POS	O
system	POS	O
side	POS	O
effects	POS	O
has	POS	O
been	POS	O
well	POS	O
established	POS	O
.	POS	O
Only	POS	O
a	POS	O
few	POS	O
reports	POS	O
exist	POS	O
,	POS	O
however	POS	O
,	POS	O
on	POS	O
the	POS	O
relationship	POS	O
between	POS	O
the	POS	O
serum	POS	O
concentrations	POS	O
of	POS	O
selective	POS	O
serotonin	POS	O
reuptake	POS	O
inhibitors	POS	O
(	POS	O
SSRIs	POS	O
)	POS	O
and	POS	O
their	POS	O
toxic	POS	O
effects	POS	O
.	POS	O
In	POS	O
some	POS	O
cases	POS	O
,	POS	O
a	POS	O
high	POS	O
serum	POS	O
concentration	POS	O
of	POS	O
citalopram	POS	O
(	POS	O
>	POS	O
600	POS	O
nmol	POS	O
/	POS	O
L	POS	O
)	POS	O
in	POS	O
elderly	POS	O
patients	POS	O
has	POS	O
been	POS	O
associated	POS	O
with	POS	O
increased	POS	O
somnolence	POS	B-NP
and	POS	O
movement	POS	B-NP
difficulties	POS	I-NP
.	POS	O
Widespread	POS	B-NP
cognitive	POS	I-NP
disorders	POS	I-NP
,	POS	O
such	POS	O
as	POS	O
delirium	POS	B-NP
,	POS	O
have	POS	O
not	POS	O
been	POS	O
previously	POS	O
linked	POS	O
with	POS	O
high	POS	O
blood	POS	O
levels	POS	O
of	POS	O
SSRIs	POS	O
.	POS	O
In	POS	O
this	POS	O
report	POS	O
,	POS	O
we	POS	O
describe	POS	O
a	POS	O
patient	POS	O
with	POS	O
acute	POS	O
hyperkinetic	POS	B-NP
delirium	POS	I-NP
connected	POS	O
with	POS	O
a	POS	O
high	POS	O
serum	POS	O
total	POS	O
fluoxetine	POS	O
(	POS	O
fluoxetine	POS	O
plus	POS	O
desmethylfluoxetine	POS	O
)	POS	O
concentration	POS	O
.	POS	O
Pulmonary	POS	B-NP
edema	POS	I-NP
and	POS	O
shock	POS	B-NP
after	POS	O
high	POS	O
-	POS	O
dose	POS	O
aracytine	POS	O
-	POS	O
C	POS	O
for	POS	O
lymphoma	POS	B-NP
;	POS	O
possible	POS	O
role	POS	O
of	POS	O
TNF	POS	O
-	POS	O
alpha	POS	O
and	POS	O
PAF	POS	O
.	POS	O
Four	POS	O
out	POS	O
of	POS	O
23	POS	O
consecutive	POS	O
patients	POS	O
treated	POS	O
with	POS	O
high	POS	O
-	POS	O
dose	POS	O
Ara	POS	O
-	POS	O
C	POS	O
for	POS	O
lymphomas	POS	B-NP
in	POS	O
our	POS	O
institution	POS	O
developed	POS	O
a	POS	O
strikingly	POS	O
similar	POS	O
syndrome	POS	O
during	POS	O
the	POS	O
perfusion	POS	O
.	POS	O
It	POS	O
was	POS	O
characterized	POS	O
by	POS	O
the	POS	O
onset	POS	O
of	POS	O
fever	POS	B-NP
,	POS	O
diarrhea	POS	B-NP
,	POS	O
shock	POS	B-NP
,	POS	O
pulmonary	POS	B-NP
edema	POS	I-NP
,	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
,	POS	O
metabolic	POS	B-NP
acidosis	POS	I-NP
,	POS	O
weight	POS	B-NP
gain	POS	I-NP
and	POS	O
leukocytosis	POS	B-NP
.	POS	O
Thorough	POS	O
bacteriological	POS	O
screening	POS	O
failed	POS	O
to	POS	O
provide	POS	O
evidence	POS	O
of	POS	O
infection	POS	O
.	POS	O
Sequential	POS	O
biological	POS	O
assays	POS	O
of	POS	O
IL	POS	O
-	POS	O
1	POS	O
,	POS	O
IL	POS	O
-	POS	O
2	POS	O
,	POS	O
TNF	POS	O
and	POS	O
PAF	POS	O
were	POS	O
performed	POS	O
during	POS	O
Ara	POS	O
-	POS	O
C	POS	O
infusion	POS	O
to	POS	O
ten	POS	O
patients	POS	O
,	POS	O
including	POS	O
the	POS	O
four	POS	O
who	POS	O
developed	POS	O
the	POS	O
syndrome	POS	O
.	POS	O
TNF	POS	O
and	POS	O
PAF	POS	O
activity	POS	O
was	POS	O
found	POS	O
in	POS	O
the	POS	O
serum	POS	O
of	POS	O
respectively	POS	O
two	POS	O
and	POS	O
four	POS	O
of	POS	O
the	POS	O
cases	POS	O
,	POS	O
but	POS	O
not	POS	O
in	POS	O
the	POS	O
six	POS	O
controls	POS	O
.	POS	O
As	POS	O
TNF	POS	O
and	POS	O
PAF	POS	O
are	POS	O
thought	POS	O
to	POS	O
be	POS	O
involved	POS	O
in	POS	O
the	POS	O
development	POS	O
of	POS	O
septic	POS	B-NP
shock	POS	I-NP
and	POS	O
adult	POS	O
respiratory	POS	B-NP
distress	POS	I-NP
syndrome	POS	I-NP
,	POS	O
we	POS	O
hypothesize	POS	O
that	POS	O
high	POS	O
-	POS	O
dose	POS	O
Ara	POS	O
-	POS	O
C	POS	O
may	POS	O
be	POS	O
associated	POS	O
with	POS	O
cytokine	POS	O
release	POS	O
.	POS	O
Protective	POS	O
effect	POS	O
of	POS	O
clentiazem	POS	O
against	POS	O
epinephrine	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
injury	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
We	POS	O
investigated	POS	O
the	POS	O
effects	POS	O
of	POS	O
clentiazem	POS	O
,	POS	O
a	POS	O
1	POS	O
,	POS	O
5	POS	O
-	POS	O
benzothiazepine	POS	O
calcium	POS	O
antagonist	POS	O
,	POS	O
on	POS	O
epinephrine	POS	O
-	POS	O
induced	POS	O
cardiomyopathy	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
With	POS	O
2	POS	O
-	POS	O
week	POS	O
chronic	POS	O
epinephrine	POS	O
infusion	POS	O
,	POS	O
16	POS	O
of	POS	O
30	POS	O
rats	POS	O
died	POS	O
within	POS	O
4	POS	O
days	POS	O
,	POS	O
and	POS	O
severe	POS	O
ischemic	POS	B-NP
lesions	POS	I-NP
and	POS	O
fibrosis	POS	B-NP
of	POS	O
the	POS	O
left	POS	O
ventricles	POS	O
were	POS	O
observed	POS	O
.	POS	O
In	POS	O
epinephrine	POS	O
-	POS	O
treated	POS	O
rats	POS	O
,	POS	O
left	POS	O
atrial	POS	O
and	POS	O
left	POS	O
ventricular	POS	O
papillary	POS	O
muscle	POS	O
contractile	POS	O
responses	POS	O
to	POS	O
isoproterenol	POS	O
were	POS	O
reduced	POS	O
,	POS	O
but	POS	O
responses	POS	O
to	POS	O
calcium	POS	O
were	POS	O
normal	POS	O
or	POS	O
enhanced	POS	O
compared	POS	O
to	POS	O
controls	POS	O
.	POS	O
Left	POS	O
ventricular	POS	O
alpha	POS	O
and	POS	O
beta	POS	O
adrenoceptor	POS	O
densities	POS	O
were	POS	O
also	POS	O
reduced	POS	O
compared	POS	O
to	POS	O
controls	POS	O
.	POS	O
Treatment	POS	O
with	POS	O
clentiazem	POS	O
prevented	POS	O
epinephrine	POS	O
-	POS	O
induced	POS	O
death	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
05	POS	O
)	POS	O
,	POS	O
and	POS	O
attenuated	POS	O
the	POS	O
ventricular	POS	B-NP
ischemic	POS	I-NP
lesions	POS	I-NP
and	POS	O
fibrosis	POS	B-NP
,	POS	O
in	POS	O
a	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
manner	POS	O
.	POS	O
Left	POS	O
atrial	POS	O
and	POS	O
left	POS	O
ventricular	POS	O
papillary	POS	O
muscle	POS	O
contractile	POS	O
responses	POS	O
to	POS	O
isoproterenol	POS	O
were	POS	O
reduced	POS	O
compared	POS	O
to	POS	O
controls	POS	O
in	POS	O
groups	POS	O
treated	POS	O
with	POS	O
clentiazem	POS	O
alone	POS	O
,	POS	O
but	POS	O
combined	POS	O
with	POS	O
epinephrine	POS	O
,	POS	O
clentiazem	POS	O
restored	POS	O
left	POS	O
atrial	POS	O
responses	POS	O
and	POS	O
enhanced	POS	O
left	POS	O
ventricular	POS	O
papillary	POS	O
responses	POS	O
to	POS	O
isoproterenol	POS	O
.	POS	O
On	POS	O
the	POS	O
other	POS	O
hand	POS	O
clentiazem	POS	O
did	POS	O
not	POS	O
prevent	POS	O
epinephrine	POS	O
-	POS	O
induced	POS	O
down	POS	O
-	POS	O
regulation	POS	O
of	POS	O
alpha	POS	O
and	POS	O
beta	POS	O
adrenoceptors	POS	O
.	POS	O
Interestingly	POS	O
,	POS	O
clentiazem	POS	O
,	POS	O
infused	POS	O
alone	POS	O
,	POS	O
resulted	POS	O
in	POS	O
decreased	POS	O
adrenergic	POS	O
receptor	POS	O
densities	POS	O
in	POS	O
the	POS	O
left	POS	O
ventricle	POS	O
.	POS	O
Clentiazem	POS	O
also	POS	O
did	POS	O
not	POS	O
prevent	POS	O
the	POS	O
enhanced	POS	O
responses	POS	O
to	POS	O
calcium	POS	O
seen	POS	O
in	POS	O
the	POS	O
epinephrine	POS	O
-	POS	O
treated	POS	O
animals	POS	O
,	POS	O
although	POS	O
the	POS	O
high	POS	O
dose	POS	O
of	POS	O
clentiazem	POS	O
partially	POS	O
attenuated	POS	O
the	POS	O
maximal	POS	O
response	POS	O
to	POS	O
calcium	POS	O
compared	POS	O
to	POS	O
epinephrine	POS	O
-	POS	O
treated	POS	O
animals	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
clentiazem	POS	O
attenuated	POS	O
epinephrine	POS	O
-	POS	O
induced	POS	O
cardiac	POS	B-NP
injury	POS	I-NP
,	POS	O
possibly	POS	O
through	POS	O
its	POS	O
effect	POS	O
on	POS	O
the	POS	O
adrenergic	POS	O
pathway	POS	O
.	POS	O
Kaliuretic	POS	O
effect	POS	O
of	POS	O
L	POS	O
-	POS	O
dopa	POS	O
treatment	POS	O
in	POS	O
parkinsonian	POS	B-NP
patients	POS	O
.	POS	O
Hypokalemia	POS	B-NP
,	POS	O
sometimes	POS	O
severe	POS	O
,	POS	O
was	POS	O
observed	POS	O
in	POS	O
some	POS	O
L	POS	O
-	POS	O
dopa	POS	O
-	POS	O
treated	POS	O
parkinsonian	POS	B-NP
patients	POS	O
.	POS	O
The	POS	O
influence	POS	O
of	POS	O
L	POS	O
-	POS	O
dopa	POS	O
on	POS	O
the	POS	O
renal	POS	O
excretion	POS	O
of	POS	O
potassium	POS	O
was	POS	O
studied	POS	O
in	POS	O
3	POS	O
patients	POS	O
with	POS	O
hypokalemia	POS	B-NP
and	POS	O
in	POS	O
5	POS	O
normokalemic	POS	B-NP
patients	POS	O
by	POS	O
determination	POS	O
of	POS	O
renal	POS	O
plasma	POS	O
flow	POS	O
,	POS	O
glomerular	POS	O
filtration	POS	O
rate	POS	O
,	POS	O
plasma	POS	O
concentration	POS	O
of	POS	O
potassium	POS	O
and	POS	O
sodium	POS	O
as	POS	O
well	POS	O
as	POS	O
urinary	POS	O
excretion	POS	O
of	POS	O
potassium	POS	O
,	POS	O
sodium	POS	O
and	POS	O
aldosterone	POS	O
.	POS	O
L	POS	O
-	POS	O
Dopa	POS	O
intake	POS	O
was	POS	O
found	POS	O
to	POS	O
cause	POS	O
an	POS	O
increased	POS	O
excretion	POS	O
of	POS	O
potassium	POS	O
,	POS	O
and	POS	O
sometimes	POS	O
also	POS	O
of	POS	O
sodium	POS	O
,	POS	O
in	POS	O
the	POS	O
hypokalemic	POS	B-NP
but	POS	O
not	POS	O
in	POS	O
the	POS	O
normokalemic	POS	B-NP
patients	POS	O
.	POS	O
This	POS	O
effect	POS	O
on	POS	O
the	POS	O
renal	POS	O
function	POS	O
could	POS	O
be	POS	O
prohibited	POS	O
by	POS	O
the	POS	O
administration	POS	O
of	POS	O
a	POS	O
peripheral	POS	O
dopa	POS	O
decarbodylase	POS	O
inhibitor	POS	O
.	POS	O
It	POS	O
is	POS	O
not	POS	O
known	POS	O
why	POS	O
this	POS	O
effect	POS	O
occurred	POS	O
in	POS	O
some	POS	O
individuals	POS	O
but	POS	O
not	POS	O
in	POS	O
others	POS	O
,	POS	O
but	POS	O
our	POS	O
results	POS	O
indicate	POS	O
a	POS	O
correlation	POS	O
between	POS	O
aldosterone	POS	O
production	POS	O
and	POS	O
this	POS	O
renal	POS	O
effect	POS	O
of	POS	O
L	POS	O
-	POS	O
dopa	POS	O
.	POS	O
Cocaine	POS	O
induced	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
induced	POS	O
by	POS	O
cocaine	POS	O
.	POS	O
The	POS	O
ischemia	POS	B-NP
probably	POS	O
induced	POS	O
by	POS	O
coronary	POS	B-NP
artery	POS	I-NP
spasm	POS	I-NP
was	POS	O
reversed	POS	O
by	POS	O
nitroglycerin	POS	O
and	POS	O
calcium	POS	O
blocking	POS	O
agents	POS	O
.	POS	O
Doxorubicin	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
monitored	POS	O
by	POS	O
ECG	POS	O
in	POS	O
freely	POS	O
moving	POS	O
mice	POS	O
.	POS	O
A	POS	O
new	POS	O
model	POS	O
to	POS	O
test	POS	O
potential	POS	O
protectors	POS	O
.	POS	O
In	POS	O
laboratory	POS	O
animals	POS	O
,	POS	O
histology	POS	O
is	POS	O
most	POS	O
commonly	POS	O
used	POS	O
to	POS	O
study	POS	O
doxorubicin	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
.	POS	O
However	POS	O
,	POS	O
for	POS	O
monitoring	POS	O
during	POS	O
treatment	POS	O
,	POS	O
large	POS	O
numbers	POS	O
of	POS	O
animals	POS	O
are	POS	O
needed	POS	O
.	POS	O
Recently	POS	O
we	POS	O
developed	POS	O
a	POS	O
new	POS	O
method	POS	O
to	POS	O
measure	POS	O
ECG	POS	O
values	POS	O
in	POS	O
freely	POS	O
moving	POS	O
mice	POS	O
by	POS	O
telemetry	POS	O
.	POS	O
With	POS	O
this	POS	O
model	POS	O
we	POS	O
investigated	POS	O
the	POS	O
effect	POS	O
of	POS	O
chronic	POS	O
doxorubicin	POS	O
administration	POS	O
on	POS	O
the	POS	O
ECG	POS	O
of	POS	O
freely	POS	O
moving	POS	O
BALB	POS	O
/	POS	O
c	POS	O
mice	POS	O
and	POS	O
the	POS	O
efficacy	POS	O
of	POS	O
ICRF	POS	O
-	POS	O
187	POS	O
as	POS	O
a	POS	O
protective	POS	O
agent	POS	O
.	POS	O
The	POS	O
ST	POS	O
interval	POS	O
significantly	POS	O
widened	POS	O
from	POS	O
15	POS	O
.	POS	O
0	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
5	POS	O
to	POS	O
56	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
11	POS	O
.	POS	O
8	POS	O
ms	POS	O
in	POS	O
week	POS	O
10	POS	O
(	POS	O
7	POS	O
weekly	POS	O
doses	POS	O
of	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
doxorubicin	POS	O
given	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
plus	POS	O
3	POS	O
weeks	POS	O
of	POS	O
observation	POS	O
)	POS	O
.	POS	O
The	POS	O
ECG	POS	O
of	POS	O
the	POS	O
control	POS	O
animals	POS	O
did	POS	O
not	POS	O
change	POS	O
during	POS	O
the	POS	O
entire	POS	O
study	POS	O
.	POS	O
After	POS	O
sacrifice	POS	O
the	POS	O
hearts	POS	O
of	POS	O
doxorubicin	POS	O
-	POS	O
treated	POS	O
animals	POS	O
were	POS	O
enlarged	POS	O
and	POS	O
the	POS	O
atria	POS	O
were	POS	O
hypertrophic	POS	B-NP
.	POS	O
As	POS	O
this	POS	O
schedule	POS	O
exerted	POS	O
more	POS	O
toxicity	POS	B-NP
than	POS	O
needed	POS	O
to	POS	O
investigate	POS	O
protective	POS	O
agents	POS	O
,	POS	O
the	POS	O
protection	POS	O
of	POS	O
ICRF	POS	O
-	POS	O
187	POS	O
was	POS	O
determined	POS	O
using	POS	O
a	POS	O
dose	POS	O
schedule	POS	O
with	POS	O
lower	POS	O
general	POS	O
toxicity	POS	B-NP
(	POS	O
6	POS	O
weekly	POS	O
doses	POS	O
of	POS	O
4	POS	O
mg	POS	O
/	POS	O
kg	POS	O
doxorubicin	POS	O
given	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
plus	POS	O
2	POS	O
weeks	POS	O
of	POS	O
observation	POS	O
)	POS	O
.	POS	O
On	POS	O
this	POS	O
schedule	POS	O
,	POS	O
the	POS	O
animals	POS	O
'	POS	O
hearts	POS	O
appeared	POS	O
normal	POS	O
after	POS	O
sacrifice	POS	O
and	POS	O
ICRF	POS	O
-	POS	O
187	POS	O
(	POS	O
50	POS	O
mg	POS	O
/	POS	O
kg	POS	O
given	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
1	POS	O
h	POS	O
before	POS	O
doxorubicin	POS	O
)	POS	O
provided	POS	O
almost	POS	O
full	POS	O
protection	POS	O
.	POS	O
These	POS	O
data	POS	O
were	POS	O
confirmed	POS	O
by	POS	O
histology	POS	O
.	POS	O
The	POS	O
results	POS	O
indicate	POS	O
that	POS	O
this	POS	O
new	POS	O
model	POS	O
is	POS	O
very	POS	O
sensitive	POS	O
and	POS	O
enables	POS	O
monitoring	POS	O
of	POS	O
the	POS	O
development	POS	O
of	POS	O
cardiotoxicity	POS	B-NP
with	POS	O
time	POS	O
.	POS	O
These	POS	O
findings	POS	O
result	POS	O
in	POS	O
a	POS	O
model	POS	O
that	POS	O
allows	POS	O
the	POS	O
testing	POS	O
of	POS	O
protectors	POS	O
against	POS	O
doxorubicin	POS	O
-	POS	O
induced	POS	O
cardiotoxicity	POS	B-NP
as	POS	O
demonstrated	POS	O
by	POS	O
the	POS	O
protection	POS	O
provided	POS	O
by	POS	O
ICRF	POS	O
-	POS	O
187	POS	O
.	POS	O
Epinephrine	POS	O
dysrhythmogenicity	POS	O
is	POS	O
not	POS	O
enhanced	POS	O
by	POS	O
subtoxic	POS	O
bupivacaine	POS	O
in	POS	O
dogs	POS	O
.	POS	O
Since	POS	O
bupivacaine	POS	O
and	POS	O
epinephrine	POS	O
may	POS	O
both	POS	O
precipitate	POS	O
dysrhythmias	POS	B-NP
,	POS	O
circulating	POS	O
bupivacaine	POS	O
during	POS	O
regional	POS	O
anesthesia	POS	O
could	POS	O
potentiate	POS	O
dysrhythmogenic	POS	O
effects	POS	O
of	POS	O
epinephrine	POS	O
.	POS	O
We	POS	O
therefore	POS	O
examined	POS	O
whether	POS	O
bupivacaine	POS	O
alters	POS	O
the	POS	O
dysrhythmogenicity	POS	O
of	POS	O
subsequent	POS	O
administration	POS	O
of	POS	O
epinephrine	POS	O
in	POS	O
conscious	POS	O
,	POS	O
healthy	POS	O
dogs	POS	O
and	POS	O
in	POS	O
anesthetized	POS	O
dogs	POS	O
with	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
Forty	POS	O
-	POS	O
one	POS	O
conscious	POS	O
dogs	POS	O
received	POS	O
10	POS	O
micrograms	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
.	POS	O
min	POS	O
-	POS	O
1	POS	O
epinephrine	POS	O
.	POS	O
Seventeen	POS	O
animals	POS	O
responded	POS	O
with	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
(	POS	O
VT	POS	B-NP
)	POS	O
within	POS	O
3	POS	O
min	POS	O
.	POS	O
After	POS	O
3	POS	O
h	POS	O
,	POS	O
these	POS	O
responders	POS	O
randomly	POS	O
received	POS	O
1	POS	O
or	POS	O
2	POS	O
mg	POS	O
/	POS	O
kg	POS	O
bupivacaine	POS	O
or	POS	O
saline	POS	O
over	POS	O
5	POS	O
min	POS	O
,	POS	O
followed	POS	O
by	POS	O
10	POS	O
micrograms	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
.	POS	O
min	POS	O
-	POS	O
1	POS	O
epinephrine	POS	O
.	POS	O
In	POS	O
the	POS	O
bupivacaine	POS	O
groups	POS	O
,	POS	O
epinephrine	POS	O
caused	POS	O
fewer	POS	O
prodysrhythmic	POS	O
effects	POS	O
than	POS	O
without	POS	O
bupivacaine	POS	O
.	POS	O
VT	POS	B-NP
appeared	POS	O
in	POS	O
fewer	POS	O
dogs	POS	O
and	POS	O
at	POS	O
a	POS	O
later	POS	O
time	POS	O
,	POS	O
and	POS	O
there	POS	O
were	POS	O
more	POS	O
sinoatrial	POS	O
beats	POS	O
and	POS	O
less	POS	O
ectopies	POS	O
.	POS	O
Epinephrine	POS	O
shortened	POS	O
QT	POS	O
less	POS	O
after	POS	O
bupivacaine	POS	O
than	POS	O
in	POS	O
control	POS	O
animals	POS	O
.	POS	O
One	POS	O
day	POS	O
after	POS	O
experimental	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
,	POS	O
six	POS	O
additional	POS	O
halothane	POS	O
-	POS	O
anesthetized	POS	O
dogs	POS	O
received	POS	O
4	POS	O
micrograms	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
.	POS	O
min	POS	O
-	POS	O
1	POS	O
epinephrine	POS	O
until	POS	O
VT	POS	O
appeared	POS	O
.	POS	O
After	POS	O
45	POS	O
min	POS	O
,	POS	O
1	POS	O
mg	POS	O
/	POS	O
kg	POS	O
bupivacaine	POS	O
was	POS	O
injected	POS	O
over	POS	O
5	POS	O
min	POS	O
,	POS	O
again	POS	O
followed	POS	O
by	POS	O
4	POS	O
micrograms	POS	O
.	POS	O
kg	POS	O
-	POS	O
1	POS	O
.	POS	O
min	POS	O
-	POS	O
1	POS	O
epinephrine	POS	O
.	POS	O
In	POS	O
these	POS	O
dogs	POS	O
,	POS	O
the	POS	O
prodysrhythmic	POS	O
response	POS	O
to	POS	O
epinephrine	POS	O
was	POS	O
also	POS	O
mitigated	POS	O
by	POS	O
preceding	POS	O
bupivacaine	POS	O
.	POS	O
Bupivacaine	POS	O
antagonizes	POS	O
epinephrine	POS	O
dysrhythmogenicity	POS	O
in	POS	O
conscious	POS	O
dogs	POS	O
susceptible	POS	O
to	POS	O
VT	POS	B-NP
and	POS	O
in	POS	O
anesthetized	POS	O
dogs	POS	O
with	POS	O
spontaneous	POS	O
postinfarct	POS	B-NP
dysrhythmias	POS	I-NP
.	POS	O
There	POS	O
is	POS	O
no	POS	O
evidence	POS	O
that	POS	O
systemic	POS	O
subtoxic	POS	O
bupivacaine	POS	O
administration	POS	O
enhances	POS	O
the	POS	O
dysrhythmogenicity	POS	O
of	POS	O
subsequent	POS	O
epinephrine	POS	O
.	POS	O
Milk	POS	O
-	POS	O
alkali	POS	O
syndrome	POS	O
induced	POS	O
by	POS	O
1	POS	O
,	POS	O
25	POS	O
(	POS	O
OH	POS	O
)	POS	O
2D	POS	O
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
hypoparathyroidism	POS	B-NP
.	POS	O
Milk	POS	B-NP
-	POS	I-NP
alkali	POS	I-NP
syndrome	POS	I-NP
was	POS	O
first	POS	O
described	POS	O
70	POS	O
years	POS	O
ago	POS	O
in	POS	O
the	POS	O
context	POS	O
of	POS	O
the	POS	O
treatment	POS	O
of	POS	O
peptic	POS	B-NP
ulcer	POS	I-NP
disease	POS	I-NP
with	POS	O
large	POS	O
amounts	POS	O
of	POS	O
calcium	POS	O
and	POS	O
alkali	POS	O
.	POS	O
Although	POS	O
with	POS	O
current	POS	O
ulcer	POS	O
therapy	POS	O
(	POS	O
H	POS	O
-	POS	O
2	POS	O
blockers	POS	O
,	POS	O
omeprazole	POS	O
,	POS	O
and	POS	O
sucralfate	POS	O
)	POS	O
,	POS	O
the	POS	O
frequency	POS	O
of	POS	O
milk	POS	O
-	POS	O
alkali	POS	O
syndrome	POS	O
has	POS	O
decreased	POS	O
significantly	POS	O
,	POS	O
the	POS	O
classic	POS	O
triad	POS	O
of	POS	O
hypercalcemia	POS	B-NP
,	POS	O
alkalosis	POS	B-NP
,	POS	O
and	POS	O
renal	POS	B-NP
impairment	POS	I-NP
remains	POS	O
the	POS	O
hallmark	POS	O
of	POS	O
the	POS	O
syndrome	POS	O
.	POS	O
Milk	POS	B-NP
-	POS	I-NP
alkali	POS	I-NP
syndrome	POS	I-NP
can	POS	O
present	POS	O
serious	POS	O
and	POS	O
occasionally	POS	O
life	POS	O
-	POS	O
threatening	POS	O
illness	POS	O
unless	POS	O
diagnosed	POS	O
and	POS	O
treated	POS	O
appropriately	POS	O
.	POS	O
This	POS	O
article	POS	O
presents	POS	O
a	POS	O
patient	POS	O
with	POS	O
hypoparathyroidism	POS	B-NP
who	POS	O
was	POS	O
treated	POS	O
with	POS	O
calcium	POS	O
carbonate	POS	O
and	POS	O
calcitriol	POS	O
resulting	POS	O
in	POS	O
two	POS	O
admissions	POS	O
to	POS	O
the	POS	O
hospital	POS	O
for	POS	O
milk	POS	B-NP
-	POS	I-NP
alkali	POS	I-NP
syndrome	POS	I-NP
.	POS	O
The	POS	O
patient	POS	O
was	POS	O
successfully	POS	O
treated	POS	O
with	POS	O
intravenous	POS	O
pamidronate	POS	O
on	POS	O
his	POS	O
first	POS	O
admission	POS	O
and	POS	O
with	POS	O
hydrocortisone	POS	O
on	POS	O
the	POS	O
second	POS	O
.	POS	O
This	POS	O
illustrates	POS	O
intravenous	POS	O
pamidronate	POS	O
as	POS	O
a	POS	O
valuable	POS	O
therapeutic	POS	O
tool	POS	O
when	POS	O
milk	POS	B-NP
-	POS	I-NP
alkali	POS	I-NP
syndrome	POS	I-NP
presents	POS	O
as	POS	O
hypercalcemic	POS	B-NP
emergency	POS	O
.	POS	O
Famotidine	POS	O
-	POS	O
associated	POS	O
delirium	POS	B-NP
.	POS	O
A	POS	O
series	POS	O
of	POS	O
six	POS	O
cases	POS	O
.	POS	O
Famotidine	POS	O
is	POS	O
a	POS	O
histamine	POS	O
H2	POS	O
-	POS	O
receptor	POS	O
antagonist	POS	O
used	POS	O
in	POS	O
inpatient	POS	O
settings	POS	O
for	POS	O
prevention	POS	O
of	POS	O
stress	POS	B-NP
ulcers	POS	I-NP
and	POS	O
is	POS	O
showing	POS	O
increasing	POS	O
popularity	POS	O
because	POS	O
of	POS	O
its	POS	O
low	POS	O
cost	POS	O
.	POS	O
Although	POS	O
all	POS	O
of	POS	O
the	POS	O
currently	POS	O
available	POS	O
H2	POS	O
-	POS	O
receptor	POS	O
antagonists	POS	O
have	POS	O
shown	POS	O
the	POS	O
propensity	POS	O
to	POS	O
cause	POS	O
delirium	POS	B-NP
,	POS	O
only	POS	O
two	POS	O
previously	POS	O
reported	POS	O
cases	POS	O
have	POS	O
been	POS	O
associated	POS	O
with	POS	O
famotidine	POS	O
.	POS	O
The	POS	O
authors	POS	O
report	POS	O
on	POS	O
six	POS	O
cases	POS	O
of	POS	O
famotidine	POS	O
-	POS	O
associated	POS	O
delirium	POS	B-NP
in	POS	O
hospitalized	POS	O
patients	POS	O
who	POS	O
cleared	POS	O
completely	POS	O
upon	POS	O
removal	POS	O
of	POS	O
famotidine	POS	O
.	POS	O
The	POS	O
pharmacokinetics	POS	O
of	POS	O
famotidine	POS	O
are	POS	O
reviewed	POS	O
,	POS	O
with	POS	O
no	POS	O
change	POS	O
in	POS	O
its	POS	O
metabolism	POS	O
in	POS	O
the	POS	O
elderly	POS	O
population	POS	O
seen	POS	O
.	POS	O
The	POS	O
implications	POS	O
of	POS	O
using	POS	O
famotidine	POS	O
in	POS	O
elderly	POS	O
persons	POS	O
are	POS	O
discussed	POS	O
.	POS	O
Encephalopathy	POS	B-NP
during	POS	O
amitriptyline	POS	O
therapy	POS	O
:	POS	O
are	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
and	POS	O
serotonin	POS	B-NP
syndrome	POS	I-NP
spectrum	POS	I-NP
disorders	POS	I-NP
?	POS	O
This	POS	O
report	POS	O
describes	POS	O
a	POS	O
case	POS	O
of	POS	O
encephalopathy	POS	B-NP
developed	POS	O
in	POS	O
the	POS	O
course	POS	O
of	POS	O
amitriptyline	POS	O
therapy	POS	O
,	POS	O
during	POS	O
a	POS	O
remission	POS	O
of	POS	O
unipolar	POS	B-NP
depression	POS	I-NP
.	POS	O
This	POS	O
patient	POS	O
could	POS	O
have	POS	O
been	POS	O
diagnosed	POS	O
as	POS	O
having	POS	O
either	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
(	POS	O
NMS	POS	B-NP
)	POS	O
or	POS	O
serotonin	POS	B-NP
syndrome	POS	I-NP
(	POS	O
SS	POS	B-NP
)	POS	O
.	POS	O
The	POS	O
major	POS	O
determinant	POS	O
of	POS	O
the	POS	O
symptoms	POS	O
may	POS	O
have	POS	O
been	POS	O
dopamine	POS	O
/	POS	O
serotonin	POS	O
imbalance	POS	O
in	POS	O
the	POS	O
central	POS	O
nervous	POS	O
system	POS	O
.	POS	O
The	POS	O
NMS	POS	B-NP
-	POS	O
like	POS	O
encephalopathy	POS	B-NP
that	POS	O
develops	POS	O
in	POS	O
association	POS	O
with	POS	O
the	POS	O
use	POS	O
of	POS	O
antidepressants	POS	O
indicates	POS	O
that	POS	O
NMS	POS	B-NP
and	POS	O
SS	POS	B-NP
are	POS	O
spectrum	POS	O
disorders	POS	O
induced	POS	O
by	POS	O
drugs	POS	O
with	POS	O
both	POS	O
antidopaminergic	POS	O
and	POS	O
serotonergic	POS	O
effects	POS	O
.	POS	O
Genetic	POS	O
separation	POS	O
of	POS	O
tumor	POS	B-NP
growth	POS	O
and	POS	O
hemorrhagic	POS	B-NP
phenotypes	POS	O
in	POS	O
an	POS	O
estrogen	POS	O
-	POS	O
induced	POS	O
tumor	POS	B-NP
.	POS	O
Chronic	POS	O
administration	POS	O
of	POS	O
estrogen	POS	O
to	POS	O
the	POS	O
Fischer	POS	O
344	POS	O
(	POS	O
F344	POS	O
)	POS	O
rat	POS	O
induces	POS	O
growth	POS	O
of	POS	O
large	POS	O
,	POS	O
hemorrhagic	POS	B-NP
pituitary	POS	I-NP
tumors	POS	I-NP
.	POS	O
Ten	POS	O
weeks	POS	O
of	POS	O
diethylstilbestrol	POS	O
(	POS	O
DES	POS	O
)	POS	O
treatment	POS	O
caused	POS	O
female	POS	O
F344	POS	O
rat	POS	O
pituitaries	POS	O
to	POS	O
grow	POS	O
to	POS	O
an	POS	O
average	POS	O
of	POS	O
109	POS	O
.	POS	O
2	POS	O
+	POS	O
/	POS	O
-	POS	O
6	POS	O
.	POS	O
3	POS	O
mg	POS	O
(	POS	O
mean	POS	O
+	POS	O
/	POS	O
-	POS	O
SE	POS	O
)	POS	O
versus	POS	O
11	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
4	POS	O
mg	POS	O
for	POS	O
untreated	POS	O
rats	POS	O
,	POS	O
and	POS	O
to	POS	O
become	POS	O
highly	POS	O
hemorrhagic	POS	B-NP
.	POS	O
The	POS	O
same	POS	O
DES	POS	O
treatment	POS	O
produced	POS	O
no	POS	O
significant	POS	O
growth	POS	O
(	POS	O
8	POS	O
.	POS	O
9	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
for	POS	O
treated	POS	O
females	POS	O
versus	POS	O
8	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
1	POS	O
for	POS	O
untreated	POS	O
females	POS	O
)	POS	O
or	POS	O
morphological	POS	O
changes	POS	O
in	POS	O
Brown	POS	O
Norway	POS	O
(	POS	O
BN	POS	O
)	POS	O
rat	POS	O
pituitaries	POS	O
.	POS	O
An	POS	O
F1	POS	O
hybrid	POS	O
of	POS	O
F344	POS	O
and	POS	O
BN	POS	O
exhibited	POS	O
significant	POS	O
pituitary	POS	B-NP
growth	POS	I-NP
after	POS	O
10	POS	O
weeks	POS	O
of	POS	O
DES	POS	O
treatment	POS	O
with	POS	O
an	POS	O
average	POS	O
mass	POS	O
of	POS	O
26	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
mg	POS	O
compared	POS	O
with	POS	O
8	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
9	POS	O
mg	POS	O
for	POS	O
untreated	POS	O
rats	POS	O
.	POS	O
Surprisingly	POS	O
,	POS	O
the	POS	O
F1	POS	O
hybrid	POS	O
tumors	POS	B-NP
were	POS	O
not	POS	O
hemorrhagic	POS	B-NP
and	POS	O
had	POS	O
hemoglobin	POS	O
content	POS	O
and	POS	O
outward	POS	O
appearance	POS	O
identical	POS	O
to	POS	O
that	POS	O
of	POS	O
BN	POS	O
.	POS	O
Expression	POS	O
of	POS	O
both	POS	O
growth	POS	O
and	POS	O
morphological	POS	O
changes	POS	O
is	POS	O
due	POS	O
to	POS	O
multiple	POS	O
genes	POS	O
.	POS	O
However	POS	O
,	POS	O
while	POS	O
DES	POS	O
-	POS	O
induced	POS	O
pituitary	POS	O
growth	POS	O
exhibited	POS	O
quantitative	POS	O
,	POS	O
additive	POS	O
inheritance	POS	O
,	POS	O
the	POS	O
hemorrhagic	POS	B-NP
phenotype	POS	O
exhibited	POS	O
recessive	POS	O
,	POS	O
epistatic	POS	O
inheritance	POS	O
.	POS	O
Only	POS	O
5	POS	O
of	POS	O
the	POS	O
160	POS	O
F2	POS	O
pituitaries	POS	O
exhibited	POS	O
the	POS	O
hemorrhagic	POS	B-NP
phenotype	POS	O
;	POS	O
36	POS	O
of	POS	O
the	POS	O
160	POS	O
F2	POS	O
pituitaries	POS	O
were	POS	O
in	POS	O
the	POS	O
F344	POS	O
range	POS	O
of	POS	O
mass	POS	O
,	POS	O
but	POS	O
31	POS	O
of	POS	O
these	POS	O
were	POS	O
not	POS	O
hemorrhagic	POS	B-NP
,	POS	O
indicating	POS	O
that	POS	O
the	POS	O
hemorrhagic	POS	B-NP
phenotype	POS	O
is	POS	O
not	POS	O
merely	POS	O
a	POS	O
consequence	POS	O
of	POS	O
extensive	POS	O
growth	POS	O
.	POS	O
The	POS	O
hemorrhagic	POS	B-NP
F2	POS	O
pituitaries	POS	O
were	POS	O
all	POS	O
among	POS	O
the	POS	O
most	POS	O
massive	POS	O
,	POS	O
indicating	POS	O
that	POS	O
some	POS	O
of	POS	O
the	POS	O
genes	POS	O
regulate	POS	O
both	POS	O
phenotypes	POS	O
.	POS	O
Increased	POS	O
expression	POS	O
of	POS	O
neuronal	POS	O
nitric	POS	O
oxide	POS	O
synthase	POS	O
in	POS	O
bladder	POS	O
afferent	POS	O
pathways	POS	O
following	POS	O
chronic	POS	B-NP
bladder	POS	I-NP
irritation	POS	I-NP
.	POS	O
Immunocytochemical	POS	O
techniques	POS	O
were	POS	O
used	POS	O
to	POS	O
examine	POS	O
alterations	POS	O
in	POS	O
the	POS	O
expression	POS	O
of	POS	O
neuronal	POS	O
nitric	POS	O
oxide	POS	O
synthase	POS	O
(	POS	O
NOS	POS	O
)	POS	O
in	POS	O
bladder	POS	O
pathways	POS	O
following	POS	O
acute	POS	O
and	POS	O
chronic	POS	O
irritation	POS	O
of	POS	O
the	POS	O
urinary	POS	O
tract	POS	O
of	POS	O
the	POS	O
rat	POS	O
.	POS	O
Chemical	POS	O
cystitis	POS	B-NP
was	POS	O
induced	POS	O
by	POS	O
cyclophosphamide	POS	O
(	POS	O
CYP	POS	O
)	POS	O
which	POS	O
is	POS	O
metabolized	POS	O
to	POS	O
acrolein	POS	O
,	POS	O
an	POS	O
irritant	POS	O
eliminated	POS	O
in	POS	O
the	POS	O
urine	POS	O
.	POS	O
Injection	POS	O
of	POS	O
CYP	POS	O
(	POS	O
n	POS	O
=	POS	O
10	POS	O
,	POS	O
75	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
)	POS	O
2	POS	O
hours	POS	O
prior	POS	O
to	POS	O
perfusion	POS	O
(	POS	O
acute	POS	O
treatment	POS	O
)	POS	O
of	POS	O
the	POS	O
animals	POS	O
increased	POS	O
Fos	POS	O
-	POS	O
immunoreactivity	POS	O
(	POS	O
IR	POS	O
)	POS	O
in	POS	O
neurons	POS	O
in	POS	O
the	POS	O
dorsal	POS	O
commissure	POS	O
,	POS	O
dorsal	POS	O
horn	POS	O
,	POS	O
and	POS	O
autonomic	POS	O
regions	POS	O
of	POS	O
spinal	POS	O
segments	POS	O
(	POS	O
L1	POS	O
-	POS	O
L2	POS	O
and	POS	O
L6	POS	O
-	POS	O
S1	POS	O
)	POS	O
which	POS	O
receive	POS	O
afferent	POS	O
inputs	POS	O
from	POS	O
the	POS	O
bladder	POS	O
,	POS	O
urethra	POS	O
,	POS	O
and	POS	O
ureter	POS	O
.	POS	O
Fos	POS	O
-	POS	O
IR	POS	O
in	POS	O
the	POS	O
spinal	POS	O
cord	POS	O
was	POS	O
not	POS	O
changed	POS	O
in	POS	O
rats	POS	O
receiving	POS	O
chronic	POS	O
CYP	POS	O
treatment	POS	O
(	POS	O
n	POS	O
=	POS	O
15	POS	O
,	POS	O
75	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
i	POS	O
.	POS	O
p	POS	O
.	POS	O
,	POS	O
every	POS	O
3rd	POS	O
day	POS	O
for	POS	O
2	POS	O
weeks	POS	O
)	POS	O
.	POS	O
In	POS	O
control	POS	O
animals	POS	O
and	POS	O
in	POS	O
animals	POS	O
treated	POS	O
acutely	POS	O
with	POS	O
CYP	POS	O
,	POS	O
only	POS	O
small	POS	O
numbers	POS	O
of	POS	O
NOS	POS	O
-	POS	O
IR	POS	O
cells	POS	O
(	POS	O
0	POS	O
.	POS	O
5	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
cell	POS	O
profiles	POS	O
/	POS	O
sections	POS	O
)	POS	O
were	POS	O
detected	POS	O
in	POS	O
the	POS	O
L6	POS	O
-	POS	O
S1	POS	O
dorsal	POS	O
root	POS	O
ganglia	POS	O
(	POS	O
DRG	POS	O
)	POS	O
.	POS	O
Chronic	POS	O
CYP	POS	O
administration	POS	O
significantly	POS	O
(	POS	O
P	POS	O
<	POS	O
or	POS	O
=	POS	O
.	POS	O
002	POS	O
)	POS	O
increased	POS	O
bladder	POS	O
weight	POS	O
by	POS	O
60	POS	O
%	POS	O
and	POS	O
increased	POS	O
(	POS	O
7	POS	O
-	POS	O
to	POS	O
11	POS	O
-	POS	O
fold	POS	O
)	POS	O
the	POS	O
numbers	POS	O
of	POS	O
NOS	POS	O
-	POS	O
immunoreactive	POS	O
(	POS	O
IR	POS	O
)	POS	O
afferent	POS	O
neurons	POS	O
in	POS	O
the	POS	O
L6	POS	O
-	POS	O
S1	POS	O
DRG	POS	O
.	POS	O
A	POS	O
small	POS	O
increase	POS	O
(	POS	O
1	POS	O
.	POS	O
5	POS	O
-	POS	O
fold	POS	O
)	POS	O
also	POS	O
occurred	POS	O
in	POS	O
the	POS	O
L1	POS	O
DRG	POS	O
,	POS	O
but	POS	O
no	POS	O
change	POS	O
was	POS	O
detected	POS	O
in	POS	O
the	POS	O
L2	POS	O
and	POS	O
L5	POS	O
DRG	POS	O
.	POS	O
Bladder	POS	O
afferent	POS	O
cells	POS	O
in	POS	O
the	POS	O
L6	POS	O
-	POS	O
S1	POS	O
DRG	POS	O
labeled	POS	O
by	POS	O
Fluorogold	POS	O
(	POS	O
40	POS	O
microliters	POS	O
)	POS	O
injected	POS	O
into	POS	O
the	POS	O
bladder	POS	O
wall	POS	O
did	POS	O
not	POS	O
exhibit	POS	O
NOS	POS	O
-	POS	O
IR	POS	O
in	POS	O
control	POS	O
animals	POS	O
;	POS	O
however	POS	O
,	POS	O
following	POS	O
chronic	POS	O
CYP	POS	O
administration	POS	O
,	POS	O
a	POS	O
significant	POS	O
percentage	POS	O
of	POS	O
bladder	POS	O
afferent	POS	O
neurons	POS	O
were	POS	O
NOS	POS	O
-	POS	O
IR	POS	O
:	POS	O
L6	POS	O
(	POS	O
19	POS	O
.	POS	O
8	POS	O
+	POS	O
/	POS	O
-	POS	O
4	POS	O
.	POS	O
6	POS	O
%	POS	O
)	POS	O
and	POS	O
S1	POS	O
(	POS	O
25	POS	O
.	POS	O
3	POS	O
+	POS	O
/	POS	O
-	POS	O
2	POS	O
.	POS	O
9	POS	O
%	POS	O
)	POS	O
.	POS	O
These	POS	O
results	POS	O
indicate	POS	O
that	POS	O
neuronal	POS	O
gene	POS	O
expression	POS	O
in	POS	O
visceral	POS	O
sensory	POS	O
pathways	POS	O
can	POS	O
be	POS	O
upregulated	POS	O
by	POS	O
chemical	POS	O
irritation	POS	O
of	POS	O
afferent	POS	O
receptors	POS	O
in	POS	O
the	POS	O
urinary	POS	O
tract	POS	O
and	POS	O
/	POS	O
or	POS	O
that	POS	O
pathological	POS	O
changes	POS	O
in	POS	O
the	POS	O
urinary	POS	O
tract	POS	O
can	POS	O
initiate	POS	O
chemical	POS	O
signals	POS	O
that	POS	O
alter	POS	O
the	POS	O
chemical	POS	O
properties	POS	O
of	POS	O
visceral	POS	O
afferent	POS	O
neurons	POS	O
.	POS	O
Effects	POS	O
of	POS	O
a	POS	O
new	POS	O
calcium	POS	O
antagonist	POS	O
,	POS	O
CD	POS	O
-	POS	O
832	POS	O
,	POS	O
on	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
in	POS	O
dogs	POS	O
with	POS	O
partial	POS	O
coronary	POS	B-NP
stenosis	POS	I-NP
.	POS	O
Effects	POS	O
of	POS	O
CD	POS	O
-	POS	O
832	POS	O
on	POS	O
isoproterenol	POS	O
(	POS	O
ISO	POS	O
)	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
were	POS	O
studied	POS	O
in	POS	O
dogs	POS	O
with	POS	O
partial	POS	O
coronary	POS	B-NP
stenosis	POS	I-NP
of	POS	O
the	POS	O
left	POS	O
circumflex	POS	O
coronary	POS	O
artery	POS	O
and	POS	O
findings	POS	O
were	POS	O
compared	POS	O
with	POS	O
those	POS	O
for	POS	O
nifedipine	POS	O
or	POS	O
diltiazem	POS	O
.	POS	O
In	POS	O
the	POS	O
presence	POS	O
of	POS	O
coronary	POS	B-NP
artery	POS	I-NP
stenosis	POS	I-NP
,	POS	O
3	POS	O
-	POS	O
min	POS	O
periods	POS	O
of	POS	O
intracoronary	POS	O
ISO	POS	O
infusion	POS	O
(	POS	O
10	POS	O
ng	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
)	POS	O
increased	POS	O
heart	POS	O
rate	POS	O
and	POS	O
maximal	POS	O
rate	POS	O
of	POS	O
left	POS	O
ventricular	POS	O
pressure	POS	O
rise	POS	O
,	POS	O
which	POS	O
resulted	POS	O
in	POS	O
a	POS	O
decrease	POS	O
in	POS	O
percentage	POS	O
segmental	POS	O
shortening	POS	O
and	POS	O
ST	POS	O
-	POS	O
segment	POS	O
elevation	POS	O
of	POS	O
the	POS	O
epicardial	POS	O
electrocardiogram	POS	O
.	POS	O
After	POS	O
the	POS	O
control	POS	O
ISO	POS	O
infusion	POS	O
with	POS	O
stenosis	POS	B-NP
was	POS	O
performed	POS	O
,	POS	O
equihypotensive	POS	O
doses	POS	O
of	POS	O
CD	POS	O
-	POS	O
832	POS	O
(	POS	O
3	POS	O
and	POS	O
10	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
,	POS	O
n	POS	O
=	POS	O
7	POS	O
)	POS	O
,	POS	O
nifedipine	POS	O
(	POS	O
1	POS	O
and	POS	O
3	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
,	POS	O
n	POS	O
=	POS	O
9	POS	O
)	POS	O
or	POS	O
diltiazem	POS	O
(	POS	O
10	POS	O
and	POS	O
30	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
,	POS	O
n	POS	O
=	POS	O
7	POS	O
)	POS	O
were	POS	O
infused	POS	O
5	POS	O
min	POS	O
before	POS	O
and	POS	O
during	POS	O
the	POS	O
second	POS	O
and	POS	O
third	POS	O
ISO	POS	O
infusion	POS	O
.	POS	O
Both	POS	O
CD	POS	O
-	POS	O
832	POS	O
and	POS	O
diltiazem	POS	O
,	POS	O
but	POS	O
not	POS	O
nifedipine	POS	O
,	POS	O
significantly	POS	O
reduced	POS	O
the	POS	O
increase	POS	O
in	POS	O
heart	POS	O
rate	POS	O
induced	POS	O
by	POS	O
ISO	POS	O
infusion	POS	O
.	POS	O
In	POS	O
contrast	POS	O
to	POS	O
nifedipine	POS	O
,	POS	O
CD	POS	O
-	POS	O
832	POS	O
(	POS	O
10	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
)	POS	O
prevented	POS	O
the	POS	O
decrease	POS	O
in	POS	O
percentage	POS	O
segmental	POS	O
shortening	POS	O
from	POS	O
32	POS	O
+	POS	O
/	POS	O
-	POS	O
12	POS	O
%	POS	O
to	POS	O
115	POS	O
+	POS	O
/	POS	O
-	POS	O
26	POS	O
%	POS	O
of	POS	O
the	POS	O
control	POS	O
value	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
01	POS	O
)	POS	O
and	POS	O
ST	POS	O
-	POS	O
segment	POS	O
elevation	POS	O
from	POS	O
5	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
0	POS	O
mV	POS	O
to	POS	O
1	POS	O
.	POS	O
6	POS	O
+	POS	O
/	POS	O
-	POS	O
1	POS	O
.	POS	O
3	POS	O
mV	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
01	POS	O
)	POS	O
at	POS	O
3	POS	O
min	POS	O
after	POS	O
ISO	POS	O
infusion	POS	O
with	POS	O
stenosis	POS	O
.	POS	O
Diltiazem	POS	O
(	POS	O
30	POS	O
micrograms	POS	O
/	POS	O
kg	POS	O
/	POS	O
min	POS	O
)	POS	O
also	POS	O
prevented	POS	O
the	POS	O
decrease	POS	O
in	POS	O
percentage	POS	O
segmental	POS	O
shortening	POS	O
from	POS	O
34	POS	O
+	POS	O
/	POS	O
-	POS	O
14	POS	O
%	POS	O
to	POS	O
63	POS	O
+	POS	O
/	POS	O
-	POS	O
18	POS	O
%	POS	O
of	POS	O
the	POS	O
control	POS	O
value	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
05	POS	O
)	POS	O
and	POS	O
ST	POS	O
-	POS	O
segment	POS	O
elevation	POS	O
from	POS	O
4	POS	O
.	POS	O
7	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
mV	POS	O
to	POS	O
2	POS	O
.	POS	O
1	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
7	POS	O
mV	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
01	POS	O
)	POS	O
at	POS	O
3	POS	O
min	POS	O
after	POS	O
ISO	POS	O
infusion	POS	O
with	POS	O
stenosis	POS	B-NP
.	POS	O
These	POS	O
data	POS	O
show	POS	O
that	POS	O
CD	POS	O
-	POS	O
832	POS	O
improves	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
during	POS	O
ISO	POS	O
infusion	POS	O
with	POS	O
stenosis	POS	B-NP
and	POS	O
suggest	POS	O
that	POS	O
the	POS	O
negative	POS	O
chronotropic	POS	O
property	POS	O
of	POS	O
CD	POS	O
-	POS	O
832	POS	O
plays	POS	O
a	POS	O
major	POS	O
role	POS	O
in	POS	O
the	POS	O
beneficial	POS	O
effects	POS	O
of	POS	O
CD	POS	O
-	POS	O
832	POS	O
.	POS	O
The	POS	O
effect	POS	O
of	POS	O
recombinant	POS	O
human	POS	O
insulin	POS	O
-	POS	O
like	POS	O
growth	POS	O
factor	POS	O
-	POS	O
I	POS	O
on	POS	O
chronic	POS	O
puromycin	POS	O
aminonucleoside	POS	O
nephropathy	POS	B-NP
in	POS	O
rats	POS	O
.	POS	O
We	POS	O
recently	POS	O
demonstrated	POS	O
that	POS	O
recombinant	POS	O
hGH	POS	O
exacerbates	POS	O
renal	POS	O
functional	POS	O
and	POS	O
structural	POS	O
injury	POS	O
in	POS	O
chronic	POS	O
puromycin	POS	O
aminonucleoside	POS	O
(	POS	O
PAN	POS	O
)	POS	O
nephropathy	POS	B-NP
,	POS	O
an	POS	O
experimental	POS	O
model	POS	O
of	POS	O
glomerular	POS	B-NP
disease	POS	I-NP
.	POS	O
Therefore	POS	O
,	POS	O
we	POS	O
examined	POS	O
whether	POS	O
recombinant	POS	O
human	POS	O
(	POS	O
rh	POS	O
)	POS	O
IGF	POS	O
-	POS	O
I	POS	O
is	POS	O
a	POS	O
safer	POS	O
alternative	POS	O
for	POS	O
the	POS	O
treatment	POS	O
of	POS	O
growth	POS	B-NP
failure	POS	I-NP
in	POS	O
rats	POS	O
with	POS	O
chronic	POS	O
PAN	POS	O
nephropathy	POS	B-NP
.	POS	O
The	POS	O
glomerulopathy	POS	B-NP
was	POS	O
induced	POS	O
by	POS	O
seven	POS	O
serial	POS	O
injections	POS	O
of	POS	O
PAN	POS	O
over	POS	O
12	POS	O
wk	POS	O
.	POS	O
Experimental	POS	O
animals	POS	O
(	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
received	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
,	POS	O
400	POS	O
micrograms	POS	O
/	POS	O
d	POS	O
,	POS	O
whereas	POS	O
control	POS	O
rats	POS	O
(	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
received	POS	O
the	POS	O
vehicle	POS	O
.	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
improved	POS	O
weight	POS	O
gain	POS	O
by	POS	O
14	POS	O
%	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
,	POS	O
without	POS	O
altering	POS	O
hematocrit	POS	O
or	POS	O
blood	POS	O
pressure	POS	O
in	POS	O
rats	POS	O
with	POS	O
renal	POS	B-NP
disease	POS	I-NP
.	POS	O
Urinary	POS	O
protein	POS	O
excretion	POS	O
was	POS	O
unaltered	POS	O
by	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
treatment	POS	O
in	POS	O
rats	POS	O
with	POS	O
chronic	POS	O
PAN	POS	O
nephropathy	POS	B-NP
.	POS	O
After	POS	O
12	POS	O
wk	POS	O
,	POS	O
the	POS	O
inulin	POS	O
clearance	POS	O
was	POS	O
higher	POS	O
in	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
-	POS	O
treated	POS	O
rats	POS	O
,	POS	O
0	POS	O
.	POS	O
48	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
08	POS	O
versus	POS	O
0	POS	O
.	POS	O
24	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
06	POS	O
mL	POS	O
/	POS	O
min	POS	O
/	POS	O
100	POS	O
g	POS	O
of	POS	O
body	POS	O
weight	POS	O
in	POS	O
untreated	POS	O
PAN	POS	O
nephropathy	POS	B-NP
animals	POS	O
,	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
.	POS	O
The	POS	O
improvement	POS	O
in	POS	O
GFR	POS	O
was	POS	O
not	POS	O
associated	POS	O
with	POS	O
enhanced	POS	O
glomerular	POS	B-NP
hypertrophy	POS	I-NP
or	POS	O
increased	POS	O
segmental	POS	O
glomerulosclerosis	POS	B-NP
,	POS	O
tubulointerstitial	POS	B-NP
injury	POS	I-NP
,	POS	O
or	POS	O
renal	POS	O
cortical	POS	O
malondialdehyde	POS	O
content	POS	O
.	POS	O
In	POS	O
rats	POS	O
with	POS	O
PAN	POS	O
nephropathy	POS	B-NP
,	POS	O
administration	POS	O
of	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
increased	POS	O
IGF	POS	O
-	POS	O
I	POS	O
and	POS	O
GH	POS	O
receptor	POS	O
gene	POS	O
expression	POS	O
,	POS	O
without	POS	O
altering	POS	O
the	POS	O
steady	POS	O
state	POS	O
level	POS	O
of	POS	O
IGF	POS	O
-	POS	O
I	POS	O
receptor	POS	O
mRNA	POS	O
.	POS	O
In	POS	O
normal	POS	O
rats	POS	O
with	POS	O
intact	POS	O
kidneys	POS	O
,	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
administration	POS	O
(	POS	O
n	POS	O
=	POS	O
4	POS	O
)	POS	O
did	POS	O
not	POS	O
alter	POS	O
weight	POS	O
gain	POS	O
,	POS	O
blood	POS	O
pressure	POS	O
,	POS	O
proteinuria	POS	B-NP
,	POS	O
GFR	POS	O
,	POS	O
glomerular	POS	O
planar	POS	O
area	POS	O
,	POS	O
renal	POS	O
cortical	POS	O
malondialdehyde	POS	O
content	POS	O
,	POS	O
or	POS	O
glomerular	POS	O
or	POS	O
tubulointerstitial	POS	B-NP
damage	POS	I-NP
,	POS	O
compared	POS	O
with	POS	O
untreated	POS	O
animals	POS	O
(	POS	O
n	POS	O
=	POS	O
4	POS	O
)	POS	O
.	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
treatment	POS	O
reduced	POS	O
the	POS	O
steady	POS	O
state	POS	O
renal	POS	O
IGF	POS	O
-	POS	O
I	POS	O
mRNA	POS	O
level	POS	O
but	POS	O
did	POS	O
not	POS	O
modify	POS	O
gene	POS	O
expression	POS	O
of	POS	O
the	POS	O
IGF	POS	O
-	POS	O
I	POS	O
or	POS	O
GH	POS	O
receptors	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
:	POS	O
1	POS	O
)	POS	O
administration	POS	O
of	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
improves	POS	O
growth	POS	O
and	POS	O
GFR	POS	O
in	POS	O
rats	POS	O
with	POS	O
chronic	POS	O
PAN	POS	O
nephropathy	POS	B-NP
and	POS	O
2	POS	O
)	POS	O
unlike	POS	O
rhGH	POS	O
,	POS	O
long	POS	O
-	POS	O
term	POS	O
use	POS	O
of	POS	O
rhIGF	POS	O
-	POS	O
I	POS	O
does	POS	O
not	POS	O
worsen	POS	O
renal	POS	O
functional	POS	O
and	POS	O
structural	POS	O
injury	POS	O
in	POS	O
this	POS	O
disease	POS	O
model	POS	O
.	POS	O
Nefiracetam	POS	O
(	POS	O
DM	POS	B-NP
-	POS	O
9384	POS	O
)	POS	O
reverses	POS	O
apomorphine	POS	O
-	POS	O
induced	POS	O
amnesia	POS	B-NP
of	POS	O
a	POS	O
passive	POS	O
avoidance	POS	O
response	POS	O
:	POS	O
delayed	POS	O
emergence	POS	O
of	POS	O
the	POS	O
memory	POS	O
retention	POS	O
effects	POS	O
.	POS	O
Nefiracetam	POS	O
is	POS	O
a	POS	O
novel	POS	O
pyrrolidone	POS	O
derivative	POS	O
which	POS	O
attenuates	POS	O
scopolamine	POS	O
-	POS	O
induced	POS	O
learning	POS	O
and	POS	O
post	POS	O
-	POS	O
training	POS	O
consolidation	POS	O
deficits	POS	O
.	POS	O
Given	POS	O
that	POS	O
apomorphine	POS	O
inhibits	POS	O
passive	POS	O
avoidance	POS	O
retention	POS	O
when	POS	O
given	POS	O
during	POS	O
training	POS	O
or	POS	O
in	POS	O
a	POS	O
defined	POS	O
10	POS	O
-	POS	O
12h	POS	O
post	POS	O
-	POS	O
training	POS	O
period	POS	O
,	POS	O
we	POS	O
evaluated	POS	O
the	POS	O
ability	POS	O
of	POS	O
nefiracetam	POS	O
to	POS	O
attenuate	POS	O
amnesia	POS	B-NP
induced	POS	O
by	POS	O
dopaminergic	POS	O
agonism	POS	O
.	POS	O
A	POS	O
step	POS	O
-	POS	O
down	POS	O
passive	POS	O
avoidance	POS	O
paradigm	POS	O
was	POS	O
employed	POS	O
and	POS	O
nefiracetam	POS	O
(	POS	O
3	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
apomorphine	POS	O
(	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
were	POS	O
given	POS	O
alone	POS	O
or	POS	O
in	POS	O
combination	POS	O
during	POS	O
training	POS	O
and	POS	O
at	POS	O
the	POS	O
10	POS	O
-	POS	O
12h	POS	O
post	POS	O
-	POS	O
training	POS	O
period	POS	O
of	POS	O
consolidation	POS	O
.	POS	O
Co	POS	O
-	POS	O
administration	POS	O
of	POS	O
nefiracetam	POS	O
and	POS	O
apomorphine	POS	O
during	POS	O
training	POS	O
or	POS	O
10h	POS	O
thereafter	POS	O
produced	POS	O
no	POS	O
significant	POS	O
anti	POS	O
-	POS	O
amnesic	POS	O
effect	POS	O
.	POS	O
However	POS	O
,	POS	O
administration	POS	O
of	POS	O
nefiracetam	POS	O
during	POS	O
training	POS	O
completely	POS	O
reversed	POS	O
the	POS	O
amnesia	POS	B-NP
induced	POS	O
by	POS	O
apomorphine	POS	O
at	POS	O
the	POS	O
10h	POS	O
post	POS	O
-	POS	O
training	POS	O
time	POS	O
and	POS	O
the	POS	O
converse	POS	O
was	POS	O
also	POS	O
true	POS	O
.	POS	O
These	POS	O
effects	POS	O
were	POS	O
not	POS	O
mediated	POS	O
by	POS	O
a	POS	O
dopaminergic	POS	O
mechanism	POS	O
as	POS	O
nefiracetam	POS	O
,	POS	O
at	POS	O
millimolar	POS	O
concentrations	POS	O
,	POS	O
failed	POS	O
to	POS	O
displace	POS	O
either	POS	O
[	POS	O
3H	POS	O
]	POS	O
SCH	POS	O
23390	POS	O
or	POS	O
[	POS	O
3H	POS	O
]	POS	O
spiperone	POS	O
binding	POS	O
from	POS	O
D1	POS	O
or	POS	O
D2	POS	O
dopamine	POS	O
receptor	POS	O
subtypes	POS	O
,	POS	O
respectively	POS	O
.	POS	O
It	POS	O
is	POS	O
suggested	POS	O
that	POS	O
nefiracetam	POS	O
augments	POS	O
molecular	POS	O
processes	POS	O
in	POS	O
the	POS	O
early	POS	O
stages	POS	O
of	POS	O
events	POS	O
which	POS	O
ultimately	POS	O
lead	POS	O
to	POS	O
consolidation	POS	O
of	POS	O
memory	POS	O
.	POS	O
Phenytoin	POS	O
encephalopathy	POS	B-NP
as	POS	O
probable	POS	O
idiosyncratic	POS	O
reaction	POS	O
:	POS	O
case	POS	O
report	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
phenytoin	POS	O
(	POS	O
DPH	POS	O
)	POS	O
encephalopathy	POS	B-NP
with	POS	O
increasing	POS	O
seizures	POS	B-NP
and	POS	O
EEG	POS	O
and	POS	O
mental	POS	O
changes	POS	O
is	POS	O
described	POS	O
.	POS	O
Despite	POS	O
adequate	POS	O
oral	POS	O
dosage	POS	O
of	POS	O
DPH	POS	O
(	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
/	POS	O
daily	POS	O
)	POS	O
the	POS	O
plasma	POS	O
level	POS	O
was	POS	O
very	POS	O
low	POS	O
(	POS	O
2	POS	O
.	POS	O
8	POS	O
microgramg	POS	O
/	POS	O
ml	POS	O
)	POS	O
.	POS	O
The	POS	O
encephalopathy	POS	B-NP
was	POS	O
probably	POS	O
an	POS	O
idiosyncratic	POS	O
and	POS	O
not	POS	O
toxic	POS	O
or	POS	O
allergic	POS	B-NP
reaction	POS	I-NP
.	POS	O
In	POS	O
fact	POS	O
the	POS	O
concentration	POS	O
of	POS	O
free	POS	O
DPH	POS	O
was	POS	O
normal	POS	O
,	POS	O
the	POS	O
patient	POS	O
presented	POS	O
a	POS	O
retarded	POS	O
morbilliform	POS	B-NP
rash	POS	I-NP
during	POS	O
DPH	POS	B-NP
treatment	POS	O
,	POS	O
the	POS	O
protidogram	POS	O
was	POS	O
normal	POS	O
,	POS	O
and	POS	O
an	POS	O
intradermic	POS	O
DPH	POS	O
injection	POS	O
had	POS	O
no	POS	O
local	POS	O
effect	POS	O
.	POS	O
The	POS	O
authors	POS	O
conclude	POS	O
that	POS	O
in	POS	O
a	POS	O
patient	POS	O
starting	POS	O
DPH	POS	O
treatment	POS	O
an	POS	O
unexpected	POS	O
increase	POS	O
in	POS	O
seizures	POS	B-NP
,	POS	O
with	POS	O
EEG	POS	O
and	POS	O
mental	POS	O
changes	POS	O
occurring	POS	O
simultaneously	POS	O
,	POS	O
should	POS	O
alert	POS	O
the	POS	O
physician	POS	O
to	POS	O
the	POS	O
possible	POS	O
need	POS	O
for	POS	O
eliminating	POS	O
DPH	POS	O
from	POS	O
the	POS	O
therapeutic	POS	O
regimen	POS	O
,	POS	O
even	POS	O
if	POS	O
plasma	POS	O
concentrations	POS	O
are	POS	O
low	POS	O
.	POS	O
Prevention	POS	O
and	POS	O
treatment	POS	O
of	POS	O
endometrial	POS	B-NP
disease	POS	I-NP
in	POS	O
climacteric	POS	B-NP
women	POS	O
receiving	POS	O
oestrogen	POS	O
therapy	POS	O
.	POS	O
The	POS	O
treatment	POS	O
regimens	POS	O
are	POS	O
described	POS	O
in	POS	O
74	POS	O
patients	POS	O
with	POS	O
endometrial	POS	B-NP
disease	POS	I-NP
among	POS	O
850	POS	O
climacteric	POS	B-NP
women	POS	O
receiving	POS	O
oestrogen	POS	O
therapy	POS	O
.	POS	O
Cystic	POS	B-NP
hyperplasia	POS	I-NP
was	POS	O
associated	POS	O
with	POS	O
unopposed	POS	O
oestrogen	POS	O
therapy	POS	O
without	POS	O
progestagen	POS	O
.	POS	O
Two	POS	O
courses	POS	O
of	POS	O
21	POS	O
days	POS	O
of	POS	O
5	POS	O
mg	POS	O
norethisterone	POS	O
daily	POS	O
caused	POS	O
reversion	POS	O
to	POS	O
normal	POS	O
in	POS	O
all	POS	O
57	POS	O
cases	POS	O
of	POS	O
cystic	POS	B-NP
hyperplasia	POS	I-NP
and	POS	O
6	POS	O
of	POS	O
the	POS	O
8	POS	O
cases	POS	O
of	POS	O
atypical	POS	O
hyperplasia	POS	B-NP
.	POS	O
4	POS	O
cases	POS	O
of	POS	O
endometrial	POS	B-NP
carcinoma	POS	I-NP
referred	POS	O
from	POS	O
elsewhere	POS	O
demonstrated	POS	O
the	POS	O
problems	POS	O
of	POS	O
inappropriate	POS	O
and	POS	O
unsupervised	POS	O
unopposed	POS	O
oestrogen	POS	O
therapy	POS	O
and	POS	O
the	POS	O
difficulty	POS	O
in	POS	O
distinguishing	POS	O
severe	POS	O
hyperplasia	POS	B-NP
from	POS	O
malignancy	POS	B-NP
.	POS	O
Cyclical	POS	O
low	POS	O
-	POS	O
dose	POS	O
oestrogen	POS	O
therapy	POS	O
with	POS	O
7	POS	O
-	POS	O
-	POS	O
13	POS	O
days	POS	O
of	POS	O
progestagen	POS	O
does	POS	O
not	POS	O
seem	POS	O
to	POS	O
increase	POS	O
the	POS	O
risk	POS	O
of	POS	O
endometrial	POS	B-NP
hyperplasia	POS	I-NP
or	POS	O
carcinoma	POS	B-NP
.	POS	O
Effects	POS	O
of	POS	O
exercise	POS	O
on	POS	O
the	POS	O
severity	POS	O
of	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
.	POS	O
The	POS	O
effect	POS	O
of	POS	O
exercise	POS	O
on	POS	O
the	POS	O
severity	POS	O
of	POS	O
isoproterenol	POS	O
-	POS	O
induced	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
was	POS	O
studied	POS	O
in	POS	O
male	POS	O
rats	POS	O
.	POS	O
Ninety	POS	O
-	POS	O
three	POS	O
rats	POS	O
were	POS	O
randomly	POS	O
divided	POS	O
into	POS	O
three	POS	O
groups	POS	O
.	POS	O
The	POS	O
exercise	POS	O
-	POS	O
isoproterenol	POS	O
(	POS	O
E	POS	O
-	POS	O
1	POS	O
)	POS	O
and	POS	O
exercise	POS	O
control	POS	O
(	POS	O
EC	POS	O
)	POS	O
groups	POS	O
exercised	POS	O
daily	POS	O
for	POS	O
thirty	POS	O
days	POS	O
on	POS	O
a	POS	O
treadmill	POS	O
at	POS	O
1	POS	O
mph	POS	O
,	POS	O
2	POS	O
%	POS	O
grade	POS	O
while	POS	O
animals	POS	O
of	POS	O
the	POS	O
sedentary	POS	O
-	POS	O
isoproterenol	POS	O
(	POS	O
S	POS	O
-	POS	O
I	POS	O
)	POS	O
group	POS	O
remained	POS	O
sedentary	POS	O
.	POS	O
Eight	POS	O
animals	POS	O
were	POS	O
assigned	POS	O
to	POS	O
the	POS	O
sedentary	POS	O
control	POS	O
(	POS	O
SC	POS	O
)	POS	O
group	POS	O
which	POS	O
remained	POS	O
sedentary	POS	O
throughout	POS	O
the	POS	O
experimental	POS	O
period	POS	O
.	POS	O
Forty	POS	O
-	POS	O
eight	POS	O
hours	POS	O
after	POS	O
the	POS	O
final	POS	O
exercise	POS	O
period	POS	O
,	POS	O
S	POS	O
-	POS	O
I	POS	O
and	POS	O
E	POS	O
-	POS	O
I	POS	O
animals	POS	O
received	POS	O
a	POS	O
single	POS	O
subcutaneous	POS	O
injection	POS	O
of	POS	O
isoproterenol	POS	O
(	POS	O
250	POS	O
mg	POS	O
/	POS	O
kg	POS	O
body	POS	O
weight	POS	O
)	POS	O
.	POS	O
Animals	POS	O
of	POS	O
the	POS	O
S	POS	O
-	POS	O
I	POS	O
group	POS	O
exhibited	POS	O
significantly	POS	O
(	POS	O
Pp	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
greater	POS	O
mortality	POS	O
from	POS	O
the	POS	O
effects	POS	O
of	POS	O
isoproterenol	POS	O
than	POS	O
animals	POS	O
of	POS	O
the	POS	O
E	POS	O
-	POS	O
I	POS	O
group	POS	O
.	POS	O
Serum	POS	O
CPK	POS	O
activity	POS	O
for	POS	O
E	POS	O
-	POS	O
I	POS	O
animals	POS	O
was	POS	O
significantly	POS	O
(	POS	O
p	POS	O
less	POS	O
than	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
greater	POS	O
than	POS	O
for	POS	O
animals	POS	O
in	POS	O
the	POS	O
S	POS	O
-	POS	O
I	POS	O
and	POS	O
EC	POS	O
groups	POS	O
twenty	POS	O
hours	POS	O
following	POS	O
isoproterenol	POS	O
injection	POS	O
.	POS	O
No	POS	O
statistically	POS	O
significant	POS	O
differences	POS	O
were	POS	O
observed	POS	O
between	POS	O
the	POS	O
two	POS	O
isoproterenol	POS	O
treated	POS	O
groups	POS	O
for	POS	O
severity	POS	O
of	POS	O
the	POS	O
induced	POS	O
lesions	POS	B-NP
,	POS	O
changes	POS	O
in	POS	O
heart	POS	O
weight	POS	O
,	POS	O
or	POS	O
heart	POS	O
weight	POS	O
to	POS	O
body	POS	O
weight	POS	O
ratios	POS	O
.	POS	O
The	POS	O
results	POS	O
indicated	POS	O
that	POS	O
exercise	POS	O
reduced	POS	O
the	POS	O
mortality	POS	O
associated	POS	O
with	POS	O
the	POS	O
effects	POS	O
of	POS	O
large	POS	O
dosages	POS	O
of	POS	O
isoproterenol	POS	O
but	POS	O
had	POS	O
little	POS	O
on	POS	O
the	POS	O
severity	POS	O
of	POS	O
the	POS	O
infarction	POS	B-NP
.	POS	O
Human	POS	O
corticotropin	POS	O
-	POS	O
releasing	POS	O
hormone	POS	O
and	POS	O
thyrotropin	POS	O
-	POS	O
releasing	POS	O
hormone	POS	O
modulate	POS	O
the	POS	O
hypercapnic	POS	O
ventilatory	POS	O
response	POS	O
in	POS	O
humans	POS	O
.	POS	O
Human	POS	O
corticotropin	POS	O
-	POS	O
releasing	POS	O
hormone	POS	O
(	POS	O
hCRH	POS	O
)	POS	O
and	POS	O
thyrotropin	POS	O
-	POS	O
releasing	POS	O
hormone	POS	O
(	POS	O
TRH	POS	O
)	POS	O
are	POS	O
known	POS	O
to	POS	O
stimulate	POS	O
ventilation	POS	O
after	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
administration	POS	O
in	POS	O
humans	POS	O
.	POS	O
In	POS	O
a	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
,	POS	O
single	POS	O
-	POS	O
blind	POS	O
study	POS	O
we	POS	O
aimed	POS	O
to	POS	O
clarify	POS	O
if	POS	O
both	POS	O
peptides	POS	O
act	POS	O
by	POS	O
altering	POS	O
central	POS	O
chemosensitivity	POS	O
.	POS	O
Two	POS	O
subsequent	POS	O
CO2	POS	O
-	POS	O
rebreathing	POS	O
tests	POS	O
were	POS	O
performed	POS	O
in	POS	O
healthy	POS	O
young	POS	O
volunteers	POS	O
.	POS	O
During	POS	O
the	POS	O
first	POS	O
test	POS	O
0	POS	O
.	POS	O
9	POS	O
%	POS	O
NaCl	POS	O
was	POS	O
given	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
;	POS	O
during	POS	O
the	POS	O
second	POS	O
test	POS	O
200	POS	O
micrograms	POS	O
of	POS	O
hCRH	POS	O
(	POS	O
n	POS	O
=	POS	O
12	POS	O
)	POS	O
or	POS	O
400	POS	O
micrograms	POS	O
of	POS	O
TRH	POS	O
(	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
was	POS	O
administered	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
Nine	POS	O
subjects	POS	O
received	POS	O
0	POS	O
.	POS	O
9	POS	O
%	POS	O
NaCl	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
during	POS	O
both	POS	O
rebreathing	POS	O
manoeuvres	POS	O
.	POS	O
The	POS	O
CO2	POS	O
-	POS	O
response	POS	O
curves	POS	O
for	POS	O
the	POS	O
two	POS	O
tests	POS	O
were	POS	O
compared	POS	O
within	POS	O
the	POS	O
same	POS	O
subject	POS	O
.	POS	O
In	POS	O
the	POS	O
hCRH	POS	O
group	POS	O
a	POS	O
marked	POS	O
parallel	POS	O
shift	POS	O
of	POS	O
the	POS	O
CO2	POS	O
-	POS	O
response	POS	O
curve	POS	O
to	POS	O
the	POS	O
left	POS	O
was	POS	O
observed	POS	O
after	POS	O
hCRH	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
.	POS	O
The	POS	O
same	POS	O
effect	POS	O
occurred	POS	O
following	POS	O
TRH	POS	O
but	POS	O
was	POS	O
less	POS	O
striking	POS	O
(	POS	O
P	POS	O
=	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
hCRH	POS	O
and	POS	O
TRH	POS	O
caused	POS	O
a	POS	O
reduction	POS	O
in	POS	O
the	POS	O
CO2	POS	O
threshold	POS	O
.	POS	O
The	POS	O
CO2	POS	O
-	POS	O
response	POS	O
curves	POS	O
in	POS	O
the	POS	O
control	POS	O
group	POS	O
were	POS	O
nearly	POS	O
identical	POS	O
.	POS	O
The	POS	O
results	POS	O
indicate	POS	O
an	POS	O
additive	POS	O
effect	POS	O
of	POS	O
both	POS	O
releasing	POS	O
hormones	POS	O
on	POS	O
the	POS	O
hypercapnic	POS	O
ventilatory	POS	O
response	POS	O
in	POS	O
humans	POS	O
,	POS	O
presumably	POS	O
independent	POS	O
of	POS	O
central	POS	O
chemosensitivity	POS	O
.	POS	O
Lamivudine	POS	O
is	POS	O
effective	POS	O
in	POS	O
suppressing	POS	O
hepatitis	POS	O
B	POS	O
virus	POS	O
DNA	POS	O
in	POS	O
Chinese	POS	O
hepatitis	POS	O
B	POS	O
surface	POS	O
antigen	POS	O
carriers	POS	O
:	POS	O
a	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
trial	POS	O
.	POS	O
Lamivudine	POS	O
is	POS	O
a	POS	O
novel	POS	O
2	POS	O
'	POS	O
,	POS	O
3	POS	O
'	POS	O
-	POS	O
dideoxy	POS	O
cytosine	POS	O
analogue	POS	O
that	POS	O
has	POS	O
potent	POS	O
inhibitory	POS	O
effects	POS	O
on	POS	O
hepatitis	POS	O
B	POS	O
virus	POS	O
replication	POS	O
in	POS	O
vitro	POS	O
and	POS	O
in	POS	O
vivo	POS	O
.	POS	O
We	POS	O
performed	POS	O
a	POS	O
single	POS	O
-	POS	O
blind	POS	O
,	POS	O
placebo	POS	O
-	POS	O
controlled	POS	O
study	POS	O
to	POS	O
assess	POS	O
its	POS	O
effectiveness	POS	O
and	POS	O
safety	POS	O
in	POS	O
Chinese	POS	O
hepatitis	POS	O
B	POS	O
surface	POS	O
antigen	POS	O
(	POS	O
HBsAg	POS	O
)	POS	O
carriers	POS	O
.	POS	O
Forty	POS	O
-	POS	O
two	POS	O
Chinese	POS	O
HBsAg	POS	O
carriers	POS	O
were	POS	O
randomized	POS	O
to	POS	O
receive	POS	O
placebo	POS	O
(	POS	O
6	POS	O
patients	POS	O
)	POS	O
or	POS	O
lamivudine	POS	O
orally	POS	O
in	POS	O
dosages	POS	O
of	POS	O
25	POS	O
mg	POS	O
,	POS	O
100	POS	O
mg	POS	O
,	POS	O
or	POS	O
300	POS	O
mg	POS	O
daily	POS	O
(	POS	O
12	POS	O
patients	POS	O
for	POS	O
each	POS	O
dosage	POS	O
)	POS	O
.	POS	O
The	POS	O
drug	POS	O
was	POS	O
given	POS	O
for	POS	O
4	POS	O
weeks	POS	O
.	POS	O
The	POS	O
patients	POS	O
were	POS	O
closely	POS	O
monitored	POS	O
clinically	POS	O
,	POS	O
biochemically	POS	O
,	POS	O
and	POS	O
serologically	POS	O
up	POS	O
to	POS	O
4	POS	O
weeks	POS	O
after	POS	O
drug	POS	O
treatment	POS	O
.	POS	O
All	POS	O
36	POS	O
patients	POS	O
receiving	POS	O
lamivudine	POS	O
had	POS	O
a	POS	O
decrease	POS	O
in	POS	O
hepatitis	POS	B-NP
B	POS	I-NP
virus	POS	O
(	POS	O
HBV	POS	O
)	POS	O
DNA	POS	O
values	POS	O
of	POS	O
>	POS	O
90	POS	O
%	POS	O
(	POS	O
P	POS	O
<	POS	O
.	POS	O
001	POS	O
compared	POS	O
with	POS	O
placebo	POS	O
)	POS	O
.	POS	O
Although	POS	O
25	POS	O
mg	POS	O
of	POS	O
lamivudine	POS	O
was	POS	O
slightly	POS	O
less	POS	O
effective	POS	O
than	POS	O
100	POS	O
mg	POS	O
(	POS	O
P	POS	O
=	POS	O
.	POS	O
011	POS	O
)	POS	O
and	POS	O
300	POS	O
mg	POS	O
(	POS	O
P	POS	O
=	POS	O
.	POS	O
005	POS	O
)	POS	O
,	POS	O
it	POS	O
still	POS	O
induced	POS	O
94	POS	O
%	POS	O
suppression	POS	O
of	POS	O
HBV	POS	O
DNA	POS	O
after	POS	O
the	POS	O
fourth	POS	O
week	POS	O
of	POS	O
therapy	POS	O
.	POS	O
HBV	POS	O
DNA	POS	O
values	POS	O
returned	POS	O
to	POS	O
pretreatment	POS	O
levels	POS	O
within	POS	O
4	POS	O
weeks	POS	O
of	POS	O
cessation	POS	O
of	POS	O
therapy	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
change	POS	O
in	POS	O
the	POS	O
hepatitis	POS	O
B	POS	O
e	POS	O
antigen	POS	O
status	POS	O
or	POS	O
in	POS	O
aminotransferase	POS	O
levels	POS	O
.	POS	O
No	POS	O
serious	POS	O
adverse	POS	O
events	POS	O
were	POS	O
observed	POS	O
.	POS	O
In	POS	O
conclusion	POS	O
,	POS	O
a	POS	O
4	POS	O
-	POS	O
week	POS	O
course	POS	O
of	POS	O
lamivudine	POS	O
was	POS	O
safe	POS	O
and	POS	O
effective	POS	O
in	POS	O
suppression	POS	O
of	POS	O
HBV	POS	O
DNA	POS	O
in	POS	O
Chinese	POS	O
HBsAg	POS	O
carriers	POS	O
.	POS	O
The	POS	O
suppression	POS	O
was	POS	O
>	POS	O
90	POS	O
%	POS	O
but	POS	O
reversible	POS	O
.	POS	O
Studies	POS	O
with	POS	O
long	POS	O
-	POS	O
term	POS	O
lamivudine	POS	O
administration	POS	O
should	POS	O
be	POS	O
performed	POS	O
to	POS	O
determine	POS	O
if	POS	O
prolonged	POS	O
suppression	POS	O
of	POS	O
HBV	POS	O
DNA	POS	O
can	POS	O
be	POS	O
achieved	POS	O
.	POS	O
Population	POS	O
-	POS	O
based	POS	O
study	POS	O
of	POS	O
risk	POS	O
of	POS	O
venous	POS	B-NP
thromboembolism	POS	I-NP
associated	POS	O
with	POS	O
various	POS	O
oral	POS	O
contraceptives	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
Four	POS	O
studies	POS	O
published	POS	O
since	POS	O
December	POS	O
,	POS	O
1995	POS	O
,	POS	O
reported	POS	O
that	POS	O
the	POS	O
incidence	POS	O
of	POS	O
venous	POS	B-NP
thromboembolism	POS	I-NP
(	POS	O
VTE	POS	B-NP
)	POS	O
was	POS	O
higher	POS	O
in	POS	O
women	POS	O
who	POS	O
used	POS	O
oral	POS	O
contraceptives	POS	O
(	POS	O
OCs	POS	O
)	POS	O
containing	POS	O
the	POS	O
third	POS	O
-	POS	O
generation	POS	O
progestagens	POS	O
gestodene	POS	O
or	POS	O
desogestrel	POS	O
than	POS	O
in	POS	O
users	POS	O
of	POS	O
OCs	POS	O
containing	POS	O
second	POS	O
-	POS	O
generation	POS	O
progestagens	POS	O
.	POS	O
However	POS	O
,	POS	O
confounding	POS	O
and	POS	O
bias	POS	O
in	POS	O
the	POS	O
design	POS	O
of	POS	O
these	POS	O
studies	POS	O
may	POS	O
have	POS	O
affected	POS	O
the	POS	O
findings	POS	O
.	POS	O
The	POS	O
aim	POS	O
of	POS	O
our	POS	O
study	POS	O
was	POS	O
to	POS	O
re	POS	O
-	POS	O
examine	POS	O
the	POS	O
association	POS	O
between	POS	O
risk	POS	O
of	POS	O
VTE	POS	B-NP
and	POS	O
OC	POS	O
use	POS	O
with	POS	O
a	POS	O
different	POS	O
study	POS	O
design	POS	O
and	POS	O
analysis	POS	O
to	POS	O
avoid	POS	O
some	POS	O
of	POS	O
the	POS	O
bias	POS	O
and	POS	O
confounding	POS	O
of	POS	O
the	POS	O
earlier	POS	O
studies	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
We	POS	O
used	POS	O
computer	POS	O
records	POS	O
of	POS	O
patients	POS	O
from	POS	O
143	POS	O
general	POS	O
practices	POS	O
in	POS	O
the	POS	O
UK	POS	O
.	POS	O
The	POS	O
study	POS	O
was	POS	O
based	POS	O
on	POS	O
the	POS	O
medical	POS	O
records	POS	O
of	POS	O
about	POS	O
540	POS	O
,	POS	O
000	POS	O
women	POS	O
born	POS	O
between	POS	O
1941	POS	O
and	POS	O
1981	POS	O
.	POS	O
All	POS	O
women	POS	O
who	POS	O
had	POS	O
a	POS	O
recorded	POS	O
diagnosis	POS	O
of	POS	O
deep	POS	B-NP
-	POS	I-NP
vein	POS	I-NP
thrombosis	POS	I-NP
,	POS	O
venous	POS	B-NP
thrombosis	POS	I-NP
not	POS	O
otherwise	POS	O
specified	POS	O
,	POS	O
or	POS	O
pulmonary	POS	B-NP
embolus	POS	I-NP
during	POS	O
the	POS	O
study	POS	O
period	POS	O
,	POS	O
and	POS	O
who	POS	O
had	POS	O
been	POS	O
treated	POS	O
with	POS	O
an	POS	O
anticoagulant	POS	O
were	POS	O
identified	POS	O
as	POS	O
potential	POS	O
cases	POS	O
of	POS	O
VTE	POS	B-NP
.	POS	O
We	POS	O
did	POS	O
a	POS	O
cohort	POS	O
analysis	POS	O
to	POS	O
estimate	POS	O
and	POS	O
compare	POS	O
incidence	POS	O
of	POS	O
VTE	POS	B-NP
in	POS	O
users	POS	O
of	POS	O
the	POS	O
main	POS	O
OC	POS	O
preparations	POS	O
,	POS	O
and	POS	O
a	POS	O
nested	POS	O
case	POS	O
-	POS	O
control	POS	O
study	POS	O
to	POS	O
calculate	POS	O
the	POS	O
odds	POS	O
ratios	POS	O
of	POS	O
VTE	POS	B-NP
associated	POS	O
with	POS	O
use	POS	O
of	POS	O
different	POS	O
types	POS	O
of	POS	O
OC	POS	O
,	POS	O
after	POS	O
adjustment	POS	O
for	POS	O
potential	POS	O
confounding	POS	O
factors	POS	O
.	POS	O
In	POS	O
the	POS	O
case	POS	O
-	POS	O
control	POS	O
study	POS	O
,	POS	O
we	POS	O
matched	POS	O
cases	POS	O
to	POS	O
controls	POS	O
by	POS	O
exact	POS	O
year	POS	O
of	POS	O
birth	POS	O
,	POS	O
practice	POS	O
,	POS	O
and	POS	O
current	POS	O
use	POS	O
of	POS	O
OCs	POS	O
.	POS	O
We	POS	O
used	POS	O
a	POS	O
multiple	POS	O
logistic	POS	O
regression	POS	O
model	POS	O
that	POS	O
included	POS	O
body	POS	O
-	POS	O
mass	POS	O
index	POS	O
,	POS	O
number	POS	O
of	POS	O
cycles	POS	O
,	POS	O
change	POS	O
in	POS	O
type	POS	O
of	POS	O
OC	POS	O
prescribed	POS	O
within	POS	O
3	POS	O
months	POS	O
of	POS	O
the	POS	O
event	POS	O
,	POS	O
previous	POS	O
pregnancy	POS	O
,	POS	O
and	POS	O
concurrent	POS	O
disease	POS	O
.	POS	O
FINDINGS	POS	O
:	POS	O
85	POS	O
women	POS	O
met	POS	O
the	POS	O
inclusion	POS	O
criteria	POS	O
for	POS	O
VTE	POS	B-NP
,	POS	O
two	POS	O
of	POS	O
whom	POS	O
were	POS	O
users	POS	O
of	POS	O
progestagen	POS	O
-	POS	O
only	POS	O
OCs	POS	O
.	POS	O
Of	POS	O
the	POS	O
83	POS	O
cases	POS	O
of	POS	O
VTE	POS	B-NP
associated	POS	O
with	POS	O
use	POS	O
of	POS	O
combined	POS	O
OCs	POS	O
,	POS	O
43	POS	O
were	POS	O
recorded	POS	O
as	POS	O
deep	POS	B-NP
-	POS	I-NP
vein	POS	I-NP
thrombosis	POS	I-NP
,	POS	O
35	POS	O
as	POS	O
pulmonary	POS	B-NP
thrombosis	POS	I-NP
,	POS	O
and	POS	O
five	POS	O
as	POS	O
venous	POS	B-NP
thrombosis	POS	I-NP
not	POS	O
otherwise	POS	O
specified	POS	O
.	POS	O
The	POS	O
crude	POS	O
rate	POS	O
of	POS	O
VTE	POS	B-NP
per	POS	O
10	POS	O
,	POS	O
000	POS	O
woman	POS	O
-	POS	O
years	POS	O
was	POS	O
4	POS	O
.	POS	O
10	POS	O
in	POS	O
current	POS	O
users	POS	O
of	POS	O
any	POS	O
OC	POS	O
,	POS	O
3	POS	O
.	POS	O
10	POS	O
in	POS	O
users	POS	O
of	POS	O
second	POS	O
-	POS	O
generation	POS	O
OCs	POS	O
,	POS	O
and	POS	O
4	POS	O
.	POS	O
96	POS	O
in	POS	O
users	POS	O
of	POS	O
third	POS	O
-	POS	O
generation	POS	O
preparations	POS	O
.	POS	O
After	POS	O
adjustment	POS	O
for	POS	O
age	POS	O
,	POS	O
the	POS	O
rate	POS	O
ratio	POS	O
of	POS	O
VTE	POS	B-NP
in	POS	O
users	POS	O
of	POS	O
third	POS	O
-	POS	O
generation	POS	O
relative	POS	O
to	POS	O
second	POS	O
-	POS	O
generation	POS	O
OCs	POS	O
was	POS	O
1	POS	O
.	POS	O
68	POS	O
(	POS	O
95	POS	O
%	POS	O
CI	POS	O
1	POS	O
.	POS	O
04	POS	O
-	POS	O
2	POS	O
.	POS	O
75	POS	O
)	POS	O
.	POS	O
Logistic	POS	O
regression	POS	O
showed	POS	O
no	POS	O
significant	POS	O
difference	POS	O
in	POS	O
the	POS	O
risk	POS	O
of	POS	O
VTE	POS	B-NP
between	POS	O
users	POS	O
of	POS	O
third	POS	O
-	POS	O
generation	POS	O
and	POS	O
second	POS	O
-	POS	O
generation	POS	O
OCs	POS	O
.	POS	O
Among	POS	O
users	POS	O
of	POS	O
third	POS	O
-	POS	O
generation	POS	O
progestagens	POS	O
,	POS	O
the	POS	O
risk	POS	O
of	POS	O
VTE	POS	B-NP
was	POS	O
higher	POS	O
in	POS	O
users	POS	O
of	POS	O
desogestrel	POS	O
with	POS	O
20	POS	O
g	POS	O
ethinyloestradiol	POS	O
than	POS	O
in	POS	O
users	POS	O
of	POS	O
gestodene	POS	O
or	POS	O
desogestrel	POS	O
with	POS	O
30	POS	O
g	POS	O
ethinyloestradiol	POS	O
.	POS	O
With	POS	O
all	POS	O
second	POS	O
-	POS	O
generation	POS	O
OCs	POS	O
as	POS	O
the	POS	O
reference	POS	O
,	POS	O
the	POS	O
odds	POS	O
ratios	POS	O
for	POS	O
VTE	POS	B-NP
were	POS	O
3	POS	O
.	POS	O
49	POS	O
(	POS	O
1	POS	O
.	POS	O
21	POS	O
-	POS	O
10	POS	O
.	POS	O
12	POS	O
)	POS	O
for	POS	O
desogestrel	POS	O
plus	POS	O
20	POS	O
g	POS	O
ethinyloestradiol	POS	O
and	POS	O
1	POS	O
.	POS	O
18	POS	O
(	POS	O
0	POS	O
.	POS	O
66	POS	O
-	POS	O
2	POS	O
.	POS	O
17	POS	O
)	POS	O
for	POS	O
the	POS	O
other	POS	O
third	POS	O
-	POS	O
generation	POS	O
progestagens	POS	O
.	POS	O
INTERPRETATION	POS	O
:	POS	O
The	POS	O
previously	POS	O
reported	POS	O
increase	POS	O
in	POS	O
odds	POS	O
ratio	POS	O
associated	POS	O
with	POS	O
third	POS	O
-	POS	O
generation	POS	O
OCs	POS	O
when	POS	O
compared	POS	O
with	POS	O
second	POS	O
-	POS	O
generation	POS	O
products	POS	O
is	POS	O
likely	POS	O
to	POS	O
have	POS	O
been	POS	O
the	POS	O
result	POS	O
of	POS	O
residual	POS	O
confounding	POS	O
by	POS	O
age	POS	O
.	POS	O
The	POS	O
increased	POS	O
odds	POS	O
ratio	POS	O
associated	POS	O
with	POS	O
products	POS	O
containing	POS	O
20	POS	O
micrograms	POS	O
ethinyloestradiol	POS	O
and	POS	O
desogestrel	POS	O
compared	POS	O
with	POS	O
the	POS	O
30	POS	O
micrograms	POS	O
product	POS	O
is	POS	O
biologically	POS	O
implausible	POS	O
,	POS	O
and	POS	O
is	POS	O
likely	POS	O
to	POS	O
be	POS	O
the	POS	O
result	POS	O
of	POS	O
preferential	POS	O
prescribing	POS	O
and	POS	O
,	POS	O
thus	POS	O
,	POS	O
confounding	POS	O
.	POS	O
MK	POS	O
-	POS	O
801	POS	O
augments	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
electrographic	POS	O
seizure	POS	B-NP
but	POS	O
protects	POS	O
against	POS	O
brain	POS	B-NP
damage	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
1	POS	O
.	POS	O
The	POS	O
authors	POS	O
examined	POS	O
the	POS	O
anticonvulsant	POS	O
effects	POS	O
of	POS	O
MK	POS	O
-	POS	O
801	POS	O
on	POS	O
the	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
seizure	POS	B-NP
model	POS	O
.	POS	O
Intraperitoneal	POS	O
injection	POS	O
of	POS	O
pilocarpine	POS	O
(	POS	O
400	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
induced	POS	O
tonic	POS	O
and	POS	O
clonic	POS	B-NP
seizure	POS	B-NP
.	POS	O
Scopolamine	POS	O
(	POS	O
10	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
and	POS	O
pentobarbital	POS	O
(	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
prevented	POS	O
development	POS	O
of	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
behavioral	POS	O
seizure	POS	B-NP
but	POS	O
MK	POS	O
-	POS	O
801	POS	O
(	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
)	POS	O
did	POS	O
not	POS	O
.	POS	O
2	POS	O
.	POS	O
An	POS	O
electrical	POS	O
seizure	POS	B-NP
measured	POS	O
with	POS	O
hippocampal	POS	O
EEG	POS	O
appeared	POS	O
in	POS	O
the	POS	O
pilocarpine	POS	O
-	POS	O
treated	POS	O
group	POS	O
.	POS	O
Scopolamine	POS	O
and	POS	O
pentobarbital	POS	O
blocked	POS	O
the	POS	O
pilocarpine	POS	O
-	POS	O
induced	POS	O
electrographic	POS	B-NP
seizure	POS	I-NP
,	POS	O
MK	POS	O
-	POS	O
801	POS	O
treatment	POS	O
augmented	POS	O
the	POS	O
electrographic	POS	O
seizure	POS	B-NP
induced	POS	O
by	POS	O
pilocarpine	POS	O
.	POS	O
3	POS	O
.	POS	O
Brain	POS	B-NP
damage	POS	I-NP
was	POS	O
assessed	POS	O
by	POS	O
examining	POS	O
the	POS	O
hippocampus	POS	O
microscopically	POS	O
.	POS	O
Pilocarpine	POS	O
produced	POS	O
neuronal	POS	O
death	POS	O
in	POS	O
the	POS	O
hippocampus	POS	O
,	POS	O
which	POS	O
showed	POS	O
pyknotic	POS	O
changes	POS	O
.	POS	O
Pentobarbital	POS	O
,	POS	O
scopolamine	POS	O
and	POS	O
MK	POS	O
-	POS	O
801	POS	O
protected	POS	O
the	POS	O
brain	POS	O
damage	POS	O
by	POS	O
pilocarpine	POS	O
,	POS	O
though	POS	O
in	POS	O
the	POS	O
MK	POS	O
-	POS	O
801	POS	O
-	POS	O
treated	POS	O
group	POS	O
,	POS	O
the	POS	O
pyramidal	POS	O
cells	POS	O
of	POS	O
hippocampus	POS	O
appeared	POS	O
darker	POS	O
than	POS	O
normal	POS	O
.	POS	O
In	POS	O
all	POS	O
treatments	POS	O
,	POS	O
granule	POS	O
cells	POS	O
of	POS	O
the	POS	O
dentate	POS	O
gyrus	POS	O
were	POS	O
not	POS	O
affected	POS	O
.	POS	O
4	POS	O
.	POS	O
These	POS	O
results	POS	O
indicate	POS	O
that	POS	O
status	POS	B-NP
epilepticus	POS	I-NP
induced	POS	O
by	POS	O
pilocarpine	POS	O
is	POS	O
initiated	POS	O
by	POS	O
cholinergic	POS	O
overstimulation	POS	O
and	POS	O
propagated	POS	O
by	POS	O
glutamatergic	POS	O
transmission	POS	O
,	POS	O
the	POS	O
elevation	POS	O
of	POS	O
which	POS	O
may	POS	O
cause	POS	O
brain	POS	O
damage	POS	O
through	POS	O
an	POS	O
excitatory	POS	O
NMDA	POS	O
receptor	POS	O
-	POS	O
mediated	POS	O
mechanism	POS	O
.	POS	O
Paclitaxel	POS	O
,	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
,	POS	O
and	POS	O
folinic	POS	O
acid	POS	O
in	POS	O
metastatic	POS	O
breast	POS	B-NP
cancer	POS	I-NP
:	POS	O
BRE	POS	O
-	POS	O
26	POS	O
,	POS	O
a	POS	O
phase	POS	O
II	POS	O
trial	POS	O
.	POS	O
5	POS	O
-	POS	O
Fluorouracil	POS	O
plus	POS	O
folinic	POS	O
acid	POS	O
and	POS	O
paclitaxel	POS	O
(	POS	O
Taxol	POS	O
;	POS	O
Bristol	POS	O
-	POS	O
Myers	POS	O
Squibb	POS	O
Company	POS	O
,	POS	O
Princeton	POS	O
,	POS	O
NJ	POS	O
)	POS	O
are	POS	O
effective	POS	O
salvage	POS	O
therapies	POS	O
for	POS	O
metastatic	POS	O
breast	POS	B-NP
cancer	POS	I-NP
patients	POS	O
.	POS	O
Paclitaxel	POS	O
and	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
have	POS	O
additive	POS	O
cytotoxicity	POS	B-NP
in	POS	O
MCF	POS	O
-	POS	O
7	POS	O
cell	POS	O
lines	POS	O
.	POS	O
We	POS	O
performed	POS	O
a	POS	O
phase	POS	O
II	POS	O
trial	POS	O
of	POS	O
paclitaxel	POS	O
175	POS	O
mg	POS	O
/	POS	O
m2	POS	O
over	POS	O
3	POS	O
hours	POS	O
on	POS	O
day	POS	O
I	POS	O
followed	POS	O
by	POS	O
folinic	POS	O
acid	POS	O
300	POS	O
mg	POS	O
over	POS	O
1	POS	O
hour	POS	O
before	POS	O
5	POS	O
-	POS	O
fluorouracil	POS	O
350	POS	O
mg	POS	O
/	POS	O
m2	POS	O
on	POS	O
days	POS	O
1	POS	O
to	POS	O
3	POS	O
every	POS	O
28	POS	O
days	POS	O
(	POS	O
TFL	POS	O
)	POS	O
in	POS	O
women	POS	O
with	POS	O
metastatic	POS	O
breast	POS	B-NP
cancer	POS	I-NP
.	POS	O
Analysis	POS	O
is	POS	O
reported	POS	O
on	POS	O
37	POS	O
patients	POS	O
with	POS	O
a	POS	O
minimum	POS	O
of	POS	O
6	POS	O
months	POS	O
follow	POS	O
-	POS	O
up	POS	O
who	POS	O
received	POS	O
a	POS	O
total	POS	O
of	POS	O
192	POS	O
cycles	POS	O
of	POS	O
TFL	POS	O
:	POS	O
nine	POS	O
cycles	POS	O
(	POS	O
5	POS	O
%	POS	O
)	POS	O
were	POS	O
associated	POS	O
with	POS	O
grade	POS	O
3	POS	O
/	POS	O
4	POS	O
neutropenia	POS	B-NP
requiring	POS	O
hospitalization	POS	O
;	POS	O
seven	POS	O
(	POS	O
4	POS	O
%	POS	O
)	POS	O
cycles	POS	O
in	POS	O
two	POS	O
patients	POS	O
required	POS	O
granulocyte	POS	O
colony	POS	O
-	POS	O
stimulating	POS	O
factor	POS	O
due	POS	O
to	POS	O
neutropenia	POS	B-NP
;	POS	O
no	POS	O
patient	POS	O
required	POS	O
platelet	POS	B-NP
transfusions	POS	I-NP
.	POS	O
Grade	POS	O
3	POS	O
/	POS	O
4	POS	O
nonhematologic	POS	O
toxicities	POS	B-NP
were	POS	O
uncommon	POS	O
.	POS	O
Among	POS	O
the	POS	O
34	POS	O
patients	POS	O
evaluable	POS	O
for	POS	O
response	POS	O
,	POS	O
there	POS	O
were	POS	O
three	POS	O
complete	POS	O
responses	POS	O
(	POS	O
9	POS	O
%	POS	O
)	POS	O
and	POS	O
18	POS	O
partial	POS	O
responses	POS	O
(	POS	O
53	POS	O
%	POS	O
)	POS	O
for	POS	O
an	POS	O
overall	POS	O
response	POS	O
rate	POS	O
of	POS	O
62	POS	O
%	POS	O
.	POS	O
Of	POS	O
the	POS	O
19	POS	O
evaluable	POS	O
patients	POS	O
with	POS	O
prior	POS	O
doxorubicin	POS	O
exposure	POS	O
,	POS	O
11	POS	O
(	POS	O
58	POS	O
%	POS	O
)	POS	O
responded	POS	O
compared	POS	O
with	POS	O
nine	POS	O
of	POS	O
15	POS	O
(	POS	O
60	POS	O
%	POS	O
)	POS	O
without	POS	O
prior	POS	O
doxorubicin	POS	O
.	POS	O
Plasma	POS	O
paclitaxel	POS	O
concentrations	POS	O
were	POS	O
measured	POS	O
at	POS	O
the	POS	O
completion	POS	O
of	POS	O
paclitaxel	POS	O
infusion	POS	O
and	POS	O
at	POS	O
24	POS	O
hours	POS	O
in	POS	O
19	POS	O
patients	POS	O
.	POS	O
TFL	POS	O
is	POS	O
an	POS	O
active	POS	O
,	POS	O
well	POS	O
-	POS	O
tolerated	POS	O
regimen	POS	O
in	POS	O
metastatic	POS	O
breast	POS	B-NP
cancer	POS	I-NP
.	POS	O
Efficacy	POS	O
and	POS	O
proarrhythmia	POS	B-NP
with	POS	O
the	POS	O
use	POS	O
of	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
for	POS	O
sustained	POS	O
ventricular	POS	B-NP
tachyarrhythmias	POS	I-NP
.	POS	O
This	POS	O
study	POS	O
prospectively	POS	O
evaluated	POS	O
the	POS	O
clinical	POS	O
efficacy	POS	O
,	POS	O
the	POS	O
incidence	POS	O
of	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
,	POS	O
and	POS	O
the	POS	O
presumable	POS	O
risk	POS	O
factors	POS	O
for	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
in	POS	O
patients	POS	O
treated	POS	O
with	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
for	POS	O
sustained	POS	O
ventricular	POS	B-NP
tachyarrhythmias	POS	I-NP
.	POS	O
Eighty	POS	O
-	POS	O
one	POS	O
consecutive	POS	O
patients	POS	O
(	POS	O
54	POS	O
with	POS	O
coronary	POS	B-NP
artery	POS	I-NP
disease	POS	I-NP
,	POS	O
and	POS	O
20	POS	O
with	POS	O
dilated	POS	B-NP
cardiomyopathy	POS	I-NP
)	POS	O
with	POS	O
inducible	POS	O
sustained	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
or	POS	O
ventricular	POS	B-NP
fibrillation	POS	I-NP
received	POS	O
oral	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
to	POS	O
prevent	POS	O
induction	POS	O
of	POS	O
the	POS	O
ventricular	POS	B-NP
tachyarrhythmia	POS	I-NP
.	POS	O
During	POS	O
oral	POS	O
loading	POS	O
with	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
,	POS	O
continuous	POS	O
electrocardiographic	POS	O
(	POS	O
ECG	POS	O
)	POS	O
monitoring	POS	O
was	POS	O
performed	POS	O
.	POS	O
Those	POS	O
patients	POS	O
in	POS	O
whom	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
prevented	POS	O
induction	POS	O
of	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
or	POS	O
ventricular	POS	B-NP
fibrillation	POS	I-NP
were	POS	O
discharged	POS	O
with	POS	O
the	POS	O
drug	POS	O
and	POS	O
followed	POS	O
up	POS	O
on	POS	O
an	POS	O
outpatient	POS	O
basis	POS	O
for	POS	O
21	POS	O
+	POS	O
/	POS	O
-	POS	O
18	POS	O
months	POS	O
.	POS	O
Induction	POS	O
of	POS	O
the	POS	O
ventricular	POS	B-NP
tachyarrhythmia	POS	I-NP
was	POS	O
prevented	POS	O
by	POS	O
oral	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
in	POS	O
35	POS	O
(	POS	O
43	POS	O
%	POS	O
)	POS	O
patients	POS	O
;	POS	O
the	POS	O
ventricular	POS	B-NP
tachyarrhythmia	POS	I-NP
remained	POS	O
inducible	POS	O
in	POS	O
40	POS	O
(	POS	O
49	POS	O
%	POS	O
)	POS	O
patients	POS	O
;	POS	O
and	POS	O
two	POS	O
(	POS	O
2	POS	O
.	POS	O
5	POS	O
%	POS	O
)	POS	O
patients	POS	O
did	POS	O
not	POS	O
tolerate	POS	O
even	POS	O
40	POS	O
mg	POS	O
of	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
once	POS	O
daily	POS	O
.	POS	O
Four	POS	O
(	POS	O
5	POS	O
%	POS	O
)	POS	O
patients	POS	O
had	POS	O
from	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
during	POS	O
the	POS	O
initial	POS	O
oral	POS	O
treatment	POS	O
with	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
.	POS	O
Neither	POS	O
ECG	POS	O
[	POS	O
sinus	POS	O
-	POS	O
cycle	POS	O
length	POS	O
(	POS	O
SCL	POS	O
)	POS	O
,	POS	O
QT	POS	O
or	POS	O
QTc	POS	O
interval	POS	O
,	POS	O
or	POS	O
U	POS	O
wave	POS	O
]	POS	O
nor	POS	O
clinical	POS	O
parameters	POS	O
identified	POS	O
patients	POS	O
at	POS	O
risk	POS	O
for	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
.	POS	O
However	POS	O
,	POS	O
the	POS	O
oral	POS	O
dose	POS	O
of	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
was	POS	O
significantly	POS	O
lower	POS	O
in	POS	O
patients	POS	O
with	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
(	POS	O
200	POS	O
+	POS	O
/	POS	O
-	POS	O
46	POS	O
vs	POS	O
.	POS	O
328	POS	O
+	POS	O
/	POS	O
-	POS	O
53	POS	O
mg	POS	O
/	POS	O
day	POS	O
;	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
0017	POS	O
)	POS	O
.	POS	O
Risk	POS	O
factors	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
were	POS	O
the	POS	O
appearance	POS	O
of	POS	O
an	POS	O
U	POS	O
wave	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
049	POS	O
)	POS	O
,	POS	O
female	POS	O
gender	POS	O
(	POS	O
p	POS	O
=	POS	O
0	POS	O
.	POS	O
015	POS	O
)	POS	O
,	POS	O
and	POS	O
significant	POS	O
dose	POS	O
-	POS	O
corrected	POS	O
changes	POS	O
of	POS	O
SCL	POS	O
,	POS	O
QT	POS	O
interval	POS	O
,	POS	O
and	POS	O
QTc	POS	O
interval	POS	O
(	POS	O
p	POS	O
<	POS	O
0	POS	O
.	POS	O
05	POS	O
)	POS	O
.	POS	O
During	POS	O
follow	POS	O
-	POS	O
up	POS	O
,	POS	O
seven	POS	O
(	POS	O
20	POS	O
%	POS	O
)	POS	O
patients	POS	O
had	POS	O
a	POS	O
nonfatal	POS	O
ventricular	POS	B-NP
tachycardia	POS	I-NP
recurrence	POS	O
,	POS	O
and	POS	O
two	POS	O
(	POS	O
6	POS	O
%	POS	O
)	POS	O
patients	POS	O
died	POS	O
suddenly	POS	O
.	POS	O
One	POS	O
female	POS	O
patient	POS	O
with	POS	O
stable	POS	O
cardiac	POS	B-NP
disease	POS	I-NP
had	POS	O
recurrent	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
after	POS	O
2	POS	O
years	POS	O
of	POS	O
successful	POS	O
treatment	POS	O
with	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
.	POS	O
Torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
occurred	POS	O
early	POS	O
during	POS	O
treatment	POS	O
even	POS	O
with	POS	O
low	POS	O
doses	POS	O
of	POS	O
oral	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
.	POS	O
Pronounced	POS	O
changes	POS	O
in	POS	O
the	POS	O
surface	POS	O
ECG	POS	O
(	POS	O
cycle	POS	O
length	POS	O
,	POS	O
QT	POS	O
,	POS	O
and	POS	O
QTc	POS	O
)	POS	O
in	POS	O
relation	POS	O
to	POS	O
the	POS	O
dose	POS	O
of	POS	O
oral	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
might	POS	O
identify	POS	O
a	POS	O
subgroup	POS	O
of	POS	O
patients	POS	O
with	POS	O
an	POS	O
increased	POS	O
risk	POS	O
for	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
.	POS	O
Other	POS	O
ECG	POS	O
parameters	POS	O
before	POS	O
the	POS	O
application	POS	O
of	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
did	POS	O
not	POS	O
identify	POS	O
patients	POS	O
at	POS	O
increased	POS	O
risk	POS	O
for	POS	O
torsades	POS	B-NP
de	POS	I-NP
pointes	POS	I-NP
.	POS	O
Recurrence	POS	O
rates	POS	O
of	POS	O
ventricular	POS	B-NP
tachyarrhythmias	POS	I-NP
are	POS	O
high	POS	O
despite	POS	O
complete	POS	O
suppression	POS	O
of	POS	O
the	POS	O
arrhythmia	POS	B-NP
during	POS	O
programmed	POS	O
stimulation	POS	O
.	POS	O
Therefore	POS	O
programmed	POS	O
electrical	POS	O
stimulation	POS	O
in	POS	O
the	POS	O
case	POS	O
of	POS	O
d	POS	O
,	POS	O
l	POS	O
-	POS	O
sotalol	POS	O
seems	POS	O
to	POS	O
be	POS	O
of	POS	O
limited	POS	O
prognostic	POS	O
value	POS	O
.	POS	O
Chronic	POS	O
hyperprolactinemia	POS	B-NP
and	POS	O
changes	POS	O
in	POS	O
dopamine	POS	O
neurons	POS	O
.	POS	O
The	POS	O
tuberoinfundibular	POS	O
dopaminergic	POS	O
(	POS	O
TIDA	POS	O
)	POS	O
system	POS	O
is	POS	O
known	POS	O
to	POS	O
inhibit	POS	O
prolactin	POS	O
(	POS	O
PRL	POS	O
)	POS	O
secretion	POS	O
.	POS	O
In	POS	O
young	POS	O
animals	POS	O
this	POS	O
system	POS	O
responds	POS	O
to	POS	O
acute	POS	O
elevations	POS	O
in	POS	O
serum	POS	O
PRL	POS	O
by	POS	O
increasing	POS	O
its	POS	O
activity	POS	O
.	POS	O
However	POS	O
,	POS	O
this	POS	O
responsiveness	POS	O
is	POS	O
lost	POS	O
in	POS	O
aging	POS	O
rats	POS	O
with	POS	O
chronically	POS	O
high	POS	O
serum	POS	O
PRL	POS	O
levels	POS	O
.	POS	O
The	POS	O
purpose	POS	O
of	POS	O
this	POS	O
study	POS	O
was	POS	O
to	POS	O
induce	POS	O
hyperprolactinemia	POS	B-NP
in	POS	O
rats	POS	O
for	POS	O
extended	POS	O
periods	POS	O
of	POS	O
time	POS	O
and	POS	O
examine	POS	O
its	POS	O
effects	POS	O
on	POS	O
dopaminergic	POS	O
systems	POS	O
in	POS	O
the	POS	O
brain	POS	O
.	POS	O
Hyperprolactinemia	POS	B-NP
was	POS	O
induced	POS	O
by	POS	O
treatment	POS	O
with	POS	O
haloperidol	POS	O
,	POS	O
a	POS	O
dopamine	POS	O
receptor	POS	O
antagonist	POS	O
,	POS	O
and	POS	O
Palkovits	POS	O
'	POS	O
microdissection	POS	O
technique	POS	O
in	POS	O
combination	POS	O
with	POS	O
high	POS	O
-	POS	O
performance	POS	O
liquid	POS	O
chromatography	POS	O
was	POS	O
used	POS	O
to	POS	O
measure	POS	O
neurotransmitter	POS	O
concentrations	POS	O
in	POS	O
several	POS	O
areas	POS	O
of	POS	O
the	POS	O
brain	POS	O
.	POS	O
After	POS	O
6	POS	O
months	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
,	POS	O
dopamine	POS	O
(	POS	O
DA	POS	O
)	POS	O
concentrations	POS	O
in	POS	O
the	POS	O
median	POS	O
eminence	POS	O
(	POS	O
ME	POS	O
)	POS	O
increased	POS	O
by	POS	O
84	POS	O
%	POS	O
over	POS	O
the	POS	O
control	POS	O
group	POS	O
.	POS	O
Nine	POS	O
months	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
produced	POS	O
a	POS	O
50	POS	O
%	POS	O
increase	POS	O
in	POS	O
DA	POS	O
concentrations	POS	O
in	POS	O
the	POS	O
ME	POS	O
over	POS	O
the	POS	O
control	POS	O
group	POS	O
.	POS	O
However	POS	O
,	POS	O
DA	POS	O
response	POS	O
was	POS	O
lost	POS	O
if	POS	O
a	POS	O
9	POS	O
-	POS	O
month	POS	O
long	POS	O
haloperidol	POS	O
-	POS	O
induced	POS	O
hyperprolactinemia	POS	B-NP
was	POS	O
followed	POS	O
by	POS	O
a	POS	O
1	POS	O
1	POS	O
/	POS	O
2	POS	O
month	POS	O
-	POS	O
long	POS	O
extremely	POS	O
high	POS	O
increase	POS	O
in	POS	O
serum	POS	O
PRL	POS	O
levels	POS	O
produced	POS	O
by	POS	O
implantation	POS	O
of	POS	O
MMQ	POS	O
cells	POS	O
under	POS	O
the	POS	O
kidney	POS	O
capsule	POS	O
.	POS	O
There	POS	O
was	POS	O
no	POS	O
change	POS	O
in	POS	O
the	POS	O
levels	POS	O
of	POS	O
DA	POS	O
,	POS	O
norepinephrine	POS	O
(	POS	O
NE	POS	O
)	POS	O
,	POS	O
serotonin	POS	O
(	POS	O
5	POS	O
-	POS	O
HT	POS	O
)	POS	O
,	POS	O
or	POS	O
their	POS	O
metabolites	POS	O
in	POS	O
the	POS	O
arcuate	POS	O
nucleus	POS	O
(	POS	O
AN	POS	O
)	POS	O
,	POS	O
medial	POS	O
preoptic	POS	O
area	POS	O
(	POS	O
MPA	POS	O
)	POS	O
,	POS	O
caudate	POS	O
putamen	POS	O
(	POS	O
CP	POS	O
)	POS	O
,	POS	O
substantia	POS	O
nigra	POS	O
(	POS	O
SN	POS	O
)	POS	O
,	POS	O
and	POS	O
zona	POS	O
incerta	POS	O
(	POS	O
ZI	POS	O
)	POS	O
,	POS	O
except	POS	O
for	POS	O
a	POS	O
decrease	POS	O
in	POS	O
5	POS	O
-	POS	O
hydroxyindoleacetic	POS	O
acid	POS	O
(	POS	O
5	POS	O
-	POS	O
HIAA	POS	O
)	POS	O
in	POS	O
the	POS	O
AN	POS	O
after	POS	O
6	POS	O
-	POS	O
months	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
and	POS	O
an	POS	O
increase	POS	O
in	POS	O
DA	POS	O
concentrations	POS	O
in	POS	O
the	POS	O
AN	POS	B-NP
after	POS	O
9	POS	O
-	POS	O
months	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
.	POS	O
These	POS	O
results	POS	O
demonstrate	POS	O
that	POS	O
hyperprolactinemia	POS	B-NP
specifically	POS	O
affects	POS	O
TIDA	POS	O
neurons	POS	O
and	POS	O
these	POS	O
effects	POS	O
vary	POS	O
,	POS	O
depending	POS	O
on	POS	O
the	POS	O
duration	POS	O
and	POS	O
intensity	POS	O
of	POS	O
hyperprolactinemia	POS	B-NP
.	POS	O
The	POS	O
age	POS	O
-	POS	O
related	POS	O
decrease	POS	O
in	POS	O
hypothalamic	POS	O
dopamine	POS	O
function	POS	O
may	POS	O
be	POS	O
associated	POS	O
with	POS	O
increases	POS	O
in	POS	O
PRL	POS	O
secretion	POS	O
.	POS	O
Treatment	POS	O
-	POS	O
related	POS	O
disseminated	POS	O
necrotizing	POS	B-NP
leukoencephalopathy	POS	I-NP
with	POS	O
characteristic	POS	O
contrast	POS	O
enhancement	POS	O
of	POS	O
the	POS	O
white	POS	O
matter	POS	O
.	POS	O
This	POS	O
report	POS	O
describes	POS	O
unique	POS	O
contrast	POS	O
enhancement	POS	O
of	POS	O
the	POS	O
white	POS	O
matter	POS	O
on	POS	O
T1	POS	O
-	POS	O
weighted	POS	O
magnetic	POS	O
resonance	POS	O
images	POS	O
of	POS	O
two	POS	O
patients	POS	O
with	POS	O
disseminated	POS	O
necrotizing	POS	B-NP
leukoencephalopathy	POS	I-NP
,	POS	O
which	POS	O
developed	POS	O
from	POS	O
acute	POS	B-NP
lymphoblastic	POS	I-NP
leukemia	POS	I-NP
treated	POS	O
with	POS	O
high	POS	O
-	POS	O
dose	POS	O
methotrexate	POS	O
.	POS	O
In	POS	O
both	POS	O
patients	POS	O
,	POS	O
the	POS	O
enhancement	POS	O
was	POS	O
more	POS	O
pronounced	POS	O
near	POS	O
the	POS	O
base	POS	O
of	POS	O
the	POS	O
brain	POS	O
than	POS	O
at	POS	O
the	POS	O
vertex	POS	O
.	POS	O
Necropsy	POS	O
of	POS	O
the	POS	O
first	POS	O
case	POS	O
revealed	POS	O
loss	POS	O
of	POS	O
myelination	POS	O
and	POS	O
necrosis	POS	B-NP
of	POS	O
the	POS	O
white	POS	O
matter	POS	O
.	POS	O
Possible	POS	O
mechanisms	POS	O
causing	POS	O
such	POS	O
a	POS	O
leukoencephalopathy	POS	B-NP
are	POS	O
discussed	POS	O
.	POS	O
Thrombotic	POS	B-NP
complications	POS	I-NP
in	POS	O
acute	POS	B-NP
promyelocytic	POS	I-NP
leukemia	POS	I-NP
during	POS	O
all	POS	O
-	POS	O
trans	POS	O
-	POS	O
retinoic	POS	O
acid	POS	O
therapy	POS	O
.	POS	O
A	POS	O
case	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
,	POS	O
due	POS	O
to	POS	O
occlusion	POS	O
of	POS	O
renal	POS	O
vessels	POS	O
in	POS	O
a	POS	O
patient	POS	O
with	POS	O
acute	POS	B-NP
promyelocytic	POS	I-NP
leukemia	POS	I-NP
(	POS	O
APL	POS	B-NP
)	POS	O
treated	POS	O
with	POS	O
all	POS	O
-	POS	O
trans	POS	O
-	POS	O
retinoic	POS	O
acid	POS	O
(	POS	O
ATRA	POS	O
)	POS	O
and	POS	O
tranexamic	POS	O
acid	POS	O
has	POS	O
been	POS	O
described	POS	O
recently	POS	O
.	POS	O
We	POS	O
report	POS	O
a	POS	O
case	POS	O
of	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
in	POS	O
an	POS	O
APL	POS	B-NP
patient	POS	O
treated	POS	O
with	POS	O
ATRA	POS	O
alone	POS	O
.	POS	O
This	POS	O
case	POS	O
further	POS	O
supports	POS	O
the	POS	O
concern	POS	O
about	POS	O
thromboembolic	POS	B-NP
complications	POS	I-NP
associated	POS	O
with	POS	O
ATRA	POS	O
therapy	POS	O
in	POS	O
APL	POS	B-NP
patients	POS	O
.	POS	O
The	POS	O
patients	POS	O
,	POS	O
a	POS	O
43	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
,	POS	O
presented	POS	O
all	POS	O
the	POS	O
signs	POS	O
and	POS	O
symptoms	POS	O
of	POS	O
APL	POS	B-NP
and	POS	O
was	POS	O
included	POS	O
in	POS	O
a	POS	O
treatment	POS	O
protocol	POS	O
with	POS	O
ATRA	POS	O
.	POS	O
After	POS	O
10	POS	O
days	POS	O
of	POS	O
treatment	POS	O
,	POS	O
he	POS	O
developed	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
that	POS	O
was	POS	O
completely	POS	O
reversible	POS	O
after	POS	O
complete	POS	O
remission	POS	O
of	POS	O
APL	POS	B-NP
was	POS	O
achieved	POS	O
and	POS	O
therapy	POS	O
discontinued	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
ATRA	POS	O
is	POS	O
a	POS	O
valid	POS	O
therapeutic	POS	O
choice	POS	O
for	POS	O
patients	POS	O
with	POS	O
APL	POS	B-NP
,	POS	O
although	POS	O
the	POS	O
procoagulant	POS	O
tendency	POS	O
is	POS	O
not	POS	O
completely	POS	O
corrected	POS	O
.	POS	O
Thrombotic	POS	B-NP
events	POS	I-NP
,	POS	O
however	POS	O
,	POS	O
could	POS	O
be	POS	O
avoided	POS	O
by	POS	O
using	POS	O
low	POS	O
-	POS	O
dose	POS	O
heparin	POS	O
.	POS	O
Pupillary	POS	O
changes	POS	O
associated	POS	O
with	POS	O
the	POS	O
development	POS	O
of	POS	O
stimulant	POS	O
-	POS	O
induced	POS	O
mania	POS	B-NP
:	POS	O
a	POS	O
case	POS	O
report	POS	O
.	POS	O
A	POS	O
30	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
cocaine	POS	O
-	POS	O
dependent	POS	O
man	POS	O
who	POS	O
was	POS	O
a	POS	O
subject	POS	O
in	POS	O
a	POS	O
study	POS	O
evaluating	POS	O
the	POS	O
anticraving	POS	O
efficacy	POS	O
of	POS	O
the	POS	O
stimulant	POS	O
medication	POS	O
diethylpropion	POS	O
(	POS	O
DEP	POS	O
)	POS	O
became	POS	O
manic	POS	B-NP
during	POS	O
his	POS	O
second	POS	O
week	POS	O
on	POS	O
the	POS	O
study	POS	O
drug	POS	O
.	POS	O
Pupillometric	POS	O
changes	POS	O
while	POS	O
on	POS	O
DEP	POS	O
,	POS	O
especially	POS	O
changes	POS	O
in	POS	O
the	POS	O
total	POS	O
power	POS	O
of	POS	O
pupillary	POS	O
oscillation	POS	O
,	POS	O
were	POS	O
dramatically	POS	O
different	POS	O
than	POS	O
those	POS	O
observed	POS	O
in	POS	O
the	POS	O
eight	POS	O
other	POS	O
study	POS	O
subjects	POS	O
who	POS	O
did	POS	O
not	POS	O
become	POS	O
manic	POS	B-NP
.	POS	O
The	POS	O
large	POS	O
changes	POS	O
in	POS	O
total	POS	O
power	POS	O
of	POS	O
pupillary	POS	B-NP
oscillation	POS	I-NP
occurred	POS	O
a	POS	O
few	POS	O
days	POS	O
before	POS	O
the	POS	O
patient	POS	O
became	POS	O
fully	POS	O
manic	POS	B-NP
.	POS	O
Such	POS	O
medication	POS	O
-	POS	O
associated	POS	O
changes	POS	O
in	POS	O
the	POS	O
total	POS	O
power	POS	O
of	POS	O
pupillary	POS	O
oscillation	POS	O
might	POS	O
be	POS	O
of	POS	O
utility	POS	O
in	POS	O
identifying	POS	O
persons	POS	O
at	POS	O
risk	POS	O
for	POS	O
manic	POS	B-NP
-	POS	O
like	POS	O
adverse	POS	O
effects	POS	O
during	POS	O
the	POS	O
medical	POS	O
use	POS	O
of	POS	O
psychomotor	POS	O
stimulants	POS	O
or	POS	O
sympathomimetic	POS	O
agents	POS	O
.	POS	O
Fetal	POS	O
risks	POS	O
due	POS	O
to	POS	O
warfarin	POS	O
therapy	POS	O
during	POS	O
pregnancy	POS	O
.	POS	O
Two	POS	O
mothers	POS	O
with	POS	O
heart	POS	B-NP
valve	POS	I-NP
prosthesis	POS	I-NP
were	POS	O
treated	POS	O
with	POS	O
warfarin	POS	O
during	POS	O
pregnancy	POS	O
.	POS	O
In	POS	O
the	POS	O
first	POS	O
case	POS	O
a	POS	O
caesarean	POS	O
section	POS	O
was	POS	O
done	POS	O
one	POS	O
week	POS	O
after	POS	O
replacement	POS	O
of	POS	O
warfarin	POS	O
with	POS	O
heparin	POS	O
.	POS	O
The	POS	O
baby	POS	O
died	POS	O
of	POS	O
cerebral	POS	O
and	POS	O
pulmonary	POS	B-NP
hemorrhage	POS	I-NP
.	POS	O
The	POS	O
second	POS	O
mother	POS	O
had	POS	O
a	POS	O
male	POS	O
infant	POS	O
by	POS	O
caesarean	POS	O
section	POS	O
.	POS	O
The	POS	O
baby	POS	O
showed	POS	O
warfarin	POS	O
-	POS	O
induced	POS	O
embryopathy	POS	B-NP
with	POS	O
nasal	POS	B-NP
hypoplasia	POS	I-NP
and	POS	O
stippled	POS	B-NP
epiphyses	POS	I-NP
(	POS	O
chondrodysplasia	POS	B-NP
punctata	POS	I-NP
)	POS	O
.	POS	O
Nasal	POS	B-NP
hypoplasia	POS	I-NP
with	POS	O
or	POS	O
without	POS	O
stippled	POS	O
epiphyses	POS	O
has	POS	O
now	POS	O
been	POS	O
reported	POS	O
in	POS	O
11	POS	O
infants	POS	O
born	POS	O
to	POS	O
mothers	POS	O
treated	POS	O
with	POS	O
warfarin	POS	O
during	POS	O
the	POS	O
first	POS	O
trimester	POS	O
,	POS	O
and	POS	O
a	POS	O
causal	POS	O
association	POS	O
is	POS	O
probable	POS	O
.	POS	O
In	POS	O
view	POS	O
of	POS	O
the	POS	O
risks	POS	O
to	POS	O
both	POS	O
mother	POS	O
and	POS	O
fetus	POS	O
in	POS	O
women	POS	O
with	POS	O
prosthetic	POS	O
cardiac	POS	O
valves	POS	O
it	POS	O
is	POS	O
recommended	POS	O
that	POS	O
therapeutic	POS	O
abortion	POS	O
be	POS	O
advised	POS	O
as	POS	O
the	POS	O
first	POS	O
alternative	POS	O
.	POS	O
The	POS	O
negative	POS	O
mucosal	POS	O
potential	POS	O
:	POS	O
separating	POS	O
central	POS	O
and	POS	O
peripheral	POS	O
effects	POS	O
of	POS	O
NSAIDs	POS	O
in	POS	O
man	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
We	POS	O
wanted	POS	O
to	POS	O
test	POS	O
whether	POS	O
assessment	POS	O
of	POS	O
both	POS	O
a	POS	O
central	POS	O
pain	POS	O
-	POS	O
related	POS	O
signal	POS	O
(	POS	O
chemo	POS	O
-	POS	O
somatosensory	POS	O
evoked	POS	O
potential	POS	O
,	POS	O
CSSEP	POS	O
)	POS	O
and	POS	O
a	POS	O
concomitantly	POS	O
recorded	POS	O
peripheral	POS	O
signal	POS	O
(	POS	O
negative	POS	O
mucosal	POS	O
potential	POS	O
,	POS	O
NMP	POS	O
)	POS	O
allows	POS	O
for	POS	O
separation	POS	O
of	POS	O
central	POS	O
and	POS	O
peripheral	POS	O
effects	POS	O
of	POS	O
NSAIDs	POS	O
.	POS	O
For	POS	O
this	POS	O
purpose	POS	O
,	POS	O
experimental	POS	O
conditions	POS	O
were	POS	O
created	POS	O
in	POS	O
which	POS	O
NSAIDs	POS	O
had	POS	O
previously	POS	O
been	POS	O
observed	POS	O
to	POS	O
produce	POS	O
effects	POS	O
on	POS	O
phasic	POS	O
and	POS	O
tonic	POS	O
pain	POS	B-NP
by	POS	O
either	POS	O
central	POS	O
or	POS	O
peripheral	POS	O
mechanisms	POS	O
.	POS	O
METHODS	POS	O
:	POS	O
According	POS	O
to	POS	O
a	POS	O
double	POS	O
-	POS	O
blind	POS	O
,	POS	O
randomised	POS	O
,	POS	O
controlled	POS	O
,	POS	O
threefold	POS	O
cross	POS	O
-	POS	O
over	POS	O
design	POS	O
,	POS	O
18	POS	O
healthy	POS	O
subjects	POS	O
(	POS	O
11	POS	O
males	POS	O
,	POS	O
7	POS	O
females	POS	O
;	POS	O
mean	POS	O
age	POS	O
26	POS	O
years	POS	O
)	POS	O
received	POS	O
either	POS	O
placebo	POS	O
,	POS	O
400	POS	O
mg	POS	O
ibuprofen	POS	O
,	POS	O
or	POS	O
800	POS	O
mg	POS	O
ibuprofen	POS	O
.	POS	O
Phasic	POS	O
pain	POS	B-NP
was	POS	O
applied	POS	O
by	POS	O
means	POS	O
of	POS	O
short	POS	O
pulses	POS	O
of	POS	O
CO2	POS	O
to	POS	O
the	POS	O
nasal	POS	O
mucosa	POS	O
(	POS	O
stimulus	POS	O
duration	POS	O
500	POS	O
ms	POS	O
,	POS	O
interval	POS	O
approximately	POS	O
60	POS	O
s	POS	O
)	POS	O
,	POS	O
and	POS	O
tonic	POS	O
pain	POS	B-NP
was	POS	O
induced	POS	O
in	POS	O
the	POS	O
nasal	POS	O
cavity	POS	O
by	POS	O
means	POS	O
of	POS	O
dry	POS	O
air	POS	O
of	POS	O
controlled	POS	O
temperature	POS	O
,	POS	O
humidity	POS	O
and	POS	O
flow	POS	O
rate	POS	O
(	POS	O
22	POS	O
degrees	POS	O
C	POS	O
,	POS	O
0	POS	O
%	POS	O
relative	POS	O
humidity	POS	O
,	POS	O
145	POS	O
ml	POS	O
.	POS	O
s	POS	O
-	POS	O
1	POS	O
)	POS	O
.	POS	O
Both	POS	O
CSSEPs	POS	O
as	POS	O
central	POS	O
and	POS	O
NMPs	POS	O
as	POS	O
peripheral	POS	O
correlates	POS	O
of	POS	O
pain	POS	B-NP
were	POS	O
obtained	POS	O
in	POS	O
response	POS	O
to	POS	O
the	POS	O
CO2	POS	O
stimuli	POS	O
.	POS	O
Additionally	POS	O
,	POS	O
the	POS	O
subjects	POS	O
rated	POS	O
the	POS	O
intensity	POS	O
of	POS	O
both	POS	O
phasic	POS	O
and	POS	O
tonic	POS	O
pain	POS	B-NP
by	POS	O
means	POS	O
of	POS	O
visual	POS	O
analogue	POS	O
scales	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
As	POS	O
described	POS	O
earlier	POS	O
,	POS	O
administration	POS	O
of	POS	O
ibuprofen	POS	O
was	POS	O
followed	POS	O
by	POS	O
a	POS	O
decrease	POS	O
in	POS	O
tonic	POS	O
pain	POS	B-NP
but	POS	O
-	POS	O
relative	POS	O
to	POS	O
placebo	POS	O
-	POS	O
an	POS	O
increase	POS	O
in	POS	O
correlates	POS	O
of	POS	O
phasic	POS	B-NP
pain	POS	I-NP
,	POS	O
indicating	POS	O
a	POS	O
specific	POS	O
effect	POS	O
of	POS	O
ibuprofen	POS	O
on	POS	O
the	POS	O
interaction	POS	O
between	POS	O
the	POS	O
pain	POS	B-NP
stimuli	POS	O
under	POS	O
these	POS	O
special	POS	O
experimental	POS	O
conditions	POS	O
.	POS	O
Based	POS	O
on	POS	O
the	POS	O
similar	POS	O
behaviour	POS	O
of	POS	O
CSSEP	POS	O
and	POS	O
NMP	POS	O
,	POS	O
it	POS	O
was	POS	O
concluded	POS	O
that	POS	O
the	POS	O
pharmacological	POS	O
process	POS	O
underlying	POS	O
this	POS	O
phenomenon	POS	O
was	POS	O
localised	POS	O
in	POS	O
the	POS	O
periphery	POS	O
.	POS	O
By	POS	O
means	POS	O
of	POS	O
the	POS	O
simultaneous	POS	O
recording	POS	O
of	POS	O
interrelated	POS	O
peripheral	POS	O
and	POS	O
central	POS	O
electrophysiologic	POS	O
correlates	POS	O
of	POS	O
nociception	POS	O
,	POS	O
it	POS	O
was	POS	O
possible	POS	O
to	POS	O
separate	POS	O
central	POS	O
and	POS	O
peripheral	POS	O
effects	POS	O
of	POS	O
an	POS	O
NSAID	POS	O
.	POS	O
The	POS	O
major	POS	O
advantage	POS	O
of	POS	O
this	POS	O
pain	POS	B-NP
model	POS	O
is	POS	O
the	POS	O
possibility	POS	O
of	POS	O
obtaining	POS	O
peripheral	POS	O
pain	POS	O
-	POS	O
related	POS	O
activity	POS	O
directly	POS	O
using	POS	O
a	POS	O
non	POS	O
-	POS	O
invasive	POS	O
technique	POS	O
in	POS	O
humans	POS	O
.	POS	O
Effect	POS	O
of	POS	O
D	POS	O
-	POS	O
Glucarates	POS	O
on	POS	O
basic	POS	O
antibiotic	POS	O
-	POS	O
induced	POS	O
renal	POS	B-NP
damage	POS	I-NP
in	POS	O
rats	POS	O
.	POS	O
Dehydrated	POS	O
rats	POS	O
regularly	POS	O
develop	POS	O
acute	POS	B-NP
renal	POS	I-NP
failure	POS	I-NP
following	POS	O
single	POS	O
injection	POS	O
of	POS	O
aminoglycoside	POS	O
antibiotics	POS	O
combined	POS	O
with	POS	O
dextran	POS	O
or	POS	O
of	POS	O
antibiotics	POS	O
only	POS	O
.	POS	O
Oral	POS	O
administration	POS	O
of	POS	O
2	POS	O
,	POS	O
5	POS	O
-	POS	O
di	POS	O
-	POS	O
O	POS	O
-	POS	O
acetyl	POS	O
-	POS	O
D	POS	O
-	POS	O
glucaro	POS	O
-	POS	O
1	POS	O
,	POS	O
4	POS	O
-	POS	O
6	POS	O
,	POS	O
3	POS	O
-	POS	O
dilactone	POS	O
protected	POS	O
rats	POS	O
against	POS	O
renal	POS	B-NP
failure	POS	I-NP
induced	POS	O
by	POS	O
kanamycin	POS	O
-	POS	O
dextran	POS	O
.	POS	O
The	POS	O
protective	POS	O
effect	POS	O
was	POS	O
prevalent	POS	O
among	POS	O
D	POS	O
-	POS	O
glucarates	POS	O
,	POS	O
and	POS	O
also	POS	O
to	POS	O
other	POS	O
saccharic	POS	O
acid	POS	O
,	POS	O
hexauronic	POS	O
acids	POS	O
and	POS	O
hexaaldonic	POS	O
acids	POS	O
,	POS	O
although	POS	O
to	POS	O
a	POS	O
lesser	POS	O
degree	POS	O
,	POS	O
but	POS	O
not	POS	O
to	POS	O
a	POS	O
hexaaldose	POS	O
,	POS	O
sugar	POS	O
alcohols	POS	O
,	POS	O
substances	POS	O
inthe	POS	O
TCA	POS	O
cycle	POS	O
and	POS	O
other	POS	O
acidic	POS	O
compounds	POS	O
.	POS	O
D	POS	O
-	POS	O
Glucarates	POS	O
were	POS	O
effective	POS	O
against	POS	O
renal	POS	O
damage	POS	O
induced	POS	O
by	POS	O
peptide	POS	O
antibiotics	POS	O
as	POS	O
well	POS	O
as	POS	O
various	POS	O
aminoglycoside	POS	O
antibitocis	POS	O
.	POS	O
Dose	POS	O
-	POS	O
responses	POS	O
were	POS	O
observed	POS	O
in	POS	O
the	POS	O
protective	POS	O
effect	POS	O
of	POS	O
D	POS	O
-	POS	O
Glucarates	POS	O
.	POS	O
With	POS	O
a	POS	O
D	POS	O
-	POS	O
glucarate	POS	O
of	POS	O
a	POS	O
fixed	POS	O
size	POS	O
of	POS	O
dose	POS	O
,	POS	O
approximately	POS	O
the	POS	O
same	POS	O
degree	POS	O
of	POS	O
protection	POS	O
was	POS	O
obtained	POS	O
against	POS	O
renal	POS	O
damages	POS	O
induced	POS	O
by	POS	O
different	POS	O
basic	POS	O
antibiotics	POS	O
despite	POS	O
large	POS	O
disparities	POS	O
in	POS	O
administration	POS	O
doses	POS	O
of	POS	O
different	POS	O
antibiotics	POS	O
.	POS	O
D	POS	O
-	POS	O
Glucarates	POS	O
had	POS	O
the	POS	O
ability	POS	O
to	POS	O
prevent	POS	O
renal	POS	B-NP
damage	POS	I-NP
but	POS	O
not	POS	O
to	POS	O
cure	POS	O
it	POS	O
.	POS	O
Rats	POS	O
excreted	POS	O
acidic	POS	O
urine	POS	O
when	POS	O
they	POS	O
were	POS	O
spared	POS	O
from	POS	O
renal	POS	B-NP
lesions	POS	I-NP
by	POS	O
monosaccharides	POS	O
.	POS	O
The	POS	O
reduction	POS	O
effect	POS	O
of	POS	O
D	POS	O
-	POS	O
glucarates	POS	O
against	POS	O
nephrotoxicity	POS	B-NP
of	POS	O
basic	POS	O
antibiotics	POS	O
was	POS	O
discussed	POS	O
.	POS	O
Acute	POS	O
severe	POS	O
depression	POS	B-NP
following	POS	O
peri	POS	O
-	POS	O
operative	POS	O
ondansetron	POS	O
.	POS	O
A	POS	O
41	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
woman	POS	O
with	POS	O
a	POS	O
strong	POS	O
history	POS	O
of	POS	O
postoperative	POS	B-NP
nausea	POS	I-NP
and	POS	O
vomiting	POS	B-NP
presented	POS	O
for	POS	O
abdominal	POS	O
hysterectomy	POS	O
3	POS	O
months	POS	O
after	POS	O
a	POS	O
previous	POS	O
anaesthetic	POS	O
where	POS	O
ondansetron	POS	O
prophylaxis	POS	B-NP
had	POS	O
been	POS	O
used	POS	O
.	POS	O
She	POS	O
had	POS	O
developed	POS	O
a	POS	O
severe	POS	O
acute	POS	O
major	POS	O
depression	POS	B-NP
disorder	POS	O
almost	POS	O
immediately	POS	O
thereafter	POS	O
,	POS	O
possibly	POS	O
related	POS	O
to	POS	O
the	POS	O
use	POS	O
of	POS	O
a	POS	O
serotonin	POS	O
antagonist	POS	O
.	POS	O
Nine	POS	O
years	POS	O
before	POS	O
she	POS	O
had	POS	O
experienced	POS	O
a	POS	O
self	POS	O
-	POS	O
limited	POS	O
puerperal	POS	B-NP
depressive	POS	I-NP
episode	POS	O
.	POS	O
Anaesthesia	POS	B-NP
with	POS	O
a	POS	O
propofol	POS	O
infusion	POS	O
and	POS	O
avoidance	POS	O
of	POS	O
serotonin	POS	O
antagonists	POS	O
provided	POS	O
a	POS	O
nausea	POS	B-NP
-	POS	O
free	POS	O
postoperative	POS	O
course	POS	O
without	POS	O
exacerbation	POS	O
of	POS	O
the	POS	O
depression	POS	B-NP
disorder	POS	I-NP
.	POS	O
Hypertensive	POS	B-NP
response	POS	O
during	POS	O
dobutamine	POS	O
stress	POS	O
echocardiography	POS	O
.	POS	O
Among	POS	O
3	POS	O
,	POS	O
129	POS	O
dobutamine	POS	O
stress	POS	O
echocardiographic	POS	O
studies	POS	O
,	POS	O
a	POS	O
hypertensive	POS	B-NP
response	POS	O
,	POS	O
defined	POS	O
as	POS	O
systolic	POS	O
blood	POS	O
pressure	POS	O
(	POS	O
BP	POS	O
)	POS	O
>	POS	O
or	POS	O
=	POS	O
220	POS	O
mm	POS	O
Hg	POS	O
and	POS	O
/	POS	O
or	POS	O
diastolic	POS	O
BP	POS	O
>	POS	O
or	POS	O
=	POS	O
110	POS	O
mm	POS	O
Hg	POS	O
,	POS	O
occurred	POS	O
in	POS	O
30	POS	O
patients	POS	O
(	POS	O
1	POS	O
%	POS	O
)	POS	O
.	POS	O
Patients	POS	O
with	POS	O
this	POS	O
response	POS	O
more	POS	O
often	POS	O
had	POS	O
a	POS	O
history	POS	O
of	POS	O
hypertension	POS	B-NP
and	POS	O
had	POS	O
higher	POS	O
resting	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
BP	POS	O
before	POS	O
dobutamine	POS	O
infusion	POS	O
.	POS	O
Continuously	POS	O
nebulized	POS	O
albuterol	POS	O
in	POS	O
severe	POS	O
exacerbations	POS	O
of	POS	O
asthma	POS	B-NP
in	POS	O
adults	POS	O
:	POS	O
a	POS	O
case	POS	O
-	POS	O
controlled	POS	O
study	POS	O
.	POS	O
A	POS	O
retrospective	POS	O
,	POS	O
case	POS	O
-	POS	O
controlled	POS	O
analysis	POS	O
comparing	POS	O
patients	POS	O
admitted	POS	O
to	POS	O
a	POS	O
medical	POS	O
intensive	POS	O
care	POS	O
unit	POS	O
with	POS	O
severe	POS	O
exacerbations	POS	B-NP
of	POS	O
asthma	POS	B-NP
who	POS	O
received	POS	O
continuously	POS	O
nebulized	POS	O
albuterol	POS	O
(	POS	O
CNA	POS	O
)	POS	O
versus	POS	O
intermittent	POS	O
albuterol	POS	O
(	POS	O
INA	POS	O
)	POS	O
treatments	POS	O
is	POS	O
reported	POS	O
.	POS	O
Forty	POS	O
matched	POS	O
pairs	POS	O
of	POS	O
patients	POS	O
with	POS	O
asthma	POS	B-NP
are	POS	O
compared	POS	O
.	POS	O
CNA	POS	O
was	POS	O
administered	POS	O
for	POS	O
a	POS	O
mean	POS	O
of	POS	O
11	POS	O
+	POS	O
/	POS	O
-	POS	O
10	POS	O
hr	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
cardiac	POS	B-NP
dysrhythmias	POS	I-NP
was	POS	O
similar	POS	O
between	POS	O
groups	POS	O
.	POS	O
Symptomatic	POS	O
hypokalemia	POS	B-NP
did	POS	O
not	POS	O
occur	POS	O
.	POS	O
CNA	POS	O
patients	POS	O
had	POS	O
higher	POS	O
heart	POS	O
rates	POS	O
during	POS	O
treatment	POS	O
,	POS	O
which	POS	O
may	POS	O
reflect	POS	O
severity	POS	O
of	POS	O
illness	POS	B-NP
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
intubation	POS	O
was	POS	O
similar	POS	O
.	POS	O
We	POS	O
conclude	POS	O
that	POS	O
CNA	POS	O
and	POS	O
INA	POS	O
demonstrated	POS	O
similar	POS	O
profiles	POS	O
with	POS	O
regard	POS	O
to	POS	O
safety	POS	O
,	POS	O
morbidity	POS	O
,	POS	O
and	POS	O
mortality	POS	O
.	POS	O
Paraplegia	POS	B-NP
following	POS	O
intrathecal	POS	O
methotrexate	POS	O
:	POS	O
report	POS	O
of	POS	O
a	POS	O
case	POS	O
and	POS	O
review	POS	O
of	POS	O
the	POS	O
literature	POS	O
.	POS	O
A	POS	O
patient	POS	O
who	POS	O
developed	POS	O
paraplegia	POS	B-NP
following	POS	O
the	POS	O
intrathecal	POS	O
instillation	POS	O
of	POS	O
methotrexate	POS	O
is	POS	O
discribed	POS	O
.	POS	O
The	POS	O
ten	POS	O
previously	POS	O
reported	POS	O
cases	POS	O
of	POS	O
this	POS	O
unusual	POS	O
complication	POS	O
are	POS	O
reviewed	POS	O
.	POS	O
The	POS	O
following	POS	O
factors	POS	O
appear	POS	O
to	POS	O
predispose	POS	O
to	POS	O
the	POS	O
development	POS	O
of	POS	O
this	POS	O
complication	POS	O
:	POS	O
abnormal	POS	O
cerebrospinal	POS	O
dynamics	POS	O
related	POS	O
to	POS	O
the	POS	O
presence	POS	O
of	POS	O
central	POS	B-NP
nervous	POS	I-NP
system	POS	I-NP
leukemia	POS	I-NP
,	POS	O
and	POS	O
epidural	POS	O
cerebrospinal	POS	O
leakage	POS	O
;	POS	O
elevated	POS	O
cerebrospinal	POS	O
fluid	POS	O
methothexate	POS	O
concentration	POS	O
related	POS	O
to	POS	O
abnormal	POS	O
cerebrospinal	POS	O
fluid	POS	O
dynamics	POS	O
and	POS	O
to	POS	O
inappropriately	POS	O
high	POS	O
methotrexate	POS	O
doses	POS	O
based	POS	O
on	POS	O
body	POS	O
surface	POS	O
area	POS	O
calculations	POS	O
in	POS	O
older	POS	O
children	POS	O
and	POS	O
adults	POS	O
;	POS	O
the	POS	O
presence	POS	O
of	POS	O
neurotoxic	POS	O
preservatives	POS	O
in	POS	O
commercially	POS	O
available	POS	O
methotrexate	POS	O
preparations	POS	O
and	POS	O
diluents	POS	O
;	POS	O
and	POS	O
the	POS	O
use	POS	O
of	POS	O
methotrexate	POS	O
diluents	POS	O
of	POS	O
unphysiologic	POS	O
pH	POS	O
,	POS	O
ionic	POS	O
content	POS	O
and	POS	O
osmolarity	POS	O
.	POS	O
The	POS	O
role	POS	O
of	POS	O
methotrexate	POS	O
contaminants	POS	O
,	POS	O
local	POS	O
folate	POS	B-NP
deficiency	POS	I-NP
,	POS	O
and	POS	O
cranial	POS	O
irradiation	POS	O
in	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
intrathecal	POS	O
methotrexate	POS	O
toxicity	POS	B-NP
is	POS	O
unclear	POS	O
.	POS	O
The	POS	O
incidence	POS	O
of	POS	O
neurotoxicity	POS	B-NP
may	POS	O
be	POS	O
reduced	POS	O
by	POS	O
employing	POS	O
lower	POS	O
doses	POS	O
of	POS	O
methotrexate	POS	O
in	POS	O
the	POS	O
presence	POS	O
of	POS	O
central	POS	B-NP
nervous	POS	I-NP
system	POS	I-NP
leukemia	POS	I-NP
,	POS	O
in	POS	O
older	POS	O
children	POS	O
and	POS	O
adults	POS	O
,	POS	O
and	POS	O
in	POS	O
the	POS	O
presence	POS	O
of	POS	O
epidural	POS	O
leakage	POS	O
.	POS	O
Only	POS	O
preservative	POS	O
-	POS	O
free	POS	O
methotrexate	POS	O
in	POS	O
Elliott	POS	O
'	POS	O
s	POS	O
B	POS	O
Solution	POS	O
at	POS	O
a	POS	O
concentration	POS	O
of	POS	O
not	POS	O
more	POS	O
than	POS	O
1	POS	O
mg	POS	O
/	POS	O
ml	POS	O
should	POS	O
be	POS	O
used	POS	O
for	POS	O
intrathecal	POS	O
administration	POS	O
.	POS	O
Periodic	POS	O
monitoring	POS	O
of	POS	O
cerebruspinal	POS	O
fluid	POS	O
methotrexate	POS	O
levels	POS	O
may	POS	O
be	POS	O
predictive	POS	O
of	POS	O
the	POS	O
development	POS	O
of	POS	O
serious	POS	O
neurotoxicity	POS	B-NP
.	POS	O
Hyperosmolar	POS	B-NP
nonketotic	POS	I-NP
coma	POS	I-NP
precipitated	POS	O
by	POS	O
lithium	POS	O
-	POS	O
induced	POS	O
nephrogenic	POS	B-NP
diabetes	POS	I-NP
insipidus	POS	I-NP
.	POS	O
A	POS	O
45	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
man	POS	O
,	POS	O
with	POS	O
a	POS	O
10	POS	O
-	POS	O
year	POS	O
history	POS	O
of	POS	O
manic	POS	B-NP
depression	POS	I-NP
treated	POS	O
with	POS	O
lithium	POS	O
,	POS	O
was	POS	O
admitted	POS	O
with	POS	O
hyperosmolar	POS	B-NP
,	POS	O
nonketotic	POS	B-NP
coma	POS	I-NP
.	POS	O
He	POS	O
gave	POS	O
a	POS	O
five	POS	O
-	POS	O
year	POS	O
history	POS	O
of	POS	O
polyuria	POS	B-NP
and	POS	O
polydipsia	POS	B-NP
,	POS	O
during	POS	O
which	POS	O
time	POS	O
urinalysis	POS	O
had	POS	O
been	POS	O
negative	POS	O
for	POS	O
glucose	POS	O
.	POS	O
After	POS	O
recovery	POS	O
from	POS	O
hyperglycaemia	POS	B-NP
,	POS	O
he	POS	O
remained	POS	O
polyuric	POS	B-NP
despite	POS	O
normal	POS	O
blood	POS	O
glucose	POS	O
concentrations	POS	O
;	POS	O
water	POS	O
deprivation	POS	O
testing	POS	O
indicated	POS	O
nephrogenic	POS	B-NP
diabetes	POS	I-NP
insipidus	POS	I-NP
,	POS	O
likely	POS	O
to	POS	O
be	POS	O
lithium	POS	O
-	POS	O
induced	POS	O
.	POS	O
We	POS	O
hypothesize	POS	O
that	POS	O
when	POS	O
this	POS	O
man	POS	O
developed	POS	O
type	POS	B-NP
2	POS	I-NP
diabetes	POS	I-NP
,	POS	O
chronic	POS	B-NP
polyuria	POS	I-NP
due	POS	O
to	POS	O
nephrogenic	POS	B-NP
diabetes	POS	I-NP
insipidus	POS	I-NP
was	POS	O
sufficient	POS	O
to	POS	O
precipitate	POS	O
hyperosmolar	POS	B-NP
dehydration	POS	I-NP
.	POS	O
Effects	POS	O
of	POS	O
the	POS	O
intracoronary	POS	O
infusion	POS	O
of	POS	O
cocaine	POS	O
on	POS	O
left	POS	O
ventricular	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
function	POS	O
in	POS	O
humans	POS	O
.	POS	O
BACKGROUND	POS	O
:	POS	O
In	POS	O
dogs	POS	O
,	POS	O
a	POS	O
large	POS	O
amount	POS	O
of	POS	O
intravenous	POS	O
cocaine	POS	O
causes	POS	O
a	POS	O
profound	POS	O
deterioration	POS	O
of	POS	O
left	POS	O
ventricular	POS	O
(	POS	O
LV	POS	O
)	POS	O
systolic	POS	O
function	POS	O
and	POS	O
an	POS	O
increase	POS	O
in	POS	O
LV	POS	O
end	POS	O
-	POS	O
diastolic	POS	O
pressure	POS	O
.	POS	O
This	POS	O
study	POS	O
was	POS	O
done	POS	O
to	POS	O
assess	POS	O
the	POS	O
influence	POS	O
of	POS	O
a	POS	O
high	POS	O
intracoronary	POS	O
cocaine	POS	O
concentration	POS	O
on	POS	O
LV	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
function	POS	O
in	POS	O
humans	POS	O
.	POS	O
METHODS	POS	O
AND	POS	O
RESULTS	POS	O
:	POS	O
In	POS	O
20	POS	O
patients	POS	O
(	POS	O
14	POS	O
men	POS	O
and	POS	O
6	POS	O
women	POS	O
aged	POS	O
39	POS	O
to	POS	O
72	POS	O
years	POS	O
)	POS	O
referred	POS	O
for	POS	O
cardiac	POS	O
catheterization	POS	O
for	POS	O
the	POS	O
evaluation	POS	O
of	POS	O
chest	POS	B-NP
pain	POS	I-NP
,	POS	O
we	POS	O
measured	POS	O
heart	POS	O
rate	POS	O
,	POS	O
systemic	POS	O
arterial	POS	O
pressure	POS	O
,	POS	O
LV	POS	O
pressure	POS	O
and	POS	O
its	POS	O
first	POS	O
derivative	POS	O
(	POS	O
dP	POS	O
/	POS	O
dt	POS	O
)	POS	O
,	POS	O
and	POS	O
LV	POS	O
volumes	POS	O
and	POS	O
ejection	POS	O
fraction	POS	O
before	POS	O
and	POS	O
during	POS	O
the	POS	O
final	POS	O
2	POS	O
to	POS	O
3	POS	O
minutes	POS	O
of	POS	O
a	POS	O
15	POS	O
-	POS	O
minute	POS	O
intracoronary	POS	O
infusion	POS	O
of	POS	O
saline	POS	O
(	POS	O
n	POS	O
=	POS	O
10	POS	O
,	POS	O
control	POS	O
subjects	POS	O
)	POS	O
or	POS	O
cocaine	POS	O
hydrochloride	POS	O
1	POS	O
mg	POS	O
/	POS	O
min	POS	O
(	POS	O
n	POS	O
=	POS	O
10	POS	O
)	POS	O
.	POS	O
No	POS	O
variable	POS	O
changed	POS	O
with	POS	O
saline	POS	O
.	POS	O
With	POS	O
cocaine	POS	O
,	POS	O
the	POS	O
drug	POS	O
concentration	POS	O
in	POS	O
blood	POS	O
obtained	POS	O
from	POS	O
the	POS	O
coronary	POS	O
sinus	POS	O
was	POS	O
3	POS	O
.	POS	O
0	POS	O
+	POS	O
/	POS	O
-	POS	O
0	POS	O
.	POS	O
4	POS	O
(	POS	O
mean	POS	O
+	POS	O
/	POS	O
-	POS	O
SD	POS	O
)	POS	O
mg	POS	O
/	POS	O
L	POS	O
,	POS	O
similar	POS	O
in	POS	O
magnitude	POS	O
to	POS	O
the	POS	O
blood	POS	O
cocaine	POS	O
concentration	POS	O
reported	POS	O
in	POS	O
abusers	POS	O
dying	POS	O
of	POS	O
cocaine	POS	B-NP
intoxication	POS	I-NP
.	POS	O
Cocaine	POS	O
induced	POS	O
no	POS	O
significant	POS	O
change	POS	O
in	POS	O
heart	POS	O
rate	POS	O
,	POS	O
LV	POS	O
dP	POS	O
/	POS	O
dt	POS	O
(	POS	O
positive	POS	O
or	POS	O
negative	POS	O
)	POS	O
,	POS	O
or	POS	O
LV	POS	O
end	POS	O
-	POS	O
diastolic	POS	O
volume	POS	O
,	POS	O
but	POS	O
it	POS	O
caused	POS	O
an	POS	O
increase	POS	O
in	POS	O
systolic	POS	O
and	POS	O
mean	POS	O
arterial	POS	O
pressures	POS	O
,	POS	O
LV	POS	O
end	POS	O
-	POS	O
diastolic	POS	O
pressure	POS	O
,	POS	O
and	POS	O
LV	POS	O
end	POS	O
-	POS	O
systolic	POS	O
volume	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
a	POS	O
decrease	POS	O
in	POS	O
LV	POS	O
ejection	POS	O
fraction	POS	O
.	POS	O
CONCLUSIONS	POS	O
:	POS	O
In	POS	O
humans	POS	O
,	POS	O
the	POS	O
intracoronary	POS	O
infusion	POS	O
of	POS	O
cocaine	POS	O
sufficient	POS	O
in	POS	O
amount	POS	O
to	POS	O
achieve	POS	O
a	POS	O
high	POS	O
drug	POS	O
concentration	POS	O
in	POS	O
coronary	POS	O
sinus	POS	O
blood	POS	O
causes	POS	O
a	POS	O
deterioration	POS	O
of	POS	O
LV	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
performance	POS	O
.	POS	O
Ascending	POS	O
dose	POS	O
tolerance	POS	O
study	POS	O
of	POS	O
intramuscular	POS	O
carbetocin	POS	O
administered	POS	O
after	POS	O
normal	POS	O
vaginal	POS	O
birth	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
To	POS	O
determine	POS	O
the	POS	O
maximum	POS	O
tolerated	POS	O
dose	POS	O
(	POS	O
MTD	POS	O
)	POS	O
of	POS	O
carbetocin	POS	O
(	POS	O
a	POS	O
long	POS	O
-	POS	O
acting	POS	O
synthetic	POS	O
analogue	POS	O
of	POS	O
oxytocin	POS	O
)	POS	O
,	POS	O
when	POS	O
administered	POS	O
immediately	POS	O
after	POS	O
vaginal	POS	O
delivery	POS	O
at	POS	O
term	POS	O
.	POS	O
MATERIALS	POS	O
AND	POS	O
METHODS	POS	O
:	POS	O
Carbetocin	POS	O
was	POS	O
given	POS	O
as	POS	O
an	POS	O
intramuscular	POS	O
injection	POS	O
immediately	POS	O
after	POS	O
the	POS	O
birth	POS	O
of	POS	O
the	POS	O
infant	POS	O
in	POS	O
45	POS	O
healthy	POS	O
women	POS	O
with	POS	O
normal	POS	B-NP
singleton	POS	O
pregnancies	POS	O
who	POS	O
delivered	POS	O
vaginally	POS	O
at	POS	O
term	POS	O
.	POS	O
Dosage	POS	O
groups	POS	O
of	POS	O
15	POS	O
,	POS	O
30	POS	O
,	POS	O
50	POS	O
,	POS	O
75	POS	O
,	POS	O
100	POS	O
,	POS	O
125	POS	O
,	POS	O
150	POS	O
,	POS	O
175	POS	O
or	POS	O
200	POS	O
microg	POS	O
carbetocin	POS	O
were	POS	O
assigned	POS	O
to	POS	O
blocks	POS	O
of	POS	O
three	POS	O
women	POS	O
according	POS	O
to	POS	O
the	POS	O
continual	POS	O
reassessment	POS	O
method	POS	O
(	POS	O
CRM	POS	O
)	POS	O
.	POS	O
RESULTS	POS	O
:	POS	O
All	POS	O
dosage	POS	O
groups	POS	O
consisted	POS	O
of	POS	O
three	POS	O
women	POS	O
,	POS	O
except	POS	O
those	POS	O
with	POS	O
100	POS	O
microg	POS	O
(	POS	O
n	POS	O
=	POS	O
6	POS	O
)	POS	O
and	POS	O
200	POS	O
microg	POS	O
(	POS	O
n	POS	O
=	POS	O
18	POS	O
)	POS	O
.	POS	O
Recorded	POS	O
were	POS	O
dose	POS	O
-	POS	O
limiting	POS	O
adverse	POS	O
events	POS	O
:	POS	O
hyper	POS	O
-	POS	O
or	POS	O
hypotension	POS	B-NP
(	POS	O
three	POS	O
)	POS	O
,	POS	O
severe	POS	O
abdominal	POS	B-NP
pain	POS	I-NP
(	POS	O
0	POS	O
)	POS	O
,	POS	O
vomiting	POS	B-NP
(	POS	O
0	POS	O
)	POS	O
and	POS	O
retained	POS	O
placenta	POS	O
(	POS	O
four	POS	O
)	POS	O
.	POS	O
Serious	POS	O
adverse	POS	O
events	POS	O
occurred	POS	O
in	POS	O
seven	POS	O
women	POS	O
:	POS	O
six	POS	O
cases	POS	O
with	POS	O
blood	POS	B-NP
loss	POS	I-NP
>	POS	O
or	POS	O
=	POS	O
1000	POS	O
ml	POS	O
,	POS	O
four	POS	O
cases	POS	O
of	POS	O
manual	POS	O
placenta	POS	O
removal	POS	O
,	POS	O
five	POS	O
cases	POS	O
of	POS	O
additional	POS	O
oxytocics	POS	O
administration	POS	O
and	POS	O
five	POS	O
cases	POS	O
of	POS	O
blood	POS	O
transfusion	POS	O
.	POS	O
Maximum	POS	O
blood	POS	O
loss	POS	O
was	POS	O
greatest	POS	O
at	POS	O
the	POS	O
upper	POS	O
and	POS	O
lower	POS	O
dose	POS	O
levels	POS	O
,	POS	O
and	POS	O
lowest	POS	O
in	POS	O
the	POS	O
70	POS	O
-	POS	O
125	POS	O
microg	POS	O
dose	POS	O
range	POS	O
.	POS	O
Four	POS	O
out	POS	O
of	POS	O
six	POS	O
cases	POS	O
with	POS	O
blood	POS	O
loss	POS	O
>	POS	O
or	POS	O
=	POS	O
1000	POS	O
ml	POS	O
occurred	POS	O
in	POS	O
the	POS	O
200	POS	O
microg	POS	O
group	POS	O
.	POS	O
The	POS	O
majority	POS	O
of	POS	O
additional	POS	O
administration	POS	O
of	POS	O
oxytocics	POS	O
(	POS	O
4	POS	O
/	POS	O
5	POS	O
)	POS	O
and	POS	O
blood	POS	O
transfusion	POS	O
(	POS	O
3	POS	O
/	POS	O
5	POS	O
)	POS	O
occurred	POS	O
in	POS	O
the	POS	O
dose	POS	O
groups	POS	O
of	POS	O
200	POS	O
microg	POS	O
.	POS	O
All	POS	O
retained	POS	O
placentae	POS	O
were	POS	O
found	POS	O
in	POS	O
the	POS	O
group	POS	O
of	POS	O
200	POS	O
microg	POS	O
.	POS	O
CONCLUSION	POS	O
:	POS	O
The	POS	O
MTD	POS	O
was	POS	O
calculated	POS	O
to	POS	O
be	POS	O
at	POS	O
200	POS	O
microg	POS	O
carbetocin	POS	O
.	POS	O
Heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
,	POS	O
paradoxical	POS	B-NP
thromboembolism	POS	I-NP
,	POS	O
and	POS	O
other	POS	O
side	POS	O
effects	POS	O
of	POS	O
heparin	POS	O
therapy	POS	O
.	POS	O
Although	POS	O
several	POS	O
new	POS	O
anticoagulant	POS	O
drugs	POS	O
are	POS	O
in	POS	O
development	POS	O
,	POS	O
heparin	POS	O
remains	POS	O
the	POS	O
drug	POS	O
of	POS	O
choice	POS	O
for	POS	O
most	POS	O
anticoagulation	POS	O
needs	POS	O
.	POS	O
The	POS	O
clinical	POS	O
effects	POS	O
of	POS	O
heparin	POS	O
are	POS	O
meritorious	POS	O
,	POS	O
but	POS	O
side	POS	O
effects	POS	O
do	POS	O
exist	POS	O
.	POS	O
Important	POS	O
untoward	POS	O
effects	POS	O
of	POS	O
heparin	POS	O
therapy	POS	O
including	POS	O
heparin	POS	O
-	POS	O
induced	POS	O
thrombocytopenia	POS	B-NP
,	POS	O
heparin	POS	B-NP
-	POS	I-NP
associated	POS	I-NP
osteoporosis	POS	I-NP
,	POS	O
eosinophilia	POS	B-NP
,	POS	O
skin	POS	B-NP
reactions	POS	I-NP
,	POS	O
allergic	POS	B-NP
reactions	POS	I-NP
other	POS	O
than	POS	O
thrombocytopenia	POS	B-NP
and	POS	O
alopecia	POS	B-NP
will	POS	O
be	POS	O
discussed	POS	O
in	POS	O
this	POS	O
article	POS	O
.	POS	O
Nonopaque	POS	O
crystal	POS	O
deposition	POS	O
causing	POS	O
ureteric	POS	B-NP
obstruction	POS	I-NP
in	POS	O
patients	POS	O
with	POS	O
HIV	POS	O
undergoing	POS	O
indinavir	POS	O
therapy	POS	O
.	POS	O
OBJECTIVE	POS	O
:	POS	O
We	POS	O
describe	POS	O
the	POS	O
unique	POS	O
CT	POS	O
features	POS	O
of	POS	O
ureteric	POS	O
calculi	POS	O
in	POS	O
six	POS	O
HIV	POS	O
-	POS	O
infected	POS	O
patients	POS	O
receiving	POS	O
indinavir	POS	O
,	POS	O
the	POS	O
most	POS	O
commonly	POS	O
used	POS	O
HIV	POS	O
protease	POS	O
inhibitor	POS	O
,	POS	O
which	POS	O
is	POS	O
associated	POS	O
with	POS	O
an	POS	O
increased	POS	O
incidence	POS	O
of	POS	O
urolithiasis	POS	B-NP
.	POS	O
CONCLUSION	POS	O
:	POS	O
Ureteric	POS	B-NP
obstruction	POS	I-NP
caused	POS	O
by	POS	O
precipitated	POS	O
indinavir	POS	O
crystals	POS	O
may	POS	O
be	POS	O
difficult	POS	O
to	POS	O
diagnose	POS	O
with	POS	O
unenhanced	POS	O
CT	POS	O
.	POS	O
The	POS	O
calculi	POS	O
are	POS	O
not	POS	O
opaque	POS	O
,	POS	O
and	POS	O
secondary	POS	O
signs	POS	O
of	POS	O
obstruction	POS	O
may	POS	O
be	POS	O
absent	POS	O
or	POS	O
minimal	POS	O
and	POS	O
should	POS	O
be	POS	O
sought	POS	O
carefully	POS	O
.	POS	O
Images	POS	O
may	POS	O
need	POS	O
to	POS	O
be	POS	O
obtained	POS	O
using	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
contrast	POS	O
material	POS	O
to	POS	O
enable	POS	O
diagnosis	POS	O
of	POS	O
ureteric	POS	B-NP
stones	POS	I-NP
or	POS	O
obstruction	POS	O
in	POS	O
patients	POS	O
with	POS	O
HIV	POS	B-NP
infection	POS	I-NP
who	POS	O
receive	POS	O
indinavir	POS	O
therapy	POS	O
.	POS	O
Ischemic	POS	B-NP
colitis	POS	I-NP
and	POS	O
sumatriptan	POS	O
use	POS	O
.	POS	O
Sumatriptan	POS	O
succinate	POS	O
,	POS	O
a	POS	O
serotonin	POS	O
-	POS	O
1	POS	O
(	POS	O
5	POS	O
-	POS	O
hydroxytryptamine	POS	O
-	POS	O
1	POS	O
)	POS	O
receptor	POS	O
agonist	POS	O
,	POS	O
is	POS	O
an	POS	O
antimigraine	POS	O
drug	POS	O
that	POS	O
is	POS	O
reported	POS	O
to	POS	O
act	POS	O
by	POS	O
selectively	POS	O
constricting	POS	O
intracranial	POS	O
arteries	POS	O
.	POS	O
Recently	POS	O
,	POS	O
vasopressor	POS	O
responses	POS	O
that	POS	O
are	POS	O
distinct	POS	O
from	POS	O
the	POS	O
cranial	POS	O
circulation	POS	O
have	POS	O
been	POS	O
demonstrated	POS	O
to	POS	O
occur	POS	O
in	POS	O
the	POS	O
systemic	POS	O
,	POS	O
pulmonary	POS	O
,	POS	O
and	POS	O
coronary	POS	B-NP
circulations	POS	I-NP
.	POS	O
Cases	POS	O
have	POS	O
been	POS	O
published	POS	O
of	POS	O
coronary	POS	B-NP
vasospasm	POS	I-NP
,	POS	O
myocardial	POS	B-NP
ischemia	POS	I-NP
,	POS	O
and	POS	O
myocardial	POS	B-NP
infarction	POS	I-NP
occurring	POS	O
after	POS	O
sumatriptan	POS	O
use	POS	O
.	POS	O
We	POS	O
report	POS	O
on	POS	O
the	POS	O
development	POS	O
of	POS	O
8	POS	O
serious	POS	O
cases	POS	O
of	POS	O
ischemic	POS	B-NP
colitis	POS	I-NP
in	POS	O
patients	POS	O
with	POS	O
migraine	POS	B-NP
treated	POS	O
with	POS	O
sumatriptan	POS	O
.	POS	O
Pallidotomy	POS	B-NP
with	POS	O
the	POS	O
gamma	POS	O
knife	POS	O
:	POS	O
a	POS	O
positive	POS	O
experience	POS	O
.	POS	O
51	POS	O
patients	POS	O
with	POS	O
medically	POS	O
refractory	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
underwent	POS	O
stereotactic	POS	O
posteromedial	POS	O
pallidotomy	POS	O
between	POS	O
August	POS	O
1993	POS	O
and	POS	O
February	POS	O
1997	POS	O
for	POS	O
treatment	POS	O
of	POS	O
bradykinesia	POS	B-NP
,	POS	O
rigidity	POS	B-NP
,	POS	O
and	POS	O
L	POS	O
-	POS	O
DOPA	POS	O
-	POS	O
induced	POS	O
dyskinesias	POS	B-NP
.	POS	O
In	POS	O
29	POS	O
patients	POS	O
,	POS	O
the	POS	O
pallidotomies	POS	O
were	POS	O
performed	POS	O
with	POS	O
the	POS	O
Leksell	POS	O
Gamma	POS	O
Knife	POS	O
and	POS	O
in	POS	O
22	POS	O
they	POS	O
were	POS	O
performed	POS	O
with	POS	O
the	POS	O
standard	POS	O
radiofrequency	POS	O
(	POS	O
RF	POS	O
)	POS	O
method	POS	O
.	POS	O
Clinical	POS	O
assessment	POS	O
as	POS	O
well	POS	O
as	POS	O
blinded	POS	O
ratings	POS	O
of	POS	O
Unified	POS	O
Parkinson	POS	O
'	POS	O
s	POS	O
Disease	POS	O
Rating	POS	O
Scale	POS	O
(	POS	O
UPDRS	POS	O
)	POS	O
scores	POS	O
were	POS	O
carried	POS	O
out	POS	O
pre	POS	O
-	POS	O
and	POS	O
postoperatively	POS	O
.	POS	O
Mean	POS	O
follow	POS	O
-	POS	O
up	POS	O
time	POS	O
is	POS	O
20	POS	O
.	POS	O
6	POS	O
months	POS	O
(	POS	O
range	POS	O
6	POS	O
-	POS	O
48	POS	O
)	POS	O
and	POS	O
all	POS	O
except	POS	O
4	POS	O
patients	POS	O
have	POS	O
been	POS	O
followed	POS	O
more	POS	O
than	POS	O
one	POS	O
year	POS	O
.	POS	O
85	POS	O
percent	POS	O
of	POS	O
patients	POS	O
with	POS	O
dyskinesias	POS	B-NP
were	POS	O
relieved	POS	O
of	POS	O
symptoms	POS	O
,	POS	O
regardless	POS	O
of	POS	O
whether	POS	O
the	POS	O
pallidotomies	POS	O
were	POS	O
performed	POS	O
with	POS	O
the	POS	O
Gamma	POS	O
Knife	POS	O
or	POS	O
radiofrequency	POS	O
methods	POS	O
.	POS	O
About	POS	O
2	POS	O
/	POS	O
3	POS	O
of	POS	O
the	POS	O
patients	POS	O
in	POS	O
both	POS	O
Gamma	POS	O
Knife	POS	O
and	POS	O
radiofrequency	POS	O
groups	POS	O
showed	POS	O
improvements	POS	O
in	POS	O
bradykinesia	POS	B-NP
and	POS	O
rigidity	POS	B-NP
,	POS	O
although	POS	O
when	POS	O
considered	POS	O
as	POS	O
a	POS	O
group	POS	O
neither	POS	O
the	POS	O
Gamma	POS	O
Knife	POS	O
nor	POS	O
the	POS	O
radiofrequency	POS	O
group	POS	O
showed	POS	O
statistically	POS	O
significant	POS	O
improvements	POS	O
in	POS	O
UPDRS	POS	O
scores	POS	O
.	POS	O
One	POS	O
patient	POS	O
in	POS	O
the	POS	O
Gamma	POS	O
Knife	POS	O
group	POS	O
(	POS	O
3	POS	O
.	POS	O
4	POS	O
%	POS	O
)	POS	O
developed	POS	O
a	POS	O
homonymous	POS	B-NP
hemianopsia	POS	I-NP
9	POS	O
months	POS	O
following	POS	O
treatment	POS	O
and	POS	O
5	POS	O
patients	POS	O
(	POS	O
27	POS	O
.	POS	O
7	POS	O
%	POS	O
)	POS	O
in	POS	O
the	POS	O
radiofrequency	POS	O
group	POS	O
became	POS	O
transiently	POS	O
confused	POS	O
postoperatively	POS	O
.	POS	O
No	POS	O
other	POS	O
complications	POS	O
were	POS	O
seen	POS	O
.	POS	O
Gamma	POS	O
Knife	POS	O
pallidotomy	POS	O
is	POS	O
as	POS	O
effective	POS	O
as	POS	O
radiofrequency	POS	O
pallidotomy	POS	O
in	POS	O
controlling	POS	O
certain	POS	O
of	POS	O
the	POS	O
symptoms	POS	O
of	POS	O
Parkinson	POS	B-NP
'	POS	I-NP
s	POS	I-NP
disease	POS	I-NP
.	POS	O
It	POS	O
may	POS	O
be	POS	O
the	POS	O
only	POS	O
practical	POS	O
technique	POS	O
available	POS	O
in	POS	O
certain	POS	O
patients	POS	O
,	POS	O
such	POS	O
as	POS	O
those	POS	O
who	POS	O
take	POS	O
anticoagulants	POS	O
,	POS	O
have	POS	O
bleeding	POS	B-NP
diatheses	POS	I-NP
or	POS	O
serious	POS	O
systemic	POS	O
medical	POS	O
illnesses	POS	O
.	POS	O
It	POS	O
is	POS	O
a	POS	O
viable	POS	O
option	POS	O
for	POS	O
other	POS	O
patients	POS	O
as	POS	O
well	POS	O
.	POS	O
Centrally	POS	O
mediated	POS	O
cardiovascular	POS	O
effects	POS	O
of	POS	O
intracisternal	POS	O
application	POS	O
of	POS	O
carbachol	POS	O
in	POS	O
anesthetized	POS	O
rats	POS	O
.	POS	O
The	POS	O
pressor	POS	O
response	POS	O
to	POS	O
the	POS	O
intracisternal	POS	O
(	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
)	POS	O
injection	POS	O
of	POS	O
carbachol	POS	O
(	POS	O
1	POS	O
mug	POS	O
)	POS	O
in	POS	O
anesthetized	POS	O
rats	POS	O
was	POS	O
analyzed	POS	O
.	POS	O
This	POS	O
response	POS	O
was	POS	O
significantly	POS	O
reduced	POS	O
by	POS	O
the	POS	O
intravenous	POS	O
(	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
)	POS	O
injection	POS	O
of	POS	O
guanethidine	POS	O
(	POS	O
5	POS	O
mg	POS	O
)	POS	O
,	POS	O
hexamethonium	POS	O
(	POS	O
10	POS	O
mg	POS	O
)	POS	O
or	POS	O
phentolamine	POS	O
(	POS	O
5	POS	O
mg	POS	O
)	POS	O
,	POS	O
and	POS	O
conversely	POS	O
,	POS	O
potentiated	POS	O
by	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
desmethylimipramine	POS	O
(	POS	O
0	POS	O
.	POS	O
3	POS	O
mg	POS	O
)	POS	O
,	POS	O
while	POS	O
propranolol	POS	O
(	POS	O
0	POS	O
.	POS	O
5	POS	O
mg	POS	O
)	POS	O
i	POS	O
.	POS	O
v	POS	O
.	POS	O
selectively	POS	O
inhibited	POS	O
the	POS	O
enlargement	POS	O
of	POS	O
pulse	POS	O
pressure	POS	O
and	POS	O
the	POS	O
tachycardia	POS	B-NP
following	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
carbachol	POS	O
(	POS	O
1	POS	O
mug	POS	O
)	POS	O
.	POS	O
On	POS	O
the	POS	O
other	POS	O
hand	POS	O
,	POS	O
the	POS	O
pressor	POS	O
response	POS	O
to	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
carbachol	POS	O
(	POS	O
1	POS	O
mug	POS	O
)	POS	O
was	POS	O
almost	POS	O
completely	POS	O
blocked	POS	O
by	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
atropine	POS	O
(	POS	O
3	POS	O
mug	POS	O
)	POS	O
or	POS	O
hexamethonium	POS	O
(	POS	O
500	POS	O
mug	POS	O
)	POS	O
,	POS	O
and	POS	O
significantly	POS	O
reduced	POS	O
by	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
chlorpromazine	POS	O
(	POS	O
50	POS	O
mug	POS	O
)	POS	O
but	POS	O
significantly	POS	O
potentiated	POS	O
by	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
desmethylimipramine	POS	O
(	POS	O
30	POS	O
mug	POS	O
)	POS	O
.	POS	O
The	POS	O
pressor	POS	O
response	POS	O
to	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
carbachol	POS	O
(	POS	O
1	POS	O
mug	POS	O
)	POS	O
remained	POS	O
unchanged	POS	O
after	POS	O
sectioning	POS	O
of	POS	O
the	POS	O
bilateral	POS	O
cervical	POS	O
vagal	POS	O
nerves	POS	O
but	POS	O
disappeared	POS	O
after	POS	O
sectioning	POS	O
of	POS	O
the	POS	O
spinal	POS	O
cord	POS	O
(	POS	O
C7	POS	O
-	POS	O
C8	POS	O
)	POS	O
.	POS	O
From	POS	O
the	POS	O
above	POS	O
result	POS	O
it	POS	O
is	POS	O
suggested	POS	O
that	POS	O
the	POS	O
pressor	POS	O
response	POS	O
to	POS	O
i	POS	O
.	POS	O
c	POS	O
.	POS	O
carbachol	POS	O
ortral	POS	O
and	POS	O
peripheral	POS	O
adrenergic	POS	O
mechanisms	POS	O
,	POS	O
and	POS	O
that	POS	O
the	POS	O
sympathetic	POS	O
trunk	POS	O
is	POS	O
the	POS	O
main	POS	O
pathway	POS	O
.	POS	O
Neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
and	POS	O
methylphenidate	POS	O
.	POS	O
A	POS	O
1	POS	O
-	POS	O
year	POS	O
-	POS	O
old	POS	O
female	POS	O
presented	POS	O
with	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
probably	POS	O
caused	POS	O
by	POS	O
methylphenidate	POS	O
.	POS	O
She	POS	O
had	POS	O
defects	POS	O
in	POS	O
the	POS	O
supratentorial	POS	O
brain	POS	O
including	POS	O
the	POS	O
basal	POS	O
ganglia	POS	O
and	POS	O
the	POS	O
striatum	POS	O
(	POS	O
multicystic	POS	B-NP
encephalomalacia	POS	I-NP
)	POS	O
due	POS	O
to	POS	O
severe	POS	O
perinatal	POS	O
hypoxic	POS	O
-	POS	O
ischemic	POS	B-NP
encephalopathy	POS	I-NP
,	POS	O
which	POS	O
was	POS	O
considered	POS	O
to	POS	O
be	POS	O
a	POS	O
possible	POS	O
predisposing	POS	O
factor	POS	O
causing	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
.	POS	O
A	POS	O
dopaminergic	POS	O
blockade	POS	O
mechanism	POS	O
generally	POS	O
is	POS	O
accepted	POS	O
as	POS	O
the	POS	O
pathogenesis	POS	O
of	POS	O
this	POS	O
syndrome	POS	O
.	POS	O
However	POS	O
,	POS	O
methylphenidate	POS	O
is	POS	O
a	POS	O
dopamine	POS	O
agonist	POS	O
via	POS	O
the	POS	O
inhibition	POS	O
of	POS	O
uptake	POS	O
of	POS	O
dopamine	POS	O
,	POS	O
and	POS	O
therefore	POS	O
dopaminergic	POS	O
systems	POS	O
in	POS	O
the	POS	O
brainstem	POS	O
(	POS	O
mainly	POS	O
the	POS	O
midbrain	POS	O
)	POS	O
and	POS	O
the	POS	O
spinal	POS	O
cord	POS	O
were	POS	O
unlikely	POS	O
to	POS	O
participate	POS	O
in	POS	O
the	POS	O
onset	POS	O
of	POS	O
this	POS	O
syndrome	POS	O
.	POS	O
A	POS	O
relative	POS	O
gamma	POS	O
-	POS	O
aminobutyric	POS	O
acid	POS	O
-	POS	O
ergic	POS	O
deficiency	POS	O
might	POS	O
occur	POS	O
because	POS	O
diazepam	POS	O
,	POS	O
a	POS	O
gamma	POS	O
-	POS	O
aminobutyric	POS	O
acid	POS	O
-	POS	O
mimetic	POS	O
agent	POS	O
,	POS	O
was	POS	O
strikingly	POS	O
effective	POS	O
.	POS	O
This	POS	O
is	POS	O
the	POS	O
first	POS	O
reported	POS	O
patient	POS	O
with	POS	O
neuroleptic	POS	B-NP
malignant	POS	I-NP
syndrome	POS	I-NP
probably	POS	O
caused	POS	O
by	POS	O
methylphenidate	POS	O
.	POS	O
Differential	POS	O
effects	POS	O
of	POS	O
17alpha	POS	O
-	POS	O
ethinylestradiol	POS	O
on	POS	O
the	POS	O
neutral	POS	O
and	POS	O
acidic	POS	O
pathways	POS	O
of	POS	O
bile	POS	O
salt	POS	O
synthesis	POS	O
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
Effects	POS	O
of	POS	O
17alpha	POS	O
-	POS	O
ethinylestradiol	POS	O
(	POS	O
EE	POS	O
)	POS	O
on	POS	O
the	POS	O
neutral	POS	O
and	POS	O
acidic	POS	O
biosynthetic	POS	O
pathways	POS	O
of	POS	O
bile	POS	O
salt	POS	O
(	POS	O
BS	POS	O
)	POS	O
synthesis	POS	O
were	POS	O
evaluated	POS	O
in	POS	O
rats	POS	O
with	POS	O
an	POS	O
intact	POS	O
enterohepatic	POS	O
circulation	POS	O
and	POS	O
in	POS	O
rats	POS	O
with	POS	O
long	POS	O
-	POS	O
term	POS	O
bile	POS	O
diversion	POS	O
to	POS	O
induce	POS	O
BS	POS	O
synthesis	POS	O
.	POS	O
For	POS	O
this	POS	O
purpose	POS	O
,	POS	O
bile	POS	O
salt	POS	O
pool	POS	O
composition	POS	O
,	POS	O
synthesis	POS	O
of	POS	O
individual	POS	O
BS	POS	O
in	POS	O
vivo	POS	O
,	POS	O
hepatic	POS	O
activities	POS	O
,	POS	O
and	POS	O
expression	POS	O
levels	POS	O
of	POS	O
cholesterol	POS	O
7alpha	POS	O
-	POS	O
hydroxylase	POS	O
(	POS	O
CYP7A	POS	O
)	POS	O
,	POS	O
and	POS	O
sterol	POS	O
27	POS	O
-	POS	O
hydroxylase	POS	O
(	POS	O
CYP27	POS	O
)	POS	O
,	POS	O
as	POS	O
well	POS	O
as	POS	O
of	POS	O
other	POS	O
enzymes	POS	O
involved	POS	O
in	POS	O
BS	POS	O
synthesis	POS	O
,	POS	O
were	POS	O
analyzed	POS	O
in	POS	O
rats	POS	O
treated	POS	O
with	POS	O
EE	POS	O
(	POS	O
5	POS	O
mg	POS	O
/	POS	O
kg	POS	O
,	POS	O
3	POS	O
days	POS	O
)	POS	O
or	POS	O
its	POS	O
vehicle	POS	O
.	POS	O
BS	POS	O
pool	POS	O
size	POS	O
was	POS	O
decreased	POS	O
by	POS	O
27	POS	O
%	POS	O
but	POS	O
total	POS	O
BS	POS	O
synthesis	POS	O
was	POS	O
not	POS	O
affected	POS	O
by	POS	O
EE	POS	O
in	POS	O
intact	POS	O
rats	POS	O
.	POS	O
Synthesis	POS	O
of	POS	O
cholate	POS	O
was	POS	O
reduced	POS	O
by	POS	O
68	POS	O
%	POS	O
in	POS	O
EE	POS	O
-	POS	O
treated	POS	O
rats	POS	O
,	POS	O
while	POS	O
that	POS	O
of	POS	O
chenodeoxycholate	POS	O
was	POS	O
increased	POS	O
by	POS	O
60	POS	O
%	POS	O
.	POS	O
The	POS	O
recently	POS	O
identified	POS	O
Delta22	POS	O
-	POS	O
isomer	POS	O
of	POS	O
beta	POS	O
-	POS	O
muricholate	POS	O
contributed	POS	O
for	POS	O
5	POS	O
.	POS	O
4	POS	O
%	POS	O
and	POS	O
18	POS	O
.	POS	O
3	POS	O
%	POS	O
(	POS	O
P	POS	O
<	POS	O
0	POS	O
.	POS	O
01	POS	O
)	POS	O
to	POS	O
the	POS	O
pool	POS	O
in	POS	O
control	POS	O
and	POS	O
EE	POS	O
-	POS	O
treated	POS	O
rats	POS	O
,	POS	O
respectively	POS	O
,	POS	O
but	POS	O
could	POS	O
not	POS	O
be	POS	O
detected	POS	O
in	POS	O
bile	POS	O
after	POS	O
exhaustion	POS	O
of	POS	O
the	POS	O
pool	POS	O
.	POS	O
A	POS	O
clear	POS	O
reduction	POS	O
of	POS	O
BS	POS	O
synthesis	POS	O
was	POS	O
found	POS	O
in	POS	O
bile	POS	O
-	POS	O
diverted	POS	O
rats	POS	O
treated	POS	O
with	POS	O
EE	POS	O
,	POS	O
yet	POS	O
biliary	POS	O
BS	POS	O
composition	POS	O
was	POS	O
only	POS	O
minimally	POS	O
affected	POS	O
.	POS	O
Activity	POS	O
of	POS	O
CYP7A	POS	O
was	POS	O
decreased	POS	O
by	POS	O
EE	POS	O
in	POS	O
both	POS	O
intact	POS	O
and	POS	O
bile	POS	O
-	POS	O
diverted	POS	O
rats	POS	O
,	POS	O
whereas	POS	O
the	POS	O
activity	POS	O
of	POS	O
the	POS	O
CYP27	POS	O
was	POS	O
not	POS	O
affected	POS	O
.	POS	O
Hepatic	POS	O
mRNA	POS	O
levels	POS	O
of	POS	O
CYP7A	POS	O
were	POS	O
significantly	POS	O
reduced	POS	O
by	POS	O
EE	POS	O
in	POS	O
bile	POS	O
-	POS	O
diverted	POS	O
rats	POS	O
only	POS	O
;	POS	O
CYP27	POS	O
mRNA	POS	O
levels	POS	O
were	POS	O
not	POS	O
affected	POS	O
by	POS	O
EE	POS	O
.	POS	O
In	POS	O
addition	POS	O
,	POS	O
mRNA	POS	O
levels	POS	O
of	POS	O
sterol	POS	O
12alpha	POS	O
-	POS	O
hydroxylase	POS	O
and	POS	O
lithocholate	POS	O
6beta	POS	O
-	POS	O
hydroxylase	POS	O
were	POS	O
increased	POS	O
by	POS	O
bile	POS	O
diversion	POS	O
and	POS	O
suppressed	POS	O
by	POS	O
EE	POS	O
.	POS	O
This	POS	O
study	POS	O
shows	POS	O
that	POS	O
17alpha	POS	O
-	POS	O
ethinylestradiol	POS	O
(	POS	O
EE	POS	O
)	POS	O
-	POS	O
induced	POS	O
intrahepatic	POS	B-NP
cholestasis	POS	I-NP
in	POS	O
rats	POS	O
is	POS	O
associated	POS	O
with	POS	O
selective	POS	O
inhibition	POS	O
of	POS	O
the	POS	O
neutral	POS	O
pathway	POS	O
of	POS	O
bile	POS	O
salt	POS	O
(	POS	O
BS	POS	O
)	POS	O
synthesis	POS	O
.	POS	O
Simultaneous	POS	O
impairment	POS	O
of	POS	O
other	POS	O
enzymes	POS	O
in	POS	O
the	POS	O
BS	POS	O
biosynthetic	POS	O
pathways	POS	O
may	POS	O
contribute	POS	O
to	POS	O
overall	POS	O
effects	POS	O
of	POS	O
EE	POS	O
on	POS	O
BS	POS	O
synthesis	POS	O
.	POS	O
Glibenclamide	POS	O
-	POS	O
sensitive	POS	O
hypotension	POS	B-NP
produced	POS	O
by	POS	O
helodermin	POS	O
assessed	POS	O
in	POS	O
the	POS	O
rat	POS	O
.	POS	O
The	POS	O
effects	POS	O
of	POS	O
helodermin	POS	O
,	POS	O
a	POS	O
basic	POS	O
35	POS	O
-	POS	O
amino	POS	O
acid	POS	O
peptide	POS	O
isolated	POS	O
from	POS	O
the	POS	O
venom	POS	O
of	POS	O
a	POS	O
lizard	POS	O
salivary	POS	O
gland	POS	O
,	POS	O
on	POS	O
arterial	POS	O
blood	POS	O
pressure	POS	O
and	POS	O
heart	POS	O
rate	POS	O
were	POS	O
examined	POS	O
in	POS	O
the	POS	O
rat	POS	O
,	POS	O
focusing	POS	O
on	POS	O
the	POS	O
possibility	POS	O
that	POS	O
activation	POS	O
of	POS	O
ATP	POS	O
sensitive	POS	O
K	POS	O
+	POS	O
(	POS	O
K	POS	O
(	POS	O
ATP	POS	O
)	POS	O
)	POS	O
channels	POS	O
is	POS	O
involved	POS	O
in	POS	O
the	POS	O
responses	POS	O
.	POS	O
The	POS	O
results	POS	O
were	POS	O
also	POS	O
compared	POS	O
with	POS	O
those	POS	O
of	POS	O
vasoactive	POS	O
intestinal	POS	O
polypeptide	POS	O
(	POS	O
VIP	POS	O
)	POS	O
.	POS	O
Helodermin	POS	O
produced	POS	O
hypotension	POS	B-NP
in	POS	O
a	POS	O
dose	POS	O
-	POS	O
dependent	POS	O
manner	POS	O
with	POS	O
approximately	POS	O
similar	POS	O
potency	POS	O
and	POS	O
duration	POS	O
to	POS	O
VIP	POS	O
.	POS	O
Hypotension	POS	B-NP
induced	POS	O
by	POS	O
both	POS	O
peptides	POS	O
was	POS	O
significantly	POS	O
attenuated	POS	O
by	POS	O
glibenclamide	POS	O
,	POS	O
which	POS	O
abolished	POS	O
a	POS	O
levcromakalim	POS	O
-	POS	O
produced	POS	O
decrease	POS	O
in	POS	O
arterial	POS	O
blood	POS	O
pressure	POS	O
.	POS	O
Oxyhemoglobin	POS	O
did	POS	O
not	POS	O
affect	POS	O
helodermin	POS	O
-	POS	O
induced	POS	O
hypotension	POS	B-NP
,	POS	O
whereas	POS	O
it	POS	O
shortened	POS	O
the	POS	O
duration	POS	O
of	POS	O
acetylcholine	POS	O
(	POS	O
ACh	POS	O
)	POS	O
-	POS	O
produced	POS	O
hypotension	POS	B-NP
.	POS	O
These	POS	O
findings	POS	O
suggest	POS	O
that	POS	O
helodermin	POS	O
-	POS	O
produced	POS	O
hypotension	POS	B-NP
is	POS	O
partly	POS	O
attributable	POS	O
to	POS	O
the	POS	O
activation	POS	O
of	POS	O
glibenclamide	POS	O
-	POS	O
sensitive	POS	O
K	POS	O
+	POS	O
channels	POS	O
(	POS	O
K	POS	O
(	POS	O
ATP	POS	O
)	POS	O
channels	POS	O
)	POS	O
,	POS	O
which	POS	O
presumably	POS	O
exist	POS	O
on	POS	O
arterial	POS	O
smooth	POS	O
muscle	POS	O
cells	POS	O
.	POS	O
EDRF	POS	O
(	POS	O
endothelium	POS	O
-	POS	O
derived	POS	O
relaxing	POS	O
factor	POS	O
)	POS	O
/	POS	O
nitric	POS	O
oxide	POS	O
does	POS	O
not	POS	O
seem	POS	O
to	POS	O
play	POS	O
an	POS	O
important	POS	O
role	POS	O
in	POS	O
the	POS	O
peptide	POS	O
-	POS	O
produced	POS	O
hypotension	POS	B-NP
.	POS	O
Long	POS	O
-	POS	O
term	POS	O
efficacy	POS	O
and	POS	O
adverse	POS	O
event	POS	O
of	POS	O
nifedipine	POS	O
sustained	POS	O
-	POS	O
release	POS	O
tablets	POS	O
for	POS	O
cyclosporin	POS	O
A	POS	O
-	POS	O
induced	POS	O
hypertension	POS	B-NP
in	POS	O
patients	POS	O
with	POS	O
psoriasis	POS	B-NP
.	POS	O
Thirteen	POS	O
psoriatic	POS	B-NP
patients	POS	O
with	POS	O
hypertension	POS	B-NP
during	POS	O
the	POS	O
course	POS	O
of	POS	O
cyclosporin	POS	O
A	POS	O
therapy	POS	O
were	POS	O
treated	POS	O
for	POS	O
25	POS	O
months	POS	O
with	POS	O
a	POS	O
calcium	POS	O
channel	POS	O
blocker	POS	O
,	POS	O
sustained	POS	O
-	POS	O
release	POS	O
nifedipine	POS	O
,	POS	O
to	POS	O
study	POS	O
the	POS	O
clinical	POS	O
antihypertensive	POS	O
effects	POS	O
and	POS	O
adverse	POS	O
events	POS	O
during	POS	O
treatment	POS	O
with	POS	O
both	POS	O
drugs	POS	O
.	POS	O
Seven	POS	O
of	POS	O
the	POS	O
13	POS	O
patients	POS	O
had	POS	O
exhibited	POS	O
a	POS	O
subclinical	POS	O
hypertensive	POS	B-NP
state	POS	O
before	POS	O
cyclosporin	POS	O
A	POS	O
therapy	POS	O
.	POS	O
Both	POS	O
systolic	POS	O
and	POS	O
diastolic	POS	O
blood	POS	O
pressures	POS	O
of	POS	O
these	POS	O
13	POS	O
patients	POS	O
were	POS	O
decreased	POS	O
significantly	POS	O
after	POS	O
4	POS	O
weeks	POS	O
of	POS	O
nifedipine	POS	O
therapy	POS	O
,	POS	O
and	POS	O
blood	POS	O
pressure	POS	O
was	POS	O
maintained	POS	O
within	POS	O
the	POS	O
normal	POS	O
range	POS	O
thereafter	POS	O
for	POS	O
25	POS	O
months	POS	O
.	POS	O
The	POS	O
adverse	POS	O
events	POS	O
during	POS	O
combined	POS	O
therapy	POS	O
with	POS	O
cyclosporin	POS	O
A	POS	O
and	POS	O
nifedipine	POS	O
included	POS	O
an	POS	O
increase	POS	O
in	POS	O
blood	POS	O
urea	POS	O
nitrogen	POS	O
levels	POS	O
in	POS	O
9	POS	O
of	POS	O
the	POS	O
13	POS	O
patients	POS	O
and	POS	O
development	POS	O
of	POS	O
gingival	POS	B-NP
hyperplasia	POS	I-NP
in	POS	O
2	POS	O
of	POS	O
the	POS	O
13	POS	O
patients	POS	O
.	POS	O
Our	POS	O
findings	POS	O
indicate	POS	O
that	POS	O
sustained	POS	O
-	POS	O
release	POS	O
nifedipine	POS	O
is	POS	O
useful	POS	O
for	POS	O
hypertensive	POS	B-NP
psoriatic	POS	I-NP
patients	POS	O
under	POS	O
long	POS	O
-	POS	O
term	POS	O
treatment	POS	O
with	POS	O
cyclosporin	POS	O
A	POS	O
,	POS	O
but	POS	O
that	POS	O
these	POS	O
patients	POS	O
should	POS	O
be	POS	O
monitored	POS	O
for	POS	O
gingival	POS	B-NP
hyperplasia	POS	I-NP
.	POS	O

